pid	title	journal	year	x	y	citation_count	size
38078948	Development of PD-1 blockade peptide-cell conjugates to enhance cellular therapies for T-cell acute lymphoblastic leukemia.	Medical oncology (Northwood, London, England)	2023	-41.82370897518916	-46.62205660708031	0	0.0
38077396	Anti-PD1 does not improve pyroptosis induced by γδ T cells but promotes tumor regression in a pleural mesothelioma mouse model.	Frontiers in immunology	2023	-35.83411794593387	3.4918050134126117	0	0.0
38076194	An extension of cancer immunotherapy with dostarlimab, the PD1-PD L1 pathway blocker.	Heliyon	2023	28.66005797826153	-6.36500430512824	0	0.0
38074660	Hepatoid adenocarcinoma of the lung with PD-L1 expression and the response to anti-PD-1 therapy: a case report.	Frontiers in oncology	2023	32.64271375765133	-53.30595165069188	0	0.0
38073110	Does the use of low-molecular-weight heparin during pregnancy change the expression of PD-1 and PDL-1 in women with recurrent pregnancy loss?	Turkish journal of obstetrics and gynecology	2023	-74.62700678062572	-18.84908743542281	0	0.0
38072158	Final analysis of phase II results with cemiplimab in metastatic basal cell carcinoma after hedgehog pathway inhibitors.	Annals of oncology : official journal of the European Society for Medical Oncology	2023	56.61250821426577	3.795879168319824	0	0.0
38070624	Soluble PD-L1 reprograms blood monocytes to prevent cerebral edema and facilitate recovery after ischemic stroke.	Brain, behavior, and immunity	2023	-77.44786562733272	-7.838583108978427	0	0.0
38069638	Programmed death receptor 1 (PD-1) ligand Fc fusion proteins reduce T-cell proliferation in vitro independently of PD-1.	Immunology and cell biology	2023	-52.522078818171806	-8.940213469969866	0	0.0
38069222	Opaganib (ABC294640) Induces Immunogenic Tumor Cell Death and Enhances Checkpoint Antibody Therapy.	International journal of molecular sciences	2023	30.81057810763137	-27.668824189249307	0	0.0
38067610	Effect of Fragment 1 on the Binding of Epigallocatechin Gallate to the PD-L1 Dimer Explored by Molecular Dynamics.	Molecules (Basel, Switzerland)	2023	-31.61675309019348	-36.19738020989767	0	0.0
38067379	Clinical Application of ImmunoPET Targeting Checkpoint Inhibitors.	Cancers	2023	28.640052673747235	-11.840095693053309	0	0.0
38066312	Altered levels of cytokine, T- and B-lymphocytes, and PD-1 expression rates in drug-naïve schizophrenia patients with acute phase.	Scientific reports	2023	-88.04550601427361	11.153887782172712	0	0.0
38066025	Correlation of PD-1 and PD-L1 expression in oral leukoplakia and oral squamous cell carcinoma: an immunohistochemical study.	Scientific reports	2023	-8.939928052376104	-12.29213093423538	0	0.0
38063949	Increased PAFAH1B3 was associated with poor prognosis and T-cell exhaustion microenvironment in hepatocellular carcinoma.	Discover. Oncology	2023	-15.557463986593763	42.330283452937685	0	0.0
38058705	Severe cardiac events induced by combination immunotherapy in patients with cancer: a meta-analysis.	Archives of medical science : AMS	2023	81.44284592476394	3.636472366740028	0	0.0
38058537	Epigenome-Driven Strategies for Personalized Cancer Immunotherapy.	Cancer management and research	2023	11.54811447201919	9.759654590285717	0	0.0
38058259	Akkermansia muciniphila might improve anti-PD-1 therapy against HCC by changing host bile acid metabolism.	The journal of gene medicine	2023	24.72209607839021	41.26461041321824	0	0.0
38057799	Immune checkpoints are predominantly co-expressed by clonally expanded CD4+FoxP3+ intratumoral T-cells in primary human cancers.	Journal of experimental & clinical cancer research : CR	2023	3.5509054722700677	25.271777641109335	0	0.0
38057736	Comparison of efficacy and safety between PD-1 inhibitors and PD-L1 inhibitors plus platinum-etoposide as first-line treatment for extensive-stage small-cell lung cancer: a multicenter, real-world analysis.	BMC cancer	2023	46.80769991698151	-40.28697198674907	0	0.0
38055623	IL-2 produced by HBV-specific T cells as a biomarker of viral control and predictor of response to PD-1 therapy across clinical phases of chronic hepatitis B.	Hepatology communications	2023	-74.0846839227765	23.17991304501309	0	0.0
38054258	Molecular interactions of antibodies with PD-1/PD-L1 proteins.	Immunotherapy	2023	-52.349993050440034	-37.74482747847805	0	0.0
38053848	Design and selection of anti-PD-L1 single-domain antibody and tumor necrosis factor superfamily ligands for an optimal vectorization in an oncolytic virus.	Frontiers in bioengineering and biotechnology	2023	-44.37832170084452	-27.910312683413864	0	0.0
38053355	Therapeutic Potential of Targeting Transforming Growth Factor-beta (TGF-β) and Programmed Death-ligand 1 (PD-L1) in Pancreatic Cancer.	Current drug targets	2023	-14.301929906344329	-2.13974616303285	0	0.0
38052215	Tumor-immune microenvironment and NRF2 associate with clinical efficacy of PD-1 blockade combined with chemotherapy in lung squamous cell carcinoma.	Cell reports. Medicine	2023	9.276086215638353	-7.435640290530694	0	0.0
38051328	Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer: The ORIENT-16 Randomized Clinical Trial.	JAMA	2023	49.300514623255765	14.929226129305668	0	0.0
38050871	The genomic and immune landscapes of gastric cancer and their correlations with HER2 amplification and PD-L1 expression.	Cancer medicine	2023	-8.117528299173529	2.7977483674337136	0	0.0
38050808	Characterization of colorectal cancer by hierarchical clustering analyses of five immune cell markers.	Pathology international	2023	10.392449179965704	38.90245226526428	0	0.0
38050789	Phytochemicals in regulating PD-1/PD-L1 and immune checkpoint blockade therapy.	Phytotherapy research : PTR	2023	-29.05422222447488	-37.92642881184511	0	0.0
38050338	Plant-derived Durvalumab variants show efficient PD-1/PD-L1 blockade and therapeutically favourable FcR binding.	Plant biotechnology journal	2023	-33.97936114211271	-35.60128574830457	0	0.0
38049658	The discovery and evaluation of [18F]BMS-986229, a novel macrocyclic peptide PET radioligand for the measurement of PD-L1 expression and in-vivo PD-L1 target engagement.	European journal of nuclear medicine and molecular imaging	2023	5.147824075429659	-57.71737425566101	0	0.0
38048058	TROP2 is associated with primary resistance to immune checkpoint inhibition in patients with advanced non-small cell lung cancer.	Clinical cancer research : an official journal of the American Association for Cancer Research	2023	13.52463550144861	-25.53647138321527	0	0.0
38047502	Development and pharmacokinetic assessment of a fully canine anti-PD-1 monoclonal antibody for comparative translational research in dogs with spontaneous tumors.	mAbs	2023	-0.7635045377540762	-57.78131769951528	0	0.0
38046711	The Relationship Between PD-1(rs2227981) and PD-L1(rs2890658) Polymorphisms and Urothelial Cell Carcinoma.	Cureus	2023	14.476880703341722	58.41459548067408	0	0.0
38043270	An anti-PD-1 antisense oligonucleotide promotes the expression of soluble PD-1 by blocking the interaction between SRSF3 and an exonic splicing enhancer of PD-1 exon 3.	International immunopharmacology	2023	-13.284168121701295	-5.311058274388193	0	0.0
38042137	Anti-PD-1/PD-L1 therapy for colorectal cancer: Clinical implications and future considerations.	Translational oncology	2023	34.5302313528244	22.625887210881107	0	0.0
38040417	Hsa-LINC02418/mmu-4930573I07Rik regulated by METTL3 dictates anti-PD-L1 immunotherapeutic efficacy via enhancement of Trim21-mediated PD-L1 ubiquitination.	Journal for immunotherapy of cancer	2023	3.3625204086171725	-29.781119642227505	0	0.0
38039947	Silencing of PD-1 combined with EBV-specific killer T cells for the treatment of EBV-associated B lymphoma.	Translational oncology	2023	-38.322506059397206	8.78070622043333	0	0.0
38038414	The prognostic significance of tumor-immune microenvironment in ascites of patients with high-grade serous carcinoma.	Radiology and oncology	2023	3.8166265478968513	29.929181269880782	0	0.0
38037076	Efficacy and safety of PD-1 inhibitors in recurrent or metastatic nasopharyngeal carcinoma patients after failure of platinum-containing regimens: a systematic review and meta-analysis.	BMC cancer	2023	57.63557947052783	-1.4608209795642808	0	0.0
38033955	Expression of immune checkpoint protein in oral squamous cell carcinoma and its clinicopathological correlation: A tertiary care center cross-sectional study.	Journal of oral and maxillofacial pathology : JOMFP	2023	-7.458867597485056	-12.019561525525049	0	0.0
38032149	Molecular profiles of different PD-L1 expression in patients with esophageal squamous cell carcinoma.	Cancer biology & therapy	2023	-13.83245202322592	8.538340947802734	0	0.0
38031902	Immune checkpoint inhibitor-induced epidermal necrolysis: A narrative review evaluating demographics, clinical features, and culprit medications.	The Journal of dermatology	2023	76.60201318823702	-25.88306190477284	0	0.0
38031589	Whole-genome resequencing to explore genome‑wide single nucleotide polymorphisms and genes associated with avian leukosis virus subgroup J infection in chicken.	3 Biotech	2023	-79.93583167398651	8.850109723352686	0	0.0
38030173	Correlation of Intra-tumoral and Peripheral PD-1/PD-L1 Immunity in Head and Neck Cancer.	Anticancer research	2023	-7.506362169150003	-7.011829304860632	0	0.0
38028139	Cost-effectiveness analysis of serplulimab in combination with cisplatin plus 5-fluorouracil chemotherapy compared to cisplatin plus 5-fluorouracil chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma in China.	Therapeutic advances in medical oncology	2023	54.84331953950955	-25.068582277365717	0	0.0
38026994	Targeting PD-1/PD-L1 inhibits rejection in a heterotopic tracheal allograft model of lung transplantation.	Frontiers in pharmacology	2023	-63.41590723498509	-3.558626501123352	0	0.0
38026930	Anti-PD-1/PD-L1 for nasopharyngeal carcinoma: a comprehensive analysis of registered trials on ClinicalTrials.gov.	Frontiers in pharmacology	2023	57.792879463724994	-1.3078659698487882	0	0.0
38022872	Expression of tumoral GSK3-β, PD-L1, and CD8 cell density in urothelial carcinomas, association with tumor grade and overall survival.	American journal of clinical and experimental immunology	2023	8.847876073937263	59.45514501245143	0	0.0
38022521	Novel nomogram for predicting survival in advanced non-small cell lung cancer receiving anti-PD-1 plus chemotherapy with or without antiangiogenic therapy.	Frontiers in immunology	2023	16.831964522512436	-26.485791470770984	0	0.0
38019931	A T cell receptor β chain-directed antibody fusion molecule activates and expands subsets of T cells to promote antitumor activity.	Science translational medicine	2023	-29.6300945444269	-21.09457248507127	0	0.0
38019590	Sitravatinib combined with PD1 blockade enhances cytotoxic T-Cell infiltration by M2 to M1 tumor macrophage repolarization in esophageal adenocarcinoma.	Carcinogenesis	2023	-25.471125093461808	-25.181869139661384	0	0.0
38016718	Randomized, open-label, phase II, biomarker study of immune-mediated mechanism of action of neoadjuvant subcutaneous trastuzumab in patients with locally advanced, inflammatory, or early HER2-positive breast cancer-Immun-HER trial (GOIRC-01-2016).	Journal for immunotherapy of cancer	2023	46.44841384754852	4.894269154009748	0	0.0
38015913	PD-1 inhibits T cell actin remodeling at the immunological synapse independently of its signaling motifs.	Science signaling	2023	-48.49568679632044	-8.416998746221285	0	0.0
38014028	Exclusion of PD-1 from the immune synapse: a novel strategy to modulate T cell function.	bioRxiv : the preprint server for biology	2023	-48.28768537901868	-8.497336993951071	0	0.0
38010745	Predicting the Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer Using Soluble Immune Checkpoints.	Cancer biotherapy & radiopharmaceuticals	2023	2.982447210878909	23.73823156644247	0	0.0
38010641	[Relationship between PD-L1 expression and tumor stem cell marker CD44 as a promising basis for the development of new approaches to cancer targeted therapy].	Arkhiv patologii	2023	-38.45944303345009	-14.181847120052383	0	0.0
38008641	Influence of Tumor Cavitation on Assessing the Clinical Benefit of Anti-PD1 or PD-L1 Inhibitors in Advanced Lung Squamous Cell Carcinoma.	Clinical lung cancer	2023	23.00256637502736	-47.30449480868717	0	0.0
38008278	LRP5 competes for SPOP binding to enhance tumorigenesis mediated by Daxx and PD-L1 in prostate cancer.	Experimental cell research	2023	-17.618927959264585	-9.057709168088778	0	0.0
38007784	Study on Targeted Drugs for Non-Small Cell NSCLC with PD-1PD-L1 Signaling Pathway.	Studies in health technology and informatics	2023	9.195552732993905	-31.167968295690027	0	0.0
38007770	The Effect of Oxaliplatin on the Immunogenic Cell Death and Cell Apoptosis of Human Merkel Cell Cancerous Tumor.	Studies in health technology and informatics	2023	47.79019026135564	49.67353941257475	0	0.0
38007240	CDK5 destabilizes PD-L1 via chaperon-mediated autophagy to control cancer immune surveillance in hepatocellular carcinoma.	Journal for immunotherapy of cancer	2023	-20.721523404911903	39.14036788284117	0	0.0
38002057	Intercellular Molecular Crosstalk Networks within Invasive and Immunosuppressive Tumor Microenvironment Subtypes Associated with Clinical Outcomes in Four Cancer Types.	Biomedicines	2023	-1.0964143508314717	34.570533189975166	0	0.0
38001973	Prior Anti-Angiogenic TKI-Based Treatment as Potential Predisposing Factor to Nivolumab-Mediated Recurrent Thyroid Disorder Adverse Events in mRCC Patients: A Case Series.	Biomedicines	2023	76.96939277045217	-17.327829270956276	0	0.0
38001604	A Comparison of the Antitumor Efficacy of Novel Multi-Specific Tribodies with Combinations of Approved Immunomodulatory Antibodies.	Cancers	2023	-17.8425347707444	-41.47649336765776	0	0.0
37997595	Understanding immune checkpoints and PD-1/PD-L1-mediated immune resistance towards tumour immunotherapy.	3 Biotech	2023	-41.08954503624337	-16.746829973896922	0	0.0
37997380	Checkpoint inhibitor associated autoimmune diabetes mellitus is characterised by C-peptide loss and pancreatic atrophy.	The Journal of clinical endocrinology and metabolism	2023	88.12084417609128	-12.697678443614908	0	0.0
37995002	Current state of the art: immunotherapy in esophageal cancer and gastroesophageal junction cancer.	Cancer immunology, immunotherapy : CII	2023	54.30341302179434	15.006612338675213	0	0.0
37994340	Enfortumab vedotin and pembrolizumab as monotherapies and combination treatment in locally advanced or metastatic urothelial carcinoma: A narrative review.	Current urology	2023	68.5159456213831	13.210187781470092	0	0.0
37993847	TH-302-loaded nanodrug reshapes the hypoxic tumour microenvironment and enhances PD-1 blockade efficacy in gastric cancer.	Journal of nanobiotechnology	2023	-7.268210786848524	-46.240756337254666	0	0.0
37993085	IRGM is a novel regulator of PD-L1 via promoting S6K1-mediated phosphorylation of YBX1 in hepatocellular carcinoma.	Cancer letters	2023	-19.732598923282488	40.27271615399876	0	0.0
37992445	Immunotherapy for colorectal cancer: Rational strategies and novel therapeutic progress.	International immunopharmacology	2023	35.8214795806993	19.303314751971897	0	0.0
37992168	ATM deficiency confers specific therapeutic vulnerabilities in bladder cancer.	Science advances	2023	6.90255708032128	57.1896148883218	0	0.0
37990855	Circulating CD8 lymphocytes predict response to atezolizumab-bevacizumab in hepatocellular carcinoma.	European journal of immunology	2023	15.228450645835032	-9.149847706995148	0	0.0
37990063	Cell fusion upregulates PD-L1 expression for evasion from immunosurveillance.	Cancer gene therapy	2023	-25.80845522666678	-2.984048662173833	0	0.0
37989364	Pembrolizumab monotherapy for non-small cell lung cancer (NSCLC): can patient stratification be improved in the UK Tayside population? A retrospective cohort study.	BMJ open	2023	49.287716269150216	-28.42729204879333	0	0.0
37984251	The role and mechanisms of PD-L1 in immune evasion during Talaromyces marneffei infection.	International immunopharmacology	2023	-68.92517297819096	9.065214867016834	0	0.0
37984107	Long-term survival of patients with advanced non-small cell lung cancer treated using immune checkpoint inhibitors.	Respiratory investigation	2023	36.82946468968667	-23.041892375253497	0	0.0
37982696	Establishment of CD8+ T Cell Thymic Central Tolerance to Tissue-Restricted Antigen Requires PD-1.	Journal of immunology (Baltimore, Md. : 1950)	2023	-58.826639308047085	-1.9710150296177091	0	0.0
37982288	Maprotiline Prompts an Antitumour Effect by Inhibiting PD-L1 Expression in Mice with Melanoma.	Current molecular pharmacology	2024	-23.085713959399392	-25.760772329143705	0	0.0
37978401	Immunological and senescence biomarker profiles in patients after spontaneous clearance of hepatitis C virus: gender implications for long-term health risk.	Immunity & ageing : I & A	2023	-13.764790616855564	42.41053911293152	0	0.0
37977237	Non-linear modifications enhance prediction of pathological response to pre-operative PD-1 blockade in lung cancer: A longitudinal hybrid radiological model.	Pharmacological research	2023	11.393031441259437	-11.677635064084733	0	0.0
37974395	Engineering high-affinity dual targeting cellular nanovesicles for optimised cancer immunotherapy.	Journal of extracellular vesicles	2023	-36.13454498246295	-56.47417542993095	0	0.0
37974194	Circulating memory PD-1+CD8+ T cells and PD-1+CD8+T/PD-1+CD4+T cell ratio predict response and outcome to immunotherapy in advanced gastric cancer patients.	Cancer cell international	2023	-6.465798787240674	1.840717639907841	0	0.0
37973660	Targeting alternative splicing as a new cancer immunotherapy-phosphorylation of serine arginine-rich splicing factor (SRSF1) by SR protein kinase 1 (SRPK1) regulates alternative splicing of PD1 to generate a soluble antagonistic isoform that prevents T cell exhaustion.	Cancer immunology, immunotherapy : CII	2023	-13.081255347128277	-5.3240216621924	0	0.0
37971722	Nivolumab for Patients With High-Risk Oral Leukoplakia: A Nonrandomized Controlled Trial.	JAMA oncology	2023	54.18681609117963	10.288499014255548	0	0.0
37971626	Unraveling the genetic associations between PD-1/PD-L1 and 13 circulating biomarkers linked to physiological and pathological processes.	Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico	2023	-61.55554325397717	15.012135896320093	0	0.0
37971453	Efficacy and Safety of PD-1/PD-L1 Inhibitor and Chemotherapy in Treatment of Advanced Small Cell Lung Cancer.	Alternative therapies in health and medicine	2023	46.57073629094219	-41.299390125022434	0	0.0
37970206	Understanding the feasibility of chemotherapeutic and immunotherapeutic targets against non-small cell lung cancers: an update of resistant responses and recent combinatorial therapies.	Exploration of targeted anti-tumor therapy	2023	37.18784289191783	-36.00567973675572	0	0.0
37969256	Efficacy and safety of anti-programmed cell death protein 1 antibody combination therapy in patients with advanced experienced epidermal growth factor receptor-tyrosine kinase inhibitor-resistant lung adenocarcinoma: a retrospective cohort study.	Journal of thoracic disease	2023	47.63292366383903	-20.84481412656378	0	0.0
37968806	Immunotherapy and lung cytopathology: Overview and possibilities.	Cytopathology : official journal of the British Society for Clinical Cytology	2023	18.085807063226493	-39.849835437555534	0	0.0
37968047	Programmed cell death ligand 1 (PD-L1) expression in non-small cell lung cancer: Findings from a tertiary care institute in western part of India.	The Indian journal of tuberculosis	2023	12.583120837433931	-30.974495129285344	0	0.0
37964265	Expression of PD-1/PD-L1 axis in mediastinal lymph nodes and lung tissue of human and experimental lung fibrosis indicates a potential therapeutic target for idiopathic pulmonary fibrosis.	Respiratory research	2023	7.578549976062079	-24.895890400902207	0	0.0
37963566	The antipsychotic drug penfluridol inhibits N-linked glycoprotein processing and enhances T-cell-mediated tumor immunity.	Molecular cancer therapeutics	2023	-34.70616883017156	-32.759377974282394	0	0.0
37961361	In vivo quantification of programmed death-ligand-1 expression heterogeneity in tumors using fluorescence lifetime imaging.	Research square	2023	4.701630248280294	-53.830512083025205	0	0.0
37958404	CD47: The Next Frontier in Immune Checkpoint Blockade for Non-Small Cell Lung Cancer.	Cancers	2023	31.961920309334683	-28.77541845751391	0	0.0
37955535	Status of PD-1 and PD-L1 expression in invasive urothelial carcinoma of the bladder with mismatch repair protein deficiency.	Polish journal of pathology : official journal of the Polish Society of Pathologists	2023	12.799778567935606	59.09034829349504	0	0.0
37952972	Gene expression profiles associated with early relapse during first remission induction in canine multicentric high-grade B-cell lymphoma.	The Journal of veterinary medical science	2023	-26.88090256255091	30.73541584397953	0	0.0
37952913	New developments and standard of care in the management of advanced gastric cancer.	Clinics and research in hepatology and gastroenterology	2023	46.43633872919644	16.10320333044208	0	0.0
37946873	Pretreatment albumin is a prognostic and predictive biomarker for response to atezolizumab across solid tumors.	Clinical & translational immunology	2023	30.431079810211106	-43.40767203573459	0	0.0
37945764	Progress in systemic therapy for advanced-stage urothelial carcinoma.	Nature reviews. Clinical oncology	2023	69.54288396772098	17.573546250692786	0	0.0
37943489	Safflower Yellow Inhibits Progression of Hepatocellular Carcinoma by Modulating Immunological Tolerance via FAK Pathway.	Chinese journal of integrative medicine	2023	-17.6442899657904	-33.781284257776335	0	0.0
37942799	Systematic characterization of m6A proteomics across 12 cancer types: a multi-omics integration study.	Molecular omics	2023	-7.742454100421252	56.25089092776762	0	0.0
37941549	Acute low back pain as infusion-related reaction to monoclonal antibodies.	Frontiers in oncology	2023	70.70220466353382	-17.35474936094667	0	0.0
37939766	Recent progress, perspectives, and issues of engineered PD-L1 regulation nano-system to better cure tumor: A review.	International journal of biological macromolecules	2023	-32.47703251865209	-50.59940190227786	0	0.0
37939515	The blockage signal for PD-L1/CD274 gene variants and their potential impact on lung carcinoma susceptibility.	International immunopharmacology	2023	5.79507980354767	-14.34074207321581	0	0.0
37936161	Mechanisms and biomarkers of immune-related adverse events in gastric cancer.	European journal of medical research	2023	77.25365628203825	-10.593578259379694	0	0.0
37934397	Pulmonary Toxicity Associated with Immune Checkpoint Inhibitors-Based Therapy: Current Perspectives and Future Directions.	Drug safety	2023	69.35109645037366	-9.002904875812977	0	0.0
37933048	Expression of PD-1/PD-L1 in peripheral blood and tumor tissues of patients with classical Hodgkin's lymphoma.	Medicine	2023	-31.387824299102647	22.947846406572427	0	0.0
37932810	Immune checkpoint analysis in ear cancer.	Head & face medicine	2023	-4.297047351021517	-13.733709441080762	0	0.0
37931332	Pathogenicity of functionally activated PD-1+CD8+ cells and counterattacks by muscular PD-L1 through IFNγ in myositis.	Journal of autoimmunity	2023	-70.18089163265911	12.827311404963686	0	0.0
37930659	PDL1 and molecular biomarkers expression in non-small cell lung cancer in Tunisian patients.	Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace	2023	10.130031954998254	-31.00528717054397	0	0.0
37929188	The GSH responsive indocyanine green loaded PD-1 inhibitory polypeptide AUNP12 modified MOF nanoparticles for photothermal and immunotherapy of melanoma.	Frontiers in bioengineering and biotechnology	2023	-31.14675938487152	-54.39152872321558	0	0.0
37926852	Neoadjuvant PD-1/PD-L1 combined with CTLA-4 inhibitors for solid malignancies: a systematic review and meta-analysis.	World journal of surgical oncology	2023	50.27125648455405	-10.65758200072955	0	0.0
37926648	Relationships between intravoxel incoherent motion parameters and expressions of programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1) in patients with cervical cancer.	Clinical radiology	2023	15.035625886069756	-53.60101055111395	0	0.0
37926435	TIM-3 expression induces resistance to PD-1 inhibitor in G-CSF-producing lung spindle cell carcinoma: A case report.	Thoracic cancer	2023	4.898858453029674	-25.66222620043111	0	0.0
37925511	Novel PD-L1- and collagen-expressing patient-derived cell line of undifferentiated pleomorphic sarcoma (JBT19) as a model for cancer immunotherapy.	Scientific reports	2023	9.77388009389305	15.785725059256462	0	0.0
37924153	The prognostic value of a combined immune score in tumor and immune cells assessed by immunohistochemistry in triple-negative breast cancer.	Breast cancer research : BCR	2023	1.304916484406161	44.71292199012992	0	0.0
37923822	In vitro modelling of local gene therapy with IL-15/IL-15Rα and a PD-L1 antagonist in melanoma reveals an interplay between NK cells and CD4+ T cells.	Scientific reports	2023	-27.125456504329463	-1.1538911575577555	0	0.0
37920474	Comprehensive immune profiling reveals that Orbivirus infection activates immune checkpoints during acute T cell immunosuppression.	Frontiers in immunology	2023	-79.22861356772384	4.346113080937921	0	0.0
37914685	A2AR eGFP reporter mouse enables elucidation of A2AR expression dynamics during anti-tumor immune responses.	Nature communications	2023	-5.037802283636306	-49.22377553410807	0	0.0
37913682	Tumour-agnostic plasma assay for circulating tumour DNA predicts outcome in recurrent and/or metastatic squamous cell carcinoma of the head and neck treated with a PD-1 inhibitor.	European journal of cancer (Oxford, England : 1990)	2023	24.81029346783913	-12.33730655124462	0	0.0
37909316	Radix Bupleuri-Radix Paeoniae Alba Inhibits the Development of Hepatocellular Carcinoma through Activation of the PTEN/PD-L1 Axis within the Immune Microenvironment.	Nutrition and cancer	2023	-18.84122330176408	-35.08774372424397	0	0.0
37908728	Nanobody-mediated SPECT/CT imaging reveals the spatiotemporal expression of programmed death-ligand 1 in response to a CD8+ T cell and iNKT cell activating mRNA vaccine.	Theranostics	2023	5.147956944975743	-54.42623381886904	0	0.0
37908246	Hypothyroidism After Use of Immune Checkpoint Inhibitor Therapy in Patient With Graves' Disease: Cure?	JCEM case reports	2023	80.23251747081234	-15.7825168837413	0	0.0
37905387	The programed death-1/programed death ligand-1 axis and its potential as a therapeutic target for virus-associated tumours.	Reviews in medical virology	2023	-50.43230067474163	-18.493495735153484	0	0.0
37904615	PD-1 expression on tumour-infiltrating cells is a prognostic factor for relapsed or refractory diffuse large B-cell lymphoma.	Immunology	2023	-33.59905181421168	26.89799138762443	0	0.0
37902625	Site-Selective Functionalized PD-1 Mutant for a Modular Immunological Activity against Cancer Cells.	Biomacromolecules	2023	-43.32673853454399	-34.173427267704525	0	0.0
37901220	Single-cell mass cytometric analysis of peripheral immunity and multiplex plasma marker profiling of non-small cell lung cancer patients receiving PD-1 targeting immune checkpoint inhibitors in comparison with platinum-based chemotherapy.	Frontiers in immunology	2023	25.41410929988734	-30.364937082717848	0	0.0
37901032	Hyperprogression after anti-programmed death-1 therapy in a patient with urothelial bladder carcinoma: A case report.	World journal of clinical cases	2023	62.92619351953532	17.89395413803609	0	0.0
37900166	Case report: Remarkable response to sintilimab, lenvatinib, and nab-paclitaxel in postoperative metastatic chemotherapy-resistant combined hepatocellular-cholangiocarcinoma.	Frontiers in pharmacology	2023	55.63602877738078	21.585816274049	0	0.0
37897562	Metabolic interventions combined with CTLA-4 and PD-1/PD-L1 blockade for the treatment of tumors: mechanisms and strategies.	Frontiers of medicine	2023	28.73209262083213	14.876916948553534	0	0.0
37895958	Development and Preclinical Evaluation of [68Ga]BMSH as a New Potent Positron Emission Tomography Tracer for Imaging Programmed Death-Ligand 1 Expression.	Pharmaceuticals (Basel, Switzerland)	2023	5.250568689111519	-56.70535608133099	0	0.0
37894913	Expression of PD-1 and PD-L1 in Endometrial Cancer: Molecular and Clinical Significance.	International journal of molecular sciences	2023	-18.44653162404641	8.574044661166399	0	0.0
37894449	Ultra-Hypofractionated Re-Irradiation with Anti-PD-1 Immunotherapy for Locoregionally Recurrent (after Radical Chemo-Radiotherapy) Non-Small Cell Lung Cancer.	Cancers	2023	29.669040669558264	23.7319100777672	0	0.0
37894448	Immunogenic Biomarkers HMGB1 and sRAGE Are Potential Diagnostic Tools for Ovarian Malignancies.	Cancers	2023	-19.93034247244689	14.845808966110177	0	0.0
37894298	Immunotherapy Enhancement by Targeting Extracellular Tumor pH in Triple-Negative Breast Cancer Mouse Model.	Cancers	2023	-31.96061015806709	-42.95190084362908	0	0.0
37889617	Prediction of Prognosis and Immunotherapy Response with a Novel Natural Killer Cell Marker Genes Signature in Osteosarcoma.	Cancer biotherapy & radiopharmaceuticals	2023	-0.011881766739414	49.38681696599859	0	0.0
37889392	Clinical and molecular impact of concurrent thyroid autoimmune disease and thyroid cancer: From the bench to bedside.	Reviews in endocrine & metabolic disorders	2023	-62.07450741426102	10.850706269750102	0	0.0
37887902	Engineering Cell-Derived Nanovesicles for Targeted Immunomodulation.	Nanomaterials (Basel, Switzerland)	2023	-37.696382346581466	-58.71268643051006	0	0.0
37887283	Intratumoral Administration of High-Concentration Nitric Oxide and Anti-mPD-1 Treatment Improves Tumor Regression Rates and Survival in CT26 Tumor-Bearing Mice.	Cells	2023	32.09908767260792	-14.537567747924548	0	0.0
37886174	2-Year survival benefit from immunotherapy for squamous cell cancer with cancer of unknown primary in mediastinum: a case report.	Frontiers in oncology	2023	-4.331104286967734	-11.768094879747528	0	0.0
37885893	Case Report: Overcoming challenges in pancreatic cancer with liver metastases: a personalized therapeutic odyssey of TACE, ablation, and immunotherapy.	Frontiers in immunology	2023	-10.95095231974526	64.45742938273816	0	0.0
37885460	Efficacy and safety of first-line PD-1/PD-L1 inhibitor combinations for extensive-stage small-cell lung cancer: a Bayesian network meta-analysis.	Therapeutic advances in medical oncology	2023	47.635507446662615	-40.12322665585938	0	0.0
37884996	Canine diffuse large b-cell lymphoma downregulates the activity of CD8 + T-cells through tumor-derived extracellular vesicles.	Cancer cell international	2023	-39.839869824475706	-58.9350510214575	0	0.0
37881432	The nexus of dynamic T cell states and immune checkpoint blockade therapy in the periphery and tumor microenvironment.	Frontiers in immunology	2023	12.66792917029982	14.490236053670042	0	0.0
37881181	Musculoskeletal adverse events induced by immune checkpoint inhibitors: a large-scale pharmacovigilance study.	Frontiers in pharmacology	2023	84.95403779918688	-2.18691609652875	0	0.0
37880184	PD-1-expressing macrophages and CD8 T cells are independent predictors of clinical benefit from PD-1 inhibition in advanced mesothelioma.	Journal for immunotherapy of cancer	2023	6.5601539415785135	11.683561002003332	0	0.0
37877820	AIM2 fosters lung adenocarcinoma immune escape by modulating PD-L1 expression in tumor-associated macrophages via JAK/STAT3.	Human vaccines & immunotherapeutics	2023	14.301463456133057	-13.208067637827668	0	0.0
37877043	Overlapping Hepatotoxicity and Colitis Associated with Immune Checkpoint Inhibitors.	Journal of community hospital internal medicine perspectives	2023	75.67398528567281	-3.079235281522197	0	0.0
37876834	Spatial heterogeneity of T cell repertoire across NSCLC tumors, tumor edges, adjacent and distant lung tissues.	Oncoimmunology	2023	1.1638115627666883	19.39223023414191	0	0.0
37875785	Modern diagnostics and treatment of Merkel cell carcinoma.	Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG	2023	45.64818428632425	51.40320026705192	0	0.0
37875473	Tumor-repopulating cell-derived microparticles elicit cascade amplification of chemotherapy-induced antitumor immunity to boost anti-PD-1 therapy.	Signal transduction and targeted therapy	2023	-29.75591340068139	-51.77770483922095	0	0.0
37875143	Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial.	The Lancet. Oncology	2023	47.78535461159059	13.849545943740214	0	0.0
37874352	Standardized and quality-assured predictive PD-L1 testing in the upper gastrointestinal tract.	Journal of cancer research and clinical oncology	2023	18.703429307973582	-47.93270089101977	0	0.0
37872060	[Profile and immune environment of upper tract urothelial carcinoma].	Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie	2023	6.4833290313356216	60.913392039923146	0	0.0
37871604	Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial.	Lancet (London, England)	2023	47.722266845011625	13.978032276992554	0	0.0
37871574	Tissue-infiltrating Alloreactive T Cells Require Id3 to Deflect PD-1-mediated Immune Suppression during GVHD.	Blood	2023	-65.72424481143757	-4.211226028710216	0	0.0
37870920	Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma.	The New England journal of medicine	2023	68.15531252453589	15.231858138978764	0	0.0
37870169	Inhibition of CK2/ING4 Pathway Facilitates Non-Small Cell Lung Cancer Immunotherapy.	Advanced science (Weinheim, Baden-Wurttemberg, Germany)	2023	-3.4411643369801257	-25.906738757905728	0	0.0
37866747	Mechanisms of the PD-1/PD-L1 pathway in itch: From acute itch model establishment to the role in chronic itch in mouse.	European journal of pharmacology	2023	-72.54981111532986	-13.430735504635171	0	0.0
37866745	Develop a PD-1-blockade peptide to reinvigorate T-cell activity and inhibit tumor progress.	European journal of pharmacology	2023	-42.08726112529753	-44.33996760294085	0	0.0
37866544	LINC00926 promotes progression of renal cell carcinoma via regulating miR-30a-5p/SOX4 axis and activating IFNγ-JAK2-STAT1 pathway.	Cancer letters	2023	-6.20216621760418	54.145734082265605	0	0.0
37865914	Targeting VCP potentiates immune checkpoint therapy for colorectal cancer.	Cell reports	2023	33.757012185541285	21.5654346558665	0	0.0
37865395	Classification of the tumor immune microenvironment and associations with outcomes in patients with metastatic melanoma treated with immunotherapies.	Journal for immunotherapy of cancer	2023	4.326702943180453	16.849454892947357	0	0.0
37864726	Fibroblast growth factor inhibition by molecular-targeted agents mitigates immunosuppressive tissue microenvironment in hepatocellular carcinoma.	Hepatology international	2023	27.201469870560818	52.00637537477442	0	0.0
37864420	Efficacy and safety of tislelizumab for malignant solid tumor: a systematic review and meta-analysis of phase III randomized trials.	Expert review of clinical pharmacology	2023	56.861421446045725	-23.11497729485239	0	0.0
37862939	GSDME has prognostic and immunotherapeutic significance in residual hepatocellular carcinoma after insufficient radiofrequency ablation.	Translational oncology	2024	-20.26044176586247	44.59636109121824	0	0.0
37862871	Mogroside V ameliorates broiler pulmonary inflammation via modulating lung microbiota and rectifying Th17/Treg dysregulation in lipopolysaccharides-induced lung injury.	Poultry science	2023	-63.66062259677563	33.66072796730662	0	0.0
37862114	Comprehensive analysis of integrin αvβ3/α6β1 in prognosis and immune escape of prostate cancer.	Aging	2023	-4.023094376180763	41.40689619583187	0	0.0
37861545	Do patients receive any benefit from the addition of perioperative immunotherapy-chemotherapy for solid tumors?	Medicine	2023	42.27758827418695	9.700046712747035	0	0.0
37859326	Development of a Functional Nanobody Targeting Programmed Cell Death Protein-1 as Immune Checkpoint Inhibitor.	Current pharmaceutical design	2023	-37.821796699954334	-47.41964150095511	0	0.0
37858677	Identification of the functional PD-L1 interface region responsible for PD-1 binding and initiation of PD-1 signaling.	The Journal of biological chemistry	2023	-44.12765244166838	-41.86134400595272	0	0.0
37857711	The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial.	Nature medicine	2023	52.23769184137433	-5.24025292422576	0	0.0
37857598	Anti-PD-1 antibody armored γδ T cells enhance anti-tumor efficacy in ovarian cancer.	Signal transduction and targeted therapy	2023	-36.73664465180443	3.377499708409406	0	0.0
37857525	Identification of tumor-intrinsic drivers of immune exclusion in acral melanoma.	Journal for immunotherapy of cancer	2023	3.0992309341052637	17.536866923002894	0	0.0
37856075	FAP is a prognostic marker, but not a viable therapeutic target for clinical translation in HNSCC.	Cellular oncology (Dordrecht)	2023	1.6689909525012088	34.31770513689769	0	0.0
37854154	The differential prognostic implications of PD-L1 expression in the outcomes of Filipinos with EGFR-mutant NSCLC treated with tyrosine kinase inhibitors.	Translational lung cancer research	2023	8.776879503815472	-32.04716825276168	0	0.0
37851072	A multi-cohort phase 1b trial of rituximab in combination with immunotherapy doublets in relapsed/refractory follicular lymphoma.	Annals of hematology	2023	55.241327636510526	29.09560237509437	0	0.0
37851052	Characterization of immunosuppressive myeloid cells in Merkel cell carcinoma: correlation with resistance to PD-1 pathway blockade.	Clinical cancer research : an official journal of the American Association for Cancer Research	2023	43.246283639521394	52.230230927877095	0	0.0
37849747	A cyclic peptide-based PROTAC induces intracellular degradation of palmitoyltransferase and potently decreases PD-L1 expression in human cervical cancer cells.	Frontiers in immunology	2023	-45.99134560981837	-45.093008708710535	0	0.0
37848996	The effect of PD-1/PD-L1 signaling axis on the interaction between CD19+B cells and CD4+T cells in peripheral blood of patients with systemic lupus erythematosus.	Advances in rheumatology (London, England)	2023	-53.68933180008498	10.731842967013243	0	0.0
37848682	Functional enhancement of mesothelin-targeted TRuC-T cells by a PD1-CD28 chimeric switch receptor.	Cancer immunology, immunotherapy : CII	2023	-41.77376819565828	1.3832987118392832	0	0.0
37848259	Efficacy and safety of cosibelimab, an anti-PD-L1 antibody, in metastatic cutaneous squamous cell carcinoma.	Journal for immunotherapy of cancer	2023	55.85951486341723	5.6385075314455575	0	0.0
37847894	Effective Antitumor Immunity Can Be Triggered by Targeting VISTA in Combination with a TLR3-Specific Adjuvant.	Cancer immunology research	2023	-38.75349659031129	38.5400924495008	0	0.0
37847301	Bis-indole-derived NR4A1 antagonists inhibit colon tumor and splenic growth and T-cell exhaustion.	Cancer immunology, immunotherapy : CII	2023	-26.48117142369416	-27.44427320711393	0	0.0
37845557	Immune Checkpoint Inhibitor-Induced (Type 3) Autoimmune Pancreatitis.	Current gastroenterology reports	2023	85.38312998119	-12.117961614056943	0	0.0
37844479	The co-inhibitory immune checkpoint proteins B7-H1(PD-L1) and B7-H4 in high grade glioma: From bench to bedside.	Translational oncology	2024	-28.89731400359968	59.7308780327316	0	0.0
37844355	Enhanced antitumor efficacy, proliferative capacity, and alleviation of T cell exhaustion by fifth-generation chimeric antigen receptor T cells targeting B cell maturation antigen in multiple myeloma.	Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie	2023	-42.43294402120056	5.857785882465638	0	0.0
37844209	PD-L1-Expressing Extracellular Vesicles for the Treatment of Pneumonia.	ACS biomaterials science & engineering	2023	-56.27087582007241	24.162372866749536	0	0.0
37844197	Tumor-Reactive CD8+ T Cells Enter a TCF1+PD-1- Dysfunctional State.	Cancer immunology research	2023	-26.7039628568152	41.92607727323077	0	0.0
37842091	ICOSLG-associated immunological landscape and diagnostic value in oral squamous cell carcinoma: a prospective cohort study.	Frontiers in cell and developmental biology	2023	4.128885294807086	35.99416700456166	0	0.0
37841435	PD-1/PD-L1 inhibitor treatment and its impact on clinical imaging in non-small cell lung cancer: a systematic review and meta-analysis of immune-related adverse events.	Frontiers in oncology	2023	72.86554477510694	-12.272550619997537	0	0.0
37841432	Arthralgia adverse events due to immune-checkpoint inhibitors for lung cancer patients: a systematic review and meta-analysis.	Frontiers in oncology	2023	63.31964572160639	-14.775889581327348	0	0.0
37841258	A novel [89Zr]-anti-PD-1-PET-CT to assess response to PD-1/PD-L1 blockade in lung cancer.	Frontiers in immunology	2023	7.359667435352557	-56.60478892654509	0	0.0
37839181	Immunotherapy in combination with chemotherapy vs. immunotherapy alone for advanced non-small cell lung cancer and programmed death ligand 1 score <50.	Cancer treatment and research communications	2023	46.32593738964622	-18.089573965992063	0	0.0
37835580	Current and Emerging Strategies to Treat Urothelial Carcinoma.	Cancers	2023	71.11016180357844	19.18758143412456	0	0.0
37831146	PD-1 and PD-L1 inhibitors in cold colorectal cancer: challenges and strategies.	Cancer immunology, immunotherapy : CII	2023	35.57282738384896	24.0329991895209	0	0.0
37830603	Morphological and Immunocytochemical Characterization of Tumor Spheroids in Ascites from High-Grade Serous Carcinoma.	Cells	2023	3.862755743821882	29.943757077188884	0	0.0
37828609	Astrocyte interferon-gamma signaling dampens inflammation during chronic central nervous system autoimmunity via PD-L1.	Journal of neuroinflammation	2023	-75.64837316963678	-4.9549204891203225	0	0.0
37828434	Association of Radiochemotherapy to Immunotherapy in unresectable locally advanced Oesophageal carciNoma-randomized phase 2 trial ARION UCGI 33/PRODIGE 67: the study protocol.	BMC cancer	2023	54.8909781793021	13.985990345346838	0	0.0
37827123	The balance of CD8-positive T cells and PD-L1 expression in the myocardium predicts prognosis in lymphocytic fulminant myocarditis.	Cardiology	2023	-25.306022543102436	22.214509487835368	0	0.0
37826990	Harnessing the druggability at orthosteric and allosteric sites of PD-1 for small molecule discovery by an integrated in silico pipeline.	Computational biology and chemistry	2023	-47.73017290355442	-41.904174564232896	0	0.0
37822924	Progress of research on PD-1/PD-L1 in leukemia.	Frontiers in immunology	2023	-40.12914267958959	-7.162510827683537	0	0.0
37822876	Exosomes released from PD-L1+ tumor associated macrophages promote peritoneal metastasis of epithelial ovarian cancer by up-regulating T cell lipid metabolism.	Biochemistry and biophysics reports	2023	-25.83107399746695	4.27574530906846	0	0.0
37820857	Sex-oriented perspectives in immunopharmacology.	Pharmacological research	2023	-50.97013891096852	-15.311994629294444	0	0.0
37820473	Charting new frontiers: Co-inhibitory immune checkpoint proteins in therapeutics, biomarkers, and drug delivery systems in cancer care.	Translational oncology	2023	28.759869144320643	12.234764846959504	0	0.0
37818135	Discontinuation of anti‑programmed cell death protein 1 immune checkpoint inhibition after complete remission in head and neck squamous cell carcinoma: A case report and literature review.	Oncology letters	2023	56.05041457582859	30.97690195672138	0	0.0
37814950	Efficacy and safety of immune checkpoint inhibitors in recurrent or metastatic head and neck squamous cell carcinoma: A systematic review and meta-analysis of randomized clinical trials.	Cancer medicine	2023	49.68568932816249	32.55600371885059	0	0.0
37813891	A BRCA2 germline mutation and high expression of immune checkpoints in a TNBC patient.	Cell death discovery	2023	7.508007009950112	30.404835652551405	0	0.0
37809208	Pembrolizumab-Induced Myasthenia Gravis and Peripheral Neuropathy: A Case Series.	Cureus	2023	74.1645958605678	-16.247698898074745	0	0.0
37809094	Inflammation-mediated fibroblast activation and immune dysregulation in collagen VII-deficient skin.	Frontiers in immunology	2023	-0.1023872107578062	35.09928756947848	0	0.0
37806516	LW-213 induces immunogenic tumor cell death via ER stress mediated by lysosomal TRPML1.	Cancer letters	2023	-25.355027274336702	-34.385939581798795	0	0.0
37805922	Upregulation of exosome secretion from tumor-associated macrophages plays a key role in the suppression of anti-tumor immunity.	Cell reports	2023	-46.09411326234579	-58.40119933293789	0	0.0
37805869	THE ROLE GENE EXPRESSION OF PD-1 AND PD-L1 IN NEWELY DIAGNOSED AND TREATED PATIENTS WITH ACUTE MYELOID LEUKEMIA.	Georgian medical news	2023	-35.81373757297568	16.78313868878759	0	0.0
37805094	Combining local cryoablation with PD-L1 blockade synergistically eradicates established murine lung cancer by modulating mitochondrial in PD-1+CD8+ T cell.	Immunology letters	2023	-24.558630564921422	-39.93751427065956	0	0.0
37804657	Anti-PD-L1 × anti-CD3 bispecific T-cell engager-armed T cells can overcome immunosuppression and redirect T cells to kill breast cancer cells expressing PD-L1.	International immunopharmacology	2023	-40.719925969084485	10.227343143264436	0	0.0
37802608	Short-course radiotherapy combined with chemotherapy and PD-1 inhibitor in low-lying early rectal cancer: study protocol for a single-arm, multicentre, prospective, phase II trial (TORCH-E).	BMJ open	2023	46.44680347156783	10.1932920034135	0	0.0
37802025	Targeting LYPLAL1-mediated cGAS depalmitoylation enhances the response to anti-tumor immunotherapy.	Molecular cell	2023	-24.092073577756743	-43.66622779752055	0	0.0
37801695	Focus on Immune Checkpoint Inhibitors-related Intestinal Inflammation: From Pathogenesis to Therapeutical Approach.	Inflammatory bowel diseases	2023	76.01995382410524	-4.1931515982198295	0	0.0
37801207	Optimal Therapeutic Strategy for PD-L1 Negative Metastatic Non-Small Cell Lung Cancer: A Decision-Making Guide Based on Clinicopathological and Molecular Features.	Current treatment options in oncology	2023	36.18271548010427	-25.399181116717926	0	0.0
37797632	Safety and antitumour activity of cadonilimab, an anti-PD-1/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b/2 trial.	The Lancet. Oncology	2023	45.174447934365226	-0.953245096191546	0	0.0
37796835	Interplay between inflammasomes and PD-1/PD-L1 and their implications in cancer immunotherapy.	Carcinogenesis	2023	-32.8675855303021	-8.458618996842034	0	0.0
37796477	TCR ligand potency differentially impacts PD-1 inhibitory effects on diverse signaling pathways.	The Journal of experimental medicine	2023	-47.59497621667104	-7.081601997180624	0	0.0
37796282	The sound and surprise: overlapping meta-analyses on the topic of safety and efficacy of PD-1 and PD-L1 inhibitors in the treatment of non-small cell lung cancer.	European journal of clinical pharmacology	2023	48.7257850028253	-18.38223980456545	0	0.0
37794819	Use of PD-1 blockade in refractory/relapsed natural killer T-cell lymphomas: a systematic review and synthesis of case reports.	Leukemia & lymphoma	2023	45.662110916550034	-4.6929807911757	0	0.0
37794698	Interactions of Indoleamine 2,3-dioxygenase-expressing LAMP3+ dendritic cells with CD4+ regulatory T cells and CD8+ exhausted T cells: synergistically remodeling of the immunosuppressive microenvironment in cervical cancer and therapeutic implications.	Cancer communications (London, England)	2023	-3.493422993248516	37.21701985463333	0	0.0
37793856	Non-invasive PD-L1 quantification using [18F]DK222-PET imaging in cancer immunotherapy.	Journal for immunotherapy of cancer	2023	6.786418768280937	-56.132583486312924	0	0.0
37793852	PD-1 blockade in combination with dasatinib potentiates induction of anti-acute lymphocytic leukemia immunity.	Journal for immunotherapy of cancer	2023	-38.79283591418778	11.346554122767362	0	0.0
37793811	Prognostic Significance of Soluble PD-L1 on Cardiovascular Outcomes in Patients with Coronary Artery Disease.	Journal of atherosclerosis and thrombosis	2023	-46.95289856280404	23.732004568664088	0	0.0
37792142	Immunotherapy Guided by Immunohistochemistry PD-L1 Testing for Patients with NSCLC: A Microsimulation Model-Based Effectiveness and Cost-Effectiveness Analysis.	BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy	2023	18.268871493510243	-37.7354397264115	0	0.0
37787808	Lysates from the probiotic bacterium Streptococcus thermophilus enhances the survival of T cells and triggers programmed cell death in neuroblastoma cells.	Medical oncology (Northwood, London, England)	2023	-24.056427925977243	1.2077632622147672	0	0.0
37787790	Real-world cohort study of PD-1 blockade plus lenvatinib for advanced intrahepatic cholangiocarcinoma: effectiveness, safety, and biomarker analysis.	Cancer immunology, immunotherapy : CII	2023	55.2515303164795	21.389193837865506	0	0.0
37783677	A primary luminal/HER2 negative breast cancer patient with mismatch repair deficiency.	Cell death discovery	2023	11.238641827508603	45.47404535852876	0	0.0
37781487	The Effect of Secreted IL-10 from Mesenchymal Stem Cell on Immune Checkpoint Molecules.	Acta informatica medica : AIM : journal of the Society for Medical Informatics of Bosnia & Herzegovina : casopis Drustva za medicinsku informatiku BiH	2023	-57.84551773375241	31.792755311245823	0	
37781078	Comprehensive analysis of prognostic value and immune infiltration of IAPs family in hepatocellular carcinoma.	Journal of Cancer	2023	-11.14313384463964	48.24925633027946	0	
37777635	A multitier virtual screening of antagonists targeting PD-1/PD-L1 interface for the management of triple-negative breast cancer.	Medical oncology (Northwood, London, England)	2023	-40.39847994425199	-40.313314054404906	0	
37773572	Dynamics of Soluble Forms of the Immune Checkpoint Components PD-1/PD-L1/B7-H3, CD314/ULBP1, and HLA-G in Peripheral Blood of Melanoma Patients Receiving Blockers of Programmed Cell Death Protein PD-1.	Bulletin of experimental biology and medicine	2023	8.040556167371065	6.135006498474098	0	
37772613	Programmed cell death ligand 1 expression associated with subtypes of post-transplant lymphoproliferative disorder among pediatric kidney transplant recipients.	Clinical transplantation	2023	-32.276058040328806	20.25433825774752	0	
37771939	Noncoding RNA-Mediated High Expression of PFKFB3 Correlates with Poor Prognosis and Tumor Immune Infiltration of Lung Adenocarcinoma.	OncoTargets and therapy	2023	-3.021077348401556	56.16055789695272	0	
37769390	The therapeutic potential of PD-1/PD-L1 pathway on immune-related diseases: Based on the innate and adaptive immune components.	Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie	2023	-48.297837351758695	-12.168045806713907	0	
37768345	An alternatively spliced PD-L1 isoform PD-L1∆3, and PD-L2 expression in breast cancers: implications for eligibility scoring and immunotherapy response.	Cancer immunology, immunotherapy : CII	2023	-8.224963895094323	14.372481035045505	0	
37766594	Deficiency of SR-B1 reduced the tumor load of colitis-induced or APCmin /+ -induced colorectal cancer.	Cancer medicine	2023	3.775479327040376	39.636559624804335	0	
37766150	PD-L1 Is Involved in the Development of Non-Hodgkin's Lymphoma by Mediating Circulating Lymphocyte Apoptosis.	Vaccines	2023	-35.71028534984972	23.034519683012338	0	
37764924	Can sPD-1 and sPD-L1 Plasma Concentrations Predict Treatment Response among Patients with Extraparenchymal Neurocysticercosis?	Pathogens (Basel, Switzerland)	2023	-44.14060967375769	22.663994972259346	0	
37760923	Change in Splenic Volume as a Surrogate Marker for Immunotherapy Response in Patients with Advanced Urothelial and Renal Cell Carcinoma-Evaluation of a Novel Approach of Fully Automated Artificial Intelligence Based Splenic Segmentation.	Biomedicines	2023	11.152626906769653	-9.976202094218532	0	
37760602	Immune Checkpoint Inhibitors Targeting the PD-1/PD-L1 Pathway in Advanced, Recurrent Endometrial Cancer: A Scoping Review with SWOT Analysis.	Cancers	2023	40.46994595879468	34.16924742243531	0	
37760531	A Review of Biomarkers and Their Clinical Impact in Resected Early-Stage Non-Small-Cell Lung Cancer.	Cancers	2023	15.789039189849158	-27.77451339755314	0	
37760457	The Association between Immune Checkpoint Proteins and Therapy Outcomes in Acute Myeloid Leukaemia Patients.	Cancers	2023	18.771425045690865	17.968948514252208	0	
37760436	Increased Response to Immune Checkpoint Inhibitors with Dietary Methionine Restriction in a Colorectal Cancer Model.	Cancers	2023	-19.701982951728976	-31.763434603378148	0	
37759777	Recent Advances in Perioperative Immunotherapies in Lung Cancer.	Biomolecules	2023	32.032920738101865	-22.51815669248116	0	
37759311	Development of a high-affinity anti-bovine PD-1 rabbit-bovine chimeric antibody using an efficient selection and large production system.	Veterinary research	2023	-58.73039198078988	-27.350931096590035	0	
37759291	Circulating extracellular vesicles are monitoring biomarkers of anti-PD1 response and enhancer of tumor progression and immunosuppression in metastatic melanoma.	Journal of experimental & clinical cancer research : CR	2023	1.0768339245045573	-40.360819587551774	0	
37759229	Establishment and validation of an immune infiltration predictive model for ovarian cancer.	BMC medical genomics	2023	4.321674620300215	46.15779233057173	0	
37758653	RIG-I promotes immune evasion of colon cancer by modulating PD-L1 ubiquitination.	Journal for immunotherapy of cancer	2023	-19.534091086856822	-6.142352383653011	0	
37756307	The distribution of myeloid-derived suppressor cells subsets and up-regulation of programmed death-1/PD-L1 axis in peripheral blood of adult CAP patients.	PloS one	2023	-51.7426977466933	27.590150857203454	0	
37754265	Safety and Efficacy of Neoadjuvant Chemoimmunotherapy in Gastric Cancer Patients with a PD-L1 Positive Status: A Case Report.	Current issues in molecular biology	2023	47.66438615874006	11.948293724780468	0	
37753089	The prognostic biological markers of immunotherapy for non-small cell lung cancer: current landscape and future perspective.	Frontiers in immunology	2023	21.427313528542825	-32.491232993945964	0	
37753076	PD-1 blockade and radiotherapy combination for advanced Epstein-Barr virus-associated intrahepatic cholangiocarcinoma: a case report and literature review.	Frontiers in immunology	2023	55.81302686774162	22.84252275479509	0	
37752094	Development and validation of a risk-prediction model for immune-related adverse events in patients with non-small-cell lung cancer receiving PD-1/PD-L1 inhibitors.	Journal of Zhejiang University. Science. B	2023	73.4030356830404	-11.659286309925436	0	
37749638	CHSY1 promotes CD8+ T cell exhaustion through activation of succinate metabolism pathway leading to colorectal cancer liver metastasis based on CRISPR/Cas9 screening.	Journal of experimental & clinical cancer research : CR	2023	2.540316539197517	38.73856311105639	0	
37749237	Rosmarinic acid in combination with ginsenoside Rg1 suppresses colon cancer metastasis via co-inhition of COX-2 and PD1/PD-L1 signaling axis.	Acta pharmacologica Sinica	2023	-22.683972998444357	-33.12484440316393	0	
37748935	Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: Analysis of Number Needed To Treat and Number Needed To Harm.	Clinical therapeutics	2023	49.04739131661383	14.00404862160896	0	
37747062	Progress in immune checkpoint inhibition in early-stage triple-negative breast cancer.	Expert review of anticancer therapy	2023	40.50980663721503	9.201919458567042	0	
37746718	Expansion of Pathogenic Cardiac Macrophages in Immune Checkpoint Inhibitor Myocarditis.	Circulation	2023	85.6511611133058	3.1156925651871403	0	
37745839	Role of immunotherapy in chondrosarcoma: A case report and review of the literature.	Therapeutic advances in medical oncology	2023	35.74808469809621	13.73215298594526	0	
37745414	PD-1 Mediated Regulation of Unique Activated CD8 + T Cells by NK Cells in the Submandibular Gland.	bioRxiv : the preprint server for biology	2023	-64.16024037986551	3.006301906797501	0	
37738123	Engineering of dendritic cell bispecific extracellular vesicles for tumor-targeting immunotherapy.	Cell reports	2023	-37.503451317981	-58.30967717198477	0	
37737264	Regulation of human and mouse bystander T cell activation responses by PD-1.	JCI insight	2023	-54.70238927090075	-4.1267420454848684	0	
37736550	ExoPD-L1: an assistant for tumor progression and potential diagnostic marker.	Frontiers in oncology	2023	-43.34978543961148	-58.41203975701748	0	
37733002	Spatial proteomics of immune microenvironment in nonalcoholic steatohepatitis-associated hepatocellular carcinoma.	Hepatology (Baltimore, Md.)	2023	-12.369776820250728	43.8807439973703	0	
37731383	Down-regulation of interleukin-2 predicts poor prognosis and associated with immune escape in lung adenocarcinoma.	International journal of immunopathology and pharmacology	2023	15.520732539438448	-13.9792362810556	0	
37728572	Combination of downregulating FEN1 and PD-1 blockade enhances antitumor activity of CD8+ T cells against HNSCC cells in vitro.	Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology	2023	-8.849916780193727	-7.713995327256469	0	
37723150	Intracellular Fusobacterium nucleatum infection attenuates antitumor immunity in esophageal squamous cell carcinoma.	Nature communications	2023	18.100313686757364	41.41254497089387	0	
37722965	Human placenta-derived mesenchymal stem cells ameliorate diabetic kidney disease by modulating the T helper 17 cell/ regulatory T-cell balance through the programmed death 1 / programmed death-ligand 1 pathway.	Diabetes, obesity & metabolism	2024	-55.31474925288621	20.527456547922355	0	
37720351	Retrospective immunophenotypical evaluation of MET, PD-1/PD-L1, and mTOR pathways in primary tumors and pulmonary metastases of renal cell carcinoma: the RIVELATOR study addresses the issue of biomarkers heterogeneity.	Exploration of targeted anti-tumor therapy	2023	13.687684689524051	26.12400961825163	0	
37718766	Reversing T Cell Exhaustion by Converting Membrane PD-1 to Its Soluble form in Jurkat Cells; Applying The CRISPR/Cas9 Exon Skipping Strategy.	Cell journal	2023	-44.02879317349728	0.7993935648782559	0	
37716115	Cancer cell-intrinsic PD-1: Its role in malignant progression and immunotherapy.	Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie	2023	-36.78627836654732	-12.506409002010148	0	
37715724	PD-L1 and PD-1 expression in pediatric post-transplant Burkitt lymphoma and other monomorphic post-transplant lymphoproliferative disorders.	Pediatric blood & cancer	2023	-32.33560499172002	20.42597505124528	0	
37715690	Transforming growth factor-β, Interleukin-23 and interleukin-1β modulate TH22 response during active multidrug-resistant tuberculosis.	Immunology	2024	-86.06662657244317	0.8472242997620199	0	
37713790	Constructing heterogeneous single-cell landscape and identifying microenvironment molecular characteristics of primary and lymphatic metastatic head and neck squamous cell carcinoma.	Computers in biology and medicine	2023	-8.882826765377436	35.43649845465014	0	
37712124	Long noncoding RNA Regulating ImMune Escape regulates mixed lineage leukaemia protein-1-H3K4me3-mediated immune escape in oesophageal squamous cell carcinoma.	Clinical and translational medicine	2023	-5.499330218262112	53.39476616305049	0	
37708707	Attenuated Salmonella-delivered PD-1 siRNA enhances the antitumor effects of EZH2 inhibitors in colorectal cancer.	International immunopharmacology	2023	-12.514399250388514	-28.736203539503755	0	
37705322	Design, Synthesis, and Activity Evaluation of Novel Dual-Target Inhibitors with Antifungal and Immunoregulatory Properties.	Journal of medicinal chemistry	2023	-39.46900710854375	-42.34648154767937	0	
37703867	Immunotherapy for GTN: a new paradigm.	Gynecologic and obstetric investigation	2023	44.16195735593447	39.97543845334713	0	
37699402	Immune-Checkpoint Inhibitor-Related Myocarditis: Where We Are and Where We Will Go.	Angiology	2023	84.48990983816002	1.795585635554386	0	
37697956	CD8+ T cell infiltration and proliferation in the brainstem during experimental cerebral malaria.	CNS neuroscience & therapeutics	2023	-76.11231161467133	-2.780324745247921	0	
37696903	High risk clear cell renal cell carcinoma microenvironments contain protumour immunophenotypes lacking specific immune checkpoints.	NPJ precision oncology	2023	15.729295784440492	33.047434306137305	0	
37696888	A magneto-activated nanoscale cytometry platform for molecular profiling of small extracellular vesicles.	Nature communications	2023	-42.92391659396503	-56.765284256766655	0	
37695569	Acquired bleeding disorders secondary to immune checkpoint inhibitors: a case report and systematic literature review.	Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis	2023	70.86870123037257	-10.509624038381489	0	
37692949	Raloxifene, a SERM targets PD-L1: an in-silico study.	American journal of translational research	2023	-36.99169937905194	-39.57767808131387	0	
37691941	CXCR5 and TIM-3 expressions define distinct exhausted T cell subsets in experimental cutaneous infection with Leishmania mexicana.	Frontiers in immunology	2023	-72.97039414492727	4.876831167475646	0	
37691915	Combining PD-1/PD-L1 blockade with type I interferon in cancer therapy.	Frontiers in immunology	2023	-21.451720961488924	-19.38923344996497	0	
37690647	Design and evaluation of α-helix-based peptide inhibitors for blocking PD-1/PD-L1 interaction.	International journal of biological macromolecules	2023	-43.34162379819156	-44.08625611734384	0	
37690432	KSCBi005-A-8(hiPSC-PD-L1KO), a PD-L1 knockout human induced pluripotent stem cell line for demonstrating the role of the PD-1/PD-L1 axis.	Stem cell research	2023	-48.45710476814793	-18.464318195177245	0	
37689786	PD-L1 positive astrocytes attenuate inflammatory functions of PD-1 positive microglia in models of autoimmune neuroinflammation.	Nature communications	2023	-75.93313697912151	-4.920086023742897	0	
37689039	Clinicopathological and prognostic significance of PD-L1 expression in colon adenocarcinoma tumor budding.	Annals of diagnostic pathology	2023	-4.478844525520041	12.105702467332268	0	
37688463	Elevated programmed cell death-1 protein/ligand (PD-1/PD-L1) and variants are associated with susceptibility to multiple myeloma: a case-control study in the Chinese cohort.	Nucleosides, nucleotides & nucleic acids	2023	-32.434350494287706	11.16794846829568	0	
37686533	Vascular Immune Evasion of Mesenchymal Glioblastoma Is Mediated by Interaction and Regulation of VE-Cadherin on PD-L1.	Cancers	2023	-28.09416177857591	52.86651636746206	0	
37686291	A Case of Curative Treatment with Apatinib and Camrelizumab Following Liver Resection for Advanced Hepatocellular Carcinoma.	International journal of molecular sciences	2023	31.312532618926983	52.5543597624857	0	
37685714	The Possible Clinical Significance of a Decreased Serum Level of Soluble PD-L1 in Discoid Lupus Erythematosus, but Not in Subacute Cutaneous Lupus Erythematosus-A Pilot Study.	Journal of clinical medicine	2023	-48.59759427540463	21.50831437743864	0	
37681488	Anti‑PD‑1/PD‑L1 and anti‑CTLA‑4 associated checkpoint inhibitor pneumonitis in non‑small cell lung cancer: Occurrence, pathogenesis and risk factors (Review).	International journal of oncology	2023	66.76359218378894	-8.806469410094863	0	
37680007	Inhibitory checkpoint molecule mRNA expression in canine soft tissue sarcoma.	Veterinary and comparative oncology	2023	-15.24216343853868	-12.533008496627314	0	
37679051	TSC2 inactivation, low mutation burden and high macrophage infiltration characterise hepatic angiomyolipomas.	Histopathology	2023	8.010934537251376	49.44964795428695	0	
37675710	An overview of current advances of PD-L1 targeting immuno-imaging in cancers.	Journal of cancer research and therapeutics	2023	6.20995808569494	-53.813145243068	0	
37675321	Developments in targeted therapy & immunotherapy-how non-small cell lung cancer management will change in the next decade: a narrative review.	Annals of translational medicine	2023	36.14449110012848	-34.9778971009627	0	
37673631	[Hematological immune-related adverse events of immune checkpoint inhibitors and their management].	[Rinsho ketsueki] The Japanese journal of clinical hematology	2023	80.10520639934064	-8.943462713829797	0	
37671597	Decreased serum soluble programmed cell death ligand-1 level as a potential biomarker for missed miscarriage.	Human reproduction (Oxford, England)	2023	-74.44146023855102	-20.95824601900973	0	
37671167	Role of ICAM1 in tumor immunity and prognosis of triple-negative breast cancer.	Frontiers in immunology	2023	2.4122025278328505	42.51437472690389	0	
37670038	USP2 promotes tumor immune evasion via deubiquitination and stabilization of PD-L1.	Cell death and differentiation	2023	-18.10368667043985	-6.253175490694577	0	
37667784	Programmed Cell Death Protein 1 (PD-1) and Programmed Cell Death Ligand 1 (PD-L1) Immunotherapy: A Promising Breakthrough in Cancer Therapeutics.	Cureus	2023	-42.70393235534827	-17.122613622607364	0	
37667781	Exceptional response to cetuximab monotherapy after failure of immunotherapy with a checkpoint inhibitor in a patient with metastatic head and neck squamous cell cancer: case report and review of the literature.	Therapeutic advances in medical oncology	2023	54.65665237409912	29.85960981202193	0	
37667169	Evaluation of ITGB1 expression as a predictor of the therapeutic effects of immune checkpoint inhibitors in gastric cancer.	BMC gastroenterology	2023	-7.565875975915388	6.652447267974882	0	
37667098	Heterogeneity and Adjuvant Therapeutic Approaches in MSI-H/dMMR Resectable Gastric Cancer: Emerging Trends in Immunotherapy.	Annals of surgical oncology	2023	12.591283649846332	43.72073970235168	2	
37665572	CXCL8 induces M2 macrophage polarization and inhibits CD8+ T cell infiltration to generate an immunosuppressive microenvironment in colorectal cancer.	FASEB journal : official publication of the Federation of American Societies for Experimental Biology	2023	3.4210142325084503	38.07552340166287	0	
37663758	NUP62CL as an Immunological and Prognostic Biomarker of Oral Squamous Cell Carcinoma.	Journal of inflammation research	2023	-7.163724340088307	-14.328039994236782	0	
37661910	PD-1, PD-L1, IDO, CD70 and microsatellite instability as potential targets to prevent immune evasion in sarcomas.	Immunotherapy	2023	-19.251820872142822	20.02930699825907	0	
37658906	Radiation-associated secondary malignancies: a novel opportunity for applying immunotherapies.	Cancer immunology, immunotherapy : CII	2023	27.818168746820284	20.9147386331968	0	
37657175	Dendritic polymer-functionalized nanomedicine potentiates immunotherapy via lethal energy crisis-induced PD-L1 degradation.	Biomaterials	2023	-31.734351096801277	-53.4083034657038	0	
37654479	Prognostic role of different PD-L1 expression patterns and tumor-infiltrating lymphocytes in high-grade serous ovarian cancer: a systematic review and meta-analysis.	Frontiers in immunology	2023	-19.32644878616645	13.453322590077546	0	
37653721	Corneal Perforation in a Patient Treated with Atezolizumab-Bevacizumab Combination Therapy for Unresectable Hepatocellular Carcinoma.	The American journal of case reports	2023	82.43455112196374	-23.514274892324483	0	
37653078	Re-immunotherapy with nivolumab plus ipilimumab in advanced non-small cell lung cancer patients previously treated with anti-programmed death-1 and/or anti-programmed death ligand-1 antibodies.	Discover. Oncology	2023	41.503521835613554	-35.58132023441521	0	
37652558	Children with extended oligoarticular and polyarticular juvenile idiopathic arthritis have alterations in B and T follicular cell subsets in peripheral blood and a cytokine profile sustaining B cell activation.	RMD open	2023	-86.11069733029403	6.869107029632624	0	
37652367	Cuproptosis-immunotherapy using PD-1 overexpressing T cell membrane-coated nanosheets efficiently treats tumor.	Journal of controlled release : official journal of the Controlled Release Society	2023	-31.827634228372503	-51.8043538372557	0	
37651059	Diagnosis and management of gastrointestinal SMARCA4-deficient undifferentiated tumors.	Clinical journal of gastroenterology	2023	58.03482163971323	-37.74105065874696	0	
37649480	Marsdenia tenacissima enhances immune response of tumor infiltrating T lymphocytes to colorectal cancer.	Frontiers in immunology	2023	-21.622264161542184	-34.24008012895283	0	
37649479	Case Report: Replacement of PD-1 inhibitors with PD-L1 inhibitors in the treatment of squamous non-small-cell lung carcinoma.	Frontiers in immunology	2023	82.7193427938943	0.8946559553741731	0	
37647025	m6A methyltransferase METTL16 mediates immune evasion of colorectal cancer cells via epigenetically regulating PD-L1 expression.	Aging	2023	-6.830960581513313	42.70430761419127	0	
37646974	ISG20L2: an RNA nuclease regulating T cell activation.	Cellular and molecular life sciences : CMLS	2023	-36.38176438003487	42.42982430309733	0	
37646958	A novel bivalent anti-c-MET/PD-1 bispecific antibody exhibits potent cytotoxicity against c-MET/PD-L1-positive colorectal cancer.	Investigational new drugs	2023	-15.460047796946428	-47.777155650634654	0	
37646696	PD-1 and PD-L1 Blockade plus Chemotherapy in Endometrial Cancer. Reply.	The New England journal of medicine	2023	-15.800736033050883	-65.65824678507555	0	
37646695	PD-1 and PD-L1 Blockade plus Chemotherapy in Endometrial Cancer. Reply.	The New England journal of medicine	2023	-15.8007360309645	-65.65824678223954	0	
37646694	PD-1 and PD-L1 Blockade plus Chemotherapy in Endometrial Cancer.	The New England journal of medicine	2023	-15.801002009909103	-65.65998156648696	0	
37646693	PD-1 and PD-L1 Blockade plus Chemotherapy in Endometrial Cancer.	The New England journal of medicine	2023	-15.801002009908824	-65.65998156648695	0	
37645980	Mechanical force regulates ligand binding and function of PD-1.	bioRxiv : the preprint server for biology	2023	-49.40824082144249	-39.56628413943055	0	
37642071	Programmed Death 1 (PD-1) Expression in Relapsing and Remitting Hodgkin Lymphoma as Prognostic Factor.	Asian Pacific journal of cancer prevention : APJCP	2023	-29.837748149214327	22.892143746915952	0	
37638041	Analysis of the mechanisms regulating soluble PD-1 production and function in human NK cells.	Frontiers in immunology	2023	-46.3456220429084	17.67199547836259	0	
37635247	Targeted delivery of a PD-1-blocking scFv by CD133-specific CAR-T cells using nonviral Sleeping Beauty transposition shows enhanced antitumour efficacy for advanced hepatocellular carcinoma.	BMC medicine	2023	-43.38240748374912	7.210190824407772	0	
37635168	Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends.	Signal transduction and targeted therapy	2023	26.80429914351982	13.60001858912165	0	
37633293	How I Do It: Maintenance avelumab for advanced urothelial carcinoma.	The Canadian journal of urology	2023	69.47583686255328	17.710669600408735	0	
37631013	Machine Learning Approaches for Assessing Risk Factors of Adrenal Insufficiency in Patients Undergoing Immune Checkpoint Inhibitor Therapy.	Pharmaceuticals (Basel, Switzerland)	2023	84.331502374968	-15.083295604963892	0	
37626908	Lacking Immunotherapy Biomarkers for Biliary Tract Cancer: A Comprehensive Systematic Literature Review and Meta-Analysis.	Cells	2023	21.85185579150255	36.94282723159684	0	
37625814	Phase Ib study of anlotinib in combination with anti-PD-L1 antibody (TQB2450) in patients with advanced acral melanoma.	Journal of the European Academy of Dermatology and Venereology : JEADV	2023	52.91092049570558	-3.1488923941172318	0	
37623817	BCL2 Inhibition Reveals a Dendritic Cell-Specific Immune Checkpoint That Controls Tumor Immunosurveillance.	Cancer discovery	2023	-30.153164025237267	-12.901164978077365	0	
37623461	Unveiling the Etiopathogenic Spectrum of Hypophysitis: A Narrative Review.	Journal of personalized medicine	2023	84.58513117751592	-17.598947752866685	0	
37622123	A CD64/FcγRI-mediated mechanism hijacks PD-1 from PD-L1/2 interaction and enhances anti-PD-1 functional recovery of exhausted T cells.	Frontiers in immunology	2023	-52.185395552799285	-8.824491031244662	0	
37621251	Study on the allosteric activation mechanism of SHP2 via elastic network models and neural relational inference molecular dynamics simulation.	Physical chemistry chemical physics : PCCP	2023	-48.34141312357486	-41.9060654789924	0	
37620622	High-dose ascorbic acid potentiates immune modulation through STAT1 phosphorylation inhibition and negative regulation of PD-L1 in experimental sepsis.	Inflammopharmacology	2023	-61.4966950595914	34.69345844230601	0	
37620318	Acquired resistance to anti-PD1 therapy in patients with NSCLC associates with immunosuppressive T cell phenotype.	Nature communications	2023	29.71853921818611	-31.347608689029805	0	
37614504	Mechanisms underlying response and resistance to immune checkpoint blockade in cancer immunotherapy.	Frontiers in oncology	2023	28.29091582260433	15.112884881518587	0	
37614117	Electro-nape-acupuncture regulates the differentiation of microglia through PD-1/PD-L1 reducing secondary brain injury in acute phase intracerebral hemorrhage rats.	Brain and behavior	2023	-75.22142719129013	-11.273755020004712	0	
37606566	Exploring the role of m6A methylation regulators in glioblastoma multiforme and their impact on the tumor immune microenvironment.	FASEB journal : official publication of the Federation of American Societies for Experimental Biology	2023	-8.420334559350708	56.70640427830204	0	
37605497	Epigenetic Regulation of the Expression of T Cell Stimulatory and Inhibitory Factors by Histone H3 Lysine Modification Enzymes and Its Prognostic Roles in Glioblastoma.	Journal of Korean medical science	2023	-16.871354800402468	53.55180950270883	0	
37605389	Targeting Histone 3 Variants Epigenetic Landscape and Inhibitory Immune Checkpoints: An Option for Paediatric Brain Tumours Therapy.	Current neuropharmacology	2023	-28.21654776695338	62.59870328070147	0	
37603905	Novel targets for immune-checkpoint inhibition in cancer.	Cancer treatment reviews	2023	24.677841570641814	10.940371375455904	0	
37602229	Clustering molecular dynamics conformations of the CC'-loop of the PD-1 immuno-checkpoint receptor.	Computational and structural biotechnology journal	2023	-48.994767110995056	-40.745708824181285	0	
37602125	A Systematic Review of Myocarditis Induced by Immune Checkpoint Inhibitors: How Concerning Is the Most Common Cardiotoxicity of Immune Checkpoint Inhibitors?	Cureus	2023	84.00767694801256	1.5218347506068934	0	
37599552	Identification of HPV16 positive cervical cancer subsets characterized by divergent immune and oncogenic phenotypes with potential implications for immunotherapy.	Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine	2023	-5.174360098419405	35.970545392310335	0	
37599324	Japanese Society of Medical Oncology/Japan Society of Clinical Oncology/Japanese Society of Pediatric Hematology/Oncology-led clinical recommendations on the diagnosis and use of immunotherapy in patients with DNA mismatch repair deficient (dMMR) tumors, third edition.	International journal of clinical oncology	2023	37.39623304996908	31.03256678430945	0	
37599296	Effects of TRPV2 on the Expression of PD-L1 and Its Binding Ability to PD-1 in Gastric Cancer.	Annals of surgical oncology	2023	-9.615987782500586	1.0570978161565112	2	
37598406	Clinico-characteristics of patients which correlated with preferable treatment outcomes in immunotherapy for advanced hepatocellular carcinoma: a systematic review and meta-analysis.	International journal of surgery (London, England)	2023	33.67248797437297	48.67785544080488	0	
37594534	Progress of immunotherapies in gestational trophoblastic neoplasms.	Journal of cancer research and clinical oncology	2023	44.16153153798191	39.982307066366594	0	
37593364	Genomic and Immune Features in an Intrahepatic Cholangiocarcinoma Patient with Microsatellite Instability-High Suffered Rapid Acquired Resistance to PD-1 Inhibitor.	Liver cancer	2023	13.161600523437205	42.65368524965925	0	
37593227	AK112, a novel PD-1/VEGF bispecific antibody, in combination with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC): an open-label, multicenter, phase II trial.	EClinicalMedicine	2023	48.1565277044037	-21.348068385887103	0	
37592104	Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial.	Nature medicine	2023	36.07284562175059	2.1094303656217352	0	
37589946	Evaluation of the relationship between de-novo DSA development and CXCR5+PD-1+CD8+ T cells and PD-1/PD-L1 mRNA expression in kidney transplant recipients.	Clinical transplantation	2023	-32.000907820432154	19.634029478750826	0	
37589044	The role of lenvatinib in the era of immunotherapy of hepatocellular carcinoma.	Journal of liver cancer	2023	31.39051455709583	50.82764060985372	0	
37588227	The link between intracellular calcium signaling and exosomal PD-L1 in cancer progression and immunotherapy.	Genes & diseases	2024	-42.97143169796886	-59.142803757915296	1	
37583448	Computational Identification of Most Deleterious Missense Mutations in Human PD-1 Gene.	TheScientificWorldJournal	2023	4.104952715196413	7.674008020619666	0	
37582744	Unleashing T cell anti-tumor immunity: new potential for 5-Nonloxytryptamine as an agent mediating MHC-I upregulation in tumors.	Molecular cancer	2023	-24.06485068370237	-27.02694387802605	0	
37580352	Camrelizumab combined with apatinib in patients with first-line platinum-resistant or PD-1 inhibitor resistant recurrent/metastatic nasopharyngeal carcinoma: a single-arm, phase 2 trial.	Nature communications	2023	56.36371484832232	-1.8463791854416176	0	
37580269	[Tyro3 and CDK9 as biomarkers for drug resistance to breast cancer anti-PD-1 therapies].	Zhonghua zhong liu za zhi [Chinese journal of oncology]	2023	-26.868316813644824	-24.74378021393656	0	
37579913	Induction of a different immune response in non-titanized compared to titanized polypropylene meshes.	Acta biomaterialia	2023	-1.7765239641714152	36.23912969389027	0	
37576433	A multidisciplinary approach to treating a unique case of recurrent metastatic thymic carcinoma: case report.	Therapeutic advances in rare disease	2023	54.23428646717965	2.2476508446421017	0	
37575393	Establishment of Human PD-1/PD-L1 Blockade Assay Based on Surface Plasmon Resonance (SPR) Biosensor.	Bio-protocol	2023	-42.33005885730213	-41.12889437027672	0	
37573685	Electroacupuncture alleviates neuropathic pain caused by SNL by promoting M2 microglia polarization through PD-L1.	International immunopharmacology	2023	-75.12845350484112	-11.463850737108377	0	
37573354	Synergistic efficacy of simultaneous anti-TGF-β/VEGF bispecific antibody and PD-1 blockade in cancer therapy.	Journal of hematology & oncology	2023	-12.929412136315973	-47.17913224691824	1	
37569880	Role of Next Generation Immune Checkpoint Inhibitor (ICI) Therapy in Philadelphia Negative Classic Myeloproliferative Neoplasm (MPN): Review of the Literature.	International journal of molecular sciences	2023	20.411912970170945	17.420253030506746	0	
37569758	Synthesis and Evaluation of 177Lu-DOTA-PD-L1-i and 225Ac-HEHA-PD-L1-i as Potential Radiopharmaceuticals for Tumor Microenvironment-Targeted Radiotherapy.	International journal of molecular sciences	2023	4.7440802539393525	-55.64225523598865	0	
37568390	Biomarkers for Immune Checkpoint Inhibitors in Renal Cell Carcinoma.	Journal of clinical medicine	2023	65.58212514168544	25.585052986452595	0	
37567584	Bivalent Gadolinium Ions Forming Injectable Hydrogels for Simultaneous In Situ Vaccination Therapy and Imaging of Soft Tissue Sarcoma.	Advanced healthcare materials	2023	-28.84633600301351	-51.41817706587936	0	
37567322	CD3ζ as a novel predictive biomarker of PD-1 inhibitor resistance in melanoma.	Molecular and cellular probes	2023	10.247258477017596	-1.4455400862725118	0	
37566222	Immune Marker Spatial Distribution and Clinical Outcome after PD-1 Blockade in Mismatch Repair-deficient, Advanced Colorectal Carcinomas.	Clinical cancer research : an official journal of the American Association for Cancer Research	2023	7.8331608419327825	36.41731332454198	0	
37564011	Immune-related adverse events and outcomes among pan-cancer patients receiving immune checkpoint inhibitors: A monocentric real-world observational study.	Cancer medicine	2023	73.9328970288478	-13.454871843747352	0	
37563723	Target delivery of a PD-1-TREM2 scFv by CAR-T cells enhances anti-tumor efficacy in colorectal cancer.	Molecular cancer	2023	-42.93041057119477	5.535653404124487	0	
37563075	Effect of PD-L1 Expression for the PD-1/L1 Inhibitors on Non-small Cell Lung Cancer: A Meta-analysis Based on Randomised Controlled Trials.	Clinical oncology (Royal College of Radiologists (Great Britain))	2023	16.406612242992964	-30.84640336591464	0	
37562584	Immune Inhibitory Molecule PD-1 Homolog (VISTA) Colocalizes with CD11b Myeloid Cells in Melanoma and Is Associated with Poor Outcomes.	The Journal of investigative dermatology	2023	-39.44485971466094	37.34704730913014	0	
37561598	Aptamers Targeting the PD-1/PD-L1 Axis: A Perspective.	Journal of medicinal chemistry	2023	-24.80254556922625	-59.76739718983502	0	
37561347	ASO Author Reflections: Effects of TRPV2 on the Expression of PD-L1 and Its Ability to Bind to PD-1 in Gastric Cancer.	Annals of surgical oncology	2023	-9.61698749694411	1.0612638872525084	0	
37560314	Recruitment of myeloid‑derived suppressor cells and regulatory T‑cells is associated with the occurrence of acute myocardial infarction.	Biomedical reports	2023	-51.94060339020901	26.96610818027783	0	
37559573	Monocyte subsets associated with the efficacy of anti‑PD‑1 antibody monotherapy.	Oncology letters	2023	6.397595223232093	-20.263409209654373	0	
37556937	Establishment of comorbidity target pools and prediction of drugs candidate for multiple sclerosis and autoimmune thyroid diseases based on GWAS and transcriptome data.	Multiple sclerosis and related disorders	2023	-2.0392659010436134	43.27814945928648	0	
37555904	Preclinical evaluation and pilot clinical study of [68Ga]Ga-THP-APN09, a novel PD-L1 targeted nanobody radiotracer for rapid one-step radiolabeling and PET imaging.	European journal of nuclear medicine and molecular imaging	2023	5.444708047238995	-56.64469410748926	0	
37554324	Regulation of post-translational modification of PD-L1 and advances in tumor immunotherapy.	Frontiers in immunology	2023	-44.97699780665904	-22.74924504391266	0	
37554182	A novel in vitro prognostic model of bladder cancer based on urine-derived living tumor cells.	Genes & diseases	2023	10.21636283969625	59.99453695806069	0	
37553911	The immune microenvironment characterisation and dynamics in hormone receptor-positive breast cancer before and after neoadjuvant endocrine therapy.	Cancer medicine	2023	0.1445765460890539	24.425581186772128	0	
37552307	Multidimensional biomarker predicts disease control in response to immunotherapy in recurrent or metastatic head and neck squamous-cell carcinoma.	Journal of cancer research and clinical oncology	2023	-6.224833351938162	-4.678801674940387	0	
37547603	Serum sodium levels associate with recovery of kidney function in immune checkpoint inhibitor nephrotoxicity.	Frontiers in medicine	2023	70.60859830236792	1.5373694352976723	0	
37547182	Retroviral b-Zip protein (HBZ) contributes to the release of soluble and exosomal immune checkpoint molecules in the context of neuroinflammation.	Journal of extracellular biology	2023	-67.66078361968714	18.50082276964412	1	
37546948	Propionyl-CoA carboxylase subunit B modulates PIK3CA-regulated immune-surveillance in a pancreatic cancer mouse model.	bioRxiv : the preprint server for biology	2023	-7.586138270529688	38.21892990735381	0	
37545498	Tumor-resident memory T cells as a biomarker of the response to cancer immunotherapy.	Frontiers in immunology	2023	-12.313390441083634	27.19849834027489	0	
37543491	High PD-L1 expression is associated with unfavorable clinical features in myelodysplastic neoplasms.	Hematology, transfusion and cell therapy	2023	-35.11620394908769	13.31706031932714	0	
37540187	Multiomics identifies metabolic subtypes based on fatty acid degradation allocating personalized treatment in hepatocellular carcinoma.	Hepatology (Baltimore, Md.)	2023	-13.16457342589615	51.24249911312683	0	
37538192	Inverse relationship between Fusobacterium nucleatum amount and tumor CD274 (PD-L1) expression in colorectal carcinoma.	Clinical & translational immunology	2023	18.012703391645225	41.5703477984995	0	
37535195	Evaluation of PD-1 T lymphocytes in bronchoalveolar lavage in lung cancer compared to benign lung diseases.	Clinical and experimental medicine	2023	4.780835649173168	-19.34402918025342	0	
37534246	Real-world study of PD-1/L1 immune checkpoint inhibitors for advanced non-small cell lung cancer after resistance to EGFR-TKIs.	Frontiers in oncology	2023	37.90345226359102	-37.87819407311528	0	
37533324	Identification of neutrophil-related genes and development of a prognostic model for cholangiocarcinoma.	The journal of gene medicine	2023	-1.921920873898175	60.34371225728511	0	
37532831	Immunosuppressive effect of small extracellular vesicle PD-L1 is restricted by co-expression of CD80.	British journal of cancer	2023	-40.817092796625865	-61.789558176012925	0	
37530414	Advances in the structural characterization of complexes of therapeutic antibodies with PD-1 or PD-L1.	mAbs	2023	-45.31173382831842	-34.91959329986596	0	
37528319	Clinical trials of neoadjuvant immune checkpoint inhibitors for early-stage operable colon and rectal cancer.	Cancer immunology, immunotherapy : CII	2023	35.84663960409899	18.5358457133494	0	
37526084	Donor T cell STAT3 deficiency enables tissue PD-L1-dependent prevention of graft-versus-host disease while preserving graft-versus-leukemia activity.	The Journal of clinical investigation	2023	-65.65225476331908	-4.999862038138397	1	
37523793	PD1 is transcriptionally regulated by LEF1 in mature T cells.	Immunobiology	2023	-40.28457431742853	-10.798835006910648	0	
37520581	Aerosolized miR-138-5p and miR-200c targets PD-L1 for lung cancer prevention.	Frontiers in immunology	2023	0.3649892138972954	-36.92809551705857	0	
37520574	Immune-related adverse events associated with nab-paclitaxel/paclitaxel combined with immune checkpoint inhibitors: a systematic review and network meta-analysis.	Frontiers in immunology	2023	73.7916719715066	-8.422214699396582	0	
37520536	Case Report: Genetic and immune microenvironmental characteristics of a rectal cancer patient with MSS/PD-L1-negative recurrent hepatopulmonary metastasis who achieved complete remission after treatment with PD-1 inhibitor.	Frontiers in immunology	2023	11.594565861439817	41.37471910059318	0	
37520520	Bispecific antibody targeting TGF-β and PD-L1 for synergistic cancer immunotherapy.	Frontiers in immunology	2023	-12.988064907215644	-46.66574836226452	0	
37518940	Immune checkpoints as potential theragnostic biomarkers for epithelial ovarian cancer.	The International journal of biological markers	2023	2.05511273105401	30.36808711434896	0	
37517547	"Deoxynivalenol upregulates hypoxia-inducible factor-1α to promote an ""immune evasion"" process by activating STAT3 signaling."	Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association	2023	-45.64514067491213	26.998678226328884	0	
37513975	Therapies Targeting Immune Cells in Tumor Microenvironment for Non-Small Cell Lung Cancer.	Pharmaceutics	2023	16.79522323151252	11.74342420199662	0	
37511658	Immunohistochemical Profiling of PD-1, PD-L1, CD8, MSI, and p53 and Prognostic Implications in Advanced Serous Ovarian Carcinoma: A Retrospective Study.	Journal of personalized medicine	2023	-18.5956872340054	13.947707185616114	0	
37511338	Expression of Immune-Related and Inflammatory Markers and Their Prognostic Impact in Colorectal Cancer Patients.	International journal of molecular sciences	2023	6.957002238162852	41.46992783006163	1	
37509655	The Prognostic and Predictive Value of Human Gastrointestinal Microbiome and Exosomal mRNA Expression of PD-L1 and IFNγ for Immune Checkpoint Inhibitors Response in Metastatic Melanoma Patients: PROTOCOL TRIAL.	Biomedicines	2023	22.711426617934613	41.15962085869212	0	
37509393	Breaking the 'Undruggable' Barrier: Anti-PD-1/PD-L1 Immunotherapy for Non-Small Cell Lung Cancer Patients with KRAS Mutations-A Comprehensive Review and Description of Single Site Experience.	Cancers	2023	22.94438132316637	-22.82421519660093	0	
37507765	Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 1st-3rd, 2022-Naples, Italy).	Journal of translational medicine	2023	30.572585300959695	28.6195647400368	0	
37506784	Circulating extracellular vesicles derived from tumor endothelial cells hijack the local and systemic anti-tumor immune response: Role of mTOR/G-CSF pathway.	Pharmacological research	2023	-40.7907398866993	-58.63291722913488	0	
37504358	Molecular Mechanisms of Cutaneous Immune-Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitors.	Current oncology (Toronto, Ont.)	2023	78.20227189755572	-12.252519823982771	0	
37503043	Vactosertib, a novel TGF-β1 type I receptor kinase inhibitor, improves T-cell fitness: a single-arm, phase 1b trial in relapsed/refractory multiple myeloma.	Research square	2023	58.65335453034238	16.886363262965006	0	
37501397	Prostate cancer cells synergistically defend against CD8+ T cells by secreting exosomal PD-L1.	Cancer medicine	2023	-44.1960529960367	-58.52977442865804	1	
37501393	Serum soluble immune checkpoint levels predict cervical lymph node metastasis of differentiated thyroid carcinoma patients.	Cancer medicine	2023	6.355936114058646	23.964952884819525	0	
37501167	Dissociated response to PD-1 inhibitors combined with radiotherapy in patients with advanced metastatic solid tumors: a single-center experience.	World journal of surgical oncology	2023	49.923045907391646	-12.55167005236327	0	
37499395	Association of the CD4+/CD8+ ratio with response to PD-1 inhibitor-based combination therapy and dermatological toxicities in patients with advanced gastric and esophageal cancer.	International immunopharmacology	2023	-6.461944434969143	1.8274188551343349	0	
37498324	Decoding the genetic links between serum lipidomic profile, amino acid biomarkers, and programmed cell death protein-1/programmed cell death-ligand-1.	Cancer immunology, immunotherapy : CII	2023	-30.11677076161676	-29.317495089953884	0	
37496925	Role of β-catenin in PD-L1 expression of nasopharyngeal carcinoma.	Heliyon	2023	-17.93575738363789	31.876007266508456	0	
37492791	Two primary cancers appeared after discontinuation of nivolumab in the course of treating Hodgkin lymphoma: a case report.	AME case reports	2023	41.24817076550907	-7.677180815520509	0	
37491735	Crosstalk among T cells, epithelial cells, and fibroblasts identifies a prognostic signature in oral squamous cell carcinoma.	Oral diseases	2023	-7.30047702708904	34.62969761987822	0	
37488983	Prognostic value of programmed death ligand-1 and programmed death-1 expression in patients with upper tract urothelial carcinoma.	BJU international	2023	13.494913681582169	56.69408320786327	0	
37487915	Application of peptide barcoding to obtain high-affinity anti-PD-1 nanobodies.	Journal of bioscience and bioengineering	2023	-39.237485943823934	-47.22714409654228	0	
37486225	PD-L1/BTLA Checkpoint Axis Exploited for Bacterial Immune Escape by Restraining CD8+ T Cell-Initiated Adaptive Immunity in Zebrafish.	Journal of immunology (Baltimore, Md. : 1950)	2023	-54.92718750804199	-23.24667264916787	0	
37486131	Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction.	Journal of visualized experiments : JoVE	2023	-25.576783609147014	-14.115279520444764	0	
37484526	The introduction of LAG-3 checkpoint blockade in melanoma: immunotherapy landscape beyond PD-1 and CTLA-4 inhibition.	Therapeutic advances in medical oncology	2023	33.02193203714394	2.256453726415569	0	
37482654	Immune-Checkpoint Inhibitors-Induced Type 1 Diabetes Mellitus: From Its Molecular Mechanisms to Clinical Practice.	Diabetes & metabolism journal	2023	87.18412748732288	-13.72207417349751	0	
37481380	Lower PTEN may be associated with CD8+ T cell exhaustion in diffuse large B-cell lymphoma.	Human immunology	2023	-28.45379777642296	29.847026590353934	0	
37480058	Does it fit in your pocket? economic burden of PD-1 inhibitors' toxicity in the supplementary health system: evidence from Brazil.	BMC health services research	2023	58.60135259736239	-15.714783200073022	0	
37479756	Identification of cytokine-predominant immunosuppressive class and prognostic risk signatures in glioma.	Journal of cancer research and clinical oncology	2023	-23.538014683699867	56.41384657664973	1	
37477253	Molecular insights into binding of bioactive compounds from essential oil of Trachyspermum ammi with human programmed cell death protein 1.	Journal of biomolecular structure & dynamics	2023	-33.10743100812392	-37.57313996593823	0	
37470920	Probing the origins of programmed death ligand-1 inhibition by implementing machine learning-assisted sequential virtual screening techniques.	Molecular diversity	2023	-41.33289432342354	-40.32201655844194	0	
37469718	Do macrophages follow the beat of circadian rhythm in TIME (Tumor Immune Microenvironment)?	F1000Research	2023	-55.53530404226668	27.502972774082064	0	
37469254	Targeting PI3Kα increases the efficacy of anti-PD-1 antibody in cervical cancer.	Immunology	2023	2.051499850362616	-13.364532440511203	0	
37468749	Photodynamic therapy changes tumour immunogenicity and promotes immune-checkpoint blockade response, particularly when combined with micromechanical priming.	Scientific reports	2023	-30.73447037636939	-56.54980851974297	0	
37468608	Screening and validation of plasma cell-derived, purinergic, and calcium signalling-related genetic signature to predict prognosis and PD-L1/PD-1 blockade responses in lung adenocarcinoma.	Journal of cancer research and clinical oncology	2023	16.705442539560725	-14.279680280612826	0	
37467967	Small cell neuroendocrine carcinoma of the cervix: From molecular basis to therapeutic advances.	Biomedical journal	2023	41.97358084811585	-2.479297011841074	0	
37466080	Atezolizumab as the First Systemic Therapy Approved for Alveolar Soft Part Sarcoma.	The Annals of pharmacotherapy	2023	53.27011501539745	-37.96064622981515	0	
37464232	Prognostic value and clinicopathological roles of the tumor immune microenvironment in salivary duct carcinoma.	Virchows Archiv : an international journal of pathology	2023	-2.9482929785116405	-0.7048392183805232	0	
37462017	[Clinical analysis of immunotherapy rechallenge in advanced gastric cancer].	Zhonghua zhong liu za zhi [Chinese journal of oncology]	2023	49.831673630746096	17.772697173633457	0	
37461218	PD-1 Deficiency in Regulatory T Cells May be Involved in the Pathogenesis of Takayasu's Arteritis.	Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis	2023	-59.31598959984465	11.38058449406149	0	
37459782	Dual anti-PD-(L)1/TGF-β inhibitors in cancer immunotherapy - Updated.	International immunopharmacology	2023	-12.483510342438896	-46.31701501797167	0	
37457376	Spotlight on Cemiplimab-rwlc in the Treatment of Non-Small Cell Lung Cancer (NSCLC): Focus on Patient Selection and Considerations.	Cancer management and research	2023	52.46350621741839	-21.98246444847466	0	
37456237	Case Report: Advanced pulmonary sarcomatoid carcinoma with adrenal gland metastasis after sintilimab combined with anlotinib treatment.	Frontiers in oncology	2023	54.692291594991104	-32.961821075648466	0	
37455830	Potential tactics with vitamin D and certain phytochemicals for enhancing the effectiveness of immune-checkpoint blockade therapies.	Exploration of targeted anti-tumor therapy	2023	-29.35185622098781	-38.48404143910214	0	
37454966	The opportunities and challenges in immunotherapy: Insights from the regulation of PD-L1 in cancer cells.	Cancer letters	2023	-40.2445120508412	-11.995249819281844	0	
37453913	Detailed characterization of PD-1/PD-L1 and CTLA4 expression and tumor-infiltrating lymphocytes in yolk sac tumors.	Human immunology	2023	-15.89759672757319	24.895857530951844	0	
37452851	Identification of pyroptosis-related signature and development of a novel prognostic model in diffuse large B-cell lymphoma.	Journal of cancer research and clinical oncology	2023	0.8601914943610313	57.77961236658172	0	
37452307	Flubendazole inhibits PD-1 and suppresses melanoma growth in immunocompetent mice.	Journal of translational medicine	2023	-44.81953682346484	27.2900584492967	1	
37451673	Lenalidomide arrests cell cycle and modulates PD1-dependent downstream mTOR intracellular signals in melanoma cells.	Melanoma research	2023	-32.478888928685606	4.410842412266815	0	
37451295	Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from a randomised, open-label, phase 2 trial.	Lancet (London, England)	2023	47.064523120378034	49.971709401804574	2	
37450120	The Detection of Exosomal PD-L1 in Peripheral Blood.	Methods in molecular biology (Clifton, N.J.)	2023	-43.36838187038263	-57.96234573578098	0	
37449971	HLA-I Evolutionary Divergence Confers Response to PD-1 Blockade plus Chemotherapy in Untreated Advanced Non-Small Cell Lung Cancer.	Clinical cancer research : an official journal of the American Association for Cancer Research	2023	18.35294996496542	-26.240506041887368	0	
37449519	Treatment of steroid-refractory immune checkpoint Inhibitor-induced intestinal pseudo-obstruction with infliximab.	Revista espanola de enfermedades digestivas	2023	77.53083320760787	-4.540042036953375	0	
37449210	Expression and role of the immune checkpoint regulator PD-L1 in the tumor-stroma interplay of pancreatic ductal adenocarcinoma.	Frontiers in immunology	2023	-3.749217731970075	3.495528831952832	0	
37446260	Tumor-TME Bipartite Landscape of PD-1/PD-L1 in Endometrial Cancers.	International journal of molecular sciences	2023	-1.5104526089867818	33.715930085624606	0	
37446095	Pembrolizumab-Induced Fatal Myasthenia, Myocarditis, and Myositis in a Patient with Metastatic Melanoma: Autopsy, Histological, and Immunohistochemical Findings-A Case Report and Literature Review.	International journal of molecular sciences	2023	85.46854230988909	-0.513704136995219	0	
37446081	The Synergistic Potential of Combining PD-1/PD-L1 Immune Checkpoint Inhibitors with NOD2 Agonists in Alzheimer's Disease Treatment.	International journal of molecular sciences	2023	-78.44661235461886	-7.680178809859303	1	
37446056	GSK-3 Inhibitor Elraglusib Enhances Tumor-Infiltrating Immune Cell Activation in Tumor Biopsies and Synergizes with Anti-PD-L1 in a Murine Model of Colorectal Cancer.	International journal of molecular sciences	2023	-10.28217354481344	43.2672632130179	0	
37445859	Investigation of Molecular Interactions Mechanism of Pembrolizumab and PD-1.	International journal of molecular sciences	2023	-51.855750475489984	-37.44859068574959	0	
37445704	RNA Sequencing Reveals Unique Transcriptomic Signatures of the Thyroid in a Murine Lung Cancer Model Treated with PD-1 and PD-L1 Antibodies.	International journal of molecular sciences	2023	78.40749933238988	-19.528463727097023	0	
37445336	Review of the Immune Checkpoint Inhibitors in the Context of Cancer Treatment.	Journal of clinical medicine	2023	26.43101236390392	8.792380566541576	0	
37445304	Tissue Expression of Programmed Cell Death 1 Ligand1 (PD-L1) in Biopsies of Transplant Livers of Pediatric Patients as a Possible Marker of Acute Cellular Rejection.	Journal of clinical medicine	2023	-65.9680750130668	25.59855296349372	0	
37445214	The Impact of Biologic Treatment on PD-1/PD-L1 Pathway Disturbances in Psoriasis.	Journal of clinical medicine	2023	-58.45625794224748	-18.31502696314365	0	
37444609	Double Guard Efficiency and Safety-Overcoming Resistance to Immunotherapy by Blocking or Stimulating Several Immune Checkpoints in Non-Small Cell Lung Cancer Patients.	Cancers	2023	34.506154764914854	-29.84167430929203	0	
37444427	Combined Blockade of TIGIT and PD-L1 Enhances Anti-Neuroblastoma Efficacy of GD2-Directed Immunotherapy with Dinutuximab Beta.	Cancers	2023	-13.054430251425783	-53.903267741555375	0	
37443346	Immunohistochemical characterisation of the immune landscape in primary uveal melanoma and liver metastases.	British journal of cancer	2023	3.889513128543067	2.684932687317024	0	
37443122	Assessments of therapeutic effects according to timings for combined therapy with axitinib and immune check point inhibitor in a mouse renal cell carcinoma model.	Scientific reports	2023	66.75344527179313	29.6336882576276	0	
37441678	Comparative analysis of calcified soft tissues revealed shared deregulated pathways.	Frontiers in aging neuroscience	2023	-10.689809367057194	54.35866096385031	0	
37436778	Therapy of autoimmune inflammation in sporadic amyotrophic lateral sclerosis: Dimethyl fumarate and H-151 downregulate inflammatory cytokines in the cGAS-STING pathway.	FASEB journal : official publication of the Federation of American Societies for Experimental Biology	2023	-71.93234610021653	-5.456473454935163	0	
37434092	Cuproptosis-related signature for clinical prognosis and immunotherapy sensitivity in hepatocellular carcinoma.	Journal of cancer research and clinical oncology	2023	-10.887765729584704	51.42590693893591	0	
37433716	Combination oncolytic virus, radiation therapy, and immune checkpoint inhibitor treatment in anti-PD-1-refractory cancer.	Journal for immunotherapy of cancer	2023	25.8181953357165	24.2645747036385	0	
37430006	Construction and validation of a gene expression classifier to predict immunotherapy response in primary triple-negative breast cancer.	Communications medicine	2023	1.3488130865859933	44.83165579111853	1	
37429982	Associated Factors to Efficacy and Tolerance of Immunotherapy in Older Patients with Cancer Aged 70 Years and Over: Impact of Coprescriptions.	Drugs & aging	2023	56.12252520806907	-20.00168144838555	1	
37427589	Reprogramming of PD-1+ M2-like tumor-associated macrophages with anti-PD-L1 and lenalidomide in cutaneous T cell lymphoma.	JCI insight	2023	-31.94494829530366	3.974782593526153	3	
37424276	Pathology for severe inflammatory PML with PD1/PD-L1 expression of favorable prognosis: What's a prognostic factor for PML-IRIS?	Neuropathology : official journal of the Japanese Society of Neuropathology	2023	-40.91469479296709	42.63571449550223	0	
37424161	Expression pattern of PD-1/PD-L1 in primary liver cancer with clinical correlation.	Liver international : official journal of the International Association for the Study of the Liver	2023	-23.45437494037005	38.17770996119168	0	
37419794	The association between PD-1 / PD-L1 expression and clinicopathological features in sarcomatoid renal cell carcinoma.	Asian journal of surgery	2023	19.035365418850297	26.71895098072312	0	
37418134	Tumor immune microenvironment in pituitary neuroendocrine tumors (PitNETs): increased M2 macrophage infiltration and PD-L1 expression in PIT1-lineage subset.	Journal of neuro-oncology	2023	0.5546884806069173	14.316958198166066	0	
37417283	EXPRESSION OF PROGRAMMED CELL DEATH RECEPTOR IN ENDOMETRIAL CANCER PATIENTS WITH METABOLIC DISORDERS.	Experimental oncology	2023	-18.47402562307012	9.949361251156148	0	
37415977	Emerging role of deubiquitination modifications of programmed death-ligand 1 in cancer immunotherapy.	Frontiers in immunology	2023	-19.16519547143592	-6.989897017613562	0	
37415817	Comprehensive immune landscape of lung-resident memory CD8+ T cells after influenza infection and reinfection in a mouse model.	Frontiers in microbiology	2023	-74.52469217548881	7.63427081484633	0	
37414322	Targeted miR-34a delivery with PD1 displayed bacterial outer membrane vesicles-coated zeolitic imidazolate framework nanoparticles for enhanced tumor therapy.	International journal of biological macromolecules	2023	-35.60158349082695	-54.6312863055613	0	
37413931	Mitochondrial ROS-dependent CD4+PD-1+T cells are pathological expansion in patients with primary immune thrombocytopenia.	International immunopharmacology	2023	-51.64786504758831	3.7746776027805446	0	
37410805	Germline variants of the immune checkpoint proteins PD-1, PD-l1 and CTLA-4 and immune tolerance induction outcome in patients with inherited haemophilia A.	Haemophilia : the official journal of the World Federation of Hemophilia	2023	21.719955583022347	-9.694966291439806	0	
37410239	Assessment of PD-L1 Status in Urothelial Cancer.	Methods in molecular biology (Clifton, N.J.)	2023	67.84844983645492	17.887120849831632	0	
37410080	Decreased programmed cell death ligand 2-positive monocytic myeloid-derived suppressor cells and programmed cell death protein 1-positive T-regulatory cells in patients with type 2 diabetes: implications for immunopathogenesis.	Endocrine connections	2023	-51.98712221614624	26.9362026417487	0	
37408777	Implications of inflammatory cell death-related IFNG and co-expressed RNAs (AC006369.1 and CCR7) in breast carcinoma prognosis, and anti-tumor immunity.	Frontiers in genetics	2023	-0.1811794802435987	46.86529462283723	0	
37407848	Immune micro-environment analysis and establishment of response prediction model for PD-1 blockade immunotherapy in glioblastoma based on transcriptome deconvolution.	Journal of cancer research and clinical oncology	2023	-27.221476295896647	54.07107211479104	0	
37405419	Dysregulated PD-L2 is correlated with disease activity and inflammation in rheumatoid arthritis.	Immunogenetics	2023	-51.86146256413927	14.337497278681456	0	
37404814	An updated review of gastrointestinal toxicity induced by PD-1 inhibitors: from mechanisms to management.	Frontiers in immunology	2023	70.8737180955907	-14.628698287076013	0	
37403098	Initial analysis of the synergy of programmed cell death-1 (PD-1) inhibitor and concurrent chemoradiotherapy treatment for recurrent/metastatic head and neck squamous cell carcinoma patients.	Radiation oncology (London, England)	2023	58.68003554920422	1.7028051647577849	0	
37402054	PD-L2 overexpression on tumor-associated macrophages is one of the predictors for better prognosis in lung adenocarcinoma.	Medical molecular morphology	2023	3.674983645959353	-26.32417540812285	0	
37401452	Serum sPD-L1 levels are elevated in patients with viral diseases, bacterial sepsis or in patients with impaired renal function compared to healthy blood donors.	Clinical chemistry and laboratory medicine	2023	-46.50826563529132	22.474133662409493	0	
37400680	Rational design of PD-1-CD28 immunostimulatory fusion proteins for CAR T cell therapy.	British journal of cancer	2023	-45.68546277482002	-1.131880015454457	0	
37399357	Association between gene expression signatures and clinical outcomes of pembrolizumab versus paclitaxel in advanced gastric cancer: exploratory analysis from the randomized, controlled, phase III KEYNOTE-061 trial.	Journal for immunotherapy of cancer	2023	22.818615177116488	-12.526648575042817	1	
37397537	Targeting PD-1/PD-L1 in cancer immunotherapy: An effective strategy for treatment of triple-negative breast cancer (TNBC) patients.	Genes & diseases	2023	-41.97215461541456	-17.774767469531497	0	
37397533	PD-L1 expression is regulated by ATP-binding of the ERBB3 pseudokinase domain.	Genes & diseases	2023	-19.505196424616955	4.714133557984399	0	
37397393	Traditional Chinese medicine inhibits PD-1/PD-L1 axis to sensitize cancer immunotherapy: a literature review.	Frontiers in oncology	2023	-24.575344925935116	-36.36631953981695	1	
37396957	Microbiota-associated immunotherapy resistance caused by deficient PD-L2 - RGMb signaling.	Oncoimmunology	2023	-23.62135879370976	0.5372925120462883	0	
37396098	Myeloid-derived suppressor cells (MDSCs): what do we currently know about the effect they have against anti-PD-1/PD-L1 therapies?	Ecancermedicalscience	2023	-50.78728886967806	27.62594698496381	1	
37394245	First-line immunotherapy with anti-PD-1 antibody for extranodal NK/T-cell lymphoma: A retrospective study.	British journal of haematology	2023	48.61314627876708	-6.751453750669971	0	
37391072	Tissue Resistance Decrease during Irreversible Electroporation of Pancreatic Cancer as a Biomarker for the Adaptive Immune Response and Survival.	Journal of vascular and interventional radiology : JVIR	2023	-11.547391733560362	-39.88188127218867	0	
37390646	Recent advances in immune checkpoint inhibitor-induced type 1 diabetes mellitus.	International immunopharmacology	2023	86.93213453221355	-13.655753385303084	0	
37389416	The programmed death ligand 1 interactome demonstrates bidirectional signaling coordinating immune suppression and cancer progression in head and neck squamous cell carcinoma.	Journal of the National Cancer Institute	2023	-36.759010658377306	-9.303556264849702	0	
37389188	Efficacy and safety of nab-paclitaxel or combined nab-paclitaxel and immune checkpoint inhibitors in relapsed small-cell lung cancer.	Therapeutic advances in medical oncology	2023	45.054837915355634	-39.59447700764064	0	
37389074	Development of a highly sensitive chemiluminescence immunoassay using a novel signal-enhanced detection system for quantitation of durvalumab, an immune-checkpoint inhibitor monoclonal antibody used for immunotherapy of lung cancer.	Heliyon	2023	14.540482741145324	-44.73091345036988	0	
37388220	Chronic obstructive pulmonary disease alters the genetic landscape and tumor immune microenvironment in lung cancer patients.	Frontiers in oncology	2023	1.006290461028955	-22.660604392190315	0	
37387587	Bioactive compounds derived from marine source: a potential immunotherapy treatment.	Journal of biomolecular structure & dynamics	2023	-35.763904697655235	-41.15991079559242	0	
37383651	Development of polyclonal heavy chain antibodies targeting programmed death ligand-1.	Veterinary research forum : an international quarterly journal	2023	-37.57465661063183	-46.98901073317543	0	
37373192	Molecular Farming of Pembrolizumab and Nivolumab.	International journal of molecular sciences	2023	42.40629200197245	14.450950230935106	0	
37373038	Regulation of PD-L1 Expression by Nuclear Receptors.	International journal of molecular sciences	2023	-40.72981185870204	-10.88581559035295	0	
37372432	Immunohistochemical Expression of Programmed Cell Death Ligand 1 (PD-L1) in Human Cutaneous Malignant Melanoma: A Narrative Review with Historical Perspectives.	Genes	2023	-46.13263247813697	-18.120924415506607	0	
37372349	Microsatellite Instability and Immune Response: From Microenvironment Features to Therapeutic Actionability-Lessons from Colorectal Cancer.	Genes	2023	11.600187108011848	42.82612268683437	1	
37371863	Clinical Significance of PD-L1 Status in Circulating Tumor Cells for Cancer Management during Immunotherapy.	Biomedicines	2023	8.479291479664996	-39.60020593334984	0	
37371594	Identification of a Favorable Prognostic Subgroup in Oral Squamous Cell Carcinoma: Characterization of ITGB4/PD-L1high with CD8/PD-1high.	Biomolecules	2023	-6.483551958116879	-13.872006243151857	0	
37371079	PD-L1's Role in Preventing Alloreactive T Cell Responses Following Hematopoietic and Organ Transplant.	Cells	2023	-63.88870522027617	-4.393683069588888	0	
37370868	The Histological Background of Recurrence in Laryngeal Squamous Cell Carcinoma: An Insight into the Modifications of Tumor Microenvironment.	Cancers	2023	6.257814668372102	21.707368788034437	0	
37370866	Spatial Distribution of Immune Cells in Primary and Recurrent Glioblastoma: A Small Case Study.	Cancers	2023	-24.22446048338721	57.815935650822745	0	
37370706	Immuno-Contexture and Immune Checkpoint Molecule Expression in Mismatch Repair Proficient Colorectal Carcinoma.	Cancers	2023	11.337180522021306	39.31365734102015	0	
37370700	Regulations of Tumor Microenvironment by Prostaglandins.	Cancers	2023	-17.834242110052315	-1.9018642049032848	0	
37368947	Linear Peptide-Based PET Tracers for Imaging PD-L1 in Tumors.	Molecular pharmaceutics	2023	5.279669916986082	-56.90771615095535	0	
37366893	Biomarkers for Predicting Anti-Programmed Cell Death-1 Antibody Treatment Effects in Head and Neck Cancer.	Current oncology (Toronto, Ont.)	2023	-5.921779936004322	-4.878678022005068	0	
37366435	Nivolumab-Induced Pneumonitis in a Patient With Urothelial Cancer.	Cureus	2023	66.87037633757033	-11.790901610015244	0	
37363103	Preclinical evaluation of chimeric antigen receptor T cells targeting the carcinoembryonic antigen as a potential immunotherapy for gallbladder cancer.	Oncoimmunology	2023	-41.03597974147476	6.661183531240807	0	
37359565	Serum cytokine analysis in a cohort of advanced non-small cell lung cancer treated with PD-1 inhibitors reveals predictive markers of CXCL12.	Frontiers in immunology	2023	23.407811345700324	-29.096691492149358	0	
37359551	Pancreatic adverse events of immune checkpoint inhibitors therapy for solid cancer patients: a systematic review and meta-analysis.	Frontiers in immunology	2023	84.8577555635146	-11.449660273786035	0	
37359545	PD-1 blockade attenuates surgery-mediated immunosuppression and boosts Th1 immunity perioperatively in oesophagogastric junctional adenocarcinoma.	Frontiers in immunology	2023	21.560470842026508	21.864796386549237	1	
37353792	Single-cell analysis reveals HBV-specific PD-1+CD8+ TRM cells in tumor borders are associated with HBV-related hepatic damage and fibrosis in HCC patients.	Journal of experimental & clinical cancer research : CR	2023	-75.46535160385875	26.989266874651715	0	
37351175	Targeting β-catenin and PD-L1 simultaneously by a racemic supramolecular peptide for the potent immunotherapy of hepatocellular carcinoma.	Theranostics	2023	-41.90905816455806	-49.53281742090313	0	
37350807	Fluctuations in Gut Microbiome Composition During Immune Checkpoint Inhibitor Therapy.	World journal of oncology	2023	23.044891123527325	41.3855694562775	0	
37349318	Nivolumab plus chemoradiotherapy in locally-advanced cervical cancer: the NICOL phase 1 trial.	Nature communications	2023	43.1943839391888	-23.532723133840022	0	
37348508	PD-L1/PD-1 checkpoint pathway regulates hippocampal neuronal excitability and learning and memory behavior.	Neuron	2023	-76.94758371521364	-5.738966892023464	1	
37348413	Frequent expression of PD-L1 in lymphocyte-rich hepatocellular carcinoma: A report of 4 cases.	Annals of diagnostic pathology	2023	-23.330401189968786	39.07973677405132	0	
37345194	Immune Checkpoint Inhibitors Combined with Targeted Therapy: The Recent Advances and Future Potentials.	Cancers	2023	34.730141076236016	10.219554627670504	2	
37345160	T-Cell Engagers in Solid Cancers-Current Landscape and Future Directions.	Cancers	2023	-14.731434885871105	-43.43928456594588	0	
37345086	Breaking the Invisible Barriers: Unleashing the Full Potential of Immune Checkpoint Inhibitors in Oncogene-Driven Lung Adenocarcinoma.	Cancers	2023	39.4967515797858	-36.91533788433023	0	
37345075	TIM-3 Qualifies as a Potential Immunotherapeutic Target in Specific Subsets of Patients with High-Risk Soft Tissue Sarcomas (HR-STS).	Cancers	2023	-2.241293283538339	26.01899890366597	0	
37344099	Discovery of a novel dual-targeting D-peptide to block CD24/Siglec-10 and PD-1/PD-L1 interaction and synergize with radiotherapy for cancer immunotherapy.	Journal for immunotherapy of cancer	2023	-29.503478143119608	-43.78003390011958	0	
37342323	Immune-related adverse effects of checkpoint immunotherapy and implications for the treatment of patients with cancer and autoimmune diseases.	Frontiers in immunology	2023	80.29803868027591	-9.586620913628623	0	
37342091	Immunoprofiling bronchoalveolar lavage cells reveals multifaceted smoking-associated immune dysfunction.	ERJ open research	2023	4.720312439707462	-18.98874583377908	0	
37341216	AKT inhibition interferes with the expression of immune checkpoint proteins and increases NK-induced killing of HL60-AML cells.	Einstein (Sao Paulo, Brazil)	2023	-29.233871507156373	-24.104031222379955	0	
37334368	Abrine, an IDO1 inhibitor, suppresses the immune escape and enhances the immunotherapy of anti-PD-1 antibody in hepatocellular carcinoma.	Frontiers in immunology	2023	-16.119168747879552	-31.12601232663232	0	
37331822	Meta-analysis of perioperative immunotherapy in renal cell carcinoma: Available, but the jury is still out.	Urologic oncology	2023	66.78597525578037	27.513075956037568	0	
37331333	Efficacy of PD-1 inhibitors in first-line treatment for advanced gastroesophageal junction and gastric cancer by subgroups: A systematic review and meta-analysis.	Chemotherapy	2023	49.73751380609534	15.76334754938263	0	
37329869	Personal immune profiles: Diversity and prognostic value for oral tongue squamous cell carcinoma evaluated by comprehensive immune parameter analyses with multiplex immunofluorescence.	Oral oncology	2023	-6.984508218568021	33.12841314371267	0	
37329540	Programmed Cell Death Protein 1/Programmed Cell Death Ligand 1 Signaling Pathway Mediated Interleukin-10 and Bacterial Biofilm Formation to Drug Resistance Mechanism of Pneumoniae Meningitis.	Cellular and molecular biology (Noisy-le-Grand, France)	2023	-81.0939124674171	-0.3330354757662249	0	
37328649	Bispecific antibody targeting both B7-H3 and PD-L1 exhibits superior antitumor activities.	Acta pharmacologica Sinica	2023	-15.23991367074108	-46.88602972177991	0	
37325672	Successful treatment of severe immune checkpoint inhibitor associated autoimmune hepatitis with basiliximab: a case report.	Frontiers in immunology	2023	76.24359444921824	0.0605011014853359	0	
37324014	Afatinib combined with anti-PD1 enhances immunotherapy of hepatocellular carcinoma via ERBB2/STAT3/PD-L1 signaling.	Frontiers in oncology	2023	26.10651619658477	50.67939029161885	0	
37323603	Expression of PD-L1 in Lung Carcinoma and Its Correlation with Histopathological Grade, Stage, and Survival of Patients.	Journal of laboratory physicians	2023	7.9992913035904545	-27.317363539771836	0	
37323168	Blood tumor mutational burden and dynamic changes in circulating tumor DNA predict response to pembrolizumab treatment in advanced non-small cell lung cancer.	Translational lung cancer research	2023	24.586901982228788	-12.978729491832256	0	
37321468	Dermatomyositis unleashed by immune checkpoint inhibitors. Three additional cases and a review of the literature.	Autoimmunity reviews	2023	85.31916909702755	-1.3297267632315308	0	
37318496	Programmed cell death ligand-1 (PD-L1) expression in desmoid tumors: a retrospective study.	European review for medical and pharmacological sciences	2023	-16.965635829378485	23.00544996824573	0	
37316937	The tumor promoter cysteinyl leukotriene receptor 1 regulates PD-L1 expression in colon cancer cells via the Wnt/β-catenin signaling axis.	Cell communication and signaling : CCS	2023	-19.524005112255725	3.8705144423980697	1	
37316381	Study Design and Rationale for Marble Study: A Phase II Trial of Atezolizumab (MPDL3280A) Plus Carboplatin and Paclitaxel in Patients With Advanced or Recurrent Thymic Carcinoma (JTD2101).	Clinical lung cancer	2023	54.33587952419336	2.2668192581315543	0	
37314798	Increased PD-1 expression of bone marrow T-cells in acute myeloid leukaemia patients after stem cell transplantation, and its association with overall survival.	Annals of clinical biochemistry	2023	-36.17544071449999	15.704326447228617	0	
37314514	Association of CDKN2A/B mutations, PD-1, and PD-L1 with the risk of acute lymphoblastic leukemia in children.	Journal of cancer research and clinical oncology	2023	-36.35979843848355	21.912357537090337	0	
37311357	Immunogenetic polymorphisms predict therapeutic efficacy and survival outcomes in tumor patients receiving PD-1/PD-L1 blockade.	International immunopharmacology	2023	21.67064472599489	-9.275177655938132	0	
37306905	Traditional Treatment Approaches and Role of Immunotherapy in Lung Malignancy and Mesothelioma.	Cancer treatment and research	2023	37.35921681476309	-24.64173874538981	0	
37306710	PD-1 blockade combined with ICE regimen in relapsed/refractory diffuse large B-cell lymphoma.	Annals of hematology	2023	46.05020894782088	-7.698082472240712	0	
37306349	The prognostic role of epidermal growth factor receptor mutation in completely resected ampullary adenocarcinoma.	Polish journal of pathology : official journal of the Polish Society of Pathologists	2023	7.498608980426988	-29.987484902534927	0	
37305530	Drug therapy for myocarditis induced by immune checkpoint inhibitors.	Frontiers in pharmacology	2023	84.14457204542471	1.9991419136139927	0	
37305016	The effect of Wnt/β-catenin signaling on PD-1/PDL-1 axis in HPV-related cervical cancer.	Oncology research	2022	-0.643000157422456	-12.837761011543249	3	
37304273	On-treatment lung immune prognostic index is predictive for first-line PD-1 inhibitor combined with chemotherapy in patients with non-small cell lung cancer.	Frontiers in immunology	2023	27.046744234914968	-45.49235060397467	0	
37302371	Shikonin inhibits immune checkpoint PD-L1 expression on macrophage in sepsis by modulating PKM2.	International immunopharmacology	2023	-61.20646498423667	35.97224592706623	1	
37302368	Immunosensitivity mediated by downregulated AKT1-SKP2 induces anti-PD-1-associated thyroid immune injury.	International immunopharmacology	2023	77.56307232047956	-19.664996327256905	0	
37301098	FGFR3 mutation characterization identifies prognostic and immune-related gene signatures in bladder cancer.	Computers in biology and medicine	2023	5.061908121239609	57.88682961246508	0	
37300724	Gastric cancer mesenchymal stem cells via the CXCR2/HK2/PD-L1 pathway mediate immunosuppression.	Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association	2023	-13.31069857950508	1.3619446960248107	0	
37296684	Chemo-Free Treatment Using Anti-PD-1 Antibodies with Lenvatinib in Unresectable Gallbladder Cancer: PD-L1 May Be a Potential Biomarker for a Better Outcome.	Diagnostics (Basel, Switzerland)	2023	52.861364486234926	21.624680172402204	0	
37292799	Global stability and parameter analysis reinforce therapeutic targets of PD-L1-PD-1 and MDSCs for glioblastoma.	bioRxiv : the preprint server for biology	2023	-28.183403209454685	55.76225193484337	0	
37291608	Co-inhibition of TIGIT and PD-1/PD-L1 in Cancer Immunotherapy: Mechanisms and Clinical Trials.	Molecular cancer	2023	-12.684732119872724	-57.02665432936994	1	
37290119	Regulation of PD-L1 Trafficking from Synthesis to Degradation.	Cancer immunology research	2023	-46.321445631419394	-15.643632578728138	0	
37288582	Neoadjuvant immunochemotherapy for locally advanced resectable oral squamous cell carcinoma: a prospective single-arm trial (Illuminate Trial).	International journal of surgery (London, England)	2023	55.70818167589318	10.587381583307678	0	
37287968	Insights into anti-tumor immunity via the polyomavirus shared across human Merkel cell carcinomas.	Frontiers in immunology	2023	43.95754505429184	51.89788760240559	0	
37287284	Research on the Regulatory Mechanism of Ginseng on the Tumor Microenvironment of Colorectal Cancer based on Network Pharmacology and Bioinformatics Validation.	Current computer-aided drug design	2023	-20.66634991876418	-37.40936199624515	0	
37286702	Identification of immune-related gene signature for predicting prognosis in uterine corpus endometrial carcinoma.	Scientific reports	2023	2.0683487864793	48.03844406167149	0	
37286115	Salvia mitiorrhiza Bunge aqueous extract attenuates infiltration of tumor-associated macrophages and potentiates anti-PD-L1 immunotherapy in colorectal cancer through modulating Cox2/PGE2 cascade.	Journal of ethnopharmacology	2023	-22.526100247861272	-34.40597622472849	1	
37285333	CCX559 is a potent, orally-administered small molecule PD-L1 inhibitor that induces anti-tumor immunity.	PloS one	2023	-37.961129292570206	-38.11978148424276	0	
37284189	Real-world treatment patterns and outcomes among individuals receiving first-line pembrolizumab therapy for recurrent/metastatic head and neck squamous cell carcinoma.	Frontiers in oncology	2023	53.30902532987798	7.194449945080179	0	
37283762	Real-world retrospective study of immune checkpoint inhibitors in combination with radiotherapy or chemoradiotherapy as a bladder-sparing treatment strategy for muscle-invasive bladder urothelial cancer.	Frontiers in immunology	2023	72.81991157196238	21.86287561874654	0	
37279009	Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma.	Cancer immunology research	2023	19.9689610125215	29.96092963540707	0	
37275884	Spatial distribution of tumor-infiltrating T cells indicated immune response status under chemoradiotherapy plus PD-1 blockade in esophageal cancer.	Frontiers in immunology	2023	4.084918420628847	20.855144175822804	0	
37275876	PD-1/PD-L1 axis in organ fibrosis.	Frontiers in immunology	2023	-56.5898723683599	16.76704146208626	0	
37274775	Integrated phenotyping of the anti-cancer immune response in HIV-associated hepatocellular carcinoma.	JHEP reports : innovation in hepatology	2023	-13.891637471415764	43.37543889773768	0	
37274772	PD-1 and PD-L1 expression in rare lung tumors.	Pathology oncology research : POR	2023	7.096291705401707	-26.88791860887408	0	
37274471	Sequential administration of PD‑1 inhibitor and cetuximab causes pneumonia.	Oncology letters	2023	64.28015812919593	-10.296392869876636	0	
37273534	The significance of PD-1/PD-L1 imbalance in ulcerative colitis.	PeerJ	2023	-60.117501532504015	19.755122769675538	0	
37272261	Interobserver Agreement on the Interpretation of Programmed Death-ligand 1 (PD-L1) Combined Positive Score (CPS) Among Gynecologic Pathologists.	The American journal of surgical pathology	2023	15.120784054215887	-42.256166532893566	0	
37268394	Interplay between MAP kinases and tumor microenvironment: Opportunity for immunotherapy in pancreatic cancer.	Advances in cancer research	2023	-7.515713732411372	38.37377863870448	0	
37267514	Treating Cancer in People With HIV.	Journal of clinical oncology : official journal of the American Society of Clinical Oncology	2023	32.96617212031338	-6.700525012132672	0	
37267050	Automated Analysis of PD1 and PDL1 Expression in Lymph Nodes and the Microenvironment of Transmissible Tumors in Tasmanian Devils.	Immunological investigations	2023	-42.35598078229626	29.336534091878303	0	
37266436	New molecular targets in Hodgkin and Reed-Sternberg cells.	Frontiers in immunology	2023	-29.411851020357936	26.81186362742873	0	
37266424	Soluble monomeric human programmed cell death-ligand 1 inhibits the functions of activated T cells.	Frontiers in immunology	2023	-46.01837445520628	-4.25640765954263	0	
37264298	Characterization of immune checkpoints expression and lymphocyte densities of iranian breast cancer patients; the co-expression status and clinicopathological associates.	BMC cancer	2023	-2.893344543413697	23.99942050583001	0	
37263182	Pre-existing tumor host immunity characterization in resected non-small cell lung cancer.	Lung cancer (Amsterdam, Netherlands)	2023	13.144935225888222	-17.051572745846908	0	
37261603	Extracellular vesicle-based drug delivery in cancer immunotherapy.	Drug delivery and translational research	2023	-38.52900943650474	-58.83741917574254	4	
37261522	TP53 or CDKN2A/B covariation in ALK/RET/ROS1-rearranged NSCLC is associated with a high TMB, tumor immunosuppressive microenvironment and poor prognosis.	Journal of cancer research and clinical oncology	2023	18.761836410071247	-19.982696378976343	0	
37261359	The role of PD-1 signaling in health and immune-related diseases.	Frontiers in immunology	2023	-48.49224706438482	-12.423270447702368	3	
37261086	CD8 T cell-mediated depletion of HBV surface-antigen-expressing, bilineal-differentiated liver carcinoma cells generates highly aggressive escape variants.	Oncoimmunology	2023	-75.7657426372734	26.89545067838014	0	
37259771	6-Mercaptopurine potently inhibits recruitment of SHP2 by phosphorylated PD-1 to inhibit PD-1 signalling and enhance T cell function.	Immunology	2023	-38.333454311721965	-39.25481802515269	0	
37257766	Everolimus combined with PD-1 blockade inhibits progression of triple-negative breast cancer.	Cellular signalling	2023	3.2089449430017227	-14.70611731109303	0	
37256434	Inter-rater and intra-rater agreement of [99mTc]-labelled NM-01, a single-domain programmed death-ligand 1 (PD-L1) antibody, using quantitative SPECT/CT in non-small cell lung cancer.	EJNMMI research	2023	11.858723836948643	-51.44952032509488	0	
37251628	Safety and efficacy of CRISPR-based non-viral PD1 locus specifically integrated anti-CD19 CAR-T cells in patients with relapsed or refractory Non-Hodgkin's lymphoma: a first-in-human phase I study.	EClinicalMedicine	2023	-44.36279882577196	2.231793633655057	1	
37250156	Sequential delivery of PD-1/PD-L1 blockade peptide and IDO inhibitor for immunosuppressive microenvironment remodeling via an MMP-2 responsive dual-targeting liposome.	Acta pharmaceutica Sinica. B	2023	-32.69502339880699	-49.51718506784228	2	
37249038	TROPION-Lung08: phase III study of datopotamab deruxtecan plus pembrolizumab as first-line therapy for advanced NSCLC.	Future oncology (London, England)	2023	48.54773441078217	-31.47075223732364	0	
37247023	Efficacy, safety, and prognostic factors of PD-1 inhibitors combined with lenvatinib and Gemox chemotherapy as first-line treatment in advanced intrahepatic cholangiocarcinoma: a multicenter real-world study.	Cancer immunology, immunotherapy : CII	2023	55.145060008833845	21.28010252293944	1	
37246810	PD-1 Carried on Small Extracellular Vesicles Leads to OSCC Metastasis.	Journal of dental research	2023	-41.59082706171883	-61.692065930401455	0	
37246200	Nuclear AhR and membranous PD-L1 in predicting response of non-small cell lung cancer to PD-1 blockade.	Signal transduction and targeted therapy	2023	12.095840692346812	-35.650552456873385	0	
37245872	Chang Wei Qing Decoction enhances the anti-tumor effect of PD-1 inhibitor therapy by regulating the immune microenvironment and gut microbiota in colorectal cancer.	Chinese journal of natural medicines	2023	-22.986205764766357	-35.64752238510526	0	
37245442	Immune checkpoint inhibition in patients with NRAS mutated and NRAS wild type melanoma: a multicenter Dermatologic Cooperative Oncology Group study on 637 patients from the prospective skin cancer registry ADOREG.	European journal of cancer (Oxford, England : 1990)	2023	13.815044862022354	2.959625081153112	0	
37244230	Recent development of selective inhibitors targeting the HDAC6 as anti-cancer drugs: Structure, function and design.	Bioorganic chemistry	2023	-10.004502185537008	-33.13121583577697	1	
37244159	Immunoscore immune checkpoint using spatial quantitative analysis of CD8 and PD-L1 markers is predictive of the efficacy of anti- PD1/PD-L1 immunotherapy in non-small cell lung cancer.	EBioMedicine	2023	15.452524407826743	-29.991795912181026	3	
37239166	Checkpoint Inhibitor-Induced Colitis: An Update.	Biomedicines	2023	75.67811276285553	-3.245371990523489	0	
37235656	PD-L1 methylation restricts PD-L1/PD-1 interactions to control cancer immune surveillance.	Science advances	2023	-1.3964962244808596	-33.25944071079352	3	
37233406	Next generation sequencing predicting clinical effect of immunotherapy on adult rhabdomyosarcoma patient: A case report.	Medicine	2023	16.7816889546651	48.16104350017487	0	
37231946	Combining Poly-(ARD-Ribose) Polymerase and Programmed Cell Death Protein 1 Inhibition in a Patient with Esophagogastric Adenocarcinoma.	Oncology research and treatment	2023	34.24979814782291	40.11996343857664	0	
37229906	Patient-derived melanoma organoid models facilitate the assessment of immunotherapies.	EBioMedicine	2023	0.282722964136051	-40.60280348783341	0	
37229447	Immune checkpoint inhibitors in first-line therapies of metastatic or early triple-negative breast cancer: a systematic review and network meta-analysis.	Frontiers in endocrinology	2023	41.73763490345216	11.185257764483072	1	
37228892	Identifying Hub Genes and miRNA-mRNA Regulatory Networks in Mice Infected with H1N1 Influenza Virus.	Disease markers	2023	-78.08096398709174	6.760592090603787	0	
37228770	PD-L1: expression regulation.	Blood science (Baltimore, Md.)	2023	-40.23987610702533	-11.332965635800972	0	
37227919	BRCA1 Insufficiency Induces a Hypersialylated Acidic Tumor Microenvironment That Promotes Metastasis and Immunotherapy Resistance.	Cancer research	2023	-5.779653716479896	48.33642012113536	0	
37227611	Efficacy relevance of PD-L1 expression on circulating tumor cells in metastatic breast cancer patients treated with anti-PD-1 immunotherapy.	Breast cancer research and treatment	2023	8.246378255782712	-38.989630229688	0	
37226257	Dual inhibition of IDO1/TDO2 enhances anti-tumor immunity in platinum-resistant non-small cell lung cancer.	Cancer & metabolism	2023	-15.090112658336444	-30.92150363711049	1	
37225011	Combination therapy with PD-1 inhibition plus rapamycin and metformin enhances anti-tumor efficacy in triple negative breast cancer.	Experimental cell research	2023	-16.112433534023612	-25.42118153848242	1	
37224427	Exceptional Response to Dual Colony-Stimulating Factor 1 Receptor/PD-L1 Targeting After Primary Resistance to PD-1 Inhibition in a Patient With a Metastatic Uveal Melanoma.	JCO precision oncology	2023	44.15960415277178	1.805381834846614	0	
37223924	Immunogenomic Landscape of Neuroendocrine Prostate Cancer.	Clinical cancer research : an official journal of the American Association for Cancer Research	2023	2.1357012976255283	14.90870971757048	1	
37223338	Circulating CXCR5+ natural killer cells are expanded in patients with myasthenia gravis.	Clinical & translational immunology	2023	-70.88051275867946	5.558631546375441	0	
37222922	Immunotherapy in Early-Stage Triple-Negative Breast Cancer: Where Are We Now and Where Are We Headed?	Current treatment options in oncology	2023	40.34704327858985	9.7270282819845	0	
37220262	Risk Factors and Characteristics of Checkpoint Inhibitor-Associated Autoimmune Diabetes Mellitus (CIADM): A Systematic Review and Delineation From Type 1 Diabetes.	Diabetes care	2023	88.12820681043921	-12.685732141234553	0	
37218160	Retrospective study on the efficacy and tolerability of dose modification of PD-1 and PD-L1 inhibitors in hospital-system community outpatient cancer clinics.	Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners	2023	56.80858685145456	-15.963704206011	0	
37217353	[Short-course radiotherapy combined with CAPOX and PD-1 inhibitor for the total neoadjuvant therapy of locally advanced rectal cancer: the preliminary single-center findings of a prospective, multicentre, randomized phase II trial (TORCH)].	Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery	2023	46.45268828186849	10.201229272836574	0	
37217096	Brief Report: Severe Sotorasib-Related Hepatotoxicity and Non-Liver Adverse Events Associated With Sequential Anti-Programmed Cell Death (Ligand)1 and Sotorasib Therapy in KRASG12C-Mutant Lung Cancer.	Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer	2023	59.505767495433865	-21.2912568578123	1	
37215978	Human recombinant soluble PD1 can interference in T cells and Treg cells function in response to MDA-MB-231 cancer cell line.	American journal of clinical and experimental immunology	2023	-45.96710862178587	-4.233534954000339	0	
37215452	Evaluating prognostic value of biliary stone in intrahepatic cholangiocarcinoma by propensity score matching analysis.	Journal of Cancer	2023	21.96221627716616	36.75878370338669	0	
37214445	Emerging trends and focus on immune checkpoint inhibitors for non-small cell lung cancer treatment: visualization and bibliometric analysis.	Frontiers in pharmacology	2023	37.45641209295205	-20.964463854330305	0	
37210651	Nivolumab for locally advanced and metastatic cutaneous squamous cell carcinoma (NIVOSQUACS study)-Phase II data covering impact of concomitant haematological malignancies.	Journal of the European Academy of Dermatology and Venereology : JEADV	2023	55.7073727466788	5.908596212032078	1	
37208329	ERK and USP5 govern PD-1 homeostasis via deubiquitination to modulate tumor immunotherapy.	Nature communications	2023	-18.37479383899135	-6.3235828217754575	0	
37208221	Predictive Capability of PD-L1 Protein Expression for Patients With Advanced NSCLC: Any Differences Based on Histology?	Clinical lung cancer	2023	13.804363552721131	-29.561049138180834	0	
37208129	Combining histological grade, TILs, and the PD-1/PD-L1 pathway to identify immunogenic tumors and de-escalate radiotherapy in early breast cancer: a secondary analysis of a randomized clinical trial.	Journal for immunotherapy of cancer	2023	-6.680919886723474	17.015357248038935	0	
37207581	PD-L1 exosomes electrochemical sensor based on coordination of AgNCs and Zr4+: Multivalent peptide enhancing target capture efficiency and antifouling performance.	Biosensors & bioelectronics	2023	-42.96991067040414	-53.53991065273696	0	
37207535	Design, synthesis, and evaluation of PD-1/PD-L1 small-molecule inhibitors bearing a rigid indane scaffold.	European journal of medicinal chemistry	2023	-41.13724282043452	-39.18121649560261	0	
37207445	The current advances and future directions of PD-1/PD-L1 blockade in head and neck squamous cell carcinoma (HNSCC) in the era of immunotherapy.	International immunopharmacology	2023	-8.412869121695305	-6.747285177540861	2	
37207152	Hepatic myofibroblasts exert immunosuppressive effects independent of the immune checkpoint regulator PD-L1 in liver metastasis of pancreatic ductal adenocarcinoma.	Frontiers in oncology	2023	-3.5924231150704977	3.36162531313811	2	
37206267	IGH::CD274 (PD-L1) rearrangement in diffuse large B cell lymphoma and its therapeutic implication.	EJHaem	2023	-32.07068288456443	27.57110969240517	0	
37205993	A BRAF mutation-associated gene risk model for predicting the prognosis of melanoma.	Heliyon	2023	-1.600353048274986	49.89191173574429	0	
37205768	PD-L1 checkpoint blockade promotes regulatory T cell activity that underlies therapy resistance.	Science immunology	2023	-28.72097941280336	-7.167186980432014	2	
37205200	Gustave Roussy immune score is a prognostic marker in patients with small cell lung cancer undergoing immunotherapy: a real-world retrospective study.	Frontiers in oncology	2023	28.539311588125106	-43.41762369512374	0	
37205112	Repurposing pentamidine for cancer immunotherapy by targeting the PD1/PD-L1 immune checkpoint.	Frontiers in immunology	2023	-36.72850073064016	-38.09685261614372	0	
37205107	Clinical benefits of PD-1 inhibitors in specific subgroups of patients with advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis of phase 3 randomized clinical trials.	Frontiers in immunology	2023	52.18191431565575	14.492058103325505	0	
37201379	Molecular characterization of immunoinhibitory factors PD-1/PD-L1 in sheep.	Veterinary immunology and immunopathology	2023	-57.82917882080836	-26.494747333175773	0	
37197440	Non-small cell lung cancer patients treated with Anti-PD1 immunotherapy show distinct microbial signatures and metabolic pathways according to progression-free survival and PD-L1 status.	Oncoimmunology	2023	23.46221510797988	40.93917135349864	1	
37196547	Inside PD-1/PD-L1,2 with their inhibitors.	European journal of medicinal chemistry	2023	-41.96199905570563	-36.016376124079635	1	
37196303	Investigation of the PD-1/PD-L1 Expression in the Lesional Skins of Patients With Psoriasis.	Dermatology practical & conceptual	2023	-59.07420867756036	-17.881008364623398	0	
37195370	[99mTc]-labelled anti-Programmed Death-Ligand 1 single-domain antibody SPECT/CT: a novel imaging biomarker for myocardial PD-L1 expression.	EJNMMI research	2023	11.799987163591869	-51.52406821347429	0	
37193972	PD-L1 stimulation can promote proliferation and survival of leukemic cells by influencing glucose and fatty acid metabolism in acute myeloid leukemia.	BMC cancer	2023	-37.61640601174453	-4.783045700754615	0	
37193763	Single cell profiling at the maternal-fetal interface reveals a deficiency of PD-L1+ non-immune cells in human spontaneous preterm labor.	Scientific reports	2023	-75.76189221729705	-19.41068907403916	0	
37193754	Bis(benzonitrile) dichloroplatinum (II) interrupts PD-1/PD-L1 interaction by binding to PD-1.	Acta pharmacologica Sinica	2023	-38.78077203614292	-40.531675664512846	0	
37191345	Combination immunotherapy of PEG-modified preladenant thermosensitive liposomes and PD-1 inhibitor effectively enhances the anti-tumor immune response and therapeutic effects.	Pharmaceutical development and technology	2023	-32.06291261347364	-48.10458823504416	0	
37190279	Local Delivery of Immunomodulatory Antibodies for Gastrointestinal Tumors.	Cancers	2023	40.54764492902893	15.80699458233893	0	
37190201	Current Progress on Predictive Biomarkers for Response to Immune Checkpoint Inhibitors in Gastric Cancer: How to Maximize the Immunotherapeutic Benefit?	Cancers	2023	43.71832269074337	19.301356485001897	0	
37189453	Dose-Dependent Effects in Plasma Oncotherapy: Critical In Vivo Immune Responses Missed by In Vitro Studies.	Biomolecules	2023	-24.6111969675425	-41.1704223710953	2	
37189103	Epigenetic reprogramming of Runx3 reinforces CD8 + T-cell function and improves the clinical response to immunotherapy.	Molecular cancer	2023	-13.194988315756753	28.25360952690137	3	
37188764	Clinical roles of soluble PD-1 and PD-L1 in plasma of NSCLC patients treated with immune checkpoint inhibitors.	Cancer immunology, immunotherapy : CII	2023	22.034647451801952	-28.225416401979142	0	
37188668	Clinical efficacy and biomarker analysis of dual PD-1/CTLA-4 blockade in recurrent/metastatic EBV-associated nasopharyngeal carcinoma.	Nature communications	2023	42.61226689290745	26.64958551023249	0	
37188271	Management and prediction of immune-related adverse events for PD1/PDL-1 immunotherapy in colorectal cancer.	Frontiers in pharmacology	2023	71.43811312188897	-15.123312882875208	0	
37188188	PD-1 inhibitor combined with radiotherapy and GM-CSF in MSS/pMMR metastatic colon cancer: a case report.	Frontiers in oncology	2023	36.452386410636485	25.248578566794915	0	
37184049	Infection pattern and immunological characteristics of Epstein-Barr virus latent infection in cervical squamous cell carcinoma.	Journal of medical virology	2023	-16.395063080554497	35.870912263477365	0	
37184030	Neutrophils as key regulators of tumor immunity that restrict immune checkpoint blockade in liver cancer.	Cancer biology & medicine	2023	-17.110708974487924	40.955585245151646	0	
37180201	Expression and Clinical Correlation of PD-1/PD-L1 and VE1(BRAFp.V600E) in Pediatric Langerhans Cell Histiocytosis.	Mediterranean journal of hematology and infectious diseases	2023	-29.141656260516225	17.451199317633115	0	
37180131	Study protocol: a prospective single-center study for non-invasive biomonitoring of renal complications in cancer patients treated with immune checkpoint inhibitors.	Frontiers in immunology	2023	70.49973535027479	1.3666859536164124	0	
37179293	Low plasma PD-L1 levels, early tumor onset and absence of peritoneal carcinomatosis improve prognosis of women with advanced high-grade serous ovarian cancer.	BMC cancer	2023	-19.077390262348608	14.86793872395883	1	
37178411	Identification of m6A-related lncRNAs as prognostic signature within colon tumor immune microenvironment.	Cancer reports (Hoboken, N.J.)	2023	-6.29618787085079	55.76745341118913	1	
37175900	PD-L1 Exon 3 Is a Hidden Switch of Its Expression and Function in Oral Cancer Cells.	International journal of molecular sciences	2023	-13.341541204464455	-5.422635972887083	1	
37175653	The Tumor Immune Microenvironment in Clear Cell Renal Cell Carcinoma.	International journal of molecular sciences	2023	15.656883134449888	33.39954211826436	1	
37175055	Correction: Sari, M.I.; Ilyas, S. The Expression Levels and Concentrations of PD-1 and PD-L1 Proteins in Septic Patients: A Systematic Review. Diagnostics 2022, 12, 2004.	Diagnostics (Basel, Switzerland)	2023	-56.95215818857089	35.22705974010817	0	
37174080	Immune Checkpoint Profiling in Humanized Breast Cancer Mice Revealed Cell-Specific LAG-3/PD-1/TIM-3 Co-Expression and Elevated PD-1/TIM-3 Secretion.	Cancers	2023	-2.649780097664024	25.428850342368204	1	
37173350	Radiomics models based on multisequence MRI for predicting PD-1/PD-L1 expression in hepatocellular carcinoma.	Scientific reports	2023	10.429693633029066	-10.767275844469893	0	
37170090	Comparative efficacy and safety of PD-1/PD-L1 inhibitors in triple negative breast cancer: a systematic review and network meta-analysis of randomized controlled trials.	Cancer cell international	2023	56.20199226051539	-11.759007386665228	0	
37166484	Single-center phase 2 study of PD-1 inhibitor combined with DNA hypomethylation agent + CAG regimen in patients with relapsed/refractory acute myeloid leukemia.	Cancer immunology, immunotherapy : CII	2023	47.82259876439174	-4.313769614451978	0	
37166471	Tucatinib promotes immune activation and synergizes with programmed cell death-1 and programmed cell death-ligand 1 inhibition in HER2-positive breast cancer.	Journal of the National Cancer Institute	2023	-12.978479481961172	-34.66350359134131	0	
37165196	Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer.	Nature	2023	-20.847054912822315	-13.17086941945003	31	
37164450	AR-A014418 regulates intronic polyadenylation and transcription of PD-L1 through inhibiting CDK12 and CDK13 in tumor cells.	Journal for immunotherapy of cancer	2023	-37.93212995074957	-6.969774763158448	0	
37163215	HLA-DR+ mucosal-associated invariant T cells predict poor prognosis in patients with sepsis: A prospective observational study.	Scandinavian journal of immunology	2023	-53.9713752525369	33.79622764567237	0	
37162929	Expansion of Disease Specific Cardiac Macrophages in Immune Checkpoint Inhibitor Myocarditis.	bioRxiv : the preprint server for biology	2023	85.68723953880102	3.14137190815065	0	
37155024	Identification and verification of an ALYREF-involved 5-methylcytosine based signature for stratification of prostate cancer patients and prediction of clinical outcome and response to therapies.	Discover. Oncology	2023	-8.953506297798429	57.67176583903988	0	
37153768	Value assessment of PD-1/PD-L1 inhibitors in the treatment of oesophageal and gastrointestinal cancers.	Frontiers in pharmacology	2023	51.10774411762641	16.40115740271193	0	
37153387	Persistent T cell proliferation and MDSCs expansion precede incomplete CD4+ T cell recovery in people with acute HIV-1 infection with early ART.	Heliyon	2023	-78.9243008781106	16.066108191797767	0	
37152526	Over-expression of programmed death-ligand 1 and programmed death-1 on antigen-presenting cells as a predictor of organ dysfunction and mortality during early sepsis: a prospective cohort study.	World journal of emergency medicine	2023	-57.379752412054266	33.68947796599296	0	
37152047	Concurrent sintilimab with sequential chemoradiotherapy for unresectable, stage III non-small cell lung cancer: a retrospective study.	Frontiers in oncology	2023	41.2368468043927	-23.582270918732966	0	
37151388	The Real-world Therapeutic Analysis of First-line Immunotherapy in Chinese Patients with Drive Gene Positive for Advanced Non-Small Cell Lung Cancer.	Journal of Cancer	2023	25.886714750178943	-22.628151771423543	0	
37150782	Programmed death ligand 1 expression in diffuse large B cell lymphoma: correlation with clinicopathological prognostic factors.	Journal of the Egyptian National Cancer Institute	2023	-34.52515736875857	26.64374377012986	0	
37150404	Tumor lysates-constructed hydrogel to potentiate tumor immunotherapy.	Journal of controlled release : official journal of the Controlled Release Society	2023	-28.10440466328285	-51.32433816262142	0	
37150013	Combination therapy with immune checkpoint inhibitors in recurrent or metastatic squamous cell carcinoma of the head and neck: A meta-analysis.	International immunopharmacology	2023	49.531823753147215	32.45243212926945	0	
37148978	Identification of a novel small-molecule inhibitor targeting TIM-3 for cancer immunotherapy.	Biochemical pharmacology	2023	-38.0851073850451	-36.56837610227664	0	
37147977	First-line immune-checkpoint inhibitor treatment in extensive-disease small-cell lung cancer: A classical and network meta-analysis.	Journal of cancer research and therapeutics	2023	46.29890173675624	-40.74729561798705	0	
37146474	Combination therapy with anti-programmed cell death 1 antibody plus angiokinase inhibitor exerts synergistic antitumor effect against malignant mesothelioma via tumor microenvironment modulation.	Lung cancer (Amsterdam, Netherlands)	2023	43.55521361437068	-11.3642505591065	1	
37143946	Anti-PD-1 immunotherapy combined with stereotactic body radiation therapy and GM-CSF for the treatment of advanced malignant PEComa: A case report.	Frontiers in oncology	2023	57.07140725942524	14.32205942891968	0	
37142983	Identification of SPRYD4 as a tumour suppressor predicts prognosis and correlates with immune infiltration in cholangiocarcinoma.	BMC cancer	2023	-1.9520002765991111	60.4524230177541	0	
37141978	Immune checkpoint inhibitor-induced cutaneous toxicities: a review of histopathologic and clinical features.	Human pathology	2023	75.79690803531457	-22.3208747953036	1	
37141702	CD69 on Tumor-Infiltrating Cells Correlates With Neuroblastoma Suppression by Simultaneous PD-1 and PD-L1 Blockade.	The Journal of surgical research	2023	-26.34750175253863	12.848891830745004	0	
37139744	Association between programmed death-1 pathway and major depression.	The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry	2023	-50.04436725515143	-13.974150674319429	0	
37138876	Prognostic value of programmed cell death ligand 1 expression in patients with intrahepatic cholangiocarcinoma: a meta-analysis.	Frontiers in immunology	2023	0.1985096484567283	5.690745975343671	0	
37138100	Modulation of immune checkpoint regulators in interferon γ induced urothelial carcinoma and activated T-lymphocyte cells by cytostatics.	Genes and immunity	2023	-10.75285649665236	-36.03448527309744	0	
37138075	Targeting PD-L2-RGMb overcomes microbiome-related immunotherapy resistance.	Nature	2023	-23.518687899530743	0.5572753958762922	4	
37132280	LAG-3 transcriptomic expression patterns across malignancies: Implications for precision immunotherapeutics.	Cancer medicine	2023	9.588868854977006	23.17534810035874	1	
37132258	Predicting immune-related adverse events using a simplified frailty score in cancer patients treated with checkpoint inhibitors: A retrospective cohort study.	Cancer medicine	2023	74.0443291885704	-12.200814031192516	1	
37132038	Toxicities associated with immune checkpoint inhibitors: a systematic study.	International journal of surgery (London, England)	2023	64.83702736735668	-16.225652512742975	1	
37131900	Analysis of Antibody Induction by Macrophages Treated Ex Vivo with Human Proteins in Mice.	Reports of biochemistry & molecular biology	2023	-32.062475213078855	-7.062911459243962	0	
37127775	DNMT3AR882H accelerates angioimmunoblastic T-cell lymphoma in mice.	Oncogene	2023	-31.34852464408593	36.90460596879116	0	
37127565	Clinical significance of serum-derived exosomal PD-L1 expression in patients with advanced pancreatic cancer.	BMC cancer	2023	-44.51138576971282	-56.30080109671677	1	
37124885	Immunotherapy for recurrent hepatocellular carcinoma.	World journal of gastroenterology	2023	29.235454198516717	49.4428078721677	0	
37124509	Case Report: PD-L1-negative advanced bladder cancer effectively treated with anlotinib and tislelizumab: A report of two cases.	Frontiers in oncology	2023	68.92746624852134	16.050726809151765	0	
37124495	Emerging trends of BCG immunotherapy for bladder cancer in last decade: a bibliometric and visualization analysis.	Frontiers in oncology	2023	71.67991877548431	22.71921294285632	0	
37124488	Cardiotoxicity of lung cancer-related immunotherapy versus chemotherapy: a systematic review and network meta-analysis of randomized controlled trials.	Frontiers in oncology	2023	82.4738870934666	3.055465681208463	0	
37124234	Comparison of pneumonitis risk between immunotherapy alone and in combination with chemotherapy: an observational, retrospective pharmacovigilance study.	Frontiers in pharmacology	2023	65.85125941753681	-8.098865422201127	0	
37122752	Case report: Complete response of an anaplastic thyroid carcinoma patient with NRAS Q61R/BRAF D594N mutations to the triplet of dabrafenib, trametinib and PD-1 antibody.	Frontiers in immunology	2023	26.92275843311012	32.82634713208539	0	
37122540	Computational design of a cyclic peptide that inhibits the CTLA4 immune checkpoint.	RSC medicinal chemistry	2023	-46.07561434887105	-47.19598054281314	2	
37122279	Editorial: Twenty Years On from Sequencing the Human Genome, Personalized/Precision Oncology Prepares to Meet the Challenges of Checkpoint Inhibitor Therapy.	Medical science monitor : international medical journal of experimental and clinical research	2023	16.620787581231955	4.494420460551221	0	
37117135	Immune mechanisms of toxicity from checkpoint inhibitors.	Trends in cancer	2023	80.4487139777913	-5.375773489229687	3	
37114540	Dihydropyrimidine Dehydrogenase (DPD) as a Bridge between the Immune Microenvironment of Colon Cancers and 5-FU Resistance.	Frontiers in bioscience (Landmark edition)	2023	11.797773720331971	41.126340569363606	0	
37114136	Efficacy and safety of PD-1/PD-L1 inhibitor combined with chemotherapy versus chemotherapy alone in the treatment of advanced gastric or gastroesophageal junction adenocarcinoma: a systematic review and meta-analysis.	Frontiers in oncology	2023	49.731193908965714	15.362020658558931	0	
37114049	Impact of endogenous glucocorticoid on response to immune checkpoint blockade in patients with advanced cancer.	Frontiers in immunology	2023	24.734904855075243	-26.811336125400285	1	
37113606	Application of single cell multiomics points to changes in chromatin accessibility near calcitonin receptor like receptor and a possible role for adrenomedullin in the post-shock lung.	Frontiers in medicine	2023	-0.0891604476666696	-22.6689561122182	0	
37108474	Immune Checkpoint Inhibitor, Nivolumab, Combined with Chemotherapy Improved the Survival of Unresectable Advanced and Metastatic Esophageal Squamous Cell Carcinoma: A Real-World Experience.	International journal of molecular sciences	2023	53.26646834503006	12.798117303616594	0	
37108276	Circulating CD137+ T Cell Levels Are Correlated with Response to Pembrolizumab Treatment in Advanced Head and Neck Cancer Patients.	International journal of molecular sciences	2023	14.921330661822418	-6.720322003966406	0	
37106265	An HPK1 inhibitor enhanced the tumour response to anti-PD-1 immunotherapy in non-Hodgkin's lymphoma.	Clinical and experimental medicine	2023	-12.38936216065172	-24.3594626111198	0	
37105516	PPARγ agonist pioglitazone enhances colorectal cancer immunotherapy by inducing PD-L1 autophagic degradation.	European journal of pharmacology	2023	-24.6338321994394	-29.15707911017404	1	
37103651	Immune-related thyroid dysfunctions during anti PD-1/PD-L1 inhibitors: new evidence from a single centre experience.	Clinical and experimental medicine	2023	78.99965382303401	-17.4839000067642	0	
37100904	De novo design of protein interactions with learned surface fingerprints.	Nature	2023	-46.93970339792306	-42.18455490761495	6	
37098880	Clinicopathological assessment of PD-1/PD-L1 immune checkpoint expression in desmoid tumors.	European journal of histochemistry : EJH	2023	-16.934175382798355	23.02732015068715	1	
37096255	PPARγ inhibited tumor immune escape by inducing PD-L1 autophagic degradation.	Cancer science	2023	-24.626434618063783	-29.155042729698337	2	
37095958	Effectiveness and safety of first-line immune checkpoint inhibitors for patients with extensive-stage small cell lung carcinoma: A systematic review and network meta-analysis.	Heliyon	2023	46.41242481815296	-39.7651061256354	0	
37095139	Development of anti-feline PD-1 antibody and its functional analysis.	Scientific reports	2023	-16.066196085124027	-15.573359762461076	0	
37089888	Clinical characteristics and management of immune checkpoint inhibitor-related cardiotoxicity: A single-center experience.	Frontiers in cardiovascular medicine	2023	82.45889896407901	1.790321432882203	0	
37086293	Characterization and digital spatial deconvolution of the immune microenvironment of intraductal oncocytic papillary neoplasms (IOPN) of the pancreas.	Virchows Archiv : an international journal of pathology	2023	-0.0875260908208304	15.420840628768987	0	
37084635	Tumor immunosuppression relief via acidity modulation combined PD-L1 siRNA for enhanced immunotherapy.	Biomaterials advances	2023	-32.95404891216237	-52.621650447830206	1	
37084488	DC101, an anti-VEGFR2 agent, promotes high-endothelial venule formation and immune infiltration versus SAR131675 and fruquintinib.	Biochemical and biophysical research communications	2023	-8.080101788576783	-44.73709317317883	0	
37081973	Tumor immune microenvironment of cutaneous angiosarcoma with cancer testis antigens and the formation of tertiary lymphoid structures.	Frontiers in oncology	2023	-19.3948108444978	24.15073942813255	0	
37081867	Antitumor activity and safety of camrelizumab combined with apatinib in patients with relapsed or refractory peripheral T-cell lymphoma: An open-label, multicenter, phase II study.	Frontiers in immunology	2023	55.03315709424672	-1.9305580769844084	0	
37081866	Immune-related pulmonary toxicities of checkpoint inhibitors in non-small cell lung cancer: Diagnosis, mechanism, and treatment strategies.	Frontiers in immunology	2023	66.85301164799351	-8.945412176919868	0	
37081776	Metastatic sites and lesion numbers cooperated to predict efficacy of PD-1 inhibitor-based combination therapy for patients with metastatic colorectal cancer.	Cancer medicine	2023	36.745380067502325	23.975164121093087	1	
37079975	The programmed cell death protein 1 (PD1) and the programmed cell death ligand 1 (PD-L1) are significantly downregulated on macrophages and Hofbauer cells in the placenta of preeclampsia patients.	Journal of reproductive immunology	2023	-74.7439170252445	-18.11101959675845	1	
37078210	[Expert consensus on PD-L1 expression testing in esophageal carcinoma in China].	Zhonghua zhong liu za zhi [Chinese journal of oncology]	2023	18.847603419344157	-48.55219445308493	0	
37077473	Beyond antibody fucosylation: α-(1,6)-fucosyltransferase (Fut8) as a potential new therapeutic target for cancer immunotherapy.	Antibody therapeutics	2023	8.325276138174255	3.36411987648136	2	
37076508	A novel immune score model predicting the prognosis and immunotherapy response of breast cancer.	Scientific reports	2023	1.0357008030447676	45.6536062449067	0	
37076040	Immune-checkpoint inhibitor resistance in cancer treatment: Current progress and future directions.	Cancer letters	2023	31.53798174207424	14.545381383337704	3	
37075702	The success of anti-PD-1 with chemotherapy for esophageal squamous cell carcinoma.	Cell reports. Medicine	2023	52.43421801865152	15.61292976520144	0	
37072748	"The ""Great Debate"" at Melanoma Bridge 2022, Naples, December 1st-3rd, 2022."	Journal of translational medicine	2023	30.897509784039	26.940112296720624	0	
37072108	PD-L1 and MCL-1 markers and the relationship with prognostic characteristics of differentiated thyroid carcinoma.	Molecular and cellular endocrinology	2023	-6.416776298250952	-21.65418338574953	0	
37071269	A review of recent advances in the novel therapeutic targets and immunotherapy for lung cancer.	Medical oncology (Northwood, London, England)	2023	41.46190494424594	-40.16415633270076	2	
37070426	PD-1/PD-L1 inhibitors-associated cardiac adverse events: a retrospective and real-world study based on the FDA Adverse Event Reporting System (FAERS).	Expert opinion on drug safety	2023	61.78745905168285	-18.068771896585613	0	
37067955	Bevacizumab/PD-1 inhibitor plus chemotherapy as first-line treatment of advanced non-squamous non-small-cell lung cancer.	Journal of comparative effectiveness research	2023	50.74908386043855	-23.854294128681172	0	
37066240	Increased response to immune checkpoint inhibitors with dietary methionine restriction.	bioRxiv : the preprint server for biology	2023	-19.683725707599447	-31.69837575927579	1	
37065996	Pathologic complete response of hepatoid adenocarcinoma of the stomach after chemo-immunotherapy: A rare case report and literature review.	Frontiers in surgery	2023	48.563816161544295	19.956058026767582	0	
37064132	Dysregulation of systemic soluble immune checkpoints in early breast cancer is attenuated following administration of neoadjuvant chemotherapy and is associated with recovery of CD27, CD28, CD40, CD80, ICOS and GITR and substantially increased levels of PD-L1, LAG-3 and TIM-3.	Frontiers in oncology	2023	3.907703873034993	24.27293028919149	1	
37063927	Progress in the clinical application of immune checkpoint inhibitors in small cell lung cancer.	Frontiers in immunology	2023	44.32472369358574	-41.1121870460127	0	
37062259	Research progress on PD-1 and PD-L1 inhibitors in the treatment of metastatic urothelial carcinoma.	International immunopharmacology	2023	66.56744569349729	22.122795222786795	0	
37056754	Soluble immune checkpoints as correlates for HIV persistence and T cell function in people with HIV on antiretroviral therapy.	Frontiers in immunology	2023	-80.89646987843206	15.02804835103724	0	
37056572	Strategies targeting PD-L1 expression and associated opportunities for cancer combination therapy.	Theranostics	2023	-31.779475924606505	-45.62627748813602	5	
37055842	Targeting inhibition of prognosis-related lipid metabolism genes including CYP19A1 enhances immunotherapeutic response in colon cancer.	Journal of experimental & clinical cancer research : CR	2023	0.2803535610690962	54.91630059874809	1	
37055838	Immunotherapy of thymic epithelial tumors: molecular understandings and clinical perspectives.	Molecular cancer	2023	38.75835489303397	-1.6762939212534125	0	
37054586	ICI-based therapies: A new strategy for oral potentially malignant disorders.	Oral oncology	2023	54.37404753288824	35.26544845315924	0	
37052807	CircSCUBE3 Reduces the Anti-gastric Cancer Activity of Anti-PD-L1.	Molecular biotechnology	2023	-5.119620716882531	58.955507164264375	0	
37048719	Updated Immunotherapy for Gastric Cancer.	Journal of clinical medicine	2023	43.10221302455845	18.739300637413635	0	
37047817	Engineering a HER2-CAR-NK Cell Secreting Soluble Programmed Cell Death Protein with Superior Antitumor Efficacy.	International journal of molecular sciences	2023	-42.43374670475789	4.516520664663156	2	
37047395	PD-1 Independent Role of PD-L1 in Triple-Negative Breast Cancer Progression.	International journal of molecular sciences	2023	-35.6644504285711	-5.814114994125787	1	
37046787	The Immune Checkpoint Receptor CD96: A Local and Systemic Immune Modulator in Oral Cancer?	Cancers	2023	-7.799364637482665	-13.934516718727105	1	
37045913	5-methyladenosine regulators play a crucial role in development of chronic hypersensitivity pneumonitis and idiopathic pulmonary fibrosis.	Scientific reports	2023	-9.252954673502476	58.09506893297085	0	
37044092	MYC activation impairs cell-intrinsic IFNγ signaling and confers resistance to anti-PD1/PD-L1 therapy in lung cancer.	Cell reports. Medicine	2023	-17.972644662711794	-18.678104820654237	1	
37040183	Combination of AFP vaccine and immune checkpoint inhibitors slows hepatocellular carcinoma progression in preclinical models.	The Journal of clinical investigation	2023	28.98813701124706	50.07200887190987	0	
37038154	Cancer immunotherapy with immune checkpoint inhibitors (ICIs): potential, mechanisms of resistance, and strategies for reinvigorating T cell responsiveness when resistance is acquired.	Cancer cell international	2023	31.723040528623915	14.203215399831851	2	
37037616	Prior anti-CTLA-4 therapy impacts molecular characteristics associated with anti-PD-1 response in advanced melanoma.	Cancer cell	2023	13.538040121840888	-0.3242024033571508	1	
37036990	Blockade of trans PD-L1 interaction with CD80 augments antitumor immunity.	Proceedings of the National Academy of Sciences of the United States of America	2023	-48.78444355568941	-2.6545855888133043	0	
37036892	Tumor-Derived PD-L1+ Exosomes with Natural Inflammation Tropism for Psoriasis-Targeted Treatment.	Bioconjugate chemistry	2023	-45.16404605355534	-59.51597288859368	0	
37036308	Targeting GPC3high cancer-associated fibroblasts sensitizing the PD-1 blockage therapy in gastric cancer.	Annals of medicine	2023	0.6095823656613502	33.98699011077928	1	
37035883	[Correlation between Immune Microenvironment Features and EGFR Mutation Status  in Lung Adenocarcinoma].	Zhongguo fei ai za zhi = Chinese journal of lung cancer	2023	16.544848556336166	-17.500221661315702	0	
37035192	Cardiac infarction caused by PD-1 inhibitor during small cell neuroendocrine carcinoma of the ureter treatment: A case report.	Frontiers in oncology	2023	61.63564930108778	-19.52777559483413	0	
37033947	PathwayKO: An integrated platform for deciphering the systems-level signaling pathways.	Frontiers in immunology	2023	-2.829507400565863	43.052438346895904	0	
37033653	Hematologic side effects of immune checkpoint inhibitor with or without chemotherapy in patients with advanced and metastatic gastrointestinal cancer: A systematic review and network meta-analysis of phase 3 trials.	Frontiers in pharmacology	2023	73.52693581951803	-5.282825850085931	1	
37033602	Global trends in the health economics field of PD-1/PD-L1 inhibitors: A bibliometric and visualized study.	Frontiers in pharmacology	2023	19.74603281417077	-50.58817891495695	1	
37031362	High baseline tumor burden-associated macrophages promote an immunosuppressive microenvironment and reduce the efficacy of immune checkpoint inhibitors through the IGFBP2-STAT3-PD-L1 pathway.	Cancer communications (London, England)	2023	-2.2816893536648317	31.12164621640881	2	
37030592	Development of mouse models with restricted HLA-B∗57:01 presentation for the study of flucloxacillin-driven T-cell activation and tolerance in liver injury.	The Journal of allergy and clinical immunology	2023	-68.91827528996234	28.391909673034352	1	
37028818	Glucocorticoid activation by HSD11B1 limits T cell-driven interferon signaling and response to PD-1 blockade in melanoma.	Journal for immunotherapy of cancer	2023	-31.062238292736343	-18.205158228092166	0	
37028800	Anaplastic Classic Kaposi Sarcoma: PD-L1 Expression and Response to Immunotherapy: A Case Report and Review of the Literature.	Journal of the National Comprehensive Cancer Network : JNCCN	2023	56.95088068675948	-29.83492301197096	0	
37028278	B7x in cancer immunity and immunotherapy.	International immunopharmacology	2023	-28.999620156646117	5.451603739936856	5	
37025485	Immunotherapies for advanced hepatocellular carcinoma.	Frontiers in pharmacology	2023	30.945706619159814	49.53381331077563	2	
37024504	Targeting USP2 regulation of VPRBP-mediated degradation of p53 and PD-L1 for cancer therapy.	Nature communications	2023	-17.853550166474754	-5.745203589781763	2	
37021811	Neoadjuvant therapy with camrelizumab plus gemcitabine and cisplatin for patients with muscle-invasive bladder cancer: A multi-center, single-arm, phase 2 study.	Cancer medicine	2023	74.37826438314497	19.98358525580316	1	
37020545	Case report: Preliminary response to tislelizumab plus S-1 in patients with metastatic gallbladder carcinoma: A report of five cases and a literature review.	Frontiers in immunology	2023	52.538382780455	22.03579294145704	0	
37019647	MiR-10b-5p Impairs TET2-Mediated Inhibition of PD-L1 Transcription Thus Promoting Immune Evasion and Tumor Progression in Glioblastoma.	The Tohoku journal of experimental medicine	2023	-28.626217223636544	51.64971449795745	0	
37019172	Active immunization with a structurally aggregated PD-L1 antigen breaks T and B immune tolerance in non-human primates and exhibits in vivo anti-tumoral effects in immunocompetent mouse tumor models.	Cancer letters	2023	-26.36089104731635	-12.920711381945502	0	
37017695	Combined therapeutic effect of YHO-1701 with PD-1 blockade is dependent on natural killer cell activity in syngeneic mouse models.	Cancer immunology, immunotherapy : CII	2023	-17.81753393131029	-39.33131887743859	0	
37017116	Pemetrexed combined with dual immune checkpoint blockade enhances cytotoxic T lymphocytes against lung cancer.	Cancer science	2023	34.45592008477491	-42.20154326160893	1	
37014700	Long noncoding RNA HITT coordinates with RGS2 to inhibit PD-L1 translation in T cell immunity.	The Journal of clinical investigation	2023	-35.225952507345255	42.21989182942433	3	
37012543	Antigen-specific B cells direct T follicular-like helper cells into lymphoid follicles to mediate Mycobacterium tuberculosis control.	Nature immunology	2023	-85.73962008241507	6.028125614854128	3	
37012357	HX009, a novel BsAb dual targeting PD1 x CD47, demonstrates potent anti-lymphoma activity in preclinical models.	Scientific reports	2023	-16.230497007948113	-46.8643161137132	1	
37012213	Avelumab for the treatment of locally advanced or metastatic Merkel cell carcinoma-A multicenter real-world experience in Israel.	Cancer medicine	2023	46.84745845039176	50.16287601905272	2	
37011999	Immunotherapy Approaches for Breast Cancer Patients in 2023.	Cold Spring Harbor perspectives in medicine	2023	40.80567293797069	7.727387983098934	2	
37009698	Targeting PD-1/PD-L1 in biliary tract cancer: role and available data.	Immunotherapy	2023	58.43260538054621	24.37723516522814	0	
37007867	Clinical Characteristics and Pharmacokinetics Change of Long-Term Responders to Antiprogrammed Cell Death Protein 1 Inhibitor Among Patients With Advanced NSCLC.	JTO clinical and research reports	2023	32.07475388516421	-41.24915010671236	0	
37007042	Pneumocystis jirovecii pneumonia associated with immune checkpoint inhibitors: A systematic literature review of published case reports and disproportionality analysis based on the FAERS database.	Frontiers in pharmacology	2023	66.12477665297138	-7.680017533409855	1	
37006303	Do peripheral neuropathies differ among immune checkpoint inhibitors? Reports from the European post-marketing surveillance database in the past 10 years.	Frontiers in immunology	2023	79.74734908762116	-13.335476850794118	1	
37006252	The relationship between autophagy and PD-L1 and their role in antitumor therapy.	Frontiers in immunology	2023	-41.32510304242254	-22.346317053302023	0	
37006239	Pan-cancer analysis identifies PD-L2 as a tumor promotor in the tumor microenvironment.	Frontiers in immunology	2023	-6.744480464895605	10.955817313917358	1	
37005095	Clinical impact of first-line PD-1 or PD-L1 inhibitors combined with chemotherapy in extensive-stage small cell lung cancer patients: A real-world multicenter propensity score-matched study.	Thoracic cancer	2023	46.58832075410483	-39.8774953529397	1	
37004983	Promise of dostarlimab in cancer therapy: Advancements and cross-talk considerations.	Drug discovery today	2023	28.796441510622003	-6.544914884960432	0	
37004344	Dynamic changes of circulating soluble PD-1/PD-L1 and its association with patient survival in immune checkpoint blockade-treated melanoma.	International immunopharmacology	2023	7.920811529790758	5.653809080133823	0	
37004328	Reinstating immunogenicity using bispecific anti-checkpoint/agent inhibitors.	Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie	2023	-12.62501746666375	-45.28355273073535	1	
37003083	Comprehensive evaluation of surrogate endpoints to predict overall survival in trials with PD1/PD-L1 immune checkpoint inhibitors plus chemotherapy.	Cancer treatment reviews	2023	39.20228915303544	-15.304368967023445	0	
37002343	Spatially resolved multimarker evaluation of CD274 (PD-L1)/PDCD1 (PD-1) immune checkpoint expression and macrophage polarisation in colorectal cancer.	British journal of cancer	2023	8.224375875147082	36.36980358471668	2	
37001908	ANXA1-derived peptide for targeting PD-L1 degradation inhibits tumor immune evasion in multiple cancers.	Journal for immunotherapy of cancer	2023	-18.04918124189317	-7.013763181169188	0	
37001752	Local delivery of optimized nanobodies targeting the PD-1/PD-L1 axis with a self-amplifying RNA viral vector induces potent antitumor responses.	Cancer letters	2023	-37.09264644362191	-49.56138309219725	2	
37001736	The implication of anti-PD-1 therapy in cancer patients for the vaccination against viral and other infectious diseases.	Pharmacology & therapeutics	2023	-44.72876529886593	11.706240420994035	2	
36999976	Kidney Adverse Events Associated with Immune Checkpoint Inhibitor Therapy: A Systematic Review and Bayesian Network Meta-Analysis.	Clinical journal of the American Society of Nephrology : CJASN	2023	71.45595396802199	-0.7268578294765451	1	
36993949	Tumor immune microenvironment changes are associated with response to neoadjuvant chemotherapy and long-term survival benefits in advanced epithelial ovarian cancer: A pilot study.	Frontiers in immunology	2023	1.7387745610971024	24.11011814142241	0	
36992842	Efficacy and safety of PD-1/PD-L1 inhibitors in the treatment of recurrent and refractory ovarian cancer: A systematic review and a meta-analysis.	Frontiers in pharmacology	2023	48.55874797801136	-9.48412414005696	0	
36992143	Enhancement of Vaccine-Induced T-Cell Responses by PD-L1 Blockade in Calves.	Vaccines	2023	-58.47718039063378	-26.37367090824276	0	
36991160	Association between response to anti-PD-1 treatment and blood soluble PD-L1 and IL-8 changes in patients with NSCLC.	Discover. Oncology	2023	21.205341997704306	-27.826020725338225	0	
36990798	Oral azacitidine modulates the bone marrow microenvironment in patients with acute myeloid leukaemia in remission: A subanalysis from the QUAZAR AML-001 trial.	British journal of haematology	2023	-39.41993037974278	15.019514894650245	0	
36990776	Enhanced PD-L1 expression on tumor cells in primary CD30-positive cutaneous large T-cell lymphoma: a report of lymph node lesions of four cases.	Journal of clinical and experimental hematopathology : JCEH	2023	-36.61311175160231	29.746205571576358	0	
36990133	The role of autoimmunity and autoinflammation in giant cell arteritis: A systematic literature review.	Autoimmunity reviews	2023	-57.27732222079774	10.69237383711212	0	
36986475	First Evidence of Activity of Enfortumab Vedotin on Brain Metastases in Urothelial Cancer Patients.	Pharmaceuticals (Basel, Switzerland)	2023	68.54024280656387	12.390980429972553	0	
36983708	Immunotherapy Targeting PD-1/PD-L1 in Early-Stage Triple-Negative Breast Cancer.	Journal of personalized medicine	2023	39.56180156393744	8.897178494288225	2	
36982735	PD-1/PD-L1 Control of Antigen-Specifically Activated CD4 T-Cells of Neonates.	International journal of molecular sciences	2023	-63.66574014896713	4.823093085435839	2	
36980795	Examination of the Functional Relationship between PD-L1 DNA Methylation and mRNA Expression in Non-Small-Cell Lung Cancer.	Cancers	2023	-1.1017925631489132	-32.302095473918584	1	
36980547	Low-Baseline PD1+ Granulocytes Predict Responses to Atezolizumab-Bevacizumab in Hepatocellular Carcinoma.	Cancers	2023	15.28569976761114	-9.172895349324502	1	
36980349	PD-L1 Tumor Expression as a Predictive Biomarker of Immune Checkpoint Inhibitors' Response and Survival in Advanced Melanoma Patients in Brazil.	Diagnostics (Basel, Switzerland)	2023	13.852129990967882	-1.903057656799474	0	
36980323	Retrospective Analysis of the Predictive Value of 18F-FDG PET/CT Metabolic Parameters for PD-L1 Expression in Cervical Cancer.	Diagnostics (Basel, Switzerland)	2023	14.689345499414449	-55.56836054319133	0	
36980192	Expression of Checkpoint Molecules in the Tumor Microenvironment of Intrahepatic Cholangiocarcinoma: Implications for Immune Checkpoint Blockade Therapy.	Cells	2023	1.5493768535754335	26.637972239102574	1	
36979667	Prognostic Value of Liver Kinase B1 (LKB1) in Gastric Cancer-Associated Tumor Microenvironment Immunity.	Biomedicines	2023	-8.13261365403141	7.125231792657042	1	
36978108	NF-κB Activator 1 downregulation in macrophages activates STAT3 to promote adenoma-adenocarcinoma transition and immunosuppression in colorectal cancer.	BMC medicine	2023	2.850104181330454	38.3935338307161	1	
36976297	BLEACH&STAIN 15-marker Multiplexed Imaging in 3,098 Human Carcinomas Reveals Six Major PD-L1-driven Immune Phenotypes with Distinct Spatial Orchestration.	Molecular cancer research : MCR	2023	3.751423025876581	-47.56952518184772	1	
36975733	Mutational Profile and Pathological Features of a Case of Interleukin-10 and RGS1-Positive Spindle Cell Variant Diffuse Large B-Cell Lymphoma.	Hematology reports	2023	-30.15623787616682	32.644349649797725	0	
36971229	The effect of nursing intervention combined with PD-1 inhibitor on platelets, white blood cells, tumor markers and quality of life in patients with lung cancer.	Biotechnology & genetic engineering reviews	2023	48.51994799496616	-16.42886620777553	0	
36971192	G9a promotes immune suppression by targeting the Fbxw7/Notch pathway in glioma stem cells.	CNS neuroscience & therapeutics	2023	-24.07216619599073	56.38076474597628	2	
36969544	Role of PD-1 Inhibitors in the Treatment of Esophagogastric Adenocarcinoma: Patient Selection and Reported Outcomes.	Cancer management and research	2023	49.20583276401926	16.800391042629453	0	
36969249	Causal relationships between gut microbiota and programmed cell death protein 1/programmed cell death-ligand 1: A bidirectional Mendelian randomization study.	Frontiers in immunology	2023	-22.39096232888124	1.3329595996731751	0	
36969238	Case report: Targeting the PD-1 receptor and genetic mutations validated in primary histiocytic sarcoma with hemophagocytic lymphohistiocytosis.	Frontiers in immunology	2023	23.79932911809088	26.748478711846463	0	
36969168	Role of regulation of PD-1 and PD-L1 expression in sepsis.	Frontiers in immunology	2023	-57.96068550176487	35.63022042297934	3	
36969150	Outcomes of programmed death protein-1 inhibitors treatment of chronic active Epstein Barr virus infection: A single center retrospective analysis.	Frontiers in immunology	2023	63.3094288623712	3.754699205241323	1	
36969074	Squamous cell carcinoma of ascending colon with pMMR/MSS showed a partial response to PD-1 blockade combined with chemotherapy: A case report.	Frontiers in oncology	2023	36.48297140299476	25.470641115750453	0	
36968576	Randomized phase II trial in prostate cancer with hormone-sensitive OligometaSTatic relapse: Combining stereotactic ablative radiotherapy and durvalumab (POSTCARD GETUG P13): Study protocol.	Clinical and translational radiation oncology	2023	60.39981825135354	12.778602820439778	1	
36966808	PD-1 monoclonal antibodies enhance the cryoablation-induced antitumor immune response: a breast cancer murine model research.	International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group	2023	-24.579419394881214	-39.97367647083329	1	
36966501	Window-of-opportunity clinical trials for biomarker discovery in head and neck squamous cell carcinoma.	Current opinion in oncology	2023	53.55540107691497	31.51501959718216	0	
36966236	The prognostic value of tumour-infiltrating lymphocytes, programmed cell death protein-1 and programmed cell death ligand-1 in Stage I-III triple-negative breast cancer.	British journal of cancer	2023	-4.125187463135653	21.27522090759981	1	
36965092	The predictive value of PD-L1 expression in patients with advanced hepatocellular carcinoma treated with PD-1/PD-L1 inhibitors: A systematic review and meta-analysis.	Cancer medicine	2023	51.97567476734874	-15.104630123920048	3	
36965083	The screening of compounds regulating PD-L1 transcriptional activity in a cell functional high-throughput manner.	Cancer medicine	2023	-39.96576386206864	-34.003988990556394	1	
36960400	Quantitative, Spatially Defined Expression of Leukocyte-associated Immunoglobulin-like Receptor in Non-small Cell Lung Cancer.	Cancer research communications	2023	4.558848031885375	-24.381223114093302	0	
36960067	The combination of oxaliplatin and anti-PD-1 inhibitor promotes immune cells infiltration and enhances anti-tumor effect of PD-1 blockade in bladder cancer.	Frontiers in immunology	2023	25.898136971705394	28.495844826044	0	
36960055	Inhibiting efferocytosis reverses macrophage-mediated immunosuppression in the leukemia microenvironment.	Frontiers in immunology	2023	-28.671288111505586	-24.660077370099323	2	
36960049	PD-1 and CTLA-4 exert additive control of effector regulatory T cells at homeostasis.	Frontiers in immunology	2023	-66.84665304090932	2.7806772019202386	1	
36951654	Efficacy and toxicity profile of first-line treatment for extensive-stage small cell lung cancer: A Bayesian network meta-analysis.	Cancer medicine	2023	47.328157099195	-39.75169034852035	2	
36950765	Metastatic pulmonary pleomorphic carcinoma replaced by a granulomatous lesion after spontaneous regression and PD-1 blockade-induced regression: can epithelioid granuloma be a histological hallmark of cancer immunity?	Immunological medicine	2023	58.39519653331365	-31.37455674933611	0	
36949956	Immune checkpoint inhibitor-associated toxicity in advanced non-small cell lung cancer: An updated understanding of risk factors.	Frontiers in immunology	2023	73.28179046060119	-9.945762498801422	1	
36949040	Checkpoint kinase 1/2 inhibition potentiates anti-tumoral immune response and sensitizes gliomas to immune checkpoint blockade.	Nature communications	2023	-25.78011218563549	55.55055638295036	0	
36947705	PD-L1ATTAC mice reveal the potential of depleting PD-L1 expressing cells in cancer therapy.	Aging	2023	-34.888691561413964	-9.014990982426154	0	
36945365	Angiotensin II receptor inhibition ameliorates liver fibrosis and enhances hepatocellular carcinoma infiltration by effector T cells.	bioRxiv : the preprint server for biology	2023	26.14311428353399	51.96311249872906	0	
36944944	Immune profiling and prognostic model of pancreatic cancer using quantitative pathology and single-cell RNA sequencing.	Journal of translational medicine	2023	-2.973779398931745	46.41455234068319	2	
36944686	Chlorin e6-associated photodynamic therapy enhances abscopal antitumor effects via inhibition of PD-1/PD-L1 immune checkpoint.	Scientific reports	2023	-30.715347908560656	-56.647132262457376	3	
36943877	O-GlcNAcylation promotes tumor immune evasion by inhibiting PD-L1 lysosomal degradation.	Proceedings of the National Academy of Sciences of the United States of America	2023	-34.742626570407275	-31.282523420631456	3	
36940110	Neoadjuvant immunotherapy in colorectal cancer beyond immune checkpoint inhibitors: emerging from bench to bedside.	Minerva surgery	2023	35.703552590017786	18.71348302997764	1	
36940038	Boron Derivatives Inhibit the Proliferation of Breast Cancer Cells and Affect Tumor-Specific T Cell Activity In Vitro by Distinct Mechanisms.	Biological trace element research	2023	-27.090283289712687	-34.92592630096587	3	
36939927	 Concurrent/sequential versus sequential immune checkpoint inhibition in inoperable large stage III non-small cell lung cancer patients treated with chemoradiotherapy: a prospective observational study.	Journal of cancer research and clinical oncology	2023	41.3801454838891	-23.748021109627125	0	
36938364	A Potential Off-Target Effect of the Wnt/β-Catenin Inhibitor KYA1797K: PD-L1 Binding and Checkpoint Inhibition.	Biomedicine hub	2023	-40.20693447595829	-40.4589297414561	0	
36937385	Self-supervised contrastive learning using CT images for PD-1/PD-L1 expression prediction in hepatocellular carcinoma.	Frontiers in oncology	2023	9.585245636775676	-10.133011743262642	0	
36934638	Neoadjuvant PD-1 blockade plus chemotherapy versus chemotherapy alone in locally advanced stage II-III gastric cancer: A single-centre retrospective study.	Translational oncology	2023	48.565401609591774	11.760892834629091	1	
36933247	Warming Menstruation and Analgesic Soup Inhibits PD-1/PD-L1 Pathway in Rats with Endometriosis.	Alternative therapies in health and medicine	2023	-70.74751049358964	-18.317183371848238	0	
36932387	Exosome-derived circCCAR1 promotes CD8 + T-cell dysfunction and anti-PD1 resistance in hepatocellular carcinoma.	Molecular cancer	2023	-5.411842173066758	58.75518563841654	12	
36931170	Triptolide reduces PD-L1 through the EGFR and IFN-γ/IRF1 dual signaling pathways.	International immunopharmacology	2023	-30.51648250589471	-33.73263660753382	2	
36931099	Programmed cell death-1 and its ligands: Current knowledge and possibilities in immunotherapy.	Clinics (Sao Paulo, Brazil)	2023	-44.71070187623568	-16.50323126053477	3	
36927289	Structure-based small inhibitors search combined with molecular dynamics driven energies for human programmed cell death-1 (PD-1) protein.	Journal of biomolecular structure & dynamics	2023	-41.85000092155639	-39.390693624106	1	
36926390	Immune-related adverse events induced by programmed death protein-1 inhibitors from the perspective of lymphoma immunotherapy.	World journal of clinical cases	2023	72.21878344724502	-14.838276871685926	0	
36926265	Identification of GZMA as a Potential Therapeutic Target Involved in Immune Infiltration in Breast Cancer by Integrated Bioinformatical Analysis.	Breast cancer (Dove Medical Press)	2023	-14.938351766011175	55.76524232667384	0	
36924563	HUVECs affect HuT-78 cell apoptosis and cytokine production via the HIF-1α-PD-L1/PD-1 pathway under hypoxia.	International immunopharmacology	2023	-60.84489647951621	24.243578287376195	0	
36923080	A real-world retrospective study of incidence and associated factors of endocrine adverse events related to PD-1/PD-L1 inhibitors.	Annals of translational medicine	2023	72.23353958839071	-16.854871238139864	0	
36918817	A text-mining approach to study the real-world effectiveness and potentially fatal immune-related adverse events of PD-1 and PD-L1 inhibitors in older patients with stage III/IV non-small cell lung cancer.	BMC cancer	2023	54.96875100934636	-18.669784810348386	0	
36917954	Tumor PD-L1 engages myeloid PD-1 to suppress type I interferon to impair cytotoxic T lymphocyte recruitment.	Cancer cell	2023	-33.80792335275099	-7.018571753009464	6	
36917924	Immunogenetic variations predict immune-related adverse events for PD-1/PD-L1 inhibitors.	European journal of cancer (Oxford, England : 1990)	2023	21.681433505313095	-9.202454453359111	2	
36916491	Bioorthogonal Activation of TLR7 Agonists Provokes Innate Immunity to Reinforce Aptamer-Based Checkpoint Blockade.	ACS nano	2023	-26.219236586370958	-58.39607164038422	1	
36916374	[Effect of continuous blood purification on immunity and endothelial cell function in patients with sepsis].	Zhonghua wei zhong bing ji jiu yi xue	2023	-57.31057519353239	38.431919323264886	0	
36915615	ICOS/ICOSLG and PD-1 Co-Expression is Associated with the Progression of Colorectal Precancerous- Carcinoma Immune Microenvironment.	Journal of inflammation research	2023	4.374246416469632	36.173924706860845	0	
36915465	Anti-PD-1 plus anti-angiogenesis combined with chemotherapy in patients with HER2-negative advanced or metastatic gastric cancer: a multi-institutional retrospective study.	Journal of gastrointestinal oncology	2023	48.41338445777989	18.779269889395614	0	
36915210	Metastasis of breast cancer to bones alters the tumor immune microenvironment.	European journal of medical research	2023	-2.622207064623392	16.025125729049954	0	
36915197	Proximity proteome mapping reveals PD-L1-dependent pathways disrupted by anti-PD-L1 antibody specifically in EGFR-mutant lung cancer cells.	Cell communication and signaling : CCS	2023	-15.82092759208374	-10.042463285662016	1	
36910633	Case report: PD-1 inhibitor-based treatment strategies in gastric cancer complicated by bone marrow metastasis and disseminated intravascular coagulation: A report of two cases.	Frontiers in oncology	2023	48.56935111719984	18.712819719091268	0	
36908315	Immune-related adverse events associated with immune checkpoint inhibitors for advanced gastric and gastroesophageal junction cancer: A meta-analysis.	World journal of gastrointestinal oncology	2023	75.63775026440324	-10.3563357917008	0	
36905697	Prospective role of PD-1/PD-L1 immune checkpoint inhibitors in GI cancer.	Pathology, research and practice	2023	-43.88706566205566	-17.699796211661752	1	
36902820	PD-1 and PD-L1 Expression Levels as a Potential Biomarker of Chronic Rhinosinusitis and Head and Neck Cancers.	Journal of clinical medicine	2023	-65.73714932085755	-25.820438367931963	0	
36902456	Why Don't the Mutant Cells That Evade DNA Repair Cause Cancer More Frequently? Importance of the Innate Immune System in the Tumor Microenvironment.	International journal of molecular sciences	2023	-31.720245408480704	54.212351872237015	1	
36902442	Effect of SARS-CoV-2 mRNA-Vaccine on the Induction of Myocarditis in Different Murine Animal Models.	International journal of molecular sciences	2023	86.97550915958102	2.4879994182942644	0	
36902214	Acral Melanoma Is Infiltrated with cDC1s and Functional Exhausted CD8 T Cells Similar to the Cutaneous Melanoma of Sun-Exposed Skin.	International journal of molecular sciences	2023	2.9941853021602034	17.482007704371302	0	
36902139	The Role of BCL-2 and PD-1/PD-L1 Pathway in Pathogenesis of Myelodysplastic Syndromes.	International journal of molecular sciences	2023	-35.17357145708016	12.357238768657414	0	
36901916	Variable Intrinsic Expression of Immunoregulatory Biomarkers in Breast Cancer Cell Lines, Mammospheres, and Co-Cultures.	International journal of molecular sciences	2023	-3.1583522940286235	24.24770493728013	1	
36901697	Prognostic Value of EMT Gene Signature in Malignant Mesothelioma.	International journal of molecular sciences	2023	-0.7661150618885992	39.88142083375151	1	
36900182	PD-1+CD8+ T Cells Proximal to PD-L1+CD68+ Macrophages Are Associated with Poor Prognosis in Pancreatic Ductal Adenocarcinoma Patients.	Cancers	2023	-9.340865268681316	27.474164924695717	1	
36900006	Diagnostic Predictors of Immunotherapy Response in Head and Neck Squamous Cell Carcinoma.	Diagnostics (Basel, Switzerland)	2023	-7.014620126729226	-5.293370999316661	0	
36899322	Severe hematuria in a patient receiving bevacizumab and pembrolizumab for metastatic cervical cancer: a case report.	BMC nephrology	2023	67.42440587165675	14.306242499421892	0	
36898366	Primary Mediastinal B-Cell Lymphoma in Children and Young Adults.	Journal of the National Comprehensive Cancer Network : JNCCN	2023	43.89912063845751	-8.427941041149722	1	
36897739	Identification of a PD1/PD-L1 inhibitor by structure-based pharmacophore modelling, virtual screening, molecular docking and biological evaluation.	Molecular informatics	2023	-40.879644156294574	-40.67868721099074	1	
36897183	Glycan-Controlled Human PD-1 Variants Displaying Broad-Spectrum High Binding to PD-1 Ligands Potentiate T Cell.	Molecular pharmaceutics	2023	-37.37935233733777	-32.049094876552985	0	
36896779	Bispecific GPC3/PD‑1 CAR‑T cells for the treatment of HCC.	International journal of oncology	2023	-43.10838939167842	7.762435799960444	0	
36896323	Tumor Suppression by PD-1/PD-L1 Interaction Blockage in Mice Model.	Iranian journal of pharmaceutical research : IJPR	2022	-48.642786207706834	-26.20903830632509	0	
36895933	Narrative review: immunotherapy in anaplastic lymphoma kinase (ALK)+ lung cancer-current status and future directions.	Translational lung cancer research	2023	34.83487279571761	-36.08084312578015	1	
36894965	B7-H3 expression is associated with high PD-L1 expression in clear cell renal cell carcinoma and predicts poor prognosis.	Diagnostic pathology	2023	17.04473781422587	30.95655410171389	1	
36894899	Characterisation of tumor microenvironment and prevalence of CD274/PD-L1 genetic alterations difference in colorectal Cancer.	BMC cancer	2023	9.53925424577996	37.92102866253364	0	
36894873	Immune checkpoint inhibitors associated granulomatous small vessel vasculitis accompanied with tubulointerstitial nephritis: a case report.	BMC nephrology	2023	71.2962448491629	1.933838781860398	1	
36893957	Genetically engineered PD-1 displaying nanovesicles for synergistic checkpoint blockades and chemo-metabolic therapy against non-small cell lung cancer.	Acta biomaterialia	2023	-35.87694708124252	-55.92895845035002	3	
36893266	Dysregulation of PD-L1 by UFMylation imparts tumor immune evasion and identified as a potential therapeutic target.	Proceedings of the National Academy of Sciences of the United States of America	2023	-35.195082392882284	-29.832317880791944	0	
36893014	Tumor Microenvironment and Its Clinicopathologic and Prognostic Association in Cutaneous and Noncutaneous Angiosarcomas.	American journal of clinical pathology	2023	-19.22612333612292	24.413648319333326	0	
36892260	Safety and efficacy of PD-1 and PD-L1 inhibitors in relapsed and refractory Hodgkin's lymphoma: a systematic review and meta-analysis of 20 prospective studies.	Hematology (Amsterdam, Netherlands)	2023	48.40173951766309	-9.40006065318032	0	
36891313	Cutaneous manifestations associated with immune checkpoint inhibitors.	Frontiers in immunology	2023	75.7739915649252	-22.572879726250957	2	
36890557	Roles and mechanisms of tumour-infiltrating B cells in human cancer: a new force in immunotherapy.	Biomarker research	2023	4.066163272676302	26.001035166660117	1	
36889057	Multi-Institutional Study of Pathologist Reading of the Programmed Cell Death Ligand-1 Combined Positive Score Immunohistochemistry Assay for Gastric or Gastroesophageal Junction Cancer.	Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc	2023	15.134297673223683	-42.2722732200221	4	
36884083	Correlation of immune makers with HPV 16 infections and the prognosis in oropharyngeal squamous cell carcinoma.	Clinical oral investigations	2023	-3.581454332758729	-10.55209045676244	0	
36883630	Tertiary Lymphoid Structure Raises Survival and Immunotherapy in HPV- HNSCC.	Journal of dental research	2023	-11.980496179451317	33.817894337594566	0	
36883235	Overexpression of complement C5a indicates poor survival and therapeutic response in metastatic renal cell carcinoma.	The International journal of biological markers	2023	20.060467573741715	34.68648283973918	0	
36880750	Tumor immune microenvironment predicts the pathologic response of neoadjuvant chemoimmunotherapy in non-small-cell lung cancer.	Cancer science	2023	31.45082306792678	-20.924478988231687	2	
36876839	Knockdown of Programmed Death 1 Inhibited Progression of Papillary Thyroid Carcinoma in Mice.	Protein and peptide letters	2023	-7.0388650566238455	-20.06102849107835	0	
36876140	Immune checkpoint expression and relationships to anti-PD-L1 immune checkpoint blockade cancer immunotherapy efficacy in aged versus young mice.	Aging and cancer	2022	56.51738671855889	-19.53509569607657	1	
36875112	Immunological priming of mesenchymal stromal/stem cells and their extracellular vesicles augments their therapeutic benefits in experimental graft-versus-host disease via engagement of PD-1 ligands.	Frontiers in immunology	2023	-55.20731718152366	22.70575260462848	2	
36875061	Correlative analysis from a phase I clinical trial of intrapleural administration of oncolytic vaccinia virus (Olvi-vec) in patients with malignant pleural mesothelioma.	Frontiers in immunology	2023	-35.24719035937413	51.25367552150626	1	
36874117	Unexpected curative effect of PD-1 inhibitor in gastric cancer with brain metastasis: A case report.	Frontiers in oncology	2023	48.50339571643112	18.71243989127933	0	
36870904	Hematological toxicities of immune checkpoint inhibitors and the impact of blood transfusion and its microbiome on therapeutic efficacy and recipient's safety and survival outcome:A systematic narrative appraisal of where we are now!	Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis	2023	74.24375821021587	-5.583436235495643	0	
36867228	Blocking of programmed cell death-ligand 1 (PD-L1) expressed on endothelial cells promoted the recruitment of CD8+IFN-γ+ T cells in atherosclerosis.	Inflammation research : official journal of the European Histamine Research Society ... [et al.]	2023	-59.3599976368402	8.6544369105374	2	
36864784	Polio virotherapy targets the malignant glioma myeloid infiltrate with diffuse microglia activation engulfing the CNS.	Neuro-oncology	2023	-25.200193612188823	58.47468865881389	4	
36864257	Immune evasion phenotype is common in Richter transformation diffuse large B-cell lymphoma variant.	Virchows Archiv : an international journal of pathology	2023	-33.82603075991433	28.91410290253537	0	
36860322	Review of biomarkers for response to immunotherapy in HNSCC microenvironment.	Frontiers in oncology	2023	53.52881400170627	32.513898390644165	0	
36857863	Thyroid cells from normal and autoimmune thyroid glands suppress T lymphocytes proliferation upon contact revealing a new regulatory inhibitory type of interaction independent of PD1/PDL1.	Journal of autoimmunity	2023	-62.07190275338201	10.94743383593115	1	
36855844	Combining radiation and the ATR inhibitor berzosertib activates STING signaling and enhances immunotherapy via inhibiting SHP1 function in colorectal cancer.	Cancer communications (London, England)	2023	34.29005407863512	25.515190600151943	7	
36854755	Supplementation with α-ketoglutarate improved the efficacy of anti-PD1 melanoma treatment through epigenetic modulation of PD-L1.	Cell death & disease	2023	-27.7273162451188	-30.585395659902044	2	
36852791	Cancer-associated Fibroblast-derived Extracellular Vesicles Mediate Immune Escape of Bladder Cancer via PD-L1/PD-1 Expression.	Endocrine, metabolic & immune disorders drug targets	2023	-40.03844286596074	-58.58408175586623	1	
36851089	Ex Vivo Blockade of the PD-1 Pathway Improves Recall IFNγ Responses of HIV-Infected Persons on Antiretroviral Therapy.	Vaccines	2023	-82.95076940361673	15.53959458238389	0	
36846928	CD169+ sinus macrophages in regional lymph nodes do not predict mismatch-repair status of patients with colorectal cancer.	Cancer medicine	2023	10.807576324758694	39.799740373168206	1	
36846683	Identify AGAP2 as prognostic biomarker in clear cell renal cell carcinoma based on bioinformatics and IHC staining.	Heliyon	2023	16.962484576955383	35.51563021218626	1	
36846007	The efficacy and safety of PD-1 inhibitors for EGFR-mutant non-small cell lung cancer after tyrosine kinase inhibitor failure: a retrospective real-world cohort study.	Annals of translational medicine	2023	37.90138867157721	-38.43968015320186	1	
36845719	TOMM34 serves as a candidate therapeutic target associated with immune cell infiltration in colon cancer.	Frontiers in oncology	2023	4.327381141028647	41.02485458896446	0	
36845690	Immunotherapy progress and clinical strategy of unresectable locally advanced non-small cell lung cancer.	Frontiers in oncology	2023	36.56226200219504	-29.64194953584012	1	
36845098	Functional characterization of TSPAN7 as a novel indicator for immunotherapy in glioma.	Frontiers in immunology	2023	-23.20839396749738	55.35997774387957	0	
36844955	Classic and new strategies for the treatment of advanced melanoma and non-melanoma skin cancer.	Frontiers in medicine	2022	32.1188453760933	29.866881526559595	1	
36844924	Combinatory analysis of immune cell subsets and tumor-specific genetic variants predict clinical response to PD-1 blockade in patients with non-small cell lung cancer.	Frontiers in oncology	2022	18.80053146084447	-30.029346970177414	0	
36842764	N6-methyladenosine RNA modification in PD-1/PD-L1: Novel implications for immunotherapy.	Biochimica et biophysica acta. Reviews on cancer	2023	-32.00397637547192	41.38837970068152	1	
36841853	Prognostic impact of PD-L1 and TIGIT expression in non-small cell lung cancer following concurrent chemo-radiotherapy.	Scientific reports	2023	15.049065891821837	-24.5972368669942	1	
36841031	The impact of oncolytic adenoviral therapy on the therapeutic efficacy of PD-1/PD-L1 blockade.	Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie	2023	27.7501038056608	36.43853609099912	1	
36835382	Identification of CBPA as a New Inhibitor of PD-1/PD-L1 Interaction.	International journal of molecular sciences	2023	-39.510511367114525	-39.42017222610136	3	
36829496	Targets of Immune Escape Mechanisms in Cancer: Basis for Development and Evolution of Cancer Immune Checkpoint Inhibitors.	Biology	2023	28.988970794035904	12.594330885964776	7	
36828029	Hypophysitis and Secondary Adrenal Insufficiency From Immune Checkpoint Inhibitors: Diagnostic Challenges and Link With Survival.	Journal of the National Comprehensive Cancer Network : JNCCN	2023	83.9422354958313	-17.44647178654577	1	
36825029	Digital expression profile of immune checkpoint genes in medulloblastomas identifies CD24 and CD276 as putative immunotherapy targets.	Frontiers in immunology	2023	-19.369346106651253	50.30690285536216	2	
36825025	The safety of combining immune checkpoint inhibitors and platinum-based chemotherapy for the treatment of solid tumors: A systematic review and network meta-analysis.	Frontiers in immunology	2023	72.07734063614504	-7.485924842611817	1	
36823366	The HLA ligandome of oropharyngeal squamous cell carcinomas reveals shared tumour-exclusive peptides for semi-personalised vaccination.	British journal of cancer	2023	-8.756810533594706	30.726031197601856	1	
36823182	Rhamnazin Enhanced Anti-Tumor Efficacy of Anti-PD-1 Therapy for Lung Cancer in Mice through Inhibition of PD-L1 Expression.	The Tohoku journal of experimental medicine	2023	-4.887216823324308	-30.71522313206123	0	
36823122	Immune Checkpoint Inhibitors and Associated Pituitary Dysfunctions: A Mini-Review.	Journal of Nippon Medical School = Nippon Ika Daigaku zasshi	2023	83.66624764156202	-16.504870213759848	0	
36823017	The role of immune checkpoint inhibitors (ICI) as adjuvant treatment in renal cell carcinoma (RCC): A systematic review and meta-analysis.	Clinical genitourinary cancer	2023	67.27648523055892	27.06909444949278	0	
36822667	Concurrent durvalumab and radiation therapy (DUART) followed by adjuvant durvalumab in patients with localized urothelial cancer of bladder: results from phase II study, BTCRC-GU15-023.	Journal for immunotherapy of cancer	2023	64.72352578912705	12.071024830191051	3	
36822438	The role of m6A-mediated PD-1/PD-L1 in antitumor immunity.	Biochemical pharmacology	2023	-31.961577883359546	41.38651916816625	2	
36821809	Functional Engagement of the PD-1/PD-L1 Complex But Not PD-L1 Expression Is Highly Predictive of Patient Response to Immunotherapy in Non-Small-Cell Lung Cancer.	Journal of clinical oncology : official journal of the American Society of Clinical Oncology	2023	7.491425852373577	-8.030800509011609	1	
36821067	Three cases of immune-related hypopituitarism after atezolizumab-bevacizumab treatment for hepatocellular carcinoma.	Clinical journal of gastroenterology	2023	84.45728293995495	-18.66541039890847	0	
36820408	Identification of Immune-Related Seven-Long Non-Coding RNA Signature for Overall Survival and Validation of the Effect of LINC01270 in Malignant Phenotypes of Clear Cell Renal Carcinoma.	Cancer management and research	2023	-5.849777027712494	54.367945129238834	0	
36814961	Neoadjuvant PD-1 Blockade in Non-Small Cell Lung Cancer: Current perspectives and Moving Forward.	OncoTargets and therapy	2023	31.08992548432052	-22.879823704381085	2	
36814396	Phenotypic characterization of disease-initiating stem cells in JAK2- or CALR-mutated myeloproliferative neoplasms.	American journal of hematology	2023	-40.71169702577512	16.549591184799795	1	
36812781	Heterogeneous expression of predictive biomarkers PD-L1 and TIGIT in non-mucinous lung adenocarcinoma and corresponding lymph node metastasis: A challenge for clinical biomarker testing.	Neoplasia (New York, N.Y.)	2023	14.39359173800542	-35.00816781077394	0	
36811409	Nivolumab and relatlimab for the treatment of melanoma.	Drugs of today (Barcelona, Spain : 1998)	2023	33.73912041981196	1.5894963966857358	0	
36810892	Systematic analysis identifies REST as an oncogenic and immunological biomarker in glioma.	Scientific reports	2023	-21.479303274295827	56.72093019277168	4	
36809405	Correction to: Determinants of activity and efficacy of anti-PD1/PD-L1 therapy in patients with advanced solid tumors recruited in a clinical trials unit: a longitudinal prospective biomarker-based study.	Cancer immunology, immunotherapy : CII	2023	-4.016116249043868	-41.49063917718403	0	
36807772	Role of tumor microenvironment in cancer progression and therapeutic strategy.	Cancer medicine	2023	16.473264623187294	11.773007636558654	9	
36807510	Reverse Translation Identifies the Synergistic Role of Immune Checkpoint Blockade and IL15 to Enhance Immunotherapy of Ovarian Cancer.	Cancer immunology research	2023	37.534381643183	37.33570933779399	2	
36807440	Tumour necrosis factor stimulated gene 6 intrinsically regulates PD-L1 expressions in breast cancer cells, leading to modulation of tumour microenvironment.	Veterinary and comparative oncology	2023	-19.74408986478589	35.64732877946165	0	
36804777	PD-1 and PDL-1 gene expression in nasal polyp tissue from patients with asthma exacerbated by non-steroidal anti-inflammatory drugs correlates with the severity of the disease.	Otolaryngologia polska = The Polish otolaryngology	2023	-65.74207884155165	-25.861536769158533	0	
36800834	Expression of PD-L1 and PD-1 in stage T4 rectal cancer tissues and surrounding metastatic lymph nodes and correlation with prognosis.	Cellular and molecular biology (Noisy-le-Grand, France)	2022	-4.503533220885674	9.89294302059679	0	
36797356	A Phase 1/2 study of the PD-L1 inhibitor, BGB-A333, alone and in combination with the PD-1 inhibitor, tislelizumab, in patients with advanced solid tumours.	British journal of cancer	2023	56.89839365733344	-23.05063841268704	0	
36796366	OX40 agonism enhances PD-L1 checkpoint blockade by shifting the cytotoxic T cell differentiation spectrum.	Cell reports. Medicine	2023	-26.28197483768511	-20.394161195960688	3	
36794259	Corrigendum: Case report: Potential predictive value of MMR/MSI status and PD-1 expression in immunotherapy for urothelial carcinoma.	Pathology oncology research : POR	2023	15.865775310098035	54.55133433639847	0	
36794070	Tislelizumab plus chemotherapy is more cost-effective than chemotherapy alone as first-line therapy for advanced non-squamous non-small cell lung cancer.	Frontiers in public health	2023	55.004012825197016	-24.977912110276577	2	
36793050	Tumor-associated macrophages and Tregs influence and represent immune cell infiltration of muscle-invasive bladder cancer and predict prognosis.	Journal of translational medicine	2023	5.887866293723588	58.98936122235623	3	
36788687	Programmed Cell Death Protein 1 (PD-1) in Relation to PANoptosis: Immune Pharmacological Targets for Management of Breast Adenocarcinoma.	Endocrine, metabolic & immune disorders drug targets	2023	-44.97965574368981	-19.178416912450803	1	
36788067	Analysis of Immune Intratumor Heterogeneity Highlights Immunoregulatory and Coinhibitory Lymphocytes as Hallmarks of Recurrence in Stage I Non-Small Cell Lung Cancer.	Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc	2023	1.9070396782208408	19.29828269739702	0	
36781089	PD-1: A New Candidate Target for Analgesic Peptide Design.	The journal of pain	2023	-74.40896914636349	-13.203338630455834	1	
36780540	CD8/PD-L1 immunohistochemical reactivity and gene alterations in cutaneous squamous cell carcinoma.	PloS one	2023	-1.519029002950219	-3.822942003400818	0	
36776882	Decreased monocyte-to-lymphocyte ratio was associated with satisfied outcomes of first-line PD-1 inhibitors plus chemotherapy in stage IIIB-IV non-small cell lung cancer.	Frontiers in immunology	2023	27.7185422206326	-41.11020925571896	3	
36776847	Do proton pump inhibitors alter the response to immune checkpoint inhibitors in cancer patients? A meta-analysis.	Frontiers in immunology	2023	65.00950422225628	-3.208282177295435	3	
36776837	Incorporation of a TGF-β2-inhibiting oligodeoxynucleotide molecular adjuvant into a tumor cell lysate vaccine to enhance antiglioma immunity in mice.	Frontiers in immunology	2023	-28.745769553943163	56.9096042555249	1	
36773776	A Novel Radiogenomics Biomarker for Predicting Treatment Response and Pneumotoxicity From Programmed Cell Death Protein or Ligand-1 Inhibition Immunotherapy in NSCLC.	Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer	2023	17.899865231591814	-31.45565385561464	3	
36773442	A systematic review and meta-analysis of immune checkpoint therapy in relapsed or refractory non-Hodgkin lymphoma; a friend or foe?	Translational oncology	2023	36.47660942497343	-10.221261546562474	2	
36773295	Periostin deficiency reduces PD-1+ tumor-associated macrophage infiltration and enhances anti-PD-1 efficacy in colorectal cancer.	Cell reports	2023	-23.214667225198664	-34.40789772701159	1	
36769297	Association between Loss of Immune Checkpoint Programmed Cell Death Protein 1 and Active ANCA-Associated Renal Vasculitis.	International journal of molecular sciences	2023	70.45797570833926	2.121666001957682	2	
36769093	Implication of the Gut Microbiome and Microbial-Derived Metabolites in Immune-Related Adverse Events: Emergence of Novel Biomarkers for Cancer Immunotherapy.	International journal of molecular sciences	2023	75.21082298446811	-5.7315235640905255	1	
36768213	Antitumor Effect of Korean Red Ginseng through Blockade of PD-1/PD-L1 Interaction in a Humanized PD-L1 Knock-In MC38 Cancer Mouse Model.	International journal of molecular sciences	2023	-26.895420478629923	-37.040652843255344	0	
36768201	Pro- vs. Anti-Inflammatory Features of Monocyte Subsets in Glioma Patients.	International journal of molecular sciences	2023	-26.21369212766077	56.92448487345122	2	
36765649	Immune-Related Adverse Events of the Gastrointestinal System.	Cancers	2023	75.91625364239059	-4.116803664497124	1	
36765615	Novel Computed-Tomography-Based Transformer Models for the Noninvasive Prediction of PD-1 in Pre-Operative Settings.	Cancers	2023	9.673497483291367	-10.175885874545576	0	
36765356	Efficacy of PD-1/PD-L1 inhibitors in gastric or gastro-oesophageal junction cancer based on clinical characteristics: a meta-analysis.	BMC cancer	2023	50.47610865502419	16.32537341209315	1	
36764316	Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial.	Lancet (London, England)	2023	59.31753504226533	-21.55494494750824	34	
36763173	The M2 macrophages infiltration of sebaceous tumors is linked to the aggressiveness of tumors but not to the mismatch repair pathway.	Journal of cancer research and clinical oncology	2023	-14.23751659256665	35.44381866798243	1	
36762067	BRAF RNA is prognostic and widely expressed in lung adenocarcinoma.	Translational lung cancer research	2023	6.591249017853843	-24.0526847710028	1	
36761750	Multi-omics profiling and digital image analysis reveal the potential prognostic and immunotherapeutic properties of CD93 in stomach adenocarcinoma.	Frontiers in immunology	2023	2.8236069523240057	26.983879218708893	0	
36761426	Progress on neoadjuvant immunotherapy in resectable non-small cell lung cancer and potential biomarkers.	Frontiers in oncology	2022	34.268737229265405	-22.60102081012827	0	
36759928	Drug-loaded microbubble delivery system to enhance PD-L1 blockade immunotherapy with remodeling immune microenvironment.	Biomaterials research	2023	-27.2327668179466	-52.56763413114897	4	
36759392	Common inherited variants of PDCD1, CD274 and HAVCR2 genes differentially modulate the risk and prognosis of adenocarcinoma and squamous cell carcinoma.	Journal of cancer research and clinical oncology	2023	6.21172405270722	-14.36791786477752	0	
36759214	[Immunotherapy in oncogynaecology].	Bulletin du cancer	2023	41.06577810109791	34.519047503404416	0	
36758174	Tumor Cell-Derived Microparticles Induced by Methotrexate Augment T-cell Antitumor Responses by Downregulating Expression of PD-1 in Neutrophils.	Cancer immunology research	2023	-15.0279423021823	-34.15265429908056	2	
36756152	MMP11 is associated with the immune response and immune microenvironment in EGFR-mutant lung adenocarcinoma.	Frontiers in oncology	2023	16.412060453586495	-16.468619198955842	0	
36755909	Incidence of endocrine-related immune-related adverse events in Japanese subjects with various types of cancer.	Frontiers in endocrinology	2023	81.57149563528398	-15.826474082014457	1	
36754859	CD70 and PD-L1 (CD274) co-expression predicts poor clinical outcomes in patients with pleural mesothelioma.	The journal of pathology. Clinical research	2023	7.068799622282154	11.926139815089266	1	
36753982	STAT3 regulation of Mtb-specific T cell function in active pulmonary tuberculosis patients.	International immunopharmacology	2023	-85.4324767952008	4.963358811625152	0	
36750253	Targeting Cbl-b in cancer immunotherapy.	Journal for immunotherapy of cancer	2023	-9.997755805697471	-38.17163193144442	6	
36748760	A Rare Case Presentation of Vitiligo Associated With Atezolizumab.	Journal of investigative medicine high impact case reports	2023	76.71146712804045	-22.37293835124578	0	
36748438	Anti-Tumor Efficacy of Anti-PD-1/PD-L1 Antibodies in Combination With Other Anticancer Drugs in Solid Tumors: A Systematic Review and Meta-Analysis.	Cancer control : journal of the Moffitt Cancer Center	2022	51.135553524235526	-12.76687684367828	0	
36747853	Reprogramming Intrahepatic Cholangiocarcinoma Immune Microenvironment by Chemotherapy and CTLA-4 Blockade Enhances Anti-PD1 Therapy.	bioRxiv : the preprint server for biology	2023	56.16527577514977	23.46786948140883	0	
36747292	Hypoxia-associated circPRDM4 promotes immune escape via HIF-1α regulation of PD-L1 in hepatocellular carcinoma.	Experimental hematology & oncology	2023	-5.4067551236192095	58.74231505866104	2	
36747118	Safety and efficacy of Pucotenlimab (HX008) - a humanized immunoglobulin G4 monoclonal antibody in patients with locally advanced or metastatic melanoma: a single-arm, multicenter, phase II study.	BMC cancer	2023	56.30252042858809	-6.873190334818619	1	
36746349	Cellular senescence and the host immune system in aging and age-related disorders.	Biomedical journal	2023	-53.66440362218327	1.677695590564171	3	
36745223	Carbon ion irradiation induces DNA damage in melanoma and optimizes the tumor microenvironment based on the cGAS-STING pathway.	Journal of cancer research and clinical oncology	2023	-24.313738369911984	-44.47989604508167	1	
36741391	Circulating exosomal immuno-oncological checkpoints and cytokines are potential biomarkers to monitor tumor response to anti-PD-1/PD-L1 therapy in non-small cell lung cancer patients.	Frontiers in immunology	2022	25.20007389578431	-30.830267444721184	2	
36741384	Protective effects of blocking PD-1 pathway on retinal ganglion cells in a mouse model of chronic ocular hypertension.	Frontiers in immunology	2022	-68.55139132359128	-13.912002689984645	3	
36738309	The role of spatial interplay patterns between PD-L1-positive tumor cell and T cell in recurrence of locally advanced non-small cell lung cancer.	Cancer immunology, immunotherapy : CII	2023	9.476868977752702	-18.76646423914648	0	
36737759	Identification and validation of a novel survival prediction model based on the T-cell phenotype in the tumor immune microenvironment and peripheral blood for gastric cancer prognosis.	Journal of translational medicine	2023	-8.734229408353963	22.26911311928487	0	
36734432	Evaluation of pd-1, pd-l1, and cytotoxic T-lymphocyteassociated protein 4 expressions together with clinicopathological findings in clear cell, papillary, and chromophobe types of renal cell carcinoma.	Polish journal of pathology : official journal of the Polish Society of Pathologists	2022	18.407765343422305	27.69157051860828	0	
36733484	The E3 ubiquitin ligases regulate PD-1/PD-L1 protein levels in tumor microenvironment to improve immunotherapy.	Frontiers in immunology	2023	-19.53096851472249	-7.564144999229013	9	
36731129	Establishment of Cell-Based Assay System for Evaluating Cytotoxic Activity Modulated by the Blockade of PD-1 and PD-L1 Interactions with a Therapeutic Antibody.	Immunological investigations	2023	12.46899141606844	-47.30372919297233	0	
36727298	The CTLA-4 immune checkpoint protein regulates PD-L1:PD-1 interaction via transendocytosis of its ligand CD80.	The EMBO journal	2023	-49.0981597764149	-1.6990599107981792	3	
36726489	Exosome-Associated Gene Signature for Predicting the Prognosis of Ovarian Cancer Patients.	Journal of immunology research	2023	0.879321266230275	48.13499287675484	0	
36726488	Coexpression of PD-L1/PD-1 with CXCR3/CD36 and IL-19 Increase in Extranodal Lymphoma.	Journal of immunology research	2023	-35.94554909940241	22.786616460363117	0	
36725772	Study protocol of KeyPemls-004: A phase 2 study of pembrolizumab in combination with plinabulin and docetaxel in previously treated patients with metastatic non-small cell lung cancer and progressive disease (PD) after immunotherapy (PD-1/PD-L1 inhibitor) alone or in combination with platinum-doublet chemotherapy.	Thoracic cancer	2023	46.171088266959536	-28.963189773097817	1	
36724255	Losartan controls immune checkpoint blocker-induced edema and improves survival in glioblastoma mouse models.	Proceedings of the National Academy of Sciences of the United States of America	2023	-30.566495353149996	58.315335325274766	6	
36721805	Immunotherapy in Cancer Management: A Literature Review of Clinical Efficacy of Pembrolizumab in the Non-small Cell Lung Cancer Treatment.	Advanced pharmaceutical bulletin	2023	46.53692180685009	-33.14669496569877	1	
36720496	Antitumor effect of CAR-T cells targeting transmembrane tumor necrosis factor alpha combined with PD-1 mAb on breast cancers.	Journal for immunotherapy of cancer	2023	-43.643320584903286	5.567124200292456	1	
36719382	PD-L1 translocation to the plasma membrane enables tumor immune evasion through MIB2 ubiquitination.	The Journal of clinical investigation	2023	-21.08067941844472	-7.309058694788861	0	
36717219	Phenotypic CD8 T cell profiling in chronic hepatitis B to predict HBV-specific CD8 T cell susceptibility to functional restoration in vitro.	Gut	2023	-74.93559451119411	24.18081585010632	2	
36713848	Case Report: Chemotherapy-free treatment with camrelizumab and anlotinib for elderly patients with KRAS and TP53 mutated advanced lung cancer.	Frontiers in pharmacology	2023	23.54070626749873	-22.957416679472217	0	
36713530	A signature-based classification of lung adenocarcinoma that stratifies tumor immunity.	Frontiers in oncology	2022	16.174325533240047	-14.63920737123039	0	
36712869	Interferon gamma-related gene signature based on anti-tumor immunity predicts glioma patient prognosis.	Frontiers in genetics	2022	-19.80511039581454	56.26423764511856	1	
36709596	Immune checkpoint receptors in autoimmunity.	Current opinion in immunology	2023	26.52375567512903	11.830397391029898	5	
36707424	Using EGFR amplification to stratify recurrent glioblastoma treated with immune checkpoint inhibitors.	Cancer immunology, immunotherapy : CII	2023	46.03301725331255	27.929408224556266	2	
36707233	Combining ferroptosis induction with MDSC blockade renders primary tumours and metastases in liver sensitive to immune checkpoint blockade.	Gut	2023	-4.987048871852399	50.078889232851225	9	
36705526	KEYNOTE-991: pembrolizumab plus enzalutamide and androgen deprivation for metastatic hormone-sensitive prostate cancer.	Future oncology (London, England)	2023	52.05730864213859	2.8850899606396423	1	
36705186	Design of a protease-activated PD-L1 inhibitor.	Protein science : a publication of the Protein Society	2023	-42.52804022940079	-42.36742128852777	2	
36703728	A novel cuproptosis-related prognostic gene signature and validation of differential expression in hepatocellular carcinoma.	Frontiers in pharmacology	2022	-10.882638799720157	51.44722866648716	1	
36701994	Liujunzi decoction exerts potent antitumor activity in oesophageal squamous cell carcinoma by inhibiting miR-34a/STAT3/IL-6R feedback loop, and modifies antitumor immunity.	Phytomedicine : international journal of phytotherapy and phytopharmacology	2023	-22.86440095577261	-35.54887869469812	0	
36701715	A lung squamous cell carcinoma-associated membranous nephropathy patient free of tumor and membranous nephropathy after the treatment of surgery and radiochemotherapy following pembrolizumab: A rare case report.	Medicine	2023	68.90818168338228	1.461727801287014	0	
36701405	Molecular characterization of feline immune checkpoint molecules and establishment of PD-L1 immunohistochemistry for feline tumors.	PloS one	2023	-15.205761867279586	-15.463962838629124	2	
36700075	Study on the molecular mechanism of anti-liver cancer effect of Evodiae fructus by network pharmacology and QSAR model.	Frontiers in chemistry	2022	-20.117538122633785	-37.156847186402366	1	
36698265	Reversing T Cell Dysfunction to Boost Glioblastoma Immunotherapy by Paroxetine-Mediated GRK2 Inhibition and Blockade of Multiple Checkpoints through Biomimetic Nanoparticles.	Advanced science (Weinheim, Baden-Wurttemberg, Germany)	2023	-28.163726927040923	55.35735276544658	4	
36698098	Peripheral blood lymphocytes differentiation patterns in responses / outcomes to immune checkpoint blockade therapies in non-small cell lung cancer: a retrospective study.	BMC cancer	2023	13.040482223999126	-6.632655368598301	1	
36697459	Data mining combines bioinformatics discover immunoinfiltration-related gene SERPINE1 as a biomarker for diagnosis and prognosis of stomach adenocarcinoma.	Scientific reports	2023	-17.07111363726168	56.0483239659728	3	
36697078	Real-world Efficacy and Safety of Atezolizumab Plus Bevacizumab, Paclitaxel and Carboplatin for First-line Treatment of Japanese Patients With Metastatic Non-squamous Non-small Cell Lung Cancer.	Anticancer research	2023	52.61785989888588	-37.5464666272659	2	
36694901	Comprehensive Analysis of Stromal and Serum Markers in Gastric Cancer.	Acta naturae	2022	-8.114567847214788	8.354010815788392	0	
36689847	The establishment of B cell-deficient Igh-J KO mouse model by gene editing and efficacy evaluation.	International immunopharmacology	2023	-38.275433244317455	-27.04575873614693	0	
36687266	The Programmed Death-1 Signaling Axis Modulates Inflammation and LV Structure/Function in a Stress-Induced Cardiomyopathy Model.	JACC. Basic to translational science	2022	-62.166174649642656	7.842496777289226	7	1.8
36686809	The value of metabolic LncRNAs in predicting prognosis and immunotherapy efficacy of gastric cancer.	Frontiers in oncology	2022	-3.410575672991791	53.95654800094089	0	
36686648	YIV-906 enhances nuclear factor of activated T-cells (NFAT) activity of T cells and promotes immune checkpoint blockade antibody action and CAR T-cell activity.	Frontiers in pharmacology	2022	-18.58844485824693	-35.07871644440049	2	
36685883	Pan-cancer analysis of the prognostic and immunological role of Fanconi anemia complementation group E.	Frontiers in genetics	2022	-1.831680611752881	48.00461230225713	1	
36683533	Efficacy of PD-1/PD-L1 plus CTLA-4 inhibitors in solid tumors based on clinical characteristics: a meta-analysis.	Immunotherapy	2023	50.098253866903946	-11.469442286072214	0	
36674951	Spatial Profile of Tumor Microenvironment in PD-L1-Negative and PD-L1-Positive Triple-Negative Breast Cancer.	International journal of molecular sciences	2023	-9.499886475578274	17.945661885438877	1	
36674929	Is the Triggering of PD-L1 Dimerization a Potential Mechanism for Food-Derived Small Molecules in Cancer Immunotherapy? A Study by Molecular Dynamics.	International journal of molecular sciences	2023	-31.633536958268603	-36.30077815478383	0	
36672620	Patient-Derived Primary Cancer-Associated Fibroblasts Mediate Resistance to Anti-Angiogenic Drug in Ovarian Cancers.	Biomedicines	2023	0.8770332099306787	32.86533376697631	3	
36672387	Paving the Path for Immune Enhancing Nutrition in Colon Cancer: Modulation of Tumor Microenvironment and Optimization of Outcomes and Costs.	Cancers	2023	4.023748198828112	34.41927664044294	2	
36662367	Prognostic significance of tumor infiltrating lymphocytes on first-line pembrolizumab efficacy in advanced non-small cell lung cancer.	Discover. Oncology	2023	-4.660462787148718	19.06983323866388	2	
36661747	Immune Checkpoint Glycoproteins Have Polymorphism: Are Monoclonal Antibodies Too Specific?	Current oncology (Toronto, Ont.)	2023	23.345696702011672	4.080286485224498	0	
36656970	Immunology of Giant Cell Arteritis.	Circulation research	2023	-57.295814817492015	10.674839574569036	5	
36656207	PD-L1 and PD-L2 expression in colorectal cancer.	Indian journal of pathology & microbiology	2023	-6.039164913562287	11.39168348415955	1	
36656137	A Novel Humanized PD-1/PD-L1 Mouse Model Permits Direct Comparison of Antitumor Immunity Generated by Food and Drug Administration-Approved PD-1 and PD-L1 Inhibitors.	ImmunoHorizons	2023	-38.22201500512677	-26.559944205334933	0	
36654823	Mutant and non-mutant neoantigen-based cancer vaccines: recent advances and future promises.	Exploration of targeted anti-tumor therapy	2022	16.096030644661656	6.237515268307927	0	
36654786	Disruption of CISH promotes the antitumor activity of human T cells and decreases PD-1 expression levels.	Molecular therapy oncolytics	2023	-44.609714608179225	-4.864435504901787	1	
36652667	High PD-L2 Predicts Early Recurrence of ER-Positive Breast Cancer.	JCO precision oncology	2023	-7.961248325211298	14.991305319350404	4	
36652534	CD200+ cytotoxic T lymphocytes in the tumor microenvironment are crucial for efficacious anti-PD-1/PD-L1 therapy.	Science translational medicine	2023	-30.29127432742577	-8.792956784277953	2	
36650632	Comprehensive immunoprofile analysis of prognostic markers in pancreaticobiliary tract cancers.	Cancer medicine	2023	-7.706526629497838	27.75446583976477	2	
36650004	[Safety and efficacy of laparoscopic surgery in locally advanced gastric cancer patients with neoadjuvant chemotherapy combined with immunotherapy].	Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery	2023	48.53887895935306	11.749052079798671	0	
36648843	The Role of Immune Checkpoint Inhibitors in Cancer Therapy.	Clinics and practice	2022	26.191089002960982	7.528300413722527	5	1.22
36647464	Efficacy and safety comparison of PD-1 inhibitors vs. PD-L1 inhibitors in extensive-stage small-cell lung cancer: a retrospective comparative cohort study.	Journal of thoracic disease	2022	47.796659964053575	-40.38507521394423	0	
36646351	Study on endogenous inhibitors against PD-L1: cAMP as a potential candidate.	International journal of biological macromolecules	2023	-40.54642026756648	-39.37225358690505	0	
36645621	Treating Head and Neck Cancer in the Age of Immunotherapy: A 2023 Update.	Drugs	2023	52.45093319546005	31.298988385414805	7	
36645031	Programmed cell death-1 blockade therapy in melanoma: Resistance mechanisms and combination strategies.	Experimental dermatology	2023	-35.48533381263542	-16.660244642043622	1	
36644138	BTK inhibitor combined with anti-PD-1 monoclonal antibody for the treatment of CD20-negative primary central nervous system lymphoma: A case report.	Oncology letters	2023	-33.53423619460967	31.79270958270624	1	
36642178	Long-chain polyunsaturated lipids associated with responsiveness to anti-PD-1 therapy are colocalized with immune infiltrates in the tumor microenvironment.	The Journal of biological chemistry	2023	-29.980600477184453	-29.200782755002	0	
36640261	Anti-CD40L therapy prevents the formation of precursor lesions to gastric B-cell MALT lymphoma in a mouse model.	The Journal of pathology	2023	-12.430415765771675	1.4779469403838357	1	
36640052	Expression of PD-1 in Tumor Cells is Associated with Shorter Survival in Non-metastatic Intestinal-type Gastric Adenocarcinoma.	Iranian journal of allergy, asthma, and immunology	2022	-9.535717907111229	6.57143793629247	1	
36636446	LAG3 Regulates T Cell Activation and Plaque Infiltration in Atherosclerotic Mice.	JACC. CardioOncology	2022	-73.53349273574898	2.426646887265972	1	
36636085	Efficacy and safety of camrelizumab plus chemotherapy versus chemotherapy alone in patients with untreated, HER2-negative, unresectable locally advanced, or metastatic gastric cancer or gastroesophageal junction cancer: a retrospective comparative cohort study.	Journal of gastrointestinal oncology	2022	48.85276980930649	14.120333775577866	0	
36630914	Bispecific PD1-IL2v and anti-PD-L1 break tumor immunity resistance by enhancing stem-like tumor-reactive CD8+ T cells and reprogramming macrophages.	Immunity	2023	-11.391243944402346	-46.245322398253045	8	
36630848	PD-1/PD-L1 pathway: A double-edged sword in periodontitis.	Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie	2023	-64.8794740033123	-21.17414838072376	1	
36629068	Enhanced anti-tumor immunity of vaccine combined with anti-PD-1 antibody in a murine bladder cancer model.	Investigative and clinical urology	2023	-25.35800191038356	-12.191452951621985	1	
36627334	CAR-tropic extracellular vesicles carry tumor-associated antigens and modulate CAR T cell functionality.	Scientific reports	2023	-39.119692915824906	-59.645689213348405	0	
36625938	Determinants of activity and efficacy of anti-PD1/PD-L1 therapy in patients with advanced solid tumors recruited in a clinical trials unit: a longitudinal prospective biomarker-based study.	Cancer immunology, immunotherapy : CII	2023	38.44233367421857	-14.585832666856412	0	
36625080	Transforming growth factor-β signalling in tumour resistance to the anti-PD-(L)1 therapy: Updated.	Journal of cellular and molecular medicine	2023	-21.94991346214305	-9.258826089696548	3	
36624155	Interaction of glioma-associated microglia/macrophages and anti-PD1 immunotherapy.	Cancer immunology, immunotherapy : CII	2023	-28.087590326072338	53.63256055212802	2	
36623238	Pan-cancer Landscape of Programmed Death Ligand-1 and Programmed Death Ligand-2 Structural Variations.	JCO precision oncology	2023	4.005834036252348	7.735115583744954	0	
36621515	The complex network of transcription factors, immune checkpoint inhibitors and stemness features in colorectal cancer: A recent update.	Seminars in cancer biology	2023	5.337627121350528	37.33261007386283	2	
36615128	Response to Immune Checkpoint Inhibitors Is Affected by Deregulations in the Antigen Presentation Machinery: A Systematic Review and Meta-Analysis.	Journal of clinical medicine	2022	30.12653416858365	15.16669763858018	5	1.23
36614254	Clinical Significance of Molecular Subtypes in Western Advanced Gastric Cancer: A Real-World Multicenter Experience.	International journal of molecular sciences	2023	-10.8424896942489	21.226295485861154	5	
36614248	Sorting Transcriptomics Immune Information from Tumor Molecular Features Allows Prediction of Response to Anti-PD1 Therapy in Patients with Advanced Melanoma.	International journal of molecular sciences	2023	9.165773822076437	-4.76411594029323	0	
36613776	Natural Killer Cell Receptors and Endometriosis: A Systematic Review.	International journal of molecular sciences	2022	-42.87416497166669	33.8970728842179	1	
36612211	Exploring the Dynamic Crosstalk between the Immune System and Genetics in Gastrointestinal Stromal Tumors.	Cancers	2022	-9.446336672587194	24.851519330000208	4	
36612204	CD3+ and CD8+ T-Cell-Based Immune Cell Score and PD-(L)1 Expression in Pulmonary Metastases of Microsatellite Stable Colorectal Cancer.	Cancers	2022	11.872813017928108	35.006222541487	2	
36612193	Intrinsic and Extrinsic Transcriptional Profiles That Affect the Clinical Response to PD-1 Inhibitors in Patients with Non-Small Cell Lung Cancer.	Cancers	2022	18.6023428470984	-27.825326551276078	1	
36612181	Immunohistochemical Study of Bladder Cancer Molecular Subtypes and Their Association with PD-L1 Expression.	Cancers	2022	8.991290250771685	59.76528664749996	1	
36612100	Mechanisms and Strategies to Overcome PD-1/PD-L1 Blockade Resistance in Triple-Negative Breast Cancer.	Cancers	2022	39.07388148690489	8.917295331599009	5	1.13
36611037	IL-1β neutralization prevents diastolic dysfunction development, but lacks hepatoprotective effect in an aged mouse model of NASH.	Scientific reports	2023	-64.68195935135263	21.795152694602383	0	
36610303	Discovery of small-molecule PD-1/PD-L1 antagonists through combined virtual screening and experimental validation.	Computational biology and chemistry	2023	-40.4292201714791	-40.13622750421579	3	
36609566	A comprehensive single-cell map of T cell exhaustion-associated immune environments in human breast cancer.	Nature communications	2023	-45.99248467089984	12.504697476139038	5	
36608303	Role of Immunotherapy in Breast Cancer.	JCO oncology practice	2023	39.47365987075899	9.764013837498164	8	
36607420	[Rheumatological side effects of checkpoint inhibitors and their treatment].	Zeitschrift fur Rheumatologie	2023	77.49119773319222	-13.429475825781989	0	
36606190	Expression of Programmed Death Ligand-2 is associated with Prognosis in Nasopharyngeal Carcinoma Microenviroment.	Journal of Cancer	2022	-16.84205514857365	31.744220363872408	2	
36606115	The Clinical Relevance and Immune Correlation of SLC10 Family Genes in Liver Cancer.	Journal of hepatocellular carcinoma	2022	-9.43862375465878	48.64964187713269	2	
36605848	Complete response to pembrolizumab in a patient with recurrent and metastatic urothelial bladder carcinoma reflecting coexisting sarcomatoid subtype and glandular differentiation: a case report.	International cancer conference journal	2023	66.33341981770478	16.225294023737348	0	
36605217	Study of epirubicin sustained-release chemoablation in tumor suppression and tumor microenvironment remodeling.	Frontiers in immunology	2022	-27.95856772183294	-51.72833434239135	1	
36603108	Aptamer-Based Immunotheranostic Strategies.	Cancer biotherapy & radiopharmaceuticals	2023	-24.565291150059828	-59.4538893526823	2	
36602827	A Novel TrxR1 Inhibitor Regulates NK and CD8+ T Cell Infiltration and Cytotoxicity, Enhancing the Efficacy of Anti-PD-1 Immunotherapy against Hepatocarcinoma.	Journal of immunology (Baltimore, Md. : 1950)	2023	-17.911826509046538	45.52704169402643	1	
36601120	PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy.	Frontiers in immunology	2022	27.61145175369408	49.26357603342317	11	2.7
36601114	Case report: Variable response to immunotherapy in ovarian cancer: Our experience within the current state of the art.	Frontiers in immunology	2022	38.244628461979374	38.89273119539352	1	
36600662	Macrophage GSK3β-deficiency inhibits the progression of hepatocellular carcinoma and enhances the sensitivity of anti-PD1 immunotherapy.	Journal for immunotherapy of cancer	2022	-10.652221986366772	43.47621600081447	5	1.23
36600271	Patterns of toxicity burden for FDA-approved immune checkpoint inhibitors in the United States.	Journal of experimental & clinical cancer research : CR	2023	74.67521386432625	-9.52850168222899	2	
36598199	Combined Immune Checkpoint Blockade Enhances Antiviral Immunity against Bovine Leukemia Virus.	Journal of virology	2023	-79.51760753367967	4.045270836666739	1	
36597662	Spatial PD-L1, immune-cell microenvironment, and genomic copy-number alteration patterns and drivers of invasive-disease transition in prospective oral precancer cohort.	Cancer	2023	-6.495989901956594	30.747273012465897	1	
36595561	IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC.	Clinical cancer research : an official journal of the American Association for Cancer Research	2023	5.336276103019278	-33.65831059371822	5	
36594471	Canagliflozin primes antitumor immunity by triggering PD-L1 degradation in endocytic recycling.	The Journal of clinical investigation	2023	-34.016390589841606	-29.976895478687943	3	
36593610	Two rare cases of bullous pemphigoid associated with immune checkpoint inhibitors.	BMJ case reports	2022	71.27046247074362	-26.71559291586585	1	
36593103	MicroRNA-223 attenuates hepatocarcinogenesis by blocking hypoxia-driven angiogenesis and immunosuppression.	Gut	2023	-19.51194391725317	42.108527043546864	5	
36587500	Advances in pharmacokinetics and pharmacodynamics of PD-1/PD-L1 inhibitors.	International immunopharmacology	2023	32.92082760295446	-9.16509988350784	3	
36586643	PD-L1 upregulation promotes drug-induced pulmonary fibrosis by inhibiting vimentin degradation.	Pharmacological research	2023	-56.2660232907466	17.99714650541251	3	
36585674	Adverse effects of low serum lipoprotein cholesterol on the immune microenvironment in gastric cancer: a case‒control study.	Lipids in health and disease	2022	-11.508966720013374	25.392860385846785	0	
36585209	18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Predicts Tumor Immune Microenvironment Function in Early Triple-negative Breast Cancer.	Anticancer research	2023	16.048740796791993	-57.44331091195788	1	
36584716	Classic Hodgkin lymphoma with marked granulomatous reaction: A clinicopathologic study of 20 cases.	Human pathology	2023	-29.884632613813974	25.414699493031847	0	
36583862	Inhibition of MYC suppresses programmed cell death ligand-1 expression and enhances immunotherapy in triple-negative breast cancer.	Chinese medical journal	2022	3.6104187036620776	-6.850726616994649	1	
36583762	PD-L1 Expression is not a Predictive Factor for Recurrence in Resected Non-small Cell Lung Cancer.	Lung	2023	12.112614465609637	-28.63426867113376	0	
36579489	Novel Small-Molecule PD-L1 Inhibitor Induces PD-L1 Internalization and Optimizes the Immune Microenvironment.	Journal of medicinal chemistry	2023	-39.21750283401104	-38.189551527821344	5	
36575785	[Immune checkpoint inhibitors induced pituitary immune-related adverse events: diagnosis and management].	Zhonghua zhong liu za zhi [Chinese journal of oncology]	2022	83.72031994350789	-16.43961295293067	0	
36575294	Similar programmed death ligand 1 (PD-L1) expression profile in patients with mild COPD and lung cancer.	Scientific reports	2022	1.8153276133186336	-24.13255592064345	2	
36574773	The ectonucleotidase CD39 identifies tumor-reactive CD8+ T cells predictive of immune checkpoint blockade efficacy in human lung cancer.	Immunity	2023	10.85180196555858	-20.91642796937368	8	
36572780	Proteomic profiling of a patient with cutaneous melanoma metastasis regression following topical contact sensitizer diphencyprone and immune checkpoint inhibitor treatment.	Scientific reports	2022	12.809906797582157	-0.8612554590455543	1	
36572651	Personalized immune subtypes based on machine learning predict response to checkpoint blockade in gastric cancer.	Briefings in bioinformatics	2023	-9.585075581969988	22.40421631483953	0	
36569934	Combination TIGIT/PD-1 blockade enhances the efficacy of neoantigen vaccines in a model of pancreatic cancer.	Frontiers in immunology	2022	-20.89149932308442	-13.178233340146052	2	
36569674	Role of Immunotherapy in the Treatment of Triple-Negative Breast Cancer: A Literature Review.	Cureus	2022	40.17326479650988	8.396301204657696	1	
36568653	APOBEC3G expression correlates with unfavorable prognosis and immune infiltration in kidney renal clear cell carcinoma.	Heliyon	2022	17.901613920498555	35.82668266014556	0	
36568362	CMTM7 recognizes an immune-hot tumor microenvironment and predicts therapeutic response of immunotherapy in breast cancer well.	Frontiers in genetics	2022	5.529804979789996	-9.757132918159146	0	
36568253	Current and novel therapeutic strategies for optimizing immunotherapy outcomes in advanced non-small cell lung cancer.	Frontiers in oncology	2022	35.99690529997967	-24.635523660085447	3	
36566982	Prognostic and immunotherapeutic predictive value of interleukin enhancer-binding factor 3 in hepatocellular carcinoma: Integrated bioinformatics and experimental analysis.	Gene	2023	-7.34187151303733	46.38009895251996	0	
36561623	Diabetes insipidus: A rare endocrine complication of immune check point inhibitors: A case report and literature review.	Experimental and therapeutic medicine	2023	85.04495186902611	-16.575835888731778	2	
36560951	Identification of antibodies cross-reactive with woodchuck immune cells and activation of virus-specific and global cytotoxic T cell responses by anti-PD-1 and anti-PD-L1 in experimental chronic hepatitis B and persistent occult hepadnaviral infection.	Frontiers in microbiology	2022	-72.66387030613402	20.03832881690032	0	
36559282	Anti-Tumor Effects of Engineered VNP20009-Abvec-Igκ-mPD-1 Strain in Melanoma Mice via Combining the Oncolytic Therapy and Immunotherapy.	Pharmaceutics	2022	-42.3432234089135	-26.09342088997125	0	
36556355	Adverse Events of PD-1 or PD-L1 Inhibitors in Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis.	Life (Basel, Switzerland)	2022	60.7464424728376	-14.804072313605364	0	
36555714	B7-H3/CD276 Inhibitors: Is There Room for the Treatment of Metastatic Non-Small Cell Lung Cancer?	International journal of molecular sciences	2022	1.9180287954455175	-17.217604290533373	1	
36555243	Comprehensive Analysis of FASN in Tumor Immune Infiltration and Prognostic Value for Immunotherapy and Promoter DNA Methylation.	International journal of molecular sciences	2022	-13.373076955275822	51.68968363816322	1	
36555180	Immunomodulation of HDAC Inhibitor Entinostat Potentiates the Anticancer Effects of Radiation and PD-1 Blockade in the Murine Lewis Lung Carcinoma Model.	International journal of molecular sciences	2022	30.266314501579075	44.36297056766539	3	
36552000	Role of Nivolumab in the Modulation of PD-1 and PD-L1 Expression in Papillary and Clear Cell Renal Carcinoma (RCC).	Biomedicines	2022	17.799880314081083	24.714541777733885	0	
36551910	The High-Resolution Structure Reveals Remarkable Similarity in PD-1 Binding of Cemiplimab and Dostarlimab, the FDA-Approved Antibodies for Cancer Immunotherapy.	Biomedicines	2022	-22.439288895871623	-40.97704523244746	1	
36551742	Natural Blockers of PD-1/PD-L1 Interaction for the Immunotherapy of Triple-Negative Breast Cancer-Brain Metastasis.	Cancers	2022	44.68786817817274	-14.132133680746607	2	
36551672	Development of Monoclonal Antibodies Targeting Canine PD-L1 and PD-1 and Their Clinical Relevance in Canine Apocrine Gland Anal Sac Adenocarcinoma.	Cancers	2022	-16.588029036433092	-13.358689738425827	1	
36547185	Immunotherapy Use Prior to Liver Transplant in Patients with Hepatocellular Carcinoma.	Current oncology (Toronto, Ont.)	2022	28.111601844610025	48.40972776303905	0	
36547132	Optimal Choice as First-Line Therapy for Patients with Triple-Negative Breast Cancer: A Bayesian Network Meta-Analysis.	Current oncology (Toronto, Ont.)	2022	56.74758243139905	-12.138699148617055	0	
36545310	Sources of inter-individual variability leading to significant changes in anti-PD-1 and anti-PD-L1 efficacy identified in mouse tumor models using a QSP framework.	Frontiers in pharmacology	2022	-1.392075646418374	-44.366823290124096	1	
36544779	Correlation of the TIGIT-PVR immune checkpoint axis with clinicopathological features in triple-negative breast cancer.	Frontiers in immunology	2022	-4.890789622708868	29.05033120662345	4	
36544769	Combining PD-1 or PD-L1 inhibitors with chemotherapy is a good strategy for the treatment of extensive small cell lung cancer: A retrospective analysis of clinical studies.	Frontiers in immunology	2022	47.740352615418864	-40.17967506300946	0	
36540715	Efficacy and Safety of the PD-1 Inhibitor Combined with Albumin-Bound Paclitaxel and Nedaplatin in Preoperative Neoadjuvant Therapy of Unresectable Stage III Lung Squamous Cell Carcinoma.	Drug design, development and therapy	2022	32.838769827715446	-19.1625807005804	1	
36539510	Targeting ubiquitin-specific protease 8 sensitizes anti-programmed death-ligand 1 immunotherapy of pancreatic cancer.	Cell death and differentiation	2023	-18.183152715484557	-6.138016973644275	7	
36539429	Comparative efficacy and tolerability of targeted and immunotherapy combined with chemotherapy as first-line treatment for advanced gastric cancer: a Bayesian network meta-analysis.	Scientific reports	2022	48.08036567750543	17.18565885178702	0	
36538147	The negative impact of opioids on cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis.	Journal of cancer research and clinical oncology	2023	64.98970456677317	-3.1731612044993778	2	
36538073	Association of computed tomography-based body composition with survival in metastatic renal cancer patient received immunotherapy: a multicenter, retrospective study.	European radiology	2023	30.468327657739785	-46.89933832053906	2	
36537046	Galectin-3 interacts with PD-1 and counteracts the PD-1 pathway-driven regulation of T cell and osteoclast activity in Rheumatoid Arthritis.	Scandinavian journal of immunology	2023	-51.79070871222636	15.890556491525148	2	
36536236	Morpho-functional analysis of patient-derived xenografts reveals differential impact of gastric cancer and chemotherapy on the tumor ecosystem, affecting immune check point, metabolism, and sarcopenia.	Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association	2023	-11.447854292319176	24.090249724724654	0	
36534236	Immunotherapeutics in lung cancers: from mechanistic insight to clinical implications and synergistic perspectives.	Molecular biology reports	2023	39.10852865970718	-33.196995640995326	0	
36532284	Enhancer of zeste homolog 2 is a negative prognostic biomarker and correlated with immune infiltrates in meningioma.	Frontiers in neuroscience	2022	-14.230382478903817	58.50326771699825	0	
36532083	Ensemble deep learning enhanced with self-attention for predicting immunotherapeutic responses to cancers.	Frontiers in immunology	2022	10.81543155879619	50.97548758853229	18	3.92
36532042	Tumor immune microenvironment in endometrial cancer of different molecular subtypes: evidence from a retrospective observational study.	Frontiers in immunology	2022	6.512543970437672	45.90260264953057	3	
36532019	Lung cancer patients with chronic obstructive pulmonary disease benefit from anti-PD-1/PD-L1 therapy.	Frontiers in immunology	2022	31.39933781465103	-34.76208056010871	2	
36531688	Biglycan as a mediator of proinflammatory response and target for MDS and sAML therapy.	Oncoimmunology	2023	-37.88674695934022	15.19614197484827	2	
36531611	Enrichment of genomic pathways based on differential DNA methylation profiles associated with knee osteoarthritis pain.	Neurobiology of pain (Cambridge, Mass.)	2022	-10.56725814796367	54.44350743103789	0	
36531246	Prognostic implications of necroptosis-related long noncoding RNA signatures in muscle-invasive bladder cancer.	Frontiers in genetics	2022	3.1457050694666298	56.91128988116338	2	
36531217	T cell exhaustion assessment algorism in tumor microenvironment predicted clinical outcomes and immunotherapy effects in glioma.	Frontiers in genetics	2022	-23.00888581531108	55.99378983252717	0	
36531043	Extremely high infiltration of CD8+PD-L1+ cells detected in a stage III non-small cell lung cancer patient exhibiting hyperprogression during anti-PD-L1 immunotherapy after chemoradiation: A case report.	Frontiers in oncology	2022	28.544511995885863	-17.739427943533894	1	
36531034	Immune-based treatment re-challenge in renal cell carcinoma: A systematic review and meta-analysis.	Frontiers in oncology	2022	66.42670273828388	27.822590578555985	1	
36530971	Identification of a novel gene signature of lung adenocarcinoma based on epidermal growth factor receptor-tyrosine kinase inhibitor resistance.	Frontiers in oncology	2022	17.052300610902137	-15.328588672383312	1	
36529697	The Single-Cell Landscape of Intratumoral Heterogeneity and The Immunosuppressive Microenvironment in Liver and Brain Metastases of Breast Cancer.	Advanced science (Weinheim, Baden-Wurttemberg, Germany)	2023	-14.442052860838055	38.5183626938498	44	
36527888	Research progress of therapeutic effects and drug resistance of immunotherapy based on PD-1/PD-L1 blockade.	Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy	2023	-37.140214330697845	-19.98892061000875	5	
36523973	Hyperprogressive disease in non-small cell lung cancer treated with immune checkpoint inhibitor therapy, fact or myth?	Frontiers in oncology	2022	30.28801967286143	-17.138034564683963	0	
36523676	Pembrolizumab-Induced Lichen Planus in a Patient With Non-Small-Cell Lung Carcinoma (NSCLC) That Correlates to Therapeutic Response.	Cureus	2022	71.8132350298058	-23.14892346685926	0	
36522474	Evolving landscape of PD-L2: bring new light to checkpoint immunotherapy.	British journal of cancer	2023	-8.490877954450813	-6.704918784328969	4	
36521657	Role of COL6A2 in malignant progression and temozolomide resistance of glioma.	Cellular signalling	2023	-21.732279966423956	57.48852643940528	1	
36521418	MOVIE: a phase I, open-label, multicenter study to evaluate the safety and tolerability of metronomic vinorelbine combined with durvalumab plus tremelimumab in patients with advanced solid tumors.	ESMO open	2022	60.85185426561301	3.701314238244816	4	
36520345	Establishment and comprehensive analysis of a new human cell line (NK-NJ) with NK-cell characteristics established from extranodal natural killer cell lymphoma/leukemia.	Human cell	2023	-39.07571319224376	31.772621160346805	0	
36519392	Expression and Clinical Significance of Various Checkpoint Molecules in Advanced Osteosarcoma: Possibilities for Novel Immunotherapy.	Orthopaedic surgery	2023	-17.437785592651487	19.449539476865425	2	
36519023	Immune profile analysis of peripheral blood and tumors of lung cancer patients treated with immune checkpoint inhibitors.	Translational lung cancer research	2022	26.030786977542064	-29.07828989432066	2	
36518753	Baseline immune signature score of Tregs × HLA-DR+CD4+ T cells × PD1+CD8+ T cells predicts outcome to immunotherapy in cancer patients.	Frontiers in immunology	2022	12.18351957342937	-8.096309836164405	0	
36518249	Role of cytotoxic T cells and PD-1 immune checkpoint pathway in papillary thyroid carcinoma.	Frontiers in endocrinology	2022	-8.357096363479384	-21.67674259703037	3	
36517459	An efficient combination immunotherapy for antitumor immunity without accelerating cardiac allograft rejection.	Immunology	2023	27.666416713113232	47.32646909243719	0	
36516370	Monitoring PD-L1 Expression on Circulating Tumor-Associated Cells in Recurrent Metastatic Non-Small-Cell Lung Carcinoma Predicts Response to Immunotherapy With Radiation Therapy.	JCO precision oncology	2022	11.106249275806071	-37.57162521198905	6	1.4
36516270	Combination bezafibrate and nivolumab treatment of patients with advanced non-small cell lung cancer.	Science translational medicine	2022	29.211582109349667	-56.54406014652475	5	0.97
36515782	Prognostic Significance of the Severity of Immune-Related Adverse Events in Advanced Cancer Patients Treated with PD-1/PD-L1 Inhibitors: A Real-World Data Analysis.	Targeted oncology	2023	73.95969817645737	-13.660861725347008	2	
36511268	The 2022 Updated European Association of Urology Guidelines on the Use of Adjuvant Immune Checkpoint Inhibitor Therapy for Renal Cell Carcinoma.	European urology	2023	67.58508242424405	27.03698098800325	16	
36509766	PRDM1/BLIMP1 induces cancer immune evasion by modulating the USP22-SPI1-PD-L1 axis in hepatocellular carcinoma cells.	Nature communications	2022	-20.69030434025628	-3.958313506605125	2	
36509717	New Insight into the Role of AhR in Lung Carcinogenesis.	Biochemistry. Biokhimiia	2022	-8.899160505308567	-16.8681504356418	2	
36509464	Lymphocyte activation gene (LAG)-3 is a potential immunotherapeutic target for microsatellite stable, programmed death-ligand 1 (PD-L1)-positive endometrioid endometrial cancer.	Journal of gynecologic oncology	2023	8.269309218920585	45.58310123371736	1	
36509402	Idarubicin-loaded biodegradable microspheres enhance sensitivity to anti-PD1 immunotherapy in transcatheter arterial chemoembolization of hepatocellular carcinoma.	Acta biomaterialia	2023	-11.311016809104784	63.46745780650742	1	
36505782	Encouraging efficacy of a comprehensive therapy consisting of sintilimab, bevacizumab biosimilar IBI305, hypo-fractionated intensity-modulated radiotherapy, and oxaliplatin for a maxillary metastasis from hepatocellular carcinoma: A case report and literature review.	Frontiers in oncology	2022	57.06992923819154	20.84230390287973	0	
36505302	The predictive value of pyroptosis for the prognosis and immune escape of bladder cancer.	American journal of translational research	2022	1.5852037460493045	57.88247686912909	1	
36504905	Effects of hepatic or renal impairment on the pharmacokinetics of immune checkpoint inhibitors.	American journal of cancer research	2022	70.06251722517173	-0.2039394063712012	3	
36504279	Sensitive and quantitative in vivo analysis of PD-L1 using magnetic particle imaging and imaging-guided immunotherapy.	European journal of nuclear medicine and molecular imaging	2023	4.701004013393347	-53.67227262356558	2	
36503610	A phase II single arm study of Nivolumab with stereotactic Ablative radiation Therapy after induction chemotherapy in CHOlangiocarcinoma (NATCHO).	BMC cancer	2022	55.91764946018026	23.13341762004926	1	
36502695	Development of an automated combined positive score prediction pipeline using artificial intelligence on multiplexed immunofluorescence images.	Computers in biology and medicine	2023	6.528271757017658	-48.579265364783154	3	
36497437	Beyond Platinum, ICIs in Metastatic Cervical Cancer: A Systematic Review.	Cancers	2022	44.51330936282168	36.53073463579623	3	
36497235	The Prognostic Value of Plasma Programmed Death Protein-1 (PD-1) and Programmed Death-Ligand 1 (PD-L1) in Patients with Gastrointestinal Stromal Tumor.	Cancers	2022	-5.381378325785796	6.46935778087766	1	
36495598	Characterization of the impact of immune checkpoint inhibitors on platelet activation and aggregation.	Immunobiology	2023	82.57948476737553	-7.886037333965904	0	
36494467	Effects of small molecule-induced dimerization on the programmed death ligand 1 protein life cycle.	Scientific reports	2022	-44.12792392544571	-38.8190743067623	3	
36494415	Soluble immune checkpoint molecules in patients with antineutrophil cytoplasmic antibody-associated vasculitis.	Scientific reports	2022	-58.81597131193509	13.463170254456358	3	
36493599	A first-in-human study of the anti-LAG-3 antibody favezelimab plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer.	ESMO open	2022	48.26900325492685	4.09960467080486	19	4.03
36484721	HRS Regulates Small Extracellular Vesicle PD-L1 Secretion and Is Associated with Anti-PD-1 Treatment Efficacy.	Cancer immunology research	2023	-41.64584292940882	-61.63632027130236	2	
36483588	The Role of Interleukin-7 in the Formation of Tertiary Lymphoid Structures and Their Prognostic Value in Gastrointestinal Cancers.	Journal of immunotherapy and precision oncology	2022	4.647987993409238	32.42373480410174	1	
36483582	Tumor Infiltrating Lymphocyte Expression of PD-1 Predicts Response to Anti-PD-1/PD-L1 Immunotherapy.	Journal of immunotherapy and precision oncology	2022	-5.992920600456375	18.210684000077183	3	
36483569	Identification and validation of transferrin receptor protein 1 for predicting prognosis and immune infiltration in lower grade glioma.	Frontiers in molecular neuroscience	2022	-19.31798232893249	55.78364256712643	1	
36482103	Atezolizumab plus anthracycline-based chemotherapy in metastatic triple-negative breast cancer: the randomized, double-blind phase 2b ALICE trial.	Nature medicine	2022	53.683012613952165	-39.61890807139838	10	1.95
36481226	Risk monitoring and pharmacovigilance of programmed cell death protein 1 / programmed cell death 1 ligand 1 in cancer patients after solid organ transplantation.	Therapie	2023	62.46221523300499	-18.148635709542155	0	
36479076	Dynamic alterations in PD-1/PD-L1 expression level and immune cell profiles based on radiation response status in mouse tumor model.	Frontiers in oncology	2022	-14.155301699924816	-17.89775845921977	1	
36478592	T-box transcription factor 2 mediates antitumor immune response in cutaneous squamous cell carcinoma by regulating the expression of programmed death ligand 1.	Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI)	2023	-1.955588372086732	-4.084560301773722	1	
36477737	Proteomic mapping of intercellular synaptic environments via flavin-dependent photoredox catalysis.	Organic & biomolecular chemistry	2022	-49.56878398383639	-44.70696464647686	0	
36476907	[Expression and Significance of PD-1, PD-L1 and CTLA-4 in the Bone Marrow of Patients with Multiple Myeloma].	Zhongguo shi yan xue ye xue za zhi	2022	-33.43610332588857	10.202290709765595	0	
36476897	[Effect of HDAC Inhibitor Chidamide on PD-L1 Expression in Peripheral T-Cell Lymphoma].	Zhongguo shi yan xue ye xue za zhi	2022	-35.16679274926457	-2.989396946864308	1	
36475449	Screening and identification of an anti-PD-1 nanobody with antitumor activity.	Bioscience reports	2022	-38.49809456427744	-47.83136891804688	2	
36473145	Clinical Benefit of First-Line Programmed Death-1 Antibody Plus Chemotherapy in Low Programmed Cell Death Ligand 1-Expressing Esophageal Squamous Cell Carcinoma: A Post Hoc Analysis of JUPITER-06 and Meta-Analysis.	Journal of clinical oncology : official journal of the American Society of Clinical Oncology	2023	52.371081695060646	13.661259611315511	8	
36472770	Plasma GDF15 levels associated with circulating immune cells predict the efficacy of PD-1/PD-L1 inhibitor treatment and prognosis in patients with advanced non-small cell lung cancer.	Journal of cancer research and clinical oncology	2023	21.80354050709868	-29.43777916764332	1	
36472588	Cxcr3 constrains pancreatic cancer dissemination through instructing T cell fate.	Cancer immunology, immunotherapy : CII	2023	-9.06494509121747	28.40972962375822	0	
36471481	The dual role of CD70 in B-cell lymphomagenesis.	Clinical and translational medicine	2022	-30.22177961147183	29.393393005655707	1	
36470427	Identification, binding, and structural characterization of single domain anti-PD-L1 antibodies inhibitory of immune regulatory proteins PD-1 and CD80.	The Journal of biological chemistry	2023	-45.71693238613449	-36.46676544278844	1	
36470334	Inhaled dry powder cisplatin increases antitumour response to anti-PD1 in a murine lung cancer model.	Journal of controlled release : official journal of the Controlled Release Society	2023	-1.0789508967031196	-27.27655697472087	0	
36468024	GOLM1 is related to the inflammatory/immune nature of uveal melanoma and acts as a promising indicator for prognosis and immunotherapy response.	Frontiers in genetics	2022	3.5487372423835435	2.2216011052037925	1	
36467068	Serine and glycine metabolism-related gene expression signature stratifies immune profiles of brain gliomas, and predicts prognosis and responses to immunotherapy.	Frontiers in pharmacology	2022	-20.282535755463623	57.56821280779939	2	
36466997	Research progress on the intrinsic non-immune function of PD-L1 in tumors (Review).	Oncology letters	2023	-38.08532489720451	-12.890628899454176	0	
36466860	Single cell sequencing revealed the mechanism of PD-1 resistance affected by the expression profile of peripheral blood immune cells in ESCC.	Frontiers in immunology	2022	-6.2041336081212615	26.0381680895835	1	
36466837	Identification of fatty acid metabolism-related molecular subtype biomarkers and their correlation with immune checkpoints in cutaneous melanoma.	Frontiers in immunology	2022	-13.253046386488382	51.446848879566446	0	
36465399	Research trends on anti-PD-1/PD-L1 immunotherapy for esophageal cancer: A bibliometric analysis.	Frontiers in oncology	2022	19.4768490372112	-50.04839120983608	0	
36465365	PD-1 inhibitors plus nab-paclitaxel-containing chemotherapy for advanced gallbladder cancer in a second-line setting: A retrospective analysis of a case series.	Frontiers in oncology	2022	52.46622105500345	21.08358292281945	0	
36465184	CD4+ CTLs Act as a Key Effector Population for Allograft Rejection of MSCs in a Donor MHC-II Dependent Manner in Injured Liver.	Aging and disease	2022	-55.03523921514522	23.2848359852016	2	
36464675	CD97 serves as a novel biomarker of immune cell infiltration in hepatocellular carcinoma.	World journal of surgical oncology	2022	-13.32480835586919	45.56247882953841	0	
36463853	Novel Treatment Options in Metastatic Esophageal Carcinoma: Checkpoint Inhibitors in Combination Therapies.	Pharmacology	2023	54.84690673416891	16.782996906530013	1	
36463104	Pembrolizumab in combination with gemcitabine for patients with HER2-negative advanced breast cancer: GEICAM/2015-04 (PANGEA-Breast) study.	BMC cancer	2022	47.11615941881302	4.571516825490601	1	
36461598	Chloroquine treatment influences immunologicalmemory through the PD-1/PD-L1 pathway during the initiation of Plasmodium chabaudi infection.	International immunopharmacology	2022	-75.63475842452152	2.2836731721404315	0	
36458012	The β-carboline Harmine improves the therapeutic benefit of anti-PD1 in melanoma by increasing the MHC-I-dependent antigen presentation.	Frontiers in immunology	2022	-31.137465090057155	-17.97106389828442	1	
36455456	Butein suppresses PD-L1 expression via downregulating STAT1 in non-small cell lung cancer.	Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie	2023	-16.809387244314628	-7.530127341774754	1	
36454780	A cohort study using IL-6/Stat3 activity and PD-1/PD-L1 expression to predict five-year survival for patients after gastric cancer resection.	PloS one	2022	-8.490761267330612	6.116560486937317	0	
36453573	Immunogenic Nanovesicle-Tandem-Augmented Chemoimmunotherapy via Efficient Cancer-Homing Delivery and Optimized Ordinal-Interval Regime.	Advanced science (Weinheim, Baden-Wurttemberg, Germany)	2022	-35.14407720666211	-56.793957767213946	6	1.2
36451303	Immunotherapies targeting neoantigens are effective in PD-1 blockade-resistant tumors.	International journal of cancer	2023	-37.77088979844317	51.18750739069028	0	
36451045	Characteristics and outcomes of cancer patients with pre-existing microscopic colitis after exposure to PD-1 and PD-L1 inhibitors.	Journal of cancer research and clinical oncology	2023	75.94320666965794	-2.6593141653455192	1	
36449662	Gallium-68-labeled Peptide PET Quantifies Tumor Exposure of PD-L1 Therapeutics.	Clinical cancer research : an official journal of the American Association for Cancer Research	2023	4.103836989494451	-56.2173029938691	5	
36449057	Anti-programmed death-1 inhibitor nivolumab-induced immune-related adverse events: hepatitis, renal insufficiency, myositis, vitiligo, and hypothyroidism: a case-based review.	Rheumatology international	2023	74.30360908129076	-18.0348236234648	0	
36448335	Next-generation immunotherapy for solid tumors: combination immunotherapy with crosstalk blockade of TGFβ and PD-1/PD-L1.	Expert opinion on investigational drugs	2022	-21.85024670947479	-9.663058445659392	0	
36447159	Prevalence of immune-related adverse events and anti-tumor efficacy following immune checkpoint inhibitor therapy in Japanese patients with various solid tumors.	BMC cancer	2022	75.39559924335468	-11.046293064118265	3	
36445569	Development of Effective Siglec-9 Antibodies Against Cancer.	Current oncology reports	2023	-13.516401269291938	-49.903496791256494	0	
36445478	Nutrient deprivation and hypoxia alter T cell immune checkpoint expression: potential impact for immunotherapy.	Journal of cancer research and clinical oncology	2023	21.86419644490131	22.24767726603621	1	
36445393	Follicular CD8+ T Cells Are Elevated in HIV Infection and Induce PD-L1 on B Cells.	Journal of immunology (Baltimore, Md. : 1950)	2023	-85.27492576692961	9.921338382630978	1	
36443097	Programmed death-ligand 1 expression in non-small cell lung carcinoma - mechanism of regulation, association with other markers, and therapeutic implication.	Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti	2022	4.382630651557871	-30.098819333309503	0	
36443091	Gastrointestinal toxicity of systemic oncology immunotherapy.	Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti	2022	73.42006024492134	-4.759566323493326	1	
36442821	Functionalized biomimetic nanoparticles combining programmed death-1/programmed death-ligand 1 blockade with photothermal ablation for enhanced colorectal cancer immunotherapy.	Acta biomaterialia	2023	-30.858928510635145	-54.23270928327368	6	
36441248	Expression of programmed cell death-1 on neuroblastoma cells in TH-MYCN transgenic mice.	Pediatric surgery international	2022	-26.45786307207278	14.414979168864008	0	
36440057	Correlation of PD-L1 immunohistochemical expression with microsatellite instability and p53 status in endometrial carcinoma.	European journal of obstetrics & gynecology and reproductive biology: X	2022	12.66560852844903	46.74799232025147	0	
36439441	PD-1 inhibitor versus bevacizumab in combination with platinum-based chemotherapy for first-line treatment of advanced lung adenocarcinoma: A retrospective-real world study.	Frontiers in oncology	2022	50.85324490187171	-24.080858433058875	2	
36439117	Toxicity profile of combined immune checkpoint inhibitors and thoracic radiotherapy in esophageal cancer: A meta-analysis and systematic review.	Frontiers in immunology	2022	71.20044006015637	-6.433252418738313	3	
36439116	Inhibition of the CD47-SIRPα axis for cancer therapy: A systematic review and meta-analysis of emerging clinical data.	Frontiers in immunology	2022	-29.2348869985034	-43.61134012994504	1	
36438805	Purine metabolism-related gene expression signature predicts survival outcome and indicates immune microenvironment profile of gliomas.	Frontiers in pharmacology	2022	-20.226825693033984	57.59404183286836	1	
36438661	Comprehensive analyses of one-carbon metabolism related genes and their association with prognosis, tumor microenvironment, chemotherapy resistance and immunotherapy in lung adenocarcinoma.	Frontiers in molecular biosciences	2022	16.586415243176678	-13.400750223653995	0	
36435066	Anti-CD19 chimeric antigen receptor T cells secreting anti-PD-L1 single-chain variable fragment attenuate PD-L1 mediated T cell inhibition.	International immunopharmacology	2022	-42.530313677406	5.507103524257802	2	
36434688	Identification of potential immunomodulators from Pulsatilla decoction that act on therapeutic targets for ulcerative colitis based on pharmacological activity, absorbed ingredients, and in-silico molecular docking.	Chinese medicine	2022	-23.60711213537838	-35.40838234225866	1	
36428951	Identification and Application of a Novel Immune-Related lncRNA Signature on the Prognosis and Immunotherapy for Lung Adenocarcinoma.	Diagnostics (Basel, Switzerland)	2022	-3.827118141777373	55.87209385142414	2	
36428939	The Role of Cytokinome in the HNSCC Tumor Microenvironment: A Narrative Review and Our Experience.	Diagnostics (Basel, Switzerland)	2022	50.981785996332725	33.58470559875489	1	
36428769	Combined Vaccination with B Cell Peptides Targeting Her-2/neu and Immune Checkpoints as Emerging Treatment Option in Cancer.	Cancers	2022	-25.13058262619408	-15.185123848384018	1	
36428703	CD155 Cooperates with PD-1/PD-L1 to Promote Proliferation of Esophageal Squamous Cancer Cells via PI3K/Akt and MAPK Signaling Pathways.	Cancers	2022	-6.869514735901929	25.29127319121833	2	
36426382	Arrhythmic events associated with immune checkpoint inhibitors therapy: A real-world study based on the Food and Drug Administration Adverse Event Reporting System database.	Cancer medicine	2023	81.43737329476873	1.4647074321574356	2	
36425096	Artificial intelligence-based immunoprofiling serves as a potentially predictive biomarker of nivolumab treatment for advanced hepatocellular carcinoma.	Frontiers in medicine	2022	12.79782685079613	5.350926117997905	0	
36422564	Integrated Chemical Characterization, Network Pharmacology and Transcriptomics to Explore the Mechanism of Sesquiterpenoids Isolated from Gynura divaricata (L.) DC. against Chronic Myelogenous Leukemia.	Pharmaceuticals (Basel, Switzerland)	2022	-20.55278940604957	-35.74574396716235	0	
36420848	Efficacy and safety of PD-1/PD-L1 inhibitors plus chemotherapy for triple-negative breast cancer: a systematic review and meta-analysis.	Recenti progressi in medicina	2022	56.423028128605935	-11.624332538389998	2	
36420773	A phase 2 trial of chemotherapy plus pembrolizumab in patients with advanced non-small cell lung cancer previously treated with a PD-1 or PD-L1 inhibitor: Big Ten Cancer Research Consortium BTCRC-LUN15-029.	Cancer	2023	48.396891362090905	-30.00497886513389	3	
36419668	Activated TLR2/4-positive T cells boost cell exhaustion during lepromatous leprosy infection via PD-1 upregulation.	Heliyon	2022	-70.63600862408337	33.15726226842438	1	
36418243	Role of Surgical Pathologist for Detection of Predictive Immuno-oncological Factors in Breast Cancer.	Advances in anatomic pathology	2023	39.56042524692486	10.994323874528988	1	
36413976	Efficacy of Anti-PD1 Blockade in Treating Recurrent or Metastatic Nasopharyngeal Cancer: A Systematic Review and Meta-analysis.	Oral oncology	2023	57.680426839522255	-1.4331681669958156	2	
36412002	Antitumor Activity of Anti-miR-21 Delivered through Lipid Nanoparticles.	Advanced healthcare materials	2023	-36.16626477323098	-50.83529695139967	1	
36410984	Targeted Therapy and Immunotherapy in Melanoma.	Dermatologic clinics	2023	32.54354580583424	30.592879089877076	5	
36410086	The impact of single agent PD-1 or PD-L1 inhibition on advanced endometrial cancers: meta-analysis.	ESMO open	2022	39.55503386205572	33.67754861263419	2	
36409294	Tumor Growth Rate in Spinal Giant Cell Tumors of Bone and Association With the Immune Microenvironment and Denosumab Treatment Responsiveness: A Multicenter Study.	Neurosurgery	2023	-16.083603535125064	27.69143423347258	2	
36408130	Identification of immuno-infiltrating MAP1A as a prognosis-related biomarker for bladder cancer and its ceRNA network construction.	Frontiers in oncology	2022	4.525670483986413	57.58589383459665	1	
36405753	Interplay between programmed death-ligand 1 and non-coding RNAs.	Frontiers in immunology	2022	-38.48546576539555	-10.992366929780207	1	
36399316	Efficacy and Safety of PD-1/PD-L1 Inhibitors in Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-analysis.	Advances in therapy	2023	52.1703246659957	-15.032193192926757	0	
36399037	Atezolizumab plus tivozanib for immunologically cold tumor types: the IMMCO-1 trial.	Future oncology (London, England)	2022	30.94609477885209	-6.364926583202926	0	
36398067	ncRNA-Regulated LAYN Serves as a Prognostic Biomarker and Correlates with Immune Cell Infiltration in Hepatocellular Carcinoma: A Bioinformatics Analysis.	BioMed research international	2022	-7.926356550985878	52.092449059487805	0	
36396553	Cytotoxic activity of anti-mucin 1 chimeric antigen receptor T cells expressing PD-1-CD28 switch receptor against cholangiocarcinoma cells.	Cytotherapy	2023	-40.83081841547696	6.406711325032371	2	
36395141	Somatic 9p24.1 alterations in HPV- head and neck squamous cancer dictate immune microenvironment and anti-PD-1 checkpoint inhibitor activity.	Proceedings of the National Academy of Sciences of the United States of America	2022	-7.416202257150064	35.58800805042721	4	
36394352	Expression and T cell regulatory action of the PD-1 immune checkpoint in the ovary and fallopian tube.	American journal of reproductive immunology (New York, N.Y. : 1989)	2023	-20.93703803998945	11.181194170253905	0	
36389750	Comprehensive analysis of transient receptor potential channels-related signature for prognosis, tumor immune microenvironment, and treatment response of colorectal cancer.	Frontiers in immunology	2022	3.3691385995153422	48.26885468470106	2	
36388466	Clinical and Biological Activity of Chemoimmunotherapy in Advanced Endometrial Adenocarcinoma: A Phase II Trial of the Big Ten Cancer Research Consortium.	Cancer research communications	2022	49.23326801778202	3.621690173365617	2	
36387259	Prognostic stratification based on the levels of tumor-infiltrating myeloid-derived suppressor cells and PD-1/PD-L1 axis in locally advanced rectal cancer.	Frontiers in oncology	2022	-4.3958958027272175	13.308904133404926	0	
36387141	Case report: Significant response to PD-L1 inhibitor after resistance to PD-1 inhibitor in an advanced alpha-fetoprotein-positive gastric cancer.	Frontiers in oncology	2022	48.74508320470934	19.24590189262469	1	
36387113	Novel small 99mTc-labeled affibody molecular probe for PD-L1 receptor imaging.	Frontiers in oncology	2022	6.047080338601342	-57.10032311124995	2	
36387109	A meta-analysis with systematic review: Efficacy and safety of immune checkpoint inhibitors in patients with advanced gastric cancer.	Frontiers in oncology	2022	42.94873639464104	12.751321579928089	4	
36386464	KRAS mutation predict response and outcome in advanced non-small cell lung carcinoma without driver alterations receiving PD-1 blockade immunotherapy combined with platinum-based chemotherapy: a retrospective cohort study from China.	Translational lung cancer research	2022	22.997937600215057	-22.78789262388097	4	
36386216	Prognosis prediction and tumor immune microenvironment characterization based on tryptophan metabolism-related genes signature in brain glioma.	Frontiers in pharmacology	2022	-20.259927860159635	57.532258626115286	2	
36385210	Pre-treatment soluble PD-L1 as a predictor of overall survival for immune checkpoint inhibitor therapy: a systematic review and meta-analysis.	Cancer immunology, immunotherapy : CII	2023	7.930194534703453	6.927140429543066	2	
36385048	Development of Acute Adult T-cell Leukemia Following PD-1 Blockade Therapy for Lung Cancer.	Internal medicine (Tokyo, Japan)	2022	41.45844470161158	-8.834536832601419	1	
36384978	"SIRPα-Fc fusion protein IMM01 exhibits dual anti-tumor activities by targeting CD47/SIRPα signal pathway via blocking the ""don't eat me"" signal and activating the ""eat me"" signal."	Journal of hematology & oncology	2022	-29.45949885008006	-43.75805769247999	4	
36380108	Combinations of Chemotherapy and PD-1/PD-L1 Inhibitors in Sarcoma.	Current treatment options in oncology	2022	48.77283687708277	-11.422693508913484	2	
36379463	Profound tumor response to combined CTLA-4 and PD-1 inhibition in systemic fourth line therapy observed in a patient with hepatocellular carcinoma harboring SETD2 and LRP1B mutations.	Zeitschrift fur Gastroenterologie	2023	32.904300089784805	50.38891413416852	1	
36378537	mTOR regulates T cell exhaustion and PD-1-targeted immunotherapy response during chronic viral infection.	The Journal of clinical investigation	2023	-72.18619715025571	15.094362121796602	10	
36375474	Efficacy of zinc carnosine in the treatment of colorectal cancer and its potential in combination with immunotherapy in vivo.	Aging	2022	-21.23100390831588	-32.38417526083817	0	
36373309	Identification of prognostic biomarkers among ICAMs in the breast cancer microenvironment.	Cancer biomarkers : section A of Disease markers	2022	2.4375448931375927	42.47824221600808	0	
36368129	Profiling the immune landscape in mucinous ovarian carcinoma.	Gynecologic oncology	2023	1.027639136478526	29.498162293440124	4	
36366925	Cascade Immune Activation of Self-Delivery Biomedicine for Photodynamic Immunotherapy Against Metastatic Tumor.	Small (Weinheim an der Bergstrasse, Germany)	2023	-30.800026308269484	-56.48902212162408	4	
36363529	Dostarlimab an Inhibitor of PD-1/PD-L1: A New Paradigm for the Treatment of Cancer.	Medicina (Kaunas, Lithuania)	2022	28.772301496272625	-6.397859544522111	2	
36362023	Spatial and Quantitative Analysis of Tumor-Associated Macrophages: Intratumoral CD163-/PD-L1+ TAMs as a Marker of Favorable Clinical Outcomes in Triple-Negative Breast Cancer.	International journal of molecular sciences	2022	-2.8105872786787898	30.08605194938063	3	
36361541	Classification of Subgroups with Immune Characteristics Based on DNA Methylation in Luminal Breast Cancer.	International journal of molecular sciences	2022	-6.830576871192156	40.69900685271528	1	
36359911	Bioinformatics Analysis and Validation of the Role of Lnc-RAB11B-AS1 in the Development and Prognosis of Hepatocellular Carcinoma.	Cells	2022	-8.597453671031305	51.22941198692883	0	
36359736	CXCR4-CXCL12-CXCR7 and PD-1/PD-L1 in Pancreatic Cancer: CXCL12 Predicts Survival of Radically Resected Patients.	Cells	2022	-3.5467302601364694	6.962051277411568	1	
36359346	The Role of TIM-3 and LAG-3 in the Microenvironment and Immunotherapy of Ovarian Cancer.	Biomedicines	2022	10.97098403928219	22.769179045613843	8	1.76
36358792	The Proliferative Role of Immune Checkpoints in Tumors: Double Regulation.	Cancers	2022	22.204939930946537	12.729983272809124	1	
36358766	Clinical Outcomes in Fibrolamellar Hepatocellular Carcinoma Treated with Immune Checkpoint Inhibitors.	Cancers	2022	32.83305163118664	48.572972253115246	2	
36358638	Next-Generation Antisense Oligonucleotide of TGF-β2 Enhances T Cell-Mediated Anticancer Efficacy of Anti-PD-1 Therapy in a Humanized Mouse Model of Immune-Excluded Melanoma.	Cancers	2022	-23.88075164675562	-20.781030731133978	2	
36355079	Generation of NK cells with chimeric-switch receptors to overcome PD1-mediated inhibition in cancer immunotherapy.	Cancer immunology, immunotherapy : CII	2023	-33.300765327093224	3.155472829967996	1	
36353623	Case report: Long response to PD-1 blockade after failure of trastuzumab plus chemotherapy in advanced Epstein-Barr virus-associated gastric cancer.	Frontiers in immunology	2022	46.27189554782144	13.486930455516609	2	
36353552	Neoadjuvant immunotherapy combined with chemotherapy significantly improved patients' overall survival when compared with neoadjuvant chemotherapy in non-small cell lung cancer: A cohort study.	Frontiers in oncology	2022	32.684122024921926	-21.34324884737937	3	
36353126	MELK is a prognostic biomarker and correlated with immune infiltration in glioma.	Frontiers in neurology	2022	-19.9348805631117	56.99416769697412	0	
36347860	Single cell sequencing reveals that CD39 inhibition mediates changes to the tumor microenvironment.	Nature communications	2022	5.365925277564198	62.44069761233236	2	
36346290	SPARC in cancer-associated fibroblasts is an independent poor prognostic factor in non-metastatic triple-negative breast cancer and exhibits pro-tumor activity.	International journal of cancer	2023	-3.353899471629364	22.630643553523456	4	
36343761	Metabolic reprogramming mediated PD-L1 depression and hypoxia reversion to reactivate tumor therapy.	Journal of controlled release : official journal of the Controlled Release Society	2022	-32.02032056205367	-55.196443083621496	24	6.05
36341552	Safety and efficacy analysis of PD-1 inhibitors in combination with chemotherapy for advanced pancreatic cancer.	Immunotherapy	2022	52.369674435356245	-17.52117192271639	0	
36341410	Prognostic value of hematologic parameters in advanced non-small cell lung cancer patients receiving anti-PD-1 inhibitors.	Frontiers in immunology	2022	29.216867607941627	-40.16599488081171	0	
36341395	Sex difference in the expression of PD-1 of non-small cell lung cancer.	Frontiers in immunology	2022	10.814832713279204	-30.15479793491521	3	
36341340	Bioengineering and computational analysis of programmed cell death ligand-1 monoclonal antibody.	Frontiers in immunology	2022	-48.56417521092184	-29.857915678970308	1	
36339292	Small bowel villous atrophy due to immune-checkpoint inhibitors: report of two cases and literature review.	Drugs in context	2022	74.15204166841744	-3.090263709978148	0	
36338826	Case Report: Potential Predictive Value of MMR/MSI Status and PD-1 Expression in Immunotherapy for Urothelial Carcinoma.	Pathology oncology research : POR	2022	15.91166701741783	54.46818212802229	0	
36332452	Combination therapy with nivolumab (anti-PD-1 monoclonal antibody): A new era in tumor immunotherapy.	International immunopharmacology	2022	33.27934575934824	8.000227550110367	3	
36331328	Multiplexed imaging of tumor immune microenvironmental markers in locally advanced or metastatic non-small-cell lung cancer characterizes the features of response to PD-1 blockade plus chemotherapy.	Cancer communications (London, England)	2022	11.644297514976452	-17.84189483422294	4	
36328434	[Regulation of PD-L1 posttranslational modification and its application progress in tumor immunotherapy].	Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology	2022	-45.06204484679445	-22.850893486267097	0	
36328377	FRACTION-RCC: nivolumab plus ipilimumab for advanced renal cell carcinoma after progression on immuno-oncology therapy.	Journal for immunotherapy of cancer	2022	65.4959433742112	29.892988168125505	4	
36327869	Recent advances in atezolizumab-based programmed death-ligand 1 (PD-L1) blockade therapy for breast cancer.	International immunopharmacology	2022	53.269287720782735	-39.66834802244032	2	
36326416	The correlation of serum sPD-1 and sPD-L1 levels with clinical, pathological characteristics and lymph node metastasis in nonsmall cell lung cancer patients.	Turkish journal of medical sciences	2022	20.57112923590787	-27.733146137549028	0	
36324736	Comorbidity between lung cancer and COVID-19 pneumonia: role of immunoregulatory gene transcripts in high ACE2-expressing normal lung.	Therapeutic advances in medical oncology	2022	13.575292893021256	-26.839517500061596	1	
36323784	Blocking PD-L1-PD-1 improves senescence surveillance and ageing phenotypes.	Nature	2022	-53.733034965612525	1.6451462141721025	51	11.72
36323361	Factors predisposing to humoral autoimmunity against brain-antigens in health and disease: Analysis of 49 autoantibodies in over 7000 subjects.	Brain, behavior, and immunity	2023	-60.94057340705938	14.019536209961258	4	
36321642	PD-1 engineered cytomembrane cloaked molybdenum nitride for synergistic photothermal and enhanced immunotherapy of breast cancer.	Journal of materials chemistry. B	2022	-30.53262333465161	-54.8421314566895	0	
36320712	Rational development of molecularly imprinted nanoparticles for blocking PD-1/PD-L1 axis.	Chemical science	2022	-38.57658356022359	-44.96607209645458	2	
36320412	Combined PD-L1 and TIM3 blockade improves expansion of fit human CD8+ antigen-specific T cells for adoptive immunotherapy.	Molecular therapy. Methods & clinical development	2022	-41.38511334713514	-2.7594853228994403	4	
36319076	Correlation between PD-L1 expression of the tumour cells and lymphocytes infiltration in the invasive front of urothelial carcinoma.	Journal of clinical pathology	2022	11.95068925864797	58.41569682310341	1	
36317676	Selection of a PD-1 blocking antibody from a novel fully human phage display library.	Protein science : a publication of the Protein Society	2022	-47.05775233459931	-32.16631624639397	4	
36315960	A Novel Engineered AAV-Based Neoantigen Vaccine in Combination with Radiotherapy Eradicates Tumors.	Cancer immunology research	2023	-20.43785587204045	-13.908234928239716	2	
36314696	Anti-PD1 Agents in the Treatment of Cutaneous Squamous Cell Carcinoma.	Skinmed	2022	57.00953399508566	6.519981951449939	0	
36313661	The immune landscape of undifferentiated pleomorphic sarcoma.	Frontiers in oncology	2022	9.196698557464996	16.038903880789128	3	
36313654	Location matters: LAG3 levels are lower in renal cell carcinoma metastatic sites compared to primary tumors, and expression at metastatic sites only may have prognostic importance.	Frontiers in oncology	2022	9.71829329057	23.573905717938608	6	1.12
36313041	Clinical implications of the interaction between PD-1/PD-L1 and PI3K/AKT/mTOR pathway in progression and treatment of non-small cell lung cancer.	Journal of Cancer	2022	2.9556144999484766	-31.11906525761952	9	2.31
36310639	Current Options for Second-Line Systemic Therapy in Metastatic Renal Cell Carcinoma.	Journal of kidney cancer and VHL	2022	64.31435241264037	32.59148705401531	1	
36309837	Phase 1/2 study of epacadostat in combination with durvalumab in patients with metastatic solid tumors.	Cancer	2023	60.79861576223107	5.312335061519587	2	
36309224	The impact of microbiota on PD-1/PD-L1 inhibitor therapy outcomes: A focus on solid tumors.	Life sciences	2022	22.82272333057443	41.87868438631865	7	1.67
36309154	Docosahexaenoic acid reverses PD-L1-mediated immune suppression by accelerating its ubiquitin-proteasome degradation.	The Journal of nutritional biochemistry	2023	-29.503415685286296	-31.58167645619968	0	
36308601	Pucotenlimab: First Approval.	Drugs	2022	56.37710924809516	-6.902488291774076	3	
36308190	PD-L1 expression in muscle invasive urothelial carcinoma: Comparison of SP142 and SP263 assay.	Indian journal of pathology & microbiology	2022	12.503839566908718	59.32606975018038	0	
36307151	Targeting cathepsin B by cycloastragenol enhances antitumor immunity of CD8 T cells via inhibiting MHC-I degradation.	Journal for immunotherapy of cancer	2022	-24.75774397048925	-33.75261044871137	6	1.39
36307001	Nanobubble-mediated co-delivery of Ce6 and miR-195 for synergized sonodynamic and checkpoint blockade combination therapy with elicitation of robust immune response in hepatocellular carcinoma.	European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V	2022	-26.94368985559985	-54.526138534897065	1	
36306594	Cancer stem cells in immunoregulation and bypassing anti-checkpoint therapy.	Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie	2022	15.119369062389907	11.376791708934617	22	5.01
36300124	Gemcitabine-mediated depletion of immunosuppressive dendritic cells enhances the efficacy of therapeutic vaccination.	Frontiers in immunology	2022	-28.255524945427027	-14.45148835137935	0	
36293034	The Detection of Immunity against WT1 and SMAD4P130L of EpCAM+ Cancer Cells in Malignant Pleural Effusion.	International journal of molecular sciences	2022	6.548015458633874	14.655191024993323	1	
36291950	Precision Medicine in the Treatment of Locally Advanced or Metastatic Urothelial Cancer: New Molecular Targets and Pharmacological Therapies.	Cancers	2022	69.8400234633931	19.21071523986835	0	
36291942	The Optimal Therapy after Progression on Immune Checkpoint Inhibitors in MSI Metastatic Gastrointestinal Cancer Patients: A Multicenter Retrospective Cohort Study.	Cancers	2022	40.21404365289184	16.631799354655588	3	
36291098	Comparing T Cell Subsets in Broncho-Alveolar Lavage (BAL) and Peripheral Blood in Patients with Advanced Lung Cancer.	Cells	2022	4.771376597329261	-19.119964197464267	0	
36290857	Immunotherapy and Radiotherapy as an Antitumoral Long-Range Weapon-A Partnership with Unsolved Challenges: Dose, Fractionation, Volumes, Therapeutic Sequence.	Current oncology (Toronto, Ont.)	2022	27.244815775156184	19.86105265291153	4	
36290852	First- and Second-Line Treatments for Patients with Advanced Hepatocellular Carcinoma in China: A Systematic Review.	Current oncology (Toronto, Ont.)	2022	32.02171285174765	51.60100989516413	1	
36289918	Prognostic Impact of LAG-3 mRNA Expression in Early Breast Cancer.	Biomedicines	2022	9.102707056234818	23.161012407125764	2	
36289796	Robust Preanalytical Performance of Soluble PD-1, PD-L1 and PD-L2 Assessed by Sensitive ELISAs in Blood.	Biomedicines	2022	14.524398179376034	-45.71748668194262	0	
36289665	High Quality Performance of Novel Immunoassays for the Sensitive Quantification of Soluble PD-1, PD-L1 and PD-L2 in Blood.	Biomedicines	2022	14.500751764455732	-45.59342568479212	1	
36289520	Recall of reactive cutaneous capillary endothelial proliferation (RCCEP) induced by stereotactic body radiation therapy (SBRT) in a patient with lung squamous cell carcinoma.	Experimental hematology & oncology	2022	62.682328866860274	-1.1774271870977806	0	
36289396	Development of a bispecific antibody targeting PD-L1 and TIGIT with optimal cytotoxicity.	Scientific reports	2022	-14.271268219774678	-48.11678661185406	3	
36287248	A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLL.	Blood advances	2023	43.6768887419202	-3.8106589935482296	8	
36280825	Role of a lipid metabolism-related lncRNA signature in risk stratification and immune microenvironment for colon cancer.	BMC medical genomics	2022	0.0585544031222641	54.89669872017711	6	1.15
36280166	Rational design of a Nivolumab-based ANTI-PD-1 single chain variable fragment that blocks the interaction between PD-1 expressed on T-CELLS and PD-L1 ON CHO cells.	Protein expression and purification	2023	-45.83032208059959	-30.887117874035557	2	
36277392	Molecular dynamics identifies semi-rigid domains in the PD-1 checkpoint receptor bound to its natural ligand PD-L1.	Frontiers in bioengineering and biotechnology	2022	-48.63884079085918	-40.54382433163316	1	
36276141	Transcriptome profile and clinical characterization of ICOS expression in gliomas.	Frontiers in oncology	2022	-23.271232963801346	56.70757612558155	1	
36276090	Immune checkpoint inhibitors in advanced and recurrent/metastatic cervical cancer.	Frontiers in oncology	2022	44.59479912853051	36.32718127306433	1	
36275930	Upregulation of programmed cell death 1 by interferon gamma and its biological functions in human monocytes.	Biochemistry and biophysics reports	2022	-51.83785966120322	-3.433232663274252	1	
36275893	The Oncogenic and Immunological Roles of Apoptosis Antagonistic Transcription Factors in Human Tumors: A Pan-Cancer Analysis.	Oxidative medicine and cellular longevity	2022	-6.850733364165266	45.76115815954645	0	
36275782	Role of Nivolumab in the Management of First-Line Unresectable Advanced or Recurrent Gastric Cancer in Combination with Chemotherapy: Lessons from the Japanese Experience.	Cancer management and research	2022	43.40281199909305	15.28869686034404	1	
36275754	Integrated machine learning methods identify FNDC3B as a potential prognostic biomarker and correlated with immune infiltrates in glioma.	Frontiers in immunology	2022	-20.13493437460391	55.83781307501505	0	
36275748	A durable response to programmed cell death 1 blockade in a multidrug-resistant recurrent ovarian cancer patient with HLA-B44 supertype: A case report.	Frontiers in immunology	2022	38.565066251756384	41.05298547045807	0	
36275726	Case report: A successful re-challenge report of GLS-010 (Zimberelimab), a novel fully humanized mAb to PD-1, in a case of recurrent endometrial cancer.	Frontiers in immunology	2022	82.49856759489568	-3.714503027438176	1	
36273464	Resolution of Melanoma to Programmed Death-1 Blockade but Simultaneous Rapid Progression of Concomitant Chronic Lymphocytic Leukemia.	Acta haematologica	2023	31.35029217614161	5.999565782689128	2	
36273231	Highly efficient hybridoma generation and screening strategy for anti-PD-1 monoclonal antibody development.	Scientific reports	2022	-47.90403914778413	-29.85152635013141	2	
36272280	IL-9 stimulates an anti-tumor immune response and facilitates immune checkpoint blockade in the CMT167 mouse model.	Lung cancer (Amsterdam, Netherlands)	2022	-0.5128592226295716	-25.93074754783584	2	
36268880	Construction of an Iodine-Labeled CS1001 Antibody for Targeting PD-L1 Detection and Comparison with Low-Molecular-Peptide Micro-PET Imaging.	Molecular pharmaceutics	2022	6.032265201458599	-56.46965863603438	1	
36267281	Prognostic value of cuproptosis-related genes signature and its impact on the reshaped immune microenvironment of glioma.	Frontiers in pharmacology	2022	-11.0863533240124	51.79079844927925	1	
36265523	YB-1 promotes cell proliferation and metastasis by targeting cell-intrinsic PD-1/PD-L1 pathway in breast cancer.	The international journal of biochemistry & cell biology	2022	-35.486868494591484	-5.71951352408829	0	
36265003	The PD-1/PD-L1 pathway is induced during Borrelia burgdorferi infection and inhibits T cell joint infiltration without compromising bacterial clearance.	PLoS pathogens	2022	-73.55645186717254	16.27642271918889	1	
36263183	Integrated pathological analysis to develop a Gal-9 based immune survival stratification to predict the outcome of lung large cell neuroendocrine carcinoma and its usefulness in immunotherapy.	International journal of biological sciences	2022	10.412878883733384	-15.380284041211796	0	
36263134	The role of immune checkpoints in cardiovascular disease.	Frontiers in pharmacology	2022	84.17810419306758	2.6761375421368334	3	
36263036	PD-1/PD-L1 combined with LAG3 is associated with clinical activity of immune checkpoint inhibitors in metastatic primary pulmonary lymphoepithelioma-like carcinoma.	Frontiers in immunology	2022	46.31493272046254	-37.16909042408348	1	
36262348	Unveiling the Noncanonical Autophagy-Independent Role of ATG7 and ATG9B in Head and Neck Squamous Cell Carcinoma (HNSCC).	Journal of oncology	2022	-9.15465821383722	35.87003371258068	1	
36261109	Comprehensive analysis of treatment-related adverse events of immunotherapy in advanced gastric or gastroesophageal junction cancer: A meta-analysis of randomized controlled trials.	Clinics and research in hepatology and gastroenterology	2022	72.25836517647103	-6.140070731146716	1	
36252564	Transcriptional and functional analyses of neoantigen-specific CD4 T cells during a profound response to anti-PD-L1 in metastatic Merkel cell carcinoma.	Journal for immunotherapy of cancer	2022	43.24925569128106	52.00516929418304	3	
36252486	Immune checkpoint blockade in melanoma: Advantages, shortcomings and emerging roles of the nanoparticles.	International immunopharmacology	2022	26.20894930942969	13.930563719135668	2	
36252287	Biomarker analysis from a phase II multi-institutional study of nivolumab in patients with advanced refractory biliary tract cancer.	European journal of cancer (Oxford, England : 1990)	2022	13.057384520323232	6.225413603153092	0	
36252282	Exosomes in malignant pleural effusion from lung cancer patients impaired the cytotoxicity of double-negative T cells.	Translational oncology	2023	6.511095870715419	14.487667339407558	1	
36251503	A phase 1/2, open-label, multicenter study of isatuximab in combination with cemiplimab in patients with lymphoma.	Hematological oncology	2023	53.768947805067576	-21.661801287098378	3	
36251031	Influence of chemoradiation on the immune microenvironment of cervical cancer patients.	Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]	2023	-4.219576567455172	36.05053784779903	3	
36248912	Prognostic value of programmed cell death ligand-1 expression in patients with bladder urothelial carcinoma undergoing radical cystectomy: A meta-analysis.	Frontiers in immunology	2022	12.50283418626694	56.508790613231405	0	
36248793	Specific circulating neutrophils subsets are present in clinically stable adults with cystic fibrosis and are further modulated by pulmonary exacerbations.	Frontiers in immunology	2022	12.742024771299604	-20.31683794437196	5	1.5
36248788	PD-1 inhibition plus platinum-based chemotherapy (PBC) or PBC alone in the first-line treatment of locally advanced or metastatic pulmonary lymphoepithelioma-like carcinoma.	Frontiers in immunology	2022	46.34122294926895	-37.18534115031149	1	
36246799	Treatment of refractory/relapsed extranodal NK/T cell lymphoma with decitabine plus anti-PD-1: A case report.	World journal of clinical cases	2022	48.26392525946165	-6.477812388080145	0	
36245826	The immune landscape of hepatocellular carcinoma-where we are?	Oncology letters	2022	-13.148100046443918	44.85488963761824	4	
36239950	Immune checkpoint inhibitors in patients aged 80 or older with advanced non-small cell lung cancer or melanoma: a real-life multicentre study.	Acta oncologica (Stockholm, Sweden)	2022	55.93673119118328	-19.725997207529115	1	
36238278	Mechanism and strategies of immunotherapy resistance in colorectal cancer.	Frontiers in immunology	2022	34.8679629307688	18.073334227756348	4	
36237240	Successful outcome of neoadjuvant PD-1 blockade, VEGFR-2 inhibitor plus chemotherapy for potentially unresectable esophagogastric junctional squamous cell carcinoma: a case report.	Translational cancer research	2022	50.27949412350375	12.567532658606922	1	
36232331	Tumor-Intrinsic PD-L1 Exerts an Oncogenic Function through the Activation of the Wnt/β-Catenin Pathway in Human Non-Small Cell Lung Cancer.	International journal of molecular sciences	2022	5.939496061201074	-28.782611746310053	1	
36231113	Immunomodulatory Effect and Bone Homeostasis Regulation in Osteoblasts Differentiated from hADMSCs via the PD-1/PD-L1 Axis.	Cells	2022	-52.83340385489351	18.512136214029155	0	
36230753	Durable Responses to Anti-PD1 and Anti-CTLA4 in a Preclinical Model of Melanoma Displaying Key Immunotherapy Response Biomarkers.	Cancers	2022	15.49657341200665	0.6078883104966135	0	
36230584	Expansion of Colorectal Cancer Biomarkers Based on Gut Bacteria and Viruses.	Cancers	2022	20.744544823642467	41.98485448149015	7	1.47
36229267	Targeting HER2 in metastatic gastroesophageal adenocarcinomas: What is new?	Bulletin du cancer	2023	47.242071560362895	15.496390308341136	1	
36227341	αVEGFR2-MICA fusion antibodies enhance immunotherapy effect and synergize with PD-1 blockade.	Cancer immunology, immunotherapy : CII	2023	17.407156971295564	-10.301926910340113	2	
36226537	Tumor immune checkpoints and their associated inhibitors.	Journal of Zhejiang University. Science. B	2022	29.526553126735195	15.133326965491683	4	
36224560	Analysis of gene expression levels and their impact on survival in 31 cancer-types patients identifies novel prognostic markers and suggests unexplored immunotherapy treatment options in a wide range of malignancies.	Journal of translational medicine	2022	4.695173081147542	19.02179496390019	2	
36220994	Tumor extracellular vesicles mediate anti-PD-L1 therapy resistance by decoying anti-PD-L1.	Cellular & molecular immunology	2022	-42.15445099543731	-59.12747768127706	4	
36219364	Diminished PD-L1 regulation along with dysregulated T lymphocyte subsets and chemokine in ANCA-associated vasculitis.	Clinical and experimental medicine	2023	-58.52100320475285	13.092661796756907	1	
36217590	Treatment-related adverse events of PD-1/PD-L1 inhibitors combined with CTLA-4 inhibitors in clinical trials: a meta-analysis.	Artificial cells, nanomedicine, and biotechnology	2022	61.302122058382224	-14.775774027290494	2	
36213689	ncRNAs-mediated high expression of TICRR promotes tumor cell proliferation and migration and is correlated with poor prognosis and tumor immune infiltration of hepatocellular carcinoma.	Molecular therapy. Nucleic acids	2022	-7.552454748020231	52.41249408949927	0	
36212528	Navigating the cellular landscape in tissue: Recent advances in defining the pathogenesis of human disease.	Computational and structural biotechnology journal	2022	2.863546007146008	-47.29690940404017	2	
36212445	Can circulating PD-1, PD-L1, BTN3A1, pan-BTN3As, BTN2A1 and BTLA levels enhance prognostic power of CA125 in patients with advanced high-grade serous ovarian cancer?	Frontiers in oncology	2022	-19.03716638184957	14.993214805867725	5	1.43
36212419	Neoadjuvant immunotherapy and neoadjuvant chemotherapy in resectable non-small cell lung cancer: A systematic review and single-arm meta-analysis.	Frontiers in oncology	2022	32.66870102852669	-21.09909820790236	2	
36212004	Efficacy of bivalent CEACAM6/4-1BBL genetic vaccine combined with anti-PD1 antibody in MC38 tumor model of mice.	Heliyon	2022	-25.99269909303786	-12.380451286182929	0	
36211807	A newly discovered PD-L1 B-cell epitope peptide vaccine (PDL1-Vaxx) exhibits potent immune responses and effective anti-tumor immunity in multiple syngeneic mice models and (synergizes) in combination with a dual HER-2 B-cell vaccine (B-Vaxx).	Oncoimmunology	2022	-25.686272467495503	-14.004952161652728	11	2.46
36206367	Engineered DBCO+PD-1 Nanovesicles Carrying 1-MT for Cancer-Targeted Immunotherapy.	ACS biomaterials science & engineering	2022	-35.601657655460905	-55.922311060689005	0	
36205325	TNF-α-dependent lung inflammation upregulates PD-L1 in monocyte-derived macrophages to contribute to lung tumorigenesis.	FASEB journal : official publication of the Federation of American Societies for Experimental Biology	2022	2.2229134679744207	-26.284242245883597	1	
36203954	A platinum@polymer-catechol nanobraker enables radio-immunotherapy for crippling melanoma tumorigenesis, angiogenesis, and radioresistance.	Bioactive materials	2023	-31.196237581762592	-52.819260827505786	6	1.12
36203609	Circulating CD81-expressing extracellular vesicles as biomarkers of response for immune-checkpoint inhibitors in advanced NSCLC.	Frontiers in immunology	2022	2.399982686025814	-39.7573724506922	3	
36203575	Case report: Two PD-L1 positive unresectable advanced pancreatic carcinoma patients with microsatellite stability achieved R0 resection after PD-1 antibody plus chemotherapy as a successful downstaging therapy: A report of two cases.	Frontiers in immunology	2022	48.95447376474119	21.0911842406373	0	
36203421	Clinical implications of immune checkpoint markers and immune infiltrates in patients with thymic neuroendocrine neoplasms.	Frontiers in oncology	2022	1.3703829505805785	14.282914219702535	0	
36202556	Durable response of anaplastic thyroid carcinoma to FS118, a bispecific LAG-3/PD-L1 antibody, after checkpoint inhibitor progression: a case report.	Journal for immunotherapy of cancer	2022	53.88187799800805	-5.417469226276726	1	
36200668	SOLTI-1904 ACROPOLI TRIAL: efficacy of spartalizumab monotherapy across tumor-types expressing high levels of PD1 mRNA.	Future oncology (London, England)	2022	48.63052079527413	-12.930981758365457	1	
36200242	Small-Molecule Drugs in Immunotherapy.	Mini reviews in medicinal chemistry	2023	-24.11437358037984	-48.62368693504375	2	
36199693	EPM2A acts as a protective factor in prostate cancer, evidence from a real-world patient cohort.	Frontiers in pharmacology	2022	-9.264173083138177	12.801182186025342	0	
36194583	Up-Frameshift Suppressor 3 as a prognostic biomarker and correlated with immune infiltrates: A pan-cancer analysis.	PloS one	2022	-7.036620678401047	46.56362291418874	0	
36194211	"A ""Cell Space Station"" for Spatiotemporal Molecular Manipulation of Immune Checkpoint."	ACS nano	2022	-49.29061048147594	-42.49902645819976	1	
36193525	Immune-associated plasma proteins in oral and oropharyngeal cancer patients.	Heliyon	2022	-7.582934631580398	31.260881870662523	1	
36189296	m6A methylation regulators as predictors for treatment of advanced urothelial carcinoma with anti-PDL1 agent.	Frontiers in immunology	2022	-8.682762673852139	57.30119528383639	3	
36189269	Immune landscape and risk prediction based on pyroptosis-related molecular subtypes in triple-negative breast cancer.	Frontiers in immunology	2022	0.9926356838371642	57.62045308468127	4	
36189237	Case report: Pneumonia with clinical symptoms precedes imaging evidence after immune checkpoint inhibitors combined with radiotherapy in lung squamous cell cancer.	Frontiers in immunology	2022	66.60267664216249	-9.156692070603455	0	
36189226	Regulatory T-cells-related signature for identifying a prognostic subtype of hepatocellular carcinoma with an exhausted tumor microenvironment.	Frontiers in immunology	2022	-10.595001805025491	49.75152892682237	7	1.55
36189211	Cardiotoxicity of immune checkpoint inhibitors: A frequency network meta-analysis.	Frontiers in immunology	2022	82.36169323515071	2.5353886653913382	0	
36188589	Efficacy and safety of PD-1 and PD-L1 inhibitors combined with chemotherapy in randomized clinical trials among triple-negative breast cancer.	Frontiers in pharmacology	2022	41.71729058004499	10.879094756155348	4	
36188343	Disrupting the Interplay between Programmed Cell Death Protein 1 and Programmed Death Ligand 1 with Spherical Nucleic Acids in Treating Cancer.	ACS central science	2022	-34.765459026752545	-50.61162196324607	2	
36186259	Expression of Programmed Cell Death-1 (PD-1) and Its Ligand (PD-L1) in Breast Cancers and Its Association with Clinicopathological Parameters.	Journal of laboratory physicians	2022	-10.417279368566676	16.11620515331367	0	0.0
36185638	The DPY30-H3K4me3 Axis-Mediated PD-L1 Expression in Melanoma.	Journal of inflammation research	2022	-31.89343180584373	-8.780975607584416	1	
36185379	PD-1 expression on mouse intratumoral NK cells and its effects on NK cell phenotype.	iScience	2022	-35.053248039443154	-0.5784511379344398	3	
36185285	PD-1/PD-L1 immune-checkpoint blockade induces immune effector cell modulation in metastatic non-small cell lung cancer patients: A single-cell flow cytometry approach.	Frontiers in oncology	2022	30.249883319792392	-36.8231818910921	1	
36183436	Correlation study of PD-L1, CD4, CD8, and PD-1 in primary diffuse large B-cell lymphoma of the central nervous system.	Pathology, research and practice	2022	-33.96828171250312	31.204755408731398	0	
36180897	A change of PD-1/PD-L1 expression on peripheral T cell subsets correlates with the different stages of Alzheimer's Disease.	Cell & bioscience	2022	-77.84958669746327	-3.97775590002432	5	1.35
36177035	Discovery of the first PD-1 ligand encoded by a pathogen.	Frontiers in immunology	2022	-54.48643272990964	-23.94339572202632	1	
36177034	The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers.	Frontiers in immunology	2022	-43.162003548860746	-16.980917335458052	30	7.4
36177029	Identification of cuproptosis-related subtypes, cuproptosis-related gene prognostic index in hepatocellular carcinoma.	Frontiers in immunology	2022	-10.968557672356903	51.56791872247131	5	1.04
36176616	Ex vivo anchored PD-L1 functionally prevent in vivo renal allograft rejection.	Bioengineering & translational medicine	2022	-63.08125147891143	-4.751117042911296	1	
36175939	Role of Surgical Pathologist for Detection of Immunooncologic Predictive Factors in Head and Neck Cancer.	Advances in anatomic pathology	2023	-7.396261265864498	-4.421343801996367	2	
36175889	Construction of a ferroptosis-related five-lncRNA signature for predicting prognosis and immune response in thyroid carcinoma.	Cancer cell international	2022	-3.4055121590163995	52.06475674319613	3	
36175741	Extracellular vesicle-based checkpoint regulation and immune state in cancer.	Medical oncology (Northwood, London, England)	2022	-39.80939531632129	-59.539096211519336	8	1.59
36175677	Tumor immune microenvironment and systemic response in breast cancer.	Medical oncology (Northwood, London, England)	2022	17.386499199739166	9.9252042144161	2	
36175334	Primary and secondary immune checkpoint inhibitors resistance in colorectal cancer: Key mechanisms and ways to overcome resistance.	Cancer treatment and research communications	2022	34.508834381949406	17.589896547709532	3	
36174769	Lymphopenic condition enhanced the antitumor immunity of PD-1-knockout T cells mediated by CRISPR/Cas9 system in malignant melanoma.	Immunology letters	2022	-43.97561716463103	0.0628397104949311	0	
36172167	Further investigation of blockade effects and binding affinities of selected natural compounds to immune checkpoint PD-1/PD-L1.	Frontiers in oncology	2022	-31.299899014087163	-38.23253757717712	2	
36171288	PD-1 combination therapy with IL-2 modifies CD8+ T cell exhaustion program.	Nature	2022	-73.36398736118706	13.711030404478564	49	9.33
36171284	PD-1-cis IL-2R agonism yields better effectors from stem-like CD8+ T cells.	Nature	2022	-72.9128882541889	13.756593687825692	38	7.08
36169985	CD103 and periplakin are potential biomarkers for response of metastatic melanoma to pembrolizumab.	Melanoma research	2022	12.70877196063797	-3.141265295007063	2	
36169795	Simultaneous Expression of PD-1 and PD-L1 in Peripheral and Central Immune Cells and Tumor Cells in the Benign and Malignant Salivary Gland Tumors Microenvironment.	Head and neck pathology	2023	-4.116568809262596	-0.8094963097838482	3	
36169332	The association between the tumor immune microenvironments and clinical outcome in low-grade, early-stage endometrial cancer patients.	The Journal of pathology	2022	-1.8097269859448932	33.37376714701389	3	
36169194	Role of allogeneic natural killer T cells in the treatment of a patient with gefitinib-sensitive lung adenocarcinoma.	Immunotherapy	2022	36.43210781112943	-37.74411915575445	0	
36167732	Interferon-γ induces immunosuppression in salivary adenoid cystic carcinoma by regulating programmed death ligand 1 secretion.	International journal of oral science	2022	-19.18034788083441	-17.565720628967362	2	
36165915	Novel Lymphocyte-Independent Antitumor Activity by PD-1 Blocking Antibody against PD-1+ Chemoresistant Lung Cancer Cells.	Clinical cancer research : an official journal of the American Association for Cancer Research	2023	12.94432192543944	-23.029014558194348	2	
36164623	Expression of Recombinant CTLA-4 and PD-L1 Proteins Fused with Thioredoxin, and Determination of Their Ligand-Binding Activities.	Reports of biochemistry & molecular biology	2022	-51.34853198839328	-29.189261538196444	1	
36162037	Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915).	Journal of clinical oncology : official journal of the American Society of Clinical Oncology	2023	37.43908731487617	1.9740808396490093	34	
36159902	Programmed death 1 (PD-1) and ligand (PD-L1) inhibitors in head and neck squamous cell carcinoma: A meta-analysis.	World journal of otorhinolaryngology - head and neck surgery	2022	58.55098322518523	1.664105588385163	0	
36159840	Serological biomarkers predict immune-related adverse events and clinical benefit in patients with advanced gastrointestinal cancers.	Frontiers in immunology	2022	76.28811961981185	-10.821739909757747	5	1.05
36158854	Scleroderma-like Syndrome in the Setting of Pembrolizumab Therapy for Non-Small Cell Lung Cancer: Diagnosis and Dermatologic Management.	Case reports in dermatology	2022	49.56340203264872	-32.360999786761845	3	
36158692	Neoadjuvant tislelizumab and tegafur/gimeracil/octeracil (S-1) plus oxaliplatin in patients with locally advanced gastric or gastroesophageal junction cancer: Early results of a phase 2, single-arm trial.	Frontiers in oncology	2022	49.62553543286441	12.194754234037404	6	1.08
36156383	DNAzyme-Assisted Nano-Herb Delivery System for Multiple Tumor Immune Activation.	Small (Weinheim an der Bergstrasse, Germany)	2022	-33.02834959406496	-53.01831205867509	9	1.94
36156004	[The Development of Combinatorial Cancer Immunotherapy with Anti-PD-1 Therapy and Radiotherapy for Patients with Esophageal Squamous Cell Carcinoma].	Gan to kagaku ryoho. Cancer & chemotherapy	2022	55.4507530887733	15.085432712073796	0	
36154662	Upregulation of PD-L1 in Senescence and Aging.	Molecular and cellular biology	2022	-53.71175772243924	1.6519269094162443	9	2.04
36154597	Comparative Combinatorial Implications and Theranostics of Immunotherapy in the Impediment of Alveolar Soft Part Sarcoma.	Current pharmaceutical design	2022	41.24490965959963	-12.908717277153968	2	
36150452	Mathematical modeling for the combination treatment of IFN-γ and anti-PD-1 in cancer immunotherapy.	Mathematical biosciences	2022	-21.37845893723069	-19.330113338409856	1	
36150362	Immune checkpoint expression on HIV-specific CD4+ T cells and response to their blockade are dependent on lineage and function.	EBioMedicine	2022	-81.17530893928576	15.350727352666809	1	
36148227	Programmed Cell Death-Ligand-1 expression in Bladder Schistosomal Squamous Cell Carcinoma - There's room for Immune Checkpoint Blockage?	Frontiers in immunology	2022	11.62243091009495	58.207197431074015	2	
36147906	The immune escape signature predicts the prognosis and immunotherapy sensitivity for pancreatic ductal adenocarcinoma.	Frontiers in oncology	2022	-2.703382904852648	46.5316086983506	0	
36147250	Analysis of combination therapy of immune checkpoint inhibitors in osteosarcoma.	Frontiers in chemistry	2022	35.574873177456226	13.463464484906916	2	
36146933	Fibrotic immune microenvironment remodeling mediates superior anti-tumor efficacy of a nano-PD-L1 trap in hepatocellular carcinoma.	Molecular therapy : the journal of the American Society of Gene Therapy	2023	-22.76661463137312	-17.240638533598492	6	
36145376	Response to Anti-PD1/L1 Antibodies in Advanced Urothelial Cancer in the 'Real-Life' Setting.	Pharmaceuticals (Basel, Switzerland)	2022	66.04437755686912	22.45061937522082	0	
36142866	Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: A Systematic Review.	International journal of molecular sciences	2022	83.52254084802865	1.818701467941198	5	1.06
36142591	Chidamide plus Tyrosine Kinase Inhibitor Remodel the Tumor Immune Microenvironment and Reduce Tumor Progression When Combined with Immune Checkpoint Inhibitor in Naïve and Anti-PD-1 Resistant CT26-Bearing Mice.	International journal of molecular sciences	2022	17.65598285137437	13.333165357008246	2	
36140182	The Features of Checkpoint Receptor-Ligand Interaction in Cancer and the Therapeutic Effectiveness of Their Inhibition.	Biomedicines	2022	-3.093378257036976	27.537057032211923	3	
36139524	Identification and Validation of the lncRNA MYOSLID as a Regulating Factor of Necroptosis and Immune Cell Infiltration in Colorectal Cancer following Necroptosis-Related LncRNA Model Establishment.	Cancers	2022	-1.214832528400701	54.91408697903049	0	
36139451	Augmented Antitumor Effect of Unripe Rubus coreanus Miquel Combined with Oxaliplatin in a Humanized PD-1/PD-L1 Knock-In Colorectal Cancer Mouse Model.	Cells	2022	25.986470941827523	28.57204567190282	0	
36139401	Regulatory T-Cells Suppress Cytotoxic T Lymphocyte Responses against Microglia.	Cells	2022	-70.4323721081842	2.602476261827192	1	
36139358	The BET Protein Inhibitor JQ1 Decreases Hypoxia and Improves the Therapeutic Benefit of Anti-PD-1 in a High-Risk Neuroblastoma Mouse Model.	Cells	2022	-28.579859207167985	10.591363839191676	0	
36137397	Solid-type poorly differentiated adenocarcinoma of the stomach: A characteristic morphology reveals a distinctive immunoregulatory tumor microenvironment.	Pathology, research and practice	2022	-12.0984390955732	23.757543649448845	2	
36136862	PD-L1 Over-Expression Varies in Different Subtypes of Lung Cancer: Will This Affect Future Therapies?	Clinics and practice	2022	6.032960046777806	-29.95850447812224	4	
36136614	Tumor-Homing and Immune-Reprogramming Cellular Nanovesicles for Photoacoustic Imaging-Guided Phototriggered Precise Chemoimmunotherapy.	ACS nano	2022	-34.67393232741377	-55.96682774466412	15	3.67
36136350	Machine learning-based tumor-infiltrating immune cell-associated lncRNAs for predicting prognosis and immunotherapy response in patients with glioblastoma.	Briefings in bioinformatics	2022	-4.630420050746326	53.941235817528245	28	6.33
36134371	Bacteria-mediated tumor immunotherapy via photothermally-programmed PD1 expression.	Nanoscale advances	2022	-30.138480191216438	-55.13409290472656	2	
36133806	Pancreatic injury following immune checkpoint inhibitors: A systematic review and meta-analysis.	Frontiers in pharmacology	2022	84.90853149761597	-11.414383080245502	2	
36133741	Anti-PD-1 Therapy is Beneficial for the Survival of Patients with Oral Squamous Cell Carcinoma.	Cancer management and research	2022	-6.809165256572908	-11.593325052376224	0	
36132136	Overcoming resistance to PD-1/PD-L1 inhibitors in esophageal cancer.	Frontiers in oncology	2022	18.602797423557867	-48.90699530025866	1	
36132125	Immunotherapies of retinoblastoma: Effective methods for preserving vision in the future.	Frontiers in oncology	2022	45.21943942633312	28.7891744367246	1	
36129987	PD-1/PD-L1 blockade abrogates a dysfunctional innate-adaptive immune axis in critical β-coronavirus disease.	Science advances	2022	-52.01886660801486	42.15906907754576	5	0.92
36128588	Expression of Programmed Death Ligand 1 in Breast Cancer in Mexican Women.	World journal of oncology	2022	-10.912830154073736	16.0502170227789	2	
36126447	Biphenyl-based small molecule inhibitors: Novel cancer immunotherapeutic agents targeting PD-1/PD-L1 interaction.	Bioorganic & medicinal chemistry	2022	-37.954432310150594	-41.39591209146651	4	
36125660	Molecular characterization of ESR1 variants in breast cancer.	Breast cancer research and treatment	2022	8.678139665441284	29.94434453435351	1	
36123711	The immune microenvironment of HPV-positive and HPV-negative oropharyngeal squamous cell carcinoma: a multiparametric quantitative and spatial analysis unveils a rationale to target treatment-naïve tumors with immune checkpoint inhibitors.	Journal of experimental & clinical cancer research : CR	2022	-6.274770055685231	34.499560183510184	8	1.98
36120342	Understanding the functional inflammatory factors involved in therapeutic response to immune checkpoint inhibitors for pan-cancer.	Frontiers in pharmacology	2022	77.41990018441143	-11.961092920754975	3	
36119464	PD-1 inhibitor therapy causes multisystem immune adverse reactions: a case report and literature review.	Frontiers in oncology	2022	79.57638586898064	-10.73529239669413	3	
36119046	Prognostic value of PD-1, PD-L1 and PD-L2 deserves attention in head and neck cancer.	Frontiers in immunology	2022	-4.58101061472024	-5.45807781815682	4	
36118947	Analysis of the Relationship between Scleritis and T Cell Activation in Patients with Hepatocellular Carcinoma Treated with PD-1 Carrelizumab.	Contrast media & molecular imaging	2022	-25.250695980033868	41.76564732891727	1	
36115921	Effects of tumor-infiltrating CD8+ T cells, PD1/PD-L1 axis, and expression patterns of HLA class I on the prognosis of patients with malignant pleural mesothelioma who underwent extra-pleural pneumonectomy.	Cancer immunology, immunotherapy : CII	2023	6.396224267943728	11.94534062255318	2	
36114029	Cancer-associated fibroblasts-derived FMO2 as a biomarker of macrophage infiltration and prognosis in epithelial ovarian cancer.	Gynecologic oncology	2022	0.9202759557304224	33.04618304964417	3	
36111402	Space Is the Place: Mapping the Cell-Cell Interactions That Predict Immunotherapy Responses in Melanoma.	Cancer research	2022	8.795131811217567	-3.0955548333519216	0	
36111282	Datasets for gene expression profiles of head and neck squamous cell carcinoma and lung cancer treated or not by PD1/PD-L1 inhibitors.	Data in brief	2022	-5.4654453630485405	-3.4490538603288905	4	
36110938	Dissecting a hypoxia-related angiogenic gene signature for predicting prognosis and immune status in hepatocellular carcinoma.	Frontiers in oncology	2022	-10.408182366636884	50.15631036245853	1	
36110551	Cardiotoxicity associated with immune checkpoint inhibitors: Current status and future challenges.	Frontiers in pharmacology	2022	82.99879692100835	1.5636083577321986	4	
36108528	Inhibition of APOC1 promotes the transformation of M2 into M1 macrophages via the ferroptosis pathway and enhances anti-PD1 immunotherapy in hepatocellular carcinoma based on single-cell RNA sequencing.	Redox biology	2022	-11.827274763859904	43.81860313995237	22	4.99
36107620	Immune tolerance against infused FVIII in hemophilia A is mediated by PD-L1+ Tregs.	The Journal of clinical investigation	2022	-65.16729480578503	0.7954993383519023	5	1.3
36106641	Moving beyond the T cell synapse for combination neoadjuvant immunotherapy in head and neck cancer.	The Journal of clinical investigation	2022	53.12879524050915	33.39675740734278	1	
36105623	Immunotherapy in head and neck squamous cell carcinoma: a narrative review.	Frontiers of oral and maxillofacial medicine	2022	51.63819493344253	30.07604776824424	3	
36105495	PD-1/PD-L1 expression in pancreatic cancer and its implication in novel therapies.	Medicine and pharmacy reports	2021	12.43465678934198	12.043396394458917	7	0.75
36104974	PD-1/PD-L1 blockade is a potent adjuvant in treatment of Staphylococcus aureus osteomyelitis in mice.	Molecular therapy : the journal of the American Society of Gene Therapy	2023	-51.56939204879973	16.764281393673702	3	
36104949	Combination of PD-1/PD-L1 checkpoint inhibition and dendritic cell therapy in mice models and in patients with mesothelioma.	International journal of cancer	2023	9.95665237892346	11.971480231752828	2	
36104728	Expression of immune checkpoint regulators, programmed death-ligand 1 (PD-L1/PD-1), cytotoxic T lymphocyte antigen 4 (CTLA-4), and indolaimine-2, 3-deoxygenase (IDO) in uterine mesenchymal tumors.	Diagnostic pathology	2022	-17.6626798206426	10.400736672546808	0	
36104103	FBW7-mediated ubiquitination and destruction of PD-1 protein primes sensitivity to anti-PD-1 immunotherapy in non-small cell lung cancer.	Journal for immunotherapy of cancer	2022	-18.881026691485143	-8.456672892032481	5	1.12
36100320	Cisplatin and gemcitabine exert opposite effects on immunotherapy with PD-1 antibody in K-ras-driven cancer.	Journal of advanced research	2022	28.217346391899216	-24.572662606279813	8	1.59
36099881	NKG2A and HLA-E define an alternative immune checkpoint axis in bladder cancer.	Cancer cell	2022	70.53734674198705	24.446074976263844	21	4.66
36094816	Enhanced Programmed Cell Death Protein 1/Programmed Cell Death Ligand 1 Expression Induced by Severe Influenza A Virus Infection Impairs Host's Antiviral Response.	Viral immunology	2022	-77.21666197468174	7.356411219009702	1	
36093941	Differential expression of checkpoint markers in the normoxic and hypoxic microenvironment of glioblastomas.	Brain pathology (Zurich, Switzerland)	2023	-21.96720428784766	54.93988379158507	4	
36093549	Anlotinib improved the reactive cutaneous capillary endothelial proliferation induced by camrelizumab: a case report.	Translational cancer research	2022	62.701893818069	-1.193961143811731	0	
36093529	Development and validation of a prognostic predictive model of pulmonary spindle cell carcinoma from the surveillance, epidemiology and end results database.	Translational cancer research	2022	16.766937874882835	-26.55600776618852	0	
36093111	The changes in peripheral blood Th17 and Treg ratios in Hashimoto's thyroiditis are accompanied by differential PD-1/PD-L1 expression.	Frontiers in endocrinology	2022	-62.81423022934978	11.793398699641967	1	
36091822	Qingfei Jiedu decoction inhibits PD-L1 expression in lung adenocarcinoma based on network pharmacology analysis, molecular docking and experimental verification.	Frontiers in pharmacology	2022	-20.37498278541432	-36.44525267885705	2	
36091778	Integrated analysis of inflammatory response subtype-related signature to predict clinical outcomes, immune status and drug targets in lower-grade glioma.	Frontiers in pharmacology	2022	-19.019991926101085	55.84483703462584	3	
36091687	Identification of N7-methylguanosine related signature for prognosis and immunotherapy efficacy prediction in lung adenocarcinoma.	Frontiers in medicine	2022	17.00407086893404	-14.157455850305734	0	
36091159	POD1UM-303/InterAACT 2: A phase III, global, randomized, double-blind study of retifanlimab or placebo plus carboplatin-paclitaxel in patients with locally advanced or metastatic squamous cell anal carcinoma.	Frontiers in oncology	2022	57.37292289047798	9.946858606139331	1	
36091070	Sintilimab induced ICIAM in the treatment of advanced HCC: A case report and analysis of research progress.	Frontiers in immunology	2022	84.12018950504758	0.3011029360148587	4	
36090967	Robust pyroptosis risk score guides the treatment options and predicts the prognosis of bladder carcinoma.	Frontiers in immunology	2022	1.879931567110087	57.95669288797874	1	
36090644	Locally advanced undifferentiated small round cell sarcoma of the lung with novel SDCCAG8-AKT3 fusion and type II tumor immunity in the microenvironment: a rare case report.	Translational lung cancer research	2022	15.741142022888637	-19.48832803263597	0	
36088412	Consistent expression of PD-L1 in tumor microenvironment with peripheral PD-1/PD-L1 in circulating T lymphocytes of operable breast cancer: a diagnostic test.	Diagnostic pathology	2022	-9.697380429907364	17.978518647311958	1	
36083496	PD-1/PD-L1 Inhibition Enhances Chemotherapy-Induced Neuropathic Pain by Suppressing Neuroimmune Antinociceptive Signaling.	Cancer immunology research	2022	-73.82668708691851	-13.051385089045173	1	
36083129	Sequential pembrolizumab and AVD are highly effective at any PD-L1 expression level in untreated Hodgkin lymphoma.	Blood advances	2023	44.22556684830581	-5.1853073066524775	4	
36081999	A prognostic exosome-related LncRNA risk model correlates with the immune microenvironment in liver cancer.	Frontiers in genetics	2022	-3.855111013503232	54.67445397890567	0	
36077868	The Efficacy of PD-1/PD-L1 Inhibitors in Patients with Liver Metastasis of Non-Small Cell Lung Cancer: A Real-World Study.	Cancers	2022	50.24343582175096	-17.264461187793408	3	
36077799	Defining the Immune Checkpoint Landscape in Human Colorectal Cancer Highlights the Relevance of the TIGIT/CD155 Axis for Optimizing Immunotherapy.	Cancers	2022	5.22282312994212	36.970816875589385	3	
36077679	Adjuvant PD-1 and PD-L1 Inhibitors and Relapse-Free Survival in Cancer Patients: The MOUSEION-04 Study.	Cancers	2022	51.431200272827866	-12.792104652676167	2	
36077671	Reversing PD-1 Resistance in B16F10 Cells and Recovering Tumour Immunity Using a COX2 Inhibitor.	Cancers	2022	-34.33506668109955	-23.1147369779884	7	1.74
36077620	Temsirolimus Enhances Anti-Cancer Immunity by Inducing Autophagy-Mediated Degradation of the Secretion of Small Extracellular Vesicle PD-L1.	Cancers	2022	-30.942883709637773	-33.4693450167095	2	
36077380	The Oncolytic Adenovirus XVir-N-31, in Combination with the Blockade of the PD-1/PD-L1 Axis, Conveys Abscopal Effects in a Humanized Glioblastoma Mouse Model.	International journal of molecular sciences	2022	-34.8856005021383	54.20662302067954	5	1.25
36073781	The prognostic value of a 4-factor neoimmunologic score system in non-small cell lung cancer.	Journal of leukocyte biology	2022	11.79445653530697	-14.638917820806965	0	
36073303	Comparison of the tumor immune microenvironment phenotypes in different breast cancers after neoadjuvant therapy.	Cancer medicine	2023	0.6749255594950228	23.717768703182323	1	
36072949	Incidence and characteristics of adverse drug reactions in a cohort of patients treated with PD-1/PD-L1 inhibitors in real-world practice.	Frontiers in medicine	2022	71.16817337372439	-16.95614108766536	0	
36071464	Novel tri-specific tribodies induce strong T cell activation and anti-tumor effects in vitro and in vivo.	Journal of experimental & clinical cancer research : CR	2022	-14.775129646376955	-43.591828450930336	2	
36067541	Evaluation of PD-L1 expression in a large set of gastroenteropancreatic neuroendocrine tumours and correlation with clinicopathological data.	Translational oncology	2022	0.0195187887311774	11.439892305559756	2	
36067356	Discovery of Cyclic Peptide Inhibitors Targeting PD-L1 for Cancer Immunotherapy.	Journal of medicinal chemistry	2022	-45.25519282990425	-43.969010626898985	6	1.58
36065492	Anti-tumour potential of PD-L1/PD-1 post-translational modifications.	Immunology	2022	-45.0559679861759	-22.83040132769698	6	1.34
36064338	Prognostic impact of activin subunit inhibin beta A in gastric and esophageal adenocarcinomas.	BMC cancer	2022	-12.074352409475702	8.54161681414084	2	
36061419	Old is new again: emergence of thromboembolic complications in cancer patients on immunotherapy.	Thrombosis research	2022	82.39913307408979	-8.007315243290622	3	
36061356	The Efficacy of Immune Checkpoint Inhibitors vs. Chemotherapy for KRAS-Mutant or EGFR-Mutant Non-Small-Cell Lung Cancers: A Meta-Analysis Based on Randomized Controlled Trials.	Disease markers	2022	44.839350759562905	-19.873792195723965	2	
36059952	The expression and significance of efferocytosis and immune checkpoint related molecules in pancancer samples and the correlation of their expression with anticancer drug sensitivity.	Frontiers in pharmacology	2022	2.105692410261551	30.746975213460782	0	
36059699	Respiratory system toxicity induced by immune checkpoint inhibitors: A real-world study based on the FDA adverse event reporting system database.	Frontiers in oncology	2022	72.50661725036034	-8.494486720236097	3	
36058143	Indoleamine 2,3-dioxygenase (IDO) inhibitors and cancer immunotherapy.	Cancer treatment reviews	2022	30.899382054051426	19.10834795635212	32	7.42
36057921	0.1% Nano-silver mediates PD-1/PD-L1 pathway and alleviates chronic apical periodontitis in rats.	Odontology	2023	-65.93715945212033	-21.176446124216884	0	
36057740	PD-L1 and PD-1 expression in pediatric central nervous system germ cell tumors.	Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc	2022	-24.92805417634232	33.778608757744884	1	
36055113	Focus on immune checkpoint PD-1/PD-L1 pathway: New advances of polyphenol phytochemicals in tumor immunotherapy.	Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie	2022	-29.59579004475712	-37.19482553365975	5	1.22
36054729	Lichen-planus-pemphigoides-like reaction to PD-1 checkpoint blockade.	Journal of cutaneous pathology	2022	70.79842324572975	-25.83321419758551	5	2.03
36053290	PD-L1 antibody enhanced β-glucan antitumor effects via blockade of the immune checkpoints in a melanoma model.	Cancer immunology, immunotherapy : CII	2023	-26.378687730957875	-32.43927259934493	1	
36052121	Anti-PD-L1 immunoconjugates for cancer therapy: Are available antibodies good carriers for toxic payload delivering?	Frontiers in pharmacology	2022	-41.11682600517813	-18.31832793229839	3	
36051332	Bifidobacterium infantis regulates the programmed cell death 1 pathway and immune response in mice with inflammatory bowel disease.	World journal of gastroenterology	2022	-65.48398549166531	9.20505910635432	2	
36051079	Targetable alterations in primary extranodal diffuse large B-cell lymphoma.	EJHaem	2022	-33.02545138933873	29.82767285695645	3	
36051020	Progressive multifocal leukoencephalopathy after durvalumab treatment for acute myeloid leukemia: A consequence of an immune reconstitution inflammatory syndrome?	EJHaem	2022	-40.95414170337309	42.69425684543391	1	
36050478	Sphingosine kinase 1 promotes tumor immune evasion by regulating the MTA3-PD-L1 axis.	Cellular & molecular immunology	2022	-34.24105912603252	-16.37670570205494	1	
36048468	The Efficacy of Fosbretabulin Disodium Combined with Radiofrequency Ablation in Lung Cancer.	Radiation research	2022	26.07082552970665	53.6673557486964	0	
36046467	Long-Term Survival of FOLFIRINOX +toripalimab in a Patient with Metastatic Pancreatic Ductal Adenocarcinoma: A Case Report.	OncoTargets and therapy	2022	61.6196526983103	8.893147888131319	0	
36044158	Immune checkpoint inhibition improves antimyeloma activity of bortezomib and STING agonist combination in Vk*MYC preclinical model.	Clinical and experimental medicine	2023	-22.73174535328941	-45.53933089463325	0	
36043445	Mechanisms and network pharmacological analysis of Yangyin Fuzheng Jiedu prescription in the treatment of hepatocellular carcinoma.	Cancer medicine	2023	-20.383306473655185	-37.23726508352435	1	
36042639	Microsatellite instability/mismatch repair deficiency and activation of the Wnt/β-catenin signaling pathway in gastric adenocarcinoma of the fundic gland: A case report.	Medicine	2022	13.018913536010135	44.0072299873836	1	
36042498	SPOP promotes cervical cancer progression by inducing the movement of PD-1 away from PD-L1 in spatial localization.	Journal of translational medicine	2022	0.8155468753662631	-13.7378540652839	4	
36042378	Homodimerized cytoplasmic domain of PD-L1 regulates its complex glycosylation in living cells.	Communications biology	2022	-35.56213278992996	-33.52477385165894	3	
36039414	An In Vivo Study of Local Administration of Low-dose Anti-PD-1 Antibody Using an Oral Cancer Cell Line.	Anticancer research	2022	52.546342533074736	-8.68975656158215	0	
36035942	Cardiovascular adverse events induced by immune checkpoint inhibitors: A real world study from 2018 to 2022.	Frontiers in cardiovascular medicine	2022	81.51458979394859	2.490322767136362	7	1.65
36035072	Clinical Significance of Negative Costimulatory Molecule PD-1/PD-L1 on Peripheral Blood Regulatory T Cell Levels among Patients with Pulmonary Tuberculosis.	Journal of tropical medicine	2022	-86.11709746047806	3.455958940356944	0	
36033972	Obesity and adipose tissue impact on T-cell response and cancer immune checkpoint blockade therapy.	Immunotherapy advances	2022	-30.713800247329416	-25.86959725573324	1	
36032657	The Prognostic Value of Eight Immunohistochemical Markers Expressed in the Tumor Microenvironment and on Hodgkin Reed-Sternberg Cells in Pediatric Patients With Classical Hodgkin Lymphoma.	Pathology oncology research : POR	2022	-29.068864661382136	23.33014929445599	0	
36032124	Heterogeneity of tumor immune microenvironment and real-world analysis of immunotherapy efficacy in lung adenosquamous carcinoma.	Frontiers in immunology	2022	16.59680260588626	-18.545835168150408	1	
36032097	Identifying immune cells-related phenotype to predict immunotherapy and clinical outcome in gastric cancer.	Frontiers in immunology	2022	-9.77889824097112	23.695946436094044	1	
36031328	Systemic Checkpoint Blockade by PD-L1 Single-Chain Antibody Confers Potent Antitumor Immunity and Long-term Survival.	Molecular cancer therapeutics	2022	-44.50186907066024	-29.194942227750968	3	
36018829	Full-length recombinant antibodies from Escherichia coli: production, characterization, effector function (Fc) engineering, and clinical evaluation.	mAbs	2022	-15.518636181238868	-49.32974865318454	4	
36018466	Anti-PD-1/PD-L1 immunotherapy in conversion treatment of locally advanced hepatocellular carcinoma.	Clinical and experimental medicine	2023	27.332326211678808	49.38198744015518	2	
36016960	PD-L1+ neutrophils as novel biomarkers for stage IV melanoma patients treated with nivolumab.	Frontiers in immunology	2022	10.885722441507278	-2.2587877120462543	3	
36015348	Immune Checkpoint Inhibitors for Vaccine Improvements: Current Status and New Approaches.	Pharmaceutics	2022	30.83417098957073	13.264514317143888	5	1.15
36013315	New Potential Immune Biomarkers in the Era of Precision Medicine: Lights and Shadows in Colorectal Cancer.	Life (Basel, Switzerland)	2022	6.9367630114303545	42.38468260943333	2	
36013050	Does Elevated Pre-Treatment Plasma PD-L1 Level Indicate an Increased Tumor Burden and Worse Prognosis in Metastatic Colorectal Cancer?	Journal of clinical medicine	2022	-4.0897308097973735	10.728894441276474	0	
36010840	Circulating Low Density Neutrophils Are Associated with Resistance to First Line Anti-PD1/PDL1 Immunotherapy in Non-Small Cell Lung Cancer.	Cancers	2022	19.03592638131206	-32.29844400130032	10	2.17
36010357	The Expression Levels and Concentrations of PD-1 and PD-L1 Proteins in Septic Patients: A Systematic Review.	Diagnostics (Basel, Switzerland)	2022	-57.838728158643725	35.271002547660295	6	1.49
36009387	T-Cell Infiltration and Immune Checkpoint Expression Increase in Oral Cavity Premalignant and Malignant Disorders.	Biomedicines	2022	-6.703870937832181	32.0600674511052	1	
36009373	Pilot Study: Immune Checkpoints Polymorphisms in Greek Primary Breast Cancer Patients.	Biomedicines	2022	2.7530806130109515	9.91993923084664	2	
36008722	Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial.	Nature medicine	2022	52.36971003776713	-22.030584811538034	43	8.9
36007963	Phase II study of durvalumab (anti-PD-L1) and trametinib (MEKi) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC).	Journal for immunotherapy of cancer	2022	38.031622797503296	24.370570539102225	10	2.16
36005172	Drug Treatment for Advanced Hepatocellular Carcinoma: First-Line and Beyond.	Current oncology (Toronto, Ont.)	2022	31.411643569731822	51.01433194264023	12	3.1
36004638	Overcoming immunosuppression and pro-tumor inflammation in lung cancer with combined IL-1β and PD-1 inhibition.	Future oncology (London, England)	2022	35.577169545250065	-24.93278368290897	5	1.04
36003776	Expression profiles of m6A RNA methylation regulators, PD-L1 and immune infiltrates in gastric cancer.	Frontiers in oncology	2022	-8.547883614817964	56.366330833723	9	1.77
36003379	Dynamics of PD-1 expression are associated with treatment efficacy and prognosis in patients with intermediate/high-risk myelodysplastic syndromes under hypomethylating treatment.	Frontiers in immunology	2022	-34.94403047099173	13.34051784533828	0	
36003341	Comprehensive analysis of 7-methylguanosine and immune microenvironment characteristics in clear cell renal cell carcinomas.	Frontiers in genetics	2022	15.916534719223607	33.97796262072571	0	
36002439	The fusion of quantitative molecular proteomics and immune-oncology: a step towards precision medicine in cancer therapeutics.	FEBS letters	2022	1.407892171702684	-49.7890641119993	1	
36002185	Antitumor efficacy of 90Y-NM600 targeted radionuclide therapy and PD-1 blockade is limited by regulatory T cells in murine prostate tumors.	Journal for immunotherapy of cancer	2022	27.42139054501755	22.27503682496327	5	1.23
36002182	Spatially resolved proteomic profiling identifies tumor cell CD44 as a biomarker associated with sensitivity to PD-1 axis blockade in advanced non-small-cell lung cancer.	Journal for immunotherapy of cancer	2022	13.940500125727295	-19.37473584284202	10	2.11
36000541	HERIZON-GEA-01: Zanidatamab + chemo ± tislelizumab for 1L treatment of HER2-positive gastroesophageal adenocarcinoma.	Future oncology (London, England)	2022	47.14373848761984	15.254149810341945	9	1.87
35999569	A comprehensive review about the utilization of immune checkpoint inhibitors and combination therapy in hepatocellular carcinoma: an updated review.	Cancer cell international	2022	31.956833691904347	48.70594334147969	1	
35998502	Roles of circulating tumor DNA in PD-1/PD-L1 immune checkpoint Inhibitors: Current evidence and future directions.	International immunopharmacology	2022	25.03637780525553	-12.72980938674988	1	
35997657	The evolving role of checkpoint inhibitors in the treatment of urothelial carcinoma.	British journal of clinical pharmacology	2023	69.29365160515017	20.06142328525728	1	
35996170	A novel signature to predict thyroid cancer prognosis and immune landscape using immune-related LncRNA pairs.	BMC medical genomics	2022	-2.5405864247538403	52.630826381186026	1	
35996120	Development of a human phage display-derived anti-PD-1 scFv antibody: an attractive tool for immune checkpoint therapy.	BMC biotechnology	2022	-46.01810372753506	-30.45996908486336	5	1.19
35995615	[New drug approval: Nivolumab for adjuvant treatment of patients with PD-L1-positive (≥1%), muscle invasive urothelial carcinoma who are at high risk of recurrence after radical resection].	Bulletin du cancer	2022	64.32430156718132	19.657060021390024	0	
35995141	Immune checkpoints in osteosarcoma: Recent advances and therapeutic potential.	Cancer letters	2022	35.31351627929261	13.468072635028776	12	3.18
35994596	Immunotherapy-chemotherapy combinations for non-small cell lung cancer: current trends and future perspectives.	Expert opinion on biological therapy	2022	35.48728356516465	-29.67718754576757	4	
35992887	Tumor-specific T cell-mediated upregulation of PD-L1 in myelodysplastic syndrome cells does not affect T-cell killing.	Frontiers in oncology	2022	-40.02701829928085	-4.805428058806764	1	
35992834	Synergistic effects of nab-PTX and anti-PD-1 antibody combination against lung cancer by regulating the Pi3K/AKT pathway through the Serpinc1 gene.	Frontiers in oncology	2022	2.2799543997934943	-30.93881918435435	3	
35992832	Immunotherapy in non-small cell lung cancer: Past, present, and future directions.	Frontiers in oncology	2022	35.40424424240554	-32.6097849547598	15	3.39
35992269	Characterizing the role of SLC3A2 in the molecular landscape and immune microenvironment across human tumors.	Frontiers in molecular biosciences	2022	-5.307265652258638	48.99624999847597	2	
35990262	Quantification of pharmacokinetic profiles of a recombinant canine PD-1 fusion protein by validated sandwich ELISA method.	Frontiers in veterinary science	2022	-0.5677111708590898	-57.58819220968815	0	
35989738	Onychopathy Induced by Nivolumab: A Targeted Immunotherapy.	Cureus	2022	73.63887829917225	-28.59537092027932	1	
35989085	Immunotherapy for cancer treatment.	Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti	2022	21.372535377426612	2.48975776173556	1	
35988519	Methionine enkephalin inhibits colorectal cancer by remodeling the immune status of the tumor microenvironment.	International immunopharmacology	2022	-19.98963493709228	-31.824705998666214	5	1.49
35987146	A review of PD-1/PD-L1 siRNA delivery systems in immune T cells and cancer cells.	International immunopharmacology	2022	-51.190970651939374	-21.199198565426443	0	
35986758	Distinct cellular immune profiles in lung adenocarcinoma manifesting as pure ground glass opacity versus solid nodules.	Journal of cancer research and clinical oncology	2023	15.818643639806991	-15.267096232286644	1	
35986535	Immune Checkpoint Inhibitors: Recent Clinical Advances and Future Prospects.	Current medicinal chemistry	2023	23.41633215625517	10.193254992182522	2	
35983558	Neoadjuvant chemoradiotherapy with camrelizumab in patients with locally advanced esophageal squamous cell carcinoma.	Frontiers in surgery	2022	50.93055006628475	12.288627021223247	4	
35982979	PD-L1 expression on circulating tumor cells can be a predictive biomarker to PD-1 inhibitors combined with radiotherapy and antiangiogenic therapy in advanced hepatocellular carcinoma.	Frontiers in oncology	2022	7.960684451964947	-40.274153748982144	13	3.17
35982961	Phase 1b clinical trial of pucotenlimab (HX008), a novel anti-PD-1 monoclonal antibody, combined with gemcitabine and cisplatin in the first-line treatment of metastatic triple-negative breast cancer.	Frontiers in oncology	2022	56.28034873276694	-6.937179277265079	2	
35982880	Immunoexpression of PD-L1 and PD-1 and Its Clinicopathological Correlation in Urothelial Carcinomas.	Journal of laboratory physicians	2022	12.571828992447353	59.4171823016802	0	0.0
35982052	Predicting response to immunotherapy in gastric cancer via multi-dimensional analyses of the tumour immune microenvironment.	Nature communications	2022	-9.900926361607247	23.730891112287747	13	2.55
35980974	Murine precursors to type 1 conventional dendritic cells induce tumor cytotoxicity and exhibit activated PD-1/PD-L1 pathway.	PloS one	2022	-59.55338796714499	-7.599838933739599	1	
35979531	Immunohistochemical Study of the PD-1/PD-L1 Pathway in Cutaneous Lupus Erythematosus.	Pathology oncology research : POR	2022	-48.75376907948531	21.56020609031176	1	
35978433	Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts.	Journal of hematology & oncology	2022	30.51481511247542	12.36345812626468	54	11.97
35976415	A blood-based immune marker for resistance to pembrolizumab in patients with metastatic urothelial cancer.	Cancer immunology, immunotherapy : CII	2023	15.934479862063826	-7.409464602054585	1	
35975195	A Case of Systemic Severe Bullous Pemphigoid Caused by Long-Term Sintilimab Treatment for Renal Cell Carcinoma.	Clinical, cosmetic and investigational dermatology	2022	71.13840377839668	-26.786178614432163	1	
35973200	Pembrolizumab for the treatment of disease relapse after allogeneic hematopoietic stem cell transplantation.	Blood advances	2023	44.52006765849088	-4.926965950444796	1	
35972693	PD-1, PD-L1 and cAMP immunohistochemical expressions are associated with worse oncological outcome in patients with bladder cancer.	Journal of cancer research and clinical oncology	2023	9.16568460061835	58.63562434544219	4	
35970031	TCF1+PD-1+ tumour-infiltrating lymphocytes predict a favorable response and prolonged survival after immune checkpoint inhibitor therapy for non-small-cell lung cancer.	European journal of cancer (Oxford, England : 1990)	2022	-0.1840174664128707	20.08704558394994	2	
35968783	Upregulated PD-1 signaling antagonizes glomerular health in aged kidneys and disease.	The Journal of clinical investigation	2022	-53.202645357838136	7.07266460136647	10	2.31
35968349	An immune-inflamed tumor microenvironment as defined by CD8 score is associated with favorable oncologic outcomes in hepatocellular carcinoma independent of measures of tumor mutational burden.	American journal of cancer research	2022	-14.274584001991355	43.87956106100461	4	
35967452	Lenvatinib Plus Programmed Cell Death Protein-1 Inhibitor Beyond First-Line Systemic Therapy in Refractory Advanced Biliary Tract Cancer: A Real-World Retrospective Study in China.	Frontiers in immunology	2022	54.822524521333705	21.124531024612917	8	1.52
35966587	Machine learning-based identification of tumor-infiltrating immune cell-associated lncRNAs for improving outcomes and immunotherapy responses in patients with low-grade glioma.	Theranostics	2022	-4.605141082952568	53.89030176099453	32	7.34
35965575	Case report: A case of heterogeneity of the antitumor response to immune checkpoint inhibitors in a patient with relapsed hepatocellular carcinoma.	Frontiers in oncology	2022	14.629766537772984	-35.038670100679724	0	
35964407	siRNA targeting PD-L1 delivered with attenuated Salmonella enhanced the anti-tumor effect of lenvatinib on mice bearing Hepatocellular carcinoma.	International immunopharmacology	2022	10.702607987562024	3.3545963459445747	1	
35964287	PD-L1 testing by immunohistochemistry in immuno-oncology.	Biomolecules & biomedicine	2023	18.63985085124769	-42.88671242454163	2	
35964269	Expression and potential role of CCL4 in CD8+T cells in NSCLC.	Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico	2022	12.379328805780723	-15.983689464286098	0	
35963023	Design, synthesis and biological evaluation of PD-1 derived peptides as inhibitors of PD-1/PD-L1 complex formation for cancer therapy.	Bioorganic chemistry	2022	-43.18202965192765	-43.766557880777896	5	1.12
35962325	Bioinformatic analysis of PD-1 checkpoint blockade response in influenza infection.	BMC genomic data	2022	-77.86739263127065	6.8719349083543575	1	
35961684	Response to PD-1 inhibitor after progression on PD-L1 inhibitor in advanced HCC.	BMJ case reports	2022	39.01404113309674	13.726904688144138	0	
35958493	Prognostic value of PD-1, PD-L1 and P53 in patients with non-small cell lung cancer after postoperative adjuvant chemoradiotherapy.	American journal of translational research	2022	12.274504727818424	-28.401743040454857	0	
35957899	Case Report: Sustained complete remission on combination therapy with olaparib and pembrolizumab in BRCA2-mutated and PD-L1-positive metastatic cholangiocarcinoma after platinum derivate.	Frontiers in oncology	2022	55.52728953784144	23.33677547514541	3	
35957546	Hepatocytes infected with hepatitis C virus change immunological features in the liver microenvironment.	Clinical and molecular hepatology	2023	-77.75501743471409	24.661990503401203	6	
35955855	Microsatellite Instability: From the Implementation of the Detection to a Prognostic and Predictive Role in Cancers.	International journal of molecular sciences	2022	11.905715681354446	42.9376418037947	11	2.66
35955729	Beyond Cancer: Regulation and Function of PD-L1 in Health and Immune-Related Diseases.	International journal of molecular sciences	2022	-45.99276333039544	-15.467947542448703	7	1.72
35954496	The Role of Pathology-Based Methods in Qualitative and Quantitative Approaches to Cancer Immunotherapy.	Cancers	2022	5.572291729748843	-48.622761399081824	0	
35954471	Neither Tumor-Infiltrating Lymphocytes nor Cytotoxic T Cells Predict Enhanced Benefit from Chemotherapy in the DBCG77B Phase III Clinical Trial.	Cancers	2022	-0.6148732984652312	22.24577862465279	2	
35954341	Circulating Exhausted PD-1+CD39+ Helper CD4 T Cells Are Tumor-Antigen-Specific and Predict Response to PD-1/PD-L1 Axis Blockade.	Cancers	2022	-45.74089643482058	11.40169221646343	1	
35954316	Advances in Cutaneous Squamous Cell Carcinoma Management.	Cancers	2022	57.90611358477832	6.8660861638652095	8	2.11
35951282	Extracellular vesicle-mediated immunoregulation in cancer.	International journal of hematology	2023	-39.36694148499904	-59.46239386079635	3	
35951090	Fibroblast activation protein in the tumor microenvironment predicts outcomes of PD-1 blockade therapy in advanced non-small cell lung cancer.	Journal of cancer research and clinical oncology	2023	1.7108023702689903	34.33525347232816	3	
35948846	Progress in programmed cell death-1/programmed cell death-ligand 1 pathway inhibitors and binding mode analysis.	Molecular diversity	2023	-42.93306637716104	-39.52748068477553	1	
35948516	Genetically Engineered Hematopoietic Stem Cells Deliver TGF-β Inhibitor to Enhance Bone Metastases Immunotherapy.	Advanced science (Weinheim, Baden-Wurttemberg, Germany)	2022	-52.704440393079565	18.437892539917712	5	0.95
35940218	A novel pyroptosis-related LncRNA signature predicts prognosis and indicates tumor immune microenvironment in skin cutaneous melanoma.	Life sciences	2022	-2.7354143530652317	54.12966961717159	5	1.06
35939675	PD-1 blockade following ART interruption enhances control of pathogenic SIV in rhesus macaques.	Proceedings of the National Academy of Sciences of the United States of America	2022	-84.27038769960818	14.944293926793048	1	
35938242	Prognostic significance of programmed death-1 and programmed death ligand-1 proteins in breast cancer.	Human antibodies	2022	-10.87499080970166	14.922807871789496	0	
35937946	Alteration in the Immune Microenvironment Based on APC Status in MSS/pMMR Colon Cancer.	Disease markers	2022	9.7698817474459	39.83347078353883	0	
35936746	Availability and Affordability of Oncology Drugs in 2012-2021 in China and the United States.	Frontiers in oncology	2022	36.93854288482619	-17.45778840549327	2	
35936682	Immune-Related Biomarkers Improve Performance of Risk Prediction Models for Survival in Patients With Hepatocellular Carcinoma.	Frontiers in oncology	2022	-12.958649061954045	46.83743085636814	0	
35935985	The interaction between the soluble programmed death ligand-1 (sPD-L1) and PD-1+ regulator B cells mediates immunosuppression in triple-negative breast cancer.	Frontiers in immunology	2022	-14.243020047857629	18.261705922682214	3	
35935973	Receptor-ligand pair typing and prognostic risk model for papillary thyroid carcinoma based on single-cell sequencing.	Frontiers in immunology	2022	-2.140607884195024	52.66714604285181	1	
35935874	Combinatorial Strategies With PD-1/PD-L1 Immune Checkpoint Blockade for Breast Cancer Therapy: Mechanisms and Clinical Outcomes.	Frontiers in pharmacology	2022	26.569845217194715	-3.476693256493524	0	
35934154	Anti-PD-1 combined with targeted therapy: Theory and practice in gastric and colorectal cancer.	Biochimica et biophysica acta. Reviews on cancer	2022	34.76813280349252	22.245781562187258	6	1.22
35930112	Local Therapy for Oligoprogression or Consolidation in High Mutational Burden Stage 4 Colorectal Cancer Treated With PD-1 or PD-L1 Blockade.	Annals of surgical oncology	2022	45.00259664075013	7.811108354075896	2	
35930001	Signaling new therapeutic opportunities: cytokines in prostate cancer.	Expert opinion on biological therapy	2022	23.58261513226225	17.025727911973778	1	
35929803	Escherichia coli-Specific CXCL13-Producing TFH Are Associated with Clinical Efficacy of Neoadjuvant PD-1 Blockade against Muscle-Invasive Bladder Cancer.	Cancer discovery	2022	8.527906458601235	62.83529674852863	12	2.06
35929305	Anti-tumor immunity and ferroptosis of hepatocellular carcinoma are enhanced by combined therapy of sorafenib and delivering modified GO-based PD-L1 siRNAs.	Biomaterials advances	2022	-35.017150588354134	-52.62501947282289	2	
35926369	PVR/TIGIT and PD-L1/PD-1 expression predicts survival and enlightens combined immunotherapy in lung squamous cell carcinoma.	Translational oncology	2022	2.984937343411251	-20.57410853368185	4	
35926155	Tislelizumab: A Modified Anti-tumor Programmed Death Receptor 1 Antibody.	Cancer control : journal of the Moffitt Cancer Center	2022	56.52974631823077	-24.12527775953162	4	
35925787	A Comparison of Murine PD-1 and PD-L1 Monoclonal Antibodies.	Monoclonal antibodies in immunodiagnosis and immunotherapy	2022	-38.97320972062626	-25.65219775869423	3	
35925682	Immune cells and their inflammatory mediators modify β cells and cause checkpoint inhibitor-induced diabetes.	JCI insight	2022	89.84582295505712	-14.448916251869584	9	2.0
35924382	An affinity threshold for maximum efficacy in anti-PD-1 immunotherapy.	mAbs	2022	-21.032615211700705	-40.122517893920296	4	
35924159	Role of ubiquitin specific proteases in the immune microenvironment of prostate cancer: A new direction.	Frontiers in oncology	2022	-17.770818912375862	-4.841204173378419	2	
35924149	The Predictive Value of Pretreatment Lactate Dehydrogenase and Derived Neutrophil-to-Lymphocyte Ratio in Advanced Non-Small Cell Lung Cancer Patients Treated With PD-1/PD-L1 Inhibitors: A Meta-Analysis.	Frontiers in oncology	2022	26.713763105723288	-44.50617056210696	2	
35922773	Expression of PD1 and PDL1 as immune-checkpoint inhibitors in mantle cell lymphoma.	BMC cancer	2022	-33.576971531206155	18.130339509550723	2	
35922089	Molecular imaging to support cancer immunotherapy.	Journal for immunotherapy of cancer	2022	28.500402444798308	-11.87160261911474	7	1.56
35921211	Influence of PD-1/PD-L1 on immune microenvironment in oral leukoplakia and oral squamous cell carcinoma.	Oral diseases	2023	-9.26879032114363	-13.30239579506095	3	
35920309	Immunohistochemical Phenotype of T Cells Invading Muscle in Inclusion Body Myositis.	Journal of neuropathology and experimental neurology	2022	-70.14283833252726	12.967788882814034	4	
35918330	BET bromodomain inhibition rescues PD-1-mediated T-cell exhaustion in acute myeloid leukemia.	Cell death & disease	2022	-28.758758505565734	10.318981932408072	14	3.14
35918269	Optimal Selection of Patients with Genitourinary Cancers for Anti-PD1/PD-L1 Treatment with a Focus on Urothelial and Renal Cell Carcinoma.	European urology focus	2022	66.12676723639997	24.37702202599973	2	
35913523	Efficacy of nivolumab as second line treatment for recurrent or metastatic head and neck squamous cell carcinoma: a national DAHANCA cohort study.	Acta oncologica (Stockholm, Sweden)	2022	53.84501151566396	10.911853656595463	1	
35911744	Safety and Efficacy of Programmed Cell Death 1 and Programmed Death Ligand-1 Inhibitors in the Treatment of Cancer: An Overview of Systematic Reviews.	Frontiers in immunology	2022	53.25688407566106	-13.113553142316636	6	1.31
35911701	Brief Research Report: Anti-SARS-CoV-2 Immunity in Long Lasting Responders to Cancer Immunotherapy Through mRNA-Based COVID-19 Vaccination.	Frontiers in immunology	2022	87.56515925113551	2.591233490300034	4	
35911672	Combination Approaches to Target PD-1 Signaling in Cancer.	Frontiers in immunology	2022	27.093471765240874	-2.6078368295406835	7	1.68
35911389	The Low Incidence of Viral Hepatitis Reactivation Among Subjects on Immunotherapy Reduces the Impact of Suboptimal Screening Rate.	Frontiers in medicine	2022	75.30706006565332	2.085071442129878	1	
35907493	Targeting PD-1/PD-L1 axis as new horizon for ovarian cancer therapy.	Life sciences	2022	37.95342488540656	39.25752437555585	7	1.7
35907001	PD-1/PD-L1 inhibitor plus chemotherapy versus standard of care in the first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma.	European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery	2023	59.145017729544975	0.7517333299338433	1	
35903685	Durvalumab After Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer: Inferior Outcomes and Lack of Health Equity in Hispanic Patients Treated With PACIFIC Protocol (LA1-CLICaP).	Frontiers in oncology	2022	40.96461706117984	-24.46060549947894	1	
35901358	Immunohistochemical Expression of Programmed Death Ligand 1(PDL1) in Endometrial Carcinoma and Its Relation to CD4 and CD8 Positive Immune Cells.	Asian Pacific journal of cancer prevention : APJCP	2022	-18.250744951437543	9.667738374725689	0	
35899493	Role of the PD-1 and PD-L1 axis in COVID-19.	Future microbiology	2022	-50.88410150127002	44.26668250616952	4	
35898927	Risk of Rash in PD-1 or PD-L1-Related Cancer Clinical Trials: A Systematic Review and Meta-Analysis.	Journal of oncology	2022	69.64985423211952	-22.678369233795507	1	
35898897	A Dramatic Response to Toripalimab With Chemotherapy and Antiangiogenic Agent Followed by Surgery in a Stage IIIB Lung Adenocarcinoma Patient With an Uncommon EGFR Mutation: A Case Report.	Frontiers in oncology	2022	58.326380319648834	-7.026357871289205	0	
35892867	The Association between Blood Indexes and Immune Cell Concentrations in the Primary Tumor Microenvironment Predicting Survival of Immunotherapy in Gastric Cancer.	Cancers	2022	-11.3615547917082	25.04692464004572	3	
35892821	The Effect of the Gut Microbiota on Systemic and Anti-Tumor Immunity and Response to Systemic Therapy against Cancer.	Cancers	2022	21.49289849294697	42.43403120974081	14	3.8
35890361	Short-Interval, Low-Dose Peptide Receptor Radionuclide Therapy in Combination with PD-1 Checkpoint Immunotherapy Induces Remission in Immunocompromised Patients with Metastatic Merkel Cell Carcinoma.	Pharmaceutics	2022	46.483356981042746	48.76387134501648	5	1.36
35887569	Atlas of PD-L1 for Pathologists: Indications, Scores, Diagnostic Platforms and Reporting Systems.	Journal of personalized medicine	2022	16.926560333563238	-43.18324489401598	20	5.29
35886427	Recent Insights into PARP and Immuno-Checkpoint Inhibitors in Epithelial Ovarian Cancer.	International journal of environmental research and public health	2022	34.92245605933974	39.75634340633559	29	6.44
35884893	PD-1/PD-L1 Pathway: A Therapeutic Target in CD30+ Large Cell Lymphomas.	Biomedicines	2022	-44.15618413134962	-10.448357480171731	2	
35884428	Drug Repurposing to Enhance Antitumor Response to PD-1/PD-L1 Immune Checkpoint Inhibitors.	Cancers	2022	30.565869225837925	-1.940086302056012	2	
35884403	Increased Soluble PD-1 Predicts Response to Nivolumab plus Ipilimumab in Melanoma.	Cancers	2022	11.581793133122344	-1.9458228611450017	3	
35884392	Impact and Novel Perspective of Immune Checkpoint Inhibitors in Patients with Early and Intermediate Stage HCC.	Cancers	2022	31.62994564223766	49.17609867956293	4	
35880172	Cardiovascular Toxicity With PD-1/PD-L1 Inhibitors in Cancer Patients: A Systematic Review and Meta-Analysis.	Frontiers in immunology	2022	60.92514209095614	-17.397969971297705	7	1.3
35880086	Brief Report: A Blood-Based MicroRNA Complementary Diagnostic Predicts Immunotherapy Efficacy in Advanced-Sta ge NSCLC With High Programmed Death-Ligand 1 Express ion.	JTO clinical and research reports	2022	3.499880333776824	-38.55399143357455	1	
35878019	An analgesic peptide H-20 attenuates chronic pain via the PD-1 pathway with few adverse effects.	Proceedings of the National Academy of Sciences of the United States of America	2022	-74.49143916143595	-13.230407904052516	3	
35874816	AP3S1 is a Novel Prognostic Biomarker and Correlated With an Immunosuppressive Tumor Microenvironment in Pan-Cancer.	Frontiers in cell and developmental biology	2022	-6.887444696808654	46.71103042068466	2	
35874720	Soluble Immune Checkpoint-Related Proteins in Blood Are Associated With Invasion and Progression in Non-Small Cell Lung Cancer.	Frontiers in immunology	2022	8.83979609678929	-13.881754128673547	6	1.35
35874628	Bioinformatics Analysis Reveals an Association between Autophagy, Prognosis, Tumor Microenvironment, and Immunotherapy in Osteosarcoma.	Journal of oncology	2022	-0.0377400794713031	49.38774997599607	1	
35872166	Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRASG12D-mutated non-small-cell lung cancer.	Annals of oncology : official journal of the European Society for Medical Oncology	2022	21.878228201595583	-22.66771097850176	14	2.83
35871223	Development of a nanoparticle-based immunotherapy targeting PD-L1 and PLK1 for lung cancer treatment.	Nature communications	2022	39.29660976913976	-34.72463212729436	27	6.51
35870429	FGFR1 promotes tumor immune evasion via YAP-mediated PD-L1 expression upregulation in lung squamous cell carcinoma.	Cellular immunology	2022	3.244067213079844	-34.14945693405427	3	
35868194	Programmed cell death protein 1 axis blockade in locally advanced squamous cell carcinoma of the head and neck: Neoadjuvant and adjuvant approaches.	Cancer treatment reviews	2022	50.276675968686206	29.539782400702546	1	
35867951	Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination.	Journal of clinical oncology : official journal of the American Society of Clinical Oncology	2023	47.27170321897522	1.996461083393096	26	
35867216	The role of immune checkpoint receptors in the malignant phenotype of cutaneous T cell lymphoma.	Immunologic research	2022	31.155665789262244	16.26544367588525	0	
35864188	Distinct antibody clones detect PD-1 checkpoint expression and block PD-L1 interactions on live murine melanoma cells.	Scientific reports	2022	-40.21545360842993	-25.684094214316215	2	
35863821	Therapeutic targeting of PD-1/PD-L1 blockade by novel small-molecule inhibitors recruits cytotoxic T cells into solid tumor microenvironment.	Journal for immunotherapy of cancer	2022	-39.28852685998928	-37.818171262388965	8	1.81
35863595	Interval- and cycle-dependent combined effect of STING agonist loaded lipid nanoparticles and a PD-1 antibody.	International journal of pharmaceutics	2022	-22.95217043784134	-45.76174288306576	3	
35862127	CTLA4 , PD-1 , PD-L1 , PD-L2 , TIM-3 , TIGIT , and LAG3 DNA Methylation Is Associated With BAP1 -Aberrancy, Transcriptional Activity, and Overall Survival in Uveal Melanoma.	Journal of immunotherapy (Hagerstown, Md. : 1997)	2022	-7.597876903016449	41.69700676274528	6	1.24
35861238	Brain-derived programmed death-ligand 1 mediates immunosuppression post intracerebral hemorrhage.	Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism	2022	-76.87649509841592	-8.224970201160854	2	
35860251	The Neonatal Innate Immune Response to Sepsis: Checkpoint Proteins as Novel Mediators of This Response and as Possible Therapeutic/Diagnostic Levers.	Frontiers in immunology	2022	-58.35527127348208	37.557899445697	0	
35860248	Bifidobacterium infantis Promotes Foxp3 Expression in Colon Cells via PD-L1-Mediated Inhibition of the PI3K-Akt-mTOR Signaling Pathway.	Frontiers in immunology	2022	-65.51247572044363	9.194489173786184	1	
35858961	APOA1 mRNA and protein in kidney renal clear cell carcinoma correlate with the disease outcome.	Scientific reports	2022	18.16939919510873	34.72386836763987	1	
35856970	[Immune checkpoint inhibitors. A breakthrough in cancer therapy].	Revista medica de Chile	2022	20.97920386608929	8.835297924303172	2	
35855807	The Correlation between the Use of the Proton Pump Inhibitor and the Clinical Efficacy of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.	Journal of oncology	2022	64.97286231538975	-3.228069000401608	2	
35855654	PTX3 mediates the infiltration, migration, and inflammation-resolving-polarization of macrophages in glioblastoma.	CNS neuroscience & therapeutics	2022	-24.71987309377564	54.42864723297876	9	2.47
35855352	Histological changes associated with laser interstitial thermal therapy for radiation necrosis: illustrative cases.	Journal of neurosurgery. Case lessons	2022	43.76114049549118	6.548882182753237	0	
35852792	PD-1T TILs as a Predictive Biomarker for Clinical Benefit to PD-1 Blockade in Patients with Advanced NSCLC.	Clinical cancer research : an official journal of the American Association for Cancer Research	2022	9.880029741302964	-19.82239393427885	8	1.67
35851153	Targeting EZH2 to overcome the resistance to immunotherapy in lung cancer.	Seminars in oncology	2022	42.872690713101896	-37.23212214334369	5	1.15
35850949	Revisiting PD-1/PD-L pathway in T and B cell response: Beyond immunosuppression.	Cytokine & growth factor reviews	2022	-48.51858377735677	-11.04548136840044	10	2.43
35850747	Chronopharmacology of immune-related diseases.	Allergology international : official journal of the Japanese Society of Allergology	2022	-55.549486325267935	27.493547833946497	1	
35850051	Blockade of PD-1/PD-L1 increases effector T cells and aggravates murine chronic graft-versus-host disease.	International immunopharmacology	2022	-64.84881956978825	-4.957400618346039	3	
35849586	Treatment with a VEGFR-2 antibody results in intra-tumor immune modulation and enhances anti-tumor efficacy of PD-L1 blockade in syngeneic murine tumor models.	PloS one	2022	-8.532302777340684	-42.76257206995026	1	
35848689	Effect of baricitinib in regulating programmed death 1 and ligand programmed cell death ligand 1 through JAK/STAT pathway in psoriasis.	Indian journal of pharmacology	2022	-59.15289659358614	-19.02282481724841	2	
35848481	Evaluation of spatial PD1 and PD-L1 expression in inflammatory bowel disease samples - a pilot study.	Polish journal of pathology : official journal of the Polish Society of Pathologists	2022	-60.22706919404352	19.84200697169589	0	
35847936	Identification of Novel Tumor Microenvironment Regulating Factor That Facilitates Tumor Immune Infiltration in Cervical Cancer.	Frontiers in oncology	2022	-4.247302553900049	35.28302291010755	2	
35846323	Negative Correlation Between 18F-RGD Uptake via PET and Tumoral PD-L1 Expression in Non-Small Cell Lung Cancer.	Frontiers in endocrinology	2022	14.051707791295312	-57.16584162299208	2	
35846123	Pyroptosis-Related Gene to Construct Prognostic Signature and Explore Immune Microenvironment and Immunotherapy Biomarkers in Bladder Cancer.	Frontiers in genetics	2022	1.5685799007328085	57.867519757303846	2	
35842661	Association of PD-1/PD-L1 expression and Epstein--Barr virus infection in patients with invasive breast cancer.	Diagnostic pathology	2022	-38.54546164091722	26.46869482556571	4	
35840950	Effects of high-fat diet on thyroid autoimmunity in the female rat.	BMC endocrine disorders	2022	-60.96175901126161	10.042149033899658	0	
35839733	Hyperprogressive disease during PD-1 blockade in patients with advanced gastric cancer.	European journal of cancer (Oxford, England : 1990)	2022	37.461360305368416	-51.014086153333466	3	
35839046	PD-1, PD-L1, NY-ESO-1, and MAGE-A4 expression in cutaneous angiosarcoma: A case report.	Medicine	2022	-21.208076163230395	23.287827998483063	0	
35838354	Pulmonary adverse events following immune checkpoint inhibitors.	Current opinion in pulmonary medicine	2022	68.6684111017713	-9.048848485893023	7	1.69
35836810	Docetaxel remodels prostate cancer immune microenvironment and enhances checkpoint inhibitor-based immunotherapy.	Theranostics	2022	-25.67278915039801	-44.71097661947972	8	1.62
35836207	Interaction between baseline HBV loads and the prognosis of patients with HCC receiving anti-PD-1 in combination with antiangiogenic therapy undergoing concurrent TAF prophylaxis.	BMC infectious diseases	2022	64.686657868127	2.90362043634371	3	
35836094	The effectivity of targeted therapy and immunotherapy in patients with advanced metastatic and non-metastatic cancer of the esophagus and esophago-gastric junction.	Updates in surgery	2023	47.3825682504954	15.718659247716634	5	
35835809	GM-CSF derived from the inflammatory microenvironment potentially enhanced PD-L1 expression on tumor-associated macrophages in human breast cancer.	Scientific reports	2022	-31.34172291586215	-5.069973638463116	7	1.42
35834991	Icariside I - A novel inhibitor of the kynurenine-AhR pathway with potential for cancer therapy by blocking tumor immune escape.	Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie	2022	-18.89935305940921	-31.70664423251893	1	
35832645	Thyroid Dysfunction as a Predictive Indicator in Camrelizumab of Advanced Esophageal Squamous Cell Carcinoma.	Journal of immunology research	2022	79.15966479515792	-18.699937668412502	0	
35831911	ZG16 promotes T-cell mediated immunity through direct binding to PD-L1 in colon cancer.	Biomarker research	2022	-32.05956106624787	-29.987745990736578	3	
35822502	Identification of T cell-related biomarkers for breast cancer based on weighted gene co-expression network analysis.	Journal of chemotherapy (Florence, Italy)	2023	-0.8945346869291702	45.05537351522764	1	
35819633	Generation, secretion and degradation of cancer immunotherapy target PD-L1.	Cellular and molecular life sciences : CMLS	2022	-42.15099819798996	-17.829690763075003	3	
35818294	The rest period between chemotherapy and immunotherapy influences the efficacy of immune checkpoint inhibitors in lung cancer.	Thoracic cancer	2022	39.62233848670237	-20.64671597867159	4	
35818263	Small molecule TKI inhibitors affect the development of non-small cell carcinoma through HIPPO/YAP/PD-L1.	Cellular and molecular biology (Noisy-le-Grand, France)	2022	3.4176697505493907	-34.37537531757635	1	
35817745	Pembrolizumab for the better treatment of EGFR-mutant T790M-negative advanced lung adenocarcinoma patients than dual treatment of pemetrexed plus platinum after tyrosine kinase inhibitor treatment failure.	Annals of palliative medicine	2022	50.06196007609759	-29.038264212740927	2	
35817627	Self-Assembly of a Multifunction DNA Tetrahedron for Effective Delivery of Aptamer PL1 and Pcsk9 siRNA Potentiate Immune Checkpoint Therapy for Colorectal Cancer.	ACS applied materials & interfaces	2022	-34.931687431017245	-52.87131280213048	10	2.7
35817517	LIGHT (TNFSF14) Costimulation Enhances Myeloid Cell Activation and Antitumor Immunity in the Setting of PD-1/PD-L1 and TIGIT Checkpoint Blockade.	Journal of immunology (Baltimore, Md. : 1950)	2022	-13.10067734870627	-55.91767595552282	2	
35816951	A phase II study of retifanlimab (INCMGA00012) in patients with squamous carcinoma of the anal canal who have progressed following platinum-based chemotherapy (POD1UM-202).	ESMO open	2022	57.36570572020933	9.902990861542651	16	3.62
35816501	Radiation therapy enhances systemic antitumor efficacy in PD-L1 therapy regardless of sequence of radiation in murine osteosarcoma.	PloS one	2022	28.36716746110416	22.188426475675342	4	
35815408	Clinical activity of 9-ING-41, a small molecule selective glycogen synthase kinase-3 beta (GSK-3β) inhibitor, in refractory adult T-Cell leukemia/lymphoma.	Cancer biology & therapy	2022	-37.74559071099626	18.96617352700689	2	
35814408	Case Report: Anti-TNF Treatment Failure in a Patient With Immune Checkpoint Inhibitor-Induced Severe Colitis.	Frontiers in oncology	2022	76.01972310186068	-3.392605550909886	0	
35813574	PD-1 is expressed in cytotoxic granules of NK cells and rapidly mobilized to the cell membrane following recognition of tumor cells.	Oncoimmunology	2022	-33.13635567665983	-0.3498049315081202	2	
35813476	Integrative Analyses of m6A Regulators Identify that METTL3 is Associated with HPV Status and Immunosuppressive Microenvironment in HPV-related Cancers.	International journal of biological sciences	2022	-7.107991708276261	56.736085555942566	8	1.82
35812997	Toxicity spectrum of immunotherapy in advanced lung cancer: A safety analysis from clinical trials and a pharmacovigilance system.	EClinicalMedicine	2022	72.62962209611328	-8.684846620049548	8	1.43
35812458	Role of the PD-1/PD-L1 Pathway in Experimental Trypanosoma cruzi Infection and Potential Therapeutic Options.	Frontiers in immunology	2022	-68.73974376739073	10.996290222570703	1	
35812439	Over-Expression of GUSB Leads to Primary Resistance of Anti-PD1 Therapy in Hepatocellular Carcinoma.	Frontiers in immunology	2022	15.00650045269443	22.1841656620756	5	1.21
35811500	KRAS-G12D mutation drives immune suppression and the primary resistance of anti-PD-1/PD-L1 immunotherapy in non-small cell lung cancer.	Cancer communications (London, England)	2022	22.20523877578337	-23.01350560598073	19	3.95
35811317	Multiplex immunohistochemistry defines the tumor immune microenvironment and immunotherapeutic outcome in CLDN18.2-positive gastric cancer.	BMC medicine	2022	-11.246334235139903	23.844701818227364	12	2.91
35811193	Photosensitive rash induced by nivolumab.	Anais brasileiros de dermatologia	2022	73.58124807167759	-28.481791454884444	1	
35809836	Clinical treatment of cholangiocarcinoma: an updated comprehensive review.	Annals of hepatology	2022	56.474795680365936	22.835409556558155	19	5.55
35809118	Dual CAR-T cells to treat cancers co-expressing NKG2D and PD1 ligands in xenograft models of peritoneal metastasis.	Cancer immunology, immunotherapy : CII	2023	-40.86670194768404	3.5498963019432197	6	
35804865	PD-1/PD-L1 Checkpoint Inhibitors Are Active in the Chicken Embryo Model and Show Antitumor Efficacy In Ovo.	Cancers	2022	-3.4748730674182537	-60.192467723637584	5	1.64
35803704	Methionine deficiency facilitates antitumour immunity by altering m6A methylation of immune checkpoint transcripts.	Gut	2023	-19.61738839229216	-31.564441966055053	28	
35803322	The Role of PD-L1 on Langerhans Cells in the Regulation of Psoriasis.	The Journal of investigative dermatology	2022	-59.68753640661156	-17.344765230042736	6	1.67
35802807	Identification and characterization of novel CD274 (PD-L1) regulating microRNAs and their functional relevance in melanoma.	Clinical and translational medicine	2022	-18.75871262617295	1.3146384485194926	2	
35800186	Impact of radiotherapy on the immune landscape in oesophageal adenocarcinoma.	World journal of gastroenterology	2022	22.051626722066786	21.94092687090282	2	
35795681	Differential Engraftment of Parental A20 PD-L1 WT and PD-L1 KO Leukemia Cells in Semiallogeneic Recipients in the Context of PD-L1/PD-1 Interaction and NK Cell-Mediated Hybrid Resistance.	Frontiers in immunology	2022	-36.09807403896991	-0.798404964457383	1	
35795680	A Novel PD-L1-Containing MSLN Targeting Vaccine for Lung Cancer Immunotherapy.	Frontiers in immunology	2022	-27.400366913582168	-13.56320612578988	2	
35795471	Detection of temozolomide-induced hypermutation and response to PD-1 checkpoint inhibitor in recurrent glioblastoma.	Neuro-oncology advances	2022	-25.555761660329107	60.75428202026691	2	
35794161	PD-L1 regulates cell proliferation and apoptosis in acute myeloid leukemia by activating PI3K-AKT signaling pathway.	Scientific reports	2022	-38.51777114985776	-6.510511541499532	7	1.86
35793874	Baseline and post-treatment biomarkers of resistance to anti-PD-1 therapy in acral and mucosal melanoma: an observational study.	Journal for immunotherapy of cancer	2022	9.47224203242	-4.231061192368256	7	1.33
35790987	Stereotactic body radiotherapy extends the clinical benefit of PD-1 inhibitors in refractory recurrent/metastatic nasopharyngeal carcinoma.	Radiation oncology (London, England)	2022	59.527726662045765	12.63884425199186	4	
35790289	Implications of PD-1, Tim-3, and TIGIT Expression for Cancer Immunity and Pancreatic Cancer Prognosis.	Anticancer research	2022	-3.13984114050286	26.6511957588826	1	
35787595	Mind the target: programmed death ligand 1 in oesophagogastric cancers.	Current opinion in oncology	2022	49.338927059567226	16.41287659198714	0	
35787385	Roles of immune cells in the concurrence of Echinococcus granulosus sensu lato infection and hepatocellular carcinoma.	Experimental parasitology	2022	-15.243950828560196	46.487275402393394	0	
35782904	Platelet-to-lymphocyte and neutrophil-to-lymphocyte ratios are associated with the efficacy of immunotherapy in stage III/IV non-small cell lung cancer.	Oncology letters	2022	27.952954621646743	-41.393938847756495	8	1.95
35780578	In vivo positron emission tomography imaging for PD-L1 expression in cancer using aptamer.	Biochemical and biophysical research communications	2022	5.330958643464278	-56.72455951710269	3	
35780243	A phase Ib dose-escalation study of troriluzole (BHV-4157), an oral glutamatergic signaling modulator, in combination with nivolumab in patients with advanced solid tumors.	European journal of medical research	2022	52.01665786844242	-2.2801396615901277	4	
35778636	The combination of gene hyperamplification and PD-L1 expression as a biomarker for the clinical benefit of tislelizumab in gastric/gastroesophageal junction adenocarcinoma.	Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association	2022	-11.822585592864757	9.422285026311805	2	
35778267	PD-1 Blockade After Avelumab in Relapsed/Refractory Classical Hodgkin Lymphoma.	Clinical lymphoma, myeloma & leukemia	2022	47.08398904076415	-7.578568114074811	1	
35777615	Lentivirus-mediated PD-L1 overexpression in bone marrow-derived dendritic cells induces immune tolerance in a rat keratoplasty model.	Transplant immunology	2022	-64.42002774899996	-15.171277700934976	0	
35774790	PD-1 Immune Checkpoint Blockade and PSGL-1 Inhibition Synergize to Reinvigorate Exhausted T Cells.	Frontiers in immunology	2022	-74.28625299153418	14.864335265392116	1	
35774424	The earlier, the better? A review of neoadjuvant immunotherapy in resectable non-small-cell lung cancer.	Chronic diseases and translational medicine	2022	34.34900632842794	-22.357789053576766	1	
35772809	Cancer cell-autonomous overactivation of PARP1 compromises immunosurveillance in non-small cell lung cancer.	Journal for immunotherapy of cancer	2022	23.183336848720923	33.69535372221797	5	0.97
35771289	Acneiform eruptions with combination targeted cancer therapy in colorectal cancer patients.	Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer	2022	31.604128675318563	34.24883514633423	0	
35771229	INK4 cyclin-dependent kinase inhibitors as potential prognostic biomarkers and therapeutic targets in hepatocellular carcinoma.	Bioscience reports	2022	-11.607671573154985	47.07715720633063	2	
35770005	High Grade Dermatologic Adverse Events Associated With Immune Checkpoint Blockade for Cancer.	Frontiers in medicine	2022	75.33709975355481	-24.177536384029608	6	2.29
35769229	Immunotherapy in Advanced Non-Small Cell Lung Cancers: Current Status and Updates.	Cancer management and research	2022	37.8798823421654	-33.21978299900438	2	
35765095	Glioma-associated mesenchymal stem cells-mediated PD-L1 expression is attenuated by Ad5-Ki67/IL-15 in GBM treatment.	Stem cell research & therapy	2022	-28.049744985692616	53.0597222656367	2	
35763678	A model-based meta-analysis of immune-related adverse events during immune checkpoint inhibitors treatment for NSCLC.	CPT: pharmacometrics & systems pharmacology	2022	73.53130571530436	-9.973559820633044	1	
35762488	Real-world utilization of PD-1/PD-L1 inhibitors with palliative radiotherapy in patients with metastatic non-small cell lung cancer.	Thoracic cancer	2022	43.58327028078773	-21.958709767580533	4	
35762092	A combination of stromal PD-L1 and tumoral nuclear β-catenin expression as an indicator of colorectal carcinoma progression and resistance to chemoradiotherapy in locally advanced rectal carcinoma.	The journal of pathology. Clinical research	2022	-5.034897704099685	12.893630090894185	5	1.15
35761436	Precision medicine: Sustained response to erdafitinib in FGFR2-mutant, multiply recurrent ameloblastoma.	Cancer reports (Hoboken, N.J.)	2022	65.3780311981681	13.783062002677903	1	
35760571	New approaches in palliative systemic therapy of anal squamous cell carcinoma.	Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti	2022	57.32152631712392	10.960527631358056	0	
35760471	Future treatment options in metastatic clear cell renal cell carcinoma.	Bulletin du cancer	2022	64.56222883493892	32.87717129793283	0	
35756927	PD-1/PD-L Axis in Neuroinflammation: New Insights.	Frontiers in neurology	2022	80.50443803105784	-12.052936640905925	7	1.78
35756842	Combination of two novel blocking antibodies, anti-PD-1 antibody ezabenlimab (BI 754091) and anti-LAG-3 antibody BI 754111, leads to increased immune cell responses.	Oncoimmunology	2022	-18.437273811598065	-41.01589723928527	1	
35756681	Pan-Cancer Integrated Analysis Identification of SASH3, a Potential Biomarker That Inhibits Lung Adenocarcinoma Progression.	Frontiers in oncology	2022	-6.581281436489962	46.93301402202098	3	
35756643	Increased Circulating Levels of CRP and IL-6 and Decreased Frequencies of T and B Lymphocyte Subsets Are Associated With Immune-Related Adverse Events During Combination Therapy With PD-1 Inhibitors for Liver Cancer.	Frontiers in oncology	2022	74.86810658561308	-12.560153452253536	8	1.94
35756611	Ethanol Exposure Up-Regulates PD-L1/PD-1 Immune Checkpoint Pathway and Promotes Mammary Tumor Development.	Frontiers in oncology	2022	-20.745092052100336	5.991072599187621	0	
35755570	Immunoexpression of Programmed Death-1 Receptor (PD-1) and Programmed Death-Ligand 1 (PD-L1) in Non-Small-Cell Lung Carcinoma and Its Correlation With Other Clinicopathological Parameters: A Cross-Sectional Study From North India.	Cureus	2022	12.39578381763696	-31.272280601987717	0	
35755282	YPD-30, a prodrug of YPD-29B, is an oral small-molecule inhibitor targeting PD-L1 for the treatment of human cancer.	Acta pharmaceutica Sinica. B	2022	-38.09000108147509	-37.73673626233305	5	1.38
35755033	Compartmentalization of Intrarenal Programmed Cell Death Protein 1-Ligand 1 and Its Receptor in Kidney Injury Related to Immune Checkpoint Inhibitor Nephrotoxicity.	Frontiers in medicine	2022	70.52250622337385	1.675746602697672	5	1.17
35754074	Comparison of tumor immune environment between newly diagnosed and recurrent glioblastoma including matched patients.	Journal of neuro-oncology	2022	-24.37684632939236	57.76412496741057	3	
35753157	Clinical trial data of Anti-PD-1/PD-L1 therapy for recurrent or metastatic nasopharyngeal Carcinoma: A review.	Cancer treatment reviews	2022	57.82559091434491	-1.3706332807919868	9	2.05
35753122	Immune checkpoint inhibitor-based therapy for advanced clear cell renal cell carcinoma: A narrative review.	International immunopharmacology	2022	65.36318390466339	28.72038357735846	7	1.44
35752425	Application of molecular imaging in immune checkpoints therapy: From response assessment to prognosis prediction.	Critical reviews in oncology/hematology	2022	6.464490715272525	-53.199624176711446	1	
35751489	Immune checkpoint blockades in gynecological cancers: A review of clinical trials.	Acta obstetricia et gynecologica Scandinavica	2022	40.861025952129694	35.458555187655264	10	2.33
35748713	MIAMI: mutual information-based analysis of multiplex imaging data.	Bioinformatics (Oxford, England)	2022	1.6406673056076655	-47.80509263610695	3	
35745835	PD-1 Cellular Nanovesicles Carrying Gemcitabine to Inhibit the Proliferation of Triple Negative Breast Cancer Cell.	Pharmaceutics	2022	-35.36950044508587	-55.9925741957553	3	
35745666	Development of Radiotracers for Imaging of the PD-1/PD-L1 Axis.	Pharmaceuticals (Basel, Switzerland)	2022	6.236548670137594	-54.214931590139024	8	2.58
35741779	Profiling the Tumor-Infiltrating Lymphocytes in Gastric Cancer Reveals Its Implication in the Prognosis.	Genes	2022	-9.198494673311504	22.435489822266845	1	
35741107	Programmed Cell Death-1/Programmed Cell Death-1 Ligand as Prognostic Markers of Coronavirus Disease 2019 Severity.	Cells	2022	-50.80215824868477	44.34273718674951	10	2.18
35740660	Contribution of the Skin-Gut Axis to Immune-Related Adverse Events with Multi-System Involvement.	Cancers	2022	75.46294879343533	-7.627364404243353	4	
35740512	Real-World Treatments and Clinical Outcomes in Advanced NSCLC without Actionable Mutations after Introduction of Immunotherapy in Japan.	Cancers	2022	40.62715346321976	-21.586172451786325	4	
35740384	Increased Abundances of CD16+ Non-Classical Monocytes Accompany with Elevated Monocytic PD-L1 and CD4+ T Cell Disturbances in Oropharyngeal Cancer.	Biomedicines	2022	-7.833135051969393	31.533810903330902	1	
35740259	Multi-Omics Approaches for the Prediction of Clinical Endpoints after Immunotherapy in Non-Small Cell Lung Cancer: A Comprehensive Review.	Biomedicines	2022	26.123931630585403	-29.78920891212486	3	
35739536	A lung adenocarcinoma patient with co-mutations of MET and EGFR exon20 insertion responded to crizotinib.	BMC medical genomics	2022	36.60364944263574	-39.69730897023539	0	
35738802	Novel immunoprofiling method for diagnosing SLE and evaluating therapeutic response.	Lupus science & medicine	2022	-54.18780675453621	12.1517013565237	1	
35737383	Efficacy of Ipilimumab vs FOLFOX in Combination With Nivolumab and Trastuzumab in Patients With Previously Untreated ERBB2-Positive Esophagogastric Adenocarcinoma: The AIO INTEGA Randomized Clinical Trial.	JAMA oncology	2022	48.31460855162639	15.16116591967984	17	3.93
35737090	Serum biomarker panel diagnostics in pancreatic ductal adenocarcinoma: the clinical utility of soluble interleukins, IFN-γ, TNF-α and PD-1/PD-L1 in comparison to established serum tumor markers.	Journal of cancer research and clinical oncology	2023	-3.877751018890563	5.19184974866248	3	
35736816	Tumor Immune Microenvironment Changes by Multiplex Immunofluorescence Staining in a Pilot Study of Neoadjuvant Talazoparib for Early-Stage Breast Cancer Patients with a Hereditary BRCA Mutation.	Clinical cancer research : an official journal of the American Association for Cancer Research	2022	1.112596316258486	23.350323000485783	3	
35734168	m6A-Regulator Expression Signatures Identify a Subset of Follicular Lymphoma Harboring an Exhausted Tumor Microenvironment.	Frontiers in immunology	2022	-7.963875170101084	56.50663973593521	3	
35732880	Soluble PD-L1 in blood correlates positively with neutrophil and negatively with lymphocyte mRNA markers and implies adverse sepsis outcome.	Immunologic research	2022	-56.719131731290446	34.4926890692638	2	
35731974	Preclinical platforms to study therapeutic efficacy of human γδ T cells.	Clinical and translational medicine	2022	-36.854345578636334	4.030743997764308	6	1.18
35731051	Extranodal NK/T-cell lymphoma: a case report of renal insufficiency during PD1 inhibitor treatment.	European review for medical and pharmacological sciences	2022	48.5217415053298	-6.619207836501961	1	
35729210	Small extracellular vesicle PD-L1 in cancer: the knowns and unknowns.	NPJ precision oncology	2022	-41.30116751285841	-61.15641373506499	9	2.15
35728870	L-5-hydroxytryptophan promotes antitumor immunity by inhibiting PD-L1 inducible expression.	Journal for immunotherapy of cancer	2022	-35.7948055305842	-37.71431912367942	3	
35725444	Mass cytometry reveals immune atlas of urothelial carcinoma.	BMC cancer	2022	6.756446256108908	61.38833606698344	4	
35725413	The feasibility of proteomics sequencing based immune-related prognostic signature for predicting clinical outcomes of bladder cancer patients.	BMC cancer	2022	4.318688017917311	58.04804109396744	2	
35720783	Does the Combined Use of Aspirin and Immunotherapy Result in Better Outcomes in Non-Small Cell Lung Cancer Than Immunotherapy Alone?	Cureus	2022	34.205144530741066	-31.52616143096472	4	
35720000	Soluble PD-L1 Expression After Intravenous Treatment of Cancer Patients With Selenite in Phase I Clinical Trial.	Frontiers in oncology	2022	7.256253843866491	8.753698934564774	4	
35719979	The Efficacy and Safety of Sintilimab Combined With Nab-Paclitaxel as a Second-Line Treatment for Advanced or Metastatic Gastric Cancer and Gastroesophageal Junction Cancer.	Frontiers in oncology	2022	49.04490839291796	14.779259292780225	2	
35711379	Cardiotoxicity Related to Immune Checkpoint Inhibitors: A Real-World Retrospective Analysis.	Frontiers in cardiovascular medicine	2022	82.02533180612755	1.7889029538698098	0	
35709617	Immunophenotype of tumor-infiltrating lymphocytes in atypical Spitzoid tumors according to the risk of progression.	Annals of diagnostic pathology	2022	-1.9328322600126684	19.78840241741721	0	
35708671	Association of High Tumor Mutation Burden in Non-Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels.	JAMA oncology	2022	22.7511869906822	-17.183927562586902	61	12.72
35707528	Overview of Checkpoint Inhibitors Mechanism of Action: Role of Immune-Related Adverse Events and Their Treatment on Progression of Underlying Cancer.	Frontiers in medicine	2022	79.7884297126386	-9.81666958489776	8	1.89
35707390	Prognostic Nutritional Index Predicts Outcome of PD-L1 Negative and MSS Advanced Cancer Treated with PD-1 Inhibitors.	BioMed research international	2022	28.91264865778717	-43.33406111527735	1	
35707221	Glucose metabolism inhibitor PFK-015 combined with immune checkpoint inhibitor is an effective treatment regimen in cancer.	Oncoimmunology	2022	-29.70880605625189	-27.949087465675685	5	1.17
35705312	Increase in serum choline levels predicts for improved progression-free survival (PFS) in patients with advanced cancers receiving pembrolizumab.	Journal for immunotherapy of cancer	2022	23.28194633514366	-12.51131647081388	2	
35698606	Successful Treatment of Metastatic Gallbladder Carcinoma with PD-L1 Expression by the Combination of PD-1 Inhibitor Plus Bevacizumab with Chemotherapy: A Case Report.	OncoTargets and therapy	2022	52.55619602922545	21.742325396586544	1	
35697717	Role of CD47 in tumor immunity: a potential target for combination therapy.	Scientific reports	2022	-27.096659574246605	23.440508056421404	7	1.65
35696453	Computational discovery of small drug-like compounds as potential inhibitors of PD-1/PD-L1 interactions.	Journal of biomolecular structure & dynamics	2023	-41.35542994718183	-39.77040375005326	1	
35694998	Immune checkpoint inhibitors in luminal gastrointestinal malignancies: going beyond MSI-H/dMMR, TMB and PD-L1.	Immunotherapy	2022	40.066300841083226	16.307895662482284	6	1.39
35693805	The Long-Term and Short-Term Efficacy of Immunotherapy in Non-Small Cell Lung Cancer Patients With Brain Metastases: A Systematic Review and Meta-Analysis.	Frontiers in immunology	2022	41.700379566635206	-16.373909707238663	9	1.92
35692198	[Effects and molecular mechanism of histone methyltransferase enhancer of zeste homolog 2 on regulating sepsis-induced T cell dysfunction].	Zhonghua wei zhong bing ji jiu yi xue	2022	-14.213539413199152	58.55970196495896	1	
35689298	Ileus in patients treated with immune checkpoint inhibitors: A retrospective, pharmacovigilance study using Food and Drug Administration Adverse Event Reporting System database.	Pharmacoepidemiology and drug safety	2022	74.50749714443423	-3.506930410956167	0	
35688553	Targeting of GSDMD sensitizes HCC to anti-PD-1 by activating cGAS pathway and downregulating PD-L1 expression.	Journal for immunotherapy of cancer	2022	-20.266915244113505	44.47195001333757	10	2.23
35687697	ATR-mediated CD47 and PD-L1 up-regulation restricts radiotherapy-induced immune priming and abscopal responses in colorectal cancer.	Science immunology	2022	26.85558252788831	22.83309574950105	28	6.22
35684392	Biphenyl Ether Analogs Containing Pomalidomide as Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction.	Molecules (Basel, Switzerland)	2022	-38.46294748447055	-41.730985511089024	3	
35682571	Preparation of Novel Pyrazolo[4,3-e]tetrazolo[1,5-b][1,2,4]triazine Sulfonamides and Their Experimental and Computational Biological Studies.	International journal of molecular sciences	2022	-35.35889292200516	-41.8497067478479	11	3.91
35681761	Current Evidence on Immunotherapy for Gestational Trophoblastic Neoplasia (GTN).	Cancers	2022	44.195614109100525	39.99828487733651	7	2.37
35681695	SAR131675, a VEGRF3 Inhibitor, Modulates the Immune Response and Reduces the Growth of Colorectal Cancer Liver Metastasis.	Cancers	2022	13.15942747978896	38.729016115107136	3	
35681627	An Update on the Pathology and Molecular Features of Hodgkin Lymphoma.	Cancers	2022	-29.358676836805905	26.024685032962104	7	1.99
35681616	Pilot Trial of Arginine Deprivation Plus Nivolumab and Ipilimumab in Patients with Metastatic Uveal Melanoma.	Cancers	2022	35.295524172495625	4.141888109943608	8	2.11
35680805	[Expression of PD-L1 and PD-1 in Pathological Tissue of Patients Newly Diagnosed with Diffuse Large B-Cell Lymphoma].	Zhongguo shi yan xue ye xue za zhi	2022	-35.00147398367729	26.96594690012787	0	
35679646	Bimodal liquid biopsy for cancer immunotherapy based on peptide engineering and nanoscale analysis.	Biosensors & bioelectronics	2022	-42.80196898590269	-55.40794999683192	7	1.98
35679518	In Vivo Syngeneic Tumor Models with Acquired Resistance to Anti-PD-1/PD-L1 Therapies.	Cancer immunology research	2022	-33.63580455885539	-22.388612169328766	5	0.99
35677739	Comparison of Pneumonitis Rates and Severity in Patients With Lung Cancer Treated by Immunotherapy, Radiotherapy, and Immunoradiotherapy.	Cureus	2022	65.08394842699143	-8.121811675498206	4	
35677058	Identification of New Prognostic Markers and Therapeutic Targets for Non-Muscle Invasive Bladder Cancer: HER2 as a Potential Target Antigen.	Frontiers in immunology	2022	4.864243328818329	59.26077380340456	0	
35677056	Retention of Donor T Cells in Lymphohematopoietic Tissue and Augmentation of Tissue PD-L1 Protection for Prevention of GVHD While Preserving GVL Activity.	Frontiers in immunology	2022	-66.2306988995193	-6.536514495459088	1	
35676750	Immunology and immunotherapy in breast cancer.	Cancer biology & medicine	2022	24.62135224973745	-1.0704910245580812	6	1.57
35675517	Single-cell spatial analysis of tumor immune architecture in diffuse large B-cell lymphoma.	Blood advances	2022	-29.77509720796278	31.431250497482942	10	1.89
35675028	Sequence-specific 1H, 13C and 15N backbone NMR assignments for the N-terminal IgV-like domain (D1) and full extracellular region (D1D2) of PD-L1.	Biomolecular NMR assignments	2022	-47.85582876522706	-38.14639474612835	2	
35673884	PD-1/L1 With or Without CTLA-4 Inhibitors Versus Chemotherapy in Advanced Non-Small Cell Lung Cancer.	Cancer control : journal of the Moffitt Cancer Center	2022	43.88133583674825	-19.068474315395637	1	
35672305	Regulatory B cell repertoire defects predispose lung cancer patients to immune-related toxicity following checkpoint blockade.	Nature communications	2022	29.574889134343195	-36.44052982499049	12	2.62
35671120	Systemic treatment of recurrent and/or metastatic squamous cell carcinomas of the head and neck: what is the best therapeutic sequence?	Current opinion in oncology	2022	52.86368232015004	29.35122848827512	3	
35669431	The Alteration of T-Cell Heterogeneity and PD-L1 Colocalization During dMMR Colorectal Cancer Progression Defined by Multiplex Immunohistochemistry.	Frontiers in oncology	2022	10.56271018241102	39.95938078426138	0	
35668012	Real-life safety of PD-1 and PD-L1 inhibitors in older patients with cancer: An observational study.	Journal of geriatric oncology	2022	55.494292543494765	-17.957837561899797	3	
35666353	The Role of Immunotherapy in the Treatment of Anal Cancer and Future Strategies.	Current treatment options in oncology	2022	57.25902369147724	10.86193493640899	4	
35665369	Programmed death-ligand 1 expression on CD22-specific chimeric antigen receptor-modified T cells weakens antitumor potential.	MedComm	2022	-43.18782787267482	3.7682049895827	4	
35665024	Immunotherapy in Special and Rare Situations: A Brief Review.	Journal of immunotherapy and precision oncology	2021	36.137501084620624	-19.366784110643263	2	0.27
35664082	Evaluation of cancer immunotherapy using mini-tumor chips.	Theranostics	2022	-0.5191299487060874	-45.46959877565699	11	2.66
35663968	Noncanonical PD-1/PD-L1 Axis in Relation to the Efficacy of Anti-PD Therapy.	Frontiers in immunology	2022	-37.89984764947296	-12.999125164288332	3	
35663958	Increased Tuberculosis Incidence Due to Immunotherapy Based on PD-1 and PD-L1 Blockade: A Systematic Review and Meta-Analysis.	Frontiers in immunology	2022	62.62010950598199	-22.24771311519983	6	1.56
35663534	Clinical Development of Colony-Stimulating Factor 1 Receptor (CSF1R) Inhibitors.	Journal of immunotherapy and precision oncology	2021	-24.89337034932812	-25.040757060107637	18	2.02
35663389	Comprehensive Analysis of the Butyrate-Metabolism-Related Gene Signature in Tumor Microenvironment-Infiltrating Immune Cells in Clear Cell Renal Cell Carcinoma.	Frontiers in cell and developmental biology	2022	15.552800142544202	35.19155893356515	2	
35662989	Immune checkpoint inhibitors in head and neck squamous cell carcinoma: A systematic review of phase-3 clinical trials.	World journal of clinical oncology	2022	50.75877040742196	32.222027595157975	7	1.7
35662985	Neoadjuvant treatment in non-small cell lung cancer: New perspectives with the incorporation of immunotherapy.	World journal of clinical oncology	2022	33.053314836377595	-22.13223787566058	3	
35662701	Calf Thymus Polypeptide Restrains the Growth of Colorectal Tumor via Regulating the Intestinal Microbiota-Mediated Immune Function.	Frontiers in pharmacology	2022	-16.56599786983297	48.45287190845416	1	
35662108	Prediction of lung cancer immunotherapy response via machine learning analysis of immune cell lineage and surface markers.	Cancer biomarkers : section A of Disease markers	2022	18.788143796349	-30.28669263144233	1	
35661198	"The ""Inside"" Story on Tumor-Expressed PD-L1."	Cancer research	2022	-36.98355333067327	-10.80575350703068	1	
35659479	Biomarker-Driven Studies With Multi-targets and Multi-drugs by Next-Generation Sequencing for Patients With Non-Small-Cell Lung Cancer: An Open-Label, Multi-center, Phase II Adaptive Umbrella Trial and a Real-World Observational Study (CTONG1702&CTONG1705).	Clinical lung cancer	2022	21.342198431352	-19.16444830997031	1	
35659326	How we treat NK/T-cell lymphomas.	Journal of hematology & oncology	2022	38.63179933033569	28.644923102405517	20	5.26
35656514	PD-L1 Mediates IFNγ-Regulation of Glucose but Not of Tryptophan Metabolism in Clear Cell Renal Cell Carcinoma.	Frontiers in oncology	2022	-18.636448385009867	-18.7130391894922	4	
35656315	A DNA Damage Repair Gene Signature Associated With Immunotherapy Response and Clinical Prognosis in Clear Cell Renal Cell Carcinoma.	Frontiers in genetics	2022	17.069085643558978	34.19292823641058	1	
35656179	Development and characterization of single domain monoclonal antibody against programmed cell death ligand-1; as a cancer inhibitor candidate.	Iranian journal of basic medical sciences	2022	-38.01437560948413	-47.496389487500615	0	
35655630	Survival Benefit of Pembrolizumab for Patients With Pancreatic Adenocarcinoma: A Case Series.	Journal of medical cases	2022	61.22464051913227	8.316392911024728	5	1.09
35654378	Thermodynamic stability of cisplatin-loaded polymeric micelles and the phenotypic switching of the tumor-associated macrophages induced by combination of cisplatin-loaded micelles and Anti-PD-L1 antibody.	International journal of pharmaceutics	2022	-30.18278637214861	-49.84050385348749	2	
35652897	PD-L1-Targeted Radionuclide Therapy Combined with αPD-L1 Antibody Immunotherapy Synergistically Improves the Antitumor Effect.	Molecular pharmaceutics	2022	5.532589094074768	-54.69289661084065	10	2.22
35651784	Development and Validation of an Immune-Related Prognostic Signature in Cervical Cancer.	Frontiers in oncology	2022	-0.7934072511610342	51.32872439127739	1	
35651625	Computational Discovery of Cancer Immunotherapy Targets by Intercellular CRISPR Screens.	Frontiers in immunology	2022	-24.990740046677672	-22.56517996987229	2	
35649657	Role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-small cell lung cancer.	Journal for immunotherapy of cancer	2022	0.4770604136534069	19.693184873492083	28	5.51
35646678	Preclinical Studies of a Novel Human PD-1 B-Cell Peptide Cancer Vaccine PD1-Vaxx From BALB/c Mice to Beagle Dogs and to Non-Human Primates (Cynomolgus Monkeys).	Frontiers in oncology	2022	-25.44537848916764	-13.88533218838008	10	2.42
35646114	Machine Learning-Based Integration Develops a Pyroptosis-Related lncRNA Model to Enhance the Predicted Value of Low-Grade Glioma Patients.	Journal of oncology	2022	-4.008529339085951	54.02762660690897	6	1.46
35644823	The prognostic role of PD-1, PD-L1, ALK, and ROS1 proteins expression in non-small cell lung carcinoma patients from Egypt.	Journal of the Egyptian National Cancer Institute	2022	10.89329125774489	-33.000264482327864	1	
35644780	Concurrent High PD-L1 Expression and CD8+ Immune Cell Infiltration Predict PD-1 Blockade Efficacy in Advanced EGFR-Mutant NSCLC Patients.	Clinical lung cancer	2022	11.25508067160607	-19.87377900425336	7	1.47
35643870	Altered mucosal immunity in HIV-positive colon adenoma: decreased CD4+ T cell infiltration is correlated with nadir but not current CD4+ T cell blood counts.	International journal of clinical oncology	2022	6.176788383949646	38.26140917506834	0	
35642038	mTOR pathway gene mutations predict response to immune checkpoint inhibitors in multiple cancers.	Journal of translational medicine	2022	-2.37270963112127	42.622169486281294	5	1.07
35641819	Immune checkpoint inhibitors alone vs immune checkpoint inhibitors-combined chemotherapy for NSCLC patients with high PD-L1 expression: a network meta-analysis.	British journal of cancer	2022	41.504790158811616	-18.750030290311628	6	1.15
35641200	Immune Checkpoint Inhibitor-related New-onset Thyroid Dysfunction: A Retrospective Analysis Using the US FDA Adverse Event Reporting System.	The oncologist	2022	79.84116878401389	-17.26727348017602	4	
35640711	Strategies for developing PD-1 inhibitors and future directions.	Biochemical pharmacology	2022	-39.80387233989254	-35.66207449266276	7	1.61
35638418	Oncolytic Viruses as an Adjunct to Immune Checkpoint Inhibition.	Frontiers in bioscience (Landmark edition)	2022	-35.09473855148388	52.51184090448961	8	1.92
35635377	Bone Microenvironment-Suppressed T Cells Increase Osteoclast Formation and Osteolytic Bone Metastases in Mice.	Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research	2022	-2.5230442126983577	15.95797033701614	5	1.22
35634343	Burgeoning Exploration of the Role of Natural Killer Cells in Anti-PD-1/PD-L1 Therapy.	Frontiers in immunology	2022	-34.20908663456867	0.1059630847947867	0	
35634309	Multi-Scale Spatial Analysis of the Tumor Microenvironment Reveals Features of Cabozantinib and Nivolumab Efficacy in Hepatocellular Carcinoma.	Frontiers in immunology	2022	-12.30718820143492	43.76271271847728	15	3.37
35631359	Real-World Analysis of Nivolumab and Atezolizumab Efficacy in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer.	Pharmaceuticals (Basel, Switzerland)	2022	51.67620716837749	-37.10879861177456	4	
35630835	Immuno-Imaging (PET/SPECT)-Quo Vadis?	Molecules (Basel, Switzerland)	2022	28.7128138923722	-12.385584788168217	2	
35630791	Antioxidant Properties and Aldehyde Reactivity of PD-L1 Targeted Aryl-Pyrazolone Anticancer Agents.	Molecules (Basel, Switzerland)	2022	-35.552505378830546	-41.55757213387019	3	
35628549	Short-Chain Fatty Acids Augment Differentiation and Function of Human Induced Regulatory T Cells.	International journal of molecular sciences	2022	-68.83577860160092	1.6361699556211498	9	2.26
35628540	Combination Strategies Involving Immune Checkpoint Inhibitors and Tyrosine Kinase or BRAF Inhibitors in Aggressive Thyroid Cancer.	International journal of molecular sciences	2022	29.306270368839343	32.19451130047675	6	1.57
35628499	"Correlation of Immunological and Molecular Profiles with Response to Crizotinib in Alveolar Soft Part Sarcoma: An Exploratory Study Related to the EORTC 90101 ""CREATE"" Trial."	International journal of molecular sciences	2022	15.709715748653563	-21.032978188028636	3	
35626147	Mutational Activation of the NRF2 Pathway Upregulates Kynureninase Resulting in Tumor Immunosuppression and Poor Outcome in Lung Adenocarcinoma.	Cancers	2022	-14.476879574643238	-30.818191898400503	12	2.54
35625987	Immune Profile of BRAF-Mutated Metastatic Colorectal Tumors with Good Prognosis after Palliative Chemotherapy.	Cancers	2022	8.747507408545617	39.29801134200663	1	
35623735	Psoriasis and Anti-PD-1 and Anti-PD-L1 Immunotherapy: Three Cases, a Review of the Literature, and a Proposed Management Algorithm.	Actas dermo-sifiliograficas	2022	68.36648362602936	-24.650588320166765	1	
35623069	The current management and biomarkers of immunotherapy in advanced gastric cancer.	Medicine	2022	42.61012692937324	15.640525511262062	6	1.34
35622885	Differences in PD-L1 Expression between oral and oropharyngeal squamous cell carcinoma.	PloS one	2022	-6.370897864749789	-10.888736273959214	5	1.35
35622442	Steroid treatment in the management of destructive thyrotoxicosis induced by PD1 blockade.	European thyroid journal	2022	77.58208579767431	-18.430078347074023	2	
35621637	Immune Checkpoint Inhibitors in Cancer Therapy.	Current oncology (Toronto, Ont.)	2022	30.804141921524774	11.26643450236128	87	21.62
35621125	Mechanisms underlying immune-related adverse events during checkpoint immunotherapy.	Clinical science (London, England : 1979)	2022	79.32641532694765	-9.675946331897556	2	
35620459	TGFβ2 is a Prognostic Biomarker for Gastric Cancer and is Associated With Methylation and Immunotherapy Responses.	Frontiers in genetics	2022	-9.11610260685759	56.04356367268513	2	
35619918	PD-1/PD-L1 Correlates With the Efficacy of the Treatment of Concurrent Chemoradiotherapy in Cervical Cancer.	Frontiers in oncology	2022	1.510046225569322	-11.560908598128025	2	
35619897	Isolated Renal Calyceal Urothelial Carcinoma Effectively Treated With PD-1 Inhibitor Alone: A Case Report And Literature Review.	Frontiers in oncology	2022	66.62498435661328	21.872468485497706	0	
35619700	PD-L1 Inhibits T Cell-Induced Cytokines and Hyaluronan Expression via the CD40-CD40L Pathway in Orbital Fibroblasts From Patients With Thyroid Associated Ophthalmopathy.	Frontiers in immunology	2022	-67.01859570222156	-15.784740037926214	3	
35619108	An individual nomogram can reliably predict tumor spread through air spaces in non-small-cell lung cancer.	BMC pulmonary medicine	2022	16.8448865333831	-26.15526026974925	0	
35618627	Efficacy of Immune Checkpoint Inhibitors in SMARCA4-Deficient Thoracic Tumor.	Clinical lung cancer	2022	58.00772878201444	-37.71778665645204	5	1.23
35618288	Spatial transcriptomics of macrophage infiltration in non-small cell lung cancer reveals determinants of sensitivity and resistance to anti-PD1/PD-L1 antibodies.	Journal for immunotherapy of cancer	2022	-2.85972877760357	30.299496076142137	22	4.27
35615996	A novel DNA damage and repair-related gene signature to improve predictive capacity of overall survival for patients with gliomas.	Journal of cellular and molecular medicine	2022	-18.86097688928403	57.128682371666336	4	
35615798	[Real-world study on the efficacy and prognostic predictive biomarker of patients with metastatic non-small cell lung cancer treated with programmed death-1/programmed death ligand 1 inhibitors].	Zhonghua zhong liu za zhi [Chinese journal of oncology]	2022	49.907637167006094	-17.41452147778198	0	
35615793	[CXCL5 inhibits tumor immune of lung cancer via modulating PD1/PD-L1 signaling].	Zhonghua zhong liu za zhi [Chinese journal of oncology]	2022	11.6234733704457	-22.941830506730916	0	
35615530	Platelet-Related Molecular Subtype to Predict Prognosis in Hepatocellular Carcinoma.	Journal of hepatocellular carcinoma	2022	-11.03628495482185	49.65179255485082	4	
35614201	Identification and validation of a novel pyroptosis-related lncRNAs signature associated with prognosis and immune regulation of hepatocellular carcinoma.	Scientific reports	2022	-3.239454092817895	54.8938813432208	3	
35612829	Association of Bullous Pemphigoid With Immune Checkpoint Inhibitor Therapy in Patients With Cancer: A Systematic Review.	JAMA dermatology	2022	71.12364762287199	-26.76352450298377	14	4.06
35612299	Combination of chemotherapy and immune checkpoint therapy by the immunoconjugates-based nanocomplexes synergistically improves therapeutic efficacy in SCLC.	Drug delivery	2022	46.53331224173676	-40.75681691819364	1	
35611948	Directed Evolution of PD-L1-Targeted Affibodies by mRNA Display.	ACS chemical biology	2022	-42.80555300127898	-33.29303565904982	0	
35610758	Expression of PD-L1 on regulatory B cells in patients with acute myeloid leukaemia and its effect on prognosis.	Journal of cellular and molecular medicine	2022	-35.81078990779937	15.790665801838191	3	
35609735	MTDH antisense oligonucleotides reshape the immunosuppressive tumor microenvironment to sensitize Hepatocellular Carcinoma to immune checkpoint blockade therapy.	Cancer letters	2022	-15.317245047215096	50.159382881872936	7	1.64
35609559	A comprehensive profiling of the immune microenvironment of breast cancer brain metastases.	Neuro-oncology	2022	-14.55829907368133	38.27047281085589	6	1.12
35603657	[Combination therapy based on PD-1/PD-L1 blocking in the treatment of non-small cell lung cancer].	Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology	2022	32.21130833988339	-30.41813401326976	0	
35602291	Abrine Elicits Liver Carcinoma Immunity and Enhances Antitumor Efficacy of Immune Checkpoint Blockade by Modulating PD-L1 Signaling.	Journal of oncology	2022	-16.353726491197364	-31.502260486178407	5	1.36
35600045	The PD-1 with PD-L1 Axis Is Pertinent with the Immune Modulation of Atrial Fibrillation by Regulating T Cell Excitation and Promoting the Secretion of Inflammatory Factors.	Journal of immunology research	2022	-57.5203974114279	15.015471892723005	7	2.18
35598173	Nasopharyngeal cancer cell-derived exosomal PD-L1 inhibits CD8+ T-cell activity and promotes immune escape.	Cancer science	2022	-44.32248822206477	-58.08286879973087	9	2.08
35595823	STAT1 is regulated by TRIM24 and promotes immunosuppression in head and neck squamous carcinoma cells, but enhances T cell antitumour immunity in the tumour microenvironment.	British journal of cancer	2022	-10.933985484354048	-8.131471691506912	4	
35595632	A Systematic Review and Meta-Analysis of the Role of Immune Checkpoint Inhibitors (ICI) as Adjuvant Treatment for Localized High-Risk Muscle-Invasive Urothelial Carcinoma (MIUC).	Clinical genitourinary cancer	2022	67.48167800783	26.575803465430678	1	
35595321	The paradox of immune checkpoint inhibition re-activating tuberculosis.	The European respiratory journal	2022	-85.12610410672421	-0.6570481238348311	4	
35595021	Tislelizumab combined with chemotherapy as neoadjuvant therapy for surgically resectable esophageal cancer: A prospective, single-arm, phase II study (TD-NICE).	International journal of surgery (London, England)	2022	50.2577706524153	12.10542511991822	41	9.78
35593325	Tumor-associated macrophages regulate the function of cytotoxic T lymphocyte through PD-1/PD-L1 pathway in multiple myeloma.	Cancer medicine	2022	-32.275189586492324	-3.578622080710306	5	1.16
35592856	A Somatic Mutation Signature Predicts the Best Overall Response to Anti-programmed Cell Death Protein-1 Treatment in Epidermal Growth Factor Receptor/Anaplastic Lymphoma Kinase-Negative Non-squamous Non-small Cell Lung Cancer.	Frontiers in medicine	2022	21.256866503853928	-20.859990270860425	2	
35592338	Tumor-Associated Macrophages Regulate PD-1/PD-L1 Immunosuppression.	Frontiers in immunology	2022	-32.61473111747341	-4.903450800497959	32	7.15
35592313	Killing Two Birds With One Stone: Effective Control of Both Non-Small Cell Lung Cancer and Progressive Multifocal Leukoencephalopathy With Atezolizumab, A Case Report.	Frontiers in immunology	2022	51.53625958797127	-40.058464716039104	2	
35592310	Clinical, Virological and Immunological Subphenotypes in a Cohort of Early Treated HIV-Infected Children.	Frontiers in immunology	2022	-13.089698205588066	41.92459919366326	2	
35589776	In vitro preliminary study on different anti-PD-1 antibody concentrations on T cells activation.	Scientific reports	2022	34.96710991629467	-12.355906477115182	0	
35589125	Detection of PD-L1-Expressing Myeloid Cell Clusters in the Hyaluronan-Enriched Stroma in Tumor Tissue and Tumor-Draining Lymph Nodes.	Journal of immunology (Baltimore, Md. : 1950)	2022	-25.952976530092688	-2.956230812423666	7	1.53
35586668	Efficacy and Safety of PD-1/PD-L1 Inhibitor Chemotherapy Combined with Lung Cancer Fang No. 1 in Relapsed and Refractory SCLC: A Retrospective Observational Study.	Computational and mathematical methods in medicine	2022	46.9095472528012	-41.50276299917213	2	
35585982	Small Molecule Agents Targeting PD-1 Checkpoint Pathway for Cancer Immunotherapy: Mechanisms of Action and Other Considerations for Their Advanced Development.	Frontiers in immunology	2022	25.62299763018216	5.999852618519786	8	1.63
35584229	Ex silico engineering of cystine-dense peptides yielding a potent bispecific T cell engager.	Science translational medicine	2022	-45.85670810328727	-43.24537697576419	1	
35581130	Natural killer cells: unlocking new treatments for bladder cancer.	Trends in cancer	2022	70.51847958076202	24.23727286962845	4	
35578936	[A Case of Non-Small Cell Lung Cancer Successfully Treated with Anti-PD-L1 Therapy after Exacerbation Caused by Anti-PD-1 Therapy].	Gan to kagaku ryoho. Cancer & chemotherapy	2022	51.27195768206023	-36.057787883715385	0	
35577211	The roles of TGF-β and VEGF pathways in the suppression of antitumor immunity in melanoma and other solid tumors.	Pharmacology & therapeutics	2022	28.311050865703937	15.561051970178744	15	3.71
35576957	Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study.	The Lancet. Oncology	2022	51.1886881909062	-38.10489724219819	96	20.18
35575882	Advances in the study of CD47-based bispecific antibody in cancer immunotherapy.	Immunology	2022	-16.242210367250276	-47.01490521143207	8	1.75
35574612	Phase 1/2 Trial Results of a Large Surface Area Microparticle Docetaxel for the Treatment of High-Risk Nonmuscle-Invasive Bladder Cancer.	The Journal of urology	2022	72.32869079039318	23.43824508515668	1	
35574317	Meta-Analysis of Efficacy From CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients.	Frontiers in oncology	2022	42.86599743322893	12.555207129676544	2	
35571808	Bio-Conjugated Magnetic-Fluorescence Nanoarchitectures for the Capture and Identification of Lung-Tumor-Derived Programmed Cell Death Lighand 1-Positive Exosomes.	ACS omega	2022	-42.153611336648254	-54.75974520040588	3	
35571422	Efficacy and safety of camrelizumab plus apatinib as second-line treatment for advanced squamous non-small cell lung cancer.	Annals of translational medicine	2022	55.005190968378336	-1.8362512059053944	8	1.5
35571340	Hemophagocytic Lymphohistiocytosis Secondary to Immune Checkpoint Inhibitor Therapy.	World journal of oncology	2022	71.4928019144479	-10.401623205429088	4	
35569724	Tissue and circulating PD-L2: moving from health and immune-mediated diseases to head and neck oncology.	Critical reviews in oncology/hematology	2022	-8.861938290426803	-5.309354820768909	6	1.52
35569432	Adverse and unconventional reactions related to immune checkpoint inhibitor therapy for cancer.	International immunopharmacology	2022	81.32462231214836	-8.731919248671224	2	
35568771	Novel immune subtypes identification of HER2-positive breast cancer based on immunogenomic landscape.	Medical oncology (Northwood, London, England)	2022	6.378937771656484	28.28046393382792	0	
35567672	Antibody-Drug Conjugates in Uro-Oncology.	Targeted oncology	2022	70.44042933675844	15.139988029952242	2	
35567369	PD-1 mediates decidual γδ T cells cytotoxicity during recurrent pregnancy loss.	American journal of reproductive immunology (New York, N.Y. : 1989)	2022	-76.11573642597183	-18.838337195424145	2	
35563896	Cellular and Molecular Signaling as Targets for Cancer Vaccine Therapeutics.	Cells	2022	-28.619322046509883	-37.90374878507254	0	
35559250	Immune Checkpoint Inhibitors in Peripheral T-Cell Lymphoma.	Frontiers in pharmacology	2022	24.533766080863774	12.665362401817234	7	1.61
35553632	Immune microenvironment characteristics and their implications for immune checkpoint inhibitor efficacy in HER2-overexpressing gastric cancer.	Clinical and experimental immunology	2022	-10.282864920722586	23.078225876992978	2	
35553630	Extracellular vesicles containing PD-L1 contribute to CD8+ T-cell immune suppression and predict poor outcomes in small cell lung cancer.	Clinical and experimental immunology	2022	-40.42343987689042	-60.07616541585725	10	2.56
35552655	CSF-1R inhibitor, pexidartinib, sensitizes esophageal adenocarcinoma to PD-1 immune checkpoint blockade in a rat model.	Carcinogenesis	2022	-25.311469051612477	-25.213166338160125	7	1.39
35551662	Immune-Based Therapeutic Interventions for Acute Myeloid Leukemia.	Cancer treatment and research	2022	17.5155299266164	17.238403700833317	2	
35550174	Three-Year Follow-Up of Neoadjuvant Programmed Cell Death Protein-1 Inhibitor (Sintilimab) in NSCLC.	Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer	2022	33.186313885002605	-18.888157807488067	17	3.43
35549674	Perioperative treatment in resectable gastric cancer with spartalizumab in combination with fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT): a phase II study (GASPAR).	BMC cancer	2022	48.68405915959286	12.59936790992497	7	1.53
35547263	Establishment and Application of a Prognostic Risk Score Model Based on Characteristics of Different Immunophenotypes for Lung Adenocarcinoma.	Frontiers in genetics	2022	16.114663049020592	-14.52056212981534	0	
35547095	Current status and advances of immunotherapy in nasopharyngeal carcinoma.	Therapeutic advances in medical oncology	2022	42.31454771478336	27.151887834788177	12	3.08
35545291	Treatment of ovarian clear cell carcinoma with immune checkpoint blockade: a case series.	International journal of gynecological cancer : official journal of the International Gynecological Cancer Society	2022	38.676048629061626	40.10172191395675	3	
35541908	New insights into checkpoint inhibitor immunotherapy and its combined therapies in hepatocellular carcinoma: from mechanisms to clinical trials.	International journal of biological sciences	2022	30.954937054901364	49.11862475231855	16	3.87
35538491	"The ""Great Debate"" at Melanoma Bridge 2021, December 2nd-4th, 2021."	Journal of translational medicine	2022	30.90019916619612	26.954315872874275	0	
35537231	Association of immune response with overall and disease-free survival in laryngeal squamous cell carcinomas.	American journal of otolaryngology	2022	-4.37450242562768	16.892268432441504	0	
35530307	Distinct Functional Metagenomic Markers Predict the Responsiveness to Anti-PD-1 Therapy in Chinese Non-Small Cell Lung Cancer Patients.	Frontiers in oncology	2022	23.41615280439691	40.91435893162052	3	
35526483	CBX7 represses the POU2F2 to inhibit the PD-L1 expression and regulate the immune response in bladder cancer.	Biochemical and biophysical research communications	2022	12.015898240159656	61.70872071761122	2	
35525858	Macrophage-mediated anti-tumor immunity against high-risk neuroblastoma.	Genes and immunity	2022	-27.081593799731717	14.227665538331571	2	
35524371	Gut Microbiota Modulates the Efficiency of Programmed Cell Death Protein 1 Cancer Immunotherapies.	Iranian journal of allergy, asthma, and immunology	2022	-23.238334912241918	0.8232344067800208	0	
35523436	NKG2A and PD-L1 expression panel predicts clinical benefits from adjuvant chemotherapy and PD-L1 blockade in muscle-invasive bladder cancer.	Journal for immunotherapy of cancer	2022	9.836140733001864	58.98957849773007	1	
35517410	BET inhibitor JQ1 enhances anti-tumor immunity and synergizes with PD-1 blockade in CRC.	Journal of Cancer	2022	-28.64593037207276	10.483805266939145	5	1.01
35511238	Human adipose-derived mesenchymal stem cells prevent type 1 diabetes induced by immune checkpoint blockade.	Diabetologia	2022	-55.30197718573357	20.457994122575364	8	2.34
35509603	Lactate Transporter SLC16A3 (MCT4) as an Onco-Immunological Biomarker Associating Tumor Microenvironment and Immune Responses in Lung Cancer.	International journal of general medicine	2022	-5.589873424065846	48.60591339091464	0	
35508972	Pan-cancer analysis reveals RIPK2 predicts prognosis and promotes immune therapy resistance via triggering cytotoxic T lymphocytes dysfunction.	Molecular medicine (Cambridge, Mass.)	2022	-4.339051779090365	45.48427144889712	8	1.85
35507079	The worsening impact of programmed cell death ligand 1 in ovarian clear cell carcinomas.	Archives of gynecology and obstetrics	2022	-18.92203638074915	12.39714171442972	3	
35507017	A Randomized Phase II Study of MEDI0680 in Combination with Durvalumab versus Nivolumab Monotherapy in Patients with Advanced or Metastatic Clear-cell Renal Cell Carcinoma.	Clinical cancer research : an official journal of the American Association for Cancer Research	2022	61.642384395800825	5.229396643124953	5	0.91
35504202	Efficacy and safety of PD-1 inhibitors combined with chemotherapy as first-line therapy for advanced esophageal cancer: A systematic review and network meta-analysis.	International immunopharmacology	2022	51.441914380471566	15.012595756737626	13	2.88
35504179	Engineered PD-1/TIGIT dual-activating cell-membrane nanoparticles with dexamethasone act synergistically to shape the effector T cell/Treg balance and alleviate systemic lupus erythematosus.	Biomaterials	2022	-33.54027905166027	-59.02424651256396	11	2.75
35501298	Relationship and prognostic significance of IL-33, PD-1/PD-L1, and tertiary lymphoid structures in cervical cancer.	Journal of leukocyte biology	2022	1.80210652045016	-11.551365232913014	3	
35501263	Immune checkpoint inhibitor-related thyroid dysfunction.	Best practice & research. Clinical endocrinology & metabolism	2022	79.92046286885643	-15.91025414663192	13	3.39
35499294	Real-World longitudinal practice patterns in the use of PD-1 and PD-L1 inhibitors as First-Line therapy in patients with Non-Small cell lung cancer in the United States.	Cancer medicine	2022	46.74964519117859	-19.2225036566991	2	
35496499	Targeting HSP90 sensitizes pancreas carcinoma to PD-1 blockade.	Oncoimmunology	2022	-19.72512576378396	-19.2252361320627	4	
35496272	Platycodon grandiflorum Triggers Antitumor Immunity by Restricting PD-1 Expression of CD8+ T Cells in Local Tumor Microenvironment.	Frontiers in pharmacology	2022	-26.737482284744942	-34.19088352343808	2	
35495754	The Effect of Anlotinib Combined with anti-PD-1 in the Treatment of Gastric Cancer.	Frontiers in surgery	2022	27.55666827305273	-52.31845343575736	0	
35494078	How Immunotherapy Modified the Therapeutic Scenario of Endometrial Cancer: A Systematic Review.	Frontiers in oncology	2022	39.58417804665234	33.80029552400773	3	
35493461	TNF-α-Secreting Lung Tumor-Infiltrated Monocytes Play a Pivotal Role During Anti-PD-L1 Immunotherapy.	Frontiers in immunology	2022	2.026072852720564	-26.35820619182502	7	1.52
35489718	Radiotherapy and Immunotherapy: The Power of the Teamwork for the Treatment of NSCLC.	Anticancer research	2022	36.1200875230266	-26.86805061974481	3	
35489160	Clinical relevance of PD-L2 expression in surgically resected lung adenocarcinoma.	Lung cancer (Amsterdam, Netherlands)	2022	9.694431546204711	-27.746675223313016	4	
35487167	CLSPN is a potential biomarker associated with poor prognosis in low-grade gliomas based on a multi-database analysis.	Current research in translational medicine	2022	-18.40688968285811	54.26263432810185	2	
35485300	Everolimus (RAD001) combined with programmed death-1 (PD-1) blockade enhances radiosensitivity of cervical cancer and programmed death-ligand 1 (PD-L1) expression by blocking the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR)/S6 kinase 1 (S6K1) pathway.	Bioengineered	2022	3.042521054203703	-14.588458010539998	3	
35484402	Engineered nanomedicines block the PD-1/PD-L1 axis for potentiated cancer immunotherapy.	Acta pharmacologica Sinica	2022	-32.3167413190188	-50.748715844395775	8	1.92
35484298	Pressure increases PD-L1 expression in A549 lung adenocarcinoma cells and causes resistance to anti-ROR1 CAR T cell-mediated cytotoxicity.	Scientific reports	2022	3.2324078302243366	-22.130594928325337	3	
35483877	Tumor-immune microenvironment revealed by Imaging Mass Cytometry in a metastatic sarcomatoid urothelial carcinoma with a prolonged response to pembrolizumab.	Cold Spring Harbor molecular case studies	2022	66.23423130131543	16.89064234502719	4	
35481923	The intrinsic and microenvironmental features of diffuse midline glioma: Implications for the development of effective immunotherapeutic treatment strategies.	Neuro-oncology	2022	-27.085619141133066	58.525430290736026	13	2.93
35480107	Restored CD8+PD-1+ T Cells Facilitate the Response to Anti-PD-1 for Patients With Pancreatic Ductal Adenocarcinoma.	Frontiers in oncology	2022	-8.815560697137707	27.156140143580963	2	
35479647	HSP90 as an emerging barrier to immune checkpoint blockade therapy.	Oncoscience	2022	-31.39159882463464	-18.903505173242696	1	
35479097	Pyroptosis-Related Signature Predicts Prognosis and Immunotherapy Efficacy in Muscle-Invasive Bladder Cancer.	Frontiers in immunology	2022	1.427253207475374	57.84599745893063	11	2.28
35479081	Inhibitors of PD-1 in Non-Small Cell Lung Cancer: A Meta-Analysis of Clinical and Molecular Features.	Frontiers in immunology	2022	48.98193905413809	-18.30450814201558	7	1.39
35478147	Effect of Systemic or Intraperitoneal Administration of Anti-PD-1 Antibody for Peritoneal Metastases from Gastric Cancer.	In vivo (Athens, Greece)	2022	-19.765832809117445	10.92525878645886	4	
35471840	Resistance Mechanisms to Anti-PD Cancer Immunotherapy.	Annual review of immunology	2022	-35.12351782363341	-21.192994022224017	64	12.72
35466317	Inhibition of PARP Potentiates Immune Checkpoint Therapy through miR-513/PD-L1 Pathway in Hepatocellular Carcinoma.	Journal of oncology	2022	33.978240340686554	40.14228425461158	3	
35464480	Checkpoint Inhibitor Pneumonitis Induced by Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer: Occurrence and Mechanism.	Frontiers in immunology	2022	66.79248279379613	-9.4190469326033	18	4.17
35463314	ERBB2D16 Expression in HER2 Positive Gastric Cancer Is Associated With Resistance to Trastuzumab.	Frontiers in oncology	2022	4.2570307996396455	5.822025034321194	2	
35462503	[The relation between residual β-cell function and autoimmune status in long-term type 1 diabetes patients].	Zhonghua yi xue za zhi	2022	-60.32736729868108	4.497252803542612	1	
35459855	The combination of PD-1 blockade with interferon-α has a synergistic effect on hepatocellular carcinoma.	Cellular & molecular immunology	2022	-22.54207494289793	-17.48600864251746	17	3.44
35456895	In Situ PD-L1 Expression in Oral Squamous Cell Carcinoma Is Induced by Heterogeneous Mechanisms among Patients.	International journal of molecular sciences	2022	-11.902827825190773	-11.297521647315016	2	
35456394	Deconstructing Immune Cell Infiltration in Human Colorectal Cancer: A Systematic Spatiotemporal Evaluation.	Genes	2022	6.531576999642351	37.908047512373535	1	
35455289	Exploring the Mechanisms Underlying the Cardiotoxic Effects of Immune Checkpoint Inhibitor Therapies.	Vaccines	2022	83.59275964894688	2.2176546799342387	5	0.96
35454906	T-Cells Expressing a Highly Potent PRAME-Specific T-Cell Receptor in Combination with a Chimeric PD1-41BB Co-Stimulatory Receptor Show a Favorable Preclinical Safety Profile and Strong Anti-Tumor Reactivity.	Cancers	2022	-29.94446200898902	-21.998225781634265	2	
35453784	Target Therapy for Hepatocellular Carcinoma: Beyond Receptor Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors.	Biology	2022	29.681228346949734	50.906768789544586	4	
35453635	Clinicopathological Features of Gastric Cancer with Autoimmune Gastritis.	Biomedicines	2022	-14.339872401973375	21.796763217130017	5	1.68
35451929	2-methoxyestradiol inhibits melanoma cell growth by activating adaptive immunity.	Immunopharmacology and immunotoxicology	2022	-24.59622111350999	-31.0778473766116	3	
35449134	PD-L1 signaling selectively regulates T cell lymphatic transendothelial migration.	Nature communications	2022	-55.42319935863688	-0.5992853996362104	12	2.41
35448937	Immunohistochemical expression and clinicopathological assessment of PD-1, PD-L1, NY-ESO-1, and MAGE-A4 expression in highly aggressive soft tissue sarcomas.	European journal of histochemistry : EJH	2022	-20.03027060122142	18.863936408554704	4	
35448208	Cutaneous Adverse Events Associated with Immune Checkpoint Inhibitors: A Review Article.	Current oncology (Toronto, Ont.)	2022	75.79514540407466	-22.47231039252773	15	3.66
35448174	Immunotherapy in Squamous Cell Cancer of the Esophagus.	Current oncology (Toronto, Ont.)	2022	53.20244144744397	13.3206656087781	8	1.78
35445765	Immune cell subsets in interface cutaneous immune-related adverse events associated with anti-PD-1 therapy resemble acute graft versus host disease more than lichen planus.	Journal of cutaneous pathology	2022	69.60778531705	-21.083618809862383	4	
35444349	Immunolocalization of CD80 and CD86 in Non-Small Cell Lung Carcinoma: CD80 as a Potent Prognostic Factor.	Acta histochemica et cytochemica	2022	7.895709821685309	-23.07842005760994	4	
35443604	Programmed Death Ligand-1 is Frequently Expressed in Primary Acute Myeloid Leukemia and B-Acute Lymphoblastic Leukemia.	Clinical laboratory	2022	-35.7346997269735	16.906797189871796	0	
35439641	When artificial intelligence meets PD-1/PD-L1 inhibitors: Population screening, response prediction and efficacy evaluation.	Computers in biology and medicine	2022	7.482164626805099	-48.88038690075961	3	
35438468	Lipopolysaccharide facilitates immune escape of hepatocellular carcinoma cells via m6A modification of lncRNA MIR155HG to upregulate PD-L1 expression.	Cell biology and toxicology	2022	-20.03329790407283	41.350918629788765	24	4.93
35437326	PD-L1-PD-1 interactions limit effector regulatory T cell populations at homeostasis and during infection.	Nature immunology	2022	-66.6038284223158	2.6376682419742346	30	5.65
35435450	Gene expression profile of high PD-L1 non-small cell lung cancers refractory to pembrolizumab.	Cancer immunology, immunotherapy : CII	2022	20.56011597447766	-14.313854509011714	0	
35435206	[Pituitary immune-related adverse events induced by programmed cell death protein 1 inhibitors in advanced lung cancer patients: A report of 3 cases].	Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences	2022	82.43671172467862	-18.77615291756552	1	
35434938	A Three-In-One Assembled Nanoparticle Containing Peptide-Radio-Sensitizer Conjugate and TLR7/8 Agonist Can Initiate the Cancer-Immunity Cycle to Trigger Antitumor Immune Response.	Small (Weinheim an der Bergstrasse, Germany)	2022	-29.13556260135581	-55.0606052429669	10	2.19
35433941	Identification of molecular subtypes premised on the characteristics of immune infiltration of endometrial cancer.	Annals of translational medicine	2022	6.182620269611151	45.95031594774026	1	
35433707	A Systematic Review of the Mechanisms Involved in Immune Checkpoint Inhibitors Cardiotoxicity and Challenges to Improve Clinical Safety.	Frontiers in cell and developmental biology	2022	83.46934659990235	1.8036445746975545	10	2.38
35432443	Integrative Analysis of Multi-Omics Data-Identified Key Genes With KLRC3 as the Core in a Gene Regulatory Network Related to Immune Phenotypes in Lung Adenocarcinoma.	Frontiers in genetics	2022	-2.887876936862205	44.82493818969708	1	
35432346	Holistic Approach to Immune Checkpoint Inhibitor-Related Adverse Events.	Frontiers in immunology	2022	78.4244905305835	-10.201268813327436	22	5.18
35432324	Inhibitory Immune Checkpoint Receptors and Ligands as Prognostic Biomarkers in COVID-19 Patients.	Frontiers in immunology	2022	-51.20221247914962	43.9510552611309	8	1.75
35431930	High Expression of RAI14 in Triple-Negative Breast Cancer Participates in Immune Recruitment and Implies Poor Prognosis Through Bioinformatics Analyses.	Frontiers in pharmacology	2022	1.4155072468582337	43.25177507783917	1	
35429911	Pyrazolones as inhibitors of immune checkpoint blocking the PD-1/PD-L1 interaction.	European journal of medicinal chemistry	2022	-35.57923463084476	-41.53439842571388	8	2.39
35422950	Clinical efficacy of turtle shell decocted pills for endometriosis and their influence on cellular immunity.	American journal of translational research	2022	69.02057570631149	-36.89782739152629	1	
35422629	Clinical Response to Neoadjuvant Immunotherapy Combined with Targeted Therapy and Chemotherapy in Oral Squamous Cell Carcinoma: Experience in Three Patients.	OncoTargets and therapy	2022	51.247792822205206	29.33553933217585	3	
35420421	Traversing through the Dynamic Protein-Protein Interaction Landscape and Conformational Plasticity of PD-1 for Small-Molecule Discovery.	Journal of medicinal chemistry	2022	-47.33500988251798	-40.99430806460051	7	1.7
35418272	Survival Outcomes and Safety of Programmed Cell Death/Programmed Cell Death Ligand 1 Inhibitors for Unresectable Hepatocellular Carcinoma: Result From Phase III Trials.	Cancer control : journal of the Moffitt Cancer Center	2022	52.496344463629626	-15.208931801411888	3	
35418151	Lymph node-targeted neoantigen nanovaccines potentiate anti-tumor immune responses of post-surgical melanoma.	Journal of nanobiotechnology	2022	-32.667296299463146	-48.0119773631734	13	3.02
35417187	NK cells limit therapeutic vaccine-induced CD8+T cell immunity in a PD-L1-dependent manner.	Science translational medicine	2022	-76.55922691946847	20.639352934185013	10	2.16
35416931	An unexpected role for PD-L1 in front-rear polarization and directional migration.	The Journal of cell biology	2022	-44.76760628794521	-14.495855779733873	0	
35414780	MGP promotes CD8+ T cell exhaustion by activating the NF-κB pathway leading to liver metastasis of colorectal cancer.	International journal of biological sciences	2022	2.747062991109951	38.53491831236656	9	1.88
35414591	Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial.	Journal for immunotherapy of cancer	2022	46.63491452911682	6.271495121271288	38	8.97
35412706	Various clinical presentations of uveitis associated with durvalumab treatment.	Radiology and oncology	2022	81.74321921973701	-24.716662726294278	0	
35411241	FOXO3-dependent suppression of PD-L1 promotes anticancer immune responses via activation of natural killer cells.	American journal of cancer research	2022	-18.057720173558103	-24.571829286357	1	
35411177	Construction of a Prognostic Signature of 10 Autophagy-Related lncRNAs in Gastric Cancer.	International journal of general medicine	2022	-3.502113219814833	53.861425663076446	3	
35410325	Neoantigen-specific CD8 T cell responses in the peripheral blood following PD-L1 blockade might predict therapy outcome in metastatic urothelial carcinoma.	Nature communications	2022	13.371977080642036	-7.718022366065072	25	4.82
35408827	Novel Bi-Specific Immuno-Modulatory Tribodies Potentiate T Cell Activation and Increase Anti-Tumor Efficacy.	International journal of molecular sciences	2022	-14.635608113622585	-43.95989939829333	4	
35406584	Beyond PD-L1-Identification of Further Potential Therapeutic Targets in Oral Cancer.	Cancers	2022	-7.983034239899029	-13.871469627080812	6	1.78
35406533	Utilization of Immunotherapy for the Treatment of Hepatocellular Carcinoma in the Peri-Transplant Setting: Transplant Oncology View.	Cancers	2022	28.36174669652388	48.42729943584417	16	3.54
35406483	Immunomodulatory Properties of Immune Checkpoint Inhibitors-More than Boosting T-Cell Responses?	Cancers	2022	30.8873700365756	15.267957149520631	8	1.95
35404483	Activation of T cell checkpoint pathways during β-cell antigen presentation by engineered dendritic cells promotes protection from type 1 diabetes.	Immunology	2022	-61.21454919975713	1.9979171535835327	1	
35402739	PD-1 and PD-L1 expression predict regression and prognosis following neoadjuvant radiochemotherapy of oesophageal adenocarcinoma.	Clinical and translational radiation oncology	2022	-12.141793894512617	7.665070840254455	2	
35402601	Immune checkpoint inhibitors and adrenal insufficiency: a large-sample case series study.	Annals of translational medicine	2022	84.21622302269967	-15.26489097589856	10	3.03
35402216	Oncological Patients With Endocrine Complications After Immunotherapy With Checkpoint Inhibitors Present Longer Progression-Free and Overall Survival.	Frontiers in oncology	2022	81.61173030130428	-17.244110573480818	9	2.42
35402083	LILRB4 promotes tumor metastasis by regulating MDSCs and inhibiting miR-1 family miRNAs.	Oncoimmunology	2022	-49.55828663763101	27.823482152920896	14	3.37
35401534	Relationship Between Programmed Death Ligand 1 Expression and Other Clinicopathological Features in a Large Cohort of Gastric Cancer Patients.	Frontiers in immunology	2022	-8.547500384915498	4.99024212939775	3	
35400002	Immune-related Thyroid Dysfunction (irTD) in Non-small Cell Lung Cancer (NSCLC) Correlates With Response and Survival.	Cancer diagnosis & prognosis	2022	79.75578864013728	-19.259211586393803	1	
35399573	Evaluation of PD-L1 expression on circulating tumour cells in small-cell lung cancer.	Translational lung cancer research	2022	9.947567177117612	-38.59756254734263	5	1.24
35399232	COX-2-related tumor immune microenvironment in non-small cell lung cancer: a novel signature to predict hot and cold tumor.	Journal of thoracic disease	2022	13.727389619834582	-15.791529980537666	1	
35398850	Dynamic Observation: Immune-Privileged Microenvironment Limited the Effectiveness of Immunotherapy in an Intraocular Metastasis Mouse Model.	Ophthalmic research	2022	3.967400649694781	2.9781099121502668	3	
35392977	Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade.	Journal of experimental & clinical cancer research : CR	2022	-25.20315719480619	-18.11915446132312	9	2.0
35392976	Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons.	Cell communication and signaling : CCS	2022	30.96240611561036	13.110128000284236	73	17.26
35392432	Aspirin Suppressed PD-L1 Expression through Suppressing KAT5 and Subsequently Inhibited PD-1 and PD-L1 Signaling to Attenuate OC Development.	Journal of oncology	2022	-22.89206138084454	10.43582897781226	4	
35392221	A Novel Sushi-IL15-PD1 CAR-NK92 Cell Line With Enhanced and PD-L1 Targeted Cytotoxicity Against Pancreatic Cancer Cells.	Frontiers in oncology	2022	-40.45008968477659	5.382443824286878	3	
35390767	Immune Checkpoint Inhibitor Use in Solid Organ Transplant Recipients: A Systematic Review.	Journal of the National Comprehensive Cancer Network : JNCCN	2022	71.15478332233387	28.946554540506156	18	4.84
35389889	Bronchoalveolar lavage fluid reveals factors contributing to the efficacy of PD-1 blockade in lung cancer.	JCI insight	2022	4.6530473381936925	-19.090694753311965	6	1.46
35388635	Evaluation of a Radiolabeled Macrocyclic Peptide as Potential PET Imaging Probe for PD-L1.	ChemMedChem	2022	4.97737349748238	-57.87155873851695	8	2.3
35388548	Analysis of anti-apoptotic PVT1 oncogene and apoptosis-related proteins (p53, Bcl2, PD-1, and PD-L1) expression in thyroid carcinoma.	Journal of clinical laboratory analysis	2022	-6.088830082130492	-21.93015875659893	3	
35387050	Pharmacological, Technological, and Digital Innovative Aspects in Rhinology.	Frontiers in allergy	2021	18.48545438042185	4.697797282170915	0	0.0
35386715	Biological Characteristics and Clinical Significance of Soluble PD-1/PD-L1 and Exosomal PD-L1 in Cancer.	Frontiers in immunology	2022	-48.66055448696914	-16.270992279901513	27	6.55
35385963	[The efficacy and prognostic factors of immunotherapy in advanced non-small cell lung cancer patients with different driver gene mutations].	Zhonghua yi xue za zhi	2022	25.64203961988907	-22.51982318229085	0	
35385574	Phosphorylation and Stabilization of PD-L1 by CK2 Suppresses Dendritic Cell Function.	Cancer research	2022	-18.355893553262373	-9.38079257908286	9	2.25
35383112	Selective estrogen receptor modulators contribute to prostate cancer treatment by regulating the tumor immune microenvironment.	Journal for immunotherapy of cancer	2022	-23.537099245853003	4.843242708803328	8	1.93
35379805	The engineered CD80 variant fusion therapeutic davoceticept combines checkpoint antagonism with conditional CD28 costimulation for anti-tumor immunity.	Nature communications	2022	-46.54985354616768	-1.3758090223861814	8	1.66
35377102	Multi-target combinatory strategy to overcome tumor immune escape.	Frontiers of medicine	2022	30.26901497142513	2.017085130221348	5	1.15
35373781	PD-1 and PD-L1 expression in mycosis fungoides and Sézary Syndrome.	Italian journal of dermatology and venereology	2022	-31.985949873314244	16.44353855324281	0	
35373505	PD-L1 expressed from tumor cells promotes tumor growth and invasion in lung cancer via modulating TGF-β1/SMAD4 expression.	Thoracic cancer	2022	6.839359754027818	-28.633689294786144	3	
35373463	Identification and validation of a ferroptosis-related gene signature for predicting survival in skin cutaneous melanoma.	Cancer medicine	2022	-3.087039426172125	50.54462217428072	15	3.53
35373420	Silencing oncogene cell division cycle associated 5 induces apoptosis and G1 phase arrest of non-small cell lung cancer cells via p53-p21 signaling pathway.	Journal of clinical laboratory analysis	2022	3.4718909001330034	-28.842860390005992	4	
35372076	Neurological Manifestations Related to Immune Checkpoint Inhibitors: Reverse Translational Research by Using the European Real-World Safety Data.	Frontiers in oncology	2022	79.80314369289728	-13.324414705049753	7	1.71
35371563	Effects of PD-1 Signaling on Immunometabolic Reprogramming.	Immunometabolism	2022	-50.02336165309384	-7.943400171181684	6	1.16
35371041	Case Report: A PD-L1-Positive Patient With Pleomorphic Rhabdomyosarcoma Achieving an Impressive Response to Immunotherapy.	Frontiers in immunology	2022	56.680507016930406	-30.112049924761827	2	
35370654	Efficacy and Adverse Events of PD-1 Inhibitors in Patients With Advanced Urothelial Carcinoma From a Real-World Experience.	Frontiers in pharmacology	2022	64.81668958415243	15.78482785717078	2	
35370422	Programmed Cell Death-1 and Its Ligands as Targets for Therapy of Multiple Myeloma Patients.	Cancer management and research	2022	-32.46351241550389	11.181890976746734	0	
35368852	Characterization of the Different Subtypes of Immune Cell Infiltration to Aid Immunotherapy.	Frontiers in cell and developmental biology	2021	12.401040286430746	-18.54998936258953	1	
35366537	Cooperation between chemotherapy and immune checkpoint blockade to enhance anti-tumour T cell immunity in oesophageal adenocarcinoma.	Translational oncology	2022	21.89424549916021	21.73030073087921	1	
35366112	Programmed death receptor ligand-2 (PD-L2) bearing extracellular vesicles as a new biomarker to identify early triple-negative breast cancer patients at high risk for relapse.	Journal of cancer research and clinical oncology	2023	1.247932764169372	-40.34382745265469	3	
35365595	Blockade of PD-L1/PD-1 signaling promotes osteo-/odontogenic differentiation through Ras activation.	International journal of oral science	2022	-53.28647050237748	19.40908663530981	3	
35365585	Genetic characteristics involving the PD-1/PD-L1/L2 and CD73/A2aR axes and the immunosuppressive microenvironment in DLBCL.	Journal for immunotherapy of cancer	2022	-30.996894595238636	29.962767057792927	7	1.4
35365044	Camrelizumab combined with anlotinib for the treatment of small cell lung cancer: a case report and literature review.	Annals of palliative medicine	2022	45.84002630330015	-42.77113217947792	2	
35364526	Current methods and emerging approaches for detection of programmed death ligand 1.	Biosensors & bioelectronics	2022	19.389954153639877	-41.45440584744593	0	
35359980	IDO1 Inhibition Reduces Immune Cell Exclusion Through Inducing Cell Migration While PD-1 Blockage Increases IL-6 and -8 Secretion From T Cells in Head and Neck Cancer.	Frontiers in immunology	2022	48.52478884644145	31.47094023208673	7	1.83
35356229	Case Report: Management of Recurrent Ovarian Squamous Cell Carcinoma With PD-1 Inhibitor.	Frontiers in oncology	2022	38.686600576966434	41.813638584876536	2	
35356070	Soluble Programmed Cell Death Protein 1 and Its Ligand: Potential Biomarkers to Predict Acute Kidney Injury After Surgery in Critically Ill Patients.	Journal of inflammation research	2022	-57.82944330312427	29.07804736454849	0	
35356000	The Programmed Death-1 Pathway Counter-Regulates Inflammation-Induced Osteoclast Activity in Clinical and Experimental Settings.	Frontiers in immunology	2022	-51.72280432307257	15.945342389194304	5	1.26
35355427	Immune-related gene signature predicts clinical outcomes and immunotherapy response in acute myeloid leukemia.	Cancer medicine	2022	-0.293080264186878	48.18586717933747	2	
35352168	The expression of PD-1 ligand 1 on macrophages and its clinical impacts and mechanisms in lung adenocarcinoma.	Cancer immunology, immunotherapy : CII	2022	3.5720932738876834	-26.2125498900843	10	2.38
35348117	Mesenchymal Stromal Cells Inhibit Aerobic Glycolysis in Activated T Cells by Negatively Regulating Hexokinase II Activity Through PD-1/PD-L1 Interaction.	Transplantation and cellular therapy	2021	-55.02400768894937	21.382195733812654	2	0.34
35347572	SEOM-SOGUG clinical guideline for localized muscle invasive and advanced bladder cancer (2021).	Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico	2022	73.5655693003354	19.71148548332994	5	1.51
35347072	eEF2K promotes PD-L1 stabilization through inactivating GSK3β in melanoma.	Journal for immunotherapy of cancer	2022	-15.0842179122782	-21.3594254042766	6	1.4
35346313	Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: findings from the CAVE-Lung trial.	Journal of experimental & clinical cancer research : CR	2022	49.792415568933926	-25.986569243696927	5	0.97
35342409	Durvalumab as Consolidation Therapy in Post-Multimodal Interventional Treatment for Patients with Advanced Solid Tumors: A Preliminary Study.	Journal of oncology	2022	40.19958312279557	-26.33874176000448	0	
35341912	The evolutionary legacy of immune checkpoint inhibitors.	Seminars in cancer biology	2022	31.75751528384916	13.066054003053818	22	5.04
35338086	DNA methylation profiles differ in responders versus non-responders to anti-PD-1 immune checkpoint inhibitors in patients with advanced and metastatic head and neck squamous cell carcinoma.	Journal for immunotherapy of cancer	2022	11.399921650257912	8.329086423957195	6	1.49
35337339	Combined angiogenesis and PD-1 inhibition for immunomodulatory TNBC: concept exploration and biomarker analysis in the FUTURE-C-Plus trial.	Molecular cancer	2022	38.32915664278006	7.467395617539378	25	5.37
35337133	Revolutionization in Cancer Therapeutics via Targeting Major Immune Checkpoints PD-1, PD-L1 and CTLA-4.	Pharmaceuticals (Basel, Switzerland)	2022	28.99094721291943	13.620392448287934	22	5.59
35332576	PD-L1 immunohistochemistry: Clones, cutoffs, and controversies.	APMIS : acta pathologica, microbiologica, et immunologica Scandinavica	2022	18.67939844029168	-42.61273395072375	4	
35331250	Clinical benefits of PD-1/PD-L1 inhibitors in patients with metastatic colorectal cancer: a systematic review and meta-analysis.	World journal of surgical oncology	2022	36.56344736268023	23.47415236141966	9	2.25
35329953	Correlation of KRAS G12C Mutation and High PD-L1 Expression with Clinical Outcome in NSCLC Patients Treated with Anti-PD1 Immunotherapy.	Journal of clinical medicine	2022	22.20639161848033	-22.89271065276902	10	2.28
35328833	Endometrial Cancer Stem Cells: Where Do We Stand and Where Should We Go?	International journal of molecular sciences	2022	-0.2200021429388691	36.54690652770975	8	2.14
35328239	Clinic, Endoscopic and Histological Features in Patients Treated with ICI Developing GI Toxicity: Some News and Reappraisal from a Mono-Institutional Experience.	Diagnostics (Basel, Switzerland)	2022	74.81072783082952	-4.1846463392560045	1	
35327662	PD-L1 Silencing in Liver Using siRNAs Enhances Efficacy of Therapeutic Vaccination for Chronic Hepatitis B.	Biomolecules	2022	-73.6064729475927	20.980732897192663	6	1.59
35327512	Prognosis Value of Immunoregulatory Molecules in Oral Cancer Microenvironment: An Immunohistochemical Study.	Biomedicines	2022	-6.608645494591156	-12.39437044813517	1	
35327456	Assessing the Future of Solid Tumor Immunotherapy.	Biomedicines	2022	19.61052622464853	2.811912523329015	21	5.12
35326658	Expression of PD-1, PD-L1 and PD-L2 in Lymphomas in Patients with Pre-Existing Rheumatic Diseases-A Possible Association with High Rheumatoid Arthritis Disease Activity.	Cancers	2022	-35.4908193615967	25.65186678907373	2	
35321832	Liver Immune-related Adverse Effects of Programmed Cell Death 1 (PD-1) and Programmed Cell Death Ligand 1 (PD-L1) Inhibitors: A Propensity Score Matched Study with Competing Risk Analyses.	Clinical oncology (Royal College of Radiologists (Great Britain))	2022	64.87274337271738	-17.40503735841683	6	1.35
35321433	Successful Treatment of a Patient With Multiple-Line Relapsed Extensive-Stage Small-Cell Lung Cancer Receiving Penpulimab Combined With Anlotinib: A Case Report.	Frontiers in oncology	2022	46.02765756052816	-42.54053690840086	3	
35317832	SIRPα and PD1 expression on tumor-associated macrophage predict prognosis of intrahepatic cholangiocarcinoma.	Journal of translational medicine	2022	1.347793892602572	6.004342443670423	9	2.01
35317524	A novel PD-L1-targeted shark VNAR single-domain-based CAR-T cell strategy for treating breast cancer and liver cancer.	Molecular therapy oncolytics	2022	-40.75904862758473	4.461225383061805	9	2.23
35316767	Tumor-derived PD1 and PD-L1 could promote hepatocellular carcinoma growth through autophagy induction in vitro.	Biochemical and biophysical research communications	2022	-14.844834896778694	2.705656669904592	7	1.8
35314433	Unique characteristics of tertiary lymphoid structures in kidney clear cell carcinoma: prognostic outcome and comparison with bladder cancer.	Journal for immunotherapy of cancer	2022	7.892895799868778	56.20662881623504	8	1.4
35311148	Pyroptosis-Related LncRNA Signatures Correlate With Lung Adenocarcinoma Prognosis.	Frontiers in oncology	2022	-3.095407454820056	55.26230738149456	5	1.11
35311117	TGF-β1-Mediated PD-L1 Glycosylation Contributes to Immune Escape via c-Jun/STT3A Pathway in Nasopharyngeal Carcinoma.	Frontiers in oncology	2022	-35.220093458735484	-31.1551551164604	4	
35311098	Case Report: Complete Remission With Anti-PD-1 and Anti-VEGF Combined Therapy of a Patient With Metastatic Primary Splenic Angiosarcoma.	Frontiers in oncology	2022	59.34267399628224	-27.35135125486348	6	1.35
35311077	Lymphocytes Infiltration and Expression of PD-1 and PD-L1 in Colorectal Cancer Between HIV-Infected and Non-HIV-Infected Patients: A Propensity Score Matched Cohort Study.	Frontiers in oncology	2022	-6.046244468519724	12.242011920098928	2	
35309324	PD-1 N58-Glycosylation-Dependent Binding of Monoclonal Antibody Cemiplimab for Immune Checkpoint Therapy.	Frontiers in immunology	2022	-36.26325457447872	-32.64498761609483	11	2.81
35308243	Predictive Simulations in Preclinical Oncology to Guide the Translation of Biologics.	Frontiers in pharmacology	2022	-0.4278966180229315	-53.20889222236874	3	
35301709	Checkpoint CD47 expression in classical Hodgkin lymphoma.	British journal of haematology	2022	-27.37377235980076	23.580270450439297	7	1.67
35301651	Roles of PTEN inactivation and PD-1/PD-L1 activation in esophageal squamous cell carcinoma.	Molecular biology reports	2022	-14.453128823733348	8.703788207485168	3	
35301639	Immune checkpoint inhibitor therapy for recurrent meningiomas: a retrospective chart review.	Journal of neuro-oncology	2022	51.28528615818239	-1.4615694126862764	5	1.27
35300724	Adverse Cardiovascular Complications following prescription of programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) inhibitors: a propensity-score matched Cohort Study with competing risk analysis.	Cardio-oncology (London, England)	2022	61.27054860380862	-17.728280780237483	10	2.31
35300341	Effect of CRISPR/Cas9-Edited PD-1/PD-L1 on Tumor Immunity and Immunotherapy.	Frontiers in immunology	2022	-44.435504050912506	0.8597724626929641	6	1.16
35299752	Response of Tonsil Follicular Dendritic Cell Sarcoma to Multimodal Treatment Including Pembrolizumab: A Case Report and Literature Review.	Frontiers in oncology	2022	51.18809634182905	28.557179504703107	1	
35298699	Discovery and pharmacological characterization of cetrelimab (JNJ-63723283), an anti-programmed cell death protein-1 (PD-1) antibody, in human cancer models.	Cancer chemotherapy and pharmacology	2022	-20.413072404018475	-41.03097952656408	4	
35298069	Melatonin inhibits EMT and PD-L1 expression through the ERK1/2/FOSL1 pathway and regulates anti-tumor immunity in HNSCC.	Cancer science	2022	-11.483992888934589	-9.122298355366953	9	2.39
35298067	High PD-L1 level of advanced hepatic lymphoepithelioma-like carcinoma response favorably to lenvatinib plus toripalimab.	Cancer science	2022	19.083673111682774	-8.558703025154257	5	1.32
35297099	Xenogeneic Sertoli cells modulate immune response in an evolutionary distant mouse model through the production of interleukin-10 and PD-1 ligands expression.	Xenotransplantation	2022	-67.53778506631825	-2.1263976356290937	1	
35295948	Identification of the Crucial Role of CCL22 in F. nucleatum-Related Colorectal Tumorigenesis that Correlates With Tumor Microenvironment and Immune Checkpoint Therapy.	Frontiers in genetics	2022	18.029377063436133	41.66458259783933	6	1.31
35294592	CMTM6 as a master regulator of PD-L1.	Cancer immunology, immunotherapy : CII	2022	-23.252847847417744	-3.4971404317855708	4	
35293692	Program death ligand-1 immunocytochemistry in lung cancer cytological samples: A systematic review.	Diagnostic cytopathology	2022	18.332008554960485	-39.86815984276616	6	1.19
35289329	Phase 2 study of pembrolizumab in patients with recurrent and residual high-grade meningiomas.	Nature communications	2022	51.23481314136492	-1.4432107968649452	24	6.96
35288066	Health-related Quality of Life with Adjuvant Nivolumab After Radical Resection for High-risk Muscle-invasive Urothelial Carcinoma: Results from the Phase 3 CheckMate 274 Trial.	European urology oncology	2022	63.99961821585461	19.808965847728317	3	
35284546	IL-12RB1: a novel immune prognostic biomarker for oral squamous cell carcinoma and linked to PD-1/PD-L1 expression in the tumor immune microenvironment.	Annals of translational medicine	2022	-6.438013248889984	-12.952605114140598	0	
35283645	Integrated Bioinformatics Analysis and Validation of the Prognostic Value of RBM10 Expression in Hepatocellular Carcinoma.	Cancer management and research	2022	-9.60350036926902	48.77952418059832	1	
35281839	Exploring Immune-Related Prognostic Signatures in the Tumor Microenvironment of Colon Cancer.	Frontiers in genetics	2022	1.4091210556581355	49.225357698743714	8	1.79
35281415	Granzyme B for predicting the durable clinical benefit of anti-PD-1/PD-L1 immunotherapy in patients with non-small cell lung cancer.	Translational cancer research	2022	20.30050163171528	-31.30544949392433	3	
35281032	Associations of HER2 Mutation With Immune-Related Features and Immunotherapy Outcomes in Solid Tumors.	Frontiers in immunology	2022	5.06962477561449	27.222795025911857	1	
35280322	Risk factors for immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer.	Translational lung cancer research	2022	66.33351868401785	-8.579356154648046	10	2.52
35279535	Immunotherapy in advanced anal cancer: Is the beginning of a new era?	Cancer treatment reviews	2022	57.317894992103206	10.838851028734643	5	1.17
35279217	Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation.	Journal of hematology & oncology	2022	-35.79016349271517	-18.064099251815747	72	16.45
35278198	The clinical and prognostic significance of CMTM6/PD-L1 in oncology.	Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico	2022	-22.97531625054008	-3.367475814918964	0	
35277462	MER4 endogenous retrovirus correlated with better efficacy of anti-PD1/PD-L1 therapy in non-small cell lung cancer.	Journal for immunotherapy of cancer	2022	14.821057157393094	-27.020930939739213	6	1.23
35276636	The expression of PD-1 and its ligands increases in Leishmania infection and its blockade reduces the parasite burden.	Cytokine	2022	-67.37659577483839	11.504410444017008	3	
35275990	Combining nilotinib and PD-L1 blockade reverses CD4+ T-cell dysfunction and prevents relapse in acute B-cell leukemia.	Blood	2022	-41.79704608732045	10.771064777762346	10	1.85
35273908	"Case Report: An ""Immune-Cold"" EGFR Mutant NSCLC With Strong PD-L1 Expression Shows Resistance to Chemo-Immunotherapy."	Frontiers in oncology	2022	32.71093928764454	-25.16569995252922	2	
35272536	Small Molecule Inhibitors of Programmed Cell Death Ligand 1 (PD-L1): A Patent Review (2019-2021).	Expert opinion on therapeutic patents	2022	-41.097147283566514	-37.54520820038909	4	
35269846	PD-1/PD-L1 Immuno-Mediated Therapy in NAFLD: Advantages and Obstacles in the Treatment of Advanced Disease.	International journal of molecular sciences	2022	-20.70569151267957	-15.952444188720415	6	1.34
35269524	Evaluation of Immunoregulatory Biomarkers on Plasma Small Extracellular Vesicles for Disease Progression and Early Therapeutic Response in Head and Neck Cancer.	Cells	2022	-40.61622166868009	-62.173636242173984	8	1.92
35268583	Novel Complex of PD-L1 Aptamer and Albumin Enhances Antitumor Efficacy In Vivo.	Molecules (Basel, Switzerland)	2022	-25.68142625049999	-58.93965941285626	4	
35267651	Dual Effect of Combined Metformin and 2-Deoxy-D-Glucose Treatment on Mitochondrial Biogenesis and PD-L1 Expression in Triple-Negative Breast Cancer Cells.	Cancers	2022	-16.310305480080633	-25.67428541132509	7	2.03
35267546	Oncologic Outcome and Immune Responses of Radiotherapy with Anti-PD-1 Treatment for Brain Metastases Regarding Timing and Benefiting Subgroups.	Cancers	2022	41.81660768996179	-15.836140533237453	5	1.26
35267483	Differential Effects on the Translation of Immune-Related Alternatively Polyadenylated mRNAs in Melanoma and T Cells by eIF4A Inhibition.	Cancers	2022	-14.468683661740558	-22.20019258598796	5	1.12
35267453	Immune Checkpoint Inhibitors-Associated Cardiotoxicity.	Cancers	2022	82.31749281003586	2.225105730639674	16	3.65
35265200	HDAC5 modulates PD-L1 expression and cancer immunity via p65 deacetylation in pancreatic cancer.	Theranostics	2022	-9.891724030974853	-31.74923253083188	9	2.05
35265199	Heterogeneity of tyrosine-based melanin anabolism regulates pulmonary and cerebral organotropic colonization microenvironment of melanoma cells.	Theranostics	2022	-15.558473884510368	-22.54613159114278	2	
35265193	Macitentan improves antitumor immune responses by inhibiting the secretion of tumor-derived extracellular vesicle PD-L1.	Theranostics	2022	-25.280908636342502	-34.50877489511048	21	5.21
35265072	CLCF1 Is a Novel Potential Immune-Related Target With Predictive Value for Prognosis and Immunotherapy Response in Glioma.	Frontiers in immunology	2022	-23.775417022830773	52.744900471988	3	
35264434	Phase IB study of ziv-aflibercept plus pembrolizumab in patients with advanced solid tumors.	Journal for immunotherapy of cancer	2022	48.65247336736053	2.904725659950828	7	1.44
35263569	Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8+ T cell responses.	Immunity	2022	-13.00908253623589	-56.4862525834054	62	12.62
35263149	Innate PD-L1 limits T cell-mediated adipose tissue inflammation and ameliorates diet-induced obesity.	Science translational medicine	2022	-58.54590312069085	5.774775499538842	15	3.3
35262683	CD155 expression impairs anti-PD1 therapy response in non-small cell lung cancer.	Clinical and experimental immunology	2022	10.655644350228163	-23.204315080132822	4	
35261895	A novel immune checkpoint-related gene signature for predicting overall survival and immune status in triple-negative breast cancer.	Translational cancer research	2022	1.2518964594093691	45.19625639180784	3	
35261880	Tumor-endogenous PD-1 promotes cell proliferation and predicts poor survival in non-small cell lung cancer.	Translational cancer research	2022	14.521089256818444	-27.45577366187571	2	
35259922	The effect of low-dose chemotherapy on the tumor microenvironment and its antitumor activity combined with anti-PD-1 antibody.	Immunotherapy	2022	-7.550838752192716	0.4503239131751821	4	
35256940	Abrogation of HnRNP L enhances anti-PD-1 therapy efficacy via diminishing PD-L1 and promoting CD8+ T cell-mediated ferroptosis in castration-resistant prostate cancer.	Acta pharmaceutica Sinica. B	2022	-14.874548371390244	13.18332513350988	21	4.63
35256589	Heterogeneity induced GZMA-F2R communication inefficient impairs antitumor immunotherapy of PD-1 mAb through JAK2/STAT1 signal suppression in hepatocellular carcinoma.	Cell death & disease	2022	-11.09180368782768	44.30099299426728	9	2.17
35256551	Preoperative immunotherapy for head and neck cancers: state of art.	Current opinion in oncology	2022	54.46866662797953	31.93568553994108	6	1.47
35255355	Systemic levels of the soluble co-inhibitory immune checkpoints, CTLA-4, LAG-3, PD-1/PD-L1 and TIM-3 are markedly increased in basal cell carcinoma.	Translational oncology	2022	4.580198842878193	24.092865964031567	6	1.63
35254478	Immunosuppressive properties of human PD-1 + , PDL-1 + and CD80 + dendritic cells from lymph nodes aspirates of lung cancer patients.	Cancer immunology, immunotherapy : CII	2022	7.084836496558329	-18.445009271597595	1	
35254416	Characterization of INCB086550: A Potent and Novel Small-Molecule PD-L1 Inhibitor.	Cancer discovery	2022	-38.21583192363977	-38.16853777321758	19	4.48
35253386	Downregulation of PD-L1 and HLA-I in non-small cell lung cancer with ALK fusion.	Thoracic cancer	2022	10.994478350182904	-34.076765817621066	4	
35253011	The Evolving Role of PD-L1 Inhibition in Non-Small Cell Lung Cancer: A Review of Durvalumab and Avelumab.	Cancer medicine journal	2022	42.11678946912762	-31.896168344738733	3	
35252165	CMTM Family Genes Affect Prognosis and Modulate Immunocytes Infiltration in Grade II/III Glioma Patients by Influencing the Tumor Immune Landscape and Activating Associated Immunosuppressing Pathways.	Frontiers in cell and developmental biology	2022	-18.604610507806267	55.51011242689061	3	
35252014	Gut Microbiota: A Promising Milestone in Enhancing the Efficacy of PD1/PD-L1 Blockade Therapy.	Frontiers in oncology	2022	-23.10287115403799	0.585426167172655	5	1.17
35251353	PD-1/PD-L1 blockade, a novel strategy for targeting metastatic colorectal cancer: A systematic review and meta-analysis of randomized trials.	Oncology letters	2022	36.48557813270251	23.21058460119218	0	
35251033	Blockade of the PD-1/PD-L1 Immune Checkpoint Pathway Improves Infection Outcomes and Enhances Fungicidal Host Defense in a Murine Model of Invasive Pulmonary Mucormycosis.	Frontiers in immunology	2022	-69.00283376883391	8.915598613372417	8	2.28
35250546	Is Immune Suppression Involved in the Ischemic Stroke? A Study Based on Computational Biology.	Frontiers in aging neuroscience	2022	-12.724640360719194	55.1209965448414	8	2.3
35249433	Current and emerging role of sacituzumab govitecan in the management of urothelial carcinoma.	Expert review of anticancer therapy	2022	70.3333542662973	14.846554870674549	2	
35248047	DFNA5 regulates immune cells infiltration and exhaustion.	Cancer cell international	2022	-5.684260118977361	45.10470063002966	8	1.73
35247906	Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial.	Clinical cancer research : an official journal of the American Association for Cancer Research	2022	38.3397186712913	6.931507368171912	19	3.81
35247717	PD-1/PD-L1 inhibitor ameliorates silica-induced pulmonary fibrosis by maintaining systemic immune homeostasis.	Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie	2022	68.02413590837241	-8.088723653076634	10	2.61
35246776	Recombinant human interleukin-7 reverses T cell exhaustion ex vivo in critically ill COVID-19 patients.	Annals of intensive care	2022	-52.9648419498001	42.55478694164754	9	1.83
35246703	The nuclear transportation of PD-L1 and the function in tumor immunity and progression.	Cancer immunology, immunotherapy : CII	2022	-46.89829662114899	-21.99747899189956	3	
35246494	Long Noncoding RNA lncNDEPD1 Regulates PD-1 Expression via miR-3619-5p in CD8+ T Cells.	Journal of immunology (Baltimore, Md. : 1950)	2022	-35.323674468331106	42.22627104791575	2	
35246475	In PD-1+ human colon cancer cells NIVOLUMAB promotes survival and could protect tumor cells from conventional therapies.	Journal for immunotherapy of cancer	2022	33.141684451925066	23.12942678209094	11	2.39
35242761	CD93 Correlates With Immune Infiltration and Impacts Patient Immunotherapy Efficacy: A Pan-Cancer Analysis.	Frontiers in cell and developmental biology	2022	3.126171323777076	26.944269231588	6	1.58
35242475	Pembrolizumab-Induced Immune-Mediated Glossitis.	Cureus	2022	71.91525548096554	-22.40994043646907	2	
35242133	Case Report: Durable Complete Response After Combined Immunotherapy Following Resection of Primary Tumor in a Gallbladder Cancer Patient With Distant Metastatic Lymph Nodes of Favorable Immune-Microenvironment.	Frontiers in immunology	2022	52.236058864621846	22.286855868600824	1	
35242027	Identification of lncRNA Signature of Tumor-Infiltrating T Lymphocytes With Potential Implications for Prognosis and Chemotherapy of Head and Neck Squamous Cell Carcinoma.	Frontiers in pharmacology	2021	-4.453334509133637	53.01728401492801	5	1.36
35240902	Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer.	Expert opinion on investigational drugs	2022	38.373525534321885	8.503210225411783	15	3.15
35238899	Immune Checkpoint Inhibitors and Risk of Type 1 Diabetes.	Diabetes care	2022	87.1464497332224	-13.451020349508523	15	3.85
35238073	PD-L1 and PD-1 expression in thyroid follicular epithelial dysplasia: Hashimoto thyroiditis related atypia and potential papillary carcinoma precursor.	APMIS : acta pathologica, microbiologica, et immunologica Scandinavica	2022	-7.350044664385525	-21.05477061284848	3	
35237322	Meloxicam Inhibits Hepatocellular Carcinoma Progression and Enhances the Sensitivity of Immunotherapy via the MicroRNA-200/PD-L1 Pathway.	Journal of oncology	2022	27.090473360326445	52.15267604889669	1	
35236415	Targeting PD-1/PD-L1 pathway in myelodysplastic syndromes and acute myeloid leukemia.	Experimental hematology & oncology	2022	-35.42724390225686	12.306800802806222	19	4.81
35235931	Expression of Programmed Cell Death-1 and Programmed Cell Death Ligands in Nodal Peripheral T-Cell Lymphoma: Expression Pattern and Potential Prognostic Relevance.	Acta haematologica	2022	-34.062564397006774	22.25858036703748	0	
35235473	Emerging drugs for the treatment of cutaneous T-cell lymphoma.	Expert opinion on emerging drugs	2022	42.98308612367483	-53.81075009021628	2	
35232680	Immune checkpoints inhibitors in the management of high-risk non-muscle-invasive bladder cancer. A scoping review.	Urologic oncology	2022	71.58312766336077	22.64834619707296	4	
35232247	Immunotherapy-based combination strategies for treatment of EGFR-TKI-resistant non-small-cell lung cancer.	Future oncology (London, England)	2022	38.454123002383575	-38.180041239970265	9	2.1
35231913	Efficacy and Safety of PD-1 Immune Checkpoint Inhibitors in Locally Advanced and Advanced Non-Small-Cell Lung Cancer Patients with Chronic Infection.	Oncology research and treatment	2022	51.40221858672618	-18.2865326748428	2	
35228677	Biomarkers of response to PD-1 pathway blockade.	British journal of cancer	2022	19.96904773961831	-2.730083849612539	25	5.02
35228614	PD-1 blockade enhances chemotherapy toxicity in oesophageal adenocarcinoma.	Scientific reports	2022	21.925236042169733	21.55010847389256	4	
35228265	Immune checkpoint silencing using RNAi-incorporated nanoparticles enhances antitumor immunity and therapeutic efficacy compared with antibody-based approaches.	Journal for immunotherapy of cancer	2022	-34.5458454220754	-51.08935758644871	5	1.29
35227680	Immune Contexture and Differentiation Features Predict Outcome in Bladder Cancer.	European urology oncology	2022	5.429187607080515	58.84810275388672	8	1.43
37383538	The effects of immune checkpoint modulators on the clinical course of patients with resectable hepatocellular carcinoma.	Journal of liver cancer	2022	-13.90213913137864	46.27217965022482	0	
35225873	Diagnostic Performance of PD-L1 versus PD-1 Expression in Circulating CD20 Cells in Diffuse Large B-Cell Lymphoma.	Antibodies (Basel, Switzerland)	2022	-35.17168420510212	27.035945355870243	1	
35225458	Frequency of Expression of PD-1 and PD-L1 In Head And Neck Squamous Cell Carcinoma And their Association With Nodal Metastasis: A Cross-Sectional Study.	Asian Pacific journal of cancer prevention : APJCP	2022	-5.971500700276022	-8.72662285629443	0	
35224979	Candida auris Bloodstream Infection Induces Upregulation of the PD-1/PD-L1 Immune Checkpoint Pathway in an Immunocompetent Mouse Model.	mSphere	2022	-61.63894509547956	37.71910974583296	6	1.91
35224963	[Dual Immunotherapy in Advanced Non-small Cell Lung Cancer:  the Progress and Clinical Application].	Zhongguo fei ai za zhi = Chinese journal of lung cancer	2022	35.24001967076455	-30.17040288248439	1	
35224310	Exosomal PD-L1 induces osteogenic differentiation and promotes fracture healing by acting as an immunosuppressant.	Bioactive materials	2022	-45.18563564530555	-60.65243608742789	22	3.09
35223501	Elevated Levels of Soluble CTLA-4, PD-1, PD-L1, LAG-3 and TIM-3 and Systemic Inflammatory Stress as Potential Contributors to Immune Suppression and Generalized Tumorigenesis in a Cohort of South African Xeroderma Pigmentosum Patients.	Frontiers in oncology	2022	4.882599503791855	23.986507872612773	2	
35223454	Immune Checkpoint and Telomerase Crosstalk Is Mediated by miRNA-138 in Bladder Cancer.	Frontiers in oncology	2021	6.900716485127471	57.41487232081265	2	
35222440	Case Report: A Peculiar Case of Inflammatory Colitis After SARS-CoV-2 Infection.	Frontiers in immunology	2022	-59.94375570097052	20.843876265159192	4	
35222387	Combined Consideration of Tumor-Associated Immune Cell Density and Immune Checkpoint Expression in the Peritumoral Microenvironment for Prognostic Stratification of Non-Small-Cell Lung Cancer Patients.	Frontiers in immunology	2022	10.79287974647683	-15.908661893929906	2	
35220300	Programmed Cell Death Protein 1 Blockade Elicits Ongoing Remission in 2 Cases of Refractory Epstein-Barr Virus-Associated Metastatic Gastric Carcinoma.	Oncology research and treatment	2022	45.44731980905183	14.366480432782108	2	
35220229	Programmed Cell Death Ligand-1 (PDL-1) Correlates With Tumor Infiltration by Immune Cells and Represents a Promising Target for Immunotherapy in Endometrial Cancer.	Anticancer research	2022	-18.220962809435505	9.50379702564778	3	
35217706	In vitro and in vivo functions of T cells produced in complemented thymi of chimeric mice generated by blastocyst complementation.	Scientific reports	2022	-45.988935121254926	4.024449135206153	3	
35217573	Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma.	Journal for immunotherapy of cancer	2022	22.765302232922465	-13.688060650166994	22	4.27
35211760	High farnesoid X receptor expression predicts favorable clinical outcomes in PD‑L1low/negative non‑small cell lung cancer patients receiving anti‑PD‑1‑based chemo‑immunotherapy.	International journal of oncology	2022	14.858633592258618	-29.10394851308973	2	
35210547	TUSC2 immunogene enhances efficacy of chemo-immuno combination on KRAS/LKB1 mutant NSCLC in humanized mouse model.	Communications biology	2022	19.783694399657964	-23.265069325854803	4	
35210305	Insufficiency of compound immune checkpoint blockade to overcome engineered T cell exhaustion in pancreatic cancer.	Journal for immunotherapy of cancer	2022	-48.33731780663872	1.0920752744685305	5	1.04
35210298	Dynamic Tumor-Specific MHC-II Immuno-PET Predicts the Efficacy of Checkpoint Inhibitor Immunotherapy in Melanoma.	Journal of nuclear medicine : official publication, Society of Nuclear Medicine	2022	6.3842479480199605	-4.449339975004295	0	
35209909	Predictive role of ferroptosis-related long non-coding RNAs in bladder cancer and their association with immune microenvironment and immunotherapy response.	World journal of surgical oncology	2022	-3.669957792446492	52.29919067909364	4	
35207516	Landscape of Immunotherapy Options for Colorectal Cancer: Current Knowledge and Future Perspectives beyond Immune Checkpoint Blockade.	Life (Basel, Switzerland)	2022	37.12238212093207	20.12062909243236	12	2.78
35205802	The New Era of Immunotherapy in Gastric Cancer.	Cancers	2022	43.062071301029256	15.450566414537333	47	11.87
35205789	Tumor Cell-Autonomous Pro-Metastatic Activities of PD-L1 in Human Breast Cancer Are Mediated by PD-L1-S283 and Chemokine Axes.	Cancers	2022	-35.43009350878689	-5.702085348164316	7	1.66
35205752	VISTA in Soft Tissue Sarcomas: A Perspective for Immunotherapy?	Cancers	2022	-38.95253239382564	37.70668811490273	2	
35204793	Evaluation of PD-L1 Expression in Undifferentiated Pleomorphic Sarcomas, Liposarcomas and Chondrosarcomas.	Biomolecules	2022	-20.017360495643924	20.637055024421965	5	1.42
35204029	Comparison of Immune Checkpoint Molecules PD-1 and PD-L1 in Paired Primary and Recurrent Glioma: Increasing Trend When Recurrence.	Brain sciences	2022	-23.11976226693066	51.28891441138443	0	
35203620	Immune-Checkpoint Inhibitors in Advanced Bladder Cancer: Seize the Day.	Biomedicines	2022	68.42088067806358	22.473983611634694	7	1.57
35203450	Differential Expression of Genes Involved in Metabolism and Immune Response in Diffuse and Intestinal Gastric Cancers, a Pilot Ptudy.	Biomedicines	2022	-13.000865736491363	24.51778857745629	0	
35203446	What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review (Part 6): Correlation of PD-L1 Expression with the Status of Mismatch Repair System, BRCA, PTEN, and Other Genes.	Biomedicines	2022	-13.493228282275812	14.413925603699033	8	1.91
35203032	Ag nanoparticles enhance immune checkpoint blockade efficacy by promoting of immune surveillance in melanoma.	Journal of colloid and interface science	2022	-30.3773683999223	-47.21729745274463	10	3.07
35202544	Investigation of Unprecedented Sites and Proposition of New Ligands for Programmed Cell Death Protein I through Molecular Dynamics with Probes and Virtual Screening.	Journal of chemical information and modeling	2022	-46.90492662353007	-39.113376850966624	2	
35199960	Anti-PD1 or anti-PD-L1 antibodies alone or in combination with chemotherapy first-line treatment of advanced non-small cell lung cancer.	Thoracic cancer	2022	41.17414378293721	-29.78266204304294	1	
35198440	ARID1A Downregulation Predicts High PD-L1 Expression and Worse Clinical Outcome in Patients With Gallbladder Cancer.	Frontiers in oncology	2022	-1.6039396401729549	7.586009006105517	1	
35195152	Immunoexpression of PD-L1, CD4+ and CD8+ cell infiltrates and tumor-infiltrating lymphocytes (TILs) in the microenvironment of actinic cheilitis and lower lip squamous cell carcinoma.	Journal of applied oral science : revista FOB	2022	-4.975190618003118	-13.593430070142851	1	
35194801	Expression of immune checkpoint molecules programmed death protein 1, programmed death-ligand 1 and inducible T-cell co-stimulator in mycosis fungoides and Sézary syndrome: association with disease stage and clinical outcome.	The British journal of dermatology	2022	-32.10095962864918	16.258888810116982	7	1.97
35193933	ISA101 and nivolumab for HPV-16+ cancer: updated clinical efficacy and immune correlates of response.	Journal for immunotherapy of cancer	2022	41.08096258430462	-2.7162263605489456	30	7.43
35193932	Toripalimab plus axitinib in patients with metastatic mucosal melanoma: 3-year survival update and biomarker analysis.	Journal for immunotherapy of cancer	2022	57.12432057047192	-4.576188455859868	10	2.12
35192932	A systematic review and meta-analysis of trials assessing PD-1/PD-L1 immune checkpoint inhibitors activity in pre-treated advanced stage malignant mesothelioma.	Critical reviews in oncology/hematology	2022	42.84881954895087	-13.03024610888088	10	2.15
35192053	Interim analysis of the efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy (nab-paclitaxel and carboplatin) in potentially resectable stage IIIA/IIIB non-small cell lung cancer: a single-arm, phase 2 trial.	Journal of cancer research and clinical oncology	2023	33.02202066528331	-19.06609904496523	6	
35190830	Diurnal Expression of PD-1 on Tumor-Associated Macrophages Underlies the Dosing Time-Dependent Antitumor Effects of the PD-1/PD-L1 Inhibitor BMS-1 in B16/BL6 Melanoma-Bearing Mice.	Molecular cancer research : MCR	2022	-32.1622911774646	-6.407393367075817	10	2.07
35190718	Catch and release: freeing up PD-L1 ameliorates autoimmunity.	Nature immunology	2022	-49.106930224133855	-3.4997930859042	2	
35189471	Effect of immunotherapy on the immune microenvironment in advanced recurrent cervical cancer.	International immunopharmacology	2022	-4.037169723202092	35.952773167619895	5	1.2
35188817	Gastric Carcinoma with Lymphoid Stroma: A Combination of Mismatch Repair Deficient Medullary Type and Epstein-Barr Virus-associated Gastric Carcinomas.	International journal of surgical pathology	2022	-12.95438084312874	22.33443114515285	3	
35187044	CD44-Mediated Poor Prognosis in Glioma Is Associated With M2-Polarization of Tumor-Associated Macrophages and Immunosuppression.	Frontiers in surgery	2021	-21.75151818544953	55.61293130186927	12	2.91
35184226	Cellular and soluble immune checkpoint signaling forms PD-L1 and PD-1 in renal tumor tissue and in blood.	Cancer immunology, immunotherapy : CII	2022	15.776120480341955	25.769618075558245	1	
35182927	Evaluating management of progressive disease for control arm patients in trials of first line PD-1 or PD-L1 inhibitor-based treatment for metastatic solid tumours.	European journal of cancer (Oxford, England : 1990)	2022	54.206566259236574	-13.571730401133584	0	
35181792	Loss of LRRC33-Dependent TGFβ1 Activation Enhances Antitumor Immunity and Checkpoint Blockade Therapy.	Cancer immunology research	2022	-27.872117782558743	-3.4220668618567247	5	1.09
35181605	D-mannose facilitates immunotherapy and radiotherapy of triple-negative breast cancer via degradation of PD-L1.	Proceedings of the National Academy of Sciences of the United States of America	2022	-33.25717438416483	-31.964206845543384	35	8.62
35181584	Expression of DNA Mismatch Repair Proteins, PD1 and PDL1 in Barrett's Neoplasia.	Cancer genomics & proteomics	2022	13.2841502123252	44.817959103352536	0	
35181583	Mapping Proteome Changes in Microsatellite Stable, Recurrent Colon Cancer Reveals a Significant Immune System Signature.	Cancer genomics & proteomics	2022	9.68798990340327	42.37690849295604	0	
35177112	RelB upregulates PD-L1 and exacerbates prostate cancer immune evasion.	Journal of experimental & clinical cancer research : CR	2022	-30.544404705687217	-7.011962848801413	10	2.52
35176979	Cancer Immunotherapy: An Overview of Small Molecules as Inhibitors of the Immune Checkpoint PD-1/PD-L1 (2015-2021).	Mini reviews in medicinal chemistry	2022	-40.78843548569616	-36.55846950081434	3	
35176955	Immune checkpoint inhibitors for recurrent endometrial cancer.	Expert review of anticancer therapy	2022	40.10133751234921	34.638443195869506	6	1.22
37396527	Emerging role of ubiquitination/deubiquitination modification of PD-1/PD-L1 in cancer immunotherapy.	Genes & diseases	2023	-19.05380081072056	-7.087400712262643	1	
35175500	Cabozantinib plus Nivolumab: A Review in Advanced Renal Cell Carcinoma.	Targeted oncology	2022	65.41710373623081	30.85994085011413	1	
35174180	Preclinical Pharmacokinetics and Dosimetry of an 89Zr Labelled Anti-PDL1 in an Orthotopic Lung Cancer Murine Model.	Frontiers in medicine	2021	7.376607864418471	-56.664837978042144	2	
35173719	Case Report: Sarcoid-Like Reactions and Tertiary Lymphoid Structures Following Dual Checkpoint Inhibition in a Patient with Early-Stage Lung Adenocarcinoma.	Frontiers in immunology	2022	60.380321330981786	-30.88927330170265	2	
35169085	[Evolving Exploration of the Pathogenesis of CNS Germ Cell Tumors with Regard to Precision Medicine].	No shinkei geka. Neurological surgery	2022	-19.025512776594724	61.284934807047655	1	
35168438	A look towards the clonal origin of metastatic pulmonary carcinosarcoma: Report of a patient with an unexpected long-term survival.	Tumori	2022	15.993777720890606	-19.671050061818185	0	
35168061	Molecular basis of PD-1 blockade by dostarlimab, the FDA-approved antibody for cancer immunotherapy.	Biochemical and biophysical research communications	2022	-22.264038466077164	-40.97832153215575	11	2.39
35165868	Monoclonal Antibodies to CTLA-4 with Focus on Ipilimumab.	Experientia supplementum (2012)	2022	28.722626508009647	6.015381000461326	3	
35164813	Blockade of novel immune checkpoints and new therapeutic combinations to boost antitumor immunity.	Journal of experimental & clinical cancer research : CR	2022	27.65266996601856	13.987428926594212	23	5.39
35164673	Programmed death-ligand 1 signaling and expression are reversible by lycopene via PI3K/AKT and Raf/MEK/ERK pathways in tongue squamous cell carcinoma.	Genes & nutrition	2022	-29.080215164176288	-34.07588126734252	4	
35163542	PD-L1 Expression in Monocytes Correlates with Bacterial Burden and Treatment Outcomes in Active Pulmonary Tuberculosis.	International journal of molecular sciences	2022	-85.5390581551184	1.7516888551053054	2	
35163049	Epigenetic Modification of PD-1/PD-L1-Mediated Cancer Immunotherapy against Melanoma.	International journal of molecular sciences	2022	-8.065247116365358	-31.25119030926	4	
35159059	Oral Immune-Related Adverse Events Caused by Immune Checkpoint Inhibitors: Salivary Gland Dysfunction and Mucosal Diseases.	Cancers	2022	84.15569477599804	-9.018582698462671	3	
35158952	Low-Dose Nivolumab with or without Ipilimumab as Adjuvant Therapy Following the Resection of Melanoma Metastases: A Sequential Dual Cohort Phase II Clinical Trial.	Cancers	2022	37.69974321579637	1.9831951358934552	5	1.08
35158883	Immune Microenvironment Characteristics of Urachal Carcinoma and Its Implications for Prognosis and Immunotherapy.	Cancers	2022	6.999710702967445	61.83735094454394	4	
35158865	Recent Advances in the Diagnosis and Treatment of Natural Killer Cell Malignancies.	Cancers	2022	38.62245699899648	28.646200569987005	4	
35158783	Chemokine Receptor-Targeted Therapies: Special Case for CCR8.	Cancers	2022	18.799390454684776	10.692458730028406	7	1.71
35158779	Evolution and Targeting of Myeloid Suppressor Cells in Cancer: A Translational Perspective.	Cancers	2022	18.16400311164758	10.558497487706108	4	
35158748	The Clinical, Pathological, and Prognostic Value of High PD-1 Expression and the Presence of Epstein-Barr Virus Reactivation in Patients with Laryngeal Cancer.	Cancers	2022	-7.817921729634661	-1.1454150156565577	0	
35154907	Accumulation of dysfunctional tumor-infiltrating PD-1+ DCs links PD-1/PD-L1 blockade immunotherapeutic response in cervical cancer.	Oncoimmunology	2022	-30.14893226554156	-13.684964124930804	9	2.11
35154905	Functional and molecular characterization of PD1+ tumor-infiltrating lymphocytes from lung cancer patients.	Oncoimmunology	2022	-12.730363559259503	28.212207849367164	4	
35154469	LncRNA AC099850.3 promotes hepatocellular carcinoma proliferation and invasion through PRR11/PI3K/AKT axis and is associated with patients prognosis.	Journal of Cancer	2022	-7.20024707760096	52.69979254269735	22	5.54
35154166	Decreased Expression of Programmed Death Ligand-L1 by Seven in Absentia Homolog 2 in Cholangiocarcinoma Enhances T-Cell-Mediated Antitumor Activity.	Frontiers in immunology	2022	-31.073263471686776	41.41218498453423	13	2.68
35153753	Case Report: Successful Avatrombopag Treatment for Two Cases of Anti-PD-1 Antibody-Induced Acquired Amegakaryocytic Thrombocytopenia.	Frontiers in pharmacology	2021	72.00983786404305	-13.956634273032805	2	
35151947	Identification and characterization of three Siglec15-related immune and prognostic subtypes of breast-invasive cancer.	International immunopharmacology	2022	-4.803838684909368	27.800844923332527	4	
35150786	Dynamics of Circulating Immune Cells During Chemoradiotherapy in Patients with Non-Small Cell Lung Cancer Support Earlier Administration of Anti-PD-1/PD-L1 Therapy.	International journal of radiation oncology, biology, physics	2022	15.544891907145264	-23.78657305685861	5	1.14
35148413	Ferroptosis, as the most enriched programmed cell death process in glioma, induces immunosuppression and immunotherapy resistance.	Neuro-oncology	2022	-4.894211460777927	50.11971839132972	36	8.46
35147894	First-Line Treatment of Advanced Non-Small-Cell Lung Cancer with Immune-Checkpoint Inhibitors: New Combinations and Long-Term Data.	BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy	2022	39.116040162594985	-22.37784872443043	5	1.03
35147355	[Immunotherapy in oncology].	La Revue du praticien	2021	21.936093425796948	2.4753366431501846	0	0.0
35146396	PD-L1+CD8+ T cells enrichment in lung cancer exerted regulatory function and tumor-promoting tolerance.	iScience	2022	4.851527243433532	-21.598083725280564	9	1.76
35146104	Understanding the impact of chemotherapy on the immune landscape of high-grade serous ovarian cancer.	Gynecologic oncology reports	2022	0.3732475604065071	29.004466309694894	7	1.68
35145965	Ferroptosis Mediation Patterns Reveal Novel Tool to Implicate Immunotherapy and Multi-Omics Characteristics in Bladder Cancer.	Frontiers in cell and developmental biology	2022	-3.8390535524388447	51.31740298255079	4	
35145517	Histone Acetylation Regulator-Mediated Acetylation Patterns Define Tumor Malignant Pathways and Tumor Microenvironment in Hepatocellular Carcinoma.	Frontiers in immunology	2022	-13.06871993941033	49.31258513818207	12	2.65
35145510	Coexpression of HHLA2 and PD-L1 on Tumor Cells Independently Predicts the Survival of Spinal Chordoma Patients.	Frontiers in immunology	2021	-17.750857421358084	27.11317033561749	6	1.38
35145482	Metabolic and Nutritional Disorders Following the Administration of Immune Checkpoint Inhibitors: A Pharmacovigilance Study.	Frontiers in endocrinology	2021	73.94584959358617	-6.962596229633272	0	
35145298	PD-1 agonism by anti-CD80 inhibits T cell activation and alleviates autoimmunity.	Nature immunology	2022	-49.01207460887971	-3.3595030782888484	21	4.43
35145164	Tissue miR-200c-3p and circulating miR-1290 as potential prognostic biomarkers for colorectal cancer.	Scientific reports	2022	0.3045102491796932	40.10046542553822	7	1.95
35144055	Addition of immune checkpoint inhibitors to chemotherapy versus chemotherapy alone in first-line metastatic triple-negative breast cancer: A systematic review and meta-analysis.	Cancer treatment reviews	2022	41.70845765410575	10.96920785354722	10	2.18
35143542	Retrospective analysis of clinical trial safety data for pembrolizumab reveals the effect of co-occurring infections on immune-related adverse events.	PloS one	2022	73.09625727338035	-16.086819207394687	2	
35142593	Cilengitide, an αvβ3-integrin inhibitor, enhances the efficacy of anti-programmed cell death-1 therapy in a murine melanoma model.	Bioengineered	2022	-25.998019466049296	-31.70758723773076	4	
35141280	Immune Response on Optimal Timing and Fractionation Dose for Hypofractionated Radiotherapy in Non-Small-Cell Lung Cancer.	Frontiers in molecular biosciences	2022	29.6897593494632	23.644250955779697	3	
35141051	T cell-mediated elimination of cancer cells by blocking CEACAM6-CEACAM1 interaction.	Oncoimmunology	2022	-12.990848735191532	-41.91247120281773	9	0.94
35140722	Expression Profiles and Prognostic Value of Multiple Inhibitory Checkpoints in Head and Neck Lymphoepithelioma-Like Carcinoma.	Frontiers in immunology	2022	-4.127004941055052	-4.925097589316627	1	
35140716	Regulating Histone Deacetylase Signaling Pathways of Myeloid-Derived Suppressor Cells Enhanced T Cell-Based Immunotherapy.	Frontiers in immunology	2022	-10.434838581591098	-31.662177928091797	17	3.97
35140113	Single-cell transcriptome analysis revealed a suppressive tumor immune microenvironment in EGFR mutant lung adenocarcinoma.	Journal for immunotherapy of cancer	2022	16.50666885324904	-16.91356896913593	40	7.9
35137343	Diagnostic Utility of the PD-L1 Immunostaining in Biopsy Specimens of Patients with Biliary Tract Neoplasms.	Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract	2022	-1.3897100487409089	5.457880346488445	0	
35135866	Next steps for clinical translation of adenosine pathway inhibition in cancer immunotherapy.	Journal for immunotherapy of cancer	2022	-4.758526387032114	-49.80259375261255	32	7.55
35135580	PD-L1 signaling in reactive astrocytes counteracts neuroinflammation and ameliorates neuronal damage after traumatic brain injury.	Journal of neuroinflammation	2022	-76.19209068237797	-5.244403325922466	12	3.23
35133214	Pericardial effusion with pembrolizumab.	Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners	2022	69.90469472322576	-18.67478035217457	1	
35132224	Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics.	Nature reviews. Clinical oncology	2022	-39.32271577210754	-35.275415262128824	92	19.45
35131864	CD8+PD-1+ to CD4+PD-1+ ratio (PERLS) is associated with prognosis of patients with advanced NSCLC treated with PD-(L)1 blockers.	Journal for immunotherapy of cancer	2022	8.253704115332692	-19.46986019482108	10	1.97
35131863	Soluble PD-L1 as an early marker of progressive disease on nivolumab.	Journal for immunotherapy of cancer	2022	8.409687578114898	6.818531709332182	26	5.15
35131574	Hypothesis for the development of immune-related adverse events in immune checkpoint inhibitors therapy.	Cancer treatment and research communications	2022	78.16184816059778	-10.651225554567445	0	
35130363	Serial changes in two immune checkpoint receptors and ligands, Tim-3/Gal-9 and PD-1/PD-L1 in peripheral blood prior to miscarriage: Comparison with pregnancies resulting in a live birth.	American journal of reproductive immunology (New York, N.Y. : 1989)	2022	-76.2600601513885	-20.780274303452856	3	
35129371	Frontline anti-PD-1/PD-L1 versus bevacizumab in advanced non-small-cell lung cancer: a network meta-analysis.	Future oncology (London, England)	2022	50.7645453513312	-23.836066728955583	3	
35128931	Toxic epidermal necrolysis associated with chemoimmunotherapy for lymphoma: case report and literature review.	Immunotherapy	2022	75.68297751972676	-26.328880327259316	4	
35128628	Soluble Programmed Death-Ligand 1 (sPD-L1) is Elevated in Aggressive Prostate Cancer Disease Among African Men.	Oncology and therapy	2022	-12.495254541010429	13.616632283224597	1	
35127482	Primary Thyroid NUT Carcinoma With High PD-L1 Expression and Novel Massive IGKV Gene Fusions: A Case Report With Treatment Implications and Literature Review.	Frontiers in oncology	2021	5.829570614978353	-16.5088987955768	6	1.74
35126664	A Review on the Application of PD-1 Blockade in EBV-Associated Nasopharyngeal Carcinoma Immunotherapy.	Applied bionics and biomechanics	2022	41.71786055934897	27.941246488847373	3	
35125995	PD1/PD-L1 pathway in psoriasis and psoriatic arthritis: a review.	Postepy dermatologii i alergologii	2021	-58.34844204663336	-18.318245958942008	4	0.53
35124851	Immune checkpoint upregulation in periprosthetic joint infection.	Journal of orthopaedic research : official publication of the Orthopaedic Research Society	2022	-19.38958203679044	18.238414760499044	3	
35122292	Clinicopathological analysis of immunohistochemical expression of immune checkpoint molecules in follicular lymphoma.	Hematological oncology	2022	-22.523305697739417	29.987443438490512	0	
35120895	Myricetin inhibits interferon-γ-induced PD-L1 and IDO1 expression in lung cancer cells.	Biochemical pharmacology	2022	-17.11062189559586	-30.833129466703216	13	3.23
35120032	Lichen Planus Pemphigoides Associated With PD-1 and PD-L1 Inhibitors: A Case Series and Review of the Literature.	The American Journal of dermatopathology	2022	70.81441951089087	-25.620865462873663	10	3.27
35119931	Loss of TSC1/TSC2 sensitizes immune checkpoint blockade in non-small cell lung cancer.	Science advances	2022	20.07050164459064	-19.81375556163536	7	1.44
35119692	Presence of Tim3+ and PD-1+ CD8+ T cells identifies microsatellite stable colorectal carcinomas with immune exhaustion and distinct clinicopathological features.	The Journal of pathology	2022	6.993166812765259	39.225131607450464	5	0.98
35118423	Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression.	Nature cancer	2021	4.570227369669162	32.31849408405815	95	8.31
35117990	Overexpression of PD-L1 is an Independent Predictor for Recurrence in HCC Patients Who Receive Sorafenib Treatment After Surgical Resection.	Frontiers in oncology	2021	-21.757799705921546	41.2675301064527	5	1.04
35116672	Bioinformatics analysis for the biomarkers of the tumor-infiltrating lymphocytes in head and neck squamous cell carcinoma.	Translational cancer research	2021	-9.45918247156249	32.778271191317714	2	0.17
35116571	Combinations of immunotherapy and radiation therapy in head and neck squamous cell carcinoma: a narrative review.	Translational cancer research	2021	51.0314482821276	33.27230520818824	3	0.3
35116547	PD-L1 combined with HDAC9 is a useful prognostic predictor in hepatocellular carcinoma.	Translational cancer research	2021	-22.271469705111468	41.54957506772936	2	0.29
35116258	KCTD12 is a prognostic marker of breast cancer and correlates with tumor immune cell infiltration.	Translational cancer research	2021	-2.35021762032852	45.07543968773078	1	0.11
35116193	Identification and validation of an epithelial mesenchymal transition-related gene pairs signature for prediction of overall survival in patients with skin cutaneous melanoma.	PeerJ	2022	-1.9781188014324904	49.47724358314374	1	
35115949	A FAK Inhibitor Boosts Anti-PD1 Immunotherapy in a Hepatocellular Carcinoma Mouse Model.	Frontiers in pharmacology	2021	26.209439391819508	50.75247982932998	3	
35115705	Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer.	Nature medicine	2022	24.075752556249405	41.23165964710876	127	28.41
35111894	Non-gestational choriocarcinoma with hyperprogression on pembrolizumab: A case report and review of the literature.	Gynecologic oncology reports	2022	57.63385094652741	-34.13702406999397	3	
35111680	Prospects of Immunotherapy for Triple-Negative Breast Cancer.	Frontiers in oncology	2021	38.720095603457125	9.236808250103923	10	2.55
35111244	Association of PD-L1 and ZEB-1 expression patterns with clinicopathological characteristics and prognosis in oral squamous cell carcinoma.	Oncology letters	2022	-8.840006584761948	-10.838144680724682	2	
35111150	PRMT5 Inhibition Promotes PD-L1 Expression and Immuno-Resistance in Lung Cancer.	Frontiers in immunology	2021	-19.768438462596063	-2.8494926088982635	9	1.96
35107396	Adverse cutaneous toxicities by PD-1/PD-L1 immune checkpoint inhibitors: pathogenesis, treatment, and surveillance.	Cutaneous and ocular toxicology	2022	73.02958422251726	-24.309904941461127	16	4.79
35106596	Measurement of soluble PD-1 and soluble PD-L1 as well as PD-L1 and PD-1 from perioperative patients with gastric carcinoma.	Japanese journal of clinical oncology	2022	-9.20939217669943	4.280130320318144	4	
35105171	Developing an immune signature for triple-negative breast cancer to predict prognosis and immune checkpoint inhibitor response.	Future oncology (London, England)	2022	1.4177143248436408	45.16426722186916	3	
35104808	A forced marriage of IL-2 and PD-1 antibody nurtures tumor-infiltrating T cells.	The Journal of clinical investigation	2022	-26.598027279222148	-17.800463249051596	1	
35104594	Research progress of tumor targeted drug delivery based on PD-1/PD-L1.	International journal of pharmaceutics	2022	-37.62463591196798	-19.82780538829394	9	2.3
35101883	Continuation of Pembrolizumab with Additional Chemotherapy after Progression with PD-1/PD-L1 Inhibitor Monotherapy in Patients with Advanced NSCLC: A Randomized, Placebo-Controlled Phase II Study.	Clinical cancer research : an official journal of the American Association for Cancer Research	2022	48.23283583249682	-29.87572261600461	4	
35101349	Immune-related adverse events in various organs caused by immune checkpoint inhibitors.	Allergology international : official journal of the Japanese Society of Allergology	2022	80.21271814400964	-10.124516373454885	23	5.6
35096916	Molecular Characterization and Clinical Relevance of ALDH2 in Human Cancers.	Frontiers in medicine	2021	-15.23729519599435	50.25087107167453	1	
35096582	Recurrent Gallbladder Carcinoma With pMMR/MSS Achieved a Complete Response Following Camrelizumab Combined With Apatinib: A Case Report.	Frontiers in oncology	2021	52.37041144001353	22.08276031885157	1	
35096571	Case Report: Favorable Response and Manageable Toxicity to the Combination of Camrelizumab, Oxaliplatin, and Oral S-1 in a Patient With Advanced Epstein-Barr Virus-Associated Gastric Cancer.	Frontiers in oncology	2021	46.10108013270751	13.277004397794087	3	
35096146	Cost-effectiveness of enfortumab vedotin in previously treated advanced urothelial carcinoma.	Therapeutic advances in medical oncology	2022	68.55590447949712	12.37489299926683	4	
35095930	Dosimetric Risk Factors for Acute Radiation Pneumonitis in Patients With Prior Receipt of Immune Checkpoint Inhibitors.	Frontiers in immunology	2021	65.07389261328902	-7.632230216123212	3	
35095878	Neoadjuvant PD-1 Blockade Combined With Chemotherapy Followed by Concurrent Immunoradiotherapy in Locally Advanced Anal Canal Squamous Cell Carcinoma Patients: Antitumor Efficacy, Safety and Biomarker Analysis.	Frontiers in immunology	2021	56.45277110379932	10.679210892922487	2	
35094638	ADAM metallopeptidase domain 12 overexpression correlates with prognosis and immune cell infiltration in clear cell renal cell carcinoma.	Bioengineered	2022	17.11201935121422	35.064904951336665	5	1.36
35094125	Immune escape mechanism behind resistance to anti-PD-1 therapy in gastrointestinal tract metastasis in malignant melanoma patients with multiple metastases.	Cancer immunology, immunotherapy : CII	2022	-24.450056367367267	-1.7101439633198865	5	1.12
35093898	Treatment Efficacy of PD-1 Inhibitor Therapy in Patients With Recurrent and/or Metastatic Salivary Gland Carcinoma.	Anticancer research	2022	60.4739553235274	0.4930987632272746	1	
35093742	Efficacy and activity of PD-1 blockade in patients with advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis with focus on the value of PD-L1 combined positive score.	ESMO open	2022	52.298973609322005	14.417421774696376	24	5.06
35093688	High expression of CD28 enhanced the anti-cancer effect of siRNA-PD-1 through prompting the immune response of melanoma-bearing mice.	International immunopharmacology	2022	-31.21939705520024	-16.1969366079118	3	
35092506	Balstilimab and other immunotherapy for recurrent and metastatic cervical cancer.	Medical oncology (Northwood, London, England)	2022	44.55308808795706	34.840335593626264	7	1.62
35092481	PD1/PD-L1 immune checkpoint as a potential target for preventing brain tumor progression.	Cancer immunology, immunotherapy : CII	2022	-43.91010142386066	-15.0702455552195	9	1.94
35092391	Induction Immunotherapy Followed by Thoracic Radiation without Chemotherapy in Unresectable Stage III Non-Small Cell Lung Cancer: A Case Series.	Asian Pacific journal of cancer prevention : APJCP	2022	40.23517957671376	-24.83421813302652	1	
35090497	Extracellular vesicle PD-L1 in reshaping tumor immune microenvironment: biological function and potential therapy strategies.	Cell communication and signaling : CCS	2022	-41.919838649212245	-60.28535659398432	19	4.46
35090328	Increased expression of PD-L1 in endometrial cancer stem-like cells is regulated by hypoxia.	Frontiers in bioscience (Landmark edition)	2022	-18.270293665716764	7.519703028796622	4	
35089375	Visualizing dynamic changes in PD-L1 expression in non-small cell lung carcinoma with radiolabeled recombinant human PD-1.	European journal of nuclear medicine and molecular imaging	2022	12.361826111525977	-35.73875776185663	5	1.4
35087563	Development and Validation of a Tumor Mutation Burden-Related Immune Prognostic Signature for Ovarian Cancers.	Frontiers in genetics	2021	5.804030316416913	50.074929054264366	5	1.09
35086457	Human Umbilical Cord Mesenchymal Stem Cells Promote Macrophage PD-L1 Expression and Attenuate Acute Lung Injury in Mice.	Current stem cell research & therapy	2022	-56.338510720258434	24.15943597174346	6	1.5
35085484	ICAM-1-mediated adhesion is a prerequisite for exosome-induced T cell suppression.	Developmental cell	2022	-42.47641132757055	-58.35642590754092	33	7.36
35083874	BRD4-IRF1 axis regulates chemoradiotherapy-induced PD-L1 expression and immune evasion in non-small cell lung cancer.	Clinical and translational medicine	2022	14.428035237816488	-23.459646268140474	10	2.24
35081690	Programmed cell death ligand 1 expression in aggressive pediatric non-Hodgkin lymphomas: frequency, genetic mechanisms, and clinical significance.	Haematologica	2022	-35.415970032120924	24.37618842705341	4	
35075611	Constructing a Novel Signature Based on Immune-Related lncRNA to Improve Prognosis Prediction of Cervical Squamous Cell Carcinoma Patients.	Reproductive sciences (Thousand Oaks, Calif.)	2022	-1.0991625984412352	51.6995666619957	4	
35073733	PIVOT-12: a phase III study of adjuvant bempegaldesleukin plus nivolumab in resected stage III/IV melanoma at high risk for recurrence.	Future oncology (London, England)	2022	37.11796167243688	2.649121552771609	5	1.13
35072571	Durvalumab: an investigational agent for unresectable hepatocellular carcinoma.	Expert opinion on investigational drugs	2022	31.813064042634235	48.14369036461901	6	1.5
35071830	A Phase 2 Trial Combining Pembrolizumab and Palliative Radiation Therapy in Gastroesophageal Cancer to Augment Abscopal Immune Responses.	Advances in radiation oncology	2022	48.44002818008968	7.363057888424986	4	0.42
35069587	PTRF/Cavin-1 as a Novel RNA-Binding Protein Expedites the NF-κB/PD-L1 Axis by Stabilizing lncRNA NEAT1, Contributing to Tumorigenesis and Immune Evasion in Glioblastoma.	Frontiers in immunology	2021	-28.52619795668173	51.51434583248426	13	3.33
35069581	Therapeutic Implications of Tumor Microenvironment in Lung Cancer: Focus on Immune Checkpoint Blockade.	Frontiers in immunology	2021	17.15748706735242	11.784817007728243	54	12.4
35069542	A Practical Strategy for Exploring the Pharmacological Mechanism of Luteolin Against COVID-19/Asthma Comorbidity: Findings of System Pharmacology and Bioinformatics Analysis.	Frontiers in immunology	2021	-50.94932185096384	45.54783433424099	13	3.52
35065582	Monitoring EBV infection, MSI, PDL-1 expression, Her-2/neu amplification as a biomarker for PD-1 inhibition in gastric cancer.	Bratislavske lekarske listy	2022	23.67463164133825	-52.33946452852249	1	
35065344	A whole-slide image (WSI)-based immunohistochemical feature prediction system improves the subtyping of lung cancer.	Lung cancer (Amsterdam, Netherlands)	2022	18.334519924404702	-16.61069957776166	6	1.52
35064455	Tumor microenvironment and its clinicopathological and prognostic associations in surgically resected cutaneous angiosarcoma.	Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico	2022	-19.474101483800798	24.175848106184844	1	
35064011	Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET-a phase I, single-arm study.	Journal for immunotherapy of cancer	2022	44.19956618620491	-0.9617001523620132	89	19.4
35062949	Combination strategies with PD-1/PD-L1 blockade: current advances and future directions.	Molecular cancer	2022	26.83490544153474	-3.429621576079476	204	46.13
35061208	A risk scoring system based on tumor microenvironment cells to predict prognosis and immune activity in triple-negative breast cancer.	Breast cancer (Tokyo, Japan)	2022	0.6726768152387146	46.62836641156568	4	
35060694	A Dual-Channel Intelligent Point-of-Care Testing System for Soluble Programmed Death-1 and Programmed Death-Ligand 1 Detection Based on Folding Paper-Based Immunosensors.	ACS sensors	2022	-43.1367829618277	-52.93706641924037	3	
35060518	A high density of PD-L1-expressing immune cells is significantly correlated with favorable disease free survival in nonmetastatic colorectal cancer.	Medicine	2022	6.830070047727529	35.177745273298754	4	
35060001	Role of CTLA Inhibition in Management of Non-Small Cell Lung Cancer.	Current oncology reports	2022	37.8410709777294	-29.93510313222172	4	
35059863	The combination therapy of Everolimus and anti-PD-1 improves the antitumor effect by regulating CD8+ T cells in bladder cancer.	Medical oncology (Northwood, London, England)	2022	25.991998426790367	27.717094384141884	2	
35059588	PD-1 and PD-L1 Expression in Indian Women with Breast Cancer.	European journal of breast health	2022	-9.980346541585677	16.838001209220977	0	0.0
35058326	Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: results from a phase I/II open-label, multicenter study.	Journal for immunotherapy of cancer	2022	53.60975626607953	-21.68079690031621	16	3.41
35054356	Clinical Relevance of Soluble Forms of Immune Checkpoint Molecules sPD-1, sPD-L1, and sCTLA-4 in the Diagnosis and Prognosis of Ovarian Cancer.	Diagnostics (Basel, Switzerland)	2022	-20.9679420578218	15.591820020610124	3	
35053573	Valganciclovir as Add-On Therapy Modifies the Frequency of NK and NKT Cell Subpopulations in Disseminated Kaposi Sarcoma Patients.	Cancers	2022	-82.69826155635702	17.848480093629526	0	
35053457	Potential Role of CXCL13/CXCR5 Signaling in Immune Checkpoint Inhibitor Treatment in Cancer.	Cancers	2022	29.99147426760327	11.668854620525114	13	2.66
35051754	Reducing number of target lesions for RECIST1.1 to predict survivals in patients with advanced non-small-cell lung cancer undergoing anti-PD1/PD-L1 monotherapy.	Lung cancer (Amsterdam, Netherlands)	2022	23.062902675749203	-47.30851973371175	2	0.23
35051616	LncRNA IFITM4P promotes immune escape by up-regulating PD-L1 via dual mechanism in oral carcinogenesis.	Molecular therapy : the journal of the American Society of Gene Therapy	2022	-10.107247375788011	-13.688743563586916	23	6.06
35049699	Immune-Related Pneumonitis Was Decreased by Addition of Chemotherapy with PD-1/L1 Inhibitors: Systematic Review and Network Meta-Analysis of Randomized Controlled Trials (RCTs).	Current oncology (Toronto, Ont.)	2022	64.92522008190531	-9.036919087702769	0	
35048057	Characterization of Oral Squamous Cell Carcinoma Associated Inflammation: A Pilot Study.	Frontiers in oral health	2021	-7.210008537367314	-14.674235690748729	6	0.95
35048002	Tumor Microenvironment in Oral Cancer Following Neoadjuvant Pembrolizumab: Preliminary Analysis of the Histopathologic Findings.	Frontiers in oral health	2021	-6.079573637776064	-15.258330429129236	1	0.07
35047501	Bridging the Gap: Connecting the Mechanisms of Immune-Related Adverse Events and Autoimmunity Through PD-1.	Frontiers in cell and developmental biology	2021	80.27415014954589	-10.998313977606673	8	1.76
35046943	Spatial Distribution and Predictive Significance of Dendritic Cells and Macrophages in Esophageal Cancer Treated With Combined Chemoradiotherapy and PD-1 Blockade.	Frontiers in immunology	2021	4.076616548982129	20.80808946322198	9	1.72
35044010	Immuno-Engineered Nanodecoys for the Multi-Target Anti-Inflammatory Treatment of Autoimmune Diseases.	Advanced materials (Deerfield Beach, Fla.)	2022	-33.56357908048821	-59.05561286452082	28	6.53
35043369	Analysis of PD-1, PD-L1, and T-cell infiltration in angiosarcoma pathogenetic subgroups.	Immunologic research	2022	-20.293993215313392	23.443950185014103	3	
35042524	Circulating extracellular vesicles expressing PD1 and PD-L1 predict response and mediate resistance to checkpoint inhibitors immunotherapy in metastatic melanoma.	Molecular cancer	2022	1.272266185090032	-40.2817502057613	38	8.99
35042477	N6-Methyladenosine-Related lncRNAs as potential biomarkers for predicting prognoses and immune responses in patients with cervical cancer.	BMC genomic data	2022	-7.058482363705387	56.02504276811956	7	1.68
35042311	Immunohistochemical analysis of PD-L1 and tumor-infiltrating immune cells expression in the tumor microenvironment of primary signet ring cell carcinoma of the prostate.	Asian journal of andrology	2022	-11.12138418035794	12.322564554005742	1	
35039625	TIGIT and PD-1 expression atlas predicts response to adjuvant chemotherapy and PD-L1 blockade in muscle-invasive bladder cancer.	British journal of cancer	2022	6.435508101712054	58.94630244445448	6	1.28
35039334	Control of Memory Phenotype T Lymphocyte Homeostasis: Role of Costimulation.	Journal of immunology (Baltimore, Md. : 1950)	2022	-67.48358576293704	3.2514301642625933	5	1.05
35038934	Cutaneous Stevens Johnson - Toxic Epidermal Necrolysis Immunotherapy related Toxicities in Lung Cancer Patients.	Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners	2022	76.58100095125637	-25.919144544248663	0	
35038432	Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial.	The Lancet. Oncology	2022	51.86199969527939	-22.04232274912126	65	13.94
35037417	PD-L1 and PD-L2 expression in pancreatic ductal adenocarcinoma and their correlation with immune infiltrates and DNA damage response molecules.	The journal of pathology. Clinical research	2022	-4.203575333655083	4.156841929722565	6	1.3
35036121	Development of a T-cell activation-related module with predictive value for the prognosis and immune checkpoint blockade therapy response in glioblastoma.	PeerJ	2021	-22.98668144710795	56.02273097877914	1	0.07
35034561	Squamous cell carcinoma of the lung: improving the detection and management of immune-related adverse events.	Expert review of anticancer therapy	2022	73.59898751014602	-10.087108334980591	1	
35034046	Association of Baseline and Pharmacodynamic Biomarkers With Outcomes in Patients Treated With the PD-1 Inhibitor Budigalimab.	Journal of immunotherapy (Hagerstown, Md. : 1997)	2022	34.24808861196907	-15.491095097158714	3	
35033247	Imaging and quantifying analysis the binding behavior of PD-L1 at molecular resolution by atomic force microscopy.	Analytica chimica acta	2022	-49.421131421655744	-39.2312052952553	4	
35033226	Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial.	The Lancet. Oncology	2022	41.13259760552759	-26.14498603633401	87	19.3
35033066	Immune-related lncRNA classification of head and neck squamous cell carcinoma.	Cancer cell international	2022	-4.774876127797197	53.046773944800094	6	1.35
35032188	Prognostic implication of CTLA-4, PD-1, and PD-L1 expression in aggressive adult T-cell leukemia-lymphoma.	Annals of hematology	2022	-37.5620668300439	19.26143491513372	1	
35030031	PD-1 or PD-L1 Blockade Adds Little to Combination of BRAF and MEK Inhibition in the Treatment of BRAF V600-Mutated Melanoma.	Journal of clinical oncology : official journal of the American Society of Clinical Oncology	2022	31.206688538387475	32.563406073895955	3	
35027673	Genomic features and tumor immune microenvironment alteration in NSCLC treated with neoadjuvant PD-1 blockade.	NPJ precision oncology	2022	30.458164022389088	-20.316466688054565	14	2.81
35026655	NLRP3 promotes immune escape by regulating immune checkpoints: A pan-cancer analysis.	International immunopharmacology	2022	3.158826643575125	27.043858688851085	14	3.53
35024096	miR-4759 suppresses breast cancer through immune checkpoint blockade.	Computational and structural biotechnology journal	2022	-17.714143474054993	1.47309422763586	1	0.1
35023361	Efficacy and safety of PD-1/PD-L1 and CTLA-4 immune checkpoint inhibitors in colorectal cancer: a meta-analysis.	Journal of comparative effectiveness research	2022	35.909950394663554	22.90349390541032	3	
35022270	Long Noncoding RNA HOTAIRM1 Promotes Immunosuppression in Sepsis by Inducing T Cell Exhaustion.	Journal of immunology (Baltimore, Md. : 1950)	2022	-59.16200164017168	32.970282424503736	8	2.08
35022193	Neoadjuvant programmed cell death 1 blockade combined with chemotherapy for resectable esophageal squamous cell carcinoma.	Journal for immunotherapy of cancer	2022	50.59263308421273	12.287302021627012	58	13.62
35020842	CMTM6: increased circulating level and up-regulated expression in labial salivary glands in patients with primary Sjogren's syndrome.	Clinical and experimental immunology	2022	-51.46735365706249	13.052423348227151	0	
35019948	Association of Cutaneous Immune-Related Adverse Events With Increased Survival in Patients Treated With Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Therapy.	JAMA dermatology	2022	69.65336034102239	-21.12912656236773	41	9.42
35017217	Sweet Immune Checkpoint Targets to Enhance T Cell Therapy.	Journal of immunology (Baltimore, Md. : 1950)	2022	-36.77098238011484	-30.52580434472401	12	3.23
35015209	Immunotherapy toxicity: identification and management.	Breast cancer research and treatment	2022	77.9165458186622	-9.286101415304053	13	2.76
35008669	Current Immunotherapeutic Strategies Targeting the PD-1/PD-L1 Axis in Non-Small Cell Lung Cancer with Oncogenic Driver Mutations.	International journal of molecular sciences	2021	34.75246750670317	-24.53633804496217	7	0.74
35008256	CANDIED: A Pan-Canadian Cohort of Immune Checkpoint Inhibitor-Induced Insulin-Dependent Diabetes Mellitus.	Cancers	2021	87.50183851648744	-13.52878584052579	5	0.65
35008004	Effects of ESCO2 or its methylation on the prognosis, clinical characteristics, immune microenvironment, and pathogenesis of low-grade glioma.	International immunopharmacology	2022	-18.120884466127027	54.08202661167328	0	
35007928	Subclonal landscape of cancer drives resistance to immune therapy.	Cancer treatment and research communications	2022	24.934722099987265	-15.95063490830791	5	1.08
35004689	External Validation of the Prognostic Value of an Immune-Associated Gene Panel for Clear Cell Renal Cell Carcinomas.	Frontiers in cell and developmental biology	2021	16.978317741542703	34.21749113396249	2	0.18
35004669	LCK and CD3E Orchestrate the Tumor Microenvironment and Promote Immunotherapy Response and Survival of Muscle-Invasive Bladder Cancer Patients.	Frontiers in cell and developmental biology	2021	5.616649413843485	58.251025317278994	4	0.44
35004282	Case Report: Tumor Microenvironment Characteristics in a Patient With HER2 Mutant Lung Squamous Cell Carcinoma Harboring High PD-L1 Expression Who Presented Hyperprogressive Disease.	Frontiers in oncology	2021	28.49234200150012	-17.76035460826098	6	0.66
35004242	Predictive value of mRNA expression and dynamic changes from immune related biomarkers in liquid biopsies before and after start of pembrolizumab in stage IV non-small cell lung cancer (NSCLC).	Translational lung cancer research	2021	21.14952573188708	-14.394020654256916	4	0.43
35003414	Effects of Maxingloushi decoction on immune inflammation and programmed death markers in mice with chronic obstructive pulmonary disease.	World journal of emergency medicine	2022	1.588789614767808	-24.2210000682217	3	
35003115	pH Low Insertion Peptide-Modified Programmed Cell Death-Ligand 1 Potently Suppresses T-Cell Activation Under Acidic Condition.	Frontiers in immunology	2021	-51.173450561243286	-41.4144534685197	0	0.0
35003107	A Case Report of Non-Bacterial Cystitis Caused by Immune Checkpoint Inhibitors.	Frontiers in immunology	2021	73.50869736065157	-17.81602215031442	3	0.45
35002724	Emerging Role of PD-1/PD-L1 Inhibitors in Chronic Liver Diseases.	Frontiers in pharmacology	2021	-47.16793819935332	-16.916942917654286	10	1.12
34996924	In vitro characterization of a small molecule PD-1 inhibitor that targets the PD-l/PD-L1 interaction.	Scientific reports	2022	-40.896390589679726	-38.90096406252257	4	
34996890	The expression and clinical significance of programmed cell death receptor 1 and its ligand in tumor tissues of patients with extranodal nasal NK/T cell lymphoma.	Scientific reports	2022	-39.03244955597936	24.35884094509193	4	
34992611	Immune Checkpoint Inhibitor-Associated Colitis: From Mechanism to Management.	Frontiers in immunology	2021	76.10677842923805	-3.962810800850352	32	3.45
34987640	Tumor-infiltrating lymphocytes are functionally inactivated by CD90+ stromal cells and reactivated by combined Ibrutinib and Rapamycin in human pleural mesothelioma.	Theranostics	2022	5.909329354746747	13.891965487419414	4	
34987061	COX-2 Inhibitors Decrease Expression of PD-L1 in Colon Tumors and Increase the Influx of Type I Tumor-infiltrating Lymphocytes.	Cancer prevention research (Philadelphia, Pa.)	2022	-22.52886666078376	-31.35130960204843	7	1.74
34986841	The clinical significance of adenomatous polyposis coli (APC) and catenin Beta 1 (CTNNB1) genetic aberrations in patients with melanoma.	BMC cancer	2022	7.428003089089173	48.02747506503701	3	
34985920	First-Line Immunotherapy for Non-Small-Cell Lung Cancer.	Journal of clinical oncology : official journal of the American Society of Clinical Oncology	2022	39.66413489838264	-29.94296427448902	179	39.65
34980000	High efficacy of PD-1 inhibitor after initial failure of PD-L1 inhibitor in Relapsed/Refractory classical Hodgkin Lymphoma.	BMC cancer	2022	-29.58218741338509	22.94653520314672	4	
34977341	Oncolytic measles vaccines encoding PD-1 and PD-L1 checkpoint blocking antibodies to increase tumor-specific T cell memory.	Molecular therapy oncolytics	2022	-25.1823295527323	-13.847266598606822	7	0.96
34976018	Ferroptosis-Related Long Non-Coding RNA Signature Contributes to the Prediction of Prognosis Outcomes in Head and Neck Squamous Cell Carcinomas.	Frontiers in genetics	2021	-3.699855466823833	52.4611119730089	14	1.67
34976004	Association of a Novel Prognosis Model with Tumor Mutation Burden and Tumor-Infiltrating Immune Cells in Thyroid Carcinoma.	Frontiers in genetics	2021	-2.367265957472397	52.4303240825035	5	0.57
34975867	Colorectal Cancer-Associated Immune Exhaustion Involves T and B Lymphocytes and Conventional NK Cells and Correlates With a Shorter Overall Survival.	Frontiers in immunology	2021	6.257457386165708	39.3905665888127	15	1.45
34975854	PARP Inhibitor Upregulates PD-L1 Expression and Provides a New Combination Therapy in Pancreatic Cancer.	Frontiers in immunology	2021	32.98466821677733	40.29638241683589	15	1.39
34973084	Blocking GARP-mediated activation of TGF-β1 did not alter innate or adaptive immune responses to bacterial infection or protein immunization in mice.	Cancer immunology, immunotherapy : CII	2022	-81.61983877362292	-14.086973445703311	2	
34972977	Immune-Related Oral, Otologic, and Ocular Adverse Events.	Advances in experimental medicine and biology	2021	80.29488729291913	-8.605319567461677	2	0.37
34972681	Correlation between body mass index and efficacy of anti-PD-1 inhibitor in patients with non-small cell lung cancer.	Respiratory investigation	2022	31.127838209887223	-48.05503958644468	3	
37199300	Immunotherapy and Targeted Therapy in the Management of Oral Cancers.	Critical reviews in oncogenesis	2022	54.177240653971886	34.790801263725534	0	
34970268	Development and Clinical Validation of Novel 8-Gene Prognostic Signature Associated With the Proportion of Regulatory T Cells by Weighted Gene Co-Expression Network Analysis in Uterine Corpus Endometrial Carcinoma.	Frontiers in immunology	2021	2.3484233568924933	48.16824217443646	10	1.03
34969998	The multi-specific VH-based Humabody CB213 co-targets PD1 and LAG3 on T cells to promote anti-tumour activity.	British journal of cancer	2022	-18.077592481316533	-40.09989807290862	6	1.42
34968298	Firing up Cold Tumors-Targeting the Epigenetic Machinery to Enhance Cancer Immunotherapy.	Epigenomes	2021	-19.47291102885368	-56.645945609834165	1	0.1
34968160	microRNA-20b-5p overexpression combing Pembrolizumab potentiates cancer cells to radiation therapy via repressing programmed death-ligand 1.	Bioengineered	2022	23.821316013800377	23.98479481006984	10	2.75
34966689	Immunotherapy in Ovarian Cancer: Thinking Beyond PD-1/PD-L1.	Frontiers in oncology	2021	38.11716016723135	38.98534689227994	26	2.73
34966652	Clinicopathological and Prognostic Value of Programmed Cell Death 1 Expression in Hepatitis B Virus-related Hepatocellular Carcinoma: A Meta-analysis.	Journal of clinical and translational hepatology	2021	-23.054496490367747	40.26974016382099	1	0.18
34966607	Efficacy of Immune Checkpoint Inhibitors in Patients with Mismatch Repair-Deficient or Microsatellite Instability-High Metastatic Colorectal Cancer: Analysis of Three Phase-II Trials.	Cureus	2021	38.3979544154632	22.81586031256591	7	0.63
34966391	Siglec Signaling in the Tumor Microenvironment.	Frontiers in immunology	2021	-5.538031557212715	38.6335097816134	21	2.78
34965960	Reverse Translating Molecular Determinants of Anti-Programmed Death 1 Immunotherapy Response in Mouse Syngeneic Tumor Models.	Molecular cancer therapeutics	2022	21.62859294473428	-11.972968960459472	5	1.07
34965944	Intralesional SD-101 in Combination with Pembrolizumab in Anti-PD-1 Treatment-Naïve Head and Neck Squamous Cell Carcinoma: Results from a Multicenter, Phase II Trial.	Clinical cancer research : an official journal of the American Association for Cancer Research	2022	53.67083496695861	6.792575593555028	8	2.08
34958105	Anti‑VEGF antibody triggers the effect of anti‑PD‑L1 antibody in PD‑L1low and immune desert‑like mouse tumors.	Oncology reports	2022	-8.299845697982082	-42.21753383369944	11	2.29
34957008	Economic Evaluation of First-Line Camrelizumab for Advanced Non-small-cell Lung Cancer in China.	Frontiers in public health	2021	54.58801516496384	-25.105682216810845	13	1.2
34956912	The Role of Immune Checkpoint Blockade in the Hepatocellular Carcinoma: A Review of Clinical Trials.	Frontiers in oncology	2021	30.024287741869397	48.768082424155175	16	1.82
34956906	Clinical and Prognostic Significance of Tumor-Infiltrating CD8+ T Cells and PD-L1 Expression in Primary Gastrointestinal Stromal Tumors.	Frontiers in oncology	2021	-7.690762913994545	8.925487142062675	6	0.76
34956460	Integrin signaling gene alterations and outcomes of cancer patients receiving immune checkpoint inhibitors.	American journal of translational research	2021	-2.379401458597356	42.27726390087586	3	0.34
34956221	Immune Thrombocytopenia Induced by Immune Checkpoint Inhibitrs in Lung Cancer: Case Report and Literature Review.	Frontiers in immunology	2021	69.95320101756045	-11.516213804498486	5	0.46
34954864	Immune microenvironment in patients with mismatch-repair-proficient oligometastatic colorectal cancer exposed to chemotherapy: the randomized MIROX GERCOR cohort study.	Molecular oncology	2022	11.034155362900243	39.32951258429539	2	
34953898	The mechanism underlying arsenic-induced PD-L1 upregulation in transformed BEAS-2B cells.	Toxicology and applied pharmacology	2022	-34.61553982060398	38.80461063977127	3	
34953097	Use of PD-1 inhibitor tislelizumab in the treatment of advanced pulmonary sarcomatoid carcinoma: A case report.	Thoracic cancer	2022	54.23406285311851	-32.75531489439162	6	1.64
34950137	A PD-L1 Negative Advanced Gastric Cancer Patient With a Long Response to PD-1 Blockade After Failure of Systematic Treatment: A Case Report.	Frontiers in immunology	2021	47.81288304264628	19.96601178723161	7	0.7
34945784	What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 7: PD-L1 Expression in Liquid Biopsy.	Journal of personalized medicine	2021	8.748563594025343	-38.45367322418413	4	0.48
34944961	Enhancing Adoptive Cell Transfer with Combination BRAF-MEK and CDK4/6 Inhibitors in Melanoma.	Cancers	2021	30.591666596396305	32.25224403587795	3	0.24
34944837	Shooting at Moving and Hidden Targets-Tumour Cell Plasticity and the Notch Signalling Pathway in Head and Neck Squamous Cell Carcinomas.	Cancers	2021	-10.415436215846322	36.48790976060069	8	1.21
34944780	Disruption of Her2-Induced PD-L1 Inhibits Tumor Cell Immune Evasion in Patient-Derived Gastric Cancer Organoids.	Cancers	2021	-11.5485456838838	0.4212632350261359	10	0.99
34940076	The Challenge to the Pathologist of PD-L1 Expression in Tumor Cells of Non-Small-Cell Lung Cancer-An Overview.	Current oncology (Toronto, Ont.)	2021	19.187365747355145	-36.77497536660872	4	0.33
34938730	Identification of Therapeutic Targets and Prognostic Biomarkers Among Chemokine (C-C Motif) Ligands in the Liver Hepatocellular Carcinoma Microenvironment.	Frontiers in cell and developmental biology	2021	-11.840609416959916	45.68695593210691	7	0.83
34938618	Pembrolizumab-Induced Vitiligo in Esophageal Squamous Cell Carcinoma Patient With Durable Complete Response.	Cureus	2021	72.14574580429579	-21.71557252299636	2	0.27
34938300	Incidence and Distinct Features of Immune Checkpoint Inhibitor-Related Myositis From Idiopathic Inflammatory Myositis: A Single-Center Experience With Systematic Literature Review and Meta-Analysis.	Frontiers in immunology	2021	85.2864844552451	-0.928208502591818	14	1.86
34937742	Costimulation of γδTCR and TLR7/8 promotes Vδ2 T-cell antitumor activity by modulating mTOR pathway and APC function.	Journal for immunotherapy of cancer	2021	-37.11025471270392	4.042214764592459	11	1.14
34937475	Camrelizumab: an investigational agent for hepatocellular carcinoma.	Expert opinion on investigational drugs	2022	32.44449221517932	53.49979152491287	4	
34934351	The Role of Critical N6-Methyladenosine-Related Long Non-Coding RNAs and Their Correlations with Immune Checkpoints in Renal Clear Cell Carcinoma.	International journal of general medicine	2021	-5.945021514753058	54.87325987031085	4	0.42
34933430	[PD-1 is associated with CD8(+)T lymphocyte dysfunction in patients with acute and chronic liver failure].	Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology	2021	-70.87061392541187	25.710680791273447	0	0.0
34931590	Curcumin Inhibits T Follicular Helper Cell Differentiation in Mice with Dextran Sulfate Sodium (DSS)-Induced Colitis.	The American journal of Chinese medicine	2022	-64.98273883879149	10.381343535001273	6	1.86
34931541	Expression of Programmed Cell Death-L1 (PD-L1) Protein and Mismatch Repair Mutations in Orbital Tumours-a Pilot Study.	European journal of ophthalmology	2022	13.245678532567933	47.83070635251315	1	
34930650	Locally advanced breast cancer.	Breast (Edinburgh, Scotland)	2022	44.229446446319	9.816550956601828	7	2.1
34930486	Liquid biopsy to identify biomarkers for immunotherapy in hepatocellular carcinoma.	Biomarker research	2021	32.18756283095739	47.35490229121093	3	0.33
34930465	Identification of a novel signature based on unfolded protein response-related gene for predicting prognosis in bladder cancer.	Human genomics	2021	3.692808694711013	57.416910640776045	7	0.72
34930377	The developing landscape of combinatorial therapies of immune checkpoint blockade with DNA damage repair inhibitors for the treatment of breast and ovarian cancers.	Journal of hematology & oncology	2021	28.12369149596488	16.300160798934414	16	1.55
34930041	Splenic CD4+ and CD8+ T-cells highly expressed PD-1 and Tim-3 in cirrhotic patients with HCV infection and portal hypertension.	International journal of immunopathology and pharmacology	2021	-78.05980391839364	26.285581102307585	1	0.11
34929601	Strong expression of PD-L1 in invasive front of MELF pattern in endometrioid carcinoma.	Pathology, research and practice	2022	-17.54350333015609	8.028581228147553	1	
34926305	Gastrin Vaccine Alone and in Combination With an Immune Checkpoint Antibody Inhibits Growth and Metastases of Gastric Cancer.	Frontiers in oncology	2021	44.54366362246976	18.43976060782425	5	0.58
34926253	Case Report: Sequential Combination Targeted Therapy With Type I and II MET Inhibitors in a Metastatic EGFR-Mutated, MET-Amplified NSCLC Patient With Acquired MET Y1230H Mutation.	Frontiers in oncology	2021	36.78009292118958	-39.62664265641224	0	0.0
34925437	An Integrated Analysis of Tumor Purity of Common Central Nervous System Tumors in Children Based on Machine Learning Methods.	Frontiers in genetics	2021	1.8186654103855584	50.55380099921111	3	0.46
34925348	Improving Immunotherapy Efficacy in Soft-Tissue Sarcomas: A Biomarker Driven and Histotype Tailored Review.	Frontiers in immunology	2021	14.020570477871644	8.79038732296206	29	3.46
34925311	Identification and Validation of a Novel Six-Gene Expression Signature for Predicting Hepatocellular Carcinoma Prognosis.	Frontiers in immunology	2021	-10.3592586479664	49.89561769097366	5	0.42
34923987	Assessment of anti-PD-(L)1 for patients with coexisting malignant tumor and tuberculosis classified by active, latent, and obsolete stage.	BMC medicine	2021	62.289577071738975	-22.33262971351892	0	0.0
34923192	Evaluation of PD-1 and PD-L1 expression in canine urothelial carcinoma cell lines.	Veterinary immunology and immunopathology	2022	14.119122345659342	59.49633724010173	5	1.31
34923183	Gemcitabine-facilitated modulation of the tumor microenvironment and PD-1/PD-L1 blockade generate a synergistic antitumor effect in a murine hepatocellular carcinoma model.	Clinics and research in hepatology and gastroenterology	2022	-22.726407367077478	-17.48845033644757	4	
34917675	Checkpoint inhibitors: literature review of new treatments for hepatocellular carcinoma.	Stem cell investigation	2021	30.750524875562306	50.13148121779359	1	0.15
34917090	Imaging of Glioblastoma Tumor-Associated Myeloid Cells Using Nanobodies Targeting Signal Regulatory Protein Alpha.	Frontiers in immunology	2021	-22.91689114423943	60.03275248434189	11	1.12
34916808	Effective Disease Control After Combinatorial Treatment with a PD-1 Antibody and an mTOR Inhibitor for Recurrent Ovarian Clear Cell Carcinomas: A Case Report and Literature Review.	OncoTargets and therapy	2021	38.64282826518888	41.76228044633755	1	0.21
34915894	Using the co-expression network of T cell-activation-related genes to assess the disease activity in Takayasu's arteritis patients.	Arthritis research & therapy	2021	-59.39132171387837	11.498067083465838	6	0.79
34915639	[The influence of cachexia on the immunotherapy efficacy of Sintilimab for non-small cell lung cancer].	Zhonghua zhong liu za zhi [Chinese journal of oncology]	2021	31.3613804292229	-46.25678261510231	2	0.36
34914185	Fibroblast Activation Protein-α Responsive Peptide Assembling Prodrug Nanoparticles for Remodeling the Immunosuppressive Microenvironment and Boosting Cancer Immunotherapy.	Small (Weinheim an der Bergstrasse, Germany)	2022	-29.716748403924168	-51.648727303016095	7	1.83
34913597	Neoadjuvant PD-1 inhibitor combines with chemotherapy versus neoadjuvant chemotherapy in resectable squamous cell carcinoma of the lung.	Thoracic cancer	2022	32.563495303188795	-20.976768312217636	3	
34912726	Plasminogen Activating Inhibitor-1 Might Predict the Efficacy of Anti-PD1 Antibody in Advanced Melanoma Patients.	Frontiers in oncology	2021	-21.8002818742103	-51.49479531150065	8	1.04
34912719	A Novel Type of PD-L1 Inhibitor rU1 snRNPA From Human-Derived Protein Scaffolds Library.	Frontiers in oncology	2021	-43.67615275245054	-45.25385731292394	1	0.13
34907653	B7-1 and programmed cell death-ligand 1 in primary and lymph node metastasis lesions of non-small cell lung carcinoma.	Cancer medicine	2022	5.385704691224207	-27.930221691517296	4	
34907083	Clinical Impact of Immune Cells and Their Spatial Interactions in Diffuse Large B-Cell Lymphoma Microenvironment.	Clinical cancer research : an official journal of the American Association for Cancer Research	2022	-30.09486237204381	31.652276597009195	12	2.75
34899751	Neutrophil Extracellular Traps Promote T Cell Exhaustion in the Tumor Microenvironment.	Frontiers in immunology	2021	-16.998565926626263	40.28251504684872	50	5.44
34899747	Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.	Frontiers in immunology	2021	30.587041418414653	50.02342856686997	40	4.28
34899689	Anti-Angiogenic Agent Combined with Anti-PD-1 Immunotherapy Showed Activity in Patients With Classical Hodgkin Lymphoma Who Have Failed Immunotherapy: A Retrospective Case Report Study.	Frontiers in immunology	2021	54.94774723113211	-2.145336060423958	1	0.11
34895063	Engineered mRNA-expressed bispecific antibody prevent intestinal cancer via lipid nanoparticle delivery.	Bioengineered	2021	-13.458291703980642	-48.2116218937837	3	0.27
34888252	Anti-PD-1 Immunotherapy Combined With Stereotactic Body Radiation Therapy and GM-CSF as Salvage Therapy in a PD-L1-Positive Patient With Refractory Metastatic Thyroid Hürthle Cell Carcinoma: A Case Report and Literature Review.	Frontiers in oncology	2021	57.05354793040648	14.771848760278395	3	0.54
34887574	A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma.	Nature medicine	2021	34.89703713470958	3.448150705744607	65	6.13
34887262	Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3.	Journal for immunotherapy of cancer	2021	-17.981602490081602	-24.589349421676605	19	2.11
34885169	Immunotherapy of Ovarian Cancer with Particular Emphasis on the PD-1/PDL-1 as Target Points.	Cancers	2021	38.21233937616104	39.32036420311634	7	0.72
34881845	Prognostic importance of SUVmax values evaluated by 18F-FDG-PET/CT before nivolumab treatment in patients with metastatic renal cell carcinoma.	The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of...	2023	12.70640268955056	-55.80879127365051	1	
34881181	Metformin Downregulates PD-L1 Expression in Esophageal Squamous Cell Catrcinoma by Inhibiting IL-6 Signaling Pathway.	Frontiers in oncology	2021	-16.389607289838214	-24.90295911986605	10	1.35
34880861	CD247, a Potential T Cell-Derived Disease Severity and Prognostic Biomarker in Patients With Idiopathic Pulmonary Fibrosis.	Frontiers in immunology	2021	8.834126906199126	-13.6753958176657	6	0.76
34877770	Clinical and prognostic implications of an immune-related risk model based on TP53 status in lung adenocarcinoma.	Journal of cellular and molecular medicine	2022	16.190639986418947	-14.57118969919584	3	
34876826	Classic Type 1 Diabetes Mellitus and Fulminant Type 1 Diabetes Mellitus: Similarity and Discrepancy of Immunological Characteristics and Cytokine Profile.	Diabetes, metabolic syndrome and obesity : targets and therapy	2021	-60.33778261676278	4.6647092348038885	1	0.35
34876047	The prevalence and prognostic impact of tumor-infiltrating lymphocytes in uterine carcinosarcoma.	BMC cancer	2021	-2.2486706780264267	33.654392117036366	1	0.12
34874185	Soluble PD-L1 as a predictive biomarker in lung cancer: a systematic review and meta-analysis.	Future oncology (London, England)	2022	21.75003761775704	-28.297871133601014	7	1.47
34869583	Activity of PD-1 Inhibitor Combined With Anti-Angiogenic Therapy in Advanced Sarcoma: A Single-Center Retrospective Analysis.	Frontiers in molecular biosciences	2021	40.87820183081718	-12.460586684155192	10	1.13
34869005	Various Uses of PD1/PD-L1 Inhibitor in Oncology: Opportunities and Challenges.	Frontiers in oncology	2021	29.07839984062028	-3.1180447931793176	18	2.62
34869003	Case Report: Response With Immunotherapy in a Patient With Mixed Neuroendocrine Non-Neuroendocrine Neoplasms of the Gallbladder.	Frontiers in oncology	2021	51.79823412986024	22.69562268855325	2	0.21
34868999	A Novel Approach Using FDG-PET/CT-Based Radiomics to Assess Tumor Immune Phenotypes in Patients With Non-Small Cell Lung Cancer.	Frontiers in oncology	2021	11.455983451465736	-12.872088119730888	18	2.79
34868284	Programmed death ligand 2 expression plays a limited role in adenocarcinomas of the gastroesophageal junction after preoperative chemotherapy.	European surgery : ACA : Acta chirurgica Austriaca	2021	-14.839361600476945	6.83918109588823	2	0.39
34867988	Severe Adaptive Immune Suppression May Be Why Patients With Severe COVID-19 Cannot Be Discharged From the ICU Even After Negative Viral Tests.	Frontiers in immunology	2021	-53.19784885588413	42.51948997883665	8	0.94
34867321	Adverse Effects and Toxicity of Immune Checkpoint Inhibitors For Patients With Urothelial Carcinoma.	Frontiers in pharmacology	2021	66.58916071692937	22.31915011018813	7	0.65
34866510	Triterpenoids of Rhus chinensis Supressed Colorectal Cancer Progress by Enhancing Antitumor Immunity and CD8 + T Cells Tumor Infiltration.	Nutrition and cancer	2022	-21.41223642826463	-34.17386298814703	2	
34866423	PD-1 Blockade With Concurrent Radiotherapy for Locally Advanced Inoperable Cutaneous Squamous Cell Carcinoma.	Journal of cutaneous medicine and surgery	2022	57.22570298424862	5.824660612248026	1	
34866044	Abdominopelvic FLASH Irradiation Improves PD-1 Immune Checkpoint Inhibition in Preclinical Models of Ovarian Cancer.	Molecular cancer therapeutics	2022	28.19975303945666	23.477247319079986	20	5.13
34863286	Role of PD-L1 in licensing immunoregulatory function of dental pulp mesenchymal stem cells.	Stem cell research & therapy	2021	-53.374449143943416	19.526994415739555	14	1.94
34862664	Prognostic implications of the tumor immune microenvironment and immune checkpoint pathway in primary central nervous system diffuse large B-cell lymphoma in the North Indian population.	APMIS : acta pathologica, microbiologica, et immunologica Scandinavica	2022	-31.90603443581439	31.701080457498747	4	
34861397	Future of PD-1/PD-L1 axis modulation for the treatment of triple-negative breast cancer.	Pharmacological research	2022	-25.0354912928887	-59.23284136987749	14	3.67
34860431	Enhancing the therapeutic efficacy of programmed death ligand 1 antibody for metastasized liver cancer by overcoming hepatic immunotolerance in mice.	Hepatology (Baltimore, Md.)	2022	-22.80484470653676	-17.241775628370505	8	1.85
34859919	Self-Blockade of PD-L1 with Bacteria-Derived Outer-Membrane Vesicle for Enhanced Cancer Immunotherapy.	Advanced materials (Deerfield Beach, Fla.)	2022	-38.43326395936988	-57.06926309141415	29	6.85
34858816	Disulfiram Improves the Anti-PD-1 Therapy Efficacy by Regulating PD-L1 Expression via Epigenetically Reactivation of IRF7 in Triple Negative Breast Cancer.	Frontiers in oncology	2021	-21.0863403996437	-26.05970474768592	6	0.82
34858800	Prognostic Influence of Residual Tumor-Infiltrating Lymphocyte Subtype After Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.	Frontiers in oncology	2021	1.0930821012475664	24.32197177273878	4	0.5
34853646	Shuyu pills inhibit immune escape and enhance chemosensitization in hepatocellular carcinoma.	World journal of gastrointestinal oncology	2021	-17.651784414229514	-33.67604540074104	4	0.47
34853040	Augmenting Adoptive T-cell Immunotherapy by Targeting the PD-1/PD-L1 Axis.	Cancer research	2021	23.572941248614555	1.6527009261066592	2	0.25
34852840	Body mass index is not associated with survival outcomes and immune-related adverse events in patients with Hodgkin lymphoma treated with the immune checkpoint inhibitor nivolumab.	Journal of translational medicine	2021	31.090769886218396	-48.16594377681361	6	0.61
34847253	A newly intervention strategy in preeclampsia: Targeting PD-1/Tim-3 signaling pathways to modulate the polarization of decidual macrophages.	FASEB journal : official publication of the Federation of American Societies for Experimental Biology	2022	-74.83616062863041	-17.76244118777749	12	3.29
34844980	Anlotinib Induces a T Cell-Inflamed Tumor Microenvironment by Facilitating Vessel Normalization and Enhances the Efficacy of PD-1 Checkpoint Blockade in Neuroblastoma.	Clinical cancer research : an official journal of the American Association for Cancer Research	2022	27.540673723715763	-52.30181333090515	25	4.82
34844086	Comparative investigation of cell cycle and immunomodulatory genes in mucosal and cutaneous melanomas: Preliminary data suggest a potential promising clinical role for p16 and the PD-1/PD-L1 axis.	Pathology, research and practice	2022	6.18757646745616	-1.1212808919342356	1	
34843822	Increased soluble programed cell death-ligand 1 is associated with acute coronary syndrome.	International journal of cardiology	2022	-46.98774036260895	23.720001067346523	2	
34843570	Gene expression signatures as candidate biomarkers of response to PD-1 blockade in non-small cell lung cancers.	PloS one	2021	18.67304230403386	-28.104410515305347	1	0.08
34841450	Splenic T lymphocytes induce the formation of immunosuppressive neutrophils through IFN-γ in sepsis.	Inflammation research : official journal of the European Histamine Research Society ... [et al.]	2022	-55.71345742969381	35.4693907217933	3	
34840210	Current Trends in Anti-Cancer Molecular Targeted Therapies: Renal Complications and Their Histological Features.	Journal of Nippon Medical School = Nippon Ika Daigaku zasshi	2022	71.76237097331538	0.786691222805428	1	
34839857	[Effect of dendritic cells on immune function regulated by programmed cell death-1/programmed cell death-ligand 1 in sepsis].	Zhonghua wei zhong bing ji jiu yi xue	2021	-57.15575173655313	33.95041972204647	0	0.0
34839351	Effector memory cytotoxic CD3+/CD8+/CD45RO+ T cells are predictive of good survival and a lower risk of recurrence in triple-negative breast cancer.	Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc	2022	-4.016415485436408	21.35320134111525	6	1.49
34838956	Anticancer natural products targeting immune checkpoint protein network.	Seminars in cancer biology	2022	-29.24322970536112	-38.29689179551862	5	1.29
34837214	Preparation of Radiolabeled Antibodies for Nuclear Medicine Applications in Immuno-Oncology.	Methods in molecular biology (Clifton, N.J.)	2022	8.835865553244373	-55.79336068870666	0	
34833153	Treatment-Related Adverse Events with PD-1 or PD-L1 Inhibitors: A Systematic Review and Meta-Analysis.	Life (Basel, Switzerland)	2021	61.50809769763821	-15.119016051685124	3	0.29
34833111	Distinctive Role of the Systemic Inflammatory Profile in Non-Small-Cell Lung Cancer Younger and Elderly Patients Treated with a PD-1 Immune Checkpoint Blockade: A Real-World Retrospective Multi-Institutional Analysis.	Life (Basel, Switzerland)	2021	30.409063394414	-37.39084609040159	7	1.02
34832887	The Potential Advantage of Targeting Both PD-L1/PD-L2/PD-1 and IL-10-IL-10R Pathways in Acute Myeloid Leukemia.	Pharmaceuticals (Basel, Switzerland)	2021	-39.5060301168776	-6.739941982774031	5	0.56
34832863	EGCG Inhibits Tumor Growth in Melanoma by Targeting JAK-STAT Signaling and Its Downstream PD-L1/PD-L2-PD1 Axis in Tumors and Enhancing Cytotoxic T-Cell Responses.	Pharmaceuticals (Basel, Switzerland)	2021	-28.12949586837891	-34.05153629963293	20	3.34
34831468	The Importance of Exosomal PD-L1 in Cancer Progression and Its Potential as a Therapeutic Target.	Cells	2021	-43.69586311110178	-59.03085594023496	19	2.46
34830971	Colorectal Cancer Progression Is Potently Reduced by a Glucose-Free, High-Protein Diet: Comparison to Anti-EGFR Therapy.	Cancers	2021	-27.023804020240387	-29.80193620122085	4	0.61
34830888	Relationship between Tumor Mutational Burden, PD-L1, Patient Characteristics, and Response to Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma.	Cancers	2021	22.939302799948784	-14.53929854354262	11	1.5
34830884	Inhibition of DCLK1 with DCLK1-IN-1 Suppresses Renal Cell Carcinoma Invasion and Stemness and Promotes Cytotoxic T-Cell-Mediated Anti-Tumor Immunity.	Cancers	2021	62.80368339364728	35.03506679859411	9	1.01
34830867	Diagnostic and Prognostic Implications of Caspase-1 and PD-L1 Co-Expression Patterns in Myelodysplastic Syndromes.	Cancers	2021	-35.26504698861772	13.760346112657569	5	0.64
34830803	(Pro)renin Receptor Is a Novel Independent Prognostic Marker in Invasive Urothelial Carcinoma of the Bladder.	Cancers	2021	98.75667825304176	-13.979988476222823	2	0.31
34830454	PODNL1 Methylation Serves as a Prognostic Biomarker and Associates with Immune Cell Infiltration and Immune Checkpoint Blockade Response in Lower-Grade Glioma.	International journal of molecular sciences	2021	-18.693428035578368	53.46189911964434	5	0.45
34829931	Posttranslational Modifications in PD-L1 Turnover and Function: From Cradle to Grave.	Biomedicines	2021	-45.18299908824731	-22.95548296716567	8	0.95
34827698	Overweight as a Favorable Clinical Biomarker for Checkpoint Inhibitor Therapy Response in Recurrent Gynecologic Cancer Patients.	Biomolecules	2021	31.03447010264665	-48.41263153714837	2	0.27
34827528	Molecular and Clinical Characterization of a Novel Prognostic and Immunologic Biomarker GPSM3 in Low-Grade Gliomas.	Brain sciences	2021	-18.95443501409768	55.7198843810604	0	0.0
34826742	Clinicopathological features and genomic profiles of hepatoid adenocarcinoma of the lung: Report of four cases.	Pathology, research and practice	2022	18.08142271847144	-19.984616824033147	4	
34826600	Clinical experience with CTLA-4 blockade for cancer immunotherapy: From the monospecific monoclonal antibody ipilimumab to probodies and bispecific molecules targeting the tumor microenvironment.	Pharmacological research	2022	28.78615025491644	5.947200401736331	26	6.03
34825855	PD-1/PD-L1 Inhibitors Monotherapy for the Treatment of Endometrial Cancer: Meta-Analysis and Systematic Review.	Cancer investigation	2022	52.67485664763241	-12.891896753774535	0	
34825707	Microglial PD-1 stimulation by astrocytic PD-L1 suppresses neuroinflammation and Alzheimer's disease pathology.	The EMBO journal	2021	-76.84903136505609	-4.888725184057208	21	2.25
34825383	Tumor-derived exosomal PD-L1 in progression of cancer and immunotherapy.	Journal of cellular physiology	2022	-43.389729753238015	-59.70441579558877	8	2.2
34824161	Low peripheral blood derived neutrophil-to-lymphocyte ratio (dNLR) is associated with increased tumor T-cell infiltration and favorable outcomes to first-line pembrolizumab in non-small cell lung cancer.	Journal for immunotherapy of cancer	2021	28.37448259065057	-41.346920654584615	32	3.0
34823493	Patterns and outcomes of immune-related adverse events in solid tumor patients treated with immune checkpoint inhibitors in Thailand: a multicenter analysis.	BMC cancer	2021	75.19250173730673	-10.911127693053926	7	0.58
34820569	Engineered extracellular vesicles for concurrent Anti-PDL1 immunotherapy and chemotherapy.	Bioactive materials	2022	-37.76914640894085	-58.250859933258	19	2.32
34819055	Sulforaphane enhances the antitumor response of chimeric antigen receptor T cells by regulating PD-1/PD-L1 pathway.	BMC medicine	2021	-41.32591269641663	2.6358282379491875	9	1.05
34817950	The efficacies and biomarker investigations of antiprogrammed death-1 (anti-PD-1)-based therapies for metastatic bone and soft tissue sarcoma.	Cancer biology & medicine	2021	58.6753379885162	-26.25429209271072	7	0.71
34815353	Metformin reduces PD-L1 on tumor cells and enhances the anti-tumor immune response generated by vaccine immunotherapy.	Journal for immunotherapy of cancer	2021	-16.243852333001296	-25.214230188168337	22	2.83
34813798	Simultaneous silencing of the A2aR and PD-1 immune checkpoints by siRNA-loaded nanoparticles enhances the immunotherapeutic potential of dendritic cell vaccine in tumor experimental models.	Life sciences	2022	-34.45693923019737	-51.51683547638705	8	2.02
34810048	Anti-programmed death ligand 1 immunotherapies in cancer patients with pre-existing systemic sclerosis: A postmarketed phase IV safety assessment study.	European journal of cancer (Oxford, England : 1990)	2022	54.435275980348166	-14.838973928466707	8	1.75
34805163	Identification and Validation of Immune- and Stemness-Related Prognostic Signature of Melanoma.	Frontiers in cell and developmental biology	2021	-1.5760272432762292	49.90790307143947	3	0.29
34804001	Anti-PD-1 Therapy-A Potential Treatment for Myocardial Metastasis From Nasopharyngeal Carcinoma: A Case Report.	Frontiers in immunology	2021	58.963238750023926	-1.8469778359619389	0	0.0
34804000	Case Report: Complete Response to Nivolumab in a Patient With Programmed Cell Death 1 Ligand 1-Positive and Multiple Gene-Driven Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor-Resistant Lung Adenocarcinoma.	Frontiers in immunology	2021	34.39008855738348	-37.86808453807175	0	0.0
34803491	Cullin3 deficiency shapes tumor microenvironment and promotes cholangiocarcinoma in liver-specific Smad4/Pten mutant mice.	International journal of biological sciences	2021	-2.0432717620825374	60.4431818550412	1	0.12
34802879	A Multicenter, Randomized Phase III Study Comparing Platinum Combination Chemotherapy Plus Pembrolizumab With Platinum Combination Chemotherapy Plus Nivolumab and Ipilimumab for Treatment-Naive Advanced Non-Small Cell Lung Cancer Without Driver Gene Alterations: JCOG2007 (NIPPON Study).	Clinical lung cancer	2022	43.920844381274975	-30.820297600643347	4	
34802204	[Expert Consensus on Tumor Mutational Burden for Immunotherapy in Lung Cancer].	Zhongguo fei ai za zhi = Chinese journal of lung cancer	2021	23.688379504208637	-17.505825776528514	3	0.25
34801695	Addition of immunotherapy to chemotherapy for metastatic triple-negative breast cancer: A systematic review and meta-analysis of randomized clinical trials.	Critical reviews in oncology/hematology	2021	56.62793783599955	-11.95993258732669	9	0.87
34799582	Interplay between copy number alterations and immune profiles in the early breast cancer Scandinavian Breast Group 2004-1 randomized phase II trial: results from a feasibility study.	NPJ breast cancer	2021	-4.101443997952413	39.63519024762111	2	0.16
34799400	Treatment-free survival over extended follow-up of patients with advanced melanoma treated with immune checkpoint inhibitors in CheckMate 067.	Journal for immunotherapy of cancer	2021	37.31077009614816	0.9240615801698544	8	0.86
34798858	Tumor response as defined by iRECIST in gastrointestinal malignancies treated with PD-1 and PD-L1 inhibitors and correlation with survival.	BMC cancer	2021	23.328701809537623	-47.43851429791069	0	0.0
34797860	The role of the immunoescape in colorectal cancer liver metastasis.	PloS one	2021	-3.5471994968449074	11.647787409121182	1	0.1
34795918	Clinical observation of pulmonary lymphoepithelioma-like carcinoma.	Journal of thoracic disease	2021	39.70638855894043	-46.052898440381576	3	0.38
34795901	Robust response of pulmonary pleomorphic carcinoma to pembrolizumab and sequential radiotherapy: A case report.	Respirology case reports	2021	56.24338365625967	-32.23431946257956	0	0.0
34795530	Dl-3-N-Butylphthalide Presents Anti-Cancer Activity in Lung Cancer by Targeting PD-1/PD-L1 Signaling.	Cancer management and research	2021	-1.0473843426025111	-23.7977766501718	1	0.11
34795443	Dynamic CD4+ T cell heterogeneity defines subset-specific suppression and PD-L1-blockade-driven functional restoration in chronic infection.	Nature immunology	2021	-55.06625547940618	-2.4242724396914843	18	1.47
34795387	A pan-cancer analysis revealing the role of TIGIT in tumor microenvironment.	Scientific reports	2021	-4.9885023584314325	29.18586630652311	12	1.24
34795206	Fusobacterium nucleatum enhances the efficacy of PD-L1 blockade in colorectal cancer.	Signal transduction and targeted therapy	2021	-22.56578492835364	0.0716008330636425	55	5.52
34794831	Efficacy and Safety of Programmed Cell Death 1 Inhibitor Monotherapy Versus Chemotherapy as Second-Line Treatment for Advanced Esophageal Cancer: A Meta-analysis and Systematic Review.	Clinical therapeutics	2021	51.804918345573874	15.000293895548952	2	0.19
34794456	Explore association of genes in PDL1/PD1 pathway to radiotherapy survival benefit based on interaction model strategy.	Radiation oncology (London, England)	2021	-23.540197283231635	46.11788498657862	1	0.09
34793567	PD-L1 is expressed on human activated naive effector CD4+ T cells. Regulation by dendritic cells and regulatory CD4+ T cells.	PloS one	2021	-55.69978144382925	-6.000571213561461	3	0.32
34790707	Stimulation of the PD-1 Pathway Decreases Atherosclerotic Lesion Development in Ldlr Deficient Mice.	Frontiers in cardiovascular medicine	2021	-59.1026731736699	8.841216748138972	5	0.57
34790403	Molecular characterization of squamous cell carcinoma of the anal canal.	Journal of gastrointestinal oncology	2021	9.852561763833917	19.167963132465346	4	0.43
34789592	Enhancement of interleukin-2 production by bovine peripheral blood mononuclear cells treated with the combination of anti-programmed death-ligand 1 and cytotoxic T lymphocyte antigen 4 chimeric monoclonal antibodies.	The Journal of veterinary medical science	2022	-59.04301180459158	-27.60469841649963	2	
34789550	Empirical identification and validation of tumor-targeting T cell receptors from circulation using autologous pancreatic tumor organoids.	Journal for immunotherapy of cancer	2021	-10.151880557598655	27.62924840629655	13	1.11
34787500	Efficacy of PD-1/L1 inhibitors in brain metastases of non-small-cell lung cancer: pooled analysis from seven randomized controlled trials.	Future oncology (London, England)	2022	46.36803847052997	-14.986224191298165	6	1.22
34787022	Outcomes of Critically Ill Lung Cancer Patients Initiating Targeted Therapy or Immunotherapy in the Intensive Care Unit: A Single-Center Report.	Journal of intensive care medicine	2022	38.74077970259176	-21.026095760685404	0	
34785583	A PD-1/PD-L1 Proximity Assay as a Theranostic Marker for PD-1 Blockade in Patients with Metastatic Melanoma.	Clinical cancer research : an official journal of the American Association for Cancer Research	2022	8.833789180705535	-2.684377335492923	4	
34784300	PD-1 blockade counteracts post-COVID-19 immune abnormalities and stimulates the anti-SARS-CoV-2 immune response.	JCI insight	2021	-51.93232917835935	42.2734227870282	37	3.73
34782757	Distinct roles but cooperative effect of TLR3/9 agonists and PD-1 blockade in converting the immunotolerant microenvironment of irreversible electroporation-ablated tumors.	Cellular & molecular immunology	2021	-11.577979321276668	-39.90242665899536	11	1.4
34778231	Tumor Microenvironment Profiles Reveal Distinct Therapy-Oriented Proteogenomic Characteristics in Colorectal Cancer.	Frontiers in bioengineering and biotechnology	2021	7.351072100827728	36.32829339138999	6	0.53
34778030	Spatial Distribution of Immune Cells in Head and Neck Squamous Cell Carcinomas.	Frontiers in oncology	2021	-9.968339101226231	33.570415970725065	3	0.26
34778027	Diagnostic and Prognostic Significances of SOX9 in Thymic Epithelial Tumor.	Frontiers in oncology	2021	0.8210427670684823	41.12721688820393	12	1.31
34777920	PD-1 blockade improves the anti-tumor potency of exhausted CD3+CD56+ NKT-like cells in patients with primary hepatocellular carcinoma.	Oncoimmunology	2021	-17.769990018682233	43.92880526648311	22	2.61
34777402	Editorial: The Roles of Checkpoint Inhibitors in Inflammatory Diseases.	Frontiers in immunology	2021	15.27460341835289	-3.768661848162268	0	0.0
34774995	Contemporary clinical trials in pancreatic cancer immunotherapy targeting PD-1 and PD-L1.	Seminars in cancer biology	2022	12.470705086718771	12.046800348859795	12	2.69
34774916	The oncolytic virus VT09X optimizes immune checkpoint therapy in low immunogenic melanoma.	Immunology letters	2022	-35.70045592551052	52.3608593068145	2	
34774004	The relationship between blood-based tumor mutation burden level and efficacy of PD-1/PD-L1 inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis.	BMC cancer	2021	23.6912026459522	-16.880270271022034	5	0.45
34771650	CD8+ T Lymphocytes Immune Depletion and LAG-3 Overexpression in Hodgkin Lymphoma Tumor Microenvironment Exposed to Anti-PD-1 Immunotherapy.	Cancers	2021	-27.67124545850956	28.592975751629037	7	0.69
34771631	Factors Associated with Thyroid-Related Adverse Events in Patients Receiving PD-1 or PD-L1 Inhibitors Using Machine Learning Models.	Cancers	2021	78.52220334326289	-16.549394886414536	1	0.27
34771578	Immune Checkpoint Inhibitors for Genitourinary Cancers: Treatment Indications, Investigational Approaches and Biomarkers.	Cancers	2021	66.56238704671334	24.32013939478021	12	1.01
34771505	An Immune-Related Gene Prognostic Index for Triple-Negative Breast Cancer Integrates Multiple Aspects of Tumor-Immune Microenvironment.	Cancers	2021	1.136777462708903	44.82212179551674	9	1.06
34771441	The Continuum of Thyroid Disorders Related to Immune Checkpoint Inhibitors: Still Many Pending Queries.	Cancers	2021	79.67138009006585	-16.924480463533516	6	0.84
34769327	New Insights into the Role of PD-1 and Its Ligands in Allergic Disease.	International journal of molecular sciences	2021	-65.2184026045209	-10.81391811386876	7	0.88
34768993	Clinical and Prognostic Value of Antigen-Presenting Cells with PD-L1/PD-L2 Expression in Ovarian Cancer Patients.	International journal of molecular sciences	2021	-21.119430218057904	13.09354609001817	11	1.43
34768806	Reconstitution of Monocyte Subsets and PD-L1 Expression but Not T Cell PD-1 Expression in Obstructive Sleep Apnea Patients upon PAP Therapy.	International journal of molecular sciences	2021	-60.8047168986452	25.67838074975201	4	0.71
34768776	Simultaneous Inhibition of PD-1 and Stimulation of CD40 Signaling Pathways by Anti-PD-L1/CD40L Bispecific Fusion Protein Synergistically Activate Target and Effector Cells.	International journal of molecular sciences	2021	-15.151383691985206	-47.33413781919304	4	0.53
34765307	PD-1 antibody camrelizumab for Epstein-Barr virus-positive metastatic gastric cancer: a single-arm, open-label, phase 2 trial.	American journal of cancer research	2021	46.12185819005422	13.282518801041649	6	0.48
34763593	Novel immune targets for the treatment of triple-negative breast cancer.	Expert opinion on therapeutic targets	2021	37.97613285342524	9.63028952432368	10	1.04
34760688	H2AFZ Is a Prognostic Biomarker Correlated to TP53 Mutation and Immune Infiltration in Hepatocellular Carcinoma.	Frontiers in oncology	2021	-11.912077399175937	48.47551068591803	10	1.07
34760687	Identification and Validation of an Immune-Related lncRNA Signature to Facilitate Survival Prediction in Gastric Cancer.	Frontiers in oncology	2021	-3.827861411542707	53.910179333936114	8	0.82
34758782	PD-1 inhibitors versus chemotherapy as second-line treatment for advanced esophageal squamous cell carcinoma: a meta-analysis.	BMC cancer	2021	51.90298120348854	15.007404570720064	4	0.38
34758170	IFN-γ-induced PD-L1 expression on human melanocytes is impaired in vitiligo.	Experimental dermatology	2022	-60.26399776378865	-16.522972900793395	4	
34754934	PD-L1 testing and immunotherapy selection - early laboratory experience and its potential role in head and neck cancer management.	Archive of clinical cases	2021	-7.590975467835738	-5.029194462851268	1	0.18
34753889	Epigenetic therapy to enhance therapeutic effects of PD-1 inhibition in therapy-resistant melanoma.	Melanoma research	2022	-8.60029671738092	-31.37698600505198	5	1.13
34752418	Overexpression of PD-1 on T cells promotes tolerance in cardiac transplantation via ICOS-dependent mechanisms.	JCI insight	2021	-62.45223898495245	-3.460152453134159	7	0.65
34751685	Surface engineering of oncolytic adenovirus for a combination of immune checkpoint blockade and virotherapy.	Biomaterials science	2021	-36.53664675980483	53.74218651470717	6	0.66
34751039	Immune-checkpoint inhibitors in renal transplanted patients affected by melanoma: a systematic review.	Immunotherapy	2022	71.00156394091174	28.93686241035861	2	
34746975	NRAS expression is associated with prognosis and tumor immune microenvironment in lung adenocarcinoma.	Journal of cancer research and clinical oncology	2022	14.922703395374176	-14.757847871093624	4	
34745852	Tubeimoside-1 induces TFEB-dependent lysosomal degradation of PD-L1 and promotes antitumor immunity by targeting mTOR.	Acta pharmaceutica Sinica. B	2021	-30.913566672126397	-33.48699557430031	20	2.23
34745152	Editorial: Dynamic Biomarkers of Response to Anti-Immune Checkpoint Inhibitors in Cancer.	Frontiers in immunology	2021	15.367457593949442	-3.7531172166321327	3	0.33
34745124	Construction of an Immune Cell Infiltration Score to Evaluate the Prognosis and Therapeutic Efficacy of Ovarian Cancer Patients.	Frontiers in immunology	2021	4.700631585504264	46.22791775012266	12	1.12
34745002	The Upregulation of Molecules Related to Tumor Immune Escape in Human Pituitary Adenomas.	Frontiers in endocrinology	2021	-3.5215520861977248	-19.06823855993904	8	1.27
34743329	Tumor-immune landscape patterns before and after chemoradiation in resectable esophageal adenocarcinomas.	The Journal of pathology	2022	4.859378923467549	21.55810956060545	5	1.09
34742294	Large cell morphology, CMYC+ tumour cells, and PD-1+ tumour cell/intense PD-L1+ cell reactions are important prognostic factors in nodal peripheral T-cell lymphomas with T follicular helper markers.	Diagnostic pathology	2021	-34.009008842689546	21.83511435374622	1	0.13
34741349	The role of ferroptosis-related genes for overall survival prediction in breast cancer.	Journal of clinical laboratory analysis	2021	-3.762435642156335	50.48181955597198	4	0.49
34739560	Targeting the immune checkpoint B7-H3 for next-generation cancer immunotherapy.	Cancer immunology, immunotherapy : CII	2022	1.981232921282232	-16.774734259821994	13	3.14
34739319	PD-1 independent of PD-L1 ligation promotes glioblastoma growth through the NFκB pathway.	Science advances	2021	-27.29423096566473	49.95881897262124	11	1.06
34738731	Engineered Small Extracellular Vesicles as a FGL1/PD-L1 Dual-Targeting Delivery System for Alleviating Immune Rejection.	Advanced science (Weinheim, Baden-Wurttemberg, Germany)	2022	-39.75881837196008	-61.21100823895723	14	3.85
34738358	Assessment of PD-L1 expression in patients with neuroblastoma and renal tumors.	The Turkish journal of pediatrics	2021	-27.370365288214792	16.62171806848601	1	0.09
34737749	Mucosal-Associated Invariant T (MAIT) Cell Dysfunction and PD-1 Expression in Prostate Cancer: Implications for Immunotherapy.	Frontiers in immunology	2021	-10.576550626039475	12.83874987741122	4	0.39
34736474	Increased expression of TAZ and associated upregulation of PD-L1 in cervical cancer.	Cancer cell international	2021	0.4055724306484272	-12.625654120591156	2	0.24
34734020	Lymphocyte activation gene-3 is associated with programmed death-ligand 1 and programmed cell death protein 1 in small cell lung cancer.	Annals of translational medicine	2021	9.81967712128528	22.28152167454159	9	1.17
34734011	Bioinformatic analysis of differentially expressed genes and pathways in idiopathic pulmonary fibrosis.	Annals of translational medicine	2021	14.947472886259735	-12.676113036045338	6	0.94
34733999	T cell exhaustion drives osteosarcoma pathogenesis.	Annals of translational medicine	2021	-43.27441460245426	12.512274590092254	7	1.04
34733283	New Artificial Intelligence Score and Immune Infiltrates as Prognostic Factors in Colorectal Cancer With Brain Metastases.	Frontiers in immunology	2021	12.03669427428111	36.06404965905714	2	0.29
34732817	Multiplexed immunofluorescence identifies high stromal CD68+PD-L1+ macrophages as a predictor of improved survival in triple negative breast cancer.	Scientific reports	2021	-3.556123843360418	22.220541651181893	11	1.02
34732447	Smoking History Predicts High Presence of TILs and Efficacy of PD-1 Blockade in PD-L1 Expression-negative Non-small Cell Lung Cancer Patients.	Anticancer research	2021	16.285019869281534	-33.30484176992267	4	0.36
34729305	PD0325901, an ERK inhibitor, enhances the efficacy of PD-1 inhibitor in non-small cell lung carcinoma.	Acta pharmaceutica Sinica. B	2021	5.578857864672894	-31.20062926475625	13	1.42
34729098	Advancements in Human Breast Cancer Targeted Therapy and Immunotherapy.	Journal of Cancer	2021	22.49492356420528	-1.459313365615443	8	0.91
34727927	Immune checkpoint blockade in the treatment of malignant tumor: current statue and future strategies.	Cancer cell international	2021	25.39237816403393	6.984011376205859	11	1.01
34727912	Oral reactive capillary hemangiomas induced by SHR-1210 in the treatment of non-small cell lung cancer: a case report and literature review.	BMC oral health	2021	51.51259987284523	18.42316107074353	3	0.44
34727389	CPI-203 improves the efficacy of anti-PD-1 therapy by inhibiting the induced PD-L1 overexpression in liver cancer.	Cancer science	2022	-21.103860711363303	-3.991462444922248	3	
34727262	Evaluation of single domain antibodies as nuclear tracers for imaging of the immune checkpoint receptor human lymphocyte activation gene-3 in cancer.	EJNMMI research	2021	7.54110358316168	-55.01131981549482	3	0.43
34722633	Engineered Removal of PD-1 From the Surface of CD19 CAR-T Cells Results in Increased Activation and Diminished Survival.	Frontiers in molecular biosciences	2021	-43.26888622193115	3.714220911852583	9	0.81
34722568	Patients With Microscopic Colitis Have Altered Levels of Inhibitory and Stimulatory Biomarkers in Colon Biopsies and Sera Compared to Non-inflamed Controls.	Frontiers in medicine	2021	76.63547076893255	-1.769803213128882	5	0.72
34722545	Effects of Tumor-Derived Exosome Programmed Death Ligand 1 on Tumor Immunity and Clinical Applications.	Frontiers in cell and developmental biology	2021	-43.52450899010852	-59.09948717174741	6	0.7
34722283	Complete Response of Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC)-Associated Renal Cell Carcinoma to Pembrolizumab Immunotherapy: A Case Report.	Frontiers in oncology	2021	20.18069380637067	27.807314361796337	3	0.46
34720089	CHI3L1 regulates PD-L1 and anti-CHI3L1-PD-1 antibody elicits synergistic antitumor responses.	The Journal of clinical investigation	2021	-28.37797693938815	-5.178929150904011	15	1.74
34718847	Intravesical Pseudomonas aeruginosa mannose-sensitive Hemagglutinin vaccine triggers a tumor-preventing immune environment in an orthotopic mouse bladder cancer model.	Cancer immunology, immunotherapy : CII	2022	4.743555060294688	60.956641117257895	7	1.53
34717645	Serum-derived exosomes promote CD8+ T cells to overexpress PD-1, affecting the prognosis of hypopharyngeal carcinoma.	Cancer cell international	2021	-44.58328208446084	-57.48138087386297	4	0.54
34717150	Potential role of immune cell genetic variants associated with tumor microenvironment response in laryngeal squamous cell carcinoma (LSCC) in terms of clinicopathological features.	Pathology, research and practice	2021	5.4134298605099564	-13.88395863420222	1	0.2
34716871	Emerging combination immunotherapy strategies for breast cancer: dual immune checkpoint modulation, antibody-drug conjugates and bispecific antibodies.	Breast cancer research and treatment	2022	40.91055017022489	7.324929936829332	14	3.21
34715905	Plasma cell infiltration and treatment effect in breast cancer patients treated with neoadjuvant chemotherapy.	Breast cancer research : BCR	2021	0.6713475887609229	21.77147947695147	12	1.33
34713856	Characterization of PD-1/PD-L1 immune checkpoint expression in the pathogenesis of musculoskeletal Langerhans cell histiocytosis: A retrospective study.	Medicine	2021	-29.267373124561853	17.471492069034706	6	0.7
34712512	PD-1 checkpoint blockade enhances adoptive immunotherapy by human Vγ2Vδ2 T cells against human prostate cancer.	Oncoimmunology	2021	-36.7745601383707	3.552723698984036	12	1.32
37425126	Induction of Hypopituitarism Following Ipilimumab/Nivolumab Therapy Followed by Radiation in the Treatment of Metastatic Scalp Melanoma.	HCA healthcare journal of medicine	2021	83.69482547569345	-17.429000409846907	0	0.0
34708250	How to diagnose and manage neurological toxicities of immune checkpoint inhibitors: an update.	Journal of neurology	2022	79.56829545749167	-13.287213777556582	10	2.45
34708079	Tumor Microenvironment Characterization in Breast Cancer Identifies Prognostic and Neoadjuvant Chemotherapy Relevant Signatures.	Frontiers in molecular biosciences	2021	0.1794024283453484	24.70035120569215	2	0.32
34706799	Nano-Coated si-SNHG14 Regulated PD-L1 Expression and Decreased Epithelial-Mesenchymal Transition in Nasopharyngeal Carcinoma Cells.	Journal of biomedical nanotechnology	2021	-19.37498662758817	33.34674406921161	3	0.3
34706720	Development and validation of a novel lipid metabolism-related gene prognostic signature and candidate drugs for patients with bladder cancer.	Lipids in health and disease	2021	3.2538754244061985	57.19231012738062	15	1.83
34706521	Prognostic and predictive value of EZH2 expression and the tumor immune microenvironment in Merkel cell carcinoma.	Polish journal of pathology : official journal of the Polish Society of Pathologists	2021	44.08493387043952	52.686872812589804	1	0.12
34705520	Alloantigen-specific type 1 regulatory T cells suppress through CTLA-4 and PD-1 pathways and persist long-term in patients.	Science translational medicine	2021	-66.89576435923698	-5.696343176717436	22	2.2
34703882	Local adenoviral delivery of soluble CD200R-Ig enhances antitumor immunity by inhibiting CD200-β-catenin-driven M2 macrophage.	Molecular therapy oncolytics	2021	-38.17742509633865	53.7991565774835	2	0.22
34702924	Development of a novel humanized mouse model for improved evaluation of in vivo anti-cancer effects of anti-PD-1 antibody.	Scientific reports	2021	11.099468991793788	-47.75756002989346	3	0.36
34699595	Asxl1 loss cooperates with oncogenic Nras in mice to reprogram the immune microenvironment and drive leukemic transformation.	Blood	2022	-39.64439350531203	13.62010578537924	16	3.47
34699068	PD-1 inhibitors for cutaneous squamous cell carcinoma: A meta-analysis.	The Australasian journal of dermatology	2022	57.31767387136748	5.989581809326874	2	
34694529	Association of Tumor Mutational Burden and Immune Gene Expression with Response to PD-1 Blockade by Sasanlimab Across Tumor Types and Routes of Administration.	Targeted oncology	2021	20.41491467258159	-12.384376387737106	2	0.17
34692530	Case Report: Anlotinib Reverses Nivolumab Resistance in Advanced Primary Pulmonary Lymphoepithelioma-Like Carcinoma With FGFR3 Gene Amplification.	Frontiers in oncology	2021	38.95427342094414	-43.1227490293836	3	0.28
34692478	Prognostic Value of the Pretreatment Lung Immune Prognostic Index in Advanced Small Cell Lung Cancer Patients Treated With First-Line PD-1/PD-L1 Inhibitors Plus Chemotherapy.	Frontiers in oncology	2021	26.95277254491238	-45.19704972408624	8	0.82
34691038	Mechanism of Rhinovirus Immunity and Asthma.	Frontiers in immunology	2021	-77.76441656321649	8.81641624397086	10	1.28
34689789	PD-L1 immunostaining: what pathologists need to know.	Diagnostic pathology	2021	-42.170499352085976	-14.936427643312951	21	2.27
34689435	[IMMUNE CHECKPOINT INHIBITOR-INDUCED DIABETES MELLITUS].	Harefuah	2021	87.72315255430004	-13.928438276495111	0	0.0
34689344	Programmed death 1 expressing CD8+ CXCR5+ follicular T cells constitute effector rather than exhaustive phenotype in patients with chronic hepatitis B.	Hepatology (Baltimore, Md.)	2022	-75.26706449686125	28.09647081102889	7	1.64
34688987	Therapeutic supramolecular tubustecan hydrogel combined with checkpoint inhibitor elicits immunity to combat cancer.	Biomaterials	2021	-28.172194124056507	-51.37341152970805	12	1.19
34688855	Immune checkpoint inhibition for the treatment of cancers: An update and critical review of ongoing clinical trials.	Clinical immunology (Orlando, Fla.)	2021	30.72875154636772	11.81030485205691	17	1.77
34688105	A systematic review of phase II trials exploring anti-PD-1/PD-L1 combinations in patients with solid tumors.	Cancer treatment reviews	2021	51.22394528536693	-12.003359452678554	7	0.73
34688030	Development and validation of a host-dependent, PDL1-independent, biomarker to predict 6-month progression-free survival in metastatic non-small cell lung cancer (mNSCLC) patients treated with anti-PD1 immune checkpoint inhibitors (ICI) in the CERTIM Cohort: The ELY study.	EBioMedicine	2021	30.1584202757973	-45.47014048831096	5	0.59
34686497	Association of PD-1/PD-L1 Co-location with Immunotherapy Outcomes in Non-Small Cell Lung Cancer.	Clinical cancer research : an official journal of the American Association for Cancer Research	2022	14.45184997450721	-30.305128232862952	11	1.93
34686154	Antiangiogenic antibody BD0801 combined with immune checkpoint inhibitors achieves synergistic antitumor activity and affects the tumor microenvironment.	BMC cancer	2021	17.454390331985877	-10.212535732600482	5	0.58
34685625	Adipose-Tissue-Derived Mesenchymal Stem Cells Mediate PD-L1 Overexpression in the White Adipose Tissue of Obese Individuals, Resulting in T Cell Dysfunction.	Cells	2021	-58.59613750892406	5.814057242186398	13	1.4
34681854	LncRNAs in the Regulation of Genes and Signaling Pathways through miRNA-Mediated and Other Mechanisms in Clear Cell Renal Cell Carcinoma.	International journal of molecular sciences	2021	-6.28830486097353	54.2220874767302	12	1.52
34681840	PD-L1 Status in Gastric Cancers, Association with the Transcriptional, Growth Factors, AKT/mTOR Components Change, and Autophagy Initiation.	International journal of molecular sciences	2021	-9.974225302565188	2.991342562697408	2	0.35
34681584	Molecular Mechanism of Food-Derived Polyphenols on PD-L1 Dimerization: A Molecular Dynamics Simulation Study.	International journal of molecular sciences	2021	-31.40966540879544	-36.22324846333463	5	0.64
34681187	Contribution of Ezrin on the Cell Surface Plasma Membrane Localization of Programmed Cell Death Ligand-1 in Human Choriocarcinoma JEG-3 Cells.	Pharmaceuticals (Basel, Switzerland)	2021	-27.3459344985066	-41.17947381050264	7	1.06
34680601	Insights into Potential Pathogenesis and Treatment Options for Immune-Checkpoint Inhibitor-Related Pneumonitis.	Biomedicines	2021	68.39396049836786	-8.68041267087595	7	0.96
34680439	Anticancer Targets and Signaling Pathways Activated by Britannin and Related Pseudoguaianolide Sesquiterpene Lactones.	Biomedicines	2021	-30.636496151868865	-35.47860844919124	5	1.07
34680397	Antigen Presenting Cells from Tumor and Colon of Colorectal Cancer Patients Are Distinct in Activation and Functional Status, but Comparably Responsive to Activated T Cells.	Cancers	2021	5.18118903014255	38.941660014509935	2	0.26
34680373	Currently Used Laboratory Methodologies for Assays Detecting PD-1, PD-L1, PD-L2 and Soluble PD-L1 in Patients with Metastatic Breast Cancer.	Cancers	2021	16.723979115753973	-43.64562516502176	6	0.73
34680292	Limited Predictive or Prognostic Role of Tumor-Infiltrating Tissue-Resident Memory CD8 T Cells in Patients with Hepatocellular Carcinoma Receiving Immunotherapy.	Cancers	2021	-14.706677858602063	43.58809466908353	2	0.25
34679113	Prospective observational study of nutritional/immunologic indices as predictive biomarkers for the response to anti-PD-1 drugs in non-small cell lung cancer (ICI-PREDICT study).	PloS one	2021	30.040174430525745	-44.9012056061982	1	0.13
34678907	Response to toripalimab combined with radiotherapy in advanced non-small cell lung cancer-not otherwise specified: A case report.	Medicine	2021	43.65745020953485	-21.88415949741337	2	0.2
34675925	Case Report: Sustained Remission Due to PD-1-Inhibition in a Metastatic Melanoma Patient With Depleted B Cells.	Frontiers in immunology	2021	33.679433603802465	0.4161066392447808	3	0.31
34675810	Pulmonary Toxicities Associated With the Use of Immune Checkpoint Inhibitors: An Update From the Immuno-Oncology Subgroup of the Neutropenia, Infection & Myelosuppression Study Group of the Multinational Association for Supportive Care in Cancer.	Frontiers in pharmacology	2021	68.60054328882337	-8.856270463735678	8	1.0
34675601	Different Induction of PD-L1 (CD274) and PD-1 (CD279) Expression in THP-1-Differentiated Types 1 and 2 Macrophages.	Journal of inflammation research	2021	-51.434391378724094	0.115907942867353	6	0.7
34675481	Immunotherapeutic Advances for NSCLC.	Biologics : targets & therapy	2021	34.89312573908467	-23.971088111761848	9	1.05
34674460	[Advances in immunotherapy for neuroendocrine neoplasms].	Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery	2021	44.49484133994456	24.718500890954903	0	0.0
34673583	Programmed cell death ligand - 1 expression in triple negative breast carcinoma and its prognostic significance in Indian population.	Indian journal of pathology & microbiology	2021	-8.411881647040806	18.52675639271799	0	0.0
34673297	Adaptive resistance in tumors to anti-PD-1 therapy through re-immunosuppression by upregulation of GPNMB expression.	International immunopharmacology	2021	-33.666771598008786	-21.743717707203437	4	0.36
34670827	Spatially resolved analysis of the T cell immune contexture in lung cancer-associated brain metastases.	Journal for immunotherapy of cancer	2021	-0.2620230372078563	18.201567124791104	7	0.62
34670173	BP-180-specific IgG antibodies: A potential useful candidate for early diagnosis of Bullous pemphigoid during anti-PD-1/anti-PDL-1 of melanoma patients.	Medical hypotheses	2021	70.54517545694897	-27.31468042551284	1	0.14
34668681	The impact of immune checkpoint inhibitors on cost and quality of life in the initial treatment of patients with advanced or metastatic NSCLC.	The American journal of managed care	2021	37.51325547262751	-22.68753249756217	1	0.23
34668680	Immunotherapy in the frontline management of advanced and metastatic NSCLC.	The American journal of managed care	2021	35.588958683754896	-23.88473005761956	3	0.31
34667028	Morphologic and Genomic Characteristics of Breast Cancers Occurring in Individuals with Lynch Syndrome.	Clinical cancer research : an official journal of the American Association for Cancer Research	2022	11.847006157846227	45.64967953021088	10	2.25
34666214	Immune infiltrates in patients with localised high-risk soft tissue sarcoma treated with neoadjuvant chemotherapy without or with regional hyperthermia: A translational research program of the EORTC 62961-ESHO 95 randomised clinical trial.	European journal of cancer (Oxford, England : 1990)	2021	0.8132547769564021	21.860872001737008	9	1.17
34665339	Systemic Therapy for Metastatic Pancreatic Cancer.	Current treatment options in oncology	2021	61.98351553555237	9.283339600319875	19	2.19
34663638	Combined CTLA-4 and PD-L1 blockade in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer is associated with increased myeloid and neutrophil immune subsets in the bone microenvironment.	Journal for immunotherapy of cancer	2021	22.128253860556995	17.171232360866913	20	2.04
34661406	Rational Design of Potent Peptide Inhibitors of the PD-1:PD-L1 Interaction for Cancer Immunotherapy.	Journal of the American Chemical Society	2021	-43.71688966185886	-43.25044058231845	15	1.66
34661332	Genetically Programmable Fusion Cellular Vesicles for Cancer Immunotherapy.	Angewandte Chemie (International ed. in English)	2021	-36.893196634180576	-57.66655903583757	33	3.55
34660264	Immunotherapy and Targeting the Tumor Microenvironment: Current Place and New Insights in Primary Pulmonary NUT Carcinoma.	Frontiers in oncology	2021	5.907276982964199	-16.592925929325595	10	1.34
34659697	Current and emerging treatment options in primary mediastinal B-cell lymphoma.	Therapeutic advances in hematology	2021	43.88165313858907	-8.488130503951231	9	1.17
34659427	Ovarian Cancer Risk Scores Based on Immune-Related Pseudogenes to Predict Overall Survival and Guide Immunotherapy and Chemotherapy.	Evidence-based complementary and alternative medicine : eCAM	2021	2.352709408967355	47.29558105080612	1	0.42
34659228	Sanguisorbae Radix Suppresses Colorectal Tumor Growth Through PD-1/PD-L1 Blockade and Synergistic Effect With Pembrolizumab in a Humanized PD-L1-Expressing Colorectal Cancer Mouse Model.	Frontiers in immunology	2021	33.599694278116445	22.54870012015328	5	0.56
34657509	Identification of Immune Subtypes for Predicting the Prognosis of Patients in Head and Neck Squamous Cell Carcinoma.	Technology in cancer research & treatment	2021	-8.625327827411231	34.88706207383255	2	0.2
34657203	A HER2 target antibody drug conjugate combined with anti-PD-(L)1 treatment eliminates hHER2+ tumors in hPD-1 transgenic mouse model and contributes immune memory formation.	Breast cancer research and treatment	2022	-25.618043939198152	-15.956528533455558	11	2.38
34656856	PD-L1 expression in sarcomas: An immunohistochemical study and review of the literature.	Annals of diagnostic pathology	2021	-21.647954719334702	20.246696922731545	2	0.25
34656305	Infiltrating T lymphocytes and programmed cell death protein-1/programmed death-ligand 1 expression in endometriosis-associated ovarian cancer.	Fertility and sterility	2022	-19.066157575890983	11.689909878148072	4	
34655837	Combining immune checkpoint inhibitors with chemotherapy in advanced solid tumours: A review.	European journal of cancer (Oxford, England : 1990)	2021	34.435948471597285	10.269099047539727	21	2.12
34655506	Increased Expressions of Programmed Death Ligand 1 and Galectin 9 in Transplant Recipients Who Achieved Tolerance After Immunosuppression Withdrawal.	Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society	2022	-65.76423807994372	25.72933049976366	0	
34654698	Uncovering the Immunoregulatory Function and Therapeutic Potential of the PD-1/PD-L1 Axis in Cancer.	Cancer research	2021	-39.35114041539873	-16.51390321252029	6	0.57
34649221	Emerging targets for anticancer vaccination: PD-1.	ESMO open	2021	-41.562123074006855	-43.09841687424287	10	1.02
34649052	Carcinoma showing thymus-like differentiation (CASTLE) of the salivary gland: Report of 2 cases of a hitherto under-recognized extrathyroid counterpart.	Pathology, research and practice	2021	-5.835441737280562	-34.36819981163984	1	0.42
34648658	Tumor DNA-methylome derived epigenetic fingerprint identifies HPV-negative head and neck patients at risk for locoregional recurrence after postoperative radiochemotherapy.	International journal of cancer	2022	-9.591678689661768	40.121767308899805	1	
34646378	Accelerating precision anti-cancer therapy by time-lapse and label-free 3D tumor slice culture platform.	Theranostics	2021	3.389885539628441	-49.172558517392986	9	1.01
34646363	Is there any room for PD-1 inhibitors in combination with platinum-based chemotherapy as frontline treatment of extensive-stage small cell lung cancer? A systematic review and meta-analysis with indirect comparisons among subgroups and landmark survival analyses.	Therapeutic advances in medical oncology	2021	46.970292064390485	-39.82861453801032	4	0.43
34645670	Helicobacter pylori infection disturbs the tumor immune microenvironment and is associated with a discrepant prognosis in gastric de novo diffuse large B-cell lymphoma.	Journal for immunotherapy of cancer	2021	-14.556268230267062	21.75029656082605	6	0.69
34645646	Phase Ib/II Study of Cetuximab plus Pembrolizumab in Patients with Advanced RAS Wild-Type Colorectal Cancer.	Clinical cancer research : an official journal of the American Association for Cancer Research	2021	39.229278690690144	22.33919570653023	4	0.27
34642425	Prognostic implications of tumor-infiltrating T cells in early-stage endometrial cancer.	Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc	2022	-1.8523828276336896	33.3126608947916	9	2.05
34640601	PD-L1 Inhibitors as Monotherapy for the First-Line Treatment of Non-Small-Cell Lung Cancer in PD-L1 Positive Patients: A Safety Data Network Meta-Analysis.	Journal of clinical medicine	2021	50.59669090625383	-18.698115900172123	3	0.25
34638399	Lung Cancer Surgery after Treatment with Anti-PD1/PD-L1 Immunotherapy for Non-Small-Cell Lung Cancer: A Case-Cohort Study.	Cancers	2021	34.6429983496128	-21.22080311617104	4	0.43
34638296	Management of Resectable Stage III-N2 Non-Small-Cell Lung Cancer (NSCLC) in the Age of Immunotherapy.	Cancers	2021	38.501284492116014	-26.310625493079087	11	1.01
34638219	Immunohistochemical expression of programmed death-ligand 1 and CD8 in glioblastomas.	Journal of pathology and translational medicine	2021	-24.43277206604383	50.95002142673234	2	0.23
34637577	Characterization and function of circulating mucosal-associated invariant T cells and γδT cells in oral lichen planus.	Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology	2022	-53.71792951047495	33.768133132407286	9	2.87
34636350	Novel immunotherapeutic drugs for the treatment of lung cancer.	Current opinion in oncology	2022	34.04903003187304	-33.4490859136494	5	1.22
34631560	Targeting Tim-3 in Cancer With Resistance to PD-1/PD-L1 Blockade.	Frontiers in oncology	2021	-32.97571719436114	-20.1900462212706	31	3.27
34631528	A Focal Adhesion-Related Gene Signature Predicts Prognosis in Glioma and Correlates With Radiation Response and Immune Microenvironment.	Frontiers in oncology	2021	-18.66960054774018	56.94123896122312	8	0.99
34630077	Immune Checkpoint Inhibitor-Associated Tumor Lysis Syndrome: A Real-World Pharmacovigilance Study.	Frontiers in pharmacology	2021	71.62346094887275	-1.282127056100831	2	0.28
34628932	Immunotherapy with toripalimab for lung adenocarcinoma in a real-world patient with an Eastern Cooperative Oncology Group performance status (ECOG PS) score of 4: a case report.	Annals of palliative medicine	2021	58.3898906323223	-7.095407503044086	0	0.0
34628927	A narrative review of combination therapy of PD-1/PD-L1 blockade with standard approaches for the treatment of breast cancer: clinical application and immune mechanism.	Annals of palliative medicine	2021	26.619003017478192	-3.503222486276168	1	0.2
34627664	The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry.	European journal of cancer (Oxford, England : 1990)	2021	75.08905625024533	-11.765980957322828	25	3.08
34627641	The Significance of PARP1 as a biomarker for Predicting the Response to PD-L1 Blockade in Patients with PBRM1-mutated Clear Cell Renal Cell Carcinoma.	European urology	2022	18.432313302729813	31.97243032823007	11	2.1
34625602	Immune checkpoint molecule expression is altered in the skin and peripheral blood in vasculitis.	Scientific reports	2021	-58.25263987998449	12.943128502993702	1	0.2
34625514	Increased coexpression of PD-L1 and TIM3/TIGIT is associated with poor overall survival of patients with esophageal squamous cell carcinoma.	Journal for immunotherapy of cancer	2021	-4.793314773853277	26.87037592337639	32	3.55
34620502	A review of immune checkpoint blockade in breast cancer.	Seminars in oncology	2021	27.34577528850232	14.668738091200415	7	0.78
34619915	[Application and prospect of PD-1 or PD-L1 inhibitor in advanced hepatocellular carcinoma].	Zhonghua wai ke za zhi [Chinese journal of surgery]	2021	26.73867959889171	49.54038820453737	0	0.0
34615710	Single-cell profiling reveals the importance of CXCL13/CXCR5 axis biology in lymphocyte-rich classic Hodgkin lymphoma.	Proceedings of the National Academy of Sciences of the United States of America	2021	-28.1489060631484	27.718120616514717	14	1.18
34612587	Cancer testis antigen PRAME: An anti-cancer target with immunomodulatory potential.	Journal of cellular and molecular medicine	2021	-29.966738411308185	-22.071563521494458	10	1.27
34611432	Evaluation of Ferroptosis-related Gene AKR1C1 as a Novel Biomarker Associated with the Immune Microenvironment and Prognosis in Breast Cancer.	International journal of general medicine	2021	-3.842109799955365	50.47179029919223	13	1.57
34611166	Antigen presentation by lung epithelial cells directs CD4+ TRM cell function and regulates barrier immunity.	Nature communications	2021	-72.16456071155491	0.6246625205259999	44	4.1
34610423	Design, synthesis, and structure-activity relationship of PD-1/PD-L1 inhibitors with a benzo[d]isoxazole scaffold.	Bioorganic & medicinal chemistry letters	2021	-39.64350624124677	-41.79470938792871	3	0.38
34608935	A novel prognostic immunoscore based on The Cancer Genome Atlas to predict overall survival in colorectal cancer patients.	Bioscience reports	2021	5.115385758662371	43.13646387947048	1	0.12
34608245	Biomarkers of response to checkpoint inhibitors beyond PD-L1 in lung cancer.	Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc	2022	22.901567411395494	-33.730077879117324	23	4.74
34607896	Predicting cardiac adverse events in patients receiving immune checkpoint inhibitors: a machine learning approach.	Journal for immunotherapy of cancer	2021	80.91824336664783	2.640833392204748	11	1.16
34604752	Avelumab in newly diagnosed glioblastoma.	Neuro-oncology advances	2021	45.80524760724689	28.343506696016767	7	0.95
34604074	Preclinical Characterization of GLS-010 (Zimberelimab), a Novel Fully Human Anti-PD-1 Therapeutic Monoclonal Antibody for Cancer.	Frontiers in oncology	2021	-3.22952002307606	-55.10657881632208	2	0.14
34603331	Successful Treatment of Advanced Intrahepatic Cholangiocarcinoma With a High Tumor Mutational Burden and PD-L1 Expression by PD-1 Blockade Combined With Tyrosine Kinase Inhibitors: A Case Report.	Frontiers in immunology	2021	55.9315027415705	22.324928936081555	9	0.97
34598945	First-in-Class Anti-immunoglobulin-like Transcript 4 Myeloid-Specific Antibody MK-4830 Abrogates a PD-1 Resistance Mechanism in Patients with Advanced Solid Tumors.	Clinical cancer research : an official journal of the American Association for Cancer Research	2022	52.68412183604132	-6.13711370678301	16	3.1
34598713	Pharmacology-based ranking of anti-cancer drugs to guide clinical development of cancer immunotherapy combinations.	Journal of experimental & clinical cancer research : CR	2021	27.46219322978512	-2.269410935495048	23	2.52
34596210	T-cell-intrinsic and -extrinsic regulation of PD-1 function.	International immunology	2021	-50.15108192136241	-5.150823371407995	6	0.53
34595140	Current Landscape and Future Directions of Biomarkers for Immunotherapy in Hepatocellular Carcinoma.	Journal of hepatocellular carcinoma	2021	-13.261994160841198	46.05814640847256	19	1.9
34593621	Trans-arterial chemoembolization as a loco-regional inducer of immunogenic cell death in hepatocellular carcinoma: implications for immunotherapy.	Journal for immunotherapy of cancer	2021	-11.245020831280474	63.66353812370184	46	5.43
34593617	Phase II study of pembrolizumab in refractory esophageal cancer with correlates of response and survival.	Journal for immunotherapy of cancer	2021	48.49299690623974	7.083895019413409	10	0.92
34593437	The Expression of Immune Checkpoint Receptors and Ligands in the Colorectal Cancer Tumor Microenvironment.	Anticancer research	2021	5.448781747733197	37.40466932336615	5	0.4
34592487	The effect of Curcumin on multi-level immune checkpoint blockade and T cell dysfunction in head and neck cancer.	Phytomedicine : international journal of phytotherapy and phytopharmacology	2021	-17.19196333021545	-37.38006490433392	21	2.88
34590054	Programmed Cell Death Protein-1 Inhibitors Versus Programmed Death-Ligand 1 Inhibitors in Addition to Chemotherapy for the First-Line Treatment of Advanced NSCLC: A Systematic Review and Meta-Analysis.	JTO clinical and research reports	2021	49.42615535815153	-19.527308168531896	3	0.23
34589734	Serum programmed cell death proteins in amyotrophic lateral sclerosis.	Brain, behavior, & immunity - health	2021	-46.719449080963166	20.627120449884323	3	0.36
34589081	Functional Exhaustion of HBV-Specific CD8 T Cells Impedes PD-L1 Blockade Efficacy in Chronic HBV Infection.	Frontiers in immunology	2021	-74.58136122801247	23.21868564656602	13	1.56
34585994	Characteristics and clinical correlation of TIM-3 and PD-1/PD-L1 expressions in leukemic cells and tumor microenvironment in newly diagnosed acute myeloid leukemia.	Leukemia & lymphoma	2022	-38.51194994957961	14.169913195031356	2	
34585023	Atezolizumab-induced bilateral anterior uveitis: A case report.	American journal of ophthalmology case reports	2021	82.83081691817148	-24.571684350984853	1	0.09
34583980	Paclitaxel Induces Micronucleation and Activates Pro-Inflammatory cGAS-STING Signaling in Triple-Negative Breast Cancer.	Molecular cancer therapeutics	2021	-25.201479508217275	-44.76384690157066	24	2.37
34583971	Trends in clinical development of pediatric cancer for PD-1 and PD-L1 inhibitors: an analysis of ClinicalTrials.gov.	Journal for immunotherapy of cancer	2021	30.758917062591387	8.183336974728165	4	0.41
34580473	Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways.	Nature reviews. Clinical oncology	2022	28.5519526876654	12.28977193782126	215	47.92
34577564	Role of Ezrin/Radixin/Moesin in the Surface Localization of Programmed Cell Death Ligand-1 in Human Colon Adenocarcinoma LS180 Cells.	Pharmaceuticals (Basel, Switzerland)	2021	-27.343600396410867	-41.1698345991552	8	1.13
34577118	Ezrin Modulates the Cell Surface Expression of Programmed Cell Death Ligand-1 in Human Cervical Adenocarcinoma Cells.	Molecules (Basel, Switzerland)	2021	-27.33712811434172	-41.16675530131747	7	0.93
34576141	Ex Vivo Expanded and Activated Natural Killer Cells Prolong the Overall Survival of Mice with Glioblastoma-like Cell-Derived Tumors.	International journal of molecular sciences	2021	-30.355178543905375	56.84859913921196	6	0.71
34575296	Elevated Plasma Soluble PD-L1 Levels in Out-of-Hospital Cardiac Arrest Patients.	Journal of clinical medicine	2021	-47.04293766052886	23.77961615245767	1	0.1
34572944	How Immunotherapy Has Changed the Continuum of Care in Hepatocellular Carcinoma.	Cancers	2021	30.586711831470502	50.331000609748365	5	0.43
34572764	Tumor-Derived Exosomes: Hidden Players in PD-1/PD-L1 Resistance.	Cancers	2021	-43.52446636178474	-59.91570160835478	11	1.46
34572736	PD-1/PD-L1 Checkpoints and Resveratrol: A Controversial New Way for a Therapeutic Strategy.	Cancers	2021	-29.953049573043803	-37.22474389560908	9	1.15
34572586	Dual Blockade of Lactate/GPR81 and PD-1/PD-L1 Pathways Enhances the Anti-Tumor Effects of Metformin.	Biomolecules	2021	-16.273200612618627	-25.415882781398643	17	2.18
34572463	Targeting TIGIT for Immunotherapy of Cancer: Update on Clinical Development.	Biomedicines	2021	-12.172008685818213	-57.29321612664589	30	3.19
34572311	Immunological Status of Bladder Cancer Patients Based on Urine Leukocyte Composition at Radical Cystectomy.	Biomedicines	2021	6.5879027125826815	59.749928948116576	1	0.13
34572263	Immune Checkpoint Inhibitors in Colorectal Cancer: Challenges and Future Prospects.	Biomedicines	2021	35.701873585563355	19.191095143509283	31	3.36
34572108	Radiotherapy Combined with PD-1 Inhibition Increases NK Cell Cytotoxicity towards Nasopharyngeal Carcinoma Cells.	Cells	2021	40.78100857430125	27.13493088728948	12	1.37
34572014	PD-L1 Expression Fluctuates Concurrently with Cyclin D in Glioblastoma Cells.	Cells	2021	-25.38712321381142	49.02083620966286	11	1.41
34571982	Glucocorticoid and PD-1 Cross-Talk: Does the Immune System Become Confused?	Cells	2021	-42.36090716140004	-11.797210284027756	9	1.23
34571336	Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006.	European journal of cancer (Oxford, England : 1990)	2021	47.14725007046002	0.7626174834291881	8	0.64
34571335	Absence of significant clinical benefit for a systematic routine creatine phosphokinase measurement in asymptomatic patients treated with anti-programmed death protein (ligand) 1 immune checkpoint inhibitor to screen cardiac or neuromuscular immune-related toxicities.	European journal of cancer (Oxford, England : 1990)	2021	75.09323881267579	-12.77393779371333	3	0.38
34570671	Successful PD-1 inhibitor treatment in a patient with refractory transformed follicular lymphoma who failed to respond to CAR-T cell therapy: a case report and literature review.	Cancer biology & therapy	2021	45.63900029590497	-7.74747262518434	1	0.08
34567113	PD-1/PD-L1 Inhibitors versus Chemotherapy for Previously Treated Advanced Gastroesophageal Cancer: A Meta-Analysis of Randomized Controlled Trials.	Journal of oncology	2021	50.162594433717295	15.611544765884192	3	0.26
34567049	Functional Characterization of Pembrolizumab Produced in Nicotiana benthamiana Using a Rapid Transient Expression System.	Frontiers in plant science	2021	47.24911966266366	24.014481562321524	12	1.8
34565440	Granulocytic myeloid-derived suppressor cells inhibit T follicular helper cells during experimental Schistosoma japonicum infection.	Parasites & vectors	2021	-67.40428985203589	14.654474522783646	9	1.38
34563045	Regulation of Immunity in Clear Cell Renal Carcinoma: Role of PD-1, PD-L1, and PD-L2.	Current issues in molecular biology	2021	14.870982406580818	28.30251345343588	2	0.22
34560683	A Comprehensive Clinicopathologic and Molecular Study of 19 Primary Effusion Lymphomas in HIV-infected Patients.	The American journal of surgical pathology	2022	-38.06706427712928	27.991519493038567	9	2.45
34560561	Development of bifunctional anti-PD-L1 antibody MMAE conjugate with cytotoxicity and immunostimulation.	Bioorganic chemistry	2021	31.281443627897456	-13.275640372560831	6	0.65
34558800	Inhibition of CMTM4 Sensitizes Cholangiocarcinoma and Hepatocellular Carcinoma to T Cell-Mediated Antitumor Immunity Through PD-L1.	Hepatology communications	2022	-22.493683005636463	-3.368572235972945	13	2.95
34557714	Current Status and Future Perspective of Immunotherapy in Gastrointestinal Cancers.	Innovation (Cambridge (Mass.))	2020	41.8606759143587	19.528296486979208	24	1.41
34557415	The Predictive Value of Clinical and Molecular Characteristics or Immunotherapy in Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials.	Frontiers in oncology	2021	40.95793800335938	-19.39490213089186	9	0.9
34555935	Endothelial Stromal PD-L1 (Programmed Death Ligand 1) Modulates CD8+ T-Cell Infiltration After Heart Transplantation.	Circulation. Heart failure	2021	-63.1394955586627	-2.759208464735907	10	1.12
34553519	Evaluation of circulating PD-1 and PD-L1 as diagnostic biomarkers in dogs with tumors.	Journal of veterinary science	2021	-15.152897202320242	-14.374843399764629	2	0.45
34553222	PD-1 inhibitors in esophageal cancer: a systematic review of the oncological outcomes associated with PD-1 blockade and the evolving therapeutic paradigm.	Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus	2022	50.57272740228443	15.883957903038642	3	
34552590	PD-1 Blockade Restores the Proliferation of Peripheral Blood Lymphocyte and Inhibits Lymphocyte Apoptosis in a BALB/c Mouse Model of CP BVDV Acute Infection.	Frontiers in immunology	2021	-78.98025427585155	19.11772829275036	8	1.49
34552581	PD-L1-Mediated Immunosuppression in Oral Squamous Cell Carcinoma: Relationship With Macrophage Infiltration and Epithelial to Mesenchymal Transition Markers.	Frontiers in immunology	2021	-9.084865305385769	-10.805566475206067	16	2.01
34552580	The Immune Landscape of Chinese Head and Neck Adenoid Cystic Carcinoma and Clinical Implication.	Frontiers in immunology	2021	1.0460627984022273	8.676384939228708	9	1.51
34552009	Anti-VEGF Antibody Protects against Alveolar Exudate Leakage Caused by Vascular Hyperpermeability, Resulting in Mitigation of Pneumonitis Induced by Immunotherapy.	Molecular cancer therapeutics	2021	64.40688586954256	-10.947970179913462	3	0.24
34547468	PD-L1P146R is prognostic and a negative predictor of response to immunotherapy in gastric cancer.	Molecular therapy : the journal of the American Society of Gene Therapy	2022	-11.238292381936946	5.331107783698876	12	2.57
34541456	The role of immunotherapy for management of advanced thymic epithelial tumors: a narrative review.	Mediastinum (Hong Kong, China)	2021	38.72997104866888	-1.6870387371574922	5	0.68
34539885	Programmed Cell Death Protein 1/Programmed Cell Death Ligand-1 Axis activates Intracellular ERK Signaling in Tumor Cells to Mediate Poor Prognosis in T-cell Lymphoma.	Journal of Cancer	2021	-37.50755276656359	24.09216921129249	1	0.17
34539884	Expression of cancer cell-intrinsic PD-1 associates with PD-L1 and p-S6 and predicts a good prognosis in nasopharyngeal carcinoma.	Journal of Cancer	2021	-17.390052228546356	31.61116725988805	3	0.43
34539412	PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy.	Frontiers in pharmacology	2021	-42.74164422159244	-17.29912988787384	90	10.82
34538865	Perforated appendicitis induced by pembrolizumab: a case report and review of the literature.	Anti-cancer drugs	2022	68.79258190804663	-16.209530059588072	3	
34538007	PD-1/PD-L1 blockade: Prospectives for immunotherapy in cancer and autoimmunity.	IUBMB life	2021	26.159342704518767	15.544273900218265	7	1.05
34537809	A costimulatory molecule-related signature in regard to evaluation of prognosis and immune features for clear cell renal cell carcinoma.	Cell death discovery	2021	17.14731709625979	34.37713443234717	7	0.62
34535611	Human Immunodeficiency Virus Infection Promotes Human Papillomavirus-Mediated Anal Squamous Carcinogenesis: An Immunologic and Pathobiologic Review.	Pathobiology : journal of immunopathology, molecular and cellular biology	2022	0.9765944678919272	-6.590019645066818	7	1.74
34533552	Blockade of the checkpoint PD-1 by its ligand PD-L1 and the immuno-oncological drugs pembrolizumab and nivolumab.	Physical chemistry chemical physics : PCCP	2021	-51.78161757837866	-37.44338558204943	1	0.12
34533233	Expression, prognostic significance and therapeutic implications of PD-L1 in gliomas.	Neuropathology and applied neurobiology	2022	-25.046025500244387	50.78603379522554	5	1.21
34532495	Two severe adverse events triggered by an anti-PD-1 immune checkpoint inhibitor in an advanced lung cancer patient: a case report and review of the literature.	Annals of translational medicine	2021	67.98380768216846	-17.737579518179505	1	0.11
34532285	BTLA-HVEM Couple in Health and Diseases: Insights for Immunotherapy in Lung Cancer.	Frontiers in oncology	2021	28.94706535100177	-29.48397570048431	18	2.03
34531249	Pembrolizumab with low-dose carboplatin for recurrent platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer: survival and immune correlates.	Journal for immunotherapy of cancer	2021	50.60622362496843	4.835440749378748	8	0.9
34530089	Construction and verification of a prognostic risk model based on immunogenomic landscape analysis of bladder caner.	Gene	2022	4.206353699382099	58.17902070121853	0	
34527524	Checkpoint inhibitor-induced fulminant myocarditis, complete atrioventricular block and myasthenia gravis-a case report.	Cardiovascular diagnosis and therapy	2021	85.31497140646938	0.6519299137947119	15	2.05
34527431	Stromal infiltrating mast cells identify immunoevasive subtype high-grade serous ovarian cancer with poor prognosis and inferior immunotherapeutic response.	Oncoimmunology	2021	-0.8490947087315383	28.623066717095647	13	1.19
34527250	Anti-programmed cell death-1 (PD-1) monoclonal antibodies involve reversible cranial dura matter.	Oxford medical case reports	2021	76.21780046476664	-15.565704964264189	0	0.0
34526987	CTLA-4 Synergizes With PD1/PD-L1 in the Inhibitory Tumor Microenvironment of Intrahepatic Cholangiocarcinoma.	Frontiers in immunology	2021	1.4947466460051662	5.134727851887126	9	0.97
34526323	PD-1/PD-L1-Associated Immunoarchitectural Patterns Stratify Pancreatic Cancer Patients into Prognostic/Predictive Subgroups.	Cancer immunology research	2021	-3.916522883213065	3.859517750097373	14	1.36
34525931	Current Challenges in Targeting Tumor Desmoplasia to Improve the Efficacy of Immunotherapy.	Current cancer drug targets	2021	12.79386917812373	1.251221723796292	0	0.0
34524861	Attenuation of peripheral serotonin inhibits tumor growth and enhances immune checkpoint blockade therapy in murine tumor models.	Science translational medicine	2021	-24.08590082294423	-27.01041552118956	26	2.76
34524124	The Programmed Cell Death Ligand-1/Programmed Cell Death-1 Pathway Mediates Pregnancy-Induced Analgesia via Regulating Spinal Inflammatory Cytokines.	Anesthesia and analgesia	2021	-74.5805935563603	-16.048355246619476	2	0.19
34522863	PD-1-stimulated T cell subsets are transcriptionally and functionally distinct.	iScience	2021	-54.702043611005294	-2.751354185056203	4	0.38
34522452	Emerging role of PD-L1 modification in cancer immunotherapy.	American journal of cancer research	2021	-45.751838585124624	-22.762119271511136	17	1.65
34521783	[Association between Immunotherapy with Immune Checkpoint Inhibitors(Anti-PD-1 Antibodies)and Intestinal Microbiota].	Gan to kagaku ryoho. Cancer & chemotherapy	2021	23.023979379701867	41.7341070171187	1	0.14
34518538	TRAPPC4 regulates the intracellular trafficking of PD-L1 and antitumor immunity.	Nature communications	2021	-47.05025796667563	-60.18542446367836	18	1.78
34517693	Histone Deacetylase as a Valuable Predictive Biomarker and Therapeutic Target in Immunotherapy for Non-Small Cell Lung Cancer.	Cancer research and treatment	2022	26.659476452343736	-26.45295388465149	5	1.17
34516743	PD-1 blockade and vaccination provide therapeutic benefit against SIV by inducing broad and functional CD8+ T cells in lymphoid tissue.	Science immunology	2021	-84.4589734599817	14.750280346646228	12	1.18
34516729	Assessment of PD-L1 Expression on Circulating Tumor Cells for Predicting Clinical Outcomes in Patients with Cancer Receiving PD-1/PD-L1 Blockade Therapies.	The oncologist	2021	8.255201811070814	-38.95280186988628	14	1.66
34515880	Programmed cell death-ligand 1 (PD-L1)+ tumour cells and low-reacting programmed cell death 1 (PD1)+ tumour-infiltrating lymphocytes predict poor prognosis in Epstein-Barr virus+ diffuse large B-cell lymphoma.	Clinical and experimental medicine	2022	-37.3158682061791	27.24742342818888	1	
34513918	Molecular and Clinical Characterization of LIGHT/TNFSF14 Expression at Transcriptional Level via 998 Samples With Brain Glioma.	Frontiers in molecular biosciences	2021	-21.67608694501313	55.96685398010432	2	0.34
34512972	Autophagy controls programmed death-ligand 1 expression on cancer cells (Review).	Biomedical reports	2021	-41.57184524564087	-22.23746148528532	9	1.09
34512623	ARID1A, ARID1B, and ARID2 Mutations Serve as Potential Biomarkers for Immune Checkpoint Blockade in Patients With Non-Small Cell Lung Cancer.	Frontiers in immunology	2021	26.477511798376007	-20.223647416316656	20	1.74
34512366	Immune Checkpoint Inhibitors Regulate K+ Channel Activity in Cytotoxic T Lymphocytes of Head and Neck Cancer Patients.	Frontiers in pharmacology	2021	-10.952372814979904	-7.560715813807014	5	0.75
34511582	Diagnostic utility of programmed cell death ligand 1 (clone SP142) immunohistochemistry for malignant lymphoma and lymphoproliferative disorders: A brief review.	Journal of clinical and experimental hematopathology : JCEH	2021	-32.69034078642358	24.216420928243277	7	0.73
34508005	Pharmacodynamic measures within tumors expose differential activity of PD(L)-1 antibody therapeutics.	Proceedings of the National Academy of Sciences of the United States of America	2021	3.2833717027656166	-55.966535510533255	13	1.44
34506637	IgG4-related disease is characterised by the overexpression of immunomodulatory proteins.	Histopathology	2022	-55.469349623497976	14.42426162011885	1	
34504494	Case Report: Complete Response of Primary Massive Hepatocellular Carcinoma to Anti-Programmed Death Ligand-1 Antibody Following Progression on Anti-Programmed Death-1 Antibody.	Frontiers in immunology	2021	28.29431283802906	49.5844176073551	4	0.37
34504192	Depletion of PD-1 or PD-L1 did not affect the mortality of mice infected with Mycobacterium avium.	Scientific reports	2021	-83.82820846868711	2.349370734705501	4	0.58
34503248	Ovarian Cancer in the Era of Immune Checkpoint Inhibitors: State of the Art and Future Perspectives.	Cancers	2021	37.72754052688438	37.97409541728577	34	3.55
34503236	The Role of Oncogenes and Redox Signaling in the Regulation of PD-L1 in Cancer.	Cancers	2021	-40.08590867298832	-10.082768189709215	13	1.42
34503220	Immune Checkpoint Inhibitors in Urothelial Bladder Cancer: State of the Art and Future Perspectives.	Cancers	2021	70.942784761875	21.837746018186944	23	2.67
34503155	Immune-Checkpoint Inhibitors for Metastatic Colorectal Cancer: A Systematic Review of Clinical Outcomes.	Cancers	2021	36.30129648109073	22.03367820707144	10	0.9
34503087	Soluble Biomarkers with Prognostic and Predictive Value in Advanced Non-Small Cell Lung Cancer Treated with Immunotherapy.	Cancers	2021	24.318248586103447	-32.30593623427812	13	1.25
34502071	Allicin May Promote Reversal of T-Cell Dysfunction in Periodontitis via the PD-1 Pathway.	International journal of molecular sciences	2021	-65.33948202867106	-22.21522816223712	1	0.16
34498490	Combination of bevacizumab and dual immunotherapy for extensive-disease small-cell lung cancer: a case report.	Immunotherapy	2021	44.63989993370362	-42.61496036244297	0	0.0
34497850	Programmed Cell Death Ligand 1-Transfected Mouse Bone Marrow Mesenchymal Stem Cells as Targeted Therapy for Rheumatoid Arthritis.	BioMed research international	2021	-52.694255981055214	16.93370426257509	2	0.27
34497758	Molecular Imaging and the PD-L1 Pathway: From Bench to Clinic.	Frontiers in oncology	2021	6.165291301948948	-54.30364386149167	7	1.06
34496466	An update on immunotherapy with PD-1 and PD-L1 blockade.	Yeungnam University journal of medicine	2021	28.24852318012621	-1.957927560493672	0	0.0
34494503	PD-1 gene polymorphisms and thyroid expression of PD-1 ligands differ between Graves' and Hashimoto's diseases.	Autoimmunity	2021	-62.35210589910815	12.33798069935382	3	0.46
34491911	Cell-targeted PD-1 agonists that mimic PD-L1 are potent T cell inhibitors.	JCI insight	2021	-46.510641291536	-6.891761525686178	16	1.89
34491549	Recombinant adenovirus expressing the fusion protein PD1PVR improves CD8+ T cell-mediated antitumor efficacy with long-term tumor-specific immune surveillance in hepatocellular carcinoma.	Cellular oncology (Dordrecht)	2021	-36.79448407389015	53.3809581401702	4	0.48
34490104	Current Status of Immune Checkpoint Inhibitor Immunotherapy for Lung Cancer.	Frontiers in oncology	2021	36.61132884291539	-21.52040974826572	14	1.79
34489963	Immune Checkpoints Expression in Chronic Lung Allograft Rejection.	Frontiers in immunology	2021	8.723051929280572	-14.30203097772681	4	0.65
34488792	Synergy of nanodiamond-doxorubicin conjugates and PD-L1 blockade effectively turns tumor-associated macrophages against tumor cells.	Journal of nanobiotechnology	2021	-29.968329048451142	-51.39604700529974	15	1.9
34485603	Formatting and gene-based delivery of a human PD-L1 single domain antibody for immune checkpoint blockade.	Molecular therapy. Methods & clinical development	2021	-44.63119448346601	-32.925710450061004	5	0.62
34485117	Curcumin as an Adjuvant to Cancer Immunotherapy.	Frontiers in oncology	2021	-17.181557891716658	-37.56441774634472	12	2.01
34484468	Differences in Immunological Landscape between EGFR-Mutated and Wild-Type Lung Adenocarcinoma.	Disease markers	2021	16.539620764094117	-17.462832823702236	2	0.25
34484235	A Robust Hypoxia Risk Score Predicts the Clinical Outcomes and Tumor Microenvironment Immune Characters in Bladder Cancer.	Frontiers in immunology	2021	2.8827242619297606	58.24187775598138	17	1.75
34483944	Toxicity of Immune-Checkpoint Inhibitors in Hematological Malignancies.	Frontiers in pharmacology	2021	76.99422711291538	-7.083029459139107	6	0.5
34482260	Soluble PD-1 (sPD-1) is expressed in human macrophages.	Cellular immunology	2021	-46.10092750573645	19.038232066866467	3	0.39
34480337	Role of the PD-1/PD-L1 Signaling in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis: Recent Insights and Future Directions.	Molecular neurobiology	2021	-73.55980080887132	-5.083356339849378	12	1.48
34480145	Dendritic cells in cancer immunology.	Cellular & molecular immunology	2022	-23.04781659921777	26.383596488282784	53	10.93
34479175	Characterization of CD66b and its relationship between immune checkpoints and their synergistic impact in the prognosis of surgically resected lung adenocarcinoma.	Lung cancer (Amsterdam, Netherlands)	2021	14.344180119026632	-14.2860349214185	5	0.63
34478166	JASPER: Phase 2 trial of first-line niraparib plus pembrolizumab in patients with advanced non-small cell lung cancer.	Cancer	2022	50.42105155207519	-28.372332708713287	36	7.34
34477147	Prognostic significance of volume-based 18F-FDG PET/CT parameters and correlation with PD-L1 expression in patients with surgically resected lung adenocarcinoma.	Medicine	2021	14.46306133212578	-56.15175764569528	4	0.57
34475850	FGF-Receptors and PD-L1 in Anaplastic and Poorly Differentiated Thyroid Cancer: Evaluation of the Preclinical Rationale.	Frontiers in endocrinology	2021	10.688504473316232	2.7022238261883715	12	1.75
34473230	Upregulated PD-L1 delays human neutrophil apoptosis and promotes lung injury in an experimental mouse model of sepsis.	Blood	2021	-60.322774382140345	32.95061461866387	41	5.06
34472429	Antitumor immune response is associated with favorable survival in GEP-NEN G3.	Endocrine-related cancer	2021	2.2287378600300745	13.744166083379476	1	0.09
34471106	Integrin-αV-mediated activation of TGF-β regulates anti-tumour CD8 T cell immunity and response to PD-1 blockade.	Nature communications	2021	-26.953854847062168	-3.989785368792021	21	2.11
34465724	NOTCH1 signaling promotes protein stability of HER3 through the AKT pathway in squamous cell carcinoma of head and neck.	Oncogenesis	2021	-10.461709167701532	36.49801362732252	0	0.0
34465342	T cell exhaustion is associated with the risk of papillary thyroid carcinoma and can be a predictive and sensitive biomarker for diagnosis.	Diagnostic pathology	2021	-8.040236233976753	-21.714687499277098	4	0.54
34462666	Expression of immune checkpoint PD-1 in non-small cell lung cancer is associated with tumor cell DNA-dependent protein kinase.	Molecular and clinical oncology	2021	13.42446711797566	-30.388768729473785	5	0.58
34462476	Myocarditis occurrence with cancer immunotherapy across indications in clinical trial and post-marketing data.	Scientific reports	2021	84.91809698761666	1.5650788992607587	17	1.84
34461854	The epigenetic immunomodulator, HBI-8000, enhances the response and reverses resistance to checkpoint inhibitors.	BMC cancer	2021	30.53802361824564	15.62112826431144	11	1.1
34458785	Finding and characterizing a catalytic antibody light chain, H34, capable of degrading the PD-1 molecule.	RSC chemical biology	2021	-48.8509016607706	-34.23879496075641	6	0.75
34458782	A peptidic inhibitor for PD-1 palmitoylation targets its expression and functions.	RSC chemical biology	2021	-46.06796108737547	-45.18809419428605	15	0.98
34458761	Harnessing the PD-L1 interface peptide for positron emission tomography imaging of the PD-1 immune checkpoint.	RSC chemical biology	2020	4.344477139880699	-57.44095691797549	6	0.39
34458319	Role of a Modified Urothelium Immune Prognostic Index in Patients With Metastatic Urothelial Carcinoma Treated With Anti-PD-1/PD-L1-Based Therapy.	Frontiers in molecular biosciences	2021	65.03689727347125	22.25326148504699	2	0.26
34456733	Preclinical Characterization of a Novel Anti-Cancer PD-L1 Inhibitor RPH-120.	Frontiers in pharmacology	2021	-40.61971177158691	-30.47612448889311	1	0.14
34455737	[Correlation Study on Expression of PD-1 and PD-L1 in Non-small Cell Lung Cancer and Epidermal Growth Factor Receptor Mutations].	Zhongguo fei ai za zhi = Chinese journal of lung cancer	2021	8.479226474442116	-31.401525581850454	1	0.18
34455068	Programmed Death-Ligand 1 Tumor Proportion Score and Overall Survival From First-Line Pembrolizumab in Patients With Nonsquamous Versus Squamous NSCLC.	Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer	2021	49.19171815637073	-28.27691762167717	14	1.26
34454491	Lymphocyte activating gene 3 protein expression in nasopharyngeal carcinoma is correlated with programmed cell death-1 and programmed cell death ligand-1, tumor-infiltrating lymphocytes.	Cancer cell international	2021	9.15102115716018	22.668080534270317	6	0.86
34453440	STAT5 interferes with PD-1 transcriptional activation and affects CD8+ T-cell sensitivity to PD-1-dependent immunoregulation.	International immunology	2021	-53.1203919818055	-4.745388435009255	3	0.23
34448188	[Management of toxicities from immunotherapy].	Deutsche medizinische Wochenschrift (1946)	2021	78.4130800604662	-8.30667886817854	0	0.0
34447305	Differential Dermatologic Adverse Events Associated With Checkpoint Inhibitor Monotherapy and Combination Therapy: A Meta-Analysis of Randomized Control Trials.	Frontiers in pharmacology	2021	70.05498610505548	-22.610586826457048	1	0.08
34445735	Failure of Immunotherapy-The Molecular and Immunological Origin of Immunotherapy Resistance in Lung Cancer.	International journal of molecular sciences	2021	34.541463167054324	-23.487811596865644	22	2.07
34445631	Genetic Variants and Tumor Immune Microenvironment: Clues for Targeted Therapies in Inflammatory Breast Cancer (IBC).	International journal of molecular sciences	2021	8.532127010130617	31.625565554222742	0	0.0
34445462	Atorvastatin Attenuates Programmed Death Ligand-1 (PD-L1) Induction in Human Hepatocellular Carcinoma Cells.	International journal of molecular sciences	2021	-23.168105033242902	-20.18103322608796	3	0.42
34442054	Effect of Systemic Steroid Use for Immune-Related Adverse Events in Patients with Non-Small Cell Lung Cancer Receiving PD-1 Blockade Drugs.	Journal of clinical medicine	2021	79.61725847723085	-19.97081263377457	10	1.04
34441907	Comparative Impact of PD-1 and PD-L1 Inhibitors on Advanced Esophageal or Gastric/Gastroesophageal Junction Cancer Treatment: A Systematic Review and Meta-Analysis.	Journal of clinical medicine	2021	50.45164866469696	16.065097682189162	5	0.56
34441386	PD-L1 Expression in Non-Small Cell Lung Cancer: Data from a Referral Center in Spain.	Diagnostics (Basel, Switzerland)	2021	13.225841887262284	-30.9597055751709	4	0.38
34440380	A Systematic Review on the Therapeutic Potentiality of PD-L1-Inhibiting MicroRNAs for Triple-Negative Breast Cancer: Toward Single-Cell Sequencing-Guided Biomimetic Delivery.	Genes	2021	-17.614406905450522	1.7607742130707842	24	3.06
34439305	PD-L1 Overexpression, SWI/SNF Complex Deregulation, and Profound Transcriptomic Changes Characterize Cancer-Dependent Exhaustion of Persistently Activated CD4+ T Cells.	Cancers	2021	-46.2312840405117	12.09477144928364	17	1.91
34439104	Combination Treatment of Topical Imiquimod Plus Anti-PD-1 Antibody Exerts Significantly Potent Antitumor Effect.	Cancers	2021	-22.109180152352558	-21.649011746045925	6	0.68
34437586	Genomic data from NSCLC tumors reveals correlation between SHP-2 activity and PD-L1 expression and suggests synergy in combining SHP-2 and PD-1/PD-L1 inhibitors.	PloS one	2021	13.48003341879567	-25.51151125157593	5	0.59
34433588	Spatial UMAP and Image Cytometry for Topographic Immuno-oncology Biomarker Discovery.	Cancer immunology research	2021	3.4373768718828623	-46.94293201701075	5	0.33
34432955	Integrated analysis on the N6-methyladenosine-related long noncoding RNAs prognostic signature, immune checkpoints, and immune cell infiltration in clear cell renal cell carcinoma.	Immunity, inflammation and disease	2021	-5.93814274361407	54.86251603196418	12	1.1
34432868	Coevolving JAK2V617F+relapsed AML and donor T cells with PD-1 blockade after stem cell transplantation: an index case.	Blood advances	2021	-38.84134998789472	11.606503478506824	6	0.48
34430353	Subsequent systemic therapy for non-small cell lung cancer patients with immune checkpoint inhibitor-related interstitial lung disease.	Translational lung cancer research	2021	38.9480511608239	-21.0703652873591	1	0.13
34430349	Randomized phase II trial of a first-in-human cancer cell lysate vaccine in patients with thoracic malignancies.	Translational lung cancer research	2021	3.538512345243235	22.486906712688164	6	0.95
34430146	Immunotherapy-Induced Anterior Hypophysitis.	Cureus	2021	82.93288238622468	-14.720265579905227	1	0.21
34429756	Interleukin-22 promotes PD-L1 expression via STAT3 in colon cancer cells.	Oncology letters	2021	-20.712190986224734	4.124923977010111	5	0.65
34424568	Built-in PD-1 blocker to rescue NK-92 activity from PD-L1-mediated tumor escape mechanisms.	FASEB journal : official publication of the Federation of American Societies for Experimental Biology	2021	-42.02735879187631	-1.426607571164834	3	0.35
34424268	Characterization of human FDCs reveals regulation of T cells and antigen presentation to B cells.	The Journal of experimental medicine	2021	-20.57864821236145	29.01526127286881	21	2.05
34424037	Anti-PD-1 treatment-induced immediate central diabetes insipidus: a case report.	Immunotherapy	2021	85.67583268477104	-16.548866080819636	10	1.64
34422119	Immune checkpoint inhibitors in ovarian cancer: where do we stand?	Therapeutic advances in medical oncology	2021	37.13122571331823	39.43100691924447	28	3.06
34421928	Multi-Parameter Quantitative Imaging of Tumor Microenvironments Reveals Perivascular Immune Niches Associated With Anti-Tumor Immunity.	Frontiers in immunology	2021	-9.537324568551016	27.377454354858227	10	0.74
34414683	Programmed death-ligand 1 expression in swine chronic infections and enhancement of interleukin-2 production via programmed death-1/programmed death-ligand 1 blockade.	Immunity, inflammation and disease	2021	-69.4201492250219	-1.9627946487185888	4	0.52
34414125	Immunological Microenvironment Predicts the Survival of the Patients with Hepatocellular Carcinoma Treated with Anti-PD-1 Antibody.	Liver cancer	2021	26.621012076715765	48.17401251692577	40	4.15
34414122	Exploring Markers of Exhausted CD8 T Cells to Predict Response to Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma.	Liver cancer	2021	-15.635948101493058	42.77519876681575	40	3.88
34410881	The effects of PD-1/PD-L1 checkpoint inhibitors on recurrent/metastatic head and neck squamous cell carcinoma: a critical review of the literature and meta-analysis.	Acta oncologica (Stockholm, Sweden)	2021	58.56372246048415	1.6365343194407214	10	1.18
34408926	YTHDF1 and YTHDF2 are associated with better patient survival and an inflamed tumor-immune microenvironment in non-small-cell lung cancer.	Oncoimmunology	2021	13.052002849698551	-24.82022932582942	43	4.06
34408922	Antitumor activity of the third generation EphA2 CAR-T cells against glioblastoma is associated with interferon gamma induced PD-L1.	Oncoimmunology	2021	-45.3458009740545	6.437988219144284	15	1.63
34407968	Association of AXL and PD-L1 Expression with Clinical Outcomes in Patients with Advanced Renal Cell Carcinoma Treated with PD-1 Blockade.	Clinical cancer research : an official journal of the American Association for Cancer Research	2021	14.87158279679254	28.34511797854342	30	3.2
34407878	Exosomes from primed MSCs can educate monocytes as a cellular therapy for hematopoietic acute radiation syndrome.	Stem cell research & therapy	2021	-56.69421746530666	24.551703062944345	5	0.72
34407491	Human Vγ9Vδ2 T cells exert anti-tumor activity independently of PD-L1 expression in tumor cells.	Biochemical and biophysical research communications	2021	-36.71034732869174	3.348262014592672	11	1.2
34404561	Expression of programmed cell death protein 1 (PD-1) and programmed cell death 1 ligand (PD-L1) in adenocarcinomas of the gastroesophageal junction change significantly after neoadjuvant treatment.	European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology	2022	-14.881220637100364	6.751508216174508	2	
34400305	Cisplatin nanoparticles possess stronger anti-tumor synergy with PD1/PD-L1 inhibitors than the parental drug.	Acta biomaterialia	2021	-30.328258360538136	-49.87901089881456	17	1.87
34399818	Anticancer bispecific antibody R&D advances: a study focusing on research trend worldwide and in China.	Journal of hematology & oncology	2021	-16.726149710060806	-48.11314309147608	9	0.88
34394102	Expression of Immune Checkpoint Receptors in Placentae With Infectious and Non-Infectious Chronic Villitis.	Frontiers in immunology	2021	-76.42183625039148	-18.66251965490202	4	0.7
34392493	Downregulation of Programmed Death-1 Pathway Promoting CD8 + T Cell Cytotoxicity in Primary Biliary Cholangitis.	Digestive diseases and sciences	2022	-66.44823343186941	23.18139825159982	4	
34392396	Immunohistochemical analysis of glassy cell carcinoma of the cervix reveals robust lymphocyte infiltrate and the expression of targetable inhibitory immune checkpoints.	Archives of gynecology and obstetrics	2022	-2.902591303630438	-1.889179897839469	0	
34392185	Dissecting the biological heterogeneity of HER2-positive breast cancer.	Breast (Edinburgh, Scotland)	2021	6.478535335236244	28.222706150939825	25	2.59
34391508	Treatment-related adverse events of PD-1 and PD-L1 inhibitor-based combination therapies in clinical trials: a systematic review and meta-analysis.	The Lancet. Oncology	2021	61.3023840214058	-15.03633147757891	74	6.7
34389558	TMB and Inflammatory Gene Expression Associated with Clinical Outcomes following Immunotherapy in Advanced Melanoma.	Cancer immunology research	2021	24.039301246133608	-15.074873398393269	48	4.48
34388391	Targeting Pin1 renders pancreatic cancer eradicable by synergizing with immunochemotherapy.	Cell	2021	-20.362129815445275	-10.243233780097302	69	6.64
34387382	EBV-positive B-cell lymphomas and lymphoproliferative disorders: Review from the perspective of immune escape and immunodeficiency.	Cancer medicine	2021	-37.27459146549421	27.95649768429864	18	2.47
34386930	MicroRNA-4458 Regulates PD-L1 Expression to Enhance Anti-tumor Immunity in NSCLC via Targeting STAT3.	Molecular biotechnology	2021	2.519341898247067	-37.97831949267452	5	0.72
34384429	Peptide vaccine-conjugated mesoporous carriers synergize with immunogenic cell death and PD-L1 blockade for amplified immunotherapy of metastatic spinal.	Journal of nanobiotechnology	2021	-30.40616285889506	-54.24725151910968	10	1.09
34382032	Prolonged Complete Response of Early Stage Primary Adenocarcinoma of the Lung to Nivolumab Monotherapy.	Clinical oncology, case reports	2021	44.10617815927786	-25.9388638792373	0	0.0
34381786	BRAF Mutation as a Potential Therapeutic Target for Checkpoint Inhibitors: A Comprehensive Analysis of Immune Microenvironment in BRAF Mutated Colon Cancer.	Frontiers in cell and developmental biology	2021	8.671076929444894	39.34154884176852	12	1.19
34381456	Combination Therapy of Mithramycin A and Immune Checkpoint Inhibitor for the Treatment of Colorectal Cancer in an Orthotopic Murine Model.	Frontiers in immunology	2021	34.1772816145203	22.76239541839019	6	0.53
34380768	Overcoming microenvironmental resistance to PD-1 blockade in genetically engineered lung cancer models.	Science translational medicine	2021	13.557394035754037	-22.08648995162546	30	2.49
34378081	Anti-PD-(L)1 for KRAS-mutant advanced non-small-cell lung cancers: a meta-analysis of randomized-controlled trials.	Cancer immunology, immunotherapy : CII	2022	23.10065566313552	-22.758924116499895	20	4.04
34377595	Prognostic value of Thyroid Transcription Factor-1 expression in lung adenocarcinoma in patients treated with anti PD-1/PD-L1.	Oncoimmunology	2021	25.076453217693302	-28.89431078510067	7	0.6
34377593	Association of PIK3CA mutation and PTEN loss with expression of CD274 (PD-L1) in colorectal carcinoma.	Oncoimmunology	2021	9.793191985383077	36.86675613823832	9	0.84
34371300	Poor performance status patient with long-lasting major response to pembrolizumab in advanced non-small-cell lung cancer with coexisting POLE mutation and deficient mismatch repair pathway.	Lung cancer (Amsterdam, Netherlands)	2021	35.9475361153781	-20.047419051883075	5	0.42
34369992	Clinical Response to Immunotherapy Targeting Programmed Cell Death Receptor 1/Programmed Cell Death Ligand 1 in Patients With Treatment-Resistant Microsatellite Stable Colorectal Cancer With and Without Liver Metastases.	JAMA network open	2021	36.60858100186666	24.236949821572047	42	4.06
34367961	Analysis of Immune-Related Signatures Related to CD4+ T Cell Infiltration With Gene Co-Expression Network in Pancreatic Adenocarcinoma.	Frontiers in oncology	2021	-2.74700875453431	46.43485729659439	2	0.12
34367960	Case Report: A Squamous Cell Lung Carcinoma Patient Who Responded to Neoadjuvant Immunochemotherapy but Died From Anastomosis Leakage or/and irAEs: Immune Microenvironment and Genomic Features Changes.	Frontiers in oncology	2021	30.20139850703101	-20.416878768117662	0	0.0
34367937	Occurrence of High Microsatellite-Instability/Mismatch Repair Deficiency in Nearly 2,000 Human Adenocarcinomas of the Gastrointestinal Tract, Pancreas, and Bile Ducts: A Study From a Large German Comprehensive Cancer Center.	Frontiers in oncology	2021	12.719065202779031	44.080263896479885	8	0.98
34367478	Immunotherapy against programmed death-1/programmed death ligand 1 in hepatocellular carcinoma: Importance of molecular variations, cellular heterogeneity, and cancer stem cells.	World journal of stem cells	2021	27.00119564948213	48.54883079809203	6	0.63
34367146	Diagnostic and Therapeutic Approach in a Metastatic Vaginal Adenocarcinoma: A Case Report.	Frontiers in immunology	2021	42.00612083292462	33.24406095085955	1	0.14
34367064	Are Markers of Systemic Inflammatory Response Useful in the Management of Patients With Neuroendocrine Neoplasms?	Frontiers in endocrinology	2021	2.094561838640135	13.198319826475725	7	0.7
34363898	The crosstalk between H. pylori virulence factors and the PD1:PD-L1 immune checkpoint inhibitors in progression to gastric cancer.	Immunology letters	2021	-12.123601247947622	3.4893086047490027	11	1.37
34363829	Recent advances in immune checkpoint therapy in non-small cell lung cancer and opportunities for nanoparticle-based therapy.	European journal of pharmacology	2021	39.08648417762	-34.14385847974845	15	1.66
34362830	Novel oncolytic adenovirus expressing enhanced cross-hybrid IgGA Fc PD-L1 inhibitor activates multiple immune effector populations leading to enhanced tumor killing in vitro, in vivo and with patient-derived tumor organoids.	Journal for immunotherapy of cancer	2021	-37.02602745357403	54.270207991878536	18	1.96
34362334	A high CD8 to FOXP3 ratio in the tumor stroma and expression of PTEN in tumor cells are associated with improved survival in non-metastatic triple-negative breast carcinoma.	BMC cancer	2021	-3.506208351617775	22.08315738788556	14	1.52
34359633	Targeting Replication Stress Using CHK1 Inhibitor Promotes Innate and NKT Cell Immune Responses and Tumour Regression.	Cancers	2021	-25.9715071443001	-21.200598508753863	8	0.73
34359579	Follicular Helper T Cells Remodel the Immune Microenvironment of Pancreatic Cancer via Secreting CXCL13 and IL-21.	Cancers	2021	-46.421605102703424	30.82772829885415	27	2.53
34359568	Role of Oncogenic Pathways on the Cancer Immunosuppressive Microenvironment and Its Clinical Implications in Hepatocellular Carcinoma.	Cancers	2021	-12.80264264822159	44.77300674813159	19	1.82
34359249	PD-L1/PD-1 and CTLA-4 Expression in Equine Penile Squamous Cell Carcinomas.	Animals : an open access journal from MDPI	2021	-0.2157923449288337	-8.179966070910158	3	0.52
34357128	Molecular Pathology and Targeted Therapies for Personalized Management of Central Nervous System Germinoma.	Journal of personalized medicine	2021	-19.027358496021584	61.311695894627945	8	2.29
34357118	The Role of Soluble LAG3 and Soluble Immune Checkpoints Profile in Advanced Head and Neck Cancer: A Pilot Study.	Journal of personalized medicine	2021	6.462611095838316	23.963599934549443	20	2.51
34356594	Expression of Programmed Death Receptor 1 (PD-1) Gene and Its Ligand (PD-L1) in Patients with Laryngeal Cancer.	Biomolecules	2021	-9.61109294133157	-2.6736129785967875	5	0.59
34353349	Comparing syngeneic and autochthonous models of breast cancer to identify tumor immune components that correlate with response to immunotherapy in breast cancer.	Breast cancer research : BCR	2021	6.249481493443312	17.534821372507263	9	0.76
34352997	Engineering a High-Affinity PD-1 Peptide for Optimized Immune Cell-Mediated Tumor Therapy.	Cancer research and treatment	2022	-41.85360541893963	-46.59025860382485	2	
34351518	Planning target volume as a predictor of disease progression in inoperable stage III non-small cell lung cancer patients treated with chemoradiotherapy and concurrent and/or sequential immune checkpoint inhibition.	Investigational new drugs	2022	41.448583662146746	-23.7198532400758	4	
34350483	Phase II study of single-agent nivolumab in patients with myelofibrosis.	Annals of hematology	2021	41.04246833641685	-4.662892182113108	8	0.88
34350177	Effect of ISM1 on the Immune Microenvironment and Epithelial-Mesenchymal Transition in Colorectal Cancer.	Frontiers in cell and developmental biology	2021	3.854804475561797	41.310159013402114	10	1.19
34350060	Genomic complexity is associated with epigenetic regulator mutations and poor prognosis in diffuse large B-cell lymphoma.	Oncoimmunology	2021	-29.080565479422045	32.48167048052477	4	0.49
34350059	Development of bispecific anti-c-Met/PD-1 diabodies for the treatment of solid tumors and the effect of c-Met binding affinity on efficacy.	Oncoimmunology	2021	-15.109010204708266	-48.146526542420034	8	0.74
34349843	Research progress in immune checkpoint inhibitors for lung cancer in China.	Therapeutic advances in medical oncology	2021	36.79567275059498	-21.11182054641985	10	1.16
34348839	Locally advanced undifferentiated sarcomatoid carcinoma of the right maxillary sinus with PDCD6-TERT fusion: A rare case report.	Oral oncology	2022	10.533337397505491	15.314502594895554	0	
34347720	Molecular and Immune Correlates of PDCD1 (PD-1), PD-L1 (CD274), and PD-L2 (PDCD1LG2) DNA Methylation in Triple Negative Breast Cancer.	Journal of immunotherapy (Hagerstown, Md. : 1997)	2021	-7.1388706139013385	41.21335047991205	7	0.9
34347390	MAGE-C3 promotes cancer metastasis by inducing epithelial-mesenchymal transition and immunosuppression in esophageal squamous cell carcinoma.	Cancer communications (London, England)	2021	-11.034571795065624	29.833573285077694	8	0.84
34343940	PD-1 inhibitor combined with apatinib modulate the tumor microenvironment and potentiate anti-tumor effect in mice bearing gastric cancer.	International immunopharmacology	2021	47.49016040828352	21.24233123993873	13	1.58
34341578	Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial.	Nature medicine	2021	57.243605431871536	-2.6547982166485875	124	12.74
34341132	High potency STING agonists engage unique myeloid pathways to reverse pancreatic cancer immune privilege.	Journal for immunotherapy of cancer	2021	-22.80528120655465	-44.97512434792583	21	1.99
34341015	Ipilimumab Combination Dosing: Less is More.	Clinical cancer research : an official journal of the American Association for Cancer Research	2021	35.44245297282223	1.9744125423008692	5	0.36
34340254	Phase II study of azacitidine with pembrolizumab in patients with intermediate-1 or higher-risk myelodysplastic syndrome.	British journal of haematology	2021	47.697744476113016	-4.193122447278726	27	2.72
34339045	Infiltration of NK and plasma cells is associated with a distinct immune subset in non-small cell lung cancer.	The Journal of pathology	2021	12.057716975236833	-15.67156133640886	12	1.1
34337277	Management of Thyrotoxicosis Induced by PD1 or PD-L1 Blockade.	Journal of the Endocrine Society	2021	77.25454745408956	-18.43910434985077	4	0.43
34337142	ExoHCR: a sensitive assay to profile PD-L1 level on tumor exosomes for immunotherapeutic prognosis.	Biophysics reports	2020	-42.96061270930576	-55.66963766192961	1	0.1
34336422	Successful Use of Immunotherapy in a Patient with Metastatic Squamous Cell Lung Cancer and Underlying Autoimmune Disease.	Cureus	2021	51.28337877017865	-33.07653172019203	1	0.15
34336290	Association of Antibiotics and Other Drugs with Clinical Outcomes in Metastatic Melanoma Patients Treated with Immunotherapy.	Journal of skin cancer	2021	74.9238306799034	-5.693920585693693	5	0.51
34335618	Inhibitory Molecules PD-1, CD73 and CD39 Are Expressed by CD8+ T Cells in a Tissue-Dependent Manner and Can Inhibit T Cell Responses to Stimulation.	Frontiers in immunology	2021	-76.30320577981178	14.304934750315445	4	0.33
34332787	[Current landscape of biomarker development for immune checkpoint inhibitors targeting PD-1/PD-L1 pathway in oncology].	Therapie	2021	18.47402421804413	-4.463857569115387	1	0.09
34327360	The changing landscape of anti-lung cancer drug clinical trials in mainland China from 2005 to 2020.	The Lancet regional health. Western Pacific	2021	36.95163971953603	-17.63244610097291	13	1.18
34326692	New insights into the important roles of tumor cell-intrinsic PD-1.	International journal of biological sciences	2021	-36.68779296904276	-12.39810193755496	11	1.09
34324079	An Integrated Analysis of Dostarlimab Immunogenicity.	The AAPS journal	2021	44.00869071519528	-1.1009796175750608	7	0.69
34324065	Genetic evidence for the causal association between programmed death-ligand 1 and lung cancer.	Journal of cancer research and clinical oncology	2021	5.721712167603971	-14.499692959118487	1	0.18
34323149	How to Choose a Survival Period? The Impact of Antibiotic Use on OS or PFS in NSCLC Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.	Technology in cancer research & treatment	2021	39.83560635559509	-20.264319066493	6	0.54
34322779	Circulating PD-L1 is associated with T cell infiltration and predicts prognosis in patients with CRLM following hepatic resection.	Cancer immunology, immunotherapy : CII	2022	-15.454749161312176	4.90613390405391	5	1.27
34321489	Changes in expression of PD-L1 on peripheral T cells in patients with melanoma and lung cancer treated with PD-1 inhibitors.	Scientific reports	2021	13.08451505782742	-5.577911007985809	11	1.01
34321165	Biomarkers for immune checkpoint therapy targeting programmed death 1 and programmed death ligand 1.	Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie	2020	19.4738302367472	-4.6752347310640125	8	0.56
34321099	A deep insight into CRISPR/Cas9 application in CAR-T cell-based tumor immunotherapies.	Stem cell research & therapy	2021	-44.42927407957964	1.9680676721236623	42	4.34
34319029	Effect of Primary Systemic Therapy on PD-1, PD-L1, and PD-L2 mRNA Expression in Advanced Breast Cancer.	Asian Pacific journal of cancer prevention : APJCP	2021	-8.632104929846522	15.762291302738888	1	0.08
34319001	RRM2 Regulates Sensitivity to Sunitinib and PD-1 Blockade in Renal Cancer by Stabilizing ANXA1 and Activating the AKT Pathway.	Advanced science (Weinheim, Baden-Wurttemberg, Germany)	2021	62.97565190808459	34.76390588994967	46	5.06
34316400	Role of ferroptosis-related genes in prognostic prediction and tumor immune microenvironment in colorectal carcinoma.	PeerJ	2021	-3.879524142454031	50.53104208999554	9	0.98
34316332	Actionability evaluation of biliary tract cancer by genome transcriptome analysis and Asian cancer knowledgebase.	Oncotarget	2021	21.755887841668063	37.231095421611045	4	0.46
34313545	Preclinical characterization of dostarlimab, a therapeutic anti-PD-1 antibody with potent activity to enhance immune function in in vitro cellular assays and in vivo animal models.	mAbs	2021	-20.585144215079037	-40.93534892926312	13	1.12
34313248	Prognostic value and immunological characteristics of a novel autophagy-related signature in pancreatic cancer.	Journal of biosciences	2021	-2.867490994801758	47.10964168664508	0	0.0
34311143	Cellular and molecular regulation of the programmed death-1/programmed death ligand system and its role in multiple sclerosis and other autoimmune diseases.	Journal of autoimmunity	2021	-73.6556886561641	-5.36261438389568	14	1.81
34310947	Differential Involvement of Programmed Cell Death Ligands in Skin Immune Responses.	The Journal of investigative dermatology	2022	-60.2565355987971	-16.9766122390474	10	2.65
34310275	A Review of Therapeutic Antibodies in Breast Cancer.	Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques	2021	23.7914118564673	3.198022077056748	1	0.14
34309588	A Preclinical Human-Derived Autologous Gastric Cancer Organoid/Immune Cell Co-Culture Model to Predict the Efficacy of Targeted Therapies.	Journal of visualized experiments : JoVE	2021	-11.809567023870494	-0.5796696441678251	11	1.15
34309063	The PD-1/PD-L1 binding inhibitor BMS-202 suppresses the synthesis and secretion of gonadotropins and enhances apoptosis via p38 MAPK signaling pathway.	Drug development research	2022	-36.5791221495236	-35.94326728559612	2	
34307450	Deep Sequencing of T-Cell Receptors for Monitoring Peripheral CD8+ T Cells in Chinese Advanced Non-Small-Cell Lung Cancer Patients Treated With the Anti-PD-L1 Antibody.	Frontiers in molecular biosciences	2021	13.539729590516671	-8.660839168339692	9	0.79
34306258	Systematic Analysis of the Oncogenic Role of WDR62 in Human Tumors.	Disease markers	2021	-4.743345836747687	44.63698623349488	4	0.37
34306031	Mechanisms and Clinical Trials of Hepatocellular Carcinoma Immunotherapy.	Frontiers in genetics	2021	28.991171862528525	50.94430313316087	20	2.27
34306014	P2RY14 Is a Potential Biomarker of Tumor Microenvironment Immunomodulation and Favorable Prognosis in Patients With Head and Neck Cancer.	Frontiers in genetics	2021	-8.330275373787366	36.25191050012353	8	0.88
34305619	Comparisons of Underlying Mechanisms, Clinical Efficacy and Safety Between Anti-PD-1 and Anti-PD-L1 Immunotherapy: The State-of-the-Art Review and Future Perspectives.	Frontiers in pharmacology	2021	26.119203494265943	-5.704480264035932	8	0.87
34301762	M6A Demethylase ALKBH5 Regulates PD-L1 Expression and Tumor Immunoenvironment in Intrahepatic Cholangiocarcinoma.	Cancer research	2021	-31.12182389357593	41.408926785532806	82	7.81
34301276	A vision of immuno-oncology: the Siena think tank of the Italian network for tumor biotherapy (NIBIT) foundation.	Journal of experimental & clinical cancer research : CR	2021	19.105894938645815	5.6480209820667255	2	0.17
34298779	Targeting Metastatic Colorectal Cancer with Immune Oncological Therapies.	Cancers	2021	37.17390377773502	20.781399445515994	5	0.51
34297160	Efficacy and safety of PD-L1 inhibitors versus PD-1 inhibitors in first-line treatment with chemotherapy for extensive-stage small-cell lung cancer.	Cancer immunology, immunotherapy : CII	2022	47.71236641568862	-40.28512020519933	11	2.36
34295674	Immunotherapy in oncogene addicted non-small cell lung cancer.	Translational lung cancer research	2021	35.62845089266832	-23.10640533318368	6	0.52
34295662	Differences in treatment effect size between progression-free survival and overall survival in anti-PD-1/PD-L1 inhibitors-based trials in advanced NSCLC: a systematic review and meta-analysis.	Translational lung cancer research	2021	46.48790477262244	-18.81070581224332	0	0.0
34295326	Combination Therapy With Anti-PD-1 or PD-1 Antibody Alone in Asian Pediatric Patients With Relapsed or Refractory Cancer.	Frontiers in immunology	2021	51.36317141536964	-9.763863658048656	3	0.35
34295319	HIV-1-Specific CAR-T Cells With Cell-Intrinsic PD-1 Checkpoint Blockade Enhance Anti-HIV Efficacy in vivo.	Frontiers in microbiology	2021	-44.53071891058374	4.209457760849488	8	0.73
34291084	An Immune-Gene-Based Classifier Predicts Prognosis in Patients With Cervical Squamous Cell Carcinoma.	Frontiers in molecular biosciences	2021	-0.9399850293111904	51.49981584108548	1	0.1
34290992	Increased PD-1 Level in Severe Cervical Injury Is Associated With the Rare Programmed Cell Death 1 (PDCD1) rs36084323 A Allele in a Dominant Model.	Frontiers in cellular and infection microbiology	2021	-0.6513899662753626	-11.721834222184532	2	0.24
34290906	Phase 1b study of pegylated arginine deiminase (ADI-PEG 20) plus Pembrolizumab in advanced solid cancers.	Oncoimmunology	2021	48.80027487436879	2.163926075933522	19	2.05
34290705	Total Glucosides of Paeony Ameliorate Pristane-Induced Lupus Nephritis by Inducing PD-1 ligands+ Macrophages via Activating IL-4/STAT6/PD-L2 Signaling.	Frontiers in immunology	2021	-50.829967954466845	9.907442587426074	22	2.99
34290245	A human CD137×PD-L1 bispecific antibody promotes anti-tumor immunity via context-dependent T cell costimulation and checkpoint blockade.	Nature communications	2021	-13.652708300592437	-45.54011986755862	39	3.63
34288370	CELF2 is a candidate prognostic and immunotherapy biomarker in triple-negative breast cancer and lung squamous cell carcinoma: A pan-cancer analysis.	Journal of cellular and molecular medicine	2021	-4.872439312405069	25.022576394491235	8	1.04
34286340	Determining PD-L1 Status in Patients With Triple-Negative Breast Cancer: Lessons Learned From IMpassion130.	Journal of the National Cancer Institute	2022	55.98618659669456	-11.024023903185387	22	4.68
34285059	The Liver-Immunity Nexus and Cancer Immunotherapy.	Clinical cancer research : an official journal of the American Association for Cancer Research	2022	29.020889777551293	46.90745207324055	31	6.34
34281988	CD137 and PD-L1 targeting with immunovirotherapy induces a potent and durable antitumor immune response in glioblastoma models.	Journal for immunotherapy of cancer	2021	-33.95147286936801	55.166582934972894	20	2.41
34278517	Circulating regulatory T cells predict efficacy and atypical responses in lung cancer patients treated with PD-1/PD-L1 inhibitors.	Cancer immunology, immunotherapy : CII	2022	28.91105210360469	-16.705855731845933	21	4.36
34277841	The dark side of immunotherapy.	Annals of translational medicine	2021	79.90388793513053	-8.1134275723366	9	0.9
34277839	Turning 'Cold' tumors 'Hot': immunotherapies in sarcoma.	Annals of translational medicine	2021	17.787894561164755	8.196171486645492	14	1.62
34277837	Immune checkpoint inhibitors in lymphoma: challenges and opportunities.	Annals of translational medicine	2021	31.558362886572688	11.854694178767138	22	2.43
34273876	Characterization of ASP8374, a fully-human, antagonistic anti-TIGIT monoclonal antibody.	Cancer treatment and research communications	2021	-11.661071944187151	-57.635189343760594	6	0.76
34272316	Study of 89Zr-Pembrolizumab PET/CT in Patients With Advanced-Stage Non-Small Cell Lung Cancer.	Journal of nuclear medicine : official publication, Society of Nuclear Medicine	2022	8.366720904207785	-57.712454718102535	33	8.54
34272285	Computational design of a synthetic PD-1 agonist.	Proceedings of the National Academy of Sciences of the United States of America	2021	-46.37106833056325	-38.8799385600047	21	2.88
34271938	The immune checkpoint regulator PD-L1 expression are associated with clinical progression in prostate cancer.	World journal of surgical oncology	2021	-12.665110693479908	13.131596571238555	8	0.96
34268872	Efficacy and safety profile of combining programmed cell death-1 (PD-1) inhibitors and antiangiogenic targeting agents as subsequent therapy for advanced or metastatic non-small cell lung cancer (NSCLC).	Thoracic cancer	2021	48.389199746345255	-20.225513772865668	2	0.15
34267616	Co-stimulatory agonists: An insight into the immunotherapy of cancer.	EXCLI journal	2021	22.041254106369163	10.560192865299546	13	1.15
34267181	Lack of intrafollicular memory CD4 + T cells is predictive of early clinical failure in newly diagnosed follicular lymphoma.	Blood cancer journal	2021	-22.18802305872187	30.179366232383764	20	1.72
34266881	Multi-institutional TSA-amplified Multiplexed Immunofluorescence Reproducibility Evaluation (MITRE) Study.	Journal for immunotherapy of cancer	2021	4.087585031791317	-46.53728710376517	31	3.42
34266329	Programmed Death Ligand 1 Expression and Related Markers in Pleuropulmonary Blastoma.	Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society	2021	19.69064824164329	-16.301090365240704	2	0.36
34262942	TRPV4 is a Prognostic Biomarker that Correlates with the Immunosuppressive Microenvironment and Chemoresistance of Anti-Cancer Drugs.	Frontiers in molecular biosciences	2021	3.459336551600279	48.31512939865131	13	1.58
34262855	miRNA-Based Signature Associated With Tumor Mutational Burden in Colon Adenocarcinoma.	Frontiers in oncology	2021	5.072186719324296	50.698240379563984	4	0.56
34259900	Multiplexed single-cell pathology reveals the association of CD8 T-cell heterogeneity with prognostic outcomes in renal cell carcinoma.	Cancer immunology, immunotherapy : CII	2021	15.103640584940944	32.39428631875457	12	1.17
34259259	Residue-specific binding mechanisms of PD-L1 to its monoclonal antibodies by computational alanine scanning.	Physical chemistry chemical physics : PCCP	2021	-46.595375693503456	-39.776999795733154	1	0.12
34257721	PD-1 blockade enhances cytokine-induced killer cell-mediated cytotoxicity in B-cell non-Hodgkin lymphoma cell lines.	Oncology letters	2021	-12.715559559804824	-24.29287605796385	7	0.71
34256897	A case of the third-line treatment of lung adenocarcinoma using nivolumab combined with anlotinib.	Die Pharmazie	2021	39.00897585425003	-43.08676009882264	0	0.0
34256042	Advance investigation on synthetic small-molecule inhibitors targeting PD-1/PD-L1 signaling pathway.	Life sciences	2021	-40.039849158580935	-36.66923978699269	15	1.72
34253637	Dichotomous impact of affinity on the function of T cell engaging bispecific antibodies.	Journal for immunotherapy of cancer	2021	-15.589193018837667	-44.88262222079573	9	0.95
34253205	Relationship between PD-L1 expression, CD8+ T-cell infiltration and prognosis in intrahepatic cholangiocarcinoma patients.	Cancer cell international	2021	0.6737091258053173	5.597179150154548	15	1.87
34252266	Pyroptosis, a new bridge to tumor immunity.	Cancer science	2021	-45.2043408258927	-19.559106224350334	82	8.88
34249934	Immunity-Related Gene Signature Identifies Subtypes Benefitting From Adjuvant Chemotherapy or Potentially Responding to PD1/PD-L1 Blockage in Pancreatic Cancer.	Frontiers in cell and developmental biology	2021	-2.8682653242991085	46.48275493441093	3	0.34
34249685	Genomic Landscape of Chinese Clear Cell Renal Cell Carcinoma Patients With Venous Tumor Thrombus Identifies Chromosome 9 and 14 Deletions and Related Immunosuppressive Microenvironment.	Frontiers in oncology	2021	15.896209363373169	34.33360753729798	7	0.72
34249005	Regulatory Dendritic Cells Induced by Bendamustine Are Associated With Enhanced Flt3 Expression and Alloreactive T-Cell Death.	Frontiers in immunology	2021	-55.36279891128759	-18.95040106142353	8	0.93
34249000	Plasma Extracellular Vesicles Enhance HIV-1 Infection of Activated CD4+ T Cells and Promote the Activation of Latently Infected J-Lat10.6 Cells via miR-139-5p Transfer.	Frontiers in immunology	2021	-85.98924195728966	14.975612509491503	12	1.43
34248982	Defects in Macrophage Reprogramming in Cancer Therapy: The Negative Impact of PD-L1/PD-1.	Frontiers in immunology	2021	-30.42718930058729	-3.8114617481940942	37	3.96
34248561	Durable Response to PD1 Inhibitor Pembrolizumab in a Metastatic, Metaplastic Breast Cancer.	Case reports in oncology	2021	41.71140281466603	6.662862160544472	4	0.59
34246701	Manipulation of TAMs functions to facilitate the immune therapy effects of immune checkpoint antibodies.	Journal of controlled release : official journal of the Controlled Release Society	2021	-32.95768299830155	-4.89694294970245	14	1.6
34244605	Multiplexed imaging analysis of the tumor-immune microenvironment reveals predictors of outcome in triple-negative breast cancer.	Communications biology	2021	2.1458115550753574	-47.88112864981008	17	1.4
34241781	Pembrolizumab in Patients with Refractory Cutaneous Squamous Cell Carcinoma: A Phase II Trial.	Advances in therapy	2021	55.14160277683336	5.711894237027418	6	0.66
34239774	Anti-tumor efficacy of a combination therapy with PD-L1 targeted alpha therapy and adoptive cell transfer of PD-1 deficient melanoma-specific human T-lymphocytes.	Oncoimmunology	2021	-43.493236636961655	-0.525432411201966	1	0.07
34239621	Hyperprogressive Disease Caused by PD-1 Inhibitors for the Treatment of Pan-Cancer.	Disease markers	2021	37.45476607345324	-50.97623698111034	11	1.21
34239134	An ex vivo tumor fragment platform to dissect response to PD-1 blockade in cancer.	Nature medicine	2021	-36.13582574521799	-24.586527605281493	116	10.06
34236760	Pulmonary Aerosol Delivery of Let-7b microRNA Confers a Striking Inhibitory Effect on Lung Carcinogenesis through Targeting the Tumor Immune Microenvironment.	Advanced science (Weinheim, Baden-Wurttemberg, Germany)	2021	0.3411167913026716	-36.95489477325472	13	1.71
34235004	The clinicopathological significance and predictive value for immunotherapy of programmed death ligand-1 expression in Epstein-Barr virus-associated gastric cancer.	Oncoimmunology	2021	-10.220074471506084	8.777503148704168	7	0.82
34234460	PD-L1 Expressing Recurrent Clear Cell Carcinoma of the Vulva with Durable Partial Response to Pembrolizumab: A Case Report.	OncoTargets and therapy	2021	52.369746240154015	5.202424482338685	2	0.34
34234443	Adverse Events Induced by PD-1/PD-L1 Inhibitors: A Real-World Single-Centre Experience with a Management-Based Approach.	Therapeutics and clinical risk management	2021	59.422242071334544	-14.820649140449287	5	0.5
34231370	Immune checkpoint inhibitors for brain metastases in non-small-cell lung cancer: from rationale to clinical application.	Immunotherapy	2021	42.57331089804941	-16.53699867929318	12	1.21
34230169	Possible Pseudo-progression of Non-small Cell Lung Carcinoma in a Patient With Clinical Hyper-progression Associated With Trousseau Syndrome Who Was Treated With Pembrolizumab: A Case Report.	Anticancer research	2021	58.43413510726284	-31.590807811234843	2	0.35
34230109	Novel anti-4-1BB×PD-L1 bispecific antibody augments anti-tumor immunity through tumor-directed T-cell activation and checkpoint blockade.	Journal for immunotherapy of cancer	2021	-14.169761398185686	-46.09705231163399	19	1.91
34228218	Small cell lung cancer stem cells display mesenchymal properties and exploit immune checkpoint pathways in activated cytotoxic T lymphocytes.	Cancer immunology, immunotherapy : CII	2022	7.306763736795846	-17.710842229534496	8	1.75
34226280	Ocular adverse events in PD-1 and PD-L1 inhibitors.	Journal for immunotherapy of cancer	2021	82.27302698791894	-23.380313135642844	8	1.27
34225766	Anti-PD-1 antibodies as a salvage therapy for patients with diffuse large B cell lymphoma who progressed/relapsed after CART19/20 therapy.	Journal of hematology & oncology	2021	45.76126735005207	-7.71628426163986	14	1.25
34221988	A PD-1 Inhibitor Induces Complete Response of Advanced Bladder Urothelial Carcinoma: A Case Report.	Frontiers in oncology	2021	68.47725974462098	17.99429453319128	6	0.75
34221962	Tumor Immune Microenvironment Components and Checkpoint Molecules in Anaplastic Variant of Diffuse Large B-Cell Lymphoma.	Frontiers in oncology	2021	-30.848915114525592	31.638610327300867	3	0.32
34221958	Case Report: Exceptional Response to Avelumab After Failure of Electrochemotherapy in a Patient With Rapidly Progressive, PD-L1-Negative Merkel Cell Carcinoma.	Frontiers in oncology	2021	46.72554928649449	50.67478859385287	1	0.1
34221914	PD-1 Involvement in Peripheral Blood CD8+ T Lymphocyte Dysfunction in Patients with Acute-on-chronic Liver Failure.	Journal of clinical and translational hepatology	2021	-70.84251294528195	25.63249249608576	2	0.24
34220824	Significance of PD1 Alternative Splicing in Celiac Disease as a Novel Source for Diagnostic and Therapeutic Target.	Frontiers in immunology	2021	-13.038733635856104	-4.259794967185475	5	0.62
34219393	Clinical course of patients with renal cell carcinoma or urothelial carcinoma who had stable disease as an initial response to a PD-1 or PD-L1 inhibitor.	Asia-Pacific journal of clinical oncology	2022	63.5318239447946	15.41550065685844	1	
34218652	Characterization of PD-1/PD-L1 immune checkpoint expression in soft tissue sarcomas.	European journal of histochemistry : EJH	2021	-19.859508830447297	19.10585933244715	17	2.02
34217271	Upregulation of ARNTL2 is associated with poor survival and immune infiltration in clear cell renal cell carcinoma.	Cancer cell international	2021	16.866390103191403	35.63056663204252	10	0.99
34216247	First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinoma.	Cancer immunology, immunotherapy : CII	2022	34.2717283968643	-15.486241132963436	5	1.06
34215690	STING agonist loaded lipid nanoparticles overcome anti-PD-1 resistance in melanoma lung metastasis via NK cell activation.	Journal for immunotherapy of cancer	2021	-22.87993135893293	-45.522848368115504	81	8.73
34215688	Systematic review of combinations of targeted or immunotherapy in advanced solid tumors.	Journal for immunotherapy of cancer	2021	51.10556520945936	-11.902567685880475	33	3.21
34214067	Update on immunotherapy for renal cancer.	Medwave	2021	64.18647166823335	29.88225798996228	1	0.32
34211839	The Prognostic Value of Pre-treatment Hemoglobin (Hb) in Patients With Advanced or Metastatic Gastric Cancer Treated With Immunotherapy.	Frontiers in oncology	2021	55.97443267464247	-4.521996875364061	9	1.12
34211455	Leishmania Parasites Drive PD-L1 Expression in Mice and Human Neutrophils With Suppressor Capacity.	Frontiers in immunology	2021	-67.47087234838267	11.545419844078916	8	0.94
34209830	Prognostic Value of PD-L1, PD-1 and CD8A in Canine Diffuse Large B-Cell Lymphoma Detected by RNAscope.	Veterinary sciences	2021	-16.243461748397724	-12.68392194749497	8	1.53
34208673	Splenic Volume as a Surrogate Marker of Immune Checkpoint Inhibitor Efficacy in Metastatic Non Small Cell Lung Cancer.	Cancers	2021	29.161467779243548	-45.06303933594226	4	0.26
34208111	Anti-PD1/PD-L1 Immunotherapy for Non-Small Cell Lung Cancer with Actionable Oncogenic Driver Mutations.	International journal of molecular sciences	2021	31.49270674647432	-25.742903724889626	37	3.69
34204509	Soluble Programmed Death Ligand-1 (sPD-L1): A Pool of Circulating Proteins Implicated in Health and Diseases.	Cancers	2021	-46.18435270897493	19.876799973105687	40	4.48
34203915	The PD-L1/PD-1 Axis Blocks Neutrophil Cytotoxicity in Cancer.	Cells	2021	-34.8481300970185	-8.01996610645315	24	2.58
34202040	Programmed Death-Ligand 1 (PD-L1) Expression Is Induced by Insulin in Pancreatic Ductal Adenocarcinoma Cells Pointing to Its Role in Immune Checkpoint Control.	Medical sciences (Basel, Switzerland)	2021	-58.50233460733792	3.652853937819928	10	1.28
34201323	Site-Specific Radiolabeling of a Human PD-L1 Nanobody via Maleimide-Cysteine Chemistry.	Pharmaceuticals (Basel, Switzerland)	2021	5.539087309480488	-56.19058408229502	12	1.72
34201082	Immunomodulatory mAbs as Tools to Investigate on Cis-Interaction of PD-1/PD-L1 on Tumor Cells and to Set Up Methods for Early Screening of Safe and Potent Combinatorial Treatments.	Cancers	2021	20.90068107398497	6.39032352204209	10	1.28
34196308	Immunostimulatory bacterial antigen-armed oncolytic measles virotherapy significantly increases the potency of anti-PD1 checkpoint therapy.	The Journal of clinical investigation	2021	-34.85020544489555	56.18959619026408	25	2.74
34196068	Systematic Review of PD-1/PD-L1 Inhibitors in Oncology: From Personalized Medicine to Public Health.	The oncologist	2021	53.93904605217816	-13.547029204394311	39	4.18
34195862	Risk factors for adverse events induced by immune checkpoint inhibitors in patients with non-small-cell lung cancer: a systematic review and meta-analysis.	Cancer immunology, immunotherapy : CII	2021	74.03731284293275	-10.273598685850912	23	2.44
34195327	Drug-induced hypersensitivity syndrome like reaction with angioedema and hypotension associated with BRAF inhibitor use and antecedent immune checkpoint therapy.	JAAD case reports	2021	77.05432862849926	-24.34272435050226	2	0.37
34195096	Interferon Regulatory Factor 4 Correlated With Immune Cells Infiltration Could Predict Prognosis for Patients With Lung Adenocarcinoma.	Frontiers in oncology	2021	15.614290927194045	-13.990042862066906	6	0.69
34195086	Inflammatory Markers and Procalcitonin Predict the Outcome of Metastatic Non-Small-Cell-Lung-Cancer Patients Receiving PD-1/PD-L1 Immune-Checkpoint Blockade.	Frontiers in oncology	2021	30.285891232242875	-37.42091340375506	13	1.67
34194394	Adrenocortical Carcinoma Steroid Profiles: In Silico Pan-Cancer Analysis of TCGA Data Uncovers Immunotherapy Targets for Potential Improved Outcomes.	Frontiers in endocrinology	2021	12.213177464676912	18.363753150097985	5	0.6
34193756	Significance of trogocytosis and exosome-mediated transport in establishing and maintaining the tumor microenvironment in lymphoid malignancies.	Journal of clinical and experimental hematopathology : JCEH	2021	-45.21515981724859	-58.27948608004584	4	0.5
34193185	An immune-related pseudogene signature to improve prognosis prediction of endometrial carcinoma patients.	Biomedical engineering online	2021	1.8451103590918392	47.792070882683866	2	0.2
34193182	Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 3rd-5th, 2020, Italy).	Journal of translational medicine	2021	30.619109254350143	28.7570622433042	0	0.0
34190696	Camrelizumab plus Zoledronic Acid Showed Sustained Efficacy in a Patient with Cranial and Spinal Metastases from Lung Adenocarcinoma.	Iranian journal of immunology : IJI	2021	45.99333396870969	-15.204870765462584	0	0.0
34189130	VISTA: A Promising Target for Cancer Immunotherapy?	ImmunoTargets and therapy	2021	22.35452924723437	57.96124468279293	23	2.46
34188273	Expression of Programmed Death-Ligand 1 and Programmed Death-1 in Patients with Extramammary Paget's Disease.	Indian journal of dermatology	2021	-15.122241109965548	11.144874338853	3	0.66
34188068	YIV-906 potentiated anti-PD1 action against hepatocellular carcinoma by enhancing adaptive and innate immunity in the tumor microenvironment.	Scientific reports	2021	-18.627650349060364	-35.061567685297	8	0.99
34186238	Asynchronous blockade of PD-L1 and CD155 by polymeric nanoparticles inhibits triple-negative breast cancer progression and metastasis.	Biomaterials	2021	-31.12831812716024	-52.47062533558138	24	3.02
34182269	Clinical decision support algorithm based on machine learning to assess the clinical response to anti-programmed death-1 therapy in patients with non-small-cell lung cancer.	European journal of cancer (Oxford, England : 1990)	2021	18.53804883085908	-30.336845524812595	9	1.22
34181666	Hydroxychloroquine (HCQ) decreases the benefit of anti-PD-1 immune checkpoint blockade in tumor immunotherapy.	PloS one	2021	19.067084038080623	21.01573903641112	7	0.77
34179721	Identification ACTA2 and KDR as key proteins for prognosis of PD-1/PD-L1 blockade therapy in melanoma.	Animal models and experimental medicine	2021	7.539362450505196	-3.0017862270034814	1	0.11
34179006	The Pyroptosis-Related Signature Predicts Prognosis and Indicates Immune Microenvironment Infiltration in Gastric Cancer.	Frontiers in cell and developmental biology	2021	0.9712286951117276	57.65989469292203	109	12.25
34177954	A Signature-Based Classification of Gastric Cancer That Stratifies Tumor Immunity and Predicts Responses to PD-1 Inhibitors.	Frontiers in immunology	2021	-9.656073088578449	22.422312435566266	11	1.08
34177939	Reversal of the CD8+ T-Cell Exhaustion Induced by Chronic HIV-1 Infection Through Combined Blockade of the Adenosine and PD-1 Pathways.	Frontiers in immunology	2021	-81.54310085492716	14.262143462151451	14	1.54
34177799	Immune Checkpoint Inhibitors-Related Thyroid Dysfunction: Epidemiology, Clinical Presentation, Possible Pathogenesis, and Management.	Frontiers in endocrinology	2021	80.12221351187031	-15.800220782536217	15	1.8
34174446	Non-cytomembrane PD-L1: An atypical target for cancer.	Pharmacological research	2021	-44.01444280827293	16.711148366540172	13	1.54
34172932	Activated T cell-derived exosomal PD-1 attenuates PD-L1-induced immune dysfunction in triple-negative breast cancer.	Oncogene	2021	-43.862561910898194	-58.54129449853995	48	6.02
34172518	Combination of radiation therapy, bempegaldesleukin, and checkpoint blockade eradicates advanced solid tumors and metastases in mice.	Journal for immunotherapy of cancer	2021	25.451061092973777	21.413357833008877	20	1.79
34172514	Generation of a safe and efficacious llama single-domain antibody fragment (vHH) targeting the membrane-proximal region of 4-1BB for engineering therapeutic bispecific antibodies for cancer.	Journal for immunotherapy of cancer	2021	-14.560222030291376	-45.90368240885372	19	2.04
34170628	The PD-1 Interactome.	Advanced biology	2021	-49.98301360677081	-8.923680726021079	17	1.73
34169800	PD-1, PD-L1, and PD-L2 Gene Expression and Tumor Infiltrating Lymphocytes in Canine Melanoma.	Veterinary pathology	2021	-15.487777381778567	-13.056968647075385	13	1.76
34168333	Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC.	Nature reviews. Clinical oncology	2021	33.11663578972665	-26.85777851169277	106	10.05
34168239	GREB1L overexpression correlates with prognosis and immune cell infiltration in lung adenocarcinoma.	Scientific reports	2021	15.987853504246395	-13.559877314702364	9	1.0
34168052	A Subset of Localized Prostate Cancer Displays an Immunogenic Phenotype Associated with Losses of Key Tumor Suppressor Genes.	Clinical cancer research : an official journal of the American Association for Cancer Research	2021	-10.57462154283257	12.733705248871251	14	1.27
34166680	The role of PD-1/PD-L1 checkpoint in arsenic lung tumorigenesis.	Toxicology and applied pharmacology	2021	-34.617916899647575	38.803400992045134	3	0.48
34164269	Neoadjuvant chemoimmunotherapy in resectable stage IIIA/IIIB non-small cell lung cancer.	Translational lung cancer research	2021	31.75490560533644	-20.8947629030699	9	0.72
34164187	Immune checkpoint inhibitors combined with chemotherapy/bevacizumab therapy for patients with advanced lung cancer and heavily treated with EGFR mutation: a retrospective analysis.	Journal of thoracic disease	2021	50.91795844611421	-24.256881068514858	2	0.15
34163753	Target-templated de novo design of macrocyclic d-/l-peptides: discovery of drug-like inhibitors of PD-1.	Chemical science	2021	-45.29678810300091	-43.75206301792496	10	1.27
34163490	PD-L1 Dysregulation in COVID-19 Patients.	Frontiers in immunology	2021	-50.93780340607668	44.31276840050575	43	4.61
34162346	Gliosarcoma vs. glioblastoma: a retrospective case series using molecular profiling.	BMC neurology	2021	-22.30826392906188	58.5777229304918	6	0.86
34161006	[Management of adverse events associated with cancer immunotherapy].	La Revue du praticien	2021	79.43873097480024	-7.240309368088358	1	0.09
34158961	Pembrolizumab dramatically resolves choroidal metastatis from esophageal adenocarcinoma and restores vision: a case report.	Oxford medical case reports	2021	49.06600170532509	8.555734413035946	0	0.0
34158858	Generation of triacyl lipopeptide-modified glycoproteins by metabolic glycoengineering as the neoantigen to boost anti-tumor immune response.	Theranostics	2021	-32.98609073678613	-46.79471278717704	4	0.46
34158594	Functional inactivation of pulmonary MAIT cells following 5-OP-RU treatment of non-human primates.	Mucosal immunology	2021	-82.78821295366049	3.103199631580365	13	1.25
34158475	Interaction between HLA-G and NK cell receptor KIR2DL4 orchestrates HER2-positive breast cancer resistance to trastuzumab.	Signal transduction and targeted therapy	2021	-43.509704508140885	34.150320724384635	25	2.66
34157799	[Cardiotoxicity of Anti-PD-L1 Antibody and the Effect of Levothyroxine  in Attenuating the Related Mortality in Mice].	Zhongguo fei ai za zhi = Chinese journal of lung cancer	2021	82.8218263039285	0.4929845242438395	4	0.66
34157461	Expression regulation and function of PD-1 and PD-L1 in T lymphoma cells.	Cellular immunology	2021	-45.734071874501815	-10.175027905261452	5	0.49
34156708	PD-L1 expression and immune stromal features in HPV-independent cervical adenocarcinoma.	Histopathology	2021	0.8663867701741162	-10.759819737392316	5	0.79
34156677	Screening and characterization of aptamers for recombinant human programmed death-1 and recombinant extracellular domain of human programmed death ligand-1.	European review for medical and pharmacological sciences	2021	-24.961312676722773	-60.861052790268666	3	0.4
34156285	First-line pembrolizumab with or without platinum doublet chemotherapy in non-small-cell lung cancer patients with PD-L1 expression ≥50.	Future oncology (London, England)	2021	46.94818796031043	-30.47834527594476	6	0.48
34153830	Differences in oncological and toxicity outcomes between programmed cell death-1 and programmed cell death ligand-1 inhibitors in metastatic renal cell carcinoma: A systematic review and meta-analysis.	Cancer treatment reviews	2021	52.83284904092239	-11.784663408439584	9	0.84
34153661	PD-1 and PD-L1 inhibitors foster the progression of adult T-cell Leukemia/Lymphoma.	International immunopharmacology	2021	-6.114141875331399	-24.850762692371923	8	0.92
34149911	Suitability of Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration versus Paired Transbronchial Biopsy Specimens for Evaluating Programmed Death Ligand-1 Expression in Stage III and IV Lung Cancer: A Comparative Retrospective Study.	Journal of Cancer	2021	15.45596052390491	-37.07106372365038	0	0.0
34149702	Atezolizumab Monotherapy or Plus Chemotherapy in First-Line Treatment for Advanced Non-Small Cell Lung Cancer Patients: A Meta-Analysis.	Frontiers in immunology	2021	52.28083539060277	-37.96919951397384	1	0.1
34148613	Immunotherapy in colorectal cancer.	Advances in cancer research	2021	35.707141786103826	20.176799980407637	12	1.19
34146865	Immune checkpoint inhibitors for triple-negative breast cancer: From immunological mechanisms to clinical evidence.	International immunopharmacology	2021	38.79138689631775	9.645666128304397	9	1.35
34146376	Contributions of PD-L1 reverse signaling to dendritic cell trafficking.	The FEBS journal	2022	-53.514238325889934	-11.081122349328814	3	
34141773	Atezolizumab-induced anaphylactic shock in a patient with hepatocellular carcinoma undergoing immunotherapy: A case report.	World journal of clinical cases	2021	77.81471836660097	-24.09268884830029	3	0.42
34141625	Regulatory T-Cells as an Emerging Barrier to Immune Checkpoint Inhibition in Lung Cancer.	Frontiers in oncology	2021	15.323956119361208	14.843720578968655	24	2.56
34140315	Massive PD-L1 and CD8 double positive TILs characterize an immunosuppressive microenvironment with high mutational burden in lung cancer.	Journal for immunotherapy of cancer	2021	10.618540987209428	-17.833191531249888	20	1.84
34140198	Immune checkpoint analysis in lip cancer.	Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery	2021	-4.565848985256603	-13.624230873774223	2	0.43
34140079	[Progress on tumor immune checkpoints and their inhibitors in tumor therapy].	Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology	2021	27.169705774988795	10.93008150038644	1	0.13
34138742	Weighting tumor-specific TCR repertoires as a classifier to stratify the immunotherapy delivery in non-small cell lung cancers.	Science advances	2021	13.339550789238814	-8.702225275265945	8	0.72
34135884	Excellent Response to Atezolizumab After Clinically Defined Hyperprogression Upon Previous Treatment With Pembrolizumab in Metastatic Triple-Negative Breast Cancer: A Case Report and Review of the Literature.	Frontiers in immunology	2021	31.178658082696924	-16.376580179018205	9	1.03
34135059	Alveolar Macrophages Inherently Express Programmed Death-1 Ligand 1 for Optimal Protective Immunity and Tolerance.	Journal of immunology (Baltimore, Md. : 1950)	2021	-59.24594532804171	30.633990074159627	6	0.62
34133356	Current and future drug combination strategies based on programmed death-1/programmed death-ligand 1 inhibitors in non-small cell lung cancer.	Chinese medical journal	2021	35.949012010911595	-24.808554107266605	6	0.57
34130052	Knockdown of CDK5 down-regulates PD-L1 via the ubiquitination-proteasome pathway and improves antitumor immunity in lung adenocarcinoma.	Translational oncology	2021	-17.95185704945142	-8.923930658132178	10	1.2
34129469	Standardizing immunohistochemistry methodology for evaluation of PD-1 and PDL-1 expression in upper tract urothelial carcinoma.	The Canadian journal of urology	2021	14.248538729543686	57.019286587247386	2	0.27
34128893	Precise medicine of programmed cell death-1/programmed cell death 1 ligand 1 inhibitor immunotherapy combined radiotherapy for inoperable advanced lung cancer: A protocol for systematic review and meta-analysis.	Medicine	2021	43.24548938213848	-21.64514653043946	0	0.0
34127811	T-regulatory cells predict clinical outcome in soft tissue sarcoma patients: a clinico-pathological study.	British journal of cancer	2021	-2.810914104440249	21.154321620600648	8	0.96
36286830	[Kidney injury associated with antitumor therapy: focus on the adverse events of modern immuno-oncological drugs].	Terapevticheskii arkhiv	2021	71.12587185089716	0.3052764487293775	0	0.0
34124265	PD-1 Coexpression Gene Analysis and the Regulatory Network in Endometrial Cancer Based on Bioinformatics Analysis.	BioMed research international	2021	-18.819833427195935	7.961390128920546	3	0.55
34123823	The Incorporation of Immunotherapy and Targeted Therapy Into Chemoradiation for Cervical Cancer: A Focused Review.	Frontiers in oncology	2021	44.66937443401887	35.68074320647172	10	1.34
34123795	Risk of Cardiac Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-Analysis.	Frontiers in oncology	2021	82.14017017719509	3.0396294279642677	7	0.88
34123476	Management of Hematologic Adverse Events Associated With Immune Checkpoint Inhibitors.	Journal of the advanced practitioner in oncology	2021	77.92310918967323	-8.077812610982125	3	0.5
34122444	Impact of PD-L1 and PD-1 Expression on the Prognostic Significance of CD8+ Tumor-Infiltrating Lymphocytes in Non-Small Cell Lung Cancer.	Frontiers in immunology	2021	10.134270001457155	-18.705514043460507	17	1.5
34122422	Immune Checkpoint Inhibitor-Associated Pneumonitis in Non-Small Cell Lung Cancer: Current Understanding in Characteristics, Diagnosis, and Management.	Frontiers in immunology	2021	66.6983777119138	-9.073507189970412	35	3.79
34120295	PD-1 and PD-L1 gene expressions and their association with Epstein-Barr virus infection in chronic lymphocytic leukemia.	Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico	2021	-39.67382896908143	21.46193649051183	3	0.42
34119606	Sonodynamic therapy complements PD-L1 immune checkpoint inhibition in a murine model of pancreatic cancer.	Cancer letters	2021	-26.95810390070161	-54.81153708934295	15	1.79
34117723	Identification of the FDA-Approved Drug Pyrvinium as a Small-Molecule Inhibitor of the PD-1/PD-L1 Interaction.	ChemMedChem	2021	-39.47423500737224	-39.971072806974185	9	1.33
34115240	The prognostic significance of PD-L1 expression on tumor and immune cells in Merkel cell carcinoma.	Journal of cancer research and clinical oncology	2021	-11.399716661517068	39.7148984267101	4	0.3
34113560	Immunotherapy in Treating EGFR-Mutant Lung Cancer: Current Challenges and New Strategies.	Frontiers in oncology	2021	38.58493749477982	-37.372336016462405	58	7.1
34113555	Rectosigmoid-Junction Squamous Cell Carcinoma With pMMR/MSS Achieved a Partial Response Following PD-1 Blockade Combined With Chemotherapy: A Case Report.	Frontiers in oncology	2021	36.49410714752546	25.56200744487859	2	0.24
34113339	Enhancement of the Tolerogenic Phenotype in the Liver by ImmTOR Nanoparticles.	Frontiers in immunology	2021	-67.36420709140134	29.488535342219976	7	0.96
34112740	T follicular helper cells: linking cancer immunotherapy and immune-related adverse events.	Journal for immunotherapy of cancer	2021	80.6863530448359	-10.490970686531394	23	1.99
34112666	Analysis of multispectral imaging with the AstroPath platform informs efficacy of PD-1 blockade.	Science (New York, N.Y.)	2021	4.791623609638269	-49.83858872200253	73	6.07
34111025	Carbon nanotubes (CNT)-loaded ginsenosides Rb3 suppresses the PD-1/PD-L1 pathway in triple-negative breast cancer.	Aging	2021	-26.37831644579543	-37.26030676513479	19	2.99
34109986	The role of immunotherapy and molecular‑targeted therapy in the treatment of melanoma (Review).	Oncology reports	2021	32.909083387175315	29.810694343603096	9	1.0
34107622	Serum Soluble PD-L1, PD-L2, and B7-H5 as Potential Diagnostic Biomarkers of Human Pancreatic Cancer.	Clinical laboratory	2021	-3.61450286522392	5.331100886255069	4	0.64
34107449	Neoadjuvant immunotherapy is reshaping cancer management across multiple tumour types: The future is now!	European journal of cancer (Oxford, England : 1990)	2021	41.835233973026426	9.18117467670863	15	1.21
34106820	PDL-1 expression in lung carcinoma and its correlation with clinicopathological and prognostic characteristics.	Journal of immunoassay & immunochemistry	2021	11.20162995096387	-29.08347709276574	4	0.52
34104539	Tertiary lymphoid structure signatures are associated with survival and immunotherapy response in muscle-invasive bladder cancer.	Oncoimmunology	2021	7.776508233219064	56.425351272006	14	1.2
34103944	Near Complete Pathologic Response to PD-1 Inhibitor and Radiotherapy in a Patient with Locally Advanced Pancreatic Ductal Adenocarcinoma.	OncoTargets and therapy	2021	42.66000833629539	4.146344704959098	7	0.68
34103942	Comparative Analysis and in vitro Experiments of Signatures and Prognostic Value of Immune Checkpoint Genes in Colorectal Cancer.	OncoTargets and therapy	2021	4.803004552510624	43.12567016934367	6	0.65
34103659	PD-1 derived CA-170 is an oral immune checkpoint inhibitor that exhibits preclinical anti-tumor efficacy.	Communications biology	2021	-38.881920678356266	-37.35005369225914	53	5.4
34103354	Anti-PD-1 elicits regression of undifferentiated pleomorphic sarcomas with UV-mutation signatures.	Journal for immunotherapy of cancer	2021	10.0720840847717	15.51027809067291	6	0.78
34102454	Spatial distribution of immune checkpoint proteins in histological subtypes of lung adenocarcinoma.	Neoplasia (New York, N.Y.)	2021	15.1875023823781	-18.0715626640953	7	0.85
34102137	First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial.	Lancet (London, England)	2021	48.895189630274224	14.170065926846464	795	98.58
34101874	The benefits and risks of CTLA4 inhibitor plus PD1/PDL1 inhibitor in stage IIIB/IV non-small cell lung cancer: A systematic analysis and meta-analysis based on randomized controlled trials.	Journal of clinical pharmacy and therapeutics	2021	43.82846675108997	-19.03791346421104	1	0.21
34101153	Usefulness of 18F-FDG PET/CT in treatment-naive patients with thymic squamous cell carcinoma.	Annals of nuclear medicine	2021	16.39567864590188	-57.78024416280402	2	0.59
34101053	Checkpoint inhibitor therapy for metastatic triple-negative breast cancer.	Cancer metastasis reviews	2021	40.31818414068488	7.781750910447003	42	5.01
34099659	Genetic variation associated with thyroid autoimmunity shapes the systemic immune response to PD-1 checkpoint blockade.	Nature communications	2021	74.14821292136008	-19.85507895674432	24	2.12
34099106	Review of immune checkpoint inhibitors in immuno-oncology.	Advances in pharmacology (San Diego, Calif.)	2021	31.536808413574697	12.574118642798831	37	4.27
34098061	miR-105-5p regulates PD-L1 expression and tumor immunogenicity in gastric cancer.	Cancer letters	2021	-16.18722713833588	1.3192446780847735	24	2.96
34097308	Reduced expression of programmed cell death 1 and programmed cell death ligand 1 in infiltrating inflammatory cells of lichen planus without administration of immune checkpoint inhibitors.	The Journal of dermatology	2021	-62.45555234740457	-16.51854178473195	2	0.27
34096690	Sotorasib for Lung Cancers with KRAS p.G12C Mutation.	The New England journal of medicine	2021	59.3022997286248	-21.591786231416275	568	62.62
34094933	Immune-Related Gene SERPINE1 Is a Novel Biomarker for Diffuse Lower-Grade Gliomas via Large-Scale Analysis.	Frontiers in oncology	2021	-17.3969509660654	55.99997411635397	19	2.35
34093872	An innovative NRF2 nano-modulator induces lung cancer ferroptosis and elicits an immunostimulatory tumor microenvironment.	Theranostics	2021	-33.380854921775885	-54.21039123826246	77	9.1
34093837	Network Meta-analysis Comparing Efficacy, Safety and Tolerability of Anti-PD-1/PD-L1 Antibodies in Solid Cancers.	Journal of Cancer	2021	55.9315399862125	-15.990042599371998	4	0.47
34093814	FUT8 and Protein Core Fucosylation in Tumours: From Diagnosis to Treatment.	Journal of Cancer	2021	8.323000170147562	3.354197356986615	18	2.28
34093591	Highly Multiplexed Phenotyping of Immunoregulatory Proteins in the Tumor Microenvironment by CODEX Tissue Imaging.	Frontiers in immunology	2021	3.406555659670637	-48.2127839928766	39	3.7
34091590	Cisplatin remodels the tumor immune microenvironment via the transcription factor EB in ovarian cancer.	Cell death discovery	2021	0.3398052555045218	31.15821951720776	6	0.61
34088514	Prognostic significance of T cells, PD-L1 immune checkpoint and tumour associated macrophages in clear cell carcinoma of the ovary.	Gynecologic oncology	2021	1.325349414655631	29.62974714072567	8	1.04
34088360	Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer.	Journal of experimental & clinical cancer research : CR	2021	24.444969763585625	8.93827222526849	140	16.05
34086780	Comparative efficacy of treatments for previously treated patients with advanced esophageal and esophagogastric junction cancer: A network meta-analysis.	PloS one	2021	50.48424540628646	13.837753579351638	2	0.25
34084999	Response Rate and Survival at Key Timepoints With PD-1 Blockade vs Chemotherapy in PD-L1 Subgroups: Meta-Analysis of Metastatic NSCLC Trials.	JNCI cancer spectrum	2021	50.38526988303691	-15.802193629741994	14	1.28
34084750	Immunophenotyping Reveals Longitudinal Changes in Circulating Immune Cells During Radium-223 Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer.	Frontiers in oncology	2021	21.84017241077601	18.027345547294896	6	0.6
34084221	Effects of transarterial chemoembolization on the immunological function of patients with hepatocellular carcinoma.	Oncology letters	2021	-11.134531100751053	64.00736662317644	18	2.6
34084203	Rapamycin attenuates gene expression of programmed cell death protein-ligand 1 and Foxp3 in the brain; a novel mechanism proposed for immunotherapy in the brain.	Research in pharmaceutical sciences	2021	-71.65752817496329	-10.158110252290736	1	0.08
34083418	Neoadjuvant immunotherapy for non-small cell lung cancer: right drugs, right patient, right time?	Journal for immunotherapy of cancer	2021	32.988026182637775	-22.05326872849728	24	2.64
34082870	Engineering Cell Membrane-Based Nanovesicles for Melanoma Tumor Treatment.	Journal of biomedical nanotechnology	2021	-36.273090062760105	-56.43135642767261	0	0.0
34082770	Identification of potential therapeutic targets for atherosclerosis by analysing the gene signature related to different immune cells and immune regulators in atheromatous plaques.	BMC medical genomics	2021	-12.692124767608698	55.11104205149618	14	1.73
34081621	Characterization of immune infiltration in sarcomatoid hepatocellular carcinoma.	Aging	2021	-14.555808781211285	45.48562259500766	7	1.08
34081342	The immunoregulatory axis (programmed death-1/programmed death ligand-1) on CD4+ T cells in lupus nephritis: association with vitamin D and chemokine C-X-C motif ligand 12.	Microbiology and immunology	2021	-53.50829171136432	9.231894436650526	1	0.13
34081039	Response To: PD-1 and PD-L1 Immunohistochemistry as a Diagnostic Tool for Classic Hodgkin Lymphoma in Small-volume Biopsies.	The American journal of surgical pathology	2021	-31.523815374468047	24.244546416237107	0	0.0
34080738	Critical COVID-19 is associated with distinct leukocyte phenotypes and transcriptome patterns.	Journal of internal medicine	2021	-52.8953840045211	42.90852122706924	19	1.74
34080369	[PD-L1 : a natural immunosuppressor related to carcinogenesis. A pathologist's point of view].	Revue medicale de Liege	2021	-43.21008983157375	-15.395430002903632	0	0.0
34079767	PD-1-Positive Tumor-Associated Macrophages Define Poor Clinical Outcomes in Patients With Muscle Invasive Bladder Cancer Through Potential CD68/PD-1 Complex Interactions.	Frontiers in oncology	2021	9.965997091825397	56.85353545077036	9	1.08
34077347	Efficacy of PD-1 or PD-L1 Inhibitors and Central Nervous System Metastases in Advanced Cancer: A Meta-Analysis.	Current cancer drug targets	2021	46.3590697076426	-14.811254379145543	1	0.13
34077007	Clinical significance of PD-1 and PD-L1 molecules in patients with diffuse large B-cell lymphoma, not otherwise specified: Correlation with clinical and pathological findings.	Journal of B.U.ON. : official journal of the Balkan Union of Oncology	2021	-34.5364879999899	26.7182440344797	1	0.12
34074094	Programmed Cell Death-Ligand 1 (PD-L1) gene Single Nucleotide Polymorphism in Graves' Disease and Hashimoto's Thyroiditis in Korean Patients.	Endocrinology and metabolism (Seoul, Korea)	2021	-62.35930732011506	12.574065718256922	0	0.0
34073885	Paradigm Change in First-Line Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma.	Cancers	2021	53.11538439544108	30.228270734134643	9	1.07
34071938	Clinical Significance of Tumor Infiltrating Lymphocytes in Association with Hormone Receptor Expression Patterns in Epithelial Ovarian Cancer.	International journal of molecular sciences	2021	-5.475578545409803	21.56793954564878	4	0.43
34071888	Immune Monitoring in Melanoma and Urothelial Cancer Patients Treated with Anti-PD-1 Immunotherapy and SBRT Discloses Tumor Specific Immune Signatures.	Cancers	2021	11.73191205131191	-4.246008875229087	2	0.14
34071393	Immune System-Related Changes in Preclinical GL261 Glioblastoma under TMZ Treatment: Explaining MRSI-Based Nosological Imaging Findings with RT-PCR Analyses.	Cancers	2021	-24.934713644909504	58.30597726910363	3	0.41
34067837	Activity and Safety of Immune Checkpoint Inhibitors in Neuroendocrine Neoplasms: A Systematic Review and Meta-Analysis.	Pharmaceuticals (Basel, Switzerland)	2021	42.087725892737694	11.847585279197116	11	1.13
34067485	Molecular Mechanisms of PD-1 and PD-L1 Activity on a Pan-Cancer Basis: A Bioinformatic Exploratory Study.	International journal of molecular sciences	2021	-18.931457782578157	1.6578570016481098	4	0.58
34066087	PD-1/PD-L1 in Cancer: Pathophysiological, Diagnostic and Therapeutic Aspects.	International journal of molecular sciences	2021	-41.44973073290713	-13.61569457599845	52	5.76
34066060	CXCR2 Levels Correlate with Immune Infiltration and a Better Prognosis of Triple-Negative Breast Cancers.	Cancers	2021	-4.181281487585722	21.981657433748403	18	2.24
34065315	Cripto-1 as a Potential Target of Cancer Stem Cells for Immunotherapy.	Cancers	2021	14.848793974905366	11.291838116297674	8	1.03
34064720	Longitudinal Evaluation of PD-L1 Expression on Circulating Tumor Cells in Non-Small Cell Lung Cancer Patients Treated with Nivolumab.	Cancers	2021	10.266841251256343	-37.57826436425722	11	1.07
34063455	Expectations and Challenges of First-Line Maintenance Therapy for Advanced Ovarian Cancer.	Medicina (Kaunas, Lithuania)	2021	36.89261602425084	39.07866501254795	3	0.35
34063096	Mechanisms of PD-L1 Regulation in Malignant and Virus-Infected Cells.	International journal of molecular sciences	2021	-40.90405018862327	-11.697541497512944	8	0.93
34061408	CMTM4 regulates epithelial-mesenchymal transition and PD-L1 expression in head and neck squamous cell carcinoma.	Molecular carcinogenesis	2021	-12.003888421195482	35.61838283990069	10	1.19
34055632	Identification of Mutator-Derived Alternative Splicing Signatures of Genomic Instability for Improving the Clinical Outcome of Cholangiocarcinoma.	Frontiers in oncology	2021	-1.9373171639868685	60.34915745669888	3	0.32
34054853	Association of Dynamic Changes in Peripheral Blood Indexes With Response to PD-1 Inhibitor-Based Combination Therapy and Survival Among Patients With Advanced Non-Small Cell Lung Cancer.	Frontiers in immunology	2021	27.578323495738363	-40.26930014546352	12	1.33
34054817	A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy.	Frontiers in immunology	2021	-38.81638840639918	-37.88799615127051	12	1.55
34053784	PD-L1 expression and its clinicopathologic and genomic correlation in the non-small cell lung carcinoma patients: An Indian perspective.	Pathology, research and practice	2021	12.258008196759237	-30.758695210268748	8	0.79
34053196	Immunotherapy in advanced Merkel cell carcinoma: Sydney west cancer network experience.	Journal of medical imaging and radiation oncology	2021	46.54215630413663	49.92791710845611	3	0.38
34053179	The immunotherapeutic role of indoleamine 2,3-dioxygenase in head and neck squamous cell carcinoma: A systematic review.	Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery	2021	-3.255517834293822	37.71286159121161	13	1.45
34052328	Luteolin and its derivative apigenin suppress the inducible PD-L1 expression to improve anti-tumor immunity in KRAS-mutant lung cancer.	Cancer letters	2021	-28.978061075253624	-35.087340392572045	59	8.92
34051805	GM-CSF mediates immune evasion via upregulation of PD-L1 expression in extranodal natural killer/T cell lymphoma.	Molecular cancer	2021	-39.53778032135923	31.585363636294428	12	1.29
34051513	RHAMM in liver metastases of stage IV colorectal cancer with mismatch-repair proficient status correlates with tumor budding, cytotoxic T-cells and PD-1/PD-L1.	Pathology, research and practice	2021	11.69876735840996	39.103355959553184	4	0.49
34051178	Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial.	The Lancet. Oncology	2021	67.18448962183986	15.542073222184232	226	24.85
34049595	A retrospective analysis of cardiovascular adverse events associated with immune checkpoint inhibitors.	Cardio-oncology (London, England)	2021	81.682183592889	3.273012888442325	11	1.13
34046338	Treatment-Related Serious Adverse Events of Immune Checkpoint Inhibitors in Clinical Trials: A Systematic Review.	Frontiers in oncology	2021	72.68538975296548	-6.30383489932813	10	0.98
34045311	Cytidine Deaminase APOBEC3A Regulates PD-L1 Expression in Cancer Cells in a JNK/c-JUN-Dependent Manner.	Molecular cancer research : MCR	2021	-14.946162580792576	-6.990170620587159	6	0.66
34044584	KEYNOTE-641: a Phase III study of pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer.	Future oncology (London, England)	2021	52.07003662192993	2.9844559632048635	15	1.41
34043264	Coupling Aptamer-based Protein Tagging with Metabolic Glycan Labeling for In Situ Visualization and Biological Function Study of Exosomal Protein-Specific Glycosylation.	Angewandte Chemie (International ed. in English)	2021	-44.90299465023902	-54.03169252769898	36	4.76
34042092	The utility of evaluating mismatch repair proteins in endometrial carcinoma: an experience from a tertiary referral centre in North India.	Pathologica	2021	11.94890140796812	45.94774781428512	2	0.18
34042015	Pembrolizumab for the treatment of renal cell carcinoma.	Expert opinion on biological therapy	2021	66.21797427591788	31.66030779749949	2	0.14
34039647	High Response Rate and Durability Driven by HLA Genetic Diversity in Patients with Kidney Cancer Treated with Lenvatinib and Pembrolizumab.	Molecular cancer research : MCR	2021	21.89137905359929	29.85750858528208	10	0.7
34036623	Lenvatinib Targets FGF Receptor 4 to Enhance Antitumor Immune Response of Anti-Programmed Cell Death-1 in HCC.	Hepatology (Baltimore, Md.)	2021	10.740029966616705	3.3757917932058787	109	11.75
34035415	Systemic inflammation and pro-inflammatory cytokine profile predict response to checkpoint inhibitor treatment in NSCLC: a prospective study.	Scientific reports	2021	26.09930976372802	-28.97331149233633	27	2.82
34033895	Optimal timing of PD-1 blockade in combination with oncolytic virus therapy.	Seminars in cancer biology	2022	-36.21510368278378	51.03182463565894	15	3.79
34032986	M2 tumor-associated macrophages play important role in predicting response to neoadjuvant chemotherapy in triple-negative breast carcinoma.	Breast cancer research and treatment	2021	-2.3889100543920234	29.9200219527086	12	1.54
34030532	Targeting MSS colorectal cancer with immunotherapy: are we turning the corner?	Expert opinion on biological therapy	2021	37.25126540420486	20.99967438200638	11	1.18
34026795	PD-L1 in Cytological Samples: A Review and a Practical Approach.	Frontiers in medicine	2021	18.23260981808912	-39.84199515852638	12	1.91
34026621	IL-21 Is an Accomplice of PD-L1 in the Induction of PD-1-Dependent Treg Generation in Head and Neck Cancer.	Frontiers in oncology	2021	-48.66090653605661	32.680642555559864	8	1.01
34026438	Aldehyde Dehydrogenase 2 Mediates Alcohol-Induced Colorectal Cancer Immune Escape through Stabilizing PD-L1 Expression.	Advanced science (Weinheim, Baden-Wurttemberg, Germany)	2021	-20.6590489110781	5.953780970866449	22	2.5
34026336	The immune microenvironment and relation to outcome in patients with advanced breast cancer treated with docetaxel with or without gemcitabine.	Oncoimmunology	2021	-0.7855490044700022	22.526725009903508	7	1.05
34026331	PPARγ induces PD-L1 expression in MSS+ colorectal cancer cells.	Oncoimmunology	2021	-24.629086790688017	-29.158456561546764	14	1.27
34025677	IDO1 Expression in Ovarian Cancer Induces PD-1 in T Cells via Aryl Hydrocarbon Receptor Activation.	Frontiers in immunology	2021	-15.471340369896376	-30.747673313400952	32	3.71
34025646	TIGIT and PD-1 Immune Checkpoint Pathways Are Associated With Patient Outcome and Anti-Tumor Immunity in Glioblastoma.	Frontiers in immunology	2021	-26.96373606289345	55.65759556664516	21	2.13
34025438	Clinical Insights Into Novel Immune Checkpoint Inhibitors.	Frontiers in pharmacology	2021	30.084132184800445	12.41926019933658	56	6.28
34024901	Relationship of Programmed Death-1 (PD-1) and Programmed Death Ligand-1 (PD-L1) Polymorphisms with Overall Cancer Susceptibility: An Updated Meta-Analysis of 28 Studies with 60 612 Subjects.	Medical science monitor : international medical journal of experimental and clinical research	2021	3.324431788570934	9.50152747439073	5	0.74
34023785	Identification of vitamin B6 as a PD-L1 suppressor and an adjuvant for cancer immunotherapy.	Biochemical and biophysical research communications	2021	-34.23807852236579	-39.21950438254704	5	0.65
34022844	Downregulation of the PD-1/PD-Ls pathway in peripheral cells correlates with asbestosis severity.	BMC pulmonary medicine	2021	6.336992746479752	10.329840599829222	1	0.11
34022684	Immune checkpoints and cancer development: Therapeutic implications and future directions.	Pathology, research and practice	2021	26.681732489990075	9.91116914802981	17	1.76
34021604	Overexpression of PD-L1 in gingival basal keratinocytes reduces periodontal inflammation in a ligature-induced periodontitis model.	Journal of periodontology	2022	-65.03757932985968	-20.85439044375662	6	1.84
34021249	Thyroid MALT lymphoma: self-harm to gain potential T-cell help.	Leukemia	2021	-31.35920352204692	36.9088024090649	15	1.66
34021032	Pathways of immune exclusion in metastatic osteosarcoma are associated with inferior patient outcomes.	Journal for immunotherapy of cancer	2021	-16.63477009515925	20.120003608153272	32	3.84
34018286	A Durable Response to Pembrolizumab in a Patient with Uterine Serous Carcinoma and Lynch Syndrome due to the MSH6 Germline Mutation.	The oncologist	2021	40.70195306073375	32.23215963586876	5	0.39
34017684	Epigenetic Silencing of Immune-Checkpoint Receptors in Bone Marrow- Infiltrating T Cells in Acute Myeloid Leukemia.	Frontiers in oncology	2021	-38.68701152625434	12.713037828275924	12	1.13
34015129	Activity of PD-1 blockade with nivolumab among patients with recurrent atypical/anaplastic meningioma: phase II trial results.	Neuro-oncology	2022	51.35800961933303	-1.6014351434932654	30	8.22
34014492	PD-L1 Regulates Inflammation in LPS-Induced Lung Epithelial Cells and Vascular Endothelial Cells by Interacting with the HIF-1α Signaling Pathway.	Inflammation	2021	-60.31381820593717	32.69701162840255	9	1.36
34012784	Identification of PD-1 ligands: PD-L1 and PD-L2 on macrophages in lung cancer milieu by flow cytometry.	Translational lung cancer research	2021	3.3072502511085387	-26.25461044031687	5	0.54
34012777	Prognostic impact of PD-1 and PD-L1 expression in malignant pleural mesothelioma: an international multicenter study.	Translational lung cancer research	2021	6.667742097239246	11.209333632192042	14	1.64
34011562	LAG3-PD-1 Combo Impresses in Melanoma.	Cancer discovery	2021	33.2881003438178	1.9889304509274384	9	0.93
34011561	Neutralization of PD-L2 is Essential for Overcoming Immune Checkpoint Blockade Resistance in Ovarian Cancer.	Clinical cancer research : an official journal of the American Association for Cancer Research	2021	-32.92967317419721	-15.632563135711578	22	2.19
34011535	Genomic profiling of advanced cervical cancer to predict response to programmed death-1 inhibitor combination therapy: a secondary analysis of the CLAP trial.	Journal for immunotherapy of cancer	2021	19.463366878171712	-10.676176620097596	18	1.59
34009385	Anti-PD-L1 Therapy Does Not Improve Survival in a Murine Model of Lethal Staphylococcus aureus Pneumonia.	The Journal of infectious diseases	2021	-59.60831690625573	39.11759581671391	6	0.66
34008365	[PD-1/PD-L1 expression and its interaction with interferon-γ in Toxoplasma gondii-infected mice at middle and late pregnancy].	Zhongguo xue xi chong bing fang zhi za zhi = Chinese journal of schistosomiasis control	2021	-75.93353481307786	-17.548998067755885	0	0.0
34006632	FOXP3-based immune risk model for recurrence prediction in small-cell lung cancer at stages I-III.	Journal for immunotherapy of cancer	2021	8.95148833220481	-15.84646596722886	13	1.27
34006584	Ginseng polysaccharides alter the gut microbiota and kynurenine/tryptophan ratio, potentiating the antitumour effect of antiprogrammed cell death 1/programmed cell death ligand 1 (anti-PD-1/PD-L1) immunotherapy.	Gut	2022	-23.362656955055712	-33.621715601300565	100	25.6
34006497	Clinical Outcomes of Platinum-ineligible Patients with Advanced Urothelial Carcinoma Treated With First-line PD1/L1 Inhibitors.	Clinical genitourinary cancer	2021	64.1696281231645	15.531427127981884	12	1.39
34006473	Emerging concepts in PD-1 checkpoint biology.	Seminars in immunology	2021	-48.66449856623091	-10.621567641954536	56	5.55
34002648	PD-L1 SNPs as biomarkers to define benefit in patients with advanced NSCLC treated with immune checkpoint inhibitors.	Tumori	2022	20.40837051021852	-25.477453745012504	4	
34002348	Mechanisms of primary and acquired resistance to PD-1/PD-L1 blockade and the emerging role of gut microbiome.	Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico	2021	-23.390272830902116	0.4485445226902745	5	0.47
34001680	Clinical Perspectives to Overcome Acquired Resistance to Anti-Programmed Death-1 and Anti-Programmed Death Ligand-1 Therapy in Non-Small Cell Lung Cancer.	Molecules and cells	2021	31.2064494789378	-31.923525806368765	8	0.7
34001635	Blocking Wnt/β-catenin Signal Amplifies Anti-PD-1 Therapeutic Efficacy by Inhibiting Tumor Growth, Migration, and Promoting Immune Infiltration in Glioblastomas.	Molecular cancer therapeutics	2021	-28.29253026512845	50.59578701263189	17	1.86
34000287	Inhibition of PAI-1 Blocks PD-L1 Endocytosis and Improves the Response of Melanoma Cells to Immune Checkpoint Blockade.	The Journal of investigative dermatology	2021	-21.81825671359606	-51.49677970313738	14	1.62
33999039	Erratum: Molecular Biomarkers of Response to PD-1/ PD-L1 Immune Checkpoint Blockade in Advanced Bladder Cancer.	Bladder cancer (Amsterdam, Netherlands)	2021	10.181083383628993	61.42602044793724	0	0.0
33998534	Immunotherapy: New insights in breast cancer treatment.	Human antibodies	2021	23.043470575414307	-0.1396249409468681	1	0.12
33996602	Glioma-Associated Stromal Cells Stimulate Glioma Malignancy by Regulating the Tumor Immune Microenvironment.	Frontiers in oncology	2021	-21.02179566846833	55.71886114111159	12	1.63
33996291	Discordant Immune Marker Expression Between Preoperatively Biopsied and Matched Surgically Resected Specimens in Patients With Oral Squamous Cell Carcinoma.	Cureus	2021	-7.005500789544872	-13.465846477030365	1	0.16
33996267	Analysis of the tumor microenvironment and anti-tumor efficacy of subcutaneous vs systemic delivery of the bifunctional agent bintrafusp alfa.	Oncoimmunology	2021	-12.025399896820993	-47.54289459545487	4	0.38
33995529	Advanced Molecular Characterization Using Digital Spatial Profiling Technology on Immunooncology Targets in Methylated Compared with Unmethylated IDH-Wildtype Glioblastoma.	Journal of oncology	2021	-22.51586636115133	58.87935482007028	4	0.42
33994797	IFNγ/PD-L1 Signaling Improves the Responsiveness of Anti-PD-1 Therapy in Colorectal Cancer: An in vitro Study.	OncoTargets and therapy	2021	-19.43329299225309	-19.10428139341789	2	0.27
33993220	PD-1 blockade prevents the progression of oral carcinogenesis.	Carcinogenesis	2021	-10.88300175961653	-14.488870924220018	12	1.4
33991512	Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial.	The Lancet. Oncology	2021	68.53266396693489	12.601033622343143	81	9.01
33990697	PD-L2 suppresses T cell signaling via coinhibitory microcluster formation and SHP2 phosphatase recruitment.	Communications biology	2021	-47.93223295720199	-6.591863711590877	10	1.12
33989559	Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial.	The Lancet. Oncology	2021	53.44746965287471	7.055061667965409	92	10.65
33989092	Use of PD-1 and PD-L1 inhibitors after first-line therapy in esophageal cancer patients in the US.	Current medical research and opinion	2021	52.03740518375019	15.888330196735245	5	0.4
33987445	Molecular Mechanism of Expression Changes of Immunological Indexes of PD-1/sPD-L1 after Radiotherapy in Nonsmall Cell Lung Cancer.	BioMed research international	2021	15.164636983464572	-25.73762689813193	2	0.35
33987375	A comprehensive pan-cancer analysis of CD274 gene amplification, tumor mutation burden, microsatellite instability, and PD-L1 expression in Chinese cancer patients.	Annals of translational medicine	2021	11.786676624549962	-25.06440711714148	5	0.46
33984254	Resistance mechanisms to programmed cell death protein 1 and programmed death ligand 1 inhibitors.	Expert opinion on biological therapy	2021	-36.06215418670087	-20.946697467667946	4	0.52
33981830	Secretion of bispecific protein of anti-PD-1 fused with TGF-β trap enhances antitumor efficacy of CAR-T cell therapy.	Molecular therapy oncolytics	2021	-42.81904100752904	4.928399808498465	25	2.53
33980853	PD-1 suppresses TCR-CD8 cooperativity during T-cell antigen recognition.	Nature communications	2021	-47.86097453187341	-6.189656920093047	29	2.61
33979178	Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma.	Journal of clinical oncology : official journal of the American Society of Clinical Oncology	2021	34.59449592449525	35.84341402096131	94	9.43
33977344	Comprehensive analysis of a chemokine- and chemokine receptor family-based signature for patients with lung adenocarcinoma.	Cancer immunology, immunotherapy : CII	2021	16.899969431155117	-14.249333204237884	11	1.14
33977343	Mechanistic insights into immune checkpoint inhibitor-related hypophysitis: a form of paraneoplastic syndrome.	Cancer immunology, immunotherapy : CII	2021	83.8981292248934	-17.29863458330039	20	2.81
33975004	Intratumoral CD39+CD8+ T Cells Predict Response to Programmed Cell Death Protein-1 or Programmed Death Ligand-1 Blockade in Patients With NSCLC.	Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer	2021	10.878402033396378	-20.872982365794247	28	2.29
33974508	Simlukafusp alfa (FAP-IL2v) immunocytokine is a versatile combination partner for cancer immunotherapy.	mAbs	2021	-10.892622143158482	-46.40469322596685	39	4.01
33972557	Th17 cells contribute to combination MEK inhibitor and anti-PD-L1 therapy resistance in KRAS/p53 mutant lung cancers.	Nature communications	2021	18.109665618783083	-23.84236429861352	32	2.97
33972504	Distinct immune signatures in chronic lymphocytic leukemia and Richter syndrome.	Blood cancer journal	2021	-31.59465575861269	32.8084360223484	12	1.16
33970843	Microsatellite Instability as a Predictor of Outcomes in Colorectal Cancer in the Era of Immune-Checkpoint Inhibitors.	Current drug targets	2021	10.1209946525975	42.532565172422416	3	0.35
33970759	Risk of Ophthalmic Adverse Events in Patients Treated with Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis.	Ocular immunology and inflammation	2022	81.79546815461326	-22.961332564830943	3	
33964937	EMP3 mediates glioblastoma-associated macrophage infiltration to drive T cell exclusion.	Journal of experimental & clinical cancer research : CR	2021	-25.369599638170904	54.99721164297923	14	1.55
33964809	APE1 facilitates PD-L1-mediated progression of laryngeal and hypopharyngeal squamous cell carcinoma.	International immunopharmacology	2021	-7.951328732125234	-8.514968211928574	7	0.97
33963820	A Programmed Cell-Mimicking Nanoparticle Driven by Potato Alkaloid for Targeted Cancer Chemoimmunotherapy.	Advanced healthcare materials	2021	-34.57716684573514	-55.263675165762095	5	0.7
33961890	ATR and BRCA2 Simultaneous Mutation in a ccRCC With Sarcomatoid Differentiation and Extensive Metastases: A Case Report.	Urology	2021	18.202752756174338	32.44891661856372	2	0.24
33959132	Soluble BTN2A1 Is a Potential Prognosis Biomarker in Pre-Treated Advanced Renal Cell Carcinoma.	Frontiers in immunology	2021	9.14529119471211	6.990338778323122	7	0.68
33958876	Exploration of the Associations of lncRNA Expression Patterns with Tumor Mutation Burden and Prognosis in Colon Cancer.	OncoTargets and therapy	2021	4.903029011913133	50.75435900589598	7	0.76
33958794	A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer.	Nature medicine	2021	2.3675079907795995	21.410634439988108	206	17.82
33957184	Emerging immune checkpoints in the tumor microenvironment: Implications for cancer immunotherapy.	Cancer letters	2021	16.656452597890755	11.79407455884484	27	2.75
33957086	Oleic acid and oleoylethanolamide decrease interferon-γ-induced expression of PD-L1 and induce apoptosis in human lung carcinoma cells.	European journal of pharmacology	2021	-29.21883941679398	-31.961106193158678	7	1.38
33956235	The Role of Programmed Death-1 in Type 1 Diabetes.	Current diabetes reports	2021	-57.59887926055158	2.236885946166578	6	0.69
33955303	Characterization of the Clinical Significance of PD-1/PD-Ls Expression and Methylation in Patients With Low-Grade Glioma.	Technology in cancer research & treatment	2021	-18.822677525053468	53.42084272935711	5	0.65
33955235	Management of PD-1/PD-L1 blockade immune-related skin toxicities: perspectives and issues.	Immunotherapy	2021	68.58181364530127	-24.60198400733246	0	0.0
33955097	PD-L1 and beyond: Immuno-oncology in cytopathology.	Cytopathology : official journal of the British Society for Clinical Cytology	2021	18.22704067463329	-40.35803510949639	8	1.41
33954988	Myelodysplastic syndrome patients display alterations in their immune status reflected by increased PD-L1-expressing stem cells and highly dynamic exhausted T-cell frequencies.	British journal of haematology	2021	-36.53250961848237	14.228285536991187	6	0.67
33953302	Identification of molecular signatures associated with early relapse after complete resection of lung adenocarcinomas.	Scientific reports	2021	14.213657242890374	-17.240286715663284	2	0.23
33953290	T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments.	Leukemia	2021	17.391929548349946	17.241388108594816	81	8.7
33950415	Cancer neoantigens as potential targets for immunotherapy.	Clinical & experimental metastasis	2022	16.84185932483674	5.278555973389773	16	3.53
33949196	Discovery of Pyrrole-imidazole Polyamides as PD-L1 Expression Inhibitors and Their Anticancer Activity via Immune and Nonimmune Pathways.	Journal of medicinal chemistry	2021	-34.98459856355258	-39.41259298744959	5	0.54
33946676	Phenotypic Characteristics of the Tumour Microenvironment in Primary and Secondary Hepatocellular Carcinoma.	Cancers	2021	-13.245898139476097	43.99628924969746	8	0.73
33946261	Molecular Mechanism of Small-Molecule Inhibitors in Blocking the PD-1/PD-L1 Pathway through PD-L1 Dimerization.	International journal of molecular sciences	2021	-42.37493978534523	-39.8669602863769	14	2.07
33945288	Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma.	Journal of clinical oncology : official journal of the American Society of Clinical Oncology	2021	46.49787117668589	1.0829096293955247	62	5.59
33943047	Emerging agents for the treatment of metastatic urothelial cancer.	Investigative and clinical urology	2021	71.14756370917924	17.301219213995992	6	0.56
33941684	The aryl hydrocarbon receptor suppresses immunity to oral squamous cell carcinoma through immune checkpoint regulation.	Proceedings of the National Academy of Sciences of the United States of America	2021	-8.935799746091158	-16.56012412083982	23	2.86
33941556	PD1/PD-L1 Expressions in Plasmablastic Lymphoma with Clinicopathological Correlation.	Annals of clinical and laboratory science	2021	-34.3920591116501	24.88491219285086	3	0.58
33939321	Programmed death ligand-1 regulates angiogenesis and metastasis by participating in the c-JUN/VEGFR2 signaling axis in ovarian cancer.	Cancer communications (London, England)	2021	-22.33078146739755	10.075461541905982	24	2.72
33938739	Discovery of 4-Arylindolines Containing a Thiazole Moiety as Potential Antitumor Agents Inhibiting the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction.	Journal of medicinal chemistry	2021	-39.956455872481726	-41.66856530884419	13	1.54
33937012	Response Efficacy of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-Analysis.	Frontiers in oncology	2021	51.96301728691456	-13.252413758647474	29	2.71
33936069	IFNγ, and to a Lesser Extent TNFα, Provokes a Sustained Endothelial Costimulatory Phenotype.	Frontiers in immunology	2021	-62.33061359353452	-12.592783912471791	6	0.8
33934451	Casp8 acts through A20 to inhibit PD-L1 expression: The mechanism and its implication in immunotherapy.	Cancer science	2021	-31.24839581173019	-10.46459293310256	12	1.24
33934440	5-Aminolevulinic acid/sodium ferrous citrate enhanced the antitumor effects of programmed cell death-ligand 1 blockade by regulation of exhausted T cell metabolism in a melanoma model.	Cancer science	2021	-28.634824571840383	-28.448701915116917	5	0.48
33933843	Evaluating the efficacy and safety of immune checkpoint inhibitors by detecting the exposure-response: An inductive review.	International immunopharmacology	2021	32.857108992083454	-9.51877632836741	2	0.22
33932141	Immune checkpoint inhibitors in Wilms' tumor and Neuroblastoma: What now?	Cancer reports (Hoboken, N.J.)	2021	10.693885929708513	26.865160325917227	5	0.61
33930176	Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.	The Cochrane database of systematic reviews	2021	42.8221403546704	-29.58871087780396	21	2.36
33930105	The role of PD-1/PD-Ls in the pathogenesis of IgG4-related disease.	Rheumatology (Oxford, England)	2022	-55.4263084676894	14.360852576596791	5	1.24
33925671	Prognostic Role of Plasma PD-1, PD-L1, pan-BTN3As and BTN3A1 in Patients Affected by Metastatic Gastrointestinal Stromal Tumors: Can Immune Checkpoints Act as a Sentinel for Short-Term Survival?	Cancers	2021	-5.214032346700139	6.415338031653424	18	1.92
33925565	LAG-3 Blockade with Relatlimab (BMS-986016) Restores Anti-Leukemic Responses in Chronic Lymphocytic Leukemia.	Cancers	2021	11.727104002708062	21.637341279384287	41	4.55
33923463	Anti-PD-1/PD-L1 Based Combination Immunotherapy to Boost Antigen-Specific CD8+ T Cell Response in Hepatocellular Carcinoma.	Cancers	2021	-18.142835837382822	43.55454482597448	18	1.82
33922569	Small Extracellular Vesicles in Pre-Therapy Plasma Predict Clinical Outcome in Non-Small-Cell Lung Cancer Patients.	Cancers	2021	3.712708769408552	-41.32526586269299	5	0.54
33920689	PD-L1 as a Prognostic Factor in Early-Stage Colon Carcinoma within the Immunohistochemical Molecular Subtype Classification.	Cancers	2021	-4.423699626878345	11.826897781284137	13	1.76
33920514	Myeloid and T-Cell Microenvironment Immune Features Identify Two Prognostic Sub-Groups in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms.	Journal of clinical medicine	2021	2.058940627158452	13.620452641235612	4	0.42
33920423	The Future of Cancer Diagnosis, Treatment and Surveillance: A Systemic Review on Immunotherapy and Immuno-PET Radiotracers.	Molecules (Basel, Switzerland)	2021	28.695891507948303	-11.816015832161506	15	2.17
33918661	Circulating Biomarkers of Response and Toxicity of Immunotherapy in Advanced Non-Small Cell Lung Cancer (NSCLC): A Comprehensive Review.	Cancers	2021	24.83334043153288	-32.31440215147329	27	3.29
33918309	Programmed Death Ligand-1 (PD-L1) Is an Independent Negative Prognosticator in Western-World Gallbladder Cancer.	Cancers	2021	-1.5583324127979867	7.535812960439611	14	1.78
33916348	Immunotherapy Predictive Molecular Markers in Advanced Gastroesophageal Cancer: MSI and Beyond.	Cancers	2021	45.44004755857193	20.077887214401592	10	1.13
33916279	Clinical Significance of Tumor Microenvironment in Acral Melanoma: A Large Single-Institution Study of Caucasians.	Journal of clinical medicine	2021	-2.018767101082134	19.50635917857877	2	0.32
33915250	Prevalence and Heterogeneity of PD-L1 Expression by 22C3 Assay in Routine Population-Based and Reflexive Clinical Testing in Lung Cancer.	Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer	2021	14.456320698454048	-36.91897970880213	18	1.6
33914067	Targeting the CSF1/CSF1R axis is a potential treatment strategy for malignant meningiomas.	Neuro-oncology	2021	-20.10298197967549	48.1698939992385	21	2.6
33913053	Programmed cell death 1 (PD-1) receptor and programmed death ligand 1 (PD-L1) gene expression in primary breast cancer.	Breast cancer research and treatment	2021	-10.38023253773795	15.59298932367516	4	0.43
33912442	High TIL, HLA, and Immune Checkpoint Expression in Conventional High-Grade and Dedifferentiated Chondrosarcoma and Poor Clinical Course of the Disease.	Frontiers in oncology	2021	-19.424576781827565	21.43055886414764	1	0.12
33912192	The Ratio of IP10 to IL-8 in Plasma Reflects and Predicts the Response of Patients With Lung Cancer to Anti-PD-1 Immunotherapy Combined With Chemotherapy.	Frontiers in immunology	2021	22.879999042531296	-31.55048507712319	11	1.21
33910834	PD-1 Expression and its Correlation With Prognosis in Clear Cell Renal Cell Carcinoma.	In vivo (Athens, Greece)	2021	16.494907637507705	26.86484951410404	4	0.51
33910221	Histopathologic PD-L1 Tumor Expression and Prognostic Significance in Nonmelanoma Skin Cancers: A Systematic Review.	The American Journal of dermatopathology	2021	1.5187128020377316	-4.192198964664034	2	0.34
33910164	A preclinical study: correlation between PD-L1 PET imaging and the prediction of therapy efficacy of MC38 tumor with 68Ga-labeled PD-L1 targeted nanobody.	Aging	2021	5.697036711486941	-55.937741758589446	10	1.21
33909988	Energy status dictates PD-L1 protein abundance and anti-tumor immunity to enable checkpoint blockade.	Molecular cell	2021	-27.77521146412345	-30.2963794137324	73	7.34
33909103	IL-7 coupled with IL-12 increases intratumoral T cell clonality, leading to complete regression of non-immunogenic tumors.	Cancer immunology, immunotherapy : CII	2021	4.9625106983790985	26.077474771748733	9	0.98
33905818	PD-1 signaling pathway in sepsis: Does it have a future?	Clinical immunology (Orlando, Fla.)	2021	-58.77718022131954	34.59129271068212	12	1.42
33903974	COM902, a novel therapeutic antibody targeting TIGIT augments anti-tumor T cell function in combination with PVRIG or PD-1 pathway blockade.	Cancer immunology, immunotherapy : CII	2021	-12.102679851108643	-56.91801242097844	13	1.46
33901179	PD-L1 signaling on human memory CD4+ T cells induces a regulatory phenotype.	PLoS biology	2021	-54.61611306428905	-4.285538172367862	26	2.82
33900817	Development of Anti-human T Cell Immunoreceptor with Ig and ITIM Domains (TIGIT) Monoclonal Antibodies for Flow Cytometry.	Monoclonal antibodies in immunodiagnosis and immunotherapy	2021	-11.919342805839564	-57.41059753396843	10	1.26
33899001	EZH2 inhibition activates a dsRNA-STING-interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer.	Nature cancer	2021	-12.517686237964014	-28.71972369117402	88	8.41
33897693	Programmed Death-1/Programmed Death-Ligand 1-Axis Blockade in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Stratified by Human Papillomavirus Status: A Systematic Review and Meta-Analysis.	Frontiers in immunology	2021	-4.328094019327408	-7.201638010259409	18	2.06
33896649	Immunity reloaded: Deconstruction of the PD-1 axis in B cell lymphomas.	Blood reviews	2021	-29.17842432956846	20.361765479536334	2	0.17
33895919	Immunosuppression Factors PD-1, PD-L1, and IDO1 and Colorectal Cancer.	Doklady. Biochemistry and biophysics	2021	-6.085408673660721	11.451788265974232	2	0.33
33895183	Peptide-based and small molecule PD-1 and PD-L1 pharmacological modulators in the treatment of cancer.	Pharmacology & therapeutics	2021	-40.70808795463213	-36.651203827212136	10	1.03
33893689	Safety and Feasibility of Radiotherapy Plus Camrelizumab for Locally Advanced Esophageal Squamous Cell Carcinoma.	The oncologist	2021	51.42415633469154	12.48930531945086	40	4.0
33891607	Mesencephalic astrocyte-derived neurotrophic factor is secreted from interferon-γ-activated tumor cells through ER calcium depletion.	PloS one	2021	-13.019044730714738	-8.395439133593548	3	0.4
33890340	Multifunctionality of CD8+ T cells and PD-L1 expression as a biomarker of anti-PD-1 antibody efficacy in advanced melanoma.	The Journal of dermatology	2021	10.969258082065704	-2.5339142927287828	3	0.36
33890177	Decreased expression of programmed death-1 on CD8+ effector memory T lymphocytes correlates with the pathogenesis of type 1 diabetes.	Acta diabetologica	2021	-60.35638331379752	3.6989141298451615	2	0.25
33889438	VISTA and PD-L1 synergistically predict poor prognosis in patients with extranodal natural killer/T-cell lymphoma.	Oncoimmunology	2021	-38.911893262129766	35.20612801079277	18	1.92
33888298	[Impact of the use of systemic corticosteroid therapy on the effectiveness of immune checkpoint inhibitors].	Bulletin du cancer	2021	81.81065026050653	-6.559675337173618	2	0.31
33884540	Correlation between the immune checkpoints and EMT genes proposes potential prognostic and therapeutic targets in ESCC.	Journal of molecular histology	2021	-0.8761559810614568	39.177853026282826	12	1.3
33883178	ZEBRA: A Multicenter Phase II Study of Pembrolizumab in Patients with Advanced Small-Bowel Adenocarcinoma.	Clinical cancer research : an official journal of the American Association for Cancer Research	2021	48.38744316139899	3.774004363088885	19	1.83
33882890	A composite biomarker of neutrophil-lymphocyte ratio and hemoglobin level correlates with clinical response to PD-1 and PD-L1 inhibitors in advanced non-small cell lung cancers.	BMC cancer	2021	27.83242627399196	-40.7319519618054	16	1.51
33879556	Durvalumab Combined with Immunomodulatory Drugs (IMiD) Overcomes Suppression of Antitumor Responses due to IMiD-induced PD-L1 Upregulation on Myeloma Cells.	Molecular cancer therapeutics	2021	-32.30117725304618	7.441981535036035	1	0.08
33879398	The Value of 18F-FDG PET/CT in Predicting the Response to PD-1 Blocking Immunotherapy in Advanced NSCLC Patients with High-Level PD-L1 Expression.	Clinical lung cancer	2021	13.62144425413273	-56.01443842868304	12	1.45
33875760	Immuno-profiling and cellular spatial analysis using five immune oncology multiplex immunofluorescence panels for paraffin tumor tissue.	Scientific reports	2021	3.873905471124355	-46.84991482813411	19	2.38
33875611	Phase I trial of intratumoral PVSRIPO in patients with unresectable, treatment-refractory melanoma.	Journal for immunotherapy of cancer	2021	54.34200165026009	-6.7470686093405705	32	3.79
33869777	Fatal immune-related hepatitis with intrahepatic cholestasis and pneumonia associated with camrelizumab: A case report and literature review.	Open medicine (Warsaw, Poland)	2021	61.77905034642913	-10.11052370913935	4	0.6
33869045	B7 Family Members in Lymphoma: Promising Novel Targets for Tumor Immunotherapy?	Frontiers in oncology	2021	-28.23884109607205	4.854669784594128	3	0.31
33869027	Characterization of Immune Infiltration and Construction of a Prediction Model for Overall Survival in Melanoma Patients.	Frontiers in oncology	2021	4.145930669668223	17.037287308880558	5	0.46
33862558	PARP inhibitors in head and neck cancer: Molecular mechanisms, preclinical and clinical data.	Oral oncology	2021	33.4880774913207	40.26637551690026	13	1.38
33859942	Optimizing the Treatment Schedule of Radiotherapy Combined With Anti-PD-1/PD-L1 Immunotherapy in Metastatic Cancers.	Frontiers in oncology	2021	40.7030334803687	4.150182366439958	15	1.59
33859637	Toxicity Profile of Combining PD-1/PD-L1 Inhibitors and Thoracic Radiotherapy in Non-Small Cell Lung Cancer: A Systematic Review.	Frontiers in immunology	2021	71.0252607784885	-6.51390118386704	12	1.31
33859108	The impact of immune checkpoint therapy on the latent reservoir in HIV-infected individuals with cancer on antiretroviral therapy.	AIDS (London, England)	2021	19.37017334802413	44.5355067306823	11	1.1
33858847	Orphan nuclear receptor TLX promotes immunosuppression via its transcriptional activation of PD-L1 in glioma.	Journal for immunotherapy of cancer	2021	-24.577867762472184	54.22733353333849	13	1.38
33854633	A snapshot of the PD-1/PD-L1 pathway.	Journal of Cancer	2021	-39.99928761074396	-17.239018425078456	66	7.99
33849133	Neoadjuvant treatment of pembrolizumab plus platinum-doublet chemotherapy in stage IIIA squamous cell carcinoma of the lung: a case report.	Annals of palliative medicine	2021	48.89509056209919	-33.65921389127714	1	0.15
33846789	The clinical significance of PD‑L1 in colorectal cancer (Review).	Oncology reports	2021	-5.7973119676411295	10.787554355616791	2	0.28
33844854	Bone fracture as a novel immune-related adverse event with immune checkpoint inhibitors: Case series and large-scale pharmacovigilance analysis.	International journal of cancer	2021	76.30792552134288	-9.347539328889836	7	1.02
33842645	Non-small cell lung cancer with MET exon 14 skipping alteration responding to immunotherapy: a case report.	Annals of translational medicine	2021	36.30797964233111	-39.69299845391527	1	0.13
33842644	Immuno-oncology: a narrative review of gastrointestinal and hepatic toxicities.	Annals of translational medicine	2021	78.49300624442297	-5.857429417859303	5	0.67
33842618	Distinct prognostic values of programmed death-ligand 1 and programmed cell death protein 1 in lung adenocarcinoma and squamous cell carcinoma patients.	Annals of translational medicine	2021	8.677820947627573	-26.980440118538844	0	0.0
33842538	Identification of a Novel Protein-Based Signature to Improve Prognosis Prediction in Renal Clear Cell Carcinoma.	Frontiers in molecular biosciences	2021	17.535653594519633	34.23797868901073	10	1.17
33842341	A Multi-Omics Analysis of Metastatic Melanoma Identifies a Germinal Center-Like Tumor Microenvironment in HLA-DR-Positive Tumor Areas.	Frontiers in oncology	2021	4.643489215492384	16.42444526242783	3	0.38
33841677	Role of kynurenine in promoting the generation of exhausted CD8+ T cells in colorectal cancer.	American journal of translational research	2021	-15.378347453717762	-30.82819028078305	14	1.46
33841639	Identification and validation of significant gene mutations to predict clinical benefit of immune checkpoint inhibitors in lung adenocarcinoma.	American journal of translational research	2021	25.187864942476605	-20.23387981547592	5	0.48
33841630	OX40 as a novel target for the reversal of immune escape in colorectal cancer.	American journal of translational research	2021	-19.364608492706925	-43.38710043665307	6	0.56
33839580	In vitro and in vivo degradation of programmed cell death ligand 1 (PD-L1) by a proteolysis targeting chimera (PROTAC).	Bioorganic chemistry	2021	-43.73393499315976	-20.387102763537463	25	2.72
33838468	Two different patients with pulmonary pleomorphic carcinoma response to PD-1 inhibitor plus anlotinib.	Lung cancer (Amsterdam, Netherlands)	2021	56.18936145257565	-32.432713434329926	2	0.19
33837055	Enhancing clinical and immunological effects of anti-PD-1 with belapectin, a galectin-3 inhibitor.	Journal for immunotherapy of cancer	2021	49.34341098358277	5.564832071110494	30	3.85
33836800	A prospective study investigating the efficacy and toxicity of definitive ChemoRadiation and ImmunOtherapy (CRIO) in locally and/or regionally advanced unresectable cutaneous squamous cell carcinoma.	Radiation oncology (London, England)	2021	57.93114421368663	7.012070564616668	9	1.12
33836153	Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study.	The Lancet. Respiratory medicine	2021	48.40111856077102	-0.8684930745341647	35	3.17
33833987	The Efficacy and Safety of Programmed Death-1 and Programmed Death Ligand 1 Inhibitors for the Treatment of Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.	Frontiers in oncology	2021	32.759876604972554	48.67914947052711	5	0.78
33833369	Genetic variants of programmed cell death 1 are associated with HBV infection and liver disease progression.	Scientific reports	2021	-68.05784059577702	21.17412120116601	4	0.48
33832149	Expression and significance of PD-1 and PD-L1 in patients with recurrent spontaneous abortion: A protocol for systematic review and meta-analysis.	Medicine	2021	-74.16103782488777	-19.504857022359044	1	0.21
33832106	Prognostic value of lactate dehydrogenase for melanoma patients receiving anti-PD-1/PD-L1 therapy: A meta-analysis.	Medicine	2021	26.569135646216623	-44.39876519539663	10	1.1
33831809	PD-1/PD-L1 immune checkpoint blockade-based combinational treatment: Immunotherapeutic amplification strategies against colorectal cancer.	International immunopharmacology	2021	34.8611250167676	22.315474346209665	9	1.07
33831732	Tolerability and antitumor activity of cemiplimab, a human monoclonal anti-PD-1, as monotherapy in patients with pretreated non-small cell lung cancer (NSCLC): Data from the Phase 1 NSCLC expansion cohort.	Lung cancer (Amsterdam, Netherlands)	2021	52.92618963445869	-21.79627036130752	8	0.79
33831533	Post-translational regulations of PD-L1 and PD-1: Mechanisms and opportunities for combined immunotherapy.	Seminars in cancer biology	2022	-40.12731325709303	-12.714454002993854	25	5.74
33829580	Analysis of Real-World Data to Investigate the Impact of Race and Ethnicity on Response to Programmed Cell Death-1 and Programmed Cell Death-Ligand 1 Inhibitors in Advanced Non-Small Cell Lung Cancers.	The oncologist	2021	47.51234597959614	-17.233584885060562	14	1.41
33828564	Case Report: Single Dose Anti-PD1 in a Patient With Metastatic Melanoma and Cardiac Allograft.	Frontiers in immunology	2021	76.75703583868885	9.558060460309116	1	0.14
33827280	Therapeutic Approaches With Immune Checkpoint Inhibitors in Head and Neck Cancers and the Role of PD-L1 as a Biomarker.	Cancer control : journal of the Moffitt Cancer Center	2021	52.29732783625894	32.32011913619528	2	0.16
33824367	Immune checkpoint molecules B7-H6 and PD-L1 co-pattern the tumor inflammatory microenvironment in human breast cancer.	Scientific reports	2021	-4.311122503207213	15.018617172569844	5	0.54
33823768	Immune Checkpoint Inhibitors in the Treatment of Cancer.	Current reviews in clinical and experimental pharmacology	2022	31.13169193794189	11.809127533034632	20	4.74
33820396	Characteristics of Immune-Related Thyroid Adverse Events in Patients Treated with PD-1/PD-L1 Inhibitors.	Endocrinology and metabolism (Seoul, Korea)	2021	77.93288184368855	-17.067175769786456	17	1.83
33818637	CMTM6 expression in M2 macrophages is a potential predictor of PD-1/PD-L1 inhibitor response in colorectal cancer.	Cancer immunology, immunotherapy : CII	2021	5.687502586633648	-10.166969772856437	12	1.14
33816503	A Novel Immune-Related Prognostic Model for Response to Immunotherapy and Survival in Patients With Lung Adenocarcinoma.	Frontiers in cell and developmental biology	2021	15.913527787973342	-14.340924625958555	26	2.65
33816314	Imaging Biomarkers to Predict and Evaluate the Effectiveness of Immunotherapy in Advanced Non-Small-Cell Lung Cancer.	Frontiers in oncology	2021	11.3077794447662	-11.714756149827284	29	4.1
33816285	POLE and Mismatch Repair Status, Checkpoint Proteins and Tumor-Infiltrating Lymphocytes in Combination, and Tumor Differentiation: Identify Endometrial Cancers for Immunotherapy.	Frontiers in oncology	2021	12.08515172456955	46.69954254328096	19	2.3
33816230	HILPDA Is a Prognostic Biomarker and Correlates With Macrophage Infiltration in Pan-Cancer.	Frontiers in oncology	2021	-15.036008103531245	55.75894036113269	23	2.84
33813091	Tumor cell membrane-based peptide delivery system targeting the tumor microenvironment for cancer immunotherapy and diagnosis.	Acta biomaterialia	2021	-34.28858181365168	-54.05915553264558	22	2.84
33811810	The aging lung: Physiology, disease, and immunity.	Cell	2021	-75.28045345297441	34.72675156008624	109	12.57
33810560	High Expression of PD-L1 Is Associated with Better Survival in Pancreatic/Periampullary Cancers and Correlates with Epithelial to Mesenchymal Transition.	Diagnostics (Basel, Switzerland)	2021	-4.426179339041615	1.8268127538566536	5	0.46
33810354	Immune Contexture of MMR-Proficient Primary Colorectal Cancer and Matched Liver and Lung Metastases.	Cancers	2021	11.966956390663029	34.87902061629692	15	1.89
33809752	Immunotherapy in Adrenocortical Carcinoma: Predictors of Response, Efficacy, Safety, and Mechanisms of Resistance.	Biomedicines	2021	12.382764123277829	18.31268818266888	10	1.56
33809167	Anti-Tumor Efficacy of PD-L1 Targeted Alpha-Particle Therapy in a Human Melanoma Xenograft Model.	Cancers	2021	-40.91447571804354	-27.29784003418208	5	0.79
33809043	Integrin α2β1 Represents a Prognostic and Predictive Biomarker in Primary Ovarian Cancer.	Biomedicines	2021	-4.073467060735366	41.288813733362886	6	0.64
33808846	Oral Manifestations in Melanoma Patients Treated with Target or Immunomodulatory Therapies.	Journal of clinical medicine	2021	68.44022266130028	-29.313287605161992	4	1.21
33808631	Mutations Associated with No Durable Clinical Benefit to Immune Checkpoint Blockade in Non-S-Cell Lung Cancer.	Cancers	2021	25.522477587215256	-20.504002773139465	7	0.66
33808614	Imaging and Management of Bladder Cancer.	Cancers	2021	73.0938237799673	19.50312537316427	16	2.58
33806894	Epithelial Mutant p53 Promotes Resistance to Anti-PD-1-Mediated Oral Cancer Immunoprevention in Carcinogen-Induced Mouse Models.	Cancers	2021	-10.879159034323798	-14.371354803353126	4	0.39
33806774	Thyroid Dysfunction in Lung Cancer Patients Treated with Immune Checkpoint Inhibitors (ICIs): Outcomes in a Multiethnic Urban Cohort.	Cancers	2021	79.8052923778661	-19.00375768542753	6	0.57
33804850	Is There a Place for PD-1-PD-L Blockade in Acute Myeloid Leukemia?	Pharmaceuticals (Basel, Switzerland)	2021	37.89027250878635	-4.4730657887505485	14	1.75
33804698	Immune Checkpoint Inhibitors in Urothelial Carcinoma: Recommendations for Practical Approaches to PD-L1 and Other Potential Predictive Biomarker Testing.	Cancers	2021	64.13869166856146	22.61209093836492	17	1.82
33803245	CD11c-CD8 Spatial Cross Presentation: A Novel Approach to Link Immune Surveillance and Patient Survival in Soft Tissue Sarcoma.	Cancers	2021	-1.3881375570694756	21.26467231470446	1	0.16
33802622	Gamma-Chain Receptor Cytokines & PD-1 Manipulation to Restore HCV-Specific CD8+ T Cell Response during Chronic Hepatitis C.	Cells	2021	-76.98234551640171	23.84957304438528	3	0.32
33802298	Perspective of Immune Checkpoint Inhibitors in Thymic Carcinoma.	Cancers	2021	39.22486553013397	-1.4479052660599667	5	0.94
33801967	Tumor Activated Cell Penetrating Peptides to Selectively Deliver Immune Modulatory Drugs.	Pharmaceutics	2021	-26.094020263871357	-50.34596643060552	3	0.37
33796402	An experimental model of anti-PD-1 resistance exhibits activation of TGFß and Notch pathways and is sensitive to local mRNA immunotherapy.	Oncoimmunology	2021	-33.42969657744325	-21.856935377329552	13	1.25
33795251	Mesothelin-Specific CAR T Cells Target Ovarian Cancer.	Cancer research	2021	-41.67786497656633	1.604845462120081	30	3.13
33794288	A mechanistic systems pharmacology modeling platform to investigate the effect of PD-L1 expression heterogeneity and dynamics on the efficacy of PD-1 and PD-L1 blocking antibodies in cancer.	Journal of theoretical biology	2021	-37.35067901281133	-23.413990760799503	0	0.0
33794271	Design of PD-1-decorated nanocages targeting tumor-draining lymph node for promoting T cell activation.	Journal of controlled release : official journal of the Controlled Release Society	2021	-36.153032769509934	-47.810542189201584	12	1.26
33793576	An inhibitor of programmed death ligand 1 enhances natural killer cell-mediated immunity against malignant melanoma cells.	PloS one	2021	-14.970792786617825	-18.74597120838696	3	0.37
33793112	Prognostic significance of soluble forms of immune checkpoint PD-1/PDL1 receptor and ligand in blood plasma of gastric cancer patients.	Klinicheskaia laboratornaia diagnostika	2021	6.526631268920828	6.8226267159016745	3	0.54
33791390	Transcriptional Profiling Reveals Kidney Neutrophil Heterogeneity in Both Healthy People and ccRCC Patients.	Journal of immunology research	2021	15.12858910641824	33.861474092346626	11	1.14
33790580	Dramatic Responses of Recurrent Upper Urinary Tract Urothelial Carcinoma Harboring FGFR3 and TP53 Activating Mutations to Pembrolizumab in Combination with Erdafitinib: A Case Report.	OncoTargets and therapy	2021	66.0066886956869	14.785273082734951	4	0.39
33790087	Efficacies of programmed cell death 1 ligand 1 blockade in non-small cell lung cancer patients with acquired resistance to prior programmed cell death 1 inhibitor and development of diabetic ketoacidosis caused by two different etiologies: a retrospective case series.	Endocrine journal	2021	50.48508322746951	-37.29244089549585	4	0.42
33789879	Prediction of severe immune-related adverse events requiring hospital admission in patients on immune checkpoint inhibitors: study of a population level insurance claims database from the USA.	Journal for immunotherapy of cancer	2021	75.47316730227506	-9.944278464716406	27	2.6
33787090	Clinical recommendations for perioperative immunotherapy-induced adverse events in patients with non-small cell lung cancer.	Thoracic cancer	2021	32.11485271211768	-22.41909802889892	6	0.46
33783228	Immune-related adverse events with PD-1 versus PD-L1 inhibitors: a meta-analysis of 8730 patients from clinical trials.	Future oncology (London, England)	2021	73.26132690755121	-14.807466980051183	27	2.86
33782477	A novel scoring system for TIGIT expression in classic Hodgkin lymphoma.	Scientific reports	2021	-25.08882305994376	28.378998753223016	5	0.63
33779456	Distribution of mucosal PD-1 expressing T cells in patients with colitis of different etiologies.	Scandinavian journal of gastroenterology	2021	-60.16315040119022	19.830343647651336	4	0.54
33777676	Abrogation of USP7 is an alternative strategy to downregulate PD-L1 and sensitize gastric cancer cells to T cells killing.	Acta pharmaceutica Sinica. B	2021	-17.644871969666493	-6.421037319849176	42	4.41
33777025	Deep Phenotyping of CD11c+ B Cells in Systemic Autoimmunity and Controls.	Frontiers in immunology	2021	-53.95621423326582	10.796457371910297	25	2.45
33776728	The Association of Tumor-Infiltrating Lymphocytes and Programmed Cell Death 1 Expression with the Incidence of Distant Metastasis in Triple-Negative Breast Cancer Subjects in Sanglah General Hospital, Bali, Indonesia.	Case reports in oncology	2021	-6.551980624443243	19.31284735632937	0	0.0
33776727	Successful Treatment with Nivolumab in a Patient with Metastatic Salivary Duct Carcinoma.	Case reports in oncology	2021	54.97833981470784	-29.2900762189045	1	0.17
33774183	Splenectomy provides protective effects against CLP-induced sepsis by reducing TRegs and PD-1/PD-L1 expression.	The international journal of biochemistry & cell biology	2021	-60.479689461970295	35.54147340868165	6	0.76
33772569	Oral mucositis. Is it present in the immunotherapy of the immune checkpoint pd1/pd-l1 against oral cancer? A systematic review.	Medicina oral, patologia oral y cirugia bucal	2021	68.34411788153074	-29.42613984439083	5	1.16
33771881	An IFNγ/STAT1/JMJD3 Axis Induces ZEB1 Expression and Promotes Aggressiveness in Lung Adenocarcinoma.	Molecular cancer research : MCR	2021	-17.987204253812756	-17.937774676131145	3	0.36
33771483	PD-L1 induces macrophage polarization toward the M2 phenotype via Erk/Akt/mTOR.	Experimental cell research	2021	-51.4691813748179	0.1315046624779871	19	2.22
33770211	Active and latent tuberculosis infections in patients treated with immune checkpoint inhibitors in a non-endemic tuberculosis area.	Cancer immunology, immunotherapy : CII	2021	63.11369053756785	-24.626348193092294	3	0.44
33767694	Phenotypic and Functional Analyses Guiding Combination Immune Checkpoint Immunotherapeutic Strategies in HTLV-1 Infection.	Frontiers in immunology	2021	-67.64314893149471	18.51286963922368	7	0.92
33765543	Chemotherapy regimens induce inhibitory immune checkpoint protein expression on stem-like and senescent-like oesophageal adenocarcinoma cells.	Translational oncology	2021	21.94779297174477	21.58192709610766	12	1.2
33765213	Combined immunotherapy and targeted treatment for primary alveolar soft part sarcoma of the lung: case report and literature review.	Investigational new drugs	2021	41.05226350997478	-13.124200077814434	7	0.73
33763250	The prognostic value of programmed cell death protein ligand 1 in patients with non-muscle-invasive bladder cancer treated with bacille Calmette-Guérin immunotherapy: Current status.	Arab journal of urology	2020	10.227338969191493	59.58317936447072	1	0.09
33762828	Anti-PD-1 Monotherapy for Advanced NSCLC Patients with Older Age or Those with Poor Performance Status.	OncoTargets and therapy	2021	54.18733407259248	-18.97599557975486	10	1.07
33762319	Tumor DNA methylation profiles correlate with response to anti-PD-1 immune checkpoint inhibitor monotherapy in sarcoma patients.	Journal for immunotherapy of cancer	2021	11.423715554595178	8.323216457460369	17	1.91
33761725	Remarkable response to anti-PD1 immunotherapy in refractory metastatic high-grade myxofibrosarcoma patient: A case report.	Medicine	2021	58.90063573961569	-27.374705652882437	4	0.5
33761687	PD-L1 expression on peripheral T-cells and association with coronary heart disease patients: A protocol for systematic reviews and meta-analysis.	Medicine	2021	-59.22749235892938	10.00379497937832	0	0.0
33761681	The efficacy and safety of PD-1/PD-L1 inhibitors versus chemotherapy in patients with previously treated advanced non-small-cell lung cancer: A meta-analysis.	Medicine	2021	49.0706825449016	-18.60911097848408	1	0.17
33759637	PD-1 Immune Checkpoint Inhibitor Therapy Malignant Tumor Based on Monotherapy and Combined Treatment Research.	Technology in cancer research & treatment	2021	28.76163269798422	-3.681877298848815	0	0.0
33759577	Blockade of PD-1 decreases neutrophilic inflammation and lung damage in experimental COPD.	American journal of physiology. Lung cellular and molecular physiology	2021	1.6819671787492023	-24.116612709762588	4	0.55
33754355	Innate and adaptive immune responses following PD-L1 blockade in treating chronic murine alveolar echinococcosis.	Parasite immunology	2021	-50.69899672664877	20.474327613126665	10	1.6
33753620	Determining PD-L1 expression in head and neck squamous cell carcinoma using immunohistochemistry.	Indian journal of cancer	2022	-6.612198736394018	-6.112862882780669	3	
33753114	Synergistic efficacy of curcumin and anti-programmed cell death-1 in hepatocellular carcinoma.	Life sciences	2021	-17.000251421688432	-37.22856024161688	18	2.31
33749663	Hedgehog-induced PD-L1 on tumor-associated macrophages is critical for suppression of tumor-infiltrating CD8+ T cell function.	JCI insight	2021	-32.92562532371038	-6.43167790226147	40	3.97
33749484	How can we manage the cardiac toxicity of immune checkpoint inhibitors?	Expert opinion on drug safety	2021	83.37083945769088	2.3590958576708707	6	0.72
33747915	Overcoming Resistance to Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinomas.	Frontiers in oncology	2021	-8.18788272467161	-6.547357531784306	14	1.67
33745842	B7-H3 and PD-L1 Expression Are Prognostic Biomarkers in a Multi-racial Cohort of Patients with Colorectal Cancer.	Clinical colorectal cancer	2021	7.263484206334487	41.64858754898176	9	0.93
33745426	The Potential of T Cell Immunoglobulin and Mucin-Domain Containing-3 (Tim-3) in Designing Novel Immunotherapy for Bladder Cancer.	Endocrine, metabolic & immune disorders drug targets	2021	-1.9745819416577248	26.31624898221112	10	1.07
33745080	Efficacy and safety of neoadjuvant immune checkpoint inhibitors in early-stage triple-negative breast cancer: a systematic review and meta-analysis.	Journal of cancer research and clinical oncology	2021	41.68266589596074	10.93778279497258	20	2.03
33744709	Programmed death protein 1 is essential for maintaining the anti-inflammatory function of infiltrating regulatory T cells in a murine spinal cord injury model.	Journal of neuroimmunology	2021	-75.40526818139385	-7.8863778728482385	6	0.83
33743085	Biomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast Cancer.	Current treatment options in oncology	2021	38.31519051781892	10.545191991667933	18	1.82
33742767	Exploratory window-of-opportunity trial to investigate the tumor pharmacokinetics/pharmacodynamics of the IAP antagonist Debio 1143 in patients with head and neck cancer.	Clinical and translational science	2022	20.711647659591776	48.43303478548765	8	1.9
33741903	Immunotherapy for recurrent glioblastoma: practical insights and challenging prospects.	Cell death & disease	2021	45.6937879170247	28.311613272616533	20	2.36
33741356	The ABCA1-efferocytosis axis: A new strategy to protect against atherosclerosis.	Clinica chimica acta; international journal of clinical chemistry	2021	-59.667625318975766	8.20644353797742	23	3.29
33741032	Next generation of immune checkpoint inhibitors and beyond.	Journal of hematology & oncology	2021	23.10579341485123	10.206590862921033	181	20.33
33739790	MHC Class I Loss in Triple-negative Breast Cancer: A Potential Barrier to PD-1/PD-L1 Checkpoint Inhibitors.	The American journal of surgical pathology	2021	2.958189412933622	-8.144469432139829	18	1.88
33739346	Enfortumab Vedotin: Nursing Perspectives on the Management of Adverse Events in Patients With Locally Advanced or Metastatic Urothelial Carcinoma.	Clinical journal of oncology nursing	2021	68.8793368846023	12.200868539065937	9	0.97
33737812	Current Progress and Future Perspectives of Immune Checkpoint Inhibitors in Biliary Tract Cancer.	OncoTargets and therapy	2021	58.0138782871965	25.32660319063557	5	0.46
33737722	PD-1 and PD-L1 expression on TILs in peritoneal metastases compared to ovarian tumor tissues and its associations with clinical outcome.	Scientific reports	2021	-19.766210045640957	11.770280041724265	10	1.08
33737339	Primary results from TAIL: a global single-arm safety study of atezolizumab monotherapy in a diverse population of patients with previously treated advanced non-small cell lung cancer.	Journal for immunotherapy of cancer	2021	52.53518461554419	-37.69512692190606	24	2.43
33737091	PD-1 and PD-L1 expression in cardiac transplantation.	Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology	2021	-63.20193057449679	-2.6838223225316	8	0.9
33735518	Bone marrow-derived mesenchymal stem cells inhibit CD8+ T cell immune responses via PD-1/PD-L1 pathway in multiple myeloma.	Clinical and experimental immunology	2021	-34.25519679231855	9.666570987715753	7	0.95
33732647	Immunotherapy-Associated Pancreatic Adverse Events: Current Understanding of Their Mechanism, Diagnosis, and Management.	Frontiers in oncology	2021	84.6629063552548	-11.686516115769342	15	1.67
33732355	Clinical outcomes and influencing factors of PD-1/PD-L1 in hepatocellular carcinoma.	Oncology letters	2021	25.549101098910725	49.37629558697301	21	2.48
33731852	Interleukin-10 suppression enhances T-cell antitumor immunity and responses to checkpoint blockade in chronic lymphocytic leukemia.	Leukemia	2021	-41.701991219424606	18.95265450727097	22	2.1
33730957	Validation of a radiomic approach to decipher NSCLC immune microenvironment in surgically resected patients.	Tumori	2022	11.487853329406825	-12.884513492732736	5	1.09
33729216	Dostarlimab for the treatment of endometrium cancer and other solid tumors.	Drugs of today (Barcelona, Spain : 1998)	2021	29.198901399673492	-7.39222186614962	6	0.71
33725827	Development and validation of a robust immune-related risk signature for hepatocellular carcinoma.	Medicine	2021	-10.471366526130868	49.64094287732164	5	0.57
33722854	The KRASG12C Inhibitor MRTX849 Reconditions the Tumor Immune Microenvironment and Sensitizes Tumors to Checkpoint Inhibitor Therapy.	Molecular cancer therapeutics	2021	21.97090143192411	-23.148545107369607	61	5.68
33722498	Activity and Immune Correlates of Programmed Death-1 Blockade Therapy in Patients With Advanced Large Cell Neuroendocrine Carcinoma.	Clinical lung cancer	2021	8.885174490806559	-25.14516368883629	12	1.37
33721375	Soluble programmed cell death protein 1 (sPD-1) and the soluble programmed cell death ligands 1 and 2 (sPD-L1 and sPD-L2) in lymphoid malignancies.	European journal of haematology	2021	-46.07886289220118	20.90524120541481	5	0.71
33719827	Nivolumab plus ipilimumab for the first-line treatment of metastatic NSCLC.	Expert review of anticancer therapy	2021	40.94008321010987	-28.59286518548563	3	0.27
33718347	Increased Tumor Immune Microenvironment CD3+ and CD20+ Lymphocytes Predict a Better Prognosis in Oral Tongue Squamous Cell Carcinoma.	Frontiers in cell and developmental biology	2020	-7.017730677330796	33.09942804450393	13	1.86
33718196	PD-L2 Is Constitutively Expressed in Normal and Malignant Urothelium.	Frontiers in oncology	2021	12.474153950261265	59.882302472467856	5	0.58
33718041	The landscape of immune checkpoints expression in non-small cell lung cancer: a narrative review.	Translational lung cancer research	2021	34.48545106201109	-24.024659639993494	8	0.79
33718036	Identifying the prognostic significance of B3GNT3 with PD-L1 expression in lung adenocarcinoma.	Translational lung cancer research	2021	8.462792750251953	-29.017717249849245	8	0.83
33718015	Programmed death-ligand 1 expression level as a predictor of EGFR tyrosine kinase inhibitor efficacy in lung adenocarcinoma.	Translational lung cancer research	2021	8.111505961601113	-32.53512222928353	10	1.28
33718014	PD-1 restrains IL-17A production from γδ T cells to modulate acute radiation-induced lung injury.	Translational lung cancer research	2021	43.063182718995776	-20.97153393794443	4	0.47
33717062	Sunitinib Exerts In Vitro Immunomodulatory Activity on Sarcomas via Dendritic Cells and Synergizes With PD-1 Blockade.	Frontiers in immunology	2021	-22.65787648646569	-23.92949453608381	15	1.55
33716146	Our current understanding of checkpoint inhibitor therapy in cancer immunotherapy.	Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology	2021	25.862052995298505	6.729846312613448	16	1.77
33715305	Porphyromonas gingivalis induced up-regulation of PD-L1 in colon carcinoma cells.	Molecular oral microbiology	2021	-64.6738934193941	-21.067636864998583	11	1.53
33714729	Human splenic myeloid derived suppressor cells: Phenotypic and clustering analysis.	Cellular immunology	2021	-51.22031345916627	27.74076202286261	10	1.12
33713744	The Dynamic Alternation of Local and Systemic Tumor Immune Microenvironment During Concurrent Chemoradiotherapy of Cervical Cancer: A Prospective Clinical Trial.	International journal of radiation oncology, biology, physics	2021	-4.291228354885956	36.185737034414366	14	1.62
33712343	Cell membrane and nuclear expression of programmed death ligand-1 in prostate needle biopsy tissue in prostate cancer patients undergoing primary radiation therapy.	Urologic oncology	2021	-12.581123232403378	13.406431420506436	8	1.02
33710817	Synergistic effects of AAGL and anti-PD-1 on hepatocellular carcinoma through lymphocyte recruitment to the liver.	Cancer biology & medicine	2021	-21.67913388420941	-16.60294364569204	2	0.19
33710123	Immune Microenvironment in Gallbladder Adenocarcinomas.	Applied immunohistochemistry & molecular morphology : AIMM	2021	-1.5255214287690784	7.5974013073724915	2	0.3
33709564	Immune Checkpoint Inhibitor-Based Strategies for Synergistic Cancer Therapy.	Advanced healthcare materials	2021	26.23438244688683	15.53275120753705	36	3.84
33708984	Adult pulmonary Langerhans cell histiocytosis might consist of two distinct groups: isolated form and extrapulmonary recidivism type.	Annals of translational medicine	2021	3.395162689361456	-23.83765598597947	3	0.3
33692335	PKD3 promotes metastasis and growth of oral squamous cell carcinoma through positive feedback regulation with PD-L1 and activation of ERK-STAT1/3-EMT signalling.	International journal of oral science	2021	-10.559449381730287	-12.571272927915643	12	1.35
33691516	Plasma checkpoint protein levels and galectin-9 in juvenile systemic lupus erythematosus.	Lupus	2021	-53.88150863963445	12.191340993937864	1	0.13
33690225	Inhibiting the MNK1/2-eIF4E axis impairs melanoma phenotype switching and potentiates antitumor immune responses.	The Journal of clinical investigation	2021	-15.211787159815383	-22.19207191601264	24	2.26
33689225	Neoadjuvant immunotherapy for non-small cell lung cancer: State of the art.	Cancer communications (London, England)	2021	33.76380098976067	-22.352909132926047	50	5.39
33688020	Releasing the brakes of tumor immunity with anti-PD-L1 and pushing its accelerator with L19-IL2 cures poorly immunogenic tumors when combined with radiotherapy.	Journal for immunotherapy of cancer	2021	26.33424900351358	21.06080416952361	16	1.39
33687987	Therapeutic Targeting of Checkpoint Receptors within the DNAM1 Axis.	Cancer discovery	2021	-11.558170650775422	-55.94284990052687	19	1.76
33687756	Oncolytic herpes simplex virus HF10 (canerpaturev) promotes accumulation of CD8+ PD-1- tumor-infiltrating T cells in PD-L1-enriched tumor microenvironment.	International journal of cancer	2021	-37.1576301367218	51.872111099144384	11	1.44
33686894	Emerging PD-1/PD-L1 antagonists for the treatment of malignant melanoma.	Expert opinion on emerging drugs	2021	33.814420415745644	-0.4241408608945705	8	0.8
33686666	Infiltration of CD163-, PD-L1- and FoxP3-positive cells adversely affects outcome in patients with mantle cell lymphoma independent of established risk factors.	British journal of haematology	2021	-5.2530316962017976	22.712724537492587	10	1.19
33686402	Mechanisms and clinical manifestations of cardiovascular toxicities associated with immune checkpoint inhibitors.	Clinical science (London, England : 1979)	2021	83.77086927653225	2.505686143166304	13	1.66
33684223	"PD-1-specific ""Blocking"" antibodies that deplete PD-1+ T cells present an inconvenient variable in preclinical immunotherapy experiments."	European journal of immunology	2021	-39.98308908885272	-25.61856476375042	13	1.33
33684103	A computational study of co-inhibitory immune complex assembly at the interface between T cells and antigen presenting cells.	PLoS computational biology	2021	-55.2688529060996	-11.069730199188246	2	0.2
33683684	Detection of Programmed Cell Death Ligand 1 Expression in Lung Cancer Clinical Samples by an Automated Immunohistochemistry System.	Methods in molecular biology (Clifton, N.J.)	2021	19.139156105399778	-40.9610231537792	1	0.21
33680942	The Efficacy and Safety of Anlotinib Combined With PD-1 Antibody for Third-Line or Further-Line Treatment of Patients With Advanced Non-Small-Cell Lung Cancer.	Frontiers in oncology	2020	39.06885703371156	-43.07946633289297	16	1.81
33680705	Atezolizumab and granzyme B as immunotoxin against PD-L1 antigen; an insilico study.	In silico pharmacology	2021	-47.43606718857471	-35.47674948905233	5	0.63
33680122	Programmed cell death-1/programmed cell death-ligand 1 inhibitors exert antiapoptosis and antiinflammatory activity in lipopolysaccharide stimulated murine alveolar macrophages.	Experimental and therapeutic medicine	2021	-59.22615313964054	30.78578076442396	1	0.16
33679776	Low-Dose Decitabine Inhibits Cytotoxic T Lymphocytes-Mediated Platelet Destruction via Modulating PD-1 Methylation in Immune Thrombocytopenia.	Frontiers in immunology	2021	-50.82991225822021	3.513065788774993	18	2.46
33677681	Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics.	The AAPS journal	2021	30.827490487491875	-8.4562606969419	256	29.8
33676416	PD-1 immunobiology in glomerulonephritis and renal cell carcinoma.	BMC nephrology	2021	-53.3930745344864	7.228183166280578	13	1.53
33676271	Resistance mechanisms to checkpoint inhibitors.	Current opinion in immunology	2021	32.67691327059666	15.231278785224482	14	1.41
33675792	Real-World Outcomes of Patients With Advanced Non-small Cell Lung Cancer Treated With Anti-PD1 Therapy on the Basis of PD-L1 Results in EBUS-TBNA vs Histological Specimens.	Chest	2021	15.743048560811868	-36.92951368814723	6	0.93
33675535	Immune checkpoint inhibitors and cellular treatment for lymphoma immunotherapy.	Clinical and experimental immunology	2021	31.85127011015069	11.357515544898016	8	0.72
33674358	γδ T Cells in Merkel Cell Carcinomas Have a Proinflammatory Profile Prognostic of Patient Survival.	Cancer immunology research	2021	42.97359193694177	52.187822504009	16	1.78
33674305	PD-L1+ neutrophils contribute to injury-induced infection susceptibility.	Science advances	2021	-61.43043297530079	32.84437543263331	12	1.34
33673374	Immune Checkpoint Inhibition in Oesophago-Gastric Carcinoma.	Pharmaceuticals (Basel, Switzerland)	2021	52.83533326337151	13.174811945943825	17	1.91
33673133	Clinicopathological Correlates of γδ T Cell Infiltration in Triple-Negative Breast Cancer.	Cancers	2021	-4.443179795942188	20.95770885225897	11	1.21
33671892	High PD-L1/IDO-2 and PD-L2/IDO-1 Co-Expression Levels Are Associated with Worse Overall Survival in Resected Non-Small Cell Lung Cancer Patients.	Genes	2021	13.529525770389393	-27.366683820256107	9	1.26
33671555	Vaccination against PD-L1 with IO103 a Novel Immune Modulatory Vaccine in Basal Cell Carcinoma: A Phase IIa Study.	Cancers	2021	-23.498845475271715	-14.831473569397827	6	0.92
33671367	Digital Immunophenotyping Predicts Disease Free and Overall Survival in Early Stage Melanoma Patients.	Cells	2021	-1.8652181609863256	19.486039077107076	4	0.39
33670993	TIGIT/CD226 Axis Regulates Anti-Tumor Immunity.	Pharmaceuticals (Basel, Switzerland)	2021	-12.456993850430964	-56.88110254240004	45	4.7
33670397	Targeting the PD-1 Axis with Pembrolizumab for Recurrent or Metastatic Cancer of the Uterine Cervix: A Brief Update.	International journal of molecular sciences	2021	44.113851127944045	33.61758573034351	6	0.61
33669639	PD-L1 Expression Correlated with p53 Expression in Pediatric Glioblastoma Multiforme.	Brain sciences	2021	-23.897599722540587	49.87842808190272	5	0.71
33669410	Immune Profile Analysis in Peripheral Blood and Tumor in Patients with Malignant Melanoma.	International journal of molecular sciences	2021	13.139091478301648	-5.089859176984297	4	0.61
33669300	Importance of the PD-1/PD-L1 Axis for Malignant Transformation and Risk Assessment of Oral Leukoplakia.	Biomedicines	2021	-9.30174095873884	-12.567823458586444	19	2.64
33668795	Inhibition of PI3K Isoform p110γ Increases Both Anti-Tumor and Immunosuppressive Responses to Aggressive Murine Head and Neck Squamous Cell Carcinoma with Low Immunogenicity.	Cancers	2021	-7.871324303268068	37.63216385760968	8	0.88
33668625	Cross-Reactivity and Functionality of Approved Human Immune Checkpoint Blockers in Dogs.	Cancers	2021	-1.061700416690326	-58.13130928150263	12	1.98
33668025	Durable Response to PD-1 Blockade in a Patient With Metastatic Pancreatic Undifferentiated Carcinoma With Osteoclast-Like Giant Cells.	Journal of the National Comprehensive Cancer Network : JNCCN	2021	-2.563457219397434	2.451922052856577	5	0.7
33665483	Control and Toxicity in Melanoma Versus Other Brain Metastases in Response to Combined Radiosurgery and PD-(L)1 Immune Checkpoint Inhibition.	Advances in radiation oncology	2021	42.08449703345806	-15.463212859434448	4	0.33
33662590	The efficacy of PD-1/PD-L1 blockade in cold cancers and future perspectives.	Clinical immunology (Orlando, Fla.)	2021	34.5105926110376	23.489410477862677	92	9.63
33659544	Measurement of Protein-Protein Interactions through Microscale Thermophoresis (MST).	Bio-protocol	2020	-48.354027237388834	-43.36295120441347	8	0.86
33659213	Immunosuppression in Gliomas via PD-1/PD-L1 Axis and Adenosine Pathway.	Frontiers in oncology	2020	-26.427780362167496	50.94233940614527	14	1.75
33658927	Transcriptome-Based Co-Expression of BRD4 and PD-1/PD-L1 Predicts Poor Overall Survival in Patients With Acute Myeloid Leukemia.	Frontiers in pharmacology	2020	-35.17514045270077	15.34517050147786	20	2.16
33658518	Inter- and intra-tumor heterogeneity of metastatic prostate cancer determined by digital spatial gene expression profiling.	Nature communications	2021	12.738465562800728	25.848199440038798	96	9.74
33656759	Programmed cell death-ligand 1 expression in hepatocellular carcinoma and its correlation with clinicopathological characteristics.	Journal of gastroenterology and hepatology	2021	-23.23308083441029	39.125478538414825	4	0.32
33656683	Association between PD-L1 expression and 18F-FDG uptake in ovarian cancer.	Annals of nuclear medicine	2021	13.762260280487745	-57.23596882586136	3	0.37
33655698	Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.	Cancer medicine	2021	21.45309207963378	-18.566329425980413	42	4.24
33655682	Temporal Trends and Outcomes Among Patients Admitted for Immune-Related Adverse Events: A Single-Center Retrospective Cohort Study from 2011 to 2018.	The oncologist	2021	75.40303982710454	-9.825005103226438	15	1.81
33655320	Atezolizumab alleviates the immunosuppression induced by PD‑L1‑positive neutrophils and improves the survival of mice during sepsis.	Molecular medicine reports	2021	-59.95719795403315	36.05601103005483	7	1.17
33653969	APDL1-CART cells exhibit strong PD-L1-specific activity against leukemia cells.	Aging	2021	-41.53897100080355	4.504481608325377	1	0.18
33651248	LAG-3 expression in the inflammatory microenvironment of glioma.	Journal of neuro-oncology	2021	9.676182238406067	23.324477278376403	16	1.85
33647542	The role of exosomal PD-L1 in tumor immunotherapy.	Translational oncology	2021	-43.5749942194982	-59.04668950340648	27	3.15
33644151	Serum and Tissue Expression Levels of Leptin and Leptin Receptor Are Putative Markers of Specific Feline Mammary Carcinoma Subtypes.	Frontiers in veterinary science	2021	7.593921499631834	25.68772544820437	6	0.96
33643697	Improved survival without increased toxicity with influenza vaccination in cancer patients treated with checkpoint inhibitors.	Oncoimmunology	2021	65.82288355808342	-0.0251501539209434	12	0.98
33643048	Cardiotoxicity Induced by Immune Checkpoint Inhibitors: A Pharmacovigilance Study From 2014 to 2019 Based on FAERS.	Frontiers in pharmacology	2021	81.94910170836086	1.8790887251165884	21	2.72
33641589	Neuro-ophthalmic Complications of Immune-Checkpoint Inhibitors.	Seminars in ophthalmology	2021	80.4222113108927	-12.90290285446649	5	0.87
33639962	High lymphocyte population-related predictive factors for a long-term response in non-small cell lung cancer patients treated with pemetrexed: a retrospective observational study.	Journal of translational medicine	2021	33.52095334960948	-41.93162670360019	4	0.38
33637989	The binding epitope of sintilimab on PD-1 revealed by AbMap.	Acta biochimica et biophysica Sinica	2021	-47.90481414181156	-33.37698912278539	3	0.37
33637599	Frequent amplification of HDAC genes and efficacy of HDAC inhibitor chidamide and PD-1 blockade combination in soft tissue sarcoma.	Journal for immunotherapy of cancer	2021	-9.57770434523196	-31.220348074680626	34	3.59
33634137	The Tumor Microenvironment in SCC: Mechanisms and Therapeutic Opportunities.	Frontiers in cell and developmental biology	2021	48.66447597990761	29.076250076671823	7	1.02
33633793	Identification and Validation of Efficacy of Immunological Therapy for Lung Cancer From Histopathological Images Based on Deep Learning.	Frontiers in genetics	2021	23.916014429212897	-20.068549344306703	7	0.89
33633208	Identification of distinct immune landscapes using an automated nine-color multiplex immunofluorescence staining panel and image analysis in paraffin tumor tissues.	Scientific reports	2021	3.5788402142496287	-47.13022217524674	21	2.37
33628854	Clinical Implications of Exosomal PD-L1 in Cancer Immunotherapy.	Journal of immunology research	2021	-43.6342644806664	-58.84614281897223	25	3.04
33626854	[Ongoing Evaluation of Immune-related Response Assessment in Brain Metastases].	Zhongguo fei ai za zhi = Chinese journal of lung cancer	2021	42.50508676829468	-16.254629190043133	0	0.0
33624446	Tumour angiogenesis normalized by myo-inositol trispyrophosphate alleviates hypoxia in the microenvironment and promotes antitumor immune response.	Journal of cellular and molecular medicine	2021	-29.195314444503307	-1.3863274611917067	13	1.72
33624434	TTN/OBSCN 'Double-Hit' predicts favourable prognosis, 'immune-hot' subtype and potentially better immunotherapeutic efficacy in colorectal cancer.	Journal of cellular and molecular medicine	2021	7.30084180686536	43.70731631869814	31	2.86
33623668	Adverse effects of immune checkpoint inhibitor therapies on right ventricular function and pulmonary arterial dilatation.	Pulmonary circulation	2021	82.30517618642244	4.446576654083745	2	0.38
33622705	Molecular Features of Cancer-associated Fibroblast Subtypes and their Implication on Cancer Pathogenesis, Prognosis, and Immunotherapy Resistance.	Clinical cancer research : an official journal of the American Association for Cancer Research	2021	0.8881513842093818	34.00215365810237	79	8.48
33620088	Soluble PD-L1 is a promising disease biomarker but does not reflect tissue expression in classic Hodgkin lymphoma.	British journal of haematology	2021	-31.122972144589514	22.877919283462788	7	0.85
33617828	Inhibition of T-cell-mediated immune response via the PD-1/ PD-L1 axis in cholangiocarcinoma cells.	European journal of pharmacology	2021	1.166707171764109	4.612471176744444	5	0.65
33617179	Clinical Outcomes of Metastatic Renal Carcinoma Following Disease Progression to Programmed Death (PD)-1 or PD-L1 Inhibitors (IO): A Meet-URO Group Real World Study (Meet-Uro 7).	American journal of clinical oncology	2021	66.10009654179002	27.266765250004944	9	0.79
33615184	PARP Targeted Alpha-Particle Therapy Enhances Response to PD-1 Immune-Checkpoint Blockade in a Syngeneic Mouse Model of Glioblastoma.	ACS pharmacology & translational science	2021	-18.507878008262047	38.15795580858274	11	1.44
33614918	Eliminating mesothelioma by AAV-vectored, PD1-based vaccination in the tumor microenvironment.	Molecular therapy oncolytics	2021	-39.980493803615005	52.23029820242575	6	0.63
33614750	Immune Checkpoint Inhibitors: Cardiotoxicity in Pre-clinical Models and Clinical Studies.	Frontiers in cardiovascular medicine	2021	83.16059548541324	1.7213440189722768	13	1.6
33613887	Immune Checkpoint Molecules in Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System.	Basic and clinical neuroscience	2020	-33.4885314392752	31.95751250933777	9	0.63
33613563	Immune Checkpoints: Novel Therapeutic Targets to Attenuate Sepsis-Induced Immunosuppression.	Frontiers in immunology	2020	-58.55623810181923	37.675289554775794	33	4.86
33611710	"Clinical significance of checkpoint regulator ""Programmed death ligand-1 (PD-L1)"" expression in meningioma: review of the current status."	Journal of neuro-oncology	2021	-25.046228979685463	50.060875258250086	10	1.91
33611641	Combined inhibition of PD-1/PD-L1, Lag-3, and Tim-3 axes augments antitumor immunity in gastric cancer-T cell coculture models.	Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association	2021	-6.962608419570198	7.649960941278212	24	2.54
33611059	Serum levels of soluble programmed death-ligand 1 (sPD-L1): A possible biomarker in predicting post-treatment outcomes in patients with early hepatocellular carcinoma.	International immunopharmacology	2021	-25.71822912649972	38.18720661708287	17	2.13
33610190	Identification and validation of a miRNA-related expression signature for tumor mutational burden in colorectal cancer.	World journal of surgical oncology	2021	5.122358000139688	50.649740374925166	9	1.07
33609046	Hypothyroidism in Head and Neck Squamous Cell Carcinoma Patients Receiving Radiotherapy With or Without Immune Checkpoint Inhibitors.	The Laryngoscope	2021	58.01799047050458	2.0238560876415104	2	0.28
33606065	Development and validation of a PD-L1/PD-1/CD8 axis-based classifier to predict cancer survival of upper tract urothelial carcinoma after radical nephroureterectomy.	Cancer immunology, immunotherapy : CII	2021	13.349956076126176	56.464104095101085	3	0.25
33605089	Remarkable response to pembrolizumab with platinum-doublet in PD-L1-low pulmonary sarcomatoid carcinoma: A case report.	Thoracic cancer	2021	53.40407129991166	-32.59442789413504	8	0.99
33604353	Identification and Immunocorrelation of Prognosis-Related Genes Associated With Development of Muscle-Invasive Bladder Cancer.	Frontiers in molecular biosciences	2020	5.556661034852085	57.84419288984515	4	0.45
33603737	Functionally Competent, PD-1+ CD8+ Trm Cells Populate the Brain Following Local Antigen Encounter.	Frontiers in immunology	2020	-75.87130841672952	-2.290474027120841	5	0.59
33602263	Chimeric antigen receptor T cells engineered to secrete CD40 agonist antibodies enhance antitumor efficacy.	Journal of translational medicine	2021	-42.15717258990946	5.104033745324167	9	0.95
33600097	Investigation of the relationship between immune checkpoints and mismatch repair deficiency in recurrent and nonrecurrent glioblastoma.	Turkish journal of medical sciences	2021	-22.623744189338115	51.73594274615639	1	0.15
33599743	Low-density PD-1 expression on resting human natural killer cells is functional and upregulated after transplantation.	Blood advances	2021	-35.84215668480105	0.1981667651448617	17	1.61
33599061	M2-Like TAMs Function Reversal Contributes to Breast Cancer Eradication by Combination Dual Immune Checkpoint Blockade and Photothermal Therapy.	Small (Weinheim an der Bergstrasse, Germany)	2021	-30.02826671435757	-53.72318019287906	25	2.97
33597595	Ex vivo modelling of PD-1/PD-L1 immune checkpoint blockade under acute, chronic, and exhaustion-like conditions of T-cell stimulation.	Scientific reports	2021	63.05606287630503	-35.55049398247653	8	0.83
33596656	Core Role of Hydrophobic Core of Polymeric Nanomicelle in Endosomal Escape of siRNA.	Nano letters	2021	-35.42165995335412	-53.394870717500766	38	4.62
33594603	Predictive factors in the treatment of oral squamous cell carcinoma using PD-1/PD-L1 inhibitors.	Investigational new drugs	2021	-6.967047709574262	-11.27551147159805	9	1.11
33593828	Prospective development and validation of a liquid immune profile-based signature (LIPS) to predict response of patients with recurrent/metastatic cancer to immune checkpoint inhibitors.	Journal for immunotherapy of cancer	2021	37.27970547357776	-14.601693840601294	31	3.25
33590360	Characterizing the Tumor Immune Microenvironment with Tyramide-Based Multiplex Immunofluorescence.	Journal of mammary gland biology and neoplasia	2020	3.950954549218328	-46.73892821096519	22	1.43
33586297	Anti-PD1 versus anti-PD-L1 immunotherapy in first-line therapy for advanced non-small cell lung cancer: A systematic review and meta-analysis.	Thoracic cancer	2021	46.48159940488889	-19.1794280019696	11	0.86
33585195	Efficacy and Safety of PD-1/PD-L1 Inhibitors Plus Chemotherapy Versus PD-1/PD-L1 Inhibitors in Advanced Non-Small Cell Lung Cancer: A Network Analysis of Randomized Controlled Trials.	Frontiers in oncology	2020	46.128999238308445	-19.18490749990172	11	1.2
33584714	CU06-1004-Induced Vascular Normalization Improves Immunotherapy by Modulating Tumor Microenvironment via Cytotoxic T Cells.	Frontiers in immunology	2020	-7.448135875348191	-45.73144871900879	11	1.26
33584713	Inactivation of the PD-1-Dependent Immunoregulation in Mice Exacerbates Contact Hypersensitivity Resembling Immune-Related Adverse Events.	Frontiers in immunology	2020	-71.98668962655367	-13.583687769347875	2	0.16
33583384	Cancer Immunotherapy - Immune Checkpoint Inhibitors in Hepatocellular Carcinoma.	Recent patents on anti-cancer drug discovery	2021	31.736668598149365	48.81159612372901	11	1.08
33583159	C-X-C chemokine receptor 2 (Cxcr2) promotes hepatocellular carcinoma immune evasion via regulating programmed death-ligand 1 (PD-L1).	Biological chemistry	2021	-11.791516037185923	45.552639270092406	4	0.39
33583004	Peripheral blood T-cell receptor repertoire as a predictor of clinical outcomes in gastrointestinal cancer patients treated with PD-1 inhibitor.	Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico	2021	12.998010820406718	-8.412868653203375	6	0.56
33581582	Patients with autoimmune diseases have an altered activity of the PD-1 pathway and proportions of Epstein-Barr virus infected cells in benign lymphadenopathies.	Immunobiology	2021	-38.726409762006966	27.53001254976418	1	0.18
33581579	PD-1/PD-L1 enhanced cisplatin resistance in gastric cancer through PI3K/AKT mediated P-gp expression.	International immunopharmacology	2021	-11.812369918818051	2.1977125796519967	24	3.11
33580363	Pembrolizumab in advanced osteosarcoma: results of a single-arm, open-label, phase 2 trial.	Cancer immunology, immunotherapy : CII	2021	50.68629542011429	0.8047690474478476	34	4.18
33580222	PD-L1 as a biomarker of response to immune-checkpoint inhibitors.	Nature reviews. Clinical oncology	2021	18.344856772798003	-43.05460427401463	433	45.87
33580183	PD-L1 immunohistochemistry for canine cancers and clinical benefit of anti-PD-L1 antibody in dogs with pulmonary metastatic oral malignant melanoma.	NPJ precision oncology	2021	-15.86601048485962	-14.265283095667414	45	6.4
33579182	Immune checkpoints in sepsis: New hopes and challenges.	International reviews of immunology	2022	-58.44878323440035	37.6657511970391	3	
33579170	PD-L1 and IDO1 are potential targets for treatment in patients with primary diffuse large B-cell lymphoma of the CNS.	Acta oncologica (Stockholm, Sweden)	2021	-35.86969373946704	32.49892512983525	9	1.12
33578798	Mouse Preclinical Cancer Immunotherapy Modeling Involving Anti-PD-1 Therapies Reveals the Need to Use Mouse Reagents to Mirror Clinical Paradigms.	Cancers	2021	-38.494782215331135	-25.473982888003224	2	0.17
33577729	Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma.	The New England journal of medicine	2021	68.43236207241522	12.627739073829677	310	38.39
33576873	PD-L1 amplification is associated with an immune cell rich phenotype in squamous cell cancer of the lung.	Cancer immunology, immunotherapy : CII	2021	11.830639139879194	-25.41626029933312	11	1.12
33574892	Neoadjuvant immunotherapy in breast cancer: a paradigm shift?	Ecancermedicalscience	2020	40.93274100603062	8.644611155776424	10	0.62
33574677	Combination Therapy with iRGD-antiCD3 and PD-1 Blockade Enhances Antitumor Potency of Cord Blood-Derived T Cells.	OncoTargets and therapy	2021	-14.771641864213551	-44.90995593529959	4	0.61
33574265	Targeting IL-21 to tumor-reactive T cells enhances memory T cell responses and anti-PD-1 antibody therapy.	Nature communications	2021	-40.44187909122879	-0.881667963003308	41	4.04
33572655	Programmed Death-Ligand 2 Deficiency Exacerbates Experimental Autoimmune Myocarditis in Mice.	International journal of molecular sciences	2021	-62.49070395618704	7.302480716435009	6	0.81
33572196	Targeting Innate Immunity in Cancer Therapy.	Vaccines	2021	18.22223022385877	8.263684984355192	38	4.25
33571549	Recent advances in tumor microenvironment-targeted nanomedicine delivery approaches to overcome limitations of immune checkpoint blockade-based immunotherapy.	Journal of controlled release : official journal of the Controlled Release Society	2021	18.66931106580431	11.50992134739314	19	2.43
33570446	Epithelioid granulomatous lesions express abundant programmed death ligand-1 (PD-L1): a discussion of adverse events in anti-PD-1 antibody-based cancer immunotherapy.	Human vaccines & immunotherapeutics	2021	63.72399617619063	-24.30414437679274	5	0.64
33569421	Immune profiling and immunotherapeutic targets in pancreatic cancer.	Annals of translational medicine	2021	-2.990327660413465	46.32214278382885	10	0.99
33569208	Evaluation of pembrolizumab for the treatment of advanced non-small cell lung cancer: a retrospective, single-centre, single-arm study.	Journal of thoracic disease	2021	48.31296035653895	-30.665683469326968	1	0.07
33568343	A Randomized Trial of Combined PD-L1 and CTLA-4 Inhibition with Targeted Low-Dose or Hypofractionated Radiation for Patients with Metastatic Colorectal Cancer.	Clinical cancer research : an official journal of the American Association for Cancer Research	2021	30.109626551550104	23.24877891265557	38	3.45
33567792	Immunomodulatory Role of NK Cells during Antiviral Antibody Therapy.	Vaccines	2021	-76.85485004469132	20.311543404974163	5	0.53
33565499	Immune-related organizing pneumonitis in non-small cell lung cancer receiving PD-1 inhibitor treatment: A case report and literature review.	Journal of cancer research and therapeutics	2020	66.1164947111343	-11.917976113103734	4	0.25
33564898	Incidence risk of PD-1/PD-L1-related pneumonia and diarrhea in non-small cell lung cancer (NSCLC) patients: a systematic review and meta-analysis of randomized controlled trials.	European journal of clinical pharmacology	2021	66.42851803378376	-14.27057339552002	5	0.63
33562338	Soluble PD-L1 Is an Independent Prognostic Factor in Clear Cell Renal Cell Carcinoma.	Cancers	2021	15.906222245860365	26.089927395910717	20	2.16
33562324	Recent Advancements in the Mechanisms Underlying Resistance to PD-1/PD-L1 Blockade Immunotherapy.	Cancers	2021	-35.84950892107653	-20.3789668348012	20	2.08
33560388	Pembrolizumab in mycosis fungoides with PD-L1 structural variants.	Blood advances	2021	45.71932834561594	-3.19038656172044	17	2.49
33558279	Short-term response to immune-chemotherapy and immune features of a ceritinib-resistant patient with ROS1-rearranged lung adenocarcinoma.	Journal for immunotherapy of cancer	2021	32.66332555725593	-38.41151888187537	2	0.2
33556239	Spatial Regulation of T-Cell Signaling by Programmed Death-Ligand 1 on Wireframe DNA Origami Flat Sheets.	ACS nano	2021	-52.54399838613988	-9.492811088826349	26	2.91
33555085	Biomimetic Nanoemulsion for Synergistic Photodynamic-Immunotherapy Against Hypoxic Breast Tumor.	Angewandte Chemie (International ed. in English)	2021	-31.7617412445656	-55.630391949399765	54	6.35
33555016	Checkpoint Inhibitor Colitis Shows Drug-Specific Differences in Immune Cell Reaction That Overlap With Inflammatory Bowel Disease and Predict Response to Colitis Therapy.	American journal of clinical pathology	2021	77.18292521711514	-2.4548811419348917	11	1.47
33552993	Pre-Treatment Tumor Growth Rate Predicts Clinical Outcomes of Patients With Advanced Non-Small Cell Lung Cancer Undergoing Anti-PD-1/PD-L1 Therapy.	Frontiers in oncology	2020	25.72339283642376	-42.25284884191	7	0.78
33552711	Gender-related disparities in the frequencies of PD-1 and PD-L1 positive peripheral blood T and B lymphocytes in patients with alcohol-related liver disease: a single center pilot study.	PeerJ	2021	-69.04019159285222	25.023964007119872	3	0.47
33552685	Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world data.	Oncoimmunology	2021	49.51543593392639	-28.841530863720088	19	2.06
33552089	Variable Expression of Programmed Cell Death Protein 1-Ligand 1 in Kidneys Independent of Immune Checkpoint Inhibition.	Frontiers in immunology	2020	70.4671816520562	1.7160047045571474	17	1.99
33552075	Nocardia Rubra Cell Wall Skeleton Up-Regulates T Cell Subsets and Inhibits PD-1/PD-L1 Pathway to Promote Local Immune Status of Patients With High-Risk Human Papillomavirus Infection and Cervical Intraepithelial Neoplasia.	Frontiers in immunology	2020	-1.641009050490715	-12.372606490489478	7	1.15
33550887	PD-L1 expression in peripheral T-cell lymphomas is not related to either PD-L1 gene amplification or rearrangements.	Leukemia & lymphoma	2021	-33.983694356651064	22.14080608870379	6	0.62
33550044	ShRNA-mediated silencing of PD-1 augments the efficacy of chimeric antigen receptor T cells on subcutaneous prostate and leukemia xenograft.	Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie	2021	-43.071660459030205	2.4045646659054123	16	1.74
33549014	Efficacy and safety of first-line treatments with immune checkpoint inhibitors plus chemotherapy for non-squamous non-small cell lung cancer: a meta-analysis and indirect comparison.	Annals of palliative medicine	2021	39.7821273282792	-20.91059087355613	8	0.83
33545799	Tailing effect of PD-1 antibody results in the eradication of unresectable multiple primary lung cancer presenting as ground-glass opacities: a case report.	Annals of palliative medicine	2021	43.84322492782648	-26.37626213962998	3	0.31
33545655	Esophageal squamous cell carcinoma metachronous to head and neck cancers.	Pathology, research and practice	2021	-10.680315031180958	34.25997052114659	3	0.38
33544352	Immunotherapeutics at the spearhead: current status in targeting neuroendocrine neoplasms.	Endocrine	2021	44.496583015226896	24.717455771112338	1	0.26
33543377	Is there any place for novel agents in treating biliary tract cancer?	Medical oncology (Northwood, London, England)	2021	58.38530461503522	24.52811557874477	1	0.11
33541088	Immunotherapy and chimeric antigen receptor T-cell therapy in hepatocellular carcinoma.	Chinese clinical oncology	2021	29.943278649715648	49.84171186408976	5	0.53
33538768	Retinoblastoma Is Characterized by a Cold, CD8+ Cell Poor, PD-L1- Microenvironment, Which Turns Into Hot, CD8+ Cell Rich, PD-L1+ After Chemotherapy.	Investigative ophthalmology & visual science	2021	-3.753532492401918	32.32951799563936	6	0.96
33537496	Immunotherapy in Colorectal Cancer: Current and Future Strategies.	Journal of the anus, rectum and colon	2021	37.28073171172928	21.344074787980244	42	4.22
33533917	Niche-specific MHC II and PD-L1 regulate CD4+CD8αα+ intraepithelial lymphocyte differentiation.	The Journal of experimental medicine	2021	-61.03161736702009	-0.0270745167886288	13	1.01
33533279	PD-L1 ≥ 50% lung cancer refractory to PD-1 inhibition: the role of salvage chemo-immunotherapy combination.	Immunotherapy	2021	44.98793146376547	-31.654934027921502	3	0.24
33531395	A Combination of Anti-PD-L1 Treatment and Therapeutic Vaccination Facilitates Improved Retroviral Clearance via Reactivation of Highly Exhausted T Cells.	mBio	2021	-77.2267858601001	12.597147528375777	6	0.54
33530581	Dual and Opposite Costimulatory Targeting with a Novel Human Fusion Recombinant Protein Effectively Prevents Renal Warm Ischemia Reperfusion Injury and Allograft Rejection in Murine Models.	International journal of molecular sciences	2021	-62.00234041711138	-5.465400218924688	4	0.48
33530227	Anti-PD1/PD-L1 monotherapy vs standard of care in patients with recurrent or metastatic head and neck squamous cell carcinoma: A meta-analysis of randomized controlled trials.	Medicine	2021	59.142837841325225	0.7615362673820048	7	0.7
33529989	Neoadjuvant anti-programmed death-1 immunotherapy by pembrolizumab in resectable non-small cell lung cancer: First clinical experience.	Lung cancer (Amsterdam, Netherlands)	2021	48.04443064142182	-34.54503728296398	37	3.41
33529880	Discovery of a new inhibitor targeting PD-L1 for cancer immunotherapy.	Neoplasia (New York, N.Y.)	2021	-39.299940328018096	-39.256758891815736	11	1.31
33529058	Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma.	Journal of clinical oncology : official journal of the American Society of Clinical Oncology	2021	54.278727134003255	4.536273056441866	90	9.59
33527708	Tislelizumab uniquely binds to the CC' loop of PD-1 with slow-dissociated rate and complete PD-L1 blockage.	FEBS open bio	2021	-47.07350666895932	-34.823729476062034	21	2.37
33524811	Anticancer nanocage platforms for combined immunotherapy designed to harness immune checkpoints and deliver anticancer drugs.	Biomaterials	2021	-36.19715787442135	-47.74457830938096	22	2.46
33523584	A combination of extracellular matrix- and interferon-associated signatures identifies high-grade breast cancers with poor prognosis.	Molecular oncology	2021	0.1441079935447317	46.78796177047059	4	0.47
33523301	Real-world outcomes of anti-PD1 antibodies in platinum-refractory, PD-L1-positive recurrent and/or metastatic non-small cell lung cancer, and its potential practical predictors: first report from Korean Cancer Study Group LU19-05.	Journal of cancer research and clinical oncology	2021	47.24941706836052	-28.863467905645592	3	0.41
33523034	PD-L1 expression in tumor lesions and soluble PD-L1 serum levels in patients with breast cancer: TNBC versus TPBC.	Breast disease	2021	-8.209977189443482	17.961841369578387	9	1.1
33522846	Spectrum of PD-1 and PD-L1 inhibitor cutaneous adverse events in skin of color: a retrospective, single-institutional study in an urban community.	Acta oncologica (Stockholm, Sweden)	2021	69.00068061548504	-24.516649390258703	1	0.14
33521853	Peripheral CD4+ T cell signatures in predicting the responses to anti-PD-1/PD-L1 monotherapy for Chinese advanced non-small cell lung cancer.	Science China. Life sciences	2021	8.708540299426932	-20.946196297798227	6	0.56
33521133	Relationship of PD-1 (PDCD1) and PD-L1 (CD274) Single Nucleotide Polymorphisms with Polycystic Ovary Syndrome.	BioMed research international	2021	-62.601964940404976	13.838332005721218	3	0.6
33519801	Blockade of LAG-3 in PD-L1-Deficient Mice Enhances Clearance of Blood Stage Malaria Independent of Humoral Responses.	Frontiers in immunology	2020	-74.76719023139054	2.71980766291261	5	0.5
33519429	Dihydropyridine Calcium Channel Blockers Suppress the Transcription of PD-L1 by Inhibiting the Activation of STAT1.	Frontiers in pharmacology	2020	-34.00062375220076	-39.17501433415048	11	1.31
33517203	Ultrasensitive electrochemical determination of the cancer biomarker protein sPD-L1 based on a BMS-8-modified gold electrode.	Bioelectrochemistry (Amsterdam, Netherlands)	2021	-43.114538316174446	-53.02693771097144	7	1.11
33514524	Blocking TIM-3 in Treatment-refractory Advanced Solid Tumors: A Phase Ia/b Study of LY3321367 with or without an Anti-PD-L1 Antibody.	Clinical cancer research : an official journal of the American Association for Cancer Research	2021	52.15612883344812	-5.425194686128247	50	5.19
33511398	Tolerogenic anti-IL-2 mAb prevents graft-versus-host disease while preserving strong graft-versus-leukemia activity.	Blood	2021	-66.05817227219899	-6.814605266056526	9	0.81
33511078	PD-1 Blockade Aggravates Epstein-Barr Virus+ Post-Transplant Lymphoproliferative Disorder in Humanized Mice Resulting in Central Nervous System Involvement and CD4+ T Cell Dysregulations.	Frontiers in oncology	2020	-37.75841395079655	8.007548817558218	17	2.1
33511066	A Systematic Review and Meta-analysis of PD-1 and PD-L1 Inhibitors Monotherapy in Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma.	Euroasian journal of hepato-gastroenterology	2020	49.422961760055294	15.928837311955505	2	0.16
33508527	Epidermal growth factor receptor tyrosine kinase inhibitor remodels tumor microenvironment by upregulating LAG-3 in advanced non-small-cell lung cancer.	Lung cancer (Amsterdam, Netherlands)	2021	6.815581069348558	-34.12087785377958	17	1.69
33508291	SARS-CoV-2 infection: The role of PD-1/PD-L1 and CTLA-4 axis.	Life sciences	2021	-51.73421655201108	43.4932845613055	45	5.42
33506525	Tumor infiltrated immune cell types support distinct immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer.	European journal of immunology	2021	11.745346860144975	-18.66654429227919	9	1.05
33506299	Single-cell RNA sequencing reveals cellular and molecular immune profile in a Pembrolizumab-responsive PD-L1-negative lung cancer patient.	Cancer immunology, immunotherapy : CII	2021	20.702713356402388	-14.18739568783879	13	1.24
33504557	Inhibition of MDM2 Promotes Antitumor Responses in p53 Wild-Type Cancer Cells through Their Interaction with the Immune and Stromal Microenvironment.	Cancer research	2021	-27.58311208059745	-22.65177650758136	21	2.12
33499013	Soluble PD-1 but Not PD-L1 Levels Predict Poor Outcome in Patients with High-Risk Diffuse Large B-Cell Lymphoma.	Cancers	2021	-45.71379100524298	21.4357866055241	14	1.59
33498270	The Periphery of Salivary Gland Carcinoma Tumors Reveals a PD-L1/PD-1 Biomarker Niche for the Evaluation of Disease Severity and Tumor-Immune System Interplay.	Biomedicines	2021	-3.783196077501238	-0.8201321329188436	7	1.12
33498159	Survival Impact of Aggressive Treatment and PD-L1 Expression in Oligometastatic NSCLC.	Current oncology (Toronto, Ont.)	2021	15.59083569264694	-28.59456059572649	8	0.99
33492986	Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02).	Journal of clinical oncology : official journal of the American Society of Clinical Oncology	2021	57.18956316637176	-2.5977597319361294	108	11.27
33492447	PD-1/PD-L1 checkpoint inhibitors in combination with olaparib display antitumor activity in ovarian cancer patient-derived three-dimensional spheroid cultures.	Cancer immunology, immunotherapy : CII	2021	36.074498569676	39.55635352633427	13	1.37
33489468	Combined immune checkpoint blockade increases CD8+CD28+PD-1+ effector T cells and provides a therapeutic strategy for patients with neuroblastoma.	Oncoimmunology	2021	-27.543485537833835	12.514442716400849	17	1.88
33488843	The Value of PD-L1 Expression in Predicting the Efficacy of Anti-PD-1 or Anti-PD-L1 Therapy in Patients with Cancer: A Systematic Review and Meta-Analysis.	Disease markers	2020	49.38510003831144	-15.03459249429013	10	0.6
33488620	PD-L1/PD-1 Pattern of Expression Within the Bone Marrow Immune Microenvironment in Smoldering Myeloma and Active Multiple Myeloma Patients.	Frontiers in immunology	2020	-32.96607512159215	10.299701229962944	10	1.14
33488573	Research Progress Concerning Dual Blockade of Lymphocyte-Activation Gene 3 and Programmed Death-1/Programmed Death-1 Ligand-1 Blockade in Cancer Immunotherapy: Preclinical and Clinical Evidence of This Potentially More Effective Immunotherapy Strategy.	Frontiers in immunology	2020	11.129410768809986	21.8389476310036	21	2.26
33487707	Expression of Programmed Death-Ligand 1 in Cutaneous Squamous Cell Carcinoma Arising in Sun-Exposed and Nonsun-Exposed Skin.	Indian journal of dermatology	2020	-0.6278745320336765	-4.768146107112907	3	0.24
33486574	Predictive biomarkers for response to immune checkpoint inhibitors in lung cancer: PD-L1 and beyond.	Virchows Archiv : an international journal of pathology	2021	23.64542688276676	-32.55734364901528	16	1.64
33485052	Clinicopathological significance of the expression of PD-L1 in non-small cell lung cancer.	Annals of diagnostic pathology	2021	13.380850266276235	-28.78136860578276	3	0.27
33484380	Tumor-resident adenosine-producing mesenchymal stem cells as a potential target for cancer treatment.	Clinical and experimental medicine	2021	-53.488763417598825	22.364782903479664	5	0.72
33483882	Comparative incidence of immune-related adverse events and hyperprogressive disease in patients with non-small cell lung cancer receiving immune checkpoint inhibitors with and without chemotherapy.	Investigational new drugs	2021	70.5438542074616	-12.64252790268546	7	0.77
33483343	Preclinical PET imaging with the novel human antibody 89Zr-DFO-REGN3504 sensitively detects PD-L1 expression in tumors and normal tissues.	Journal for immunotherapy of cancer	2021	7.2756736229926515	-56.75405040777405	11	1.41
33482345	Immunotherapy addition to neoadjuvant chemotherapy for early triple negative breast cancer: A systematic review and meta-analysis of randomized clinical trials.	Critical reviews in oncology/hematology	2021	41.18871965587696	9.374609621428355	38	4.14
33482156	Prognostic Impact of PD-1 on Tumor-Infiltrating Lymphocytes in 433 Resected Esophageal Cancers.	The Annals of thoracic surgery	2022	-13.108863531510094	7.891436805641038	7	1.43
33480637	Hepatitis B Virus Reactivation in Cancer Patients Treated With Immune Checkpoint Inhibitors.	Journal of immunotherapy (Hagerstown, Md. : 1997)	2021	63.58361421439174	-21.58321957379421	12	1.46
33480358	Spartalizumab in metastatic, well/poorly-differentiated neuroendocrine neoplasms.	Endocrine-related cancer	2021	53.78354289931951	-6.311950529287019	46	5.66
33478285	Novel anti-PD-L1 peptide selected from combinatorial phage library inhibits tumor cell growth and restores T-cell activity.	Journal of drug targeting	2021	-42.37492021038277	-43.89166652187193	5	0.54
33478191	[Research Progress on the Mechanism and Clinical Data of Cereblon  in Reversing the Resistance of Lung Cancer to PD-1 Antibody by T cells].	Zhongguo fei ai za zhi = Chinese journal of lung cancer	2021	-13.70292359735726	-26.6326419361393	0	0.0
33475656	Metformin loaded porous particles with bio-microenvironment responsiveness for promoting tumor immunotherapy.	Biomaterials science	2021	-29.230473999771323	-52.25485073727841	6	0.69
33475525	Prognostic value of PD-L1 expression in bronchopulmonary neuroendocrine tumours.	Endocrine connections	2021	8.17981415334775	-25.885648979542072	6	0.88
33475499	PD-L1 EXPRESSION IN NORMAL ENDOCRINE TISSUES IS NOT INCREASED DESPITE HIGH INCIDENCE OF PD-1 INHIBITOR-ASSOCIATED ENDOCRINOPATHIES.	Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists	2021	88.66414047471369	-18.578867289294017	6	0.98
33472857	Mechanisms underlying low-clinical responses to PD-1/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1.	Journal for immunotherapy of cancer	2021	-43.33337061614542	-59.1168900325961	62	7.38
33470166	Oncolytic Adenovirus ORCA-010 Activates Proinflammatory Myeloid Cells and Facilitates T Cell Recruitment and Activation by PD-1 Blockade in Melanoma.	Human gene therapy	2021	-37.92170592137944	53.769800502641424	6	0.73
33468555	Rethinking immune checkpoint blockade: 'Beyond the T cell'.	Journal for immunotherapy of cancer	2021	23.836527463364938	7.335763909722826	59	6.08
33467725	Delivery of miR-424-5p via Extracellular Vesicles Promotes the Apoptosis of MDA-MB-231 TNBC Cells in the Tumor Microenvironment.	International journal of molecular sciences	2021	-39.95055430019939	-57.78217205952222	33	4.71
33466653	The Search for an Interesting Partner to Combine with PD-L1 Blockade in Mesothelioma: Focus on TIM-3 and LAG-3.	Cancers	2021	10.022047451200258	11.97130448161028	17	1.75
33463116	Up-regulation of CD200/CD200R1 Immunomodulatory Axis of Allogenic Peripheral Blood Mononuclear Cells in a Co-culture with Adipose-derived Mesenchymal Stem Cells.	Iranian journal of allergy, asthma, and immunology	2020	-53.84956782405757	24.18670283400561	2	0.23
33462141	Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer.	Journal for immunotherapy of cancer	2021	33.700209109848764	24.030104100038645	67	7.21
33460617	The recent advances of PD-1 and PD-L1 checkpoint signaling inhibition for breast cancer immunotherapy.	European journal of pharmacology	2021	25.329540097359494	-1.356055622794048	16	1.89
33457092	Identification and validation of poor prognosis immunoevasive subtype of muscle-invasive bladder cancer with tumor-infiltrating podoplanin+ cell abundance.	Oncoimmunology	2020	6.080030246831886	59.08273521522518	12	0.79
33457085	Osteosarcoma and soft-tissue sarcomas with an immune infiltrate express PD-L1: relation to clinical outcome and Th1 pathway activation.	Oncoimmunology	2020	-18.98490159521945	19.809018249508785	17	1.32
33457074	Expanded NK cells from umbilical cord blood and adult peripheral blood combined with daratumumab are effective against tumor cells from multiple myeloma patients.	Oncoimmunology	2020	56.44571813495152	-43.190512261129946	19	1.42
33456170	Anti-CTLA-4 therapy-associated granuloma annulare in chronic myelomonocytic leukemia.	Proceedings (Baylor University. Medical Center)	2020	75.8910378283383	-22.762106442191115	1	0.13
33455898	Recent advancement on PD-L1 expression quantification: the radiologist perspective on CT-guided FNAC.	Diagnostic and interventional radiology (Ankara, Turkey)	2021	14.235445648170137	-38.279893638876885	3	0.64
33455015	Immunotyping in tubo-ovarian high-grade serous carcinoma by PD-L1 and CD8+ T-lymphocytes predicts disease-free survival.	APMIS : acta pathologica, microbiologica, et immunologica Scandinavica	2021	-18.15118290281709	14.623496546670664	3	0.34
33454722	IFN-γ surmounts PD-L1/PD1 inhibition to CAR-T cell therapy by upregulating ICAM-1 on tumor cells.	Signal transduction and targeted therapy	2021	-19.976727439185996	-17.99072063369219	15	1.4
33454551	Targeting the PD-1/ PD-L1 interaction in nasopharyngeal carcinoma.	Oral oncology	2021	41.60311964328827	28.266482870174645	15	1.95
33454550	Recent advance of peptide-based molecules and nonpeptidic small-molecules modulating PD-1/PD-L1 protein-protein interaction or targeting PD-L1 protein degradation.	European journal of medicinal chemistry	2021	-41.45697400907439	-37.59905105594858	24	2.7
33453313	Incidence, risk factors, and CT characteristics of radiation recall pneumonitis induced by immune checkpoint inhibitor in lung cancer.	Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology	2021	64.39304807048336	-7.978029855733991	31	3.99
33452107	PD-1 blockade exacerbates Mycobacterium tuberculosis infection in rhesus macaques.	Science immunology	2021	-83.36640769650242	2.6877836146430987	49	5.36
33452008	At the Crossroads: COVID-19 and Immune-Checkpoint Blockade for Cancer.	Cancer immunology research	2021	80.4675920092501	-2.48254147277551	15	1.27
33450361	Anti-PD-(L)1 immunotherapy for brain metastases in non-small cell lung cancer: Mechanisms, advances, and challenges.	Cancer letters	2021	44.974893908747504	-14.44643519901794	13	1.48
33448787	Development of a Non-IgG PD-1/PD-L1 Inhibitor by in Silico Mutagenesis and an In-Cell Protein-Protein Interaction Assay.	ACS chemical biology	2021	-40.35690901090713	-38.784534578549504	6	0.65
33448648	Real-world efficacy of atezolizumab in non-small cell lung cancer: A multicenter cohort study focused on performance status and retreatment after failure of anti-PD-1 antibody.	Thoracic cancer	2021	52.1425042902233	-37.81583384147562	15	1.28
33447446	Comparison of PD-L1 immunohistochemical assays and the significance of PD-L1 expression in thymoma.	Journal of thoracic disease	2020	-5.006979668636069	-36.81166830619694	3	0.26
33447123	Predicting Responses to Checkpoint Inhibitors in Lymphoma: Are We Up to the Standards of Solid Tumors?	Clinical Medicine Insights. Oncology	2020	38.12105507508778	-9.360569861664318	5	0.31
33443105	mDKN-01, a Novel Anti-DKK1 mAb, Enhances Innate Immune Responses in the Tumor Microenvironment.	Molecular cancer research : MCR	2021	-42.64449635308206	-26.027498752237985	27	3.05
33443026	Enhanced Immunotherapeutic Efficacy of Anti-PD-L1 Antibody in Combination with an EP4 Antagonist.	ImmunoHorizons	2020	-28.0434731042503	-20.135426017922345	15	1.2
33441793	Tick saliva-induced programmed death-1 and PD-ligand 1 and its related host immunosuppression.	Scientific reports	2021	-60.89903588472926	-23.507312132277715	6	1.09
33441294	Safety and Immunogenicity of LY3415244, a Bispecific Antibody Against TIM-3 and PD-L1, in Patients With Advanced Solid Tumors.	Clinical cancer research : an official journal of the American Association for Cancer Research	2021	52.11259982029986	-5.199377218307929	35	3.74
33441183	Value of 18F-FDG-PET to predict PD-L1 expression and outcomes of PD-1 inhibition therapy in human cancers.	Cancer imaging : the official publication of the International Cancer Imaging Society	2021	13.837656817654656	-56.49893984359738	15	1.46
33440868	Identification of MicroRNAs as Diagnostic Biomarkers for Breast Cancer Based on the Cancer Genome Atlas.	Diagnostics (Basel, Switzerland)	2021	3.4905960278257044	52.52487659287671	13	2.04
33440424	Baseline monocyte and its classical subtype may predict efficacy of PD-1/PD-L1 inhibitor in cancers.	Bioscience reports	2021	25.579809399761388	-41.08490219284136	3	0.45
33439294	Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma.	Cancer immunology, immunotherapy : CII	2021	47.21117510012275	49.98644033677365	25	3.39
33437808	Complete response to immunotherapy combined with an antiangiogenic agent in multiple hepatic metastases after radical surgery for advanced gallbladder cancer: a case report.	Annals of translational medicine	2020	52.33872585702857	22.185478649190685	3	0.27
33435596	Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma.	International journal of molecular sciences	2021	39.20430881147366	-38.66908329889027	26	3.13
33435262	Tumor Microenvironment Features as Predictive Biomarkers of Response to Immune Checkpoint Inhibitors (ICI) in Metastatic Clear Cell Renal Cell Carcinoma (mccRCC).	Cancers	2021	16.684019750969334	32.63157310750994	35	3.44
33433743	Refining Immuno-Oncology Approaches in Metastatic Prostate Cancer: Transcending Current Limitations.	Current treatment options in oncology	2021	23.67283340231584	17.14358233906001	11	1.17
33433201	Interplay among Structural Stability, Plasticity, and Energetics Determined by Conformational Attuning of Flexible Loops in PD-1.	Journal of chemical information and modeling	2021	-47.52525236109773	-41.00946693167539	25	3.52
33433132	Potential of circulating immune cells as biomarkers of nivolumab treatment efficacy for advanced hepatocellular carcinoma.	Journal of the Chinese Medical Association : JCMA	2021	12.979640582454104	5.681972145605706	8	0.76
33432790	Effect of dexmedetomidine on CD4+ T cells and programmed cell death protein-1 in postoperative analgesia: a prospective, randomized, controlled study.	Minerva anestesiologica	2021	-76.82450751310806	-10.512346751483737	5	0.94
33429221	Epstein-Barr Virus Positive Gastric Cancer: A Distinct Subtype Candidate for Immunotherapy.	The Journal of surgical research	2021	-12.685164057561336	21.057666085930464	3	0.49
33428533	Effect of radiotherapy on T cell and PD-1 / PD-L1 blocking therapy in tumor microenvironment.	Human vaccines & immunotherapeutics	2021	39.97608600283833	3.586719760290314	11	1.23
33425739	Three Immune-Associated Subtypes of Diffuse Glioma Differ in Immune Infiltration, Immune Checkpoint Molecules, and Prognosis.	Frontiers in oncology	2020	-20.764132475079737	54.54152551103514	17	1.14
33425025	Low intratumor heterogeneity correlates with increased response to PD-1 blockade in renal cell carcinoma.	Therapeutic advances in medical oncology	2020	2.7868528202133587	19.192830116714934	15	0.76
33423684	The PD-1:PD-L1 axis in Inflammatory Arthritis.	BMC rheumatology	2021	-49.44048782806696	7.001517810467629	16	2.06
33422940	Immune checkpoint inhibition in syngeneic mouse cancer models by a silicasome nanocarrier delivering a GSK3 inhibitor.	Biomaterials	2021	-37.04680543698605	-52.49410635460075	21	2.73
33419803	Clinicopathological and Prognostic Analysis of PD-L1 and PD-L2 Expression in Surgically Resected Primary Tongue Squamous Cell Carcinoma.	Anticancer research	2021	-7.6772302504463	-11.196939893750104	4	0.56
33419027	Peptide Blocking CTLA-4 and B7-1 Interaction.	Molecules (Basel, Switzerland)	2021	-46.003724230912745	-47.56664303831961	10	1.11
33417300	Serum soluble PD-1 plays a role in predicting infection complications in patients with acute pancreatitis.	Immunity, inflammation and disease	2021	-55.65229795506913	31.69236399586249	8	1.06
33416945	Increased expression of adenosine 2A receptors in metastatic renal cell carcinoma is associated with poorer response to anti-vascular endothelial growth factor agents and anti-PD-1/Anti-CTLA4 antibodies and shorter survival.	Cancer immunology, immunotherapy : CII	2021	-4.416994683428984	-49.36106237263128	19	2.0
33415405	Cardiovascular Toxicity of Immune Checkpoint Inhibitors: Clinical Risk Factors.	Current oncology reports	2021	82.71070844386252	4.098656161613668	29	3.47
33414053	Immune Checkpoint Inhibition With Chemoradiotherapy in Stage III Non-small-cell Lung Cancer: A Systematic Review and Meta-analysis of Safety Results.	Clinical lung cancer	2021	41.56968258659184	-23.59106446008725	10	1.09
33413561	PD-1 blockade delays tumor growth by inhibiting an intrinsic SHP2/Ras/MAPK signalling in thyroid cancer cells.	Journal of experimental & clinical cancer research : CR	2021	-44.40364543649127	-6.40463471868765	26	2.74
33413496	Regulation of PD-L1 expression in the tumor microenvironment.	Journal of hematology & oncology	2021	-40.34730779017608	-11.317591295226965	198	22.91
33413213	Immune checkpoint inhibitors-related myocarditis in patients with cancer: an analysis of international spontaneous reporting systems.	BMC cancer	2021	84.5963639698678	1.5525902717527391	12	1.33
33409896	Nephrotoxicity in patients with solid tumors treated with anti-PD-1/PD-L1 monoclonal antibodies: a systematic review and meta-analysis.	Investigational new drugs	2021	63.63477438201758	-17.414018288093477	9	1.54
33408792	Reducing PD-L1 expression with a self-assembled nanodrug: an alternative to PD-L1 antibody for enhanced chemo-immunotherapy.	Theranostics	2021	-32.04568071772586	-50.97118289659908	18	1.88
33408272	Identification of a novel immune microenvironment signature predicting survival and therapeutic options for bladder cancer.	Aging	2020	4.619657248172086	58.53833521090218	7	0.38
33407990	Cancer immunotherapy: special issue of BMB Reports in 2021.	BMB reports	2021	20.713090187894537	2.599133518800294	4	0.35
33404287	Antibody-mediated delivery of LIGHT to the tumor boosts natural killer cells and delays tumor progression.	mAbs	2021	-21.405272434232117	62.27139898288312	2	0.2
33402127	The implications of clinical risk factors, CAR index, and compositional changes of immune cells on hyperprogressive disease in non-small cell lung cancer patients receiving immunotherapy.	BMC cancer	2021	29.64125132757406	-17.086867792354788	19	1.81
33401585	Immune Checkpoint Inhibitors for the Treatment of Bladder Cancer.	Cancers	2021	67.63093213583495	22.39010238505879	110	12.84
33401247	Identification and validation of an immune-related gene signature predictive of overall survival in colon cancer.	Aging	2020	1.26681413049857	49.15039220221692	33	2.29
33399960	The PD-1/PD-L1 pathway in murine hair cycle transition: a potential anagen phase regulator.	Archives of dermatological research	2021	-60.46487705118294	-18.650475653677173	4	0.4
33399337	PD-1 and PD-L1 Immunohistochemistry as a Diagnostic Tool for Classic Hodgkin Lymphoma in Small-volume Biopsies.	The American journal of surgical pathology	2021	-31.528444880765672	24.226309194778967	3	0.34
33399077	How we treat endocrine complications of immune checkpoint inhibitors.	ESMO open	2021	82.38799308131586	-15.60353529846344	21	2.85
33398390	Impacts of pembrolizumab therapy on immune phenotype in patients with high-grade neuroendocrine neoplasms.	Cancer immunology, immunotherapy : CII	2021	2.9441083001049435	14.011429010813307	7	0.78
33397194	Activity of murine surrogate antibodies for durvalumab and tremelimumab lacking effector function and the ability to deplete regulatory T cells in mouse models of cancer.	mAbs	2021	-39.54522897986275	-28.56112641030906	7	0.74
33395045	Value of PD-L1, PD-1, and CTLA-4 Expression in the Clinical Practice as Predictors of Response to Nivolumab and Ipilimumab in Monotherapy in Patients With Advanced Stage Melanoma.	The American Journal of dermatopathology	2021	14.158046916853849	-1.4177160324339355	7	0.72
33395033	MAPK blockade, toxicities, pathogenesis and management.	Current opinion in oncology	2021	30.67387955524454	33.11499132613051	3	0.46
33393372	Hypophysitis related to immune checkpoint inhibitors: An intriguing adverse event with many faces.	Expert opinion on biological therapy	2021	84.20912593682101	-17.598016617860132	3	0.34
33390170	Progranulin induces immune escape in breast cancer via up-regulating PD-L1 expression on tumor-associated macrophages (TAMs) and promoting CD8+ T cell exclusion.	Journal of experimental & clinical cancer research : CR	2021	-30.63903010573527	-5.397988944851798	47	5.12
33389657	A case of JAK2V617F-positive essential thrombocythemia where allele burden was reduced by a PD-1 inhibitor.	International journal of hematology	2021	49.601419850450064	-30.06274187716877	2	0.24
33388422	Emerging Role of Ubiquitination in the Regulation of PD-1/PD-L1 in Cancer Immunotherapy.	Molecular therapy : the journal of the American Society of Gene Therapy	2021	-19.027982469584703	-7.031087876534765	45	5.07
33387296	Correlation between increased immune checkpoint molecule expression and refractoriness to blinatumomab evaluated by longitudinal T cell analysis.	International journal of hematology	2021	-25.05053763151208	29.21479755499847	4	0.45
33387039	The role of clinical factors and immunocheckpoint molecules in the prognosis of patients with supratentorial extraventricular ependymoma: a single-center retrospective study.	Journal of cancer research and clinical oncology	2021	-25.99459014927213	19.925554899929725	2	0.27
33386384	Regulatory Effect of PD1/PD-Ligand 1 (PD-L1) on Treg Cells in Patients with Idiopathic Pulmonary Fibrosis.	Medical science monitor : international medical journal of experimental and clinical research	2021	-56.19208447080397	17.64840968867007	9	1.28
33385948	PD-L1 polymorphisms predict survival outcomes in advanced non-small-cell lung cancer patients treated with PD-1 blockade.	European journal of cancer (Oxford, England : 1990)	2021	20.690554753724616	-25.33927085197031	8	0.73
33384601	Role of PRDM1 in Tumor Immunity and Drug Response: A Pan-Cancer Analysis.	Frontiers in pharmacology	2020	-20.515384163289276	-3.88497966525085	7	0.44
33382229	[Immunotherapy with PD-1 and PD-L1 inhibitors for prostate cancer].	Zhonghua nan ke xue = National journal of andrology	2020	-14.755804920540555	-27.833915270413105	0	0.0
33381116	Microenvironment Remodeling and Subsequent Clinical Implications in Diffuse Large B-Cell Histologic Variant of Richter Syndrome.	Frontiers in immunology	2020	-31.599897805638975	32.897254363941435	11	0.72
33380881	Expression of PD-L1 for predicting response to immune checkpoint inhibitors in metastatic urothelial carcinoma: a systematic review and meta-analysis.	Current oncology (Toronto, Ont.)	2020	62.314334958695234	15.362463414895185	5	0.31
33380650	Good prognostic factor in patients with nonmetastatic nasopharyngeal carcinoma: Programmed death ligand-1 expression in tumor cells.	Journal of cancer research and therapeutics	2020	-17.055452470552485	31.41336443286035	0	0.0
33380242	Identification of hepatocellular carcinoma-related genes associated with macrophage differentiation based on bioinformatics analyses.	Bioengineered	2021	-10.600676488488922	49.60241381214098	14	1.86
33377131	Modulation of Immune Checkpoints by Chemotherapy in Human Colorectal Liver Metastases.	Cell reports. Medicine	2020	12.97391636868061	38.75580507004168	15	0.99
33376237	Combination of anti-PD-1 antibody with P-GEMOX as a potentially effective immunochemotherapy for advanced natural killer/T cell lymphoma.	Signal transduction and targeted therapy	2020	49.010180193625054	-7.914430605669913	39	3.09
33375020	Pembrolizumab Induces an Unexpected Conformational Change in the CC'-loop of PD-1.	Cancers	2020	-51.67715104263544	-36.95443945123881	5	0.37
33374804	The Next-Generation Immune Checkpoint LAG-3 and Its Therapeutic Potential in Oncology: Third Time's a Charm.	International journal of molecular sciences	2020	11.379994810972216	21.90272130143616	64	4.27
33372007	Metastasis and Immune Evasion from Extracellular cGAMP Hydrolysis.	Cancer discovery	2021	-11.330611672101224	29.76326442176466	93	8.33
33371077	Platinum versus immunotherapy for unresectable esophageal cancer: A protocol for systematic review and meta analysis.	Medicine	2020	53.26671045023528	14.841906281476644	0	0.0
33370819	PD-1+ Monocytes Mediate Cerebral Vasospasm Following Subarachnoid Hemorrhage.	Neurosurgery	2021	-77.38850556906326	-8.421871133343478	9	1.51
33369766	Pembrolizumab for refractory primary mediastinal B-cell lymphoma with central nervous system involvement.	Hematological oncology	2021	45.54868659116664	-5.709028308377	3	0.34
33369247	Modulatory effects of gut microbiome in cancer immunotherapy: A novel paradigm for blockade of immune checkpoint inhibitors.	Cancer medicine	2021	21.303565653425316	42.46853238996733	28	3.18
33367977	Baseline serum TSH levels predict the absence of thyroid dysfunction in cancer patients treated with immunotherapy.	Journal of endocrinological investigation	2021	79.84078560783287	-17.72331050199462	18	2.07
33367684	Practical cardiovascular imaging approach to diagnose immune checkpoint inhibitor myocarditis.	European heart journal. Cardiovascular Imaging	2021	84.90384661111109	4.653131901318186	4	0.58
33365286	Increased Expression of Programmed Death Ligand 1 in Hepatocellular Carcinoma of Patients with Hepatitis B Virus Pre-S2 Mutant.	Journal of hepatocellular carcinoma	2020	-23.127201777368636	40.24901473509526	5	0.45
33365266	Immune Thrombocytopenia Induced by Immune Checkpoint Inhibitors in Solid Cancer: Case Report and Literature Review.	Frontiers in oncology	2020	72.28584713020322	-13.782691696289213	6	0.56
33362787	3D Tumor Models and Their Use for the Testing of Immunotherapies.	Frontiers in immunology	2020	15.678351959254886	0.8797800325650943	73	5.6
33362722	The Progress of Immunotherapy in Refractory Pituitary Adenomas and Pituitary Carcinomas.	Frontiers in endocrinology	2020	-3.491710246034918	-18.910103033721256	26	2.52
33361405	Serum CD73 is a prognostic factor in patients with metastatic melanoma and is associated with response to anti-PD-1 therapy.	Journal for immunotherapy of cancer	2020	10.07334914519435	-1.4682671465819075	30	1.75
33360855	Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma.	European journal of cancer (Oxford, England : 1990)	2021	47.87988118099595	0.795430404523806	40	3.8
33360579	Design, synthesis and evaluation of PD-L1 peptide antagonists as new anticancer agents for immunotherapy.	Bioorganic & medicinal chemistry	2021	-42.196212623210805	-43.7993286512372	6	0.9
33360511	MiR-374b increases the CIK expression and mediates biological function changes in cervical cancer cells by targeting the PD-1/PD-L1 signaling pathway.	Journal of reproductive immunology	2021	-0.5014131433627926	-13.676982685771415	1	0.05
33359404	Avelumab versus standard second line treatment chemotherapy in metastatic colorectal cancer patients with microsatellite instability: The SAMCO-PRODIGE 54 randomised phase II trial.	Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver	2021	38.73764922808124	24.00398196142817	14	1.22
33358116	PD1 expression and correlation with its ligands in oral cancer specimens and peripheral blood.	Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery	2021	-7.674982750119998	-12.47934129801165	5	0.75
33357997	Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-naïve Metastatic Clear-Cell Renal Cell Carcinoma.	European urology	2021	65.16340500462752	30.461865958844932	84	9.88
33348809	Murine- and Human-Derived Autologous Organoid/Immune Cell Co-Cultures as Pre-Clinical Models of Pancreatic Ductal Adenocarcinoma.	Cancers	2020	-12.031532817476414	-0.8285732254250388	45	2.87
33348372	Evidence for Early Stage Anti-Tumor Immunity Elicited by Spatially Fractionated Radiotherapy-Immunotherapy Combinations.	Radiation research	2020	27.948736972991718	22.47783581165965	19	1.56
33344592	Overexpression of CD155 is associated with PD-1 and PD-L1 expression on immune cells, rather than tumor cells in the breast cancer microenvironment.	World journal of clinical cases	2020	-6.495946664730489	23.651156498369577	4	0.23
33344244	Intratumor Heterogeneity Correlates With Reduced Immune Activity and Worse Survival in Melanoma Patients.	Frontiers in oncology	2020	3.322133792072109	18.855389026689156	14	0.74
33342160	[Programmed cell death-1 inhibitor combined with rituximab in refractory or relapsed diffuse large B-cell lymphoma: a preliminary efficacy and safety analysis].	Zhonghua zhong liu za zhi [Chinese journal of oncology]	2020	45.9985126296006	-7.829629507234041	1	0.05
33341940	Ruxolitinib reverses checkpoint inhibition by reducing programmed cell death ligand-1 (PD-L1) expression and increases anti-tumour effects of T cells in multiple myeloma.	British journal of haematology	2021	-31.745960223649934	7.64838360449537	14	1.81
33341289	PD-1 silencing improves anti-tumor activities of human mesothelin-targeted CAR T cells.	Human immunology	2021	-42.20876381175186	2.101645219369723	22	2.26
33341200	Cutaneous immune-related adverse events to checkpoint inhibitors.	Clinics in dermatology	2020	73.96588968456852	-24.40426106266331	21	1.9
33338327	Relationship between immune checkpoint proteins, tumour microenvironment characteristics, and prognosis in primary operable colorectal cancer.	The journal of pathology. Clinical research	2021	5.911931957977545	37.17245283119356	13	1.32
33337915	Comprehensive assessment of PD-L1 and PD-L2 dysregulation in gastrointestinal cancers.	Epigenomics	2020	-12.431237907066343	5.767645892180708	3	0.18
33337613	Treatment of gestational trophoblastic disease in the 2020s.	Current opinion in obstetrics & gynecology	2021	44.24192378453708	40.031425237219736	16	2.74
33334658	The unique characteristic in peripheral immune cells in patients with advanced hepatocellular carcinoma.	Journal of the Formosan Medical Association = Taiwan yi zhi	2021	-15.27941193716409	44.39225317304509	3	0.42
33333370	Clinical and pathological significance of programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) expression in high grade serous ovarian cancer.	Translational oncology	2021	-19.12354467937144	13.010654758774702	5	0.67
33332777	The BTLA and PD-1 signaling pathways independently regulate the proliferation and cytotoxicity of human peripheral blood γδ T cells.	Immunity, inflammation and disease	2021	-51.717721176234384	-3.2141661109360493	12	1.3
33330611	Case Report: Pathologic Complete Response to Pembrolizumab in Combination With Neoadjuvant Chemotherapy in a Patient With Stage IIB Squamous Lung Cancer.	Frontiers in surgery	2020	48.7045460908413	-33.48619119581029	2	0.17
33330555	Sarcoidosis and Cancer: A Complex Relationship.	Frontiers in medicine	2020	60.46427897048865	-30.9846518291982	16	2.06
33330050	Combination of T-Cell Bispecific Antibodies With PD-L1 Checkpoint Inhibition Elicits Superior Anti-Tumor Activity.	Frontiers in oncology	2020	-14.148794414939976	-44.50902019944748	24	1.52
33330041	Imperfect Predictors for Lung Cancer Immunotherapy-A Field for Further Research.	Frontiers in oncology	2020	24.563177686149587	-36.20685251729602	11	0.74
33330040	Lung Cancer Immunotherapy in Transplant Patients and in Patients With Autoimmune Diseases.	Frontiers in oncology	2020	35.795934311745775	-21.929349099479783	1	0.08
33330025	CD8+ T Cell Co-Expressed Genes Correlate With Clinical Phenotype and Microenvironments of Urothelial Cancer.	Frontiers in oncology	2020	6.172092415863029	56.192191793036905	15	0.89
33329567	Soluble PD-1: Predictive, Prognostic, and Therapeutic Value for Cancer Immunotherapy.	Frontiers in immunology	2020	-45.90434810278183	20.91635350450682	60	4.4
33329566	Systemic CD4 Immunity as a Key Contributor to PD-L1/PD-1 Blockade Immunotherapy Efficacy.	Frontiers in immunology	2020	-24.877383485461028	-8.662410064382073	29	1.59
33328570	Deubiquitinating enzyme OTUB1 promotes cancer cell immunosuppression via preventing ER-associated degradation of immune checkpoint protein PD-L1.	Cell death and differentiation	2021	-19.02763515297745	-6.943731487449573	59	6.39
33328484	Genomic profiling reveals high frequency of DNA repair genetic aberrations in gallbladder cancer.	Scientific reports	2020	15.252965206436048	40.2999939797341	16	1.14
33326644	Transarterial chemoembolisation enhances programmed death-1 and programmed death-ligand 1 expression in hepatocellular carcinoma.	Histopathology	2021	-11.056200021724557	64.2161696169472	33	4.08
33325140	KRAS G12V mutation upregulates PD-L1 expression via TGF-β/EMT signaling pathway in human non-small-cell lung cancer.	Cell biology international	2021	20.16629402287416	-22.64675371919785	16	1.68
33324403	Regulation of PD-L1 Expression by NF-κB in Cancer.	Frontiers in immunology	2020	-39.465753131314976	-10.54432799481336	128	8.8
33324391	ROS1 Fusion Mediates Immunogenicity by Upregulation of PD-L1 After the Activation of ROS1-SHP2 Signaling Pathway in Non-Small Cell Lung Cancer.	Frontiers in immunology	2020	32.57594581955953	-38.43589392065868	5	0.33
33321969	Preclinical Rationale for Targeting the PD-1/PD-L1 Axis in Combination with a CD38 Antibody in Multiple Myeloma and Other CD38-Positive Malignancies.	Cancers	2020	-32.600125371020795	6.940568189046731	22	1.46
33321428	GD2-specific chimeric antigen receptor-modified T cells targeting retinoblastoma - assessing tumor and T cell interaction.	Translational oncology	2021	-45.25412947195802	6.096381251001551	14	1.86
33320839	PD-1 blockade improves Kupffer cell bacterial clearance in acute liver injury.	The Journal of clinical investigation	2021	-60.700442551851744	34.40039692206666	36	4.09
33320838	Ketogenic diet and ketone bodies enhance the anticancer effects of PD-1 blockade.	JCI insight	2021	-27.6985104385537	-30.35640343490017	108	11.22
33319876	Anti-PD-L1 DNA aptamer antagonizes the interaction of PD-1/PD-L1 with antitumor effect.	Journal of materials chemistry. B	2021	-25.353343083676364	-59.46597894090224	16	2.09
33318079	A phase III, randomized, double blinded trial of platinum based chemotherapy with or without atezolizumab followed by niraparib maintenance with or without atezolizumab in patients with recurrent ovarian, tubal, or peritoneal cancer and platinum treatment free interval of more than 6 months: ENGOT-Ov41/GEICO 69-O/ANITA Trial.	International journal of gynecological cancer : official journal of the International Gynecological Cancer Society	2021	65.53510131882007	7.603176293352496	16	1.5
33316104	Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.	The Cochrane database of systematic reviews	2020	42.84038210766235	-29.57317275566901	32	1.93
33314269	Systematic review with meta-analysis: safety and tolerability of immune checkpoint inhibitors in patients with pre-existing inflammatory bowel diseases.	Alimentary pharmacology & therapeutics	2021	77.24161137000337	-2.935019753538424	41	4.65
33313271	The role of the programmed cell death protein-1/programmed death-ligand 1 pathway, regulatory T cells and T helper 17 cells in tumor immunity: a narrative review.	Annals of translational medicine	2020	-45.42478137127367	-13.375054006609616	8	0.47
33313223	Comparative expression analysis of PD-1, PD-L1, and CD8A in lung adenocarcinoma.	Annals of translational medicine	2020	9.906394889238893	-27.35212599408186	9	0.61
33312349	Selection of new immunotherapy targets for NK/T cell lymphoma.	American journal of translational research	2020	38.66523073966471	28.61056368520485	12	1.0
33312174	An Immunomodulatory Gallotanin-Rich Fraction From Caesalpinia spinosa Enhances the Therapeutic Effect of Anti-PD-L1 in Melanoma.	Frontiers in immunology	2020	-24.867476241885846	-33.62644159186755	15	1.22
33311988	Complete Response to the Sequential Treatment with Regorafenib Followed by PD-1 Inhibitor in a Sorafenib-Refractory Hepatocellular Carcinoma Patient.	OncoTargets and therapy	2020	31.13406132855845	52.61889314649651	8	0.6
33310773	Galectin-9 expression defines exhausted T cells and impaired cytotoxic NK cells in patients with virus-associated solid tumors.	Journal for immunotherapy of cancer	2020	-28.1726072961732	7.810694644132464	28	2.09
33310681	Discordance of immunotherapy response predictive biomarkers between primary lesions and paired metastases in tumours: A systematic review and meta-analysis.	EBioMedicine	2021	8.010188431632129	18.225086769408897	32	3.24
33309890	Efficacy and safety of pembrolizumab based therapies in triple-negative breast cancer: A systematic review of clinical trials.	Critical reviews in oncology/hematology	2021	41.04624504706317	7.456464939227247	7	0.7
33309768	Long non-coding RNA C5orf64 is a potential indicator for tumor microenvironment and mutation pattern remodeling in lung adenocarcinoma.	Genomics	2021	-3.7051027293453394	55.92831472864459	14	1.6
33309297	Creation of a primary tumor tissue expression biomarker-augmented prognostic model for patients with metastatic renal cell carcinoma.	Urologic oncology	2021	18.20166571652392	33.58105244402374	2	0.14
33308148	Molecular dynamics of the immune checkpoint programmed cell death protein I, PD-1: conformational changes of the BC-loop upon binding of the ligand PD-L1 and the monoclonal antibody nivolumab.	BMC bioinformatics	2020	-51.33820995360153	-35.86870723861124	7	0.77
33306195	Immune checkpoint expression on peripheral cytotoxic lymphocytes in cervical cancer patients: moving beyond the PD-1/PD-L1 axis.	Clinical and experimental immunology	2021	-2.6414062509561003	27.58743048789148	7	0.82
33303017	GD2 or HER2 targeting T cell engaging bispecific antibodies to treat osteosarcoma.	Journal of hematology & oncology	2020	-16.201000635190592	-45.25810766627874	32	2.5
33302686	A case report of sustained clinical remission in patients with locally advanced lung adenocarcinoma after sequential immunotherapy following concurrent chemoradiotherapy.	Annals of palliative medicine	2020	40.30377100865041	-24.279121927552566	1	0.04
33302668	The efficiency and safety of immune checkpoint inhibitors in the treatment of small cell lung cancer: a meta-analysis.	Annals of palliative medicine	2020	45.769446414394096	-41.46477608982879	3	0.25
33301862	Pivotal role of PD-1/PD-L1 immune checkpoints in immune escape and cancer progression: Their interplay with platelets and FOXP3+Tregs related molecules, clinical implications and combinational potential with phytochemicals.	Seminars in cancer biology	2022	-29.43820843944095	-38.23563223236484	8	1.91
33299657	Soluble forms of PD-L1 and PD-1 as prognostic and predictive markers of sunitinib efficacy in patients with metastatic clear cell renal cell carcinoma.	Oncoimmunology	2020	15.308511271311154	24.797209037949223	18	1.2
33299655	PD-L1 expression in the microenvironment and the response to checkpoint inhibitors in head and neck squamous cell carcinoma.	Oncoimmunology	2020	-7.263398482301298	-6.230401363303391	15	1.03
33299330	A Partial Response of Pulmonary Pleomorphic Carcinoma to Camrelizumab (PD1 Monoclonal Antibody) Monotherapy: A Case Report.	OncoTargets and therapy	2020	56.43038802556551	-31.49734316432061	2	0.14
33298723	Immunotherapy in EGFR-Mutant and ALK-Positive Lung Cancer: Implications for Oncogene-Driven Lung Cancer.	Cancer journal (Sudbury, Mass.)	2020	39.14397626155922	-36.85462613715857	12	0.65
33298620	A20 regulates the therapeutic effect of anti-PD-1 immunotherapy in melanoma.	Journal for immunotherapy of cancer	2020	-31.14481453833699	-10.48127627792216	11	0.61
33298250	Current understanding of cancer-intrinsic PD-L1: regulation of expression and its protumoral activity.	BMB reports	2021	-38.17367843781131	-12.629215364027294	13	1.37
33298247	Hitting the complexity of the TIGIT-CD96-CD112R-CD226 axis for next-generation cancer immunotherapy.	BMB reports	2021	-11.692874237109988	-56.0452590015908	22	2.46
33292551	Recent updates on Sintilimab in solid tumor immunotherapy.	Biomarker research	2020	42.07607367980959	-0.2386478767657921	21	1.28
33291277	Immune Checkpoint Blockade in Advanced Cutaneous Squamous Cell Carcinoma: What Do We Currently Know in 2020?	International journal of molecular sciences	2020	57.92699059217887	6.927348973334177	19	1.61
33290179	Quantitative Assessment of the Immune Microenvironment in Patients With Iatrogenic Laryngotracheal Stenosis.	Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery	2021	3.297067260096118	-45.41620733398521	4	0.6
33285051	Outcomes and Biomarkers of Immune Checkpoint Inhibitor Therapy in Patients with Refractory Head and Neck Squamous Cell Carcinoma: KCSG HN18-12.	Cancer research and treatment	2021	50.28122609200512	32.56716410173643	8	0.98
33282564	Classification of ovarian cancer associated with BRCA1 mutations, immune checkpoints, and tumor microenvironment based on immunogenomic profiling.	PeerJ	2020	4.342125430803799	46.01843451916194	10	0.67
33282553	Comprehensive genomic analysis of microenvironment phenotypes in ovarian cancer.	PeerJ	2020	4.231617785735323	46.04583808980318	4	0.27
33282408	Immunotherapy in patients with autoimmune disease.	Journal of thoracic disease	2020	79.27443193111287	-10.433269340321614	10	0.65
33282406	Radiation and immunotherapy: emerging mechanisms of synergy.	Journal of thoracic disease	2020	35.58920151047789	-27.55590295354956	25	1.8
33278675	A meta-analysis of CD274 (PD-L1) assessment and prognosis in colorectal cancer and its role in predicting response to anti-PD-1 therapy.	Critical reviews in oncology/hematology	2021	9.553311160610985	35.67837839628534	21	2.3
33278498	Low-dose carboplatin reprograms tumor immune microenvironment through STING signaling pathway and synergizes with PD-1 inhibitors in lung cancer.	Cancer letters	2021	-23.61952684319281	-45.44606540033951	36	3.63
33277316	Targeting of CD40 and PD-L1 Pathways Inhibits Progression of Oral Premalignant Lesions in a Carcinogen-induced Model of Oral Squamous Cell Carcinoma.	Cancer prevention research (Philadelphia, Pa.)	2021	-11.159737104580303	-14.691890463342132	15	1.62
33277223	Expression of the Immune Checkpoint Regulators LAG-3 and TIM-3 in Classical Hodgkin Lymphoma.	Clinical lymphoma, myeloma & leukemia	2021	-27.829724418625577	28.915246714870182	26	2.97
33276580	Long-Term Systemic Expression of a Novel PD-1 Blocking Nanobody from an AAV Vector Provides Antitumor Activity without Toxicity.	Biomedicines	2020	-37.91023540427812	-48.67365638289219	8	0.57
33276030	CD40-mediated immune cell activation enhances response to anti-PD-1 in murine intrahepatic cholangiocarcinoma.	Journal of hepatology	2021	1.5328607327782655	4.306936937568259	57	5.5
33275291	Tumor-derived exosomes in the PD-1/PD-L1 axis: Significant regulators as well as promising clinical targets.	Journal of cellular physiology	2021	-43.502644483344206	-59.756534599617495	14	1.67
33273828	The Immunostimulative Effect and Mechanisms of a Novel Mouse Anti-Human PD-1 Monoclonal Antibody on Jurkat Lymphocytic Cells Cocultured with Hepatoma Cells.	OncoTargets and therapy	2020	-30.644076924721965	1.2087793023465667	4	0.4
33271389	Introducing immunotherapy for advanced hepatocellular carcinoma patients: Too early or too fast?	Critical reviews in oncology/hematology	2021	29.957249506928573	49.735836971105584	23	2.82
33271264	CD137 agonist-based combination immunotherapy enhances activated, effector memory T cells and prolongs survival in pancreatic adenocarcinoma.	Cancer letters	2021	-21.910253172230217	-13.115871586196612	14	1.45
33269718	[Current treatment options and future perspectives on first line metastatic bladder cancer.].	Archivos espanoles de urologia	2020	70.83670537604588	20.425617644124497	2	0.16
33268482	Redistribution of Monocyte Subsets in Obstructive Sleep Apnea Syndrome Patients Leads to an Imbalanced PD-1/PD-L1 Cross-Talk with CD4/CD8 T Cells.	Journal of immunology (Baltimore, Md. : 1950)	2021	-60.81112913414368	25.65061538555843	15	2.45
33267869	Immune phenotype of patients with stage IV metastatic inflammatory breast cancer.	Breast cancer research : BCR	2020	-12.144348492507197	18.67532946044392	7	0.59
33266349	PD-L1 Expression in 65 Conjunctival Melanomas and Its Association with Clinical Outcome.	International journal of molecular sciences	2020	1.4111780240983192	0.0551950862705344	5	0.48
33264717	Immune system in cancer radiotherapy: Resistance mechanisms and therapy perspectives.	Critical reviews in oncology/hematology	2021	27.384083846712905	20.63988417494836	65	8.39
33263418	MAHOGANY: margetuximab combination in HER2+ unresectable/metastatic gastric/gastroesophageal junction adenocarcinoma.	Future oncology (London, England)	2021	47.769270218070986	14.079310538189672	52	5.7
33261292	Evaluation of PD1 and PD-L1 expression in high-grade sarcomas of the limbs in the adults: possible implications of immunotherapy.	Journal of biological regulators and homeostatic agents	2020	-20.35423311608944	20.37376501380201	8	0.79
33259032	Inter- and intraobserver agreement of the quantitative assessment of [99mTc]-labelled anti-programmed death-ligand 1 (PD-L1) SPECT/CT in non-small cell lung cancer.	EJNMMI research	2020	11.86513718278878	-51.44602723197821	5	0.36
33257470	A Genetic Mouse Model Recapitulates Immune Checkpoint Inhibitor-Associated Myocarditis and Supports a Mechanism-Based Therapeutic Intervention.	Cancer discovery	2021	85.58090440339302	3.109662321114219	108	11.64
33257429	Modification of Extracellular Matrix Enhances Oncolytic Adenovirus Immunotherapy in Glioblastoma.	Clinical cancer research : an official journal of the American Association for Cancer Research	2021	-34.89636293788932	54.31836539073355	32	3.92
33256806	Targeting the myeloid checkpoint receptor SIRPα potentiates innate and adaptive immune responses to promote anti-tumor activity.	Journal of hematology & oncology	2020	-29.219611338254364	-43.58370690576756	30	1.82
33256165	Treatment Strategies and Metabolic Pathway Regulation in Urothelial Cell Carcinoma: A Comprehensive Review.	International journal of molecular sciences	2020	70.74126252006494	18.18684860267017	8	0.49
33256070	Current Progresses and Challenges of Immunotherapy in Triple-Negative Breast Cancer.	Cancers	2020	39.02052837332677	9.541992639469209	46	3.65
33255938	SNP-SNP Interaction in Genes Encoding PD-1/PD-L1 Axis as a Potential Risk Factor for Clear Cell Renal Cell Carcinoma.	Cancers	2020	13.263127415423854	28.39672716304864	6	0.47
33255375	Comprehensive Evaluation of Immune-Checkpoint DNA Cancer Vaccines in a Rat Cholangiocarcinoma Model.	Vaccines	2020	1.816762463964532	4.203783875154174	7	0.44
33255238	Epidemiologic Features of NSCLC Gene Alterations in Hispanic Patients from Puerto Rico.	Cancers	2020	21.20257497577583	-22.09453986758619	5	0.33
33254246	[Endocrine side effects of cancer immunotherapy].	Deutsche medizinische Wochenschrift (1946)	2020	82.03690539842377	-15.768038915994426	0	0.0
33252666	What is the Burden of Proof for Tumor Mutational Burden in gliomas?	Neuro-oncology	2020	23.183448316577365	-15.098198866332092	12	0.66
33250959	Programmed death 1, ligand 1 and 2 correlated genes and their association with mutation, immune infiltration and clinical outcomes of hepatocellular carcinoma.	World journal of gastrointestinal oncology	2020	-22.23610388776668	39.07821730044499	10	0.66
33250890	The Expression Pattern and Clinical Significance of the Immune Checkpoint Regulator VISTA in Human Breast Cancer.	Frontiers in immunology	2020	-38.937805991077184	37.589215183976656	23	1.52
33249211	Association between continuous decrease of plasma VEGF-A levels and the efficacy of chemotherapy in combination with anti-programmed cell death 1 antibody in non-small cell lung cancer patients.	Cancer treatment and research communications	2020	20.406394336351475	-29.77279685314367	0	0.0
33247989	Donor plasmacytoid dendritic cells modulate effector and regulatory T cell responses in mouse spontaneous liver transplant tolerance.	American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons	2021	-67.07945623879779	29.07695105213019	6	0.67
33246984	Diacylglycerol kinase ζ limits IL-2-dependent control of PD-1 expression in tumor-infiltrating T lymphocytes.	Journal for immunotherapy of cancer	2020	-33.2250842550501	-25.23018428857231	7	0.49
33244581	Current status of cancer immunotherapy for gynecologic malignancies.	Japanese journal of clinical oncology	2021	40.32493963901038	36.82306279055219	14	1.76
33243934	Antimetabolite pemetrexed primes a favorable tumor microenvironment for immune checkpoint blockade therapy.	Journal for immunotherapy of cancer	2020	34.4751988754987	-42.35006821781714	22	1.28
33241322	Current status of immunotherapy for advanced gastric cancer.	Japanese journal of clinical oncology	2021	43.3869596639124	15.589196342357976	34	3.93
33240282	Peptide Vaccination Against PD-L1 With IO103 a Novel Immune Modulatory Vaccine in Multiple Myeloma: A Phase I First-in-Human Trial.	Frontiers in immunology	2020	-23.560456737467035	-14.810711499240352	16	1.02
33239635	Cellular and gene signatures of tumor-infiltrating dendritic cells and natural-killer cells predict prognosis of neuroblastoma.	Nature communications	2020	-22.98869506575696	26.66154948023065	73	4.53
33239315	Machine learning: an approach to preoperatively predict PD-1/PD-L1 expression and outcome in intrahepatic cholangiocarcinoma using MRI biomarkers.	ESMO open	2020	10.060590516113844	-10.36214556793546	23	2.2
36003161	Inflammatory and immune checkpoint markers are associated with the severity of aortic stenosis.	JTCVS open	2021	-59.16196851668517	11.875536127697174	1	0.12
33235503	Association Between RBC Antigen Allo-Antibodies and Immune-Related Adverse Events During Immune Checkpoint Inhibitor Treatment for Advanced Cancers.	Cancer management and research	2020	75.48163947799824	-11.013943519315774	4	0.38
33232124	Bacterial Outer Membrane Vesicles Presenting Programmed Death 1 for Improved Cancer Immunotherapy via Immune Activation and Checkpoint Inhibition.	ACS nano	2020	-38.55538270230345	-57.41557399066357	90	6.64
33231859	Incidence of venous thromboembolic events in cancer patients receiving immunotherapy: a single-institution experience.	Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico	2021	70.18001389897792	-12.560944463013795	17	1.8
33231797	AKT/mTOR Signal Cascade and Expression of PD-1, PD-L1, and PD-L2 in Gastric Cancer.	Bulletin of experimental biology and medicine	2020	-10.497881567756773	2.483748220280966	4	0.37
33230745	Integrating Machine Learning and Tumor Immune Signature to Predict Oncologic Outcomes in Resected Biliary Tract Cancer.	Annals of surgical oncology	2021	1.1224897164700274	51.70464579509998	11	1.48
33229588	Targeting a scavenger receptor on tumor-associated macrophages activates tumor cell killing by natural killer cells.	Proceedings of the National Academy of Sciences of the United States of America	2020	-32.71229817454768	-4.521081699499997	73	4.82
33229539	Cytocidal macrophages in symbiosis with CD4 and CD8 T cells cause acute diabetes following checkpoint blockade of PD-1 in NOD mice.	Proceedings of the National Academy of Sciences of the United States of America	2020	-61.21453032812561	2.989575044171453	21	1.22
33228682	PD-1/PD-L1 expression profiles within intrahepatic cholangiocarcinoma predict clinical outcome.	World journal of surgical oncology	2020	0.7195980589999944	5.606047474873284	20	1.38
33228231	Immunoprofiling in Neuroendocrine Neoplasms Unveil Immunosuppressive Microenvironment.	Cancers	2020	0.924237995663667	13.748265179128548	8	0.49
33226523	Association between skeletal muscle loss and the response to nivolumab immunotherapy in advanced gastric cancer patients.	International journal of clinical oncology	2021	29.923803980389355	-47.55932062155049	16	2.24
33224152	Anticancer Effect of Salvia plebeia and Its Active Compound by Improving T-Cell Activity via Blockade of PD-1/PD-L1 Interaction in Humanized PD-1 Mouse Model.	Frontiers in immunology	2020	-28.2274701895281	-36.14015674137189	13	1.14
33223466	PD-1 in Tregs predicts the survival in sepsis patients using sepsis-3 criteria: A prospective, two-stage study.	International immunopharmacology	2020	-56.08338113922316	33.65885924218585	5	0.36
33221703	LncRNA MIAT correlates with immune infiltrates and drug reactions in hepatocellular carcinoma.	International immunopharmacology	2020	-6.984982198841687	52.86837073740647	39	2.59
33219943	Dual targeting of PD-L1 and PD-L2 by PCED1B-AS1 via sponging hsa-miR-194-5p induces immunosuppression in hepatocellular carcinoma.	Hepatology international	2021	-20.407080788386047	41.329206083234624	48	5.85
33219016	Expression of T-Cell Exhaustion Molecules and Human Endogenous Retroviruses as Predictive Biomarkers for Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma.	Clinical cancer research : an official journal of the American Association for Cancer Research	2021	20.633273338621688	32.61488640524347	36	3.49
33217946	Discovery Strategies to Maximize the Clinical Potential of T-Cell Engaging Antibodies for the Treatment of Solid Tumors.	Antibodies (Basel, Switzerland)	2020	-13.699816783757427	-44.23102909150458	12	0.89
33217647	Cell by cell immuno- and cancer marker profiling of non-small cell lung cancer tissue: Checkpoint marker expression on CD103+, CD4+ T-cells predicts circulating tumor cells.	Translational oncology	2021	11.197377536999769	-15.505421362447768	4	0.49
33216754	PD-L1 expression in equine malignant melanoma and functional effects of PD-L1 blockade.	PloS one	2020	-57.63779446523339	-26.46844346256268	7	0.63
33216211	Characterization of soluble PD-L1 in pleural effusions of mesothelioma patients: potential implications in the immune response and prognosis.	Journal of cancer research and clinical oncology	2021	6.848057872309297	10.77412452532885	4	0.7
33215561	Dosing of PD-1 and PD-L1 inhibitors: Cost saving initiatives for significantly decreasing associated expenditure.	Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners	2021	58.026267440710924	-15.79879115596348	3	0.45
33214079	Programmed Cell Death Ligand 1 Expression in Resected Non-Small Cell Lung Cancer.	Clinical lung cancer	2021	12.880994266195597	-29.022977659817883	1	0.09
33212291	Pharmacological combination of nivolumab with dendritic cell vaccines in cancer immunotherapy: An overview.	Pharmacological research	2021	33.787201747995056	7.4878809968503965	7	0.86
33212090	Clinicopathologic features, tumor immune microenvironment and genomic landscape of Epstein-Barr virus-associated intrahepatic cholangiocarcinoma.	Journal of hepatology	2021	-16.48116273129338	36.162924717661305	32	3.9
33211281	The optimal immune checkpoint inhibitors combined with chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis.	Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico	2021	44.11923257825163	-19.175559225163248	2	0.18
33208183	Evodiamine suppresses non-small cell lung cancer by elevating CD8+ T cells and downregulating the MUC1-C/PD-L1 axis.	Journal of experimental & clinical cancer research : CR	2020	2.6221032918465017	-39.84340353609682	33	2.96
33203665	Nivolumab and sunitinib combination in advanced soft tissue sarcomas: a multicenter, single-arm, phase Ib/II trial.	Journal for immunotherapy of cancer	2020	40.1863823476585	0.9662964585664914	65	4.56
33203661	Immune profiling of uveal melanoma identifies a potential signature associated with response to immunotherapy.	Journal for immunotherapy of cancer	2020	3.857848050045734	2.662998880473517	26	1.95
33203644	Entinostat plus Pembrolizumab in Patients with Metastatic NSCLC Previously Treated with Anti-PD-(L)1 Therapy.	Clinical cancer research : an official journal of the American Association for Cancer Research	2021	47.28041161470634	-29.73919213830739	42	4.15
33203196	[Incidence and Risk of PD-1/PD-L1 Inhibitor-associated Pneumonia in Advance Cancer Patients: A Meta-analysis].	Zhongguo fei ai za zhi = Chinese journal of lung cancer	2020	64.84703653642028	-10.279242666787708	0	0.0
33202823	Virtual Screening and In Vitro Evaluation of PD-1 Dimer Stabilizers for Uncoupling PD-1/PD-L1 Interaction from Natural Products.	Molecules (Basel, Switzerland)	2020	-40.0759587720972	-39.01404963422698	5	0.54
33200250	Autoimmune polyendocrine syndrome induced by immune checkpoint inhibitors: a systematic review.	Cancer immunology, immunotherapy : CII	2021	83.70156092596139	-13.424487569076408	15	1.96
33200027	In silico and in vitro studies reveal complement system drives coagulation cascade in SARS-CoV-2 pathogenesis.	Computational and structural biotechnology journal	2020	-49.16523246723523	46.3940433894858	16	1.11
33199494	Tumor Mutational Burden as a Predictor of Immunotherapy Response: Is More Always Better?	Clinical cancer research : an official journal of the American Association for Cancer Research	2021	23.271706503473236	-15.409481478883608	170	17.76
33199209	PD-L1 and B7-1 Cis-Interaction: New Mechanisms in Immune Checkpoints and Immunotherapies.	Trends in molecular medicine	2021	-54.48811451912873	-13.27376301660718	15	1.4
33197221	Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance.	Annual review of pathology	2021	31.575420400243548	13.692251160910114	645	76.28
33195412	Identification of an Immune-Related Prognostic Predictor in Hepatocellular Carcinoma.	Frontiers in molecular biosciences	2020	-10.61939757845327	49.04279995411769	8	0.55
33194598	Biological Function of PD-L2 and Correlation With Overall Survival in Type II Endometrial Cancer.	Frontiers in oncology	2020	-18.616992111685427	8.811421597482726	7	0.4
33194434	Increased expression of POLR3G predicts poor prognosis in transitional cell carcinoma.	PeerJ	2020	5.264809857515989	56.69704719006756	6	0.47
33193857	Immune cell infiltration and cytokine secretion analysis reveal a non-inflammatory microenvironment of medulloblastoma.	Oncology letters	2020	-19.384794051962952	50.3279656596027	16	1.13
33193426	PD-1 Blockade Reverses Obesity-Mediated T Cell Priming Impairment.	Frontiers in immunology	2020	-58.878294173959695	5.37141854847442	5	0.3
33193366	Quaternary Ammonium Compound Disinfectants Reduce Lupus-Associated Splenomegaly by Targeting Neutrophil Migration and T-Cell Fate.	Frontiers in immunology	2020	-50.43914113550969	9.829488912020167	9	0.96
33193363	Programmed Cell Death Ligand (PD-L)-1 Contributes to the Regulation of CD4+ T Effector and Regulatory T Cells in Cutaneous Leishmaniasis.	Frontiers in immunology	2020	-67.41961874141397	11.482921828699157	12	1.0
33193345	The Extrinsic and Intrinsic Roles of PD-L1 and Its Receptor PD-1: Implications for Immunotherapy Treatment.	Frontiers in immunology	2020	-43.59093004339206	-16.311316749787164	75	5.15
33193306	The Antigen Presenting Potential of CD21low B Cells.	Frontiers in immunology	2020	-58.53645307961926	-6.655757143359875	18	1.27
33192094	The Effect and Safety of Anti-PD-1 Single/Combination Therapy in Refractory Thymic Carcinoma: A Case-Series Study.	Cancer management and research	2020	54.85599837796503	1.4311534374120374	2	0.11
33185750	Immune Checkpoint Blockade in Cancer Immunotherapy: Mechanisms, Clinical Outcomes, and Safety Profiles of PD-1/PD-L1 Inhibitors.	Archivum immunologiae et therapiae experimentalis	2020	-39.94659757663438	-17.70651979568456	17	1.04
33183120	Pembrolizumab for advanced cervical cancer: safety and efficacy.	Expert review of anticancer therapy	2021	44.23735129570564	33.417333889540124	14	1.78
33178750	TP53 mutation and tumoral PD-L1 expression are associated with depth of invasion in desmoplastic melanomas.	Annals of translational medicine	2020	5.452860185313576	0.7981564192322245	7	0.45
33178688	Exosomal PD-L1: New Insights Into Tumor Immune Escape Mechanisms and Therapeutic Strategies.	Frontiers in cell and developmental biology	2020	-43.61351223905909	-58.68101302526689	46	3.39
33178494	Baseline plasma levels of soluble PD-1, PD-L1, and BTN3A1 predict response to nivolumab treatment in patients with metastatic renal cell carcinoma: a step toward a biomarker for therapeutic decisions.	Oncoimmunology	2020	8.698227513491386	6.9110423280952205	37	2.35
33176206	Discrepant antitumor efficacies of three CpG oligodeoxynucleotide classes in monotherapy and co-therapy with PD-1 blockade.	Pharmacological research	2020	-15.417648129564954	-40.90811898580772	10	0.72
33173935	Hypofractionated stereotactic re-irradiation with pembrolizumab and bevacizumab in patients with recurrent high-grade gliomas: results from a phase I study.	Neuro-oncology	2021	52.38102353098165	-0.1055809232096892	44	5.03
33173388	The risk of diarrhea and colitis in patients with lung cancer treated with immune checkpoint inhibitors: a systematic review and meta-analysis.	Current oncology (Toronto, Ont.)	2020	67.50007368276185	-14.359872161535616	12	0.81
33172030	The Immune Checkpoint PD-1 in Natural Killer Cells: Expression, Function and Targeting in Tumour Immunotherapy.	Cancers	2020	-34.550803138847535	0.0819220862234294	65	4.58
33171686	First line Immunotherapy for Non-Small Cell Lung Cancer.	Pharmaceuticals (Basel, Switzerland)	2020	39.98275229594027	-30.103587207732552	40	2.68
33171529	PD-L1 versus tumor mutation burden: Which is the better immunotherapy biomarker in advanced non-small cell lung cancer?	The journal of gene medicine	2021	22.96062850613825	-15.71308521832027	12	1.3
33171025	The Pattern of Time to Onset and Resolution of Immune-Related Adverse Events Caused by Immune Checkpoint Inhibitors in Cancer: A Pooled Analysis of 23 Clinical Trials and 8,436 Patients.	Cancer research and treatment	2021	74.89768022864953	-10.472405307707708	51	5.72
33169618	Epigenetic regulation of immune checkpoints and T cell exhaustion markers in tumor-infiltrating T cells of colorectal cancer patients.	Epigenomics	2020	-6.50027732742129	41.82673911713716	10	0.55
33169486	Therapeutic implications of immune-profiling and EGFR expression in salivary gland carcinoma.	Head & neck	2021	-3.199097724983015	-0.8543300852318394	9	1.32
33169322	Immune Cell Infiltration and the Expression of PD-1 and PD-L1 in Primary PDGFRA-Mutant Gastrointestinal Stromal Tumors.	Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract	2021	-7.624993325160848	8.998991059990832	10	1.31
33168847	Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors.	Scientific reports	2020	-35.13600002591386	-7.85666875755024	28	1.99
33163407	Pembrolizumab-Induced Psoriasis in Metastatic Melanoma: Activity and Safety of Apremilast, a Case Report.	Frontiers in oncology	2020	72.8282920756624	-23.14234371340089	11	1.33
33162990	The Use of Immune Checkpoint Inhibitors in Oncology and the Occurrence of AKI: Where Do We Stand?	Frontiers in immunology	2020	71.0161370348334	0.4197359707832603	76	5.6
33162477	Pathological Findings of the Host Immune Reaction in the Tumor Microenvironment of Gastroenteropancreatic Neuroendocrine Neoplasms.	Internal medicine (Tokyo, Japan)	2021	1.840690805931975	13.455924831350751	3	0.37
33160076	Neoadjuvant Gene-Mediated Cytotoxic Immunotherapy for Non-Small-Cell Lung Cancer: Safety and Immunologic Activity.	Molecular therapy : the journal of the American Society of Gene Therapy	2021	-31.78867886662371	56.14826686048525	6	0.81
33159481	Immune checkpoint expression in HNSCC patients before and after definitive chemoradiotherapy.	Head & neck	2021	50.88747659714487	34.03378914242454	9	1.11
33159034	PD-L1 degradation pathway and immunotherapy for cancer.	Cell death & disease	2020	-43.63014089322181	-19.985713421842583	78	5.31
33158814	Enhanced Efficacy of Simultaneous PD-1 and PD-L1 Immune Checkpoint Blockade in High-Grade Serous Ovarian Cancer.	Cancer research	2021	-14.99889920426724	-41.960045618359445	60	6.22
33158004	Prognostic significance of PD-L1 in advanced non-small cell lung carcinoma.	Medicine	2020	12.825632572794126	-28.450555979078494	11	0.8
33157383	Comparability of laboratory-developed and commercial PD-L1 assays in non-small cell lung carcinoma.	Annals of diagnostic pathology	2021	16.202761281562257	-40.577688856187294	2	0.14
33156203	PD-1 inhibitors might limit the development of brain metastases in patients with advanced melanoma.	Melanoma research	2020	42.49376945250217	-15.812047247389362	4	0.21
33156018	Immune Checkpoint Markers in Superficial Angiosarcomas: PD-L1, PD-1, CD8, LAG-3, and Tumor-Infiltrating Lymphocytes.	The American Journal of dermatopathology	2021	-20.02874501899665	23.394026017014387	7	0.72
33155587	Selection of threose nucleic acid aptamers to block PD-1/PD-L1 interaction for cancer immunotherapy.	Chemical communications (Cambridge, England)	2020	-25.6526105922814	-59.85208502682904	30	2.35
33154673	PD-L1 Predicts Poor Prognosis in Surgically Resected Limited Stage Small-Cell Lung Cancer.	Cancer management and research	2020	9.644614546581964	-23.808246566572965	9	0.61
33151368	Telomerase-specific oncolytic immunotherapy for promoting efficacy of PD-1 blockade in osteosarcoma.	Cancer immunology, immunotherapy : CII	2021	-36.60701926193501	52.68020994036123	15	1.89
33150045	Converging focal radiation and immunotherapy in a preclinical model of triple negative breast cancer: contribution of VISTA blockade.	Oncoimmunology	2020	28.87936131445253	21.25141717951682	28	1.56
33148626	iPSC-derived NK cells maintain high cytotoxicity and enhance in vivo tumor control in concert with T cells and anti-PD-1 therapy.	Science translational medicine	2020	-34.32508057352802	2.1441117077530105	102	6.65
33147777	Unripe Black Raspberry (Rubus coreanus Miquel) Extract and Its Constitute, Ellagic Acid Induces T Cell Activation and Antitumor Immunity by Blocking PD-1/PD-L1 Interaction.	Foods (Basel, Switzerland)	2020	-25.77524648487037	-35.92256563567591	7	0.78
33145319	Hyperprogressive disease in advanced cancer patients with liver metastasis treated with PD-1 inhibitors: two case reports.	Annals of translational medicine	2020	37.52971877656272	-51.03513112451472	3	0.18
33145316	The effect of intestinal flora on immune checkpoint inhibitors in tumor treatment: a narrative review.	Annals of translational medicine	2020	22.860705046128693	42.15120745767127	3	0.19
33142852	Tumour PD-L1 Expression in Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.	Cells	2020	10.02142963338647	-24.20342402859757	24	1.7
33142805	Delicate Role of PD-L1/PD-1 Axis in Blood Vessel Inflammatory Diseases: Current Insight and Future Significance.	International journal of molecular sciences	2020	-58.31503956875634	9.76994581171168	21	1.43
33142232	Tumor-infiltrating CD8+ T cells in ALK-positive lung cancer are functionally impaired despite the absence of PD-L1 on tumor cells.	Lung cancer (Amsterdam, Netherlands)	2020	5.633308681071164	-22.453197655270124	9	0.53
33141168	An miRNA signature associated with tumor mutation burden in endometrial cancer.	Bioscience reports	2020	5.308290006484463	50.5634258571728	5	0.42
33140128	Breast ductal Carcinoma in situ associated with microinvasion induces immunological response and predicts ipsilateral invasive recurrence.	Virchows Archiv : an international journal of pathology	2021	-3.1019669612366068	17.963599486927382	10	1.15
33137949	Quantifying PD-L1 Expression to Monitor Immune Checkpoint Therapy: Opportunities and Challenges.	Cancers	2020	6.216588985820852	-54.052003484042	23	1.58
33136674	Neuro-Ophthalmic Complications in Patients Treated With CTLA-4 and PD-1/PD-L1 Checkpoint Blockade.	Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society	2021	81.45443500530814	-23.868857124990672	12	1.87
33136179	Prognostic significance of PD-1/PD-L1 expression in uveal melanoma: correlation with tumor-infiltrating lymphocytes and clinicopathological parameters.	Cancer immunology, immunotherapy : CII	2021	1.6670347937656262	0.3569313439438478	14	1.98
33134907	Epigenetics in hepatocellular carcinoma development and therapy: The tip of the iceberg.	JHEP reports : innovation in hepatology	2020	-12.99591512755858	49.45668324100135	48	3.49
33133428	Exosomal PD-L1 functions as an immunosuppressant to promote wound healing.	Journal of extracellular vesicles	2019	-45.03653125789338	-60.436377425101	54	3.15
33132244	PD-1/PD-L1 affects Graves progression through lymphocytes on the proliferation, apoptosis and inflammatory cytokine secretion of thyroid follicular epithelial cells.	The Journal of toxicological sciences	2020	-61.92990685464424	11.52136744839158	6	0.59
33129844	PD-1 Signaling Promotes Tumor-Infiltrating Myeloid-Derived Suppressor Cells and Gastric Tumorigenesis in Mice.	Gastroenterology	2021	-12.468656940649064	1.791900711178553	49	5.6
35117332	Additional possibilities of chimeric antigen receptor T-cells in B-cell lymphoma: combination therapy.	Translational cancer research	2020	-46.46338936409494	34.7322014898045	0	0.0
33128595	Immune checkpoint inhibition in upper tract urothelial carcinoma.	World journal of urology	2021	67.97701733925916	19.04939217224152	23	2.59
33128107	[Stimulatory and inhibitory signaling pathways of the T cell-APC interaction and the effect of TLR agonists on APCs].	HNO	2020	-44.13148029533362	10.12543421579146	0	0.0
33127884	Soluble PD-L1 improved direct ARDS by reducing monocyte-derived macrophages.	Cell death & disease	2020	-60.30316751626815	31.24153346991556	7	0.56
33127761	CXCR4 inhibition in human pancreatic and colorectal cancers induces an integrated immune response.	Proceedings of the National Academy of Sciences of the United States of America	2020	3.1875182135718103	37.58084061045614	106	7.08
33126649	Id1 and PD-1 Combined Blockade Impairs Tumor Growth and Survival of KRAS-mutant Lung Cancer by Stimulating PD-L1 Expression and Tumor Infiltrating CD8+ T Cells.	Cancers	2020	17.574933207234352	-24.216935344581504	5	0.24
33125732	Clinicopathological and prognostic analyses of 86 resected pulmonary lymphoepithelioma-like carcinomas.	Journal of surgical oncology	2021	39.69454876165637	-46.18121204803102	25	4.12
33125511	Characterization of the tumor immune microenvironment in human papillomavirus-positive and -negative head and neck squamous cell carcinomas.	Cancer immunology, immunotherapy : CII	2021	-2.852789149191093	-7.936678329578043	18	2.02
33123755	Nivolumab for esophageal squamous cell carcinoma and the predictive role of PD-L1 or CD8 expression in its therapeutic effect.	Cancer immunology, immunotherapy : CII	2021	53.227443210675126	12.605694166559918	12	1.14
33123197	Significance of Detection of the HER2 Gene and PD-1/PD-L1 in Gastric Cancer.	Journal of oncology	2020	-8.172278745790688	2.76197612491151	10	0.78
33122306	Lipopolysaccharide-Mediated Chronic Inflammation Promotes Tobacco Carcinogen-Induced Lung Cancer and Determines the Efficacy of Immunotherapy.	Cancer research	2021	0.5195976961927796	-23.180118899595453	41	5.3
33121190	PD-1 and PD-L1 Expression on Circulating Lymphocytes as a Marker of Epstein-Barr Virus Reactivation-Associated Proliferative Glomerulonephritis.	International journal of molecular sciences	2020	-51.833043472624375	7.774268641557692	7	0.63
33119547	Sustained cellular immune dysregulation in individuals recovering from SARS-CoV-2 infection.	The Journal of clinical investigation	2021	-52.557195572624906	43.41163562944764	75	6.88
33119034	Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer.	JAMA oncology	2020	74.00502816556472	-11.072990543288965	182	12.59
33117602	Immunogenicity and antitumor efficacy of a novel human PD-1 B-cell vaccine (PD1-Vaxx) and combination immunotherapy with dual trastuzumab/pertuzumab-like HER-2 B-cell epitope vaccines (B-Vaxx) in a syngeneic mouse model.	Oncoimmunology	2020	-25.55470113934171	-14.061621998769928	19	1.27
33117170	First-Line Immune-Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Current Landscape and Future Progress.	Frontiers in pharmacology	2020	37.02643057288367	-22.10468970462256	42	3.05
33116828	Programmed Death-1 Receptor (PD-1) as a Potential Prognosis Biomarker for Ovarian Cancer Patients.	Cancer management and research	2020	-20.931172309003628	12.94217259815527	7	0.52
33116590	Increased SNX20 and PD-L1 Levels Can Predict the Clinical Response to PD-1 Inhibitors in Lung Adenocarcinoma.	OncoTargets and therapy	2020	9.882754502945174	-27.02381171743194	6	0.34
33115942	Synergizing sunitinib and radiofrequency ablation to treat hepatocellular cancer by triggering the antitumor immune response.	Journal for immunotherapy of cancer	2020	26.20082049490932	53.4882257821844	37	2.08
33114576	The Mechanisms of PD-L1 Regulation in Non-Small-Cell Lung Cancer (NSCLC): Which Are the Involved Players?	Cancers	2020	4.4066967852663295	-30.48703853681939	23	1.49
33113552	Tumor and microenvironment response but no cytotoxic T-cell activation in classic Hodgkin lymphoma treated with anti-PD1.	Blood	2020	-27.76657724417445	26.18921756226925	35	2.21
33113541	Role of PD-L1 Expression during the Progression of Submucosal Gastric Cancer.	Oncology	2021	-10.943867879221251	3.987945316609471	7	0.76
33113363	Calcium Channel Blocker Nifedipine Suppresses Colorectal Cancer Progression and Immune Escape by Preventing NFAT2 Nuclear Translocation.	Cell reports	2020	-21.717908466202555	-29.000945790733905	15	1.35
33113005	Biphasic prognostic significance of PD-L1 expression status in patients with early- and locally advanced-stage non-small cell lung cancer.	Cancer immunology, immunotherapy : CII	2021	12.534526765366838	-28.337360233194342	8	0.85
33112575	Evaluating the Possible Association between PD-1 (Rs11568821, Rs2227981, Rs2227982) and PD-L1 (Rs4143815, Rs2890658) Polymorphisms and Susceptibility to Breast Cancer in a Sample of Southeast Iranian Women.	Asian Pacific journal of cancer prevention : APJCP	2020	3.046474378562242	9.668261203172458	5	0.37
33110706	Small-molecule PD-L1 inhibitor BMS1166 abrogates the function of PD-L1 by blocking its ER export.	Oncoimmunology	2020	-37.36702745437825	-34.97361950960522	21	1.41
33110170	A pilot clinical study of the therapeutic antibody against canine PD-1 for advanced spontaneous cancers in dogs.	Scientific reports	2020	-15.978586349516004	-14.592739776448685	39	3.34
33110110	Gene expression analysis in formalin fixed paraffin embedded melanomas is associated with density of corresponding immune cells in those tissues.	Scientific reports	2020	5.53507105343399	-46.01819192431177	6	0.41
33108411	A low-intensity focused ultrasound-assisted nanocomposite for advanced triple cancer therapy: local chemotherapy, therapeutic extracellular vesicles and combined immunotherapy.	Biomaterials science	2020	-34.67728781253305	-56.963334627354506	10	0.66
33106165	Molecular correlates and therapeutic targets in T cell-inflamed versus non-T cell-inflamed tumors across cancer types.	Genome medicine	2020	-3.853819189881373	43.561992631808494	22	1.25
33104972	PET/CT Imaging of 89Zr-N-sucDf-Pembrolizumab in Healthy Cynomolgus Monkeys.	Molecular imaging and biology	2021	7.836419063768483	-57.39497710467384	13	1.97
33102962	Incidence and Clinical Features of Immune-Related Acute Kidney Injury in Patients Receiving Programmed Cell Death Ligand-1 Inhibitors.	Kidney international reports	2020	70.8432556387046	0.615141927361142	35	2.45
33102523	Investigating the Role of the N-Terminal Loop of PD-1 in Binding Process Between PD-1 and Nivolumab via Molecular Dynamics Simulation.	Frontiers in molecular biosciences	2020	-51.45047736062229	-36.10973869410493	5	0.42
33102239	Estrogen Receptor Downregulates Expression of PD-1/PD-L1 and Infiltration of CD8+ T Cells by Inhibiting IL-17 Signaling Transduction in Breast Cancer.	Frontiers in oncology	2020	-23.028236621934035	6.176314876450443	29	2.24
33102221	Clinical Outcomes for PD-1 Inhibitor Plus Chemotherapy as Second-Line or Later Therapy Compared to PD-1/PD-L1 Inhibitor Alone in Advanced Non-small-cell Lung Cancer.	Frontiers in oncology	2020	48.198281533594745	-20.029661529255105	5	0.27
33101772	Better prognosis of gastric cancer patients with high levels of tumor infiltrating lymphocytes is counteracted by PD-1 expression.	Oncoimmunology	2020	-8.440018108689838	22.04771087035232	10	0.68
33100329	Trastuzumab upregulates programmed death ligand-1 expression through interaction with NK cells in gastric cancer.	British journal of cancer	2021	-10.600813800020529	4.558011314640489	15	1.59
33100099	Liothyronine could block the programmed death-ligand 1 (PDL1) activity: an e-Pharmacophore modeling and virtual screening study.	Journal of receptor and signal transduction research	2022	-41.0882292772124	-40.42665435249867	11	2.97
33096620	Distinct Expression Patterns of VEGFR 1-3 in Gastroenteropancreatic Neuroendocrine Neoplasms: Supporting Clinical Relevance, but not a Prognostic Factor.	Journal of clinical medicine	2020	0.9191467985350324	11.973247679297724	2	0.13
33095222	Conjugation of biphenyl groups with poly(ethylene glycol) to enhance inhibitory effects on the PD-1/PD-L1 immune checkpoint interaction.	Journal of materials chemistry. B	2020	-37.86173297803726	-41.59027045511367	0	0.0
33087896	Baseline immunity and impact of chemotherapy on immune microenvironment in cervical cancer.	British journal of cancer	2021	-4.185445667679813	36.04543765786621	30	3.28
33085193	The Stone Guest: How Does pH Affect Binding Properties of PD-1/PD-L1 Inhibitors?	ChemMedChem	2021	-50.88492824006951	-41.313369191562565	6	0.98
33084943	Overcoming acquired resistance to PD-1 inhibitor with the addition of metformin in small cell lung cancer (SCLC).	Cancer immunology, immunotherapy : CII	2021	-15.936089991863945	-25.450087511808174	22	2.57
33083827	The circadian rhythm and core gene Period2 regulate the chemotherapy effect and multidrug resistance of ovarian cancer through the PI3K signaling pathway.	Bioscience reports	2020	0.4200363562823841	31.547739942901835	9	0.7
33083746	Uncoupling Therapeutic Efficacy from Immune-Related Adverse Events in Immune Checkpoint Blockade.	iScience	2020	78.34793866969052	-9.960087865013088	17	1.23
33080912	The Immune Microenvironment in Penile Cancer and Rationale for Immunotherapy.	Journal of clinical medicine	2020	17.11471926496484	20.917461641913093	17	1.26
33079077	Anti-PD-1 And Anti-PD-L1 Antibodies as Immunotherapy Against Cancer: A Structural Perspective.	Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion	2020	-45.47944901978818	-36.25229414701658	7	0.48
33078980	A T-cell-dependent antibody response study using a murine surrogate anti-PD-1 monoclonal antibody as an alternative to a non-human primate model.	Journal of immunotoxicology	2020	62.56733396764381	-35.927999909835776	4	0.25
33078970	Determination of PD-1 expression in peripheral blood cells in patients with endometriosis.	Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology	2021	-69.85246496879041	-18.411668221231768	4	0.54
33076951	Increased percentage of PD-L1+ natural killer cells predicts poor prognosis in sepsis patients: a prospective observational cohort study.	Critical care (London, England)	2020	-56.44656943282752	33.68907252902967	16	1.3
33076728	Killing efficiency affected by mutually modulated PD-1 and PD-L1 expression via NKT-hepatoma cell interactions.	Immunotherapy	2021	-31.445888289860743	1.7559293371428115	1	0.11
33076423	Ramucirumab in Combination with Pembrolizumab in Treatment-Naïve Advanced Gastric or GEJ Adenocarcinoma: Safety and Antitumor Activity from the Phase 1a/b JVDF Trial.	Cancers	2020	50.425083281222165	9.430533302509511	14	0.84
33076303	The Confounders of Cancer Immunotherapy: Roles of Lifestyle, Metabolic Disorders and Sociological Factors.	Cancers	2020	-30.67779596731603	-25.92569405250681	50	3.36
33073996	PD-L1 Glycosylation and Its Impact on Binding to Clinical Antibodies.	Journal of proteome research	2021	-35.55244623489613	-32.402027735699825	20	2.47
33073988	Local and Targeted Delivery of Immune Checkpoint Blockade Therapeutics.	Accounts of chemical research	2020	25.18746902953588	14.735652870553734	51	3.33
33073043	Finding the hot spot: identifying immune sensitive gastrointestinal tumors.	Translational gastroenterology and hepatology	2020	27.218063190885125	16.527771416391815	4	0.3
35019367	Isolation of DNA Aptamer Targeting PD-1 with an Antitumor Immunotherapy Effect.	ACS applied bio materials	2020	-25.140768800889145	-59.63143920323065	11	0.87
33070515	[Immune Characteristics of Small Cell Lung Cancer].	Zhongguo fei ai za zhi = Chinese journal of lung cancer	2020	44.13694849628958	-41.5683122544789	1	0.05
33070260	Efficacy and safety of sintilimab in combination with chemotherapy in previously untreated advanced or metastatic nonsquamous or squamous NSCLC: two cohorts of an open-label, phase 1b study.	Cancer immunology, immunotherapy : CII	2021	33.364538107189475	-18.68327584236394	18	1.64
33070259	Tuberculosis following programmed cell death receptor-1 (PD-1) inhibitor in a patient with non-small cell lung cancer. Case report and literature review.	Cancer immunology, immunotherapy : CII	2021	63.203952475764005	-24.504531722383245	14	1.56
33069081	Increased PD-L1 expression in high-grade bladder cancer with squamous cell differentiation in Bulgarian and French patients' samples.	Annals of diagnostic pathology	2020	11.85733278498159	59.2324904971283	4	0.33
33067320	Impact of COVID-19 on patients with rheumatic complications of cancer immunotherapy: results of a registry survey.	Journal for immunotherapy of cancer	2020	80.36428878070508	-2.7208327344510845	1	0.03
33066260	High PD-L1/CD274 Expression of Monocytes and Blood Dendritic Cells Is a Risk Factor in Lung Cancer Patients Undergoing Treatment with PD1 Inhibitor Therapy.	Cancers	2020	6.888681310663249	-20.614705717483048	13	0.8
33065994	Polymorphisms within Immune Regulatory Pathways Predict Cetuximab Efficacy and Survival in Metastatic Colorectal Cancer Patients.	Cancers	2020	7.61545694111985	41.89350686111276	3	0.21
33065386	Combination therapy: Future directions of immunotherapy in small cell lung cancer.	Translational oncology	2021	44.41390763382343	-42.2233035526738	25	2.93
33064985	Blood-Based Biomarkers for Predicting Immunotherapy Benefit in Lung Cancer.	Cell	2020	25.374623354682203	-34.2970125083441	3	0.17
33063473	N-glycosylation of PD-1 promotes binding of camrelizumab.	EMBO reports	2020	-35.99306689759842	-32.33752951428244	38	2.17
33062194	PD-1/PD-L1 expression in anal squamous intraepithelial lesions.	Oncotarget	2020	-10.219085234795294	-10.220364204674762	5	0.37
33061627	Application and Prospects of Molecular Imaging in Immunotherapy.	Cancer management and research	2020	6.50250317701456	-53.08438223242504	5	0.36
33060149	HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric or gastroesophageal junction cancer: a multicenter, single-arm phase II trial.	Journal for immunotherapy of cancer	2020	50.360110968670114	17.19439080845243	9	0.48
33059196	Machine learning reveals a PD-L1-independent prediction of response to immunotherapy of non-small cell lung cancer by gene expression context.	European journal of cancer (Oxford, England : 1990)	2020	18.15720361073493	-30.234104428160062	21	1.23
33058325	Distinct roles of programmed death ligand 1 alternative splicing isoforms in colorectal cancer.	Cancer science	2021	-5.538735433147575	10.148208988483653	17	1.89
33053760	Platelet Induced Functional Alteration of CD4+ and CD8+ T Cells in HNSCC.	International journal of molecular sciences	2020	-52.74695214229115	25.54131642776628	10	0.81
33053342	PD-L1 Reverse Signaling in Dermal Dendritic Cells Promotes Dendritic Cell Migration Required for Skin Immunity.	Cell reports	2020	-53.548550299666445	-11.108480810669006	22	1.29
33051342	Novel, non-invasive imaging approach to identify patients with advanced non-small cell lung cancer at risk of hyperprogressive disease with immune checkpoint blockade.	Journal for immunotherapy of cancer	2020	28.781223522072388	-16.61239371549631	42	2.72
33051330	Immune Checkpoint Inhibitor-Associated Diabetes: A Single-Institution Experience.	Diabetes care	2020	88.0425029170038	-13.658476799015547	17	1.31
33050090	Influence of Nivolumab for Intercellular Adhesion Force between a T Cell and a Cancer Cell Evaluated by AFM Force Spectroscopy.	Sensors (Basel, Switzerland)	2020	-50.274472631221	-39.00600494744602	0	0.0
33049542	Durable disease control with local treatment for oligoprogression of metastatic solid tumors treated with immune checkpoint blockade.	Cancer treatment and research communications	2020	45.00162852346329	7.71786258587754	5	0.28
33047598	Antipeptide Immunocapture with In-Sample Calibration Curve Strategy for Sensitive and Robust LC-MS/MS Bioanalysis of Clinical Protein Biomarkers in Formalin-Fixed Paraffin-Embedded Tumor Tissues.	Analytical chemistry	2020	5.884240207823856	-46.01434357152385	10	1.13
33047430	Tislelizumab in Asian patients with previously treated locally advanced or metastatic urothelial carcinoma.	Cancer science	2021	56.74213044337032	-23.51099896223731	41	3.94
33046870	Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial.	Nature medicine	2020	64.13978429702767	20.58086808690058	177	10.46
33045304	ADAM protease inhibition overcomes resistance of breast cancer stem-like cells to γδ T cell immunotherapy.	Cancer letters	2021	-36.84998521880024	4.4362664691225735	4	0.47
33045001	Impact of sidedness of colorectal cancer on tumor immunity.	PloS one	2020	11.38380688044236	37.48586347271711	9	0.81
33044117	Tislelizumab: an investigational anti-PD-1 antibody for the treatment of advanced non-small cell lung cancer (NSCLC).	Expert opinion on investigational drugs	2020	56.4223062577558	-24.243146941162028	33	1.98
33043814	Expression of STAT1 is positively correlated with PD-L1 in human ovarian cancer.	Cancer biology & therapy	2020	-20.294016559280777	12.983350210235598	8	0.59
33042828	Transcriptome-Based Network Analysis Unveils Eight Immune-Related Genes as Molecular Signatures in the Immunomodulatory Subtype of Triple-Negative Breast Cancer.	Frontiers in oncology	2020	-0.5000846734549478	44.88941912024325	22	1.5
33042618	Synergistic effect of programmed death-1 inhibitor and programmed death-1 ligand-1 inhibitor combined with chemotherapeutic drugs on DLBCL cell lines in vitro and in vivo.	American journal of cancer research	2020	46.26095372925943	-9.163359641454152	7	0.39
33040839	Craniopharyngiomas: A clinicopathological and molecular study of 52 cases - Experience in the Complejo Hospitalario de Toledo and Hospital Universitario 12 de Octubre (Madrid).	Clinical neuropathology	2021	20.224325760776992	53.033711201513	3	0.66
33039811	Impact of chemoradiotherapy on the immune-related tumour microenvironment and efficacy of anti-PD-(L)1 therapy for recurrences after chemoradiotherapy in patients with unresectable locally advanced non-small cell lung cancer.	European journal of cancer (Oxford, England : 1990)	2020	15.351195812060215	-23.928445933281424	13	0.73
33038863	Association of immune checkpoint inhibitors with respiratory infections: A review.	Cancer treatment reviews	2020	68.80788983363098	-7.997770751645629	5	0.29
33035640	Immunotherapy efficacy on mismatch repair-deficient colorectal cancer: From bench to bedside.	Biochimica et biophysica acta. Reviews on cancer	2020	11.151979462084606	40.28747322272657	80	4.99
33032816	Literature meta-analysis about the efficacy of re-challenge with PD-1 and PD-L1 inhibitors in cancer patients.	Bulletin du cancer	2020	38.73317434274865	-14.453815371013384	6	0.31
33031808	Tumor-associated macrophages induce PD-L1 expression in gastric cancer cells through IL-6 and TNF-ɑ signaling.	Experimental cell research	2020	-13.504171723935526	4.072723026530325	53	4.1
33031304	The relationship between pneumonitis and programmed cell death-1/programmed cell death ligand 1 inhibitors among cancer patients: A systematic review and meta-analysis.	Medicine	2020	64.45785261282599	-11.734299314135876	1	0.12
33029887	Clinical significance of tumor-associated immune cells in patients with oral squamous cell carcinoma.	Head & neck	2021	-7.116964534559298	-13.597596677786582	6	0.81
33024998	Triggering interferon signaling in T cells with avadomide sensitizes CLL to anti-PD-L1/PD-1 immunotherapy.	Blood	2021	-20.339423209432915	-20.761073030072605	28	2.8
33024921	Hepatocellular Carcinoma-Circulating Tumor Cells Expressing PD-L1 Are Prognostic and Potentially Associated With Response to Checkpoint Inhibitors.	Hepatology communications	2020	7.959417586386865	-40.19574552685384	43	2.88
33020648	Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i.	Nature medicine	2020	30.964471218330747	33.907033438542044	66	3.6
33019813	Effects of Brief Adjunctive Metformin Therapy in Virologically Suppressed HIV-Infected Adults on Polyfunctional HIV-Specific CD8 T Cell Responses to PD-L1 Blockade.	AIDS research and human retroviruses	2021	-83.09411870346266	16.92707939253913	4	0.55
33019546	Genetic Co-Administration of Soluble PD-1 Ectodomains Modifies Immune Responses against Influenza A Virus Induced by DNA Vaccination.	Vaccines	2020	-87.98769011561129	14.16347949439294	6	0.56
33017026	Safety, Antitumor Activity, and Pharmacokinetics of Toripalimab, a Programmed Cell Death 1 Inhibitor, in Patients With Advanced Non-Small Cell Lung Cancer: A Phase 1 Trial.	JAMA network open	2020	57.55053459533479	-5.996179663391253	27	1.51
33015859	Immune checkpoint blockade and biomarkers of clinical response in non-small cell lung cancer.	Scandinavian journal of immunology	2020	24.88047519411821	-34.06368914227545	13	0.79
33014820	Correlation Patterns Among B7 Family Ligands and Tryptophan Degrading Enzymes in Hepatocellular Carcinoma.	Frontiers in oncology	2020	-10.816597127349985	47.09497739644216	5	0.31
33014817	Anti-PD-1 Immunotherapy Combined With Stereotactic Body Radiation Therapy and GM-CSF as Salvage Therapy in a PD-L1-Negative Patient With Refractory Metastatic Esophageal Squamous Cell Carcinoma: A Case Report and Literature Review.	Frontiers in oncology	2020	56.6780667890704	14.594741298264363	10	0.85
33014787	Pembrolizumab in a Patient With Heavily Pre-Treated Squamous Cell Thymic Carcinoma and Cardiac Impairment: A Case Report and Literature Review.	Frontiers in oncology	2020	54.65834711315235	1.5941538573200391	4	0.29
33011679	In Vivo-assembled phthalocyanine/albumin supramolecular complexes combined with a hypoxia-activated prodrug for enhanced photodynamic immunotherapy of cancer.	Biomaterials	2021	-31.587300690872414	-55.80185552719151	41	4.95
33010422	Immune checkpoint inhibitors and diabetes: Mechanisms and predictors.	Diabetes & metabolism	2021	89.74600811796931	-14.92208948599171	7	0.69
33007259	The PD-1/PD-L1-Checkpoint Restrains T cell Immunity in Tumor-Draining Lymph Nodes.	Cancer cell	2020	-31.74418883392242	-12.426598729543471	225	13.29
33006786	Enhanced anti-tumor effects of the PD-1 blockade combined with a highly absorptive form of curcumin targeting STAT3.	Cancer science	2020	-17.125653649372044	-37.4382645413976	37	3.04
33006479	Pembrolizumab for the treatment of Hodgkin Lymphoma.	Expert opinion on biological therapy	2020	42.85243057509748	-6.163408170710913	9	0.64
33003425	Immune Checkpoint Inhibitors and Cardiac Toxicity in Patients Treated for Non-Small Lung Cancer: A Review.	International journal of molecular sciences	2020	83.10778248886061	1.2744002151424194	37	2.63
33003392	Analysis of CXCL9, PD1 and PD-L1 mRNA in Stage T1 Non-Muscle Invasive Bladder Cancer and Their Association with Prognosis.	Cancers	2020	7.906897434796846	58.18686020161026	11	0.72
33000173	Immune Co-inhibitory Receptors PD-1, CTLA-4, TIM-3, LAG-3, and TIGIT in Medullary Thyroid Cancers: A Large Cohort Study.	The Journal of clinical endocrinology and metabolism	2021	-3.349116628349187	27.550519667509707	32	3.57
32999045	A Novel Bispecific Antibody with PD-L1-assisted OX40 Activation for Cancer Treatment.	Molecular cancer therapeutics	2020	-14.86137496547396	-47.43848448021048	8	0.42
32998997	Local Targeting of NAD+ Salvage Pathway Alters the Immune Tumor Microenvironment and Enhances Checkpoint Immunotherapy in Glioblastoma.	Cancer research	2020	-26.13800697373174	54.74611083295607	24	1.6
35117264	Perioperative immunotherapy in muscle-invasive bladder cancer.	Translational cancer research	2020	73.70391192395012	20.972414374990876	3	0.26
32997833	Topical Delivery of Nivolumab, a Therapeutic Antibody, by Fractional Laser and Pneumatic Injection.	Lasers in surgery and medicine	2021	73.31906266180269	-29.49958932783184	6	1.26
32995356	Safety and Efficacy of an Immune Cell-Specific Chimeric Promoter in Regulating Anti-PD-1 Antibody Expression in CAR T Cells.	Molecular therapy. Methods & clinical development	2020	-43.68901036113495	4.420248472193464	8	0.53
32995000	Partial absence of PD-1 expression by tumor-infiltrating EBV-specific CD8+ T cells in EBV-driven lymphoepithelioma-like carcinoma.	Clinical & translational immunology	2020	-16.856747163929505	35.0872070501692	6	0.38
32993274	Systematic review of neoadjuvant therapy by immune checkpoint inhibitors before radical cystectomy: where do we stand?	Minerva urologica e nefrologica = The Italian journal of urology and nephrology	2020	68.3591648813247	24.04393550255905	12	0.8
32992658	Spatial and Temporal Changes in PD-L1 Expression in Cancer: The Role of Genetic Drivers, Tumor Microenvironment and Resistance to Therapy.	International journal of molecular sciences	2020	-34.06321779658329	-17.705974249750962	29	1.91
35118291	The role of EBUS-TBNA in lung cancer restaging and mutation analysis.	Mediastinum (Hong Kong, China)	2020	16.035658755368498	-36.80141819645189	4	0.56
32989552	Phase I, first-in-human trial of programmed cell death receptor-1 (PD-1) inhibitor, JTX-4014, in adult patients with advanced, refractory, solid tumors.	Cancer immunology, immunotherapy : CII	2021	54.11896177108834	-8.31474513633416	2	0.18
32988398	Small-molecule MMP2/MMP9 inhibitor SB-3CT modulates tumor immune surveillance by regulating PD-L1.	Genome medicine	2020	3.469676834551485	27.638365398687714	58	4.29
32987122	Characterization of a single chain variable fragment of nivolumab that targets PD-1 and blocks PD-L1 binding.	Protein expression and purification	2021	-45.85635921473534	-30.90213200661452	6	0.61
32986884	Association between CD8 and PD-L1 expression and outcomes after radical prostatectomy for localized prostate cancer.	The Prostate	2021	-10.444112557648577	12.76084420061984	18	1.98
32986357	Transcriptome Related to Avoiding Immune Destruction in Nasopharyngeal Cancer in Indonesian Patients Using Next-Generation Sequencing.	Asian Pacific journal of cancer prevention : APJCP	2020	-15.466300681049626	32.79943243958001	1	0.18
32984844	eIF5B drives integrated stress response-dependent translation of PD-L1 in lung cancer.	Nature cancer	2020	-16.357657182595243	-9.990569625128698	54	3.08
32984358	Anti-PD-1 Immunotherapy and Radiotherapy for Stage IV Intrahepatic Cholangiocarcinoma: A Case Report.	Frontiers in medicine	2020	55.91927048584264	22.887720843651323	16	1.08
32983959	Excision Repair Cross Complementation Group 1 Single Nucleotide Polymorphisms and Nivolumab in Advanced Non-Small Cell Lung Cancer.	Frontiers in oncology	2020	21.02317662963475	-24.53312500887784	7	0.38
32983126	Anti-angiogenic Agents in Combination With Immune Checkpoint Inhibitors: A Promising Strategy for Cancer Treatment.	Frontiers in immunology	2020	29.34447334995181	13.77738489109212	118	8.19
32980653	Immune checkpoint inhibitors versus second line chemotherapy for patients with lung cancer refractory to first line chemotherapy.	Respiratory medicine and research	2020	39.56220238335028	-21.210357793888544	3	0.17
32979832	Persistent lentivirus infection induces early myeloid suppressor cells expansion to subvert protective memory CD8 T cell response✰,✰✰.	EBioMedicine	2020	-78.84426530062512	16.02159436625568	6	0.52
32977151	Differential expression of programmed death-1 and its ligand, programmed death ligand-1 in oral squamous cell carcinoma with and without oral submucous fibrosis.	Archives of oral biology	2020	-8.715271430606466	-11.62105266394748	7	0.58
32976876	Can radiation-recall predict long lasting response to immune checkpoint inhibitors?	Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology	2021	38.65421223796557	-23.43077804748625	6	0.69
32976705	Programmed death-ligand 1 (PD-L1)/thyroid transcription factor-1 double immunohistochemical staining facilitates scoring of tumor PD-L1 expression in cytopathology specimens from lung adenocarcinoma patients.	Cancer cytopathology	2021	13.675908681444223	-40.69721099154887	4	0.48
32975728	PD-1 expression is elevated in monocytes from hepatocellular carcinoma patients and contributes to CD8 T cell suppression.	Immunologic research	2020	-24.927120637889484	40.93920318660639	8	0.52
32974346	Augmenting the Effectiveness of CAR-T Cells by Enhanced Self-Delivery of PD-1-Neutralizing scFv.	Frontiers in cell and developmental biology	2020	-43.10505608282886	5.146554342637693	22	1.43
32973682	Role of the PD-1/PD-L1 Dyad in the Maintenance of Pancreatic Immune Tolerance for Prevention of Type 1 Diabetes.	Frontiers in endocrinology	2020	-58.97982114796689	1.4917755207681436	28	2.01
32972288	N6-methyladenosine (m6A) RNA methylation signature as a predictor of stomach adenocarcinoma outcomes and its association with immune checkpoint molecules.	The Journal of international medical research	2020	-8.30115635205885	56.38840579747091	18	1.11
32969795	Nodular primary cutaneous melanoma is associated with PD-L1 expression.	European journal of dermatology : EJD	2020	6.385820060076989	-0.6559870647839134	3	0.24
32968446	Circulating microRNAs and their role in the immune response in triple-negative breast cancer.	Oncology letters	2020	3.492300965876918	52.52910444492026	12	0.78
32967768	[Role and application of programmed death protein 1 (PD-1) and its ligand PD-L1 in immune cell dysfunction in sepsis: An update].	Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology	2020	-58.384864748346494	35.85651574352222	0	0.0
32966352	[Immunotherapy of lung cancer].	Magyar onkologia	2020	36.47704988979486	-30.853105016608616	1	0.09
32963532	Genes Involved in the PD-L1 Pathway Might Associate with Radiosensitivity of Patients with Gastric Cancer.	Journal of oncology	2020	-12.405482714296964	5.053672891921472	5	0.37
32962812	The role of macrophages type 2 and T-regs in immune checkpoint inhibitor related adverse events.	Immunobiology	2020	83.6461402475056	-16.89867644389154	14	0.91
32962247	The Emergence of a vv + MDV Can Break through the Protections Provided by the Current Vaccines.	Viruses	2020	-77.05948364086737	19.47493136385515	13	2.06
32961934	Predicting Response to Immunotherapy in Metastatic Renal Cell Carcinoma.	Cancers	2020	21.496327622552727	29.84023597566422	28	1.62
32960847	Incidence and Risk of Colitis With Programmed Death 1 Versus Programmed Death Ligand 1 Inhibitors for the Treatment of Cancer.	Journal of immunotherapy (Hagerstown, Md. : 1997)	2020	67.35173119130297	-14.720845452963996	6	0.35
32960817	Inhibition of TRPV1 by SHP-1 in nociceptive primary sensory neurons is critical in PD-L1 analgesia.	JCI insight	2020	-74.10825257522613	-13.167596037203811	19	1.36
32960261	Radiation therapy enhanced therapeutic efficacy of anti-PD1 against gastric cancer.	Journal of radiation research	2020	27.68078585950484	24.71755817574104	9	0.62
32959668	Is Weak Acid Beneficial for Addressing Checkpoint Inhibitor-Triggered Cancer Hyper Progression in Anti-PD1/PD-L1 Immunotherapies?	Cancer control : journal of the Moffitt Cancer Center	2020	-32.02812394920138	-42.86255913595862	1	0.21
32959594	[Mechanism on moxibustion for rheumatoid arthritis based on PD-1/PD-L1 signaling pathway].	Zhongguo zhen jiu = Chinese acupuncture & moxibustion	2020	-51.33417614866098	15.077164805225149	4	0.45
32956826	Nutritional supplements in combination with chemotherapy or targeted therapy reduces tumor progression in mice bearing triple-negative breast cancer.	The Journal of nutritional biochemistry	2021	-20.391923568353743	-33.2005064490621	12	1.93
32955188	Monoclonal antibodies in multiple myeloma.	Panminerva medica	2021	-9.17709174247918	-52.235638417796125	7	0.99
32954856	Platinum-based chemotherapy in combination with PD-1/PD-L1 inhibitors: preclinical and clinical studies and mechanism of action.	Expert opinion on drug delivery	2021	38.80356712203524	-11.9654332800489	49	5.59
32953520	CD39: the potential target in small cell lung cancer.	Translational lung cancer research	2020	9.890410738960368	-22.65857033447695	9	0.53
32953506	Compare the efficacy and safety of programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1) inhibitors for advanced non-small cell lung cancer: a Bayesian analysis.	Translational lung cancer research	2020	45.26252451563912	-30.24027833873213	15	0.92
32952954	Liposomal gp100 vaccine combined with CpG ODN sensitizes established B16F10 melanoma tumors to anti PD-1 therapy.	Iranian journal of basic medical sciences	2020	-32.4513237922194	-48.32647689331228	9	0.74
32952659	Integrative assessment of clinicopathological parameters and the expression of PD-L1, PD-L2 and PD-1 in tumor cells of retroperitoneal sarcoma.	Oncology letters	2020	-19.922945799604097	19.835280381904603	8	0.55
32948597	Revisiting the PD-1 pathway.	Science advances	2020	-50.05054368796301	-8.969169407931437	202	13.56
32944405	Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer.	Cancer biology & medicine	2020	17.092911822895633	-19.01715592265579	31	1.9
32944395	Comprehensive insights into the effects and regulatory mechanisms of immune cells expressing programmed death-1/programmed death ligand 1 in solid tumors.	Cancer biology & medicine	2020	-41.24242523806542	-10.529474345093693	7	0.4
32943934	Moxibustion Enhances Chemotherapy of Breast Cancer by Affecting Tumor Microenvironment.	Cancer management and research	2020	-26.43614549490074	-45.86733236272472	9	0.71
32943749	Immunophenotype based on inflammatory cells, PD-1/PD-L1 signalling pathway and M2 macrophages predicts survival in gastric cancer.	British journal of cancer	2020	-8.60240512344382	6.843624393560507	9	0.63
32943323	Successful treatment of advanced pulmonary sarcomatoid carcinoma with the PD-1 inhibitor toripalimab: A case report.	Oral oncology	2021	54.38867281238368	-32.76712734813516	12	1.55
32943072	Radiation recall pneumonitis induced by PD-1/PD-L1 blockades: mechanisms and therapeutic implications.	BMC medicine	2020	63.8951063710446	-8.155909747808636	29	2.18
32939320	PD-1 checkpoint blockade in advanced melanoma patients: NK cells, monocytic subsets and host PD-L1 expression as predictive biomarker candidates.	Oncoimmunology	2020	12.134018684710286	-2.882398230107035	25	1.67
32938429	Development and validation of a novel pseudogene pair-based prognostic signature for prediction of overall survival in patients with hepatocellular carcinoma.	BMC cancer	2020	-9.959530131803527	50.15754419423315	5	0.4
32937178	Comparative efficacy and safety of PD-1/PD-L1 Inhibitors versus platinum-based chemotherapy for the first-line treatment of advanced non-small cell lung cancer: a meta analysis of randomized controlled trials.	Pharmacological research	2020	49.33215452442042	-18.97555828950634	10	0.81
32937024	PDCD1 and IFNL4 genetic variants and risk of developing hepatitis C virus-related diseases.	Liver international : official journal of the International Association for the Study of the Liver	2021	-67.95925673071501	21.08369433228936	3	0.32
32936368	[The use of immune checkpoint inhibitors in routine oncology].	Zeitschrift fur Rheumatologie	2020	27.436105768344884	8.27530967813829	2	0.08
32935602	Voluntary wheel running can lead to modulation of immune checkpoint molecule expression.	Acta oncologica (Stockholm, Sweden)	2020	-46.92232369843704	10.383118188419312	10	0.78
32934877	Trial watch: TLR3 agonists in cancer therapy.	Oncoimmunology	2020	-20.479438801520715	-22.593428494756797	52	3.33
32931951	Challenges for immunotherapy for the treatment of platinum resistant ovarian cancer.	Seminars in cancer biology	2021	38.50428156068171	40.32360666742982	39	4.08
32929052	Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer.	Journal for immunotherapy of cancer	2020	31.547739537218284	-20.18968196999028	87	5.38
32923143	A meta-analysis comparing responses of Asian versus non-Asian cancer patients to PD-1 and PD-L1 inhibitor-based therapy.	Oncoimmunology	2020	49.632809938234914	-14.861722359901629	26	1.44
32923134	Efficacy and safety of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer (NSCLC): a systematic literature review.	Oncoimmunology	2020	39.29423148559136	-20.91759706796373	26	1.89
32923111	Genomic and immunologic correlates of LAG-3 expression in cancer.	Oncoimmunology	2020	9.636748323661417	23.41178236669013	15	0.97
32922519	Dramatic response to combination pembrolizumab and radiation in metastatic castration resistant prostate cancer.	Therapeutic advances in medical oncology	2020	52.22161711327238	3.3571480737642334	17	1.21
32922086	A Novel Epitope Quality-Based Immune Escape Mechanism Reveals Patient's Suitability for Immune Checkpoint Inhibition.	Cancer management and research	2020	28.21583764048137	-30.160365552773445	6	0.36
32919004	Application prospect of peptide-modified nano targeting drug delivery system combined with PD-1/PD-L1 based immune checkpoint blockade in glioblastoma.	International journal of pharmaceutics	2020	-31.767581440935203	-49.8522675865118	6	0.62
32917656	Melanoma Evolves Complete Immunotherapy Resistance through the Acquisition of a Hypermetabolic Phenotype.	Cancer immunology research	2020	13.953535109347014	1.014599335564281	28	1.57
32917410	PD-1 blockade in recurrent or metastatic cervical cancer: Data from cemiplimab phase I expansion cohorts and characterization of PD-L1 expression in cervical cancer.	Gynecologic oncology	2020	58.45519999179695	4.079882115525671	39	2.61
32915772	Chloride intracellular channel protein 2: prognostic marker and correlation with PD-1/PD-L1 in breast cancer.	Aging	2020	14.119480288655312	-11.300297443596012	9	0.74
32913444	Current status of treatment with immune checkpoint inhibitors for gastrointestinal, hepatobiliary, and pancreatic cancers.	Therapeutic advances in gastroenterology	2020	40.07121328969377	16.31550150741469	36	2.28
32909947	Dissecting the immunosuppressive tumor microenvironments in Glioblastoma-on-a-Chip for optimized PD-1 immunotherapy.	eLife	2020	-27.59080538919464	54.40536082163288	61	4.46
32909077	Immune checkpoint-related serum proteins and genetic variants predict outcomes of localized prostate cancer, a cohort study.	Cancer immunology, immunotherapy : CII	2021	6.059134777803554	19.159725619296378	28	3.33
32908154	Collagen promotes anti-PD-1/PD-L1 resistance in cancer through LAIR1-dependent CD8+ T cell exhaustion.	Nature communications	2020	-10.692815227365612	-23.03942236323579	158	10.71
32905579	ICPis-Induced Autoimmune Polyendocrine Syndrome Type 2: A Review of the Literature and a Protocol for Optimal Management.	The Journal of clinical endocrinology and metabolism	2020	83.63150497621082	-13.341130071027338	8	0.48
32903606	Immunohistochemistry and Radiomic Features for Survival Prediction in Small Cell Lung Cancer.	Frontiers in oncology	2020	11.3707004014023	-13.101735755210496	8	0.9
32902555	Microneedles loaded with anti-PD-1-cisplatin nanoparticles for synergistic cancer immuno-chemotherapy.	Nanoscale	2020	-30.345551460313217	-49.817512602138464	42	3.69
32902402	The possible regulatory effect of the PD-1/PD-L1 signaling pathway on Tregs in ovarian cancer.	General physiology and biophysics	2020	-22.003932483589537	10.34312153688206	6	0.55
32900864	Immune-checkpoint inhibitors plus chemotherapy versus chemotherapy as first-line treatment for patients with extensive-stage small cell lung cancer.	Journal for immunotherapy of cancer	2020	46.3499817309665	-39.56772457616096	14	0.93
32899191	Combined Methylome and Transcriptome Analyses Reveals Potential Therapeutic Targets for EGFR Wild Type Lung Cancers with Low PD-L1 Expression.	Cancers	2020	-0.8323729769288332	-32.15580469469001	10	0.78
32898555	Buparlisib modulates PD-L1 expression in head and neck squamous cell carcinoma cell lines.	Experimental cell research	2020	-9.404574361466254	-6.957262631892878	7	0.44
32898522	Ectonucleotidase CD73 and CD39 expression in non-small cell lung cancer relates to hypoxia and immunosuppressive pathways.	Life sciences	2020	5.036603432749777	4.927484032826893	27	1.96
32896829	The immunologic aspects in hormone receptor positive breast cancer.	Cancer treatment and research communications	2020	-0.2056701402189315	24.34099589481388	6	0.36
32896258	Immune-related adverse events in patients with solid-organ tumours treated with immunotherapy: a 3-year study of 102 cases from a single centre.	Clinical and experimental rheumatology	2021	76.3518938530017	-8.518956163074996	4	0.53
32894642	Inhibition of NF-κB is required for oleanolic acid to downregulate PD-L1 by promoting DNA demethylation in gastric cancer cells.	Journal of biochemical and molecular toxicology	2021	-29.164183640481237	-32.01745621900963	12	1.76
32894535	Association between immunotherapy biomarkers and glucose metabolism from F-18 FDG PET.	European review for medical and pharmacological sciences	2020	15.334186663776675	-56.2799163905084	10	0.91
32891685	Abnormal membrane-bound and soluble programmed death ligand 2 (PD-L2) expression in systemic lupus erythematosus is associated with disease activity.	Immunology letters	2020	-52.70769186373113	12.2553339904319	9	0.81
32887724	PD1 Blockade Enhances ICAM1-Directed CAR T Therapeutic Efficacy in Advanced Thyroid Cancer.	Clinical cancer research : an official journal of the American Association for Cancer Research	2020	-9.298664861845978	-20.23138681220085	15	0.88
32884390	Efficacy of Docetaxel Plus Ramucirumab as Palliative Third-Line Therapy Following Second-Line Immune-Checkpoint-Inhibitor Treatment in Patients With Non-Small-Cell Lung Cancer Stage IV.	Clinical Medicine Insights. Oncology	2020	46.07375068064507	-22.45214934663744	16	0.97
32884290	Cervical Cancer: Emerging Immune Landscape and Treatment.	OncoTargets and therapy	2020	-4.529838131114293	36.54064414601946	19	1.51
32879421	Genome-wide identification of differentially methylated promoters and enhancers associated with response to anti-PD-1 therapy in non-small cell lung cancer.	Experimental & molecular medicine	2020	-0.9019458772922988	-32.17646963399451	68	3.7
32878065	A Tumor-Immune Interaction Model for Synergistic Combinations of Anti PD-L1 and Ionizing Irradiation Treatment.	Pharmaceutics	2020	39.35002234951229	4.169000837601592	5	0.43
32875727	Study and analysis of antitumor resistance mechanism of PD1/PD-L1 immune checkpoint blocker.	Cancer medicine	2020	-36.831284860833264	-20.49395843226147	73	4.78
32875254	Synthesis and Evaluation of Biphenyl-1,2,3-Triazol-Benzonitrile Derivatives as PD-1/PD-L1 Inhibitors.	ACS omega	2020	-39.166039284834696	-41.739229735004905	3	0.22
32873605	Bispecific Targeting of PD-1 and PD-L1 Enhances T-cell Activation and Antitumor Immunity.	Cancer immunology research	2020	-13.72286341212162	-46.774686697235126	25	1.44
32872094	Through Predictive Personalized Medicine.	Brain sciences	2020	-3.0294307268506104	-44.75011810749603	1	0.13
32871843	Association Between the Efficacy of Pembrolizumab and Low STK11/LKB1 Expression in High-PD-L1-expressing Non-small-cell Lung Cancer.	In vivo (Athens, Greece)	2020	18.41347758847479	-22.3738282276471	7	0.44
32871584	Spatial signatures identify immune escape via PD-1 as a defining feature of T-cell/histiocyte-rich large B-cell lymphoma.	Blood	2021	-29.70408601005733	30.94874818666296	23	2.34
32871472	N-glycosylation and ubiquitinylation of PD-L1 do not restrict interaction with BMS-202: A molecular modeling study.	Computational biology and chemistry	2020	-35.64003343391004	-32.59778495186604	13	0.92
32871087	Clinical Pharmacology and Interplay of Immune Checkpoint Agents: A Yin-Yang Balance.	Annual review of pharmacology and toxicology	2021	81.28419770831549	-10.772758186736004	37	3.95
32870120	Promising predictors of checkpoint inhibitor response in NSCLC.	Expert review of anticancer therapy	2020	21.994348660099654	-33.6451768563454	14	1.02
32868929	The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies.	Nature immunology	2020	-30.20110036654893	-9.305973837688631	324	20.01
32868392	IFN-γ treatment protocol for MHC-Ilo/PD-L1+ pancreatic tumor cells selectively restores their TAP-mediated presentation competence and CD8 T-cell priming potential.	Journal for immunotherapy of cancer	2020	-19.301135476288824	-17.151353136945936	8	0.54
32867715	Phase II study on first-line treatment of NIVolumab in combination with folfoxiri/bevacizumab in patients with Advanced COloRectal cancer RAS or BRAF mutated - NIVACOR trial (GOIRC-03-2018).	BMC cancer	2020	38.94428866708288	23.95830569754504	11	0.66
32867046	Addition of Radiotherapy to Immunotherapy: Effects on Outcome of Different Subgroups Using a Propensity Score Matching.	Cancers	2020	40.91878766727468	4.902629988504741	2	0.11
32865367	[Development of programmed death receptor-1 and programmed death receptor-1 ligand in oral squamous cell carcinoma].	Hua xi kou qiang yi xue za zhi = Huaxi kouqiang yixue zazhi = West China journal of stomatology	2020	-9.093837339161311	-11.514300616901188	1	0.1
32864684	PD-L1 Positivity Associated With Presence of Tertiary Lymphoid Structures and High-Stage Disease in Upper Tract Urothelial Carcinoma.	American journal of clinical pathology	2020	13.543640562939055	57.8533345714048	3	0.15
32863271	Immune-related pneumonitis associated with immune checkpoint inhibitors in lung cancer: a network meta-analysis.	Journal for immunotherapy of cancer	2020	65.9066132902484	-8.164154562509	23	1.43
32859743	Combination therapy with T cell engager and PD-L1 blockade enhances the antitumor potency of T cells as predicted by a QSP model.	Journal for immunotherapy of cancer	2020	-13.511975615260434	-44.50870264512079	25	1.75
32857220	Cancer immunotherapy-related adverse events: causes and challenges.	Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer	2020	78.60943444490611	-8.558638844255386	18	1.33
32857184	Patterns of immune checkpoint protein expression in MYC-overexpressing aggressive B-cell non-Hodgkin lymphomas.	Cancer immunology, immunotherapy : CII	2021	-30.98681633458626	30.643430693508336	6	0.54
32856210	Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe gastrointestinal and hepatic toxicities from checkpoint inhibitors.	Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer	2020	75.47504516270064	-7.389442457111754	19	1.36
32855204	High PD-1/PD-L1 Checkpoint Interaction Infers Tumor Selection and Therapeutic Sensitivity to Anti-PD-1/PD-L1 Treatment.	Cancer research	2020	7.451070204168073	-7.992095901516821	20	1.07
32854477	[Expression and significance of PD-1 and PD-L1 in the specimens of epithelial ovarian cancer].	Zhonghua fu chan ke za zhi	2020	-19.68810228671383	12.395322142391858	3	0.18
32854442	HLA Expression Correlates to the Risk of Immune Checkpoint Inhibitor-Induced Pneumonitis.	Cells	2020	64.77355673727372	-9.04065224174649	28	1.92
32853912	Emerging role of immune checkpoint inhibitors and predictive biomarkers in head and neck cancers.	Oral oncology	2020	49.79866996858307	31.328882071067916	9	0.69
32850341	Prognostic Value of Vimentin Is Associated With Immunosuppression in Metastatic Renal Cell Carcinoma.	Frontiers in oncology	2020	15.410165881544582	32.32119191712831	10	0.56
32849955	Current Status and Future Perspectives of Immunotherapy in Middle-Income Countries: A Single-Center Early Experience.	World journal of oncology	2020	53.53820375348352	-25.56010735337322	0	0.0
32849603	PD-L1 Is Expressed and Promotes the Expansion of Regulatory T Cells in Acute Myeloid Leukemia.	Frontiers in immunology	2020	-40.11421714388023	13.58716182645481	38	2.71
32847983	Pharmacologic Properties and Preclinical Activity of Sasanlimab, A High-affinity Engineered Anti-Human PD-1 Antibody.	Molecular cancer therapeutics	2020	-20.36110192723044	-41.05148918292183	8	0.56
32846790	The prediction potential of neutrophil-to-lymphocyte ratio for the therapeutic outcomes of programmed death receptor-1/programmed death ligand 1 inhibitors in non-small cell lung cancer patients: A meta-analysis.	Medicine	2020	27.65620161150436	-41.54127600807812	7	0.48
32843385	Complete response with anti-PD-L1 antibody following progression on anti-PD-1 antibody in advanced non-small cell lung cancer.	BMJ case reports	2020	42.18446526163583	-30.287190973340262	3	0.18
32843031	A novel tumor mutational burden estimation model as a predictive and prognostic biomarker in NSCLC patients.	BMC medicine	2020	6.480706238908373	50.0824254229085	14	0.8
32842436	[Expert consensus on PD-L1 expression testing in non-small-cell lung cancer in China].	Zhonghua zhong liu za zhi [Chinese journal of oncology]	2020	21.605517396535493	-37.03038777173938	6	0.36
32842016	Type 1 diabetes induced by immune checkpoint inhibitors.	Chinese medical journal	2020	87.28022284287688	-13.818077081161976	9	0.66
32841527	New technology on the horizon: Fast analytical screening technique FNA (FAST-FNA) enables rapid, multiplex biomarker analysis in head and neck cancers.	Cancer cytopathology	2020	13.334147824431614	-38.50832144240061	5	0.22
32839553	Manganese is critical for antitumor immune responses via cGAS-STING and improves the efficacy of clinical immunotherapy.	Cell research	2020	-23.236702887761357	-44.83886662377744	211	14.1
32839551	Acetylation-dependent regulation of PD-L1 nuclear translocation dictates the efficacy of anti-PD-1 immunotherapy.	Nature cell biology	2020	-46.70414137654507	-22.189347876351437	138	8.81
32832992	Transforming growth factor beta orchestrates PD-L1 enrichment in tumor-derived exosomes and mediates CD8 T-cell dysfunction regulating early phosphorylation of TCR signalome in breast cancer.	Carcinogenesis	2021	-44.50313816721028	-58.8468711083716	35	4.17
32832572	Profound Functional Suppression of Tumor-Infiltrating T-Cells in Ovarian Cancer Patients Can Be Reversed Using PD-1-Blocking Antibodies or DARPin® Proteins.	Journal of immunology research	2020	-32.36012232505663	-15.365962445427732	6	0.46
32831157	Analysis of the inflammatory tumor microenvironment in meningeal neoplasms.	Clinical neuropathology	2020	-19.948725738500052	47.79072549938777	7	0.6
32827111	Anti-PD-1 and Anti-PD-L1 Monoclonal Antibodies in People Living with HIV and Cancer.	Current HIV/AIDS reports	2020	32.879199383028464	-6.540671914522442	16	1.1
32826237	Morphoproteomics Identifies the Foamy Alveolar Macrophage as an M2 Phenotype with PD-L1 Expression in the Early Lesion of Post-Primary Tuberculosis: Implications for Host Immune Surveillance and Therapy.	Annals of clinical and laboratory science	2020	-86.12286811275449	1.445859515524729	2	0.25
32825588	TILs Immunophenotype in Breast Cancer Predicts Local Failure and Overall Survival: Analysis in a Large Radiotherapy Trial with Long-Term Follow-Up.	Cancers	2020	-3.401490010146743	20.7825667972074	16	0.95
32824580	C-Reactive Protein (CRP) Levels in Immune Checkpoint Inhibitor Response and Progression in Advanced Non-Small Cell Lung Cancer: A Bi-Center Study.	Cancers	2020	24.057705999508297	-27.42516460523208	44	2.93
32824462	Endocrine Adverse Events of Nivolumab in Non-Small Cell Lung Cancer Patients-Literature Review.	Cancers	2020	75.83437984619499	-17.829747221005928	10	0.62
32820659	The influence of programmed cell death ligand 2 (PD-L2) expression on survival outcome and tumor microenvironment in diffuse large B cell lymphoma.	Leukemia & lymphoma	2020	-34.22584283538291	26.80459030345561	3	0.24
32820489	[Operability and Pathological Response of Non-Small Cell Lung Cancer (NSCLC) after Neoadjuvant Therapy with Immune Checkpoint Inhibition].	Pneumologie (Stuttgart, Germany)	2020	34.459992248565136	-21.42870663842977	2	0.09
32819974	M2-like macrophages dictate clinically relevant immunosuppression in metastatic ovarian cancer.	Journal for immunotherapy of cancer	2020	-0.5488409945877487	29.549030848115976	46	3.08
32817069	Mycobacterial infections due to PD-1 and PD-L1 checkpoint inhibitors.	ESMO open	2020	62.84762630243707	-22.181785972050264	23	1.61
32814714	Ovarian granulosa cell tumor characterization identifies FOXL2 as an immunotherapeutic target.	JCI insight	2020	-1.0486588641867176	27.96882002315654	12	0.86
32810436	DNA Damage and Cancer Immunotherapy: A STING in the Tale.	Molecular cell	2020	-24.06651226350428	-44.227584970978185	122	7.29
32808188	PD-L1+ lung cancer stem cells modify the metastatic lymph-node immunomicroenvironment in nsclc patients.	Cancer immunology, immunotherapy : CII	2021	7.29925119967767	-17.962684141289945	13	1.52
32806051	Translational Nanomedicine Boosts Anti-PD1 Therapy to Eradicate Orthotopic PTEN-Negative Glioblastoma.	ACS nano	2020	-31.4125756430428	-50.474218346154814	28	1.92
32805756	PD-1 antibody and ruxolitinib enhances graft-versus-lymphoma effect without increasing acute graft-versus-host disease in mice.	American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons	2021	-31.35718069771737	7.648666657258327	5	0.39
32805322	A PD-1 peptide antagonist exhibits potent anti-tumor and immune regulatory activity.	Cancer letters	2020	-41.77792736519499	-44.37806966384225	5	0.42
32803453	Clinicopathological analysis of neoplastic PD-L1-positive EBV+ diffuse large B cell lymphoma, not otherwise specified, in a Japanese cohort.	Virchows Archiv : an international journal of pathology	2021	-37.43269293654076	26.97625153609418	12	1.57
32803433	Immune Oncology Biomarkers in Lung Cancer: an Overview.	Current oncology reports	2020	24.00699023134767	-32.52531276818627	5	0.29
32802199	Hypoxia dynamics on FMISO-PET in combination with PD-1/PD-L1 expression has an impact on the clinical outcome of patients with Head-and-neck Squamous Cell Carcinoma undergoing Chemoradiation.	Theranostics	2020	-10.449265033447052	-5.835989469751242	15	1.15
32802195	USP7 targeting modulates anti-tumor immune response by reprogramming Tumor-associated Macrophages in Lung Cancer.	Theranostics	2020	-17.75788210538418	-4.808177513226977	78	5.42
32801888	A Review About Pembrolizumab in First-Line Treatment of Advanced NSCLC: Focus on KEYNOTE Studies.	Cancer management and research	2020	46.60025274258902	-31.983667598032188	12	0.86
32801879	PD-L1 in Lung Adenocarcinoma: Insights into the Role of 18F-FDG PET/CT.	Cancer management and research	2020	14.148546836728803	-56.21580244160448	9	0.63
32800530	NK cells and ILCs in tumor immunotherapy.	Molecular aspects of medicine	2021	-43.20171335412405	32.55442441569023	100	10.28
32799412	Alopecia areata as an immune-related adverse event of immune checkpoint inhibitors: A review.	Dermatologic therapy	2020	75.62647403987911	-21.927114975959515	17	1.77
32798974	BxPC-3-Derived Small Extracellular Vesicles Induce FOXP3+ Treg through ATM-AMPK-Sirtuins-Mediated FOXOs Nuclear Translocations.	iScience	2020	-24.038850201773137	14.536120892006643	11	0.71
32796628	Genomic Mapping Identifies Mutations in RYR2 and AHNAK as Associated with Favorable Outcome in Basal-Like Breast Tumors Expressing PD1/PD-L1.	Cancers	2020	8.885888966488322	30.100887495829173	20	1.22
32793733	Hypoproteinemia being a manifestation of immunotherapy-related liver dysfunction.	Annals of translational medicine	2020	66.13275942943669	-17.669071434177972	1	0.05
32792499	Targeting PD-L1 in non-small cell lung cancer using CAR T cells.	Oncogenesis	2020	30.5468798656448	-30.30285981441873	34	2.36
32787475	Bispecific anti-PD-L1/PD-1 antibodies for advanced solid tumors: a patent evaluation of US2019010232.	Expert opinion on therapeutic patents	2020	-13.026574699311125	-46.84079199294938	0	0.0
32785929	Predictive Biomarkers for Immunotherapy Response Beyond PD-1/PD-L1.	Oncology (Williston Park, N.Y.)	2020	17.447608760287093	-4.557750505327932	6	0.35
32784389	Immuno-Oncotherapeutic Approaches in Advanced Hepatocellular Carcinoma.	Vaccines	2020	30.095934547007055	50.38355719898185	17	1.22
32782728	Are anti-PD1 and anti-PD-L1 alike? The non-small-cell lung cancer paradigm.	Oncology reviews	2020	46.82708514884732	-20.075571598665512	27	1.67
32781525	Investigation of the PD-1 and PD-L1 Immune Checkpoint Molecules Throughout Healthy Human Pregnancy and in Nonpregnant Women.	Journal of clinical medicine	2020	-75.50458341466263	-19.11779115531447	13	1.25
32779383	Different patterns of treatment-related adverse events of programmed cell death-1 and its ligand-1 inhibitors in different cancer types: A meta-analysis and systemic review of clinical trials.	Asia-Pacific journal of clinical oncology	2020	62.6918769439677	-16.31960727129525	4	0.28
32779238	PD-1 and PD-L1 expression in Kaposi sarcoma: A comparative study according to the pathological stage and clinical characteristics.	Journal of cutaneous pathology	2021	-22.44794916853544	21.313904212364708	5	0.76
32778827	A peripheral immune signature of responsiveness to PD-1 blockade in patients with classical Hodgkin lymphoma.	Nature medicine	2020	-27.201152647734343	24.89735437191008	65	3.61
32778505	Characterization of PD-1 and PD-L1 Expression in Papillary Renal Cell Carcinoma: Results of a Large Multicenter Study.	Clinical genitourinary cancer	2021	17.470384918779228	26.561216098958045	5	0.46
32777942	Immuno-oncology for esophageal cancer.	Future oncology (London, England)	2020	53.35127576201284	13.178046560742512	15	1.14
32776100	Immunotherapy for squamous cell carcinoma of the head and neck.	Japanese journal of clinical oncology	2020	50.13943400583653	30.08390830262896	34	2.59
32775813	Immune Checkpoint Inhibitors and Immune-Related Adverse Renal Events.	Kidney international reports	2020	71.12452810523348	0.2808224275032432	55	3.98
32775040	The frequency and inter-relationship of PD-L1 expression and tumour mutational burden across multiple types of advanced solid tumours in China.	Experimental hematology & oncology	2020	21.23716318623713	-16.63330028760295	20	1.12
32774723	FOXP3+ Tregs exhibit different infiltrating status and predict a distinct prognosis in primary lesions and hepatic metastases in stage III&IV advanced gastric cancer.	American journal of translational research	2020	-2.6720399972602262	14.150672146611097	2	0.1
32774487	Safety and tolerability of PD-1/PD-L1 inhibitors in elderly and frail patients with advanced malignancies.	Oncology letters	2020	55.51555756829412	-17.806918342711363	10	0.68
32774415	Network Pharmacology Analysis and Experiments Validation of the Inhibitory Effect of JianPi Fu Recipe on Colorectal Cancer LoVo Cells Metastasis and Growth.	Evidence-based complementary and alternative medicine : eCAM	2020	-20.45026720378808	-37.329843883060896	10	1.13
32774054	Combining protein arginine methyltransferase inhibitor and anti-programmed death-ligand-1 inhibits pancreatic cancer progression.	World journal of gastroenterology	2020	-5.113729350554407	3.3961347405576725	19	1.23
32772342	Dual-function chimeric antigen receptor T cells targeting c-Met and PD-1 exhibit potent anti-tumor efficacy in solid tumors.	Investigational new drugs	2021	-41.674732612329095	3.525697665166989	12	1.42
32770720	Model Informed Dosing Regimen and Phase I Results of the Anti-PD-1 Antibody Budigalimab (ABBV-181).	Clinical and translational science	2021	34.32160979013326	-15.413484559171325	4	0.44
32769920	Adverse cardiac events in the treatment of non-small cell lung cancer with programmed death-1and programmed death-ligand 1 inhibitors: A protocol for systematic review and meta-analysis.	Medicine	2020	60.87477913246473	-17.38350805986802	0	0.0
32768804	Soluble PD-L1 and Circulating CD8+PD-1+ and NK Cells Enclose a Prognostic and Predictive Immune Effector Score in Immunotherapy Treated NSCLC patients.	Lung cancer (Amsterdam, Netherlands)	2020	25.19344624336234	-29.04140768181055	54	3.5
32767058	Chemotherapy negatively impacts the tumor immune microenvironment in NSCLC: an analysis of pre- and post-treatment biopsies in the multi-center SAKK19/09 study.	Cancer immunology, immunotherapy : CII	2021	12.407245221195856	-17.39881753031446	6	0.63
32766875	Avelumab for the treatment of relapsed or refractory extranodal NK/T-cell lymphoma: an open-label phase 2 study.	Blood	2020	48.88048807894752	-6.751352931986054	54	4.02
32763116	Early T cell infiltration is modulated by programed cell death-1 protein and its ligand (PD-1/PD-L1) interactions in murine kidney transplants.	Kidney international	2020	-54.93168096756847	5.834028227899173	8	0.48
32762583	The clinical application of camrelizumab on advanced hepatocellular carcinoma.	Expert review of gastroenterology & hepatology	2020	32.50214944082373	53.54157342120873	10	0.65
32762373	Clinical Impact of PD-L1 Expression for Survival in Curatively Resected Colon Cancer.	Cancer investigation	2020	-4.779237906939729	12.11470504037712	10	0.76
32762233	Complete remission in a patient with advanced renal pelvis carcinoma with lung metastasis treated with durvalumab immunotherapy: a case report.	Annals of palliative medicine	2020	66.48820861856441	18.293975283465947	2	0.09
32761894	COVID-19 and immunological regulations - from basic and translational aspects to clinical implications.	Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG	2020	-51.81645567080327	43.2455901308135	40	3.15
32761424	Evaluation of antitumor immunity by a combination treatment of high-dose irradiation, anti-PDL1, and anti-angiogenic therapy in murine lung tumors.	Cancer immunology, immunotherapy : CII	2021	26.41026971148392	21.87436407296965	22	2.24
32760603	Blockade of programmed cell death protein 1 (PD-1) in Sézary syndrome reduces Th2 phenotype of non-tumoral T lymphocytes but may enhance tumor proliferation.	Oncoimmunology	2020	-32.42248885633901	15.766055393680338	26	2.22
32759235	Combining BRAF inhibition with oncolytic herpes simplex virus enhances the immune-mediated antitumor therapy of BRAF-mutant thyroid cancer.	Journal for immunotherapy of cancer	2020	27.322615725272588	33.61868368449915	10	0.61
32759049	The relative and absolute benefit of programmed death receptor-1 vs programmed death ligand 1 therapy in advanced non-small-cell lung cancer: A systematic review and meta-analysis.	International immunopharmacology	2020	49.56576419521426	-19.43901426864649	3	0.15
32757454	Programmed cell death 1 (PD-1)/PD-ligand 1(PD-L1) inhibitors-related pneumonitis in patients with advanced non-small cell lung cancer.	Asia-Pacific journal of clinical oncology	2020	65.41751367772875	-11.217444560446276	11	0.81
32757378	In Vitro Assays to Study PD-1 Biology in Human T Cells.	Current protocols in immunology	2020	-51.21739661918331	-7.765124613672079	1	0.06
32757318	Immunotherapy-based combination strategies for advanced urothelial cancer: A long quest.	Cancer	2020	67.18539235168814	17.07971928663388	3	0.17
32757055	A high number of PD-L1+ CD14+ monocytes in peripheral blood is correlated with shorter survival in patients receiving immune checkpoint inhibitors.	Cancer immunology, immunotherapy : CII	2021	6.736538027096071	-20.510078408268804	15	1.58
32754587	MicroRNA-138-5p Suppresses Non-small Cell Lung Cancer Cells by Targeting PD-L1/PD-1 to Regulate Tumor Microenvironment.	Frontiers in cell and developmental biology	2020	0.5829748625789694	-36.693683619283725	31	2.41
32753888	Expression of PD-1 and PD-L1 on Tumor-Infiltrating Lymphocytes Predicts Prognosis in Patients with Small-Cell Lung Cancer.	OncoTargets and therapy	2020	9.68741344171718	-23.480168369936514	28	2.0
32751706	Immune-Checkpoint Blockade Therapy in Lymphoma.	International journal of molecular sciences	2020	-9.507889028823534	-25.696871488773333	21	1.29
32751195	Characterization of PD-1/PD-L1 Immune Checkpoint Expression in Osteosarcoma.	Diagnostics (Basel, Switzerland)	2020	-17.80592725468716	19.197499779054706	12	0.98
32749562	Effects of Tussilago farfara L. Polysaccharides on the Expression of PD-1 (CD279) and PD-L1 (CD274) in Peripheral Blood and Tumor Tissue Lymphocytes in Mice with Lewis Lung Carcinoma.	Bulletin of experimental biology and medicine	2020	-26.56874611197194	-32.6324231860914	1	0.22
32748597	[Construction of a novel lentiviral vector knocking down PD-1 via microRNA and its application in CAR-T cells].	Sheng wu gong cheng xue bao = Chinese journal of biotechnology	2020	-46.84228676118699	2.263030342629821	0	0.0
32746624	Cutaneous Immune-Related Adverse Events (irAEs) to Immune Checkpoint Inhibitors: A Dermatology Perspective on Management [Formula: see text].	Journal of cutaneous medicine and surgery	2021	74.87920603682873	-23.342384919286403	63	7.63
32742998	Significant benefits of pembrolizumab in treating refractory advanced pulmonary sarcomatoid carcinoma: A case report.	World journal of clinical cases	2020	53.28025330941277	-32.62078495422696	5	0.38
32741230	Safety of pembrolizumab in recurrent or advanced gastric cancer expressing PD-L1 refractory to platinum and fluoropyrimidine.	Expert opinion on drug safety	2020	50.6200522360404	7.365571338407091	1	0.18
32740092	Advances in immunotherapy for cervical cancer.	Current opinion in oncology	2020	44.75236330434784	35.31843941505028	37	2.85
32737537	Anti-PD-1 antibody increases NK cell cytotoxicity towards nasopharyngeal carcinoma cells in the context of chemotherapy-induced upregulation of PD-1 and PD-L1.	Cancer immunology, immunotherapy : CII	2021	40.93194987962498	27.217795100521347	23	2.77
32737148	Adoptive T Cell Therapy with IL-12-Preconditioned Low-Avidity T Cells Prevents Exhaustion and Results in Enhanced T Cell Activation, Enhanced Tumor Clearance, and Decreased Risk for Autoimmunity.	Journal of immunology (Baltimore, Md. : 1950)	2020	-44.114273575487225	-1.8383578859239789	15	0.91
32736208	Prognostic impact of CD8-positive tumour-infiltrating lymphocytes and PD-L1 expression in salivary gland cancer.	Oral oncology	2020	-4.357618933575682	18.184684711357654	12	1.18
32736034	Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies.	Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy	2020	31.61656478717934	14.782432053255636	85	5.93
32734832	Potential and unsolved problems of anti-PD-1/PD-L1 therapy combined with radiotherapy.	Tumori	2021	40.00108868473646	3.6530006106086574	6	0.54
32733805	Efficacy of Immune Checkpoint Inhibitors in Non-small-cell Lung Cancer Patients With Different Metastatic Sites: A Systematic Review and Meta-Analysis.	Frontiers in oncology	2020	41.7491182205454	-16.64912036278857	23	1.44
32733486	Clinical and Recent Patents Applications of PD-1/PD-L1 Targeting Immunotherapy in Cancer Treatment-Current Progress, Strategy, and Future Perspective.	Frontiers in immunology	2020	-42.45122821095004	-37.28936405253092	44	2.95
32728392	Efficacy of PD-1/PD-L1 blockade monotherapy in clinical trials.	Therapeutic advances in medical oncology	2020	50.623347725953806	-15.0444486521662	53	3.24
32727812	Comprehensive analyses of immunodynamics and immunoreactivity in response to treatment in ALK-positive non-small-cell lung cancer.	Journal for immunotherapy of cancer	2020	34.642578831144235	-37.29805722591879	15	0.9
32725437	Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from Pharmacovigilance.	Targeted oncology	2020	76.86915927061678	-10.063766654462642	74	5.04
32724880	Programmed death ligand-1 expression in gastrointestinal cancer: Clinical significance and future challenges.	Annals of gastroenterological surgery	2020	-8.749197998687313	4.330641903640483	8	0.51
32724476	Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy.	Theranostics	2020	-28.535382767484236	-48.55516460802454	33	2.18
32723363	SBRT combined with PD-1/PD-L1 inhibitors in NSCLC treatment: a focus on the mechanisms, advances, and future challenges.	Journal of hematology & oncology	2020	34.959032882727655	-27.08090555244003	59	3.59
32720769	[IMMUNOTHERAPY WITH CHECKPOINT INHIBITORS (ICPI) AND IMMUNE RELATED ADVERSE EVENTS (IRAE'S)].	Harefuah	2020	80.00221426665341	-9.800012043283749	1	0.07
32720019	Immunotherapy Alone or in Combination with Chemotherapy as First-Line Treatment of Non-Small Cell Lung Cancer.	Current treatment options in oncology	2020	42.790143075810754	-28.73065701379592	17	1.13
32719675	Early Activation of Myeloid-Derived Suppressor Cells Participate in Sepsis-Induced Immune Suppression via PD-L1/PD-1 Axis.	Frontiers in immunology	2020	-52.10259420580261	28.3280211405396	21	1.69
32718028	Prognostic Value of Immune Environment Analysis in Small Bowel Adenocarcinomas with Verified Mutational Landscape and Predisposing Conditions.	Cancers	2020	8.057492629484168	33.90447647031452	4	0.23
32710922	Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma.	Journal of hepatology	2020	12.996274122271636	5.77917932247221	193	12.72
32709714	PD-L1 Protein Expression on Both Tumor Cells and Macrophages are Associated with Response to Neoadjuvant Durvalumab with Chemotherapy in Triple-negative Breast Cancer.	Clinical cancer research : an official journal of the American Association for Cancer Research	2020	-8.519889863763478	19.33183742635149	46	2.68
32708945	Immune Checkpoint Inhibitors in Oral Cavity Squamous Cell Carcinoma and Oral Potentially Malignant Disorders: A Systematic Review.	Cancers	2020	54.34446144966381	35.16981412176541	34	2.9
32708748	The Latest Findings of PD-1/PD-L1 Inhibitor Application in Gynecologic Cancers.	International journal of molecular sciences	2020	41.0782224681049	35.91496684976194	23	1.73
32707850	Significance of Immunosuppressive Cells as a Target for Immunotherapies in Melanoma and Non-Melanoma Skin Cancers.	Biomolecules	2020	-32.575192264503336	-4.479925397574867	24	2.0
32707816	Immune Checkpoint Expression on Immune Cells of HNSCC Patients and Modulation by Chemo- and Immunotherapy.	International journal of molecular sciences	2020	-12.199883618738465	32.37900780180781	15	1.14
32705363	Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression.	Journal of cancer research and clinical oncology	2021	8.224835980076941	-32.06791884648494	38	3.81
32702794	[Analysis of the Correlation between Molecular Structural Differences of PD-1/PD-L1 Inhibitors and Adverse Events].	Zhongguo fei ai za zhi = Chinese journal of lung cancer	2020	63.69340087815622	-19.751691049180423	0	0.0
32700194	Immune Checkpoint Inhibitors and Radiotherapy in NSCLC Patients: Not Just a Fluke.	Oncology and therapy	2019	36.20799583208232	-26.704569781758227	4	0.15
32700042	RET Rearrangement as a Predictor of Unresponsiveness to Immunotherapy in Non-Small Cell Lung Cancer: Report of Two Cases with Review of the Literature.	Oncology and therapy	2020	41.52878460040714	-35.611733697232594	12	0.68
32699939	PD-L1 expression in tongue squamous cell carcinoma.	Medical molecular morphology	2021	-7.311718418269066	-9.70013289512522	3	0.49
32698074	Immune escape: A critical hallmark in solid tumors.	Life sciences	2020	18.40887176661795	8.70777701745716	76	5.37
32698059	Tumor-associated neutrophils suppress antitumor immunity of NK cells through the PD-L1/PD-1 axis.	Translational oncology	2020	-29.787679536652508	2.9986490646700514	37	2.68
32695574	Immune checkpoints bone marrow expression as the predictor of clinical outcome in myelodysplastic syndrome.	Leukemia research reports	2020	-36.125946634795135	14.135805814672413	6	0.48
32694896	Immune checkpoint inhibitors in malignant lymphoma: Advances and perspectives.	Chinese journal of cancer research = Chung-kuo yen cheng yen chiu	2020	-7.425110384347951	-26.963597383433548	22	1.58
32694895	Immune checkpoint inhibitors for treatment of advanced gastric or gastroesophageal junction cancer: Current evidence and future perspectives.	Chinese journal of cancer research = Chung-kuo yen cheng yen chiu	2020	42.593254477484166	15.68056354712438	18	0.99
32694695	Immunotherapy in older patients with non-small cell lung cancer: Young International Society of Geriatric Oncology position paper.	British journal of cancer	2020	37.514992254587774	-32.36775996444917	11	0.63
32693243	The balance of regulatory and stimulatory B cell subsets in breast cancer draining lymph nodes correlates with tumor prognostic factors.	Life sciences	2020	-14.056882457764113	18.62253096341765	5	0.34
32692233	Durvalumab monotherapy as a third-line treatment for extensive-stage small-cell lung cancer: a case report.	Annals of palliative medicine	2020	45.720389969610736	-42.15779757786111	2	0.12
32690150	Preoperative oral immunonutrition in gastrointestinal surgical patients: How the tumour microenvironment can be modified.	Clinical nutrition ESPEN	2020	3.999238097478668	34.393688928193235	8	0.67
32690037	CDK7 inhibitor THZ1 enhances antiPD-1 therapy efficacy via the p38α/MYC/PD-L1 signaling in non-small cell lung cancer.	Journal of hematology & oncology	2020	2.1409513752087257	-29.384918514992737	51	2.98
32687405	Atypical patterns of response and progression in the era of immunotherapy combinations.	Future oncology (London, England)	2020	30.33493010264516	-16.887357128187297	11	0.62
32686549	Mechanism of acquired resistance to nivolumab in lung squamous cell carcinoma: case report and review of the literature.	Immunotherapy	2020	38.20270604300431	-41.240599672016536	5	0.35
32686076	Quantitative Systems Pharmacology Approaches for Immuno-Oncology: Adding Virtual Patients to the Development Paradigm.	Clinical pharmacology and therapeutics	2021	17.157895619882655	0.8387966461227419	30	3.86
32684339	Secretion of human soluble programmed cell death protein 1 by chimeric antigen receptor-modified T cells enhances anti-tumor efficacy.	Cytotherapy	2020	-42.69031331399827	4.546061780308452	13	0.76
32684057	PD-1, CTLA4, PD-L1 and PD-L2 DNA methylation in papillary thyroid carcinoma.	Immunotherapy	2020	9.945205720165603	9.744710553092624	7	0.49
32683062	Indoleamine 2,3-Dioxygenase-1 Expression in Adrenocortical Carcinoma.	The Journal of surgical research	2020	3.814433018342745	-4.57227822956663	6	0.49
32681091	Exhausted T cell signature predicts immunotherapy response in ER-positive breast cancer.	Nature communications	2020	0.1463447531649466	25.7209834421693	78	4.9
32679050	The role of genetic polymorphism within PD-L1 gene in cancer. Review.	Experimental and molecular pathology	2020	-42.37785157122698	-11.47989142275197	14	1.0
32676564	Novel biomarkers for early targeted and individualized treatment in Juvenile Idiopathic Arthritis.	Mediterranean journal of rheumatology	2020	-53.30177120430679	14.821817421899254	1	0.17
32676356	Selected highlights of the 2019 Pulmonary Pathology Society Biennial Meeting: PD-L1 test harmonization studies.	Translational lung cancer research	2020	22.3381272321163	-39.58177491766312	3	0.18
32675558	Changes in gastrointestinal microbial communities influence HIV-specific CD8+ T-cell responsiveness to immune checkpoint blockade.	AIDS (London, England)	2020	20.2506549317566	42.91418147322141	2	0.16
32674216	Immunotherapy in Advanced Lung Cancer.	Oncology (Williston Park, N.Y.)	2020	37.86030073364562	-23.674813386696552	2	0.18
32671505	Remnant gastric cancer: a neglected group with high potential for immunotherapy.	Journal of cancer research and clinical oncology	2020	-10.797286582090752	20.566624301266195	5	0.69
32671122	Producing Soluble Human Programmed Cell Death Protein-1: A Natural Supporter for CD4+T Cell Cytotoxicity and Tumor Cells Apoptosis.	Iranian journal of biotechnology	2019	-46.10465239138936	-4.310045158730448	3	0.18
32666620	Immunoaffinity microflow liquid chromatography/tandem mass spectrometry for the quantitation of PD1 and PD-L1 in human tumor tissues.	Rapid communications in mass spectrometry : RCM	2020	12.608384461023686	-43.82897639590807	3	0.31
32665011	The deubiquitinase USP22 regulates PD-L1 degradation in human cancer cells.	Cell communication and signaling : CCS	2020	-18.151866903022967	-6.179969468429971	45	2.89
32664318	Tumor-Associated Neutrophils Dampen Adaptive Immunity and Promote Cutaneous Squamous Cell Carcinoma Development.	Cancers	2020	-29.61658958625024	3.059138960804692	19	1.27
32663833	Use of Immunotherapy in Extensive-Stage Small Cell Lung Cancer.	Oncology	2020	45.59686489019948	-42.10196483201951	15	1.19
32663198	Targeting tumor-associated macrophages and granulocytic myeloid-derived suppressor cells augments PD-1 blockade in cholangiocarcinoma.	The Journal of clinical investigation	2020	-13.77067808837586	33.68509214720019	126	7.83
32662701	Prognostic relevance of programmed cell death protein 1/programmed death-ligand 1 pathway in thymic malignancies with combined immunohistochemical and biomolecular approach.	Expert opinion on therapeutic targets	2020	-4.899015603379507	-36.32372517226448	8	0.62
32661095	CD40 Agonist Restores the Antitumor Efficacy of Anti-PD1 Therapy in Muscle-Invasive Bladder Cancer in an IFN I/II-Mediated Manner.	Cancer immunology research	2020	-25.08163088683388	-12.07702727746719	13	0.79
32659257	News on immune checkpoint inhibitors as immunotherapy strategies in adult and pediatric solid tumors.	Seminars in cancer biology	2022	31.456616124425175	13.63866518903661	29	6.79
32656988	Unexpected favorable outcome to sintilimab plus bevacizumab in an EGFR-mutated non-small cell lung cancer patient: A case report.	Thoracic cancer	2020	51.08591600871793	-24.61210468336041	7	0.45
32653774	Are immune checkpoint inhibitors a valid option for papillary renal cell carcinoma? A multicentre retrospective study.	European journal of cancer (Oxford, England : 1990)	2020	67.54218737335422	31.09283053105394	17	0.95
32649320	PD-1 and PD-L1 Immunohistochemistry as a Diagnostic Tool for Classic Hodgkin Lymphoma in Small-volume Biopsies.	The American journal of surgical pathology	2020	-31.72964102692521	24.242546900799635	8	0.66
32647635	Dual Vascular Endothelial Growth Factor Receptor and Fibroblast Growth Factor Receptor Inhibition Elicits Antitumor Immunity and Enhances Programmed Cell Death-1 Checkpoint Blockade in Hepatocellular Carcinoma.	Liver cancer	2020	10.830897417050892	3.752550992692823	71	4.77
32646546	Clinical Application of Iodine-125 Seed Brachytherapy Combined with Anti-PD-1 Antibodies in the Treatment of Lung Cancer.	Clinical therapeutics	2020	45.50309700790647	-21.07439124948454	2	0.43
32646345	Predictive biomarkers of response to immune checkpoint inhibitors.	Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria	2020	17.21502219137355	-4.167908439903099	3	0.23
32646072	Improved Prognostic Prediction in Never-Smoker Lung Cancer Patients by Integration of a Systemic Inflammation Marker with Tumor Immune Contexture Analysis.	Cancers	2020	23.921981244621964	-27.21967895775422	1	0.07
32645684	Systematic review: Soluble immunological biomarkers in advanced non-small-cell lung cancer (NSCLC).	Critical reviews in oncology/hematology	2020	24.52128592770986	-32.28031091849507	19	1.17
32645199	FDA Approves First Agent to Treat Locally Advanced, Metastatic Urothelial Cancer.	Oncology (Williston Park, N.Y.)	2020	69.10531270597801	12.763841340116675	1	0.08
32643323	Meta-analysis of immune-related adverse events of immune checkpoint inhibitor therapy in cancer patients.	Thoracic cancer	2020	74.57866329220667	-9.995587392205548	27	1.79
32642723	Downregulation of PD-L1 via FKBP5 by celecoxib augments antitumor effects of PD-1 blockade in a malignant glioma model.	Neuro-oncology advances	2020	-25.494102470317426	49.1493266953933	13	0.8
32642679	Low-dose oncolytic adenovirus therapy overcomes tumor-induced immune suppression and sensitizes intracranial gliomas to anti-PD-1 therapy.	Neuro-oncology advances	2020	-34.10673992743421	55.069397301898654	25	1.72
32637575	Engineering Chimeric Antigen Receptor T Cells against Immune Checkpoint Inhibitors PD-1/PD-L1 for Treating Pancreatic Cancer.	Molecular therapy oncolytics	2020	-40.78869135898951	5.485916316762134	33	2.18
32636837	Durable Response and Good Tolerance to the Triple Combination of Toripalimab, Gemcitabine, and Nab-Paclitaxel in a Patient With Metastatic Pancreatic Ductal Adenocarcinoma.	Frontiers in immunology	2020	61.65036487384575	8.934743013957947	8	0.43
32635549	Immunophenotypes Based on the Tumor Immune Microenvironment Allow for Unsupervised Penile Cancer Patient Stratification.	Cancers	2020	-0.7065651734985872	-6.914709486484542	22	1.69
32631957	A Serum Protein Classifier Identifying Patients with Advanced Non-Small Cell Lung Cancer Who Derive Clinical Benefit from Treatment with Immune Checkpoint Inhibitors.	Clinical cancer research : an official journal of the American Association for Cancer Research	2020	23.56575329517632	-29.863435666688037	9	0.75
32629362	The 5-Ws of immunotherapy in head and neck cancer.	Critical reviews in oncology/hematology	2020	52.09273817442983	32.39752908142534	11	0.66
32628668	PD-L1 upregulation by IFN-α/γ-mediated Stat1 suppresses anti-HBV T cell response.	PloS one	2020	-71.6571428486849	21.794971244602795	12	0.84
32627031	Mechanistic insight of predictive biomarkers for antitumor PD‑1/PD‑L1 blockade: A paradigm shift towards immunome evaluation (Review).	Oncology reports	2020	18.65658593023883	-4.2938409154049	14	0.84
32626712	Histone Deacetylase Inhibitors to Overcome Resistance to Targeted and Immuno Therapy in Metastatic Melanoma.	Frontiers in cell and developmental biology	2020	29.721894271278597	31.131066579432737	33	2.37
32623477	Potent anti-myeloma efficacy of dendritic cell therapy in combination with pomalidomide and programmed death-ligand 1 blockade in a preclinical model of multiple myeloma.	Cancer immunology, immunotherapy : CII	2021	-29.01533856273453	-13.528213135398463	16	1.68
32623229	Comprehensive analyses of the heterogeneity and prognostic significance of tumor-infiltrating immune cells in non-small-cell lung cancer: Development and validation of an individualized prognostic model.	International immunopharmacology	2020	11.764519776213346	-15.057950748418504	7	0.53
32623044	Immune checkpoint inhibitors: Key trials and an emerging role in breast cancer.	Seminars in cancer biology	2022	26.35094019911157	8.801270121294175	67	16.17
32622310	Programmed cell death-ligand 2: A neglected but important target in the immune response to cancer?	Translational oncology	2020	-45.5173883031988	-16.925201450876642	35	2.3
32620661	Effective Response of Intrahepatic Cholangiocarcinoma to Pembrolizumab: A Case Report.	Anticancer research	2020	55.327185067948015	22.960131483093825	8	0.51
32620165	The impact of PD-L1 N-linked glycosylation on cancer therapy and clinical diagnosis.	Journal of biomedical science	2020	-35.45240793118	-32.13277364780354	66	4.66
32616706	Blockade of PD-1, PD-L1, and TIM-3 Altered Distinct Immune- and Cancer-Related Signaling Pathways in the Transcriptome of Human Breast Cancer Explants.	Genes	2020	-28.460446674884437	-5.440112106245156	11	0.79
32616555	A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone.	Journal for immunotherapy of cancer	2020	51.851116250308685	2.945532820128715	67	4.41
32616532	Atezolizumab-induced type 1 diabetes mellitus in a patient with metastatic renal cell carcinoma.	BMJ case reports	2020	89.54580527704404	-15.323659814931773	6	0.68
32616192	Nagilactone E increases PD-L1 expression through activation of c-Jun in lung cancer cells.	Chinese journal of natural medicines	2020	-1.2619341294714967	-23.910639486747467	12	1.24
32614928	Development of canine PD-1/PD-L1 specific monoclonal antibodies and amplification of canine T cell function.	PloS one	2020	-16.678170027970204	-14.763631599333848	15	1.34
32613323	[Prognostic and predictive methylation biomarkers in HNSCC : Epigenomic diagnostics for head and neck squamous cell carcinoma (HNSCC)].	HNO	2020	-9.7411294728935	40.10032365065032	2	0.13
32613071	Sustained response to pembrolizumab without prior chemotherapy in high-grade serous ovarian carcinoma with CSMD3 mutation.	Gynecologic oncology reports	2020	50.590012114645255	5.115868155840995	8	0.52
32612822	Emergence of lung cancer with a low PD-L1 expression level after the administration of immune check point inhibitor for lung adenocarcinoma with a high PD-L1 expression level: A case report.	Annals of medicine and surgery (2012)	2020	50.93788057814187	-31.25329044250213	1	0.09
32612718	The implication of the PD-1/PD-L1 checkpoint in chronic periodontitis suggests novel therapeutic opportunities with natural products.	The Japanese dental science review	2020	-64.69176641156724	-21.16003096443838	16	1.56
32611684	Enhanced efficacy of mesothelin-targeted immunotoxin LMB-100 and anti-PD-1 antibody in patients with mesothelioma and mouse tumor models.	Science translational medicine	2020	47.53011985821938	-0.6643536731781852	25	1.89
32611231	Immune Profiling of Advanced Thyroid Cancers Using Fluorescent Multiplex Immunohistochemistry.	Thyroid : official journal of the American Thyroid Association	2021	-9.226644236091962	-21.658060783063316	13	1.42
32610128	The PD-1 Pathway Regulates Development and Function of Memory CD8+ T Cells following Respiratory Viral Infection.	Cell reports	2020	-76.00364210178559	8.579999806137483	50	2.53
32610067	Exosomal PD-L1: Roles in Tumor Progression and Immunotherapy.	Trends in cancer	2020	-43.57826564806193	-59.2840573156668	64	4.6
32606797	Effect of CXCR5-Positive Cell Infiltration on the Immune Contexture and Patient Prognosis in Head and Neck Squamous Cell Carcinoma.	OncoTargets and therapy	2020	-8.874990177324248	33.789854225736164	5	0.31
32606317	PD-L1+ exosomes from bone marrow-derived cells of tumor-bearing mice inhibit antitumor immunity.	Cellular & molecular immunology	2021	-44.394220623131766	-59.45923288121003	20	2.07
32606052	Development and validation of a genomic mutation signature to predict response to PD-1 inhibitors in non-squamous NSCLC: a multicohort study.	Journal for immunotherapy of cancer	2020	21.14117299061634	-20.85730865678354	33	1.96
32604843	Quantification of Pharmacokinetic Profiles of PD-1/PD-L1 Antibodies by Validated ELISAs.	Pharmaceutics	2020	0.4475545946663591	-56.334623288736495	6	0.35
35122038	PD-L1 expression by dendritic cells is a key regulator of T-cell immunity in cancer.	Nature cancer	2020	-31.042095079303422	-12.51755148157562	141	8.17
35117780	The lymphocyte-to-monocyte ratio could predict the efficacy of PD-1 inhibitors in patients with advanced cancer.	Translational cancer research	2020	26.683663089078173	-41.65532182765574	5	0.32
32602900	Modulation of the PD-1/PD-L1 immune checkpoint axis during inflammation-associated lung tumorigenesis.	Carcinogenesis	2020	0.6563258347686209	-23.1972186145766	18	1.23
32601914	Immunomodulatory Roles of VEGF Pathway Inhibitors in Renal Cell Carcinoma.	Drugs	2020	66.36104413663807	28.97483600322706	46	2.78
32601742	Systemic Therapy of Extensive Stage Small Cell Lung Cancer in the Era of Immunotherapy.	Current treatment options in oncology	2020	45.93937242358796	-41.13234849134973	19	1.22
32596285	Profiles of PD-1, PD-L1, PD-L2 in Gastric Cancer and Their Relation with Mutation, Immune Infiltration, and Survival.	BioMed research international	2020	-11.39985286827887	5.728861424849954	6	0.36
32595211	An effective peptide vaccine strategy circumventing clonal MHC heterogeneity of murine myeloid leukaemia.	British journal of cancer	2020	-26.32639707077303	-13.9291493270975	0	0.0
32593225	Soluble immune checkpoints CTLA-4, HLA-G, PD-1, and PD-L1 are associated with endometriosis-related infertility.	American journal of reproductive immunology (New York, N.Y. : 1989)	2020	-21.15979822757469	15.720574753922056	15	1.43
32592366	Predictors of the Onset of Type 1 Diabetes Obtained from Real-World Data Analysis in Cancer Patients Treated with Immune Checkpoint Inhibitors.	Asian Pacific journal of cancer prevention : APJCP	2020	76.25313103845134	-12.597032014392022	7	0.52
32591586	Diverse immune environments in human lung tuberculosis granulomas assessed by quantitative multiplexed immunofluorescence.	Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc	2020	-84.2141206383693	4.757507584198574	25	1.64
32591432	Lung metastases share common immune features regardless of primary tumor origin.	Journal for immunotherapy of cancer	2020	11.24175654093701	-16.516300785170465	44	2.63
32591392	Cutting Edge: Augmenting Muscle MHC Expression Enhances Systemic Pathogen Control at the Expense of T Cell Exhaustion.	Journal of immunology (Baltimore, Md. : 1950)	2020	-69.74374618015617	12.314709698156417	5	0.43
32589866	Lenvatinib plus pembrolizumab in patients with advanced gastric cancer in the first-line or second-line setting (EPOC1706): an open-label, single-arm, phase 2 trial.	The Lancet. Oncology	2020	47.54570246163252	2.7432238096766435	124	8.16
32589350	A phase I study of toripalimab, an anti-PD-1 antibody, in patients with refractory malignant solid tumors.	Cancer communications (London, England)	2020	57.50104952066194	-5.757842797465684	25	1.46
32587357	Increased both PD-L1 and PD-L2 expressions on monocytes of patients with hepatocellular carcinoma was associated with a poor prognosis.	Scientific reports	2020	-23.909312333058296	39.94291665634409	24	1.62
32586358	Prognostic and predictive value of PD-L2 DNA methylation and mRNA expression in melanoma.	Clinical epigenetics	2020	6.661771327219563	-2.18341423343288	23	1.37
32585818	Uncovering the Tumor Antigen Landscape: What to Know about the Discovery Process.	Cancers	2020	21.598493397488262	4.4382373196597324	15	0.86
32582792	Recombinant Expression and Purification of Extracellular Domain of the Programmed Cell Death Protein Receptor.	Reports of biochemistry & molecular biology	2020	-49.90077290125194	-28.57674302646235	1	0.1
32582176	Analysis of TCR Repertoire and PD-1 Expression in Decidual and Peripheral CD8+ T Cells Reveals Distinct Immune Mechanisms in Miscarriage and Preeclampsia.	Frontiers in immunology	2020	-77.02513841412902	-18.86231461235916	40	3.48
32581063	Immune checkpoint inhibitor-associated celiac disease.	Journal for immunotherapy of cancer	2020	73.86816599528555	-2.903523011376422	34	2.35
32581056	Combination treatment with radiotherapy and a novel oxidative phosphorylation inhibitor overcomes PD-1 resistance and enhances antitumor immunity.	Journal for immunotherapy of cancer	2020	29.2361874439512	-26.480950205203584	39	2.59
32581017	Morphoproteomics and Etiopathogenic Features of Pulmonary COVID-19 with Therapeutic Implications: A Case Study.	Annals of clinical and laboratory science	2020	-51.048792305651496	45.1727395833616	3	0.21
32580338	Combination of Ipilimumab and Nivolumab in Cancers: From Clinical Practice to Ongoing Clinical Trials.	International journal of molecular sciences	2020	32.9948375891666	8.230942726043494	54	3.86
32579975	Developing Covalent Protein Drugs via Proximity-Enabled Reactive Therapeutics.	Cell	2020	-44.22093682706912	-40.45223563114778	75	5.13
32579916	CD8+ T Cell Functional Exhaustion Overrides Pregnancy-Induced Fetal Antigen Alloimmunization.	Cell reports	2020	-77.29628142736044	-18.870596889570056	31	2.53
32579769	Tumor immune microenvironment and immune checkpoint inhibitors in esophageal squamous cell carcinoma.	Cancer science	2020	-5.867218319072001	26.40198549915117	117	8.37
32577817	Anlotinib optimizes anti-tumor innate immunity to potentiate the therapeutic effect of PD-1 blockade in lung cancer.	Cancer immunology, immunotherapy : CII	2020	27.5473916702964	-52.2833595539818	45	2.46
32572818	Clinical benefits of PD-1/PD-L1 inhibitors in advanced hepatocellular carcinoma: a systematic review and meta-analysis.	Hepatology international	2020	52.01440670463911	-14.985453976619612	22	1.63
32570793	PD-1 Immune Checkpoint Blockade Promotes Therapeutic Cancer Vaccine to Eradicate Lung Cancer.	Vaccines	2020	-27.291744832756297	-12.204688995065338	15	0.88
32570034	Gemcitabine and checkpoint blockade exhibit synergistic anti-tumor effects in a model of murine lung carcinoma.	International immunopharmacology	2020	28.23755971877404	-24.592641261713656	14	0.87
32568485	[Microbiota, cancer and immune therapy].	Revista medica del Instituto Mexicano del Seguro Social	2019	21.772062510084268	42.442435406201646	1	0.03
32568184	Effects of PD-1/PD-L1 signaling pathway on intestinal flora in patients with colorectal cancer.	Cancer biomarkers : section A of Disease markers	2020	-22.43881046638761	1.2866820460050992	3	0.19
32568023	Management of Immunotherapy Adverse Events in Oncological Patients: Anti-CTLA-4, Anti-PD-1/PD-L1.	Reviews on recent clinical trials	2020	79.89004064203415	-6.363808819831261	4	0.31
32565389	Circulating MicroRNAs and Extracellular Vesicle-Containing MicroRNAs as Response Biomarkers of Anti-programmed Cell Death Protein 1 or Programmed Death-Ligand 1 Therapy in NSCLC.	Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer	2020	3.1162046844266564	-38.71848932610605	37	2.81
32564263	Predictive Value of CD8 Expression and FoxP3 Methylation in Nasopharyngeal Carcinoma Patients Treated with Chemoradiotherapy in a Non-endemic Area.	Pathology oncology research : POR	2020	-15.168248364794923	31.54597329366426	3	0.19
32557663	Increased Expression of PD-1 and PD-L1 in Patients With Laryngotracheal Stenosis.	The Laryngoscope	2021	-9.755034681592024	-2.490941336769978	16	2.61
32555523	Analysis of Immune Checkpoint Drug Targets and Tumor Proteotypes in Non-Small Cell Lung Cancer.	Scientific reports	2020	23.667713831661896	-30.154125085871232	12	0.7
32555170	Tumor-induced neurogenesis and immune evasion as targets of innovative anti-cancer therapies.	Signal transduction and targeted therapy	2020	-26.026412614614248	10.892074234830424	88	6.46
32554931	Combination of PD-L1 and PVR determines sensitivity to PD-1 blockade.	JCI insight	2020	2.812062438907021	-20.596190104091438	24	1.53
32554614	Distinctive germline expression of class I human leukocyte antigen (HLA) alleles and DRB1 heterozygosis predict the outcome of patients with non-small cell lung cancer receiving PD-1/PD-L1 immune checkpoint blockade.	Journal for immunotherapy of cancer	2020	21.44554167984821	-25.4506742708083	26	1.77
32554516	A Bispecific DLL3/CD3 IgG-Like T-Cell Engaging Antibody Induces Antitumor Responses in Small Cell Lung Cancer.	Clinical cancer research : an official journal of the American Association for Cancer Research	2020	-15.863422541422729	-44.07272762235439	41	2.55
32554470	New emerging targets in cancer immunotherapy: the role of VISTA.	ESMO open	2020	22.355314233137364	57.96842954655049	23	1.56
32551915	Synergism Between Immunotherapy and Radiotherapy in Esophageal Cancer: An Overview of Current Knowledge and Future Perspectives.	Cancer biotherapy & radiopharmaceuticals	2021	55.22596440281481	15.150872294498944	9	1.02
32548905	Can Ipilimumab restore immune response in advanced NSCLC after progression on anti-PD-1/PD-L1 agents?	Thoracic cancer	2020	37.48139315819584	-25.79633492732369	3	0.12
32548224	Dataset on the identification of a prognostic radio-immune signature in surgically resected Non Small Cell Lung Cancer.	Data in brief	2020	11.494181894079478	-12.992707273149712	4	0.33
32547068	Anti-PD-1 Therapy Achieved Disease Control After Multiline Chemotherapy in Unresectable KRAS-Positive Hepatoid Lung Adenocarcinoma: A Case Report and Literature Review.	OncoTargets and therapy	2020	32.647934285399856	-53.3061691812529	17	1.49
32546692	Increased expression of PD-1 and PD-L1 in oral lesions progressing to oral squamous cell carcinoma: a pilot study.	Scientific reports	2020	-8.972005078241317	-12.246385956743174	41	3.43
32545559	Optimization of the Enrichment of Circulating Tumor Cells for Downstream Phenotypic Analysis in Patients with Non-Small Cell Lung Cancer Treated with Anti-PD-1 Immunotherapy.	Cancers	2020	10.204327569935971	-38.896051409237344	23	1.66
32544493	Immunomodulatory role for MicroRNAs: Regulation of PD-1/PD-L1 and CTLA-4 immune checkpoints expression.	Gene	2020	-19.06665824679113	0.3343924332384899	16	1.15
32542645	A dynamic mutational landscape associated with an inter-regionally diverse immune response in malignant rhabdoid tumour.	The Journal of pathology	2020	16.638447848924777	48.103862627928535	1	0.05
32542581	Patients with systemic lupus erythematosus show increased proportions of CD19+CD20- B cells and secretion of related autoantibodies.	Clinical rheumatology	2021	-53.67783077489909	11.07296501105614	5	0.58
32542563	Quantitative and Spatial Analysis of CD8+/PD-1 Tumor-Infiltrating Lymphocytes as a Predictive Biomarker for Clinical Response of Melanoma In-Transit Metastases to Topical Immunotherapy.	Annals of surgical oncology	2021	4.146886944591079	0.0140357007741444	4	0.74
32542150	Immune Checkpoint Inhibitors in Lung Cancer: Role of Biomarkers and Combination Therapies.	Cureus	2020	36.379333199417374	-22.540343135281773	17	1.17
32540858	Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors.	Journal for immunotherapy of cancer	2020	56.80374790635731	-23.305345823002177	65	3.91
32540726	Prognostic value of tissue-infiltrating immune cells in tumor microenvironment of follicular lymphoma: A meta-analysis.	International immunopharmacology	2020	-21.933125798317207	30.16701750130104	5	0.33
32540141	Epstein-Barr virus-negative inflammatory pseudotumor-like variant of follicular dendritic cell sarcoma of the liver: A case report and literature review.	Clinics and research in hepatology and gastroenterology	2021	-16.55753746810894	36.3126890271515	8	3.17
32535334	Low expressions of PD-L1 and CTLA-4 by induced CD4+CD25+ Foxp3+ Tregs in patients with SLE and their correlation with the disease activity.	Cytokine	2020	-67.22432857713257	4.83044333554905	11	0.82
32529584	HHV8-positive, EBV-positive Hodgkin lymphoma-like large B cell lymphoma: expanding the spectrum of HHV8 and EBV-associated lymphoproliferative disorders.	International journal of hematology	2020	-17.506986401140423	35.23768928617962	6	0.6
32529490	Spectrum and Clinical Activity of PD-1/PD-L1 Inhibitors: Regulatory Approval and Under Development.	Current oncology reports	2020	31.33566878256711	-3.441511174665947	8	0.52
32529292	Clinicopathological factors associated with tumor-infiltrating lymphocyte reactivity in breast cancer.	Cancer immunology, immunotherapy : CII	2020	-5.618646447266656	20.18312698645257	5	0.4
32528824	Epigenetic strategies synergize with PD-L1/PD-1 targeted cancer immunotherapies to enhance antitumor responses.	Acta pharmaceutica Sinica. B	2020	-36.905630354290906	-18.260465484099026	87	5.66
32528470	A New Strategy Toward B Cell-Based Cancer Vaccines by Active Immunization With Mimotopes of Immune Checkpoint Inhibitors.	Frontiers in immunology	2020	-25.14283876068101	-15.130196155860162	15	1.05
32528284	PD-1/PD-L1 Based Combinational Cancer Therapy: Icing on the Cake.	Frontiers in pharmacology	2020	28.109275422554703	-3.909277184290111	55	3.72
32528120	PD-L1 siRNA-mediated silencing in acute myeloid leukemia enhances anti-leukemic T cell reactivity.	Bone marrow transplantation	2020	-38.99642154387046	11.705662818558636	8	0.55
32527943	PD-1 Inhibitors: Do they have a Future in the Treatment of Glioblastoma?	Clinical cancer research : an official journal of the American Association for Cancer Research	2020	-29.19158310792857	59.37824118829676	69	4.46
32527929	Identification of PD1-mediated regulation of antitumor antigen response in patients with NSCLC using the trans vivo DTH assay.	Journal for immunotherapy of cancer	2020	4.591645978195473	-29.05089111959775	0	0.0
32526888	Combined PARP Inhibition and Immune Checkpoint Therapy in Solid Tumors.	Cancers	2020	34.464145087211904	39.90909102688666	111	7.12
32522567	Upregulation of programmed death ligand 1 by liver kinase B1 and its implication in programmed death 1 blockade therapy in non-small cell lung cancer.	Life sciences	2020	5.338353096094724	-30.813032058003397	18	1.14
32517311	Efficacy and Safety of Pembrolizumab for Gemcitabine/Cisplatin-Refractory Biliary Tract Cancer: A Multicenter Retrospective Study.	Journal of clinical medicine	2020	51.31202594055601	9.21185732420818	21	1.6
32516941	Non-Small-Cell Lung Cancer Signaling Pathways, Metabolism, and PD-1/PD-L1 Antibodies.	Cancers	2020	28.750089577026756	-32.13965033677169	57	3.69
32515579	Engineering Programmed Death Ligand-1/Cytotoxic T-Lymphocyte-Associated Antigen-4 Dual-Targeting Nanovesicles for Immunosuppressive Therapy in Transplantation.	ACS nano	2020	-38.590373495728976	-60.85189790010454	27	1.84
32515093	Predicting treatment response of patients with extranodal natural killer/T-cell lymphoma based on levels of PD-L1 mRNA and soluble PD-L1.	Hematological oncology	2020	-39.10470301997902	24.33614249601656	8	0.71
32514352	Chimeric antigen receptor T cells targeting PD-L1 suppress tumor growth.	Biomarker research	2020	-41.5288757471746	3.8841419441177982	33	2.09
32512320	Clinical relevance and prognostic significance of PD-1/PD-Ls in non-metastatic bladder cancer: A role for PD-L2.	Molecular immunology	2020	10.934898910199436	59.67801131626343	7	0.4
32508620	Checkpoint Inhibition Causing Complete Remission of Metastatic Combined Hepatocellular-Cholangiocarcinoma after Hepatic Resection.	Case reports in oncology	2020	54.498966072040666	24.37360897703637	13	1.11
32501724	Immunotherapy combinations for the treatment of patients with solid tumors.	Future oncology (London, England)	2020	27.108157568494256	1.1005507157932597	6	0.36
32500232	Exploratory open-label clinical study to determine the S-588410 cancer peptide vaccine-induced tumor-infiltrating lymphocytes and changes in the tumor microenvironment in esophageal cancer patients.	Cancer immunology, immunotherapy : CII	2020	5.573995170287924	20.44468311641229	12	0.86
32498695	Prognostic perspectives of PD-L1 combined with tumor-infiltrating lymphocytes, Epstein-Barr virus, and microsatellite instability in gastric carcinomas.	Diagnostic pathology	2020	-9.152795104590396	6.89190020295182	21	1.59
32497624	Regulation of PD-1 in T cells for cancer immunotherapy.	European journal of pharmacology	2020	-41.260787690461726	-11.459220393083214	21	1.44
32496434	Loss of MHC Class I Expression in HPV-associated Cervical and Vulvar Neoplasia: A Potential Mechanism of Resistance to Checkpoint Inhibition.	The American journal of surgical pathology	2020	0.9866837759799454	-9.432377566080891	14	1.04
32495519	Expression of classical human leukocyte antigen class I antigens, HLA-E and HLA-G, is adversely prognostic in pancreatic cancer patients.	Cancer science	2020	-0.8131744779016868	1.9723786260405367	23	1.62
32493990	Peripheral natural killer cells and myeloid-derived suppressor cells correlate with anti-PD-1 responses in non-small cell lung cancer.	Scientific reports	2020	18.87055211058576	-31.925439833081462	33	2.18
32493985	GATA2 Regulates Constitutive PD-L1 and PD-L2 Expression in Brain Tumors.	Scientific reports	2020	-25.04107373799544	52.42203859855093	17	1.16
32491995	High mutation load, immune-activated microenvironment, favorable outcome, and better immunotherapeutic efficacy in melanoma patients harboring MUC16/CA125 mutations.	Aging	2020	10.723156330009804	32.5708682409347	13	0.68
32489255	Nivolumab in metastatic melanoma: good efficacy and tolerability in elderly patients.	Current oncology (Toronto, Ont.)	2020	34.95954684006912	0.3350918719578324	6	0.37
32487090	The adaptive immune and immune checkpoint landscape of neoadjuvant treated esophageal adenocarcinoma using digital pathology quantitation.	BMC cancer	2020	4.778910931910689	21.690801256189864	18	1.22
32484797	Activation of CAR and non-CAR T cells within the tumor microenvironment following CAR T cell therapy.	JCI insight	2020	-44.86486083571763	5.186976987599699	41	2.19
32484460	PD-1 blockade inhibits osteoclast formation and murine bone cancer pain.	The Journal of clinical investigation	2020	-23.420918626211463	-5.956886862121016	67	5.32
32483468	Hepatoma cell-intrinsic TLR9 activation induces immune escape through PD-L1 upregulation in hepatocellular carcinoma.	Theranostics	2020	-21.27084468784533	-2.4105410174284017	20	1.32
32483460	Autoantibody profiling identifies predictive biomarkers of response to anti-PD1 therapy in cancer patients.	Theranostics	2020	18.10300730724964	-33.724614477681534	21	1.38
32481540	Serum PD-1/PD-L1 Levels, Tumor Expression and PD-L1 Somatic Mutations in HER2-Positive and Triple Negative Normal-Like Feline Mammary Carcinoma Subtypes.	Cancers	2020	-14.941664460262784	-15.485350834410388	29	2.56
32479254	The role of COL6A1and PD-1 expressions in renal cell carcinoma.	Turkish journal of urology	2020	16.6101540824052	26.207330239750977	3	0.21
32479189	Safety and Efficacy of Pembrolizumab With Chemoradiotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Phase IB Study.	Journal of clinical oncology : official journal of the American Society of Clinical Oncology	2020	52.90128333284757	6.883818338253175	68	4.37
32477462	Lymph nodes may be a source for immunetherapy in gastric cancer.	Oncotarget	2020	42.2694721649534	18.270763479404547	0	0.0
32477102	Commentary: Chronic PD-1 Checkpoint Blockade Does Not Affect Cognition or Promote Tau Clearance in a Tauopathy Mouse Model.	Frontiers in aging neuroscience	2020	-78.3359025240671	-5.554917646305887	2	0.17
32476052	Melanoma Cancer Immunotherapy Using PD-L1 siRNA and Imatinib Promotes Cancer-Immunity Cycle.	Pharmaceutical research	2020	-28.5804304652704	-47.846322011595056	16	1.36
35117748	The efficacy and safety of PD-1/PD-L1 inhibitors in breast cancer: a systematic review and meta-analysis.	Translational cancer research	2020	60.03690196705354	-14.451327168595428	6	0.4
32474752	Role of pleural and peritoneal metastasis in immune checkpoint inhibitors efficacy patients with non-small cell lung cancer: real-world data from a large cohort in France.	Journal of cancer research and clinical oncology	2020	44.90757934863473	-17.200523315691363	9	0.67
32474122	Exploration of a novel prognostic risk signatures and immune checkpoint molecules in endometrial carcinoma microenvironment.	Genomics	2020	1.1461306288170632	47.72112490759136	29	2.04
32472757	PLAP -CAR T cells mediate high specific cytotoxicity against colon cancer cells.	Frontiers in bioscience (Landmark edition)	2020	-39.27593496330493	4.617043622179028	11	0.76
32472456	High expression level of interleukin-1β is correlated with poor prognosis and PD-1 expression in patients with lung adenocarcinoma.	Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico	2021	8.381367008391969	-28.03325339256312	4	0.41
32472222	[Second-line treatment of metastatic urothelial carcinoma : Update immuno-oncology].	Der Urologe. Ausg. A	2020	68.75358778501477	17.50931990273393	3	0.19
32472221	[Immuno-oncological approaches in the perioperative therapy of muscle invasive bladder cancer].	Der Urologe. Ausg. A	2020	73.58300497312084	21.035718189389687	0	0.0
32471030	Soluble PD-L1 in NSCLC Patients Treated with Checkpoint Inhibitors and Its Correlation with Metabolic Parameters.	Cancers	2020	22.082699914317377	-28.076496003048696	19	1.3
32470632	The roles of programmed death ligand 1 in virus-associated cancers.	Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases	2020	-50.45930393728467	-18.48632687742728	12	0.91
32468061	Recombinant programmed cell death 1 inhibits psoriatic inflammation in imiquimod‑treated mice.	International journal of molecular medicine	2020	-60.04219339186665	-18.13741942976315	5	0.38
32468013	High expression of immune checkpoints is associated with the TIL load, mutation rate and patient survival in colorectal cancer.	International journal of oncology	2020	5.960004550084676	39.2706586002688	38	2.56
32467569	CS1003, a novel human and mouse cross-reactive PD-1 monoclonal antibody for cancer therapy.	Acta pharmacologica Sinica	2021	-41.92401048962098	-29.643236138475302	4	0.36
32464141	Importance of validating antibody panels: Anti-PD-L1 clone binds AF700 fluorophore.	Journal of immunological methods	2020	14.972262012443354	-43.411718856373255	3	0.33
32462248	[Checkpoint inhibitors in Hodgkin lymphoma].	Der Internist	2020	38.24673420212017	-7.795637079364283	1	0.05
32461994	The Efficacy and Safety of PD-1/PD-L1 Inhibitors in Combination with Conventional Therapies for Advanced Solid Tumors: A Meta-Analysis.	BioMed research international	2020	51.0810058819107	-12.97987464819723	6	0.47
32461344	Dual but not single PD-1 or TIM-3 blockade enhances oncolytic virotherapy in refractory lung cancer.	Journal for immunotherapy of cancer	2020	-36.22180622924335	51.296157737096216	28	1.76
32460355	Loss of core fucosylation enhances the anticancer activity of cytotoxic T lymphocytes by increasing PD-1 degradation.	European journal of immunology	2020	-34.841279711525594	-31.520513180951564	25	1.66
32459892	[The content of the soluble forms PD-1 and PD-L1 in blood serum of patients with gastric cancer and their relationship with clinical and morphological characteristics of the disease.].	Klinicheskaia laboratornaia diagnostika	2020	6.5465034428311695	6.902032956506634	5	0.32
32459310	EV PD-L1 is Correlated With Clinical Features and Contributes to T Cell Suppression in Pediatric Thyroid Cancer.	The Journal of clinical endocrinology and metabolism	2020	-7.292142146360761	-22.19320043216692	13	0.85
32458764	Safety evaluation of pembrolizumab for treating recurrent head and neck squamous cell carcinoma.	Expert opinion on drug safety	2020	52.92311265274686	6.727524193414824	4	0.36
32457754	Engineered IL-21 Cytokine Muteins Fused to Anti-PD-1 Antibodies Can Improve CD8+ T Cell Function and Anti-tumor Immunity.	Frontiers in immunology	2020	-40.47502933377123	-0.8780401192517245	26	1.57
32455628	Preparation of Biphenyl-Conjugated Bromotyrosine for Inhibition of PD-1/PD-L1 Immune Checkpoint Interactions.	International journal of molecular sciences	2020	-37.81991670413133	-41.48908615503015	6	0.42
32453005	PD1/PD-L1 therapy in metastatic renal cell carcinoma.	Current opinion in urology	2020	66.45019232221503	32.24783629684691	6	0.38
32451681	Development of CDX-527: a bispecific antibody combining PD-1 blockade and CD27 costimulation for cancer immunotherapy.	Cancer immunology, immunotherapy : CII	2020	-14.741359083022743	-46.85764741488476	12	0.64
32450594	Immunotherapy in Advanced Non-Small Cell Lung Cancer.	Seminars in respiratory and critical care medicine	2020	36.390154345816846	-31.708554575231613	3	0.23
32450532	Highly pathogenic H7N9 avian influenza virus infection associated with up-regulation of PD-1/PD-Ls pathway-related molecules.	International immunopharmacology	2020	-77.93496796045872	6.885936071207277	6	0.59
32450531	Recent advances and challenges of immune checkpoint inhibitors in immunotherapy of non-small cell lung cancer.	International immunopharmacology	2020	36.51552404056173	-21.841240343362053	20	1.36
32450493	Correlation between the expression of folate receptor alpha (FRα) and clinicopathological features in patients with lung adenocarcinoma.	Lung cancer (Amsterdam, Netherlands)	2020	16.54378629494126	-55.347531223039326	4	0.27
32449240	Differences in the immunosurveillance pattern associated with DNA mismatch repair status between right-sided and left-sided colorectal cancer.	Cancer science	2020	11.409688494612576	37.56191890448383	16	1.2
32449226	Successful treatment of unresectable recurrent cutaneous squamous cell carcinoma of the scalp with meningeal invasion with nivolumab monotherapy.	Dermatologic therapy	2020	56.37963652634326	6.571836644423063	5	0.39
32448984	PD-L1 expression correlates with tumor-infiltrating lymphocytes and better prognosis in patients with HPV-negative head and neck squamous cell carcinomas.	Cancer immunology, immunotherapy : CII	2020	-3.714280710043525	-8.34455250906953	32	2.24
32448798	Cytotoxic T-cell-related gene expression signature predicts improved survival in muscle-invasive urothelial bladder cancer patients after radical cystectomy and adjuvant chemotherapy.	Journal for immunotherapy of cancer	2020	5.820182612040115	58.50950228622288	36	2.13
32446718	The immune suppressive factors CD155 and PD-L1 show contrasting expression patterns and immune correlates in ovarian and other cancers.	Gynecologic oncology	2020	-5.034583451775791	28.84532234877989	18	0.99
32446372	Crystal structure of PD-1 in complex with an antibody-drug tislelizumab used in tumor immune checkpoint therapy.	Biochemical and biophysical research communications	2020	-46.95060991431525	-35.06506982800609	13	0.82
32446182	Real world data in the era of Immune Checkpoint Inhibitors (ICIs): Increasing evidence and future applications in lung cancer.	Cancer treatment reviews	2020	37.67536289876274	-20.707106868863864	71	4.86
32443877	Combined Anti-Cancer Strategies Based on Anti-Checkpoint Inhibitor Antibodies.	Antibodies (Basel, Switzerland)	2020	32.74672906505515	11.720960358949652	13	0.94
32440897	Adamantinomatous craniopharyngioma in the molecular age and the potential of targeted therapies: a review.	Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery	2020	20.24271679846679	53.03386409488973	11	1.41
32435885	High PD-1 expression level is associated with an unfavorable prognosis in patients with cervical adenocarcinoma.	Archives of gynecology and obstetrics	2020	1.4774769051122254	-11.023033264482052	9	0.6
32433762	Combination rhIL-15 and Anti-PD-L1 (Avelumab) Enhances HIVGag-Specific CD8 T-Cell Function.	The Journal of infectious diseases	2020	-84.64443826468006	16.366767675545734	6	0.36
32433601	Association of tumour and stroma PD-1, PD-L1, CD3, CD4 and CD8 expression with DCB and OS to nivolumab treatment in NSCLC patients pre-treated with chemotherapy.	British journal of cancer	2020	11.362662249944684	-18.915889313371466	22	1.26
32433005	Immune Checkpoint Inhibitors in Patients with Recurrent Hepatocellular Carcinoma after Liver Transplantation: A Case Report and Literature Review.	Current cancer drug targets	2020	29.033096152765744	47.89003552230439	10	0.67
32430866	PD-L1 expression correlation with metabolic parameters of FDG PET/CT and clinicopathological characteristics in non-small cell lung cancer.	EJNMMI research	2020	14.799903748771667	-56.09489589592791	17	1.5
32430334	Polygenic risk for skin autoimmunity impacts immune checkpoint blockade in bladder cancer.	Proceedings of the National Academy of Sciences of the United States of America	2020	73.8231881047563	-20.06251093133812	51	3.09
32430039	PD1/PD-L1 targeting in advanced soft-tissue sarcomas: a pooled analysis of phase II trials.	Journal of hematology & oncology	2020	41.54409432228647	-12.85827516807836	35	2.31
32430031	MHC-I genotype and tumor mutational burden predict response to immunotherapy.	Genome medicine	2020	24.45652989772689	-15.663180589930294	55	3.1
32429929	Exploratory analysis of immune checkpoint receptor expression by circulating T cells and tumor specimens in patients receiving neo-adjuvant chemotherapy for operable breast cancer.	BMC cancer	2020	3.719421025363857	24.60743525542019	10	0.64
32429721	Development and Evaluation of Novel Aptamers Specific for Human PD1 Using Hybrid Systematic Evolution of Ligands by Exponential Enrichment Approach.	Immunological investigations	2020	-25.00371205846145	-60.5436393671133	7	0.56
32429078	Co-Expression of Androgen Receptor and Cathepsin D Defines a Triple-Negative Breast Cancer Subgroup with Poorer Overall Survival.	Cancers	2020	7.384172502169783	26.060506745599945	11	0.78
32427579	Differential effects of PD-L1 versus PD-1 blockade on myeloid inflammation in human cancer.	JCI insight	2020	-32.58631405461588	5.3514249637978	33	2.07
32426177	Heterogeneity of exhausted T cells in the tumor microenvironment is linked to patient survival following resection in hepatocellular carcinoma.	Oncoimmunology	2020	-15.5028076933258	42.69836503391507	18	0.96
32426052	Association of immune-related pneumonitis with the efficacy of PD-1/PD-L1 inhibitors in non-small cell lung cancer.	Therapeutic advances in medical oncology	2020	66.07561578916432	-8.907063218330658	22	1.58
32424951	Opportunities for using in silico-based extended dosing regimens for monoclonal antibody immune checkpoint inhibitors.	British journal of clinical pharmacology	2020	32.63787314256385	-10.502875651515044	20	1.21
32424876	PD-L1 expression on tumor or stromal cells of nodal cytotoxic T-cell lymphoma: A clinicopathological study of 50 cases.	Pathology international	2020	-36.72236656653202	29.58383776115808	3	0.27
32424467	Galectin-9 expression as a poor prognostic factor in patients with renal cell carcinoma.	Cancer immunology, immunotherapy : CII	2020	18.321878941340696	28.416446308796417	11	0.91
32423643	Safety and efficacy of immune checkpoint inhibitors in patients with non-small cell lung cancer and hepatitis B or hepatitis C infection.	Lung cancer (Amsterdam, Netherlands)	2020	75.31129116411775	2.03535962507509	28	1.71
32422527	Blocking PD-1/PD-L1 by an ADCC enhanced anti-B7-H3/PD-1 fusion protein engages immune activation and cytotoxicity.	International immunopharmacology	2020	-15.207575721268269	-46.64474173179651	12	0.84
32421452	Checkpoint Blockade in Lung Cancer With Driver Mutation: Choose the Road Wisely.	American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting	2020	32.67089680979655	-27.073769896993426	57	3.4
32421224	Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.	Thoracic cancer	2020	38.63930229975127	-19.39558780749963	36	2.56
32420897	[Molecular docking study and experimental evaluation of potential CTLA-4 binding peptides].	Biomeditsinskaia khimiia	2020	-46.05738019542382	-47.44588893512661	0	0.0
32416431	Ongoing challenges of using immunotherapy in special populations: Poor performance status patients, elderly patients, and people living with HIV.	Lung cancer (Amsterdam, Netherlands)	2020	36.21410554799204	-19.882466960237544	8	0.54
32411795	Overexpression of an Immune Checkpoint (CD155) in Breast Cancer Associated with Prognostic Significance and Exhausted Tumor-Infiltrating Lymphocytes: A Cohort Study.	Journal of immunology research	2020	-6.471580707180917	23.630412062528222	23	1.57
32411711	Low Expression of Programmed Death 1 (PD-1), PD-1 Ligand 1 (PD-L1), and Low CD8+ T Lymphocyte Infiltration Identify a Subgroup of Patients With Gastric and Esophageal Adenocarcinoma With Severe Prognosis.	Frontiers in medicine	2020	-11.059173077433528	6.844357652932381	12	0.79
32409191	Infiltrating immune cells are associated with radiosensitivity and favorable survival in head and neck cancer treated with definitive radiotherapy.	Oral surgery, oral medicine, oral pathology and oral radiology	2020	-9.814759810355062	32.13198868172473	7	0.47
32407144	An evaluation of avelumab for the treatment of genitourinary tumors.	Expert opinion on biological therapy	2020	66.84502144113823	24.15830321469964	3	0.14
32403421	HIP1R Expression and Its Association with PD-1 Pathway Blockade Response in Refractory Advanced NonSmall Cell Lung Cancer: A Gene Set Enrichment Analysis.	Journal of clinical medicine	2020	10.84152305961907	-31.65336237904296	5	0.38
32402359	Advances in the Treatment of Non-Small Cell Lung Cancer: Immunotherapy.	Clinics in chest medicine	2020	37.25287504787963	-31.67819556807021	32	2.34
32400116	The Synthesis and Anti-tumour Properties of Poly Ethoxy Ethyl Glycinamide (PEE-G) Scaffolds with Multiple PD-1 Peptides Attached.	ChemMedChem	2020	-43.58155187634802	-45.37334079193355	3	0.25
32396855	Expanding the Role for Immunotherapy in Triple-Negative Breast Cancer.	Cancer cell	2020	41.11065430724626	7.404996067772203	27	1.62
32396847	Developmental Relationships of Four Exhausted CD8+ T Cell Subsets Reveals Underlying Transcriptional and Epigenetic Landscape Control Mechanisms.	Immunity	2020	-47.560360203922905	12.901101949713984	363	19.93
32395289	The impact of immune-inflammation-nutritional parameters on the prognosis of non-small cell lung cancer patients treated with atezolizumab.	Journal of thoracic disease	2020	30.02941420378464	-44.16085409511401	45	3.32
32394281	Radiomics-based prediction model for outcomes of PD-1/PD-L1 immunotherapy in metastatic urothelial carcinoma.	European radiology	2020	10.820625281090823	-10.65720477426134	33	2.39
32394185	PD-1/PD-L1 Pathway and Its Blockade in Patients with Classic Hodgkin Lymphoma and Non-Hodgkin Large-Cell Lymphomas.	Current hematologic malignancy reports	2020	-43.98400493316179	-10.552933885005215	36	2.59
32393474	Overcoming resistance to anti-PD1 and anti-PD-L1 treatment in gastrointestinal malignancies.	Journal for immunotherapy of cancer	2020	41.06617069708432	19.879343918117115	25	1.42
32392774	Immunotherapy in Bladder Cancer: Current Methods and Future Perspectives.	Cancers	2020	70.21545726972069	21.76049139385221	49	3.86
32391629	Blocking interaction between SHP2 and PD-1 denotes a novel opportunity for developing PD-1 inhibitors.	EMBO molecular medicine	2020	-38.469477523047246	-39.23351106770233	23	1.55
32391001	4-1BB Agonism Combined With PD-L1 Blockade Increases the Number of Tissue-Resident CD8+ T Cells and Facilitates Tumor Abrogation.	Frontiers in immunology	2020	-27.84281102160931	-18.66783601543259	18	1.11
35757235	Development and applications of computer image analysis algorithms for scoring of PD-L1 immunohistochemistry.	Immuno-oncology technology	2020	6.614793520343983	-48.672649877717554	13	0.9
32388240	Mechanism and potential predictive biomarkers of immune checkpoint inhibitors in NSCLC.	Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie	2020	25.149545963137108	-36.03279193812417	26	1.76
32387103	Tumor mutation burden and checkpoint immunotherapy markers in primary and metastatic synovial sarcoma.	Human pathology	2020	7.926988650353808	18.25270447161992	22	1.48
32386458	Trophoblast-secreted soluble-PD-L1 modulates macrophage polarization and function.	Journal of leukocyte biology	2020	-75.23429410493313	-17.824976625235916	37	3.66
32386245	A Novel d-Peptide Identified by Mirror-Image Phage Display Blocks TIGIT/PVR for Cancer Immunotherapy.	Angewandte Chemie (International ed. in English)	2020	-41.50822449700112	-45.2145004266448	49	3.51
32383556	Characterization of the immune profile of oral tongue squamous cell carcinomas with advancing disease.	Cancer medicine	2020	-7.010713312683504	33.17192569683478	19	1.66
32383351	Immune Escape Mediated by Exosomal PD-L1 in Cancer.	Advanced biosystems	2020	-39.970213925518586	-58.90536093544439	17	1.31
32382290	Circulating CD14+HLA-DR-/low Myeloid-Derived Suppressor Cells as Potential Biomarkers for the Identification of Psoriasis TCM Blood-Heat Syndrome and Blood-Stasis Syndrome.	Evidence-based complementary and alternative medicine : eCAM	2020	-51.18835421724439	29.045757103200675	2	0.18
32382051	Immune-related adverse events of checkpoint inhibitors.	Nature reviews. Disease primers	2020	78.25267641945439	-8.696886753114345	475	34.6
32381551	MAPK pathway mutations in head and neck cancer affect immune microenvironments and ErbB3 signaling.	Life science alliance	2020	-9.81001579365748	36.33666971016057	21	1.54
32380498	Prognostic Significance of PD-1, PD-L1 and CD8 Gene Expression Levels in Gastric Cancer.	Oncology	2020	-9.279081015837605	5.852207127722537	10	0.78
32380346	Immune Checkpoint Inhibition Followed by Tumor Infiltration of Dendritic Cells in Murine Neuro-2a Neuroblastoma.	The Journal of surgical research	2020	-26.800061690813	14.237518565611031	3	0.19
32379397	Compromise or not? A case report of successful treatment of pembrolizumab-induced hepatitis in a patient with non-small cell lung cancer with low-dose methylprednisolone and bicyclol.	Thoracic cancer	2020	51.17866153843552	-30.78177044373187	3	0.31
32378480	Non-coding RNA and immune-checkpoint inhibitors: friends or foes?	Immunotherapy	2020	14.966344811014425	19.63698043026709	11	0.75
32377193	Recent Findings in the Posttranslational Modifications of PD-L1.	Journal of oncology	2020	-45.0333725554094	-23.13533482191683	11	0.73
32376724	Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial.	Journal for immunotherapy of cancer	2020	54.50448086616804	-1.4109595173165697	63	4.63
32376419	Pharmacologic Activation of the G Protein-Coupled Estrogen Receptor Inhibits Pancreatic Ductal Adenocarcinoma.	Cellular and molecular gastroenterology and hepatology	2020	-23.61763067459187	4.186984723333624	26	2.2
32375257	Kaempferol and Its Glycoside, Kaempferol 7-O-Rhamnoside, Inhibit PD-1/PD-L1 Interaction In Vitro.	International journal of molecular sciences	2020	-31.63806749791698	-38.399433586761134	17	1.65
32372672	A metastatic intrahepatic cholangiocarcinoma treated with programmed cell death 1 inhibitor: a case report and literature review.	Immunotherapy	2020	56.35022998892142	21.490967779781027	10	0.6
32368308	IL-2 enhanced MHC class I expression in papillary thyroid cancer with Hashimoto's thyroiditis overcomes immune escape in vitro.	Journal of Cancer	2020	-62.420180474279285	-33.2686793761125	7	0.51
32368180	Biomarkers of immune checkpoint inhibitor efficacy in cancer.	Current oncology (Toronto, Ont.)	2020	19.470150966442127	-3.0247766291109315	16	0.93
32368175	Cautious optimism-the current role of immunotherapy in gastrointestinal cancers.	Current oncology (Toronto, Ont.)	2020	40.964255398547294	18.82375158897053	3	0.19
32366834	Prognostic factors, therapeutic approaches, and distinct immunobiologic features in patients with primary mediastinal large B-cell lymphoma on long-term follow-up.	Blood cancer journal	2020	43.83141168767718	-8.523180365375584	26	1.96
32366559	Plasmablastic Lymphomas: Characterization of Tumor Microenvironment Using CD163 and PD-1 Immunohistochemistry.	Annals of clinical and laboratory science	2020	-30.776432059066384	33.52302179823933	2	0.2
32365500	Inhibition of Programmed Death Receptor-1/Programmed Death Ligand-1 Interactions by Ginsenoside Metabolites.	Molecules (Basel, Switzerland)	2020	-27.17880522580297	-37.11576404872781	7	0.72
32364844	PD-1 Blockade in Anaplastic Thyroid Carcinoma.	Journal of clinical oncology : official journal of the American Society of Clinical Oncology	2020	53.80715907098216	-5.822762947666632	125	9.16
32363119	CD19-targeting fusion protein combined with PD1 antibody enhances anti-tumor immunity in mouse models.	Oncoimmunology	2020	-26.54901628368056	-15.257969225278	6	0.54
32360716	Dermatologic toxicities to immune checkpoint inhibitor therapy: A review of histopathologic features.	Journal of the American Academy of Dermatology	2020	74.14299855476958	-24.7729451344472	66	5.28
32355741	Alterations of the tumor microenvironment in glioblastoma following radiation and temozolomide with or without bevacizumab.	Annals of translational medicine	2020	-31.144539160680075	51.82327684601281	10	0.68
32353687	CD30L/CD30 signaling regulates the formation of the tumor immune microenvironment and inhibits intestinal tumor development of colitis-associated colon cancer in mice.	International immunopharmacology	2020	4.39025993741104	38.9293624200773	7	0.55
32352272	mRNA Display Discovery of a Novel Programmed Death Ligand 1 (PD-L1) Binding Peptide (a Peptide Ligand for PD-L1).	ACS chemical biology	2020	-43.953533837219496	-42.154560553360135	7	0.63
32351619	[Side effects of novel cancer immunotherapies].	Der nephrologe	2020	77.25216354007017	-9.088945257758514	1	0.07
32351559	Analysis of Blimp-1 and PD-1/PD-L1 Immune Checkpoint in an Autoimmune Thyroiditis Animal Model.	International journal of endocrinology	2020	-72.89406016559145	-19.20849330662536	3	0.21
32350779	Neurological adverse effects due to programmed death 1 (PD-1) inhibitors.	Journal of neuro-oncology	2020	74.22093963788429	-15.645988451191132	7	0.6
32350416	Evaluation of glucocorticoid-induced TNF receptor (GITR) expression in breast cancer and across multiple tumor types.	Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc	2020	-1.4443061379705928	23.794400156374643	18	1.22
32349374	Scientific Rationale for Combined Immunotherapy with PD-1/PD-L1 Antibodies and VEGF Inhibitors in Advanced Hepatocellular Carcinoma.	Cancers	2020	39.01797260461435	13.723705489492366	98	6.48
32349280	Increase in Efficacy of Checkpoint Inhibition by Cytokine-Induced-Killer Cells as a Combination Immunotherapy for Renal Cancer.	International journal of molecular sciences	2020	26.022169678675205	-8.781473006031176	11	0.72
32348468	IL-10 Restores MHC Class I Expression and Interferes With Immunity in Papillary Thyroid Cancer With Hashimoto Thyroiditis.	Endocrinology	2020	-62.42165092606031	-33.274014498197864	7	0.64
32347357	Anti-angiogenesis therapy overcomes the innate resistance to PD-1/PD-L1 blockade in VEGFA-overexpressed mouse tumor models.	Cancer immunology, immunotherapy : CII	2020	17.668380458674907	13.281241760410737	41	2.7
32346937	N-glycosylation controls inflammatory licensing-triggered PD-L1 upregulation in human mesenchymal stromal cells.	Stem cells (Dayton, Ohio)	2020	-54.89709401490824	21.51340130275985	7	0.6
32346701	[Temporal expression of PD-1 and PD-L1 during the development of experimental periodontitis in rats and its implications].	Shanghai kou qiang yi xue = Shanghai journal of stomatology	2019	-65.44811735005283	-21.03816982682212	1	0.1
32342665	Relationship between the efficacy of immunotherapy and characteristics of specific tumor mutation genes in non-small cell lung cancer patients.	Thoracic cancer	2020	25.57234405947551	-21.10320845159344	16	0.96
32340913	Inclusion of PD-L1 into a recombinant profilin antigen enhances immunity against Babesia microti in a murine model.	Ticks and tick-borne diseases	2020	-56.56327671197865	-27.699238108965847	3	0.41
32340783	Clinical pharmacology of monoclonal antibodies targeting PD-1 axis in urothelial cancers.	Critical reviews in oncology/hematology	2020	70.52015348825213	15.798612104645713	3	0.08
32336542	Effect of the hairpin structure of peptide inhibitors on the blockade of PD-1/PD-L1 axis.	Biochemical and biophysical research communications	2020	-43.55262079848867	-44.06388890308765	5	0.5
32335702	In-depth characterization of the tumor microenvironment in central nervous system lymphoma reveals implications for immune-checkpoint therapy.	Cancer immunology, immunotherapy : CII	2020	-32.28358567849907	32.08590286214491	28	1.83
32334621	Ovarian endometrioma infiltrating neutrophils orchestrate immunosuppressive microenvironment.	Journal of ovarian research	2020	-1.4914883708014557	32.89892445464582	6	0.73
32330687	Prognostic and clinicopathological significance of PD-L1 overexpression in oral squamous cell carcinoma: A systematic review and comprehensive meta-analysis.	Oral oncology	2020	-7.016766727682627	-11.73764643048897	40	3.07
32329229	Relationship between intestinal flora structure and metabolite analysis and immunotherapy efficacy in Chinese NSCLC patients.	Thoracic cancer	2020	23.505717314152218	41.16863231717839	33	1.97
32329119	Immune-related hepatitis related to checkpoint inhibitors: Clinical and prognostic factors.	Liver international : official journal of the International Association for the Study of the Liver	2020	75.37993155888415	0.2933550758753724	32	2.27
32328190	Comprehensive Analysis of the Tumor Microenvironment in Cutaneous Melanoma associated with Immune Infiltration.	Journal of Cancer	2020	4.022407740408721	17.145684319158637	15	1.27
32324435	Neoadjuvant Nivolumab for Patients With Resectable Merkel Cell Carcinoma in the CheckMate 358 Trial.	Journal of clinical oncology : official journal of the American Society of Clinical Oncology	2020	46.976353275127735	50.17257518016284	114	7.06
32322636	Data analysis of PD-1 antibody in the treatment of melanoma patients.	Data in brief	2020	8.309577377299318	-4.864031548834789	2	0.18
32321714	Safety, Efficacy, and Biomarker Analysis of Toripalimab in Previously Treated Advanced Melanoma: Results of the POLARIS-01 Multicenter Phase II Trial.	Clinical cancer research : an official journal of the American Association for Cancer Research	2020	57.11843605422155	-4.753284464805795	78	4.56
32320192	Intracellular mechanisms of tumor cells' immunoresistance.	Acta biochimica Polonica	2020	19.963495567327385	12.896581105035912	1	0.11
32319666	Molecularly targeted therapy and immunotherapy for hormone receptor‑positive/human epidermal growth factor receptor 2‑negative advanced breast cancer (Review).	Oncology reports	2020	22.36567255244309	-1.624656045655252	4	0.26
32317979	Resistance to PD-L1/PD-1 Blockade Immunotherapy. A Tumor-Intrinsic or Tumor-Extrinsic Phenomenon?	Frontiers in pharmacology	2020	-35.6781054226515	-20.96637612229281	42	2.97
32317723	Alternative macrophage polarisation associated with resistance to anti-PD1 blockade is possibly supported by the splicing of FKBP51 immunophilin in melanoma patients.	British journal of cancer	2020	-1.6264815835694428	-17.65773063285558	8	0.51
32316893	Immune Checkpoint Inhibitors in AML-A New Frontier.	Current cancer drug targets	2020	18.407821110375718	17.1644725304474	3	0.2
32314040	Prevalence of PD-L1 expression is associated with EMAST, density of peritumoral T-cells and recurrence-free survival in operable non-metastatic colorectal cancer.	Cancer immunology, immunotherapy : CII	2020	9.308120216569886	40.76807391043116	10	0.65
32313724	Liver metastases and the efficacy of the PD-1 or PD-L1 inhibitors in cancer: a meta-analysis of randomized controlled trials.	Oncoimmunology	2020	52.33746280014918	-14.232270019799248	14	0.79
32312056	Prospect of immunotherapy in neoadjuvant/adjuvant treatment for early breast cancer.	Chinese clinical oncology	2020	40.59558135198745	9.23395590764996	4	0.25
32311294	Tumor Mutation Burden Computation in Two Pan-Cancer Precision Medicine Next-Generation Sequencing Panels.	Journal of computational biology : a journal of computational molecular cell biology	2020	6.712913384153433	50.082718450513504	2	0.06
32309817	High intensity interval exercise increases the frequency of peripheral PD-1+ CD8+ central memory T-cells and soluble PD-L1 in humans.	Brain, behavior, & immunity - health	2020	-71.19464858411799	11.38963582033438	11	1.07
32308409	Combination Strategies of Checkpoint Immunotherapy in Metastatic Breast Cancer.	OncoTargets and therapy	2020	23.33472700746433	-1.1528420674965585	8	0.54
32306637	[Programmed cell death protein 1 and its ligands regulate immune balance in allergic rhinitis].	Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery	2020	-65.75949143572426	-25.746229322400943	4	0.4
32306409	Combinatorial Tim-3 and PD-1 activity sustains antigen-specific Th1 cell numbers during blood-stage malaria.	Parasite immunology	2020	-75.10657221372594	2.6044929301276496	8	0.58
32304268	Immune-checkpoint molecules on regulatory T-cells as a potential therapeutic target in head and neck squamous cell cancers.	Cancer science	2020	14.76132256527603	16.76397050044366	23	1.55
32303964	Effectiveness of PD-1/PD-L1 inhibitors in the treatment of lung cancer: Brightness and challenge.	Science China. Life sciences	2020	42.32118214043184	-30.785271209186355	18	1.4
32303615	Viral status, immune microenvironment and immunological response to checkpoint inhibitors in hepatocellular carcinoma.	Journal for immunotherapy of cancer	2020	26.258267165051333	47.81274328647506	34	2.22
32302443	Uptake of positron emission tomography tracers reflects the tumor immune status in esophageal squamous cell carcinoma.	Cancer science	2020	15.443351154510276	-57.91701596483432	10	0.56
32299915	SHP-2 and PD-L1 Inhibition Combined with Radiotherapy Enhances Systemic Antitumor Effects in an Anti-PD-1-Resistant Model of Non-Small Cell Lung Cancer.	Cancer immunology research	2020	29.241007509872475	-26.475964723227715	39	2.55
32299612	Preparation of engineered extracellular vesicles with full-length functional PD-1 membrane proteins by baculovirus expression system.	Biochemical and biophysical research communications	2020	-37.87288053817141	-58.33870122133277	4	0.37
32298485	Programmed cell death-1 (PD-1) and programmed death-ligand 1 (PD-L1) expression in PD-1 inhibitor-associated colitis and its mimics.	Histopathology	2020	-59.923801761108486	20.153437005902905	9	0.67
32296919	PD-1+ natural killer cells in human non-small cell lung cancer can be activated by PD-1/PD-L1 blockade.	Cancer immunology, immunotherapy : CII	2020	-33.97421467212976	0.2312584774156953	45	2.91
32295784	Dual Relief of T-lymphocyte Proliferation and Effector Function Underlies Response to PD-1 Blockade in Epithelial Malignancies.	Cancer immunology research	2020	-45.79770711613986	11.769559257858496	14	0.79
32295735	The Triple Positivity for EBV, PD-1, and PD-L1 Identifies a Very High Risk Classical Hodgkin Lymphoma.	Clinical lymphoma, myeloma & leukemia	2020	-38.12979891099848	26.98140296533064	4	0.44
32285442	Development and validation of a stromal immune phenotype classifier for predicting immune activity and prognosis in triple-negative breast cancer.	International journal of cancer	2020	2.097199922137144	45.48273826716665	30	1.81
32284756	Determination of the Expression of PD-L1 in the Morphologic Spectrum of Renal Cell Carcinoma.	Journal of Cancer	2020	18.26682576864718	26.68090004265356	14	1.1
32284250	Association of serine/threonine kinase 11 mutations and response to programmed cell death 1 inhibitors in metastatic gastric cancer.	Pathology, research and practice	2020	18.47669103678403	-21.68693009588117	10	0.69
32281417	TCR+CD4-CD8- (double negative) T cells protect from cisplatin-induced renal epithelial cell apoptosis and acute kidney injury.	American journal of physiology. Renal physiology	2020	-58.15088260610919	27.8377573961244	11	0.87
32279526	A retrospective study of immune checkpoint inhibitor-associated myocarditis in a single center in China.	Chinese clinical oncology	2020	84.49077195547179	1.0033713649221805	17	1.22
32278982	Tumour mutational burden as a biomarker for immunotherapy: Current data and emerging concepts.	European journal of cancer (Oxford, England : 1990)	2020	23.31873473452052	-15.407081934896576	117	7.39
32278215	Immune checkpoint inhibitors in special populations. A focus on advanced lung cancer patients.	Lung cancer (Amsterdam, Netherlands)	2020	36.23734337818715	-19.81513696778616	4	0.25
32277641	The effect of PD-L1 status on survival outcomes in patients with stage II-III non-small cell lung cancer treated with chemotherapy.	Journal of B.U.ON. : official journal of the Balkan Union of Oncology	2020	13.13652589497064	-28.59691612360845	1	0.13
32277609	Combining immune checkpoint inhibitors with denosumab: a new era in repurposing denosumab in oncology?	Journal of B.U.ON. : official journal of the Balkan Union of Oncology	2020	29.69592979026937	17.264572629286256	2	0.18
32277010	Prognostic significance of immune checkpoints in the tumour-stromal microenvironment of sebaceous gland carcinoma.	The British journal of ophthalmology	2021	-0.3889903478891705	-0.6893911083398415	4	0.79
32276643	In vitro cell culture of patient derived malignant pleural and peritoneal effusions for personalised drug screening.	Journal of translational medicine	2020	6.853627042548228	14.845110829308922	5	0.37
32275976	PD-1, PD-L1, and BIM as Predictors of Sentinel Lymph Node Metastasis in Primary Cutaneous Melanoma.	The Journal of investigative dermatology	2020	6.98934102783151	-0.5858362413553723	0	0.0
32275681	STAT1 as a potential prognosis marker for poor outcomes of early stage colorectal cancer with microsatellite instability.	PloS one	2020	8.591168457389376	41.79752300797112	17	1.6
32275468	Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study.	Journal of clinical oncology : official journal of the American Society of Clinical Oncology	2020	37.67673795421415	1.901802017399128	160	10.98
32273478	Genetic lesions in MYC and STAT3 drive oncogenic transcription factor overexpression in plasmablastic lymphoma.	Haematologica	2021	-30.655310499073	33.36146455436884	30	3.71
32271672	Randomized Double-Blind Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer.	Journal of clinical oncology : official journal of the American Society of Clinical Oncology	2020	67.09540661750955	14.92398866236164	80	4.46
32271353	Assessment of the Feasibility and Safety of Durvalumab for Treatment of Solid Tumors in Patients With HIV-1 Infection: The Phase 2 DURVAST Study.	JAMA oncology	2020	60.81796417720958	3.7334151472853216	50	3.07
32270230	Neuroendocrine tumours and their microenvironment.	Cancer immunology, immunotherapy : CII	2020	0.6741026320225468	13.457800717685211	9	0.69
32269065	Differential expression of the T-cell inhibitor TIGIT in glioblastoma and MS.	Neurology(R) neuroimmunology & neuroinflammation	2020	-26.837509469456656	55.78207839556827	20	1.3
35005121	The role of distinct co-mutation patterns with TP53 mutation in immunotherapy for NSCLC.	Genes & diseases	2022	19.76976876733649	-20.846021605012574	8	0.52
32268011	Increased expression of immune checkpoint programmed cell death protein-1 (PD-1) on T cell subsets of bone marrow aspirates in patients with B-Lymphoblastic leukemia, especially in relapse and at diagnosis.	Cytometry. Part B, Clinical cytometry	2020	-36.38571019059411	15.906362800220972	8	0.51
32267920	Spatial architecture of tumour-infiltrating lymphocytes as a prognostic parameter in resected non-small-cell lung cancer.	European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery	2020	0.369779299014554	19.655541828073485	12	0.77
32266446	Expression of the immune checkpoint VISTA in breast cancer.	Cancer immunology, immunotherapy : CII	2020	-38.967277468981685	37.41023249347059	39	2.38
32266275	Immunotherapy: From Advanced NSCLC to Early Stages, an Evolving Concept.	Frontiers in medicine	2020	41.49004948907493	-33.0730981133976	24	1.67
32266087	PD-1/PD-L1 pathway: current researches in cancer.	American journal of cancer research	2020	-45.26886712233368	-15.696420676524552	603	48.26
32265932	The Role of PD-1 in Acute and Chronic Infection.	Frontiers in immunology	2020	-48.24592703929388	-14.16689578411574	115	8.23
32260561	Current Insights into Combination Therapies with MAPK Inhibitors and Immune Checkpoint Blockade.	International journal of molecular sciences	2020	29.534789073970227	32.03627662572613	41	3.13
32259363	Evaluation of PD-L1, PD-L2, PD-1 and cytotoxic immune response in oral lichen planus.	Oral diseases	2020	-63.26351449779848	-17.00916843171042	7	0.7
32257944	Treatment-Related Adverse Events of Combination Immune Checkpoint Inhibitors: Systematic Review and Meta-Analysis.	Frontiers in oncology	2020	72.67005532645197	-6.348115067459762	28	1.64
32256205	A pooled analysis of the prognostic value of PD-L1 in melanoma: evidence from 1062 patients.	Cancer cell international	2020	6.64589673321757	-2.137189406751277	18	1.23
32255257	Development and functional analysis of an anticancer T-cell medicine with immune checkpoint inhibitory ability.	IUBMB life	2020	-42.1470604701721	-5.565941208293539	1	0.08
32255193	Hypoxia regulates the differentiation and anti-tumor effector functions of γδT cells in oral cancer.	Clinical and experimental immunology	2020	-29.80949694511629	-0.3241967775541116	18	1.27
32255127	Photothermally activatable PDA immune nanomedicine combined with PD-L1 checkpoint blockade for antimetastatic cancer photoimmunotherapy.	Journal of materials chemistry. B	2019	-30.407299261411765	-54.57084435538696	40	2.32
32253426	Immune-checkpoint profiles for T cells in bronchoalveolar lavage fluid of patients with immune-checkpoint inhibitor-related interstitial lung disease.	International immunology	2020	68.11861584691005	-8.581587692869814	12	0.74
32253223	Autoimmune complications of immunotherapy: pathophysiology and management.	BMJ (Clinical research ed.)	2020	78.76090721835557	-10.423427332501197	61	4.43
32252414	RAD51Bme Levels as a Potential Predictive Biomarker for PD-1 Blockade Response in Non-Small Cell Lung Cancer.	Journal of clinical medicine	2020	0.0809278587780117	-32.86467711772221	5	0.29
32252405	Mass Spectrometry Imaging Reveals Neutrophil Defensins as Additional Biomarkers for Anti-PD-(L)1 Immunotherapy Response in NSCLC Patients.	Cancers	2020	20.67967604921627	-33.071430348303906	12	0.78
32251621	Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial.	The Lancet. Oncology	2020	49.603726641636165	-2.2165997490241	264	18.38
32245902	A checkpoint cliffhanger at the dawn of placental mammals.	The Journal of biological chemistry	2020	-49.07166388321569	-36.83061364495858	0	0.0
32245889	The polymorphism rs975484 in the protein arginine methyltransferase 1 gene modulates expression of immune checkpoint genes in hepatocellular carcinoma.	The Journal of biological chemistry	2020	-19.83024538566685	-2.8660332027097546	15	1.11
32245463	Expression patterns of immune checkpoints in acute myeloid leukemia.	Journal of hematology & oncology	2020	18.80000745444877	18.28639702716278	73	4.93
32245016	Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence.	Cancers	2020	26.931844753981107	7.3897282434872515	642	47.61
32244422	Immunomodulatory Molecules On Lung Cancer Stem Cells From Lymph Nodes Aspirates.	Cancers	2020	7.270357834120569	-18.083674683587063	6	0.4
32244307	Programmed Cell Death-1: Programmed Cell Death-Ligand 1 Interaction Protects Human Cardiomyocytes Against T-Cell Mediated Inflammation and Apoptosis Response In Vitro.	International journal of molecular sciences	2020	10.666364321313788	-48.156594595061385	24	1.72
32243638	Serum levels of soluble programmed death-1 (sPD-1) and soluble programmed death ligand 1(sPD-L1) in systemic lupus erythematosus: Association with activity and severity.	Scandinavian journal of immunology	2020	-47.82850690051249	21.08599312950152	19	1.53
32243615	LncRNA XLOC_003810 promotes T cell activation and inhibits PD-1/PD-L1 expression in patients with myasthenia gravis-related thymoma.	Scandinavian journal of immunology	2020	-35.7508943814684	42.3119274146356	13	0.86
32242507	Comprehensive Immune Profiling of Medullary Thyroid Cancer.	Thyroid : official journal of the American Thyroid Association	2020	-3.485795211942204	28.158098218740523	26	1.85
32240819	Checkpoint inhibitors (CPI) and autoimmune chronic inflammatory diseases (ACIDs): tolerance and loss of tolerance in the occurrence of immuno-rheumatologic manifestations.	Clinical immunology (Orlando, Fla.)	2020	78.80972753833949	-11.73084060608369	16	1.17
32239325	[Microenvironment in classical Hodgkin lymphoma].	Der Pathologe	2020	-28.38768023146073	26.27406125803632	0	0.0
32238919	Diagnostic value of 18F-FDG-PET to predict the tumour immune status defined by tumoural PD-L1 and CD8+tumour-infiltrating lymphocytes in oral squamous cell carcinoma.	British journal of cancer	2020	15.077280212660394	-57.89565379813115	31	2.26
32238470	Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce.	Journal for immunotherapy of cancer	2020	-35.93483951816379	-21.20566945986336	98	5.32
32236597	Characterization of genomic alterations and the significance of PI3K/mTOR pathway mutations and tumor mutational burden in non‑small cell lung cancer.	Oncology reports	2020	21.95076469857366	-20.0044429012776	2	0.15
32236416	PD-1 and PD-L1 Expression in Peripheral CD4/CD8+ T Cells Is Restored in the Partial Remission Phase in Type 1 Diabetes.	The Journal of clinical endocrinology and metabolism	2020	-59.947106885251365	3.686626278051242	20	1.47
32235905	Molecular subtypes of oropharyngeal cancer show distinct immune microenvironment related with immune checkpoint blockade response.	British journal of cancer	2020	-8.102410213208904	31.695551001682745	15	0.96
32235584	ThymicPeptides Reverse Immune Exhaustion in Patients with Reactivated Human Alphaherpesvirus1 Infections.	International journal of molecular sciences	2020	-74.51678497895874	17.219620132111913	2	0.25
32233637	Treatment of advanced intrahepatic cholangiocarcinoma with sintilimab combined with tegafur-gimeracil-oteracil potassium capsules (S-1): a case report.	Annals of palliative medicine	2020	56.491338746376925	21.355828865164884	7	0.42
32231996	B7-Positive and B7-Negative Acute Myeloid Leukemias Display Distinct T Cell Maturation Profiles, Immune Checkpoint Receptor Expression, and European Leukemia Net Risk Profiles.	Frontiers in oncology	2020	-38.072779070849286	15.814225982334792	8	0.57
32231779	The immune microenvironment of uterine adenosarcomas.	Clinical sarcoma research	2020	-2.5356638292837728	33.99567042511339	4	0.34
32229606	Biophysical and Immunological Characterization and In Vivo Pharmacokinetics and Toxicology in Nonhuman Primates of the Anti-PD-1 Antibody Pembrolizumab.	Molecular cancer therapeutics	2020	62.63469910473634	-35.8701753387001	7	0.4
32228232	TGF-beta: a master immune regulator.	Expert opinion on therapeutic targets	2020	-22.058683851592445	-9.173854050485096	80	5.8
32226313	Identification and validation of stromal-tumor microenvironment-based subtypes tightly associated with PD-1/PD-L1 immunotherapy and outcomes in patients with gastric cancer.	Cancer cell international	2020	-10.219526784234784	23.663912965893044	36	2.36
32224717	Expression of Programmed Cell Death Proteins in Kaposi Sarcoma and Cutaneous Angiosarcoma.	Journal of immunotherapy (Hagerstown, Md. : 1997)	2020	-22.137696335358022	22.31902939758684	14	1.25
32224220	Alcohol induces programmed death receptor-1 and programmed death-ligand-1 differentially in neuroimmune cells.	Alcohol (Fayetteville, N.Y.)	2020	-73.85378233563266	-9.18339498239717	9	0.8
32224150	Immunogenicity and safety of influenza vaccination in cancer patients receiving checkpoint inhibitors targeting PD-1 or PD-L1.	Annals of oncology : official journal of the European Society for Medical Oncology	2020	65.80325165837172	-0.011641483552197	24	1.24
32222780	A comparative view on the expression patterns of PD-L1 and PD-1 in soft tissue sarcomas.	Cancer immunology, immunotherapy : CII	2020	-19.938039914981665	19.430828351809996	30	2.44
32217758	CD244 represents a new therapeutic target in head and neck squamous cell carcinoma.	Journal for immunotherapy of cancer	2020	-10.550929417525214	32.10905055100361	22	1.54
32216835	Prognosis of PD-L1 in human breast cancer: protocol for a systematic review and meta-analysis.	Systematic reviews	2020	-9.750399758192948	15.630460974829289	12	0.79
32215873	Translational Biomarkers and Rationale Strategies to Overcome Resistance to Immune Checkpoint Inhibitors in Solid Tumors.	Cancer treatment and research	2020	18.340985446416276	9.936962410107649	12	0.7
32213156	PD1/PD-L1 Axis in Uro-oncology.	Current drug targets	2020	14.04891245766556	61.19531905180787	3	0.29
32213091	A Review of Immune Checkpoint Blockade Therapy in Endometrial Cancer.	American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting	2020	40.230849795449615	34.55610071423456	65	4.85
35756142	Molecular imaging for cancer immunotherapy.	Immuno-oncology technology	2020	28.52051783489051	-12.00389771335348	3	0.19
32211312	Risk of Gastrointestinal Adverse Events in Cancer Patients Treated With Immune Checkpoint Inhibitor Plus Chemotherapy: A Systematic Review and Meta-Analysis.	Frontiers in oncology	2020	73.44635000077736	-5.21879870782651	6	0.29
32210369	Prognostic and clinical impact of PD-L2 and PD-L1 expression in a cohort of 437 oesophageal cancers.	British journal of cancer	2020	-12.97683111137338	7.713094751382551	25	1.66
32210001	Transcriptomic and Genomic Testing to Guide Individualized Treatment in Chemoresistant Gastric Cancer Case.	Biomedicines	2020	-13.32274740240952	22.37250947900873	8	0.6
32209601	Survival after checkpoint inhibitors for metastatic acral, mucosal and uveal melanoma.	Journal for immunotherapy of cancer	2020	44.76999896702975	2.690516813738087	34	2.46
32209217	Optimizing management of advanced urothelial carcinoma: A review of emerging therapies and biomarker-driven patient selection.	Canadian Urological Association journal = Journal de l'Association des urologues du Canada	2020	70.35961180796176	18.73816337150152	4	0.18
32209185	[Clinical Analysis of Primary Pulmonary Lymphoepithelioma-like Carcinoma in 8 Patients].	Zhongguo fei ai za zhi = Chinese journal of lung cancer	2020	39.72401766775528	-46.083750683901016	2	0.4
32208115	PD1 and PD-L1 Inhibitors for the Treatment of Kidney Cancer: The Role of PD-L1 Assay.	Current drug targets	2020	21.904153589225253	-5.086777364550435	6	0.35
32206559	Frontiers of ctDNA, targeted therapies, and immunotherapy in non-small-cell lung cancer.	Translational lung cancer research	2020	27.46088625454352	-36.79129527502996	21	1.37
32206098	Novel calreticulin-nanoparticle in combination with focused ultrasound induces immunogenic cell death in melanoma to enhance antitumor immunity.	Theranostics	2020	-28.431889569338573	-48.94423990491575	36	2.54
32205739	The Prognostic Significance of APOBEC3B and PD-L1/PD-1 in Nasopharyngeal Carcinoma.	Applied immunohistochemistry & molecular morphology : AIMM	2021	-17.56890748431305	30.810285280811858	6	0.56
32205040	Association Between Clinical Tumor Burden and Efficacy of Immune Checkpoint Inhibitor Monotherapy for Advanced Non-Small-Cell Lung Cancer.	Clinical lung cancer	2020	25.380407978453498	-17.434475847616508	18	1.0
32203152	Multiplexed ion beam imaging (MIBI) for characterization of the tumor microenvironment across tumor types.	Laboratory investigation; a journal of technical methods and pathology	2020	2.4382756433358117	-47.57022523033152	31	2.03
32201861	Primary CNS lymphoma commonly expresses immune response biomarkers.	Neuro-oncology advances	2020	-33.30791609170861	32.746980207050214	22	1.54
32201424	Induction of PD-L1 by Nitric Oxide via JNK Activation in A172 Glioblastoma Cells.	Biological & pharmaceutical bulletin	2020	-26.652942649694896	49.79626228663856	7	0.65
32201034	Common phenotypic dynamics of tumor-infiltrating lymphocytes across different histologies upon checkpoint inhibition: impact on clinical outcome.	Cytotherapy	2020	3.884957539751711	25.956772069288967	5	0.27
32200422	Human ovarian cancer intrinsic mechanisms regulate lymphocyte activation in response to immune checkpoint blockade.	Cancer immunology, immunotherapy : CII	2020	-23.54280532098461	-23.60046882308175	9	0.58
32199622	Early transient suppression of immune checkpoint proteins T-cell immunoglobulin mucin-3 and programmed cell death-1 in peripheral blood lymphocytes after blastocyst transfer is associated with successful implantation.	Fertility and sterility	2020	-76.34417216136855	-20.874929509954782	8	0.74
32199466	Pembrolizumab in patients with non-small-cell lung cancer of performance status 2 (PePS2): a single arm, phase 2 trial.	The Lancet. Respiratory medicine	2020	49.07986422134015	-29.47709316959852	89	6.2
32198536	TNFR2+ TILs are significantly associated with improved survival in triple-negative breast cancer patients.	Cancer immunology, immunotherapy : CII	2020	-5.749139774432164	19.95823714563853	10	0.77
32197753	The life-threatening eruptions of immune checkpoint inhibitor therapy.	Clinics in dermatology	2020	74.82221185417812	-23.92053956097187	24	2.21
32195035	GD2 chimeric antigen receptor modified T cells in synergy with sub-toxic level of doxorubicin targeting osteosarcomas.	American journal of cancer research	2020	-45.19213050411023	5.899826005661062	28	1.8
32195021	T cell recruitment triggered by optimal dose platinum compounds contributes to the therapeutic efficacy of sequential PD-1 blockade in a mouse model of colon cancer.	American journal of cancer research	2020	-19.30491541182812	-27.947502032055244	21	1.28
32194900	Metronomic paclitaxel improves the efficacy of PD-1 monoclonal antibodies in breast cancer by transforming the tumor immune microenvironment.	American journal of translational research	2020	56.82390184286442	-10.995020630279509	22	1.57
32194748	PD-L1 expression in malignant melanomas of the skin and gastrointestinal tract.	Oncology letters	2020	5.376829920373161	-1.840707435387646	2	0.19
32194436	Modeling Oncolytic Viral Therapy, Immune Checkpoint Inhibition, and the Complex Dynamics of Innate and Adaptive Immunity in Glioblastoma Treatment.	Frontiers in physiology	2020	-33.79652689804279	53.84467314856417	14	1.35
32193378	Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer.	Nature communications	2020	1.8533945398383156	28.78514831882471	144	8.38
32192573	Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1-2 trial.	The Lancet. Oncology	2020	41.190342182194485	-4.963331718559496	147	10.22
32190777	Esophageal, gastric cancer and immunotherapy: small steps in the right direction?	Translational gastroenterology and hepatology	2020	42.13599764671055	15.904901287811317	35	2.53
32190660	Astragalus membranaceus-Derived Anti-Programmed Death-1 Monoclonal Antibodies with Immunomodulatory Therapeutic Effects against Tumors.	BioMed research international	2020	-25.177109031307165	-32.39963595729831	8	0.67
32185726	Therapeutic Development of Immune Checkpoint Inhibitors.	Advances in experimental medicine and biology	2020	27.247563549427618	14.39730245912298	13	0.98
32185721	Checkpoints Under Traffic Control: From and to Organelles.	Advances in experimental medicine and biology	2020	-44.91186516433732	43.79356065362126	6	0.44
32185712	Functions of Immune Checkpoint Molecules Beyond Immune Evasion.	Advances in experimental medicine and biology	2020	22.71429792473377	11.74090207471897	84	5.72
32185706	Roles of PD-1/PD-L1 Pathway: Signaling, Cancer, and Beyond.	Advances in experimental medicine and biology	2020	-47.45697685189151	-7.382018365001261	159	11.69
32185582	Characterization of PD-L1 binding sites by a combined FMO/GRID-DRY approach.	Journal of computer-aided molecular design	2020	-46.43252507121769	-40.49106218302487	11	1.08
32185135	Current Understanding of the Mechanisms Underlying Immune Evasion From PD-1/PD-L1 Immune Checkpoint Blockade in Head and Neck Cancer.	Frontiers in oncology	2020	49.28850586948308	30.937689220354304	57	3.95
32184777	BRD4 Inhibition by AZD5153 Promotes Antitumor Immunity via Depolarizing M2 Macrophages.	Frontiers in immunology	2020	-0.6010396802540083	29.746312527242328	15	0.94
32183950	ADORA1 Inhibition Promotes Tumor Immune Evasion by Regulating the ATF3-PD-L1 Axis.	Cancer cell	2020	-32.68584331176892	-9.383684216023337	85	4.91
32183290	Pathogenesis and Clinical Management of Uterine Serous Carcinoma.	Cancers	2020	40.60637256211233	31.937723782514	16	1.14
32182550	The efficacy and safety of PD-1/PD-L1 inhibitors in patients with recurrent or metastatic nasopharyngeal carcinoma: A systematic review and meta-analysis.	Oral oncology	2020	57.70691411501076	-1.397911878446998	16	1.24
32182438	A critical evaluation of pembrolizumab in addition to lenalidomide and dexamethasone for the treatment of multiple myeloma.	Expert review of hematology	2020	38.444143544207655	-4.163339737154472	4	0.31
32179633	A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti-PD-1 antibody, in patients with advanced solid tumors.	Journal for immunotherapy of cancer	2020	53.59535116242309	-6.416002236983263	48	3.14
32178474	Pemetrexed Enhances Membrane PD-L1 Expression and Potentiates T Cell-Mediated Cytotoxicity by Anti-PD-L1 Antibody Therapy in Non-Small-Cell Lung Cancer.	Cancers	2020	34.30731745995681	-42.33117647427163	19	1.18
32174198	Pitfalls and controversies in pathology impacting breast cancer management.	Expert review of anticancer therapy	2020	8.553949916081633	28.13879433555884	2	0.36
32171024	Echinococcus multilocularis vesicular fluid induces the expression of immune checkpoint proteins in vitro.	Parasite immunology	2020	-50.8069191492062	20.767534952881157	4	0.35
32170448	Clinicopathological features of programmed cell death-1 and programmed cell death-ligand-1 expression in the tumor cells and tumor microenvironment of angioimmunoblastic T cell lymphoma and peripheral T cell lymphoma not otherwise specified.	Virchows Archiv : an international journal of pathology	2020	-34.02953203520917	22.21030980483525	10	0.69
32169871	Pre-existing inflammatory immune microenvironment predicts the clinical response of vulvar high-grade squamous intraepithelial lesions to therapeutic HPV16 vaccination.	Journal for immunotherapy of cancer	2020	-4.835189406710707	34.809461384020175	17	1.05
32168233	Study on the Expression Levels and Clinical Significance of PD-1 and PD-L1 in Plasma of NSCLC Patients.	Journal of immunotherapy (Hagerstown, Md. : 1997)	2020	20.661604573137478	-27.672886546484044	13	1.12
32166894	Programmed cell death ligand-1: A dynamic immune checkpoint in cancer therapy.	Chemical biology & drug design	2020	-39.917027618351305	-16.603207720185456	11	0.85
32162809	PD-L1 Expression on Circulating Tumor Cells May Be Predictive of Response to Pembrolizumab in Advanced Melanoma: Results from a Pilot Study.	The oncologist	2020	7.810307209555518	-38.94204944072175	39	2.65
32161879	CAMPANELLIProgrammed Death 1 (PD-1) and PD-1 Ligand (PD-L1) Expression in Chronic Apical Periodontitis.	European endodontic journal	2019	-65.79309530735691	-21.22590802933756	5	0.48
32161470	Pathological Complete Response After a Single Dose of Anti-PD-1 Therapy in Combination with Chemotherapy as a First-Line Setting in an Unresectable Locally Advanced Gastric Cancer with PD-L1 Positive and Microsatellite Instability.	OncoTargets and therapy	2020	48.17630356689194	19.605471639185424	8	0.53
32161124	Tumor cell-intrinsic PD-1 receptor is a tumor suppressor and mediates resistance to PD-1 blockade therapy.	Proceedings of the National Academy of Sciences of the United States of America	2020	-35.36990215245333	-11.698295922191445	106	7.05
32161104	Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy.	Science translational medicine	2020	-30.57935168884241	-12.785850600474983	191	11.64
32158689	Clinico-Immunological Profile of a 67-Year-Old Woman Affected by HER2-Positive Breast Cancer and Autoimmune Dermatomyositis.	Frontiers in oncology	2020	-7.287452196094453	15.36590714867217	2	0.35
32158626	Deep neural network classification based on somatic mutations potentially predicts clinical benefit of immune checkpoint blockade in lung adenocarcinoma.	Oncoimmunology	2020	24.79188984592607	-20.22050219628593	8	0.44
32158596	Peripheral blood immune cell-based biomarkers in anti-PD-1/PD-L1 therapy.	Immune network	2020	13.11755778366041	-5.58642351086294	15	0.81
32158220	Use of Programmed Death Receptor-1 and/or Programmed Death Ligand 1 Inhibitors for the Treatment of Brain Metastasis of Lung Cancer.	OncoTargets and therapy	2020	45.03863983289688	-14.509790313168564	18	1.17
32157421	Comprehensive immunohistochemical analysis of immune checkpoint molecules in adult T cell leukemia/lymphoma.	Annals of hematology	2020	-37.58740357134692	19.21425299916097	9	0.62
32156778	Targeting Glycosylated PD-1 Induces Potent Antitumor Immunity.	Cancer research	2020	-36.21170043739893	-31.560675023185205	65	4.52
32154170	Association of MSH2 Expression With Tumor Mutational Burden and the Immune Microenvironment in Lung Adenocarcinoma.	Frontiers in oncology	2020	18.79495603399569	-14.875806976851534	14	0.76
32152508	PD-L1 engagement on T cells promotes self-tolerance and suppression of neighboring macrophages and effector T cells in cancer.	Nature immunology	2020	-50.70798654777776	-5.660174472556436	187	12.2
32152439	Small molecule inhibitors targeting the PD-1/PD-L1 signaling pathway.	Acta pharmacologica Sinica	2021	-40.01075613047773	-36.54685685241898	126	15.57
32151670	A Phase 1 Trial Assessing the Safety and Tolerability of a Therapeutic DNA Vaccination Against HPV16 and HPV18 E6/E7 Oncogenes After Chemoradiation for Cervical Cancer.	International journal of radiation oncology, biology, physics	2020	47.61032563498792	36.73650850781914	22	1.68
32150668	Prognostic significance of the radiologic features of pneumonitis induced by anti-PD-1 therapy.	Cancer medicine	2020	66.4450719180949	-10.133750177388682	14	0.88
32150459	Histopathologic Characterization of Myocarditis Associated With Immune Checkpoint Inhibitor Therapy.	Archives of pathology & laboratory medicine	2020	85.29652143097236	2.286098159665102	22	1.52
32150457	Variants in Epithelial-Mesenchymal Transition and Immune Checkpoint Genes Are Associated With Immune Cell Profiles and Predict Survival in Non-Small Cell Lung Cancer.	Archives of pathology & laboratory medicine	2020	0.0045145684443019	39.074051760088594	8	0.61
32149830	PD-L1 Expression in Extramammary Paget Disease: A Case Series.	The American Journal of dermatopathology	2021	-15.11817317254784	11.14403592299659	1	0.3
32146584	Primary pulmonary lymphoepithelioma-like carcinoma.	Medical oncology (Northwood, London, England)	2020	39.752757785744464	-45.99302517107407	6	0.47
32146152	Programmed Death 1 and Programmed Death Ligand 1 Inhibitors in Advanced and Recurrent Urothelial Carcinoma: Meta-analysis of Single-Agent Studies.	Clinical genitourinary cancer	2020	63.236908554621095	15.732171668868776	11	0.8
32144552	Management of immune-related adverse events associated with immune checkpoint inhibitors in cancer patients: a patient-centred approach.	Internal and emergency medicine	2020	77.80263367297385	-9.763479609367126	11	0.81
32143684	Immunophenotyping of the PD-L1-positive cells in angioimmunoblastic T cell lymphoma and Hodgkin disease.	BMC research notes	2020	-33.556924042116826	23.620321567014205	3	0.21
32134754	The Immunohistochemical Expression of Programmed Death Ligand 1 (PD-L1) Is Affected by Sample Overfixation.	Applied immunohistochemistry & molecular morphology : AIMM	2021	13.336837848849353	-40.64723800156248	3	0.42
32132018	Immune-related Adverse Effects and Outcome of Patients With Cancer Treated With Immune Checkpoint Inhibitors.	Anticancer research	2020	78.74382362229878	-9.748293921501606	19	1.31
32131763	Increased PD-1-positive macrophages in the tissue of gastric cancer are closely associated with poor prognosis in gastric cancer patients.	BMC cancer	2020	-13.393161053902988	4.141280433547431	19	1.28
32129934	Patterns of response in metastatic NSCLC during PD-1 or PD-L1 inhibitor therapy: Comparison of the RECIST 1.1 and iRECIST criteria.	Thoracic cancer	2020	23.01155436074687	-47.27008340087861	13	0.94
32127389	Intratumoral Delivery of a PD-1-Blocking scFv Encoded in Oncolytic HSV-1 Promotes Antitumor Immunity and Synergizes with TIGIT Blockade.	Cancer immunology research	2020	-36.33294280960662	52.357899098531504	31	2.22
34589927	Desensitizing Effect of Cancer Cachexia on Immune Checkpoint Inhibitors in Patients With Advanced NSCLC.	JTO clinical and research reports	2020	31.443117797198813	-46.233562009234376	20	1.27
32124416	The Microenvironment of Head and Neck Cancers: Papillomavirus Involvement and Potential Impact of Immunomodulatory Treatments.	Head and neck pathology	2020	-2.866925471416273	-7.715311987209321	22	1.73
32122552	Characterization of the immune microenvironment of NSCLC by multispectral analysis of multiplex immunofluorescence images.	Methods in enzymology	2020	3.741482035498795	-47.13001562259375	10	0.64
32121328	The Determination of Immunomodulation and Its Impact on Survival of Rectal Cancer Patients Depends on the Area Comprising a Tissue Microarray.	Cancers	2020	6.585668620794034	35.10850765933269	5	0.37
32120230	PD-L1 expression and T cells infiltration in patients with uncommon EGFR-mutant non-small cell lung cancer and the response to immunotherapy.	Lung cancer (Amsterdam, Netherlands)	2020	11.254153669854418	-19.86071254485421	46	3.06
32117585	PT-112 induces immunogenic cell death and synergizes with immune checkpoint blockers in mouse tumor models.	Oncoimmunology	2020	-19.32029080237748	-27.94139323012719	65	4.06
32117584	Expression of TIM3/VISTA checkpoints and the CD68 macrophage-associated marker correlates with anti-PD1/PDL1 resistance: implications of immunogram heterogeneity.	Oncoimmunology	2020	-2.1540265276724284	27.54047230030211	32	1.74
32117218	Indirect Impact of PD-1/PD-L1 Blockade on a Murine Model of NK Cell Exhaustion.	Frontiers in immunology	2020	-46.68712020013608	10.685457610179872	23	1.56
32115801	Saccharide analog, 2-deoxy-d-glucose enhances 4-1BB-mediated antitumor immunity via PD-L1 deglycosylation.	Molecular carcinogenesis	2020	-33.540505585131214	-31.922397661054983	19	1.29
32115573	XCL1 expression correlates with CD8-positive T cells infiltration and PD-L1 expression in squamous cell carcinoma arising from mature cystic teratoma of the ovary.	Oncogene	2020	-1.459750239931755	-2.8967248852883176	22	1.56
32112105	Activating Antibodies to The Calcium-sensing Receptor in Immunotherapy-induced Hypoparathyroidism.	The Journal of clinical endocrinology and metabolism	2020	82.51237191181966	-17.526553012564	21	1.79
32110280	Identification of biomarkers of immune checkpoint blockade efficacy in recurrent or refractory solid tumor malignancies.	Oncotarget	2020	17.5456048660737	-1.5370218786783627	11	0.65
32109847	Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events.	European journal of cancer (Oxford, England : 1990)	2020	31.09749523583301	-48.224526743736725	69	4.68
32108916	Direct-acting antiviral treatment downregulates immune checkpoint inhibitor expression in patients with chronic hepatitis C.	Clinical and experimental medicine	2020	-78.33994759876565	24.148680450256617	7	0.58
32107458	Epithelial-mesenchymal transition gene signature is associated with prognosis and tumor microenvironment in head and neck squamous cell carcinoma.	Scientific reports	2020	-0.5515447993376683	39.765208827106456	49	3.92
32107407	Hyperprogression under Immune Checkpoint Inhibitor: a potential role for germinal immunogenetics.	Scientific reports	2020	28.30956493725925	-15.655363313658132	25	1.39
32106752	HX008: a humanized PD-1 blocking antibody with potent antitumor activity and superior pharmacologic properties.	mAbs	2020	-40.44402648817737	-29.80655937245485	19	1.21
32105362	Kinetics of pH-dependent interactions between PD-1 and PD-L1 immune checkpoint proteins from molecular dynamics.	Proteins	2020	-50.74837448156158	-41.25025574058538	2	0.2
32104613	Cancer Treatment Response to Checkpoint Inhibitors Is Associated with Cytomegalovirus Infection.	Cureus	2020	-19.849826433661438	-23.95930785941158	2	0.14
32100078	Clinical relevance of the comparative expression of immune checkpoint markers with the clinicopathological findings in patients with primary and chemoreduced retinoblastoma.	Cancer immunology, immunotherapy : CII	2020	-3.834986387322505	32.25002371966597	6	0.63
32099495	Immune Checkpoint Inhibitors for the Treatment of Unresectable Stage III Non-Small Cell Lung Cancer: Emerging Mechanisms and Perspectives.	Lung Cancer (Auckland, N.Z.)	2019	40.41975501748148	-24.68284140044	7	0.35
32097935	Programmed Cell Death Ligand Expression Drives Immune Tolerogenesis across the Diverse Subtypes of Neuroendocrine Tumours.	Neuroendocrinology	2021	0.6871321882847967	13.404156405981988	14	1.54
32097671	Immune-mediated adverse effects of immune-checkpoint inhibitors and their management in cancer.	Immunology letters	2020	82.67873651459429	-10.026666462677882	11	0.75
32096021	Mechanisms of Resistance to PD-1 Checkpoint Blockade.	Drugs	2020	32.436141724550346	14.978721736124788	4	0.28
32095185	Sarcopenia and Visceral Adiposity Did Not Affect Efficacy of Immune-Checkpoint Inhibitor Monotherapy for Pretreated Patients With Advanced Non-Small Cell Lung Cancer.	World journal of oncology	2020	30.5444580175576	-46.94700742186875	30	2.62
32092974	New First Line Treatment Options of Clear Cell Renal Cell Cancer Patients with PD-1 or PD-L1 Immune-Checkpoint Inhibitor-Based Combination Therapies.	Journal of clinical medicine	2020	65.90671859341901	30.80859738144807	27	1.74
32091646	Managing Hyperprogressive Disease in the Era of Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade: A Case Discussion and Review of the Literature.	The oncologist	2020	37.46784978589321	-51.02882358964138	11	0.61
32091388	Anti-PD-1 immunotherapy leads to tuberculosis reactivation via dysregulation of TNF-α.	eLife	2020	-85.54867540747556	0.999190170756992	53	3.89
32089543	PD-L1/L2 protein levels rapidly increase on monocytes via trogocytosis from tumor cells in classical Hodgkin lymphoma.	Leukemia	2020	-26.955958693329737	26.642376696386595	26	1.78
32088772	Critical role of PD-L1 expression on non-tumor cells rather than on tumor cells for effective anti-PD-L1 immunotherapy in a transplantable mouse hematopoietic tumor model.	Cancer immunology, immunotherapy : CII	2020	-34.15548153090374	-10.053052258985897	7	0.4
32088639	Epigenetically silenced PD-L1 confers drug resistance to anti-PD1 therapy in gastric cardia adenocarcinoma.	International immunopharmacology	2020	-2.1714861789730198	-31.161455647040743	8	0.5
32088605	Impressive clinical response to anti-PD-1 therapy in epithelioid mesothelioma with high clonal PD-L1 expression and EML4-ALK rearrangement.	Lung cancer (Amsterdam, Netherlands)	2020	48.55939133103539	-1.397839302682818	8	0.56
32086851	PD-1 and PD-L1 expression on T-cell subsets in women with unexplained recurrent pregnancy losses.	American journal of reproductive immunology (New York, N.Y. : 1989)	2020	-74.57755438897381	-19.185042788110152	14	1.4
32086577	MRI radiomics features predict immuno-oncological characteristics of hepatocellular carcinoma.	European radiology	2020	10.383139075866852	-11.507435888134962	68	6.49
32086343	Efficacy, Safety, and Biomarkers of Toripalimab in Patients with Recurrent or Metastatic Neuroendocrine Neoplasms: A Multiple-Center Phase Ib Trial.	Clinical cancer research : an official journal of the American Association for Cancer Research	2020	57.01203875957845	-4.744697935247538	54	3.31
32085927	Landscape of Immune Checkpoint Inhibition in Carcinosarcoma (MMMT): Analysis of IDO-1, PD-L1 and PD-1.	Pathology, research and practice	2020	-20.264182393497	18.02332582627105	11	0.86
32085544	Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study.	Cancers	2020	22.33101403440676	-27.733365138890743	57	4.05
32084380	PD-1/PD-L1 in cardiovascular disease.	Clinica chimica acta; international journal of clinical chemistry	2020	-58.31154787494729	8.778256995370699	22	1.82
32083780	Landscape of current and future therapies of Merkel cell carcinoma.	Dermatologic therapy	2020	45.47075613744746	50.354064379516	1	0.16
32083295	Association between PD-L1 status and immune checkpoint inhibitor response in advanced malignancies: a systematic review and meta-analysis of overall survival data.	Japanese journal of clinical oncology	2020	48.917908354944025	-14.313483472295829	11	0.67
32082425	Fatal adverse events associated with programmed cell death protein 1 or programmed cell death-ligand 1 monotherapy in cancer.	Therapeutic advances in medical oncology	2020	62.166104640844985	-18.030973930495733	7	0.44
32079442	Prognostic impact of PD-L1 in oropharyngeal cancer after primary curative radiotherapy and relation to HPV and tobacco smoking.	Acta oncologica (Stockholm, Sweden)	2020	-4.463627091084508	-10.051941936293218	8	0.64
32079180	Decitabine Augments Chemotherapy-Induced PD-L1 Upregulation for PD-L1 Blockade in Colorectal Cancer.	Cancers	2020	-19.873108555303848	-25.956857844422284	46	2.84
32078962	Toxicity management with combination chemotherapy and programmed death 1/programmed death ligand 1 inhibitor therapy in advanced lung cancer.	Cancer treatment reviews	2020	51.060214686418185	-19.70534478646429	16	0.95
32078941	Modulating the tumor immune microenvironment with sunitinib malate supports the rationale for combined treatment with immunotherapy.	International immunopharmacology	2020	-22.304182500559264	-23.91333096306495	7	0.49
32077636	Pathologic complete response to preoperative immunotherapy in a lung adenocarcinoma patient with bone metastasis: A case report.	Thoracic cancer	2020	17.25779101090223	-28.439311897721296	9	0.65
32076650	Dual pH-sensitive nanodrug blocks PD-1 immune checkpoint and uses T cells to deliver NF-κB inhibitor for antitumor immunotherapy.	Science advances	2020	-31.87862384984569	-51.494708277585104	73	5.36
32075801	Fatty Acid Oxidation Controls CD8+ Tissue-Resident Memory T-cell Survival in Gastric Adenocarcinoma.	Cancer immunology research	2020	-11.957608986119332	26.558973635266803	96	5.89
32075381	Side Effects and Efficacy of Immunotherapy.	Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti	2020	81.05501215589997	-6.62229506405396	3	0.21
32070710	PD-L1/PD-1 axis as a potent therapeutic target in breast cancer.	Life sciences	2020	-42.463423255765136	-18.252235030711173	27	2.0
32068670	Correlation of PD-L1 expression on tumor cell and tumor infiltrating immune cell with 18F-fluorodeoxyglucose uptake on PET/computed tomography in surgically resected pulmonary adenocarcinoma.	Nuclear medicine communications	2020	14.073342309708991	-57.12585043471263	5	0.46
32067682	Clinical activity of programmed cell death 1 (PD-1) blockade in never, light, and heavy smokers with non-small-cell lung cancer and PD-L1 expression ≥50.	Annals of oncology : official journal of the European Society for Medical Oncology	2020	16.388022690293106	-33.36810299025902	58	3.66
32067548	Prognostic and therapeutic molecular markers in the clinical management of esophageal cancer.	Expert review of molecular diagnostics	2020	45.48958545870351	20.646583840072196	7	0.64
32066859	PD-L1 in small bowel adenocarcinoma is associated with etiology and tumor-infiltrating lymphocytes, in addition to microsatellite instability.	Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc	2020	8.074191835596361	33.91892182278118	28	2.35
32066405	PD-L1 and CD4 are independent prognostic factors for overall survival in endometrial carcinomas.	BMC cancer	2020	-1.812347837149888	33.50370801196401	21	1.48
32063859	Berberine Maintains the Neutrophil N1 Phenotype to Reverse Cancer Cell Resistance to Doxorubicin.	Frontiers in pharmacology	2019	-15.024771916042589	-34.1571013427831	19	1.72
32059865	"Erratum to ""Evaluation of clear cell subtypes of ovarian and uterine malignancies with anti-PD-L1 and anti-PD1 immunohistochemical expression and their association with stage and survival"" [Gynecol. Oncol. 155 (2019) 483-488]."	Gynecologic oncology	2020	-17.059339949118662	12.676880453822422	1	0.1
32059674	Correction to: Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy.	Molecular cancer	2020	-4.031523521151	-41.487612318932	6	0.31
32057701	The expression and immunoregulation of immune checkpoint molecule VISTA in autoimmune diseases and cancers.	Cytokine & growth factor reviews	2020	22.385244486722737	57.95285198700216	14	0.9
32057515	Molecular regulatory network of PD-1/PD-L1 in non-small cell lung cancer.	Pathology, research and practice	2020	4.514301690746322	-30.276711024568797	7	0.52
32055496	Novel treatments for anaplastic thyroid carcinoma.	Gland surgery	2020	26.846707732092785	32.76149632119964	53	4.31
32054467	Serum levels of soluble programmed death-ligand 1 (sPD-L1) in patients with primary central nervous system diffuse large B-cell lymphoma.	BMC cancer	2020	-45.96206721640986	21.536656878845207	22	1.81
32051396	PDL1 blockage increases fetal resorption and Tfr cells but does not affect Tfh/Tfr ratio and B-cell maturation during allogeneic pregnancy.	Cell death & disease	2020	-75.27652040561674	-19.5898727310862	19	1.46
32051287	Interferon gamma inhibits CXCL8-CXCR2 axis mediated tumor-associated macrophages tumor trafficking and enhances anti-PD1 efficacy in pancreatic cancer.	Journal for immunotherapy of cancer	2020	-19.189445678150825	-17.506664300743175	76	5.18
32049776	Oncological outcomes of addition of anti-PD1/PD-L1 to chemotherapy in the therapy of patients with advanced gastric or gastro-oesophageal junction cancer: A meta-analysis.	Medicine	2020	49.93130804904876	16.308607815145635	2	0.15
32048861	PD-1 Deficiency Promotes Macrophage Activation and T-Helper Cell Type 1/T-Helper Cell Type 17 Response in Pneumocystis Pneumonia.	American journal of respiratory cell and molecular biology	2020	-70.4378347656135	8.971287187917547	16	1.42
32047958	Tumor mutational load, CD8+ T cells, expression of PD-L1 and HLA class I to guide immunotherapy decisions in NSCLC patients.	Cancer immunology, immunotherapy : CII	2020	20.577689061976876	-17.511373466705415	59	3.74
32047478	Immune Checkpoint Inhibitor-Induced Diabetic Ketoacidosis: A Report of Four Cases and Literature Review.	Frontiers in endocrinology	2020	87.88580024133071	-14.326800429055668	14	1.06
32045539	Management of Pneumonitis and Neuropathy in Patients Receiving PD-1-Based Therapy for Non-Small-Cell Lung Cancer.	JCO oncology practice	2020	67.40241610513722	-10.10432645551569	2	0.12
32045535	Management of Immune-Related Dermatitis and Mucositis Associated With Pembrolizumab in Metastatic Human Papillomavirus-Associated Squamous Cell Carcinoma of the Oropharynx.	JCO oncology practice	2020	53.25404935834131	28.217498377859723	4	0.37
32045365	Adaptive selection in the evolution of programmed cell death-1 and its ligands in vertebrates.	Aging	2020	-54.63693230157233	-24.186549608112383	11	1.17
32044366	Cordyceps militaris polysaccharide converts immunosuppressive macrophages into M1-like phenotype and activates T lymphocytes by inhibiting the PD-L1/PD-1 axis between TAMs and T lymphocytes.	International journal of biological macromolecules	2020	-24.301835242425085	-32.447789679090675	35	3.34
32042863	Predictive biomarkers for immune checkpoint blockade and opportunities for combination therapies.	Genes & diseases	2019	26.605911080142604	14.075209483846928	39	1.95
32041818	Poor outcome with anti-programmed death-ligand 1 (PD-L1) antibody due to poor pharmacokinetic properties in PD-1/PD-L1 blockade-sensitive mouse models.	Journal for immunotherapy of cancer	2020	0.5876730536173516	-55.8955969864497	17	0.98
32039367	HBeAg seroconversion is associated with a more effective PD-L1 blockade during chronic hepatitis B infection.	JHEP reports : innovation in hepatology	2019	-74.04275214721402	23.2420947847129	17	0.89
32038916	Impact of baseline steroids on efficacy of programmed cell death-1 (PD-1) and programmed death-ligand 1 (PD-L1) blockade in patients with advanced non-small cell lung cancer.	Translational lung cancer research	2019	20.88566976753029	-34.88979844182707	12	0.6
32038880	Response to anti-PD1 immunotherapy in patients with metastatic cutaneous sarcoma: case reports and literature review.	Oxford medical case reports	2020	58.45696803147612	-26.445515897956977	3	0.23
32037060	Pharmacokinetic/pharmacodynamic relationship of therapeutic monoclonal antibodies used in oncology: Part 2, immune checkpoint inhibitor antibodies.	European journal of cancer (Oxford, England : 1990)	2020	32.69057330492935	-10.249501535805315	41	2.92
32036071	Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC.	Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer	2020	33.09079123835567	-18.972264594588584	221	13.86
32035131	Regulation of PD-L1 expression on cancer cells with ROS-modulating drugs.	Life sciences	2020	-39.88782386471139	-9.682076984774836	51	4.08
32030768	Clinicopathological and prognostic significance of PD-1/PD-L1 axis expression in patients with tongue squamous cell carcinoma.	Journal of cellular physiology	2020	-7.810416624870176	-9.690044859022066	5	0.41
32030732	Pembrolizumab with R-CHOP in previously untreated diffuse large B-cell lymphoma: potential for biomarker driven therapy.	British journal of haematology	2020	45.16200469086283	-6.303107862684287	56	3.64
32028750	[Renal Cancer Tissue after Nivolumab/Ipilimumab Combination Therapy for Metastatic Renal Cell Carcinoma].	Hinyokika kiyo. Acta urologica Japonica	2020	64.61855235554957	29.643873148084023	4	0.28
32027620	Pembrolizumab plus allogeneic NK cells in advanced non-small cell lung cancer patients.	The Journal of clinical investigation	2020	48.50160697809323	-30.629260549189013	62	3.94
32022459	First-line pembrolizumab for non-small cell lung cancer patients with PD-L1 ≥50% in a multicenter real-life cohort: The PEMBREIZH study.	Cancer medicine	2020	49.21841795066527	-28.98699866528947	33	2.41
32021268	BTLA Expression in Stage I-III Non-Small-Cell Lung Cancer and Its Correlation with PD-1/PD-L1 and Clinical Outcomes.	OncoTargets and therapy	2020	12.491549432721966	-29.942595156485595	29	1.96
32021257	Resistance Mechanism of PD-1/PD-L1 Blockade in the Cancer-Immunity Cycle.	OncoTargets and therapy	2020	-35.76848738449114	-20.758329817996067	23	1.41
32020483	Checkpoint inhibitor therapy in preclinical sepsis models: a systematic review and meta-analysis.	Intensive care medicine experimental	2020	-59.546390634941744	39.22424653247877	17	1.17
32020256	Specific T-cell immune responses against colony-forming cells including leukemic progenitor cells of AML patients were increased by immune checkpoint inhibition.	Cancer immunology, immunotherapy : CII	2020	18.465254573971663	17.513654281744063	8	0.54
32020040	Checkpoint inhibitor immunotherapy in kidney cancer.	Nature reviews. Urology	2020	63.69653991351643	30.17319883909078	125	8.23
32018128	Biomarkers for immunotherapy response in head and neck cancer.	Cancer treatment reviews	2020	53.3143368731189	32.1690420107498	112	8.44
32017708	A tumor-intrinsic PD-L1/NLRP3 inflammasome signaling pathway drives resistance to anti-PD-1 immunotherapy.	The Journal of clinical investigation	2020	-34.37748999065109	-20.87681128447204	109	6.83
32015231	A conserved intratumoral regulatory T cell signature identifies 4-1BB as a pan-cancer target.	The Journal of clinical investigation	2020	14.651619999167792	15.09023653361383	48	2.95
32014811	Functional tumor specific CD8 + T cells in spleen express a high level of PD-1.	International immunopharmacology	2020	-28.28267155921676	-10.489941655660791	6	0.42
32014533	Bullous disorders associated with PD-1 and PD-L1 inhibitors: Pharmacovigilance analysis of the United States Food and Drug Administration Adverse Event Reporting System from the Research on Adverse Drug Events And Reports Program.	Journal of the American Academy of Dermatology	2020	69.83712024752037	-26.573233139910634	5	0.49
32010585	Evaluation of the lung immune prognostic index in advanced non-small cell lung cancer patients under nivolumab monotherapy.	Translational lung cancer research	2019	27.086527609204836	-45.45190378739976	31	1.44
32010568	T cell immunoglobulin and mucin-domain containing-3 in non-small cell lung cancer.	Translational lung cancer research	2019	-2.125907551128128	26.046520753665803	24	1.12
32008328	Immune checkpoint inhibitor therapy in biliary tract cancer (cholangiocarcinoma).	Chinese clinical oncology	2020	58.02356463203407	25.328563195560196	31	2.25
32007710	The progress and confusion of anti-PD1/PD-L1 immunotherapy for patients with advanced non-small cell lung cancer.	International immunopharmacology	2020	37.04020778320849	-31.810043501246657	23	1.41
32006051	Clinical application of immune checkpoints in targeted immunotherapy of prostate cancer.	Cellular and molecular life sciences : CMLS	2020	22.81208375656484	16.02877420516316	43	3.26
32005408	PD-L1 expression in tumor infiltrated lymphocytes predicts survival in triple-negative breast cancer.	Pathology, research and practice	2020	-7.727426898337923	18.719880871108774	22	1.67
32003657	The Roles of Programmed Cell Death Ligand-1/ Programmed Cell Death-1 (PD-L1/PD-1) in HPV-induced Cervical Cancer and Potential for their Use in Blockade Therapy.	Current medicinal chemistry	2021	0.2721694457304784	-11.991984290412802	18	2.48
32003655	Advances in Immuno-PET for the Detection of Cancer and Assessment of Response to Therapy.	Current medicinal chemistry	2021	28.80748260964885	-11.81731393968316	3	0.45
32003335	Frequencies of regulatory subsets of CD4+ TH cells in peripheral blood in Mycobacterium Tuberculosis-Infected individuals and healthy contacts in a high-burden setting from Assam, Northeast India.	Indian journal of medical microbiology	2019	-85.2661740102232	4.993249761104738	1	0.11
32002307	Durable tumor regression in highly refractory metastatic KIT/PDGFRA wild-type GIST following treatment with nivolumab.	Oncoimmunology	2020	42.29144274869786	21.746829385505794	6	0.43
32001626	Neoadjuvant checkpoint blockade for cancer immunotherapy.	Science (New York, N.Y.)	2020	30.752582678116408	-22.948114383830056	422	27.48
32001504	Increased antitumor efficacy of PD-1-deficient melanoma-specific human lymphocytes.	Journal for immunotherapy of cancer	2020	-43.78860488194829	-0.3136254239651114	15	0.92
32000802	Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy.	Molecular cancer	2020	-35.780865504301474	-20.547768239843293	152	10.15
32000640	Evolution of Molecular Targets in Melanoma Treatment.	Current pharmaceutical design	2020	31.80355352405314	30.683913680300744	6	0.42
32000550	Molecular markers related to immunosurveillance as predictive and monitoring tools in non-small cell lung cancer: recent accomplishments and future promises.	Expert review of molecular diagnostics	2020	22.531577105711182	-32.92746963801912	9	0.56
32000374	Cardiac adverse events of PD-1 and PD-L1 inhibitors in cancer protocol for a systematic review and network meta-analysis: A protocol for systematic review.	Medicine	2020	60.88354423727225	-17.376933779239558	1	0.06
31998636	XIST and TSIX: Novel Cancer Immune Biomarkers in PD-L1-Overexpressing Breast Cancer Patients.	Frontiers in oncology	2019	-3.2797219348188635	24.558872515673706	34	2.76
31998307	Distinct Immunological Landscapes Characterize Inherited and Sporadic Mismatch Repair Deficient Endometrial Cancer.	Frontiers in immunology	2019	11.553762537632997	46.09106421505261	38	2.43
31998304	Recalling the Biological Significance of Immune Checkpoints on NK Cells: A Chance to Overcome LAG3, PD1, and CTLA4 Inhibitory Pathways by Adoptive NK Cell Transfer?	Frontiers in immunology	2019	-43.18540044481047	33.482857368259275	42	2.93
31996766	Weighing the role of skeletal muscle mass and muscle density in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: a multicenter real-life study.	Scientific reports	2020	30.086416714906186	-47.54542712572864	55	5.03
31996725	Evaluation of PD-L1 and other immune markers in bladder urothelial carcinoma stratified by histologic variants and molecular subtypes.	Scientific reports	2020	8.131232572978686	60.24752747960264	34	2.69
31994912	Blockade of endothelial, but not epithelial, cell expression of PD-L1 following severe shock attenuates the development of indirect acute lung injury in mice.	American journal of physiology. Lung cellular and molecular physiology	2020	-60.7891900383568	31.25387742078644	17	1.48
31993961	Myositis as a neuromuscular complication of immune checkpoint inhibitors.	Acta neurologica Belgica	2020	85.36369616641275	-1.1441248560918644	13	1.04
31993774	Immune checkpoint status and tumor microenvironment in vulvar squamous cell carcinoma.	Virchows Archiv : an international journal of pathology	2020	1.014249340280992	-8.489544886833249	11	0.96
31992245	Immune classification for the PD-L1 expression and tumour-infiltrating lymphocytes in colorectal adenocarcinoma.	BMC cancer	2020	7.437223769002871	37.77201516333384	22	1.46
31991822	Adaptive and Innate Immune Cells in Fetal Human Cytomegalovirus-Infected Brains.	Microorganisms	2020	-75.7334231694092	-1.372790409918317	9	1.02
31989402	EGFRvIII-CAR-T Cells with PD-1 Knockout Have Improved Anti-Glioma Activity.	Pathology oncology research : POR	2020	-26.88307002917872	51.81041325679517	27	1.87
31985048	(Curcumin+sildenafil) enhances the efficacy of 5FU and anti-PD1 therapies in vivo.	Journal of cellular physiology	2020	-16.03074940252645	-36.710851485544055	21	1.68
31982822	Predictive effect of PD-L1 expression for immune checkpoint inhibitor (PD-1/PD-L1 inhibitors) treatment for non-small cell lung cancer: A meta-analysis.	International immunopharmacology	2020	15.965963788575234	-31.247536976042543	30	1.96
31980961	PD-1/PD-L1 expression and tumor-infiltrating lymphocytes are prognostically favorable in advanced high-grade serous ovarian carcinoma.	Virchows Archiv : an international journal of pathology	2020	-19.045314286900144	13.947223496278996	35	2.51
31980916	Digital pathology-aided assessment of tumor-infiltrating T lymphocytes in advanced stage, HPV-negative head and neck tumors.	Cancer immunology, immunotherapy : CII	2020	-9.48988758288562	32.57814061773816	16	1.2
31980560	PD-L1 expression is an unfavourable prognostic indicator in Asian renal cell carcinomas.	Journal of clinical pathology	2020	17.09423331671519	27.541462915803844	4	0.22
31978315	Pharmacodynamics of current and emerging PD-1 and PD-L1 inhibitors for the treatment of non-small cell lung cancer.	Expert opinion on drug metabolism & toxicology	2020	42.10101710539693	-29.249434552288708	5	0.35
31973911	High degree of heterogeneity of PD-L1 and PD-1 from primary to metastatic endometrial cancer.	Gynecologic oncology	2020	-18.08976243605976	8.55877257088043	24	1.79
31972166	Protein homodimer sequestration with small molecules: Focus on PD-L1.	Biochemical pharmacology	2020	-44.14877840654847	-38.80868543487021	18	1.3
31971109	Status of Programmed Death Ligand 1 (PD-L1) by Immunohistochemistry and Scoring Algorithms.	Current drug targets	2020	18.975023628372654	-42.55256207683313	7	0.46
31970790	Cytokines as potential combination agents with PD-1/PD-L1 blockade for cancer treatment.	Journal of cellular physiology	2020	28.166396148857167	-1.7264377706674678	31	1.95
31967634	Engineered scPDL1-DM1 drug conjugate with improved in vitro analysis to target PD-L1 positive cancer cells and intracellular trafficking studies in cancer therapy.	Genetics and molecular biology	2020	-43.92744014685116	-31.252060910532496	6	0.53
31960962	PD-1/PD-L1-dependent immune response in colorectal cancer.	Journal of cellular physiology	2020	34.629439519521085	22.694153876297325	63	5.02
31960363	lncRNA TCL6 correlates with immune cell infiltration and indicates worse survival in breast cancer.	Breast cancer (Tokyo, Japan)	2020	-5.88629980070175	55.23059823320752	45	3.24
31959763	Immune gene signatures for predicting durable clinical benefit of anti-PD-1 immunotherapy in patients with non-small cell lung cancer.	Scientific reports	2020	25.402046723996165	-20.045694534446003	100	5.94
31955066	Vδ2 T cell subsets, defined by PD-1 and TIM-3 expression, present varied cytokine responses in acute myeloid leukemia patients.	International immunopharmacology	2020	-38.456227491733095	14.129620094682815	18	1.32
31953603	Association between radiotherapy-induced alteration of programmed death ligand 1 and survival in patients with uterine cervical cancer undergoing preoperative radiotherapy.	Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]	2020	1.4184411633228935	-12.19104237772198	20	1.5
31951541	Dimers Aren't Forever: CD80 Breaks up with PD-L1.	Immunity	2019	23.4837942110054	-59.81460381257104	4	0.18
31951027	GZ17-6.02 initiates DNA damage causing autophagosome-dependent HDAC degradation resulting in enhanced anti-PD1 checkpoint inhibitory antibody efficacy.	Journal of cellular physiology	2020	-15.431888248716389	-36.43321545180948	17	1.34
31950498	Immune checkpoint inhibitors in advanced nasopharyngeal carcinoma: Beyond an era of chemoradiation?	International journal of cancer	2020	42.3300248271773	27.06457564882769	35	2.55
31949927	Patterns and genomic correlates of PD-L1 expression in patients with biliary tract cancers.	Journal of gastrointestinal oncology	2019	-0.9596792974252216	5.65407432661673	35	1.79
31949648	CD47 is associated with the up-regulation of the PD-1 oncogenic signaling pathway.	International journal of clinical and experimental pathology	2018	-44.25471188501282	-6.44574342094862	2	0.1
31949260	Enhanced STAT3 phosphorylation and PD-L1 expression in myeloid dendritic cells indicate impaired IL-27Ralpha signaling in type 1 diabetes.	Scientific reports	2020	-57.08201069597883	4.039351758617856	11	0.78
31948999	Targeting PD-1 or PD-L1 in Metastatic Kidney Cancer: Combination Therapy in the First-Line Setting.	Clinical cancer research : an official journal of the American Association for Cancer Research	2020	62.19513685430228	30.319612313791037	31	1.97
31947643	Modulation of Vaccine-Induced HIV-1-Specific Immune Responses by Co-Electroporation of PD-L1 Encoding DNA.	Vaccines	2020	-87.93778547902208	14.16241781702472	7	0.6
31947592	Anti-PD-1 and Novel Combinations in the Treatment of Melanoma-An Update.	Journal of clinical medicine	2020	33.780866632955494	0.0535918199883886	75	5.71
31942809	A historical turning point for the treatment of advanced renal cell carcinoma: inhibition of immune checkpoint.	Current medical research and opinion	2020	64.48108539074612	30.58071405647464	3	0.17
31942578	PD-L1-targeted microbubbles loaded with docetaxel produce a synergistic effect for the treatment of lung cancer under ultrasound irradiation.	Biomaterials science	2020	-26.98428768563713	-52.65109979897432	8	0.71
31942188	Increased Tim-3 expression on TILs during treatment with the Anchored GM-CSF vaccine and anti-PD-1 antibodies is inversely correlated with response in prostate cancer.	Journal of Cancer	2020	-24.435358751349213	-10.775495966221118	21	1.43
31941832	PD-1 Blockade Reinvigorates Bone Marrow CD8+ T Cells from Patients with Multiple Myeloma in the Presence of TGFβ Inhibitors.	Clinical cancer research : an official journal of the American Association for Cancer Research	2020	-33.830659250721304	9.053848739023383	23	1.33
31941061	Molecular Classification of Gastric Cancer among Alaska Native People.	Cancers	2020	-13.331903436692034	22.227736306861548	15	1.44
31939184	Flow Cytometry Analysis of Surface PD-L1 Expression Induced by IFNγ and Romidepsin in Ovarian Cancer Cells.	Methods in molecular biology (Clifton, N.J.)	2020	-22.710818022796428	11.884271096726618	6	0.46
31939183	Immunoblotting Analysis of Intracellular PD-L1 Levels in Interferon-γ-Treated Ovarian Cancer Cells Stably Transfected with Bcl3 shRNA.	Methods in molecular biology (Clifton, N.J.)	2020	-22.71812170779445	11.875368519265155	4	0.3
31939072	Novel Therapeutics for Recurrent Cervical Cancer: Moving Towards Personalized Therapy.	Drugs	2020	44.61481548683755	34.75344683594528	45	3.95
31938638	PD-L1, PD-1, LAG-3, and TIM-3 in Melanoma: Expression in Brain Metastases Compared to Corresponding Extracranial Tumors.	Cureus	2019	-26.56977093573083	45.61921837792688	8	0.43
31938049	Fructose-1,6-bisphosphatase loss modulates STAT3-dependent expression of PD-L1 and cancer immunity.	Theranostics	2020	-19.15769038302209	-8.616769661144534	26	1.8
31937613	Impact of EGFR-TKI Treatment on the Tumor Immune Microenvironment in EGFR Mutation-Positive Non-Small Cell Lung Cancer.	Clinical cancer research : an official journal of the American Association for Cancer Research	2020	6.88180086659718	-34.056953111541226	120	7.73
31935623	Recent advancements in the treatment of metastatic clear cell renal cell carcinoma: A review of the evidence using second-generation p-values.	Cancer treatment and research communications	2020	66.6305945240969	32.62592627350553	24	1.89
31934533	Tumor Microenvironment in Diffuse Large B-Cell Lymphoma: Role and Prognosis.	Analytical cellular pathology (Amsterdam)	2019	-30.77211523504161	31.74867752314436	42	2.35
31934294	Evaluation of PD-1 blockade using a multicellular tumor spheroid model.	American journal of translational research	2019	-11.24760154951392	-0.5698485671840633	7	0.35
31933207	Assessing the Impact of Phytochemicals on Immune Checkpoints: Implications for Cancer Immunotherapy.	Methods in molecular biology (Clifton, N.J.)	2020	-28.969600452123267	-37.94346364534884	0	0.0
31931443	Elucidation of the relationships of MET protein expression and gene copy number status with PD-L1 expression and the immune microenvironment in non-small cell lung cancer.	Lung cancer (Amsterdam, Netherlands)	2020	15.85569227907052	-21.26491154410173	14	0.86
31929892	Impact of pre-therapy glioblastoma multiforme microenvironment on clinical response to autologous CMV-specific T-cell therapy.	Clinical & translational immunology	2019	-28.44139367007532	54.62488851398445	10	0.57
31926948	Clinical and Morphological Characteristics of Anti-Programmed Death Ligand 1-Associated Retinopathy: Expanding the Spectrum of Acute Macular Neuroretinopathy.	Ophthalmology. Retina	2020	82.88128345376566	-24.33814769450328	10	1.7
31926212	Stromal PD-1+ tumor-associated macrophages predict poor prognosis in lung adenocarcinoma.	Human pathology	2020	4.039932483680075	-26.62491455004923	15	0.94
31923366	Efficacy of PD-1 blockade therapy and T cell immunity in lung cancer patients.	Immunological medicine	2020	36.580364262380265	-23.27035747011728	3	0.17
31922964	Successful immune checkpoint inhibition in an EGFR-mutant lung cancer patient refractory to epidermal growth factor receptor tyrosine kinase inhibitor treatment.	Anti-cancer drugs	2020	43.45004359685306	-32.8641768427896	2	0.07
31921710	In vitro Interactions of Chicken Programmed Cell Death 1 (PD-1) and PD-1 Ligand-1 (PD-L1).	Frontiers in cellular and infection microbiology	2019	-53.88246453460443	-28.1196404810632	5	0.44
31921686	Severe Immune-Related Pneumonitis With PD-1 Inhibitor After Progression on Previous PD-L1 Inhibitor in Small Cell Lung Cancer: A Case Report and Review of the Literature.	Frontiers in oncology	2019	65.28307812397338	-11.004572026030912	10	0.46
31920637	PD-1 Inhibitors in the Advanced Esophageal Cancer.	Frontiers in pharmacology	2019	52.30205804217877	15.802017759598955	20	0.98
31914969	Anti-PD-1 antibody decreases tumour-infiltrating regulatory T cells.	BMC cancer	2020	-34.34310834917915	-2.5619122953676605	56	3.84
31914452	Outcomes and Safety of Biweekly and Monthly Nivolumab in Patients with Metastatic Renal Cell Carcinoma and Dialysis: Three Case Reports and Literature Review.	Urologia internationalis	2020	63.08680524186019	27.95995175869273	9	0.71
31912796	Adverse event profile for immunotherapy agents compared with chemotherapy in solid organ tumors: a systematic review and meta-analysis of randomized clinical trials.	Annals of oncology : official journal of the European Society for Medical Oncology	2020	78.44801003378404	-5.88138693597224	83	6.0
31912789	Elevated baseline serum PD-1 or PD-L1 predicts poor outcome of PD-1 inhibition therapy in metastatic melanoma.	Annals of oncology : official journal of the European Society for Medical Oncology	2020	9.384085565538816	-2.3169469583850897	54	3.54
31911775	Occurrence of an Abscopal Radiation Recall Phenomenon in a Glioblastoma Patient Treated with Nivolumab and Re-Irradiation.	Case reports in oncology	2019	47.86346790987884	7.508183551240842	4	0.41
31911557	The Immunosuppressive Microenvironment in BRCA1-IRIS-Overexpressing TNBC Tumors Is Induced by Bidirectional Interaction with Tumor-Associated Macrophages.	Cancer research	2020	-1.9106117763571415	30.36667486986964	43	3.0
31911554	A Bis-Indole-Derived NR4A1 Antagonist Induces PD-L1 Degradation and Enhances Antitumor Immunity.	Cancer research	2020	-26.48978929490159	-27.442935747652683	16	1.1
31909761	[Immunotherapy in non-small cell lung cancer patients: back to the future.].	Recenti progressi in medicina	2019	35.16769601175231	-32.05709113465115	0	0.0
31907878	Microsatellite instability in Japanese female patients with triple-negative breast cancer.	Breast cancer (Tokyo, Japan)	2020	12.665950531205311	42.99403972515409	11	0.71
31906082	Retrospective Efficacy Analysis of Immune Checkpoint Inhibitor Rechallenge in Patients with Non-Small Cell Lung Cancer.	Journal of clinical medicine	2019	38.81447730057874	-19.305064280183363	36	1.69
31903901	[Next generation of anti-immune checkpoints antibodies].	Medecine sciences : M/S	2019	26.712998289885206	11.16499706806103	6	0.32
31903900	[The biology of PD1 and CTLA-4 as immunotherapeutic targets and the issue of biomarkers].	Medecine sciences : M/S	2019	20.99886269073853	8.838262437927025	4	0.19
31902695	Overcoming Primary Resistance to PD-1 Inhibitor With Anti-PD-L1 Agent in Squamous-Cell NSCLC: Case Report.	Clinical lung cancer	2020	50.602384369315	-46.42478704357652	7	0.43
31901900	Resveratrol targets PD-L1 glycosylation and dimerization to enhance antitumor T-cell immunity.	Aging	2020	-30.31740534955712	-36.89899935163825	73	6.35
31900276	Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab.	Clinical cancer research : an official journal of the American Association for Cancer Research	2020	13.91460524843443	8.76586583218275	91	6.21
31900171	Flow cytometry and targeted immune transcriptomics identify distinct profiles in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors with or without interferon-α.	Journal of translational medicine	2020	-40.4855648740966	15.421039518317109	17	1.21
31899315	Modified Bu-zhong-yi-qi decoction synergies with 5 fluorouracile to inhibits gastric cancer progress via PD-1/PD- L1-dependent T cell immunization.	Pharmacological research	2020	-22.715823804966703	-36.117948165967874	22	2.05
31897926	Difference in the hypoxic immunosuppressive microenvironment of patients with neurofibromatosis type 2 schwannomas and sporadic schwannomas.	Journal of neuro-oncology	2020	-22.09685253110464	54.1167469774509	12	1.02
31897310	The Value of Programmed Death Ligand 1 Expression in Cancer Patients Treated with Neoadjuvant Chemotherapy.	Sultan Qaboos University medical journal	2019	-15.93255925160538	6.462487045047137	2	0.13
31896512	Current status and development of anti-PD-1/PD-L1 immunotherapy for lung cancer.	International immunopharmacology	2020	31.51647723940353	-34.41592319169006	34	2.3
31895555	Nanoparticle Conjugation Stabilizes and Multimerizes β-Hairpin Peptides To Effectively Target PD-1/PD-L1 β-Sheet-Rich Interfaces.	Journal of the American Chemical Society	2020	-44.68731144595868	-44.30025899739268	26	1.91
31895048	Time to dissect the autoimmune etiology of cancer antibody immunotherapy.	The Journal of clinical investigation	2020	79.60465955401463	-10.707709389441415	56	3.58
31892597	Efficacy of Anti-PD1/PD-L1 Therapy (IO) in KRAS Mutant Non-small Cell Lung Cancer Patients: A Retrospective Analysis.	Anticancer research	2020	23.139690856723444	-22.693831537910658	12	0.68
31892360	High expression of B7-H3 on stromal cells defines tumor and stromal compartments in epithelial ovarian cancer and is associated with limited immune activation.	Journal for immunotherapy of cancer	2019	0.6516827716488052	28.33053077616285	38	1.76
34185300	Tumor Microenvironment in Penile Cancer.	Advances in experimental medicine and biology	2020	-0.5618295895531898	-6.840703507673576	0	0.0
33745258	PD-1, PD-L1 and PD-L2 Expression in Mantle Cell Lymphoma and Healthy Population.	Folia biologica	2020	-33.57452946802797	18.15920302995327	2	0.15
31891128	Programmed death ligand-1/programmed death-1 inhibition therapy and programmed death ligand-1 expression in urothelial bladder carcinoma.	Chronic diseases and translational medicine	2019	11.654836223087452	58.75579825315372	2	0.12
31889072	Immunotherapy using anti-PD-1 and anti-PD-L1 in Leishmania amazonensis-infected BALB/c mice reduce parasite load.	Scientific reports	2019	-67.45535077047778	11.50162275325828	19	1.22
31886125	Multiple lung cancers including squamous cell carcinoma with strong PD-L1 expression and adenocarcinoma with EGFR exon 19 deletion: A case report.	Respiratory medicine case reports	2020	9.36257677820202	-29.838984072350705	2	0.18
31883279	Higher densities of tumour-infiltrating lymphocytes and CD4+ T cells predict recurrence and progression of ductal carcinoma in situ of the breast.	Histopathology	2020	-3.136657174637614	18.367139098187952	20	1.45
31882544	The structural features that distinguish PD-L2 from PD-L1 emerged in placental mammals.	The Journal of biological chemistry	2020	-48.89843003998566	-36.99753603727858	46	3.08
31881699	Is There an Interplay between Immune Checkpoint Inhibitors, Thromboprophylactic Treatments and Thromboembolic Events? Mechanisms and Impact in Non-Small Cell Lung Cancer Patients.	Cancers	2019	69.87308908489342	-12.131445767700152	33	1.64
31881506	Prognostic and Predictive Value of Tumor-infiltrating Leukocytes and of Immune Checkpoint Molecules PD1 and PDL1 in Clear Cell Renal Cell Carcinoma.	Translational oncology	2020	15.823406844535787	32.94237685439908	38	2.32
31879345	CCR2 inhibition reduces tumor myeloid cells and unmasks a checkpoint inhibitor effect to slow progression of resistant murine gliomas.	Proceedings of the National Academy of Sciences of the United States of America	2020	-28.19140043961974	56.12592716794765	158	10.88
31877721	Structure and Optimization of Checkpoint Inhibitors.	Cancers	2019	32.130561285750225	-10.191136412314382	31	1.53
31876895	Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer: A Systematic Review and Meta-analysis.	JAMA oncology	2020	52.703558460004686	-13.21219612938827	171	10.69
31874674	[Advances in the Influence of EGFR Mutation on the PD-L1 Expression in Non-small Cell Lung Cancer].	Zhongguo fei ai za zhi = Chinese journal of lung cancer	2019	8.016317383645273	-31.331323197998845	0	0.0
31870882	PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology Committee.	Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer	2020	22.25845662352933	-39.653328902249335	177	12.33
31870373	Combined immune checkpoint inhibitor therapy with nivolumab and ipilimumab causing acute-onset type 1 diabetes mellitus following a single administration: two case reports.	BMC endocrine disorders	2019	87.35692313428233	-13.935791067544445	16	0.75
31869447	Considering adjuvant therapy for stage II melanoma.	Cancer	2020	31.974968529518996	31.032098686733143	28	1.91
31867425	PD-L1/PD-1 Biomarker for Metastatic Urothelial Cancer that Progress Post-platinum Therapy: A Systematic Review and Meta-analysis.	Bladder cancer (Amsterdam, Netherlands)	2019	65.44674500742963	22.373128007897257	11	0.62
31866087	Prognostic influence of tumor microenvironment after hypofractionated radiation and surgery for mesothelioma.	The Journal of thoracic and cardiovascular surgery	2020	5.721004202776778	12.121695115896156	23	1.62
31865179	Therapy Resistance in Neoadjuvantly Treated Gastric Cancer and Cancer of the Gastroesophageal Junction is Associated with an Increased Expression of Immune Checkpoint Inhibitors-Comparison Against a Therapy Naïve Cohort.	Translational oncology	2020	-39.03839955574624	36.61946047602213	9	0.62
31864288	Blocking the PD-1/PD-L1 axis enhanced cisplatin chemotherapy in osteosarcoma in vitro and in vivo.	Environmental health and preventive medicine	2019	-24.923405354199783	-6.563939237612504	21	1.22
31863604	New and Worsening Long-term Immune-Related Adverse Events with PD-1/PD-L1 Pathway Agents in Patients with Cancer.	Pharmacotherapy	2020	73.57189750231204	-14.116923331979642	5	0.33
31857857	Efficacy and safety profiles of programmed cell death-1/programmed cell death ligand-1 inhibitors in the treatment of triple-negative breast cancer: A comprehensive systematic review.	Oncology reviews	2019	56.154760649696776	-11.83494083602462	14	0.56
33569511	Immune checkpoint: The novel target for antitumor therapy.	Genes & diseases	2021	26.408030729263466	10.911856825766476	20	0.99
31855292	Merkel cell carcinoma update: the case for two tumours.	Journal of the European Academy of Dermatology and Venereology : JEADV	2020	44.78187698816735	52.22144167814215	15	1.41
31852114	Odds ratio of programmed cell death-1 or ligand 1 inhibitor-related endocrine dysfunction in patients with lung cancer: A systematic review and meta-analysis.	Medicine	2019	64.90025266309414	-14.848807772757022	1	0.06
31851923	Tissue-Resident Memory T Cells Mediate Immune Homeostasis in the Human Pancreas through the PD-1/PD-L1 Pathway.	Cell reports	2019	-58.81487915260003	1.3553564848271475	57	2.39
31851488	Multimodal Multiplexed Immunoimaging with Nanostars to Detect Multiple Immunomarkers and Monitor Response to Immunotherapies.	ACS nano	2020	4.368228203603736	-53.40183483703489	33	2.42
31850219	PD-L1 Expression on Tumor Cells Is Associated With a Poor Outcome in a Cohort of Caucasian Nasopharyngeal Carcinoma Patients.	Frontiers in oncology	2019	-16.751455206857976	31.53751569628048	10	0.56
31849495	Triterpenoid Saponins from Anemone flaccida Suppress Tumor Cell Proliferation by Regulating MAPK, PD1/PDL1, and STAT3 Signaling Pathways and Altering Cancer Metabolism.	OncoTargets and therapy	2019	-21.145639788855696	-34.13967102124581	12	0.87
31849171	Clinical manifestation and management of immune checkpoint inhibitor-associated cardiotoxicity.	Thoracic cancer	2020	83.33695812487242	1.8640455731252523	5	0.34
31848186	Effects of Tobacco Smoking on the Tumor Immune Microenvironment in Head and Neck Squamous Cell Carcinoma.	Clinical cancer research : an official journal of the American Association for Cancer Research	2020	-7.707220581924113	33.779355961143715	46	3.1
31844838	Highlights of 2019 Protein Engineering Summit (PEGS) in Boston, USA: Advancing Antibody-Based Cancer Therapies to the Clinic.	Antibody therapeutics	2019	-16.36500843238746	-48.04049310341591	3	0.2
31843962	Immunosuppression in Cows following Intramammary Infusion of Mycoplasma bovis.	Infection and immunity	2020	-80.26607296546638	2.450268394991863	9	1.31
31843013	High OX-40 expression in the tumor immune infiltrate is a favorable prognostic factor of overall survival in non-small cell lung cancer.	Journal for immunotherapy of cancer	2019	7.371062857838595	-12.264221611240275	29	1.22
31842671	Hypophysitis induced by immune checkpoint inhibitors: a 10-year assessment.	Expert review of endocrinology & metabolism	2019	83.8866228807533	-17.142353520910515	37	2.36
31842180	PD-1 and PD-L1 Expression in Osteosarcoma: Which Specimen to Evaluate?	Journal of pediatric hematology/oncology	2020	-17.70293742958526	18.828551508115805	15	1.21
31841754	The co-expression characteristics of LAG3 and PD-1 on the T cells of patients with breast cancer reveal a new therapeutic strategy.	International immunopharmacology	2020	8.87933914088326	23.146606604657208	44	2.94
31841311	Protein Footprinting and X-ray Crystallography Reveal the Interaction of PD-L1 and a Macrocyclic Peptide.	Biochemistry	2020	-47.181849869908085	-42.768269191345766	19	1.87
31841221	PD-L1 expression and infiltration by CD4+ and FoxP3+ T cells are increased in Xp11 translocation renal cell carcinoma and indicate poor prognosis.	Histopathology	2020	17.739393610931344	27.22604069904652	9	0.65
31840656	Studying the Effects of Tumor-Secreted Paracrine Ligands on Macrophage Activation using Co-Culture with Permeable Membrane Supports.	Journal of visualized experiments : JoVE	2019	-12.219830816019511	-1.1629545886544366	0	0.0
31839668	Antitumor activity of the PD-1/PD-L1 binding inhibitor BMS-202 in the humanized MHC-double knockout NOG mouse.	Biomedical research (Tokyo, Japan)	2019	-37.006514295675366	-36.4401337549898	20	1.03
31839609	Inverse Relationship Between Alzheimer's Disease and Cancer: How Immune Checkpoints Might Explain the Mechanisms Underlying Age-Related Diseases.	Journal of Alzheimer's disease : JAD	2020	-78.1444737729922	-4.1328206130386524	13	1.16
31839160	Treatment selection for patients with equivocal HER2 status and in luminal versus HER2-enriched disease.	Breast (Edinburgh, Scotland)	2019	6.478734395680255	28.166044777683723	4	0.17
31839159	Targeting immune pathways in breast cancer: review of the prognostic utility of TILs in early stage triple negative breast cancer (TNBC).	Breast (Edinburgh, Scotland)	2019	-5.107712347919633	20.3484853674604	39	2.13
31839077	[Research Advances on Programmed Cell Death Receptor-1 Antibody in the Treatment of Lymphoma--Review].	Zhongguo shi yan xue ye xue za zhi	2019	-44.3500478707333	-12.279084468132432	1	0.05
31839056	[Correlation of Nucleostemin with Programmed Death-ligand-1 in Multiple Myeloma U266 Cells].	Zhongguo shi yan xue ye xue za zhi	2019	-32.20772335791537	11.457702471058724	0	0.0
31838771	The Warburg effect and tumour immune microenvironment in extramammary Paget's disease: overexpression of lactate dehydrogenase A correlates with immune resistance.	Journal of the European Academy of Dermatology and Venereology : JEADV	2020	-14.084561206877863	25.410712233070875	20	1.49
31838340	Validation and characterisation of prognostically significant PD-L1+ immune cells in HPV+ oropharyngeal squamous cell carcinoma.	Oral oncology	2020	-3.531912450400059	-10.405569339265778	14	1.04
31838162	Emerging PD-1 and PD-1L inhibitors-associated myopathy with a characteristic histopathological pattern.	Autoimmunity reviews	2020	85.83513882851157	-1.374458778331104	38	3.08
31833942	Optimizing immunotherapy for gynecologic cancers.	Current opinion in obstetrics & gynecology	2020	40.927516912650965	35.21066797750683	18	1.1
31833274	[Endocrine consequences of immune checkpoint inhibitors].	Revue medicale de Liege	2019	82.11703743695202	-14.451792416998677	0	0.0
31829518	Concordance of PD-1 and PD-L1 (B7-H1) in paired primary and metastatic clear cell renal cell carcinoma.	Cancer medicine	2020	15.371955784352329	26.57795427331648	13	0.82
31828774	TIGIT as an emerging immune checkpoint.	Clinical and experimental immunology	2020	-12.193687984383184	-57.333669838684166	243	16.77
31827799	Immune biomarkers in thymic epithelial tumors: expression patterns, prognostic value and comparison of diagnostic tests for PD-L1.	Biomarker research	2019	-5.72556240595261	-36.98772631242928	16	0.81
31825692	Nivolumab for the treatment of unresectable pleural mesothelioma.	Expert opinion on biological therapy	2020	44.06072884269239	-11.156894624725464	10	0.72
31824482	T Regulatory Cells From Non-obese Diabetic Mice Show Low Responsiveness to IL-2 Stimulation and Exhibit Differential Expression of Anergy-Related and Ubiquitination Factors.	Frontiers in immunology	2019	-65.68475329711025	4.178508559027924	9	0.36
31823919	Comparison of laboratory-developed test & validated assay of programmed death ligand-1 immunohistochemistry in non-small-cell lung carcinoma.	The Indian journal of medical research	2019	16.514644116435615	-39.88910512111372	4	0.17
31823654	ENERGIZE: a Phase III study of neoadjuvant chemotherapy alone or with nivolumab with/without linrodostat mesylate for muscle-invasive bladder cancer.	Future oncology (London, England)	2020	74.73338257578871	20.81571309501854	50	3.17
31820040	[Merkel-cell carcinoma].	Der Pathologe	2019	44.92440499463736	52.15021945887481	6	0.79
31819973	PD-L1 Expression in Pediatric Low-Grade Gliomas Is Independent of BRAF V600E Mutational Status.	Journal of neuropathology and experimental neurology	2020	-23.459861718026705	49.25997529211287	9	0.6
31817953	Basis of PD1/PD-L1 Therapies.	Journal of clinical medicine	2019	-41.34370457230409	-16.21843737548006	67	3.52
31817109	The Interplay between Inflammation, Anti-Angiogenic Agents, and Immune Checkpoint Inhibitors: Perspectives for Renal Cell Cancer Treatment.	Cancers	2019	65.70370865563157	28.668457087948	18	0.98
31816206	Treatment of Immune Checkpoint Inhibitor Induced Colitis with Infliximab.	South Dakota medicine : the journal of the South Dakota State Medical Association	2019	77.20373767643035	-4.096503245126359	1	0.11
31814954	Structural insights and binding analysis for determining the molecular bases for programmed cell death protein ligand-1 inhibition.	MedChemComm	2019	-42.45310503722315	-39.42151403880586	4	0.26
31814756	Cost-Effectiveness Analysis Of Pembrolizumab In The Treatment Of Advanced Recurrent Metastatic Head And Neck Squamous Cell Carcinoma In China And The United States.	Cancer management and research	2019	54.24285500086015	-25.22789980594507	9	0.54
31813343	PD-L1 Inhibitor-Induced Thyroiditis Is Associated with Better Overall Survival in Cancer Patients.	Thyroid : official journal of the American Thyroid Association	2020	77.80181115603017	-17.16749580716391	91	6.48
31812554	Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial.	The Lancet. Oncology	2020	49.519885882555045	1.0462450273803965	131	8.79
31812347	A combination of check-point blockade and α-galactosylceramide elicits long-lasting suppressive effects on murine hepatoma cell growth in vivo.	Immunobiology	2020	-23.54100877285897	-16.642536285545088	4	0.26
31811434	Characterisation of tumour microenvironment and immune checkpoints in primary central nervous system diffuse large B cell lymphomas.	Virchows Archiv : an international journal of pathology	2020	-32.01456332974105	31.605626468241407	20	1.36
31811337	Mechanisms of immune evasion in bladder cancer.	Cancer immunology, immunotherapy : CII	2020	69.66984169114293	21.794251692938342	86	6.54
31810952	Association of High Neutrophil-to-Lymphocyte Ratio With Poor Outcomes of Pembrolizumab Therapy in High-PD-L1-expressing Non-small Cell Lung Cancer.	Anticancer research	2019	28.2458223786323	-41.30257267470149	20	0.88
31810126	Comprehensive characterization of tumor infiltrating natural killer cells and clinical significance in hepatocellular carcinoma based on gene expression profiles.	Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie	2020	-14.037641256693767	45.404417517054654	38	2.55
31808941	Checkpoint inhibitors in AML: are we there yet?	British journal of haematology	2020	18.529502397613783	16.76838823905415	24	1.6
31808707	Immunoscore system combining CD8 and PD-1/PD-L1: A novel approach that predicts the clinical outcomes for cervical cancer.	The International journal of biological markers	2020	2.4763567138863887	-10.799829083780368	17	1.37
31807308	Cancer biomarkers for targeted therapy.	Biomarker research	2019	19.529235379736804	-0.2546349459634441	47	2.29
31806878	Spatial proximity between T and PD-L1 expressing cells as a prognostic biomarker for oropharyngeal squamous cell carcinoma.	British journal of cancer	2020	-6.470987322498522	30.645165488257582	25	1.57
31805690	A Novel Anti-PD-L1 Vaccine for Cancer Immunotherapy and Immunoprevention.	Cancers	2019	-27.648697861041565	-13.469418116900668	9	0.4
31802108	Differences in PD-L1-Expressing Macrophages and Immune Microenvironment in Testicular Germ Cell Tumors.	American journal of clinical pathology	2020	-25.579284842933863	33.6193740385206	12	1.01
31801632	Immunomodulatory effects of interferon-γ on human fetal cardiac mesenchymal stromal cells.	Stem cell research & therapy	2019	-55.96017586940558	22.55354760442616	4	0.25
31801525	Development and clinical applications of cancer immunotherapy against PD-1 signaling pathway.	Journal of biomedical science	2019	24.573926258005173	5.772720138756558	23	0.99
31801484	EGFR mutation: novel prognostic factor associated with immune infiltration in lower-grade glioma; an exploratory study.	BMC cancer	2019	-19.707215573607986	55.15514913158567	28	1.4
31801317	A Radiosensitivity Gene Signature and PD-L1 Status Predict Clinical Outcome of Patients with Glioblastoma Multiforme in The Cancer Genome Atlas Dataset.	Cancer research and treatment	2020	-23.570324224147623	46.34696237486033	13	0.81
31799894	Nanobodies targeting the interaction interface of programmed death receptor 1 (PD-1)/PD-1 ligand 1 (PD-1/PD-L1).	Preparative biochemistry & biotechnology	2020	-39.05710011437848	-47.32254767785789	8	0.62
31799812	Oncogene addiction and tumor mutational burden in non-small-cell lung cancer: Clinical significance and limitations.	Thoracic cancer	2020	22.787378599694957	-17.449620116190786	18	1.26
31798961	Global alteration of T-lymphocyte metabolism by PD-L1 checkpoint involves a block of de novo nucleoside phosphate synthesis.	Cell discovery	2019	-29.5146302659154	-28.71982034648033	13	0.58
31798692	KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic nonsquamous NSCLC.	Therapeutic advances in medical oncology	2019	21.06520710749843	-22.153041426119103	23	1.04
31796994	Proteolytic processing of PD-L1 by ADAM proteases in breast cancer cells.	Cancer immunology, immunotherapy : CII	2020	-11.93290628442568	15.71175154484968	41	3.07
31791080	[Gastrointestinal complications of the new immune checkpoint inhibitor therapies].	Deutsche medizinische Wochenschrift (1946)	2019	75.44020287140987	-3.1444055031057627	1	0.04
31788476	Is the Combination of Immunotherapy and Radiotherapy in Non-small Cell Lung Cancer a Feasible and Effective Approach?	Frontiers in medicine	2019	35.58836806616711	-27.98619747778058	30	1.59
31788072	A subset of patients with MSS/MSI-low-colorectal cancer showed increased CD8(+) TILs together with up-regulated IFN-γ.	Oncology letters	2019	10.488637065821152	40.23832294769947	35	1.61
31787479	Dendritic cell upregulation of programmed death ligand-1 via DNA demethylation inhibits experimental autoimmune encephalomyelitis.	Journal of autoimmunity	2020	-72.07532428602919	-5.698690640217944	7	0.49
31787352	Precursor cells and implications of a T-cell inflamed immune response in the pre-malignant setting in Hodgkin lymphoma.	Immunobiology	2020	-38.48512209539937	27.41301075918448	1	0.13
31786476	The impact of body mass index on the efficacy of anti-PD-1/PD-L1 antibodies in patients with non-small cell lung cancer.	Lung cancer (Amsterdam, Netherlands)	2020	31.05511437068293	-47.93373334780076	60	4.4
31785431	Expression of Programmed Cell Death Ligand 1 and Associated Lymphocyte Infiltration in Olfactory Neuroblastoma.	World neurosurgery	2020	-27.608694474304635	16.161832118857983	12	1.32
31783783	PD1Hi CD8+ T cells correlate with exhausted signature and poor clinical outcome in hepatocellular carcinoma.	Journal for immunotherapy of cancer	2019	-15.62606511851495	42.77422804748892	164	7.86
31783776	Soluble immune checkpoint-related proteins as predictors of tumor recurrence, survival, and T cell phenotypes in clear cell renal cell carcinoma patients.	Journal for immunotherapy of cancer	2019	16.562380611467105	33.25809431731098	81	4.26
31783023	Multiplex immunofluorescence staining and image analysis assay for diffuse large B cell lymphoma.	Journal of immunological methods	2020	3.8810933600051936	-46.851484879048805	25	1.72
31782790	Differential effect of intermittent hypoxia and sleep fragmentation on PD-1/PD-L1 upregulation.	Sleep	2020	-60.83039643913213	25.46268281283468	25	2.21
31782328	Influence of age on the efficacy of immune checkpoint inhibitors in advanced cancers: a systematic review and meta-analysis.	Acta oncologica (Stockholm, Sweden)	2020	56.06589296584109	-19.356299567769963	24	1.55
31781673	Beyond T Cells: Understanding the Role of PD-1/PD-L1 in Tumor-Associated Macrophages.	Journal of immunology research	2019	-45.79605030774661	-14.73923875592936	78	4.22
31779710	MDM2 inhibitor APG-115 synergizes with PD-1 blockade through enhancing antitumor immunity in the tumor microenvironment.	Journal for immunotherapy of cancer	2019	-27.593929317527277	-22.63861203104813	75	3.56
31776089	Th9 cells are subjected to PD-1/PD-L1-mediated inhibition and are capable of promoting CD8 T cell expansion through IL-9R in colorectal cancer.	International immunopharmacology	2020	4.589270644637201	38.17670589308296	28	1.81
31773448	Tumor immune microenvironment is associated with the growth of intracranial germinomas.	Journal of neuro-oncology	2020	-23.458200594346533	32.865268923750875	5	0.69
31771985	Targeting CMTM6 Suppresses Stem Cell-Like Properties and Enhances Antitumor Immunity in Head and Neck Squamous Cell Carcinoma.	Cancer immunology research	2020	-11.959899648241082	35.64287142764311	75	4.93
31771762	Interferon signaling in cancer. Non-canonical pathways and control of intracellular immune checkpoints.	Seminars in immunology	2019	-17.78003048337213	-19.921792145948096	29	1.29
31771616	Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.	Journal of hematology & oncology	2019	-9.454066751208572	28.143488317206995	70	3.37
31770109	CD73 immune checkpoint defines regulatory NK cells within the tumor microenvironment.	The Journal of clinical investigation	2020	4.753162117339681	5.309188740069619	115	7.61
31764833	Efficacy and safety of anti-PD-1/PD-L1 agents vs chemotherapy in patients with gastric or gastroesophageal junction cancer: a systematic review and meta-analysis.	Medicine	2019	49.93080079679931	15.95165239253138	21	0.98
31762755	Immune-Related Pancytopenia Induced by Anti-PD-1 Therapy - Interrupt or Continue Treatment - The Role of Immunohistochemical Examination.	Case reports in oncology	2019	81.18496814455582	-9.528771566475283	2	0.18
31762164	Impact of PD-L1 expression and human papillomavirus status in anti-PD1/PDL1 immunotherapy for head and neck squamous cell carcinoma-Systematic review and meta-analysis.	Head & neck	2020	-4.459565687504513	-7.346021506667698	42	3.0
31761900	Relationship between the immune microenvironment of different locations in a primary tumour and clinical outcomes of oesophageal squamous cell carcinoma.	British journal of cancer	2020	-6.22790762102601	26.716593182574275	15	0.91
31758623	Phenotypic characterization of testicular immune cells expressing immune checkpoint molecules in wild-type and pituitary adenylate cyclase-activating polypeptide-deficient mice.	American journal of reproductive immunology (New York, N.Y. : 1989)	2020	-65.92836017448872	-1.1605710486183751	4	0.54
31758536	Stimulatory and Inhibitory Co-signals in Autoimmunity.	Advances in experimental medicine and biology	2019	-55.61619467136795	-10.048999115737722	8	0.35
31757674	PD-L1:CD80 Cis-Heterodimer Triggers the Co-stimulatory Receptor CD28 While Repressing the Inhibitory PD-1 and CTLA-4 Pathways.	Immunity	2019	-49.09081791266503	-1.6207683557410564	171	7.8
31756590	Primary and acquired resistance mechanisms to immune checkpoint inhibition in Hodgkin lymphoma.	Cancer treatment reviews	2020	-8.533565636331698	-25.47125807966592	27	1.58
31755641	In silico screening and surface plasma resonance-based verification of programmed death 1-targeted peptides.	Chemical biology & drug design	2020	-43.1401788544916	-41.43065130122012	2	0.23
31755433	Evaluation of PD-L1 and PD-1 expression in aggressive eyelid sebaceous gland carcinoma and its clinical significance.	Indian journal of ophthalmology	2019	0.3851119806732204	-0.5590369775759914	8	0.62
31753012	Hepatitis B virus reactivation in cancer patients with positive Hepatitis B surface antigen undergoing PD-1 inhibition.	Journal for immunotherapy of cancer	2019	64.66227758378322	2.907149685941614	93	4.7
31751845	The life and death of the germinal center.	Annals of diagnostic pathology	2020	-22.86160943921075	32.2578244073876	21	1.47
31749060	Immune Checkpoint Inhibition in Non-metastatic Non-small Cell Lung Cancer: Chance for Cure?	Drugs	2019	39.734250435099206	-26.257200819848457	4	0.2
31747091	Molecular genetics of cutaneous squamous cell carcinoma: perspective for treatment strategies.	Journal of the European Academy of Dermatology and Venereology : JEADV	2020	-9.943013633099772	37.763750489169375	22	1.8
31746428	IDO inhibitor synergized with radiotherapy to delay tumor growth by reversing T cell exhaustion.	Molecular medicine reports	2020	30.49670188450605	19.33960554717739	29	1.82
31745591	Discovery of hPRDX5-based peptide inhibitors blocking PD-1/PD-L1 interaction through in silico proteolysis and rational design.	Cancer chemotherapy and pharmacology	2020	-43.3405936847014	-44.482071743061226	8	0.61
31744830	Targeting PD-L1 Initiates Effective Antitumor Immunity in a Murine Model of Cushing Disease.	Clinical cancer research : an official journal of the American Association for Cancer Research	2020	-3.5326785644141467	-19.16028463512557	31	2.59
31744296	Biomimetic and Self-Assembled Nanoclusters Targeting β-Catenin for Potent Anticancer Therapy and Enhanced Immunotherapy.	Nano letters	2019	-41.89020808476891	-49.54999175420711	19	0.8
31743287	Clinicopathologic Correlation of Kaposi Sarcoma Involving the Ocular Adnexa: Immunophenotyping of Diagnostic and Therapeutic Targets.	Ophthalmic plastic and reconstructive surgery	2020	-22.55843885356299	22.391895791281435	3	0.37
31741780	A novel in situ multiplex immunofluorescence panel for the assessment of tumor immunopathology and response to virotherapy in pediatric glioblastoma reveals a role for checkpoint protein inhibition.	Oncoimmunology	2019	-33.26547313977634	54.03811177285501	17	0.83
31741757	Beneficial modulation of the tumor microenvironment and generation of anti-tumor responses by TLR9 agonist lefitolimod alone and in combination with checkpoint inhibitors.	Oncoimmunology	2019	-21.88666723342792	-23.14665156387089	22	1.07
31739121	Prognostic significance of programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) expression in uterine carcinosarcoma.	European journal of obstetrics, gynecology, and reproductive biology	2020	-17.0547415693109	9.5862316892785	7	0.84
31737389	A Histologically Complete Response to Immunotherapy Using Pembrolizumab in a Patient with Giant Cell Carcinoma of the Lung: An Additional Report and Literature Review.	Case reports in oncological medicine	2019	52.72635762493229	-32.59925281498031	4	0.17
31730012	Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors.	Journal for immunotherapy of cancer	2019	76.75372800970416	-11.397295660578	504	26.38
31730010	Mechanisms regulating PD-L1 expression on tumor and immune cells.	Journal for immunotherapy of cancer	2019	-38.57705095506852	-9.393016257549698	235	12.28
31729943	Anti-VEGF/VEGFR2 Monoclonal Antibodies and their Combinations with PD-1/PD-L1 Inhibitors in Clinic.	Current cancer drug targets	2020	-8.52024447121652	-42.78255192267077	34	2.41
31729418	PD-1+ melanocortin receptor dependent-Treg cells prevent autoimmune disease.	Scientific reports	2019	-67.10003909365692	0.6737076216850713	11	0.66
31729316	Soluble PD-L1 generated by endogenous retroelement exaptation is a receptor antagonist.	eLife	2019	-46.01888342990653	18.08694247646496	36	1.62
31727535	Lactate up-regulates the expression of PD-L1 in kidney and causes immunosuppression in septic Acute Renal Injury.	Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi	2021	-59.49130092397275	33.7917431887326	15	1.59
31727249	In vitro assay for the development of small molecule inhibitors targeting PD-1/PD-L1.	Methods in enzymology	2019	-40.36119603344108	-37.42840517381494	18	1.01
31727131	CRISPR-Cas9 disruption of PD-1 enhances activity of universal EGFRvIII CAR T cells in a preclinical model of human glioblastoma.	Journal for immunotherapy of cancer	2019	-44.39426841998254	1.8611677820029384	153	7.3
31724091	Role of regulatory T cells and checkpoint inhibition in hepatocellular carcinoma.	Cancer immunology, immunotherapy : CII	2019	-16.61576234649503	44.79240746475225	75	3.78
31723178	Investigation of protein-protein interactions and hot spot region between PD-1 and PD-L1 by fragment molecular orbital method.	Scientific reports	2019	-46.05253187433902	-40.49215104295057	37	2.16
31720814	PD-1+ TIGIT+ CD8+ T cells are associated with pathogenesis and progression of patients with hepatitis B virus-related hepatocellular carcinoma.	Cancer immunology, immunotherapy : CII	2019	-74.76115020071295	27.03768947512613	58	3.09
31720083	Modeling multi-needle injection into solid tumor.	American journal of cancer research	2019	20.978309106279543	1.1315989700191404	5	0.28
31719056	TCR Repertoire Diversity of Peripheral PD-1+CD8+ T Cells Predicts Clinical Outcomes after Immunotherapy in Patients with Non-Small Cell Lung Cancer.	Cancer immunology research	2020	13.262145668192227	-8.432450621012109	130	7.8
31717574	Immune Checkpoint PD-1/PD-L1 CTLA-4/CD80 are Blocked by Rhus verniciflua Stokes and its Active Compounds.	Molecules (Basel, Switzerland)	2019	-30.992812949968187	-38.247564358863	24	1.95
31712383	Adaptive Immune Resistance to Intravesical BCG in Non-Muscle Invasive Bladder Cancer: Implications for Prospective BCG-Unresponsive Trials.	Clinical cancer research : an official journal of the American Association for Cancer Research	2020	7.652164070073204	59.34616016900091	63	4.61
31710313	Galectin-1-driven T cell exclusion in the tumor endothelium promotes immunotherapy resistance.	The Journal of clinical investigation	2019	-28.16016123350473	7.769993843887305	77	3.86
31709594	Epigenetic abnormalities of classical Hodgkin lymphoma and its effect on immune escape.	Cell biochemistry and function	2020	-6.446570651438717	-27.81471023915745	2	0.13
31707719	Toxicity associated with PD-1 blockade after allogeneic haematopoietic cell transplantation.	Swiss medical weekly	2019	76.92160297576538	-6.886724308822589	2	0.15
31704289	Prognostic and clinicopathological significance of PD-1/PD-L1 expression in the tumor microenvironment and neoplastic cells for lymphoma.	International immunopharmacology	2019	-34.2221390129934	25.57250990824373	31	1.74
31704288	The incidence and relative risk of PD-1/PD-L1 inhibitors-related colitis in non-small cell lung cancer: A meta-analysis of randomized controlled trials.	International immunopharmacology	2019	67.21724758471831	-14.54746970581145	4	0.14
31704149	The PD-L1/PD-1 axis expression on tumor-infiltrating immune cells and tumor cells in pediatric rhabdomyosarcoma.	Pathology, research and practice	2019	-26.57403577952007	17.93200309744884	9	0.49
31703740	"CAR-T ""the living drugs"", immune checkpoint inhibitors, and precision medicine: a new era of cancer therapy."	Journal of hematology & oncology	2019	30.312793526310543	10.519194818897017	54	2.73
31703637	Fostering efficacy of anti-PD-1-treatment: Nivolumab plus radiotherapy in advanced non-small cell lung cancer - study protocol of the FORCE trial.	BMC cancer	2019	43.75561116342801	-22.926469319420185	24	1.07
31701469	Setting the Dose of Checkpoint Inhibitors: The Role of Clinical Pharmacology.	Clinical pharmacokinetics	2020	32.54198135529278	-10.185960302271813	6	0.29
31700871	JS001, an anti-PD-1 mAb for advanced triple negative breast cancer patients after multi-line systemic therapy in a phase I trial.	Annals of translational medicine	2019	54.01801203825352	-7.86010102678477	14	0.65
31700694	Inhibition of immune checkpoints prevents injury-induced heterotopic ossification.	Bone research	2019	-2.8706640282858333	-16.08171323578542	14	0.95
31699145	Moving forward to address key unanswered questions on targeting PD-1/PD-L1 in cancer: limitations in preclinical models and the need to incorporate human modifying factors.	Journal for immunotherapy of cancer	2019	-38.50440664741492	-25.536331378546667	4	0.19
31698313	Clinical pharmacology of monoclonal antibodies targeting anti-PD-1 axis in urothelial cancers.	Critical reviews in oncology/hematology	2019	70.51001803951911	15.789531607638564	5	0.25
31697809	The microenvironmental niche in classic Hodgkin lymphoma is enriched for CTLA-4-positive T cells that are PD-1-negative.	Blood	2019	-27.54164381611262	26.724043517393767	72	3.27
31694270	The Prognostic Role of CD8+ T Lymphocytes in Childhood Adrenocortical Carcinomas Compared to Ki-67, PD-1, PD-L1, and the Weiss Score.	Cancers	2019	12.343863447084384	18.33461593023282	21	1.34
31693657	Prediction of PD-L1 inhibition effects for HIV-infected individuals.	PLoS computational biology	2019	-82.46439166921618	14.64836592632346	6	0.29
31690319	Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4.	Molecular cancer	2019	29.41232392859088	12.260062399197606	583	30.81
31690181	Establishment of humanized tumor microenvironment mouse models based on the injection of peripheral blood mononuclear cells and IFN-γ to evaluate the efficacy of PD-L1/PD-1-targeted immunotherapy.	Cancer biology & therapy	2020	-37.90249578360461	-26.67818834749561	4	0.26
31686860	The Role Of PD-1/PD-L1 Axis In Treg Development And Function: Implications For Cancer Immunotherapy.	OncoTargets and therapy	2019	-45.50050593613023	-13.262620745984371	112	5.75
31686330	Shortened ex vivo manufacturing time of EGFRvIII-specific chimeric antigen receptor (CAR) T cells reduces immune exhaustion and enhances antiglioma therapeutic function.	Journal of neuro-oncology	2019	-45.28267781199387	4.336109867602017	23	1.16
31686036	Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial.	Nature medicine	2019	72.89633708502929	15.151778914586693	315	15.21
31685233	Prognostic implications of immune classification in a multicentre cohort of patients with small intestinal adenocarcinoma.	Pathology	2020	7.374628957451851	37.45563118174287	4	0.24
31684954	The tumor inflammation signature (TIS) is associated with anti-PD-1 treatment benefit in the CERTIM pan-cancer cohort.	Journal of translational medicine	2019	-0.4136921542464691	42.79936814461408	70	3.08
31683962	PD-L1 Expression and Tumor-Infiltrating Lymphocytes in Thymic Epithelial Neoplasms.	Journal of clinical medicine	2019	-5.518489177780424	-36.85428092251085	16	0.73
31683809	Hyperprogressive Disease during Anti-PD-1 (PDCD1) / PD-L1 (CD274) Therapy: A Systematic Review and Meta-Analysis.	Cancers	2019	37.394051838923495	-50.90637962296928	69	3.11
31683225	Gene signatures of tumor inflammation and epithelial-to-mesenchymal transition (EMT) predict responses to immune checkpoint blockade in lung cancer with high accuracy.	Lung cancer (Amsterdam, Netherlands)	2020	-0.1985056469974933	39.687705512219885	72	4.76
31683169	Immunotherapy for head and neck cancer: Recent advances and future directions.	Oral oncology	2019	52.48751087979216	30.06522812639261	165	10.07
31683168	Alterations in composition of immune cells and impairment of anti-tumor immune response in aged oral cancer-bearing mice.	Oral oncology	2019	-6.182368420471123	32.35942786829719	10	0.48
31681606	The Controversial Role of PD-1 and Its Ligands in Gynecological Malignancies.	Frontiers in oncology	2019	-19.541197850095926	9.358134751260788	25	1.25
31681591	Clinicopathologic Significance and Immunogenomic Analysis of Programmed Death-Ligand 1 (PD-L1) and Programmed Death 1 (PD-1) Expression in Thymic Epithelial Tumors.	Frontiers in oncology	2019	-5.367354888314216	-36.609716445864144	14	0.91
31681314	BATF Potentially Mediates Negative Regulation of PD-1/PD-Ls Pathway on T Cell Functions in Mycobacterium tuberculosis Infection.	Frontiers in immunology	2019	-85.0450395765741	2.3241250634638155	5	0.2
31679823	Small-Molecule MYC Inhibitors Suppress Tumor Growth and Enhance Immunotherapy.	Cancer cell	2019	-38.9081968305781	-36.67181477517053	196	9.2
31678303	Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.	Gastroenterology	2020	-20.11152447115166	39.915835860655896	40	2.69
31676387	Oncolytic Newcastle disease virus expressing a checkpoint inhibitor as a radioenhancing agent for murine melanoma.	EBioMedicine	2019	25.61859409621352	25.0031921180751	41	2.28
31675543	The clinical significance of soluble PD-1 and PD-L1 in lung cancer.	Critical reviews in oncology/hematology	2019	0.4131450176537835	-29.16293984842389	50	2.87
31674884	Expression of PD-1/PD-L1 in head and neck squamous cell carcinoma and its clinical significance.	The International journal of biological markers	2019	-5.616532759714946	-7.521922650657494	30	1.63
31673481	The efficacy and safety of combination of PD-1 and CTLA-4 inhibitors: a meta-analysis.	Experimental hematology & oncology	2019	50.271932708179136	-10.706753522544185	44	2.03
31671550	Immunotherapies and Future Combination Strategies for Head and Neck Squamous Cell Carcinoma.	International journal of molecular sciences	2019	52.58538226798397	32.08858079505883	26	1.5
31669518	PD-1 and PD-L1 inhibitors in oesophago-gastric cancers.	Cancer letters	2020	42.15911181733914	15.944532130376938	32	2.14
31668929	Mechanisms Controlling PD-L1 Expression in Cancer.	Molecular cell	2019	-41.25257273054785	-11.55927898902234	375	18.41
31667679	Perforation of small intestinal metastasis of lung adenocarcinoma treated with pembrolizumab: a case report.	Surgical case reports	2019	68.76097897447933	-16.432061189817958	5	0.34
31667366	Identification of a monoclonal antibody that targets PD-1 in a manner requiring PD-1 Asn58 glycosylation.	Communications biology	2019	-36.65393438299829	-31.7125307312197	27	1.34
31662794	Prognostic value of PD-L1 expression for surgically treated localized renal cell carcinoma: implications for risk stratification and adjuvant therapies.	Therapeutic advances in urology	2019	17.042837965960537	26.812055614588896	12	0.56
31661771	PD-L1/PD-1 Axis in Glioblastoma Multiforme.	International journal of molecular sciences	2019	-26.283749854952607	50.5437940391795	100	5.9
31661001	Targeting CXCR4 potentiates anti-PD-1 efficacy modifying the tumor microenvironment and inhibiting neoplastic PD-1.	Journal of experimental & clinical cancer research : CR	2019	-17.654522102067055	-28.01591452425369	58	3.02
31660091	Immunomodulatory aspects in the progression and treatment of oral malignancy.	The Japanese dental science review	2019	-8.005602056518347	-14.890672501311789	22	1.18
31659278	A multicenter analysis of genomic profiles and PD-L1 expression of primary lymphoepithelioma-like carcinoma of the lung.	Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc	2020	19.21836022375383	-18.90514635168326	32	2.16
31659256	Listeria-based hepatocellular carcinoma vaccine facilitates anti-PD-1 therapy by regulating macrophage polarization.	Oncogene	2020	-23.960405821874552	-18.525497578956077	42	2.7
31657376	Single droplet detection of immune checkpoints on a multiplexed electrohydrodynamic biosensor.	The Analyst	2019	-20.48688110232014	-63.559705447980974	12	0.78
31657115	PGC-1α inhibits polyamine metabolism in Cyclin E1-driven ovarian cancer.	Cancer medicine	2019	-15.443713331459636	-29.697716743193958	10	0.52
31656652	Impact of clinicopathological features on the efficacy of immune checkpoint inhibitors plus conventional treatment in patients with advanced lung cancer.	Journal of thoracic disease	2019	41.47933122500603	-18.739791222654308	3	0.11
31656061	Interobserver Reproducibility of PD-L1 Biomarker in Non-small Cell Lung Cancer: A Multi-Institutional Study by 27 Pathologists.	Journal of pathology and translational medicine	2019	15.570212515950416	-39.28592013869294	21	1.09
31654628	Cervical cancer patients that respond to chemoradiation therapy display an intense tumor infiltrating immune profile before treatment.	Experimental and molecular pathology	2019	-4.434779321742579	35.93197816956939	17	0.85
31653509	Evaluation of clear cell subtypes of ovarian and uterine malignancies with anti-PD-L1 and anti-PD1 immunohistochemical expression and their association with stage and survival.	Gynecologic oncology	2019	-17.073952021947154	12.678469771081565	5	0.39
31653140	Programmed Death Ligand 1; An Immunotarget for Renal Cell Carcinoma.	Asian Pacific journal of cancer prevention : APJCP	2019	18.156232120412277	26.42858627442264	5	0.29
31651870	PD-1/PD-L1 pathway activation restores the imbalance of Th1/Th2 and treg/Th17 cells subtypes in immune thrombocytopenic purpura patients.	Medicine	2019	-51.49522027820832	4.0264714783388	18	0.97
31651359	Avelumab monotherapy as first-line or second-line treatment in patients with metastatic renal cell carcinoma: phase Ib results from the JAVELIN Solid Tumor trial.	Journal for immunotherapy of cancer	2019	50.64513642860611	-6.582962329412839	40	1.63
31651174	PLGA Nanoparticles Codelivering siRNAs against Programmed Cell Death Protein-1 and Its Ligand Gene for Suppression of Colon Tumor Growth.	Molecular pharmaceutics	2019	-34.6260079609031	-50.62350005815412	22	1.43
31647023	The role of exosomal PD-L1 in tumor progression and immunotherapy.	Molecular cancer	2019	-43.56296022172331	-59.18408719478696	180	9.97
31646108	Aberrant upregulation of PDK1 in ovarian cancer cells impairs CD8+ T cell function and survival through elevation of PD-L1.	Oncoimmunology	2019	-22.90169905878733	9.594374134486037	19	1.0
31646107	A synergistic triad of chemotherapy, immune checkpoint inhibitors, and caloric restriction mimetics eradicates tumors in mice.	Oncoimmunology	2019	-19.18813400333797	-28.988391729885723	48	2.02
31646095	Blockade of ErbB2 and PD-L1 using a bispecific antibody to improve targeted anti-ErbB2 therapy.	Oncoimmunology	2019	-13.839737953734511	-46.86547180797584	29	1.36
31646091	Clinical impact of T cells, B cells and the PD-1/PD-L1 pathway in muscle invasive bladder cancer: a comparative study of transurethral resection and cystectomy specimens.	Oncoimmunology	2019	6.329659234882534	59.45396057848913	28	1.36
31646079	Clinical evidence that immunogenic cell death sensitizes to PD-1/PD-L1 blockade.	Oncoimmunology	2019	85.36664180415639	-7.343848365040993	49	2.29
31646074	Increased CMTM6 can predict the clinical response to PD-1 inhibitors in non-small cell lung cancer patients.	Oncoimmunology	2019	5.699720608149344	-10.193397621106268	37	1.73
31646073	MiRNA expression patterns are associated with tumor mutational burden in lung adenocarcinoma.	Oncoimmunology	2019	5.107659370638144	50.7093773712383	23	1.01
31645893	Pembrolizumab-induced necrotizing myositis in a patient with metastatic non-small-cell lung cancer: a case report.	Lung cancer management	2019	86.4900202362059	-0.4226160072275151	3	0.17
31645587	Structural and In Vitro Functional Analyses of Novel Plant-Produced Anti-Human PD1 Antibody.	Scientific reports	2019	47.25068297138958	24.019552877898317	27	1.63
31640814	Discovery of low-molecular weight anti-PD-L1 peptides for cancer immunotherapy.	Journal for immunotherapy of cancer	2019	-42.44742829941171	-43.58912442985529	53	3.03
31640780	Immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune checkpoint blockade and neoantigen-based immunotherapies.	Journal for immunotherapy of cancer	2019	-29.13803778178177	32.39905266431184	16	0.69
31640402	PD-L1 and PD-1 expressed in trigeminal ganglia may inhibit pain in an acute migraine model.	Cephalalgia : an international journal of headache	2020	-73.842843177573	-13.044355434166873	11	0.81
31640203	PD-1-Targeted Discovery of Peptide Inhibitors by Virtual Screening, Molecular Dynamics Simulation, and Surface Plasmon Resonance.	Molecules (Basel, Switzerland)	2019	-42.82642604033158	-41.174374952315134	18	1.15
31639551	Immune checkpoint protein and cytokine expression by T lymphocytes in pleural effusion of cancer patients receiving anti-PD-1 therapy.	Lung cancer (Amsterdam, Netherlands)	2019	7.49888546128748	13.129419506960708	3	0.13
31639056	Comprehensive immune profiling and immune-monitoring using body fluid of patients with metastatic gastric cancer.	Journal for immunotherapy of cancer	2019	4.407686351687015	29.71182751306605	18	0.91
31636634	The Diverse Function of PD-1/PD-L Pathway Beyond Cancer.	Frontiers in immunology	2019	-48.364389788792174	-11.191359311598733	192	10.33
31635553	NGS-analysis to the rescue: dual checkpoint inhibition in metastatic osteosarcoma - a case report and review of the literature.	Acta clinica Belgica	2021	35.647494370217764	13.542405024546364	7	0.82
31632907	Comparative Safety of PD-1/PD-L1 Inhibitors for Cancer Patients: Systematic Review and Network Meta-Analysis.	Frontiers in oncology	2019	60.260602994701095	-15.023740175818094	14	0.66
31630495	[Clinicopathological characteristics of type 2 diabetes mellitus complicated with colorectal cancer].	Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery	2019	11.9941570343746	36.99741519977367	0	0.0
31628530	[Salivary gland malignancies-highlights of the 2019 ASCO Annual Meeting].	HNO	2019	60.7768175060746	0.4332682048893267	5	0.46
31627906	[Myocarditis: Uncommon but severe toxicity of immune checkpoint inhibitors].	Bulletin du cancer	2019	84.00797694554333	3.6190638208591848	7	0.33
31627433	Emerging role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma.	Medicina (Kaunas, Lithuania)	2019	31.7057616239412	49.34001170197716	40	2.14
31626963	Screening of kinase inhibitors downregulating PD-L1 expression via on/in cell quantitative immunoblots.	European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences	2020	-40.659567819134	-38.40059554986263	6	0.46
31625630	Association of combined PD-L1 expression and tumour-infiltrating lymphocyte features with survival and treatment outcomes in patients with metastatic melanoma.	Journal of the European Academy of Dermatology and Venereology : JEADV	2020	7.874742594915982	-0.946695931560463	22	1.36
31623687	Monalizumab: inhibiting the novel immune checkpoint NKG2A.	Journal for immunotherapy of cancer	2019	25.923706795763994	10.317753613071966	147	7.43
31623665	Tumor-infiltrating B cells affect the progression of oropharyngeal squamous cell carcinoma via cell-to-cell interactions with CD8+ T cells.	Journal for immunotherapy of cancer	2019	-8.971087916881464	32.179481200086244	63	3.34
31623180	Relationship between Microsatellite Instability, Immune Cells Infiltration, and Expression of Immune Checkpoint Molecules in Ovarian Carcinoma: Immunotherapeutic Strategies for the Future.	International journal of molecular sciences	2019	9.89132406553862	45.9960150109611	17	0.89
31619231	Co-mutations of TP53 and KRAS serve as potential biomarkers for immune checkpoint blockade in squamous-cell non-small cell lung cancer: a case report.	BMC medical genomics	2019	19.88508590773605	-21.44355998437885	19	0.8
31617320	Exceptionally rapid response to pembrolizumab in a SMARCA4-deficient thoracic sarcoma overexpressing PD-L1: A case report.	Thoracic cancer	2019	58.00292809984088	-37.69569265116702	52	2.55
31616428	Immunopathogenesis of Immune Checkpoint Inhibitor-Related Adverse Events: Roles of the Intestinal Microbiome and Th17 Cells.	Frontiers in immunology	2019	75.4544464988922	-5.626586761144718	43	2.12
31615933	Immune Cell PD-L1 Colocalizes with Macrophages and Is Associated with Outcome in PD-1 Pathway Blockade Therapy.	Clinical cancer research : an official journal of the American Association for Cancer Research	2020	-26.138347941207854	5.880119289225759	161	10.05
31615069	Predictive Factors for Response to PD-1/PD-L1 Checkpoint Inhibition in the Field of Hepatocellular Carcinoma: Current Status and Challenges.	Cancers	2019	-21.363717233063596	38.84869359758826	57	2.97
31614877	Breast Cancer Cells and PD-1/PD-L1 Blockade Upregulate the Expression of PD-1, CTLA-4, TIM-3 and LAG-3 Immune Checkpoints in CD4+ T Cells.	Vaccines	2019	-28.490412845455896	-5.573307278996135	54	2.82
31612048	PD-L1 expression levels on tumor cells affect their immunosuppressive activity.	Oncology letters	2019	-41.24210402461328	-8.718854557972044	55	2.94
31611702	Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups.	Nature immunology	2019	25.2167379364974	11.428063334736192	262	12.54
31611650	Tumor-expressed B7-H3 mediates the inhibition of antitumor T-cell functions in ovarian cancer insensitive to PD-1 blockade therapy.	Cellular & molecular immunology	2020	-29.012109670747744	6.112195550809523	51	3.16
31611243	Trifluridine/Tipiracil plus Oxaliplatin Improves PD-1 Blockade in Colorectal Cancer by Inducing Immunogenic Cell Death and Depleting Macrophages.	Cancer immunology research	2019	26.1089622547687	28.65717399151704	64	3.29
31610523	Clinical heterogeneity of hypophysitis secondary to PD-1/PD-L1 blockade: insights from four cases.	Endocrinology, diabetes & metabolism case reports	2019	84.24280367574995	-17.86088171371205	36	2.2
31609651	Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma.	Journal of clinical oncology : official journal of the American Society of Clinical Oncology	2019	45.601684497584245	-5.393218001243287	158	7.44
31608320	Immune checkpoint inhibitors for treatment of thymic epithelial tumors: how to maximize benefit and optimize risk?	Mediastinum (Hong Kong, China)	2019	38.87612423518266	-1.6060073691515846	30	1.81
31607917	The Relative Risk of Immune-Related Liver Dysfunction of PD-1/PD-L1 Inhibitors Versus Chemotherapy in Solid Tumors: A Meta-Analysis of Randomized Controlled Trials.	Frontiers in pharmacology	2019	65.15909085243923	-17.008998496453373	6	0.24
31607749	Association between the exposure to anti-angiogenic agents and tumour immune microenvironment in advanced gastrointestinal stromal tumours.	British journal of cancer	2019	-9.509602978165235	24.799989591479427	1	0.07
31606777	Increased indoleamine 2,3-dioxygenase activity and expression in prostate cancer following targeted immunotherapy.	Cancer immunology, immunotherapy : CII	2019	-16.050684396143186	-31.005351643573047	17	0.82
31605795	Quantitative Assessment of CMTM6 in the Tumor Microenvironment and Association with Response to PD-1 Pathway Blockade in Advanced-Stage Non-Small Cell Lung Cancer.	Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer	2019	5.666717607123725	-10.109065694405755	40	1.7
31605439	The landscape of immune microenvironment in lung adenocarcinoma and squamous cell carcinoma based on PD-L1 expression and tumor-infiltrating lymphocytes.	Cancer medicine	2019	-8.111921474639257	23.020984882811543	29	1.39
31604533	Glycogen synthase 3 (GSK-3) regulation of PD-1 expression and and its therapeutic implications.	Seminars in immunology	2019	-38.71901436097696	-34.549553930399554	12	0.59
31604033	Hepatitis B virus-triggered PTEN/β-catenin/c-Myc signaling enhances PD-L1 expression to promote immune evasion.	American journal of physiology. Gastrointestinal and liver physiology	2020	-71.71061761065533	22.45890870862884	15	1.15
31598564	Hepatic expression of programmed death-1 (PD-1) and its ligand, PD-L1, in children with autoimmune hepatitis: relation to treatment response.	Clinical and experimental hepatology	2019	-68.37113443918471	24.22705121468797	10	0.53
31594104	[Advances in the study of programmed cell death protein 1 and its ligand inhibitors in the treatment of late stage HCC].	Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology	2019	27.81232361232781	49.47948631827349	0	0.0
31593831	Immune gene expression in head and neck squamous cell carcinoma patients.	European journal of cancer (Oxford, England : 1990)	2019	-8.808068090872998	34.380042923235656	39	2.08
31593039	The Programmed Death Pathway in Ocular Adnexal Sebaceous Carcinoma.	Ophthalmic plastic and reconstructive surgery	2020	-0.0306571950369239	-0.744870127422431	6	0.72
31591862	Local ablative radiotherapy for oligometastatic non-small cell lung cancer.	Radiation oncology journal	2019	36.97485907285047	-27.61725198416152	10	0.59
31587253	Blockage of immune checkpoint molecules increases T-cell priming potential of dendritic cell vaccine.	Immunology	2020	-29.26200831375868	-13.614674726024017	60	4.58
31586491	Prognostic significance of PD-L1 protein expression and copy number gains in locally advanced cervical cancer.	Asian Pacific journal of allergy and immunology	2021	1.3792790327872728	-10.706543865673584	3	0.38
31585483	Maternal soluble PD-1 levels are significantly increased in women with preeclampsia.	American journal of reproductive immunology (New York, N.Y. : 1989)	2020	-74.40813619756999	-20.800365339808653	9	0.85
31582355	Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial.	The Lancet. Oncology	2019	53.30775744760777	12.608369298875838	591	31.51
31582259	Current concepts of non-coding RNA regulation of immune checkpoints in cancer.	Molecular aspects of medicine	2019	14.91428760587408	19.638799974840428	37	2.06
31581738	Classical Hodgkin's Lymphoma in the Era of Immune Checkpoint Inhibition.	Journal of clinical medicine	2019	-8.126525016552032	-25.646437436899937	14	0.69
31581482	Correlation between B7-H4 and Survival of Non-Small-Cell Lung Cancer Patients Treated with Nivolumab.	Journal of clinical medicine	2019	2.632759649948127	-18.25119854435831	19	0.81
31576146	Enumeration And Characterization Of Circulating Tumor Cells And Its Application In Advanced Gastric Cancer.	OncoTargets and therapy	2019	9.883435476838086	-39.55197079691888	14	0.84
31575949	Unbalanced Expression of ICOS and PD-1 in Patients with Neuromyelitis Optica Spectrum Disorder.	Scientific reports	2019	-55.48015770884288	12.374927787604266	5	0.26
31573752	Immune checkpoint inhibitors for head and neck squamous cell carcinoma: Current landscape and future directions.	Head & neck	2019	50.35410979837391	32.05813607837994	36	2.01
31572677	Expression of Programmed Cell Death-Ligands in Hepatocellular Carcinoma: Correlation With Immune Microenvironment and Survival Outcomes.	Frontiers in oncology	2019	-22.709803277616142	39.595868848925534	30	1.57
31572609	Dual targeting of RANKL and PD-1 with a bispecific antibody improves anti-tumor immunity.	Clinical & translational immunology	2019	-16.48811281271971	-46.34033015750147	21	0.95
31572198	Antipsychotic Drug Trifluoperazine Suppresses Colorectal Cancer by Inducing G0/G1 Arrest and Apoptosis.	Frontiers in pharmacology	2019	-21.45520641086752	-26.92318653106043	33	2.11
31570880	Tumour-intrinsic resistance to immune checkpoint blockade.	Nature reviews. Immunology	2020	23.32786247791736	7.4583379852014975	627	40.98
31570691	LncRNA SNHG14/miR-5590-3p/ZEB1 positive feedback loop promoted diffuse large B cell lymphoma progression and immune evasion through regulating PD-1/PD-L1 checkpoint.	Cell death & disease	2019	-19.45529044010307	33.406812576891824	124	6.97
31570447	Expression of Immune Checkpoint Receptors on T-Cells and Their Ligands on Leukemia Blasts in Childhood Acute Leukemia.	Anticancer research	2019	-36.96375423550936	15.961980614942467	17	0.86
31570249	Using adaptive genetic algorithms combined with high sensitivity single cell-based technology to detect bladder cancer in urine and provide a potential noninvasive marker for response to anti-PD1 immunotherapy.	Urologic oncology	2020	9.106266465352828	60.73600223945839	1	0.04
31568700	MIR155HG is a prognostic biomarker and associated with immune infiltration and immune checkpoint molecules expression in multiple cancers.	Cancer medicine	2019	-4.18622319900718	55.97643900340971	79	4.27
31567999	Immunohistochemistry of immune checkpoint markers PD-1 and PD-L1 in prostate cancer.	Medicine	2019	-12.630729738479417	12.93328099989635	34	1.65
31564188	Programmed death-ligand 1 and survival in colorectal cancers: A meta-analysis.	The International journal of biological markers	2019	-4.828497532014382	10.910028337658938	7	0.34
31562760	Recombinant Human Interleukin-15 and Anti-PD-L1 Combination Therapy Expands a CXCR3+PD1-/low CD8 T-Cell Subset in Simian Immunodeficiency Virus-Infected Rhesus Macaques.	The Journal of infectious diseases	2020	-84.67384647167835	16.35519024245247	5	0.31
31558872	Significance of tumor-infiltrating immunocytes for predicting prognosis of hepatitis B virus-related hepatocellular carcinoma.	World journal of gastroenterology	2019	-12.863045239352267	47.06923829875977	17	0.86
31557787	The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy.	Journal of clinical medicine	2019	19.784404759916505	-4.266151264377352	35	1.79
31555516	The association of PD-L1 expression with the efficacy of anti-PD-1/PD-L1 immunotherapy and survival of non-small cell lung cancer patients: a meta-analysis of randomized controlled trials.	Translational lung cancer research	2019	49.0303247685258	-16.058806116767364	75	3.78
31555511	OX40 and OX40L protein expression of tumor infiltrating lymphocytes in non-small cell lung cancer and its role in clinical outcome and relationships with other immune biomarkers.	Translational lung cancer research	2019	7.349623517427121	-12.255152814087356	26	1.32
31554797	CAR exosomes derived from effector CAR-T cells have potent antitumour effects and low toxicity.	Nature communications	2019	-38.92118296340798	-59.760839711723065	204	11.49
31552181	Down Regulation of c-FLIPL Enhance PD-1 Blockade Efficacy in B16 Melanoma.	Frontiers in oncology	2019	-29.12563777257016	-8.449317080442452	9	0.39
31552167	Dramatic Response of Leptomeningeal Carcinomatosis to Nivolumab in PD-L1 Highly Expressive Non-small Cell Lung Cancer: A Case Report.	Frontiers in oncology	2019	54.485659055590745	-30.545098673700743	9	0.5
31551142	PD-1 inhibitors monotherapy in hepatocellular carcinoma: Meta-analysis and systematic review.	Hepatobiliary & pancreatic diseases international : HBPD INT	2019	51.95045791768125	-14.830005961968867	26	1.32
31550725	High-Grade Neuroendocrine Carcinoma of the Head and Neck: Human Papillomavirus Status and PD-L1 Expression.	ORL; journal for oto-rhino-laryngology and its related specialties	2019	-3.421735532967106	-7.913119866854414	3	0.18
31550464	Lymphovascular Invasion Is Associated With Mutational Burden and PD-L1 in Resected Lung Cancer.	The Annals of thoracic surgery	2020	21.33801249185869	-17.132381361821327	6	0.4
31549270	Combination therapy with PD-1 or PD-L1 inhibitors for cancer.	International journal of clinical oncology	2020	32.86483874602136	8.497751494274917	74	5.09
31547532	Current Possibilities of Gynecologic Cancer Treatment with the Use of Immune Checkpoint Inhibitors.	International journal of molecular sciences	2019	40.35037213248918	36.727946337068175	37	2.05
31545446	CTHRC1 and PD‑1/PD‑L1 expression predicts tumor recurrence in prostate cancer.	Molecular medicine reports	2019	-11.509176212974518	13.147025991562748	12	0.62
31545443	High blood levels of soluble OX40 (CD134), an immune costimulatory molecule, indicate reduced survival in patients with advanced colorectal cancer.	Oncology reports	2019	7.314006931509304	-12.149367857474	11	0.55
31542865	Endocrine toxicity in cancer patients treated with nivolumab or pembrolizumab: results of a large multicentre study.	Journal of endocrinological investigation	2020	76.33613578169988	-17.792957220237327	20	1.53
31541762	Inhibition of the PD-1/PD-L1 signaling pathway enhances innate immune response of alveolar macrophages to mycobacterium tuberculosis in mice.	Pulmonary pharmacology & therapeutics	2020	-84.71020829766279	1.6435688577251093	11	0.92
31538897	Study of Serum Soluble Programmed Death Ligand 1 as a Prognostic Factor in Hepatocellular Carcinoma in Egyptian Patients.	Current cancer drug targets	2019	-25.7056973045808	38.20597554334401	19	1.2
31536125	Immune Thrombocytopenia-A Neglected Adverse Event of PD-1 and PD-L1 Inhibitors in Clinical Trials-In Reply.	JAMA oncology	2019	66.68679455032135	-20.40652572316205	1	0.03
31536124	Immune Thrombocytopenia-A Neglected Adverse Event of PD-1 and PD-L1 Inhibitors in Clinical Trials.	JAMA oncology	2019	66.68976200562767	-20.405833516619737	1	0.08
31533840	Targeting interferon signaling and CTLA-4 enhance the therapeutic efficacy of anti-PD-1 immunotherapy in preclinical model of HPV+ oral cancer.	Journal for immunotherapy of cancer	2019	-11.600631090196895	-15.169850304911233	42	1.98
31533832	Closed system RT-qPCR as a potential companion diagnostic test for immunotherapy outcome in metastatic melanoma.	Journal for immunotherapy of cancer	2019	8.678149286933406	-0.8384877203602058	14	0.51
31533363	Nitric Oxide-Mediated Enhancement and Reversal of Resistance of Anticancer Therapies.	Antioxidants (Basel, Switzerland)	2019	-31.48735792855952	-23.43059934641165	24	1.56
31533144	[Possibilities of immune checkpoint inhibitor therapy for patients with metastatic non-small cell lung cancer].	Magyar onkologia	2019	29.024485338452696	-33.80388009749763	0	0.0
31533137	[Predictive diagnostics of the programmed cell death receptor 1 (PD-1) - programmed cell death ligand 1 (PD-L1) inhibitory therapies].	Magyar onkologia	2019	18.71952519912489	-43.37078559924476	0	0.0
31533057	The Transcription Factor Bhlhe40 Programs Mitochondrial Regulation of Resident CD8+ T Cell Fitness and Functionality.	Immunity	2019	-47.730203986385	13.351605282879415	112	4.41
31532724	Pembrolizumab in Relapsed and Refractory Mycosis Fungoides and Sézary Syndrome: A Multicenter Phase II Study.	Journal of clinical oncology : official journal of the American Society of Clinical Oncology	2020	46.15419376128648	-2.9560316726353384	122	9.13
31531785	Albumin-globulin ratio is a predictive biomarker of antitumor effect of anti-PD-1 antibody in patients with non-small cell lung cancer.	International journal of clinical oncology	2020	27.599962783388087	-42.1557403727067	17	1.29
31531021	"Corrigendum to ""Outcomes of Programmed Cell Death Protein 1 (PD-1) and Programmed Death-Ligand 1 (PD-L1) Inhibitor Therapy in HIV Patients with Advanced Cancer""."	Journal of oncology	2019	46.67131662736706	-12.26611559927818	2	0.09
31530839	Tumor Infiltrating Lymphocytes and Macrophages Improve Survival in Microsatellite Unstable Colorectal Cancer.	Scientific reports	2019	10.966607560050196	42.127918167385	69	3.28
31530560	Trabectedin Reveals a Strategy of Immunomodulation in Chronic Lymphocytic Leukemia.	Cancer immunology research	2019	-41.07623707728917	18.5380999586662	31	1.64
31527697	HPV-positive status associated with inflamed immune microenvironment and improved response to anti-PD-1 therapy in head and neck squamous cell carcinoma.	Scientific reports	2019	-4.049250737357884	-7.425564664734765	87	4.64
31526368	Role of the dynamic tumor microenvironment in controversies regarding immune checkpoint inhibitors for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations.	Molecular cancer	2019	32.82117456000532	-25.12812017812676	116	5.49
31519705	Enfortumab Vedotin Checks Urothelial Cancer.	Cancer discovery	2019	68.44317625829419	12.54953597500278	1	0.04
31519633	Plasma Levels of Soluble PD-L1 Correlate With Tumor Regression in Patients With Lung and Gastric Cancer Treated With Immune Checkpoint Inhibitors.	Anticancer research	2019	7.226261738856031	7.044795915253032	35	1.88
31516390	PD-1 and PD-L1 correlated gene expression profiles and their association with clinical outcomes of breast cancer.	Cancer cell international	2019	-9.932244381274897	15.345051262273447	34	1.77
31513320	Regulation of programmed death-ligand 1 expression in response to DNA damage in cancer cells: Implications for precision medicine.	Cancer science	2019	-40.45105813732397	-11.953968080446083	34	1.66
31511925	Desmoid tumors display a strong immune infiltration at the tumor margins and no PD-L1-driven immune suppression.	Cancer immunology, immunotherapy : CII	2019	-16.862910509225436	23.103214308058785	10	0.65
31509303	Variable indoleamine 2,3-dioxygenase expression in acral/mucosal melanoma and its possible link to immunotherapy.	Cancer science	2019	3.902439799448282	-4.51076879037265	10	0.54
31505846	Investigation of the Effect of PD-L1 Blockade on Triple Negative Breast Cancer Cells Using Fourier Transform Infrared Spectroscopy.	Vaccines	2019	54.05921083784335	-40.532833464662126	8	0.4
31502147	Measuring Tumor Mutational Burden Using Whole-Exome Sequencing.	Methods in molecular biology (Clifton, N.J.)	2020	24.48776236099656	-15.993841202920835	5	0.3
31502013	New insight on the correlation of metabolic status on 18F-FDG PET/CT with immune marker expression in patients with non-small cell lung cancer.	European journal of nuclear medicine and molecular imaging	2020	15.734060969475683	-57.04760458566992	55	3.99
31501892	The Relationship Between Tumor-Stroma Ratio, the Immune Microenvironment, and Survival in Patients With Spinal Chordoma.	Neurosurgery	2019	-16.409132598052008	27.52773463945309	25	1.33
31501534	The multifaceted immune regulation of bladder cancer.	Nature reviews. Urology	2019	5.333613517231541	59.92011390853576	95	4.38
31498037	[Immunotherapies - Overview, mode of action and clinical implications].	Therapeutische Umschau. Revue therapeutique	2019	25.40767716275372	8.144702289691708	0	0.0
31497071	The evolving immuno-oncology landscape in advanced lung cancer: first-line treatment of non-small cell lung cancer.	Therapeutic advances in medical oncology	2019	40.5906810444191	-33.72822294882978	39	1.97
31496815	Programmed cell death 1 expression and Epstein-Barr virus infection in chronic lymphocytic leukaemia: a prospective cohort study.	Cancer management and research	2019	-39.17271262699512	26.456637349808727	13	0.79
31495493	Blocking the PD-1-PD-L1 axis by a novel PD-1 specific nanobody expressed in yeast as a potential therapeutic for immunotherapy.	Biochemical and biophysical research communications	2019	-38.656557005521535	-48.004818075644	17	1.06
31493723	Genomic scoring to determine clinical benefit of immunotherapy by targeted sequencing.	European journal of cancer (Oxford, England : 1990)	2019	25.212730194344736	-19.128117919098084	22	0.82
31492714	Prognostic significance of PD-1 and PD-L1 positive tumor-infiltrating immune cells in ovarian carcinoma.	International journal of gynecological cancer : official journal of the International Gynecological Cancer Society	2019	-19.728224748771915	13.396932421376032	15	0.78
31491347	Live Cell Membranome cDNA Screen: A Novel Homogenous Live Cell Binding Assay to Study Membrane Protein-Ligand Interaction.	SLAS discovery : advancing life sciences R & D	2019	-49.998067009318376	-31.50401083136592	1	0.18
31488176	Immune checkpoint inhibitors of PD-L1 as cancer therapeutics.	Journal of hematology & oncology	2019	-41.05748884747504	-18.19358020627788	392	21.8
34805871	The potential combinational immunotherapiesfor treatment of hepatocellular carcinoma.	Journal of interventional medicine	2019	29.728046285147997	49.38741427457678	2	0.11
31485721	Evaluation of cancer testis antigen (CT10, PRAME) and MHC I expression in high-grade urothelial carcinoma of the bladder.	Virchows Archiv : an international journal of pathology	2020	7.256006925097042	60.90004607261571	7	0.48
31482306	Independent expression of circulating and tissue levels of PD-L1: correlation of clusters with tumor metabolism and outcome in patients with non-small cell lung cancer.	Cancer immunology, immunotherapy : CII	2019	21.17622185673841	-29.697128295773368	9	0.5
31481761	Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade.	Cell research	2019	-20.77505964211432	-19.847591816994505	125	5.34
31480495	Prediction of PD-L1 Expression in Neuroblastoma via Computational Modeling.	Brain sciences	2019	-3.004550151971132	-44.73828098557301	19	1.25
31475034	DNA Methylation Biomarkers Predict Objective Responses to PD-1/PD-L1 Inhibition Blockade.	Frontiers in genetics	2019	11.456854209061072	8.251561070345572	10	0.44
31475002	Sequential Anti-PD1 Therapy Following Dendritic Cell Vaccination Improves Survival in a HER2 Mammary Carcinoma Model and Identifies a Critical Role for CD4 T Cells in Mediating the Response.	Frontiers in immunology	2019	-26.824242864185827	-14.611567285003122	33	1.64
31473853	The Era of Checkpoint Inhibition: Lessons Learned from Melanoma.	Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer	2020	31.154457710104374	5.250857658511563	4	0.28
31473251	BET protein targeting suppresses the PD-1/PD-L1 pathway in triple-negative breast cancer and elicits anti-tumor immune response.	Cancer letters	2019	-28.41278805647684	10.155443715074451	30	1.56
31471540	Amplification of 9p24.1 in diffuse large B-cell lymphoma identifies a unique subset of cases that resemble primary mediastinal large B-cell lymphoma.	Blood cancer journal	2019	-30.629352256864134	27.5167548033152	27	1.31
31471333	The Clinical Significance of PD-L1/PD-1 Expression in Gastroenteropancreatic Neuroendocrine Neoplasia.	Annals of clinical and laboratory science	2019	-0.0349489008917616	11.38052269591198	11	0.72
31468071	[Immune checkpoint inhibition in Merkel cell carcinoma].	Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete	2019	46.68659718336518	49.98951458250832	3	0.15
31467175	ERK1/2 signaling regulates the immune microenvironment and macrophage recruitment in glioblastoma.	Bioscience reports	2019	-25.51809697605665	55.03172817330986	15	0.76
31464670	Sicca/Sjögren's syndrome triggered by PD-1/PD-L1 checkpoint inhibitors. Data from the International ImmunoCancer Registry (ICIR).	Clinical and experimental rheumatology	2019	83.75950443834745	-9.469826929022949	44	2.78
31464522	Exceptional Response to Nivolumab in a 13-Year-Old Female with Metastatic HPV-Negative Cervical Carcinoma.	DNA and cell biology	2019	41.28960252050621	-2.7876870087654964	0	0.0
31462297	Prim-O-glucosylcimifugin enhances the antitumour effect of PD-1 inhibition by targeting myeloid-derived suppressor cells.	Journal for immunotherapy of cancer	2019	-22.782075319378343	-32.599878094066	24	1.25
31462152	Myasthenia gravis induced by avelumab.	Immunotherapy	2019	68.25190239922966	-3.9571482155778166	5	0.48
31456438	Pembrolizumab for the treatment of diffuse large B-cell lymphoma.	Expert opinion on biological therapy	2019	44.44948407905607	-5.989214522461736	11	0.49
31455836	Synergistic antitumor effect on cervical cancer by rational combination of PD1 blockade and CRISPR-Cas9-mediated HPV knockout.	Cancer gene therapy	2020	-12.469270525661726	-16.30868439685744	32	2.55
31455014	Building a Bridge between Chemotherapy and Immunotherapy in Malignant Pleural Mesothelioma: Investigating the Effect of Chemotherapy on Immune Checkpoint Expression.	International journal of molecular sciences	2019	43.47007040544433	-11.435170968792356	10	0.5
31454748	Galectin-9 in non-small cell lung cancer.	Lung cancer (Amsterdam, Netherlands)	2019	7.834114784514133	20.305655238458726	27	1.66
31452748	Expression patterns of programmed death-1 and programmed death-1 ligand-1 on T cells in gastric cancer.	Oncology letters	2019	-9.76882083431148	4.620179194189846	4	0.14
31451484	CD8+PD-1-ILT2+ T Cells Are an Intratumoral Cytotoxic Population Selectively Inhibited by the Immune-Checkpoint HLA-G.	Cancer immunology research	2019	14.855377031791484	31.048205155441103	44	2.5
31451071	PGC-1α activator-induced fatty acid oxidation in tumor-infiltrating CTLs enhances effects of PD-1 blockade therapy in lung cancer.	Tumori	2020	29.206175999694533	-56.54396728293395	20	1.17
31449902	BP180-specific IgG is associated with skin adverse events, therapy response, and overall survival in non-small cell lung cancer patients treated with checkpoint inhibitors.	Journal of the American Academy of Dermatology	2020	18.10707175517413	-33.69243021848873	51	3.44
31449889	Serum Antibody Against NY-ESO-1 and XAGE1 Antigens Potentially Predicts Clinical Responses to Anti-Programmed Cell Death-1 Therapy in NSCLC.	Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer	2019	19.704428613702916	-33.717959961435824	28	1.28
31447840	Is There a Place for Immunotherapy for Metastatic Microsatellite Stable Colorectal Cancer?	Frontiers in immunology	2019	36.9992186222489	20.980056454339213	42	1.76
31447062	PD-L1 gene copy number and promoter polymorphisms regulate PD-L1 expression in tumor cells of non-small cell lung cancer patients.	Cancer genetics	2019	11.666027936818905	-26.51745354120533	9	0.47
31446896	Antibody targeting tumor-derived soluble NKG2D ligand sMIC provides dual co-stimulation of CD8 T cells and enables sMIC+ tumors respond to PD1/PD-L1 blockade therapy.	Journal for immunotherapy of cancer	2019	-28.40902931255954	-17.828748401645026	17	0.75
31445197	Challenging the recalcitrant disease-developing molecularly driven treatments for small cell lung cancer.	European journal of cancer (Oxford, England : 1990)	2019	42.29650023249176	-40.80325625110823	16	0.79
31444856	Neutrophilic dermatoses as adverse effects of checkpoint inhibitors: A review.	Dermatologic therapy	2019	73.81134861668623	-24.504731289669003	19	1.74
31444293	Dual Checkpoint Inhibition with Ipilimumab plus Nivolumab After Progression on Sequential PD-1/PDL-1 Inhibitors Pembrolizumab and Atezolizumab in a Patient with Lynch Syndrome, Metastatic Colon, and Localized Urothelial Cancer.	The oncologist	2019	38.65681461722858	22.813869066572792	29	1.38
31442817	Programmed cell death 1 (PD-1) targeting in patients with advanced osteosarcomas: results from the PEMBROSARC study.	European journal of cancer (Oxford, England : 1990)	2019	50.68596885863277	0.7609843146452554	84	4.59
31440705	Anti-PD-1 Immunotherapy May Induce Interstitial Nephritis With Increased Tubular Epithelial Expression of PD-L1.	Kidney international reports	2019	70.47846184350709	2.08078412237456	38	2.4
31440238	A Phase Ib Study of the Combination of Personalized Autologous Dendritic Cell Vaccine, Aspirin, and Standard of Care Adjuvant Chemotherapy Followed by Nivolumab for Resected Pancreatic Adenocarcinoma-A Proof of Antigen Discovery Feasibility in Three Patients.	Frontiers in immunology	2019	-20.82243068709185	-12.741708790178109	50	2.43
31439614	Immunopathologic Stratification of Colorectal Cancer for Checkpoint Blockade Immunotherapy.	Cancer immunology research	2019	37.88009111083085	22.767645893938383	29	1.21
31437431	Immunotherapy for Lymphangioleiomyomatosis and Tuberous Sclerosis: Progress and Future Directions.	Chest	2019	1.2894270344017038	-27.244437233580552	11	0.63
31436822	Multiomics Prediction of Response Rates to Therapies to Inhibit Programmed Cell Death 1 and Programmed Cell Death 1 Ligand 1.	JAMA oncology	2019	-1.0529462035067745	-43.830577936910345	128	5.39
31436392	The effects and safety of PD-1/PD-L1 inhibitors on head and neck cancer: A systematic review and meta-analysis.	Cancer medicine	2019	58.52363662189601	1.304413820793507	19	0.9
31436226	Pembrolizumab for the treatment of nonsmall cell lung cancer: Current status and future directions.	Journal of cancer research and therapeutics	2019	47.14973189506047	-31.97661800222226	13	0.8
31435660	Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression.	Annals of oncology : official journal of the European Society for Medical Oncology	2019	48.694186928899576	-28.784372723769252	169	7.89
31434708	EBV Latency III-Transformed B Cells Are Inducers of Conventional and Unconventional Regulatory T Cells in a PD-L1-Dependent Manner.	Journal of immunology (Baltimore, Md. : 1950)	2019	-70.05409037530404	17.053645509327367	11	0.66
31433988	Combination PD-1 and PD-L1 Blockade Promotes Durable Neoantigen-Specific T Cell-Mediated Immunity in Pancreatic Ductal Adenocarcinoma.	Cell reports	2019	-21.69501802534478	-12.513157292137835	58	2.63
31432705	Pembrolizumab in lung cancer: current evidence and future perspectives.	Future oncology (London, England)	2019	47.80379683533578	-32.45107791934526	3	0.16
31431617	The Δ133p53β isoform promotes an immunosuppressive environment leading to aggressive prostate cancer.	Cell death & disease	2019	-9.974810715555035	12.995096202372808	34	1.67
31429779	Cytolytic activity correlates with the mutational burden and deregulated expression of immune checkpoints in colorectal cancer.	Journal of experimental & clinical cancer research : CR	2019	6.80874569488876	40.34907088640075	53	2.54
31429521	PD-L1 expression, CD8+ and CD4+ lymphocyte rate are predictive of pathological complete response after neoadjuvant chemoradiotherapy for squamous cell cancer of the thoracic esophagus.	Cancer medicine	2019	4.2383579074922	22.088396572471847	19	0.92
31429085	Upregulation of PD-1 follows tumour development in the AOM/DSS model of inflammation-induced colorectal cancer in mice.	Immunology	2019	-20.487439939545684	3.9640578019142714	22	1.16
31428993	Unraveling LGALS1 as a Potential Immune Checkpoint and a Predictor of the Response to Anti-PD1 Therapy in Clear Cell Renal Carcinoma.	Pathology oncology research : POR	2020	16.206350619396176	29.713629892345804	12	0.8
31428525	High tumoral PD-L1 expression and low PD-1+ or CD8+ tumor-infiltrating lymphocytes are predictive of a poor prognosis in primary diffuse large B-cell lymphoma of the central nervous system.	Oncoimmunology	2019	-33.93117959503319	31.19251529034119	22	1.16
31428520	Atezolizumab potentiates Tcell-mediated cytotoxicity and coordinates with FAK to suppress cell invasion and motility in PD-L1+ triple negative breast cancer cells.	Oncoimmunology	2019	53.667308264099184	-40.04370533553976	33	1.67
31427630	Engineered Dendritic Cell-Directed Concurrent Activation of Multiple T cell Inhibitory Pathways Induces Robust Immune Tolerance.	Scientific reports	2019	-57.943997539761504	-2.457368601447	8	0.5
31424637	PD-1 and PD-L1 as immunotherapy targets and biomarkers in non-small cell lung cancer.	Journal of B.U.ON. : official journal of the Balkan Union of Oncology	2019	23.28988754220955	-37.08748448079959	29	1.82
31423221	Lentivirus-mediated RNA interference targeting programmed death receptor ligand 1 increases the immunologic anti-tumor effect of dendritic cell vaccination against pancreatic cancer in SCID-hu mice.	Oncology letters	2019	-14.883961430572285	-2.077204801457329	2	0.13
31421963	Balancing cancer immunotherapy and immune-related adverse events: The emerging role of regulatory T cells.	Journal of autoimmunity	2019	15.037511317595376	14.980932796149958	43	2.1
31420357	Neoadjuvant Pembrolizumab Takes on TNBC.	Cancer discovery	2019	41.255463933775445	7.81840605923575	5	0.27
31417907	Biomarkers for Predicting Efficacies of Anti-PD1 Antibodies.	Frontiers in medicine	2019	18.997630679737444	-5.94546791213474	34	1.77
33365377	Molecular Biomarkers of Response to PD-1/ PD-L1 Immune Checkpoint Blockade in Advanced Bladder Cancer.	Bladder cancer (Amsterdam, Netherlands)	2019	10.111000281319289	61.04660902923354	9	0.45
31413804	In Vitro Assessment of Putative PD-1/PD-L1 Inhibitors: Suggestions of an Alternative Mode of Action.	ACS medicinal chemistry letters	2019	-41.824636524575794	-41.07572330787784	20	0.98
31413527	Immunotherapy in colorectal cancer: Available clinical evidence, challenges and novel approaches.	World journal of gastroenterology	2019	37.07603205938627	20.462552619884143	37	1.8
31412954	Combination immunotherapy and radiotherapy causes an abscopal treatment response in a mouse model of castration resistant prostate cancer.	Journal for immunotherapy of cancer	2019	28.09331473891674	22.418695455656536	58	3.02
31412943	PD-L1 blockade engages tumor-infiltrating lymphocytes to co-express targetable activating and inhibitory receptors.	Journal for immunotherapy of cancer	2019	-27.70695738754285	-18.340794197335452	34	1.47
31409885	Quantitative assessment of PD-L1 as an analyte in immunohistochemistry diagnostic assays using a standardized cell line tissue microarray.	Laboratory investigation; a journal of technical methods and pathology	2020	13.469283364379036	-42.58025622096929	46	3.07
31409612	The Folate Pathway Inhibitor Pemetrexed Pleiotropically Enhances Effects of Cancer Immunotherapy.	Clinical cancer research : an official journal of the American Association for Cancer Research	2019	34.57348620894481	-42.41672577156579	79	3.5
31406210	Myeloid maturation potentiates STAT3-mediated atypical IFN-γ signaling and upregulation of PD-1 ligands in AML and MDS.	Scientific reports	2019	-37.157751654087285	12.465459763357892	27	1.37
31405171	Association between PD-1 and PD-L1 Polymorphisms and the Risk of Cancer: A Meta-Analysis of Case-Control Studies.	Cancers	2019	3.2057558539938125	9.576176668303171	30	1.71
31402427	Germinal Immunogenetics predict treatment outcome for PD-1/PD-L1 checkpoint inhibitors.	Investigational new drugs	2020	21.65984072841122	-9.265034868809478	20	1.21
31399602	Anthocyanins, delphinidin-3-O-glucoside and cyanidin-3-O-glucoside, inhibit immune checkpoints in human colorectal cancer cells in vitro and in silico.	Scientific reports	2019	-21.812729256672714	-32.705602600671284	32	2.46
31399473	The Genomic Landscape of Merkel Cell Carcinoma and Clinicogenomic Biomarkers of Response to Immune Checkpoint Inhibitor Therapy.	Clinical cancer research : an official journal of the American Association for Cancer Research	2019	43.79661544827088	52.44698463218934	96	4.8
31399419	USP22 Deubiquitinates CD274 to Suppress Anticancer Immunity.	Cancer immunology research	2019	-18.142944993853263	-5.850713702329792	77	3.52
31399043	Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1.	Journal for immunotherapy of cancer	2019	-35.69712164374558	52.45537998567587	68	4.08
31398571	Non-viral nano-immunotherapeutics targeting tumor microenvironmental immune cells.	Biomaterials	2019	16.465232920190193	11.781115043093669	34	1.77
31396228	Enhanced Immunomodulation in Inflammatory Environments Favors Human Cardiac Mesenchymal Stromal-Like Cells for Allogeneic Cell Therapies.	Frontiers in immunology	2019	-56.25802732947902	22.560384702744976	2	0.13
31395688	Preclinical Development of the Anti-LAG-3 Antibody REGN3767: Characterization and Activity in Combination with the Anti-PD-1 Antibody Cemiplimab in Human PD-1xLAG-3-Knockin Mice.	Molecular cancer therapeutics	2019	-18.20782842137748	-41.0279532001588	43	2.13
31394834	Single Domain Antibody-Mediated Blockade of Programmed Death-Ligand 1 on Dendritic Cells Enhances CD8 T-cell Activation and Cytokine Production.	Vaccines	2019	-54.64881819341015	-16.460797968252795	15	0.84
31394407	Expression of PD-1 and PD-Ls in Kaposi's sarcoma and regulation by oncogenic herpesvirus lytic reactivation.	Virology	2019	-22.768776772403235	21.34011078560372	23	1.41
31391510	Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling.	Scientific reports	2019	-14.329037044384052	-38.9966293872966	84	4.12
31391096	PD-1 silencing impairs the anti-tumor function of chimeric antigen receptor modified T cells by inhibiting proliferation activity.	Journal for immunotherapy of cancer	2019	-43.08036123582368	1.120113236817717	59	2.66
31390978	CD4+ T cell exhaustion revealed by high PD-1 and LAG-3 expression and the loss of helper T cell function in chronic hepatitis B.	BMC immunology	2019	-73.9482581362439	23.903691057056097	68	3.51
31390584	Emerging Multimodality Approaches to Treat Localized Esophageal Cancer.	Journal of the National Comprehensive Cancer Network : JNCCN	2019	54.50502178982648	15.206466740726254	57	3.11
31388782	Clinicopathological evaluation of PD-L1 expression and cytotoxic T-lymphocyte infiltrates across intracranial molecular subgroups of ependymomas: are these tumors potential candidates for immune check-point blockade?	Brain tumor pathology	2019	-26.105624519184424	19.86007002808116	9	0.53
31387897	Blockade of TIGIT/CD155 Signaling Reverses T-cell Exhaustion and Enhances Antitumor Capability in Head and Neck Squamous Cell Carcinoma.	Cancer immunology research	2019	-5.385571142697107	29.286506074795483	108	5.17
31387181	Effect and biomarker of Nivolumab for non-small-cell lung cancer.	Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie	2019	46.04278318976922	-26.267046215467925	21	0.88
31387102	On the Horizon: Targeting Next-Generation Immune Checkpoints for Cancer Treatment.	Chemotherapy	2019	25.28007804784148	10.856999614691276	31	1.55
31386875	Immune checkpoint inhibitors in non-small cell lung cancer: A bird's eye view.	Life sciences	2019	39.35998687933488	-31.50679452903505	35	1.76
31385405	Comprehensive immune characterization and T-cell receptor repertoire heterogeneity of retroperitoneal liposarcoma.	Cancer science	2019	0.8330602156605245	19.73083491643543	25	1.39
31384666	A PD-L1-Based Cancer Vaccine Elicits Antitumor Immunity in a Mouse Melanoma Model.	Molecular therapy oncolytics	2019	-27.27694122137558	-12.985925192543885	10	0.54
31383967	PD-L1 expression is associated with ALK positivity and STAT3 activation, but not outcome in patients with systemic anaplastic large cell lymphoma.	Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc	2020	-34.92974133864848	24.82811793680695	29	2.03
31383651	PD-1 Inhibition Achieves a Complete Metabolic Response in a Patient with Malignant Peripheral Nerve Sheath Tumor.	Cancer immunology research	2019	49.40902378896458	8.177891538750975	13	0.73
31383402	From the Hellstrom paradox toward cancer cure.	Progress in molecular biology and translational science	2019	-7.547777373100765	-61.88070552468867	7	0.25
31383016	Local and abscopal responses in advanced intrahepatic cholangiocarcinoma with low TMB, MSS, pMMR and negative PD-L1 expression following combined therapy of SBRT with PD-1 blockade.	Journal for immunotherapy of cancer	2019	55.45696814737551	22.577009831892585	49	2.51
31381142	Real-world progression, treatment, and survival outcomes during rapid adoption of immunotherapy for advanced non-small cell lung cancer.	Cancer	2019	47.5326679646254	-17.720297062374275	87	3.9
31379843	TLR9 Mediated Tumor-Stroma Interactions in Human Papilloma Virus (HPV)-Positive Head and Neck Squamous Cell Carcinoma Up-Regulate PD-L1 and PD-L2.	Frontiers in immunology	2019	-2.811495268457326	-7.4383085811300305	19	1.06
31379838	Decreased Expression of Negative Immune Checkpoint VISTA by CD4+ T Cells Facilitates T Helper 1, T Helper 17, and T Follicular Helper Lineage Differentiation in GCA.	Frontiers in immunology	2019	-39.7923607284151	37.59109215746374	19	1.11
31378988	Frontline Science: Exhaustion and senescence marker profiles on human T cells in BRGSF-A2 humanized mice resemble those in human samples.	Journal of leukocyte biology	2020	-46.8842927957524	14.955022323309947	5	0.37
31375756	A QSP Model for Predicting Clinical Responses to Monotherapy, Combination and Sequential Therapy Following CTLA-4, PD-1, and PD-L1 Checkpoint Blockade.	Scientific reports	2019	17.08476589790577	0.8126077065523953	50	2.76
31375512	Genetic Aberrations in the CDK4 Pathway Are Associated with Innate Resistance to PD-1 Blockade in Chinese Patients with Non-Cutaneous Melanoma.	Clinical cancer research : an official journal of the American Association for Cancer Research	2019	13.360616201434254	0.1334298288393221	54	2.34
31375454	Comparative Efficacy of Second- and Subsequent-line Treatments for Metastatic NSCLC: A Fractional Polynomials Network Meta-analysis of Cancer Immunotherapies.	Clinical lung cancer	2019	47.93985211921571	-26.128123612351065	7	0.29
31374917	Combined Strategies with Poly (ADP-Ribose) Polymerase (PARP) Inhibitors for the Treatment of Ovarian Cancer: A Literature Review.	Diagnostics (Basel, Switzerland)	2019	34.35674033652727	39.992668025604615	93	5.11
31374257	Unbalanced expression of membrane-bound and soluble inducible costimulator and programmed cell death 1 in patients with myasthenia gravis.	Clinical immunology (Orlando, Fla.)	2019	-55.38253675529639	12.349676324045149	10	0.53
31371317	Lessons Learned from Checkpoint Blockade Targeting PD-1 in Multiple Myeloma.	Cancer immunology research	2019	19.900083010051265	15.193024195995733	25	1.16
31367249	Distinct PD-L1/PD1 Profiles and Clinical Implications in Intrahepatic Cholangiocarcinoma Patients with Different Risk Factors.	Theranostics	2019	0.8867932952834271	5.355155477984332	49	2.4
31360302	The landscape of novel and complementary targets for immunotherapy: an analysis of gene expression in the tumor microenvironment.	Oncotarget	2019	2.947187838758609	25.82129699293881	8	0.31
31359805	Building on the anti-PD1/PD-L1 backbone: combination immunotherapy for cancer.	Expert opinion on investigational drugs	2019	27.225391021219743	-1.5599777014420189	32	1.47
31359214	Prognostic and clinicopathological value of PD-L1 expression in primary breast cancer: a meta-analysis.	Breast cancer research and treatment	2019	-8.356037075769901	16.20346488088807	55	3.09
31354723	Immunocyte Profiling Using Single-Cell Mass Cytometry Reveals EpCAM+ CD4+ T Cells Abnormal in Colon Cancer.	Frontiers in immunology	2019	7.960933545265551	35.86331966951319	16	0.7
31354294	Immune checkpoint inhibitors for small cell lung cancer: opportunities and challenges.	OncoTargets and therapy	2019	44.174044742026325	-41.514542492199936	21	0.99
31353840	Three-year follow-up results from phase II studies of nivolumab in Japanese patients with previously treated advanced non-small cell lung cancer: Pooled analysis of ONO-4538-05 and ONO-4538-06 studies.	Cancer medicine	2019	47.32487572689887	-24.124908031153637	12	0.5
31353229	MMR deficient undifferentiated/dedifferentiated endometrial carcinomas showing significant programmed death ligand-1 expression (sp 142) with potential therapeutic implications.	Pathology, research and practice	2019	-16.862911040928296	8.744132825955612	11	0.65
31350019	Pituitary-adrenal dysfunction caused by nivolumab for head and neck cancer.	Auris, nasus, larynx	2019	82.77654058921411	-19.553357856216984	4	0.35
31348245	The overall safety evaluation of programmed cell death/programmed cell death ligand 1 (PD-1/PD-L1) treatment for lung cancer patients: An updated systematic review and meta-analysis.	Medicine	2019	60.74651783590464	-16.500442168872922	2	0.1
31343665	Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung Cancer Treated With Nivolumab.	JAMA oncology	2019	47.73401009255526	-23.98515094930038	306	14.43
31342270	Programmed death-1 receptor (PD-1) and PD-ligand-1 (PD-L1) expression in non-small cell lung cancer and the immune-suppressive effect of anaerobic glycolysis.	Medical oncology (Northwood, London, England)	2019	-2.583962742553307	9.00818619742526	30	1.72
31340937	The Mechanism of Anti-PD-L1 Antibody Efficacy against PD-L1-Negative Tumors Identifies NK Cells Expressing PD-L1 as a Cytolytic Effector.	Cancer discovery	2019	-34.132418878210785	-0.50893514003465	168	8.08
31340861	Patterns of failure after immunotherapy with checkpoint inhibitors predict durable progression-free survival after local therapy for metastatic melanoma.	Journal for immunotherapy of cancer	2019	44.9470752872356	7.485916156668205	48	2.23
31340613	Strategies to Augment Natural Killer (NK) Cell Activity against Solid Tumors.	Cancers	2019	-34.12327625681638	0.7610315309446439	32	1.62
31337426	Multiplex quantitative analysis of cancer-associated fibroblasts and immunotherapy outcome in metastatic melanoma.	Journal for immunotherapy of cancer	2019	1.258256117740544	34.08687894354302	39	1.83
31336685	PD-1/PD-L1 Targeting in Breast Cancer: The First Clinical Evidences Are Emerging. A Literature Review.	Cancers	2019	24.753871472020982	-1.1827747670302913	126	7.09
31332464	CTLA-4 antibody ipilimumab negatively affects CD4+ T-cell responses in vitro.	Cancer immunology, immunotherapy : CII	2019	28.33680787873784	6.198584528516543	13	0.6
31331945	The Combined Effect of FGFR Inhibition and PD-1 Blockade Promotes Tumor-Intrinsic Induction of Antitumor Immunity.	Cancer immunology research	2019	-10.15563550855979	-42.00524222612732	83	3.87
31330525	Programmed Cell Death 1 and Programmed Cell Death Ligands in Extranodal Natural Killer/T Cell Lymphoma: Expression Pattern and Potential Prognostic Relevance.	Acta haematologica	2020	-37.91280011348366	24.352334505940767	19	1.66
31330498	Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review.	European journal of endocrinology	2019	87.71000346949731	-14.63495990246857	119	6.58
31329640	Lymph node migratory dendritic cells modulate HIV-1 transcription through PD-1 engagement.	PLoS pathogens	2019	-85.09173913855284	10.419019696881575	13	0.63
31326706	Comparative efficacy and safety of immunotherapies targeting the PD-1/PD-L1 pathway for previously treated advanced non-small cell lung cancer: A Bayesian network meta-analysis.	Critical reviews in oncology/hematology	2019	45.282802365088656	-30.29515052945252	23	0.98
31324724	Programmed Death-1 Restrains the Germinal Center in Type 1 Diabetes.	Journal of immunology (Baltimore, Md. : 1950)	2019	-57.94937269053945	2.408671175067901	11	0.51
31322926	Pembrolizumab for the treatment of cervical cancer.	Expert opinion on biological therapy	2019	44.28089422720048	33.656254699854095	18	1.03
31319991	Immune checkpoint-inhibitors and chemoradiation in stage III unresectable non-small cell lung cancer.	Lung cancer (Amsterdam, Netherlands)	2019	40.61543673269212	-24.676165574835107	26	1.25
31319988	First-line immune checkpoint blockade for advanced non-small-cell lung cancer: Travelling at the speed of light.	Lung cancer (Amsterdam, Netherlands)	2019	39.03192618936552	-29.27941184773316	31	1.46
31319978	Real-world prevalence of programmed death ligand 1 expression in locally advanced or metastatic non-small-cell lung cancer: The global, multicenter EXPRESS study.	Lung cancer (Amsterdam, Netherlands)	2019	12.053934566331565	-31.92437346914345	72	3.55
31317055	PD-L1 instead of PD-1 status is associated with the clinical features in human primary prostate tumors.	American journal of clinical and experimental urology	2019	-12.727388963140251	13.16818838429054	18	0.91
31317017	Successful therapy for autoimmune myocarditis with pembrolizumab treatment for nasopharyngeal carcinoma.	Annals of translational medicine	2019	85.79947741712229	0.7551100009945668	11	0.74
31316145	Inhibition of mTOR complex 1/p70 S6 kinase signaling elevates PD-L1 levels in human cancer cells through enhancing protein stabilization accompanied with enhanced β-TrCP degradation.	Oncogene	2019	2.683586594759868	-31.51647341836316	38	1.83
31316109	IL-17C-mediated innate inflammation decreases the response to PD-1 blockade in a model of Kras-driven lung cancer.	Scientific reports	2019	1.142393180913302	-23.5118060640974	22	1.01
31312649	Excellent Response to Anti-PD-1 Therapy in a Patient with Hepatocellular Carcinoma Intolerant to Sorafenib.	Visceral medicine	2019	30.70847305269623	52.53003358539118	5	0.28
31312140	Management of Adverse Events in Cancer Patients Treated With PD-1/PD-L1 Blockade: Focus on Asian Populations.	Frontiers in pharmacology	2019	64.01554103754042	-18.79041527870001	18	0.87
31311367	PD-L1/PD-1 Expression in Endometrial Clear Cell Carcinoma: A Potential Surrogate Marker for Clinical Trials.	International journal of surgical pathology	2020	-17.922522727935988	8.992792019921374	5	0.48
31310083	Simultaneous onset of type 1 diabetes mellitus and silent thyroiditis under durvalumab treatment.	Endocrinology, diabetes & metabolism case reports	2019	87.48776505972106	-15.310563988346596	14	0.82
31309818	PD-1 and PD-L1 expression on the prognosis of ovarian cancer.	Journal of biological regulators and homeostatic agents	2019	-19.91751730058075	13.7257534412948	1	0.01
31307547	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC).	Journal for immunotherapy of cancer	2019	52.18202766018258	31.164880133880335	317	18.01
31306553	Immunomodulatory MicroRNAs in cancer: targeting immune checkpoints and the tumor microenvironment.	The FEBS journal	2019	-18.614060321458457	0.5982820424241284	47	2.9
31302496	Identifying Cancer Driver lncRNAs Bridged by Functional Effectors through Integrating Multi-omics Data in Human Cancers.	Molecular therapy. Nucleic acids	2019	-5.098320380900305	53.61612449729141	20	0.93
31302192	A Toll-like receptor 3 (TLR3) agonist ARNAX for therapeutic immunotherapy.	Advanced drug delivery reviews	2019	-21.905036599335688	-14.48650153261784	23	1.19
31301962	Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial.	The Lancet. Oncology	2019	50.33722467103237	9.475515936954904	159	7.49
31300681	Analytical performance of a new automated chemiluminescent magnetic immunoassays for soluble PD-1, PD-L1, and CTLA-4 in human plasma.	Scientific reports	2019	14.44621393784336	-45.297388927557925	24	1.24
31299636	PD-1 and PD-L1 expression in pulmonary carcinoid tumors and their association to tumor spread.	Endocrine connections	2019	6.725025190908163	-26.382858643538945	13	0.64
31299381	The helminth-derived peptide GK-1 induces an anti-tumoral CD8 T cell response associated with downregulation of the PD-1/PD-L1 pathway.	Clinical immunology (Orlando, Fla.)	2020	-26.898377862209696	-33.45399935774038	3	0.22
31298541	Design, Synthesis, Evaluation, and Structural Studies of C2-Symmetric Small Molecule Inhibitors of Programmed Cell Death-1/Programmed Death-Ligand 1 Protein-Protein Interaction.	Journal of medicinal chemistry	2019	-41.99228706204648	-40.0547393096746	56	3.02
31297883	B-cell frequencies and immunoregulatory phenotypes in myeloproliferative neoplasms: Influence of ruxolitinib, interferon-α2, or combination treatment.	European journal of haematology	2019	-40.63233090461325	16.122823899926264	6	0.34
31296256	Baseline T cell dysfunction by single cell network profiling in metastatic breast cancer patients.	Journal for immunotherapy of cancer	2019	2.447302196862897	21.286407071394343	27	1.27
31295151	Immunologic Features of Patients With Advanced Hepatocellular Carcinoma Before and During Sorafenib or Anti-programmed Death-1/Programmed Death-L1 Treatment.	Clinical and translational gastroenterology	2019	-15.190128258310525	44.28973874453912	33	1.55
31292534	Immune recurrence score using 7 immunoregulatory protein expressions can predict recurrence in stage I-III breast cancer patients.	British journal of cancer	2019	-4.399366530450006	23.425632877369587	10	0.55
31292525	Differential expression of individual transcript variants of PD-1 and PD-L2 genes on Th-1/Th-2 status is guaranteed for prognosis prediction in PCNSL.	Scientific reports	2019	-33.50791230049029	33.41726657694723	21	1.13
31292396	Non-small Cell Lung Cancer Treated by an Anti-programmed Cell Death-1 Antibody without a Flare-up of Preexisting Granulomatosis with Polyangiitis.	Internal medicine (Tokyo, Japan)	2019	44.48749666429027	-28.94759125014331	6	0.28
31292383	A Long-term Response to Nivolumab in a Case of PD-L1-negative Lung Adenocarcinoma with an EGFR Mutation and Surrounding PD-L1-positive Tumor-associated Macrophages.	Internal medicine (Tokyo, Japan)	2019	9.913069158852933	-32.316938747492365	6	0.32
31291985	Gal9/Tim-3 expression level is higher in AML patients who fail chemotherapy.	Journal for immunotherapy of cancer	2019	-38.726170653568765	14.18447328219014	45	2.63
31291983	Contributions of T cell dysfunction to the resistance against anti-PD-1 therapy in oral carcinogenesis.	Journal of experimental & clinical cancer research : CR	2019	-32.212760227870824	-20.116364136833408	22	1.07
31291131	LAG-3 antagonists by cancer treatment: a patent review.	Expert opinion on therapeutic patents	2019	12.003322570323864	22.284838730928488	17	0.92
31287031	Rescue therapy for patients with anti-PD-1-refractory Merkel cell carcinoma: a multicenter, retrospective case series.	Journal for immunotherapy of cancer	2019	46.37874230351224	49.850507159290096	28	1.62
31286289	Japan Society of Clinical Oncology provisional clinical opinion for the diagnosis and use of immunotherapy in patients with deficient DNA mismatch repair tumors, cooperated by Japanese Society of Medical Oncology, First Edition.	International journal of clinical oncology	2020	37.39732024182434	31.033837254233926	16	1.07
31285949	Temozolomide promotes immune escape of GBM cells via upregulating PD-L1.	American journal of cancer research	2019	-28.84760407260957	51.766895352998105	34	1.91
31285612	Genetic manipulation of autonomic nerve fiber innervation and activity and its effect on breast cancer progression.	Nature neuroscience	2019	-25.973455736245462	10.753866156438532	168	9.15
31285589	Can PD-L1 expression evaluated by biopsy sample accurately reflect its expression in the whole tumour in gastric cancer?	British journal of cancer	2019	-8.020313096890064	4.295098614511075	18	0.92
31281479	Aging, Cancer and Immunity.	Journal of Cancer	2019	83.90018921698628	-5.943962993223966	40	2.48
31280073	A carrier-free multiplexed gene editing system applicable for suspension cells.	Biomaterials	2019	-44.89747449900943	1.2743075913695612	21	0.96
31279641	Shorter Survival in Malignant Pleural Mesothelioma Patients With High PD-L1 Expression Associated With Sarcomatoid or Biphasic Histology Subtype: A Series of 214 Cases From the Bio-MAPS Cohort.	Clinical lung cancer	2019	6.715591708071369	11.319464292499896	41	2.24
31277279	Possible Biomarkers for Cancer Immunotherapy.	Cancers	2019	16.101643502786906	-1.4197687325547568	31	1.55
31277179	Anti-PD-1 and anti-PD-L1 drugs treatment-related adverse events for patients with cancer: Protocol for an overview of systematic reviews with meta-analyses.	Medicine	2019	59.7426841609916	-15.829867267454572	2	0.13
31276987	Structure-based derivation and intramolecular cyclization of peptide inhibitors from PD-1/PD-L1 complex interface as immune checkpoint blockade for breast cancer immunotherapy.	Biophysical chemistry	2019	-45.15293207304488	-43.75720592190581	17	1.1
31275983	Prognostic Impact of Adenosine Receptor 2 (A2aR) and Programmed Cell Death Ligand 1 (PD-L1) Expression in Colorectal Cancer.	BioMed research international	2019	-4.313677097418663	-49.03392725870158	26	1.49
31275617	"New emerging targets in cancer immunotherapy beyond CTLA-4, PD-1 and PD-L1: Introducing an ""ESMO Open - Cancer Horizons"" Series."	ESMO open	2019	19.468183098242516	6.626645842879944	6	0.32
31275380	Outcomes of Programmed Cell Death Protein 1 (PD-1) and Programmed Death-Ligand 1(PD-L1) Inhibitor Therapy in HIV Patients with Advanced Cancer.	Journal of oncology	2019	46.695536671163175	-12.317784151153846	15	0.66
31273938	Functional systemic CD4 immunity is required for clinical responses to PD-L1/PD-1 blockade therapy.	EMBO molecular medicine	2019	-24.856987701898596	-8.624187782577765	111	5.11
31269329	PD-L1 and PD1 expression in post-transplantation lymphoproliferative disease (PTLD) of childhood and adolescence: An inter- and intra-individual descriptive study covering the whole spectrum of PTLD categories.	Cancer medicine	2019	-32.26355585392062	20.41572702448956	12	0.86
31267201	Multicentric analytical comparability study of programmed death-ligand 1 expression on tumor-infiltrating immune cells and tumor cells in urothelial bladder cancer using four clinically developed immunohistochemistry assays.	Virchows Archiv : an international journal of pathology	2019	11.665269154420642	58.87126372542293	39	1.72
31264559	Diagnostic Usefulness of Cytokine and Chemokine Levels in the Cerebrospinal Fluid of Patients with Suspected Tuberculous Meningitis.	The American journal of tropical medicine and hygiene	2019	-77.31060824885604	1.606753587865151	9	0.85
31263684	The PD-1/PD-L1 Axis and Virus Infections: A Delicate Balance.	Frontiers in cellular and infection microbiology	2019	-76.29368039519618	10.572310866925124	147	8.08
31262921	Retreatment With Anti-PD-L1 Antibody in Advanced Non-small Cell Lung Cancer Previously Treated With Anti-PD-1 Antibodies.	Anticancer research	2019	51.62679716382373	-37.14724442795968	39	1.71
31258783	Changes in Expression of Multiple Checkpoint Molecules and Infiltration of Tumor Immune Cells after Neoadjuvant Chemotherapy in Gastric Cancer.	Journal of Cancer	2019	1.8603307946142655	24.325074383758345	31	1.54
31258764	Blocking the PD-1/PD-L1 axis in dendritic cell-stimulated Cytokine-Induced Killer Cells with pembrolizumab enhances their therapeutic effects against hepatocellular carcinoma.	Journal of Cancer	2019	44.21994162787114	4.916942706568609	20	1.05
31258537	Immunity to Respiratory Infection Is Reinforced Through Early Proliferation of Lymphoid TRM Cells and Prompt Arrival of Effector CD8 T Cells in the Lungs.	Frontiers in immunology	2019	-74.5730778800613	7.650774558117558	16	0.67
31258527	Recent Findings in the Regulation of Programmed Death Ligand 1 Expression.	Frontiers in immunology	2019	-40.25715899092126	-13.18557500091596	70	3.5
31258479	Association Between Tumor Mutation Burden (TMB) and Outcomes of Cancer Patients Treated With PD-1/PD-L1 Inhibitions: A Meta-Analysis.	Frontiers in pharmacology	2019	23.46158982387551	-15.9500003550511	43	1.92
31253869	Determinants of immunological evasion and immunocheckpoint inhibition response in non-small cell lung cancer: the genetic front.	Oncogene	2019	33.96551990801453	-24.25782525554756	19	0.91
31253857	Elevated numbers of PD-L1 expressing B cells are associated with the development of AIDS-NHL.	Scientific reports	2019	-81.38909765364502	11.55913526060635	16	0.84
31253743	PET Imaging of Tumor PD-L1 Expression with a Highly Specific Nonblocking Single-Domain Antibody.	Journal of nuclear medicine : official publication, Society of Nuclear Medicine	2020	5.724429968208431	-55.9980922668794	89	6.7
31251403	Phase 2 study of pembrolizumab and circulating biomarkers to predict anticancer response in advanced, unresectable hepatocellular carcinoma.	Cancer	2019	48.22112982776282	5.873653416910775	108	5.13
31250752	Nanomedicine-Combined Immunotherapy for Cancer.	Current medicinal chemistry	2020	-29.692837737147716	-54.3989489374152	12	1.0
31250021	Immunosuppressive B cells expressing PD-1/PD-L1 in solid tumors: A mini review.	QJM : monthly journal of the Association of Physicians	2019	-41.37604032931415	-9.541667883202503	22	0.97
31244852	PD-1 Blockade During Post-partum Involution Reactivates the Anti-tumor Response and Reduces Lymphatic Vessel Density.	Frontiers in immunology	2019	-13.24159414710176	16.63993226188187	9	0.51
31242517	[50 years of systemic therapy of urinary bladder cancer].	Aktuelle Urologie	2019	67.98395577477248	16.09570513124188	2	0.14
31240875	Clinicopathological and mutational analyses of colorectal cancer with mutations in the POLE gene.	Cancer medicine	2019	9.67258633857548	43.84449291570285	20	0.86
31239825	Immunotherapy in Urological Tumors.	Reviews in urology	2019	68.30031100593737	20.841300476299477	4	0.17
31237963	The immune microenvironment and expression of PD-L1, PD-1, PRAME and MHC I in salivary duct carcinoma.	Histopathology	2019	-4.564607331066817	-0.8885493726073327	34	2.23
31236579	Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432.	Annals of oncology : official journal of the European Society for Medical Oncology	2019	56.51513329108028	-4.735309068778261	243	12.47
31234464	Evaluating a Single Domain Antibody Targeting Human PD-L1 as a Nuclear Imaging and Therapeutic Agent.	Cancers	2019	-44.48427626720496	-32.89987476316689	38	2.41
31228073	The Relationship Between Tumor-Infiltrating Lymphocytes, PD-L1 Expression, Driver Mutations and Clinical Outcome Parameters in Non-Small Cell Lung Cancer Adenocarcinoma in Patients with a Limited to no Smoking History.	Pathology oncology research : POR	2020	7.217316064049442	-23.747060677784184	4	0.28
31221619	Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study.	The Lancet. Oncology	2019	46.60207156189671	1.4643389586780484	527	26.86
31221124	Analysis of the transcriptomic features of microsatellite instability subtype colon cancer.	BMC cancer	2019	10.026618080578192	41.9918286528811	8	0.34
31217824	CD8+ PD-1+ T-cells and PD-L1+ circulating tumor cells in chemotherapy-naïve non-small cell lung cancer: towards their clinical relevance?	Therapeutic advances in medical oncology	2019	8.127541335122858	-20.921134449602636	10	0.58
31217020	Advances in cancer immunotherapy 2019 - latest trends.	Journal of experimental & clinical cancer research : CR	2019	19.468346840520297	2.768317541084484	308	16.65
31216825	[Progress in research on tumor immune PD-1/PD-L1 signaling pathway in malignant bone tumors].	Zhonghua zhong liu za zhi [Chinese journal of oncology]	2019	-46.64778024458674	-12.312909590840643	3	0.25
31216823	[Role of PD-1/PD-L1 in microenvironment of breast cancer].	Zhonghua zhong liu za zhi [Chinese journal of oncology]	2019	-42.934446394244304	-18.230748098050796	2	0.12
31216733	Clinical Impact of the Increase in Immunosuppressive Cell-Related Gene Expression in Urine Sediment during Intravesical Bacillus Calmette-Guérin.	Diseases (Basel, Switzerland)	2019	7.661100079515215	59.35537955457775	10	0.51
31216560	Immuno-Oncological Treatment and Tumor Mass in Non-Small Cell Lung Cancer: Case-Control Analysis of Overall Survival in Routine Clinical Practice.	Oncology	2019	41.85160884623426	-19.86430910810947	10	0.39
31214790	18F-FDG PET metabolic-to-morphological volume ratio predicts PD-L1 tumour expression and response to PD-1 blockade in non-small-cell lung cancer.	European journal of nuclear medicine and molecular imaging	2019	14.783985251285634	-56.320918418733136	50	2.47
31212055	Doxorubicin and siRNA-PD-L1 co-delivery with T7 modified ROS-sensitive nanoparticles for tumor chemoimmunotherapy.	International journal of pharmaceutics	2019	-30.42122028805892	-51.58224274230885	29	1.94
31210726	A Holistic Evaluation of Articles on PD-1 and PD-L1 Published Between 1975 and 2017: A Bibliometric Analysis.	Cancer informatics	2019	19.69137120769144	-50.51680760461787	3	0.12
31210370	T-bet interferes with PD-1/PD-L1-mediated suppression of CD4+ T cell inflammation and survival in Crohn's disease.	Clinical and experimental pharmacology & physiology	2019	-59.91536410613472	18.38329471691166	5	0.22
31208204	Considering B7-CD28 as a family through sequence and structure.	Experimental biology and medicine (Maywood, N.J.)	2019	-28.199867842500204	4.801111181783138	4	0.18
31208150	Bacterial Colonization in Patients with Chronic Lymphocytic Leukemia and Factors Associated with Infections and Colonization.	Journal of clinical medicine	2019	-39.82766969254539	26.86799945281312	8	0.48
31205619	Application of PD-1 Blockade in Cancer Immunotherapy.	Computational and structural biotechnology journal	2019	-40.603122092806124	-17.450002115388763	257	13.72
31205506	Can the plasma PD-1 levels predict the presence and efficiency of tumor-infiltrating lymphocytes in patients with metastatic melanoma?	Therapeutic advances in medical oncology	2019	-5.443241407330166	16.79048595194693	24	1.23
31205470	Immune Checkpoint Inhibition in Classical Hodgkin Lymphoma: From Early Achievements towards New Perspectives.	Journal of oncology	2019	36.4863781456968	-10.154364847576566	16	0.85
31201647	Recent advances in the clinical development of immune checkpoint blockade therapy.	Cellular oncology (Dordrecht)	2019	24.612100731901197	6.018125865435348	56	2.93
31201259	PD-1hi CD8+ resident memory T cells balance immunity and fibrotic sequelae.	Science immunology	2019	-74.36904453166343	7.61024414391296	74	2.97
31200951	Programmed Death-1 or Programmed Death Ligand-1 Blockade in Patients with Platinum-resistant Metastatic Urothelial Cancer: A Systematic Review and Meta-analysis.	European urology	2019	63.179720265375295	15.842779311993755	34	1.23
31200833	Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer-The ETOP NICOLAS trial.	Lung cancer (Amsterdam, Netherlands)	2019	42.952100226368856	-23.71042676479356	94	4.62
31196207	Combination of CTLA-4 and PD-1 blockers for treatment of cancer.	Journal of experimental & clinical cancer research : CR	2019	32.228949276047395	7.666033988896907	444	24.03
31196176	PD-1 signaling affects cristae morphology and leads to mitochondrial dysfunction in human CD8+ T lymphocytes.	Journal for immunotherapy of cancer	2019	-50.04950837068412	-7.556361802972896	64	2.89
31195368	B7-CD28 gene family expression is associated with prognostic and immunological characteristics of diffuse large B-cell lymphoma.	Aging	2019	-31.958889891183208	29.503149372627576	6	0.28
31192215	Biomarkers for Immune Checkpoint Inhibitor-Mediated Tumor Response and Adverse Events.	Frontiers in medicine	2019	77.06332106613772	-11.558049080290882	113	5.88
31192212	Monitoring Patient Response to Pembrolizumab With Peripheral Blood Exhaustion Marker Profiles.	Frontiers in medicine	2019	-44.70510975192606	11.852353611976252	15	0.67
31192153	Development of a PD-L1-Expressing Orthotopic Liver Cancer Model: Implications for Immunotherapy for Hepatocellular Carcinoma.	Liver cancer	2019	-22.52665148937344	38.73119572957863	17	1.03
31192136	Prognostic Value of the Neo-Immunoscore in Renal Cell Carcinoma.	Frontiers in oncology	2019	13.289950537349656	30.810609913258585	11	0.46
31192129	Rational Combination of Parvovirus H1 With CTLA-4 and PD-1 Checkpoint Inhibitors Dampens the Tumor Induced Immune Silencing.	Frontiers in oncology	2019	33.38832080780233	6.942206574069868	11	0.59
31190995	Clinical utility of pembrolizumab in the management of advanced solid tumors: an evidence-based review on the emerging new data.	Cancer management and research	2019	50.757121221103375	6.377067499075956	34	1.58
31190978	Relationship between Helicobacter pylori and expression of programmed death-1 and its ligand in gastric intraepithelial neoplasia and early-stage gastric cancer.	Cancer management and research	2019	-11.688659699253428	3.6734571469578072	15	0.81
31189800	[Genetic Alterations Involving PD-L1/PD-L2 in Human Malignancies].	Gan to kagaku ryoho. Cancer & chemotherapy	2019	-15.419569174501325	-4.319254246989797	2	0.08
31189573	Sepsis-Induced State of Immunoparalysis Is Defined by Diminished CD8 T Cell-Mediated Antitumor Immunity.	Journal of immunology (Baltimore, Md. : 1950)	2019	-56.00861637781874	38.55415775613031	18	1.0
31186768	Significance of PD-L1 clones and C-MET expression in hepatocellular carcinoma.	Oncology letters	2019	-22.07525644781699	39.67332346718935	10	0.5
31186735	MicroRNAs aid the assessment of programmed death ligand 1 expression in patients with non-small cell lung cancer.	Oncology letters	2019	3.6951537735324314	-37.7327841156148	14	0.66
31184237	Clinicopathologic correlates of MYD88 L265P mutation and programmed cell death (PD-1) pathway in primary central nervous system lymphoma.	Leukemia & lymphoma	2019	-34.61390911722401	31.035364995158798	13	0.83
31182913	The Novel Combination of Nitroxoline and PD-1 Blockade, Exerts a Potent Antitumor Effect in a Mouse Model of Prostate Cancer.	International journal of biological sciences	2019	-39.29244510732845	-32.331887312240696	17	0.95
31182340	Analysis of the PD-1/PD-L1 axis in human autoimmune thyroid disease: Insights into pathogenesis and clues to immunotherapy associated thyroid autoimmunity.	Journal of autoimmunity	2019	-62.031949409398486	11.38221321124674	54	3.1
31182061	Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis.	BMC cancer	2019	72.68990789348399	-13.091541017543737	88	4.25
31181267	Antibody therapeutics and immunoregulation in cancer and autoimmune disease.	Seminars in cancer biology	2020	24.19163635713729	2.9252002676281843	59	4.26
31180187	Molecular and clinical characterization of TMEM71 expression at the transcriptional level in glioma.	CNS neuroscience & therapeutics	2019	-21.9257963498156	57.178407369278766	19	0.97
31179566	Intratumoural immune cell landscape in germinoma reveals multipotent lineages and exhibits prognostic significance.	Neuropathology and applied neurobiology	2020	-23.101745949077067	32.69951527291534	17	1.55
31178388	PD-L1 Expression of Lung Cancer Cells, Unlike Infiltrating Immune Cells, Is Stable and Unaffected by Therapy During Brain Metastasis.	Clinical lung cancer	2019	-0.2094093986080601	17.30767101649096	23	1.08
31176871	Rheumatic immune related adverse events in patients treated with checkpoint inhibitors for immunotherapy of cancer.	Autoimmunity reviews	2019	78.67231524886867	-11.157079416699828	12	0.73
31175402	Pembrolizumab as first-line treatment for metastatic uveal melanoma.	Cancer immunology, immunotherapy : CII	2019	44.88125148455134	2.0200950719775737	45	2.91
31175329	Colorectal carcinoma with double somatic mismatch repair gene inactivation: clinical and pathological characteristics and response to immune checkpoint blockade.	Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc	2019	10.92948568401456	43.36651175473558	10	0.51
31174611	DNA damage repair gene mutations and their association with tumor immune regulatory gene expression in muscle invasive bladder cancer subtypes.	Journal for immunotherapy of cancer	2019	6.453197044921856	57.53002998625854	52	2.25
31174496	A prospective observational study to assess PD-L1 expression in small biopsy samples for non-small-cell lung cancer.	BMC cancer	2019	14.780542285177177	-37.22323890540252	28	1.61
31171876	Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients.	Nature medicine	2019	30.995518606394427	33.40692732648932	155	7.22
31169364	Immune mechanisms and possible immune therapy in testicular germ cell tumours.	Andrology	2019	-21.877791098944385	33.18047439094698	14	0.81
31167787	Protein painting, an optimized MS-based technique, reveals functionally relevant interfaces of the PD-1/PD-L1 complex and the YAP2/ZO-1 complex.	The Journal of biological chemistry	2019	-47.19721645034476	-42.74724338522092	11	0.62
31165589	Effect of sex on the efficacy of patients receiving immune checkpoint inhibitors in advanced non-small cell lung cancer.	Cancer medicine	2019	39.92550022654467	-17.536259597319425	35	1.83
31164960	EWS-FLI1 low Ewing sarcoma cells demonstrate decreased susceptibility to T-cell-mediated tumor cell apoptosis.	Oncotarget	2019	-22.88814758933564	18.30825514216165	5	0.3
31164885	The Role of Membrane Bound Complement Regulatory Proteins in Tumor Development and Cancer Immunotherapy.	Frontiers in immunology	2019	15.823292793223455	8.269430381900225	64	3.76
31164356	Tumor Cells Hijack Macrophage-Produced Complement C1q to Promote Tumor Growth.	Cancer immunology research	2019	20.031140467946376	34.70912863360621	117	5.61
31163235	Programmed cell death 1 protein and programmed death-ligand 1 inhibitors in the treatment of nonmelanoma skin cancer: A systematic review.	Journal of the American Academy of Dermatology	2020	54.16595870742765	-10.922707469382027	31	3.31
31159869	PD-L1 and PD-L2 expression correlated genes in non-small-cell lung cancer.	Cancer communications (London, England)	2019	13.210165391274424	-25.434958798826077	56	2.88
31159823	IL-17A increases MHC class I expression and promotes T cell activation in papillary thyroid cancer patients with coexistent Hashimoto's thyroiditis.	Diagnostic pathology	2019	-62.424108642511456	-33.26946336521918	9	0.75
31146499	Expression of PD-1 and PD-L1 in Extramammary Paget Disease: Implications for Immune-Targeted Therapy.	Cancers	2019	-15.10265361981076	11.163432102520868	16	1.22
31143921	Current status of immune checkpoint inhibition in early-stage NSCLC.	Annals of oncology : official journal of the European Society for Medical Oncology	2019	38.19035833861098	-22.0895569701235	70	3.51
31143376	Sustained partial remission of a metastatic NEN using off-label immunotherapy with pembrolizumab.	Oncotarget	2019	44.54735554982671	24.693947143810227	5	0.21
31142383	Metastatic Merkel cell carcinoma and myasthenia gravis: contraindication for therapy with immune checkpoint inhibitors?	Journal for immunotherapy of cancer	2019	68.26891974879254	-3.936741883382352	10	0.63
31141610	PD-L1/PD1 Expression, Composition of Tumor-Associated Immune Infiltrate, and HPV Status in Conjunctival Squamous Cell Carcinoma.	Investigative ophthalmology & visual science	2019	0.5988045232770314	-0.5920205305006145	22	1.52
31139574	Review of PD-1/PD-L1 Inhibitors in Metastatic dMMR/MSI-H Colorectal Cancer.	Frontiers in oncology	2019	35.663089573096286	22.9994022946168	106	5.33
31139018	The prognostic significance of PD-L1 and PD-1 expression in patients with nasopharyngeal carcinoma: a systematic review and meta-analysis.	Cancer cell international	2019	-17.000280247826048	31.40755081085884	35	2.1
31138229	PRIMMO study protocol: a phase II study combining PD-1 blockade, radiation and immunomodulation to tackle cervical and uterine cancer.	BMC cancer	2019	42.26533177819075	34.22413937951918	37	2.24
31138162	PD-1 high expression predicts lower local disease control in stage IV M0 nasopharyngeal carcinoma.	BMC cancer	2019	-16.124471599919357	31.421323982053952	17	0.93
31137694	Expression of PD-1 and CTLA-4 Are Negative Prognostic Markers in Renal Cell Carcinoma.	Journal of clinical medicine	2019	18.373684084278004	28.099572991924557	22	0.93
31135485	PD-L1 Expression in Urothelial Carcinoma With Predominant or Pure Variant Histology: Concordance Among 3 Commonly Used and Commercially Available Antibodies.	The American journal of surgical pathology	2019	12.456236007775471	59.535300429526494	50	2.62
31134811	FOXP3 infiltrating lymphocyte density and PD-L1 expression in operable non-small cell lung carcinoma.	Experimental lung research	2019	8.574450610166648	-16.236117682002327	17	0.95
31134385	Clinical significance of soluble forms of immune checkpoint molecules in advanced esophageal cancer.	Medical oncology (Northwood, London, England)	2019	7.873675617305503	6.953430206612625	21	1.08
31132649	Expression of programmed death ligand (PD-L1) in different tumors. Comparison of several current available antibody clones and antibody profiling.	Annals of diagnostic pathology	2019	-46.92357847452373	-19.33000915059594	31	1.6
31130676	Remarkable Alteration of PD-L1 Expression after Immune Checkpoint Therapy in Patients with Non-Small-Cell Lung Cancer: Two Autopsy Case Reports.	International journal of molecular sciences	2019	50.85914088082171	-31.18594879186575	24	1.42
31130304	New oncologic emergencies: What is there to know about inmunotherapy and its potential side effects?	European journal of internal medicine	2019	79.89690930423863	-6.67074103578806	14	0.67
31128313	Prognostic Significance of Programmed Death Ligand 1 Expression and Tumor-Infiltrating Lymphocytes in Axial Osteosarcoma.	World neurosurgery	2019	-17.159984262126876	19.78292676224362	11	0.66
31128215	The anthelmintic flubendazole blocks human melanoma growth and metastasis and suppresses programmed cell death protein-1 and myeloid-derived suppressor cell accumulation.	Cancer letters	2019	-44.77721012137362	27.309563708279164	22	1.37
31128201	Bispecific Antibody Approach for Improved Melanoma-Selective PD-L1 Immune Checkpoint Blockade.	The Journal of investigative dermatology	2019	-13.340928176532003	-46.310757065552494	18	1.0
31125062	Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry.	Annals of oncology : official journal of the European Society for Medical Oncology	2019	39.60095879752456	-19.578222342153172	669	33.84
31118808	Incidence risk of PD-1/PD-L1 related diarrhea in non-small cell lung cancer (NSCLC) patients: a systematic review and meta-analysis.	Cancer management and research	2019	66.59046141267513	-14.367382443631232	5	0.21
31115840	In vitro assessment of PD-L1+ microvesicles in the cyst fluid of non-syndromic odontogenic keratocysts.	Journal of molecular histology	2019	-64.58780757455001	-19.838146244174894	3	0.19
31113840	Tumor Characteristics Associated with Benefit from Pembrolizumab in Advanced Non-Small Cell Lung Cancer.	Clinical cancer research : an official journal of the American Association for Cancer Research	2019	21.407765434340337	-14.688000734682294	48	2.03
31111437	Pembrolizumab-Induced Thyroiditis.	Endocrine pathology	2019	76.59882965195813	-18.373377740982797	23	1.29
31110545	Peripheral blood T lymphocytes are downregulated by the PD-1/PD-L1 axis in advanced gastric cancer.	Archives of medical science : AMS	2019	-10.613365635639976	4.992096506051244	11	0.66
31109153	PD1/PD-L1 Expression in Blastic Plasmacytoid Dendritic Cell Neoplasm.	Cancers	2019	-35.80736660582607	27.084481970444315	8	0.44
31106827	Sex-Based Heterogeneity in Response to Lung Cancer Immunotherapy: A Systematic Review and Meta-Analysis.	Journal of the National Cancer Institute	2019	40.01891000273899	-17.46499147492971	111	5.94
31105707	Innate Lymphoid Cells: Expression of PD-1 and Other Checkpoints in Normal and Pathological Conditions.	Frontiers in immunology	2019	-56.996394796598594	-14.589575240878569	49	2.23
31105690	PD-1 Dynamically Regulates Inflammation and Development of Brain-Resident Memory CD8 T Cells During Persistent Viral Encephalitis.	Frontiers in immunology	2019	-75.38681083330029	-2.035020942139285	25	1.19
31104683	[The application of RNAscope technology for detection of PD-1 and PD-L1 in gastrointestinal stromal tumor].	Zhonghua bing li xue za zhi = Chinese journal of pathology	2019	10.671301578778694	-42.08894245264253	0	0.0
31102620	Role of Checkpoint Inhibition in Localized Bladder Cancer.	European urology oncology	2018	71.51783793627447	19.394079038132908	22	0.93
31101455	Functional CD3+CD8+PD1- T Cell Accumulation and PD-L1 Expression Increases During Tumor Invasion in DCIS of the Breast.	Clinical breast cancer	2019	-5.853679971248883	15.378076855428011	8	0.5
31099677	Role of Immunotherapy in Small Cell Lung Cancer, Thymic Epithelial Tumors, and Mesothelioma.	American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting	2019	37.14371758202838	-24.363567443577256	12	0.67
31098772	Efficient development and expression of scFv recombinant proteins against PD-L1 surface domain and potency in cancer therapy.	Cytotechnology	2019	-45.94656074261659	-30.434501574335822	7	0.44
31097096	Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer.	Lung cancer (Amsterdam, Netherlands)	2019	23.14832092313745	-17.61675216576102	89	3.76
31097082	Predictive value of serum protein levels in patients with advanced non-small cell lung cancer treated with nivolumab.	Lung cancer (Amsterdam, Netherlands)	2019	23.498024857210808	-29.659239469843488	35	1.67
31096532	Risk of dermatologic and mucosal adverse events associated with PD-1/PD-L1 inhibitors in cancer patients: A meta-analysis of randomized controlled trials.	Medicine	2019	69.85585418163375	-22.85556035172186	22	1.25
31095042	The programmed cell death protein-1/programmed cell death ligand 1 expression, CD3+ T cell infiltration, NY-ESO-1 expression, and microsatellite instability phenotype in primary cutaneous melanoma and mucosal melanoma and their clinical significance and prognostic value: a study of 89 consecutive cases.	Melanoma research	2020	5.126740954996547	-1.2815800677297218	5	0.4
31092922	Targeting the CBM complex causes Treg cells to prime tumours for immune checkpoint therapy.	Nature	2019	-28.612806793331877	-6.96486597511644	125	5.08
31092901	Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance.	Nature reviews. Clinical oncology	2019	77.91734979697044	-9.978551075103304	938	52.22
31090214	Specific zinc finger-induced methylation of PD-L1 promoter inhibits its expression.	FEBS open bio	2019	-1.9526711945409532	-32.64095988823419	15	0.83
31088500	PD-L1 expression and tumor mutational burden status for prediction of response to chemotherapy and targeted therapy in non-small cell lung cancer.	Journal of experimental & clinical cancer research : CR	2019	22.30764327940797	-17.260182487495307	51	2.25
31087180	Exosomal PD-L1 Retains Immunosuppressive Activity and is Associated with Gastric Cancer Prognosis.	Annals of surgical oncology	2019	-44.65903400076056	-56.23230462351434	103	5.4
31086347	Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial.	Nature medicine	2019	38.82267256580094	8.189009367875075	469	23.02
31086024	PD-L1 Expression in Mastocytosis.	International journal of molecular sciences	2019	-30.10967532072124	14.865400186635144	2	0.11
35516311	Computational analysis of hot spots and binding mechanism in the PD-1/PD-L1 interaction.	RSC advances	2019	-46.63048543491029	-39.88211505782064	4	0.22
31081058	Phospho‑STAT1 expression as a potential biomarker for anti‑PD‑1/anti‑PD‑L1 immunotherapy for breast cancer.	International journal of oncology	2019	-14.839990764289135	16.028356505459573	35	1.76
31079031	Immunotherapy of colorectal cancer: Challenges for therapeutic efficacy.	Cancer treatment reviews	2019	36.8912885444018	20.68943397058217	180	9.4
31076855	Programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) expressions in type 2 endometrial cancer.	Archives of gynecology and obstetrics	2019	-17.723100819462775	9.217463602481844	16	0.77
31076549	TIM-3 Dictates Functional Orientation of the Immune Infiltrate in Ovarian Cancer.	Clinical cancer research : an official journal of the American Association for Cancer Research	2019	-0.9065218695239724	28.2607517018015	56	2.47
31076547	Immune Suppression by PD-L2 against Spontaneous and Treatment-Related Antitumor Immunity.	Clinical cancer research : an official journal of the American Association for Cancer Research	2019	-34.13020160151625	-9.720055405146685	53	2.41
31075880	Targeting Protein Kinases to Enhance the Response to anti-PD-1/PD-L1 Immunotherapy.	International journal of molecular sciences	2019	-41.06539975702743	-20.44289249473616	29	1.48
31075727	Relevance of tumour-infiltrating lymphocytes, PD-1 and PD-L1 in patients with high-risk, nodal-metastasised breast cancer of the German Adjuvant Intergroup Node-positive study.	European journal of cancer (Oxford, England : 1990)	2019	-6.597103782694108	17.284191188294667	36	1.84
31068935	Human Pancreatic Carcinoma-Associated Fibroblasts Promote Expression of Co-inhibitory Markers on CD4+ and CD8+ T-Cells.	Frontiers in immunology	2019	-8.189245020974864	27.69972715277905	113	5.51
31067796	Immune Checkpoint Blockade for Advanced NSCLC: A New Landscape for Elderly Patients.	International journal of molecular sciences	2019	37.90523138743544	-34.77579771468803	27	1.36
31066582	Nivolumab plus ipilimumab in non-small-cell lung cancer.	Future oncology (London, England)	2019	40.99111949331954	-28.63829828981049	31	1.7
31065295	Harnessing immunotherapy for liver recipients with hepatocellular carcinoma: a review from a transplant oncology perspective.	Therapeutic advances in medical oncology	2019	28.41935845130662	48.16792215375137	19	1.01
31064777	Coexpression of Inhibitory Receptors Enriches for Activated and Functional CD8+ T Cells in Murine Syngeneic Tumor Models.	Cancer immunology research	2019	-44.989555319574805	14.34800359261413	29	1.15
31064408	Two cases of intrahepatic cholangiocellular carcinoma with high insertion-deletion ratios that achieved a complete response following chemotherapy combined with PD-1 blockade.	Journal for immunotherapy of cancer	2019	24.37344645321169	36.11813916373652	29	1.38
31063806	Understanding and overcoming the resistance of cancer to PD-1/PD-L1 blockade.	Pharmacological research	2019	31.964484652792603	14.3090553271098	88	4.28
31060602	Automated image analysis of NSCLC biopsies to predict response to anti-PD-L1 therapy.	Journal for immunotherapy of cancer	2019	17.683481686116647	-31.567501653366623	64	3.1
31060337	Beyond PD-1/PD-L1 Inhibition: What the Future Holds for Breast Cancer Immunotherapy.	Cancers	2019	24.624142395182385	-1.0431376004584263	41	2.02
31060225	Immune Checkpoint Ligand Reverse Signaling: Looking Back to Go Forward in Cancer Therapy.	Cancers	2019	32.4080605907488	14.209616612924403	23	1.11
31058077	Identification of Genetic Mutations in Cancer: Challenge and Opportunity in the New Era of Targeted Therapy.	Frontiers in oncology	2019	16.31775978636597	3.284148563488351	45	2.58
31057668	Pembrolizumab in the treatment of locally advanced or metastatic urothelial carcinoma: clinical trial evidence and experience.	Therapeutic advances in urology	2019	66.98810527957886	16.55928963758772	11	0.42
31056729	Malignant Melanoma: Autoimmunity and Supracellular Messaging as New Therapeutic Approaches.	Current treatment options in oncology	2019	33.73485378820858	29.887397345228116	16	0.92
31053471	PD-L1 (B7-H1) Competes with the RNA Exosome to Regulate the DNA Damage Response and Can Be Targeted to Sensitize to Radiation or Chemotherapy.	Molecular cell	2019	-37.9410100241519	-10.659104301625009	119	5.47
31048681	Checkpoint blockade and nanosonosensitizer-augmented noninvasive sonodynamic therapy combination reduces tumour growth and metastases in mice.	Nature communications	2019	-27.062444799809324	-54.71502909926733	270	14.76
31047727	Tumor mutation burden, DNA mismatch repair status and checkpoint immunotherapy markers in primary and relapsed malignant rhabdoid tumors.	Pathology, research and practice	2019	16.649804984567613	48.11113746117058	19	0.96
31046714	Neoadjuvant anti-programmed Death-1 immunotherapy by Pembrolizumab in resectable nodal positive stage II/IIIa non-small-cell lung cancer (NSCLC): the NEOMUN trial.	BMC cancer	2019	48.02512256648002	-34.72852044819823	48	2.64
31046547	Sym021, a promising anti-PD1 clinical candidate antibody derived from a new chicken antibody discovery platform.	mAbs	2019	-3.4945853608380357	-60.1912553080301	21	1.11
31046484	Immune checkpoint inhibition for the treatment of mesothelioma.	Expert opinion on biological therapy	2019	35.54884696425619	6.166701222556285	17	0.98
31045716	Risk of Neurological Toxicities Following the Use of Different Immune Checkpoint Inhibitor Regimens in Solid Tumors: A Systematic Review and Meta-analysis.	The neurologist	2019	79.7660748486613	-13.35492237673859	24	1.32
31045596	The emerging role of immunotherapy for esophageal cancer.	Current opinion in gastroenterology	2019	54.61539633534372	15.24976668237802	28	1.29
31044146	PD1 pathway in immune-mediated myopathies: Pathogenesis of dysfunctional T cells revisited.	Neurology(R) neuroimmunology & neuroinflammation	2019	-70.1137764708874	12.844953344736703	35	2.31
31043837	Lazarus-type tumour response to therapy with nivolumab for sarcomatoid carcinomas of the lung.	Current oncology (Toronto, Ont.)	2019	54.24615926351091	-32.365337042111086	15	1.04
31043352	PD-L1 expression in carcinoma of the esophagogastric junction is positively correlated with T-cell infiltration and overall survival.	Pathology, research and practice	2019	-11.976084057447489	7.505880760317539	6	0.26
31042863	PD-L1 Testing in Non-small Cell Lung Cancer: Past, Present, and Future.	Journal of pathology and translational medicine	2019	20.0144761382773	-38.430377655639134	44	2.18
31040917	PD-L1 checkpoint blockade delivered by retroviral replicating vector confers anti-tumor efficacy in murine tumor models.	Oncotarget	2019	-44.5733974721196	-29.18277930366254	8	0.39
31031765	Complementing the Cancer-Immunity Cycle.	Frontiers in immunology	2019	15.880252398343265	8.214515033776465	105	5.22
31030994	Optimizing Patient Selection to Maximize Drug Efficacy: the Expanding Role of Pharmacogenomics in the Clinical Development of Pembrolizumab for the Treatment of Non-small Cell Lung Cancer.	Clinical therapeutics	2019	47.27237737893973	-32.98705301328139	0	0.0
31030326	Tumor expression and usefulness as a biomarker of programmed death ligand 1 in advanced non-small cell lung cancer patients with preexisting interstitial lung disease.	Medical oncology (Northwood, London, England)	2019	13.909543349990429	-31.714602281167508	13	0.76
31030234	Systemic and local immunosuppression in patients with high-grade meningiomas.	Cancer immunology, immunotherapy : CII	2019	-20.549249210479253	47.83888908152302	25	1.65
31030093	Bibliometric analysis of global research on PD-1 and PD-L1 in the field of cancer.	International immunopharmacology	2019	19.67038143710226	-50.46991055357282	78	4.43
31029646	Phase II Study of the PD-1 Inhibitor Pembrolizumab for the Treatment of Relapsed or Refractory Mature T-cell Lymphoma.	Clinical lymphoma, myeloma & leukemia	2019	45.65603659198747	-4.575358664276176	75	3.73
31028537	Immune Checkpoint Inhibitors in Locally Advanced, Unresectable, and Metastatic Upper Gastrointestinal Malignancies.	Journal of gastrointestinal cancer	2020	46.5804674317041	17.14428939130478	11	0.7
31024834	Rescue of Immunotherapy-Refractory Metastatic Merkel Cell Carcinoma With Conventionally Fractionated Radiotherapy and Concurrent Pembrolizumab.	Frontiers in oncology	2019	46.37979805771699	48.83329732708185	17	1.17
31024205	Hepatocellular Carcinoma: Etiology and Current and Future Drugs.	Journal of clinical and experimental hepatology	2019	30.755382393341907	51.95875491339373	140	9.15
31023384	Bispecific CD3-HAC carried by E1A-engineered mesenchymal stromal cells against metastatic breast cancer by blocking PD-L1 and activating T cells.	Journal of hematology & oncology	2019	-40.477986760475865	9.32092821565654	18	1.04
31022941	Sequential Blockade of PD-1 and PD-L1 Causes Fulminant Cardiotoxicity-From Case Report to Mouse Model Validation.	Cancers	2019	60.39272799188298	-18.044166015497943	24	1.26
31022191	Association of BRCA1- and BRCA2-deficiency with mutation burden, expression of PD-L1/PD-1, immune infiltrates, and T cell-inflamed signature in breast cancer.	PloS one	2019	7.389070912074278	31.311437582527137	60	2.79
31021376	Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysis.	JAMA oncology	2019	61.578941274390914	-15.21000749040821	415	21.77
31021072	Exploring a Tumor-Intrinsic PD-L1 Signal with Proximity-Dependent Biotin Identification in Lung Cancer Cells.	Biochemistry	2019	-15.707242422692351	-10.049230398409744	4	0.18
31018834	Case report: reinitiating pembrolizumab treatment after small bowel perforation.	BMC cancer	2019	74.48993630606968	-3.22114603605024	12	0.67
31016875	Molecular characterization of clinical responses to PD-1/PD-L1 inhibitors in non-small cell lung cancer: Predictive value of multidimensional immunomarker detection for the efficacy of PD-1 inhibitors in Chinese patients.	Thoracic cancer	2019	17.741163263013338	-29.444432501494383	8	0.39
31015307	A Rationally Designed Peptide Antagonist of the PD-1 Signaling Pathway as an Immunomodulatory Agent for Cancer Therapy.	Molecular cancer therapeutics	2019	-40.316991268411805	-44.58854397785432	37	1.93
31014445	[Treatment-related Skin Toxicity Caused by Programmed Death-1 Inhibitor Nivolumab:  A Case Report].	Zhongguo fei ai za zhi = Chinese journal of lung cancer	2019	73.37177904056277	-28.016330540242038	0	0.0
31014442	[Advances of the Correlation between Driver Gene Status and Immunotherapy  in Non-small Cell Lung Cancer].	Zhongguo fei ai za zhi = Chinese journal of lung cancer	2019	25.40429833817851	-24.136579829338267	1	0.05
31011905	A Combination of Positive Tumor HLA-I and Negative PD-L1 Expression Provides an Immune Rejection Mechanism in Bladder Cancer.	Annals of surgical oncology	2019	10.790715414217422	57.84965304370144	11	0.5
31011254	Clinical significance of programmed death 1/programmed death ligand 1 pathway in gastric neuroendocrine carcinomas.	World journal of gastroenterology	2019	-10.01282310180074	3.7601375257984464	27	1.53
31008114	Unlike PD-L1, PD-1 Is Downregulated on Partial Immune Cells in Type 2 Diabetes.	Journal of diabetes research	2019	-59.10207716275495	2.915676865814381	14	0.78
31007846	The immune checkpoint molecules PD-1, PD-L1, TIM-3 and LAG-3 in diffuse large B-cell lymphoma.	Oncotarget	2019	-28.426059990472226	29.563725128033703	51	2.49
31005568	Heterogeneous Expression of Programmed Death Receptor-ligand 1 on Circulating Tumor Cells in Patients With Lung Cancer.	Clinical lung cancer	2019	9.65311739835135	-37.1598279150796	32	1.57
31002007	Tumor necrosis correlates with PD-L1 and PD-1 expression in lung adenocarcinoma.	Acta oncologica (Stockholm, Sweden)	2019	8.078668734683962	-28.74548420650568	19	0.82
31001479	Radiotherapy Both Promotes and Inhibits Myeloid-Derived Suppressor Cell Function: Novel Strategies for Preventing the Tumor-Protective Effects of Radiotherapy.	Frontiers in oncology	2019	26.64394595594478	21.612464094457863	41	2.1
31000591	Restriction of PD-1 function by cis-PD-L1/CD80 interactions is required for optimal T cell responses.	Science (New York, N.Y.)	2019	-48.87567906326812	-2.9609349701251912	206	9.68
30997535	Age and sex have no impact on expression levels of markers of immune cell infiltration and immune checkpoint pathways in patients with muscle-invasive urothelial carcinoma of the bladder treated with radical cystectomy.	Cancer immunology, immunotherapy : CII	2019	6.949508293549593	58.71284906430984	11	0.63
30997230	PD1/PD-L1 inhibitor treatment for late stage non-small cell lung carcinoma, sometimes…does more harm than good!	Journal of thoracic disease	2019	51.05880334833852	-20.82763220129297	2	0.1
30996253	JAK2/PD-L1/PD-L2 (9p24.1) amplifications in renal cell carcinomas with sarcomatoid transformation: implications for clinical management.	Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc	2019	10.760552877105262	30.05444534511582	45	2.18
30996212	Development of Hepatocellular Carcinoma During Nivolumab Treatment for Recurrent Non-Small Cell Lung Cancer: A Case Report.	The Tohoku journal of experimental medicine	2019	53.94879492926834	-28.3605420876132	3	0.17
30992011	Differential expressions of PD-1, PD-L1 and PD-L2 between primary and metastatic sites in renal cell carcinoma.	BMC cancer	2019	15.266604965413284	26.534064333759385	44	2.21
30987609	Relative efficacy of interventions in the treatment of second-line non-small cell lung cancer: a systematic review and network meta-analysis.	BMC cancer	2019	46.51459042910506	-22.62711870221567	23	1.13
30987368	Targeting the PD-1/PD-L1 Pathway in Renal Cell Carcinoma.	International journal of molecular sciences	2019	22.007891708202408	-5.084718744579919	53	2.85
30987269	Glial Cell Expression of PD-L1.	International journal of molecular sciences	2019	-75.70016804127103	-4.236897211645002	17	0.99
30987257	Targeted Therapies and Immune-Checkpoint Inhibition in Head and Neck Squamous Cell Carcinoma: Where Do We Stand Today and Where to Go?	Cancers	2019	49.93160533165676	31.22484049628811	25	1.38
30986992	Ntrk1 Promotes Resistance to PD-1 Checkpoint Blockade in Mesenchymal Kras/p53 Mutant Lung Cancer.	Cancers	2019	18.04404211279183	-23.678820364339188	19	0.74
30984969	The PD-1/PD-L1 Axis in HER2+ Ductal Carcinoma In Situ (DCIS) of the Breast.	American journal of clinical pathology	2019	-6.03727878980964	15.39087288088018	10	0.56
30984621	A Changing of the Guard: Immune Checkpoint Inhibitors With and Without Chemotherapy as First Line Treatment for Metastatic Non-small Cell Lung Cancer.	Frontiers in oncology	2019	42.79179750040696	-30.06715488839394	40	2.28
30984182	The Tumor Immune Contexture of Prostate Cancer.	Frontiers in immunology	2019	22.701333575082412	16.22874695613752	111	5.75
30983283	[Management of adverse events associated with cancer immunotherapy].	La Revue du praticien	2019	79.69336719318959	-6.911752296835734	0	0.0
30982497	PD-L1 Induces Epithelial-Mesenchymal Transition in Nasopharyngeal Carcinoma Cells Through Activation of the PI3K/AKT Pathway.	Oncology research	2019	-18.259456476697277	32.010781593279106	21	1.13
30981637	Immune expression in children with Wilms tumor: a pilot study.	Journal of pediatric urology	2019	10.705132483745787	26.88670054179134	17	0.84
30979816	FGFR2 Promotes Expression of PD-L1 in Colorectal Cancer via the JAK/STAT3 Signaling Pathway.	Journal of immunology (Baltimore, Md. : 1950)	2019	-19.479413361583468	4.517948012736671	92	5.15
30978575	PD-L1 expression by immunohistochemistry in salivary duct carcinoma.	Annals of diagnostic pathology	2019	-4.632453207026622	-0.8341140172050364	15	1.01
30978356	Silencing of PD-L2/B7-DC by Topical Application of Small Interfering RNA Inhibits Elicitation of Contact Hypersensitivity.	The Journal of investigative dermatology	2019	-52.49455156272719	-21.00148732635245	7	0.45
30977778	Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer.	Annals of oncology : official journal of the European Society for Medical Oncology	2019	37.275559916199335	-50.74681968743568	170	7.93
30976104	PD-1 (PDCD1) promoter methylation in Merkel cell carcinoma: prognostic relevance and relationship with clinico-pathological parameters.	Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc	2019	-10.795551706998914	39.90478007799189	12	0.72
30975638	PD-1/PD-L1 immune checkpoint and p53 loss facilitate tumor progression in activated B-cell diffuse large B-cell lymphomas.	Blood	2019	-30.527021250568968	29.50881807360492	51	2.47
30975201	The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation.	Journal for immunotherapy of cancer	2019	-12.50312997254673	-43.9841845154392	67	2.96
30972999	Effects of different levels of soluble PD-L1 protein on the growth of Lewis lung cancer transplanted tumor.	Journal of biological regulators and homeostatic agents	2019	-47.90569730079649	18.118733119729296	5	0.24
30972888	Clinical significance of programmed death-1 and programmed death-ligand 1 expression in the tumor microenvironment of clear cell renal cell carcinoma.	Cancer science	2019	16.126133721053648	27.93955321772088	33	1.45
30972766	MAPK pathway activity plays a key role in PD-L1 expression of lung adenocarcinoma cells.	The Journal of pathology	2019	3.959710803263077	-30.79846991584644	90	4.55
30972492	Clinical impact of PD-L1 and PD-1 expression in squamous cell cancer of the vulva.	Journal of cancer research and clinical oncology	2019	0.9928993232828828	-8.56319873556278	24	1.46
30972299	Perspectives of Induction With Chemo and/or Immune Check Point Inhibition in Head and Neck Organ Preservation Treatment.	Frontiers in oncology	2019	52.27200323570706	33.52274531244969	12	0.53
30969136	RATIONALE 301 study: tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma.	Future oncology (London, England)	2019	30.259840393847163	52.82285917834975	81	4.1
30969033	Efficacy of PD-1/PD-L1 inhibitors in patients with advanced non-small cell lung cancer: A meta-analysis of randomized clinical trials.	Thoracic cancer	2019	48.86591650009159	-18.320944890268358	6	0.24
30963193	Immune-phenotyping of pleomorphic dermal sarcomas suggests this entity as a potential candidate for immunotherapy.	Cancer immunology, immunotherapy : CII	2019	8.729555476211958	16.18911699974582	16	0.84
30962691	Anti-PD1 up-regulates PD-L1 expression and inhibits T-cell lymphoma progression: possible involvement of an IFN-γ-associated JAK-STAT pathway.	OncoTargets and therapy	2019	-34.49617661869744	-2.274180859558919	16	0.81
30962161	Lentiviral Vector-Based Dendritic Cell Vaccine Suppresses HIV Replication in Humanized Mice.	Molecular therapy : the journal of the American Society of Gene Therapy	2019	-84.96825402289443	13.36044431378416	21	1.25
30956278	Increased expression of the immunosuppressive interleukin-35 in patients with non-small cell lung cancer.	British journal of cancer	2019	8.346986966640342	-16.139059824613533	16	0.82
30953116	Heterogeneity of PD-L1 expression and CD8 tumor-infiltrating lymphocytes among subtypes of cutaneous adnexal carcinomas.	Cancer immunology, immunotherapy : CII	2019	0.3258982218249142	-2.298851920867085	15	0.96
30952089	"The FG Loop of PD-1 Serves as a ""Hotspot"" for Therapeutic Monoclonal Antibodies in Tumor Immune Checkpoint Therapy."	iScience	2019	-36.60078240433073	-31.88789540390193	21	1.03
30951669	Suppression of Exosomal PD-L1 Induces Systemic Anti-tumor Immunity and Memory.	Cell	2019	-44.11618293121106	-59.329066821942575	682	36.33
30950194	Risk of immune-related pneumonitis for PD1/PD-L1 inhibitors: Systematic review and network meta-analysis.	Cancer medicine	2019	65.02508288197453	-11.078597733794435	20	0.8
30948928	Lycopene improves the efficiency of anti-PD-1 therapy via activating IFN signaling of lung cancer cells.	Cancer cell international	2019	-29.03352275222981	-34.23445104803992	13	0.78
30943860	Immunotherapy for head and neck cancers: an update and future perspectives.	Immunotherapy	2019	50.26294517437218	30.52655242200839	4	0.19
30943859	PD-L1 expressing granulomatous reaction as an on-target mechanism of steroid-refractory immune hepatotoxicity.	Immunotherapy	2019	66.25924357810867	-18.156354998509613	4	0.24
30942469	Effect and changes in PD‑1 expression of CD19 CAR‑T cells from T cells highly expressing PD‑1 combined with reduced‑dose PD‑1 inhibitor.	Oncology reports	2019	-43.27201868133047	3.64216480663174	12	0.51
30941125	Combining Immune Checkpoint Inhibitors: Established and Emerging Targets and Strategies to Improve Outcomes in Melanoma.	Frontiers in immunology	2019	30.05537360363959	5.25136786300394	145	7.64
30940805	Crizotinib-induced immunogenic cell death in non-small cell lung cancer.	Nature communications	2019	30.945945132378192	-27.715483520537266	161	7.16
30938862	A study of PD-L1 expression in intravascular large B cell lymphoma: correlation with clinical and pathological features.	Histopathology	2019	-33.70110652334564	24.55590950614045	14	1.06
30937824	Novel Therapeutic Approaches and Targets Currently Under Evaluation for Renal Cell Carcinoma: Waiting for the Revolution.	Clinical drug investigation	2019	63.43730822108331	31.62963298486011	24	1.03
30935099	Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy: The Galectin-3 Signature in NSCLCs.	International journal of molecular sciences	2019	21.68610091442421	-33.06081194966012	33	1.79
30934955	Blockade of Lactate Dehydrogenase-A (LDH-A) Improves Efficacy of Anti-Programmed Cell Death-1 (PD-1) Therapy in Melanoma.	Cancers	2019	-31.23251807127097	-17.367209011392188	74	3.73
30934624	Renal Cell Carcinoma with Sarcomatoid Features: Finally New Therapeutic Hope?	Cancers	2019	19.437885349465752	31.226314185464386	38	1.91
30931336	Enhancement of Cytomegalovirus-Specific Cytokine Production after Modulation of the Costimulation in Kidney Transplant Patients.	Journal of immunology research	2019	-80.69241163611801	20.885279889795093	3	0.17
30931254	Expression of PD-L1 and PD-1 in Chemoradiotherapy-Naïve Esophageal and Gastric Adenocarcinoma: Relationship With Mismatch Repair Status and Survival.	Frontiers in oncology	2019	-11.208276626477256	7.268710265834723	29	1.45
30930222	Immunogenomic landscape of hepatocellular carcinoma with immune cell stroma and EBV-positive tumor-infiltrating lymphocytes.	Journal of hepatology	2019	-16.47443991331408	36.38388443042523	31	1.67
30930066	Computational Redesign of PD-1 Interface for PD-L1 Ligand Selectivity.	Structure (London, England : 1993)	2019	-46.01084615239724	-38.901581124251685	11	0.59
30929569	Expression of PD-L1 Attenuates the Positive Impacts of High-level Tumor-infiltrating Lymphocytes on Prognosis of Triple-negative Breast Cancer.	Cancer biology & therapy	2019	-6.84168999647944	18.88976611654729	17	0.9
30927016	PD-L1 Ameliorates Murine Acute Graft-Versus-Host Disease by Suppressing Effector But Not Regulatory T Cells Function.	Archivum immunologiae et therapiae experimentalis	2019	-64.7996995965347	-4.736452775725759	4	0.26
30926058	Differences of tumor-recruiting myeloid cells in murine squamous cell carcinoma influence the efficacy of immunotherapy combined with a TLR7 agonist and PD-L1 blockade.	Oral oncology	2019	-21.942206670179115	-22.33739466168569	7	0.34
30925919	Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment.	Molecular cancer	2019	29.41920998400561	13.849143289832698	287	14.43
30925913	Autophagy inhibition enhances PD-L1 expression in gastric cancer.	Journal of experimental & clinical cancer research : CR	2019	-14.744717316184436	2.6471267686320497	80	4.36
30923913	Checkpoint Blockade Strategies in the Treatment of Breast Cancer: Where We Are and Where We Are Heading.	Current treatment options in oncology	2019	24.86145745680365	0.1493241848000678	38	2.04
30922731	Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial.	The Lancet. Oncology	2019	47.56283513695666	2.705283516964144	314	15.81
30922394	Complex inter-relationship of body mass index, gender and serum creatinine on survival: exploring the obesity paradox in melanoma patients treated with checkpoint inhibition.	Journal for immunotherapy of cancer	2019	31.021715044168054	-48.02695094574728	88	4.74
30919595	Enhanced Programmed Death 1 and Diminished Programmed Death Ligand 1 Up-Regulation Capacity of Post-Activated Lupus B Cells.	Arthritis & rheumatology (Hoboken, N.J.)	2019	-53.21282108406179	10.995891405964098	20	1.09
30918149	Development of Cancer Immunotherapy Targeting the PD-1 Pathway.	Journal of Nippon Medical School = Nippon Ika Daigaku zasshi	2019	25.851131616861736	6.565008210523175	12	0.6
30917623	Molecular Interactions of Antibody Drugs Targeting PD-1, PD-L1, and CTLA-4 in Immuno-Oncology.	Molecules (Basel, Switzerland)	2019	27.568410696912125	6.164831940858076	133	7.16
30913016	PROGRAMMED CELL DEATH-LIGAND 1 OVEREXPRESSION IN THYROID CANCER.	Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists	2019	-7.530959696636295	-20.604490982926745	13	0.68
30912805	How to make the best use of immunotherapy as first-line treatment of advanced/metastatic non-small-cell lung cancer.	Annals of oncology : official journal of the European Society for Medical Oncology	2019	40.84697869762213	-30.231649898670277	59	2.8
30911684	Dynamic host immune response in virus-associated cancers.	Communications biology	2019	-2.17449378773462	-7.66201375361695	30	1.51
30911265	Immunological Agents Used in Cancer Treatment.	The Eurasian journal of medicine	2019	31.408309041958034	11.67443425419716	27	1.25
30910787	PD-L1 gene alterations identify a subset of diffuse large B-cell lymphoma harboring a T-cell-inflamed phenotype.	Blood	2019	-31.87338329424519	27.307477006024303	74	3.36
30910561	Molecular cloning, expression and characterization of Pekin duck programmed death-1.	Gene	2019	-54.85116831521566	-25.041997399877587	0	0.0
30906668	Triple threat to cancer: rationale for combining oncolytic viruses, MEK inhibitors, and immune checkpoint blockade.	Oncoimmunology	2019	28.516133929596883	36.45824538602759	1	0.05
30906655	Prognostic significance of circulating PD-1, PD-L1, pan-BTN3As, BTN3A1 and BTLA in patients with pancreatic adenocarcinoma.	Oncoimmunology	2019	-4.7704310404684245	6.063513839722524	80	4.3
30904424	Aberrant PD-1 ligand expression contributes to the myocardial inflammatory injury caused by Coxsackievirus B infection.	Antiviral research	2019	-62.71082959825733	8.013548109284912	7	0.45
30902819	Multiple Immune-Suppressive Mechanisms in Fibrolamellar Carcinoma.	Cancer immunology research	2019	-14.536759621664514	39.90315021377653	16	0.81
30901292	Silencing PD-1 and PD-L1 with nanoparticle-delivered small interfering RNA increases cytotoxicity of tumor-infiltrating lymphocytes.	Nanomedicine (London, England)	2019	-34.74639798070862	-50.61540316973753	44	2.55
30900155	Impact of EGFR mutation on the clinical efficacy of PD-1 inhibitors in patients with pulmonary adenocarcinoma.	Journal of cancer research and clinical oncology	2019	7.620080505689316	-30.89096825021377	15	0.67
30897754	PD-1 Ligand Expression in Epithelial Thyroid Cancers: Potential Clinical Implications.	International journal of molecular sciences	2019	-7.844345104089375	-20.32127654667048	30	1.72
30895352	The correlation of clinicopathological features and prognosis in extranodal natural killer/T cell lymphoma: a report of 42 cases in the early stage.	Annals of hematology	2019	-38.84809578764708	34.279791740128914	11	0.71
30895168	Combining Radiation and Immune Checkpoint Blockade in the Treatment of Head and Neck Squamous Cell Carcinoma.	Frontiers in oncology	2019	51.042258421064965	33.157212737302174	51	2.88
30894377	CD96 Is an Immune Checkpoint That Regulates CD8+ T-cell Antitumor Function.	Cancer immunology research	2019	-25.868897151073416	12.52311605953629	65	2.87
30893264	Macrophages participate in the immunosuppression of condyloma acuminatum through the PD-1/PD-L1 signaling pathway.	Journal of the Chinese Medical Association : JCMA	2019	-61.35319524643992	-17.083264598797363	7	0.38
30891423	Correlation Between PD-L2 Expression and Clinical Outcome in Solid Cancer Patients: A Meta-Analysis.	Frontiers in oncology	2019	-8.516830191026088	11.344353635732432	42	2.02
30888929	PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations.	Human vaccines & immunotherapeutics	2019	-44.06856784692447	-16.282843365666324	206	11.41
30887236	The gut microbiome and response to immune checkpoint inhibitors: preclinical and clinical strategies.	Clinical and translational medicine	2019	22.04849990589584	42.0619571609415	62	3.16
30885351	Safety and efficacy of PD-1 inhibitors in non-small cell lung cancer patients positive for antinuclear antibodies.	Lung cancer (Amsterdam, Netherlands)	2019	52.00970937127046	-19.142567794591887	31	1.49
30884772	Understanding Immune Evasion and Therapeutic Targeting Associated with PD-1/PD-L1 Pathway in Diffuse Large B-cell Lymphoma.	International journal of molecular sciences	2019	-44.28192176689802	-11.28445744200659	41	2.28
30881362	IL-10 Producing B Cells Dampen Protective T Cell Response and Allow Chlamydia muridarum Infection of the Male Genital Tract.	Frontiers in immunology	2019	-81.52747123881335	6.591119864801613	6	0.4
30877108	Pan-TAM Tyrosine Kinase Inhibitor BMS-777607 Enhances Anti-PD-1 mAb Efficacy in a Murine Model of Triple-Negative Breast Cancer.	Cancer research	2019	-26.63952956308098	-24.781118190669847	59	2.88
30872362	Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non-small cell lung cancer.	The Journal of experimental medicine	2019	3.959225799154916	-16.50104227372332	137	6.67
30872155	Expression of programmed cell death ligand 1 and programmed cell death 1 in cutaneous warts.	Journal of the American Academy of Dermatology	2019	-61.90784403609613	-16.972620059219572	3	0.29
30871493	A multicenter open-label phase II trial to evaluate nivolumab and ipilimumab for 2nd line therapy in elderly patients with advanced esophageal squamous cell cancer (RAMONA).	BMC cancer	2019	53.51568041467319	12.107198170187932	16	0.74
30871066	A Feedback Loop Formed by ATG7/Autophagy, FOXO3a/miR-145 and PD-L1 Regulates Stem-Like Properties and Invasion in Human Bladder Cancer.	Cancers	2019	-15.597949420013006	2.741331263383526	34	1.77
30870532	Varicella zoster virus productively infects human peripheral blood mononuclear cells to modulate expression of immunoinhibitory proteins and blocking PD-L1 enhances virus-specific CD8+ T cell effector function.	PLoS pathogens	2019	-78.53232249953086	19.66790900121637	26	1.54
30867826	Immune targets in the tumor microenvironment treated by radiotherapy.	Theranostics	2019	27.407927278907376	20.957030798390072	76	3.95
30866171	An update of knowledge on PD-L1 in head and neck cancers: Physiologic, prognostic and therapeutic perspectives.	Oral diseases	2020	-45.07764743777585	-15.697905484594854	37	3.31
30864556	Over-Expression of Immunosuppressive Molecules, PD-L1 and PD-L2, in Ulcerative Colitis Patients.	Iranian journal of immunology : IJI	2019	-60.044444235552255	19.443279725967116	7	0.4
30864509	"A ""Crazy Paving"" Pattern on CT Scan in a Patient Treated with Pembrolizumab."	Current drug safety	2019	65.79291917507977	-12.401639368110583	3	0.16
30863527	Checkpoint inhibition of PD-L1 and CTLA-4 in a child with refractory acute leukemia.	International journal of hematologic oncology	2019	29.83603939997072	8.166155092691223	9	0.5
30863404	FcγR-Binding Is an Important Functional Attribute for Immune Checkpoint Antibodies in Cancer Immunotherapy.	Frontiers in immunology	2019	-35.17422274131707	-27.183981512869465	97	4.84
30862891	Real-world evidenceand clinical observations of the treatment of advanced non-small cell lung cancer with PD-1/PD-L1 inhibitors.	Scientific reports	2019	48.00673723920133	-17.817144808823507	26	1.21
30861560	A Systematic Review and Meta-Analysis of Endocrine-Related Adverse Events Associated with Immune Checkpoint Inhibitors.	Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme	2019	81.60849384514404	-16.304025037733584	169	9.41
30861206	PD-1 modulating Mycobacterium tuberculosis-specific polarized effector memory T cells response in tuberculosis pleurisy.	Journal of leukocyte biology	2019	-84.57062297338196	1.0008869280513126	14	0.67
30861172	Clinicopathological evaluation of the programmed cell death 1 (PD1)/programmed cell death-ligand 1 (PD-L1) axis in post-transplant lymphoproliferative disorders: association with Epstein-Barr virus, PD-L1 copy number alterations, and outcome.	Histopathology	2019	-36.92965881409387	25.77466103418896	26	1.48
30860441	Predictive biomarkers for PD-1 and PD-L1 immune checkpoint blockade therapy.	Immunotherapy	2019	19.125126761306205	-4.326570417662222	15	0.63
30856290	A Dual-Bioresponsive Drug-Delivery Depot for Combination of Epigenetic Modulation and Immune Checkpoint Blockade.	Advanced materials (Deerfield Beach, Fla.)	2019	-32.69713320800821	-52.29772567126388	111	5.77
30856277	Presence of innate lymphoid cells in pleural effusions of primary and metastatic tumors: Functional analysis and expression of PD-1 receptor.	International journal of cancer	2019	7.607834341728361	12.905184916180737	60	2.83
30854100	PD-1 and PD-L1 Expression Predicts Radiosensitivity and Clinical Outcomes in Head and Neck Cancer and is Associated with HPV Infection.	Journal of Cancer	2019	-3.984383433493959	-9.336634065784317	30	1.73
30854074	Survival analysis with regard to PD-L1 and CD155 expression in human small cell lung cancer and a comparison with associated receptors.	Oncology letters	2019	10.047832337812912	-23.25322952691864	35	1.69
30853334	Targeting DNA Methylation and EZH2 Activity to Overcome Melanoma Resistance to Immunotherapy.	Trends in immunology	2019	11.461793196853517	9.617557452234156	127	5.79
30851633	PD-1-expressing B cells suppress CD4+ and CD8+ T cells via PD-1/PD-L1-dependent pathway.	Molecular immunology	2019	-65.93934127220207	6.406876595494842	70	3.37
30851544	Programmed Cell Death Receptor (PD-1) Ligand (PD-L1) expression in Philadelphia chromosome-negative myeloproliferative neoplasms.	Leukemia research	2019	-31.211960934399134	12.573863389000673	22	1.21
30848330	Disruption of CTLA-4 expression on peripheral blood CD8 + T cell enhances anti-tumor efficacy in bladder cancer.	Cancer chemotherapy and pharmacology	2019	24.382121013617027	-6.780617388581848	39	1.63
30847181	Pembrolizumab in newly diagnosed EBV-negative extranodal natural killer/T-cell lymphoma: A case report.	Molecular and clinical oncology	2019	48.13350469916556	-6.381563219224893	11	0.78
30846179	The effects of checkpoint inhibition on head and neck squamous cell carcinoma: A systematic review.	Oral oncology	2019	51.55352822888271	32.18934267700822	36	1.97
30845114	Biomarkers for immune therapy in gastrointestinal cancers.	Clinical advances in hematology & oncology : H&O	2019	41.17047852351617	19.83701079337694	4	0.17
30842953	Formalin fixation on HER-2 and PD-L1 expression in gastric cancer: A pilot analysis using the same surgical specimens with different fixation times.	World journal of clinical cases	2019	-8.562802381533684	2.476107779700285	3	0.12
30842061	Immunotherapy and targeted therapy combinations in metastatic breast cancer.	The Lancet. Oncology	2019	23.17375220559074	-1.2474469370454642	258	13.51
30841554	Immunotherapy Associated Pulmonary Toxicity: Biology Behind Clinical and Radiological Features.	Cancers	2019	70.19961612006732	-8.488421925732384	41	2.31
32982625	Self-Assembly of Therapeutic Peptide into Stimuli-Responsive Clustered Nanohybrids for Cancer-Targeted Therapy.	Advanced functional materials	2019	-41.95276444001084	-49.45149327112675	43	1.93
30841018	Clinical Characteristics of Korean Patients with Lung Cancer Who Have Programmed Death-Ligand 1 Expression.	Tuberculosis and respiratory diseases	2019	10.055459976671049	-29.15559008922283	8	0.46
30837208	Metastatic Clear-cell Renal Cell Carcinoma With a Long-term Response to Sunitinib: A Distinct Phenotype Independently Associated With Low PD-L1 Expression.	Clinical genitourinary cancer	2019	17.61161874905011	29.23792146105861	1	0.04
30833943	Elevated Soluble PD-L1 in Pregnant Women's Serum Suppresses the Immune Reaction.	Frontiers in immunology	2019	-74.44321150469536	-20.825821847261537	35	2.12
30833000	Immunotherapy Toxicity.	Hematology/oncology clinics of North America	2019	80.7793749908537	-6.11681143814431	11	0.47
30832606	Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer.	BMC cancer	2019	50.02760227885242	2.348485330949311	103	5.46
30827759	Programmed death ligand 1 expression in prostate cancer cells is associated with deep changes of the tumor inflammatory infiltrate composition.	Urologic oncology	2019	-12.204040156582671	12.59947467223245	28	1.64
30827742	Pseudoprogression on treatment with immune-checkpoint inhibitors in patients with gastrointestinal malignancies: Case series and short literature review.	Current problems in cancer	2019	44.553044238429806	16.67602969187873	7	0.26
30826436	OX40 stimulation and PD-L1 blockade synergistically augment HBV-specific CD4 T cells in patients with HBeAg-negative infection.	Journal of hepatology	2019	-74.49615247248387	22.75941049342137	48	2.46
30826127	"Reprint of ""Immunomodulatory effects of CD38-targeting antibodies""."	Immunology letters	2019	-8.430567206926753	-53.08103631275645	12	0.7
30825132	First-Line Treatment of Non-Small-Cell Lung Cancer (NSCLC) with Immune Checkpoint Inhibitors.	BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy	2019	39.03234952215797	-22.45818853276209	35	1.63
30824609	HDAC3 Inhibition Upregulates PD-L1 Expression in B-Cell Lymphomas and Augments the Efficacy of Anti-PD-L1 Therapy.	Molecular cancer therapeutics	2019	-10.017707614393734	-32.068111435080866	60	2.83
30824587	Immunotherapy in Non-Small Cell Lung Cancer: Facts and Hopes.	Clinical cancer research : an official journal of the American Association for Cancer Research	2019	36.59804568738574	-22.844794364574884	371	18.77
30821569	Uveitis in Patients Treated with CTLA-4 and PD-1 Checkpoint Blockade Inhibition.	Ocular immunology and inflammation	2020	81.43479167974742	-24.323326222438503	44	4.84
30821551	Modulation of immune checkpoint molecule expression in mantle cell lymphoma.	Leukemia & lymphoma	2019	-33.60202917625893	18.109438105403218	17	0.84
30819829	PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.	The oncologist	2019	35.42891130758802	-24.256177414471587	201	10.99
30816886	Abscopal effects observed in cancer radiation therapy and oncolytic virotherapy: an overview.	Drugs of today (Barcelona, Spain : 1998)	2019	28.62722382112328	21.884954040739174	3	0.18
30816679	Dendritic Cells Exposed to Triiodothyronine Deliver Pro-Inflammatory Signals and Amplify IL-17-Driven Immune Responses.	Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology	2019	-63.493999132342665	11.33215940223948	14	0.84
30815803	A Clinicopathological and Prognostic Analysis of PD-L2 Expression in Surgically Resected Primary Lung Squamous Cell Carcinoma.	Annals of surgical oncology	2019	9.175929178717563	-26.261890779786373	21	1.1
30815625	HBV and HIV/HBV Infected Patients Have Distinct Immune Exhaustion and Apoptotic Serum Biomarker Profiles.	Pathogens & immunity	2019	-72.35499919842222	25.040004835739595	11	0.59
30810279	EGFR exon 21 L858R as an acquired resistance mechanism to nivolumab in a lung cancer patient originally driver gene-negative.	Thoracic cancer	2019	38.20807025623154	-41.17600943789749	4	0.22
30809739	Inhibition of the adenosinergic pathway: the indispensable part of oncological therapy in the future.	Purinergic signalling	2019	-4.69712180203357	-50.22067761856431	9	0.51
30808044	PD-1/PD-L Pathway Potentially Involved in ITP Immunopathogenesis.	Thrombosis and haemostasis	2019	-51.65571302957282	3.964732453271712	18	0.89
30807610	Clinical significance of soluble programmed cell death-1 and soluble programmed cell death-ligand 1 in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy.	PloS one	2019	-4.490529182243957	9.037666192691075	38	2.25
30805896	Toripalimab: First Global Approval.	Drugs	2019	57.68873917326786	-5.493304616728948	93	4.33
30804928	The PD-1/PD-L1 Pathway Affects the Expansion and Function of Cytotoxic CD8+ T Cells During an Acute Retroviral Infection.	Frontiers in immunology	2019	-76.95786404558933	12.43408464767618	28	1.41
30803931	MiR-873/PD-L1 axis regulates the stemness of breast cancer cells.	EBioMedicine	2019	-17.315312040589312	3.353447921085292	99	5.53
30802679	γδ T cells in hepatocellular carcinoma patients present cytotoxic activity but are reduced in potency due to IL-2 and IL-21 pathways.	International immunopharmacology	2019	-16.648617178254067	43.31879320475613	12	0.65
30802149	Dual blockade of CXCL12-CXCR4 and PD-1-PD-L1 pathways prolongs survival of ovarian tumor-bearing mice by prevention of immunosuppression in the tumor microenvironment.	FASEB journal : official publication of the Federation of American Societies for Experimental Biology	2019	-17.601831931056534	-28.06979742928623	108	5.75
30801864	Regulation of programmed cell death ligand 1 expression by atypical protein kinase C lambda/iota in cutaneous angiosarcoma.	Cancer science	2019	-21.232559719454205	23.178243581678142	17	1.02
30799404	Non-Clear Cell Renal Cell Carcinoma - Pathology and Treatment Options.	Oncology research and treatment	2019	64.56410901868779	33.90958599591604	25	1.2
30798123	Development of a recombinant human IL-15·sIL-15Rα/Fc superagonist with improved half-life and its antitumor activity alone or in combination with PD-1 blockade in mouse model.	Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie	2019	-19.024921149845568	-53.49170365645113	16	0.69
30797818	BRCA gene mutations do not shape the extent and organization of tumor infiltrating lymphocytes in triple negative breast cancer.	Cancer letters	2019	6.903502011751221	31.26194401274612	23	0.97
30786843	Silencing PD-1 and PD-L1: the potential of PolyPurine Reverse Hoogsteen hairpins for the elimination of tumor cells.	Immunotherapy	2019	-34.77690555070901	-44.997820159990376	8	0.45
30786013	Is it true that gut microbiota is considered as panacea in cancer therapy?	Journal of cellular physiology	2019	21.58794468036425	42.50796409981299	18	1.12
30784085	PD-1/PD-L1 pathway: Basic biology and role in cancer immunotherapy.	Journal of cellular physiology	2019	-40.94065290122253	-17.19886579211204	220	12.07
30783096	Reverse signaling via PD-L1 supports malignant cell growth and survival in classical Hodgkin lymphoma.	Blood cancer journal	2019	-28.57012807333064	21.512110768932263	42	2.02
30782667	Targeted Delivery of IL2 to the Tumor Stroma Potentiates the Action of Immune Checkpoint Inhibitors by Preferential Activation of NK and CD8+ T Cells.	Cancer immunology research	2019	25.013667466834	19.799333274182093	36	1.73
30782114	The importance of the PD-1/PD-L1 pathway at the maternal-fetal interface.	BMC pregnancy and childbirth	2019	-75.53819785385753	-19.020148360324864	44	2.97
30778352	Risk of Pneumonitis and Pneumonia Associated With Immune Checkpoint Inhibitors for Solid Tumors: A Systematic Review and Meta-Analysis.	Frontiers in immunology	2019	65.02927910152142	-10.34526908204692	90	4.8
30778167	Human NK cells: surface receptors, inhibitory checkpoints, and translational applications.	Cellular & molecular immunology	2019	-43.22572174647276	33.24488561446132	253	13.56
30777131	Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition.	Journal for immunotherapy of cancer	2019	67.5527929635771	32.97453063112231	80	3.8
30777104	Infiltrating stromal immune cells in inflammatory breast cancer are associated with an improved outcome and increased PD-L1 expression.	Breast cancer research : BCR	2019	-12.096268678837548	18.63026420683735	50	2.52
30777100	Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma.	Journal of experimental & clinical cancer research : CR	2019	45.6411824283271	28.359689063419168	165	9.02
30776481	PD-L1 promotes colorectal cancer stem cell expansion by activating HMGA1-dependent signaling pathways.	Cancer letters	2019	-18.16761292757973	4.54004297949708	101	5.57
30776071	PD-L1 Expression Reveals Significant Association With Squamous Differentiation in Upper Tract Urothelial Carcinoma.	American journal of clinical pathology	2019	13.433300217297328	57.77439013884437	12	0.57
30775032	Programmed death ligand 1 immunohistochemistry in non-small cell lung carcinoma.	Journal of thoracic disease	2019	22.627065456351552	-39.061847066759846	44	2.58
30775030	Current views on tumor mutational burden in patients with non-small cell lung cancer treated by immune checkpoint inhibitors.	Journal of thoracic disease	2019	22.90696608935381	-17.617198532306283	59	2.93
30774373	Efficacy and safety of nivolumab for metastatic biliary tract cancer.	OncoTargets and therapy	2019	52.275463045521896	9.615989552762498	30	1.36
30773525	Programmed death ligand-1, tumor infiltrating lymphocytes and HLA expression in Chinese extrahepatic cholangiocarcinoma patients: Possible immunotherapy implications.	Bioscience trends	2019	-0.0254228271997042	4.888704273057957	15	0.77
30772350	Prevalence and Clinical Patterns of Ocular Complications Associated With Anti-PD-1/PD-L1 Anticancer Immunotherapy.	American journal of ophthalmology	2019	82.24252414668024	-23.394989423698757	50	3.33
30771904	PD-1 efficiently inhibits T cell activation even in the presence of co-stimulation through CD27 and GITR.	Biochemical and biophysical research communications	2019	-27.788815820717417	-19.77063683826496	7	0.29
30771521	The Combination of MEK Inhibitor With Immunomodulatory Antibodies Targeting Programmed Death 1 and Programmed Death Ligand 1 Results in Prolonged Survival in Kras/p53-Driven Lung Cancer.	Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer	2019	18.11361574461727	-23.94582480049073	40	1.7
30771277	Association Between Activation of the Programmed Cell Death-1 (PD-1)/Programmed Death-Ligand 1 (PD-L1) Pathway and Pain in Patients with Cancer.	Medical science monitor : international medical journal of experimental and clinical research	2019	-24.4732709297812	24.206795170062765	8	0.53
30770752	Insluin and epithelial growth factor (EGF) promote programmed death ligand 1(PD-L1) production and transport in colon cancer stem cells.	BMC cancer	2019	-17.840173661422842	4.773811519611136	30	1.6
30770362	PD-L1 and tumor-associated macrophages in de novo DLBCL.	Blood advances	2019	-32.99662410408556	26.39087713956729	50	2.46
30770361	Progression of mycosis fungoides occurs through divergence of tumor immunophenotype by differential expression of HLA-DR.	Blood advances	2019	-26.880827689028106	1.1317672666960807	18	1.03
30769874	Combination of Baseline LDH, Performance Status and Age as Integrated Algorithm to Identify Solid Tumor Patients with Higher Probability of Response to Anti PD-1 and PD-L1 Monoclonal Antibodies.	Cancers	2019	37.962271472579005	-14.532125578213414	16	0.73
30769852	Role of PD-L1 Expression in Non-Small Cell Lung Cancer and Their Prognostic Significance according to Clinicopathological Factors and Diagnostic Markers.	International journal of molecular sciences	2019	12.582705518582149	-30.001639795858782	96	4.98
30767115	Immunohistochemical Study of PD-1/PD-L1 Axis Expression in Oral Tongue Squamous Cell Carcinomas: Effect of Neoadjuvant Chemotherapy on Local Recurrence.	Pathology oncology research : POR	2020	-5.552354699879353	-15.698420327897972	20	1.59
30766891	Immunomodulatory Effects of Combination Therapy with Bushen Formula plus Entecavir for Chronic Hepatitis B Patients.	Journal of immunology research	2019	-73.67239755325242	25.76533787903924	3	0.21
30766539	Overcoming Resistance to Combination Radiation-Immunotherapy: A Focus on Contributing Pathways Within the Tumor Microenvironment.	Frontiers in immunology	2018	27.31554608029026	20.91186619926156	80	3.92
30765636	[The Immune Checkpoints Inhibitors for Head and Neck Cancer].	Gan to kagaku ryoho. Cancer & chemotherapy	2019	49.73438551159092	31.50845898709637	1	0.04
30765258	Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial.	The Lancet. Oncology	2019	46.98584578552698	4.628807750580274	273	13.51
30763126	Biological therapies in lung cancer treatment: using our immune system as an ally to defeat the malignancy.	Expert opinion on biological therapy	2019	33.72594095478053	-34.68537097998028	6	0.38
30762585	Differential immune profiles distinguish the mutational subtypes of gastrointestinal stromal tumor.	The Journal of clinical investigation	2019	-9.360594276790213	24.95897125336245	52	2.33
30761875	Do PD-1 and PD-L2 expressions have prognostic impact in hematologic malignancies?	Turkish journal of medical sciences	2019	-35.6231000518064	16.987088593444046	4	0.22
30760860	Immunohistochemical detection of PD-L1 among diverse human neoplasms in a reference laboratory: observations based upon 62,896 cases.	Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc	2019	16.466024875387276	-43.122018292966814	55	2.85
30760066	Inference on covariate effect types for treatment effectiveness in a randomized trial with a binary outcome.	Clinical trials (London, England)	2019	-0.8100579989765255	-43.42557382330277	0	0.0
30759726	Targeting Immune Signaling Checkpoints in Acute Myeloid Leukemia.	Journal of clinical medicine	2019	18.292402863619188	17.167394674470454	40	2.24
30755717	PD-1 is expressed by and regulates human group 3 innate lymphoid cells in human decidua.	Mucosal immunology	2019	-76.013197557641	-18.663014276183244	40	1.85
30753824	Antitumor Responses in the Absence of Toxicity in Solid Tumors by Targeting B7-H3 via Chimeric Antigen Receptor T Cells.	Cancer cell	2019	-41.71679187721829	5.961677305609801	229	10.89
30746216	Programmed cell death protein-1/programmed death-ligand 1 blockade enhances the antitumor efficacy of adoptive cell therapy against non-small cell lung cancer.	Journal of thoracic disease	2018	25.88787401594069	-9.02650848128318	9	0.36
30745900	Immunobiochemical Reconstruction of Influenza Lung Infection-Melanoma Skin Cancer Interactions.	Frontiers in immunology	2019	-75.79100256548917	7.717874832573368	4	0.18
30745366	Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL.	Cancer immunology research	2019	-30.97076370177944	30.26423761284712	77	3.83
30744168	The Role of Molecular Profiling to Predict the Response to Immune Checkpoint Inhibitors in Lung Cancer.	Cancers	2019	22.494854020872257	-33.83690610277915	44	2.12
30742278	Sintilimab: First Global Approval.	Drugs	2019	42.09882295186664	-0.2527437389654562	120	6.24
30741358	Treatment Approaches for Cisplatin-Ineligible Patients with Invasive Bladder Cancer.	Current treatment options in oncology	2019	73.63761976874417	19.507143175658783	19	1.21
30740300	A case of nivolumab-induced isolated adrenocorticotropic hormone (ACTH) deficiency.	Respiratory medicine case reports	2019	82.79416191758196	-19.628107453327125	6	0.51
30737731	Immune Checkpoint Inhibitors for Treating Advanced Cutaneous Squamous Cell Carcinoma.	American journal of clinical dermatology	2019	57.282466679203104	6.377941262887931	21	1.35
30737486	S100A9-induced overexpression of PD-1/PD-L1 contributes to ineffective hematopoiesis in myelodysplastic syndromes.	Leukemia	2019	-35.89078735283275	11.880970144913713	55	2.66
30735177	Automated Multiplex Immunofluorescence Panel for Immuno-oncology Studies on Formalin-fixed Carcinoma Tissue Specimens.	Journal of visualized experiments : JoVE	2019	5.154055046266421	-46.49095541134779	18	1.05
30730276	Predictors for clinical benefit of immune checkpoint inhibitors in advanced non-small-cell lung cancer: a meta-analysis.	Immunotherapy	2019	40.1154126515204	-18.051646452001805	48	2.28
30728907	Programmed death ligand 1 expression in early stage, resectable non-small cell lung cancer.	Oncotarget	2019	12.695116749317965	-28.96581685771723	10	0.5
30728286	Clinical implications of tumor-intrinsic mechanisms regulating PD-L1.	Science translational medicine	2019	-43.32501421722402	-16.066145937567708	32	1.35
30728114	Fragment-based screening of programmed death ligand 1 (PD-L1).	Bioorganic & medicinal chemistry letters	2019	-41.890840347928886	-38.81185071212735	34	1.96
30728081	Prognostic value of CD8 + PD-1+ immune infiltrates and PDCD1 gene expression in triple negative breast cancer.	Journal for immunotherapy of cancer	2019	-7.72235757023981	18.515361079357547	58	2.8
30723590	PD-1 in human NK cells: evidence of cytoplasmic mRNA and protein expression.	Oncoimmunology	2019	-32.16367970946179	-0.7223835930620355	62	2.57
30723578	CIITA-related block of HLA class II expression, upregulation of HLA class I, and heterogeneous expression of immune checkpoints in hepatocarcinomas: implications for new therapeutic approaches.	Oncoimmunology	2019	-18.293176215023998	43.25761617706708	19	0.79
30723303	Met inhibition revokes IFNγ-induction of PD-1 ligands in MET-amplified tumours.	British journal of cancer	2019	-17.669424675201334	-21.183051378106537	32	1.45
30723299	Combined prognostic value of CD274 (PD-L1)/PDCDI (PD-1) expression and immune cell infiltration in colorectal cancer as per mismatch repair status.	Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc	2019	9.63761350521543	36.01848672234962	28	1.33
30721928	T cell checkpoint regulators in the heart.	Cardiovascular research	2019	86.15976662215024	4.481871192913914	58	2.71
30719394	Clinical Management of Pneumonitis in Patients Receiving Anti-PD-1/PD-L1 Therapy.	Journal of the advanced practitioner in oncology	2018	66.06908510928511	-11.23092787759624	6	0.25
30718463	Mycobacterium tuberculosis antigens repress Th1 immune response suppression and promotes lung cancer metastasis through PD-1/PDl-1 signaling pathway.	Cell death & disease	2019	-85.63784014097152	1.2393152705465724	20	1.15
30716481	Cancer immunotherapy with check point inhibitor can cause autoimmune adverse events due to loss of Treg homeostasis.	Seminars in cancer biology	2020	15.02148590623028	14.98505682217173	57	4.0
30715244	Depression Promotes Hepatocellular Carcinoma Progression through a Glucocorticoids Mediated Up-Regulation of PD-1 Expression in Tumor infiltrating NK Cells.	Carcinogenesis	2019	-24.00183627987735	42.28314753383854	12	0.67
30715219	Cardiovascular toxicities associated with immune checkpoint inhibitors.	Cardiovascular research	2019	83.81798762578511	2.4673681314726177	242	13.45
30713804	DNA methylation of immune checkpoints in the peripheral blood of breast and colorectal cancer patients.	Oncoimmunology	2019	-6.932299899196004	41.68287610404973	39	1.71
30713803	Tumor-infiltrating T cells and PD-L1 expression in childhood malignant extracranial germ-cell tumors.	Oncoimmunology	2019	-23.581129139326908	33.345067945022734	13	0.57
30713795	Immunological differences between colorectal cancer and normal mucosa uncover a prognostically relevant immune cell profile.	Oncoimmunology	2019	5.964950454198578	38.29956586957173	35	1.46
30713788	ISG20 promotes local tumor immunity and contributes to poor survival in human glioma.	Oncoimmunology	2019	-20.084198106779198	54.2130145076416	30	1.32
30711051	PD-1 and PD-L1 regulate cellular immunity in canine visceral leishmaniasis.	Comparative immunology, microbiology and infectious diseases	2019	-66.94502391189054	11.639907376019428	9	0.51
30709424	Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients.	Journal for immunotherapy of cancer	2019	12.50401446023911	-27.681870969435472	52	2.43
30703170	Increased Programmed Death-Ligand 1 is an Early Epithelial Cell Response to Helicobacter pylori Infection.	PLoS pathogens	2019	-12.600482273520305	2.36893508750654	94	4.53
30702014	Immune context characterization and heterogeneity in primary tumors and pulmonary metastases from renal cell carcinoma.	Immunotherapy	2019	13.638759150931078	33.437050842263794	16	0.7
30700576	A biologic scaffold-associated type 2 immune microenvironment inhibits tumor formation and synergizes with checkpoint immunotherapy.	Science translational medicine	2019	6.385123196145905	61.982262153708895	72	3.99
30700015	Involvement of the PD-1/PD-L1 Co-Inhibitory Pathway in the Pathogenesis of the Inflammatory Stage of Early-Onset Preeclampsia.	International journal of molecular sciences	2019	-74.31059071674639	-18.07759494676328	10	0.66
30699956	Design and Synthesis of A PD-1 Binding Peptide and Evaluation of Its Anti-Tumor Activity.	International journal of molecular sciences	2019	-42.76502523587335	-43.40672206773164	16	0.91
30698054	Programmed cell death-1/programmed cell death ligand-1 checkpoint inhibitors: differences in mechanism of action.	Immunotherapy	2019	-43.51418988212829	-18.67689698019637	34	1.66
30697697	Low frequency, weak MCP-1 secretion and exhausted immune status of peripheral monocytes were associated with progression of severe enterovirus A71-infected hand, foot and mouth disease.	Clinical and experimental immunology	2019	-55.642613966836166	30.882686880849025	3	0.28
30692527	PD-1/PD-L1 checkpoint blockade harnesses monocyte-derived macrophages to combat cognitive impairment in a tauopathy mouse model.	Nature communications	2019	-78.06789978092738	-5.4360822014344174	86	4.63
30687337	Survival of Ovarian Cancer Patients Is Independent of the Presence of DC and T Cell Subsets in Ascites.	Frontiers in immunology	2018	3.728332523001186	29.951635091621945	16	0.86
30687086	The Prognostic and Therapeutic Value of PD-L1 in Glioma.	Frontiers in pharmacology	2018	-25.12221938716202	50.95952065168236	66	3.62
30686563	[Can nivolumab be used safely in idiopathic pulmonary fibrosis?].	Revue des maladies respiratoires	2019	68.58179811469836	-9.595286962151144	10	0.56
30686251	Efficacy and Safety of Addition of Anti-PD1 to Chemotherapy in Treatment of Non-Small Cell Lung Cancer.	Combinatorial chemistry & high throughput screening	2018	49.50306685650176	-20.928669465769463	5	0.15
30684971	PD-L1 expression and its clinicopathological correlation in advanced esophageal squamous cell carcinoma in a Chinese population.	Diagnostic pathology	2019	-13.50423567781862	8.26695705508514	24	1.23
30682845	The Risks and Benefits of Immune Checkpoint Blockade in Anti-AChR Antibody-Seropositive Non-Small Cell Lung Cancer Patients.	Cancers	2019	68.21460620557066	-3.932128474491785	16	0.75
30682679	Intratumoral, rather than stromal, CD8+ T cells could be a potential negative prognostic marker in invasive breast cancer patients.	Translational oncology	2019	-3.7232876880676926	20.448973047700093	31	1.75
30682108	Blockade of the PD-1 axis alone is not sufficient to activate HIV-1 virion production from CD4+ T cells of individuals on suppressive ART.	PloS one	2019	-83.38457588587144	15.07309231743905	16	0.71
30682105	Accumulation of exhausted CD8+ T cells in extramammary Paget's disease.	PloS one	2019	-43.46468765329936	14.17387672397312	9	0.48
30679180	Anti-PD-L1 Treatment Results in Functional Remodeling of the Macrophage Compartment.	Cancer research	2019	-30.25085935135748	-4.229425325577509	90	4.39
30678257	Mechanisms of Primary and Secondary Resistance to Immune Checkpoint Inhibitors in Cancer.	Medical sciences (Basel, Switzerland)	2019	32.83522975036682	15.568264727797953	36	1.63
30677255	Development and validation of nomograms integrating immune-related genomic signatures with clinicopathologic features to improve prognosis and predictive value of triple-negative breast cancer: A gene expression-based retrospective study.	Cancer medicine	2019	1.1669858576500527	45.233430688062754	18	0.91
30675316	Epigenetic treatment-mediated modulation of PD-L1 predicts potential therapy resistance over response markers in myeloid malignancies: A molecular mechanism involving effectors of PD-L1 reverse signaling.	Oncology letters	2019	-1.948052562777523	-31.284576563586917	4	0.2
30671549	Successful immunotherapy and irradiation in a HIV-positive patient with metastatic Merkel cell carcinoma.	Clinical and translational radiation oncology	2019	46.360437786290845	48.70976729352934	8	0.41
30670923	Programmed Death-ligand 1 Expression With Clone 22C3 in Non-small Cell Lung Cancer: A Single Institution Experience.	Clinical Medicine Insights. Oncology	2019	16.1598870003827	-38.43264284808763	6	0.29
30670497	irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial.	Clinical cancer research : an official journal of the American Association for Cancer Research	2019	20.641077691930278	32.61253384942516	63	2.68
30669748	[Expression of PD-1 and PD-L1 in the peripheral blood of advanced non-small-cell lung cancer patients and its implications].	Zhonghua yi xue za zhi	2019	7.784404432508148	-21.442759072851054	4	0.27
30668545	Prognostic value of immune checkpoint molecules in head and neck cancer: a meta-analysis.	Aging	2019	-4.27204936469491	-5.103300630131892	20	1.14
30666437	Characteristics and impact of programmed death-ligand 1 expression, CD8+ tumor-infiltrating lymphocytes, and p16 status in head and neck squamous cell carcinoma.	Medical oncology (Northwood, London, England)	2019	-6.503478857628536	-7.482529914930781	28	1.62
30666091	Hyperprogression after anti-programmed cell death ligand-1 therapy in a patient with recurrent metastatic urothelial bladder carcinoma following first-line cisplatin-based chemotherapy: a case report.	Drug design, development and therapy	2019	62.89898392804562	17.917700039628077	10	0.41
30666052	PD-1/PD-L1 expression and interaction by automated quantitative immunofluorescent analysis show adverse prognostic impact in patients with diffuse large B-cell lymphoma having T-cell infiltration: a study from the International DLBCL Consortium Program.	Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc	2019	-34.31951563616128	26.059971794751984	33	1.59
30665488	Microsatellite Instability Predicts Response to Anti-PD1 Immunotherapy in Metastatic Melanoma.	Acta dermatovenerologica Croatica : ADC	2018	15.02744302009905	42.77235666264115	8	0.31
30662542	Deciphering Microenvironment of NSCLC based on CD8+ TIL Density and PD-1/PD-L1 Expression.	Journal of Cancer	2019	10.77755109220808	-17.507944683814657	23	1.09
30662520	Epithelioid Trophoblastic Tumors: Treatments, Outcomes, and Potential Therapeutic Targets.	Journal of Cancer	2019	36.83445375433007	34.88889738405503	25	1.76
30662451	Embedding of Genes Using Cancer Gene Expression Data: Biological Relevance and Potential Application on Biomarker Discovery.	Frontiers in genetics	2018	-0.9754798814310296	45.18148862303461	22	1.06
30661655	Immunotherapy in advanced gastric cancer, is it the future?	Critical reviews in oncology/hematology	2019	42.92732933478913	18.733408243351207	86	4.82
30659749	Prognostic significance of PD-L2 expression in patients with oral squamous cell carcinoma-A comparison to the PD-L1 expression profile.	Cancer medicine	2019	-7.203572902450271	-12.181603752220385	15	0.94
30659133	Role of Immunotherapy in the Management of Locally Advanced and Recurrent/Metastatic Cervical Cancer.	Journal of the National Comprehensive Cancer Network : JNCCN	2019	44.70429981796913	35.80122405998022	34	1.64
30659055	Mouse PVRIG Has CD8+ T Cell-Specific Coinhibitory Functions and Dampens Antitumor Immunity.	Cancer immunology research	2019	-41.76462500010887	49.89694945611927	27	1.21
30659053	TIGIT and PD-1 Mark Intratumoral T Cells with Reduced Effector Function in B-cell Non-Hodgkin Lymphoma.	Cancer immunology research	2019	-25.04934504618006	28.503727761953733	63	2.87
30656807	Age-dependent hypoxia-induced PD-L1 upregulation in patients with obstructive sleep apnoea.	Respirology (Carlton, Vic.)	2019	-60.81802045312801	25.479639741652388	21	1.44
30655556	PD-1/PD-L1 Pathway Modulates Macrophage Susceptibility to Mycobacterium tuberculosis Specific CD8+ T cell Induced Death.	Scientific reports	2019	-84.89155618576238	1.5607570001532265	26	1.31
30652379	Durable intracranial and extracranial response to nivolumab with appearance of secondary resistance in a heavily pretreated patient with head and neck cancer.	Head & neck	2019	37.11525375798213	-12.219842838094369	2	0.07
30651289	LIN28/let-7/PD-L1 Pathway as a Target for Cancer Immunotherapy.	Cancer immunology research	2019	-17.342030998982036	0.6600014626144601	55	2.77
30650417	No Evidence of Microsatellite Instability and Loss of Mismatch-Repair-Protein Expression in Squamous Cell Carcinoma of the Penis.	Pathobiology : journal of immunopathology, molecular and cellular biology	2019	13.093845748040728	45.184639904688346	15	0.8
30649742	Safety and Tolerability of Immune Checkpoint Inhibitors (PD-1 and PD-L1) in Cancer.	Drug safety	2019	80.37441417209499	-5.523915867916009	55	2.82
30647851	STAT1 deficiency supports PD-1/PD-L1 signaling resulting in dysfunctional TNFα mediated immune responses in a model of NSCLC.	Oncotarget	2018	3.840264920159045	-32.423837233071225	9	0.4
30647844	Hedgehog signaling induces PD-L1 expression and tumor cell proliferation in gastric cancer.	Oncotarget	2018	-12.59281517194436	1.8924249877363195	79	3.29
30647082	The First-week Proliferative Response of Peripheral Blood PD-1+CD8+ T Cells Predicts the Response to Anti-PD-1 Therapy in Solid Tumors.	Clinical cancer research : an official journal of the American Association for Cancer Research	2019	13.753940760470304	-6.110736308829813	99	4.22
30643300	Author Correction: PD-L1 inhibits acute and chronic pain by suppressing nociceptive neuron activity via PD-1.	Nature neuroscience	2019	-73.75347812635516	-12.91890810028208	4	0.27
30642913	Immunotherapy for the First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer.	Clinical cancer research : an official journal of the American Association for Cancer Research	2019	39.4532780962972	-30.23026364143328	58	2.6
30642833	A CD40 Agonist and PD-1 Antagonist Antibody Reprogram the Microenvironment of Nonimmunogenic Tumors to Allow T-cell-Mediated Anticancer Activity.	Cancer immunology research	2019	-26.260220692338542	-19.64729892725595	77	3.61
30642544	The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC.	Lung cancer (Amsterdam, Netherlands)	2019	12.386335171660509	-19.8565526564809	63	2.96
30642373	Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients.	Journal of hematology & oncology	2019	53.800257004425525	-7.996451480145807	95	4.17
30640705	Immunotherapy in ovarian cancer: fake news or the real deal?	International journal of gynecological cancer : official journal of the International Gynecological Cancer Society	2019	38.771196338690665	38.655254578629	27	1.39
30637917	Expression of PD-1/PD-L1 in children's classical Hodgkin lymphomas.	Pediatric blood & cancer	2019	-29.367399095138087	23.034161161705608	14	0.79
30637710	The role of immunotherapy in small cell lung cancer.	Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico	2019	44.73005668734682	-41.76001690695541	65	3.39
30633154	Nivolumab to pembrolizumab switch induced a durable melanoma response: A case report.	Medicine	2019	36.43398731975283	0.0488349717051041	12	0.53
30631556	Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer: is there a substantial difference or not?	Journal of thoracic disease	2018	51.17773264680184	-45.71586440929247	17	0.73
30631548	PD-1 and PD-L1 inhibitor toxicities in non-small cell lung cancer.	Journal of thoracic disease	2018	51.12801436647291	-45.79908206424411	5	0.25
30630885	Trials in progress: IMagyn050/GOG 3015/ENGOT-OV39. A Phase III, multicenter, randomized study of atezolizumab versus placebo administered in combination with paclitaxel, carboplatin, and bevacizumab to patients with newly-diagnosed stage III or stage IV ovarian, fallopian tube, or primary peritoneal cancer.	International journal of gynecological cancer : official journal of the International Gynecological Cancer Society	2019	65.53244732827757	7.605659562502477	31	1.41
30628185	Nivolumab provides improved effectiveness and safety compared with docetaxel as a second-line treatment for advanced non-small cell lung cancer: A systematic review and meta-analysis.	Cancer medicine	2019	46.67990521946964	-23.822425988829547	8	0.36
30627905	Soluble Ligand of the Immune Checkpoint Receptor (sPD-L1) in Blood Serum of Patients with Renal Cell Carcinoma.	Bulletin of experimental biology and medicine	2019	8.425995265011894	7.577472281067163	17	0.8
30627815	Relationship between the expression of PD-1/PD-L1 and 18F-FDG uptake in bladder cancer.	European journal of nuclear medicine and molecular imaging	2019	13.731039936529395	-57.31889171328627	52	2.83
30624089	Immunotherapy: last bullet in platinum refractory germ cell testicular cancer.	Future oncology (London, England)	2019	49.53727395274203	25.56637808918343	14	0.83
30622744	Immunotherapy for hepatocellular carcinoma: current status and future perspectives.	ESMO open	2018	29.86405170798184	48.23146281978746	59	2.57
30622541	Regulation of GVHD and GVL Activity via PD-L1 Interaction With PD-1 and CD80.	Frontiers in immunology	2018	-65.7944324463561	-6.415380469464246	25	1.01
30619746	PD-1/PD-L1 Axis, Rather Than High-Mobility Group Alarmins or CD8+ Tumor-Infiltrating Lymphocytes, Is Associated With Survival in Head and Neck Squamous Cell Carcinoma Patients Who Received Surgical Resection.	Frontiers in oncology	2018	-7.292977015951138	-7.895169349506276	14	0.67
30619369	Novel Role for PD-1:PD-L1 as Mediator of Pulmonary Vascular Endothelial Cell Functions in Pathogenesis of Indirect ARDS in Mice.	Frontiers in immunology	2018	-60.63038738107187	31.37978423974117	25	1.11
30618263	PD-1 Upregulation Is Associated with Exhaustion of Regulatory T Cells and Reflects Immune Activation in HIV-1-Infected Individuals.	AIDS research and human retroviruses	2019	-80.26074605946783	12.943256936000491	8	0.4
30618179	KEYNOTE-025: Phase 1b study of pembrolizumab in Japanese patients with previously treated programmed death ligand 1-positive advanced non-small-cell lung cancer.	Cancer science	2019	49.04432078825255	-29.81553342401685	35	1.61
30618030	Endocrine complications of cancer immunotherapy.	Endokrynologia Polska	2018	82.15482845442308	-14.70938578280035	2	0.11
30617528	[Systemic treatment of metastatic tumors of the upper urinary tract].	Der Urologe. Ausg. A	2019	71.58615165315746	17.641619665225047	2	0.13
30617223	IL-6 Signaling Blockade during CD40-Mediated Immune Activation Favors Antitumor Factors by Reducing TGF-β, Collagen Type I, and PD-L1/PD-1.	Journal of immunology (Baltimore, Md. : 1950)	2019	-23.277529098432183	-7.934870815677201	25	1.22
30616805	Immune microenvironment and evasion mechanisms in adenoid cystic carcinomas of salivary glands.	Oral oncology	2019	1.0164359186193477	8.63624882998665	48	3.26
30616523	Differences in tumor microenvironments between primary lung tumors and brain metastases in lung cancer patients: therapeutic implications for immune checkpoint inhibitors.	BMC cancer	2019	-0.2509460354553957	17.434833518271482	53	2.62
30612418	Current status of immune checkpoint inhibitors in treatment of non-small cell lung cancer.	The Korean journal of internal medicine	2019	38.89397497264839	-36.33726865944155	10	0.45
30610038	Prognostic Significance of Categorizing Gastric Carcinoma by PD-L1 Expression and Tumor Infiltrating Lymphocytes.	Annals of clinical and laboratory science	2018	-8.601803251651479	22.800455540802584	11	0.55
30609841	Alterations of the Immunologic Co-Stimulator B7 and TNFR Families Correlate with Hepatocellular Carcinoma Prognosis and Metastasis by Inactivating STAT3.	International journal of molecular sciences	2019	-10.892921911615703	47.161294133315145	13	0.62
30608901	Immune checkpoint markers in gastroenteropancreatic neuroendocrine neoplasia.	Endocrine-related cancer	2019	0.3796342655540994	11.759513944463736	51	3.12
30607162	T-Cell Immunoglobulin Mucin 3 Expression on Tumor Infiltrating Lymphocytes as a Positive Prognosticator in Triple-Negative Breast Cancer.	Journal of breast cancer	2018	-2.3060815094927016	26.11851012078109	29	1.28
30605211	Efficacy and Safety of Avelumab Treatment in Patients With Advanced Unresectable Mesothelioma: Phase 1b Results From the JAVELIN Solid Tumor Trial.	JAMA oncology	2019	50.49747990924524	-6.627210698976835	102	5.09
30603725	Treatment of advanced hepatocellular carcinoma: immunotherapy from checkpoint blockade to potential of cellular treatment.	Translational gastroenterology and hepatology	2018	29.842860190088928	50.0232999636789	26	1.11
30603124	Pilot evaluation of PD-1 inhibition in metastatic cancer patients with a history of liver transplantation: the Mayo Clinic experience.	Journal of gastrointestinal oncology	2018	51.69277052808221	-16.067321066955135	92	4.41
30603054	The promising immune checkpoint LAG-3: from tumor microenvironment to cancer immunotherapy.	Genes & cancer	2018	11.211363342392742	22.15036816819836	213	9.25
30602320	Exploring the role of programmed cell death protein 1 and its ligand 1 in eye diseases.	Critical reviews in clinical laboratory sciences	2019	-67.58447051511162	-14.236136788520678	5	0.37
30601204	Comparison of the Inflammatory Infiltrates in Tumoral Melanosis, Regressing Nevi, and Regressing Melanoma.	The American Journal of dermatopathology	2019	6.006718608157892	1.6703083667476186	2	0.26
30600673	Bifidobacterium infantis Induces Protective Colonic PD-L1 and Foxp3 Regulatory T Cells in an Acute Murine Experimental Model of Inflammatory Bowel Disease.	Gut and liver	2019	-65.49478714804745	9.212331426283368	27	1.65
30600651	The prognostic impact of programmed cell death 1 and its ligand and the correlation with epithelial-mesenchymal transition in thymic carcinoma.	Cancer medicine	2019	-5.181839850375187	-35.92379686295316	18	0.88
32422018	New Clinical Approaches and Emerging Evidence on Immune-Checkpoint Inhibitors as Anti-Cancer Therapeutics: CTLA-4 and PD-1 Pathways and Beyond.	Critical reviews in immunology	2019	25.451693903465195	10.597936336053989	10	0.41
32421961	Back to the Light Side: The Role of Mechanotransduction in the Paradoxical Response to Checkpoint Inhibitors in Cancer Patients.	Critical reviews in immunology	2019	-37.55081458317517	-23.46074810757815	1	0.04
30595667	The Increase of Circulating PD-1- and PD-L1-Expressing Lymphocytes in Endometriosis: Correlation with Clinical and Laboratory Parameters.	Mediators of inflammation	2018	-69.89139471944767	-18.434389697432124	18	1.03
30595202	[Not Available].	Bulletin du cancer	2018	17.34380832396663	-4.464522694285844	1	0.04
30595194	[Not Available].	Bulletin du cancer	2018	37.17628531803206	-21.52360948902194	0	0.0
30595193	[Not Available].	Bulletin du cancer	2018	22.72096508764657	4.993293981922282	0	0.0
30595191	[Not Available].	Bulletin du cancer	2018	25.56560698675632	-4.031092406558422	0	0.0
30594267	Association of a PD-L2 Gene Polymorphism with Chronic Lymphatic Filariasis in a South Indian Cohort.	The American journal of tropical medicine and hygiene	2019	-65.04790533221804	14.545463291148756	2	0.1
30591531	Inhibition of COX-2 and EGFR by Melafolone Improves Anti-PD-1 Therapy through Vascular Normalization and PD-L1 Downregulation in Lung Cancer.	The Journal of pharmacology and experimental therapeutics	2019	-22.460144849845346	-31.00025694622185	23	1.15
30591493	PD-1 Expression on Circulating CD8+ T-Cells as a Prognostic Marker for Patients With Gastric Cancer.	Anticancer research	2019	-9.944026663800113	5.469075260621271	14	0.77
30591101	[First-line Combination Immunotherapy in Advanced Non-small Cell Lung Cancer].	Zhongguo fei ai za zhi = Chinese journal of lung cancer	2018	39.0996774099292	-28.67142000931966	1	0.04
30589920	Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade.	JAMA oncology	2019	14.235879474198764	44.45136221971153	345	17.22
30587849	Dynamic metrics-based biomarkers to predict responders to anti-PD-1 immunotherapy.	British journal of cancer	2019	15.82638397580238	-4.694148431762224	13	0.6
30587556	TGFβ Blockade Augments PD-1 Inhibition to Promote T-Cell-Mediated Regression of Pancreatic Cancer.	Molecular cancer therapeutics	2019	-21.11887602651868	-10.640251311972976	83	3.89
30586539	The efficacy and safety of nivolumab, pembrolizumab, and atezolizumab in treatment of advanced non-small cell lung cancer.	Discovery medicine	2018	43.58437536802265	-32.06594271659868	30	1.16
30584967	Evaluation of PD-L1 biomarker for immune checkpoint inhibitor (PD-1/PD-L1 inhibitors) treatments for urothelial carcinoma patients: A meta-analysis.	International immunopharmacology	2019	22.10368115732638	-5.232182894215713	24	1.01
30582240	PD-1 and PD-L1 in locoregionally advanced nasopharyngeal carcinoma: Substudy of a randomized phase III trial.	Head & neck	2019	-16.73204691323054	30.995305833219643	12	0.68
30578744	Identification of programmed cell death 1 and its ligand in the testicular tissue of mice.	American journal of reproductive immunology (New York, N.Y. : 1989)	2019	-65.75521121239659	-1.51713765819614	3	0.19
30577797	Recent updates in cancer immunotherapy: a comprehensive review and perspective of the 2018 China Cancer Immunotherapy Workshop in Beijing.	Journal of hematology & oncology	2018	20.441226228595	3.9104524513745846	78	3.2
30577587	Combining Radiotherapy and Immunotherapy in Lung Cancer: Can We Expect Limitations Due to Altered Normal Tissue Toxicity?	International journal of molecular sciences	2018	35.727930287210626	-28.277378545308	57	2.87
30577521	From Tumor Immunology to Immunotherapy in Gastric and Esophageal Cancer.	International journal of molecular sciences	2018	45.16686962203784	20.1013937645526	78	3.68
30576970	Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy.	European journal of cancer (Oxford, England : 1990)	2019	59.11014753731431	2.2046468622958115	148	7.66
30574211	Gene code CD274/PD-L1: from molecular basis toward cancer immunotherapy.	Therapeutic advances in medical oncology	2018	-41.746747511500665	-12.596949392428586	31	1.4
30568505	Orchestration of immune checkpoints in tumor immune contexture and their prognostic significance in esophageal squamous cell carcinoma.	Cancer management and research	2018	-5.534552169010434	26.283146800931554	23	0.86
30568113	Rapid and Long-term Response of Pulmonary Pleomorphic Carcinoma to Nivolumab.	Internal medicine (Tokyo, Japan)	2019	56.64905665705852	-31.28332656710757	21	1.38
30567732	BCL6-Mediated Silencing of PD-1 Ligands in Germinal Center B Cells Maintains Follicular T Cell Population.	Journal of immunology (Baltimore, Md. : 1950)	2019	-56.848921932978	-4.36711436567669	21	0.94
30565657	An effective dendritic cell-based vaccine containing glioma stem-like cell lysate and CpG adjuvant for an orthotopic mouse model of glioma.	International journal of cancer	2019	-29.869947304035986	55.11309219316812	29	1.6
30565043	MiR-21 Participates in the PD-1/PD-L1 Pathway-Mediated Imbalance of Th17/Treg Cells in Patients After Gastric Cancer Resection.	Annals of surgical oncology	2019	-50.03926344494192	33.57706093284336	43	2.39
30564891	A secreted PD-L1 splice variant that covalently dimerizes and mediates immunosuppression.	Cancer immunology, immunotherapy : CII	2019	-12.479734542210837	-5.086291215644303	74	3.56
30564890	Identification and characterization of an alternative cancer-derived PD-L1 splice variant.	Cancer immunology, immunotherapy : CII	2019	-12.703042943768493	-5.063730461012018	44	2.2
30564277	The suppressive effect of co-inhibiting PD-1 and CTLA-4 expression on H22 hepatomas in mice.	Cellular & molecular biology letters	2018	-51.22116594393327	-21.84627075678377	13	0.6
30563566	Agonist redirected checkpoint, PD1-Fc-OX40L, for cancer immunotherapy.	Journal for immunotherapy of cancer	2018	-27.51262979622032	-20.59732358613426	28	1.08
30561383	Predicting tumour response to anti-PD-1 immunotherapy with computational modelling.	Physics in medicine and biology	2019	-1.288573587214778	-44.28112532578479	17	0.83
30559738	Hantavirus-Driven PD-L1/PD-L2 Upregulation: An Imperfect Viral Immune Evasion Mechanism.	Frontiers in immunology	2018	-76.4436266428159	10.499087066218866	13	0.6
30559623	Immune Checkpoint Inhibitors in Pediatric Solid Tumors: Status in 2018.	Ochsner journal	2018	30.589468055312988	8.209021276534669	27	1.19
30557521	T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028.	Journal of clinical oncology : official journal of the American Society of Clinical Oncology	2019	22.3120284550938	-12.353178205367476	505	25.67
30555574	Clinical significance of PD-1/PD-Ls gene amplification and overexpression in patients with hepatocellular carcinoma.	Theranostics	2018	-21.79254380259208	40.77800047617168	39	1.62
30555473	Human CD8+HLA-DR+ Regulatory T Cells, Similarly to Classical CD4+Foxp3+ Cells, Suppress Immune Responses via PD-1/PD-L1 Axis.	Frontiers in immunology	2018	-68.72710509629181	3.982792925725926	43	1.81
30552459	Ex vivo conditioning with IL-12 protects tumor-infiltrating CD8+ T cells from negative regulation by local IFN-γ.	Cancer immunology, immunotherapy : CII	2019	-43.8470150569373	-2.256660479983452	16	0.88
30552160	Patient-Reported Outcomes with PD-1/PD-L1 Inhibitors for Advanced Cancer: A Meta-Analysis.	The oncologist	2019	55.5068019519474	-15.800899763027315	18	0.62
30549362	HLA class II expression on tumor cells and low numbers of tumor-associated macrophages predict clinical outcome in oropharyngeal cancer.	Head & neck	2019	-8.744923820442501	30.833991665228808	20	1.07
30548363	Programmed death ligand-1 is associated with tumor infiltrating lymphocytes and poorer survival in urothelial cell carcinoma of the bladder.	Cancer science	2019	11.998783144320315	58.16253701733548	54	2.49
30547271	Frequent discordance in PD-1 and PD-L1 expression between primary breast tumors and their matched distant metastases.	Clinical & experimental metastasis	2019	-9.08388321848709	15.927198931550883	42	2.07
30547218	Enhanced anti-tumor efficacy of checkpoint inhibitors in combination with the histone deacetylase inhibitor Belinostat in a murine hepatocellular carcinoma model.	Cancer immunology, immunotherapy : CII	2019	30.254402819023746	44.710441303835154	78	3.93
30547012	Progresses and Perspectives of Anti-PD-1/PD-L1 Antibody Therapy in Head and Neck Cancers.	Frontiers in oncology	2018	52.05279503680925	36.66445749087175	29	1.13
30546030	Analysis of expression of the PD-1/PD-L1 immune checkpoint system and its prognostic impact in gastroenteropancreatic neuroendocrine tumors.	Scientific reports	2018	-0.0970020751382545	11.402705799982424	35	1.68
30544743	Pathological and Molecular Characteristics of Colorectal Cancer with Brain Metastases.	Cancers	2018	11.99862819737259	36.78784511302057	16	0.71
30544524	The Role of Yes-Associated Protein (YAP) in Regulating Programmed Death-Ligand 1 (PD-L1) in Thoracic Cancer.	Biomedicines	2018	2.367795502259873	-34.52589948540874	25	1.06
30543161	Chemical Generation of Hydroxyl Radical for Oxidative 'Footprinting'.	Protein and peptide letters	2019	-47.46303717169988	-44.20365086565339	9	0.79
30542345	CTLA-4 and PD-1 Control of T-Cell Motility and Migration: Implications for Tumor Immunotherapy.	Frontiers in immunology	2018	26.46959152180048	4.041181899487687	105	4.31
30541848	Contrasting Roles of the PD-1 Signaling Pathway in Dendritic Cell-Mediated Induction and Regulation of HIV-1-Specific Effector T Cell Functions.	Journal of virology	2019	-83.5533203123348	13.278824543284696	17	0.87
30541787	MEK inhibition enhances oncolytic virus immunotherapy through increased tumor cell killing and T cell activation.	Science translational medicine	2018	28.65471822000001	36.4465193930908	83	3.54
30541755	Biomarkers for Programmed Death-1 Inhibition in Prostate Cancer.	The oncologist	2019	15.620107963457668	44.77157737747517	16	0.75
30541416	Anti-PD1 'SHR-1210' aberrantly targets pro-angiogenic receptors and this polyspecificity can be ablated by paratope refinement.	mAbs	2019	-46.21949916049501	-32.60722700654053	41	2.13
30524900	Adoptive cell therapy with tumor-infiltrating lymphocytes in patients with metastatic ovarian cancer: a pilot study.	Oncoimmunology	2018	35.22284012847079	36.555964778994735	64	2.46
30523626	Merkel Cell Carcinoma in the HIV-1/AIDS Patient.	Cancer treatment and research	2019	45.11135917510433	51.96831946840677	6	0.46
30523370	CRISPR/Cas9-mediated PD-1 disruption enhances human mesothelin-targeted CAR T cell effector functions.	Cancer immunology, immunotherapy : CII	2019	-43.78006029437113	1.5061496338996927	155	7.55
30523022	Molecular Subtype Not Immune Response Drives Outcomes in Endometrial Carcinoma.	Clinical cancer research : an official journal of the American Association for Cancer Research	2019	6.548914182845628	45.89800269414191	81	4.15
30522188	[Research progrss on resistance of PD1/PD-L1 signal pathway].	Zhonghua bing li xue za zhi = Chinese journal of pathology	2018	-35.751472376072776	-22.173568716082663	0	0.0
30539869	Expression of programmed death ligand-1 and programmed death 1 in hepatocellular carcinoma and its clinical significance.	Journal of cancer research and therapeutics	2018	-23.042277938076108	39.39213542588506	14	0.57
30539796	Immune checkpoint blockade as a potential therapeutic strategy for undifferentiated malignancies.	Human pathology	2018	9.52617861423004	15.39822579532585	2	0.05
30539511	Immune Checkpoint Inhibitors-Induced Hepatitis.	Advances in experimental medicine and biology	2018	75.85979327167296	0.1157837816917104	22	0.87
30539506	Immunotherapy in Lung Cancer: A New Age in Cancer Treatment.	Advances in experimental medicine and biology	2018	36.47742476524984	-33.12009042130091	39	1.71
30538704	Promises and Pitfalls in the Use of PD-1/PD-L1 Inhibitors in Multiple Myeloma.	Frontiers in immunology	2018	-32.890707858605964	7.766785212032367	36	1.52
30538110	The COX2 Effector Microsomal PGE2 Synthase 1 is a Regulator of Immunosuppression in Cutaneous Melanoma.	Clinical cancer research : an official journal of the American Association for Cancer Research	2019	-17.965124431732225	-2.0233129622081387	36	1.67
30534571	Association of PD-1 and PD-L1 Genetic Polymorphyisms with Type 1 Diabetes Susceptibility.	Journal of diabetes research	2018	-62.079085908398746	14.546379228215796	24	1.07
30528137	Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study.	The Lancet. Haematology	2019	72.81517493152414	-14.116400863373457	149	7.8
30528043	PD-1/PD-L1 expressions in medullary thyroid carcinoma: Clinicopathologic and prognostic analysis of Chinese population.	European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology	2019	-6.8175196065794585	-21.320840899483255	28	1.6
30527198	Validation of the immunohistochemical expression of programmed death ligand 1 (PD-L1) on cytological smears in advanced non small cell lung cancer.	Lung cancer (Amsterdam, Netherlands)	2018	16.25371510256835	-39.189103059789375	27	1.06
30522017	PD-1/ PD-L1 blockade as a novel treatment for colorectal cancer.	Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie	2019	34.655430543763934	22.62851653886917	168	9.43
30521746	Analysis of the Expression and Regulation of PD-1 Protein on the Surface of Myeloid-Derived Suppressor Cells (MDSCs).	Biomolecules & therapeutics	2019	-50.651527978319606	27.449364494551325	36	1.77
30521597	Gene landscape and correlation between B-cell infiltration and programmed death ligand 1 expression in lung adenocarcinoma patients from The Cancer Genome Atlas data set.	PloS one	2018	14.444771596312398	-13.309993353446744	17	0.74
30519815	PD-1 and PD-L1 Expression in Male Breast Cancer in Comparison with Female Breast Cancer.	Targeted oncology	2018	-10.876089506931972	16.283574750772214	9	0.42
30519541	Crosstalk Between PD-1/PD-L1 Blockade and Its Combinatorial Therapies in Tumor Immune Microenvironment: A Focus on HNSCC.	Frontiers in oncology	2018	-8.514710614307717	-6.874920767325099	25	1.02
30519342	PD-1 Blockade Overcomes Adaptive Immune Resistance in Treatment with Anchored-GM-CSF Bladder Cancer Cells Vaccine.	Journal of Cancer	2018	-24.504268916498795	-10.916414093400425	5	0.23
30519336	The Clinical and Biomarker Association of Programmed Death Ligand 1 and its Spatial Heterogeneous Expression in Colorectal Cancer.	Journal of Cancer	2018	-4.754525814010754	11.262425252796536	15	0.63
30519309	Immunoscore System for Predicting Clinical Outcome of Metastatic Renal Cell Carcinoma Patients Treated with Tyrosine Kinase Inhibitors.	Journal of Cancer	2018	13.315596159447326	30.76642037674329	7	0.28
30518694	Tumor-draining lymph nodes are pivotal in PD-1/PD-L1 checkpoint therapy.	JCI insight	2018	-31.83438759593044	-12.432590519939506	181	6.88
30508306	Promising efficacy of SHR-1210, a novel anti-programmed cell death 1 antibody, in patients with advanced gastric and gastroesophageal junction cancer in China.	Cancer	2019	50.9055871438587	17.890206646208988	44	1.91
30506460	The correlation and prognostic value of serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death-ligand 1 (sPD-L1) in patients with hepatocellular carcinoma.	Cancer immunology, immunotherapy : CII	2019	-25.577868056237104	38.27220553805397	84	4.44
30506459	Fulminant diabetes induced by PD-1 and PD-L1 inhibitors: what about glucose variability?	Acta diabetologica	2019	89.46405546279355	-16.704168652125226	2	0.11
30506221	Advances in molecular imaging of immune checkpoint targets in malignancies: current and future prospect.	European radiology	2019	27.963530063077982	-11.865214236922387	26	1.49
30505716	Tumor mutational burden in non-small cell lung cancer-the pathologist's point of view.	Translational lung cancer research	2018	23.008095661030502	-18.38411617680864	9	0.37
30505713	Predictive markers for anti-PD-1/PD-L1 therapy in non-small cell lung cancer-where are we?	Translational lung cancer research	2018	20.45169867507943	-35.96370292643047	22	0.89
30505708	The clinical utility of tumor mutational burden in non-small cell lung cancer.	Translational lung cancer research	2018	23.94131106198732	-17.80941046886005	77	3.19
30505679	The clinical benefits of immune checkpoint inhibitor for thymic carcinomas ∼experience of single public hospital in Japan∼.	Respiratory medicine case reports	2019	39.1977468215761	-1.4715199376293748	4	0.21
30505301	Update on PD-1/PD-L1 Inhibitors in Multiple Myeloma.	Frontiers in immunology	2018	38.05014360627544	-4.47689389066878	78	3.27
30504406	Comparison of PD-L1 Assays in Non-small Cell Lung Cancer: 22C3 pharmDx and SP263.	Anticancer research	2018	16.192284051132983	-40.65957633076363	17	0.68
30504313	Where does PD-1 blockade fit in HL therapy?	Hematology. American Society of Hematology. Education Program	2018	39.71767847253916	-6.633334579946685	8	0.28
30502542	The role and clinical significance of programmed cell death- ligand 1 expressed on CD19+B-cells and subsets in systemic lupus erythematosus.	Clinical immunology (Orlando, Fla.)	2019	-53.39768676276345	11.024989412661965	7	0.36
30511201	A novel tetravalent bispecific antibody targeting programmed death 1 and tyrosine-protein kinase Met for treatment of gastric cancer.	Investigational new drugs	2019	-15.476755917487209	-47.58099297127093	14	0.64
30511098	A controlled inflammation and a regulatory immune system are associated with more favorable prognosis of progressive multifocal leukoencephalopathy.	Journal of neurology	2019	-40.94894562905903	42.68617937642219	14	0.89
30500923	The role of the PD-1/PD-L1 axis in macrophage differentiation and function during pregnancy.	Human reproduction (Oxford, England)	2019	-75.03925442307141	-18.200374342668493	72	4.58
30500073	The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia.	Cancer	2019	-37.95891144765419	15.392711063671817	174	8.55
30499814	Programmed Death-ligand 1 (PD-L1) Expression in Thymic Epithelial Tumors.	Applied immunohistochemistry & molecular morphology : AIMM	2020	-5.420123856820437	-36.87601460063307	11	0.83
30498900	Transformation of Old Concepts for a New Era of Cancer Immunotherapy: Cytokine Therapy and Cancer Vaccines as Combination Partners of PD1/PD-L1 Inhibitors.	Current oncology reports	2018	28.310228914707537	-1.3449401319609433	18	0.77
30498094	Expression of PD-1 by T Cells in Malignant Glioma Patients Reflects Exhaustion and Activation.	Clinical cancer research : an official journal of the American Association for Cancer Research	2019	-25.629576140635702	52.09922333246157	46	2.11
30488824	Checkpoint immunotherapy by nivolumab for treatment of metastatic melanoma.	Journal of cancer research and therapeutics	2018	34.313167486602595	0.5332655540064475	34	1.42
30487606	FBXO38 mediates PD-1 ubiquitination and regulates anti-tumour immunity of T cells.	Nature	2018	-19.01315507255625	-8.318434658830583	141	5.15
30487133	PD-L1 Expression in Tumor Cells Is an Independent Unfavorable Prognostic Factor in Oral Squamous Cell Carcinoma.	Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology	2019	-7.390435620432049	-11.762456761339388	42	2.25
30481100	Product review: avelumab, an anti-PD-L1 antibody.	Human vaccines & immunotherapeutics	2019	61.65834365024682	-4.556345128974214	35	1.9
30477533	Patient-derived tumor immune microenvironments in patient-derived xenografts of lung cancer.	Journal of translational medicine	2018	-37.35125619422536	-26.915889816071264	10	0.44
30476528	Efficient PD-L1 gene silence promoted by hyaluronidase for cancer immunotherapy.	Journal of controlled release : official journal of the Controlled Release Society	2019	-34.20331877902828	-49.48556136633388	37	1.93
30474476	Efficacy and safety of PD-1 inhibitors for treating advanced melanoma: a systematic review and meta-analysis.	Immunotherapy	2018	53.877786269028256	-12.21846598638326	11	0.44
30474475	Risk of fatigue in cancer patients treated with anti programmed cell death-1/anti programmed cell death ligand-1 agents: a systematic review and meta-analysis.	Immunotherapy	2018	63.980128080655	-15.892516041829133	1	0.06
30470767	Proof of concept study of mass cytometry in septic shock patients reveals novel immune alterations.	Scientific reports	2018	-56.62864152689821	37.15731157563366	25	1.12
30467920	Persistent restoration to the immunosupportive tumor microenvironment in glioblastoma by bevacizumab.	Cancer science	2019	-31.193162633828283	51.80425653404214	45	2.25
30464684	Immune-related adverse events of immune checkpoint inhibitors: a brief review.	Current oncology (Toronto, Ont.)	2018	77.87767069147124	-9.75282789054533	83	3.92
30464512	Clinicopathological analysis of PD-L2 expression in colorectal cancer.	OncoTargets and therapy	2018	-6.027029180365995	11.106689719549488	13	0.56
30464501	Clinical and molecular characteristics associated with the efficacy of PD-1/PD-L1 inhibitors for solid tumors: a meta-analysis.	OncoTargets and therapy	2018	49.4052155982873	-15.33128972140042	25	1.01
30463004	PD-1 Is Involved in the Dysregulation of Type 2 Innate Lymphoid Cells in a Murine Model of Obesity.	Cell reports	2018	-58.51891312380651	5.792574944011889	57	2.12
30462163	Immune biomarkers of response to immune-checkpoint inhibitors in head and neck squamous cell carcinoma.	Annals of oncology : official journal of the European Society for Medical Oncology	2019	-6.228480249896078	-5.062160938456023	129	6.52
30459153	PD-L1 microSPECT/CT Imaging for Longitudinal Monitoring of PD-L1 Expression in Syngeneic and Humanized Mouse Models for Cancer.	Cancer immunology research	2019	5.500760774567616	-54.6816666278752	26	1.37
30458888	Acquired resistance to immunotherapy in MMR-D pancreatic cancer.	Journal for immunotherapy of cancer	2018	40.71747126363499	41.16656261460764	24	0.82
30456447	Cemiplimab: First Global Approval.	Drugs	2018	59.0741522570372	-4.402570871257487	107	4.61
30450335	The Identification of Immunological Biomarkers in Kidney Cancers.	Frontiers in oncology	2018	21.46192035131607	29.672907247025016	33	1.29
30450162	Anti-PD-1 therapy for clinical treatment of lymphoma: a single-arm meta-analysis.	Oncotarget	2018	50.2838535248752	-13.706970364325276	7	0.28
30448635	PD-1 blockade augments humoral immunity through ICOS-mediated CD4+ T cell instruction.	International immunopharmacology	2019	-31.18663693021009	-15.056662999194536	15	0.65
30448477	Round optimization for improved discovery of native bispecific antibodies.	Methods (San Diego, Calif.)	2019	-15.771284572696374	-48.64263571615441	1	0.08
30446984	Cancer immunotherapy of patients with HIV infection.	Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico	2019	25.08000296384941	4.264544851360459	17	0.88
30446226	Interferon-β signal may up-regulate PD-L1 expression through IRF9-dependent and independent pathways in lung cancer cells.	Biochemical and biophysical research communications	2018	-17.950199705085875	-19.282671817026188	45	1.7
30442814	Posttranslational Modifications of PD-L1 and Their Applications in Cancer Therapy.	Cancer research	2018	-45.24639040013587	-23.019158912915795	155	6.39
30442684	Molecular Profiling of Cohorts of Tumor Samples to Guide Clinical Development of Pembrolizumab as Monotherapy.	Clinical cancer research : an official journal of the American Association for Cancer Research	2019	22.52925521187688	-12.04320570255114	27	1.1
30431333	A novel role for programmed cell death receptor ligand 2 in sepsis-induced hepatic dysfunction.	American journal of physiology. Gastrointestinal and liver physiology	2019	-60.47897999995539	34.51269267636477	6	0.34
30430276	Review of Immune Therapies Targeting Ovarian Cancer.	Current treatment options in oncology	2018	39.1487948937506	37.915695008325365	40	1.81
30430228	Role of the HDAC6/STAT3 pathway in regulating PD-L1 expression in osteosarcoma cell lines.	Cancer chemotherapy and pharmacology	2019	-9.922746557594571	-32.69411745029204	30	1.78
30425525	The efficacy and safety of immune checkpoint inhibitor combination therapy in lung cancer: a systematic review and meta-analysis.	OncoTargets and therapy	2018	40.932019232571896	-19.375445207591696	14	0.58
30425139	Immune checkpoint inhibitors in the management of malignancies in transplant recipients.	Postgraduate medical journal	2018	23.48881002520989	5.601683300890991	6	0.35
30425059	miR-146a Controls Immune Response in the Melanoma Microenvironment.	Cancer research	2019	-18.376361688635416	1.1030017280579807	60	3.32
30424804	Targeting myeloid-inflamed tumor with anti-CSF-1R antibody expands CD137+ effector T-cells in the murine model of pancreatic cancer.	Journal for immunotherapy of cancer	2018	-22.08463756873529	-13.144506995266337	38	1.35
30421009	Combination Immune Checkpoint Blockade Strategies to Maximize Immune Response in Gynecological Cancers.	Current oncology reports	2018	40.58837199645609	36.75167792456532	34	1.24
30420753	Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade.	Nature medicine	2019	-30.71141101461881	-25.87960401610276	438	22.46
30415152	A SERS microfluidic platform for targeting multiple soluble immune checkpoints.	Biosensors & bioelectronics	2019	-20.49542781503841	-63.552051720160286	26	1.84
30412106	Immune checkpoint inhibitors of CTLA4 and PD-1 for malignant melanoma arising in ovarian cystic teratoma: A case report.	Medicine	2018	39.14223072255692	40.052587676706416	2	0.07
30411330	Monocytes show immunoregulatory capacity on CD4+ T cells in a human in-vitro model of extracorporeal photopheresis.	Clinical and experimental immunology	2019	-57.17250898457944	25.02449572428197	8	0.66
30409776	Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study.	Cancer discovery	2019	47.731648566615455	-4.265698606275233	310	14.82
30407284	Anti-PD-1 pembrolizumab induced autoimmune diabetes in Chinese patient: A case report.	Medicine	2018	88.53706487906372	-15.635471461575047	15	0.73
30406502	Immunotherapy for Urothelial Carcinoma: Current Evidence and Future Directions.	Current urology reports	2018	68.90390253141624	19.022452155054676	38	1.61
30406373	Hyperresponsiveness to interferon gamma exposure as a response mechanism to anti-PD-1 therapy in microsatellite instability colorectal cancer.	Cancer immunology, immunotherapy : CII	2019	-19.495013681706396	-19.08993588651124	7	0.32
30406030	Immune Checkpoints and Innovative Therapies in Glioblastoma.	Frontiers in oncology	2018	-28.94753062428597	58.63370675945472	61	2.88
30405135	Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer.	Nature communications	2018	12.466309575412303	-36.02637908072804	261	12.77
30401949	T cell-inflamed phenotype and increased Foxp3 expression in infiltrating T-cells of mismatch-repair deficient endometrial cancers.	Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc	2019	10.983962651756675	46.54850633101312	23	1.1
30400941	PD-1 and PD-L1 are more highly expressed in high-grade bladder cancer than in low-grade cases: PD-L1 might function as a mediator of stage progression in bladder cancer.	BMC urology	2018	11.445893990480458	59.63694188297546	31	1.55
30400799	Status of programmed death-ligand 1 expression in sarcomas.	Journal of translational medicine	2018	-21.21417837494588	20.09544751085402	26	1.27
30400003	Analysis of the immune landscape of small bowel neuroendocrine tumors.	Endocrine-related cancer	2019	0.3780870336206822	14.08949266280096	34	2.09
30399326	Promise and pitfalls of immune checkpoint inhibitors in hepato-pancreato-biliary malignancies.	Discovery medicine	2018	29.75543152699062	47.3256312242756	5	0.25
30399174	Cancer immunotherapy using PolyPurine Reverse Hoogsteen hairpins targeting the PD-1/PD-L1 pathway in human tumor cells.	PloS one	2018	-34.760994638808576	-44.978801612328574	16	0.89
30398102	Manipulation of the Immune System for Cancer Defeat: A Focus on the T Cell Inhibitory Checkpoint Molecules.	Current medicinal chemistry	2020	22.965534247019963	10.138749680864825	10	0.68
30397772	The Role of PD-1 Checkpoint Inhibition in Gynecologic Malignancies.	Current treatment options in oncology	2018	41.67381322973596	35.35796678876387	13	0.51
30397328	HIP1R targets PD-L1 to lysosomal degradation to alter T cell-mediated cytotoxicity.	Nature chemical biology	2019	-44.16533880009365	-21.72250431614714	145	7.07
30396996	Loss of VGLL4 suppresses tumor PD-L1 expression and immune evasion.	The EMBO journal	2019	-25.870367411810303	-5.098706081489377	30	1.46
30396745	PD-1 immunobiology in systemic lupus erythematosus.	Journal of autoimmunity	2019	-52.54233520923995	11.21452179217457	52	2.93
30395155	Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic.	Annals of oncology : official journal of the European Society for Medical Oncology	2019	23.819888173468662	-15.635580335564311	1350	71.88
30393621	Programmed cell death ligand-1 (PD-L1) as a biomarker for non-small cell lung cancer (NSCLC) treatment-are we barking up the wrong tree?	Translational lung cancer research	2018	20.055688292637257	-34.16128701723508	32	1.1
30393585	Antagonist of cIAP1/2 and XIAP enhances anti-tumor immunity when combined with radiation and PD-1 blockade in a syngeneic model of head and neck cancer.	Oncoimmunology	2018	20.71245863202616	48.43087002305271	39	1.47
30393583	Adipose PD-L1 Modulates PD-1/PD-L1 Checkpoint Blockade Immunotherapy Efficacy in Breast Cancer.	Oncoimmunology	2018	-33.508097470933606	-10.962572238077389	60	2.54
30391014	FDA analyses of survival in older adults with metastatic non-small cell lung cancer in controlled trials of PD-1/PD-L1 blocking antibodies.	Seminars in oncology	2018	54.16970012871303	-18.936746317636494	64	2.45
30389797	Combination cancer immunotherapy targeting PD-1 and GITR can rescue CD8+ T cell dysfunction and maintain memory phenotype.	Science immunology	2018	-27.611178582734027	-19.37207445061272	106	3.85
30389315	Stromal PD-1/PD-L1 Expression Predicts Outcome in Colon Cancer Patients.	Clinical colorectal cancer	2019	-4.820385599971003	12.091016092399933	54	3.0
30389046	PD-1 blockade inhibits lymphocyte apoptosis and restores proliferation and anti-viral immune functions of lymphocyte after CP and NCP BVDV infection in vitro.	Veterinary microbiology	2018	-79.01236011311703	19.08791694280506	7	0.48
30388926	Tumor regression after combination of radiation and PD-1 antibody nivolumab treatment in a patient with metastatic mediastinal leiomyosarcoma: a case report.	Cancer biology & therapy	2019	39.65291970541784	-9.95812920457925	6	0.29
30387047	Programmed cell death protein-1 (PD-1)/programmed death-ligand-1 (PD-L1) axis in hepatocellular carcinoma: prognostic and therapeutic perspectives.	Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico	2019	-22.66107206730216	39.51106967774799	29	1.65
30386337	Inhibitory Receptors and Pathways of Lymphocytes: The Role of PD-1 in Treg Development and Their Involvement in Autoimmunity Onset and Cancer Progression.	Frontiers in immunology	2018	-56.202198284577385	-0.4680547191041056	108	4.69
30385715	MERTK inhibition alters the PD-1 axis and promotes anti-leukemia immunity.	JCI insight	2018	-28.679746172290727	-24.623174572830383	43	1.82
30385408	MLL3 enhances the transcription of PD-L1 and regulates anti-tumor immunity.	Biochimica et biophysica acta. Molecular basis of disease	2019	-15.712861627089998	-2.679838455062926	20	1.0
30384998	Inhibition of PD1:PD-L1 interaction by an E. coli-derived optimized PD1 variant.	Biochemical and biophysical research communications	2018	-49.759952761965785	-28.79475330087365	1	0.04
30384489	Profiling Immune Escape in Hodgkin's and Diffuse large B-Cell Lymphomas Using the Transcriptome and Immunostaining.	Cancers	2018	-29.59178500739942	30.47844626539815	17	0.7
30384043	Peptide-based and small synthetic molecule inhibitors on PD-1/PD-L1 pathway: A new choice for immunotherapy?	European journal of medicinal chemistry	2019	-42.24039977105272	-39.25531942578888	48	2.58
30383701	A case report of remarkable response to association of radiofrequency ablation with subsequent Atezolizumab in stage IV nonsmall cell lung cancer.	Medicine	2018	51.166710663641865	-39.24645989665811	12	0.58
30380773	Systemic Therapy for Hepatocellular Carcinoma: Latest Advances.	Cancers	2018	31.001155974692555	51.56276661052631	125	6.08
30378264	Tumour cell-intrinsic CTLA4 regulates PD-L1 expression in non-small cell lung cancer.	Journal of cellular and molecular medicine	2019	7.734998869644746	-35.25718973333723	48	2.42
30377572	PD-L1 blockade enhances anti-tumor efficacy of NK cells.	Oncoimmunology	2018	-34.21713213962787	-1.3779314952287849	91	4.02
30377566	TIM-3 expression in breast cancer.	Oncoimmunology	2018	-2.4157914166604946	26.00917840500762	40	1.74
30377561	Predicting T cell recognition of MHC class I restricted neoepitopes.	Oncoimmunology	2018	-1.5540821992423235	65.32258000847807	50	1.84
30377341	Direct therapeutic targeting of immune checkpoint PD-1 in pancreatic cancer.	British journal of cancer	2019	12.512001312148712	12.050647186501417	27	1.39
30376867	Recent advances in immunotherapies: from infection and autoimmunity, to cancer, and back again.	Genome medicine	2018	19.75129983647406	7.190725221103475	27	1.2
30374666	Duration of adjuvant immunotherapy-biologic, clinical and economic considerations.	Medical oncology (Northwood, London, England)	2018	38.4066364833099	1.8275064277137216	9	0.31
30374610	Molecular predictors of response to PD-1/PD-L1 inhibition in urothelial cancer.	World journal of urology	2019	65.8045583425127	22.36073877845113	16	0.77
30374524	Developing combination strategies using PD-1 checkpoint inhibitors to treat cancer.	Seminars in immunopathology	2019	27.546365546365948	0.0613839598865473	47	2.35
30374200	Translational control of tumor immune escape via the eIF4F-STAT1-PD-L1 axis in melanoma.	Nature medicine	2018	-14.55813268780531	-22.161344550787188	140	5.42
30370857	Novel Small Molecule Inhibitors of Programmed Cell Death (PD)-1, and its Ligand, PD-L1 in Cancer Immunotherapy: A Review Update of Patent Literature.	Recent patents on anti-cancer drug discovery	2019	-42.60420098836898	-37.65988008057951	16	0.79
30369388	Prolonged Disease Control with Nivolumab in Metastatic Lung Adenocarcinoma During Immunotherapy Era.	Journal of the College of Physicians and Surgeons--Pakistan : JCPSP	2018	44.38632652446741	-25.84161018906475	0	0.0
30368626	A novel humanized anti-PD-1 monoclonal antibody potentiates therapy in oral squamous cell carcinoma.	Investigational new drugs	2019	-9.89337720667686	-11.493560452793377	4	0.22
30366077	PD-L1 knockdown via hybrid micelle promotes paclitaxel induced Cancer-Immunity Cycle for melanoma treatment.	European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences	2019	-28.57238270490094	-48.2336996657647	12	0.66
30361152	Diabetic ketoacidosis induced by a single dose of pembrolizumab.	The American journal of emergency medicine	2019	88.39417431928247	-15.535050016570125	23	1.2
30357491	Inhibitory functions of PD-L1 and PD-L2 in the regulation of anti-tumor immunity in murine tumor microenvironment.	Cancer immunology, immunotherapy : CII	2019	-33.95516510173392	-9.466783601753182	43	1.93
30356816	The Antitumor Activity of Combinations of Cytotoxic Chemotherapy and Immune Checkpoint Inhibitors Is Model-Dependent.	Frontiers in immunology	2018	34.324901222771096	10.488825777743113	71	3.0
30355786	Estrogen Signaling in Bystander Foxp3neg CD4+ T Cells Suppresses Cognate Th17 Differentiation in Trans and Protects from Central Nervous System Autoimmunity.	Journal of immunology (Baltimore, Md. : 1950)	2018	-72.31967213875002	-7.518691349452846	16	0.77
30353572	Polymorphism of the programmed death-ligand 1 gene is associated with its protein expression and prognosis in gastric cancer.	Journal of gastroenterology and hepatology	2019	-7.576209692930464	5.280250820368046	23	1.17
30352860	NK Cells Respond to Checkpoint Blockade.	Cancer discovery	2018	-34.45251624643866	0.4444765512714901	1	0.04
30350128	[Mode of action, new targets and potential biomarkers in modern immunotherapy].	Der Urologe. Ausg. A	2018	66.29569898070993	23.939817276496942	4	0.14
30349382	Predictive biomarkers for tumor immune checkpoint blockade.	Cancer management and research	2018	18.50536472890892	-4.180505222148812	15	0.64
30348714	Radiological Features of Programmed Cell Death-Ligand 2-positive Lung Adenocarcinoma: A Single-institution Retrospective Study.	In vivo (Athens, Greece)	2018	9.512334264327222	-28.34988020837224	4	0.15
30347480	Autoimmune hemolytic anemia associated with the use of immune checkpoint inhibitors for cancer: 68 cases from the Food and Drug Administration database and review.	European journal of haematology	2019	70.96123575754744	-10.446112139130484	55	3.4
30346474	Association of PD-L1, PD-L2, and Immune Response Markers in Matched Renal Clear Cell Carcinoma Primary and Metastatic Tissue Specimens.	American journal of clinical pathology	2019	15.064622148453768	26.604766318098708	22	1.07
30344919	In tumor cells, thyroid hormone analogues non-immunologically regulate PD-L1 and PD-1 accumulation that is anti-apoptotic.	Oncotarget	2018	-32.58532528477044	-27.439576456018692	13	0.68
30344812	An Unusual Case of Gastritis in One Patient Receiving PD-1 Blocking Therapy: Coexisting Immune-Related Gastritis and Cytomegaloviral Infection.	Gastroenterology research	2018	69.60382941488992	-15.253454691125851	15	0.6
30343514	Combination immunotherapy with interleukin-2 surface-modified tumor cell vaccine and programmed death receptor-1 blockade against renal cell carcinoma.	Cancer science	2019	-24.171775461995185	-10.46010940742622	12	0.65
30342909	Frequencies of PD-1- and PD-L1- positive T CD3+CD4+, T CD3+CD8+ and B CD19+ lymphocytes and its correlations with other immune cells in patients with recurrent furunculosis.	Microbial pathogenesis	2019	-49.93505914833147	11.833946511616436	2	0.13
30342749	Why is immunotherapy effective (or not) in patients with MSI/MMRD tumors?	Bulletin du cancer	2019	15.201712231093405	42.69840003091889	26	1.26
30341017	Immune Microenvironment Differences Between Squamous and Non-squamous Non-small-cell Lung Cancer and Their Influence on the Prognosis.	Clinical lung cancer	2019	11.051649471246048	-17.746777784343873	36	1.65
30339966	Analysis of PD-L1 expression in trophoblastic tissues and tumors.	Human pathology	2019	-37.46091517577642	-2.679631587619764	29	1.89
30338648	Influence of total glucosides of paeony on PD-1/PD-L1 expression in primary Sjögren's syndrome.	International journal of rheumatic diseases	2019	-50.90707380165607	10.004408960363612	14	0.81
30338457	Checkpoint Inhibitors Hodgkin Lymphoma and Non-Hodgkin Lymphoma.	Current hematologic malignancy reports	2018	-7.684859253657008	-26.659023156403297	28	1.25
30338242	Updates in the Clinical Development of Epacadostat and Other Indoleamine 2,3-Dioxygenase 1 Inhibitors (IDO1) for Human Cancers.	Frontiers in oncology	2018	31.025869744986764	19.05783719830201	111	4.73
30337201	[Biomarkers predictive of PD1/PD-L1 immunotherapy in non-small cell lung cancer].	Revue de pneumologie clinique	2018	23.544081573794173	-32.899811316667986	4	0.13
30334063	[Tumor assessment in immune checkpoint inhibitor therapy : Tumor response, progression and pseudoprogression].	Der Urologe. Ausg. A	2018	61.70926001663477	18.241458633482345	3	0.11
30334015	Toxicity of Checkpoint Inhibition in Advanced RCC: A Systematic Review.	Kidney cancer (Clifton, Va.)	2017	67.69256560361815	31.869594020112327	9	0.33
30333036	The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy.	Journal of neuroinflammation	2018	-25.0728417428285	52.43369535695336	144	6.38
30327605	Disruption of PD-1 Enhanced the Anti-tumor Activity of Chimeric Antigen Receptor T Cells Against Hepatocellular Carcinoma.	Frontiers in pharmacology	2018	-43.167566537949305	7.113063277574879	110	4.39
30327563	Combinations of BRAF inhibitor and anti-PD-1/PD-L1 antibody improve survival and tumour immunity in an immunocompetent model of orthotopic murine anaplastic thyroid cancer.	British journal of cancer	2018	27.31933297434516	33.56145446455898	62	2.84
30326856	Immune landscape and in vivo immunogenicity of NY-ESO-1 tumor antigen in advanced neuroblastoma patients.	BMC cancer	2018	-21.403326211966387	27.020116408081893	12	0.51
30325558	Functionally impaired follicular helper T cells induce regulatory B cells and CD14+ human leukocyte antigen-DR- cell differentiation in non-small cell lung cancer.	Cancer science	2018	-46.27999389583861	30.70968526217697	21	0.79
30325236	Expression of programmed death-1 (PD-1) and its ligand PD-L1 is upregulated in endometriosis and promoted by 17beta-estradiol.	Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology	2019	-70.39612268389702	-18.52555216647796	28	1.8
30323975	Deglycosylation of PD-L1 by 2-deoxyglucose reverses PARP inhibitor-induced immunosuppression in triple-negative breast cancer.	American journal of cancer research	2018	-33.5988707276596	-31.924412958195468	47	1.85
30323751	Nivolumab-Induced Impressive Response of Refractory Pulmonary Sarcomatoid Carcinoma with Brain Metastasis.	Case reports in oncology	2018	54.28923935421101	-31.85256529671611	24	1.14
30323626	Pembrolizumab for the treatment of patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction cancer: an evidence-based review of place in therapy.	OncoTargets and therapy	2018	45.67799955000339	14.97914001864591	9	0.38
30323352	Characterization of abscopal effects of intratumoral electroporation-mediated IL-12 gene therapy.	Gene therapy	2019	-31.85702680191703	45.25436783593985	36	2.02
30320114	Mucous Membrane Pemphigoid, Bullous Pemphigoid, and Anti-programmed Death-1/ Programmed Death-Ligand 1: A Case Report of an Elderly Woman With Mucous Membrane Pemphigoid Developing After Pembrolizumab Therapy for Metastatic Melanoma and Review of the Literature.	Frontiers in medicine	2018	70.75361767032119	-26.996953598170965	40	2.92
30319936	Pharmacometric Applications and Challenges in the Development of Therapeutic Antibodies in Immuno-Oncology.	Current pharmacology reports	2018	32.67850921319587	-10.408369847680346	5	0.32
30319648	Checkpoint Inhibition in Myeloma: Opportunities and Challenges.	Frontiers in immunology	2018	19.833132926234963	15.327385028452344	38	1.63
30319627	The Potential of CAR T Cell Therapy in Pancreatic Cancer.	Frontiers in immunology	2018	-40.49935587000883	5.725834706594389	75	3.19
30318432	[Drug-induced interstitial pneumonitis due to avelumab: A case report].	Revue des maladies respiratoires	2018	66.80673755708305	-11.244680902124804	3	0.14
30315712	The prognostic value of immune checkpoints in oral squamous cell carcinoma.	Oral diseases	2019	-6.006577874904739	-12.659465562445256	26	1.56
30315349	Histamine targets myeloid-derived suppressor cells and improves the anti-tumor efficacy of PD-1/PD-L1 checkpoint blockade.	Cancer immunology, immunotherapy : CII	2019	-11.072262457588288	-31.23685024973444	47	2.47
30315348	Association of IL-36γ with tertiary lymphoid structures and inflammatory immune infiltrates in human colorectal cancer.	Cancer immunology, immunotherapy : CII	2019	4.983714155220063	33.08472267355927	57	2.86
30314669	Expression of programmed cell death ligand 1 and immune checkpoint markers in residual tumors after neoadjuvant chemotherapy for advanced high-grade serous ovarian cancer.	Gynecologic oncology	2018	-17.9988631445582	14.686145913310348	29	1.18
30314524	Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8+ T cells in the tumor microenvironment.	Journal for immunotherapy of cancer	2018	0.0376592026742361	27.12731893446098	124	4.92
30309915	Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy.	Science (New York, N.Y.)	2018	21.87837092596452	-12.120591517394791	1271	52.56
30309710	Programmed cell death protein 1 activation preferentially inhibits CD28.CAR-T cells.	Cytotherapy	2018	-43.49561933203147	3.2657116750478243	53	2.06
30307035	Association between soluble immune mediators and tumor responses in patients with nonsmall cell lung cancer treated with anti-PD-1 inhibitor.	International journal of cancer	2019	22.49638333755689	-28.86508706706341	24	1.14
30306644	VISTA expression by microglia decreases during inflammation and is differentially regulated in CNS diseases.	Glia	2018	-39.96514091163736	38.32122254923589	45	1.81
30304963	Nivolumab for the treatment of hepatocellular carcinoma.	Expert review of anticancer therapy	2018	30.49047102299845	47.64171306526436	80	3.63
30301864	ODM-203, a Selective Inhibitor of FGFR and VEGFR, Shows Strong Antitumor Activity, and Induces Antitumor Immunity.	Molecular cancer therapeutics	2019	10.863858048821566	4.869669862961648	18	0.96
30297881	Increased CD3+ T cells with a low FOXP3+/CD8+ T cell ratio can predict anti-PD-1 therapeutic response in non-small cell lung cancer patients.	Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc	2019	10.186370060908356	-18.500275789754674	29	1.33
30295244	[Effect of PD-L1 Expression on Activity of NK Killing AML Cell Lines and Its Mechanisms].	Zhongguo shi yan xue ye xue za zhi	2018	-36.07961641370347	17.199084260387103	1	0.04
30290943	Single-Arm Trials Can Be Used for Meta-analysis to Compare PD-1 Inhibitor With PD-L1 Inhibitors on the Incidence of Pneumonitis?	Chest	2018	63.98504324964173	-12.13961560517889	0	0.0
30288357	The comprehensive molecular landscape of the immunologic co-stimulator B7 and TNFR ligand receptor families in colorectal cancer: immunotherapeutic implications with microsatellite instability.	Oncoimmunology	2018	8.610279996873832	42.55042320972338	12	0.46
30288346	Epigenetic treatment of multiple myeloma mediates tumor intrinsic and extrinsic immunomodulatory effects.	Oncoimmunology	2018	-11.779678991805133	-32.16823876106832	22	0.96
30288340	Long-term outcomes of a phase I study of agonist CD40 antibody and CTLA-4 blockade in patients with metastatic melanoma.	Oncoimmunology	2018	42.60537511278402	1.480544415329616	70	2.61
30288049	Distribution of CD4+ and CD8+ exhausted tumor-infiltrating lymphocytes in molecular subtypes of Chinese breast cancer patients.	OncoTargets and therapy	2018	-3.5802254950325687	19.9148978020167	5	0.17
30287140	Biochemical Aspects of PD-L1 Regulation in Cancer Immunotherapy.	Trends in biochemical sciences	2018	-39.931745021104064	-12.267734745045678	126	4.93
30285868	A nomogram-based immunoprofile predicts overall survival for previously untreated patients with esophageal squamous cell carcinoma after esophagectomy.	Journal for immunotherapy of cancer	2018	-5.328013416279251	25.898867148472085	43	1.75
30285856	Durable response to anti-PD-1 immunotherapy in epithelioid angiomyolipoma: a report on the successful treatment of a rare malignancy.	Journal for immunotherapy of cancer	2018	55.94206653433649	-29.40620122077112	19	1.25
30285852	Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumab.	Journal for immunotherapy of cancer	2018	-11.631458028417006	39.6274771672006	105	4.5
30285662	PD-L1/PD-1 crosstalk in colorectal cancer: are we targeting the right cells?	BMC cancer	2018	8.458415346089737	36.624582126553605	14	0.7
30284618	Diabetes mellitus induced by PD-1 and PD-L1 inhibitors: description of pancreatic endocrine and exocrine phenotype.	Acta diabetologica	2019	89.31885817332333	-16.382130298834376	52	3.07
30282672	PD-L1 Mediates Dysfunction in Activated PD-1+ NK Cells in Head and Neck Cancer Patients.	Cancer immunology research	2018	-33.25507568909997	1.973311610090789	102	4.26
30280641	First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer.	The New England journal of medicine	2018	49.94698771474831	-39.44800909911872	1721	81.58
30279188	Predictive Biomarkers for Checkpoint Immunotherapy: Current Status and Challenges for Clinical Application.	Cancer immunology research	2018	17.260417625798123	-2.076466212551812	69	2.62
30277784	Multiplex Immuno-Liquid Chromatography-Mass Spectrometry-Parallel Reaction Monitoring (LC-MS-PRM) Quantitation of CD8A, CD4, LAG3, PD1, PD-L1, and PD-L2 in Frozen Human Tissues.	Journal of proteome research	2018	12.676237315424212	-43.90547506232632	12	0.57
30277471	CD84 regulates PD-1/PD-L1 expression and function in chronic lymphocytic leukemia.	The Journal of clinical investigation	2018	-40.932573851569465	19.95954981374425	30	1.2
30275987	The intracellular signalosome of PD-L1 in cancer cells.	Signal transduction and targeted therapy	2018	-36.908097364688224	-9.473241255041568	147	6.2
30275216	PD-L2 Expression as a Potential Predictive Biomarker for the Response to Anti-PD-1 Drugs in Patients with Non-small Cell Lung Cancer.	Anticancer research	2018	14.977054742786024	-31.54362099288353	15	0.61
30275195	Increased Soluble PD-L1 Levels in the Plasma of Patients with Epithelial Ovarian Cancer Correlate with Plasma Levels of miR34a and miR200.	Anticancer research	2018	-20.849254236819498	13.843242313137528	13	0.61
30275109	Bifunctional PD-1 × αCD3 × αCD33 fusion protein reverses adaptive immune escape in acute myeloid leukemia.	Blood	2018	-40.81474646637064	10.456485209987306	67	2.72
30271205	Low tumor purity is associated with poor prognosis, heavy mutation burden, and intense immune phenotype in colon cancer.	Cancer management and research	2018	1.813706414537169	50.109299298372775	68	2.85
30270458	Macrophage polarity in cancer: A review.	Journal of cellular biochemistry	2019	-30.458391756945467	-3.685031339335974	273	15.63
30268773	Targeting Programmed Cell Death -1 (PD-1) and Ligand (PD-L1): A new era in cancer active immunotherapy.	Pharmacology & therapeutics	2019	30.680653473086625	-3.0493224177153238	206	10.78
30264678	Targeting PD-L1 Protein: Translation, Modification and Transport.	Current protein & peptide science	2019	-46.39842606713776	-15.917297709325013	18	0.88
30264329	EBV-associated gastric cancer evades T-cell immunity by PD-1/PD-L1 interactions.	Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association	2019	-10.304701121135375	9.206876356910875	59	3.24
30262187	Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study.	The Lancet. Oncology	2018	49.28338962251223	-21.86658858957986	301	12.8
30261066	Expression of PD-1 and PD-L1 increase in consecutive biopsies in patients with classical Hodgkin lymphoma.	PloS one	2018	-30.84716818332105	23.017467025101222	21	0.94
30259976	FcγR interaction is not required for effective anti-PD-L1 immunotherapy but can add additional benefit depending on the tumor model.	International journal of cancer	2019	-35.22857486776623	-27.21500268395681	11	0.58
30259750	Personalized Tumor RNA Loaded Lipid-Nanoparticles Prime the Systemic and Intratumoral Milieu for Response to Cancer Immunotherapy.	Nano letters	2018	-35.953919511376924	-50.7937962662626	37	1.69
30257954	PD-1 up-regulation on CD4+ T cells promotes pulmonary fibrosis through STAT3-mediated IL-17A and TGF-β1 production.	Science translational medicine	2018	-56.074997552132494	17.762021025068872	187	9.27
30257416	Optimized Expression and Characterization of a Novel Fully Human Bispecific Single-Chain Diabody Targeting Vascular Endothelial Growth Factor165 and Programmed Death-1 in Pichia pastoris and Evaluation of Antitumor Activity In Vivo.	International journal of molecular sciences	2018	-15.20696222165475	-48.77971872231337	9	0.39
30253080	Pleural or pericardial metastasis: A significant factor affecting efficacy and adverse events in lung cancer patients treated with PD-1/PD-L1 inhibitors.	Thoracic cancer	2018	45.16128388038828	-17.200268745625202	14	0.52
30250648	Immune-related adverse events and atypical radiological response with checkpoint inhibitor immunotherapy in an elderly patient with high PD-L1 expressing lung adenocarcinoma.	Oncotarget	2018	72.60966431908257	-10.038127105694686	9	0.36
30247204	Deep and Durable Response With Combination CTLA-4 and PD-1 Blockade in Mismatch Repair (MMR)-proficient Endometrial Cancer.	Journal of immunotherapy (Hagerstown, Md. : 1997)	2019	40.18740554896162	34.592884255408414	11	0.46
30243521	[IoNESCO trial: Immune neoajuvant therapy in early stage non-small cell lung cancer].	Revue des maladies respiratoires	2018	39.82067647258844	-26.3609214879921	10	0.33
30242022	Immunotherapy Targeting HPV16/18 Generates Potent Immune Responses in HPV-Associated Head and Neck Cancer.	Clinical cancer research : an official journal of the American Association for Cancer Research	2019	47.72578272973778	36.72854898677501	84	4.4
30241942	ERα is a negative regulator of PD-L1 gene transcription in breast cancer.	Biochemical and biophysical research communications	2018	-23.19098586363136	6.2537053369420965	29	1.11
30237743	Checkpoint molecule PD-1-assisted CD8+ T lymphocyte count in tumor microenvironment predicts overall survival of patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors.	Cancer management and research	2018	16.3926320452114	29.173902895487707	43	1.68
30236481	Increased levels of soluble co-stimulatory molecule PD-L1 (B7-H1) in the plasma of viraemic HIV-1+ individuals.	Immunology letters	2018	-82.83002541701259	11.402051340122927	11	0.57
30236470	Immune Checkpoint Molecules, Personalized Immunotherapy, and Autoimmune Diabetes.	Trends in molecular medicine	2018	90.5817700465248	-14.339067354123864	27	1.18
30232519	TIGIT: a novel immunotherapy target moving from bench to bedside.	Cancer immunology, immunotherapy : CII	2018	-12.41166733198406	-57.51933428310746	134	5.71
30230534	Comprehensive transcriptome profiling in elderly cancer patients reveals aging-altered immune cells and immune checkpoints.	International journal of cancer	2019	-5.627442065858896	32.38598634452093	16	0.76
30230418	Brain-Resident T Cells Following Viral Infection.	Viral immunology	2019	-75.51874367863725	-1.9872171337149884	17	0.76
30230111	PD-L1 expression and CD8-positive T cells are associated with favorable survival in HER2-positive invasive breast cancer.	The breast journal	2018	-7.674554249244254	15.81144883790335	43	1.88
30228953	H3K4me3 mediates the NF-κB p50 homodimer binding to the pdcd1 promoter to activate PD-1 transcription in T cells.	Oncoimmunology	2018	-42.19188417865969	-7.167360341089128	13	0.47
30228950	Inhibition of RON kinase potentiates anti-CTLA-4 immunotherapy to shrink breast tumors and prevent metastatic outgrowth.	Oncoimmunology	2018	-11.200544655163489	-18.17144635517575	20	0.79
30228943	High expression of PD-1 and PD-L1 in ocular adnexal sebaceous carcinoma.	Oncoimmunology	2018	0.1314739694772054	-0.7587417463323998	19	1.01
30221062	Expression of programmed cell death protein 1 (PD-1) and its ligand PD-L1 in colorectal cancer: Relationship with sidedness and prognosis.	Oncoimmunology	2018	-4.856692728780332	11.188598431788591	57	2.37
30221041	Intratumoral injection of activated B lymphoblast in combination with PD-1 blockade induces systemic antitumor immunity with reduction of local and distal tumors.	Oncoimmunology	2018	-28.44202350754976	-16.16081436973503	5	0.24
30219896	Advanced basal cell cancer: concise review of molecular characteristics and novel targeted and immune therapeutics.	Annals of oncology : official journal of the European Society for Medical Oncology	2018	48.13249534323153	-51.15333301507952	28	1.21
30219646	[Prognostic value of PD-1/PD-L1 expression in upper tract urothelial carcinoma].	Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie	2018	14.289014518859975	56.53894509785538	1	0.04
30217730	Molecular Recalibration of PD-1+ Antigen-Specific T Cells from Blood and Liver.	Molecular therapy : the journal of the American Society of Gene Therapy	2018	-46.15124613044808	1.316536389398825	17	0.64
30215856	Immunomodulators targeting the PD-1/PD-L1 protein-protein interaction: From antibodies to small molecules.	Medicinal research reviews	2019	-41.56125327093692	-37.11462906978847	102	5.36
30215300	New strategies in immunotherapy for lung cancer: beyond PD-1/PD-L1.	Therapeutic advances in respiratory disease	2018	34.18984120993446	-33.20504338157196	30	1.32
30214730	Efficacy and safety of Nivolumab in non-small cell lung cancer patients in Tel-Aviv tertiary medical center: Facing the reality.	Molecular and clinical oncology	2018	46.88219315990282	-24.797426872499106	5	0.2
30214445	PD1-CD28 Fusion Protein Enables CD4+ T Cell Help for Adoptive T Cell Therapy in Models of Pancreatic Cancer and Non-hodgkin Lymphoma.	Frontiers in immunology	2018	-22.12708873438655	-11.911071368780757	24	0.94
30213624	[Toxicity of immune checkpoints inhibitors].	Revue des maladies respiratoires	2018	79.64997098565095	-8.796054822581402	12	0.47
30211111	Immune Checkpoint Inhibition in Head and Neck Cancer.	Frontiers in oncology	2018	52.000841674037815	32.150303378911104	74	3.36
30209885	Comparable immunoreactivity rates of PD-L1 in archival and recent specimens from non-small cell lung cancer.	Thoracic cancer	2018	13.686678810412095	-39.764861255779486	6	0.25
30208866	'DURVIT': a phase-I trial of single low-dose durvalumab (Medi4736) IntraTumourally injected in cervical cancer: safety, toxicity and effect on the primary tumour- and lymph node microenvironment.	BMC cancer	2018	60.74564552227064	3.695963530545472	21	0.78
30207786	Pembrolizumab for the first-line treatment of non-small cell lung cancer.	Expert opinion on biological therapy	2018	46.59218394571356	-31.63063789973952	19	0.76
30207101	Checkpoint-inhibition in ovarian cancer: rising star or just a dream?	Journal of gynecologic oncology	2018	37.89730292963383	38.74487983554915	26	1.02
30206757	Activation of PD-1 Protects Intestinal Immune Defense Through IL-10/miR-155 Pathway After Intestinal Ischemia Reperfusion.	Digestive diseases and sciences	2018	-62.33711095846949	19.31221068253176	9	0.44
30206165	Antibody-Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non-small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade.	Clinical cancer research : an official journal of the American Association for Cancer Research	2019	28.861209320641542	-17.299216463022184	268	12.63
30205088	Follicular helper T cells promote the effector functions of CD8+ T cells via the provision of IL-21, which is downregulated due to PD-1/PD-L1-mediated suppression in colorectal cancer.	Experimental cell research	2018	-46.486772777964205	30.884751366805244	35	1.38
30203407	Prognostic Impact of Immune-Related Gene Expression in Preoperative Peripheral Blood from Gastric Cancer Patients.	Annals of surgical oncology	2018	-9.155131783381156	5.87613387156726	8	0.32
30203045	Immunological differences between primary and metastatic breast cancer.	Annals of oncology : official journal of the European Society for Medical Oncology	2018	-3.379846142193671	16.169763787707343	199	8.03
30202807	Safety of combining thoracic radiation therapy with concurrent versus sequential immune checkpoint inhibition.	Advances in radiation oncology	2018	70.91720730303646	-6.434009111490212	28	1.18
30201790	Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis.	BMJ (Clinical research ed.)	2018	52.75915758949584	-13.47756996944768	291	12.24
30201070	[Predictive Markers for Treating Efficacy of PD-1/PD-L1 Inhibitors in Patients with Lung Cancer: A Review of the 18th World Conference on Lung Cancer].	Zhongguo fei ai za zhi = Chinese journal of lung cancer	2018	21.37018222923712	-34.53311729279005	0	0.0
30198909	NK cells for PD-1/PD-L1 blockade immunotherapy: pinning down the NK cell.	The Journal of clinical investigation	2018	-34.749051437034126	-0.3245067637472342	14	0.53
30198904	Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade.	The Journal of clinical investigation	2018	-34.365263692571844	-0.086009521350924	467	19.52
30197907	Artificial T Cell Mimetics to Combat Melanoma Tumor Growth.	American journal of advanced drug delivery	2018	-30.381521440002576	-48.56936574937156	2	0.1
30197906	Acute Kidney Injury after Pembrolizumab-Induced Adrenalitis and Adrenal Insufficiency.	Case reports in nephrology and dialysis	2018	71.9922272033108	2.41754196428277	17	0.73
30197262	PD-1 and PD-L1 Protein Expression Predict Survival in Completely Resected Lung Adenocarcinoma.	Clinical lung cancer	2018	9.129212094573855	-27.896691602493885	19	0.75
30196908	Immuno-oncology in GI tumours: Clinical evidence and emerging trials of PD-1/PD-L1 antagonists.	Critical reviews in oncology/hematology	2018	44.29969265598246	16.795023507673164	28	1.12
30193240	Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy.	JAMA oncology	2018	37.31432552312271	-50.79543906209273	474	19.86
30193111	A Structured Tumor-Immune Microenvironment in Triple Negative Breast Cancer Revealed by Multiplexed Ion Beam Imaging.	Cell	2018	2.134268062216082	-47.82470028916257	489	18.31
30191996	PD-1/PD-L1 immune checkpoint: Potential target for cancer therapy.	Journal of cellular physiology	2019	-41.90008719856621	-14.467573282254971	225	12.58
30191140	Immuno-Oncology: Emerging Targets and Combination Therapies.	Frontiers in oncology	2018	19.62492033304376	6.513870364763817	196	9.1
30187723	Immunotherapy a New Hope for Cancer Treatment: A Review.	Pakistan journal of biological sciences : PJBS	2018	21.189089550188783	2.713295393582321	18	0.78
30187355	Immune Checkpoint Inhibitors: Toward New Paradigms in Renal Cell Carcinoma.	Drugs	2018	64.50037227752445	30.12129840261889	56	2.46
30183502	Bugs in the system: bringing the human microbiome to bear in cancer immunotherapy.	Gut microbes	2019	-23.323143763114	1.2058536688606192	14	0.68
30182073	Immune checkpoint inhibitors for urothelial carcinoma.	Investigative and clinical urology	2018	71.4111122916878	20.77658974933413	73	3.22
30178256	Epigenetic and Genetic Regulation of PDCD1 Gene in Cancer Immunology.	Methods in molecular biology (Clifton, N.J.)	2018	-7.447991767467885	-31.18548845799809	11	0.46
30177687	Profiling the Tumour Immune Microenvironment in Pancreatic Neuroendocrine Neoplasms with Multispectral Imaging Indicates Distinct Subpopulation Characteristics Concordant with WHO 2017 Classification.	Scientific reports	2018	0.0894365308480114	15.137675140506976	41	1.98
30176876	Histone deacetylase 6 in cancer.	Journal of hematology & oncology	2018	-9.995321247324783	-33.04841754104915	170	8.0
30176647	[The meaning of PD-1/PD-L1 pathway in ovarian cancer pathogenesis].	Wiadomosci lekarskie (Warsaw, Poland : 1960)	2018	-21.53898130074084	10.112708542223931	3	0.11
30174235	[Small cell lung cancer and immuno-oncologic agents: End of the cisplatin - etoposide era?].	Revue des maladies respiratoires	2018	43.94623118775738	-41.34458603847741	1	0.04
30173944	A novel case of endometrial dedifferentiated adenocarcinoma associated with MLH1 promotor hypermethylation and microsatellite instability.	Pathology, research and practice	2018	13.106681114487987	46.440158338464045	2	0.1
30173085	Current and emerging therapies for first-line treatment of metastatic clear cell renal cell carcinoma.	Cancer treatment reviews	2018	64.53123664067665	32.84727384829176	208	9.73
30172913	Immune environment in serrated lesions of the colon: intraepithelial lymphocyte density, PD-1, and PD-L1 expression correlate with serrated neoplasia pathway progression.	Human pathology	2019	7.704469451242345	34.90180305055312	16	0.82
30172273	[Study Progression on Non-small Cell Lung Cancer with EGFR Mutation  Treated by Immune Checkpoint Inhibitors].	Zhongguo fei ai za zhi = Chinese journal of lung cancer	2018	38.52058643459817	-37.56836702173547	1	0.03
30170560	The characteristics of nivolumab-induced colitis: an evaluation of three cases and a literature review.	BMC gastroenterology	2018	68.34905049257382	-14.558392488541765	32	1.65
30167862	Chemotherapy-induced apoptosis, autophagy and cell cycle arrest are key drivers of synergy in chemo-immunotherapy of epithelial ovarian cancer.	Cancer immunology, immunotherapy : CII	2018	-17.066338041474044	-28.330698341187	23	1.01
30166615	Cellular localization of PD-L1 expression in mismatch-repair-deficient and proficient colorectal carcinomas.	Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc	2019	9.872107297188215	37.88151848334203	22	1.09
30165371	PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers.	Annals of oncology : official journal of the European Society for Medical Oncology	2018	22.252630375854324	-17.1756250290611	188	7.58
30161295	The roles of PD-1/PD-L1 and its signalling pathway in gastrointestinal tract cancers.	Clinical and experimental pharmacology & physiology	2019	-24.315469048345605	-1.3256603507724816	10	0.46
30161254	CD72/CD100 and PD-1/PD-L1 markers are increased on T and B cells in HIV-1+ viremic individuals, and CD72/CD100 axis is correlated with T-cell exhaustion.	PloS one	2018	-81.22866717590071	12.702437124255882	17	0.72
30160018	CD8+ and CD163+ infiltrating cells and PD-L1 immunoexpression in oral leukoplakia and oral carcinoma.	APMIS : acta pathologica, microbiologica, et immunologica Scandinavica	2018	-9.212590375300412	-13.393392624769543	30	1.65
30159341	Anti-PD-1/PD-L1 Therapy for Non-Small-Cell Lung Cancer: Toward Personalized Medicine and Combination Strategies.	Journal of immunology research	2018	31.744985343258985	-30.983156275090213	130	5.97
30158554	EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer.	Nature communications	2018	6.248786562817653	55.826431271025896	174	6.76
30153220	Characterization of the Neuroendocrine Tumor Immune Microenvironment.	Pancreas	2018	0.5696354069044943	14.242146957099726	58	2.74
30151257	Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition.	Journal of gastrointestinal oncology	2018	9.46721884632808	43.28946963328527	160	6.32
30146693	Soluble PD-1 and PD-L1 as potential biomarkers for classical Hodgkin lymphoma.	Hematological oncology	2018	-31.368621569941244	23.08350139061067	10	0.4
30145830	LPS promotes the expression of PD-L1 in gastric cancer cells through NF-κB activation.	Journal of cellular biochemistry	2018	-11.88440957157579	3.469862843567441	38	1.78
30144808	Prognostic significance of the programmed death ligand 1 expression in clear cell renal cell carcinoma and correlation with the tumor microenvironment and hypoxia-inducible factor expression.	Diagnostic pathology	2018	16.097705749137102	27.346845601067734	20	0.89
30141009	Multiplex Immunohistochemistry for Image Analysis of Tertiary Lymphoid Structures in Cancer.	Methods in molecular biology (Clifton, N.J.)	2018	5.109174848226886	-46.935400099508925	7	0.28
30140379	Topoisomerase I inhibitor, irinotecan, depletes regulatory T cells and up-regulates MHC class I and PD-L1 expression, resulting in a supra-additive antitumor effect when combined with anti-PD-L1 antibodies.	Oncotarget	2018	-22.509071068023868	-27.693074473848064	37	1.58
30140263	Smoking Is Associated With Low Levels of Soluble PD-L1 in Rheumatoid Arthritis.	Frontiers in immunology	2018	-50.78768872309462	15.235837594834369	14	0.72
30135465	APRIL signaling via TACI mediates immunosuppression by T regulatory cells in multiple myeloma: therapeutic implications.	Leukemia	2019	-67.31682126726692	3.5002519278314264	50	2.46
30134578	DNA Mismatch Repair Protein Immunohistochemistry and MLH1 Promotor Methylation Testing for Practical Molecular Classification and the Prediction of Prognosis in Endometrial Cancer.	Cancers	2018	12.187703428796892	46.46792359120461	11	0.48
30134343	Expression of Immunomodulatory Molecules PD-1, PD-L1, and PD-L2, and their Relationship With Clinicopathologic Characteristics in Endometrial Cancer.	International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists	2019	-18.266904687478306	8.922172444481639	29	1.53
30132082	PD-1/PD-L1 co-inhibition shapes anticancer T cell immunodominance: facing the consequences of an immunological ménage à trois.	Cancer immunology, immunotherapy : CII	2018	-28.778064574833515	-17.94754732918462	1	0.05
30131600	Pembrolizumab: patient selection or immune intensification?	Nature reviews. Urology	2018	35.29873240660716	-4.3346397328435184	0	0.0
30131293	Prognostic value of PD-1 and PD-L1 expression in patients with metastatic clear cell renal cell carcinoma.	Urologic oncology	2018	16.90160136508649	26.91085739993452	36	1.4
30129176	PD-1 Blockade for Improving the Antitumor Efficiency of Polymer-Doxorubicin Nanoprodrug.	Small (Weinheim an der Bergstrasse, Germany)	2018	-30.06107067242672	-51.505547946884	40	1.75
30127393	Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response.	Nature medicine	2018	12.576971998283137	15.333442589901717	2045	89.55
30126069	Presence of few PD-1-expressing tumor-infiltrating immune cells is a potential predictor of improved response to salvage chemotherapy following nivolumab for non-small cell lung cancer: An exploratory case series.	Thoracic cancer	2018	29.127354992229616	-21.62408895259482	4	0.15
30125720	Recent advances in small molecule based cancer immunotherapy.	European journal of medicinal chemistry	2018	-24.113657067579737	-48.6384775262524	56	2.55
30123362	PD-L1 Expression Correlates With Tumor Infiltrating Lymphocytes And Response To Neoadjuvant Chemotherapy In Cervical Cancer.	Journal of Cancer	2018	0.8152976189583447	-11.49914096361007	92	4.36
30123257	CTLA-4 and PD-1 Ligand Gene Expression in Epithelial Thyroid Cancers.	International journal of endocrinology	2018	-7.990862274533689	-21.39596556448596	20	0.88
30120503	Regulatory mechanisms of PD-L1 expression in cancer cells.	Cancer immunology, immunotherapy : CII	2018	-39.54067715675832	-12.041849669899662	53	2.06
30120041	A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.	The Lancet. Oncology	2018	11.03095110218461	-11.07145781112357	615	29.42
30113497	Comparative analysis of immune checkpoint inhibitors and chemotherapy in the treatment of advanced non-small cell lung cancer: A meta-analysis of randomized controlled trials.	Medicine	2018	45.065270316985774	-19.641180529881574	73	3.26
30112112	Intratumoral immune-biomarkers and mismatch repair status in leiyomyosarcoma -potential predictive markers for adjuvant treatment: a pilot study.	Oncotarget	2018	12.13450586019946	40.21449408939049	10	0.44
30111819	Inhibition of histone lysine-specific demethylase 1 elicits breast tumor immunity and enhances antitumor efficacy of immune checkpoint blockade.	Oncogene	2019	-10.447123484431351	-29.243888424590452	114	5.14
30108590	Squamous Cell Carcinomas of the Head and Neck Cancer Response to Programmed Cell Death Protein-1 Targeting and Differential Expression of Immunological Markers: A Case Report.	Frontiers in immunology	2018	-6.961033797021498	-5.197868599763529	15	0.62
30107136	A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).	Expert opinion on therapeutic patents	2018	-41.72576645397616	-37.88801990552747	85	3.87
30105218	Review of checkpoint immunotherapy for the management of non-small cell lung cancer.	ImmunoTargets and therapy	2018	38.93693976753067	-32.83796382232094	42	1.8
30105035	Cancer Cell-Intrinsic PD-1 and Implications in Combinatorial Immunotherapy.	Frontiers in immunology	2018	-36.789301150806494	-12.42608943182403	98	4.12
30104397	Soluble PD-1 ligands regulate T-cell function in Waldenstrom macroglobulinemia.	Blood advances	2018	-47.85047455950644	17.893924209899303	33	1.37
30102929	MicroRNA in lung cancer: role, mechanisms, pathways and therapeutic relevance.	Molecular aspects of medicine	2019	3.501313078828339	-37.10740329437489	252	16.89
30102295	Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo.	Nature biotechnology	2018	-43.00866068544686	5.222207515924204	455	19.16
30100403	Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis.	The Lancet. Respiratory medicine	2018	-0.4919065430099055	-32.27028247591235	126	4.65
30099497	Heterogeneity of EGFR-mutant clones and PD-L1 highly expressing clones affects treatment efficacy of EGFR-TKI and PD-1 inhibitor.	Annals of oncology : official journal of the European Society for Medical Oncology	2018	8.448451836419347	-33.633543425707266	9	0.28
30096401	Nanotechnology-mediated immunochemotherapy combined with docetaxel and PD-L1 antibody increase therapeutic effects and decrease systemic toxicity.	Journal of controlled release : official journal of the Controlled Release Society	2018	-31.73746351098629	-51.02150344028906	56	2.78
30095976	Immune Checkpoint Ligand PD-L1 Is Upregulated in Pulmonary Lymphangioleiomyomatosis.	American journal of respiratory cell and molecular biology	2018	1.492618296435153	-27.12783201694327	28	1.36
30095468	Small Biopsies Misclassify up to 35% of PD-L1 Assessments in Advanced Lung Non-Small Cell Lung Carcinomas.	Applied immunohistochemistry & molecular morphology : AIMM	2018	14.266148303184194	-36.72351391909523	22	1.01
30092832	High mammographic density in women is associated with protumor inflammation.	Breast cancer research : BCR	2018	-3.1782969092354008	18.8986499180892	24	1.13
30090763	Rationale for Combining Bispecific T Cell Activating Antibodies With Checkpoint Blockade for Cancer Therapy.	Frontiers in oncology	2018	-13.32379620267589	-45.012429537534246	68	2.93
30089911	Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response.	Nature	2018	-43.51967186361161	-58.62481788075592	1451	68.25
30089619	Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer.	Neurology	2018	85.31893383579572	-0.8837573263527697	196	10.25
30089601	Case-control study of PD-1, PD-L1 and B7-H3 expression in lung cancer patients with and without human immunodeficiency virus (HIV) infection.	Lung cancer (Amsterdam, Netherlands)	2018	1.032041419295899	-19.17831595940582	9	0.42
30089500	The Cancer Omics Atlas: an integrative resource for cancer omics annotations.	BMC medical genomics	2018	-1.2978222891155105	45.22435885117852	16	0.66
30085937	Expression of programmed death ligand-1 and programmed death-1 in samples of invasive ductal carcinoma of the breast and its correlation with prognosis.	Anti-cancer drugs	2018	-10.838603720507525	15.857212168648823	25	1.19
30081950	DNA methylation and repressive histones in the promoters of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, PD-L1, and galectin-9 genes in human colorectal cancer.	Clinical epigenetics	2018	-6.874291064561217	41.73488652948625	60	2.36
30078052	Increased antitumor activities of glypican-3-specific chimeric antigen receptor-modified T cells by coexpression of a soluble PD1-CH3 fusion protein.	Cancer immunology, immunotherapy : CII	2018	-43.15743023150328	7.704263209937338	38	1.59
30077125	Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I study.	European journal of cancer (Oxford, England : 1990)	2018	52.0628078718306	-38.10460017429285	37	1.46
30076099	PD-1 Controls Follicular T Helper Cell Positioning and Function.	Immunity	2018	-57.45147455623501	-4.657235133488169	268	10.29
30075155	Concordance levels of PD-L1 expression by immunohistochemistry, mRNA in situ hybridization, and outcome in lung carcinomas.	Human pathology	2018	13.41745865157162	-32.91684611063456	3	0.12
30074503	Improved outcomes with pembrolizumab treatment in two cases of double cancer including non-small-cell lung cancer.	Anti-cancer drugs	2019	48.23297946662903	-32.795622869096555	4	0.21
30069193	Current views on molecularly targeted therapy for lung cancer - a review of literature from the last five years.	Kardiochirurgia i torakochirurgia polska = Polish journal of cardio-thoracic surgery	2018	38.85555736392564	-38.3194265970762	6	0.21
30066852	Upregulation of PD‑L1 expression by resveratrol and piceatannol in breast and colorectal cancer cells occurs via HDAC3/p300‑mediated NF‑κB signaling.	International journal of oncology	2018	-30.073865193272837	-36.78339961813106	63	3.59
30062756	The prognostic value of PD-L1 expression in upper tract urothelial carcinoma varies according to platelet count.	Cancer medicine	2018	13.418556001895665	57.44751509980515	18	0.8
30062658	(-)-4-O-(4-O-β-D-glucopyranosylcaffeoyl) Quinic Acid Inhibits the Function of Myeloid-Derived Suppressor Cells to Enhance the Efficacy of Anti-PD1 against Colon Cancer.	Pharmaceutical research	2018	-22.477367469369224	-32.57615745611289	11	0.43
30062558	Activation of phagocytosis by immune checkpoint blockade.	Frontiers of medicine	2018	-32.598658440435266	-5.375592951288619	13	0.52
30061887	Glyco-Engineered Anti-Human Programmed Death-Ligand 1 Antibody Mediates Stronger CD8 T Cell Activation Than Its Normal Glycosylated and Non-Glycosylated Counterparts.	Frontiers in immunology	2018	-36.32270161138822	-31.664116235639483	20	0.84
30058498	Cutaneous Adverse Events of Immune Checkpoint Inhibitors: A Summarized Overview.	Current drug safety	2019	73.90020332200643	-24.465654060941432	28	1.82
30057891	Monitoring Immune Checkpoint Regulators as Predictive Biomarkers in Hepatocellular Carcinoma.	Frontiers in oncology	2018	-13.350336225762655	46.32014371067835	90	3.88
30055582	Classification of gallbladder cancer by assessment of CD8+ TIL and PD-L1 expression.	BMC cancer	2018	-1.522640347993608	7.569085164001957	34	1.54
30042266	[Endocrine Organ Dysfunction with Immune-Checkpoint Inhibitors].	Gan to kagaku ryoho. Cancer & chemotherapy	2018	82.59567320422535	-15.54069105903806	1	0.08
30041679	Consistency of tumor and immune cell programmed cell death ligand-1 expression within and between tumor blocks using the VENTANA SP263 assay.	Diagnostic pathology	2018	15.07693762104912	-39.8519434056136	27	1.09
30040869	Evaluation of costimulatory molecules in dogs with B cell high grade lymphoma.	PloS one	2018	-16.253417589103748	-12.465155557840848	12	0.63
30036453	Pembrolizumab monotherapy versus chemotherapy for treatment of advanced urothelial carcinoma with disease progression during or following platinum-containing chemotherapy. A Cochrane Rapid Review.	The Cochrane database of systematic reviews	2018	67.30499667731753	15.62902030066294	11	0.45
30036273	Integrin and PD-1 Ligand Expression on Circulating Extracellular Vesicles in Systemic Inflammatory Response Syndrome and Sepsis.	Shock (Augusta, Ga.)	2019	-58.13808076682964	33.13346386308253	25	1.6
30034316	Avelumab inducing hypothyroidism and hypoadrenalism: A case report and review of literature.	EXCLI journal	2018	61.7665851622279	-4.596636287800031	5	0.32
30033844	Expression of PD-1, PD-L1, and PD-L2 in posttransplant lymphoproliferative disorder after solid organ transplantation.	Leukemia & lymphoma	2019	-32.35089652699389	20.406784693162624	25	1.65
30032257	Clinical Impact of the Immune Microenvironment in Spinal Chordoma: Immunoscore as an Independent Favorable Prognostic Factor.	Neurosurgery	2019	-16.31787768374804	27.56258271782333	28	1.51
30032144	MiR-195/-16 Family Enhances Radiotherapy via T Cell Activation in the Tumor Microenvironment by Blocking the PD-L1 Immune Checkpoint.	Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology	2018	23.926390506493814	23.93732078601368	64	3.16
30031096	PD-1, PD-L1, and CD163 in pancreatic undifferentiated carcinoma with osteoclast-like giant cells: expression patterns and clinical implications.	Human pathology	2018	-2.6012839533364875	2.490382459984973	37	1.99
30028010	PD-1 is highly expressed by neoplastic B-cells in Richter transformation.	British journal of haematology	2019	-34.27863894438716	28.58939306337947	26	1.17
30026866	Noninvasive imaging of the PD-1:PD-L1 immune checkpoint: Embracing nuclear medicine for the benefit of personalized immunotherapy.	Theranostics	2018	6.437012149554585	-53.41561377459072	71	3.32
30026851	Prognostic Value of Programmed Cell Death 1 Ligand-1 (PD-L1) or PD-1 Expression in Patients with Osteosarcoma: A Meta-Analysis.	Journal of Cancer	2018	-17.42360699376425	18.353030532791035	40	1.87
30026742	Combination of Cytokine-Induced Killer Cells and Programmed Cell Death-1 Blockade Works Synergistically to Enhance Therapeutic Efficacy in Metastatic Renal Cell Carcinoma and Non-Small Cell Lung Cancer.	Frontiers in immunology	2018	25.87781425888755	-9.091298023355838	11	0.48
30026337	PD-L1+ tumor-associated macrophages and PD-1+ tumor-infiltrating lymphocytes predict survival in primary testicular lymphoma.	Haematologica	2018	-26.354214295973428	32.98915522112817	57	2.3
30021908	Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of Anti-PD-1 Therapies in Metastatic Melanoma.	Clinical cancer research : an official journal of the American Association for Cancer Research	2018	8.765843136347865	-2.9931152854100667	93	3.3
30021673	An engineered PD-1-based and MMP-2/9-oriented fusion protein exerts potent antitumor effects against melanoma.	BMB reports	2018	-41.88450643282845	-26.177201228416315	2	0.07
30021426	Immune check point inhibitors for metastatic urothelial carcinoma: current evidence-based approach for urology daily practice.	Minerva urologica e nefrologica = The Italian journal of urology and nephrology	2019	67.66740448310652	18.24956759279343	1	0.12
30020768	Laser Immunotherapy in Combination with Perdurable PD-1 Blocking for the Treatment of Metastatic Tumors.	ACS nano	2018	-30.59253917149937	-54.58858009614364	108	4.81
30018250	The Transcriptomic Landscape of Gastric Cancer: Insights into Epstein-Barr Virus Infected and Microsatellite Unstable Tumors.	International journal of molecular sciences	2018	-12.891455493526196	21.338381598687725	22	0.98
30018132	A Case of Nivolumab-Induced Bullous Pemphigoid: Review of Dermatologic Toxicity Associated with Programmed Cell Death Protein-1/Programmed Death Ligand-1 Inhibitors and Recommendations for Diagnosis and Management.	The oncologist	2018	71.44126646886343	-26.520507071694997	56	2.8
30016784	Pembrolizumab in Recurrent Squamous Cell Carcinoma of the Vulva: Case Report and Review of the Literature.	Gynecologic and obstetric investigation	2019	52.36828902261794	5.2450057838398045	27	1.7
30013197	Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer.	Nature medicine	2018	24.097749014331328	-11.918533314993008	842	37.39
30012633	Programmed Cell Death Ligand 1 (PD-L1) Signaling Regulates Macrophage Proliferation and Activation.	Cancer immunology research	2018	-32.40507916783737	-5.905024994819501	187	7.92
30009488	Dendritic cells cross-talk with tumour antigen-specific CD8+ T cells, Vγ9γδT cells and Vα24NKT cells in patients with glioblastoma multiforme and in healthy donors.	Clinical and experimental immunology	2018	-29.613581507005392	56.035080263344334	6	0.26
30008262	Immunotherapy in non-small-cell lung cancer: potential predictors of response and new strategies to assess activity.	Immunotherapy	2018	27.50660692649111	-34.036786739230884	18	0.8
30007816	Evolution of PD-1 and PD-L1 Gene and Protein Expression in Primary Tumors and Corresponding Liver Metastases of Metastatic Bladder Cancer.	European urology	2018	11.864138896320718	60.55032588319112	15	0.54
30006825	Coronary Toxicities of Anti-PD-1 and Anti-PD-L1 Immunotherapies: a Case Report and Review of the Literature and International Registries.	Targeted oncology	2018	67.83502491281371	-17.763355343539114	21	0.9
30005434	[Immuno-Oncology: A Brief Overview].	Deutsche medizinische Wochenschrift (1946)	2018	19.871966563842417	4.226311924506897	4	0.14
30003113	PD-L1 Expression and CD8+ T Cell Infiltration Predict a Favorable Prognosis in Advanced Gastric Cancer.	Journal of immunology research	2018	-9.778307974431256	6.22366766013046	44	1.69
30002656	Biomarkers for Clinical Benefit of Immune Checkpoint Inhibitor Treatment-A Review From the Melanoma Perspective and Beyond.	Frontiers in immunology	2018	15.29716133232617	-1.504773235073122	147	6.3
30001476	Nivolumab for adults with Hodgkin's lymphoma (a rapid review using the software RobotReviewer).	The Cochrane database of systematic reviews	2018	41.07941688547349	-7.390944575598197	10	0.44
29998979	The expression of PD-1 ligands and IDO1 by macrophage/microglia in primary central nervous system lymphoma.	Journal of clinical and experimental hematopathology : JCEH	2018	-35.877130132402385	32.51770465582751	37	1.61
29998217	Bispecific antibodies in cancer immunotherapy.	Therapeutic advances in vaccines and immunotherapy	2018	-12.996271911184408	-45.06276571615327	120	4.95
29998005	Immune profiling of microsatellite instability-high and polymerase ε (POLE)-mutated metastatic colorectal tumors identifies predictors of response to anti-PD-1 therapy.	Journal of gastrointestinal oncology	2018	10.064395397094303	42.99408617238311	41	1.44
29997286	Immune reprogramming via PD-1 inhibition enhances early-stage lung cancer survival.	JCI insight	2018	17.185572089296663	-24.454868548239144	40	1.34
29996921	Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma.	Journal for immunotherapy of cancer	2018	50.151793246552245	2.2871999484376606	113	5.32
29996881	The association of genomic lesions and PD-1/PD-L1 expression in resected triple-negative breast cancers.	Breast cancer research : BCR	2018	9.276205538712205	30.49563948281218	46	1.87
29996099	Antigen-Presenting Cell-Intrinsic PD-1 Neutralizes PD-L1 in cis to Attenuate PD-1 Signaling in T Cells.	Cell reports	2018	-46.10385586596606	-7.942938181350933	109	4.02
29995563	Massive parallel screening of phage libraries for the generation of repertoires of human immunomodulatory monoclonal antibodies.	mAbs	2018	-46.934972779139	-31.75753714239668	32	1.37
29995439	Recent developments with immunotherapy for hepatocellular carcinoma.	Expert opinion on biological therapy	2018	30.030712127074416	49.88519326806486	69	3.15
29995236	Fulminant onset of insulin-dependent diabetes with positive anti-GAD antibody titers during treatment with nivolumab in a patient with NSCLC.	Cancer immunology, immunotherapy : CII	2018	89.06973961556113	-16.291061360360658	13	0.63
29992764	Deubiquitination and stabilization of programmed cell death ligand 1 by ubiquitin-specific peptidase 9, X-linked in oral squamous cell carcinoma.	Cancer medicine	2018	-18.25037729650468	-6.684646463707759	41	1.64
29992241	Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study.	Annals of oncology : official journal of the European Society for Medical Oncology	2018	50.9986181076992	2.5254381807073445	224	9.44
29991874	Advances in immuno-oncology biomarkers for gastroesophageal cancer: Programmed death ligand 1, microsatellite instability, and beyond.	World journal of gastroenterology	2018	45.54022476043989	19.92460269106866	18	0.69
29991744	CCL5-deficiency enhances intratumoral infiltration of CD8+ T cells in colorectal cancer.	Cell death & disease	2018	4.02200137139848	38.31852948909545	46	1.88
29991709	Cancer immune checkpoint blockade therapy and its associated autoimmune cardiotoxicity.	Acta pharmacologica Sinica	2018	24.41467825311073	7.379290278822511	30	1.24
29990692	Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors.	International immunopharmacology	2018	24.351736992315573	7.125932469985703	677	30.7
29987244	Immune Checkpoints as the Immune System Regulators and Potential Biomarkers in HIV-1 Infection.	International journal of molecular sciences	2018	23.78719684769828	10.869874208962942	25	1.18
29986511	PD-L1 Nanobody Competitively Inhibits the Formation of the PD-1/PD-L1 Complex: Comparative Molecular Dynamics Simulations.	International journal of molecular sciences	2018	-47.61133817028058	-40.49246814030411	25	1.32
29983890	Lysis-independent potentiation of immune checkpoint blockade by oncolytic virus.	Oncotarget	2018	25.563465879069263	25.18682661182558	23	1.12
29983831	DNA methylation and repressive H3K9 and H3K27 trimethylation in the promoter regions of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, and PD-L1 genes in human primary breast cancer.	Clinical epigenetics	2018	-7.1479904239843295	41.53988655970642	81	3.47
29983577	Impact of smoking on efficacy of PD-1/PD-L1 inhibitors in non-small cell lung cancer patients: a meta-analysis.	OncoTargets and therapy	2018	49.00072677455864	-17.394863518138212	38	1.47
29983240	What do we know about cancer immunotherapy? Long-term survival and immune-related adverse events.	Allergologia et immunopathologia	2019	79.29783524826078	-7.646781691237384	10	0.51
29981156	Trousseau's syndrome triggered by an immune checkpoint blockade in a non-small cell lung cancer patient.	European journal of immunology	2018	-43.11942072857658	-4.327559574556831	17	0.69
29981155	Dual TGF-β and PD-1 blockade synergistically enhances MAGE-A3-specific CD8+ T cell response in esophageal squamous cell carcinoma.	International journal of cancer	2018	-25.809281236116195	2.69045549233068	63	2.55
29978730	Immunosuppression of Human Adipose-Derived Stem Cells on T Cell Subsets via the Reduction of NF-kappaB Activation Mediated by PD-L1/PD-1 and Gal-9/TIM-3 Pathways.	Stem cells and development	2018	-53.857139666164585	24.1949126799026	31	1.81
29978725	Patient selection for anti-PD-1/PD-L1 therapy in advanced non-small-cell lung cancer: implications for clinical practice.	Future oncology (London, England)	2018	27.986828778533464	-34.015637082361295	25	1.04
29978476	Plant galactolipid dLGG suppresses lung metastasis of melanoma through deregulating TNF-α-mediated pulmonary vascular permeability and circulating oxylipin dynamics in mice.	International journal of cancer	2018	-23.507291595538295	-31.905390946692805	11	0.58
29977169	Update on the Treatment of Metastatic Urothelial Carcinoma.	TheScientificWorldJournal	2018	71.27600104537461	17.619859374959763	26	1.13
29973670	Clinical, histological and molecular predictors of metastatic melanoma responses to anti-PD-1 immunotherapy.	British journal of cancer	2018	9.825076353178153	-2.876544289023932	10	0.38
29973653	Expression of PD-L1/PD-1 in lymphoepithelioma-like carcinoma of the thymus.	Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc	2018	-4.602190348970922	-37.60815867876873	10	0.52
29970498	Heterogeneity of PD-L1 Expression and Relationship with Biology of NSCLC.	Anticancer research	2018	15.058664008354276	-34.30076515309683	48	1.9
29970158	Tumor matrix remodeling and novel immunotherapies: the promise of matrix-derived immune biomarkers.	Journal for immunotherapy of cancer	2018	18.3678964934448	9.820899502746917	96	4.21
29969606	PD-L1 expression in tumor cells and the immunologic milieu of bladder carcinomas: a pathologic review of 165 cases.	Human pathology	2018	11.660962768671991	58.95951708405653	12	0.53
29968861	[Checkpoint inhibitors in the decision-making algorithm of advanced non-small-cell lung cancer.].	Recenti progressi in medicina	2018	35.795529526769634	-30.493064734855743	0	0.0
29967259	Combined Blockade of IL6 and PD-1/PD-L1 Signaling Abrogates Mutual Regulation of Their Immunosuppressive Effects in the Tumor Microenvironment.	Cancer research	2018	-29.247751703314535	-16.332012598751074	183	7.51
29967089	PD-L1, TIM-3, and CTLA-4 Blockade Fails To Promote Resistance to Secondary Infection with Virulent Strains of Toxoplasma gondii.	Infection and immunity	2018	-73.82701037192821	5.07139237592256	11	0.52
29967015	Pembrolizumab OK'd for Cervical Cancer.	Cancer discovery	2018	44.3166951491794	33.35880112675479	10	0.4
29966370	The Genomics and Molecular Biology of Natural Killer/T-Cell Lymphoma: Opportunities for Translation.	International journal of molecular sciences	2018	-39.05106880594752	31.755174948306617	25	1.27
29963238	A versatile T cell-based assay to assess therapeutic antigen-specific PD-1-targeted approaches.	Oncotarget	2018	-46.14555920715983	0.1161174319646661	15	0.65
29963107	Lymphocyte-Activation Gene-3 Expression and Prognostic Value in Neoadjuvant-Treated Triple-Negative Breast Cancer.	Journal of breast cancer	2018	8.909769364385905	22.91048918829069	48	2.2
29962847	Harmonization of PD-L1 testing in oncology: a Canadian pathology perspective.	Current oncology (Toronto, Ont.)	2018	16.584948485842126	-42.06664341282057	31	1.24
29961183	Combining Tumor Vaccination and Oncolytic Viral Approaches with Checkpoint Inhibitors: Rationale, Pre-Clinical Experience, and Current Clinical Trials in Malignant Melanoma.	American journal of clinical dermatology	2018	27.748173207505257	36.379716970336986	14	0.63
29961175	Clinicopathological value of programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) expression in synovium of patients with rheumatoid arthritis.	Clinical and experimental medicine	2018	-51.843076109352616	14.555744384396029	14	0.63
29960819	Evaluating the PD-1 Axis and Immune Effector Cell Infiltration in Oropharyngeal Squamous Cell Carcinoma.	International journal of radiation oncology, biology, physics	2018	-4.793999535430522	-8.969922675009968	19	0.82
29960281	Immune checkpoint inhibitors in non-small cell lung cancer - towards daily practice.	Advances in respiratory medicine	2018	37.07502324355329	-22.7388249268488	11	0.59
29959712	Mouse-Derived Gastric Organoid and Immune Cell Co-culture for the Study of the Tumor Microenvironment.	Methods in molecular biology (Clifton, N.J.)	2018	-11.642342880734926	-0.443056824787497	33	1.33
29958099	Durvalumab for the treatment of non-small cell lung cancer.	Expert review of respiratory medicine	2018	41.31603477120428	-26.55534246571274	14	0.54
29957683	Biological basis and early clinical results of immunotherapy for cisplatin-resistant germ cell cancer.	Current opinion in urology	2018	49.51783415465966	25.58701376679145	4	0.24
29956749	Modulation of the tumor microenvironment by intratumoral administration of IMO-2125, a novel TLR9 agonist, for cancer immunotherapy.	International journal of oncology	2018	-21.51251485294789	-22.6611172519705	45	1.85
29955400	Anti-PD-1 Therapy-Associated Perforating Colitis.	Case reports in gastrointestinal medicine	2018	68.76276836868621	-16.0694315433143	21	0.94
29955379	PD-1/PD-L1 immune checkpoint inhibitors in advanced cervical cancer.	Integrative cancer science and therapeutics	2018	1.0741466516028642	-11.003871495101954	37	1.68
29952768	ATR kinase inhibitor AZD6738 potentiates CD8+ T cell-dependent antitumor activity following radiation.	The Journal of clinical investigation	2018	26.1879755597904	22.897881006291	115	4.26
29951302	Thymic tumors and immune checkpoint inhibitors.	Journal of thoracic disease	2018	38.6933156575087	-1.7289960595614626	22	1.04
29951298	Advanced non-small cell lung cancer: the role of PD-L1 inhibitors.	Journal of thoracic disease	2018	44.16547306490139	-34.63236569047677	8	0.25
29950964	Checkpoint Inhibitors in Breast Cancer - Current Status and Future Directions.	Breast care (Basel, Switzerland)	2018	25.564716581729712	-0.4615952653478486	8	0.39
29950349	Therapeutic Immune Modulation against Solid Cancers with Intratumoral Poly-ICLC: A Pilot Trial.	Clinical cancer research : an official journal of the American Association for Cancer Research	2018	28.370762272813163	54.1962739272408	82	3.23
29950244	[PD-1/PD-L1 Signaling Pathway and Its Anti-Tumor Effect in Lymphoma -Review].	Zhongguo shi yan xue ye xue za zhi	2018	-45.66179420769243	-10.72215727382115	1	0.11
29949442	Complete Local and Abscopal Responses from a Combination of Radiation and Nivolumab in Refractory Hodgkin's Lymphoma.	Radiation research	2018	39.1234664816138	-8.044473790148535	28	1.15
29948020	Extracellular vesicles and ctDNA in lung cancer: biomarker sources and therapeutic applications.	Cancer chemotherapy and pharmacology	2018	27.31031123256253	-36.85399027701537	14	0.67
29947424	Basal-subtype bladder tumours show a 'hot' immunophenotype.	Histopathology	2018	7.250485833352141	60.4138563708948	40	1.65
29947012	Proliferative CD8(+) PD-1(+) T-cell infiltration in a pembrolizumab-induced cutaneous adverse reaction.	Investigational new drugs	2018	63.60268763503619	-34.9494115789591	10	0.45
29945961	Inhaled TLR9 Agonist Renders Lung Tumors Permissive to PD-1 Blockade by Promoting Optimal CD4+ and CD8+ T-cell Interplay.	Cancer research	2018	-0.4942826723318464	-26.03776067838347	44	1.78
29944697	Restoration of T Cell function in multi-drug resistant bacterial sepsis after interleukin-7, anti-PD-L1, and OX-40 administration.	PloS one	2018	-59.8865976287987	37.920745227351496	37	1.79
29942309	Myeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors.	Frontiers in immunology	2018	21.281741107689623	17.029769156460265	321	14.32
29939876	Incidence of Basal Cell Carcinoma and Squamous Cell Carcinoma in Patients on Antiprogrammed Cell Death-1 Therapy for Metastatic Melanoma.	Journal of immunotherapy (Hagerstown, Md. : 1997)	2018	63.5297946291976	-27.78694683929628	7	0.41
29937998	PD-L1 is expressed on human platelets and is affected by immune checkpoint therapy.	Oncotarget	2018	-2.5558120347677677	-21.721612695644605	44	1.85
29937180	Significance of PD-L1 expression in pulmonary metastases from head and neck squamous cell carcinoma.	Surgical oncology	2018	-5.935895704526793	-7.254417501472069	12	0.62
29929551	Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA).	Journal for immunotherapy of cancer	2018	-0.4363856035143141	42.86097897503559	249	9.89
29928359	Increased tumor vascularization is associated with the amount of immune competent PD-1 positive cells in testicular germ cell tumors.	Oncology letters	2018	-25.874341497920756	34.841794399444474	12	0.56
29927336	Nivolumab and its use in the second-line treatment of metastatic urothelial cancer.	Future oncology (London, England)	2018	64.84368424647698	20.142006623094098	0	0.0
29925736	Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC).	Journal of UOEH	2018	36.77299503824724	-22.790468771530406	38	1.58
29925150	[Clinical relevance of common inhibitory immune checkpoint genes in esophageal squamous cell carcinoma].	Zhonghua yi xue za zhi	2018	-5.18845020323163	26.50081329686314	3	0.13
29920293	Rational design and development of a peptide inhibitor for the PD-1/PD-L1 interaction.	Cancer letters	2018	-43.609036707011256	-43.34377479372189	24	1.06
29915957	Transcriptional analysis of immune genes in Epstein-Barr virus-associated gastric cancer and association with clinical outcomes.	Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association	2018	-10.3074246877576	9.316518203098214	22	0.78
29915720	Cancer Immunotherapy and the Immune Response in Hodgkin Lymphoma.	Frontiers in oncology	2018	-28.1621491259906	25.765699034692958	10	0.43
29915296	Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity.	Nature immunology	2018	-13.1472141500822	-57.17086307814903	601	25.57
29914578	Near complete response to Pembrolizumab in microsatellite-stable metastatic sebaceous carcinoma.	Journal for immunotherapy of cancer	2018	46.60405267960305	-2.460235073649387	36	2.02
29914097	Oncolytic Reovirus and Immune Checkpoint Inhibition as a Novel Immunotherapeutic Strategy for Breast Cancer.	Cancers	2018	-36.01275591090764	53.36428664113186	35	1.51
29914088	The Role of Immune Checkpoint Inhibitors in Classical Hodgkin Lymphoma.	Cancers	2018	38.36664196307333	-7.76729340203423	25	1.16
29912871	"AR negative triple negative or ""quadruple negative"" breast cancers in African American women have an enriched basal and immune signature."	PloS one	2018	7.356844525520104	26.162002560373736	39	1.85
29910803	Expression of Programmed Death-Ligand 1 by Human Colonic CD90+ Stromal Cells Differs Between Ulcerative Colitis and Crohn's Disease and Determines Their Capacity to Suppress Th1 Cells.	Frontiers in immunology	2018	-59.63912503176535	19.278395495767253	42	1.75
29910795	Predictors of Response to Autologous Dendritic Cell Therapy in Glioblastoma Multiforme.	Frontiers in immunology	2018	-29.23089526414551	54.93687342763723	41	1.89
29910728	Regulation of PD-L1: Emerging Routes for Targeting Tumor Immune Evasion.	Frontiers in pharmacology	2018	-37.36152271338579	-18.55766098574048	153	6.73
29910652	Current landscape of immunotherapy for the treatment of metastatic non-small-cell lung cancer.	Current oncology (Toronto, Ont.)	2018	41.07849352889952	-33.173294316821256	34	1.3
29900067	Blockade of LAG3 enhances responses of tumor-infiltrating T cells in mismatch repair-proficient liver metastases of colorectal cancer.	Oncoimmunology	2018	12.209026925393278	38.88059059366064	48	1.95
29900065	The immune checkpoint protein PD-L1 induces and maintains regulatory T cells in glioblastoma.	Oncoimmunology	2018	-26.940822866721284	52.44269084545064	64	2.76
29900052	TIME (Tumor Immunity in the MicroEnvironment) classification based on tumor CD274 (PD-L1) expression status and tumor-infiltrating lymphocytes in colorectal carcinomas.	Oncoimmunology	2018	7.587728558221479	38.15457371540809	46	1.86
29900051	Increase in PD-L1 expression after pre-operative radiotherapy for soft tissue sarcoma.	Oncoimmunology	2018	-19.50913618032855	19.08068139963829	56	2.22
29900038	Dynamic change of PD-L1 expression on circulating tumor cells in advanced solid tumor patients undergoing PD-1 blockade therapy.	Oncoimmunology	2018	8.129713358499398	-38.794225343023626	95	4.11
29899191	Tumor mutational burden analysis of 2,000 Japanese cancer genomes using whole exome and targeted gene panel sequencing.	Biomedical research (Tokyo, Japan)	2018	6.7012777809123865	50.00861122318207	29	1.02
29898990	MET-Oncogenic and JAK2-Inactivating Alterations Are Independent Factors That Affect Regulation of PD-L1 Expression in Lung Cancer.	Clinical cancer research : an official journal of the American Association for Cancer Research	2018	16.25052725658552	-21.600825079565983	57	2.11
29898781	Thoracic and cutaneous sarcoid-like reaction associated with anti-PD-1 therapy: longitudinal monitoring of PD-1 and PD-L1 expression after stopping treatment.	Journal for immunotherapy of cancer	2018	60.33932534112315	-30.88790402934596	25	1.38
29895745	Generation of Human Breg-Like Phenotype with Regulatory Function In Vitro with Bacteria-Derived Oligodeoxynucleotides.	International journal of molecular sciences	2018	-66.17922002043166	7.006268774329302	21	0.96
29895574	Primary T Cells from Cutaneous T-cell Lymphoma Skin Explants Display an Exhausted Immune Checkpoint Profile.	Cancer immunology research	2018	-45.85553189603692	13.302966128461383	60	2.72
29894719	Soluble PD-1-based vaccine targeting MUC1 VNTR and survivin improves anti-tumor effect.	Immunology letters	2018	-26.581682973314457	-11.313414078941673	15	0.67
29894689	Non-conventional Inhibitory CD4+Foxp3-PD-1hi T Cells as a Biomarker of Immune Checkpoint Blockade Activity.	Cancer cell	2018	25.87371960341539	3.5721852427857623	99	3.57
29892935	The concentration of programmed cell death-ligand 1 in the peripheral blood is a useful biomarker for esophageal squamous cell carcinoma.	Esophagus : official journal of the Japan Esophageal Society	2018	-13.511207515195744	9.043918227656624	12	0.58
29892689	Tumor molecular profiling of responders and non-responders following pembrolizumab monotherapy in chemotherapy resistant advanced cervical cancer.	Gynecologic oncology reports	2018	44.15524539663996	33.30130497871204	8	0.36
29890018	High-affinity PD-1 molecules deliver improved interaction with PD-L1 and PD-L2.	Cancer science	2018	-46.19442616110586	-26.956689537566508	15	0.64
29889673	A case of severe Pembrolizumab-induced neutropenia.	Anti-cancer drugs	2018	71.67387918270371	-19.566647953677904	19	1.02
29887221	Pharmacologic Modulation of Human Immunity in the Era of Immuno-oncology: Something Old, Something New.	Mayo Clinic proceedings	2018	20.25595141678953	5.269141868899476	4	0.21
29882235	A Multifunctional Biomimetic Nanoplatform for Relieving Hypoxia to Enhance Chemotherapy and Inhibit the PD-1/PD-L1 Axis.	Small (Weinheim an der Bergstrasse, Germany)	2018	-32.61906032434426	-54.84944951368114	88	4.01
29880615	Mass cytometry of Hodgkin lymphoma reveals a CD4+ regulatory T-cell-rich and exhausted T-effector microenvironment.	Blood	2018	-27.73489423690526	26.739059237010423	100	4.02
29879980	The design of high affinity human PD-1 mutants by using molecular dynamics simulations (MD).	Cell communication and signaling : CCS	2018	-47.02918049985443	-39.03566593850009	20	0.89
29877249	[The microenvironment and immune status of peripheral T-cell lymphoma: focusing on AITL and ATLL].	[Rinsho ketsueki] The Japanese journal of clinical hematology	2018	-31.34814948313284	36.87042122331541	2	0.08
29876010	Concurrent, but not sequential, PD-1 blockade with a DNA vaccine elicits anti-tumor responses in patients with metastatic, castration-resistant prostate cancer.	Oncotarget	2018	-28.04661932224687	-11.207705901396272	56	2.29
29874664	Correlation of PD-1/PD-L1 Signaling Pathway with Treg/Th17 Imbalance from Asthmatic Children.	International archives of allergy and immunology	2018	-64.89833662640169	-10.20398625796781	12	0.59
29872580	Melanoma response to anti-PD-L1 immunotherapy requires JAK1 signaling, but not JAK2.	Oncoimmunology	2018	-18.065265542291343	-20.617217213624876	43	1.61
29872576	Potential immune priming of the tumor microenvironment with FOLFOX chemotherapy in locally advanced rectal cancer.	Oncoimmunology	2018	1.791260163475028	23.031423336060588	14	0.54
29872575	PD-L1 expression is an independent predictor of favorable outcome in patients with localized esophageal adenocarcinoma.	Oncoimmunology	2018	-12.961526419448736	7.699967980692231	30	1.36
29872568	PD-1/PD-L1 pathway: an adaptive immune resistance mechanism to immunogenic chemotherapy in colorectal cancer.	Oncoimmunology	2018	-19.523458853378838	-26.855194270200755	137	5.75
29872559	RANKL blockade improves efficacy of PD1-PD-L1 blockade or dual PD1-PD-L1 and CTLA4 blockade in mouse models of cancer.	Oncoimmunology	2018	-17.09563656623651	-46.098486026635385	57	2.36
29872177	Safety of combining radiotherapy with immune-checkpoint inhibition.	Nature reviews. Clinical oncology	2018	27.29870012164498	19.64932321185254	170	7.37
29871885	PD-L1 Binds to B7-1 Only In Cis on the Same Cell Surface.	Cancer immunology research	2018	-54.57575254617095	-13.138501981864152	105	3.91
29871861	Pembrolizumab Monotherapy for NSCLC Extends Survival.	Cancer discovery	2018	46.632281368227744	-31.1514455444944	1	0.02
29871672	Effect of neoadjuvant chemotherapy on the immune microenvironment in non-small cell lung carcinomas as determined by multiplex immunofluorescence and image analysis approaches.	Journal for immunotherapy of cancer	2018	12.857847274420912	-17.41930820872699	101	4.28
29869738	Rethinking medulloblastoma from a targeted therapeutics perspective.	Journal of neuro-oncology	2018	-19.266463445671448	49.8717956154151	11	0.48
29868471	The Role of Macrophage/B-Cell Interactions in the Pathophysiology of B-Cell Lymphomas.	Frontiers in oncology	2018	-32.25038090126386	-3.5183367931222187	29	1.47
29866197	Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination.	Journal for immunotherapy of cancer	2018	39.67943042233773	3.925837987513583	117	4.87
29859207	Analysis of programmed death-ligand 1 expression in primary normal human dermal fibroblasts after DNA damage.	Human immunology	2018	-21.064773595191024	-25.66424757891636	6	0.28
29855698	Development of immunotherapy in bladder cancer: present and future on targeting PD(L)1 and CTLA-4 pathways.	World journal of urology	2018	68.70596011421	22.198655701710223	61	2.87
29853658	Ramucirumab Plus Pembrolizumab in Patients with Previously Treated Advanced or Metastatic Biliary Tract Cancer: Nonrandomized, Open-Label, Phase I Trial (JVDF).	The oncologist	2018	50.955854580069165	9.33537816829316	105	4.56
29850620	Immune Checkpoint Inhibitors to Treat Malignant Lymphomas.	Journal of immunology research	2018	24.981969569352675	8.317015727397116	16	0.59
29848685	Programmed Cell Death Ligand 1 Expression Is an Independent Prognostic Factor in Colorectal Cancer.	Anticancer research	2018	-5.053414936838168	10.888570247176526	33	1.42
29848031	The Role of the Programmed Death Receptor-1/Programmed Death Ligand-1: Immunologic Checkpoint in Human Papillomavirus-Associated Head and Neck Squamous Cell Carcinoma.	Archives of pathology & laboratory medicine	2018	-9.465007915395686	-2.9109325889419995	1	0.02
29846894	Multiplatform profiling of meningioma provides molecular insight and prioritization of drug targets for rational clinical trial design.	Journal of neuro-oncology	2018	-19.189188750619188	49.02399658544126	13	0.75
29846432	PD-1/PD-L1 regulates Treg differentiation in pregnancy-induced hypertension.	Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas	2018	-73.63587361145986	-18.014289174711934	17	0.86
29844707	Response to rapamycin analogs but not PD-1 inhibitors in PTEN-mutated metastatic non-small-cell lung cancer with high tumor mutational burden.	Lung Cancer (Auckland, N.Z.)	2018	22.194891504039216	-20.041032028198632	10	0.37
29844686	Bacillus Calmette-Guérin and anti-PD-L1 combination therapy boosts immune response against bladder cancer.	OncoTargets and therapy	2018	11.956795406379245	62.66561076459304	36	1.52
29844327	Interferon-gamma drives programmed death-ligand 1 expression on islet β cells to limit T cell function during autoimmune diabetes.	Scientific reports	2018	-60.09628658951269	2.692856182571766	84	3.45
29844002	Programmed Cell Death Ligand 1 Expression in Non-Small-cell Lung Cancer Patients With Interstitial Lung Disease: A Matched Case-control Study.	Clinical lung cancer	2018	13.720122312755466	-31.54862934785554	6	0.32
29843813	Stratification of ovarian tumor pathology by expression of programmed cell death-1 (PD-1) and PD-ligand- 1 (PD-L1) in ovarian cancer.	Journal of ovarian research	2018	-19.99934502807056	12.91738856419391	51	2.35
29843754	Immune checkpoint therapy in liver cancer.	Journal of experimental & clinical cancer research : CR	2018	29.636393508507133	47.75948007397875	201	9.22
29808294	Overview of Current and Future Adjuvant Therapy for Muscle-Invasive Urothelial Carcinoma.	Current treatment options in oncology	2018	74.0204386743362	19.954494788680478	11	0.41
29808239	Management of Resistance to First-Line Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor Therapy.	Current treatment options in oncology	2018	34.54656689791577	-37.6078350323573	11	0.44
29807457	Regulation of innate and adaptive antitumor immunity by IAP antagonists.	Immunotherapy	2018	21.15905855951484	10.856847787167776	47	1.72
29805739	Prognostic value of CD8CD45RO tumor infiltrating lymphocytes in patients with extrahepatic cholangiocarcinoma.	Oncotarget	2018	0.5463821473295278	6.635551488775243	28	1.24
29805708	Tumor PD-L1 Expression and Clinical Outcomes in Advanced-stage Non-Small Cell Lung Cancer Patients Treated with Nivolumab or Pembrolizumab: Real-World Data in Taiwan.	Journal of Cancer	2018	17.264085068270184	-29.330358290493525	40	1.62
29803574	Correlation of Neutrophil to Lymphocyte Ratio and Absolute Neutrophil Count With Outcomes With PD-1 Axis Inhibitors in Patients With Advanced Non-Small-Cell Lung Cancer.	Clinical lung cancer	2018	27.813172529684422	-41.22331148276419	85	3.68
29800685	Regulation of cancer immune escape: The roles of miRNAs in immune checkpoint proteins.	Cancer letters	2018	-19.589497165137143	0.1503005165081668	27	1.22
29800567	Keeping Tumors in Check: A Mechanistic Review of Clinical Response and Resistance to Immune Checkpoint Blockade in Cancer.	Journal of molecular biology	2018	27.94981491032089	15.085602716723589	35	1.36
29799076	T-lymphocyte profiles differ between keratoacanthomas and invasive squamous cell carcinomas of the human skin.	Cancer immunology, immunotherapy : CII	2018	-0.8775455028250206	-3.880947617705589	9	0.49
29787423	Autoimmune Granulomatous Inflammation of Lacrimal Glands and Axonal Neuritis Following Treatment With Ipilimumab and Radiation Therapy.	Journal of immunotherapy (Hagerstown, Md. : 1997)	2018	79.22453381770507	-22.6687600388712	6	0.36
29786078	Targeting the upstream transcriptional activator of PD-L1 as an alternative strategy in melanoma therapy.	Oncogene	2018	-14.629341701676031	-20.44019117210668	62	2.56
29779430	Intratumoral immune cells expressing PD-1/PD-L1 and their prognostic implications in cancer: a meta-analysis.	The International journal of biological markers	2018	-7.5485325181355805	13.17680546818304	8	0.35
29774031	IL-10 Producing B Cells Ability to Induce Regulatory T Cells Is Maintained in Rheumatoid Arthritis.	Frontiers in immunology	2018	-66.5775219286253	5.689529075606206	42	1.76
29773717	STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma.	Cancer discovery	2018	18.95542393844968	-22.084850348247205	923	37.64
29770915	Cytolytic Activity Score to Assess Anticancer Immunity in Colorectal Cancer.	Annals of surgical oncology	2018	6.723720431411431	40.32638489121147	103	4.0
29765155	Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations.	Oncogene	2018	-39.73115643772743	-11.053802790533812	176	7.53
29764856	TP53, STK11, and EGFR Mutations Predict Tumor Immune Profile and the Response to Anti-PD-1 in Lung Adenocarcinoma.	Clinical cancer research : an official journal of the American Association for Cancer Research	2018	18.70905437840362	-20.8204820497894	215	8.22
29762727	Development of targeted therapy and immunotherapy for treatment of small cell lung cancer.	Japanese journal of clinical oncology	2018	41.96066591705336	-40.718468873756336	17	0.77
29762141	PD-1 Expression in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Large B-cell Richter Transformation (DLBCL-RT): A Characteristic Feature of DLBCL-RT and Potential Surrogate Marker for Clonal Relatedness.	The American journal of surgical pathology	2018	-34.09229429792365	28.3377999942932	44	1.71
29760800	Risk of immune-related colitis with PD-1/PD-L1 inhibitors vs chemotherapy in solid tumors: systems assessment.	Journal of Cancer	2018	67.443634491635	-14.695963717089302	13	0.44
29758930	The potential predictive value of circulating immune cell ratio and tumor marker in atezolizumab treated advanced non-small cell lung cancer patients.	Cancer biomarkers : section A of Disease markers	2018	30.382299900472287	-43.675892887721375	25	1.05
29758333	Hepatitis B virus-specific T cell responses after stopping nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B.	Journal of hepatology	2018	-73.9076942191112	24.95193591712657	76	3.85
29757192	CD155 loss enhances tumor suppression via combined host and tumor-intrinsic mechanisms.	The Journal of clinical investigation	2018	-7.1056353951882985	24.989366017836733	84	3.36
29756633	Immunotherapy in head and neck cancer - scientific rationale, current treatment options and future directions.	Swiss medical weekly	2018	52.349749799522456	32.45555956323171	20	0.97
29755699	Sequential immunotherapy in a patient with primary refractory Hodgkin lymphoma and novel mutations.	Oncotarget	2018	39.68800411167919	-8.664100382145515	5	0.2
29748390	The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non-Clear Cell Renal Cell Carcinoma.	Cancer immunology research	2018	19.692525796344174	26.05276363678024	77	3.11
29748004	PD-L1 expression in circulating tumor cells of advanced non-small cell lung cancer patients treated with nivolumab.	Lung cancer (Amsterdam, Netherlands)	2018	10.133521563967273	-37.868068855456144	142	6.37
29746230	Safety of Programmed Death-1 Pathway Inhibitors Among Patients With Non-Small-Cell Lung Cancer and Preexisting Autoimmune Disorders.	Journal of clinical oncology : official journal of the American Society of Clinical Oncology	2018	71.7013686832399	-12.916593941566571	226	10.32
29745928	Cancer immunotherapy and the PD-1/PD-L1 checkpoint pathway.	Archivos espanoles de urologia	2018	69.525265771985	21.50888087728701	21	0.89
29744662	Co-expression of NGF and PD-L1 on tumor-associated immune cells in the microenvironment of Merkel cell carcinoma.	Journal of cancer research and clinical oncology	2018	-11.969551857637551	39.570567300926925	10	0.5
29742518	Immune Checkpoint Inhibitors in the Treatment of Patients with Neuroendocrine Neoplasia.	Oncology research and treatment	2018	44.46887015353955	24.688343086000945	59	2.89
29742291	PD-1 and PD-L1 expression in HNSCC primary cancer and related lymph node metastasis - impact on clinical outcome.	Histopathology	2018	-6.44902142234834	-7.449212190472326	62	2.85
29740718	Combination Immunotherapy in Non-small Cell Lung Cancer.	Current oncology reports	2018	34.69710831344366	-29.70559702924146	23	0.95
29740452	Interleukin-27 Gene Therapy Prevents the Development of Autoimmune Encephalomyelitis but Fails to Attenuate Established Inflammation due to the Expansion of CD11b+Gr-1+ Myeloid Cells.	Frontiers in immunology	2018	-70.96067155421882	-5.25621039448522	14	0.53
29739808	Programmed cell death-1 and programmed cell death ligand-1 antibodies-induced dysthyroidism.	Endocrine connections	2018	78.2719175760286	-17.176647730709885	9	0.4
29737375	VISTA expression on tumor-infiltrating inflammatory cells in primary cutaneous melanoma correlates with poor disease-specific survival.	Cancer immunology, immunotherapy : CII	2018	-39.32027611145965	37.48109890672188	62	2.31
29736285	Nonsmall Cell Lung Carcinoma with Giant Cell Features Expressing Programmed Death-Ligand 1: A Report of a Patient Successfully Treated with Pembrolizumab.	Case reports in oncological medicine	2018	52.56214384674394	-32.61316018316328	7	0.49
29735366	Self-Delivering RNAi Targeting PD-1 Improves Tumor-Specific T Cell Functionality for Adoptive Cell Therapy of Malignant Melanoma.	Molecular therapy : the journal of the American Society of Gene Therapy	2018	-51.45918369819093	-21.07907664113718	29	1.24
29733528	Anti-PD-1 therapy redirects macrophages from an M2 to an M1 phenotype inducing regression of OS lung metastases.	Cancer medicine	2018	3.352571809109246	-25.69548241226908	109	4.88
29731605	The combination of anti-KIR monoclonal antibodies with anti-PD-1/PD-L1 monoclonal antibodies could be a critical breakthrough in overcoming tumor immune escape in NSCLC.	Drug design, development and therapy	2018	14.683365073331942	-32.7117820194271	27	1.21
29730815	PD-1/PD-L1 and immune-related gene expression pattern in pediatric malignant brain tumors: clinical correlation with survival data in Korean population.	Journal of neuro-oncology	2018	-26.609806920694588	18.14853144601816	18	0.75
29721192	PD-L1 expression in medulloblastoma: an evaluation by subgroup.	Oncotarget	2018	-26.270785222773647	17.629172934315047	40	1.69
29721184	Correlation between lower balance of Th2 helper T-cells and expression of PD-L1/PD-1 axis genes enables prognostic prediction in patients with glioblastoma.	Oncotarget	2018	-21.816708266681417	55.51636724110177	28	1.2
29719073	The expression of programed death ligand-1 could be related with unfavorable prognosis in salivary duct carcinoma.	Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology	2018	-4.668054322152231	-0.8211434619674939	25	1.4
29716887	Are EBV-related and EBV-unrelated Hodgkin lymphomas different with regard to susceptibility to checkpoint blockade?	Blood	2018	-25.86437916286817	25.717176872156024	33	1.53
29715119	Eribulin Promotes Antitumor Immune Responses in Patients with Locally Advanced or Metastatic Breast Cancer.	Anticancer research	2018	-6.983974893213756	14.49095832142868	35	1.52
29712568	Discovery and preclinical characterization of the antagonist anti-PD-L1 monoclonal antibody LY3300054.	Journal for immunotherapy of cancer	2018	-40.591542564647206	-30.058144651188552	16	0.57
29708143	Combination immuno-oncology therapy with immune checkpoint blockers targeting PD-L1, PD-1 or CTLA4 and epigenetic drugs targeting MYC and immune evasion for precision medicine.	Journal of thoracic disease	2018	19.44710251096478	6.572959509701982	4	0.15
29707124	BRCA1/2 and TP53 mutation status associates with PD-1 and PD-L1 expression in ovarian cancer.	Oncotarget	2018	-19.98757944941809	13.873986006040022	62	2.63
29706653	Programmed death ligand 1 promotes lymph node metastasis and glucose metabolism in cervical cancer by activating integrin β4/SNAI1/SIRT3 signaling pathway.	Oncogene	2018	0.7572594030741508	-13.311412371146147	74	3.28
29705787	Immune Checkpoint Inhibition in Gastro-Oesophageal Cancer.	Oncology research and treatment	2018	45.09514900036732	16.187492628998353	23	0.96
29704887	The siRNA-mediated downregulation of PD-1 alone or simultaneously with CTLA-4 shows enhanced in vitro CAR-T-cell functionality for further clinical development towards the potential use in immunotherapy of melanoma.	Experimental dermatology	2018	-44.00907544665265	3.681760201015415	41	1.65
29702526	Predictive Value of Soluble Programmed Death-1 for Severe Sepsis and Septic Shock During the First Week in an Intensive Care Unit.	Shock (Augusta, Ga.)	2019	-56.91400341399119	33.83618074286654	22	1.6
29702286	Expression Patterns, Prognostic Value, and Intratumoral Heterogeneity of PD-L1 and PD-1 in Thymoma and Thymic Carcinoma.	Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer	2018	-5.215525506396864	-36.752637551177365	37	1.62
29702148	Immunomodulatory effects of CD38-targeting antibodies.	Immunology letters	2018	-8.430827770148253	-53.08403011731271	58	2.72
29700411	A dualistic model of primary anal canal adenocarcinoma with distinct cellular origins, etiologies, inflammatory microenvironments and mutational signatures: implications for personalised medicine.	British journal of cancer	2018	9.839291682795697	19.167707201249968	23	1.18
29698933	Detection of immune-related adverse events by medical imaging in patients treated with anti-programmed cell death 1.	European journal of cancer (Oxford, England : 1990)	2018	73.10624519561475	-12.505439846947391	84	3.83
29694419	T cell mediated immunity after combination therapy with intralesional PV-10 and blockade of the PD-1/PD-L1 pathway in a murine melanoma model.	PloS one	2018	-29.386191352420383	-16.27235862529989	14	0.59
29689030	CHECKPOINT INHIBITOR IMMUNE THERAPY: Systemic Indications and Ophthalmic Side Effects.	Retina (Philadelphia, Pa.)	2018	81.08652543715075	-23.33508687472354	195	13.04
29687062	A case of metastatic basal cell carcinoma treated with continuous PD-1 inhibitor exposure even after subsequent initiation of radiotherapy and surgery.	JAAD case reports	2018	42.00930574503924	3.559311404125249	32	1.82
29685290	PD-1 immune checkpoint blockade promotes brain leukocyte infiltration and diminishes cyst burden in a mouse model of Toxoplasma infection.	Journal of neuroimmunology	2018	-73.87953846616296	5.10902650086248	17	0.94
29683890	Characteristics and Predictive Value of PD-L1 Status in Real-World Non-Small Cell Lung Cancer Patients.	Journal of immunotherapy (Hagerstown, Md. : 1997)	2018	12.002951925911928	-30.964240215667424	26	1.01
29680903	The expression profile of PD-L1 and CD8+ lymphocyte in pituitary adenomas indicating for immunotherapy.	Journal of neuro-oncology	2018	-3.489316887631809	-18.88909049762798	56	3.05
29679656	PD-1 blocks lytic granule polarization with concomitant impairment of integrin outside-in signaling in the natural killer cell immunological synapse.	The Journal of allergy and clinical immunology	2018	-33.10402898655112	-0.4172829421196833	12	0.5
29679564	Frequencies and expression levels of programmed death ligand 1 (PD-L1) in circulating tumor RNA (ctRNA) in various cancer types.	Biochemical and biophysical research communications	2018	8.056295557006615	-38.14770276793456	38	1.65
29677240	Uveal Effusion After Immune Checkpoint Inhibitor Therapy.	JAMA ophthalmology	2018	81.05923730502725	-24.540437436629063	33	2.13
29675979	Senescent cells re-engineered to express soluble programmed death receptor-1 for inhibiting programmed death receptor-1/programmed death ligand-1 as a vaccination approach against breast cancer.	Cancer science	2018	-26.393998463631373	-10.306182616122491	18	0.83
29675794	Association between programmed cell death ligand-1 expression and extracranial metastasis in intracranial solitary fibrous tumor/hemangiopericytoma.	Journal of neuro-oncology	2018	-26.55067629378859	45.6125572934944	17	1.12
29675791	Chemotherapy treatment is associated with altered PD-L1 expression in lung cancer patients.	Journal of cancer research and clinical oncology	2018	10.470386705338855	-25.365351239780576	48	2.26
29674442	First Report of Dramatic Tumor Responses with Ramucirumab and Paclitaxel After Progression on Pembrolizumab in Two Cases of Metastatic Gastroesophageal Adenocarcinoma.	The oncologist	2018	49.49698788138469	8.424190106989213	10	0.36
29672367	Characterization of PD-L1 and PD-1 Expression and CD8+ Tumor-infiltrating Lymphocyte in Epstein-Barr Virus-associated Nasopharyngeal Carcinoma.	American journal of clinical oncology	2018	-16.368660027042004	31.332134244276517	48	2.34
29670378	β-Catenin-driven adrenocortical carcinoma is characterized with immune exclusion.	OncoTargets and therapy	2018	12.150855186871691	18.375154492735074	17	0.8
29670099	Nuclear receptor NR2F6 inhibition potentiates responses to PD-L1/PD-1 cancer immune checkpoint blockade.	Nature communications	2018	9.068333552663228	-7.141275943332739	37	1.34
29669604	CONFIRM: a double-blind, placebo-controlled phase III clinical trial investigating the effect of nivolumab in patients with relapsed mesothelioma: study protocol for a randomised controlled trial.	Trials	2018	44.43659234110151	-10.880795518019085	32	1.46
29668526	Immunophenotyping of Monocytes During Human Sepsis Shows Impairment in Antigen Presentation: A Shift Toward Nonclassical Differentiation and Upregulation of FCγRi-Receptor.	Shock (Augusta, Ga.)	2018	-56.60804032149252	36.85223703230947	30	1.32
29665726	Dexmedetomidine Mitigates Microglia-Mediated Neuroinflammation through Upregulation of Programmed Cell Death Protein 1 in a Rat Spinal Cord Injury Model.	Journal of neurotrauma	2018	-76.71093284246966	-10.431771680337116	18	1.05
29663398	Transition of the programmed death 1 pathway from the primary colorectal cancer to its corresponding pulmonary metastasis.	Journal of surgical oncology	2018	-3.5525264473945195	11.440681527708415	4	0.17
29662549	Tumour necrosis factor, interferon-gamma and interleukins as predictive markers of antiprogrammed cell-death protein-1 treatment in advanced non-small cell lung cancer: a pragmatic approach in clinical practice.	Therapeutic advances in medical oncology	2018	21.754424799268744	-31.67693646120608	58	2.34
29662547	PD-L1 expression testing in non-small cell lung cancer.	Therapeutic advances in medical oncology	2018	22.2418285189765	-37.26477222196159	102	4.49
29662546	Combination of immunotherapy with chemotherapy and radiotherapy in lung cancer: is this the beginning of the end for cancer?	Therapeutic advances in medical oncology	2018	35.46954298895701	-28.345497979323387	89	4.23
29661350	Monocyte Programmed Death Ligand-1, A Predicator for 28-Day Mortality in Septic Patients.	The American journal of the medical sciences	2018	-57.2399336056825	33.821182645450165	10	0.5
29661225	Lymphocyte subset expression and serum concentrations of PD-1/PD-L1 in sepsis - pilot study.	Critical care (London, England)	2018	-57.53316926583878	34.873699918732214	40	1.87
29658848	Neoadjuvant PD-1 Blockade in Resectable Lung Cancer.	The New England journal of medicine	2018	31.30668127253396	-20.219973251125836	1163	48.6
29658430	Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma.	The New England journal of medicine	2018	46.678187964607424	1.2743388156925883	1113	50.76
29657128	Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer.	Cancer cell	2018	23.22800656850487	-16.814725791853995	676	27.56
29656756	Correlation of tumor-related immunity with 18F-FDG-PET in pulmonary squamous-cell carcinoma.	Lung cancer (Amsterdam, Netherlands)	2018	14.844717666070494	-57.57241930418228	40	1.83
29656492	PD-1 Blockade Cellular Vesicles for Cancer Immunotherapy.	Advanced materials (Deerfield Beach, Fla.)	2018	-36.40110152331865	-56.44168345667875	152	6.4
29654146	Role of PD-1 during effector CD8 T cell differentiation.	Proceedings of the National Academy of Sciences of the United States of America	2018	-75.5878870732255	12.163929696371286	258	9.77
29653410	Rescue of iCIKs transfer from PD-1/PD-L1 immune inhibition in patients with resectable tongue squamous cell carcinoma (TSCC).	International immunopharmacology	2018	-8.689118449955648	-9.283641989714043	7	0.31
29651624	In papillary thyroid carcinoma, expression by immunohistochemistry of BRAF V600E, PD-L1, and PD-1 is closely related.	Virchows Archiv : an international journal of pathology	2018	-6.600315587914832	-21.107204066571537	27	1.27
29650750	BRAF and MEK Inhibitors Increase PD-1-Positive Melanoma Cells Leading to a Potential Lymphocyte-Independent Synergism with Anti-PD-1 Antibody.	Clinical cancer research : an official journal of the American Association for Cancer Research	2018	3.762763651737536	-0.3055399217287051	22	0.77
29650143	Perioperative Immunotherapy in Muscle-Invasive Bladder Cancer and Upper Tract Urothelial Carcinoma.	The Urologic clinics of North America	2018	73.52340112092556	20.987447308435733	9	0.34
29644214	Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations.	Frontiers in oncology	2018	29.246730932045327	4.240554020923024	705	33.77
29642147	The research status of immune checkpoint blockade by anti-CTLA4 and anti-PD1/PD-l1 antibodies in tumor immunotherapy in China: A bibliometrics study.	Medicine	2018	26.99363343339701	15.090794782738795	5	0.2
29637937	Immune and autoimmune-related adverse events associated with immune checkpoint inhibitors in cancer therapy.	Drugs of today (Barcelona, Spain : 1998)	2018	79.10408439145483	-10.125206221364008	13	0.55
29637216	[Advanced bladder cancer : From chemo- to immunotherapy].	Der Urologe. Ausg. A	2018	67.96367083189182	16.970500065099618	0	0.0
29633300	Dermatologic toxicity from immune checkpoint blockade therapy with an interstitial granulomatous pattern.	Journal of cutaneous pathology	2018	73.80043406645197	-25.15106977437788	17	0.95
29632736	Safety and activity of PD-1 blockade-activated DC-CIK cells in patients with advanced solid tumors.	Oncoimmunology	2018	44.21767831047174	4.9067076799402445	28	1.33
29632731	A novel MDSC-induced PD-1-PD-L1+ B-cell subset in breast tumor microenvironment possesses immuno-suppressive properties.	Oncoimmunology	2018	-50.62562309437428	27.50330592314753	53	2.29
29632720	Blockade of Tumor-Expressed PD-1 promotes lung cancer growth.	Oncoimmunology	2018	12.992091738419193	-22.96985513275697	91	3.59
29632719	Combination therapy with PD-1/PD-L1 blockade: An overview of ongoing clinical trials.	Oncoimmunology	2018	26.596128212498712	-3.933574530380387	24	0.98
29632707	STINGing the Tumor's immune evasion mechanism.	Oncoimmunology	2018	-22.15393815562609	-45.00908979535768	4	0.14
29631035	Safety and Efficacy of PD-1 Inhibitors Among HIV-Positive Patients With Non-Small Cell Lung Cancer.	Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer	2018	45.426860881008295	-27.859067706333164	67	2.85
29630716	A review of bullous pemphigoid associated with PD-1 and PD-L1 inhibitors.	International journal of dermatology	2018	70.88099564843766	-26.70945048861322	111	6.87
29628312	ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial.	The Lancet. Oncology	2018	47.93871777583704	-24.6593908280772	258	10.4
29627937	Poor prognosis in Epstein-Barr virus-negative gastric cancer with lymphoid stroma is associated with immune phenotype.	Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association	2018	-12.63595433578248	20.991335986411748	11	0.63
29626502	Sustained release of anti-PD-1 peptide for perdurable immunotherapy together with photothermal ablation against primary and distant tumors.	Journal of controlled release : official journal of the Controlled Release Society	2018	-30.56216389508033	-54.5767935537128	75	3.41
29625896	Co-inhibitory Molecule B7 Superfamily Member 1 Expressed by Tumor-Infiltrating Myeloid Cells Induces Dysfunction of Anti-tumor CD8+ T Cells.	Immunity	2018	-29.25757193383861	5.743395881907055	128	4.74
29623256	Association Between Programmed Death-Ligand 1 Expression and the Vascular Endothelial Growth Factor Pathway in Angiosarcoma.	Frontiers in oncology	2018	-21.3347208485362	23.49803078933781	17	0.76
29623180	Pembrolizumab and its role in relapsed/refractory classical Hodgkin's lymphoma: evidence to date and clinical utility.	Therapeutic advances in hematology	2018	42.484926893938514	-6.265185953482228	12	0.51
29620933	Dynamics of Lymphocyte Reconstitution After Hematopoietic Transplantation During Chronic Lymphocytic Choriomeningitis Virus Infection.	AIDS research and human retroviruses	2018	-75.45269833155338	12.906644608059542	2	0.09
29620156	Expression and clinical significance of PD‑1 in hepatocellular carcinoma tissues detected by a novel mouse anti-human PD‑1 monoclonal antibody.	International journal of oncology	2018	-22.70068233763133	39.64172987745048	13	0.53
29618381	Efficacy of PD-1 & PD-L1 inhibitors in older adults: a meta-analysis.	Journal for immunotherapy of cancer	2018	55.61493261237659	-18.90920492908073	126	5.33
29617666	Systematic Analysis of Splice-Site-Creating Mutations in Cancer.	Cell reports	2018	8.037757572232719	50.67220029388944	145	5.38
29617441	PD-1/PD-L1 expression in a series of intracranial germinoma and its association with Foxp3+ and CD8+ infiltrating lymphocytes.	PloS one	2018	-23.64420212998721	32.81552863883448	18	0.9
29617057	Antigen-specific Helios- , Neuropilin-1- Tregs induce apoptosis of autoreactive B cells via PD-L1.	Immunology and cell biology	2018	-65.0814953862862	1.6510234029115622	10	0.42
29616115	Expression of multiple immune checkpoint molecules on T cells in malignant ascites from epithelial ovarian carcinoma.	Oncology letters	2018	2.1426080815419724	30.346957361102252	34	1.52
29615718	Genetic abrogation of immune checkpoints in antigen-specific cytotoxic T-lymphocyte as a potential alternative to blockade immunotherapy.	Scientific reports	2018	-45.17939032922053	0.5822125015169929	26	0.93
29615076	Use of the tumor-infiltrating CD8 to FOXP3 lymphocyte ratio in predicting treatment responses to combination therapy with pertuzumab, trastuzumab, and docetaxel for advanced HER2-positive breast cancer.	Journal of translational medicine	2018	-1.5820169931839498	22.55944789899685	28	1.18
29615063	Prediction of treatment responses to neoadjuvant chemotherapy in triple-negative breast cancer by analysis of immune checkpoint protein expression.	Journal of translational medicine	2018	-8.55441179126112	19.129197851721337	32	1.26
29614789	EBV⁺ and MSI Gastric Cancers Harbor High PD-L1/PD-1 Expression and High CD8⁺ Intratumoral Lymphocytes.	Cancers	2018	-9.660434462886537	8.636497702896662	41	2.03
29609005	Decreased PD-1 expression on circulating CD4+T cell and PD-L1 expression on myeloid dendritic cell correlate with clinical manifestations in systemic juvenile idiopathic arthritis.	Joint bone spine	2019	-53.24184189787946	14.87959156905413	10	0.65
29607153	Assessment of programmed cell death ligand-1 expression with multiple immunohistochemistry antibody clones in non-small cell lung cancer.	Journal of thoracic disease	2018	13.080369903406398	-32.10825140966175	9	0.32
29606979	PD-1 and PD-L1 inhibitors after platinum-based chemotherapy or in first-line therapy in cisplatin-ineligible patients: Dramatic improvement of prognosis and overall survival after decades of hopelessness in patients with metastatic urothelial cancer.	Memo	2018	69.58741862581303	17.39800817530502	22	0.98
31938305	Programmed death-1 and PD-1 ligand-1 expression in early onset gastric carcinoma and correlation with clinicopathological characteristics.	International journal of clinical and experimental pathology	2018	-8.325044687594179	5.015205864953352	1	0.04
29603856	Hepatotoxicity of immune checkpoint inhibitors: An evolving picture of risk associated with a vital class of immunotherapy agents.	Liver international : official journal of the International Association for the Study of the Liver	2018	75.67533736131892	0.1492506734977659	130	6.2
29602245	Reactive glia promote development of CD103+ CD69+ CD8+ T-cells through programmed cell death-ligand 1 (PD-L1).	Immunity, inflammation and disease	2018	-75.56313264061461	-2.8323732227076186	17	0.59
29602174	Expression of programmed death ligand 1 is associated with poor prognosis in myeloid sarcoma patients.	Hematological oncology	2018	-32.040844000821295	12.244794725496588	12	0.7
29600072	Aberrant status and clinicopathologic characteristic associations of 11 target genes in 1,321 Chinese patients with lung adenocarcinoma.	Journal of thoracic disease	2018	17.719994810217347	-20.141335484538203	14	0.61
29599916	PD-L1 expression and presence of TILs in small intestinal neuroendocrine tumours.	Oncotarget	2018	-0.181862428755429	13.379148323341932	28	1.39
29599908	Regulatory B cells induced by pancreatic cancer cell-derived interleukin-18 promote immune tolerance via the PD-1/PD-L1 pathway.	Oncotarget	2018	-25.74888255439515	7.83893923755996	40	1.45
29599324	PD-1 and PD-L1 Up-regulation Promotes T-cell Apoptosis in Gastric Adenocarcinoma.	Anticancer research	2018	-11.515667410569876	3.962178143147769	33	1.38
29598887	Expression of programmed cell death 1/programmed cell death ligand 1 in the tumor microenvironments of primary gastrointestinal diffuse large B cell lymphomas.	Pathology, research and practice	2018	-33.83820127625333	26.68406828986895	6	0.23
29596308	EP4 as a Therapeutic Target for Aggressive Human Breast Cancer.	International journal of molecular sciences	2018	-23.65495557979738	4.080049537638825	50	2.4
29593891	Immune checkpoint inhibitors in small cell lung cancer.	Journal of thoracic disease	2018	44.19334629855163	-41.492756103922986	39	1.66
29593890	Neoadjuvant and consolidation immuno-oncology therapy in stage III non-small cell lung cancer.	Journal of thoracic disease	2018	39.37762935087349	-26.058696667864236	32	1.31
29593889	Immunotherapy combination strategies (non-chemotherapy) in non-small cell lung cancer.	Journal of thoracic disease	2018	38.03300069907005	-30.179333929333207	12	0.49
29587324	[Immunotherapy for renal cell carcinoma - current status].	Aktuelle Urologie	2018	65.64996493329461	30.76961656111284	3	0.1
29580288	Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway.	Journal of hematology & oncology	2018	-33.24547868084715	7.3263126234849425	44	1.94
29578107	Clinical Features and Management of Acquired Resistance to PD-1 Axis Inhibitors in 26 Patients With Advanced Non-Small Cell Lung Cancer.	Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer	2018	30.439266993340308	-32.01686099654689	75	2.56
29576277	The clinicopathological and prognostic significance of PD-L1 expression in pancreatic cancer: A meta-analysis.	Hepatobiliary & pancreatic diseases international : HBPD INT	2018	-4.411134616676405	4.487481450290497	42	1.67
29575535	Inhibition of yes-associated protein down-regulates PD-L1 (CD274) expression in human malignant pleural mesothelioma.	Journal of cellular and molecular medicine	2018	2.2769614293337126	-34.536222727897304	38	1.49
29573217	The benefit and risk of nivolumab in non-small-cell lung cancer: a single-arm meta-analysis of noncomparative clinical studies and randomized controlled trials.	Cancer medicine	2018	46.8491374421123	-24.815059184494213	14	0.52
29572029	Prognostic implication of programmed cell death 1 protein and its ligand expressions in endometrial cancer.	Gynecologic oncology	2018	-17.960370596409764	9.624134277346108	31	1.4
29572000	PD-L1 expression in lung adenocarcinoma harboring EGFR mutations or ALK rearrangements.	Lung cancer (Amsterdam, Netherlands)	2018	9.34481153659955	-32.73455108773741	72	2.96
29571563	[PD-L1 testing in non-small cell lung carcinoma: Guidelines from the PATTERN group of thoracic pathologists].	Annales de pathologie	2018	22.84724945924741	-38.97470470824354	17	0.77
29571514	Development and characterization of monoclonal antibodies against canine PD-1 and PD-L1.	Veterinary immunology and immunopathology	2018	-16.727984260400884	-14.739655251948433	26	1.49
29568117	Distinct contribution of PD-L1 suppression by spatial expression of PD-L1 on tumor and non-tumor cells.	Cellular & molecular immunology	2019	-34.63555110026087	-10.650332562005508	22	0.84
29566951	Composition of the immune microenvironment differs between carcinomas metastatic to the lungs and primary lung carcinomas.	Annals of diagnostic pathology	2018	11.101309217339836	-16.949226128829018	4	0.18
29566262	Regulatory T cells: a potential target in cancer immunotherapy.	Annals of the New York Academy of Sciences	2018	14.905409845792452	15.0222804485406	142	6.26
29562816	Family history of cancer as surrogate predictor for immunotherapy with anti-PD1/PD-L1 agents: preliminary report of the FAMI-L1 study.	Immunotherapy	2018	3.683312024995726	9.394879776203318	10	0.38
29562194	Regulation and Function of the PD-L1 Checkpoint.	Immunity	2018	-40.116000855370594	-11.4849659861525	1130	50.74
29560342	Merkel Cell Carcinoma: An Update and Immunotherapy.	Frontiers in oncology	2018	44.88321300237431	51.73450455278101	31	1.6
29559741	Indoleamine 2,3-dioxygenase in endometrial cancer: a targetable mechanism of immune resistance in mismatch repair-deficient and intact endometrial carcinomas.	Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc	2018	-2.731532361958083	38.14676763341431	37	1.62
29556567	Detection of high PD-L1 expression in oral cancers by a novel monoclonal antibody L1Mab-4.	Biochemistry and biophysics reports	2018	-10.454238241108548	-11.469261339033237	4	0.23
29556566	The Pekin duck programmed death ligand-2: cDNA cloning, genomic structure, molecular characterization and expression analysis.	Biochemistry and biophysics reports	2018	-54.85828392774792	-25.098352147958565	1	0.04
29556232	Modulation of Gut Microbiota: A Novel Paradigm of Enhancing the Efficacy of Programmed Death-1 and Programmed Death Ligand-1 Blockade Therapy.	Frontiers in immunology	2018	-23.00176799403909	0.8119645954366432	43	1.76
29554041	Programmed death 1/programmed cell death-ligand 1 pathway participates in gastric surgery-induced imbalance of T-helper 17/regulatory T cells in mice.	The journal of trauma and acute care surgery	2018	-50.21304791016819	33.622737328898104	8	0.36
29553950	The emerging role of immunotherapy in advanced urothelial cancers.	Current opinion in oncology	2018	69.22635124478076	20.422743760554557	7	0.27
29552320	Effectiveness of anti-PD-1/PD-L1 antibodies in urothelial carcinoma patients with different PD-L1 expression levels: a meta-analysis.	Oncotarget	2018	62.51302789252565	15.473610091642843	13	0.46
29549910	Association of preoperative serum CRP with PD-L1 expression in 508 patients with non-small cell lung cancer: A comprehensive analysis of systemic inflammatory markers.	Surgical oncology	2018	14.190858288096583	-28.25366087348233	31	1.39
29545941	Efficacy of PD-1/PD-L1 inhibitors against pretreated advanced cancer: a systematic review and meta-analysis.	Oncotarget	2018	55.404662513544245	-15.740385734074062	1	0.03
29544515	Next generation of immune checkpoint therapy in cancer: new developments and challenges.	Journal of hematology & oncology	2018	23.05034343707926	10.365722320072042	461	20.71
29542354	Upper gastrointestinal malignancies in 2017: current perspectives and future approaches.	Future oncology (London, England)	2018	44.57877549051962	16.416919350293455	3	0.1
29540832	miR-21 depletion in macrophages promotes tumoricidal polarization and enhances PD-1 immunotherapy.	Oncogene	2018	-30.079506256254227	-4.110482870876689	79	3.69
29540345	Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis.	BMJ (Clinical research ed.)	2018	61.94799236604407	-15.048212893793822	341	15.45
29540084	Avelumab for the treatment of urothelial cancer.	Expert review of anticancer therapy	2018	68.41884895842793	18.67959561747061	6	0.29
29535912	Targeting DNA damage repair in small cell lung cancer and the biomarker landscape.	Translational lung cancer research	2018	42.36173563684455	-40.83538955493225	82	3.26
29535740	Targeting LAG-3 and PD-1 to Enhance T Cell Activation by Antigen-Presenting Cells.	Frontiers in immunology	2018	-26.3426226817383	-8.352849496429515	107	4.28
29532035	Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles.	Science advances	2018	-27.49103965546558	51.06246081409949	349	15.73
29531164	Dendritic Cell PD-L1 Limits Autoimmunity and Follicular T Cell Differentiation and Function.	Journal of immunology (Baltimore, Md. : 1950)	2018	-57.85047299197743	-5.3107359325338805	76	3.11
29530936	B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity.	Clinical cancer research : an official journal of the American Association for Cancer Research	2018	1.785906256521578	-17.60489926257727	91	3.47
29530070	Correction to: PD-1 axis expression in musculoskeletal tumors and antitumor effect of nivolumab in osteosarcoma model of humanized mouse.	Journal of hematology & oncology	2018	-23.161959693651404	-5.775691618856386	3	0.13
29526974	Adjuvant immunotherapy for cancer: both dendritic cell-priming and check-point inhibitor blockade are required for immunotherapy.	Proceedings of the Japan Academy. Series B, Physical and biological sciences	2018	-29.27937715602283	-13.579542136387202	23	0.96
29524567	PD-1 deficiency augments bone marrow failure in a minor-histocompatibility antigen mismatch lymphocyte infusion model.	Experimental hematology	2018	-36.44135868212156	10.780861165004392	3	0.12
29522785	Vitamin D3 inhibits the proliferation of T helper cells, downregulate CD4+ T cell cytokines and upregulate inhibitory markers.	Human immunology	2018	-70.14346283259093	6.273143524750749	33	2.03
29521140	Current and emerging treatment options for a patient with a second relapse of Hodgkin's lymphoma.	Expert review of hematology	2018	44.43781753622839	-48.569677631086535	5	0.19
29520442	CD274, LAG3, and IDO1 expressions in tumor-infiltrating immune cells as prognostic biomarker for patients with MSI-high colon cancer.	Journal of cancer research and clinical oncology	2018	9.38236057533954	41.42191291995013	52	2.07
29518341	Impaired Tumor-Infiltrating T Cells in Patients with Chronic Obstructive Pulmonary Disease Impact Lung Cancer Response to PD-1 Blockade.	American journal of respiratory and critical care medicine	2018	0.9161013477902092	-22.897586447927047	54	2.42
29514845	PD-1 Blockade and CD27 Stimulation Activate Distinct Transcriptional Programs That Synergize for CD8+ T-Cell-Driven Antitumor Immunity.	Clinical cancer research : an official journal of the American Association for Cancer Research	2018	-28.06454787222254	-18.58747809813889	70	2.58
29514839	Identification and Validation of Stromal Immunotype Predict Survival and Benefit from Adjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer.	Clinical cancer research : an official journal of the American Association for Cancer Research	2018	5.702610976906219	58.37169521249639	107	4.05
29510196	PD-L1 confers glioblastoma multiforme malignancy via Ras binding and Ras/Erk/EMT activation.	Biochimica et biophysica acta. Molecular basis of disease	2018	-27.82781264644696	51.07479003568862	101	4.74
29509940	Multiplexed immunofluorescence reveals potential PD-1/PD-L1 pathway vulnerabilities in craniopharyngioma.	Neuro-oncology	2018	20.21782805863389	53.03928711107088	48	2.38
29506535	Nitrosative damage during retrovirus infection-induced neuropathic pain.	Journal of neuroinflammation	2018	-73.97307106625337	-3.4628780576165745	6	0.34
29504948	PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy.	The Journal of clinical investigation	2018	-36.97527122711176	51.11707351010066	85	3.65
29502426	Immuno-PET Imaging of 89Zr Labeled Anti-PD-L1 Domain Antibody.	Molecular pharmaceutics	2018	6.845759158019693	-56.49566006274747	71	3.44
29499101	Programmed death ligand 1 testing in non-small cell lung carcinoma cytology cell block and aspirate smear preparations.	Cancer cytopathology	2018	14.950540550493455	-38.34676175990059	90	4.51
29496294	Mismatch repair deficiency is associated with MSI phenotype, increased tumor-infiltrating lymphocytes and PD-L1 expression in immune cells in ovarian cancer.	Gynecologic oncology	2018	11.4045216738209	45.91433312587083	45	2.03
29494848	Bacterially activated B-cells drive T cell differentiation towards Tr1 through PD-1/PD-L1 expression.	Molecular immunology	2018	-66.13212170211028	6.880658302770015	12	0.58
29494517	Immune Monitoring of Cancer Patients Prior to and During CTLA-4 or PD-1/PD-L1 Inhibitor Treatment.	Biomedicines	2018	25.21583678201347	4.901282251465761	15	0.6
29492229	Analysis of response rate with ANTI PD1/PD-L1 monoclonal antibodies in advanced solid tumors: a meta-analysis of randomized clinical trials.	Oncotarget	2018	50.0956762385205	-13.815171831861475	63	2.37
29490989	A Genetic Polymorphism in CTLA-4 Is Associated with Overall Survival in Sunitinib-Treated Patients with Clear Cell Metastatic Renal Cell Carcinoma.	Clinical cancer research : an official journal of the American Association for Cancer Research	2018	17.795487577888245	30.43520298274039	7	0.24
29489833	Immune checkpoint inhibitor PD-1 pathway is down-regulated in synovium at various stages of rheumatoid arthritis disease progression.	PloS one	2018	-49.41692464031747	7.0100043032868	73	3.56
29489025	Expression of PD-L1, indoleamine 2,3-dioxygenase and the immune microenvironment in gastric adenocarcinoma.	Histopathology	2018	-11.493961987167127	23.861508420446548	31	1.36
29487705	Mutations in DNA repair genes are associated with increased neo-antigen load and activated T cell infiltration in lung adenocarcinoma.	Oncotarget	2018	20.29952566164804	-17.7030417185321	47	1.51
29487385	Histone deacetylase (HDAC) inhibitor ACY241 enhances anti-tumor activities of antigen-specific central memory cytotoxic T lymphocytes against multiple myeloma and solid tumors.	Leukemia	2018	-11.438511093934622	-32.159570484868865	78	3.41
29486723	Genomics of NSCLC patients both affirm PD-L1 expression and predict their clinical responses to anti-PD-1 immunotherapy.	BMC cancer	2018	17.974092022030984	-30.131096903855823	21	0.77
29484464	PD-L1, B7-H3, and PD-1 expression in immunocompetent vs. immunosuppressed patients with cutaneous squamous cell carcinoma.	Cancer immunology, immunotherapy : CII	2018	-1.6091074431514003	-4.392219387914013	36	1.5
29484440	Importance of immune monitoring approaches and the use of immune checkpoints for the treatment of diffuse intrinsic pontine glioma: From bench to clinic and vice versa (Review).	International journal of oncology	2018	-28.21091242204269	58.43742206016409	6	0.26
29473504	Immunotherapy in Non-Small Cell Lung Cancer: Biological Principles and Future Opportunities.	Current molecular medicine	2017	34.731239488817934	-33.63810221920377	18	0.61
29473471	Malignant mesothelioma clinical trial combines immunotherapy drugs.	Immunotherapy	2018	35.55299887903524	6.158874595377206	4	0.14
29472312	Complete Remission Following Pembrolizumab in a Woman with Mismatch Repair-Deficient Endometrial Cancer and a Germline BRCA1 Mutation.	The oncologist	2018	40.71957849759004	32.25533328519585	7	0.2
29469949	Safety profile of avelumab in patients with advanced solid tumors: A pooled analysis of data from the phase 1 JAVELIN solid tumor and phase 2 JAVELIN Merkel 200 clinical trials.	Cancer	2018	50.901481836104985	-6.562394662120887	69	2.91
29468855	Major clinical research advances in gynecologic cancer in 2017.	Journal of gynecologic oncology	2018	41.801331439643256	34.50099983697576	18	0.87
29468108	Nivolumab in Renal Cell Carcinoma: Current Trends and Future Perspectives.	Journal of kidney cancer and VHL	2018	63.66734160393381	29.31037571561476	14	0.64
29467336	Frameshift events predict anti-PD-1/L1 response in head and neck cancer.	JCI insight	2018	-5.515814531245796	-6.049039669025126	162	6.55
29467301	Oncogenic JAK2V617F causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms.	Science translational medicine	2018	-30.70101452946607	12.52605655747042	144	5.87
29464975	Pembrolizumab and its use in the treatment of recurrent or metastatic head and neck cancer.	Future oncology (London, England)	2018	52.88937410825338	29.770196649109216	4	0.19
29464065	The presence of PD-1 positive tumor infiltrating lymphocytes in triple negative breast cancers is associated with a favorable outcome of disease.	Oncotarget	2018	-8.821202099384307	16.994858104034574	28	1.07
29464051	Human papillomavirus E7 oncoprotein expression by keratinocytes alters the cytotoxic mechanisms used by CD8 T cells.	Oncotarget	2018	-1.3379804805078952	-13.32495519146391	4	0.16
29463725	Tim-3 co-stimulation promotes short-lived effector T cells, restricts memory precursors, and is dispensable for T cell exhaustion.	Proceedings of the National Academy of Sciences of the United States of America	2018	-72.16482637890589	15.082252726243292	97	3.81
29459868	Characteristics of Infection Immunity Regulated by Toxoplasma gondii to Maintain Chronic Infection in the Brain.	Frontiers in immunology	2018	-73.4764790429074	4.379376888562963	30	1.76
29455872	[PD-L1 expression and PD-1/PD-L1 inhibitors in breast cancer].	Bulletin du cancer	2018	-9.15131171718605	16.63665514130607	13	0.64
29453278	Molecular signatures of circulating melanoma cells for monitoring early response to immune checkpoint therapy.	Proceedings of the National Academy of Sciences of the United States of America	2018	6.983416635979026	-39.164975662292974	86	3.5
29450544	HLA Class I Antigen Expression in Conjunctival Melanoma Is Not Associated With PD-L1/PD-1 Status.	Investigative ophthalmology & visual science	2018	-0.189645185013125	1.4653358857171688	10	0.55
29449276	Immune evasion via PD-1/PD-L1 on NK cells and monocyte/macrophages is more prominent in Hodgkin lymphoma than DLBCL.	Blood	2018	-32.27207948519714	25.88449025028466	202	8.68
29448849	Development of small-molecule immune checkpoint inhibitors of PD-1/PD-L1 as a new therapeutic strategy for tumour immunotherapy.	Journal of drug targeting	2019	-39.52855541238939	-37.38361579766666	77	4.4
31723749	Immune Checkpoint Inhibition in Hodgkin Lymphoma.	HemaSphere	2018	36.8074668510954	-6.566492001105579	13	0.52
29446180	Pigs expressing the human inhibitory ligand PD-L1 (CD 274) provide a new source of xenogeneic cells and tissues with low immunogenic properties.	Xenotransplantation	2018	-68.02187188876503	-2.224920503969652	29	1.7
29445891	Immunohistochemical analysis and prognostic significance of PD-L1, PD-1, and CD8+ tumor-infiltrating lymphocytes in Ewing's sarcoma family of tumors (ESFT).	Virchows Archiv : an international journal of pathology	2018	-21.485669163025765	18.15234098550273	41	1.91
29444087	Safety and efficacy of anti-PD-L1 therapy in the woodchuck model of HBV infection.	PloS one	2018	-72.7001692921816	20.106611765423253	30	1.32
29440366	Salmonella enterica Serovar Typhimurium Increases Functional PD-L1 Synergistically with Gamma Interferon in Intestinal Epithelial Cells via Salmonella Pathogenicity Island 2.	Infection and immunity	2018	-62.9558228226411	4.5196427623129285	8	0.35
29440293	A Correlative Analysis of PD-L1, PD-1, PD-L2, EGFR, HER2, and HER3 Expression in Oropharyngeal Squamous Cell Carcinoma.	Molecular cancer therapeutics	2018	-5.422065221429389	-9.719977659209	24	1.13
29439008	PD-1 and PD-L1 expression in thymic epithelial tumours and non-neoplastic thymus.	Journal of clinical pathology	2018	-4.900728106476305	-36.97431365629759	11	0.51
29438695	Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1.	Cancer cell	2018	-35.13243142836596	-31.80235374001992	309	13.54
29438689	Glycans Pave the Way for Immunotherapy in Triple-Negative Breast Cancer.	Cancer cell	2018	-34.78986958961416	-31.973401649832358	22	1.01
29437869	Integrative analysis of exogenous, endogenous, tumour and immune factors for precision medicine.	Gut	2018	20.440777552513897	39.75840254535083	127	5.62
29435295	Identification of candidate responders for anti-PD-L1/PD-1 immunotherapy, Rova-T therapy, or EZH2 inhibitory therapy in small-cell lung cancer.	Molecular and clinical oncology	2018	41.927338312420346	-41.366555671342624	22	0.85
29435074	Over-activated PD-1/PD-L1 axis facilitates the chemoresistance of diffuse large B-cell lymphoma cells to the CHOP regimen.	Oncology letters	2018	-32.18816259773285	27.472287036026263	13	0.66
29434933	PD-L1 expression is associated with p16INK4A expression in non-oropharyngeal head and neck squamous cell carcinoma.	Oncology letters	2018	-5.549479557033728	-8.191708037870344	9	0.4
29434915	Immunohistochemical CD73 expression status in gastrointestinal neuroendocrine neoplasms: A retrospective study of 136 patients.	Oncology letters	2018	1.357545381873837	12.61228395368796	18	0.79
29432222	Immunotherapy for recurrent/metastatic head and neck cancer.	Current opinion in otolaryngology & head and neck surgery	2018	52.69694327551522	30.744993043424497	11	0.46
29431467	Correlation Between Programmed Death Receptor-1 Expression in Tumor-Infiltrating Lymphocytes and Programmed Death Ligand-1 Expression in Non-Small Cell Lung Carcinoma.	Archives of pathology & laboratory medicine	2018	7.01058983477736	-23.323955310168927	3	0.13
29429897	Role of immunotherapy in bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer.	Urologic oncology	2018	71.58859727949866	22.696289064558297	16	0.88
29428637	Re: Prognostic Value of PD-1 and PD-L1 Expression in Patients with High Grade Upper Tract Urothelial Carcinoma: L. M. Krabbe, B. Heitplatz, S. Preuss, R. C. Hutchinson, S. L. Woldu, N. Singla, M. Boegemann, C. G. Wood, J. A. Karam, A. Z. Weizer, J. D. Raman, M. Remzi, N. Rioux-Leclercq, A. Haitel, L. M. Rapoport, P. V. Glybochko, M. Roscigno, C. Bolenz, K. Bensalah, A. I. Sagalowsky, S. F. Shariat, Y. Lotan, E. Xylinas and V. Margulis J Urol 2017;198:1253-1262.	The Journal of urology	2018	14.334997039354343	56.46643392955191	2	0.08
29428449	PD-1 /PD-L1 checkpoint in hematological malignancies.	Leukemia research	2018	-44.46165953154284	-15.221478994369138	30	1.21
29427150	Programmed death ligand 1 expression and tumor infiltrating lymphocytes in neurofibromatosis type 1 and 2 associated tumors.	Journal of neuro-oncology	2018	-24.03143816697037	16.396446015992336	42	2.09
29426340	PD-L1 diagnostic tests: a systematic literature review of scoring algorithms and test-validation metrics.	Diagnostic pathology	2018	16.005042623124353	-42.54232119086607	135	6.06
29424936	Checkpoint inhibitors in triple-negative breast cancer (TNBC): Where to go from here.	Cancer	2018	38.425292766213865	8.634862800766191	117	4.92
29423118	The efficacy and safety of anti-PD-1/PD-L1 antibody therapy versus docetaxel for pretreated advanced NSCLC: a meta-analysis.	Oncotarget	2018	49.54510793892601	-20.97425075268233	11	0.38
29416316	Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma.	Drug design, development and therapy	2018	66.41920197950189	18.31293196727289	22	1.02
29416054	Evaluation of PD-L1 expression on vortex-isolated circulating tumor cells in metastatic lung cancer.	Scientific reports	2018	10.024647931645251	-38.15277918658784	70	3.18
29415126	Central Nervous System Germinomas Express Programmed Death Ligand 1.	Journal of neuropathology and experimental neurology	2018	-24.391249173532184	32.408645876410006	9	0.54
29413757	Dendritic Cells Pulsed with Exosomes in Combination with PD-1 Antibody Increase the Efficacy of Sorafenib in Hepatocellular Carcinoma Model.	Translational oncology	2018	28.677545243849902	52.13056706378144	53	2.58
29409495	PD-1 axis expression in musculoskeletal tumors and antitumor effect of nivolumab in osteosarcoma model of humanized mouse.	Journal of hematology & oncology	2018	-23.240029140281997	-5.829741911896726	86	3.89
29407369	Immune checkpoint inhibitors for metastatic bladder cancer.	Cancer treatment reviews	2018	69.14850930042817	20.66393783328195	62	2.56
29403308	The relationship between the PD-1/PD-L1 pathway and DNA mismatch repair in cervical cancer and its clinical significance.	Cancer management and research	2018	12.959559741025933	47.204222649025965	30	1.26
29400020	Programmed death-1 (PD-1) expression in cervical intraepithelial neoplasia and its relationship with recurrence after conization.	Journal of gynecologic oncology	2018	-0.5998435984262023	-11.410312106796743	9	0.38
29399410	Poly(I:C) primes primary human glioblastoma cells for an immune response invigorated by PD-L1 blockade.	Oncoimmunology	2018	-29.676639961823625	56.54329229357353	32	1.16
29399405	Genomic landscape of advanced basal cell carcinoma: Implications for precision treatment with targeted and immune therapies.	Oncoimmunology	2018	26.232135531732723	-14.41004215095698	37	1.44
29399402	Prognostic relevance of tumor-infiltrating lymphocytes and immune checkpoints in pediatric medulloblastoma.	Oncoimmunology	2018	-19.388457912251997	50.398866736220185	61	2.16
29399400	Harnessing innate lung anti-cancer effector functions with a novel bacterial-derived immunotherapy.	Oncoimmunology	2018	18.427807397270065	40.68683788872796	11	0.47
29399399	Bromodomain inhibition exerts its therapeutic potential in malignant pleural mesothelioma by promoting immunogenic cell death and changing the tumor immune-environment.	Oncoimmunology	2018	-29.20909676424285	9.951229994098494	35	1.17
29399393	PD-1 blockade reverses adaptive immune resistance induced by high-dose hypofractionated but not low-dose daily fractionated radiation.	Oncoimmunology	2018	28.802240523998588	23.188899294263845	74	2.71
29399389	PD-L1 and PD-1 and characterization of tumor-infiltrating lymphocytes in high grade sarcomas of soft tissue - prognostic implications and rationale for immunotherapy.	Oncoimmunology	2018	-19.99957760313926	19.754627998489017	64	2.33
29399387	Analysis of PD1, PDL1, PDL2 expression and T cells infiltration in 1014 gastric cancer patients.	Oncoimmunology	2018	-8.807454893430506	7.734013206446579	99	3.84
29396294	PD-1 (PDCD1) Promoter Methylation Is a Prognostic Factor in Patients With Diffuse Lower-Grade Gliomas Harboring Isocitrate Dehydrogenase (IDH) Mutations.	EBioMedicine	2018	-18.94177265215092	53.38063673103503	49	1.92
29395863	Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study.	The Lancet. Oncology	2018	54.17991822224336	2.175682668471175	228	10.36
29395669	Significant association of increased PD-L1 and PD-1 expression with nodal metastasis and a poor prognosis in oral squamous cell carcinoma.	International journal of oral and maxillofacial surgery	2018	-7.836972404131598	-11.278713075841711	55	2.73
29395567	[Immune checkpoint inhibitors (antibodies to PD1 and PD-L1), a new therapeutic weapon against non-small cell bronchial carcinoma].	Revue des maladies respiratoires	2018	40.30405892257621	-31.49228230546988	4	0.15
29394125	Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma.	Journal of clinical oncology : official journal of the American Society of Clinical Oncology	2018	-28.42627270408081	24.887075904821963	231	8.99
29393983	A novel role for coinhibitory receptors/checkpoint proteins in the immunopathology of sepsis.	Journal of leukocyte biology	2018	-58.404660036465714	37.06258236912701	25	1.14
29387061	Combining Adoptive Cell Therapy with Cytomegalovirus-Based Vaccine Is Protective against Solid Skin Tumors.	Frontiers in immunology	2017	-36.76422247966871	47.611322265944	22	0.93
29385894	Role of immune-checkpoint inhibitors in lung cancer.	Therapeutic advances in respiratory disease	2018	38.96162281017613	-31.689478521870743	80	3.74
29385739	Precision Immuno-Oncology: Prospects of Individualized Immunotherapy for Pancreatic Cancer.	Cancers	2018	-20.390998965578383	-12.553180038131291	38	1.56
29383103	YAP regulates PD-L1 expression in human NSCLC cells.	Oncotarget	2017	2.481287781576741	-34.491714243683134	79	2.77
29383039	Diverse cutaneous adverse eruptions caused by anti-programmed cell death-1 (PD-1) and anti-programmed cell death ligand-1 (PD-L1) immunotherapies: clinical features and management.	Therapeutic advances in medical oncology	2018	70.95676703141106	-24.32355344557867	20	1.14
29383038	Evaluation of PD-L1/PD-1 on circulating tumor cells in patients with advanced non-small cell lung cancer.	Therapeutic advances in medical oncology	2018	10.061658289736297	-38.04570195393043	55	2.43
29380929	Checkpoint molecule expression by B and T cell lymphomas in dogs.	Veterinary and comparative oncology	2018	-16.20597003294499	-12.660453261120148	22	1.32
29380399	Immunohistochemical assessment of the diagnostic utility of PD-L1: a preliminary analysis of anti-PD-L1 antibody (SP142) for lymphoproliferative diseases with tumour and non-malignant Hodgkin-Reed-Sternberg (HRS)-like cells.	Histopathology	2018	-32.67622615850564	24.18998277218645	43	2.47
29378725	Variability of PD-L1 expression in mastocytosis.	Blood advances	2018	-30.11445890432258	14.868206855114448	6	0.32
29378617	PD-L1 in pancreatic ductal adenocarcinoma: a retrospective analysis of 373 Chinese patients using an in vitro diagnostic assay.	Diagnostic pathology	2018	-4.3297074697554825	4.238518598123803	24	0.99
33177023	[Soluble PD-1 over-expression enhances the anti-tumor effect of senescence tumor cell vaccine against breast cancer cell growth in tumor-bearing mice].	Nan fang yi ke da xue xue bao = Journal of Southern Medical University	2018	-26.405014737153117	-10.30731840028646	0	0.0
29377881	PD-L1 checkpoint inhibition and anti-CTLA-4 whole tumor cell vaccination counter adaptive immune resistance: A mouse neuroblastoma model that mimics human disease.	PLoS medicine	2018	-26.93626347771379	13.90615034548589	39	1.56
29374699	Prognostic Significance of NSCLC and Response to EGFR-TKIs of EGFR-Mutated NSCLC Based on PD-L1 Expression.	Anticancer research	2018	9.199443332822996	-32.0623324857176	8	0.27
29373180	Immunotherapy, an evolving approach for the management of triple negative breast cancer: Converting non-responders to responders.	Critical reviews in oncology/hematology	2018	38.34172976105869	8.553447537792538	34	1.47
29372535	PD-L1 and IDO1 Are Expressed in Poorly Differentiated Thyroid Carcinoma.	Endocrine pathology	2018	-8.636750218346998	-20.320175332469265	40	1.84
29371688	PD-L1 reverses depigmentation in Pmel-1 vitiligo mice by increasing the abundance of Tregs in the skin.	Scientific reports	2018	-60.76663333977528	-18.367715886659106	35	1.86
29370105	Tackling Cancer Resistance by Immunotherapy: Updated Clinical Impact and Safety of PD-1/PD-L1 Inhibitors.	Cancers	2018	30.41153039882006	-3.049490612721588	43	1.81
29368638	Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond.	Journal for immunotherapy of cancer	2018	22.080506055979583	-5.13640622928021	100	4.06
29366663	Soluble PD-L1 with PD-1-binding capacity exists in the plasma of patients with non-small cell lung cancer.	Immunology letters	2018	-45.473582411329446	19.14334750115175	41	1.77
29365144	Immune-Active Microenvironment in Small Cell Carcinoma of the Ovary, Hypercalcemic Type: Rationale for Immune Checkpoint Blockade.	Journal of the National Cancer Institute	2018	1.5593394136260934	16.166502682814098	96	3.79
29362727	Two Cases of Atezolizumab-Induced Hypophysitis.	Journal of the Endocrine Society	2018	84.35980498597166	-18.29924616231562	34	1.45
29362132	HLA class I antigen processing machinery (APM) component expression and PD-1:PD-L1 pathway activation in HIV-infected head and neck cancers.	Oral oncology	2018	-0.9806484427044372	1.4355903071974483	7	0.3
29360924	Neopepsee: accurate genome-level prediction of neoantigens by harnessing sequence and amino acid immunogenicity information.	Annals of oncology : official journal of the European Society for Medical Oncology	2018	-1.5544940932550897	65.32725235930539	87	3.18
29360728	Mechanisms of Resistance to PD-1 and PD-L1 Blockade.	Cancer journal (Sudbury, Mass.)	2018	-35.70498105552665	-20.78251752082892	252	10.64
29360723	PD-1/PD-L1 Axis in Lung Cancer.	Cancer journal (Sudbury, Mass.)	2018	25.55763225377982	-34.24514778442056	51	2.19
29360721	Preclinical Data Supporting Antitumor Activity of PD-1 Blockade.	Cancer journal (Sudbury, Mass.)	2018	-38.80879436842076	-25.608886307926465	5	0.19
29358573	Unwrapping the genomic characteristics of urothelial bladder cancer and successes with immune checkpoint blockade therapy.	Oncogenesis	2018	70.3863776729167	22.38528155899557	53	2.12
29357948	Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations.	Journal for immunotherapy of cancer	2018	31.674060790722145	-3.2259170530615044	764	34.26
29357563	Re: Prognostic Value of Programmed-Death-1 Receptor (PD-1) and its Ligand 1 (PD-L1) in Testicular Germ Cell Tumors.	The Journal of urology	2018	-25.78472974867581	34.786343994746225	0	0.0
29357011	Immunogenomics: A Negative Prostate Cancer Outcome Associated with TcR-γ/δ Recombinations.	Cancer microenvironment : official journal of the International Cancer Microenvironment Society	2018	-4.358110753075954	43.052732594771776	18	0.86
29356308	High number of PD-1 positive intratumoural lymphocytes predicts survival benefit of cytokine-induced killer cells for hepatocellular carcinoma patients.	Liver international : official journal of the International Association for the Study of the Liver	2018	-15.438053779606998	44.9686819121436	29	1.27
29355614	Head and neck squamous cell carcinoma: Genomics and emerging biomarkers for immunomodulatory cancer treatments.	Seminars in cancer biology	2018	-9.00530783427625	35.26760925178669	224	11.18
29352857	Combining chemotherapy with PD-1 blockade in NSCLC.	Pharmacology & therapeutics	2018	33.3201606552528	-29.47241577384593	75	2.8
29351920	Exceptional Response to Pembrolizumab in a Metastatic, Chemotherapy/Radiation-Resistant Ovarian Cancer Patient Harboring a PD-L1-Genetic Rearrangement.	Clinical cancer research : an official journal of the American Association for Cancer Research	2018	50.59609063872561	4.957781334082255	34	1.31
29350470	Specific expression of PD-L1 in RELA-fusion supratentorial ependymoma: Implications for PD-1-targeted therapy.	Pediatric blood & cancer	2018	-26.161720903842276	19.835915408363338	35	1.5
29349927	Treatment-related toxicities of immune checkpoint inhibitors in advanced cancers: A meta-analysis.	Asia-Pacific journal of clinical oncology	2018	65.05735755158801	-16.11075440591628	31	1.33
29349763	Immune Checkpoint Blockade for Breast Cancer.	Cancer treatment and research	2018	-11.885956580781942	-26.43049564925289	52	2.11
29349518	Checkpoint Inhibitors, Palliative Care, or Hospice.	Current oncology reports	2018	57.37523392205357	-17.784467526180432	8	0.42
29348848	PD-L1 expression in tumor tissue and peripheral blood of patients with oral squamous cell carcinoma.	Oncotarget	2017	-7.821194463126996	-12.220042075679054	30	1.18
29346540	Blood and lymphatic vessels contribute to the impact of the immune microenvironment on clinical outcome in non-small-cell lung cancer.	European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery	2018	9.508965385216037	-17.3472471887342	11	0.47
29345842	Programmed death-ligand 1 is a promising blood marker for predicting tumor progression and prognosis in patients with gastric cancer.	Cancer science	2018	-8.853055200224288	4.548294898348687	25	1.14
29345058	Frontline Science: Anti-PD-L1 protects against infection with common bacterial pathogens after burn injury.	Journal of leukocyte biology	2018	-61.56210297175807	33.110155452745744	40	2.32
29344157	Expression and clinical significance of programmed death-1 on lymphocytes and programmed death ligand-1 on monocytes in the peripheral blood of patients with cervical cancer.	Oncology letters	2017	0.3098332225695455	-12.081428773375652	18	0.64
29340095	Tumoral immune-infiltrate (IF), PD-L1 expression and role of CD8/TIA-1 lymphocytes in localized osteosarcoma patients treated within protocol ISG-OS1.	Oncotarget	2017	-17.06641745201095	20.22868659165711	39	1.61
29339440	Repurposing Tin Mesoporphyrin as an Immune Checkpoint Inhibitor Shows Therapeutic Efficacy in Preclinical Models of Cancer.	Clinical cancer research : an official journal of the American Association for Cancer Research	2018	25.232975115809538	28.939210152686275	37	1.47
29338562	Targeted microbubbles with ultrasound irradiation and PD-1 inhibitor to increase antitumor activity in B-cell lymphoma.	Nanomedicine (London, England)	2018	-26.85569264447892	-52.6814792940159	3	0.11
29337640	Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing.	Journal of clinical oncology : official journal of the American Society of Clinical Oncology	2018	25.23121781935109	-19.224310521146435	911	37.98
29337305	Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression.	The Journal of clinical investigation	2018	-33.5184746223718	-10.3709410215469	339	13.14
29337304	The host protecting the tumor from the host - targeting PD‑L1 expressed by host cells.	The Journal of clinical investigation	2018	-35.875913118565634	-10.860138641994162	13	0.52
29336323	Nivolumab for recurrent cutaneous squamous cell carcinoma: three cases.	European journal of dermatology : EJD	2018	56.276359475510446	6.438059653907215	33	1.63
29335088	[Role of programmed death-1 in viral infectious diseases].	Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics	2018	-76.46354291922633	11.437586546123091	1	0.04
29333980	Percentages of PD-1+CD4+T cells and PD-L1+DCs are increased and sPD-1 level is elevated in patients with immune thrombocytopenia.	Human vaccines & immunotherapeutics	2018	-51.54703398039113	4.08875856986404	15	0.81
29330750	Immunologic and gene expression profiles of spontaneous canine oligodendrogliomas.	Journal of neuro-oncology	2018	-26.659511670611334	58.41201456805703	19	1.13
29330579	[Initially undetected de novo psoriasis triggered by nivolumab for metastatic base of the tongue carcinoma].	Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete	2018	73.57992328372761	-28.395934787536845	3	0.14
29330552	Dosimetry Prediction for Clinical Translation of 64Cu-Pembrolizumab ImmunoPET Targeting Human PD-1 Expression.	Scientific reports	2018	7.852479170514226	-57.78482710144441	34	1.71
29329556	Cancer immunotherapy beyond immune checkpoint inhibitors.	Journal of hematology & oncology	2018	21.244315817694662	2.5780002014387198	131	5.77
29328389	miR-375 inhibits IFN-γ-induced programmed death 1 ligand 1 surface expression in head and neck squamous cell carcinoma cells by blocking JAK2/STAT1 signaling.	Oncology reports	2018	-12.330336350022955	-10.740542748287128	26	1.22
29327244	Antibody-based delivery of tumor necrosis factor (L19-TNFα) and interleukin-2 (L19-IL2) to tumor-associated blood vessels has potent immunological and anticancer activity in the syngeneic J558L BALB/c myeloma model.	Journal of cancer research and clinical oncology	2018	-26.77301219778909	-1.5387544642731306	16	0.69
29326088	Age effects of distinct immune checkpoint blockade treatments in a mouse melanoma model.	Experimental gerontology	2018	33.519576244783615	5.631103600389025	20	0.74
29320474	High response rate to PD-1 blockade in desmoplastic melanomas.	Nature	2018	5.486078683672155	0.9220205672589712	202	7.74
29318591	Immune checkpoint molecules in acute myeloid leukaemia: managing the double-edged sword.	British journal of haematology	2018	18.34408824356977	17.311401288357356	37	1.56
29318140	Dynamics of Neutrophils-to-Lymphocyte Ratio Predict Outcomes of PD-1/PD-L1 Blockade.	BioMed research international	2017	27.348244686550544	-41.511974236826894	41	1.46
29317703	Modeling tumor immunity of mouse glioblastoma by exhausted CD8+ T cells.	Scientific reports	2018	-45.841934740894565	11.69940040904932	21	0.78
29313208	Perspective on immune oncology with liquid biopsy, peripheral blood mononuclear cells, and microbiome with non-invasive biomarkers in cancer patients.	Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico	2018	23.6309932058612	-35.44154601251266	25	1.07
29312289	Immune Checkpoints in Leprosy: Immunotherapy As a Feasible Approach to Control Disease Progression.	Frontiers in immunology	2017	-70.74129857253706	32.93267254745412	4	0.19
29311707	Associations of Tumor PD-1 Ligands, Immunohistochemical Studies, and Textural Features in 18F-FDG PET in Squamous Cell Carcinoma of the Head and Neck.	Scientific reports	2018	13.937224746477554	-58.47139715655835	40	2.13
29311234	Mycoplasma bovis-Induced Inhibition of Bovine Peripheral Blood Mononuclear Cell Proliferation Is Ameliorated after Blocking the Immune-Inhibitory Programmed Death 1 Receptor.	Infection and immunity	2018	-80.35056309608046	2.412816043040785	10	0.87
29309297	Comprehensive Assessment of PD-L1 Staining Heterogeneity in Pulmonary Adenocarcinomas Using Tissue Microarrays: Impact of the Architecture Pattern and the Number of Cores.	The American journal of surgical pathology	2018	13.964857636621378	-36.2253525634485	26	1.01
29308323	Two immune-enhanced molecular subtypes differ in inflammation, checkpoint signaling and outcome of advanced head and neck squamous cell carcinoma.	Oncoimmunology	2018	-8.583190623330944	34.797812901711325	31	1.1
29308318	The inhibitory checkpoint, PD-L2, is a target for effector T cells: Novel possibilities for immune therapy.	Oncoimmunology	2018	-39.67808008162116	-4.462992336054296	27	0.97
29308317	High numbers of PDCD1 (PD-1)-positive T cells and B2M mutations in microsatellite-unstable colorectal cancer.	Oncoimmunology	2018	10.403662314929452	41.19712843225296	43	1.43
29308309	The T cell repertoire in tumors overlaps with pulmonary inflammatory lesions in patients treated with checkpoint inhibitors.	Oncoimmunology	2018	75.50678526251998	-14.114398980441926	51	1.83
29308306	Analysis of the immune infiltrate in undifferentiated pleomorphic sarcoma of the extremity and trunk in response to radiotherapy: Rationale for combination neoadjuvant immune checkpoint inhibition and radiotherapy.	Oncoimmunology	2018	9.189698531426252	16.14059314103519	38	1.38
29301960	Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma.	Science (New York, N.Y.)	2018	18.24636416752617	32.01634376079683	720	27.75
29299404	Evaluation of rare but severe immune related adverse effects in PD-1 and PD-L1 inhibitors in non-small cell lung cancer: a meta-analysis.	Translational lung cancer research	2017	64.98589481703222	-11.676440881667611	85	3.14
29299180	Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade.	Oncotarget	2017	-37.0921663878394	-18.73202985371942	90	3.23
29298869	Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade.	Science translational medicine	2018	-35.915997263611686	53.41176204244026	250	11.13
29296917	Checkpoint blockade in Hodgkin and non-Hodgkin lymphoma.	Blood advances	2017	-7.528428372249671	-26.936725228319336	82	2.74
29296784	High proportions of PD-1+ and PD-L1+ leukocytes in classical Hodgkin lymphoma microenvironment are associated with inferior outcome.	Blood advances	2017	-30.142683565911927	22.98450263833552	32	1.3
29296542	Bevacizumab-mediated tumor vasculature remodelling improves tumor infiltration and antitumor efficacy of GD2-CAR T cells in a human neuroblastoma preclinical model.	Oncoimmunology	2017	-45.71371177298499	6.717861431163327	66	2.42
29296536	Crk adaptor protein promotes PD-L1 expression, EMT and immune evasion in a murine model of triple-negative breast cancer.	Oncoimmunology	2017	-25.342517549121904	-22.919497964666576	31	1.18
29296533	Development of thyroid dysfunction is associated with clinical response to PD-1 blockade treatment in patients with advanced non-small cell lung cancer.	Oncoimmunology	2017	79.66923896584221	-19.42119037060128	76	2.76
29296516	PD-L1 inhibitors in the pipeline: Promise and progress.	Oncoimmunology	2017	44.156135854964624	-34.689227272933344	29	0.99
29296194	Changes in PD-L1 expression according to tumor infiltrating lymphocytes of acquired EGFR-TKI resistant EGFR-mutant non-small-cell lung cancer.	Oncotarget	2017	7.356902588637416	-33.37369590905981	15	0.49
29294043	Clinical response to PD-1 blockade correlates with a sub-fraction of peripheral central memory CD4+ T cells in patients with malignant melanoma.	International immunology	2018	12.50162213206104	-3.975670135679443	63	2.25
29291717	Heterogeneity of PD-L1 expression in primary tumors and paired lymph node metastases of triple negative breast cancer.	BMC cancer	2018	-8.466923672351554	18.344385957902603	74	3.0
31886407	Immunotherapy and next-generation sequencing guided therapy for precision oncology: What have we learnt and what does the future hold?	Expert review of precision medicine and drug development	2018	16.390576966219292	4.131537881794748	6	0.23
31119034	Evolving Management Strategies for Metastatic Esophageal and Gastroesophageal Junction Adenocarcinoma.	Oncology & hematology review	2018	48.27032023987403	16.089058412017888	2	0.12
30973135	[Combinations of chemotherapy or radiotherapy with checkpoint inhibitors].	Biologie aujourd'hui	2018	28.801684588245124	-0.3113807061061635	1	0.05
30973134	[Anti-cancer vaccines: What future in anti-cancer immunotherapy strategies?].	Biologie aujourd'hui	2018	23.13495399997486	-56.01944194992652	0	0.0
30840388	[Medical treatment of metastatic kidney cancer: targeting the tumor micro-environment].	La Revue du praticien	2018	62.19451177384127	29.65961893666469	0	0.0
29288043	Tumor-associated macrophages and the tumor immune microenvironment of primary and recurrent epithelial ovarian cancer.	Human pathology	2018	-0.1368131324434837	29.423933912550545	33	1.48
29287242	Checkpoint inhibitors in breast cancer - Current status.	Cancer treatment reviews	2018	37.197490940369306	8.00936952672119	89	3.56
29285361	Response to nivolumab in metastatic collecting duct carcinoma expressing PD-L1: A case report.	Molecular and clinical oncology	2017	54.97125934086744	-29.294208147522944	22	0.91
29283446	Potential cardiac risk of immune-checkpoint blockade as anticancer treatment: What we know, what we do not know, and what we can do to prevent adverse effects.	Medicinal research reviews	2018	83.50490936017073	4.366035257832874	21	0.75
29279705	Durable Near-Complete Response to Anti-PD-1 Checkpoint Immunotherapy in a Refractory Malignant Solitary Fibrous Tumor of the Pleura.	Case reports in oncology	2017	57.18794238632642	-27.575429179882217	6	0.29
29279690	Immune Checkpoint Inhibitor-Associated Type 1 Diabetes Mellitus: Case Series, Review of the Literature, and Optimal Management.	Case reports in oncology	2017	89.39442534969545	-15.328443002593454	43	1.72
29277762	Highly Activated PD-1/PD-L1 Pathway in Gastric Cancer with PD-L1 Expression.	Anticancer research	2018	-10.000033742121616	4.706120396246909	27	1.26
29275461	Tumor Immuno-Environment in Cancer Progression and Therapy.	Advances in experimental medicine and biology	2017	16.36526611816236	11.945654006313868	23	0.68
29274107	Tumor-associated CD204+ M2 macrophages are unfavorable prognostic indicators in uterine cervical adenocarcinoma.	Cancer science	2018	-3.254082821669108	34.92788387877046	47	2.24
29273790	TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma.	Nature communications	2017	-30.19445113139386	-10.633697594463722	233	8.17
29271789	Expression of PD-L1 on Immune Cells Shows Better Prognosis in Laryngeal, Oropharygeal, and Hypopharyngeal Cancer.	Applied immunohistochemistry & molecular morphology : AIMM	2018	-3.8032282130587687	-8.813668731460211	31	1.5
29269008	Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.	Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer	2018	9.28598890184172	-19.98284535243939	96	3.8
29267866	The Effect of Topoisomerase I Inhibitors on the Efficacy of T-Cell-Based Cancer Immunotherapy.	Journal of the National Cancer Institute	2018	-22.49192831254119	-27.652483020256167	50	1.97
29263905	Seeing is believing: anti-PD-1/PD-L1 monoclonal antibodies in action for checkpoint blockade tumor immunotherapy.	Signal transduction and targeted therapy	2016	-45.01073520571333	-34.74531496199419	43	1.47
29263903	A novel cancer vaccine with the ability to simultaneously produce anti-PD-1 antibody and GM-CSF in cancer cells and enhance Th1-biased antitumor immunity.	Signal transduction and targeted therapy	2016	-25.83094631163513	-12.941158649192491	29	0.97
29260623	PD-1/PD-L1 in disease.	Immunotherapy	2018	-47.52222036136106	-14.146501230602835	72	3.42
29258079	Immuno-Oncology in Hepatocellular Carcinoma: 2017 Update.	Oncology	2017	29.72883707881357	48.79055162846748	74	2.87
29256113	Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy.	American journal of clinical dermatology	2018	73.9369401687923	-24.508146980991185	336	17.66
29255938	Immunotherapy in triple-negative breast cancer.	Medical oncology (Northwood, London, England)	2017	38.04536896626036	9.06325348098985	68	2.66
29255458	PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?	Frontiers in immunology	2017	-36.06522419605395	-18.7912914920476	182	7.07
29254498	Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials.	Journal for immunotherapy of cancer	2017	36.14500635727728	13.155871061361468	95	3.6
29254497	Retrospective review of safety and efficacy of programmed cell death-1 inhibitors in refractory high grade gliomas.	Journal for immunotherapy of cancer	2017	52.3518598394188	-0.157955185633225	38	1.39
29254220	Expression of PD-1/PD-L1 and PD-L2 in peripheral T-cells from non-small cell lung cancer patients.	Oncotarget	2017	7.654141926942047	-21.347440033970106	65	2.22
29254184	PD-L1 promoter methylation mediates the resistance response to anti-PD-1 therapy in NSCLC patients with EGFR-TKI resistance.	Oncotarget	2017	-1.802361425990397	-31.368835882668524	38	1.33
29253115	Intratumoral immunotherapy: using the tumor as the remedy.	Annals of oncology : official journal of the European Society for Medical Oncology	2017	21.267835001159625	1.5898322709058743	183	6.81
29252914	Significance of Immune-related Lipase Increase Induced by Antiprogrammed Death-1 or Death Ligand-1 Antibodies: A Brief Communication.	Journal of immunotherapy (Hagerstown, Md. : 1997)	2018	26.874609574705165	-46.30518730745155	26	1.16
29252078	An optimized protocol for the in vitro generation and functional analysis of human PD1/PD-L1 signal.	Journal of receptor and signal transduction research	2018	-50.76895974470292	-8.787417928772793	5	0.25
29251665	Molecular pathology of lung cancer: current status and perspectives.	Current opinion in oncology	2018	40.64732011914599	-39.597705885028205	68	3.46
29250533	PD-L1 Promotes Self-Renewal and Tumorigenicity of Malignant Melanoma Initiating Cells.	BioMed research international	2017	-34.86809003627336	-12.45954858419544	15	0.52
29247952	Overexpressed miR-195 attenuated immune escape of diffuse large B-cell lymphoma by targeting PD-L1.	Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie	2018	-31.96268257545319	28.273486431334568	34	1.49
29245981	Co-targeting aurora kinase with PD-L1 and PI3K abrogates immune checkpoint mediated proliferation in peripheral T-cell lymphoma: a novel therapeutic strategy.	Oncotarget	2017	24.31635967536904	12.99110689353067	15	0.61
29245948	PD-1/PD-L1 interaction up-regulates MDR1/P-gp expression in breast cancer cells via PI3K/AKT and MAPK/ERK pathways.	Oncotarget	2017	-36.12521892022057	-13.86300107974711	62	2.69
29245905	The sexist behaviour of immune checkpoint inhibitors in cancer therapy?	Oncotarget	2017	39.708696143246655	-17.169173891567866	68	2.57
29243219	PD-1 blockade enhances the antitumor efficacy of GM-CSF surface-modified bladder cancer stem cells vaccine.	International journal of cancer	2018	-24.488147025804203	-10.858260014140685	36	1.48
29241377	Current and future immunotherapies for thyroid cancer.	Expert review of anticancer therapy	2018	27.37201481115763	9.837474929820862	38	1.85
29239195	[Immunotherapy of Colorectal and Anal Carcinoma].	Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti	2017	37.69873145790302	21.61811257313253	3	0.11
29239193	[Checkpoint Inhibitors in the Treatment of Upper Gastrointestinal Tract Tumors].	Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti	2017	46.55069253954132	17.19796320094599	0	0.0
29239187	[Immunotherapy for Bladder Cancer].	Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti	2017	70.65798940065058	20.521627808354538	0	0.0
29238207	Advances in T-cell checkpoint immunotherapy for head and neck squamous cell carcinoma.	OncoTargets and therapy	2017	52.13070882660025	32.88522115236523	11	0.37
29237087	Type, Frequency, and Spatial Distribution of Immune Cell Infiltrates in CNS Germinomas: Evidence for Inflammatory and Immunosuppressive Mechanisms.	Journal of neuropathology and experimental neurology	2018	-23.27459120541058	32.7184510048929	20	1.34
29233903	Clinical Significance of PD-L1+ Exosomes in Plasma of Head and Neck Cancer Patients.	Clinical cancer research : an official journal of the American Association for Cancer Research	2018	-44.73098553570542	-57.18492352516513	375	17.7
29230210	Checkpoint Blockade Toxicity and Immune Homeostasis in the Gastrointestinal Tract.	Frontiers in immunology	2017	78.27805290222449	-4.125687350871365	108	3.95
29228840	Investigational PD-1 inhibitors in HL and NHL and biomarkers for predictors of response and outcome.	Expert opinion on investigational drugs	2018	37.0018923589295	-5.573439016808158	2	0.07
29228642	Soluble PD-1 and PD-L1: predictive and prognostic significance in cancer.	Oncotarget	2017	-48.685619499503154	-16.266747280260404	210	8.41
33525795	Checkpoint cluster: biomarkers of response.	Emerging topics in life sciences	2017	17.068581650254245	-5.128109697479069	0	0.0
29226734	Emerging first line treatment options for bladder cancer: a review of phase II and III therapies in the pipeline.	Expert opinion on emerging drugs	2017	70.54958796344833	18.1905939624356	0	0.0
29225694	Non-small cell lung cancer treatment (r)evolution: ten years of advances and more to come.	Ecancermedicalscience	2017	37.56629304715444	-36.44712439494917	33	1.31
29224824	Circulating tumour cell PD-L1 test for head and neck cancers.	Oral oncology	2017	-7.91590685159726	-4.937796247982547	11	0.46
29223828	Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: Harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation.	Cancer treatment reviews	2018	33.650246502851914	11.590189484070947	113	4.66
29222272	Signaling pathways and immune evasion mechanisms in classical Hodgkin lymphoma.	Hematology. American Society of Hematology. Education Program	2017	-28.76684160372124	26.12481796565782	16	0.59
29221220	Significant benefit of Nivolumab treating PD-L1 positive metastatic pulmonary carcinosarcoma: a case report and literature review.	Oncotarget	2017	46.49028235678015	-26.61234810182224	6	0.28
29220578	PD-1/PD-L1 Pathway Mediates the Alleviation of Pulmonary Fibrosis by Human Mesenchymal Stem Cells in Humanized Mice.	American journal of respiratory cell and molecular biology	2018	-55.9140805363141	18.458762488872697	62	3.06
29220526	Anti-PD-L1 Treatment Induced Central Diabetes Insipidus.	The Journal of clinical endocrinology and metabolism	2018	85.2521888707097	-16.58183296412665	64	3.65
29217732	Peptide Blocking of PD-1/PD-L1 Interaction for Cancer Immunotherapy.	Cancer immunology research	2018	-41.44724037478801	-43.84303345321168	93	4.19
29217527	Merkel Cell Carcinoma in the Age of Immunotherapy: Facts and Hopes.	Clinical cancer research : an official journal of the American Association for Cancer Research	2018	45.71093379153767	50.67988387755924	59	2.88
29217299	High PD-L1/CD86 MFI ratio and IL-10 secretion characterize human regulatory dendritic cells generated for clinical testing in organ transplantation.	Cellular immunology	2018	-68.85724491020403	0.92044923568593	29	1.43
29214427	Characterization of PD-L1 expression in Chinese non-small cell lung cancer patients with PTEN expression as a means for tissue quality screening.	Cancer immunology, immunotherapy : CII	2018	13.537844923457056	-33.8852765033778	4	0.17
29212909	PD-L1 Prevents the Development of Autoimmune Heart Disease in Graft-versus-Host Disease.	Journal of immunology (Baltimore, Md. : 1950)	2018	-65.11534228419819	-4.633625416601902	19	0.77
29209572	Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications.	Oncoimmunology	2017	21.856755937056075	6.565778893063514	28	0.86
29209565	Tumor-targeted costimulation with antibody-fusion proteins improves bispecific antibody-mediated immune response in presence of immunosuppressive factors.	Oncoimmunology	2017	-13.406534908470826	-44.24773071209235	9	0.35
29209560	PD-L1 and epithelial-mesenchymal transition in circulating tumor cells from non-small cell lung cancer patients: A molecular shield to evade immune system?	Oncoimmunology	2017	10.219797351860558	-37.0719518188845	61	2.37
29208565	Mismatch repair-deficient colorectal cancer: a model of immunogenic and immune cell-rich tumor despite nonsignificant programmed cell death ligand-1 expression in tumor cells.	Human pathology	2018	11.168334794964744	39.568157846008	13	0.52
29207684	Recurrent glioma clinical trial, CheckMate-143: the game is not over yet.	Oncotarget	2017	45.87995165870165	28.11315661427768	243	9.42
29206680	Immune therapies in acute myeloid leukemia: a focus on monoclonal antibodies and immune checkpoint inhibitors.	Current opinion in hematology	2018	17.42852380704198	17.20838690357848	60	2.79
29206214	Immunotherapy for Prostate Cancer: Where We Are Headed.	International journal of molecular sciences	2017	22.78952144448062	15.690567448402357	37	1.29
29203588	Spatially Resolved and Quantitative Analysis of VISTA/PD-1H as a Novel Immunotherapy Target in Human Non-Small Cell Lung Cancer.	Clinical cancer research : an official journal of the American Association for Cancer Research	2018	-38.442520030445685	37.41412731455319	132	5.23
29203283	Understanding the structural and energetic basis of PD-1 and monoclonal antibodies bound to PD-L1: A molecular modeling perspective.	Biochimica et biophysica acta. General subjects	2018	-46.738386402027686	-40.02682361766407	20	1.03
29196189	PD-L1, inflammation, non-coding RNAs, and neuroblastoma: Immuno-oncology perspective.	Seminars in cancer biology	2018	-27.076006784805735	14.719010766214089	53	2.25
29195503	Recent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy.	Journal of hematology & oncology	2017	31.96774409527909	-3.0542518713873243	82	2.79
29194007	Product review on the Anti-PD-L1 antibody atezolizumab.	Human vaccines & immunotherapeutics	2018	52.720576246980166	-39.24073522848176	31	1.35
29191375	Rheumatologic symptoms in oncologic patients on PD-1 inhibitors.	Seminars in arthritis and rheumatism	2018	77.27694534284078	-13.600686632410795	38	1.89
29190182	Checkpoint inhibition in pediatric hematologic malignancies.	Pediatric hematology and oncology	2017	29.87042666638291	8.166677583951842	17	0.57
29189265	Development of a Diagnostic Programmed Cell Death 1-Ligand 1 Immunohistochemistry Assay for Nivolumab Therapy in Melanoma.	Applied immunohistochemistry & molecular morphology : AIMM	2018	21.10792110120291	-41.14039605587295	17	0.76
29186904	The Roles of microRNAs in Regulating the Expression of PD-1/PD-L1 Immune Checkpoint.	International journal of molecular sciences	2017	-18.950972577045604	0.2871501261708312	79	3.18
29185395	PD-L1 expression in tumor metastasis is different between uveal melanoma and cutaneous melanoma.	Immunotherapy	2017	1.9103451283699395	0.3686405178181378	53	2.3
29185392	Immunotherapy in head and neck cancer: evidence and perspectives.	Immunotherapy	2017	50.02552750556351	30.074854850339158	12	0.44
29184782	Beyond chemotherapy for advanced disease-the role of EGFR and PD-1 inhibitors.	Translational andrology and urology	2017	57.0020338459841	7.673883209215277	10	0.42
29181416	CD80 Expressed by CD8+ T Cells Contributes to PD-L1-Induced Apoptosis of Activated CD8+ T Cells.	Journal of immunology research	2017	-48.7583130191437	-2.731962112328939	29	1.06
29181191	Anti-PD-1/anti-PD-L1 immunotherapy versus docetaxel for previously treated advanced non-small cell lung cancer: a systematic review and meta-analysis of randomised clinical trials.	ESMO open	2017	49.43401582228071	-21.044769002510268	26	0.99
29179441	High-affinity human PD-L1 variants attenuate the suppression of T cell activation.	Oncotarget	2017	-46.19706681392742	-26.867030449108864	22	0.88
29178534	Immune Checkpoint PD-1/PD-L1: Is There Life Beyond Antibodies?	Angewandte Chemie (International ed. in English)	2018	-43.35481374011018	-35.972351496541904	86	3.8
29176936	Role of microRNA-33a in regulating the expression of PD-1 in lung adenocarcinoma.	Cancer cell international	2017	4.095278948452042	-36.79994685137298	34	1.41
29175457	Liposomal nanohybrid cerasomes targeted to PD-L1 enable dual-modality imaging and improve antitumor treatments.	Cancer letters	2018	-41.72553075754095	-54.58298875931737	46	2.21
29175386	Impact of Clinicopathologic Features on the Efficacy of PD-1/PD-L1 Inhibitors in Patients With Previously Treated Non-small-cell Lung Cancer.	Clinical lung cancer	2018	48.98161597837282	-16.341738920314384	6	0.23
29171986	Correlation of PD-1/PD-L1 polymorphisms and expressions with clinicopathologic features and prognosis of ovarian cancer.	Cancer biomarkers : section A of Disease markers	2018	-20.076618025715064	14.024045709522598	27	1.21
29167175	Signaling pathways and immune evasion mechanisms in classical Hodgkin lymphoma.	Blood	2017	-28.76596854970485	26.12434810901284	47	1.62
29167009	[Advances of the Role of Lung Cancer Driver Gene and PD-1/PD-L1 Pathway Interaction in the Tumorigenesis and Progression of Non-small Cell Lung Cancer].	Zhongguo fei ai za zhi = Chinese journal of lung cancer	2017	25.42227696687082	-24.554132189184788	1	0.04
29167005	[Distribution and Clinical Significance of CTLA-4, PD-1 and PD-L1 in Peripheral Blood of Patients with Small Cell Lung Cancer].	Zhongguo fei ai za zhi = Chinese journal of lung cancer	2017	8.832519197452163	-22.1902054295711	4	0.12
29163822	Structural basis of the therapeutic anti-PD-L1 antibody atezolizumab.	Oncotarget	2017	-47.24127003362173	-35.34835403385749	47	1.8
29163815	PD-L1 expression heterogeneity in non-small cell lung cancer: evaluation of small biopsies reliability.	Oncotarget	2017	14.13016004649856	-36.4357565569528	78	2.74
29163786	Axl inhibition induces the antitumor immune response which can be further potentiated by PD-1 blockade in the mouse cancer models.	Oncotarget	2017	-26.62363563091729	-24.755016104064204	57	1.93
29163783	Abundant expression of TIM-3, LAG-3, PD-1 and PD-L1 as immunotherapy checkpoint targets in effusions of mesothelioma patients.	Oncotarget	2017	6.5591247121727205	14.057717470397977	33	1.27
29163490	Immune Checkpoint Molecules on Tumor-Infiltrating Lymphocytes and Their Association with Tertiary Lymphoid Structures in Human Breast Cancer.	Frontiers in immunology	2017	-3.160761155069858	24.547647430813832	68	2.23
29160310	Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance.	Nature	2018	-18.269168518846364	-8.990457014098226	541	21.17
29158797	PD-L1 is a Prognostic Biomarker in Resected NSCLC Patients with Moderate/high Smoking History and Elevated Serum SCCA Level.	Journal of Cancer	2017	13.682412495538587	-28.59011900733957	19	0.63
29158788	Programmed Death Ligand 1 (PD-L1) Expression in Primary Angiosarcoma.	Journal of Cancer	2017	-21.31311753656276	23.476317115191524	38	1.71
29157296	Biomarkers for immunotherapy in bladder cancer: a moving target.	Journal for immunotherapy of cancer	2017	67.64791488387974	18.402710321645017	121	4.37
29156738	Impact of mismatch-repair deficiency on the colorectal cancer immune microenvironment.	Oncotarget	2017	11.199485529663365	39.672864291712855	18	0.55
29156447	PD-1 blockade in advanced NSCLC: A focus on pembrolizumab.	Cancer treatment reviews	2018	46.62926798453725	-32.30176057674441	77	3.24
29155997	Immune Activation and Benefit From Avelumab in EBV-Positive Gastric Cancer.	Journal of the National Cancer Institute	2018	-9.068157880064842	9.636317155537588	139	5.59
29153898	The Significance of the PD-L1 Expression in Non-Small-Cell Lung Cancer: Trenchant Double Swords as Predictive and Prognostic Markers.	Clinical lung cancer	2018	13.76937876862726	-29.84944461146615	49	2.04
29152083	Programmed cell death 1 expression is associated with inferior survival in patients with primary central nervous system lymphoma.	Oncotarget	2017	-34.68780562971848	32.10171639012706	23	0.95
29150702	High PDL1 mRNA expression predicts better survival of stage pT1 non-muscle-invasive bladder cancer (NMIBC) patients.	Cancer immunology, immunotherapy : CII	2018	8.058070044393666	58.08356954077341	44	2.04
29147618	Programmed cell death ligands expression in phaeochromocytomas and paragangliomas: Relationship with the hypoxic response, immune evasion and malignant behavior.	Oncoimmunology	2017	2.565065317948584	11.976377343157177	49	1.82
29147606	Temporal and spatial heterogeneity of programmed cell death 1-Ligand 1 expression in malignant mesothelioma.	Oncoimmunology	2017	6.996193753500332	10.891836816525595	24	0.94
29147605	EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer.	Oncoimmunology	2017	7.880818428340789	-31.64388724524207	267	9.22
29147602	GDNF secreted by nerves enhances PD-L1 expression via JAK2-STAT1 signaling activation in HNSCC.	Oncoimmunology	2017	-12.724514625943328	-8.333448743475042	21	0.86
29145543	Association of Ipilimumab With Safety and Antitumor Activity in Women With Metastatic or Recurrent Human Papillomavirus-Related Cervical Carcinoma.	JAMA oncology	2018	45.48566132819265	35.92653953319897	94	4.53
29143108	Immune checkpoint inhibitor colitis: the flip side of the wonder drugs.	Virchows Archiv : an international journal of pathology	2018	77.14038739266795	-3.873214535930716	46	2.32
29141863	Eight-Color Multiplex Immunohistochemistry for Simultaneous Detection of Multiple Immune Checkpoint Molecules within the Tumor Microenvironment.	Journal of immunology (Baltimore, Md. : 1950)	2018	3.9823281741957537	-48.06550291583163	142	5.85
29140105	Durvalumab in non-small-cell lung cancer patients: current developments.	Future oncology (London, England)	2018	41.43579832751232	-26.650281690112894	11	0.45
29136692	[Expression and prognostic values of PD-1, PD-L1 and IDO-1 in sinonasal malignant mucosal melanoma].	Zhonghua bing li xue za zhi = Chinese journal of pathology	2017	3.877847307890626	-4.494333383283325	4	0.14
29135922	Targeting Immune Cell Checkpoints during Sepsis.	International journal of molecular sciences	2017	-58.56020508089388	37.68139311784139	98	3.96
29131510	Pulmonary pleomorphic carcinoma with few PD-1-positive immune cells and regulatory T cells that showed a complete response to nivolumab.	Thoracic cancer	2018	56.90191172198663	-31.28596806313454	13	0.74
29129094	Rational combination of immunotherapy for triple negative breast cancer treatment.	Chinese clinical oncology	2017	3.850512588184949	-6.523626918936223	9	0.34
29128997	PD-1-PD-L1 immune-checkpoint blockade in malignant lymphomas.	Annals of hematology	2018	-43.63350246943691	-13.259285750598828	40	1.79
29126881	Triple negative breast cancer: Key role of Tumor-Associated Macrophages in regulating the activity of anti-PD-1/PD-L1 agents.	Biochimica et biophysica acta. Reviews on cancer	2018	-32.492058072158365	-4.277463613584124	117	5.18
29126088	In the immuno-oncology era, is anti-PD-1 or anti-PD-L1 immunotherapy modifying the sensitivity to conventional cancer therapies?	European journal of cancer (Oxford, England : 1990)	2017	53.64403286224	-14.847942626714978	18	0.63
29125905	Arthritis After Cancer Immunotherapy: Symptom Duration and Treatment Response.	Arthritis care & research	2019	77.22878021461058	-13.760763465761174	65	3.73
29123953	PD-1 blockade augments anti-neuroblastoma immune response induced by anti-GD2 antibody ch14.18/CHO.	Oncoimmunology	2017	-13.066479313403564	-53.82635040464875	43	1.59
29123950	Immune evasion mechanisms and immune checkpoint inhibition in advanced merkel cell carcinoma.	Oncoimmunology	2017	44.59543513782143	51.47777832796121	41	1.53
29122838	Soluble CD80 Protein Delays Tumor Growth and Promotes Tumor-Infiltrating Lymphocytes.	Cancer immunology research	2018	-47.68063662814182	-2.198518744876096	17	0.72
29122656	Programmed death-1 ligands PD-L1 and PD-L2 show distinctive and restricted patterns of expression in lymphoma subtypes.	Human pathology	2018	-34.08084804578414	24.08742048050577	89	3.93
29120224	Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part II-The Challenge of Programmed Death Ligand-1 Testing and Its Role in Microsatellite Instability-High Colorectal Cancer.	Archives of pathology & laboratory medicine	2018	35.33919192663171	22.08977021312547	24	1.02
29119407	PD-L1 Testing in Guiding Patient Selection for PD-1/PD-L1 Inhibitor Therapy in Lung Cancer.	Molecular diagnosis & therapy	2018	20.66249814030541	-39.17098798327695	115	5.05
29119113	Increased EGFR Phosphorylation Correlates with Higher Programmed Death Ligand-1 Expression: Analysis of TKI-Resistant Lung Cancer Cell Lines.	BioMed research international	2017	7.009756914957376	-32.57233681596795	10	0.36
29118761	Immunological and Clinical Effect of Diet Modulation of the Gut Microbiome in Multiple Sclerosis Patients: A Pilot Study.	Frontiers in immunology	2017	21.1738857088758	42.97584127911788	93	4.38
29118007	PD-1 expression and clinical PD-1 blockade in B-cell lymphomas.	Blood	2018	-29.762922833945986	20.11820858048	246	10.61
29117944	Small-Molecule Sigma1 Modulator Induces Autophagic Degradation of PD-L1.	Molecular cancer research : MCR	2018	-36.96499928526584	-34.531456809739815	96	4.18
29113661	Program death-1 immune checkpoint and tumor microenvironment in malignant liver tumors.	Surgical oncology	2017	-21.68760999604736	37.855992505504574	19	0.71
29112124	Gene Regulatory Network Rewiring in the Immune Cells Associated with Cancer.	Genes	2017	-13.000084594985973	28.988176174993782	9	0.37
29110262	Mutational Diversity of Lung Cancer and Associated Lymph Nodes. An Exploratory Prospective Study of 4 Resected cIIIA-N2.	Pathology oncology research : POR	2019	18.65192817876484	-18.970386429923806	2	0.07
29108460	Prior irradiation results in elevated programmed cell death protein 1 (PD-1) in T cells.	International journal of radiation biology	2018	-14.182473045319876	-17.912933042269216	18	0.66
29108454	PTEN Physically Interacts with and Regulates E2F1-mediated Transcription in Lung Cancer.	Cell cycle (Georgetown, Tex.)	2018	6.353604039081406	3.357746794880481	27	1.13
29106445	A potent hydroxamic acid-based, small-molecule inhibitor A452 preferentially inhibits HDAC6 activity and induces cytotoxicity toward cancer cells irrespective of p53 status.	Carcinogenesis	2018	-10.190512760476643	-33.35511162561061	16	0.83
29104763	Cardiotoxicity of immune checkpoint inhibitors.	ESMO open	2017	83.2715637120019	3.706754916124839	151	6.1
29100036	Nafamostat mesilate, a serine protease inhibitor, suppresses interferon-gamma-induced up-regulation of programmed cell death ligand 1 in human cancer cells.	International immunopharmacology	2018	-21.8699314270486	-28.668076842854397	14	0.84
29097600	PD-L1.	Journal of clinical pathology	2018	-44.26259289789149	-16.82341623239922	175	8.16
29097495	Epstein-Barr virus-associated primary nodal T/NK-cell lymphoma shows a distinct molecular signature and copy number changes.	Haematologica	2018	-38.051425161194906	31.056169631122803	64	3.13
29097494	Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors.	Science (New York, N.Y.)	2018	22.752873333202583	41.97493718236645	2848	139.77
29097422	Intratumoral CD8+ T-cell Apoptosis Is a Major Component of T-cell Dysfunction and Impedes Antitumor Immunity.	Cancer immunology research	2018	-27.889705184469427	0.4228098405611928	116	4.14
29095271	Immune-related adverse events associated with PD-1 and PD-L1 inhibitors for nonsmall cell lung cancer: Protocol for a systematic review and meta-analysis.	Medicine	2017	63.38625144994101	-14.944666713990069	8	0.27
29094609	Pembrolizumab for treatment of advanced gastric and gastroesophageal junction adenocarcinoma.	Future oncology (London, England)	2018	50.22704245180875	7.83585943368784	45	2.03
29093678	Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis.	Frontiers in pharmacology	2017	73.20347308445153	-14.15273439537902	288	10.92
29093082	According to Hepatitis C Virus (HCV) Infection Stage, Interleukin-7 Plus 4-1BB Triggering Alone or Combined with PD-1 Blockade Increases TRAF1low HCV-Specific CD8+ Cell Reactivity.	Journal of virology	2018	-76.70201209412996	24.31834915357329	15	0.6
29089607	The anti-PD-1 era - an opportunity to enhance radiotherapy for patients with bladder cancer.	Nature reviews. Urology	2018	72.7777277148871	21.928839226141086	25	1.04
29088776	Expression differences of programmed death ligand 1 in de-novo and recurrent glioblastoma multiforme.	Oncotarget	2017	-23.27578978343008	50.74107977347718	19	0.76
35172490	Programmed Cell Death 1 (PD-1) Ligand (PD-L1) Expression in Solid Tumors As a Predictive Biomarker of Benefit From PD-1/PD-L1 Axis Inhibitors: A Systematic Review and Meta-Analysis.	JCO precision oncology	2017	17.693179860383506	-35.597303650563674	55	1.8
29082853	Cancer gene profiling in non-small cell lung cancers reveals activating mutations in JAK2 and JAK3 with therapeutic implications.	Genome medicine	2017	21.13878366169157	-19.435276947028907	32	1.16
29081778	Pyruvate Kinase M2 Is Required for the Expression of the Immune Checkpoint PD-L1 in Immune Cells and Tumors.	Frontiers in immunology	2017	-23.373091335484816	9.083391002830757	108	3.93
29076134	Immune checkpoint inhibition by anti-PDCD1 (anti-PD1) monoclonal antibody has significant therapeutic activity against central nervous system lymphoma in an immunocompetent preclinical model.	British journal of haematology	2018	-30.181534028857328	59.42847953032363	21	0.97
29074606	Low PD-1 Expression in Cytotoxic CD8+ Tumor-Infiltrating Lymphocytes Confers an Immune-Privileged Tissue Microenvironment in NSCLC with a Prognostic and Predictive Value.	Clinical cancer research : an official journal of the American Association for Cancer Research	2018	10.91926743527501	-18.17989552845747	169	7.08
29072624	An Archaeosome-Adjuvanted Vaccine and Checkpoint Inhibitor Therapy Combination Significantly Enhances Protection from Murine Melanoma.	Vaccines	2017	-39.96498321655677	47.12908114931011	13	0.49
29071761	Combination therapy strategies for improving PD-1 blockade efficacy: a new era in cancer immunotherapy.	Journal of internal medicine	2018	-35.785266334118795	-17.744360526973125	124	4.97
29070993	Different Response to Nivolumab in a Patient with Synchronous Double Primary Carcinomas of Hypopharyngeal Cancer and Non-Small-Cell Lung Cancer.	Case reports in oncology	2017	44.02652529079987	-25.762478084847977	4	0.1
29069958	PD-L1 immunohistochemistry for non-small cell lung carcinoma: which strategy should be adopted?	Expert review of molecular diagnostics	2017	18.64437258915881	-38.932217845440896	25	0.87
29069824	Sensitive detection of PD-L1 expression on circulating epithelial tumor cells (CETCs) could be a potential biomarker to select patients for treatment with PD-1/PD-L1 inhibitors in early and metastatic solid tumors.	Oncotarget	2017	8.873843061520196	-37.63019048407806	39	1.36
29069777	Small-molecule inhibitors of PD-1/PD-L1 immune checkpoint alleviate the PD-L1-induced exhaustion of T-cells.	Oncotarget	2017	-39.304729538021576	-37.97201227304864	169	6.61
29069649	The Systemic Activation of Programmed Death 1-PD-L1 Axis Protects Systemic Lupus Erythematosus Model from Nephritis.	American journal of nephrology	2017	-54.01883636931479	8.85673626301652	24	0.92
29069302	Mechanistic overview of immune checkpoints to support the rational design of their combinations in cancer immunotherapy.	Annals of oncology : official journal of the European Society for Medical Oncology	2018	26.749793059671237	10.486456104713088	207	8.98
29067721	The perivascular microenvironment in Epstein-Barr virus positive primary central nervous system lymphoma: The role of programmed cell death 1 and programmed cell death ligand 1.	Neuropathology : official journal of the Japanese Society of Neuropathology	2018	-35.25772776412275	31.314228671182065	20	1.06
29067473	"The dawn of ""immune-revolution"" in children: early experiences with checkpoint inhibitors in childhood malignancies."	Cancer chemotherapy and pharmacology	2017	30.605023728239143	8.19654145619879	10	0.42
29066497	T-cell Localization, Activation, and Clonal Expansion in Human Pancreatic Ductal Adenocarcinoma.	Cancer immunology research	2017	-9.124397118982978	27.711122158931406	130	4.3
29065979	Not all immune-checkpoint inhibitors are created equal: Meta-analysis and systematic review of immune-related adverse events in cancer trials.	Critical reviews in oncology/hematology	2017	74.8640573546841	-10.185516512914289	116	4.57
29063313	Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study.	Breast cancer research and treatment	2018	50.51452761982708	-6.677905725554636	459	19.97
29061851	Hormonal vitamin D up-regulates tissue-specific PD-L1 and PD-L2 surface glycoprotein expression in humans but not mice.	The Journal of biological chemistry	2017	-59.40874544307281	16.649652528255256	43	1.91
29061774	Immune Checkpoint Inhibitors in Gynecological Cancers: Update of Literature and Perspectives of Clinical Research.	Anticancer research	2017	40.7163937849016	35.9235032431266	44	1.76
29061772	Monoclonal Antibodies for the Treatment of Cancer.	Anticancer research	2017	24.03032759853527	3.9650248000488273	48	1.97
29058791	In vitro and in vivo effect of PD-1/PD-L1 blockade on microglia/macrophage activation and T cell subset balance in cryptococcal meningitis.	Journal of cellular biochemistry	2018	-80.7126870802477	-0.3382168153849961	6	0.29
29057919	Identification and Validation of a PD-L1 Binding Peptide for Determination of PDL1 Expression in Tumors.	Scientific reports	2017	16.732472848153765	-45.65827338359599	28	1.16
29057236	Beyond PD-L1 testing-emerging biomarkers for immunotherapy in non-small cell lung cancer.	Annals of translational medicine	2017	23.939531497725408	-35.78778934964608	64	2.06
29056539	Tumor cell-associated immune checkpoint molecules - Drivers of malignancy and stemness.	Biochimica et biophysica acta. Reviews on cancer	2017	22.62445238388788	11.864080759060988	45	1.65
29055949	Membranous and Cytoplasmic Expression of PD-L1 in Ovarian Cancer Cells.	Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology	2017	-21.71610113395317	11.869863624467683	59	2.45
29055015	Small-Molecule Inhibition of PD-1 Transcription Is an Effective Alternative to Antibody Blockade in Cancer Therapy.	Cancer research	2018	-38.79637628746513	-34.76293614980206	69	2.7
29051990	Clinicopathologic implications of CD8+/Foxp3+ ratio and miR-574-3p/PD-L1 axis in spinal chordoma patients.	Cancer immunology, immunotherapy : CII	2018	-18.102123466468875	26.97312117888909	36	1.72
29051270	Hypoxia-induced PD-L1/PD-1 crosstalk impairs T-cell function in sleep apnoea.	The European respiratory journal	2017	-60.82125729624105	25.506054386638624	71	3.62
29050367	Expression and clinical association of programmed cell death-1, programmed death-ligand-1 and CD8+ lymphocytes in primary sarcomas is subtype dependent.	Oncotarget	2017	-21.699392218551942	19.63117338272948	64	2.49
29050282	Effective antitumor peptide vaccines can induce severe autoimmune pathology.	Oncotarget	2017	-22.092024967610133	-13.94939796545389	11	0.44
29050127	[Immune-related pneumonitis caused by programmed death-1 inhibitor Pembrolizumab: a case report and literature review].	Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases	2017	65.52009534394112	-11.45310632182992	2	0.04
29048660	Canonical and non-canonical WNT signaling in cancer stem cells and their niches: Cellular heterogeneity, omics reprogramming, targeted therapy and tumor plasticity (Review).	International journal of oncology	2017	-11.509487017115092	37.1566884310761	278	11.76
29046141	Generation and Characterization of a Bispecific Antibody Targeting Both PD-1 and c-MET.	Protein and peptide letters	2018	-15.41663351402014	-47.63845888760782	6	0.22
29046065	Investigational PD-1 inhibitors for advanced non-small lung cancer: new players in a shifting paradigm.	Expert opinion on investigational drugs	2017	50.92008428944012	-46.11496050810333	6	0.18
29045526	LAG-3+ tumor infiltrating lymphocytes in breast cancer: clinical correlates and association with PD-1/PD-L1+ tumors.	Annals of oncology : official journal of the European Society for Medical Oncology	2017	9.141736958064383	23.1707210137354	122	4.4
29045250	Clinical decision-making for immunotherapy in metastatic renal cell carcinoma.	Current opinion in urology	2018	66.39036941804159	32.418495491659094	8	0.27
29045188	RAPID EVOLUTION OF THYROID DYSFUNCTION IN PATIENTS TREATED WITH NIVOLUMAB.	Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists	2017	79.64098973380639	-17.817825447929096	19	0.78
29044503	Clinical significance of programmed cell death-ligand 1 expression and the immune microenvironment at the invasive front of colorectal cancers with high microsatellite instability.	International journal of cancer	2018	9.64317591669159	40.64549335473331	45	2.04
29042640	Validation of multiplex immunofluorescence panels using multispectral microscopy for immune-profiling of formalin-fixed and paraffin-embedded human tumor tissues.	Scientific reports	2017	4.083701050483316	-46.76547578171056	167	6.25
29042512	In vitro reconstitution of T cell receptor-mediated segregation of the CD45 phosphatase.	Proceedings of the National Academy of Sciences of the United States of America	2017	-47.70884287777236	-5.376346646117191	53	1.81
29038298	Subversion of NK-cell and TNFα Immune Surveillance Drives Tumor Recurrence.	Cancer immunology research	2017	-27.648074189540136	2.5372556731448834	18	0.67
29037958	Expression of PD-1 and PD-L1 in poorly differentiated neuroendocrine carcinomas of the digestive system: a potential target for anti-PD-1/PD-L1 therapy.	Human pathology	2017	-0.910425445877078	10.689446897965745	32	1.33
29036261	Development of Halo Nevi in a Lung Cancer Patient: A Novel Immune-Related Cutaneous Event from Atezolizumab.	Journal of drugs in dermatology : JDD	2017	77.0152772258928	-22.337401257741707	6	0.41
29034210	Biomarkers for Response of Melanoma Patients to Immune Checkpoint Inhibitors: A Systematic Review.	Frontiers in oncology	2017	14.5927319312715	-1.590331698429135	51	1.71
29032029	CXCR5+CD8+ T cells could induce the death of tumor cells in HBV-related hepatocellular carcinoma.	International immunopharmacology	2017	-75.28927602834416	28.038465876513097	23	0.78
29029530	Which treatment is preferred for advanced non-small-cell lung cancer with wild-type epidermal growth factor receptor in second-line therapy? A meta-analysis comparing immune checkpoint inhibitor, tyrosine kinase inhibitor and chemotherapy.	Oncotarget	2017	46.53598487754491	-20.94172727782569	2	0.06
29029512	PD-L1 expression indicates favorable prognosis for advanced lung adenocarcinoma patients treated with pemetrexed.	Oncotarget	2017	33.862501670442235	-42.36550536655447	9	0.35
29029502	Clinicopathologic implications of the miR-197/PD-L1 axis in oral squamous cell carcinoma.	Oncotarget	2017	-8.141031148811642	-10.538037033636108	46	1.88
29027395	Prognostic value of programmed death-ligand 1 (PD-L1) expression in ovarian clear cell carcinoma.	Journal of gynecologic oncology	2017	-19.150559134229127	12.589812147487208	35	1.43
29025984	Synthesis and Biologic Evaluation of a Novel 18F-Labeled Adnectin as a PET Radioligand for Imaging PD-L1 Expression.	Journal of nuclear medicine : official publication, Society of Nuclear Medicine	2018	5.262038439116385	-57.905183792614245	126	6.42
29025857	Endocrine side effects of cancer immunotherapy.	Endocrine-related cancer	2017	82.2404030697779	-14.897407644608773	89	3.87
29025772	Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer.	Cancer discovery	2017	28.5856418533858	-29.84725938728105	394	13.07
29019005	When theory meets experiment: the PD-1 challenge.	Journal of molecular modeling	2017	-47.26241089646636	-41.34485903533171	4	0.17
29018057	PD-1 Blockade Prevents the Development and Progression of Carcinogen-Induced Oral Premalignant Lesions.	Cancer prevention research (Philadelphia, Pa.)	2017	-11.085154901997834	-14.596213076707016	48	1.77
29016938	Preclinical investigation of combined gene-mediated cytotoxic immunotherapy and immune checkpoint blockade in glioblastoma.	Neuro-oncology	2018	-31.279937243967705	56.10131439613933	45	1.94
28994323	Atezolizumab in invasive and metastatic urothelial carcinoma.	Expert review of clinical pharmacology	2017	73.26088214311257	15.39141096010775	13	0.48
28994272	Programmed Death-Ligand 1 Expression and Its Correlation with Lymph Node Metastasis in Papillary Thyroid Carcinoma.	Journal of pathology and translational medicine	2018	-7.275031216195139	-20.717377655922924	14	0.63
28993412	IL10 Release upon PD-1 Blockade Sustains Immunosuppression in Ovarian Cancer.	Cancer research	2017	-32.27807254151481	-14.166524811472929	99	3.72
28985469	Programmed Cell Death Protein Ligand-1 Silencing with Polyethylenimine-Dermatan Sulfate Complex for Dual Inhibition of Melanoma Growth.	ACS nano	2017	-32.32574904320256	-17.410199245075837	63	2.31
28984690	PD-1/PD-L1 and VEGF-A/VEGF-C expression in lymph node microenvironment and association with melanoma metastasis and survival.	Melanoma research	2017	7.107135304181902	0.3138379167619768	17	0.69
28982883	Programmed Cell Death Ligand 1 Expression in Primary Central Nervous System Lymphomas: A Clinicopathological Study.	Anticancer research	2017	-34.938722698076994	32.047591824943645	24	1.01
28982752	Urothelial Carcinoma of the Bladder and the Rise of Immunotherapy.	Journal of the National Comprehensive Cancer Network : JNCCN	2017	68.70258254150066	19.080149345327587	27	0.85
28982322	PD-1/PD-L1 Inhibitors for Immuno-oncology: From Antibodies to Small Molecules.	Current pharmaceutical design	2018	-41.80927710012019	-36.59383348790456	29	1.51
28980429	Metabolic characteristics of programmed cell death-ligand 1-expressing lung cancer on 18 F-fluorodeoxyglucose positron emission tomography/computed tomography.	Cancer medicine	2017	14.567288326985295	-56.086936032428426	70	2.68
28978847	[PD-1 blockade therapy in lymphoid malignancies].	[Rinsho ketsueki] The Japanese journal of clinical hematology	2017	-43.733466350492144	-13.240812370059766	2	0.11
28978110	Increased PD-L1 expression in erlotinib-resistant NSCLC cells with MET gene amplification is reversed upon MET-TKI treatment.	Oncotarget	2017	6.480114038141964	-31.93634424892216	26	0.98
28978072	Immunotherapy of WAP-TNP mice with early stage mammary gland tumors.	Oncotarget	2017	-28.06503293246042	-65.58542010550569	1	0.04
28978071	Analyses of selected safety endpoints in phase 1 and late-phase clinical trials of anti-PD-1 and PD-L1 inhibitors: prediction of immune-related toxicities.	Oncotarget	2017	73.32689614009924	-14.85978800205334	15	0.54
28978018	Differentiated tumor immune microenvironment of Epstein-Barr virus-associated and negative gastric cancer: implication in prognosis and immunotherapy.	Oncotarget	2017	-12.659468519761727	21.175430735990563	38	1.52
28977890	Programmed cell death-ligand 1 expression and immunoscore in stage II and III non-small cell lung cancer patients receiving adjuvant chemotherapy.	Oncotarget	2017	15.439523615753467	-29.886859009534643	12	0.38
28975019	Novel Therapies in Platinum-refractory Metastatic Germ Cell Tumor: A Case Report with a Focus on a PD-1 Inhibitor.	Rare tumors	2017	49.53587594333342	25.55049815412165	12	0.54
28974264	PD-L1 and PD-1 expression are correlated with distinctive clinicopathological features in papillary thyroid carcinoma.	Diagnostic pathology	2017	-6.79577963661741	-21.23428655085897	25	1.05
28973671	PD-L1 Overexpression During Endotoxin Tolerance Impairs the Adaptive Immune Response in Septic Patients via HIF1α.	The Journal of infectious diseases	2018	-57.91966842837488	34.23653858891288	31	1.42
28973656	Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis.	JAMA oncology	2018	81.46567670207864	-16.46100668693028	586	28.53
28972595	Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD-1/PD-L1 pathway.	Leukemia	2018	-12.93768165719621	-36.995665468680365	83	3.46
28971752	Response of advanced stage recurrent lymphoepithelioma-like carcinoma to nivolumab.	Immunotherapy	2017	39.74575806260617	-45.07020576615479	29	1.19
28969052	PD-1 and PD-L1 co-expression predicts favorable prognosis in gastric cancer.	Oncotarget	2017	-8.88009119743895	6.209101823206467	51	2.1
28967040	Expression of PD-1 and PD-L1 on cytotoxic T lymphocytes and immune deficiency in a patient with adult T cell leukemia/lymphoma.	Annals of hematology	2018	-38.405279717603655	21.64083180892648	7	0.34
28966917	Advances on immunotherapy in genitourinary and renal cell carcinoma.	Translational cancer research	2017	66.42377061103998	24.64514922266046	8	0.35
28963773	In-vitro effect of pembrolizumab on different T regulatory cell subsets.	Clinical and experimental immunology	2018	63.36677884411152	-35.250933978396944	39	1.63
28960263	Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer: A systematic analysis of the literature.	Cancer	2018	51.08076397746984	-19.57478617346172	204	8.96
28954788	Systemic Antitumor Immunity by PD-1/PD-L1 Inhibition Is Potentiated by Vascular-Targeted Photodynamic Therapy of Primary Tumors.	Clinical cancer research : an official journal of the American Association for Cancer Research	2018	21.786065837940715	26.785349049266458	57	2.71
28953925	PD-1 and CTLA-4 up regulation on donor T cells is insufficient to prevent GvHD in allo-HSCT recipients.	PloS one	2017	-66.75065399234741	-5.710482808667336	14	0.62
28951311	PD-1 pathway and its clinical application: A 20year journey after discovery of the complete human PD-1 gene.	Gene	2018	-41.88406819793428	-19.704273647810115	67	2.8
28948509	Beyond the Percentages of PD-L1-Positive Tumor Cells: Induced Versus Constitutive PD-L1 Expression in Primary and Metastatic Head and Neck Squamous Cell Carcinoma.	Head and neck pathology	2018	-5.850849601798497	-8.573707125742613	23	0.91
28947422	PD-1 Expression in Head and Neck Squamous Cell Carcinomas Derives Primarily from Functionally Anergic CD4+ TILs in the Presence of PD-L1+ TAMs.	Cancer research	2017	-7.3066715175084065	-9.754051099480252	68	2.64
28945858	Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review.	Annals of oncology : official journal of the European Society for Medical Oncology	2017	75.29666428385784	-8.598107598169952	477	18.98
28942432	The application and mechanism of PD pathway blockade for cancer therapy.	Postgraduate medical journal	2018	-38.90637520057889	-18.24263657264274	9	0.36
28940446	The PD-1 and PD-L1 pathway in recurrent respiratory papillomatosis.	The Laryngoscope	2018	-1.2861364376966475	-10.044082778359474	23	1.45
28939757	PD-1 Blockade Promotes Epitope Spreading in Anticancer CD8+ T Cell Responses by Preventing Fratricidal Death of Subdominant Clones To Relieve Immunodomination.	Journal of immunology (Baltimore, Md. : 1950)	2017	-28.80295471225745	-17.88293311572268	47	1.53
28938692	Effectiveness and safety of PD-1/PD-L1 inhibitors in the treatment of solid tumors: a systematic review and meta-analysis.	Oncotarget	2017	51.094268954403546	-13.323338576746163	58	2.01
28938671	PD-1/PD-L1 antibodies efficacy and safety versus docetaxel monotherapy in advanced NSCLC patients after first-line treatment option: systems assessment.	Oncotarget	2017	49.56433122669123	-20.8080424699248	7	0.29
28938660	Prognostic value of programmed death-ligand 1 in sarcoma: a meta-analysis.	Oncotarget	2017	-17.426673269299304	18.20584835607541	35	1.41
28936553	Significance of evaluating tumor-infiltrating lymphocytes (TILs) and programmed cell death-ligand 1 (PD-L1) expression in breast cancer.	Medical molecular morphology	2017	-6.305773511699547	17.92762233360162	24	0.92
28935250	Engineered cells for costimulatory enhancement combined with IL-21 enhance the generation of PD-1-disrupted CTLs for adoptive immunotherapy.	Cellular immunology	2017	-44.91801495086074	0.4370594458891504	7	0.2
28932634	PD1-positive tumor-infiltrating lymphocytes are associated with poor clinical outcome after pulmonary metastasectomy for colorectal cancer.	Oncoimmunology	2017	-3.2977517152719726	11.61580577910778	22	0.75
28929192	Role of PD-1 in Immunity and Diseases.	Current topics in microbiology and immunology	2017	-47.72330313148092	-14.1267620511153	131	4.81
28928380	Predictors of responses to immune checkpoint blockade in advanced melanoma.	Nature communications	2017	13.805027607857154	-2.005316117216529	143	4.71
28926891	[Advances in immune checkpoint inhibitors in gastrointestinal cancer].	Zhonghua zhong liu za zhi [Chinese journal of oncology]	2017	41.42993123686127	19.590097541568	0	0.0
28925793	Sequential administration of MVA-based vaccines and PD-1/PD-L1-blocking antibodies confers measurable benefits on tumor growth and survival: Preclinical studies with MVA-βGal and MVA-MUC1 (TG4010) in a murine tumor model.	Human vaccines & immunotherapeutics	2018	-24.26985553027905	-13.344292238336338	21	0.8
28925087	Relationship of tumor PD-L1 (CD274) expression with lower mortality in lung high-grade neuroendocrine tumor.	Cancer medicine	2017	8.716813700922362	-25.9264807837414	35	1.39
28923211	Nivolumab and pembrolizumab: Monoclonal antibodies against programmed cell death-1 (PD-1) that are interchangeable.	Seminars in oncology	2017	34.41886617974308	-2.761911975721726	75	2.85
28922567	Determination of PD-L1 expression in effusions from mesothelioma by immuno-cytochemical staining.	Cancer cytopathology	2017	7.047397651974499	10.966988599771923	8	0.42
28916658	T Cells Deficient in Diacylglycerol Kinase ζ Are Resistant to PD-1 Inhibition and Help Create Persistent Host Immunity to Leukemia.	Cancer research	2017	-33.21542769793438	-25.22366713344019	15	0.54
28913723	Therapeutic Implications of the Molecular and Immune Landscape of Triple-Negative Breast Cancer.	Pathology oncology research : POR	2018	8.195768210086149	28.22007909551926	16	0.72
28913556	High-dose vitamin D3 supplementation decreases the number of colonic CD103+ dendritic cells in healthy subjects.	European journal of nutrition	2018	-70.01706193967493	6.454828255125262	8	0.5
28912399	[Adoptive Cell Therapy with Immune Checkpoint Blockade].	Gan to kagaku ryoho. Cancer & chemotherapy	2017	23.510347434589946	1.6172387627231326	0	0.0
28912137	Enhanced Cancer Immunotherapy by Chimeric Antigen Receptor-Modified T Cells Engineered to Secrete Checkpoint Inhibitors.	Clinical cancer research : an official journal of the American Association for Cancer Research	2017	-42.64890389285944	4.65248075700882	204	7.33
28912094	Selection of PD1/PD-L1 X-Aptamers.	Biochimie	2018	-24.97341643302413	-60.71887319375901	23	1.25
28910818	Protein Expression of Programmed Death 1 Ligand 1 and HER2 in Gastric Carcinoma.	Oncology	2017	-9.182525666898607	3.09140711261171	26	0.98
28903377	PD-L1/PD-1 expression and tumor-infiltrating lymphocytes in conjunctival melanoma.	Oncotarget	2017	1.385284776872609	0.0887695205532903	30	1.28
28903317	PD-L1 and c-MET expression and survival in patients with small cell lung cancer.	Oncotarget	2017	10.1676539866855	-24.22639830595981	29	1.15
28901560	Erythema nodosum-like panniculitis mimicking disease recurrence: A novel toxicity from immune checkpoint blockade therapy-Report of 2 patients.	Journal of cutaneous pathology	2017	73.7441838841497	-25.383511794402523	39	1.95
28900290	Alteration of PD-L1 expression and its prognostic impact after concurrent chemoradiation therapy in non-small cell lung cancer patients.	Scientific reports	2017	15.120551454408792	-24.490565350816127	59	2.25
28899983	Regulatory NK cells mediated between immunosuppressive monocytes and dysfunctional T cells in chronic HBV infection.	Gut	2018	-74.82715052862571	21.7342190218256	85	3.74
28898057	The Too Many Faces of PD-L1: A Comprehensive Conformational Analysis Study.	Biochemistry	2017	-48.14690467955169	-40.57434076739034	18	0.84
28894827	The genetic landscape of programmed death ligand-1 (PD-L1) alterations in head and neck cancer.	Laryngoscope investigative otolaryngology	2017	-7.814103659443718	-6.174912295408765	10	0.42
28894725	Safety of checkpoint inhibitors for cancer treatment: strategies for patient monitoring and management of immune-mediated adverse events.	ImmunoTargets and therapy	2017	82.73288248655066	-10.014341740242068	78	3.16
28894043	Immune disorders in sepsis and their treatment as a significant problem of modern intensive care.	Postepy higieny i medycyny doswiadczalnej (Online)	2017	-58.18032707539128	38.28181108418082	6	0.26
28893901	Expression of PD-L1 in Hormone-naïve and Treated Prostate Cancer Patients Receiving Neoadjuvant Abiraterone Acetate plus Prednisone and Leuprolide.	Clinical cancer research : an official journal of the American Association for Cancer Research	2017	-13.368452705608783	13.276835479634354	69	2.33
28893733	Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma.	Blood	2017	-27.3008244117081	26.79905218844303	217	8.06
28892775	Challenges and perspectives in the immunotherapy of Hodgkin lymphoma.	European journal of cancer (Oxford, England : 1990)	2017	38.633839453318885	-7.280534971466413	15	0.64
28892130	Fibrinogen-like protein-2 causes deterioration in cardiac function in experimental autoimmune myocarditis rats through regulation of programmed death-1 and inflammatory cytokines.	Immunology	2018	-62.66191007280347	7.180477134232491	11	0.56
28890543	The altered PD-1/PD-L1 pathway delivers the 'one-two punch' effects to promote the Treg/Th17 imbalance in pre-eclampsia.	Cellular & molecular immunology	2018	-73.6817157218491	-17.788347770652003	91	4.46
28889921	PD-1 checkpoint inhibition: Toxicities and management.	Urologic oncology	2017	70.89069969246403	-15.517682727145123	50	1.94
28889085	Immunosenescence and immunecheckpoint inhibitors in non-small cell lung cancer patients: Does age really matter?	Cancer treatment reviews	2017	56.0704079787455	-19.861513740891294	104	3.71
28884747	Adverse prognostic value of PD-L1 expression in primary resected pulmonary squamous cell carcinomas and paired mediastinal lymph node metastases.	Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc	2018	9.193655747249284	-26.21069022802619	26	1.13
28883282	[Development of immune checkpoint inhibitors].	[Rinsho ketsueki] The Japanese journal of clinical hematology	2017	31.64314458147905	4.078451620727582	5	0.18
28881856	Strategies targeting angiogenesis in advanced non-small cell lung cancer.	Oncotarget	2017	39.99724515990536	-37.33231064468091	43	1.7
28881780	PD-L1: a novel prognostic biomarker in head and neck squamous cell carcinoma.	Oncotarget	2017	-6.82932004508637	-7.115290849011052	76	3.21
28881701	PD1 signal transduction pathways in T cells.	Oncotarget	2017	-46.95908577323106	-10.013542515035043	152	5.76
28881642	PD-1 and PD-L1 expression in 132 recurrent nasopharyngeal carcinoma: the correlation with anemia and outcomes.	Oncotarget	2017	-17.09155240766522	31.12282404820597	33	1.32
28881603	PD-1 mRNA expression in peripheral blood cells and its modulation characteristics in cancer patients.	Oncotarget	2017	-31.61268322355226	-1.2599684514294922	9	0.3
28878676	PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome.	Frontiers in pharmacology	2017	29.59807201643668	-2.5856679022297286	977	41.86
28875845	New Trends in Anti-Cancer Therapy: Combining Conventional Chemotherapeutics with Novel Immunomodulators.	Current medicinal chemistry	2018	20.62216362862388	5.113790587292761	14	0.59
28875836	Coinhibitory Molecule PD-1 as a Therapeutic Target in the Microenvironment of Multiple Myeloma.	Current cancer drug targets	2017	-33.081263576128954	8.018233256812447	10	0.41
28871258	Distinctive Surface Glycosylation Patterns Associated With Mouse and Human CD4+ Regulatory T Cells and Their Suppressive Function.	Frontiers in immunology	2017	-69.66476025301009	2.3196976025008738	24	0.89
28870600	Interleukin 10 enhanced CD8+ T cell activity and reduced CD8+ T cell apoptosis in patients with diffuse large B cell lymphoma.	Experimental cell research	2017	-41.96391852861253	18.87450917051207	7	0.23
28870260	Programmed cell death ligand 1 cut-point is associated with reduced disease specific survival in resected pancreatic ductal adenocarcinoma.	BMC cancer	2017	-4.282221414261039	4.1053131747182965	30	1.29
28869441	Improvement of cytotoxicity of autologous CIKs from patients with breast cancer to MCF-7 cells by suppressed PD-1 expression.	Cancer biomarkers : section A of Disease markers	2017	-47.05150853169467	2.314155261452058	5	0.27
28868758	Programmed cell death ligand 1 (PD-L1) expression is not a predominant feature in Ewing sarcomas.	Pediatric blood & cancer	2018	-22.9481713515891	18.53144163927633	36	1.58
28866656	Immune checkpoint inhibitors in cancer therapy.	Journal of biomedical research	2018	26.348286668420105	7.307164806123925	80	3.48
28865147	Differential regulation of PD-1 and its ligands in allergic asthma.	Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology	2017	-64.96418213436218	-10.51608166176317	15	0.55
28864844	Checkpoint inhibitors: the new treatment paradigm for urothelial bladder cancer.	Medical oncology (Northwood, London, England)	2017	72.05486523835344	20.052583608485858	28	1.03
28861116	Enabling a genetically informed approach to cancer medicine: evaluation of the impact of comprehensive tumor sequencing.	Personalized medicine	2017	14.84892619343444	3.132164782190594	0	0.0
28855210	CD73 Promotes Resistance to HER2/ErbB2 Antibody Therapy.	Cancer research	2017	4.37573521556419	5.695997306362287	81	3.04
28848761	Clinical Applications of Immunotherapy Combination Methods and New Opportunities for the Future.	BioMed research international	2017	27.385152802134577	-0.7724280460050528	6	0.19
28848698	Use of programmed cell death protein ligand 1 assay to predict the outcomes of non-small cell lung cancer patients treated with immune checkpoint inhibitors.	World journal of clinical oncology	2017	20.55188105826911	-37.15104301426985	7	0.27
28848666	Educational video: the role of PD-L1 in the local tumour microenvironment.	ESMO open	2016	-42.1710726139769	-14.17715009042621	1	0.03
28848559	Functional Expression of Programmed Death-Ligand 1 (B7-H1) by Immune Cells and Tumor Cells.	Frontiers in immunology	2017	-41.23445155029929	-15.682334251973764	80	2.94
28848143	PD-L1 Expression Promotes Epithelial to Mesenchymal Transition in Human Esophageal Cancer.	Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology	2017	-13.582451076093635	7.423026069832891	77	3.19
28848055	Concurrent PD-1 Blockade Negates the Effects of OX40 Agonist Antibody in Combination Immunotherapy through Inducing T-cell Apoptosis.	Cancer immunology research	2017	-27.31738634476056	-20.361720757078697	111	3.59
28848042	The immunoinhibitory PD-1/PD-L1 pathway in inflammatory blood vessel disease.	Journal of leukocyte biology	2018	-57.587427869870304	10.09318270222412	56	2.76
28844802	Recent developments in small molecule therapies for renal cell carcinoma.	European journal of medicinal chemistry	2017	63.64048811898338	33.38134638324972	23	0.81
28842748	PD-L1 expression correlates with VEGF and microvessel density in patients with uniformly treated classical Hodgkin lymphoma.	Annals of hematology	2017	-30.26109232100317	22.395838132298618	28	1.12
28840453	Immunotherapy in Gynecologic Cancers: Are We There Yet?	Current treatment options in oncology	2017	40.185934036115206	36.95751126829305	38	1.43
28838509	Initial Experience With Lung Cancer Resection After Treatment With T-Cell Checkpoint Inhibitors.	The Annals of thoracic surgery	2017	39.40734435690397	-27.58355138207318	64	2.05
28838214	Prognostic significance of PD-L1 expression on circulating tumor cells in patients with head and neck squamous cell carcinoma.	Annals of oncology : official journal of the European Society for Medical Oncology	2017	-6.555774177566152	-6.673061033403013	132	5.12
28837142	Microenvironment inflammatory infiltrate drives growth speed and outcome of hepatocellular carcinoma: a prospective clinical study.	Cell death & disease	2017	-12.92216953668709	44.321805737384295	38	1.6
28834746	PDL1 Signals through Conserved Sequence Motifs to Overcome Interferon-Mediated Cytotoxicity.	Cell reports	2017	-18.21834564350916	-19.536724919322296	171	6.2
28833798	Expressions of programmed death (PD)-1 and PD-1 ligand (PD-L1) in cervical intraepithelial neoplasia and cervical squamous cell carcinomas are of prognostic value and associated with human papillomavirus status.	The journal of obstetrics and gynaecology research	2017	-0.1940590885185539	-11.810677754048044	59	2.42
28832979	Programmed cell death ligand 1 and tumor-infiltrating lymphocyte status in patients with renal cell carcinoma and sarcomatoid dedifferentiation.	Cancer	2017	19.292149452778062	26.60945264618613	70	2.55
28832075	Prognostic Significance of Programmed Cell Death Ligand 1 (PD-L1), CD8+ Tumor-Infiltrating Lymphocytes and p53 in Non-Small Cell Lung Cancer: An Immunohistochemical Study.	Turk patoloji dergisi	2017	7.57923991387357	-23.11224144995044	19	0.74
28831813	The Emerging Role of PD-1/PD-L1-Targeting Immunotherapy in the Treatment of Metastatic Urothelial Carcinoma.	The Annals of pharmacotherapy	2018	67.62173458840898	18.492781196488565	5	0.22
28831444	Positive PD-L1 Expression Predicts Worse Outcome in Cutaneous Angiosarcoma.	Journal of global oncology	2017	-20.790260659830903	23.312499900685857	34	1.39
28828507	Metabolic activity by 18F-FDG-PET/CT is predictive of early response after nivolumab in previously treated NSCLC.	European journal of nuclear medicine and molecular imaging	2018	12.99587309244627	-55.80699497662691	136	6.08
28827658	A canine chimeric monoclonal antibody targeting PD-L1 and its clinical efficacy in canine oral malignant melanoma or undifferentiated sarcoma.	Scientific reports	2017	-15.994472216812207	-14.337965620332367	83	3.95
28826697	[Reirradiation of head and neck cancers].	Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique	2017	59.15066110879224	12.592851306766809	1	0.07
28822887	The changing diagnostic pathway for lung cancer patients in Shanghai, China.	European journal of cancer (Oxford, England : 1990)	2017	26.25543701228631	-22.97580776045028	7	0.26
28822576	Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).	Lancet (London, England)	2017	46.40676080179366	1.3707968289300845	800	30.51
28821192	Could the PD-1 Pathway Be a Potential Target for Treating Small Intestinal Adenocarcinoma?	American journal of clinical pathology	2017	-1.977798845971917	10.383688445736912	21	0.85
28820897	Persistent infection due to a small-colony variant of Burkholderia pseudomallei leads to PD-1 upregulation on circulating immune cells and mononuclear infiltration in viscera of experimental BALB/c mice.	PLoS neglected tropical diseases	2017	-73.30256258043313	11.539756894792022	11	0.45
28820000	Novel combination strategies for enhancing efficacy of immune checkpoint inhibitors in the treatment of metastatic solid malignancies.	Expert opinion on pharmacotherapy	2017	29.70450556273786	17.217550967528798	18	0.6
28819821	Anti-PD-1 Antibodies as a Therapeutic Strategy in Classical Hodgkin Lymphoma.	Drugs	2017	-6.416157730525956	-27.132643632064045	2	0.06
28819582	Relationship of Metabolic Alterations and PD-L1 Expression in Cisplatin Resistant Lung Cancer.	Cell & developmental biology	2017	-1.902480255327948	-28.490715000562577	36	1.5
28819064	The Tumor Microenvironment Regulates Sensitivity of Murine Lung Tumors to PD-1/PD-L1 Antibody Blockade.	Cancer immunology research	2017	13.5977455576306	-21.854289350694067	98	3.2
28819027	Combination Therapy with Bispecific Antibodies and PD-1 Blockade Enhances the Antitumor Potency of T Cells.	Cancer research	2017	-15.10147779370524	-45.79950352958672	52	1.76
28818609	Multicenter Comparison of 22C3 PharmDx (Agilent) and SP263 (Ventana) Assays to Test PD-L1 Expression for NSCLC Patients to Be Treated with Immune Checkpoint Inhibitors.	Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer	2017	16.20138547514333	-40.64515270751603	69	2.55
28818019	Pembrolizumab in the treatment of metastatic non-small cell lung cancer: a review of current evidence.	Therapeutic advances in respiratory disease	2017	47.810369719410566	-31.69308631700711	22	0.78
28813417	CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity.	Nature	2017	-23.213436343101527	-3.5224851919406235	513	17.27
28813410	Identification of CMTM6 and CMTM4 as PD-L1 protein regulators.	Nature	2017	-23.26588941850732	-3.533053646594296	411	14.14
28813164	Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study.	Journal of clinical oncology : official journal of the American Society of Clinical Oncology	2017	48.53523184890816	0.4820527274644708	330	12.61
28812434	[pemetrexed + sildenafil], via autophagy-dependent HDAC downregulation, enhances the immunotherapy response of NSCLC cells.	Cancer biology & therapy	2017	34.554913329100835	-42.69139893339019	35	1.53
28810147	Macrophage Polarization Contributes to Glioblastoma Eradication by Combination Immunovirotherapy and Immune Checkpoint Blockade.	Cancer cell	2017	-33.343393882833496	54.10114869834254	348	13.42
28807336	Programmed death-1 (PD-1) receptor/PD-1 ligand (PD-L1) expression in fumarate hydratase-deficient renal cell carcinoma.	Annals of diagnostic pathology	2017	18.2386865184076	25.839819081837422	20	0.88
28807048	Response to single agent PD-1 inhibitor after progression on previous PD-1/PD-L1 inhibitors: a case series.	Journal for immunotherapy of cancer	2017	30.975064136916487	-4.245267908941624	33	0.96
28807004	Predictive role of PD-L1 expression in the response of renal Medullary carcinoma to PD-1 inhibition.	Journal for immunotherapy of cancer	2017	17.214097786174516	25.252330405631664	19	0.72
28806299	The Dynamic and Transient Immune Microenvironment in Locally Advanced Esophageal Adenocarcinoma Post Chemoradiation.	Annals of surgery	2018	5.1888983569568135	21.484093005676623	64	2.48
28803798	Radiosynthesis and preclinical PET evaluation of 89Zr-nivolumab (BMS-936558) in healthy non-human primates.	Bioorganic & medicinal chemistry	2017	8.048653352440407	-57.03795223831194	59	2.46
28803721	Conditioning neoadjuvant therapies for improved immunotherapy of cancer.	Biochemical pharmacology	2017	33.94549367268062	-30.722257415759625	8	0.27
28801607	Enhancing NK cell-mediated cytotoxicity to cisplatin-resistant lung cancer cells via MEK/Erk signaling inhibition.	Scientific reports	2017	-2.9998096555901106	-28.404028702875703	34	1.44
28800469	Immunotherapy in ovarian, endometrial and cervical cancer: State of the art and future perspectives.	Cancer treatment reviews	2017	39.72591966353823	37.48596963388593	97	3.66
28799073	Immunotherapy in Breast Cancer: the Emerging Role of PD-1 and PD-L1.	Current oncology reports	2017	24.548983324135467	-2.653872452730308	78	2.99
28797844	PD-1/PD-L1 blockade enhances the efficacy of SA-GM-CSF surface-modified tumor vaccine in prostate cancer.	Cancer letters	2017	-24.4296816543752	-10.752587404330018	29	0.99
28796808	PD-L1 and gastric cancer prognosis: A systematic review and meta-analysis.	PloS one	2017	-7.881779717953267	5.558753370094314	159	6.8
28794626	Folic acid-functionalized polyethylenimine superparamagnetic iron oxide nanoparticles as theranostic agents for magnetic resonance imaging and PD-L1 siRNA delivery for gastric cancer.	International journal of nanomedicine	2017	-34.8049886698535	-52.93707426607744	59	2.74
28789707	Checkpoint inhibitors in melanoma and early phase development in solid tumors: what's the future?	Journal of translational medicine	2017	31.035315683418936	1.606314524040357	29	0.99
28788102	Appearance of New Cutaneous Superficial Basal Cell Carcinomas during Successful Nivolumab Treatment of Refractory Metastatic Disease: Implications for Immunotherapy in Early Versus Late Disease.	International journal of molecular sciences	2017	48.13433404578885	-51.14508941299497	28	1.52
28776578	Negative immune checkpoint regulation by VISTA: a mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients.	Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc	2017	-39.65900373110534	36.68396598926735	134	4.44
28771603	Expression of PD-L1 and other immunotherapeutic targets in thymic epithelial tumors.	PloS one	2017	-5.717527730592954	-36.76667312535815	43	1.75
28770269	The PD-1/PD-L1 Inhibitory Pathway is Altered in Primary Glomerulonephritides.	Archivum immunologiae et therapiae experimentalis	2018	-51.901503323779146	7.78493085252392	12	0.68
28768162	Structural Biology of the Immune Checkpoint Receptor PD-1 and Its Ligands PD-L1/PD-L2.	Structure (London, England : 1993)	2017	-45.42652756826552	-35.15860346535138	188	7.37
28762116	Merkel Cell Carcinoma of the Head and Neck: Recommendations for Diagnostics and Treatment.	Annals of surgical oncology	2017	45.84020051349378	51.68916906488384	19	1.43
28761757	Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer.	ESMO open	2017	21.63885563547258	10.471786644177246	190	7.11
28761743	Checkpoint inhibitors in the treatment of urological malignancies.	ESMO open	2017	68.78667090051862	20.93380234839413	18	0.58
28761741	Tumour-infiltrating lymphocytes are correlated with higher expression levels of PD-1 and PD-L1 in early breast cancer.	ESMO open	2017	-7.0677308601170346	17.246740172579774	86	3.31
28761384	New PD-L1 inhibitors in non-small cell lung cancer - impact of atezolizumab.	Lung Cancer (Auckland, N.Z.)	2017	51.588620702337735	-37.96063586904856	29	1.12
28761354	PD-1 blockade restores impaired function of ex vivo expanded CD8+ T cells and enhances apoptosis in mismatch repair deficient EpCAM+PD-L1+ cancer cells.	OncoTargets and therapy	2017	-41.49538667257073	-2.86511310369432	17	0.61
28760297	Progress in Myelodysplastic Syndromes: Clinicopathologic Correlations and Immune Checkpoints.	Clinical lymphoma, myeloma & leukemia	2017	-36.04135727097334	14.026769827446754	5	0.18
28757801	PD-1 and PD-L1 as emerging therapeutic targets in gastric cancer: current evidence.	Gastrointestinal cancer : targets and therapy	2017	43.64732995045242	19.266536165909248	32	1.29
28756882	Cell genomics and immunosuppressive biomarker expression influence PD-L1 immunotherapy treatment responses in HNSCC-a computational study.	Oral surgery, oral medicine, oral pathology and oral radiology	2017	-6.3212834158358016	-4.152830479721669	8	0.31
28756808	Role of Immune Microenvironmental Factors for Improving the IPI-related Risk Stratification of Aggressive B Cell Lymphoma.	Biomedical and environmental sciences : BES	2017	-30.514809605378986	34.031000545679554	5	0.24
28756224	Treatment with a programmed cell death-1-specific antibody has little effect on afatinib- and naphthalene-induced acute pneumonitis in mice.	Biochemical and biophysical research communications	2017	63.26487476070146	-11.632365373168383	2	0.08
28754154	Prognostic value of programmed death-1, programmed death-ligand 1, programmed death-ligand 2 expression, and CD8(+) T cell density in primary tumors and metastatic lymph nodes from patients with stage T1-4N+M0 gastric adenocarcinoma.	Chinese journal of cancer	2017	-9.854603402231506	5.850804269159395	31	1.24
28749918	Immunotherapy in urothelial cancer, part 2: adjuvant, neoadjuvant, and adjunctive treatment.	Clinical advances in hematology & oncology : H&O	2017	71.73648922139994	21.41164624257534	4	0.14
28749907	Immunotherapy in urothelial cancer, part 1: T-cell checkpoint inhibition in advanced or metastatic disease.	Clinical advances in hematology & oncology : H&O	2017	71.4739898941204	21.337747662318503	4	0.13
28747424	ILC2s regulate adaptive Th2 cell functions via PD-L1 checkpoint control.	The Journal of experimental medicine	2017	-57.0057617416229	-14.507707824981953	88	2.83
28742984	Single versus combined immunoregulatory approach using PD-1 and CTLA-4 modulators in controlling sepsis.	Expert review of clinical immunology	2017	-60.05189431330973	37.36834008737333	10	0.38
28740692	Durable complete response to nivolumab in a patient with HIV and metastatic non-small cell lung cancer.	Journal of thoracic disease	2017	45.39651264557139	-27.7420968833362	26	0.91
28739315	Combination Therapy of Radiotherapy and Anti-PD-1/PD-L1 Treatment in Non-Small-cell Lung Cancer: A Mini-review.	Clinical lung cancer	2018	43.31781976673627	-21.74673563224837	52	2.1
28738360	Targeting Developmental Pathways: The Achilles Heel of Cancer?	Oncology	2017	-11.614631811408051	37.21243801503581	16	0.54
28737430	Nivolumab for the treatment of bladder cancer.	Expert opinion on biological therapy	2017	64.92630030674145	20.173778384367782	13	0.47
28735186	Development of a robust reporter gene assay to measure the bioactivity of anti-PD-1/anti-PD-L1 therapeutic antibodies.	Journal of pharmaceutical and biomedical analysis	2017	13.024484529038078	-46.94809107873113	32	1.15
28730140	Current Advances in Checkpoint Inhibitors: Lessons from Non-Central Nervous System Cancers and Potential for Glioblastoma.	Frontiers in oncology	2017	-29.124927937785944	58.60868614767367	14	0.58
28724377	Combination therapy for melanoma with BRAF/MEK inhibitor and immune checkpoint inhibitor: a mathematical model.	BMC systems biology	2017	30.564495099972405	32.489269652996896	26	1.02
28723893	In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target.	Nature	2017	-25.03695215855611	-22.601160496202827	629	20.21
28721019	Inhibitors of the PD-1/PD-L1 axis for the treatment of head and neck cancer: current status and future perspectives.	Drug design, development and therapy	2017	52.08180283088435	36.37554503706862	33	1.28
28720865	Immunology: PD-1 and PD-L1 prognostic in UTUC.	Nature reviews. Urology	2017	-16.772219135175217	15.288300156976064	3	0.11
28716652	Toxicity profiles of immunotherapy.	Pharmacology & therapeutics	2018	80.50659132397135	-5.987710153364667	46	1.91
28716437	Tumor programmed cell death ligand 1 expression correlates with nodal metastasis in patients with cutaneous squamous cell carcinoma of the head and neck.	Journal of the American Academy of Dermatology	2017	-1.5021366121161035	-4.602977799019205	37	1.75
28716069	Angiosarcoma treated successfully with anti-PD-1 therapy - a case report.	Journal for immunotherapy of cancer	2017	59.325167832773246	-27.35926752182935	79	3.3
28714780	Atezolizumab for the treatment of non-small cell lung cancer.	Expert review of clinical pharmacology	2017	52.028748232858746	-38.81823950962541	28	1.05
28713682	Predictive biomarkers of immunotherapy for non-small cell lung cancer: results from an Experts Panel Meeting of the Italian Association of Thoracic Oncology.	Translational lung cancer research	2017	24.45822565927461	-35.98112826740515	39	1.36
28710273	PD-L1 up-regulation restrains Th17 cell differentiation in STAT3 loss- and STAT1 gain-of-function patients.	The Journal of experimental medicine	2017	-53.20696324161921	-4.54122311572127	46	1.54
28706113	PD-L1 (Programmed Death Ligand 1) Protects Against Experimental Intracerebral Hemorrhage-Induced Brain Injury.	Stroke	2017	-76.81082481351571	-8.187511682442954	35	1.55
28705256	Monocyte programmed death ligand-1 expression is an early marker for predicting infectious complications in acute pancreatitis.	Critical care (London, England)	2017	-55.81872310076291	31.722256956742477	25	1.02
28705024	MEDI 4736 (durvalumab) in non-small cell lung cancer.	Expert opinion on biological therapy	2017	41.46050045899051	-26.708483931291223	10	0.38
28700789	Hair Repigmentation During Immunotherapy Treatment With an Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Agent for Lung Cancer.	JAMA dermatology	2017	70.31944128769052	-23.817767996317784	45	2.12
28697065	Accurate PD-L1 Protocols for Non-Small Cell Lung Cancer can be Developed for Automated Staining Platforms With Clone 22C3.	Applied immunohistochemistry & molecular morphology : AIMM	2017	16.447715430047747	-39.233530803562125	22	0.86
28697001	The genetics of Hodgkin lymphoma: an overview and clinical implications.	Current opinion in oncology	2017	-29.771391924894687	26.82226667426334	17	0.58
28693793	Biomarkers of response to PD-1/PD-L1 inhibition.	Critical reviews in oncology/hematology	2017	19.65560492239053	-3.1903569375241863	208	7.77
28693161	PD-L1 and PD-1 expression correlate with prognosis in extrahepatic cholangiocarcinoma.	Oncology letters	2017	-0.1931586726473976	5.065452931190781	40	1.42
28692048	Increased expression of programmed cell death protein 1 on NK cells inhibits NK-cell-mediated anti-tumor function and indicates poor prognosis in digestive cancers.	Oncogene	2017	-13.816316635282076	6.343808325419847	224	8.43
28688973	PD-1/PD-L1 checkpoint blockades in non-small cell lung cancer: New development and challenges.	Cancer letters	2017	45.21313333222646	-31.78466092988035	70	2.53
28688724	PD-1 and PD-L1 expression in bone and soft tissue sarcomas.	Pathology	2017	-20.96740435409451	20.336411219073803	52	2.19
28687658	The Effect of Inhibitory Signals on the Priming of Drug Hapten-Specific T Cells That Express Distinct Vβ Receptors.	Journal of immunology (Baltimore, Md. : 1950)	2017	-63.914269741221055	0.0569947565983792	37	1.71
28685821	PD-1/PD-L1 inhibitors in haematological malignancies: update 2017.	Immunology	2017	37.95605323809355	-4.696828589415629	93	3.41
28685773	Inhibition of the B7-H3 immune checkpoint limits tumor growth by enhancing cytotoxic lymphocyte function.	Cell research	2017	-29.177862962416715	5.690530872908974	199	7.11
28684311	Hippo effector YAP directly regulates the expression of PD-L1 transcripts in EGFR-TKI-resistant lung adenocarcinoma.	Biochemical and biophysical research communications	2017	3.194404615038801	-34.30666378683304	109	3.92
28684274	Construction of high level prokaryotic expression and purification system of PD-L1 extracellular domain by using Escherichia coli host cell machinery.	Immunology letters	2017	-50.4241779520988	-28.129776120785124	10	0.39
28683452	Potential Role of the PD-1/PD-L1 Axis in the Immune Regulation of Chronic GVHD.	Oncology research and treatment	2017	-65.523233630922	-6.089898712990048	7	0.3
28681030	Novel immunotherapy in metastatic renal cell carcinoma.	Investigative and clinical urology	2017	66.1319714735408	33.24785806998149	16	0.49
28680882	Immunotherapy for Patients with Advanced Urothelial Cancer: Current Evidence and Future Perspectives.	BioMed research international	2017	70.438542877821	21.58624934468442	10	0.31
28680745	Vaccination targeting human HER3 alters the phenotype of infiltrating T cells and responses to immune checkpoint inhibition.	Oncoimmunology	2017	-26.619109776742796	-15.428569276350366	15	0.6
28679955	Adoptively transferred Vγ9Vδ2 T cells show potent antitumor effects in a preclinical B cell lymphomagenesis model.	JCI insight	2017	-36.84701641384577	3.756645553859028	52	2.03
28679768	PD-1+ Polyfunctional T Cells Dominate the Periphery after Tumor-Infiltrating Lymphocyte Therapy for Cancer.	Clinical cancer research : an official journal of the American Association for Cancer Research	2017	-27.39728662897737	0.8515652918244636	37	1.29
28679395	Ongoing clinical trials of PD-1 and PD-L1 inhibitors for lung cancer in China.	Journal of hematology & oncology	2017	30.58456873430137	-33.83595044907447	41	1.19
28679300	The emerging role of immune checkpoint based approaches in AML and MDS.	Leukemia & lymphoma	2018	18.570736429542677	17.072547113773936	75	3.17
28676214	DNA mismatch repair deficiency in surgically resected lung adenocarcinoma: Microsatellite instability analysis using the Promega panel.	Lung cancer (Amsterdam, Netherlands)	2017	12.81799181565293	44.76700900784886	49	1.7
28675453	New Dancing Couple: PD-L1 and MicroRNA.	Scandinavian journal of immunology	2017	3.698480589600618	-37.487008408867446	28	1.06
28675174	Landmarks in the treatment of muscle-invasive bladder cancer.	Nature reviews. Urology	2017	73.14578621537126	20.00724872360143	89	3.49
28671973	PD-L1 expression in pleomorphic, spindle cell and giant cell carcinoma of the lung is related to TTF-1, p40 expression and might indicate a worse prognosis.	PloS one	2017	5.673448375012625	-25.461641730861643	31	1.41
28671728	Clonality analysis of synchronous gastro-oesophageal junction carcinoma and distal gastric cancer by whole-exome sequencing.	The Journal of pathology	2017	-13.214040797261845	22.527489159373733	9	0.29
28668287	Prognostic Value of PD-1 and PD-L1 Expression in Patients with High Grade Upper Tract Urothelial Carcinoma.	The Journal of urology	2017	14.123411620133378	56.653535980934336	50	1.86
28666643	PD-L1 expression predicts longer disease free survival in high risk head and neck cutaneous squamous cell carcinoma.	Pathology	2017	-5.902475918206188	-7.642284886001649	33	1.53
28665401	PD-L1 and IAPs co-operate to protect tumors from cytotoxic lymphocyte-derived TNF.	Cell death and differentiation	2017	-19.334040816561117	-29.270809565037283	51	1.62
28662677	A phase I/II trial of fixed-dose stereotactic body radiotherapy with sequential or concurrent pembrolizumab in metastatic urothelial carcinoma: evaluation of safety and clinical and immunologic response.	Journal of translational medicine	2017	66.51668677841107	15.23464448193735	21	0.63
28661915	Endocrine dysfunction following immune checkpoint inhibitor therapy.	Current opinion in endocrinology, diabetes, and obesity	2017	82.28980193154585	-15.847691299422918	12	0.46
28657901	Increased intraepithelial CD3+ T-lymphocytes and high PD-L1 expression on tumor cells are associated with a favorable prognosis in esophageal squamous cell carcinoma and allow prognostic immunogenic subgrouping.	Oncotarget	2017	-5.919621277679556	26.343925857321707	37	1.46
28657846	Immune Checkpoint Inhibitors in Lung Cancer: Imaging Considerations.	AJR. American journal of roentgenology	2017	41.02199471099419	-31.8337805477375	16	0.61
28657225	Programmed death-1 pathway blockade produces a synergistic antitumor effect: combined application in ovarian cancer.	Journal of gynecologic oncology	2017	-32.79543657140395	-14.793289157642844	42	1.69
28655941	The Immunological Impact of Chemotherapy on the Tumor Microenvironment of Oral Squamous Cell Carcinoma.	Acta medica Okayama	2017	-5.544811939400607	-15.749105974176564	9	0.34
28653677	Monitoring immune-checkpoint blockade: response evaluation and biomarker development.	Nature reviews. Clinical oncology	2017	27.553541874360256	15.149915291730435	628	23.18
28653522	[Immunotherapy and non-small cell lung cancer : a (r)evolution].	Revue medicale de Bruxelles	2017	34.41840801229898	-32.64875985071444	5	0.35
28652780	Overexpression of PD-L2 is associated with shorter relapse-free survival in patients with malignant salivary gland tumors.	OncoTargets and therapy	2017	-4.454013968248829	-0.7481958941578409	41	1.9
28651576	Decreased T helper 17 cells in tuberculosis is associated with increased percentages of programmed death ligand 1, T helper 2 and regulatory T cells.	Respiratory research	2017	-85.9706409698479	3.694168554644005	10	0.39
28651116	PD-1, PD-L1 and CTLA-4 in pregnancy-related - and in early-onset breast cancer: A comparative study.	Breast (Edinburgh, Scotland)	2017	-15.74214242189293	24.810379888712895	19	0.75
28650673	Evidence of Interleukin 21 Reduction in Osteosarcoma Patients Due to PD-1/PD-L1-Mediated Suppression of Follicular Helper T Cell Functionality.	DNA and cell biology	2017	-46.86103057672932	31.30449447146647	18	0.71
28650338	IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade.	The Journal of clinical investigation	2017	21.87515104847444	-11.853976838204288	2036	76.44
28648905	Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.	Gastroenterology	2017	-16.4943098265275	44.72983349153085	273	10.03
28646772	Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis.	European journal of cancer (Oxford, England : 1990)	2017	75.44726722736112	-11.480651054612478	117	5.74
28643044	PD-1 signaling and inhibition in AML and MDS.	Annals of hematology	2017	-35.36275792156767	11.969139980011333	25	0.95
28642997	PD-1 and cancer: molecular mechanisms and polymorphisms.	Immunogenetics	2018	-42.29829307785689	-11.545274193534585	80	3.48
28642819	Adoptive cell therapy using PD-1+ myeloma-reactive T cells eliminates established myeloma in mice.	Journal for immunotherapy of cancer	2017	-35.25027667626436	7.950398057819162	20	0.69
28642817	Cerebral vasculitis mimicking intracranial metastatic progression of lung cancer during PD-1 blockade.	Journal for immunotherapy of cancer	2017	75.86783570813965	-15.230182759684924	53	2.02
28638732	Serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death ligand 1 (sPD-L1) in advanced pancreatic cancer.	Oncoimmunology	2017	-46.104270850052536	21.10861771414462	97	3.6
28638730	Blockade of only TGF-β 1 and 2 is sufficient to enhance the efficacy of vaccine and PD-1 checkpoint blockade immunotherapy.	Oncoimmunology	2017	-22.26873860116219	-9.28413839664498	64	2.23
28638381	Anti-Bovine Programmed Death-1 Rat-Bovine Chimeric Antibody for Immunotherapy of Bovine Leukemia Virus Infection in Cattle.	Frontiers in immunology	2017	-58.76615328246309	-27.22747734400043	19	0.81
28637876	Monocyte-Derived Dendritic Cells with Silenced PD-1 Ligands and Transpresenting Interleukin-15 Stimulate Strong Tumor-Reactive T-cell Expansion.	Cancer immunology research	2017	-54.97075090170672	-19.234104678503208	33	1.21
28635639	Immune Checkpoints as a Target for Colorectal Cancer Treatment.	International journal of molecular sciences	2017	35.63377189311542	20.909559336375334	86	3.33
28634815	Autoimmune diabetes induced by PD-1 inhibitor-retrospective analysis and pathogenesis: a case report and literature review.	Cancer immunology, immunotherapy : CII	2017	88.95891846553194	-16.027390191951767	89	3.32
28634215	Vaccination with High-Affinity Epitopes Impairs Antitumor Efficacy by Increasing PD-1 Expression on CD8+ T Cells.	Cancer immunology research	2017	-28.495399414745453	-10.73507145757092	39	1.29
28633555	Glutamine Administration in Early or Late Septic Phase Downregulates Lymphocyte PD-1/PD-L1 Expression and the Inflammatory Response in Mice With Polymicrobial Sepsis.	JPEN. Journal of parenteral and enteral nutrition	2018	-59.71201485108928	35.01523053567124	22	1.2
28627792	β-Catenin in desmoid-type fibromatosis: deep insights into the role of T41A and S45F mutations on protein structure and gene expression.	Molecular oncology	2017	7.222697766302632	49.20999700487375	24	0.86
28626408	PD-1 Checkpoint Inhibitor Associated Autoimmune Encephalitis.	Case reports in oncology	2017	75.8827188778003	-15.271203060753804	54	2.24
28624922	Targeting the PD-1/PD-L1 Immune Checkpoint in EGFR-Mutated or ALK-Translocated Non-Small-Cell Lung Cancer.	Targeted oncology	2017	39.0985052424658	-36.09544480592943	62	2.04
28623775	Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape.	European journal of cancer (Oxford, England : 1990)	2017	21.605028742100448	3.9999417759043103	350	13.86
28623122	A Randomized Phase II Study Comparing Nivolumab With Carboplatin-Pemetrexed for Patients With EGFR Mutation-Positive Nonsquamous Non-Small-Cell Lung Cancer Who Acquire Resistance to Tyrosine Kinase Inhibitors Not Due to a Secondary T790M Mutation: Rationale and Protocol Design for the WJOG8515L Study.	Clinical lung cancer	2017	38.31463567123488	-39.7910350137999	12	0.35
28622513	Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma.	Cell	2017	-12.819984440982344	49.63464432696642	1444	56.59
28620836	SOX2 immunity and tissue resident memory in children and young adults with glioma.	Journal of neuro-oncology	2017	-27.83241850497525	57.27053193268002	24	0.79
28619999	PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer.	Clinical cancer research : an official journal of the American Association for Cancer Research	2017	-4.0686274020607325	-3.492295728809943	354	13.39
28616701	Predictive value of PD-L1 based on mRNA level in the treatment of stage IV melanoma with ipilimumab.	Journal of cancer research and clinical oncology	2017	8.863315822963907	-5.684839738474483	11	0.35
28614852	[Immunotherapy in urothelial carcinoma from a pathologist's perspective].	Aktuelle Urologie	2017	67.48498705600959	18.74585530813636	0	0.0
28611299	Cblb-deficient T cells are less susceptible to PD-L1-mediated inhibition.	Oncotarget	2017	-26.988210781240078	-6.168711653280035	16	0.47
28610825	Integrating Next-Generation Dendritic Cell Vaccines into the Current Cancer Immunotherapy Landscape.	Trends in immunology	2017	34.09829604478445	7.496490927342445	212	7.88
28608950	Assessment of programmed death-ligand 1 expression and tumor-associated immune cells in pediatric cancer tissues.	Cancer	2017	-26.71499013258795	17.913825732212736	116	4.3
28606922	In Situ Vaccination after Accelerated Hypofractionated Radiation and Surgery in a Mesothelioma Mouse Model.	Clinical cancer research : an official journal of the American Association for Cancer Research	2017	29.32567954705948	23.531980974582297	33	1.23
28605599	STAT3 Induces Immunosuppression by Upregulating PD-1/PD-L1 in HNSCC.	Journal of dental research	2017	-10.91074676462557	-8.068809468706098	120	4.69
28604383	Pyruvate controls the checkpoint inhibitor PD-L1 and suppresses T cell immunity.	The Journal of clinical investigation	2017	-57.33740125390272	7.240213564861806	67	2.22
28602029	The prognostic impact of programmed cell death ligand 1 and human leukocyte antigen class I in pancreatic cancer.	Cancer medicine	2017	-0.9036267524331552	1.9568517946736856	27	1.03
28595514	The incidence and relative risk of pulmonary toxicity in patients treated with anti-PD1/PD-L1 therapy for solid tumors: a meta-analysis of current studies.	Immunotherapy	2017	63.611308447102	-17.244080240264925	12	0.4
28595336	Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients.	Annals of oncology : official journal of the European Society for Medical Oncology	2017	11.903578849425664	-1.8341361020658364	265	9.78
28592155	Future perspectives for personalized immunotherapy in renal cell carcinoma.	Expert opinion on biological therapy	2017	21.17844838359076	30.622051593558	12	0.33
28591872	[The role of immunooncology in the treatment of urothelial cancer].	Aktuelle Urologie	2017	67.88630039484954	17.096980833064585	0	0.0
28588322	A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus).	British journal of cancer	2017	49.28114365441906	2.981331373095228	90	3.18
28585617	[Immunotherapy for lung cancer].	Magyar onkologia	2017	42.9143253323945	-32.42010660196127	0	0.0
28585615	[The role of immunotherapy in the modern treatment of urothelial carcinoma].	Magyar onkologia	2017	69.0544845576164	19.346840642899792	1	0.04
28585613	[Immunotherapy of renal cell cancer].	Magyar onkologia	2017	63.43288631707027	30.500652471506623	2	0.06
28579282	A radiosensitivity gene signature and PD-L1 status predict clinical outcome of patients with invasive breast carcinoma in The Cancer Genome Atlas (TCGA) dataset.	Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology	2017	-23.547268555574213	46.2406471717603	26	1.03
28574977	Development of a biclonal cutaneous T-cell lymphoproliferative process during treatment with immune checkpoint inhibitors for metastatic melanoma.	Melanoma research	2017	73.2711527019009	-26.13408976274127	4	0.3
28574843	Characterization of tumor-associated T-lymphocyte subsets and immune checkpoint molecules in head and neck squamous cell carcinoma.	Oncotarget	2017	-9.479055855542535	32.6842943881356	84	3.3
28572258	Immunotherapy for Breast Cancer: What Are We Missing?	Clinical cancer research : an official journal of the American Association for Cancer Research	2017	24.29851119186759	-0.9065803301663022	141	5.19
28571578	Immunotherapy in head and neck cancer: aiming at EXTREME precision.	BMC medicine	2017	50.99858710237179	30.240655144155923	50	1.89
28569410	PD-1 and PD-L1 in neoplastic cells and the tumor microenvironment of Merkel cell carcinoma.	Journal of cutaneous pathology	2017	-11.813880850878942	39.60766930270013	27	1.19
28560238	High PD-1 expression on regulatory and effector T-cells in lung cancer draining lymph nodes.	ERJ open research	2017	8.76059176611952	-20.43769792608911	21	0.68
28556912	Farnesyltransferase inhibitor FTI-277 inhibits PD-L1 expression on septic spleen lymphocytes and promotes spleen lymphocyte activation.	Clinical and experimental immunology	2017	-60.44285471916175	34.86075940682226	5	0.23
28546779	Emerging treatment options for the management of Hodgkin's lymphoma: clinical utility of nivolumab.	Journal of blood medicine	2017	41.213081320416535	-6.8038130293045125	4	0.13
28546465	Quantitative Mass Spectrometry Analysis of PD-L1 Protein Expression, N-glycosylation and Expression Stoichiometry with PD-1 and PD-L2 in Human Melanoma.	Molecular & cellular proteomics : MCP	2017	12.165595028741404	-44.019045553271184	48	1.89
28546286	Three Drugs Approved for Urothelial Carcinoma by FDA.	Cancer discovery	2017	68.34593790835686	18.480995353901253	17	0.55
28544524	Increase of cells expressing PD-1 and PD-L1 and enhancement of IFN-γ production via PD-1/PD-L1 blockade in bovine mycoplasmosis.	Immunity, inflammation and disease	2017	-80.29433646802543	2.4177162585612537	26	1.3
28539588	Cooperation of Oncolytic Herpes Virotherapy and PD-1 Blockade in Murine Rhabdomyosarcoma Models.	Scientific reports	2017	-36.39507828787324	52.23980293380991	56	2.24
28539467	B7-H3 Expression in NSCLC and Its Association with B7-H4, PD-L1 and Tumor-Infiltrating Lymphocytes.	Clinical cancer research : an official journal of the American Association for Cancer Research	2017	1.1616761631688952	-18.62361849027208	85	3.09
28537896	5T4 oncofoetal glycoprotein: an old target for a novel prostate cancer immunotherapy.	Oncotarget	2017	-24.10192483772937	-13.287906892297194	20	0.75
28537531	Clinical Features of Nivolumab-Induced Thyroiditis: A Case Series Study.	Thyroid : official journal of the American Thyroid Association	2017	76.60010137261415	-18.27021839546584	92	3.69
28533272	Chimeric PD-1:28 Receptor Upgrades Low-Avidity T cells and Restores Effector Function of Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy.	Cancer research	2017	-44.57001195317869	-1.4303036592535157	23	0.77
28533222	Fractionated Radiation Therapy Stimulates Antitumor Immunity Mediated by Both Resident and Infiltrating Polyclonal T-cell Populations when Combined with PD-1 Blockade.	Clinical cancer research : an official journal of the American Association for Cancer Research	2017	27.553190457605677	22.651537357027703	236	8.76
28532535	[Tumor Associated Fibroblasts Promote PD-L1 Expression in Lung Cancer Cells].	Zhongguo fei ai za zhi = Chinese journal of lung cancer	2017	5.367170349492439	-23.79953640676452	4	0.2
28531337	Correlation of immune phenotype with IDH mutation in diffuse glioma.	Neuro-oncology	2017	-20.58341610426273	54.0020309272748	172	6.14
28530662	PD-L1 inhibits acute and chronic pain by suppressing nociceptive neuron activity via PD-1.	Nature neuroscience	2017	-73.86867655251459	-13.097147330174852	115	4.81
28529902	Current state of immunotherapy for non-small cell lung cancer.	Translational lung cancer research	2017	41.88712986858489	-34.112327067319065	127	4.82
28524003	Targeting the Programmed Cell Death-1 Pathway in Genitourinary Tumors: Current Progress and Future Perspectives.	Current drug metabolism	2017	21.36877968639717	29.279276631180537	22	0.86
28522460	Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade.	Cancer immunology research	2017	7.932544157071525	5.953940007254713	237	9.01
28515962	Analyses of publicly available genomics resources define FGF-2-expressing bladder carcinomas as EMT-prone, proliferative tumors with low mutation rates and high expression of CTLA-4, PD-1 and PD-L1.	Signal transduction and targeted therapy	2017	5.016044619086725	56.97072802585689	31	1.19
28514966	Clinical applications of PD-L1 bioassays for cancer immunotherapy.	Journal of hematology & oncology	2017	18.90519499297927	-43.93678593788734	56	1.87
28514441	PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity.	Nature	2017	-32.426944746357584	-6.270825964669102	1207	47.23
28512174	Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma.	Clinical cancer research : an official journal of the American Association for Cancer Research	2017	11.324469293841226	-3.626114649657613	167	5.97
28511795	miR-142-5p regulates tumor cell PD-L1 expression and enhances anti-tumor immunity.	Biochemical and biophysical research communications	2017	-16.926477382017683	0.9824752514285984	116	4.75
28507805	Generation and functional characterization of MDSC-like cells.	Oncoimmunology	2017	-51.56171858658677	28.148451097743106	37	1.37
28507801	The novel negative checkpoint regulator VISTA is expressed in gastric carcinoma and associated with PD-L1/PD-1: A future perspective for a combined gastric cancer therapy?	Oncoimmunology	2017	-39.068364069600605	36.84520228377228	98	3.58
28507793	Composite biomarkers defined by multiparametric immunofluorescence analysis identify ALK-positive adenocarcinoma as a potential target for immunotherapy.	Oncoimmunology	2017	11.717190849733802	-33.39329709655707	24	0.86
28505981	Severe Exacerbation of Myasthenia Gravis Associated with Checkpoint Inhibitor Immunotherapy.	Journal of neuromuscular diseases	2017	68.24755368061554	-3.95464506422088	26	1.26
28504999	Tumor Microenvironment and Checkpoint Molecules in Primary Cutaneous Diffuse Large B-Cell Lymphoma-New Therapeutic Targets.	The American journal of surgical pathology	2017	-31.85509641794058	30.598580634093995	31	1.35
28503213	Epigenetic modifications of the immune-checkpoint genes CTLA4 and PDCD1 in non-small cell lung cancer results in increased expression.	Clinical epigenetics	2017	-0.2349335611812252	-32.00721219481464	48	1.66
28501937	Expression of PD-L1 in keratoacanthoma and different stages of progression in cutaneous squamous cell carcinoma.	Cancer immunology, immunotherapy : CII	2017	-1.090849433401066	-4.213967238362522	20	0.9
28499515	Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of Trials.	Chest	2017	64.57288684813804	-11.656147285247393	307	12.53
28497159	Current status of chimeric antigen receptor engineered T cell-based and immune checkpoint blockade-based cancer immunotherapies.	Cancer immunology, immunotherapy : CII	2017	19.20135669246761	2.6573278406543337	25	0.91
28496333	Immune checkpoint blockade: the role of PD-1-PD-L axis in lymphoid malignancies.	OncoTargets and therapy	2017	-43.8907371147763	-13.286152653610104	33	1.24
28496056	Stat3 inhibitor abrogates the expression of PD-1 ligands on lymphoma cell lines.	Journal of clinical and experimental hematopathology : JCEH	2017	-35.663554837263824	20.385450741790603	23	0.83
28494868	Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression.	Cell reports	2017	-17.861828157722396	-20.37613484001509	1000	37.46
28493410	Expression and prognostic significance of programmed death protein 1 and programmed death ligand-1, and cytotoxic T lymphocyte-associated molecule-4 in hepatocellular carcinoma.	APMIS : acta pathologica, microbiologica, et immunologica Scandinavica	2017	-22.54148152729257	39.87955874313014	49	1.9
28492290	Atezolizumab: A novel PD-L1 inhibitor in cancer therapy with a focus in bladder and non-small cell lung cancers.	Drugs of today (Barcelona, Spain : 1998)	2017	52.72307075799614	-39.259969585962914	28	0.98
28488345	Patterns of PD-1, PD-L1, and PD-L2 expression in pediatric solid tumors.	Pediatric blood & cancer	2017	-26.81997184099176	18.024054936453663	38	1.32
28488168	The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC).	Breast cancer (Tokyo, Japan)	2018	-6.120183760370441	18.944241715148884	77	3.3
28487502	PDCD1 (PD-1) promoter methylation predicts outcome in head and neck squamous cell carcinoma patients.	Oncotarget	2017	-10.030301552109556	40.057287870325005	36	1.44
28487385	Immune-Related Gene Expression Profiling After PD-1 Blockade in Non-Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma.	Cancer research	2017	9.074916182720106	-5.369758456950957	268	9.21
30466788	Expression of immunoregulatory molecules PD-L1 and PD-1 in oral cancer and precancerous lesions: A cohort study of Japanese patients.	Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery	2019	-8.372001857644626	-11.837505031817102	22	1.18
28483787	A STING Agonist Given with OX40 Receptor and PD-L1 Modulators Primes Immunity and Reduces Tumor Growth in Tolerized Mice.	Cancer immunology research	2017	-22.698237758489807	-44.8725223797927	103	3.53
28482851	Checkpoint inhibitors in hematological malignancies.	Journal of hematology & oncology	2017	35.257826318866755	-7.490660181237493	88	3.19
28480996	The PD-1/PD-L1 axis and human papilloma virus in patients with head and neck cancer after adjuvant chemoradiotherapy: A multicentre study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG).	International journal of cancer	2017	-3.871753867404254	-9.20254386995072	68	2.89
28478231	Combined Radiotherapy and Anti-PD-L1 Antibody Synergistically Enhances Antitumor Effect in Non-Small Cell Lung Cancer.	Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer	2017	14.71386740594384	-23.703016670903867	170	6.37
28476944	Impact of Age on Outcomes with Immunotherapy for Patients with Melanoma.	The oncologist	2017	55.71992059554603	-19.12060494752597	121	4.29
28472902	PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: updated survival data.	Immunotherapy	2017	16.199427841214966	-31.562155528325015	149	5.69
28465490	Type Iγ phosphatidylinositol phosphate kinase regulates PD-L1 expression by activating NF-κB.	Oncotarget	2017	-36.531443827678245	-6.353790227851869	21	0.72
28464441	Current studies of immunotherapy in head and neck cancer.	Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery	2018	51.80717301144398	32.087472087326944	47	1.99
28463413	A systematic review and network meta-analysis of immunotherapy and targeted therapy for advanced melanoma.	Cancer medicine	2017	30.923838786311688	31.928250526876887	38	1.47
28463396	T-cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death-ligand 1 expression in patients with soft tissue sarcomas.	Cancer	2017	-18.465037636829823	20.622486894131463	174	6.95
28461396	Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed/refractory multiple myeloma.	Blood	2017	46.01038605213533	-3.758664013634347	148	5.67
28461179	Immune Characterization of the Programmed Death Receptor Pathway in High Risk Prostate Cancer.	Clinical genitourinary cancer	2017	-12.692195439983678	12.930569149485292	32	1.03
28460468	PD-L1 expression and its relationship with oncogenic drivers in non-small cell lung cancer (NSCLC).	Oncotarget	2017	11.875481130770028	-32.999218026663826	47	1.65
28460462	The prognostic role of immune checkpoint markers programmed cell death protein 1 (PD-1) and programmed death ligand 1 (PD-L1) in a large, multicenter prostate cancer cohort.	Oncotarget	2017	-12.48419826168874	12.880250852488672	55	1.96
28460011	The immune microenvironment of HPV-negative oral squamous cell carcinoma from never-smokers and never-drinkers patients suggests higher clinical benefit of IDO1 and PD1/PD-L1 blockade.	Annals of oncology : official journal of the European Society for Medical Oncology	2017	-9.134332782788238	-15.329239388966077	67	2.75
28459943	Circulating tumor DNA changes for early monitoring of anti-PD1 immunotherapy: a proof-of-concept study.	Annals of oncology : official journal of the European Society for Medical Oncology	2017	24.873832923711905	-12.741681044937138	195	7.04
30190908	Are PD-1 antibodies safe for use in metastatic uveal melanoma?	Melanoma management	2017	44.34506021520923	1.8764710803327125	0	0.0
28454880	Expression of negative immune regulatory molecules, pro-inflammatory chemokine and cytokines in immunopathology of ECM developing mice.	Acta tropica	2017	-75.98050098209684	1.7968954142455174	11	0.53
28454587	Emerging therapies for breast cancer.	Journal of hematology & oncology	2017	22.336759755283733	-1.7232548831577184	40	1.51
28451792	KRAS mutation-induced upregulation of PD-L1 mediates immune escape in human lung adenocarcinoma.	Cancer immunology, immunotherapy : CII	2017	19.9600737498403	-22.690918368411197	176	6.09
28447277	Assessment of PD-1 positive cells on initial and secondary resected tumor specimens of newly diagnosed glioblastoma and its implications on patient outcome.	Journal of neuro-oncology	2017	-23.44152315360951	51.300446019400965	34	1.44
28446641	Risk of Pneumonitis Associated with Programmed Cell Death 1 Inhibitors in Cancer Patients: A Meta-analysis.	Molecular cancer therapeutics	2017	64.62546796291862	-11.558568278562005	16	0.51
28445951	PD-L1 expression in perihilar and intrahepatic cholangiocarcinoma.	Oncotarget	2017	0.9040975834134302	5.169172625763205	119	4.49
28445479	In vitro and in vivo antivirus activity of an anti-programmed death-ligand 1 (PD-L1) rat-bovine chimeric antibody against bovine leukemia virus infection.	PloS one	2017	-58.686349746649206	-27.010526877303587	27	1.32
28440953	Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: Results of a phase 2 study.	Cancer	2017	40.47040938605584	0.5607285330296955	140	5.13
28434400	Role of modern immunotherapy in gastrointestinal malignancies: a review of current clinical progress.	Journal of hematology & oncology	2017	41.759613284272056	19.435689373799093	51	1.87
28434399	The next generation of immunotherapy: keeping lung cancer in check.	Journal of hematology & oncology	2017	35.57370395718125	-31.93713213249034	72	2.59
28434031	FKBP51s signature in peripheral blood mononuclear cells of melanoma patients as a possible predictive factor for immunotherapy.	Cancer immunology, immunotherapy : CII	2017	-1.619559507515849	-17.655843959339883	10	0.38
28432789	Probing protein flexibility reveals a mechanism for selective promiscuity.	eLife	2017	-48.026722862140666	-41.17524888920551	15	0.67
28432648	Rationale for New Checkpoint Inhibitor Combinations in Melanoma Therapy.	American journal of clinical dermatology	2017	29.999067430368857	5.145529968851173	8	0.26
28432616	Prognostic impact of PD-1 and its ligands in renal cell carcinoma.	Medical oncology (Northwood, London, England)	2017	17.161493508224986	25.905220114588268	14	0.41
28430664	Identification of a novel PD-L1 positive solid tumor transplantable in HLA-A*0201/DRB1*0101 transgenic mice.	Oncotarget	2017	-22.46878177886448	19.84636510708526	4	0.15
28428947	Update on Programmed Death-1 and Programmed Death-Ligand 1 Inhibition in the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer.	Frontiers in oncology	2017	41.32527968554929	-33.237171493441735	24	0.77
28427522	The role of anti-PD-1 and anti-PD-L1 agents in the treatment of diffuse large B-cell lymphoma: The future is now.	Critical reviews in oncology/hematology	2017	-44.39592320474553	-11.356600518126266	17	0.64
28424162	Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL.	Blood	2017	43.79595508151122	-3.8693302179709352	276	9.89
28423520	Prognostic role of programmed-death ligand 1 (PD-L1) expressing tumor infiltrating lymphocytes in testicular germ cell tumors.	Oncotarget	2017	-25.6070321159704	34.4236335851895	53	2.4
28423034	Elevated frequencies of CD8 T cells expressing PD-1, CTLA-4 and Tim-3 within tumour from perineural squamous cell carcinoma patients.	PloS one	2017	-12.883403756401185	30.921144298711127	26	1.0
28421161	Incidence of Immune-Related Adverse Events with Program Death Receptor-1- and Program Death Receptor-1 Ligand-Directed Therapies in Genitourinary Cancers.	Frontiers in oncology	2017	62.8115052459318	-16.332911022251334	60	2.15
28420421	Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden.	Genome medicine	2017	7.014310121418466	49.6695760952993	2003	80.12
28419539	PD-L1 expression in extrahepatic cholangiocarcinoma.	Histopathology	2017	-0.1251734502949539	5.0027059914848	54	2.06
28419181	Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.	Annals of oncology : official journal of the European Society for Medical Oncology	2017	53.89384107396647	7.922648780937993	396	15.05
28418918	The PD-1, PD-L1 expression and CD3+ T cell infiltration in relation to outcome in advanced gastric signet-ring cell carcinoma, representing a potential biomarker for immunotherapy.	Oncotarget	2017	-8.89742805080855	7.719177175680351	30	1.27
28416578	WITHDRAWN: Quantitative mass spectrometry analysis of PD-L1 protein expression, N-glycosylation and expression stoichiometry with PD-1 and PD-L2 in human melanoma.	Molecular & cellular proteomics : MCP	2017	11.854778338130224	-44.216231907304525	0	0.0
28415798	Tumor-derived IL-18 induces PD-1 expression on immunosuppressive NK cells in triple-negative breast cancer.	Oncotarget	2017	-25.475180957599747	7.850987959885856	61	2.41
28414300	PD-L1 serves as a double agent in separating GVL from GVHD.	The Journal of clinical investigation	2017	-65.69983816442347	-6.336488090160245	8	0.33
28414296	PD-L1 interacts with CD80 to regulate graft-versus-leukemia activity of donor CD8+ T cells.	The Journal of clinical investigation	2017	-64.84098621832972	-6.136894808865712	77	2.58
28412753	Vitamin D increases programmed death receptor-1 expression in Crohn's disease.	Oncotarget	2017	-59.45612498018569	16.757840356116958	20	1.0
28409437	Prognostic significance of PD-L1 expression on tumor cells and tumor-infiltrating mononuclear cells in upper tract urothelial carcinoma.	Medical oncology (Northwood, London, England)	2017	13.685942885496788	57.45155474960789	40	1.55
28408783	Prokaryotic expression of the extracellular domain of porcine programmed death 1 (PD-1) and its ligand PD-L1 and identification of the binding with peripheral blood mononuclear cells in vitro.	Canadian journal of veterinary research = Revue canadienne de recherche veterinaire	2017	-50.54148361271345	-27.83882219515674	2	0.05
28407741	The PD-1: PD-L1 pathway promotes development of brain-resident memory T cells following acute viral encephalitis.	Journal of neuroinflammation	2017	-75.5449726613784	-2.0883504730348337	44	1.48
28406723	Aspirin Use and Colorectal Cancer Survival According to Tumor CD274 (Programmed Cell Death 1 Ligand 1) Expression Status.	Journal of clinical oncology : official journal of the American Society of Clinical Oncology	2017	9.653465474301996	35.261344195914745	97	3.45
28405521	Human papilloma virus load and PD-1/PD-L1, CD8+ and FOXP3 in anal cancer patients treated with chemoradiotherapy: Rationale for immunotherapy.	Oncoimmunology	2017	-2.4000502594384843	-9.463097923028016	68	2.77
28405512	High expression of PD-1 ligands is associated with kataegis mutational signature and APOBEC3 alterations.	Oncoimmunology	2017	-14.919050040589449	-7.0039167433803176	54	1.69
28404915	Prognostic significance of tumor-infiltrating immune cells and PD-L1 expression in esophageal squamous cell carcinoma.	Oncotarget	2017	-13.454170221319965	8.325053822955274	69	2.72
28404866	Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation.	Science translational medicine	2017	-23.600065131875454	-20.074754952867803	458	16.55
28404865	Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade.	Science translational medicine	2017	-8.741554352537618	-44.445955981274906	368	13.21
28403786	Immune Checkpoint Inhibitors and Cardiac Toxicity: An Emerging Issue.	Current medicinal chemistry	2018	83.2792962747666	3.790047411224333	82	3.88
28403223	Vascular endothelial growth factor A amplification in colorectal cancer is associated with reduced M1 and M2 macrophages and diminished PD-1-expressing lymphocytes.	PloS one	2017	8.910089919143497	37.510014515710886	14	0.59
28403071	The expression and clinical relevance of PD-1, PD-L1, and TP63 in patients with diffuse large B-cell lymphoma.	Medicine	2017	-34.10564861651981	27.250332610449224	38	1.35
28402953	Mechanisms of PD-1/PD-L1 expression and prognostic relevance in non-Hodgkin lymphoma: a summary of immunohistochemical studies.	Oncotarget	2017	-39.86455663613671	-13.7912976022685	62	2.33
28401456	Cardiovascular Complications Associated With Novel Cancer Immunotherapies.	Current treatment options in cardiovascular medicine	2017	83.65250806965766	3.5443728960274616	57	2.2
28401381	Antiangiogenic therapy combined with immune checkpoint blockade in renal cancer.	Angiogenesis	2017	66.06456699314175	32.5522230924616	49	1.83
28397821	T-cell invigoration to tumour burden ratio associated with anti-PD-1 response.	Nature	2017	11.25398361719598	-4.524748406499802	1020	36.36
28397730	Programmed Cell Death-1/Programmed Death-ligand 1 Pathway: A New Target for Sepsis.	Chinese medical journal	2017	-58.72921353167639	34.66249625175701	12	0.49
28395442	[PD-1/PD-L1 expression and its implications in patients with chronic lymphocytic leukemia].	Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi	2017	-40.26350417461266	20.859712777769435	2	0.08
28393361	Immune checkpoints and their inhibition in cancer and infectious diseases.	European journal of immunology	2017	24.38499973050496	9.59326890784518	321	12.69
28389661	CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells.	Scientific reports	2017	-44.15225112098344	1.6444089173375351	438	15.52
28388955	Blocking the PD-1/PD-L1 pathway in glioma: a potential new treatment strategy.	Journal of hematology & oncology	2017	-25.77804960670424	50.68463535940064	99	3.95
28383817	CD70 and PD-L1 in anaplastic thyroid cancer - promising targets for immunotherapy.	Histopathology	2017	-8.293247314233072	-20.684240569898048	41	1.71
28383777	The PD-1 expressing immune phenotype of T cell exhaustion is prominent in the 'immunoreactive' microenvironment of colorectal carcinoma.	Histopathology	2017	7.286723004146131	38.4775575298306	14	0.46
28383639	Immune checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directions.	Annals of oncology : official journal of the European Society for Medical Oncology	2017	64.02444657248233	30.407956166355564	96	3.15
28382562	Biomarkers to predict prognosis and response to checkpoint inhibitors.	International journal of clinical oncology	2017	22.754453273663223	-7.016416077870156	48	1.71
28376884	Cancer immunotherapies targeting the PD-1 signaling pathway.	Journal of biomedical science	2017	23.76853701080736	5.453918097994253	392	14.9
28373007	Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial.	The Lancet. Oncology	2017	50.93893920645376	-6.441841403397468	215	8.0
28371827	Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy.	Neuro-oncology	2017	-22.230039672275097	56.71258218285441	272	10.45
28367063	Understanding the role of PD-L1/PD1 pathway blockade and autophagy in cancer therapy.	OncoTargets and therapy	2017	-41.42387442760256	-22.31776303087938	52	2.01
28366014	Promising immunotherapies for esophageal cancer.	Expert opinion on biological therapy	2017	54.81065758024542	15.49190850244324	20	0.7
28359471	Targeting Immune Checkpoints in Esophageal Cancer: A High Mutational Load Tumor.	The Annals of thoracic surgery	2017	44.86507827476359	20.70896613225089	29	0.96
28356247	PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma.	Blood	2017	41.43525217484537	-5.7451245643784885	287	11.16
28353093	PD-L2: A prognostic marker in chromophobe renal cell carcinoma?	Medical oncology (Northwood, London, England)	2017	17.27974755983015	27.722986768696185	15	0.54
28351930	Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate.	Clinical cancer research : an official journal of the American Association for Cancer Research	2017	28.37361820754589	-15.723821267354012	618	22.48
28351328	Effect of EBI3 on radiation-induced immunosuppression of cervical cancer HeLa cells by regulating Treg cells through PD-1/PD-L1 pathway.	Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine	2017	2.3120596869740084	-13.56547143087268	8	0.31
28351171	Releasing the brake: safety profile of immune check-point inhibitors in non-small cell lung cancer.	Expert opinion on drug safety	2017	72.70502092416253	-11.985227909495975	19	0.68
28349740	Immunotherapy for gastric cancers: emerging role and future perspectives.	Expert review of clinical pharmacology	2017	42.77542570298004	19.101539239030465	27	0.93
28349165	Programmed death-ligand 1 and its soluble form are highly expressed in nasal natural killer/T-cell lymphoma: a potential rationale for immunotherapy.	Cancer immunology, immunotherapy : CII	2017	-38.36684661794524	23.5925032952181	106	4.23
28346916	PD-1/PD-L1 Pathway in Breast Cancer.	Oncology research and treatment	2017	-44.142181633725855	-16.02031937024218	91	3.73
28345650	Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy.	Nature communications	2017	-35.90092381686461	51.31775352567819	241	9.15
28345023	Enhancement of PSMA-Directed CAR Adoptive Immunotherapy by PD-1/PD-L1 Blockade.	Molecular therapy oncolytics	2017	-42.409425365058944	3.511017653183163	64	2.19
28344892	Clear cell ovarian cancers with microsatellite instability: A unique subset of ovarian cancers with increased tumor-infiltrating lymphocytes and PD-1/PD-L1 expression.	Oncoimmunology	2017	9.648579400448916	46.11765053585901	74	2.75
28344886	CAR T-cell intrinsic PD-1 checkpoint blockade: A two-in-one approach for solid tumor immunotherapy.	Oncoimmunology	2017	-42.29729299658192	2.8242892103348822	90	3.02
28344870	Immunological profiling of molecularly classified high-risk endometrial cancers identifies POLE-mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibition.	Oncoimmunology	2017	7.57372620169766	45.715704465961984	83	2.76
28344865	Identification of genetic determinants of breast cancer immune phenotypes by integrative genome-scale analysis.	Oncoimmunology	2017	-2.316351404144087	41.84097414923451	115	3.76
28344809	Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade.	Journal for immunotherapy of cancer	2017	0.3718026205754707	-3.6924566324328536	95	4.05
28344662	Nivolumab in renal cell carcinoma: latest evidence and clinical potential.	Therapeutic advances in medical oncology	2017	63.54044751444553	28.994212809279368	44	1.71
28341875	PD-L1 overexpression is partially regulated by EGFR/HER2 signaling and associated with poor prognosis in patients with non-small-cell lung cancer.	Cancer immunology, immunotherapy : CII	2017	5.629471573925385	-31.95536092298802	103	3.9
28335888	Second- and third-generation drugs for immuno-oncology treatment-The more the better?	European journal of cancer (Oxford, England : 1990)	2017	20.00284247196389	5.922689904775277	156	5.74
28335643	Prospects and progress of atezolizumab in non-small cell lung cancer.	Expert opinion on biological therapy	2017	51.89919092951663	-38.59362885295496	12	0.43
28334399	Association of HIV Status With Local Immune Response to Anal Squamous Cell Carcinoma: Implications for Immunotherapy.	JAMA oncology	2017	0.9605289134826756	-6.615068538200099	58	2.21
28332100	Expression of programmed death-1 and its ligands in the liver of biliary atresia.	World journal of pediatrics : WJP	2017	-67.8450220628001	24.42633553317154	0	0.0
28331615	"Nuclear IRF-1 expression as a mechanism to assess ""Capability"" to express PD-L1 and response to PD-1 therapy in metastatic melanoma."	Journal for immunotherapy of cancer	2017	9.897765761111994	-5.871867802831099	25	0.86
28327740	Molecular dynamics simulations elucidate conformational selection and induced fit mechanisms in the binding of PD-1 and PD-L1.	Molecular bioSystems	2017	-48.04766467975123	-40.7793514690041	24	1.04
28324831	Primary and acquired resistance to PD-1/PD-L1 blockade in cancer treatment.	International immunopharmacology	2017	-35.17439759554138	-21.23942456855753	88	3.3
28324060	Expression of PD-1 and PD-L1 in Anaplastic Thyroid Cancer Patients Treated With Multimodal Therapy: Results From a Retrospective Study.	The Journal of clinical endocrinology and metabolism	2017	-7.551969738533351	-20.61386979020916	69	3.05
28323141	Mechanistic and pharmacologic insights on immune checkpoint inhibitors.	Pharmacological research	2017	23.233902159033544	8.671271147609858	30	0.99
28321814	Immunotherapy in NSCLC: A Promising and Revolutionary Weapon.	Advances in experimental medicine and biology	2017	35.699817717184494	-32.207727385148296	85	3.34
28321813	Harnessing the Immune System Against Leukemia: Monoclonal Antibodies and Checkpoint Strategies for AML.	Advances in experimental medicine and biology	2017	17.42697958137384	17.202943639420855	23	0.84
28321130	Effective combinatorial immunotherapy for castration-resistant prostate cancer.	Nature	2017	21.939301968478897	17.0808713685319	352	12.39
28318951	A Comprehensive Analysis of Programmed Cell Death Ligand-1 Expression With the Clone SP142 Antibody in Non-Small-Cell Lung Cancer Patients.	Clinical lung cancer	2017	50.892910231432026	-38.320987982817776	40	1.39
28317872	Preclinical evaluation of the efficacy, pharmacokinetics and immunogenicity of JS-001, a programmed cell death protein-1 (PD-1) monoclonal antibody.	Acta pharmacologica Sinica	2017	-3.1541112961896656	-55.108123942853	38	1.18
28315964	Biological predictors of radiosensitivity in head and neck squamous cell carcinoma.	Clinical oral investigations	2018	-4.030612023670241	-9.426728166523802	21	1.0
28314298	Multi-omics Profiling of Patients with Melanoma Treated with Nivolumab in Project HOPE.	Anticancer research	2017	11.489212670107026	-0.9472388438314502	4	0.13
30657300	[Hodgkin Lymphoma].	La Revue du praticien	2017	44.43898964461236	-48.58171650515801	0	0.0
28306559	Immunotherapy: a new treatment paradigm in bladder cancer.	Current opinion in oncology	2017	69.9597859523985	22.13056430054104	33	1.33
28303311	[Immunotherapy of cancer with checkpoint inhibitors : Not only in malignant melanoma].	Der Internist	2017	31.28208125802478	3.3656058374794915	2	0.12
28302645	PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity.	The Journal of experimental medicine	2017	-33.96283562704647	-9.351456583042864	503	18.06
28300475	Epitope mapping reveals the binding mechanism of a functional antibody cross-reactive to both human and murine programmed death 1.	mAbs	2017	-47.76414232901672	-32.984934494917084	7	0.33
28293764	Immune checkpoint inhibition and its relationship with hypermutation phenoytype as a potential treatment for Glioblastoma.	Journal of neuro-oncology	2017	-25.587700792968626	60.785710977052446	7	0.35
28293123	Pembrolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectives.	Lung Cancer (Auckland, N.Z.)	2017	47.48726947380933	-31.669819335278756	10	0.33
28291636	Correlation between messenger RNA expression and protein expression of immune checkpoint-associated molecules in bladder urothelial carcinoma: A retrospective study.	Urologic oncology	2017	7.828423692283804	58.23614148309009	28	0.98
28291584	Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial.	The Lancet. Oncology	2017	48.387733521201504	-0.9081587787063676	336	12.94
28289860	"The PD-L1/PD-1 pathway promotes dysfunction, but not ""exhaustion"", in tumor-responding T cells from pleural effusions in lung cancer patients."	Cancer immunology, immunotherapy : CII	2017	4.85423605496221	-22.322586528901613	28	1.12
28288993	A Combined PD-1/C5a Blockade Synergistically Protects against Lung Cancer Growth and Metastasis.	Cancer discovery	2017	12.161541727216289	-22.759611763910986	132	4.59
28287848	Immunomodulating and Immunoresistance Properties of Cancer-Initiating Cells: Implications for the Clinical Success of Immunotherapy.	Immunological investigations	2017	18.25802900585881	6.804202464977224	68	2.57
28283653	Antibody-Drug Conjugates Bearing Pyrrolobenzodiazepine or Tubulysin Payloads Are Immunomodulatory and Synergize with Multiple Immunotherapies.	Cancer research	2017	37.06063930915914	15.480520533787448	58	2.19
28282342	New developments in the biology and the treatment of metastatic Merkel cell carcinoma.	Current opinion in oncology	2017	45.82226412759411	50.21309431041142	33	1.45
28281549	Expression of PD-1 and PD-L1 in thymic epithelial neoplasms.	Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc	2017	-4.935611673621265	-36.95665848939242	78	3.26
28280600	Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade.	Cell discovery	2017	-47.03252761389145	-36.66574605802308	114	4.58
28280247	T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition.	Science (New York, N.Y.)	2017	-47.93970631053224	-6.748493822727247	947	33.94
28276698	The role of checkpoint inhibitors immunotherapy in advanced non-small cell lung cancer in the elderly.	Expert opinion on biological therapy	2017	37.95893542496941	-34.629326497589126	21	0.74
28275910	Mechanisms of Drug Resistance in Melanoma.	Handbook of experimental pharmacology	2018	30.139663296571804	30.984684978894204	58	2.78
28275222	PD-1, PD-L1 Protein Expression in Non-Small Cell Lung Cancer and Their Relationship with Tumor-Infiltrating Lymphocytes.	Medical science monitor : international medical journal of experimental and clinical research	2017	12.964611367860302	-29.898577786659843	46	1.71
28275182	Modulation of Hepatitis C Virus-Specific CD8 Effector T-Cell Function with Antiviral Effect in Infectious Hepatitis C Virus Coculture Model.	Journal of virology	2017	-76.67980410208138	25.471855218701727	4	0.15
28275115	Safety and Tolerability of PD-1/PD-L1 Inhibitors Compared with Chemotherapy in Patients with Advanced Cancer: A Meta-Analysis.	The oncologist	2017	55.8811990147074	-15.995581213813235	192	7.44
28274143	Avelumab: combining immune checkpoint inhibition and antibody-dependent cytotoxicity.	Expert opinion on biological therapy	2017	52.36483405955631	41.81223137099426	51	1.7
28271259	Neoadjuvant Treatment for Locally Invasive Esophageal Cancer.	World journal of surgery	2017	51.07419268595069	12.18241490929914	3	0.12
28270509	In situ and in silico kinetic analyses of programmed cell death-1 (PD-1) receptor, programmed cell death ligands, and B7-1 protein interaction network.	The Journal of biological chemistry	2017	-48.8448859380445	-39.0281154532721	14	0.42
28270499	PD-L1 Is a Therapeutic Target of the Bromodomain Inhibitor JQ1 and, Combined with HLA Class I, a Promising Prognostic Biomarker in Neuroblastoma.	Clinical cancer research : an official journal of the American Association for Cancer Research	2017	-26.93172400092226	14.394509867515591	78	2.77
28265006	Characterization of the Anti-PD-1 Antibody REGN2810 and Its Antitumor Activity in Human PD-1 Knock-In Mice.	Molecular cancer therapeutics	2017	-39.80070060076641	-28.957369385519268	76	2.81
28262583	Response to anti-programmed cell death protein-1 antibodies in men treated for platinum refractory germ cell cancer relapsed after high-dose chemotherapy and stem cell transplantation.	European journal of cancer (Oxford, England : 1990)	2017	49.529630751129226	25.55950739380734	42	1.76
28259107	Expression of Programmed Cell Death Ligand in Cutaneous Squamous Cell Carcinoma and Treatment of Locally Advanced Disease With Pembrolizumab.	JAMA dermatology	2017	56.57015619014821	5.73957922146904	67	2.9
28259105	Association Between Programmed Death Ligand 1 Expression in Patients With Basal Cell Carcinomas and the Number of Treatment Modalities.	JAMA dermatology	2017	0.3269428669730955	-4.057141986013487	31	1.36
28256540	PD-L1 predicts poor prognosis for nasopharyngeal carcinoma irrespective of PD-1 and EBV-DNA load.	Scientific reports	2017	-16.929527913235646	31.128737629325872	48	2.07
28254786	Clinical Impact of Tumor DNA Repair Expression and T-cell Infiltration in Breast Cancers.	Cancer immunology research	2017	7.745802986957993	31.414265917290365	48	1.54
28247187	Development of Novel ImmunoPET Tracers to Image Human PD-1 Checkpoint Expression on Tumor-Infiltrating Lymphocytes in a Humanized Mouse Model.	Molecular imaging and biology	2017	6.652885916703816	-55.23259533980979	75	3.15
28246107	Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients.	Cancer immunology research	2017	75.2140549213366	-8.920716220307913	300	11.58
28245875	Severe nivolumab-induced pneumonitis preceding durable clinical remission in a patient with refractory, metastatic lung squamous cell cancer: a case report.	Journal of hematology & oncology	2017	54.00206364459372	-28.22488400130054	25	0.99
30190903	Immunotherapy in malignant melanoma: recent approaches and new perspectives.	Melanoma management	2017	30.710105031983872	3.4844862457836348	6	0.18
28245522	Inflammatory cytokines compromise programmed cell death-1 (PD-1)-mediated T cell suppression in inflammatory arthritis through up-regulation of soluble PD-1.	Clinical and experimental immunology	2017	-52.268130906101206	15.120791243882824	53	2.22
28242618	Onset of connective tissue disease following anti-PD1/PD-L1 cancer immunotherapy.	Annals of the rheumatic diseases	2018	67.64935714642641	-24.517577275047543	44	2.42
28242522	Targeting the programmed death-1 pathway in lymphoid neoplasms.	Cancer treatment reviews	2017	-45.57144070970567	-10.897917803738045	20	0.73
28239469	Combination immunotherapy: a road map.	Journal for immunotherapy of cancer	2017	27.209977008761268	-1.6805521048913117	255	9.26
28238417	Enhanced expression of Programmed cell death 1 (PD-1) protein in benign vascular anomalies.	Pathology	2017	-21.77878834517318	23.98985956835599	6	0.32
28236980	Significance of immune checkpoint proteins in EGFR-mutant non-small cell lung cancer.	Lung cancer (Amsterdam, Netherlands)	2017	7.644501295681083	-35.04160654913961	44	1.44
28233730	Structure-guided development of a high-affinity human Programmed Cell Death-1: Implications for tumor immunotherapy.	EBioMedicine	2017	-46.88592512082151	-37.01969499666949	41	1.43
28233576	Potential immunotherapy targets in recurrent cervical cancer.	Gynecologic oncology	2017	-3.3199015035095147	35.24625684286724	15	0.6
28231855	COX-2 expression positively correlates with PD-L1 expression in human melanoma cells.	Journal of translational medicine	2017	4.402105481251818	-2.4422109096518128	65	2.81
28228704	PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer.	Breast care (Basel, Switzerland)	2016	14.95895417785929	-49.64864136567587	36	1.26
28228279	Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma.	Immunity	2017	-34.46639065288856	-22.062470125230615	341	11.58
28228226	[Progress of PD-1/PD-L1 Inhibitors in Non-small Cell Lung Cancer].	Zhongguo fei ai za zhi = Chinese journal of lung cancer	2017	46.78594364194207	-31.13961272969609	2	0.07
28223273	PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors.	Clinical cancer research : an official journal of the American Association for Cancer Research	2017	9.303329278113456	0.673022547477159	103	3.64
28223102	Inflammatory cytokines IL-17 and TNF-α up-regulate PD-L1 expression in human prostate and colon cancer cells.	Immunology letters	2017	-22.356717701326662	5.774018311089197	195	7.63
28220772	Tumour and host cell PD-L1 is required to mediate suppression of anti-tumour immunity in mice.	Nature communications	2017	-34.31357490059915	-9.88297443164742	245	8.18
28219001	GLUT1 as a Prognostic Factor for Classical Hodgkin's Lymphoma: Correlation with PD-L1 and PD-L2 Expression.	Journal of pathology and translational medicine	2017	-30.086770798744087	22.161820978108867	17	0.66
28214651	A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: The future is now.	Cancer treatment reviews	2017	70.06428659617647	21.56922923045562	256	10.04
28214087	Targeting the PD-1/PD-L1 axis in non-small cell lung cancer.	Current problems in cancer	2017	41.68076597386899	-31.99120674338812	33	1.17
28213726	PD-1 and PD-L1 antibodies in cancer: current status and future directions.	Cancer immunology, immunotherapy : CII	2017	-42.18559422669216	-16.62946390770469	212	8.12
28213366	Tumor-Infiltrating and Peripheral Blood T-cell Immunophenotypes Predict Early Relapse in Localized Clear Cell Renal Cell Carcinoma.	Clinical cancer research : an official journal of the American Association for Cancer Research	2017	15.69016451259572	32.834613242194706	220	7.69
28212061	PD-1 and PD-L1 Inhibitors as Salvage Therapy for Urothelial Carcinoma.	The New England journal of medicine	2017	64.44148321340576	17.63263708485459	39	1.31
28212060	Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.	The New England journal of medicine	2017	67.21805828046399	15.403347743363904	2142	90.35
28211040	Anti-CD3 treatment up-regulates programmed cell death protein-1 expression on activated effector T cells and severely impairs their inflammatory capacity.	Immunology	2017	-60.31644279586136	3.127882178222644	16	0.61
28210995	Checkpoint Inhibitors for the Treatment of Renal Cell Carcinoma.	Current treatment options in oncology	2017	63.80907879052407	30.85674538056776	36	1.34
28207501	PD-L1/PD-1 check-point in gastric carcinoma with lymphoid stroma case report with immunochemical study.	Medicine	2017	-9.76321805574615	4.129117497997807	4	0.19
28201746	Evaluating the significance of density, localization, and PD-1/PD-L1 immunopositivity of mononuclear cells in the clinical course of lung adenocarcinoma patients with brain metastasis.	Neuro-oncology	2017	-0.1039237109357604	17.159203860551017	34	1.18
28199990	Activation of NK cells and disruption of PD-L1/PD-1 axis: two different ways for lenalidomide to block myeloma progression.	Oncotarget	2017	-32.8243072676224	4.305387675121093	67	2.59
28197385	Prognostic and predictive aspects of the tumor immune microenvironment and immune checkpoints in malignant pleural mesothelioma.	Oncoimmunology	2017	6.297777087014542	13.902529549543075	58	2.08
28197375	Tumor-infiltrating lymphocyte composition, organization and PD-1/ PD-L1 expression are linked in breast cancer.	Oncoimmunology	2017	-3.280418316557467	19.10275178015036	136	4.54
28197370	Infiltration of PD-1-positive cells in combination with tumor site PD-L1 expression is a positive prognostic factor in cutaneous angiosarcoma.	Oncoimmunology	2017	-20.81146212052397	23.27293865273631	51	2.03
28197365	CRISPR-Cas9-mediated disruption of PD-1 on human T cells for adoptive cellular therapies of EBV positive gastric cancer.	Oncoimmunology	2017	-37.61747232921322	6.540141930147271	62	1.9
28195250	Programmed death 1 (PD-1) and its ligand (PD-L1) as a new frontier in cancer Immunotherapy and challenges for the Pathologist: state of the art.	Pathologica	2016	-45.23263754191895	-17.893970482719542	14	0.56
28194020	CD103+ lung dendritic cells (LDCs) induce stronger Th1/Th17 immunity to a bacterial lung infection than CD11bhi LDCs.	Cellular & molecular immunology	2018	-81.40414646594812	6.437114843945993	28	1.13
28190531	Cutaneous adverse effects of the immune checkpoint inhibitors.	Current problems in cancer	2017	73.76609641419543	-24.501147380497866	116	5.24
28188185	Response to PD-1 Blockade in Microsatellite Stable Metastatic Colorectal Cancer Harboring a POLE Mutation.	Journal of the National Comprehensive Cancer Network : JNCCN	2017	10.134517875151378	43.32553039936652	148	4.97
28184224	Cbl-b Deficiency Mediates Resistance to Programmed Death-Ligand 1/Programmed Death-1 Regulation.	Frontiers in immunology	2017	-26.970983125946795	-6.137727657907344	24	0.74
28182273	Association of time-varying clearance of nivolumab with disease dynamics and its implications on exposure response analysis.	Clinical pharmacology and therapeutics	2017	33.60082827261372	-11.134128576747484	122	4.47
28180998	The prognostic value and pathobiological significance of Glasgow microenvironment score in gastric cancer.	Journal of cancer research and clinical oncology	2017	-11.072270014180004	22.78494031385474	19	0.86
28178682	Comprehensive analysis of PD-L1 expression in glioblastoma multiforme.	Oncotarget	2017	-23.9854139408011	50.14778583095108	65	2.48
28177433	Next steps in immuno-oncology: enhancing antitumor effects through appropriate patient selection and rationally designed combination strategies.	Annals of oncology : official journal of the European Society for Medical Oncology	2017	28.14300244497465	7.567818213602885	35	1.26
28174665	Metastatic small cell neuroendocrine carcinoma of the cervix treated with the PD-1 inhibitor, nivolumab: a case report.	Gynecologic oncology research and practice	2017	41.862974935911005	-2.5365041808048767	53	2.37
28174141	Checkpoint inhibition for advanced mucosal melanoma.	European journal of dermatology : EJD	2017	35.00443973913008	-0.6226319186679614	15	0.71
28169111	Expression pattern of immune checkpoint-associated molecules in radical nephrectomy specimens as a prognosticator in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors.	Urologic oncology	2017	16.46085559572733	28.94132574684946	11	0.38
28167507	PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression.	Clinical cancer research : an official journal of the American Association for Cancer Research	2017	32.78645017132541	40.33862002195243	609	22.27
28165004	An unexpected N-terminal loop in PD-1 dominates binding by nivolumab.	Nature communications	2017	-51.542466160058986	-36.18770049871812	150	5.18
28163164	Anti-PD-1/PD-L1 therapy for infectious diseases: learning from the cancer paradigm.	International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases	2017	-70.8401765815222	32.681204589604306	91	3.65
28162296	[Efficacy of PD-1/PD-L1 immune checkpoint inhibitors and PD-L1 testing in thoracic cancers].	Annales de pathologie	2017	22.52223269408291	-37.12631098838574	9	0.3
28161001	[Immune-checkpoint and hemopathies].	Annales de pathologie	2017	35.85490219777331	-7.12381336523977	0	0.0
28160999	"[The ""immune checkpoints"", how does it work]."	Annales de pathologie	2017	24.31471551171058	10.100050172364686	4	0.14
28160557	Cancer-associated oxidoreductase ERO1-α promotes immune escape through up-regulation of PD-L1 in human breast cancer.	Oncotarget	2017	-23.532087499619283	6.465915077536669	43	1.72
28159404	[PD1/PD-L1 immunohistochemistry in thoracic oncology: Where are we?].	Annales de pathologie	2017	19.14900831851701	-38.90145133844671	5	0.19
28153727	CD40 agonist converting CTL exhaustion via the activation of the mTORC1 pathway enhances PD-1 antagonist action in rescuing exhausted CTLs in chronic infection.	Biochemical and biophysical research communications	2017	-76.79547801924848	16.69641076320432	5	0.15
28147363	Immune Checkpoint Inhibition in Hepatocellular Carcinoma: Basics and Ongoing Clinical Trials.	Oncology	2017	30.056954942794015	48.15250561272143	130	5.13
28145884	The significance of programmed cell death ligand 1 expression in resected lung adenocarcinoma.	Oncotarget	2017	9.080032475987911	-27.93256073283945	45	1.79
30562859	[The development status of the next-generation immune checkpoint inhibitors].	Nihon rinsho. Japanese journal of clinical medicine	2017	27.64257210280377	10.818821106127144	0	0.0
28139862	The PD-1/PD-L1 axis may be aberrantly activated in occupational cholangiocarcinoma.	Pathology international	2017	0.1823370470260264	4.747042334190479	22	0.86
28132868	LAG-3 Protein Expression in Non-Small Cell Lung Cancer and Its Relationship with PD-1/PD-L1 and Tumor-Infiltrating Lymphocytes.	Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer	2017	9.552721802129875	22.486470785548107	160	5.96
28132417	Noncoding RNAs and immune checkpoints-clinical implications as cancer therapeutics.	The FEBS journal	2017	14.850648369206109	19.61436293950502	90	3.82
28131992	The MLL1-H3K4me3 Axis-Mediated PD-L1 Expression and Pancreatic Cancer Immune Evasion.	Journal of the National Cancer Institute	2017	-15.369078116884582	-2.3854948101023106	154	5.53
28131785	Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial.	The Lancet. Oncology	2017	64.5725789411246	20.071214731627585	1090	44.11
28130401	Distinctive Histogenesis and Immunological Microenvironment Based on Transcriptional Profiles of Follicular Dendritic Cell Sarcomas.	Molecular cancer research : MCR	2017	-20.5856269825854	29.03524450655228	19	0.68
28129007	A new frontier for targeted therapy in NSCLC: clinical efficacy of pembrolizumab in the inhibition of programmed cell death 1 (PD-1).	Expert review of anticancer therapy	2017	47.07888634734968	-31.97207123802236	8	0.3
28125702	Clinical Significance of Programmed Death Ligand‑1 and Intra-Tumoral CD8+ T Lymphocytes in Ovarian Carcinosarcoma.	PloS one	2017	-18.992746688025253	12.521332632398174	25	1.13
28123898	BTLA identifies dysfunctional PD-1-expressing CD4+ T cells in human hepatocellular carcinoma.	Oncoimmunology	2016	-26.29784321014253	41.31617608486214	31	0.97
28123896	CXCR4-CXCL12-CXCR7, TLR2-TLR4, and PD-1/PD-L1 in colorectal cancer liver metastases from neoadjuvant-treated patients.	Oncoimmunology	2016	-3.521805432628046	7.195706589388345	32	1.2
28123883	The expression profiles and regulation of PD-L1 in tumor-induced myeloid-derived suppressor cells.	Oncoimmunology	2016	-21.084078502085024	3.168755547840864	148	5.1
28123875	Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma.	Oncoimmunology	2016	30.079398322229288	31.85362671256612	103	3.27
28123870	Regulation of myeloid cells by activated T cells determines the efficacy of PD-1 blockade.	Oncoimmunology	2016	-26.591228915216067	12.20085069187238	45	1.46
28122590	PD-1, PD-L1 (B7-H1) and Tumor-Site Immune Modulation Therapy: The Historical Perspective.	Journal of hematology & oncology	2017	-53.69221046917079	-14.16234955194346	75	2.59
28122336	Distinct patterns of infiltrating CD8+ T cells in HPV+ and CD68 macrophages in HPV- oropharyngeal squamous cell carcinomas are associated with better clinical outcome but PD-L1 expression is not prognostic.	Oncotarget	2017	-3.279592466737133	-10.212613813244465	66	2.82
28122135	Programmed cell death-1 expression correlates with disease severity and IL-5 in chronic rhinosinusitis with nasal polyps.	Allergy	2017	-65.7396239333718	-25.815131015631195	19	0.95
28120417	PD-1 expression by canine T cells and functional effects of PD-1 blockade.	Veterinary and comparative oncology	2017	-16.92292339537379	-14.649817880636302	41	2.03
28115719	Immunoinhibitory checkpoint deficiency in medium and large vessel vasculitis.	Proceedings of the National Academy of Sciences of the United States of America	2017	-57.46023799404447	10.312750695262356	142	6.48
28115578	Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma.	Neuro-oncology	2017	-29.56280591283289	55.24755051501336	117	4.28
28114251	Novel Checkpoints and Cosignaling Molecules in Cancer Immunotherapy.	Cancer journal (Sudbury, Mass.)	2017	23.151529376865668	6.503019834054323	11	0.38
28114249	Inhibitors of Cytotoxic T Lymphocyte Antigen 4 and Programmed Death 1/Programmed Death 1 Ligand for Metastatic Melanoma, Dual Versus Monotherapy-Summary of Advances and Future Directions for Studying These Drugs.	Cancer journal (Sudbury, Mass.)	2017	30.169009756442147	4.0067928831392265	5	0.21
28111041	[Tissue biomarkers of response to anti-PD-1 immunotherapies in melanoma].	Annales de pathologie	2017	18.40450428063677	-5.722992461864409	1	0.02
28109400	Tumor infiltrating lymphocytes in gastrointestinal tumors: Controversies and future clinical implications.	Critical reviews in oncology/hematology	2017	-7.127766651129438	21.37449441977082	31	1.15
28107610	Tonsil-derived mesenchymal stem cells (T-MSCs) prevent Th17-mediated autoimmune response via regulation of the programmed death-1/programmed death ligand-1 (PD-1/PD-L1) pathway.	Journal of tissue engineering and regenerative medicine	2018	-54.10918577152768	21.983491060940757	48	2.65
28107571	Increased PD-L1 expression in breast and colon cancer stem cells.	Clinical and experimental pharmacology & physiology	2017	-17.806202500827474	4.768451960608108	72	2.76
28105370	Interstitial nephritis in melanoma patients secondary to PD-1 checkpoint inhibitor.	Journal for immunotherapy of cancer	2017	71.7246188264046	2.2640683219271938	37	1.52
28105074	Biomarkers come of age: PD1 in the frontline and cell cycle therapy swells the ranks of personalised therapy in the European Society of Medical Oncology (ESMO) congress, Copenhagen, 7-10 October 2016.	Ecancermedicalscience	2016	17.558202189040564	-35.467515917722665	0	0.0
28096717	Immune-Checkpoint Inhibitors in the Era of Precision Medicine: What Radiologists Should Know.	Korean journal of radiology	2017	27.99807656292022	8.68208116273524	27	1.27
28096371	COX2/mPGES1/PGE2 pathway regulates PD-L1 expression in tumor-associated macrophages and myeloid-derived suppressor cells.	Proceedings of the National Academy of Sciences of the United States of America	2017	-18.06257480731613	-2.080332337418713	304	11.9
28093480	Comprehensive screening for PD-L1 expression in thyroid cancer.	Endocrine-related cancer	2017	-6.7971721052852585	-21.195032389134177	100	4.47
28086852	PD-L1 expression in papillary renal cell carcinoma.	BMC urology	2017	17.618560791317886	26.48518864630752	32	1.2
28084337	Tumoral PD-L1 expression in desmoplastic melanoma is associated with depth of invasion, tumor-infiltrating CD8 cytotoxic lymphocytes and the mixed cytomorphological variant.	Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc	2017	5.424489333565453	0.720376378919277	23	0.76
28081914	Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study.	The Lancet. Oncology	2017	67.03392168856118	15.447987465222775	267	9.72
28077434	Transfer of Allogeneic CD4+ T Cells Rescues CD8+ T Cells in Anti-PD-L1-Resistant Tumors Leading to Tumor Eradication.	Cancer immunology research	2017	-38.11974622422929	0.1779627817933209	13	0.44
28076847	Programmed cell death-ligand 1 expression predicts survival in patients with gastric carcinoma with microsatellite instability.	Oncotarget	2017	-9.476918133611427	7.387653532570917	51	2.01
28075442	Increased expression of PD‑L1 by the human papillomavirus 16 E7 oncoprotein inhibits anticancer immunity.	Molecular medicine reports	2017	-0.768084715251131	-12.851002042626453	69	2.81
28074937	Circulating T lymphocyte subsets, cytokines, and immune checkpoint inhibitors in patients with bipolar II or major depression: a preliminary study.	Scientific reports	2017	-37.22685765583709	14.36423592962019	31	1.54
28073845	Agreement between Programmed Cell Death Ligand-1 Diagnostic Assays across Multiple Protein Expression Cutoffs in Non-Small Cell Lung Cancer.	Clinical cancer research : an official journal of the American Association for Cancer Research	2017	16.450271774492318	-39.94486376171042	238	8.77
28073774	Temporally Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune Escape.	Cancer immunology research	2017	-33.70828339679315	-10.156246881431034	205	7.22
28072971	[Expression of PD-1/PD-L1 in triple-negative breast carcinoma and its significance].	Zhonghua bing li xue za zhi = Chinese journal of pathology	2017	-8.415226399966958	18.312174053144663	3	0.12
28072716	Pneumonitis in cancer patients receiving anti-PD-1 and radiotherapies: Three case reports.	Medicine	2017	63.51235894057993	-8.299980334754805	25	0.98
28069723	A Novel Murine GITR Ligand Fusion Protein Induces Antitumor Activity as a Monotherapy That Is Further Enhanced in Combination with an OX40 Agonist.	Clinical cancer research : an official journal of the American Association for Cancer Research	2017	-17.456320576337884	-51.53540789378337	37	1.27
28063623	Immune Checkpoint Inhibitors in Lung Cancer - An Unheralded Opportunity?	Clinical oncology (Royal College of Radiologists (Great Britain))	2017	34.80740790062779	-28.530653065836177	4	0.12
28062906	Programmed cell death-1 pathway inhibition in myeloid malignancies: implications for myeloproliferative neoplasms.	Annals of hematology	2017	-35.38007778300652	11.870346245220672	17	0.64
28062513	Metastatic Melanoma Patient Had a Complete Response with Clonal Expansion after Whole Brain Radiation and PD-1 Blockade.	Cancer immunology research	2017	49.29563687792794	-2.836396372107114	38	1.19
28061450	Th1high in tumor microenvironment is an indicator of poor prognosis for patients with NSCLC.	Oncotarget	2017	10.100971782382665	-17.79727931251589	21	0.91
28059852	Immune checkpoint inhibitors in first-line therapy of advanced non-small cell lung cancer.	Current opinion in oncology	2017	39.80449617784934	-30.46753367475184	32	1.11
28058578	PD-L1 expression and tumor infiltrating PD-1+ lymphocytes associated with outcome in HER2+ breast cancer patients.	Breast cancer research and treatment	2017	-7.952051938784725	16.284315267141917	71	2.76
28058043	Programmed death-ligand 1 expression in rectal cancer.	European surgery : ACA : Acta chirurgica Austriaca	2016	-4.775383235102965	9.775473837159442	13	0.5
28057179	[Not Available].	Bulletin du cancer	2016	15.273309556644646	-2.18826507277444	4	0.13
28057177	[Not Available].	Bulletin du cancer	2016	39.64469952794192	-32.172540160672426	1	0.02
28056301	[Expression of PD-1/PD-L1 in lung adenocarcinoma and correlation with epidermal growth factor receptor mutation status].	Zhonghua bing li xue za zhi = Chinese journal of pathology	2016	8.46708435648095	-29.110721078756225	0	0.0
28055269	Targeting the PD-1 pathway: a new hope for gastrointestinal cancers.	Current medical research and opinion	2017	44.50338750082946	16.645554961288873	44	1.65
28052400	Programmed death-1 ligands 1 and 2 expression in cutaneous squamous cell carcinoma and their relationship with tumour- infiltrating dendritic cells.	Clinical and experimental immunology	2017	-1.5395723748137868	-4.334598980508968	20	0.93
28043166	Pharmacokinetic drug evaluation of atezolizumab for the treatment of locally advanced or metastatic urothelial carcinoma.	Expert opinion on drug metabolism & toxicology	2017	73.38042656275256	15.497197403296337	16	0.55
29604921	Genomic Pathology and Biomarkers in Breast Cancer.	Critical reviews in oncogenesis	2017	8.464484905500054	28.284623900083112	10	0.45
29552640	Integration of pharmacology, molecular pathology, and population data science to support precision gastrointestinal oncology.	NPJ precision oncology	2017	20.388546038168823	39.70609860992792	11	0.4
28039262	Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma.	Clinical cancer research : an official journal of the American Association for Cancer Research	2017	19.67489127562317	-21.30282803091699	621	22.06
28039162	Infiltration of CD8 T Cells and Expression of PD-1 and PD-L1 in Synovial Sarcoma.	Cancer immunology research	2017	-21.296834012609786	19.40332363975188	49	1.81
28038394	Increased IL-35 producing Tregs and CD19+IL-35+ cells are associated with disease progression in leprosy patients.	Cytokine	2017	-83.98059564696527	6.083479749124613	22	0.98
28035385	Increased expression of PD-L1 by the human papillomavirus 16 E7 oncoprotein inhibits anticancer immunity.	Molecular medicine reports	2016	-0.7675432017599648	-12.849298008386322	5	0.15
28031823	Challenges and opportunities for checkpoint blockade in T-cell lymphoproliferative disorders.	Journal for immunotherapy of cancer	2016	-8.328360126250793	-27.07708137298338	16	0.61
28031719	Potential role of immunotherapy in advanced non-small-cell lung cancer.	OncoTargets and therapy	2017	37.61978170264769	-33.88823472933842	39	1.4
28030901	Radiotherapy and immune checkpoint blockades: a snapshot in 2016.	Radiation oncology journal	2016	27.27056941763012	19.147258896997023	25	0.8
28030840	Prognostic value and clinicopathological features of PD-1/PD-L1 expression with mismatch repair status and desmoplastic stroma in Chinese patients with pancreatic cancer.	Oncotarget	2017	-4.806278566283604	4.659073354374344	32	1.17
28028993	Update on immune checkpoint inhibitors in gynecological cancers.	Journal of gynecologic oncology	2017	40.55193541274773	36.657483599314496	43	1.67
28026870	Vulvar and vaginal melanoma: A unique subclass of mucosal melanoma based on a comprehensive molecular analysis of 51 cases compared with 2253 cases of nongynecologic melanoma.	Cancer	2017	13.55248101025688	3.1115906740234656	71	3.08
28025143	Rapid PD-L1 detection in tumors with PET using a highly specific peptide.	Biochemical and biophysical research communications	2017	4.959569680767944	-56.90553699525987	108	4.46
28024695	Tumor B7-H3 (CD276) expression and smoking history in relation to lung adenocarcinoma prognosis.	Lung cancer (Amsterdam, Netherlands)	2017	1.1517516157262937	-18.71165142404469	68	2.42
28018348	PD-L1 Is Not Constitutively Expressed on Tasmanian Devil Facial Tumor Cells but Is Strongly Upregulated in Response to IFN-γ and Can Be Expressed in the Tumor Microenvironment.	Frontiers in immunology	2016	-42.36356393556646	29.33408341209337	30	1.08
28018338	The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation.	Frontiers in immunology	2016	-56.99954125844	-0.6410950205566646	346	12.78
28007776	Immune Cytolytic Activity Stratifies Molecular Subsets of Human Pancreatic Cancer.	Clinical cancer research : an official journal of the American Association for Cancer Research	2017	6.043911012973268	40.709798877105264	160	4.99
28005469	Clinical Significance of Dynamics of Programmed Death Ligand-1 Expression on Circulating CD14+ Monocytes and CD19+ B Cells with the Progression of Hepatitis B Virus Infection.	Viral immunology	2017	-71.66389694557094	23.437181804692724	17	0.58
28003187	Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy.	Cancer immunology research	2017	-8.672964612887723	-44.44915154985704	111	4.04
28000302	PD-1 inhibitor gastroenterocolitis: case series and appraisal of 'immunomodulatory gastroenterocolitis'.	Histopathology	2017	69.08138241885419	-14.955014775374584	134	5.83
28000240	Epidermal programmed cell death-ligand 1 expression in TEN associated with nivolumab therapy.	Journal of cutaneous pathology	2017	73.41480563516173	-28.203140248554533	82	4.1
27999753	PD-L1, PD-L2 and PD-1 expression in metastatic melanoma: Correlation with tumor-infiltrating immune cells and clinical outcome.	Oncoimmunology	2016	7.387212354988734	-1.0650307300832489	90	3.19
27999734	Molecular and clinical characterization of PD-L1 expression at transcriptional level via 976 samples of brain glioma.	Oncoimmunology	2016	-24.753989465479904	52.11772571294188	135	5.05
27993215	Anti-PD-L1 peptide improves survival in sepsis.	The Journal of surgical research	2017	-60.3831594736582	36.93292049297092	76	3.04
27991907	Immunomodulating property of MAPK inhibitors: from translational knowledge to clinical implementation.	Laboratory investigation; a journal of technical methods and pathology	2017	29.809040490493693	31.511536679096388	30	0.93
27989100	PD-L1 Expression and Combined Status of PD-L1/PD-1-Positive Tumor Infiltrating Mononuclear Cell Density Predict Prognosis in Glioblastoma Patients.	Journal of pathology and translational medicine	2017	-24.23211382003021	50.970676694068224	29	1.07
27986748	Clinical Use of Programmed Cell Death-1 and Its Ligand Expression as Discriminatory and Predictive Markers in Ovarian Cancer.	Clinical cancer research : an official journal of the American Association for Cancer Research	2017	-20.195371108324963	12.348351989212231	44	1.73
27980047	Practical Immuno-PET Radiotracer Design Considerations for Human Immune Checkpoint Imaging.	Journal of nuclear medicine : official publication, Society of Nuclear Medicine	2017	6.407028080897275	-55.88495123174617	91	3.84
27979840	Early Effector T Lymphocytes Coexpress Multiple Inhibitory Receptors in Primary Non-Small Cell Lung Cancer.	Cancer research	2017	-44.96132750555024	14.436495347705124	41	1.34
27979383	Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.	Lancet (London, England)	2017	51.69424491903684	-38.04631364907946	3218	135.89
27978870	[Expression and Clinical Significance of PD-1 and PD-L1 in Pulmonary Carcinoids].	Zhongguo fei ai za zhi = Chinese journal of lung cancer	2016	6.741143386664199	-26.43459134249156	0	0.0
27974689	PD-1 and its ligands are important immune checkpoints in cancer.	Oncotarget	2017	-45.327998665612334	-13.328988562744684	186	7.31
27959341	A Novel PD-L1-targeting Antagonistic DNA Aptamer With Antitumor Effects.	Molecular therapy. Nucleic acids	2016	-25.375166829837475	-59.188334208763806	76	2.91
27942391	Metastatic basal cell carcinoma with amplification of PD-L1: exceptional response to anti-PD1 therapy.	NPJ genomic medicine	2016	48.12192144675892	-51.1485650930386	89	3.18
27936870	Emerging biomarkers for PD-1 pathway cancer therapy.	Biomarkers in medicine	2017	17.702804577411847	-4.769675316819144	9	0.32
27934877	Overexpression and gene amplification of PD-L1 in cancer cells and PD-L1+ immune cells in Epstein-Barr virus-associated gastric cancer: the prognostic implications.	Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc	2017	-10.204053864847	8.859153300652988	110	4.65
27930644	Immunotherapy for the treatment of breast cancer: checkpoint blockade, cancer vaccines, and future directions in combination immunotherapy.	Clinical advances in hematology & oncology : H&O	2016	24.3597160112023	-0.2077482401686265	33	1.18
27924827	PD-1/PD-L pathway inhibits M.tb-specific CD4+ T-cell functions and phagocytosis of macrophages in active tuberculosis.	Scientific reports	2016	-85.01084934545356	1.9788348770946016	79	2.64
27924752	Predictive biomarkers for checkpoint inhibitor-based immunotherapy.	The Lancet. Oncology	2016	18.298362562428757	-4.296674466661533	1077	38.59
27923550	Treatment Design and Rationale for a Randomized Trial of Cisplatin and Etoposide Plus Thoracic Radiotherapy Followed by Nivolumab or Placebo for Locally Advanced Non-Small-Cell Lung Cancer (RTOG 3505).	Clinical lung cancer	2017	43.99569476613124	-23.42328474428224	43	1.49
27921410	Downregulation of Immunosuppressive Molecules, PD-1 and PD-L1 but not PD-L2, in the Patients with Multiple Sclerosis.	Iranian journal of allergy, asthma, and immunology	2016	-72.86450847295382	-4.303163966178984	36	1.46
27920704	Autoimmune Hemolytic Anemia as a Complication of Nivolumab Therapy.	Case reports in oncology	2016	70.8720465762806	-10.439247050794297	69	2.69
27916470	Is There Evidence for the Presence and Relevance of the PD-1/PD-L1 Pathway in Oral Squamous Cell Carcinoma? Hints From an Immunohistochemical Study.	Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons	2017	-8.140411608549323	-11.604581113481713	28	1.07
27913861	CXCL12 expression and PD-L1 expression serve as prognostic biomarkers in HCC and are induced by hypoxia.	Virchows Archiv : an international journal of pathology	2017	-20.93430058357054	42.58049726766047	61	2.48
27912781	An immune stratification reveals a subset of PD-1/LAG-3 double-positive triple-negative breast cancers.	Breast cancer research : BCR	2016	-3.8936966151878183	21.33369545340813	82	2.89
27910859	T-cell programming in pancreatic adenocarcinoma: a review.	Cancer gene therapy	2017	-21.424299520251136	-11.472665919947277	40	1.53
27909177	Editorial: Blockade of PD-1 and PD-L1 restores defective innate immune responses in leukocytes from septic humans.	Journal of leukocyte biology	2016	-57.63789146342577	36.018897000332366	1	0.04
27908252	The Combination of New Immunotherapy and Radiotherapy: A N ew Potential Treatment for Locally Advanced Non-Small Cell Lung Cancer.	Current clinical pharmacology	2017	36.04279894386914	-28.235057357416764	8	0.25
27903674	Atezolizumab: A PD-L1-Blocking Antibody for Bladder Cancer.	Clinical cancer research : an official journal of the American Association for Cancer Research	2017	73.56810203804316	15.284503010446812	144	5.79
27903604	What does PD-L1 positive or negative mean?	The Journal of experimental medicine	2016	-42.33612115132003	-9.879827307770295	216	7.15
27903500	Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations.	Cancer discovery	2017	-18.738576222703774	-21.56546937985804	829	29.41
27895920	PD1/PD-L1 inhibition as a potential radiosensitizer in head and neck squamous cell carcinoma: a case report.	Journal for immunotherapy of cancer	2016	41.78698814409077	3.249287111304392	31	1.1
27895917	Validation of biomarkers to predict response to immunotherapy in cancer: Volume I - pre-analytical and analytical validation.	Journal for immunotherapy of cancer	2016	17.316742668976776	-3.2776247852095914	123	4.39
27892511	The clinicopathological and prognostic significance of PD-L1 expression in gastric cancer: a meta-analysis of 10 studies with 1,901 patients.	Scientific reports	2016	-7.885203108722214	5.524615164362678	98	3.52
27881581	Nivolumab in the Treatment of Hodgkin Lymphoma.	Clinical cancer research : an official journal of the American Association for Cancer Research	2017	40.596493657409376	-6.437821928828574	41	1.42
27879989	CD274 (PD-L1)/PDCD1 (PD-1) expression in de novo and transformed diffuse large B-cell lymphoma.	British journal of haematology	2018	-35.22908004351031	28.276526537883186	20	0.75
27873079	Next generation predictive biomarkers for immune checkpoint inhibition.	Cancer metastasis reviews	2017	18.934507132185384	-3.5903895726993142	73	2.55
27870715	Posttranscriptional Control of PD-L1 Expression by 17β-Estradiol via PI3K/Akt Signaling Pathway in ERα-Positive Cancer Cell Lines.	International journal of gynecological cancer : official journal of the International Gynecological Cancer Society	2017	-23.08023158868631	6.112302101451059	58	2.29
27868139	Clinical, Genetic and Innate Immunity Characteristics of Melanoma in Organ Transplant Recipients.	Acta dermato-venereologica	2017	4.686173875112837	18.29208434216097	6	0.31
27867382	IL-1β, But Not Programed Death-1 and Programed Death Ligand Pathway, Is Critical for the Human Th17 Response to Mycobacterium tuberculosis.	Frontiers in immunology	2016	-84.30201754485437	1.5300210952724764	16	0.63
27867002	Trametinib plus 4-Methylumbelliferone Exhibits Antitumor Effects by ERK Blockade and CD44 Downregulation and Affects PD-1 and PD-L1 in Malignant Pleural Mesothelioma.	Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer	2017	29.609441422964696	36.0598326725309	26	1.18
27865385	The characteristic profiles of PD-1 and PD-L1 expressions and dynamic changes during treatment in active tuberculosis.	Tuberculosis (Edinburgh, Scotland)	2016	-85.70799033206676	2.728072794758226	15	0.53
27863197	Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma.	Journal of clinical oncology : official journal of the American Society of Clinical Oncology	2016	46.69141437051076	0.5518539564123076	450	16.42
27859479	Diverse types of dermatologic toxicities from immune checkpoint blockade therapy.	Journal of cutaneous pathology	2017	74.4804926868252	-25.27033383244675	150	6.7
27856426	Cytotoxic T Cells in PD-L1-Positive Malignant Pleural Mesotheliomas Are Counterbalanced by Distinct Immunosuppressive Factors.	Cancer immunology research	2016	6.722680891875697	11.973646450096371	56	1.97
27853635	Tumor-infiltrating Tim-3+ T cells proliferate avidly except when PD-1 is co-expressed: Evidence for intracellular cross talk.	Oncoimmunology	2016	-43.50597308047742	12.457001023028232	40	1.26
27846884	"Future perspectives in melanoma research : Meeting report from the ""Melanoma Bridge"". Napoli, December 1st-4th 2015."	Journal of translational medicine	2016	30.56063031344429	28.70029182140225	13	0.43
27846725	[Non-Small Cell Lung Cancer - from Immunobiology to Immunotherapy].	Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti	2016	36.02033858994803	-33.372733724602426	4	0.14
27846724	[The Role of PD-1/PD-L1 Signaling Pathway in Antitumor Immune Response].	Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti	2016	-46.24395809615887	-11.311487288891907	4	0.15
27841362	PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for head and neck cancer patients.	Scientific reports	2016	-6.5933683897000055	-7.322354537014029	188	7.01
27841146	PD1 and PD-L1 in ependymoma might not be therapeutic targets.	Clinical neuropathology	2017	-26.445663352479244	20.09193465527912	3	0.13
27841044	Anti-PD-1/PD-L1 antibodies in non-small cell lung cancer: the era of immunotherapy.	Expert review of anticancer therapy	2017	43.74558476311766	-28.497629856350397	27	0.94
27838455	Functional polymorphisms in PD-L1 gene are associated with the prognosis of patients with early stage non-small cell lung cancer.	Gene	2017	20.445254624528317	-25.43643014937156	41	1.68
27838401	The evolving role of microsatellite instability in colorectal cancer: A review.	Cancer treatment reviews	2016	11.77625829767108	43.19953204725613	162	5.88
27837027	Association of PD-1/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors.	Proceedings of the National Academy of Sciences of the United States of America	2016	7.047228474778052	-2.638364412627892	128	4.22
27836863	Checkpoint Proteins in Pediatric Brain and Extracranial Solid Tumors: Opportunities for Immunotherapy.	Clinical cancer research : an official journal of the American Association for Cancer Research	2017	-28.225532513035205	62.57153286549091	30	1.09
27835902	Squamous cell carcinomas escape immune surveillance via inducing chronic activation and exhaustion of CD8+ T Cells co-expressing PD-1 and LAG-3 inhibitory receptors.	Oncotarget	2016	-10.995580984191568	31.039914544882844	52	1.83
27834350	Quantitative and pathologist-read comparison of the heterogeneity of programmed death-ligand 1 (PD-L1) expression in non-small cell lung cancer.	Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc	2017	13.830304947031426	-40.44624531122604	114	4.27
27829019	Subset- and Antigen-Specific Effects of Treg on CD8+ T Cell Responses in Chronic HIV Infection.	PLoS pathogens	2016	-79.47800615206866	13.17148719377567	12	0.44
27827885	Is There Still Room for Cancer Vaccines at the Era of Checkpoint Inhibitors.	Vaccines	2016	26.2600731162818	2.5615195798646018	48	1.55
27825115	SCIB1, a huIgG1 antibody DNA vaccination, combined with PD-1 blockade induced efficient therapy of poorly immunogenic tumors.	Oncotarget	2016	-27.93283494367721	-11.741936519143966	12	0.46
27822406	PD-1 inhibition and treatment of advanced melanoma-role of pembrolizumab.	American journal of cancer research	2016	32.62164550010521	-0.3899683280046327	27	0.93
27821498	Established T Cell-Inflamed Tumors Rejected after Adaptive Resistance Was Reversed by Combination STING Activation and PD-1 Pathway Blockade.	Cancer immunology research	2016	-22.75463999974896	-44.89046447933439	95	2.97
27821490	Suppression of Type I IFN Signaling in Tumors Mediates Resistance to Anti-PD-1 Treatment That Can Be Overcome by Radiotherapy.	Cancer research	2017	-32.9755508302821	-21.83452046384395	159	5.55
27816403	A review of the PD-1/PD-L1 checkpoint in bladder cancer: From mediator of immune escape to target for treatment.	Urologic oncology	2017	69.5142579874223	21.479044891122367	57	2.14
27816393	Association of PD-1, PD-L1, and CTLA-4 Gene Expression and Clinicopathologic Characteristics in Patients With Non-Small-Cell Lung Cancer.	Clinical lung cancer	2017	11.96204588298393	-29.845303993841977	24	0.9
27816392	Assessing PDL-1 and PD-1 in Non-Small Cell Lung Cancer: A Novel Immunoscore Approach.	Clinical lung cancer	2017	14.51106570294718	-30.051303444193582	63	2.26
27815822	Crystal clear: visualizing the intervention mechanism of the PD-1/PD-L1 interaction by two cancer therapeutic monoclonal antibodies.	Protein & cell	2016	-44.8749322505394	-34.41224357366996	29	0.89
27813511	Clinicopathologic profile, immunophenotype, and genotype of CD274 (PD-L1)-positive colorectal carcinomas.	Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc	2017	9.633570232636895	36.15627572868482	66	2.48
27813059	Safety and efficacy of nivolumab in the treatment of cancers: A meta-analysis of 27 prospective clinical trials.	International journal of cancer	2017	47.1296075770646	-24.945362962330204	33	1.15
27749818	Single-cell RNA-seq identifies a PD-1hi ILC progenitor and defines its development pathway.	Nature	2016	-57.00748287697905	-14.618379435456724	219	6.12
27805626	PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas.	Nature reviews. Clinical oncology	2017	-9.660235014432866	-26.24935473773929	298	11.17
27803740	Antagonizing programmed death-1 and programmed death ligand-1 as a therapeutic approach for gastric cancer.	Therapeutic advances in gastroenterology	2016	-44.09260479573133	-17.52881908200469	11	0.42
27737878	Classical Hodgkin Lymphoma with Reduced β2M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status.	Cancer immunology research	2016	-28.49993627752192	25.111800182049745	124	3.99
27671167	Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade.	Cancer immunology research	2016	14.219020335719522	2.904585692979579	351	12.02
27638840	Clinical Response of a Patient to Anti-PD-1 Immunotherapy and the Immune Landscape of Testicular Germ Cell Tumors.	Cancer immunology research	2016	-25.72642233193199	34.25303522757805	40	1.36
30550688	[Development of immune checkpoint inhibitor in colorectal cancer].	Nihon rinsho. Japanese journal of clinical medicine	2016	35.670798063939515	20.89284475792032	1	0.03
27798164	Programmed Death Ligand 1 Plays a Neuroprotective Role in Experimental Autoimmune Neuritis by Controlling Peripheral Nervous System Inflammation of Rats.	Journal of immunology (Baltimore, Md. : 1950)	2016	-73.75734925279478	-6.300781632884156	22	0.8
27796306	Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy.	Nature communications	2016	-45.3313119289479	-34.978353635227435	159	5.37
27169994	Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma.	Clinical cancer research : an official journal of the American Association for Cancer Research	2016	62.97526580139858	27.89746072554112	199	6.63
27789795	Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade.	Science (New York, N.Y.)	2016	-47.83521729342852	12.729606900838178	771	23.58
27788370	Function of follicular helper T cell is impaired and correlates with survival time in non-small cell lung cancer.	International immunopharmacology	2016	-46.26093623579983	30.693671325973444	32	1.06
27785054	Prognostic value of PD-L1 and PD-1 expression in pulmonary neuroendocrine tumors.	OncoTargets and therapy	2016	8.155250907930279	-25.85622111629849	39	1.59
27595782	Expression of programmed cell death ligand 1 (PD-L1) in advanced stage EBV-associated extranodal NK/T cell lymphoma is associated with better prognosis.	Virchows Archiv : an international journal of pathology	2016	-38.04564364677151	24.478263951033	56	2.24
27510417	[Predictive PD-L1 immunohistochemistry for non-small cell lung cancer : Current state of the art and experiences of the first German harmonization study].	Der Pathologe	2016	18.34306399756569	-38.7626951961032	29	0.98
27443512	Patterns and prognostic relevance of PD-1 and PD-L1 expression in colorectal carcinoma.	Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc	2016	-5.067571283516505	11.850327173852277	120	4.42
27755140	Targeting the host immune system: PD-1 and PD-L1 antibodies and breast cancer.	Current opinion in supportive and palliative care	2016	24.79563142999938	-2.896150701080387	9	0.29
27700015	Outcomes in patients with advanced urothelial carcinoma after discontinuation of programmed death (PD)-1 or PD ligand 1 inhibitor therapy.	BJU international	2017	63.78218299259956	15.550798761711029	16	0.55
27671847	Mesenchymal Stromal Cell Secretion of Programmed Death-1 Ligands Regulates T Cell Mediated Immunosuppression.	Stem cells (Dayton, Ohio)	2017	-54.90700378194528	22.142169737866286	207	9.68
27777980	Ly6Chi monocytes regulate T cell responses in viral hepatitis.	JCI insight	2016	-75.76414444890051	21.07764794935913	10	0.36
27777774	5-Fluorouracil upregulates cell surface B7-H1 (PD-L1) expression in gastrointestinal cancers.	Journal for immunotherapy of cancer	2016	-14.68408078599828	-0.1412430335730358	82	2.98
27776441	Nivolumab in melanoma.	Expert review of anticancer therapy	2016	35.04834032134389	1.0888799731439025	15	0.49
27776338	PD-L1 expression in tonsillar cancer is associated with human papillomavirus positivity and improved survival: implications for anti-PD1 clinical trials.	Oncotarget	2016	-4.742041633642166	-10.300097857775098	38	1.47
27544053	Malignant Mesothelioma Effusions Are Infiltrated by CD3+ T Cells Highly Expressing PD-L1 and the PD-L1+ Tumor Cells within These Effusions Are Susceptible to ADCC by the Anti-PD-L1 Antibody Avelumab.	Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer	2016	7.023991399319047	11.564936162573144	78	2.88
27770382	Immune checkpoint inhibitors for cancer treatment.	Archives of pharmacal research	2016	24.54679112094851	8.970943943353795	35	1.19
27769635	Immunotherapy in melanoma: Recent advances and future directions.	European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology	2017	30.825348389392545	3.5165968724510748	176	7.28
27768639	High cytotoxic T-lymphocyte-associated antigen 4 and phospho-Akt expression in tumor samples predicts poor clinical outcomes in ipilimumab-treated melanoma patients.	Melanoma research	2017	14.425227360182214	-1.0416181169390863	15	0.51
27762298	PD-L1 is a critical mediator of regulatory B cells and T cells in invasive breast cancer.	Scientific reports	2016	-14.23471831819272	18.237051835371467	60	2.18
27757309	Intra-tumoral heterogeneity in the expression of programmed-death (PD) ligands in isogeneic primary and metastatic lung cancer: Implications for immunotherapy.	Oncoimmunology	2016	14.257862015209517	-34.882320254164554	59	1.92
27757299	Intratumoral expression levels of PD-L1, GZMA, and HLA-A along with oligoclonal T cell expansion associate with response to nivolumab in metastatic melanoma.	Oncoimmunology	2016	11.160183571806249	-2.9075422184809305	94	2.86
27756892	Targeting immune checkpoints in malignant glioma.	Oncotarget	2017	-28.978995318621063	58.90410094411578	36	1.46
27565980	Quantification of PD-L1 and PD-1 expression on tumor and immune cells in non-small cell lung cancer (NSCLC) using non-enzymatic tissue dissociation and flow cytometry.	Cancer immunology, immunotherapy : CII	2016	13.157087570802808	-37.76467687604646	16	0.64
27533448	Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies.	Cancer	2016	44.63820648887484	2.001733611498773	234	8.76
27436101	Tumor infiltrating lymphocytes and PD-L1 expression in brain metastases of small cell lung cancer (SCLC).	Journal of neuro-oncology	2016	-0.9826468109448432	18.121693178438328	83	2.83
27720992	An antigen-encapsulating nanoparticle platform for TH1/17 immune tolerance therapy.	Nanomedicine : nanotechnology, biology, and medicine	2017	-67.61834491127408	29.995748784157158	66	2.96
27490642	Programed death-1/programed death-ligand 1 expression in lymph nodes of HIV infected patients: results of a pilot safety study in rhesus macaques using anti-programed death-ligand 1 (Avelumab).	AIDS (London, England)	2016	-84.9951526159387	16.587032439921344	23	0.73
27465786	Programmed Death-Ligand 1 Expression Is Common in Gastric Cancer Associated With Epstein-Barr Virus or Microsatellite Instability.	The American journal of surgical pathology	2016	-9.623742233466505	8.00014156164462	112	4.17
27747247	Evaluation of PD-L1 Expression in Tumor Tissue of Patients with Lung Carcinoma and Correlation with Clinical and Demographic Data.	Journal of immunology research	2016	6.486401986817016	-27.312524660532457	16	0.62
27747091	The promise of PD-1 inhibitors in gastro-esophageal cancers: microsatellite instability vs. PD-L1.	Journal of gastrointestinal oncology	2016	45.72493178693226	19.84886413068463	70	2.34
27746267	PD-L1, PD-1, CD4, and CD8 expression in neoplastic and nonneoplastic thymus.	Human pathology	2017	-4.580099096070325	-37.5007828531388	34	1.36
27741514	Programmed death-ligand 1 expression in gastric adenocarcinoma is a poor prognostic factor in a high CD8+ tumor infiltrating lymphocytes group.	Oncotarget	2016	-10.256607479167382	6.0154637806067175	37	1.33
27741089	T-Cell Therapy Enabling Adenoviruses Coding for IL2 and TNFα Induce Systemic Immunomodulation in Mice With Spontaneous Melanoma.	Journal of immunotherapy (Hagerstown, Md. : 1997)	2016	-38.333808118022006	53.61269102760448	19	0.7
27737703	PD-L1 is upregulated by EBV-driven LMP1 through NF-κB pathway and correlates with poor prognosis in natural killer/T-cell lymphoma.	Journal of hematology & oncology	2016	-38.02506968712417	24.71329926414313	196	7.53
27725355	Immune exhaustion during chronic infections in cattle.	The Journal of veterinary medical science	2017	-79.95773626010977	3.942722707395133	21	1.32
27721873	Expression of Programmed Death Receptor Ligand 1 with High Tumor-Infiltrating Lymphocytes Is Associated with Better Prognosis in Breast Cancer.	Journal of breast cancer	2016	-10.430061293325906	15.733093952449211	56	2.07
27721577	Elevated Expression of Programmed Death-1 and Programmed Death Ligand-1 Negatively Regulates Immune Response against Cervical Cancer Cells.	Mediators of inflammation	2016	0.3837155506386974	-12.16420643984941	25	0.97
27718847	Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.	The New England journal of medicine	2016	48.47799622224455	-29.99803369325428	6408	262.16
27713640	The efficacy and safety of nivolumab in previously treated advanced non-small-cell lung cancer: a meta-analysis of prospective clinical trials.	OncoTargets and therapy	2016	46.91458303596568	-24.63766140878784	17	0.55
27713639	Spotlight on pembrolizumab in non-small cell lung cancer: the evidence to date.	OncoTargets and therapy	2016	47.36259253932503	-31.96442784136846	9	0.3
27708227	T-cell responses against CD19+ pediatric acute lymphoblastic leukemia mediated by bispecific T-cell engager (BiTE) are regulated contrarily by PD-L1 and CD80/CD86 on leukemic blasts.	Oncotarget	2016	-41.404124299896935	10.632265146575048	115	3.89
27704149	Checkpoint inhibitors and radiation treatment in Hodgkin's lymphoma : New study concepts of the German Hodgkin Study Group.	Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]	2017	38.44923293392861	-7.9109435530768435	11	0.44
27699275	Synergy of radiotherapy and PD-1 blockade in Kras-mutant lung cancer.	JCI insight	2016	34.587370222142404	-27.25468733179912	116	3.72
27699239	Multiparametric profiling of non-small-cell lung cancers reveals distinct immunophenotypes.	JCI insight	2016	13.3832139471167	-15.90833526856813	97	3.07
27698894	AKT-STAT3 Pathway as a Downstream Target of EGFR Signaling to Regulate PD-L1 Expression on NSCLC cells.	Journal of Cancer	2016	4.549067320472923	-32.39342069938372	77	2.77
27696202	Expression of programmed cell death 1 and programmed cell death ligand 1 in extranodal NK/T-cell lymphoma, nasal type.	Annals of hematology	2017	-38.29018742437185	23.847918030875057	72	3.18
27696122	PD-1/PD-L1 expression in chromophobe renal cell carcinoma: An immunological exception?	Medical oncology (Northwood, London, England)	2016	17.313190758120122	27.65356565993023	20	0.74
27693088	Immune checkpoint inhibitors for nonsmall cell lung cancer treatment.	Journal of the Chinese Medical Association : JCMA	2017	39.16317985756993	-31.217102398448112	31	1.12
31149119	CLINICAL SIGNIFICANCE OF PD-L1 EXPRESSION IN PARATHYROID CANCER.	Acta endocrinologica (Bucharest, Romania : 2005)	2016	-7.070316729252506	-19.023385091053107	3	0.14
29264195	Novel immunotherapy approaches for metastatic urothelial and renal cell carcinoma.	Asian journal of urology	2016	63.62519933288053	31.040236612711688	3	0.15
27688163	Predicting PD-L1 expression on human cancer cells using next-generation sequencing information in computational simulation models.	Cancer immunology, immunotherapy : CII	2016	-6.334305694877172	-3.751096248066079	16	0.55
27687306	Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up.	Annals of oncology : official journal of the European Society for Medical Oncology	2017	16.115403209473097	-14.947433279367532	124	4.01
27686176	Stromal PD-L1 Expression Is Associated With Better Disease-Free Survival in Triple-Negative Breast Cancer.	American journal of clinical pathology	2016	-8.20026751469936	18.62952993012263	74	2.61
27686004	Increased PD-1/STAT1 ratio may account for the survival benefit in decitabine therapy for lower risk myelodysplastic syndrome.	Leukemia & lymphoma	2017	-34.533400833272474	13.566198516212673	11	0.43
27683557	TGFβ1-Mediated SMAD3 Enhances PD-1 Expression on Antigen-Specific T Cells in Cancer.	Cancer discovery	2016	-28.090877306994603	-3.4210972708793714	167	5.35
27683114	Methylation of RAD51B, XRCC3 and other homologous recombination genes is associated with expression of immune checkpoints and an inflammatory signature in squamous cell carcinoma of the head and neck, lung and cervix.	Oncotarget	2016	-7.52775103144199	41.12641733378263	26	0.89
27671676	Modulation of Immune Checkpoints and Graft-versus-Leukemia in Allogeneic Transplants by Antagonizing Vasoactive Intestinal Peptide Signaling.	Cancer research	2016	-67.26199428651087	-6.979619702912524	13	0.42
27671246	Frontline Science: Defects in immune function in patients with sepsis are associated with PD-1 or PD-L1 expression and can be restored by antibodies targeting PD-1 or PD-L1.	Journal of leukocyte biology	2016	-57.45840531059974	36.20640967192283	137	5.11
27668225	The emerging role of immunotherapy in colorectal cancer.	Annals of translational medicine	2016	36.52178957027992	19.691134972509776	51	1.86
27667773	An Analytical Comparison of Dako 28-8 PharmDx Assay and an E1L3N Laboratory-Developed Test in the Immunohistochemical Detection of Programmed Death-Ligand 1.	Molecular diagnosis & therapy	2017	21.08989043978059	-41.13150274356291	28	0.97
27667465	[Upregulated PD-1 on CD8+T cells is positively correlated with activation of T cells during HIV-1 infection].	Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology	2016	-81.44444815653299	13.239720088724074	3	0.08
27665733	Programmed death-1+ T cells inhibit effector T cells at the pathological site of miliary tuberculosis.	Clinical and experimental immunology	2017	-84.14571437443996	1.4068753005980936	15	0.58
27665539	Role of the immune system in the peritoneal tumor spread of high grade serous ovarian cancer.	Oncotarget	2016	3.628815563194212	30.067010904874188	29	1.16
27663482	Immuno-pharmacodynamics for evaluating mechanism of action and developing immunotherapy combinations.	Seminars in oncology	2016	2.772767520756246	-55.78170292198998	6	0.19
27662340	Pembrolizumab-triggered Uveitis: An Additional Surrogate Marker for Responders in Melanoma Immunotherapy?	Journal of immunotherapy (Hagerstown, Md. : 1997)	2016	72.22294235442662	-21.37578611661751	40	1.84
27660709	A case report of Grover's disease from immunotherapy-a skin toxicity induced by inhibition of CTLA-4 but not PD-1.	Journal for immunotherapy of cancer	2016	74.52054055311733	-26.396209270920085	41	1.7
27660198	PD-1/PD-L and autoimmunity: A growing relationship.	Cellular immunology	2016	-56.77725656133576	1.275396099675933	182	7.12
27658492	Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) in muscle invasive and metastatic bladder cancer patients.	BMC cancer	2016	10.847888041833086	58.97114283026029	83	3.04
27657168	CD301b+ dendritic cells suppress T follicular helper cells and antibody responses to protein antigens.	eLife	2016	-58.0665746317878	-5.317561473158283	28	0.75
27656680	PD-1 pathway-mediated regulation of islet-specific CD4+ T cell subsets in autoimmune diabetes.	Immunoendocrinology (Houston, Tex.)	2016	-60.68982077171508	2.5031351561944533	20	0.71
27649554	The T-cell Receptor Repertoire Influences the Tumor Microenvironment and Is Associated with Survival in Aggressive B-cell Lymphoma.	Clinical cancer research : an official journal of the American Association for Cancer Research	2017	-29.83687704278955	31.908079055852426	59	2.18
27629881	Clinicopathological features of programmed death ligand 1 expression with tumor-infiltrating lymphocyte, mismatch repair, and Epstein-Barr virus status in a large cohort of gastric cancer patients.	Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association	2017	-10.028095452916157	6.961606515856591	149	6.14
27628745	Recent Progress in Mutation-driven Therapy, Immunotherapy and Combination Therapy for the Treatment of Melanoma.	Current cancer drug targets	2017	31.36244802625012	30.493457433026823	1	0.05
27623999	Novel immunotherapy in the treatment of advanced non-small cell lung cancer.	Expert review of clinical pharmacology	2016	37.78538802906569	-33.72998113375485	21	0.69
27623354	Independent association of PD-L1 expression with noninactivated VHL clear cell renal cell carcinoma-A finding with therapeutic potential.	International journal of cancer	2017	14.97452697947084	28.28085850845097	38	1.33
27622603	PD-1 blockade in Hodgkin's lymphoma: learning new tricks from an old teacher.	Expert review of hematology	2016	-6.767899323657542	-27.25177133646435	8	0.24
27622059	Immune checkpoint blockade reveals the stimulatory capacity of tumor-associated CD103(+) dendritic cells in late-stage ovarian cancer.	Oncoimmunology	2016	0.7538578932620468	28.591423251638364	30	1.01
27622011	Combined treatment with dabrafenib and trametinib with immune-stimulating antibodies for BRAF mutant melanoma.	Oncoimmunology	2016	30.634742994253685	33.95711792745109	70	1.93
27619200	PD-1/PD-L1 expression in extra-medullary lesions of multiple myeloma.	Leukemia research	2016	-32.86776377963044	10.181263204386248	6	0.21
27618663	Structure and Dynamics of PD-L1 and an Ultra-High-Affinity PD-1 Receptor Mutant.	Structure (London, England : 1993)	2016	-48.30971056015976	-39.58197477727028	56	1.94
27613101	Inhibition of B-cell activation and antibody production by triggering inhibitory signals via the PD-1/PD-ligand pathway.	Xenotransplantation	2016	-54.05509783282553	-8.604045648860481	21	0.87
27610620	Elevated Cellular PD1/PD-L1 Expression Confers Acquired Resistance to Cisplatin in Small Cell Lung Cancer Cells.	PloS one	2016	-1.839952576667743	-28.3560916421731	52	1.84
27609582	[Increased expressions of programmed death 1 (PD-1) and its ligands in peripheral CD3(+) T cells and CD19(+) B cells in patients with hepatocellular carcinoma].	Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology	2016	-24.472355610829435	39.76970279743083	0	0.0
27605882	Specific CD8(+) T cell response immunotherapy for hepatocellular carcinoma and viral hepatitis.	World journal of gastroenterology	2016	-76.60038300543253	27.363414636191163	38	1.36
27604386	Soluble programmed death-1 levels are associated with disease activity and treatment response in patients with autoimmune hepatitis.	Scandinavian journal of gastroenterology	2017	-68.53797000451841	24.169600432092896	33	1.5
27604282	[Immunotherapeutic studies of head and neck tumors : Highlights of the 2016 ASCO Annual Meeting].	HNO	2016	51.09100562151097	30.745573709841413	5	0.19
27601594	Neoadjuvant Chemotherapy of Ovarian Cancer Results in Three Patterns of Tumor-Infiltrating Lymphocyte Response with Distinct Implications for Immunotherapy.	Clinical cancer research : an official journal of the American Association for Cancer Research	2017	1.4779760561775668	23.347516814138945	109	3.81
27597284	Increase in soluble PD-1 is associated with prolonged survival in patients with advanced EGFR-mutated non-small cell lung cancer treated with erlotinib.	Lung cancer (Amsterdam, Netherlands)	2016	21.259226328355734	-27.78133092289444	79	2.79
27595749	FDG-PET in the evaluation of response to nivolumab in recurrent non-small-cell lung cancer.	World journal of surgical oncology	2016	35.630870936594704	-46.72959579550204	23	0.81
27594385	Poly I:C primes the suppressive function of human palatine tonsil-derived MSCs against Th17 differentiation by increasing PD-L1 expression.	Immunobiology	2017	-54.06474636219012	22.035636801615837	11	0.55
27591097	Investigation of PD-L1 Biomarker Testing Methods for PD-1 Axis Inhibition in Non-squamous Non-small Cell Lung Cancer.	The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society	2016	17.48402811710234	-36.98159228889534	26	0.97
27590194	Programmed cell death-ligand 1 expression in oral squamous cell carcinoma is associated with an inflammatory phenotype.	Pathology	2016	-8.00012678069128	-11.792776681173468	57	2.17
27589875	Response to Programmed Cell Death-1 Blockade in a Murine Melanoma Syngeneic Model Requires Costimulation, CD4, and CD8 T Cells.	Cancer immunology research	2016	-30.12838408942517	-15.69652970912736	99	3.0
27588404	Characterizing the immune microenvironment of malignant peripheral nerve sheath tumor by PD-L1 expression and presence of CD8+ tumor infiltrating lymphocytes.	Oncotarget	2016	-23.480881169071345	16.723376488923908	36	1.35
27581021	Methods to Evaluate the Antitumor Activity of Immune Checkpoint Inhibitors in Preclinical Studies.	Methods in molecular biology (Clifton, N.J.)	2016	32.251730867524294	13.037326179004909	8	0.22
27579535	T-cell epitope strength in WAP-T mouse mammary carcinomas is an important determinant in PD1/PD-L1 immune checkpoint blockade therapy.	Oncotarget	2016	-28.06540744365145	-65.58383564481551	6	0.21
27578499	"Letter to the editor referring to the publication entitled ""The role of antagonists of the PD-1:PD-L1/PD-L2 axis in head and neck cancer treatment"" by Pai et al."	Oral oncology	2016	-9.541118042723236	-4.686731085130125	1	0.02
27574444	PD-L1 expression in human cancers and its association with clinical outcomes.	OncoTargets and therapy	2016	-12.94768662278724	10.855181698029542	463	17.52
27573705	Immunological effects of the anti-programmed death-1 antibody on human peripheral blood mononuclear cells.	International journal of oncology	2016	34.829979381759735	-13.07792820120142	15	0.53
27572267	Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity.	Nature communications	2016	-35.1742121377177	-31.586806528182183	594	21.08
27565934	Nivolumab-induced organizing pneumonitis in a patient with lung sarcomatoid carcinoma.	Lung cancer (Amsterdam, Netherlands)	2016	66.71346940622402	-11.937256927278778	31	1.17
27565919	Predictive biomarkers of response to PD-1/PD-L1 immune checkpoint inhibitors in non-small cell lung cancer.	Lung cancer (Amsterdam, Netherlands)	2016	21.936463375051243	-33.889376567058804	90	3.06
27565906	Expression of programmed death 1 (PD-1) and its ligand (PD-L1) in thymic epithelial tumors: Impact on treatment efficacy and alteration in expression after chemotherapy.	Lung cancer (Amsterdam, Netherlands)	2016	-4.623093471947536	-36.60631604819379	67	2.43
27564404	An IL-27/Stat3 axis induces expression of programmed cell death 1 ligands (PD-L1/2) on infiltrating macrophages in lymphoma.	Cancer science	2016	-35.69926340365391	20.37046262333767	93	3.26
27562497	PD-L1 expression in basaloid squamous cell lung carcinoma: Relationship to PD-1+ and CD8+ tumor-infiltrating T cells and outcome.	Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc	2016	0.2267158638117019	-3.2371693553870298	23	0.84
27557830	Second-Line Treatment of Non-Small Cell Lung Cancer: New Developments for Tumours Not Harbouring Targetable Oncogenic Driver Mutations.	Drugs	2016	42.36326197340284	-34.4668533474875	13	0.5
27556047	PD-1/PD-L1 Interaction Maintains Allogeneic Immune Tolerance Induced by Administration of Ultraviolet B-Irradiated Immature Dendritic Cells.	Journal of immunology research	2016	-61.40607684293992	-1.7236439162513748	2	0.08
27553906	The Potential Value of Immunotherapy in Colorectal Cancers: Review of the Evidence for Programmed Death-1 Inhibitor Therapy.	Clinical colorectal cancer	2016	35.64354462117168	23.500288005651065	67	2.53
27553831	HHLA2, a New Immune Checkpoint Member of the B7 Family, Is Widely Expressed in Human Lung Cancer and Associated with EGFR Mutational Status.	Clinical cancer research : an official journal of the American Association for Cancer Research	2017	20.9293843472801	-18.420825373615404	71	2.32
27553175	Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor Nivolumab.	Scientific reports	2016	10.21446539958268	-37.73282391781943	204	7.56
27552968	Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer.	Molecular cancer	2016	-4.717202044970687	11.551676323602008	192	6.92
27548033	Programmed Death-Ligand 1 on Antigen-presenting Cells Facilitates the Induction of Antigen-specific Cytotoxic T Lymphocytes: Application to Adoptive T-Cell Immunotherapy.	Journal of immunotherapy (Hagerstown, Md. : 1997)	2016	-56.82065842946015	-7.7626231140872015	10	0.33
27543594	Correlation of PD-L1 Surface Expression on Leukemia Cells with the Ratio of PD-L1 mRNA Variants and with Electrophoretic Mobility.	Cancer immunology research	2016	7.427216964605294	-6.256040166293745	7	0.29
27542294	Expanding the List of Dysregulated Immunosuppressive Cells in Psoriasis.	The Journal of investigative dermatology	2016	-51.292164199711785	28.62649819703593	8	0.28
27541827	A Quantitative Comparison of Antibodies to Programmed Cell Death 1 Ligand 1.	JAMA oncology	2017	13.5090471445055	-42.31750496698751	149	5.29
27535396	Immunotherapy in Lung Cancer.	Cancer treatment and research	2016	36.084283894390666	-32.119211987426496	8	0.31
27534576	In search of a target: PD-1 and PD-L1 profiling across glioma types.	Neuro-oncology	2016	-25.13618905124236	51.58939375284834	12	0.4
27534574	Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.	The oncologist	2017	39.32993392052589	-32.08843784009282	115	4.39
27533014	Programmed Death-1 Ligand 2-Mediated Regulation of the PD-L1 to PD-1 Axis Is Essential for Establishing CD4(+) T Cell Immunity.	Immunity	2016	-75.1985988472648	2.7231536868859254	81	2.78
27532023	PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?	Journal for immunotherapy of cancer	2016	23.187262183037824	-37.843407608246096	149	5.22
27532022	Grover's-like drug eruption in a patient with metastatic melanoma under ipilimumab therapy.	Journal for immunotherapy of cancer	2016	74.37606830186284	-26.242717448018947	21	0.89
27531819	Comprehensive profiling of metaplastic breast carcinomas reveals frequent overexpression of programmed death-ligand 1.	Journal of clinical pathology	2017	-10.155584098062029	18.965308562631726	85	3.2
27525587	Acid-Activatable Versatile Micelleplexes for PD-L1 Blockade-Enhanced Cancer Photodynamic Immunotherapy.	Nano letters	2016	-31.441004691718387	-55.55250983266198	271	10.61
27511728	Suppression of Glut1 and Glucose Metabolism by Decreased Akt/mTORC1 Signaling Drives T Cell Impairment in B Cell Leukemia.	Journal of immunology (Baltimore, Md. : 1950)	2016	-65.65609352144538	17.419145890005357	97	3.03
27508049	Expression of programmed death-1 ligand (PD-L1) in tumor-infiltrating lymphocytes is associated with favorable spinal chordoma prognosis.	American journal of translational research	2016	-18.152018881751168	26.937481398743756	47	1.77
27508013	Follicular helper T cell exhaustion induced by PD-L1 expression in hepatocellular carcinoma results in impaired cytokine expression and B cell help, and is associated with advanced tumor stages.	American journal of translational research	2016	-74.60959407374958	26.9586646708012	34	1.19
27503244	The role of antagonists of the PD-1:PD-L1/PD-L2 axis in head and neck cancer treatment.	Oral oncology	2016	-9.337090178793664	-4.760354544963437	44	1.65
27502709	Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer.	Annals of oncology : official journal of the European Society for Medical Oncology	2016	-0.3624618490307362	17.58771880721125	241	8.21
27499991	Dramatic response to anti-PD-1 therapy in a patient of squamous cell carcinoma of thymus with multiple lung metastases.	Journal of thoracic disease	2016	54.79638768292303	1.373422031575196	17	0.53
27499043	Selection and characterization of the novel anti-human PD-1 FV78 antibody from a targeted epitope mammalian cell-displayed antibody library.	Cellular & molecular immunology	2018	-47.22314795098134	-32.26340076737287	8	0.35
27496729	Bioenergetic Insufficiencies Due to Metabolic Alterations Regulated by the Inhibitory Receptor PD-1 Are an Early Driver of CD8(+) T Cell Exhaustion.	Immunity	2016	-65.71203519364926	17.39031223206328	469	15.02
27496355	Validated programmed cell death ligand 1 immunohistochemistry assays (E1L3N and SP142) reveal similar immune cell staining patterns in melanoma when using the same sensitive detection system.	Histopathology	2017	13.593749557460235	-42.27242664927906	34	1.35
27493273	Preclinical Pharmacokinetics and Biodistribution Studies of 89Zr-Labeled Pembrolizumab.	Journal of nuclear medicine : official publication, Society of Nuclear Medicine	2017	7.872149799492035	-57.60518789704105	123	5.41
27491654	Treatment outcome of PD-1 immune checkpoint inhibitor in Asian metastatic melanoma patients: correlative analysis with PD-L1 immunohistochemistry.	Investigational new drugs	2016	10.517096424550187	-3.5889096228468125	27	0.96
27489432	Increased Infiltration of CD8(+) T Cells by Dacarbazine in a Patient with Mucosal Penile Melanoma Refractory to Nivolumab.	Annals of dermatology	2016	-6.221160214417957	-57.40983061950316	4	0.16
27485075	A pooled analysis of nivolumab for the treatment of advanced non-small-cell lung cancer and the role of PD-L1 as a predictive biomarker.	Immunotherapy	2016	46.05383482177992	-25.90070476033891	31	1.04
27480166	Nivolumab in the treatment of metastatic squamous non-small cell lung cancer: a review of the evidence.	Therapeutic advances in respiratory disease	2016	45.71084039519578	-25.495226497849902	19	0.59
27479178	The PD-1/PD-L1 axis contributes to immune metabolic dysfunctions of monocytes in chronic lymphocytic leukemia.	Leukemia	2017	-37.574651334244976	-4.718012866289843	67	2.19
27473266	PD-L1 expression is associated with epithelial-to-mesenchymal transition in adenocarcinoma of the lung.	Human pathology	2016	-4.451063773297138	1.684032927016966	115	4.29
27471641	Antitumor vaccination of prostate cancer patients elicits PD-1/PD-L1 regulated antigen-specific immune responses.	Oncoimmunology	2016	-28.102422606770958	-11.0431021013024	39	1.37
27471580	Immune Checkpoint Inhibitors and Prostate Cancer: A New Frontier?	Oncology reviews	2016	22.4446675593382	16.345047176824494	43	1.5
27470968	PD-1/PD-L1 Blockade Enhances T-cell Activity and Antitumor Efficacy of Imatinib in Gastrointestinal Stromal Tumors.	Clinical cancer research : an official journal of the American Association for Cancer Research	2017	42.22086055643829	21.533691691150302	103	3.71
27468881	Immune checkpoints in aggressive breast cancer subtypes.	Neoplasma	2016	-8.830714252715316	16.93348537073549	12	0.44
27468145	PD-L1 is upregulated by radiochemotherapy in rectal adenocarcinoma patients and associated with a favourable prognosis.	European journal of cancer (Oxford, England : 1990)	2016	-4.7429952109860265	9.240382627590296	97	3.46
27467911	Immune checkpoints programmed death 1 ligand 1 and cytotoxic T lymphocyte associated molecule 4 in gastric adenocarcinoma.	Oncoimmunology	2016	43.37846091616882	19.79523030163475	40	1.24
27463642	The evolving role of monoclonal antibodies in the treatment of patients with advanced renal cell carcinoma: a systematic review.	Expert opinion on biological therapy	2016	66.02024075738426	32.73039471871431	20	0.72
27462168	Fundamental effects of PD-1 antibody on the body: a brief report.	OncoTargets and therapy	2016	35.00564114779139	-12.710223068656251	3	0.14
27461275	Melanoma and immunotherapy bridge 2015 : Naples, Italy. 1-5 December 2015.	Journal of translational medicine	2016	30.39881866007532	29.357932509082232	11	0.29
27458525	Programmed cell death ligand-1 (PD-L1) expression by immunohistochemistry: could it be predictive and/or prognostic in non-small cell lung cancer?	Cancer biology & medicine	2016	19.90382956424321	-37.48333335385707	65	2.35
27458027	PD-L1 Detection in Tumors Using [(64)Cu]Atezolizumab with PET.	Bioconjugate chemistry	2016	9.339293478868385	-53.83895700219401	114	4.51
27457350	Clinical Trials Investigating Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer.	Reviews on recent clinical trials	2016	38.985890562806766	-32.8518514349156	12	0.37
27456947	Overexpression of PD-L1 and PD-L2 Is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma.	Cancer research and treatment	2017	-21.92588419001412	40.95770945907833	140	5.6
27456063	Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma.	Scientific reports	2016	-17.575004621107173	19.32443974459946	195	7.82
27454297	Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition.	The Journal of clinical investigation	2016	-42.53602164807813	2.736309783394361	632	21.93
27453950	PD-1 blockade enhances the vaccination-induced immune response in glioma.	JCI insight	2016	-30.00968876447345	55.1695606265814	112	3.92
27451022	Rapid and objective CT scan prognostic scoring identifies metastatic patients with long-term clinical benefit on anti-PD-1/-L1 therapy.	European journal of cancer (Oxford, England : 1990)	2016	24.5688025123234	-43.33749392132929	56	2.04
27450183	Pharmacokinetics, pharmacodynamics and clinical efficacy of nivolumab in the treatment of metastatic renal cell carcinoma.	Expert opinion on drug metabolism & toxicology	2016	63.17369218621844	28.454223311121265	14	0.44
27448787	Molecularly targeted agents and immunotherapy for the treatment of head and neck squamous cell cancer (HNSCC).	Discovery medicine	2016	52.59238472744318	32.32947452568807	22	0.82
27447090	Magneto-nanosensor platform for probing low-affinity protein-protein interactions and identification of a low-affinity PD-L1/PD-L2 interaction.	Nature communications	2016	-48.486467391062014	-43.38402462326454	20	0.8
27446497	High-Resolution PET Imaging with Therapeutic Antibody-based PD-1/PD-L1 Checkpoint Tracers.	Theranostics	2016	6.471059784654992	-54.86128115461888	146	5.83
27446374	Expression of PD-1, PD-L1 and PD-L2 is associated with differentiation status and histological type of endometrial cancer.	Oncology letters	2016	-18.180300053085556	8.794847350387066	62	2.45
27446371	PD-L1 expression is associated with advanced non-small cell lung cancer.	Oncology letters	2016	12.841406849142023	-30.73538029255966	18	0.64
27441513	Update on New Therapies With Immune Checkpoint Inhibitors.	Clinical journal of oncology nursing	2016	22.665381967445093	8.404021875974717	11	0.37
27440711	Myeloma Drug Resistance Induced by Binding of Myeloma B7-H1 (PD-L1) to PD-1.	Cancer immunology research	2016	-33.89925632501598	6.74884428002645	73	2.57
27438833	A Mini-Review for Cancer Immunotherapy: Molecular Understanding of PD-1/PD-L1 Pathway & Translational Blockade of Immune Checkpoints.	International journal of molecular sciences	2016	-40.134654508576816	-18.24320207836383	106	3.8
27429660	Immune checkpoint blockade in ovarian cancer.	Memo	2016	39.21567796565548	39.14244062021494	14	0.5
27429197	Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer.	Oncotarget	2016	51.94620950152851	3.018057393041769	264	9.28
27421997	Clinical and prognostic significance of PD-1 and PD-L1 expression in sarcomas.	Medical oncology (Northwood, London, England)	2016	-21.510970007079145	20.20074292082938	68	2.73
27416962	Mechanisms of immune evasion and current status of checkpoint inhibitors in non-small cell lung cancer.	Cancer medicine	2016	32.501075379942584	-32.76613439367832	50	1.8
27411930	Advances in the Treatment of Non-small Cell Lung Cancer: Focus on Nivolumab, Pembrolizumab, and Atezolizumab.	BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy	2016	41.38094236316437	-32.552573059041435	26	0.77
27411054	Clinical and Histologic Features of Lichenoid Mucocutaneous Eruptions Due to Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Immunotherapy.	JAMA dermatology	2016	70.79259580709456	-24.371853985137832	148	6.37
27406624	Exploring the induction of preproinsulin-specific Foxp3(+) CD4(+) Treg cells that inhibit CD8(+) T cell-mediated autoimmune diabetes by DNA vaccination.	Scientific reports	2016	-62.61994748589006	1.7089520534209626	5	0.19
27403706	Ipilimumab in melanoma.	Expert review of anticancer therapy	2016	31.84945623602545	33.001725438935495	22	0.72
27401477	Cancer-induced heterogeneous immunosuppressive tumor microenvironments and their personalized modulation.	International immunology	2016	19.50490694587464	12.634693577550816	39	1.26
27393509	Clinical and pathologic features of lung cancer expressing programmed cell death ligand 1 (PD-L1).	Lung cancer (Amsterdam, Netherlands)	2016	8.52335301503097	-27.835069784705183	120	4.59
27386489	The role of pembrolizumab in the treatment of advanced non-small cell lung cancer.	Annals of translational medicine	2016	47.05911032926898	-32.075893434278946	9	0.26
27381685	Rationale for immune-based therapies in Merkel polyomavirus-positive and -negative Merkel cell carcinomas.	Immunotherapy	2016	44.51080093491884	51.67503058637484	14	0.64
27378029	Sepsis in PD-1 light.	Critical care (London, England)	2016	-58.3940079097919	35.49752096363558	20	0.73
27377654	Pembrolizumab: first experience with recurrent primary central nervous system (CNS) tumors.	Journal of neuro-oncology	2016	50.34908359448808	-1.5803776102323048	60	2.07
27376121	Inhibiting Immune Checkpoints for the Treatment of Bladder Cancer.	Bladder cancer (Amsterdam, Netherlands)	2016	70.09463050468716	22.70528951266263	25	0.91
27371844	[Qiyusanlong decoction inhibits the level of PD-1/PD-L1 in mice bearing Lewis lung carcinoma].	Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology	2016	-23.655850653392445	-36.61754820502308	4	0.23
27370400	Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies.	Neuro-oncology	2016	-24.23574506519295	51.44452491386751	106	3.72
27367741	Inhibitors of programmed cell death 1 (PD-1): a patent review (2010-2015).	Expert opinion on therapeutic patents	2016	-43.03416894374616	-37.69601652157966	69	2.43
27362903	PD-L1 Expression in Human Placentas and Gestational Trophoblastic Diseases.	International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists	2017	-37.47390292218946	-2.695770186341245	108	4.72
27359084	Programmed death ligand 1 expression in hepatocellular carcinoma: Relationship With clinical and pathological features.	Hepatology (Baltimore, Md.)	2016	-22.81036214888333	39.56686056270876	293	10.87
27354476	Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure.	Journal of clinical oncology : official journal of the American Society of Clinical Oncology	2016	44.42881524308679	-5.182542170803801	488	17.45
27349981	Immune checkpoint inhibitor combinations in solid tumors: opportunities and challenges.	Immunotherapy	2016	27.219351833044957	1.2778157667880283	119	4.11
27349977	Emerging biomarkers as predictors to anti-PD1/PD-L1 therapies in advanced melanoma.	Immunotherapy	2016	18.391191764655325	-5.438588084271474	20	0.64
27341313	The tumour microenvironment influences survival and time to transformation in follicular lymphoma in the rituximab era.	British journal of haematology	2016	-21.92368658221137	30.24412129846491	51	1.8
27329602	Prognostic value, localization and correlation of PD-1/PD-L1, CD8 and FOXP3 with the desmoplastic stroma in pancreatic ductal adenocarcinoma.	Oncotarget	2016	-8.217162500996663	27.49309352853496	63	2.21
27325283	Nods for Atezolizumab and Nivolumab from FDA.	Cancer discovery	2016	66.99249179117335	19.068664355134967	9	0.25
27322149	Comprehensive immunohistochemical analysis of tumor microenvironment immune status in esophageal squamous cell carcinoma.	Oncotarget	2016	-5.946554483868012	26.26876833660614	77	2.68
27321759	Menopausal status influences the expression of programmed death (PD)-1 and its ligand PD-L1 on immune cells from the human female reproductive tract.	American journal of reproductive immunology (New York, N.Y. : 1989)	2016	-70.62330403051256	-18.581647163235598	18	0.68
27318796	The development of immunotherapy in older adults: New treatments, new toxicities?	Journal of geriatric oncology	2016	83.83761521033308	-5.9875600410655245	70	2.49
27315066	Checkpoint Inhibitors in Head and Neck Cancer: Rationale, Clinical Activity, and Potential Biomarkers.	Current treatment options in oncology	2016	52.24316602901894	32.89082799508569	18	0.61
27313464	Profile of nivolumab in the treatment of metastatic squamous non-small-cell lung cancer.	OncoTargets and therapy	2016	45.68853605041953	-25.539358098513	11	0.4
27312065	Analysis of PD-L1, T-cell infiltrate and HLA expression in chondrosarcoma indicates potential for response to immunotherapy specifically in the dedifferentiated subtype.	Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc	2016	-19.74946243366844	21.01595879255425	72	2.77
27310809	Biomarkers for the Clinical Use of PD-1/PD-L1 Inhibitors in Non-Small-Cell Lung Cancer: A Review.	JAMA oncology	2016	21.84348695372853	-34.29122109554673	187	6.39
27309382	Past, Present, and Future of Augmentation of Monocyte Function in the Surgical Patient.	Surgical infections	2016	-56.22365489220324	37.283789824119005	11	0.46
27306802	[Recent Development of Therapies for Melanoma Using Immune Checkpoint Blockades].	Gan to kagaku ryoho. Cancer & chemotherapy	2016	29.235211185917304	4.347485477983582	0	0.0
27306793	Neoadjuvant Chemotherapy Modulates the Immune Microenvironment in Metastases of Tubo-Ovarian High-Grade Serous Carcinoma.	Clinical cancer research : an official journal of the American Association for Cancer Research	2016	1.805576757311552	24.093615907639943	102	3.45
27297395	Lymphocyte-activation gene-3, an important immune checkpoint in cancer.	Cancer science	2016	10.410044534441203	21.984568681120574	124	4.22
27294527	Programmed death ligand-1 expression on donor T cells drives graft-versus-host disease lethality.	The Journal of clinical investigation	2016	-64.81179529726047	-4.72947940219739	73	2.43
27292320	Higher preoperative serum levels of PD-L1 and B7-H4 are associated with invasive and metastatic potential and predictable for poor response to VEGF-targeted therapy and unfavorable prognosis of renal cell carcinoma.	Cancer medicine	2016	18.99563151718969	29.238018796684504	44	1.55
27283895	Profiling the dynamic expression of checkpoint molecules on cytokine-induced killer cells from non-small-cell lung cancer patients.	Oncotarget	2016	25.83427594735246	-9.032014193289635	32	1.18
27283319	Correlation of Apobec Mrna Expression with overall Survival and pd-l1 Expression in Urothelial Carcinoma.	Scientific reports	2016	18.06650135721747	36.08337234607477	39	1.2
27281199	Aberrant PD-L1 expression through 3'-UTR disruption in multiple cancers.	Nature	2016	-15.399007933406136	-4.289479652075293	447	14.63
27277012	The PD-1/PD-L1 inhibitory pathway is altered in pre-eclampsia and regulates T cell responses in pre-eclamptic rats.	Scientific reports	2016	-73.69541294450735	-17.769545782319007	60	2.72
27276060	Immunohistochemical Analysis of PD-L1 Expression in Canine Malignant Cancers and PD-1 Expression on Lymphocytes in Canine Oral Melanoma.	PloS one	2016	-15.80893792023138	-13.868064238367658	76	3.58
27275485	Uveal melanoma as a target for immune-therapy.	Annals of translational medicine	2016	35.30745057510799	4.32644762261662	48	1.93
27270408	[Molecular and immunohistochemical diagnostics in melanoma].	Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete	2016	9.642821310418316	-43.9136663170414	3	0.19
27269947	Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study.	Journal of clinical oncology : official journal of the American Society of Clinical Oncology	2016	41.1160177870992	-5.315622721970157	743	27.56
27267608	Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial.	The Lancet. Oncology	2016	49.53718801774763	-2.300061144457981	715	26.75
27267211	Immune checkpoint inhibitors as first-line and salvage therapy for advanced non-small-cell lung cancer.	Future oncology (London, England)	2016	42.70902784625856	-33.335403736048896	5	0.19
27264687	Novel exosome-targeted T-cell-based vaccine counteracts T-cell anergy and converts CTL exhaustion in chronic infection via CD40L signaling through the mTORC1 pathway.	Cellular & molecular immunology	2017	-76.91503891268118	16.820064849544007	25	0.99
27259563	Programmed cell death-1 blockade in recurrent disseminated Ewing sarcoma.	Journal of hematology & oncology	2016	-23.04853526692423	18.54035424679708	27	0.83
27252415	Image Analysis-based Assessment of PD-L1 and Tumor-Associated Immune Cells Density Supports Distinct Intratumoral Microenvironment Groups in Non-small Cell Lung Carcinoma Patients.	Clinical cancer research : an official journal of the American Association for Cancer Research	2016	10.3215486828416	-16.405824149386913	111	3.72
27251642	Correlation of metabolic information on FDG-PET with tissue expression of immune markers in patients with non-small cell lung cancer (NSCLC) who are candidates for upfront surgery.	European journal of nuclear medicine and molecular imaging	2016	15.320337689670794	-56.53771967297588	108	3.85
27249753	Immunotherapy: Beyond Anti-PD-1 and Anti-PD-L1 Therapies.	American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting	2016	34.65278022682761	-31.80817800572495	37	1.29
27249684	The Evolution of Triple-Negative Breast Cancer: From Biology to Novel Therapeutics.	American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting	2016	7.331421077165131	29.861444172619244	81	3.05
27247226	Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial.	The Lancet. Oncology	2016	53.1066479138344	6.789874630866743	1124	44.24
27239172	Checkpoint Inhibitors and Their Application in Breast Cancer.	Breast care (Basel, Switzerland)	2016	26.24403960817855	8.753543533358783	35	1.2
27237031	Clinicopathological and prognostic significance of programmed cell death ligand-1 expression in lung adenocarcinoma and its relationship with p53 status.	Lung cancer (Amsterdam, Netherlands)	2016	8.900509924124924	-27.98461853084961	106	3.47
27236554	Therapeutic Antibodies in Cancer Therapy.	Advances in experimental medicine and biology	2016	23.928189074532124	3.2978506012403206	28	1.04
27235694	The present status and future prospects of peptide-based cancer vaccines.	International immunology	2016	16.08715314620983	6.231805529571449	75	2.88
27234522	Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy.	Journal of hematology & oncology	2016	24.445280395518925	5.519081168776547	238	8.45
27225694	EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis.	Clinical cancer research : an official journal of the American Association for Cancer Research	2016	8.930281189972275	-33.186005096848106	856	30.26
27221508	Actions of l-thyroxine and Nano-diamino-tetrac (Nanotetrac) on PD-L1 in cancer cells.	Steroids	2016	-32.54323313115286	-27.478361568748813	53	2.29
27213372	Variability in Immunohistochemical Detection of Programmed Death Ligand 1 (PD-L1) in Cancer Tissue Types.	International journal of molecular sciences	2016	-46.3707711281745	-18.39264144035881	30	1.0
27208063	Molecular Pathways: Targeting B7-H3 (CD276) for Human Cancer Immunotherapy.	Clinical cancer research : an official journal of the American Association for Cancer Research	2016	1.935094019483488	-16.831144347325882	303	10.79
27207108	Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure).	Annals of oncology : official journal of the European Society for Medical Oncology	2016	-40.37383214481971	-14.981042205754552	375	12.81
27198569	PD-L1 expression in colorectal cancer is associated with microsatellite instability, BRAF mutation, medullary morphology and cytotoxic tumor-infiltrating lymphocytes.	Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc	2016	8.917857014201298	38.12152786915512	183	6.55
27197542	Targeting PD-L1 for non-small-cell lung cancer.	Immunotherapy	2016	40.68624678732344	-32.100471971558186	10	0.36
27197541	PD-1 and PD-L1 inhibitors in melanoma treatment: past success, present application and future challenges.	Immunotherapy	2016	33.400212400031	-1.4008008490782684	26	0.84
27197537	Are there, or shall we discover, biomarkers to guide PD-1 inhibition?	Immunotherapy	2016	17.835143126641263	-5.262712142608901	1	0.08
27197251	TALEN-Mediated Inactivation of PD-1 in Tumor-Reactive Lymphocytes Promotes Intratumoral T-cell Persistence and Rejection of Established Tumors.	Cancer research	2016	-34.74584072787248	-14.760650393289596	62	1.88
27197062	Immune-Derived PD-L1 Gene Expression Defines a Subgroup of Stage II/III Colorectal Cancer Patients with Favorable Prognosis Who May Be Harmed by Adjuvant Chemotherapy.	Cancer immunology research	2016	8.496961965214664	41.15779331320647	31	1.03
27196573	Tumour CD274 (PD-L1) expression and T cells in colorectal cancer.	Gut	2017	9.484701723825406	36.14507317175614	155	5.62
27196116	PD-L1 testing for lung cancer in the UK: recognizing the challenges for implementation.	Histopathology	2016	22.8234216948469	-38.1737235941159	68	2.58
27192570	Targeting T Cell Co-receptors for Cancer Therapy.	Immunity	2016	25.993193205822003	4.7599492566345365	342	11.01
27191652	Expression of PD-1 on CD4+ T cells in peripheral blood associates with poor clinical outcome in non-small cell lung cancer.	Oncotarget	2016	8.023229395262087	-21.38758811868664	45	1.58
27186886	PD-1/CTLA-4 Blockade Inhibits Epstein-Barr Virus-Induced Lymphoma Growth in a Cord Blood Humanized-Mouse Model.	PLoS pathogens	2016	-37.79220825631643	7.990343133560031	82	3.02
27182556	T cell Bim levels reflect responses to anti-PD-1 cancer therapy.	JCI insight	2016	11.422846329960686	-5.216323118506528	58	1.8
27181838	PD-L1 polymorphism can predict clinical outcomes of non-small cell lung cancer patients treated with first-line paclitaxel-cisplatin chemotherapy.	Scientific reports	2016	20.43643125405963	-25.446729732459477	33	1.16
27170616	Immune-Related Adverse Events From Immune Checkpoint Inhibitors.	Clinical pharmacology and therapeutics	2016	78.43540721875016	-8.644535666771157	71	2.6
27167139	Cytotoxic CD4+ T cells are correlated with better prognosis in Han Chinese grade II and grade III glioma subjects and are suppressed by PD-1 signaling.	The International journal of neuroscience	2017	-27.32673474838308	56.90426384693095	3	0.11
27166398	Density, Distribution, and Composition of Immune Infiltrates Correlate with Survival in Merkel Cell Carcinoma.	Clinical cancer research : an official journal of the American Association for Cancer Research	2016	43.31546879485179	52.57122087825326	85	3.52
27166394	Prognostic Value of Programmed Death Ligand 1 and Programmed Death 1 Expression in Thymic Carcinoma.	Clinical cancer research : an official journal of the American Association for Cancer Research	2016	-4.762740973590397	-36.45107543027342	58	2.24
27165272	Do programmed death 1 (PD-1) and its ligand (PD-L1) play a role in patients with non-clear cell renal cell carcinoma?	Medical oncology (Northwood, London, England)	2016	17.55159244657633	26.40847160475387	19	0.7
27163740	Severe Psoriasis Flare After Anti-Programmed Death Ligand 1 (PD-L1) Therapy for Metastatic Non-Small Cell Lung Cancer (NSCLC).	Journal of immunotherapy (Hagerstown, Md. : 1997)	2016	68.15877061825213	-18.248524612031016	26	1.07
27162530	Enhanced Anti-tumor Reactivity of Cytotoxic T Lymphocytes Expressing PD-1 Decoy.	Immune network	2016	-41.82741416854017	-5.104271321403577	6	0.19
27161248	Erratum to: PD-1, PD-L1, PD-L2 expression in the chordoma microenvironment.	Journal of neuro-oncology	2016	-18.327170189233914	26.895065556036368	0	0.0
27160390	Concomitant targeting of programmed death-1 (PD-1) and CD137 improves the efficacy of radiotherapy in a mouse model of human BRAFV600-mutant melanoma.	Cancer immunology, immunotherapy : CII	2016	25.242508784883285	22.37823472778525	27	0.9
27156867	Monocyte programmed death ligand-1 expression after 3-4 days of sepsis is associated with risk stratification and mortality in septic patients: a prospective cohort study.	Critical care (London, England)	2016	-57.33448547219768	33.86941101703264	94	3.76
27147580	Abundant PD-L1 expression in Epstein-Barr Virus-infected gastric cancers.	Oncotarget	2016	-9.791876492044995	8.635903885753148	195	7.29
27147575	Co-expression of PD-L1 and p-AKT is associated with poor prognosis in diffuse large B-cell lymphoma via PD-1/PD-L1 axis activating intracellular AKT/mTOR pathway in tumor cells.	Oncotarget	2016	-33.131121077078056	27.00133020710019	48	1.73
27147225	miR-424(322) reverses chemoresistance via T-cell immune response activation by blocking the PD-L1 immune checkpoint.	Nature communications	2016	-18.912071940295323	1.387277555822905	208	8.07
27146870	[Therapy monitoring and management of adverse events in PD-1/PD-L1 immune checkpoint inhibition].	Der Urologe. Ausg. A	2016	74.19471400315334	-18.006833899375057	9	0.27
27146558	Clinical Implementation of Novel Targeted Therapeutics in Advanced Breast Cancer.	Journal of cellular biochemistry	2016	16.303510206583233	3.4440535101669645	7	0.22
27145284	Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model.	Oncotarget	2016	-41.39383885755232	5.291866990312056	212	7.2
27142582	Safety of available treatment options for renal cell carcinoma.	Expert opinion on drug safety	2016	66.41382549659835	33.29343455275367	8	0.29
27141364	EML4-ALK enhances programmed cell death-ligand 1 expression in pulmonary adenocarcinoma via hypoxia-inducible factor (HIF)-1α and STAT3.	Oncoimmunology	2016	10.219946497840027	-34.10091587507984	111	3.29
27141355	Upregulation of PD-L1 by EML4-ALK fusion protein mediates the immune escape in ALK positive NSCLC: Implication for optional anti-PD-1/PD-L1 immune therapy for ALK-TKIs sensitive and resistant NSCLC patients.	Oncoimmunology	2016	10.65147165922469	-34.087689997800204	96	2.8
27141350	A novel regulation of PD-1 ligands on mesenchymal stromal cells through MMP-mediated proteolytic cleavage.	Oncoimmunology	2016	-52.55697386579933	-9.05849072062706	54	1.8
27140411	Beyond melanoma: inhibiting the PD-1/PD-L1 pathway in solid tumors.	Immunotherapy	2016	31.372693590582735	-0.7056463265327596	62	2.24
27138582	Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study.	Journal of clinical oncology : official journal of the American Society of Clinical Oncology	2016	48.96343988026485	2.946185964775044	1002	37.39
27138562	PD-1 Shapes B Cells as Evildoers in the Tumor Microenvironment.	Cancer discovery	2016	-27.673061894638007	40.8422258854488	28	0.86
27138387	Immune infiltrates in the breast cancer microenvironment: detection, characterization and clinical implication.	Breast cancer (Tokyo, Japan)	2017	-3.2173413481881683	19.65680760314124	135	5.36
27136138	Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies.	Current opinion in oncology	2016	72.86892110828765	-24.293353216204927	159	6.55
27122549	Biomarkers associated with checkpoint inhibitors.	Annals of oncology : official journal of the European Society for Medical Oncology	2016	77.41281333338931	-11.227794362122214	129	4.35
27121883	Therapeutic vaccination strategies to treat nasopharyngeal carcinoma.	Chinese clinical oncology	2016	41.77761215558845	27.8558504851538	26	1.11
27121882	Immunotherapy for nasopharyngeal cancer-a review.	Chinese clinical oncology	2016	41.89018242635831	27.61061935118696	46	1.74
27120796	Prognostic significance of programmed death-1 and programmed death-ligand 1 expression in patients with esophageal squamous cell carcinoma.	Oncotarget	2016	-13.547902085221075	8.453114713819712	85	3.12
27119960	[Renaissance of immuno-oncology for urological tumors : Current status].	Der Urologe. Ausg. A	2016	68.56804930948869	20.79801477061528	4	0.13
27117833	PD-L1 Expression in Lung Cancer.	Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer	2016	19.804129241181823	-36.59346680707187	252	9.44
27117582	Immune response in breast cancer brain metastases and their microenvironment: the role of the PD-1/PD-L axis.	Breast cancer research : BCR	2016	-14.58484897783821	38.23194955112559	72	2.58
27112171	Emerging therapeutics in refractory renal cell carcinoma.	Expert opinion on pharmacotherapy	2016	66.12168266144951	33.10230239400848	13	0.42
27107075	Programmed Cell Death Ligand 1 Expression in Canine Cancer.	In vivo (Athens, Greece)	2016	-15.89379150867131	-14.041598842867126	43	2.0
27106868	Pan-cancer analysis of copy number changes in programmed death-ligand 1 (PD-L1, CD274) - associations with gene expression, mutational load, and survival.	Genes, chromosomes & cancer	2016	9.312229564844811	30.61051081535208	68	2.28
27099755	Tumor control with PD-1 inhibition in a patient with concurrent metastatic melanoma and renal cell carcinoma.	Journal for immunotherapy of cancer	2016	61.92952938407678	32.18291124450656	5	0.16
27094104	From monoclonal antibodies to small molecules: the development of inhibitors targeting the PD-1/PD-L1 pathway.	Drug discovery today	2016	-41.09821712245342	-37.38917869841309	110	4.0
27093365	PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma.	The New England journal of medicine	2016	46.00942955264592	49.8972824743541	848	30.71
27093328	[Immunotherapy in non-small cell lung cancer: evolution of knowledge and clinical advances].	Recenti progressi in medicina	2016	39.73291139915149	-32.903367365670924	0	0.0
27090296	The clinical utility of PD-L1 testing in selecting non-small cell lung cancer patients for PD1/PD-L1-directed therapy.	Clinical pharmacology and therapeutics	2016	21.583747702482107	-37.74829845697672	20	0.66
27083005	Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1).	Oncotarget	2016	-42.9496735117939	-39.05098271571689	227	8.25
27081325	Tumor-Infiltrating Lymphocytes in Triple Negative Breast Cancer: The Future of Immune Targeting.	Clinical Medicine Insights. Oncology	2016	-5.39673450522145	20.21824432605216	116	4.23
27077771	Lower expression of PD-1 and PD-L1 in peripheral blood from patients with chronic ITP.	Hematology (Amsterdam, Netherlands)	2016	-51.61177165488345	4.313553019716625	15	0.63
27070448	Targeting PD-1 and Tim-3 Pathways to Reverse CD8 T-Cell Exhaustion and Enhance Ex Vivo T-Cell Responses to Autologous Dendritic/Tumor Vaccines.	Journal of immunotherapy (Hagerstown, Md. : 1997)	2016	-43.63878725994937	12.36509751002546	86	3.08
27070269	Programming the immune checkpoint to treat hematologic malignancies.	Expert opinion on investigational drugs	2016	35.51524998349189	-7.469315821390113	9	0.29
27069956	PD-1, PD-L1 and PD-L2 expression in mouse prostate cancer.	American journal of clinical and experimental urology	2016	-13.036338939654971	12.516191319443802	23	0.8
27069084	PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome.	Journal of clinical oncology : official journal of the American Society of Clinical Oncology	2016	-30.21962830480481	26.655527620424014	526	18.39
27063803	The significance and therapeutic potential of PD-1 and its ligands in ovarian cancer: A systematic review.	Gynecologic oncology	2016	37.72609926814741	39.30235038974511	14	0.51
27063329	Development of amino- and dimethylcarbamate-substituted resorcinol as programmed cell death-1 (PD-1) inhibitor.	European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences	2016	-40.1724569912976	-41.571742548864506	12	0.42
27062127	An Evaluation of the Impact of PD-1 Pathway Blockade on Reproductive Safety of Therapeutic PD-1 Inhibitors.	Birth defects research. Part B, Developmental and reproductive toxicology	2016	-52.74154729037484	-16.544038995656265	56	2.28
27058572	PD-1/PD-L1 immune checkpoint blockade in non-small cell lung cancer.	Clinical advances in hematology & oncology : H&O	2015	31.631904318796472	-30.58888365482168	20	0.6
27057446	Repeated PD-1/PD-L1 monoclonal antibody administration induces fatal xenogeneic hypersensitivity reactions in a murine model of breast cancer.	Oncoimmunology	2016	-38.27434814114659	-25.281146175338996	39	1.13
27056074	Prognostic effect of different PD-L1 expression patterns in squamous cell carcinoma and adenocarcinoma of the cervix.	Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc	2016	0.9771996585270656	-10.947814328238252	188	7.5
27055470	Immune checkpoint inhibition in ovarian cancer.	International immunology	2016	38.23683255518175	39.59974813660659	101	3.62
27050074	Clinical significance of PD-L1 and PD-L2 copy number gains in non-small-cell lung cancer.	Oncotarget	2016	11.69642442667728	-26.402311972949413	90	3.14
27047959	Combination therapy for metastatic renal cell carcinoma.	Annals of translational medicine	2016	64.45182232224157	32.902772833546486	16	0.49
27045886	Tumor-Infiltrating T Cells and the PD-1 Checkpoint Pathway in Advanced Differentiated and Anaplastic Thyroid Cancer.	The Journal of clinical endocrinology and metabolism	2016	-8.684735730224581	-21.36060371727414	101	3.77
27039171	Immunotherapy in gastrointestinal cancer: Recent results, current studies and future perspectives.	European journal of cancer (Oxford, England : 1990)	2016	41.63397803498496	19.47915310450859	57	1.97
27039170	High levels of the soluble programmed death-ligand (sPD-L1) identify hepatocellular carcinoma patients with a poor prognosis.	European journal of cancer (Oxford, England : 1990)	2016	-25.685151351139357	38.21288810661938	156	5.65
27019998	GD2-specific CAR T Cells Undergo Potent Activation and Deletion Following Antigen Encounter but can be Protected From Activation-induced Cell Death by PD-1 Blockade.	Molecular therapy : the journal of the American Society of Gene Therapy	2016	-44.8571657993229	5.209238428287122	230	7.87
27019997	Immune checkpoint inhibitors in lung cancer: past, present and future.	Future oncology (London, England)	2016	38.97594070278328	-31.58296359763384	22	0.77
27016050	PD-1 function in apoptosis of T lymphocytes in canine visceral leishmaniasis.	Immunobiology	2016	-66.95792237611114	11.635969406746304	28	1.23
27015293	Negative influence of programmed death-1-ligands on the survival of esophageal cancer patients treated with chemotherapy.	Cancer science	2016	-14.133827309193489	7.560712901411991	41	1.59
27012989	Program Death 1 Immune Checkpoint and Tumor Microenvironment: Implications for Patients With Intrahepatic Cholangiocarcinoma.	Annals of surgical oncology	2016	0.4308615826316047	5.517660567671368	110	4.05
27011048	Advances in cancer immunology and cancer immunotherapy.	Discovery medicine	2016	20.9683761401316	3.881600905487325	57	2.16
27009855	PD-L1 is an independent prognostic predictor in gastric cancer of Western patients.	Oncotarget	2016	-8.83454973475334	6.126737258077465	204	7.9
26986169	The Efficacy and Safety of Programmed Cell Death 1 and Programmed Cell Death 1 Ligand Inhibitors for Advanced Melanoma: A Meta-Analysis of Clinical Trials Following the PRISMA Guidelines.	Medicine	2016	53.867539685916526	-12.261183282388505	11	0.37
26984449	FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy.	The oncologist	2016	46.85067873418779	-23.82880986350128	304	11.47
26980598	Neoantigen Load, Antigen Presentation Machinery, and Immune Signatures Determine Prognosis in Clear Cell Renal Cell Carcinoma.	Cancer immunology research	2016	16.666046802476497	33.84159400562439	63	1.91
26980049	Immune biomarkers PD-1/PD-L1 and TLR3 in malignant pleural mesotheliomas.	Human pathology	2016	6.683475435608204	11.45543738613803	65	2.53
26980039	A morphological and immunophenotypic map of the immune response in Merkel cell carcinoma.	Human pathology	2016	43.40029888528913	52.3249546851529	30	1.27
26973128	The role of PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: a network meta-analysis.	Immunotherapy	2016	15.97819195917619	-31.54255010502254	111	3.8
26972336	PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer.	Gynecologic oncology	2016	-20.02839246571573	12.93257386570722	234	8.43
26969107	Correlation between PD-L1 expression and outcome of NSCLC patients treated with anti-PD-1/PD-L1 agents: A meta-analysis.	Critical reviews in oncology/hematology	2016	48.786362431587214	-19.141810098472316	95	3.35
26968206	Intratumoral CD3 and CD8 T-cell Densities Associated with Relapse-Free Survival in HCC.	Cancer immunology research	2016	-14.68242234001572	44.25728555928105	202	7.73
26965581	Medullary carcinoma of the colon: a distinct morphology reveals a distinctive immunoregulatory microenvironment.	Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc	2016	7.428945955336052	39.74160403812349	48	1.77
26962707	Recent advances in the management of pulmonary sarcomatoid carcinoma.	Expert review of respiratory medicine	2016	54.498240254830726	-32.858332930956344	21	0.85
26959743	Intravenous administration of the selective toll-like receptor 7 agonist DSR-29133 leads to anti-tumor efficacy in murine solid tumor models which can be potentiated by combination with fractionated radiotherapy.	Oncotarget	2016	27.13552671719535	23.295880389063505	22	0.79
26958083	The Impact of PD-L1 Expression in Patients with Metastatic GEP-NETs.	Journal of Cancer	2016	-0.1647963258685918	11.355159375687917	95	4.0
26957557	Cytotoxic Cutaneous Adverse Drug Reactions during Anti-PD-1 Therapy.	Clinical cancer research : an official journal of the American Association for Cancer Research	2016	71.63448940694914	-24.46611349496332	126	5.27
26954523	PD-1/PD-L1 expression in non-small-cell lung cancer and its correlation with EGFR/KRAS mutations.	Cancer biology & therapy	2016	8.925934296222236	-30.66999691238394	98	3.22
26947883	PD-L1 Expression and Survival among Patients with Advanced Non-Small Cell Lung Cancer Treated with Chemotherapy.	Translational oncology	2016	13.765401563181657	-29.223925786685385	67	2.37
26945563	Serum levels of soluble programmed death-1 and programmed death ligand-1 in systemic sclerosis: Association with extent of skin sclerosis.	The Journal of dermatology	2016	-47.68091567948549	21.16612725521486	29	1.15
26943572	Combining BRAF inhibitor and anti PD-L1 antibody dramatically improves tumor regression and anti tumor immunity in an immunocompetent murine model of anaplastic thyroid cancer.	Oncotarget	2016	-5.920750064850084	-20.581685481020404	66	2.52
26942589	New Approaches for Immune Directed Treatment for Ovarian Cancer.	Current treatment options in oncology	2016	38.83763810843144	38.399820911720674	10	0.32
26942414	Altered expression of major immune regulatory molecules in peripheral blood immune cells associated with breast cancer.	Breast cancer (Tokyo, Japan)	2017	-13.421517927920696	18.86865888127151	17	0.62
26942080	PD-L1 expression in metastatic neuroblastoma as an additional mechanism for limiting immune surveillance.	Oncoimmunology	2016	-26.984275702340568	14.5140565620499	76	2.49
26942067	Density of tumor-infiltrating lymphocytes correlates with extent of brain edema and overall survival time in patients with brain metastases.	Oncoimmunology	2016	-1.8626811040403228	18.75868173803796	200	6.13
26941095	Counter-regulation of rejection activity against human liver grafts by donor PD-L1 and recipient PD-1 interaction.	Journal of hepatology	2016	-65.8769065129206	25.642366333183546	53	2.0
26937756	Molecular Profiling of Clear Cell Ovarian Cancers: Identifying Potential Treatment Targets for Clinical Trials.	International journal of gynecological cancer : official journal of the International Gynecological Cancer Society	2016	9.165711238046732	46.67553888828298	62	2.39
26936508	PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations.	Science translational medicine	2016	-34.319971411828966	-17.878443756344137	1544	55.84
26933808	Multi-platform molecular profiling of a large cohort of glioblastomas reveals potential therapeutic strategies.	Oncotarget	2016	-22.289989836199297	58.5832207227349	19	0.63
26933175	PD-1 Blockade Boosts Radiofrequency Ablation-Elicited Adaptive Immune Responses against Tumor.	Clinical cancer research : an official journal of the American Association for Cancer Research	2016	-27.28257612461872	-16.834268798302165	164	6.02
26929641	Exceptional response to cetuximab monotherapy in a patient with metastatic oropharyngeal squamous cell carcinoma: a molecular insight.	OncoTargets and therapy	2016	54.55849351797907	30.31366352187379	5	0.22
26928461	Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1.	Cancer immunology research	2016	71.58113086460351	-26.51756766725471	196	8.63
26928313	PD-1hi Identifies a Novel Regulatory B-cell Population in Human Hepatoma That Promotes Disease Progression.	Cancer discovery	2016	-27.482151835191825	40.88028460389342	213	7.24
26927720	Non-Small Cell Lung Cancer, PD-L1, and the Pathologist.	Archives of pathology & laboratory medicine	2016	20.523354700751277	-38.48308895678501	79	2.76
26927206	Coinhibitory Pathways in Immunotherapy for Cancer.	Annual review of immunology	2016	-45.76722633410632	38.9643651395279	590	19.72
32258540	The PD-1:PD-L1 immune inhibitory checkpoint in Helicobacter pylori infection and gastric cancer: a comprehensive review and future perspectives.	Porto biomedical journal	2016	43.495822345927074	17.082762062080306	17	0.69
26923003	Combinatorial Cancer Immunotherapies.	Advances in immunology	2016	26.781554997163845	1.605456505966929	79	2.61
26922327	Emerging Tissue and Blood-Based Biomarkers that may Predict Response to Immune Checkpoint Inhibition.	Current oncology reports	2016	20.05135803944329	-2.5572788180606505	34	1.1
26920041	[Issues and current limits for immunohistochemical assessment of PD-L1 status in bronchial biopsies].	Bulletin du cancer	2016	19.039937845818248	-38.523194524407	4	0.14
26918453	CD274/PD-L1 gene amplification and PD-L1 protein expression are common events in squamous cell carcinoma of the oral cavity.	Oncotarget	2016	-6.444928760114079	-9.728420582639565	124	4.36
26918451	PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis.	Oncotarget	2016	15.628162933879016	-31.442598416395764	116	3.9
26918260	Preclinical pharmacokinetics, pharmacodynamics, tissue distribution, and tumor penetration of anti-PD-L1 monoclonal antibody, an immune checkpoint inhibitor.	mAbs	2016	0.4760319188797449	-55.54672240607823	131	4.26
26916881	Predictive Efficacy Biomarkers of Programmed Cell Death 1/Programmed Cell Death 1 Ligand Blockade Therapy.	Recent patents on anti-cancer drug discovery	2016	19.714220565378216	-5.071786791487424	7	0.24
26916808	Implications of Programmed Cell Death 1 Ligand 1 Heterogeneity in the Selection of Patients With Non-Small Cell Lung Cancer to Receive Immunotherapy.	Clinical pharmacology and therapeutics	2016	19.238056951240257	-34.93311619911474	19	0.63
26915032	Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients.	Virchows Archiv : an international journal of pathology	2016	19.123231762042	-38.43705974451473	183	6.9
26913631	Genetic Basis for PD-L1 Expression in Squamous Cell Carcinomas of the Cervix and Vulva.	JAMA oncology	2016	0.9815173200729594	-9.307368944322691	97	3.55
26913605	Attenuation of the programmed cell death-1 pathway increases the M1 polarization of macrophages induced by zymosan.	Cell death & disease	2016	-51.50210950885277	0.1635071919565997	66	2.25
26910920	IL-15 superagonist/IL-15RαSushi-Fc fusion complex (IL-15SA/IL-15RαSu-Fc; ALT-803) markedly enhances specific subpopulations of NK and memory CD8+ T cells, and mediates potent anti-tumor activity against murine breast and colon carcinomas.	Oncotarget	2016	-19.0236802762785	-53.4974689337904	117	3.99
26910562	Poxvirus-Based Active Immunotherapy with PD-1 and LAG-3 Dual Immune Checkpoint Inhibition Overcomes Compensatory Immune Regulation, Yielding Complete Tumor Regression in Mice.	PloS one	2016	-35.65269807420146	50.37311333005671	30	1.01
26908078	The Evolving Role of Nivolumab in Non-Small-Cell Lung Cancer for Second-Line Treatment: A New Cornerstone for Our Treatment Algorithms. Results From an International Experts Panel Meeting of the Italian Association of Thoracic Oncology.	Clinical lung cancer	2016	46.12793285803674	-23.995907389145405	13	0.42
28721372	Prevalence and predictors of androgen receptor and programmed death-ligand 1 in BRCA1-associated and sporadic triple-negative breast cancer.	NPJ breast cancer	2016	-11.16597415535119	16.762817802863854	29	1.0
26899259	PD-1/PD-L1 blockade in cancer treatment: perspectives and issues.	International journal of clinical oncology	2016	-40.822098733230845	-14.466918307483883	214	7.95
26898608	PD-L1 on peripheral blood T lymphocytes is prognostic in patients with non-small cell lung cancer (NSCLC) treated with EGFR inhibitors.	Lung cancer (Amsterdam, Netherlands)	2016	7.09294547183021	-34.082912420646934	26	0.86
26898309	Emerging Immunotargets and Immunotherapies in Prostate Cancer.	Current drug targets	2016	22.77684972148029	16.01784470424277	8	0.25
26895815	PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis.	Critical reviews in oncology/hematology	2016	49.23451001357146	-14.549901347965465	264	9.71
26889250	Role of soluble programmed death-1 (sPD-1) and sPD-ligand 1 in patients with cystic echinococcosis.	Experimental and therapeutic medicine	2016	-49.31355717413734	19.563083834453543	39	1.55
26889087	PD-1/PD-L1 blockades in non-small-cell lung cancer therapy.	OncoTargets and therapy	2016	31.98445594836432	-30.47480276850776	43	1.52
26883990	Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints.	Nature communications	2016	-32.903189524872246	-20.23920608476788	986	35.8
26881392	Targeting the programmed cell death-1 pathway in breast and ovarian cancer.	Current opinion in obstetrics & gynecology	2016	-33.21666595876132	-15.46275289629762	38	1.24
26875080	Advances of Molecular Targeted Therapy in Gastric Cancer.	Journal of gastrointestinal cancer	2016	45.91547360777402	17.474135709344548	13	0.49
26871470	Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer.	Oncotarget	2016	7.170054953745835	31.306760544853763	423	14.62
26871284	Implication of combined PD-L1/PD-1 blockade with cytokine-induced killer cells as a synergistic immunotherapy for gastrointestinal cancer.	Oncotarget	2016	-12.869160311439282	-24.26725890733261	42	1.51
26869644	Where Do Programmed Death-1 Inhibitors Fit in the Management of Malignant Lymphoma?	Journal of oncology practice	2016	-9.574853488219157	-25.407210567727905	12	0.39
26867643	PD-L1-expressing neutrophils as a novel indicator to assess disease activity and severity of systemic lupus erythematosus.	Arthritis research & therapy	2016	-53.72037547665294	11.801173240141434	46	1.78
26864211	CD44+ Cells in Head and Neck Squamous Cell Carcinoma Suppress T-Cell-Mediated Immunity by Selective Constitutive and Inducible Expression of PD-L1.	Clinical cancer research : an official journal of the American Association for Cancer Research	2016	-10.938758690939885	31.346478739794435	158	5.67
26860624	Immune checkpoint therapy for non-small-cell lung cancer: an update.	Immunotherapy	2016	37.67047709268773	-33.03113185981154	47	1.6
26859684	Activation of the PD-1/PD-L1 immune checkpoint confers tumor cell chemoresistance associated with increased metastasis.	Oncotarget	2016	-34.63285436567007	-19.39440985910346	133	4.86
26851185	Epithelial-Mesenchymal Transition Is Associated with a Distinct Tumor Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung Adenocarcinoma.	Clinical cancer research : an official journal of the American Association for Cancer Research	2016	-0.1658643124040668	39.41376841442923	305	10.74
26844985	Experimental treatment strategies in primary cutaneous T-cell lymphomas.	Current opinion in oncology	2016	42.98107468731561	-53.81923493475316	2	0.1
26845193	Successful Immunotherapy against a Transplantable Mouse Squamous Lung Carcinoma with Anti-PD-1 and Anti-CD137 Monoclonal Antibodies.	Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer	2016	13.68613973443012	-21.814741934464674	42	1.23
26844572	Emerging Immunotargets in Bladder Cancer.	Current drug targets	2016	70.46356736597744	21.33150948631998	9	0.29
26841012	Checkpoint Inhibition: Programmed Cell Death 1 and Programmed Cell Death 1 Ligand Inhibitors in Hodgkin Lymphoma.	Cancer journal (Sudbury, Mass.)	2016	-8.40793215271066	-25.504340233050428	15	0.49
26838521	[Lung cancer and rheumatoid arthritis. An interdisciplinary challenge].	Zeitschrift fur Rheumatologie	2016	33.803642170473815	-28.595747912309943	1	0.04
26836475	Impaired CD98 signaling protects against graft-versus-host disease by increasing regulatory T cells.	Transplant immunology	2016	-66.51834765912592	-5.394696264371772	4	0.14
26833127	STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment.	Cancer research	2016	18.490579304997382	-22.259988756556726	375	11.92
26831889	[Progression of immunotherapy in gastric cancer].	Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery	2016	42.96912820422945	18.530463772146977	0	0.0
26824999	Programmed cell death ligand 1 alleviates psoriatic inflammation by suppressing IL-17A production from programmed cell death 1-high T cells.	The Journal of allergy and clinical immunology	2016	-60.134521460565374	-17.99505103850857	55	1.95
26824266	TGFβ-dependent expression of PD-1 and PD-L1 controls CD8(+) T cell anergy in transplant tolerance.	eLife	2016	-59.9872081028077	-2.057344627120066	87	2.94
26822383	Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy.	Nature communications	2016	6.449077904260121	-4.191828742776536	330	10.54
26818188	CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients.	Scientific reports	2016	-44.35883561038875	0.9279021750031216	220	7.11
26811622	Viro-immune therapy: A new strategy for treatment of pancreatic cancer.	World journal of gastroenterology	2016	-20.1932767233748	-12.453985025705109	14	0.46
26811456	Obeticholic acid, a synthetic bile acid agonist of the farnesoid X receptor, attenuates experimental autoimmune encephalomyelitis.	Proceedings of the National Academy of Sciences of the United States of America	2016	-65.034516678688	22.09039860328894	49	2.03
26808918	CD73-adenosine: a next-generation target in immuno-oncology.	Immunotherapy	2016	-4.876864317612405	-50.01056672410235	96	3.72
26800463	Pembrolizumab for the treatment of non-small cell lung cancer.	Expert opinion on biological therapy	2016	47.36088734185068	-31.142248539330176	49	1.73
26798585	Results of clinical trials with anti-programmed death 1/programmed death ligand 1 inhibitors in lung cancer.	Translational lung cancer research	2015	31.22144477320785	-32.78645433010493	7	0.18
26798583	Predictive factors of activity of anti-programmed death-1/programmed death ligand-1 drugs: immunohistochemistry analysis.	Translational lung cancer research	2015	19.089780695038503	-42.463199872131774	28	0.88
26794260	The promising role of nivolumab in renal cell cancers.	Cancer biology & therapy	2016	63.15570863077685	28.211260498363924	6	0.15
26786705	T cells from patients with Candida sepsis display a suppressive immunophenotype.	Critical care (London, England)	2016	-61.5923640371694	37.74261086210797	79	3.09
26780537	Programmed Death Ligand-1 Immunohistochemistry--A New Challenge for Pathologists: A Perspective From Members of the Pulmonary Pathology Society.	Archives of pathology & laboratory medicine	2016	19.55372155880824	-40.06896858207985	95	3.55
26779629	Potential biomarker for checkpoint blockade immunotherapy and treatment strategy.	Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine	2016	-37.785955198103885	-20.87168401354263	63	2.04
26778219	[PD-L1 expression: An emerging biomarker in non-small cell lung cancer].	Annales de pathologie	2016	19.40314226694607	-36.41558134349119	6	0.21
26775720	Programmed Death-Ligand 1 Expression in Muscle-Invasive Bladder Cancer Cystectomy Specimens and Lymph Node Metastasis: A Reliable Treatment Selection Biomarker?	Clinical genitourinary cancer	2016	11.194436842183878	58.92245878079174	37	1.15
26775640	Essential role of HDAC6 in the regulation of PD-L1 in melanoma.	Molecular oncology	2016	-9.956418850555243	-32.63511875264202	106	3.65
26773772	A fully human monoclonal antibody targeting PD-L1 with potent anti-tumor activity.	International immunopharmacology	2016	-40.906400961371766	-29.996551395353418	13	0.49
26771840	Expression of programmed cell death-ligand 1 and its correlation with clinical outcomes in gliomas.	Oncotarget	2016	-24.404608950147978	50.86205083976089	51	1.87
26769487	Programmed Death Ligand-1 on Microglia Regulates Th1 Differentiation via Nitric Oxide in Experimental Autoimmune Encephalomyelitis.	Neuroscience bulletin	2016	-74.1903769455179	-5.913406465448346	17	0.71
26765102	Immune-related adverse events with immune checkpoint blockade: a comprehensive review.	European journal of cancer (Oxford, England : 1990)	2016	79.06160577497185	-8.14144895571706	1375	54.18
26762844	Immunohistochemical analysis of lichenoid reactions in patients treated with anti-PD-L1 and anti-PD-1 therapy.	Journal of cutaneous pathology	2016	70.77913686008327	-24.707404283708836	84	3.69
26762740	PD-L1 Is Upregulated by Simultaneous Amplification of the PD-L1 and JAK2 Genes in Non-Small Cell Lung Cancer.	Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer	2016	11.89152738328603	-25.850689352316373	128	4.37
26756647	Programmed Death Ligand-1 Immunohistochemistry: Friend or Foe?	Archives of pathology & laboratory medicine	2016	19.59316125919712	-40.17911613102283	102	3.57
26752545	Expression of Programmed Cell Death 1 Ligands (PD-L1 and PD-L2) in Histiocytic and Dendritic Cell Disorders.	The American journal of surgical pathology	2016	-29.842600824916435	17.83851028936025	39	1.66
26741490	TIGIT Marks Exhausted T Cells, Correlates with Disease Progression, and Serves as a Target for Immune Restoration in HIV and SIV Infection.	PLoS pathogens	2016	-80.002189237635	14.621339289812326	204	7.18
26729235	Integration of genomic, transcriptomic and proteomic data identifies two biologically distinct subtypes of invasive lobular breast cancer.	Scientific reports	2016	-2.282989412027759	41.060869596980936	108	3.6
26724936	PD-L1-specific T cells.	Cancer immunology, immunotherapy : CII	2016	-39.63554245844346	-4.445277619627742	17	0.58
28798885	Tumor cell-intrinsic PD-L1 promotes tumor-initiating cell generation and functions in melanoma and ovarian cancer.	Signal transduction and targeted therapy	2016	-34.52485683120419	-12.66277524496291	71	2.32
26719429	Molecular Pathways: Mechanism of Action for Talimogene Laherparepvec, a New Oncolytic Virus Immunotherapy.	Clinical cancer research : an official journal of the American Association for Cancer Research	2016	28.71662673842164	36.83094588359172	196	6.92
26718132	Relationship between expression of PD-L1 and PD-L2 on esophageal squamous cell carcinoma and the antitumor effects of CD8⁺ T cells.	Oncology reports	2016	-13.903998317102356	8.017388604262882	51	1.83
26717105	Effect of PD-1: PD-L1 in Invariant Natural Killer T-Cell Emigration and Chemotaxis Following Sepsis.	Shock (Augusta, Ga.)	2016	-76.54473804725932	5.461521080523573	12	0.46
26713633	Immunotherapy of melanoma: efficacy and mode of action.	Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG	2016	29.856866341091365	3.310440368293297	12	0.39
26708040	The rapidly evolving therapies for advanced melanoma--Towards immunotherapy, molecular targeted therapy, and beyond.	Critical reviews in oncology/hematology	2016	32.22277508165905	29.85114922742694	71	2.64
26707383	Change in PD-L1 Expression After Acquiring Resistance to Gefitinib in EGFR-Mutant Non-Small-Cell Lung Cancer.	Clinical lung cancer	2016	7.621662542739697	-32.85625374099836	99	3.43
26699946	Immune checkpoint blockade: Releasing the brake towards hematological malignancies.	Blood reviews	2016	25.082112642117824	6.444503477559122	30	0.98
26688950	[Levels of programmed death-1 and programmed death ligand-1 in the peripheral blood of patients with oral squamous cell carcinoma and its clinical implications].	Hua xi kou qiang yi xue za zhi = Huaxi kouqiang yixue zazhi = West China journal of stomatology	2015	-8.082572375341789	-12.385212352742958	16	0.53
26681673	Regulation of PD-L1: a novel role of pro-survival signalling in cancer.	Annals of oncology : official journal of the European Society for Medical Oncology	2016	-39.78266755555141	-10.888889597430367	508	18.96
26681547	Endocrinopathies induced by immune-checkpoint inhibitors in advanced non-small cell lung cancer.	Expert review of clinical pharmacology	2016	75.60010973434487	-17.872224641278976	21	0.81
26678894	Programmed death 1 expression in the peritumoral microenvironment is associated with a poorer prognosis in classical Hodgkin lymphoma.	Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine	2016	-29.99506213125758	22.82335313883722	36	1.37
26676749	Identification of the Cell-Intrinsic and -Extrinsic Pathways Downstream of EGFR and IFNγ That Induce PD-L1 Expression in Head and Neck Cancer.	Cancer research	2016	-12.248207863361268	-11.019366062494544	216	7.95
26674132	Mismatch repair deficiency associated with complete remission to combination programmed cell death ligand immune therapy in a patient with sporadic urothelial carcinoma: immunotheranostic considerations.	Journal for immunotherapy of cancer	2015	12.144272687701	45.672711811248746	23	0.61
26673991	[Immunotherapy for the Prevention and Treatment of Breast Cancer].	Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti	2015	22.92071561135179	-0.104178155678634	0	0.0
26673119	Near complete response after single dose of nivolumab in patient with advanced heavily pre-treated KRAS mutant pulmonary adenocarcinoma.	Experimental hematology & oncology	2015	17.355718065652066	-28.06591164055211	20	0.58
26655428	BIP induces mice CD19(hi) regulatory B cells producing IL-10 and highly expressing PD-L1, FasL.	Molecular immunology	2016	-66.14917655394864	6.779549203128741	26	0.97
26648075	Emerging Immunotargets in Metastatic Renal Cell Carcinoma.	Current drug targets	2016	63.13161487940074	31.917087057815877	19	0.66
26645943	Rationale for anti-OX40 cancer immunotherapy.	European journal of cancer (Oxford, England : 1990)	2016	21.704386761806003	7.265953149588733	225	7.89
26637667	Control of PD-L1 Expression by Oncogenic Activation of the AKT-mTOR Pathway in Non-Small Cell Lung Cancer.	Cancer research	2016	3.424877454010217	-31.40161483452915	505	17.54
26637664	Correction: PD-1 Upregulated on Regulatory T Cells during Chronic Virus Infection Enhances the Suppression of CD8+ T Cell Immune Response via the Interaction with PD-L1 Expressed on CD8+ T Cells.	Journal of immunology (Baltimore, Md. : 1950)	2015	-77.7923074331431	13.78649096603379	15	0.46
26633181	PD-L1 Blockade Differentially Impacts Regulatory T Cells from HIV-Infected Individuals Depending on Plasma Viremia.	PLoS pathogens	2015	-82.60506046324724	14.751055731797589	30	0.84
26631501	Pembrolizumab for the treatment of thoracic malignancies: current landscape and future directions.	Future oncology (London, England)	2016	47.58543169091495	-34.2788167327581	5	0.19
26629423	Novel radiotherapy approaches for lung cancer: combining radiation therapy with targeted and immunotherapies.	Translational lung cancer research	2015	36.59303832962393	-28.033784368201022	63	2.06
26629188	Polymorphisms of co-inhibitory molecules (CTLA-4/PD-1/PD-L1) and the risk of non-small cell lung cancer in a Chinese population.	International journal of clinical and experimental medicine	2015	19.74948840153685	-26.16499692295265	35	1.17
26625204	Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma.	Oncotarget	2016	-19.618150883304008	13.358905971446404	184	7.12
26622321	Targeting PD-1/PD-L1 in the treatment of metastatic renal cell carcinoma.	Therapeutic advances in urology	2015	62.646382419277366	31.88716922841566	89	2.66
26619946	"Future perspectives in melanoma research: meeting report from the ""Melanoma Bridge"": Napoli, December 3rd-6th 2014."	Journal of translational medicine	2015	30.724565786080987	29.574038146389437	10	0.3
26617827	Programmed cell death ligand 1 (PD-L1) expression on gastric cancer and its relationship with clinicopathologic factors.	International journal of clinical and experimental pathology	2015	-9.694987063395132	4.487143002702927	77	2.64
26615520	Human umbilical vein endothelial cells promote the inhibitory activation of CD4(+)CD25(+)Foxp3(+) regulatory T cells via PD-L1.	Atherosclerosis	2016	-59.741063269516005	9.263912263898163	21	0.71
26608464	Soluble PD-1 aggravates progression of collagen-induced arthritis through Th1 and Th17 pathways.	Arthritis research & therapy	2015	-51.68424945093832	15.319375451971068	73	2.52
26605313	Immune checkpoint inhibitors: therapeutic advances in melanoma.	Annals of translational medicine	2015	30.835620308674216	3.912382008515226	59	1.89
26604307	Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging.	Proceedings of the National Academy of Sciences of the United States of America	2015	-42.70976460321268	-33.469902864698646	241	7.94
26602187	Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1.	Structure (London, England : 1993)	2015	-45.39357859062209	-37.77900813304256	306	10.15
26598537	Prognostic value of programmed-death-1 receptor (PD-1) and its ligand 1 (PD-L1) in testicular germ cell tumors.	Annals of oncology : official journal of the European Society for Medical Oncology	2016	-25.69770564822119	34.60197048044428	107	4.29
26590829	Immune-modulating properties of ionizing radiation: rationale for the treatment of cancer by combination radiotherapy and immune checkpoint inhibitors.	Cancer immunology, immunotherapy : CII	2016	27.22609435108458	20.92031747260704	110	4.24
26588948	Pembrolizumab for the treatment of PD-L1 positive advanced or metastatic non-small cell lung cancer.	Expert review of anticancer therapy	2016	47.44154397981373	-32.30665070613126	64	2.11
26581194	Peritumoural neutrophils negatively regulate adaptive immunity via the PD-L1/PD-1 signalling pathway in hepatocellular carcinoma.	Journal of experimental & clinical cancer research : CR	2015	-17.75146553948514	40.8247730919409	154	4.85
26578623	CD4+ T effector memory cell dysfunction is associated with the accumulation of granulocytic myeloid-derived suppressor cells in glioblastoma patients.	Neuro-oncology	2016	-27.220355804586145	56.75083213502416	112	4.06
26577822	Nivolumab for the treatment of classical Hodgkin lymphoma after failure of autologous stem cell transplant and brentuximab.	Expert review of anticancer therapy	2016	41.10515329268042	-6.960130095812903	13	0.47
26576187	Metastatic squamous cell non-small-cell lung cancer (NSCLC): disrupting the drug treatment paradigm with immunotherapies.	Drugs in context	2015	40.64677056688534	-34.27863365039473	28	0.83
26574148	Nivolumab for treating non-small cell lung cancer.	Expert opinion on biological therapy	2015	46.268222427758566	-26.45259246172795	23	0.65
26573233	PD-1 blockade attenuates immunosuppressive myeloid cells due to inhibition of CD47/SIRPα axis in HPV negative head and neck squamous cell carcinoma.	Oncotarget	2015	-9.023661099756485	-7.840827396473263	86	2.73
26567614	Emerging targets in cancer immunotherapy: beyond CTLA-4 and PD-1.	Immunotherapy	2015	2.7122154395168825	-2.5831175932162287	36	1.12
26567141	PD-1 Blunts the Function of Ovarian Tumor-Infiltrating Dendritic Cells by Inactivating NF-κB.	Cancer research	2016	-32.44175718413499	-13.781443127982202	72	2.27
26566945	Magnitude of PD-1, PD-L1 and T Lymphocyte Expression on Tissue from Castration-Resistant Prostate Adenocarcinoma: An Exploratory Analysis.	Targeted oncology	2016	-13.776696755966832	13.173300077972872	49	1.65
26564811	HLA class I downregulation is associated with enhanced NK-cell killing of melanoma cells with acquired drug resistance to BRAF inhibitors.	European journal of immunology	2016	29.11545688483038	30.9723921853489	25	0.86
26562159	Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer.	JAMA oncology	2016	14.03421065077425	-34.93230999868542	618	22.4
26560962	Checkpoint inhibitors in Hodgkin's lymphoma.	European journal of haematology	2016	37.35989566226956	-6.798708843074788	11	0.37
26560846	[Implications of TCGA Network Data on 2nd Generation Immunotherapy Concepts Based on PD-L1 and PD-1 Target Structures].	Aktuelle Urologie	2015	16.363038971585773	29.318729466948977	7	0.18
26546453	Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model.	Cancer immunology research	2016	-29.264266541509095	58.51837359547656	269	9.62
26546452	PD-L1 Antibodies to Its Cytoplasmic Domain Most Clearly Delineate Cell Membranes in Immunohistochemical Staining of Tumor Cells.	Cancer immunology research	2015	12.8044602925985	-42.31231905867256	106	3.06
26541760	The increase of circulating PD-L1-expressing CD68(+) macrophage in ovarian cancer.	Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine	2016	-21.718738783844877	12.05024406200353	42	1.55
26517811	Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1/PD-L1 immune checkpoints in human brain metastases.	Oncotarget	2015	-1.6111565486836117	18.628395489639548	90	2.84
26517304	Dysregulation of Antiviral Function of CD8(+) T Cells in the Chronic Obstructive Pulmonary Disease Lung. Role of the PD-1-PD-L1 Axis.	American journal of respiratory and critical care medicine	2016	-76.07449236035377	8.459082310738465	86	3.41
26516064	Is PD-L1 Expression a Biomarker of Response?	Cancer discovery	2015	19.191458918877487	-44.42870106552883	7	0.18
26515600	Serum levels of soluble programmed death ligand 1 predict treatment response and progression free survival in multiple myeloma.	Oncotarget	2015	-45.40000011459313	21.75950184971144	144	4.56
26511814	Association Between PD-L1 and HPV Status and the Prognostic Value of PD-L1 in Oropharyngeal Squamous Cell Carcinoma.	Cancer research and treatment	2016	-4.927313443437074	-10.204249748483267	97	3.78
26505305	Treatment of murine lupus with PD-LIg.	Clinical immunology (Orlando, Fla.)	2016	-54.91332165472418	8.297207619664713	15	0.6
26503995	Immunotherapies for NSCLC: Are We Cutting the Gordian Helix?	Anticancer research	2015	36.5581091941103	-32.93700417991399	16	0.5
26501438	Clinical Neuropathology mini-review 6-2015: PD-L1: emerging biomarker in glioblastoma?	Clinical neuropathology	2015	-24.88957760103454	50.76618223271546	25	0.83
26488004	Predictive factors for immunotherapy in melanoma.	Annals of translational medicine	2015	28.89785211590682	4.281361699962368	27	0.79
26487966	Advances in immunotherapy for treatment of lung cancer.	Cancer biology & medicine	2015	40.77273150562514	-32.813034972805745	46	1.37
26484769	PD-L1 Expression on Retrovirus-Infected Cells Mediates Immune Escape from CD8+ T Cell Killing.	PLoS pathogens	2015	-76.9856866024191	12.41187038436566	49	1.46
26483866	Programmed death-1/programmed death-L1 signaling pathway and its blockade in hepatitis C virus immunotherapy.	World journal of hepatology	2015	-77.0339160875101	23.23033345336817	26	0.85
26483406	Bovine Immunoinhibitory Receptors Contribute to Suppression of Mycobacterium avium subsp. paratuberculosis-Specific T-Cell Responses.	Infection and immunity	2016	-80.1505515804198	3.854131254854773	29	1.18
26482147	Checkpoint blockade in combination with cancer vaccines.	Vaccine	2015	26.35698651530407	2.721952439860093	31	0.92
26477470	Current Perspectives in Immunotherapy for Non-Small Cell Lung Cancer.	Seminars in oncology	2015	40.97326914890615	-32.15094738315949	47	1.43
26473645	Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer.	Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer	2015	11.48122496405704	-30.75893092325338	176	5.54
26466763	Intellectual property issues of immune checkpoint inhibitors.	mAbs	2016	28.325371115494804	9.346212768204827	10	0.25
26464193	Clinicopathologic Analysis of PD-L1 and PD-L2 Expression in Renal Cell Carcinoma: Association with Oncogenic Proteins Status.	Annals of surgical oncology	2016	17.437924761127956	27.29601178095304	125	4.7
26458459	[Cancer immunotherapy by immuno-checkpoint blockade].	[Rinsho ketsueki] The Japanese journal of clinical hematology	2015	24.527060513785187	1.5502456024754292	0	0.0
26452385	Prognostic and Predictive Biomarkers in Colorectal Cancer. From the Preclinical Setting to Clinical Practice.	Current cancer drug targets	2015	6.633190349324672	42.49664300879213	21	0.72
26451323	Anergic bone marrow Vγ9Vδ2 T cells as early and long-lasting markers of PD-1-targetable microenvironment-induced immune suppression in human myeloma.	Oncoimmunology	2015	-35.10021543915061	9.725644205678709	50	1.59
26448693	Human Cancer Immunotherapy with PD-1/PD-L1 Blockade.	Biomarkers in cancer	2015	-39.273620487157885	-17.293983205087702	44	1.45
26446939	The PD-L1/CD86 ratio is increased in dendritic cells co-infected with porcine circovirus type 2 and porcine reproductive and respiratory syndrome virus, and the PD-L1/PD-1 axis is associated with anergy, apoptosis, and the induction of regulatory T-cells in porcine lymphocytes.	Veterinary microbiology	2015	-69.86340854003122	-1.663371529457843	16	0.78
26432723	Signaling pathway and dysregulation of PD1 and its ligands in lymphoid malignancies.	Biochimica et biophysica acta	2016	-45.818789423641896	-10.888390845564212	53	1.87
26429561	Prognostic Role of PD-L1 Expression in Renal Cell Carcinoma. A Systematic Review and Meta-Analysis.	Targeted oncology	2016	17.10455873583521	26.6018459009983	133	4.84
26426431	Clinicopathological analysis of programmed cell death 1 and programmed cell death ligand 1 expression in the tumour microenvironments of diffuse large B cell lymphomas.	Histopathology	2016	-34.073659608499455	26.609946775824223	114	4.15
26424759	The Association Between PD-L1 Expression and the Clinical Outcomes to Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Clear Cell Renal Cell Carcinoma.	The oncologist	2015	16.185895793505033	27.96029318700112	36	1.05
26424414	High-Affinity PD-1 Protein Has Potential.	Cancer discovery	2015	-42.23841256466825	-33.65708692358783	0	0.0
26420858	A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition.	Clinical cancer research : an official journal of the American Association for Cancer Research	2016	-0.309141079089623	39.79542013902169	316	11.01
26419843	Tumor associated PD-L1 expression pattern in microscopically tumor positive sentinel lymph nodes in patients with melanoma.	Journal of translational medicine	2015	6.976939318571129	0.2031970941904492	21	0.58
26412670	Anti PD-1 and PDL-1 Immunotherapy in the Treatment of Advanced Non- Small Cell Lung Cancer (NSCLC): A Review on Toxicity Profile and its Management.	Current drug safety	2016	40.11424510532154	-32.76739375131369	61	2.24
26412280	PD-1 and PD-L1 blockade in gastrointestinal malignancies.	Cancer treatment reviews	2015	41.94778034004842	20.78574433079387	48	1.52
26408258	Doxil synergizes with cancer immunotherapies to enhance antitumor responses in syngeneic mouse models.	Neoplasia (New York, N.Y.)	2015	-26.74874398918623	-46.32470111963315	109	3.69
26405604	The checkpoint inhibitor TIGIT limits antitumor and antiviral CD8+ T cell responses.	Oncoimmunology	2015	-13.0966120043292	-56.97669720400527	32	0.84
26405585	Several immune escape patterns in non-Hodgkin's lymphomas.	Oncoimmunology	2015	-29.57899360149456	30.453057179188203	65	1.98
26403784	Tumor PD-L1 expression, immune cell correlates and PD-1+ lymphocytes in sentinel lymph node melanoma metastases.	Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc	2015	7.307191552619435	-0.3632017065040392	65	2.19
26396175	CD8+ T cells undergo activation and programmed death-1 repression in the liver of aged Ae2a,b-/- mice favoring autoimmune cholangitis.	Oncotarget	2015	-66.57647718368591	23.200615317914973	22	0.77
26378990	Programmed Death Ligand 1 Promotes Early-Life Chlamydia Respiratory Infection-Induced Severe Allergic Airway Disease.	American journal of respiratory cell and molecular biology	2016	-80.92962685045967	6.170956782214869	16	0.65
26376844	Immunotherapies in Early and Advanced Renal Cell Cancer.	Progress in tumor research	2015	63.556308300224615	31.466827993950886	9	0.27
26375401	Epstein-Barr Virus MicroRNA Expression Increases Aggressiveness of Solid Malignancies.	PloS one	2015	-8.10137004995405	44.37390228795166	26	0.88
26373575	PD-L1 and HLA Class I Antigen Expression and Clinical Course of the Disease in Intrahepatic Cholangiocarcinoma.	Clinical cancer research : an official journal of the American Association for Cancer Research	2016	1.1291058944738466	4.71996433053622	139	4.76
26373277	FcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis.	Cancer cell	2015	-35.30331145586511	-27.29056967818334	236	7.08
26359984	Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth.	Cell	2015	-35.03299055748698	-12.284780142039391	425	12.92
26359860	PD-1, PD-L1 and PD-L2 Gene Expression on T-Cells and Natural Killer Cells Declines in Conjunction with a Reduction in PD-1 Protein during the Intensive Phase of Tuberculosis Treatment.	PloS one	2015	-85.73523848114876	2.5337023398348024	46	1.52
26349666	PD-L1 gene polymorphism and high level of plasma soluble PD-L1 protein may be associated with non-small cell lung cancer.	The International journal of biological markers	2015	20.13415366819652	-26.95962253513363	49	1.61
26346135	Efficacy of targeted therapies after PD-1/PD-L1 blockade in metastatic renal cell carcinoma.	European journal of cancer (Oxford, England : 1990)	2015	67.12988764612324	33.80953141606706	70	2.01
26338208	Management of Dermatologic Complications of Lung Cancer Therapies.	Current treatment options in oncology	2015	72.1996388623734	-24.28640186059033	11	0.47
26337747	An HPV-E6/E7 immunotherapy plus PD-1 checkpoint inhibition results in tumor regression and reduction in PD-L1 expression.	Cancer gene therapy	2015	-12.446160811544026	-16.253394866764033	51	1.57
26331485	Stimulating immune responses to fight cancer: Basic biology and mechanisms.	Asia-Pacific journal of clinical oncology	2015	24.24921677877247	8.918671855169565	8	0.31
26330898	Differential induction of PD-1/PD-L1 in Neuroimmune cells by drug of abuse.	International journal of physiology, pathophysiology and pharmacology	2015	-73.8422135073684	-9.208134015801049	7	0.25
26329973	Programmed death-1 ligand 1 and 2 are highly expressed in pleomorphic carcinomas of the lung: Comparison of sarcomatous and carcinomatous areas.	European journal of cancer (Oxford, England : 1990)	2015	5.743532388346638	-25.41111082135036	131	4.33
26323609	PD-L1 expression and prognostic impact in glioblastoma.	Neuro-oncology	2016	-24.2963172011979	50.88587038318838	381	14.41
26321864	Programmed Death 1 (PD-1) is involved in the development of proliferative diabetic retinopathy by mediating activation-induced apoptosis.	Molecular vision	2015	-67.85962032550987	-14.11141811109008	6	0.22
26321679	Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression.	Cell	2015	-29.426637320725803	-28.500745710059917	1784	58.8
26320063	Antagonists of PD-1 and PD-L1 in Cancer Treatment.	Seminars in oncology	2015	-38.94174736160677	-15.77562406051211	221	7.42
26317899	Genomic amplification of 9p24.1 targeting JAK2, PD-L1, and PD-L2 is enriched in high-risk triple negative breast cancer.	Oncotarget	2015	9.787129825124728	30.366544814636395	104	3.28
26317305	Development of an automated PD-L1 immunohistochemistry (IHC) assay for non-small cell lung cancer.	Applied immunohistochemistry & molecular morphology : AIMM	2015	20.87081064935766	-40.6922677677628	142	4.49
26313362	PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups.	PloS one	2015	13.35548687015603	-29.579860814604054	183	6.25
26307625	PD-1 and PD-L1 Expression in Renal Cell Carcinoma with Sarcomatoid Differentiation.	Cancer immunology research	2015	18.720129053499253	26.31759078472517	120	4.06
26307602	Novel Radiotracer for ImmunoPET Imaging of PD-1 Checkpoint Expression on Tumor Infiltrating Lymphocytes.	Bioconjugate chemistry	2015	6.506980841663304	-55.21622288377601	121	4.29
26306753	PD-L1 Monoclonal Antibody Treats Ischemic Stroke by Controlling Central Nervous System Inflammation.	Stroke	2015	-77.33329355540705	-7.718404299765085	31	1.06
26306141	Anti program death-1/anti program death-ligand 1 in digestive cancers.	World journal of gastrointestinal oncology	2015	38.9089876850437	16.643652373470474	46	1.38
26305724	The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients.	Oncotarget	2015	-40.28749768567854	-19.580305632526677	56	1.78
26297712	HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade.	Cancer immunology research	2015	-9.728422036421192	-31.6903925819438	277	8.52
26287667	TLR3 agonist and Sorafenib combinatorial therapy promotes immune activation and controls hepatocellular carcinoma progression.	Oncotarget	2015	28.599432897389494	52.65830976635733	50	1.72
26286967	PD-1/PD-L1 signal pathway participates in HCV F protein-induced T cell dysfunction in chronic HCV infection.	Immunologic research	2016	-77.32174307031315	22.733479119143357	15	0.59
26282545	Immune Checkpoint Inhibitors for Cancer Therapy: Clinical Efficacy and Safety.	Current cancer drug targets	2015	26.45781181953416	7.092406701742199	74	2.44
26279307	Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer.	Scientific reports	2015	31.37148864911962	-30.65306766052664	286	9.64
26272491	Adaptive Immune Resistance: How Cancer Protects from Immune Attack.	Cancer discovery	2015	-11.289250832991316	-63.18963010031364	402	12.07
26266813	Expression of PD-L1 on CD4+CD25+Foxp3+ Regulatory T Cells of Patients with Chronic HBV Infection and Its Correlation with Clinical Parameters.	Viral immunology	2015	-74.65343601762655	19.60295709859284	19	0.57
26261892	Identification of Programmed Death Ligand 1-derived Peptides Capable of Inducing Cancer-reactive Cytotoxic T Lymphocytes From HLA-A24+ Patients With Renal Cell Carcinoma.	Journal of immunotherapy (Hagerstown, Md. : 1997)	2015	66.23442578408506	34.420426890861535	27	0.85
26261529	Association between PD-1/PD-L1 and T regulate cells in early recurrent miscarriage.	International journal of clinical and experimental pathology	2015	-74.5528336285424	-19.18928061575266	27	1.1
26260996	Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance.	Prostate cancer and prostatic diseases	2015	-13.076918400808315	13.611231964173292	129	3.8
26259671	Blocking of the PD-1/PD-L1 Interaction by a D-Peptide Antagonist for Cancer Immunotherapy.	Angewandte Chemie (International ed. in English)	2015	-41.926137968511405	-44.37480970821018	196	6.49
26250412	Programmed death-1 & its ligands: promising targets for cancer immunotherapy.	Immunotherapy	2015	33.05193179804615	-2.1441364157235787	16	0.54
26248256	Targeting the programmed death-1/programmed death-ligand 1 axis in lymphoma.	Current opinion in oncology	2015	35.909246307193165	-6.212061886617988	14	0.45
26239088	Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma.	Blood	2015	-33.81963643212114	26.655272426410413	337	11.34
26235847	High ratio of programmed cell death protein 1 (PD-1)(+)/CD8(+) tumor-infiltrating lymphocytes identifies a poor prognostic subset of extrahepatic bile duct cancer undergoing surgery plus adjuvant chemoradiotherapy.	Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology	2015	0.5188775980590825	6.713568793735378	44	1.44
26219551	Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer.	Journal of translational medicine	2015	-28.852038868877266	-18.892220330241223	49	1.53
26210691	Programmed cell death protein 1 expression is an independent prognostic factor in gastric cancer after curative resection.	Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association	2016	-9.616672836592793	4.939565603093676	104	3.82
26210046	Salmonella impairs CD8 T cell response through PD-1: PD-L axis.	Immunobiology	2015	-63.07151499711897	4.584202692014867	14	0.53
26204273	(18)F-FDG PET/CT and Melanoma: Staging, Immune Modulation and Mutation-Targeted Therapy Assessment, and Prognosis.	AJR. American journal of roentgenology	2015	28.76091975125822	-10.97280458662492	31	1.11
26199729	Update on checkpoint blockade therapy for lymphoma.	Journal for immunotherapy of cancer	2015	-43.62246055817416	-10.441835936343486	11	0.32
26189934	Reorienting the immune system in the treatment of cancer by using anti-PD-1 and anti-PD-L1 antibodies.	Drug discovery today	2015	-37.35856264606544	-16.827355568052234	27	0.79
26184792	Recent advances in antibody-based therapies for Hodgkin Lymphoma.	British journal of haematology	2015	37.52089134707011	-7.4682705048031615	3	0.1
26183035	Surgical trauma induces postoperative T-cell dysfunction in lung cancer patients through the programmed death-1 pathway.	Cancer immunology, immunotherapy : CII	2015	-50.49163694919624	33.678130104228	28	1.05
26181000	Association of Polymerase e-Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1.	JAMA oncology	2015	7.885389432418702	45.67495654407156	439	13.65
26176707	RAC1 P29S regulates PD-L1 expression in melanoma.	Pigment cell & melanoma research	2015	-12.675967846084252	-19.615950988928223	49	1.47
26175924	Assays for predicting and monitoring responses to lung cancer immunotherapy.	Cancer biology & medicine	2015	20.380011088164448	-37.50082752002715	29	0.96
26171934	Frequent PD-L1 expression in testicular germ cell tumors.	British journal of cancer	2015	-25.777099614587645	34.63232795874333	110	3.9
26162965	New immunotherapies targeting the PD-1 pathway.	Trends in pharmacological sciences	2015	-50.42151793779962	-12.731243831459174	126	3.87
26159545	Expression of Programmed Death 1 Ligand in Different Compartments of Chronic Lymphocytic Leukemia.	Acta haematologica	2015	-40.09375084306628	20.92659382573741	29	0.87
26155425	Immunotherapy of hematological cancers: PD-1 blockade for the treatment of Hodgkin's lymphoma.	Oncoimmunology	2015	37.3352231791114	-8.03369197935686	9	0.25
26155422	Interferon-γ-induced activation of JAK1 and JAK2 suppresses tumor cell susceptibility to NK cells through upregulation of PD-L1 expression.	Oncoimmunology	2015	-18.09841307305406	-20.740025940897848	205	6.34
26155415	Exosomes isolated from plasma of glioma patients enrolled in a vaccination trial reflect antitumor immune activity and might predict survival.	Oncoimmunology	2015	-16.53461767386347	60.02785085932202	81	2.96
26141938	Inflammation and Cancer: What Can We Therapeutically Expect from Checkpoint Inhibitors?	Current urology reports	2015	-43.51497188182525	-17.03554763826129	17	0.53
26141705	Immune therapy of non-small cell lung cancer. The future.	Pharmacological research	2015	37.04011002967784	-31.41047799391063	14	0.44
26140546	Prognostic significance of PD-1 expression on peripheral blood CD4+ T cells in patients with newly diagnosed chronic lymphocytic leukemia.	Polskie Archiwum Medycyny Wewnetrznej	2015	-40.389432489518725	20.595429025103147	20	0.62
26140250	Colorectal cancer: the first neoplasia found to be under immunosurveillance and the last one to respond to immunotherapy?	Oncoimmunology	2015	34.6615673038376	20.465858787651456	53	1.5
26140231	Kick-starting the cancer-immunity cycle by targeting CD40.	Oncoimmunology	2015	-26.096648983509503	-19.76445049223265	12	0.35
26134220	Programmed Death-Ligand 1 Immunohistochemistry in Lung Cancer: In what state is this art?	Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer	2015	19.319228757980863	-39.51863451351428	223	7.2
26116728	A Jekyll and Hyde Profile: Type 1 Interferon Signaling Plays a Prominent Role in the Initiation and Maintenance of a Persistent Virus Infection.	The Journal of infectious diseases	2015	-74.18822842617826	12.4941989622993	12	0.3
26116499	CD4 T Cell Depletion Substantially Augments the Rescue Potential of PD-L1 Blockade for Deeply Exhausted CD8 T Cells.	Journal of immunology (Baltimore, Md. : 1950)	2015	-74.52953311602852	13.979529683936908	27	0.7
26112079	Viral Infection of Tumors Overcomes Resistance to PD-1-immunotherapy by Broadening Neoantigenome-directed T-cell Responses.	Molecular therapy : the journal of the American Society of Gene Therapy	2015	-37.24745843349449	51.54807461309834	153	4.82
26101718	Programmed cell death protein 1 and programmed death-ligand 1 are expressed on the surface of some small-cell lung cancer lines.	American journal of cancer research	2015	-41.38604990474669	-8.401041121587953	26	0.78
26091677	Releasing the Brake on the Immune System: The PD-1 Strategy for Hematologic Malignancies.	Oncology (Williston Park, N.Y.)	2015	-40.04937972903772	-15.69530467549621	13	0.4
26086854	Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers.	PloS one	2015	33.97197032661646	-4.755947864559685	346	11.05
26081225	Epithelial PD-L2 Expression Marks Barrett's Esophagus and Esophageal Adenocarcinoma.	Cancer immunology research	2015	-13.154935020030925	7.22731830761802	104	3.27
26063974	Notch Signaling Pathway Was Involved in Regulating Programmed Cell Death 1 Expression during Sepsis-Induced Immunosuppression.	Mediators of inflammation	2015	-58.77022164293813	34.05698809142617	29	0.9
26060497	Evolving Concepts: Immunity in Oncology from Targets to Treatments.	Journal of oncology	2015	26.139833343865	5.543977272257979	16	0.5
26055074	In-situ tumor vaccination: Bringing the fight to the tumor.	Human vaccines & immunotherapeutics	2015	21.26142434731208	1.3214066773925888	52	1.62
26049755	Targeting immune checkpoints in lymphoma.	Current opinion in hematology	2015	36.186578543527325	-6.607672891974223	33	1.04
26048148	Cutting Edge: PD-1 Regulates Imiquimod-Induced Psoriasiform Dermatitis through Inhibition of IL-17A Expression by Innate γδ-Low T Cells.	Journal of immunology (Baltimore, Md. : 1950)	2015	-60.04868150833771	-17.93886473618534	45	1.37
26043977	Programmed death 1 and its ligands do not limit experimental foreign antigen-induced immune complex glomerulonephritis.	Nephrology (Carlton, Vic.)	2015	-53.76876812931295	7.67828763371184	3	0.1
26041877	Gene expression patterns through oral squamous cell carcinoma development: PD-L1 expression in primary tumor and circulating tumor cells.	Oncotarget	2015	-7.668793320397717	-11.717114365996576	87	3.04
26041735	PD-1 or PD-L1 Blockade Restores Antitumor Efficacy Following SSX2 Epitope-Modified DNA Vaccine Immunization.	Cancer immunology research	2015	-27.82571419645453	-11.119348268872104	62	1.98
26036819	Programmed death-1 checkpoint blockade in acute myeloid leukemia.	Expert opinion on biological therapy	2015	-40.199828066311376	-7.263324836318371	50	1.66
26028407	Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.	The New England journal of medicine	2015	47.132908198518656	-23.860076109210627	6114	225.97
26027431	Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.	The New England journal of medicine	2015	36.30204019551382	1.946674019096479	5406	196.4
26019170	Induction of PD-L1 Expression by the EML4-ALK Oncoprotein and Downstream Signaling Pathways in Non-Small Cell Lung Cancer.	Clinical cancer research : an official journal of the American Association for Cancer Research	2015	10.446731213923728	-34.04202885556919	359	11.35
26014098	Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells.	Cancer immunology research	2015	52.35958508628857	41.8140490323917	327	10.84
26014096	Long-term Benefit of PD-L1 Blockade in Lung Cancer Associated with JAK3 Activation.	Cancer immunology research	2015	16.589837787204267	-21.81676327764645	56	1.41
26014095	Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma.	Cancer immunology research	2015	15.24336745794671	26.548189775354707	212	6.54
26004934	Programmed death-1 (PD-1), programmed death-ligand 1 (PD-L1), and EBV-encoded RNA (EBER) expression in Hodgkin lymphoma.	Annals of hematology	2015	-38.166760884238926	26.129056896738067	63	2.16
25999209	Immunological markers predict the prognosis of patients with squamous non-small cell lung cancer.	Immunologic research	2015	20.98490445319285	-32.113819511134984	18	0.67
25993208	Current Standards and Clinical Trials in Systemic Therapy for Stage III Lung Cancer: What Is New?	American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting	2015	38.02644984391017	-27.0315963335632	4	0.14
25993145	Managing immune checkpoint-blocking antibody side effects.	American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting	2015	27.584285861050404	5.7057632549969695	280	9.61
25992292	Combination immunotherapy with α-CTLA-4 and α-PD-L1 antibody blockade prevents immune escape and leads to complete control of metastatic osteosarcoma.	Journal for immunotherapy of cancer	2015	-24.916247207898525	-6.616266214116656	140	4.89
25991832	Current status and future directions of the immune checkpoint inhibitors ipilimumab, pembrolizumab, and nivolumab in oncology.	The Annals of pharmacotherapy	2015	33.66647658524232	8.846090117475066	125	4.04
25990251	Identification and selective expansion of functionally superior T cells expressing chimeric antigen receptors.	Journal of translational medicine	2015	-44.958758108172056	4.401387427065836	21	0.59
25981182	Immune checkpoint blockade opens an avenue of cancer immunotherapy with a potent clinical efficacy.	Cancer science	2015	24.57308269955608	6.580975793426361	64	2.07
25979947	Mechanisms of PD-L1/PD-1-mediated CD8 T-cell dysfunction in the context of aging-related immune defects in the Eµ-TCL1 CLL mouse model.	Blood	2015	-40.94644648130872	19.9687042299498	91	2.72
25979932	Immune checkpoint modulation for non-small cell lung cancer.	Clinical cancer research : an official journal of the American Association for Cancer Research	2015	37.83088391586514	-30.93189438435647	80	2.34
25979549	Immune targeting in breast cancer.	Oncology (Williston Park, N.Y.)	2015	24.136960946656465	-0.2894202405321281	94	3.01
25979485	Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma.	Clinical cancer research : an official journal of the American Association for Cancer Research	2015	-32.69056401393044	4.895537973702117	239	7.52
25977331	Noninvasive Imaging of Tumor PD-L1 Expression Using Radiolabeled Anti-PD-L1 Antibodies.	Cancer research	2015	5.396462717493451	-54.69327428022624	169	5.81
25973021	PD-L1 blockade improves immune dysfunction of spleen dendritic cells and T-cells in zymosan-induced multiple organs dysfunction syndromes.	International journal of clinical and experimental pathology	2015	-64.90851344957771	29.40372011290271	3	0.11
25970248	Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity.	Nature	2015	-34.087141399853806	-13.02736878950608	1785	55.82
25965367	PD-L1 inhibition with MPDL3280A for solid tumors.	Seminars in oncology	2015	0.2634944379213003	-55.23718096426448	34	1.05
25965365	Anti-PD-1 therapy in melanoma.	Seminars in oncology	2015	33.680894039333594	-0.3546620963695455	33	1.0
25964860	Subverting the adaptive immune resistance mechanism to improve clinical responses to immune checkpoint blockade therapy.	Oncoimmunology	2014	-37.887424228638416	-21.2238513035626	8	0.21
25964334	Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses.	Proceedings of the National Academy of Sciences of the United States of America	2015	-39.8550115691612	38.34496944469423	214	6.51
25963805	The prognostic significance of PD-L1 in bladder cancer.	Oncology reports	2015	10.853797304082686	59.8022128893408	79	2.61
25949860	Distinct patterns of intratumoral immune cell infiltrates in patients with HPV-associated compared to non-virally induced head and neck squamous cell carcinoma.	Oncoimmunology	2015	-9.760752839631332	34.3504080545387	164	5.67
25944800	Differential Expression of Immune-Regulatory Genes Associated with PD-L1 Display in Melanoma: Implications for PD-1 Pathway Blockade.	Clinical cancer research : an official journal of the American Association for Cancer Research	2015	-32.28784202293037	-9.063219679856283	186	5.59
25944714	Decreased PD-1/PD-L1 Expression Is Associated with the Reduction in Mucosal Immunoglobulin A in Mice with Intestinal Ischemia Reperfusion.	Digestive diseases and sciences	2015	-62.27654238337888	19.29155779569258	9	0.34
25943534	Identification and Characterization of MEDI4736, an Antagonistic Anti-PD-L1 Monoclonal Antibody.	Cancer immunology research	2015	-40.67277144038238	-30.068615448145252	270	8.6
25941611	Tumor stroma-derived factors skew monocyte to dendritic cell differentiation toward a suppressive CD14+ PD-L1+ phenotype in prostate cancer.	Oncoimmunology	2014	-9.755943845022712	11.567999798878144	53	1.52
25941590	Differential potency of regulatory T cell-mediated immunosuppression in kidney tumors compared to subcutaneous tumors.	Oncoimmunology	2014	14.681971121645857	32.44602185875901	7	0.16
25941561	A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy.	Computational and structural biotechnology journal	2015	-4.982982671743173	-49.887565542582806	159	5.07
25934860	PD-1 upregulated on regulatory T cells during chronic virus infection enhances the suppression of CD8+ T cell immune response via the interaction with PD-L1 expressed on CD8+ T cells.	Journal of immunology (Baltimore, Md. : 1950)	2015	-77.76828845166496	13.75251060034503	134	3.96
25922726	Clinicopathological and prognostic significance of programmed cell death ligand1 (PD-L1) expression in patients with non-small cell lung cancer: a meta-analysis.	Journal of thoracic disease	2015	13.14039043944606	-29.441996339195573	112	3.85
25922725	Evaluation of the efficacy and safety of anti-PD-1 and anti-PD-L1 antibody in the treatment of non-small cell lung cancer (NSCLC): a meta-analysis.	Journal of thoracic disease	2015	50.14048353632457	-18.45102738344514	27	0.82
25919090	Targeting the PD-1/PD-L1 Immune Evasion Axis With DNA Aptamers as a Novel Therapeutic Strategy for the Treatment of Disseminated Cancers.	Molecular therapy. Nucleic acids	2015	-25.34412646440978	-59.31643884817149	82	2.98
25916783	[Effects of soluble programmed death ligand 1 on regulating the proliferation of T lymphocytes and its mechanism].	Zhonghua yi xue za zhi	2015	-48.26586389746038	19.155419665786408	9	0.33
25914862	Unleashing the immune system: PD-1 and PD-Ls in the pre-treatment tumor microenvironment and correlation with response to PD-1/PD-L1 blockade.	Oncoimmunology	2014	-5.685236616785783	18.030088716376056	57	1.49
25907244	Upregulation of PD-1 on CD4⁺CD25⁺ T cells is associated with immunosuppression in liver of mice infected with Echinococcus multilocularis.	International immunopharmacology	2015	-49.84795789496562	19.683139949580127	28	1.28
25906748	Multi-platform profiling of over 2000 sarcomas: identification of biomarkers and novel therapeutic targets.	Oncotarget	2015	-18.95141845507645	49.03163895306468	90	2.97
25904740	Monoclonal antibodies against GARP/TGF-β1 complexes inhibit the immunosuppressive activity of human regulatory T cells in vivo.	Science translational medicine	2015	-81.62054163109526	-14.086145413511236	110	3.13
25902191	Upregulation of Programmed Death-1 and Its Ligand in Cardiac Injury Models: Interaction with GADD153.	PloS one	2015	-62.09342582207657	7.836349855225096	65	2.08
25901287	The therapeutic promise of disrupting the PD-1/PD-L1 immune checkpoint in cancer: unleashing the CD8 T cell mediated anti-tumor activity results in significant, unprecedented clinical efficacy in various solid tumors.	Journal for immunotherapy of cancer	2015	24.36510279626493	5.176398004335312	52	1.73
25901283	Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma.	Journal for immunotherapy of cancer	2015	85.92923968506594	0.7102549425936553	237	7.99
25901080	Glycodelin: A New Biomarker with Immunomodulatory Functions in Non-Small Cell Lung Cancer.	Clinical cancer research : an official journal of the American Association for Cancer Research	2015	14.06106773403448	-19.94817703395944	33	1.14
25896390	Hair regrowth in alopecia areata patients following Stem Cell Educator therapy.	BMC medicine	2015	-52.37947847430924	22.968277046986703	36	1.57
25891174	Pembrolizumab for the treatment of non-small-cell lung cancer.	The New England journal of medicine	2015	48.568289611900695	-29.1843959376559	4377	154.9
25882106	Immuno-regulatory antibodies for the treatment of cancer.	Expert opinion on biological therapy	2015	28.68653036088516	1.791228482867809	33	1.11
25877928	Recovery from experimental autoimmune uveitis promotes induction of antiuveitic inducible Tregs.	Journal of leukocyte biology	2015	-67.1235621016727	0.7349062626096733	28	1.17
25877890	STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade.	Science translational medicine	2015	-22.377128707252584	-45.02606485207415	470	14.01
25867468	Regulatory function of CD4+CD25++ T cells in patients with myasthenia gravis is associated with phenotypic changes and STAT5 signaling: 1,25-Dihydroxyvitamin D3 modulates the suppressor activity.	Journal of neuroimmunology	2015	-70.44241322961234	5.700631073471469	29	1.07
25867264	IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer.	British journal of cancer	2015	-22.235830573103865	11.986735106887712	473	15.47
25866054	Ovarian cancer immunotherapy using PD-L1 siRNA targeted delivery from folic acid-functionalized polyethylenimine: strategies to enhance T cell killing.	Advanced healthcare materials	2015	-34.87253699357028	-52.7965463784242	101	3.41
25856776	Anti-programmed cell death protein-1/ligand-1 therapy in different cancers.	British journal of cancer	2015	-42.18816327991517	-16.99700940228912	184	5.89
25851293	Association of programmed cell death 1 and programmed cell death 1 ligand gene polymorphisms with delayed graft function and acute rejection in kidney allograft recipients.	Iranian journal of kidney diseases	2015	-62.620921738694	16.45242716683506	7	0.36
25850344	Liver myeloid-derived suppressor cells expand in response to liver metastases in mice and inhibit the anti-tumor efficacy of anti-CEA CAR-T.	Cancer immunology, immunotherapy : CII	2015	-42.57787575746708	6.9985153634945	161	4.92
25844720	Inducible but not constitutive expression of PD-L1 in human melanoma cells is dependent on activation of NF-κB.	PloS one	2015	-13.951429652615504	-20.266738783797976	165	5.07
25841456	Checkpoint inhibitors in the treatment of cutaneous malignant melanoma.	Chinese clinical oncology	2014	31.210333459919248	4.789452133911165	5	0.19
25839440	Efficient nontoxic delivery of PD-L1 and PD-L2 siRNA into dendritic cell vaccines using the cationic lipid SAINT-18.	Journal of immunotherapy (Hagerstown, Md. : 1997)	2015	-54.41175858178659	-19.81793439244801	37	1.19
25823918	The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.	Clinical therapeutics	2015	33.90245612843139	-0.6181759555785687	388	13.19
25810125	PD-1/PD-L1 expression on CD(4+) T cells and myeloid DCs correlates with the immune pathogenesis of atrial fibrillation.	Journal of cellular and molecular medicine	2015	-57.52817180609016	15.012776093272937	17	0.56
25802230	The Role of Anti-PD-1/PD-L1 Agents in Melanoma: Progress to Date.	Drugs	2015	31.855139945607903	-0.7559835057575596	16	0.5
25801750	Programmed Death-Ligand 1 Expression Predicts Tyrosine Kinase Inhibitor Response and Better Prognosis in a Cohort of Patients With Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma.	Clinical lung cancer	2015	8.833646040566991	-32.052601728377184	93	2.8
25797516	Overcoming T cell exhaustion in infection and cancer.	Trends in immunology	2015	-49.31119805650544	-10.178068934822816	695	20.85
25795410	Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.	The Lancet. Oncology	2015	37.02510846307752	1.2462781443335729	1955	67.79
25792524	Novel strategies for inhibiting PD-1 pathway-mediated immune suppression while simultaneously delivering activating signals to tumor-reactive T cells.	Cancer immunology, immunotherapy : CII	2015	-47.40605822691064	-2.1681919796536184	14	0.45
25787767	Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma.	Science translational medicine	2015	30.746451340323887	33.50469579390045	414	12.21
25778100	PD-L1/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma.	Leukemia	2015	-32.71221127177887	8.75628836896065	155	5.03
25776763	[Immunotherapies and melanoma].	Bulletin du cancer	2014	30.63138593865764	3.52767056690378	4	0.12
25776466	Optimal management of immune-related toxicities associated with checkpoint inhibitors in lung cancer.	Lung cancer (Amsterdam, Netherlands)	2015	70.58192043740868	-8.552944365625837	40	1.14
25774992	Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM).	PloS one	2015	6.8227034532512425	11.00434846411554	143	4.98
25769925	Cutting edge: identification of autoreactive CD4+ and CD8+ T cell subsets resistant to PD-1 pathway blockade.	Journal of immunology (Baltimore, Md. : 1950)	2015	-59.92401187771832	0.6158141460672286	38	0.97
25756928	Role of PD-1 co-inhibitory pathway in HIV infection and potential therapeutic options.	Retrovirology	2015	-81.57187409923232	13.721743424302788	105	3.61
25751499	Enhanced T-cell immunity to osteosarcoma through antibody blockade of PD-1/PD-L1 interactions.	Journal of immunotherapy (Hagerstown, Md. : 1997)	2015	-24.943522617789878	-6.592921176245557	145	5.03
25749122	Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy.	Molecular immunology	2015	30.468587052153776	-3.2085829990844714	153	5.06
25742933	CEA/CD3-bispecific T cell-engaging (BiTE) antibody-mediated T lymphocyte cytotoxicity maximized by inhibition of both PD1 and PD-L1.	Cancer immunology, immunotherapy : CII	2015	-13.36152367605662	-42.84191114119698	64	1.98
25741704	Blockade of PD-1/PD-L1 promotes adoptive T-cell immunotherapy in a tolerogenic environment.	PloS one	2015	-56.740239979368255	-2.792043866617714	31	0.86
25733707	Cancer immunotherapy: a future paradigm shift in the treatment of non-small cell lung cancer.	Clinical cancer research : an official journal of the American Association for Cancer Research	2015	35.63697217714167	-33.488189079257594	172	5.57
25733155	The yin and yang of evasion and immune activation in HCC.	Journal of hepatology	2015	28.558398893365137	50.97339905511132	215	6.72
25730880	Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK.	Proceedings of the National Academy of Sciences of the United States of America	2015	-12.925395895074372	-37.01144966550864	307	9.32
25725111	CD8+CD103+ tumor-infiltrating lymphocytes are tumor-specific tissue-resident memory T cells and a prognostic factor for survival in lung cancer patients.	Journal of immunology (Baltimore, Md. : 1950)	2015	-12.58107888045638	27.773285771421275	401	11.79
25724840	siRNA silencing of PD-1 ligands on dendritic cell vaccines boosts the expansion of minor histocompatibility antigen-specific CD8(+) T cells in NOD/SCID/IL2Rg(null) mice.	Cancer immunology, immunotherapy : CII	2015	-54.82371254081936	-19.383458478441128	37	1.21
25723350	Human PD-1 binds differently to its human ligands: a comprehensive modeling study.	Journal of molecular graphics & modelling	2015	-48.06908144021188	-38.16150418060225	31	0.96
25714590	Evaluation of Immune Restoration Potential of PD-1 Blockers.	Journal of immunoassay & immunochemistry	2015	-39.45446495212028	-17.663175919183807	1	0.03
25711759	Robust Antitumor Effects of Combined Anti-CD4-Depleting Antibody and Anti-PD-1/PD-L1 Immune Checkpoint Antibody Treatment in Mice.	Cancer immunology research	2015	-29.209772029187437	-19.49498730154213	52	1.41
28210682	Expression of Viral Antigen by the Liver Leads to Chronic Infection Through the Generation of Regulatory T Cells.	Cellular and molecular gastroenterology and hepatology	2015	-75.52744587422572	20.462248830265462	8	0.25
25702326	Co-expression of PD-1 and PD-L1 predicts poor outcome in nasopharyngeal carcinoma.	Medical oncology (Northwood, London, England)	2015	-17.05693489401773	31.44445138596527	90	3.13
25701326	PD-1+Tim-3+ CD8+ T Lymphocytes Display Varied Degrees of Functional Exhaustion in Patients with Regionally Metastatic Differentiated Thyroid Cancer.	Cancer immunology research	2015	-44.05574209692637	12.88107023188481	56	1.73
25692060	Metastatic Extramammary Paget's Disease of Scrotum Responds Completely to Single Agent Trastuzumab in a Hemodialysis Patient: Case Report, Molecular Profiling and Brief Review of the Literature.	Case reports in oncological medicine	2015	69.19982081744404	11.47638174571909	34	1.59
25688160	Orchestration and Prognostic Significance of Immune Checkpoints in the Microenvironment of Primary and Metastatic Renal Cell Cancer.	Clinical cancer research : an official journal of the American Association for Cancer Research	2015	15.745758782590318	33.05480736921392	303	9.2
25685857	Pembrolizumab: PD-1 inhibition as a therapeutic strategy in cancer.	Drugs of today (Barcelona, Spain : 1998)	2015	35.32727483987221	-3.616596945114624	60	1.92
25678581	Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma.	Cancer immunology research	2015	-21.7171059854361	-12.296787023302707	320	9.78
25674748	Prognostic significance of programmed cell death 1 (PD-1) or PD-1 ligand 1 (PD-L1) Expression in epithelial-originated cancer: a meta-analysis.	Medicine	2015	-11.705509596614084	11.189082732184287	96	3.02
25672397	Adenosine Receptor 2A Blockade Increases the Efficacy of Anti-PD-1 through Enhanced Antitumor T-cell Responses.	Cancer immunology research	2015	-5.015675079407564	-49.886605536512114	228	7.1
25668078	Cancer immunology - development of novel anti-cancer therapies.	Swiss medical weekly	2015	21.360725480505536	4.144680514236885	19	0.59
25664688	Epitope characterization of an anti-PD-L1 antibody using orthogonal approaches.	Journal of molecular recognition : JMR	2015	-47.72979639673318	-33.171174059966255	18	0.66
25662388	Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: Comparison with tumor-infiltrating T cells and the status of oncogenic drivers.	Lung cancer (Amsterdam, Netherlands)	2015	7.496539986674519	-24.670039157344075	162	5.26
25658629	Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation.	Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer	2015	4.988885970369144	-32.90728524975346	487	15.25
25653440	Role of type I interferon signaling in human metapneumovirus pathogenesis and control of viral replication.	Journal of virology	2015	-77.66853286997222	8.937912223401957	24	0.88
25645920	Novel roles of c-Met in the survival of renal cancer cells through the regulation of HO-1 and PD-L1 expression.	The Journal of biological chemistry	2015	-3.961622704270543	-23.978376197313622	117	3.67
30190830	Anti-PD1 and anti-PD-L1 in the treatment of metastatic melanoma.	Melanoma management	2015	33.598855915873905	-0.938371079962152	7	0.22
25327979	The role of programmed cell death-1 (PD-1) and its ligands in pediatric cancer.	Pediatric blood & cancer	2015	-45.08231963602988	-16.467000715393546	23	0.7
25630305	Differential control of CD4(+) T-cell subsets by the PD-1/PD-L1 axis in a mouse model of allergic asthma.	European journal of immunology	2015	-65.03800191430327	-10.336802358292555	58	1.91
25625924	PD-1 and PD-L1 antibodies for melanoma.	Human vaccines & immunotherapeutics	2014	33.35038559602209	-1.4946226045842252	45	1.4
25624956	Immune Suppression by Myeloid Cells in HIV Infection: New Targets for Immunotherapy.	The open AIDS journal	2014	-83.52577589640329	11.326962434823862	15	0.52
25623164	Induced PD-L1 expression mediates acquired resistance to agonistic anti-CD40 treatment.	Cancer immunology research	2015	-26.207766476842632	-19.637604172532026	96	2.71
25614821	Combined immune checkpoint protein blockade and low dose whole body irradiation as immunotherapy for myeloma.	Journal for immunotherapy of cancer	2015	26.33791067330844	21.300746586022253	91	2.74
25609381	PD-L1hi B cells are critical regulators of humoral immunity.	Nature communications	2015	-66.07663073798639	6.76878923050648	216	6.62
25609200	Increased expression of the immune modulatory molecule PD-L1 (CD274) in anaplastic meningioma.	Oncotarget	2015	-20.69313577811344	47.78390981247265	109	3.94
25609064	PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor-Treated Melanoma Patients.	Clinical cancer research : an official journal of the American Association for Cancer Research	2015	3.881714129287257	-0.3248306357679302	112	3.12
25605845	Immune Checkpoint Blockade in Cancer Therapy.	Journal of clinical oncology : official journal of the American Society of Clinical Oncology	2015	27.279852312669863	5.726232383179507	1803	61.72
25600565	Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma.	Annals of oncology : official journal of the European Society for Medical Oncology	2015	13.610799793215993	57.72075672077654	223	7.12
25594677	Overexpression of programmed death ligands in naturally occurring postweaning multisystemic wasting syndrome.	Viral immunology	2015	-69.70784381096311	-1.7785436625585058	8	0.4
25592115	PD-1/PD-L1 pathway in non-small-cell lung cancer and its relation with EGFR mutation.	Journal of translational medicine	2015	8.333374354486041	-31.07974976569902	61	1.92
25589619	The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4.	Clinical cancer research : an official journal of the American Association for Cancer Research	2015	30.45504362548992	34.33873980477578	309	9.09
25586601	PD-1 blockade therapy in renal cell carcinoma: current studies and future promises.	Cancer treatment reviews	2015	62.25185609023545	32.057217400371655	133	4.37
25583798	The microsatellite instable subset of colorectal cancer is a particularly good candidate for checkpoint blockade immunotherapy.	Cancer discovery	2015	10.872157291300688	42.35548585035988	264	8.2
25582496	PD-L1 expression in small cell neuroendocrine carcinomas.	European journal of cancer (Oxford, England : 1990)	2015	-1.2366530622816845	10.445687753041105	187	6.21
25572788	Pembrolizumab joins the anti-PD-1 armamentarium in the treatment of melanoma.	Future oncology (London, England)	2015	35.445440046802354	-3.4799993616239866	8	0.22
25553080	Anti-programmed death receptor 1 immunotherapy in melanoma: rationale, evidence and clinical potential.	Therapeutic advances in medical oncology	2015	-34.89697197416642	-15.323213133490464	22	0.7
27279233	Clinical Trials in Non-Small Cell Lung Cancer with Biomarker-Driven Treatment Allocation: Ready or Not, Here We Come.	Critical reviews in oncogenesis	2015	23.632481694827867	-34.184864951864704	3	0.11
25539755	[What's new in skin cancers?].	Annales de dermatologie et de venereologie	2014	32.88857721083112	31.79884281108598	1	0.08
25538263	Correlation of PD-L1 tumor expression and treatment outcomes in patients with renal cell carcinoma receiving sunitinib or pazopanib: results from COMPARZ, a randomized controlled trial.	Clinical cancer research : an official journal of the American Association for Cancer Research	2015	17.331767174917367	28.355614903573564	188	5.93
25536276	Lymphocytic alveolitis is associated with the accumulation of functionally impaired HIV-specific T cells in the lung of antiretroviral therapy-naive subjects.	American journal of respiratory and critical care medicine	2015	-80.70986183083642	14.067795611998564	36	1.32
25534375	Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers.	Journal of clinical oncology : official journal of the American Society of Clinical Oncology	2015	0.5101285312666501	22.63177368330664	720	24.08
25524312	Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma.	Clinical cancer research : an official journal of the American Association for Cancer Research	2015	37.36874340654205	2.2012255671733554	185	5.9
25517314	Failure to upregulate cell surface PD-1 is associated with dysregulated stimulation of T cells by TGN1412-like CD28 superagonist.	mAbs	2014	-55.43836554122465	-5.891188270547981	7	0.2
25510412	Soluble Programmed Death 1 (PD-1) Is Decreased in Patients With Immune Thrombocytopenia (ITP): Potential Involvement of PD-1 Pathway in ITP Immunopathogenesis.	Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis	2016	-51.5805090819881	4.103812686066013	23	0.99
25500094	Intrinsic and extrinsic control of expression of the immunoregulatory molecule PD-L1 in epithelial cells and squamous cell carcinoma.	Oral oncology	2015	-38.11900221933225	-9.000811637170802	234	7.71
25494679	Nivolumab for the treatment of cancer.	Expert opinion on investigational drugs	2015	35.36146302183543	-1.7976368514186405	54	1.6
25491730	The PD-1/PD-L1 pathway: biological background and clinical relevance of an emerging treatment target in immunotherapy.	Expert opinion on therapeutic targets	2015	-47.66095579779819	-12.105148020468796	73	2.36
25488990	B7H1/CD80 interaction augments PD-1-dependent T cell apoptosis and ameliorates graft-versus-host disease.	Journal of immunology (Baltimore, Md. : 1950)	2015	-64.43137917969611	-6.254912439013637	53	1.51
25484597	Immunologic checkpoints in cancer therapy: focus on the programmed death-1 (PD-1) receptor pathway.	Pharmacogenomics and personalized medicine	2014	26.574791597701616	6.170334469251379	88	2.55
25482239	PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.	The New England journal of medicine	2015	40.82037417580533	-6.162208968945858	2602	88.03
25480946	PD-1/SHP-2 inhibits Tc1/Th1 phenotypic responses and the activation of T cells in the tumor microenvironment.	Cancer research	2015	-44.66796847074553	-4.944109798098805	151	4.64
25465800	The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function.	Cancer cell	2014	-13.37339318252365	-56.85252495064657	703	19.81
25465288	Therapeutic targets in subependymoma.	Journal of neuroimmunology	2014	-2.18315428371591	31.597787271795504	12	0.46
25465101	Control of pathogenic effector T-cell activities in situ by PD-L1 expression on respiratory inflammatory dendritic cells during respiratory syncytial virus infection.	Mucosal immunology	2015	-77.55952920145891	8.088683766974789	37	1.17
25445176	Harnessing the PD-1 pathway in renal cell carcinoma: current evidence and future directions.	BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy	2014	-37.19822806871112	-15.326451372147597	7	0.17
25440090	Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway.	Trends in molecular medicine	2015	-40.06376985194841	-19.17769009119083	502	16.69
25433812	Synovial T cell hyporesponsiveness to myeloid dendritic cells is reversed by preventing PD-1/PD-L1 interactions.	Arthritis research & therapy	2014	-52.91788651480572	15.138176141112067	25	0.73
25428917	PD-L1 is highly expressed in Enzalutamide resistant prostate cancer.	Oncotarget	2015	-14.399709911665198	13.263712823330684	196	6.02
25428505	PD-1 blockade induces responses by inhibiting adaptive immune resistance.	Nature	2014	-30.188023029712177	-9.506673634761698	4525	142.92
25428504	Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.	Nature	2014	-33.29308983568424	-11.3659007058187	3734	118.83
25428503	MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer.	Nature	2014	10.780951523635077	60.51961442374748	1785	55.6
25424150	Prognostic implications of immunosuppressive protein expression in tumors as well as immune cell infiltration within the tumor microenvironment in gastric cancer.	Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association	2016	-11.437789265170656	23.006096823181156	196	7.6
25415283	PD-1/PD-L1 blockade together with vaccine therapy facilitates effector T-cell infiltration into pancreatic tumors.	Journal of immunotherapy (Hagerstown, Md. : 1997)	2015	-21.843129132445224	-12.519130109905486	288	9.09
25404365	OX40- and CD27-mediated costimulation synergizes with anti-PD-L1 blockade by forcing exhausted CD8+ T cells to exit quiescence.	Journal of immunology (Baltimore, Md. : 1950)	2015	-72.52149959297974	12.982347317265251	58	1.58
25404361	Both PD-1 ligands protect the kidney from ischemia reperfusion injury.	Journal of immunology (Baltimore, Md. : 1950)	2015	-57.94956480074808	28.74294206544805	58	1.86
25404033	Myeloid-derived suppressor cells impair alveolar macrophages through PD-1 receptor ligation during Pneumocystis pneumonia.	Infection and immunity	2015	-52.280694785145855	28.03988621365496	33	1.2
25399062	Association between a PD-1 gene polymorphism and antisperm antibody-related infertility in Iranian men.	Journal of assisted reproduction and genetics	2015	-62.68075110730797	13.895510393533357	12	0.46
25392179	Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type.	Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology	2014	-8.939553348442104	14.277234187329668	368	11.17
25387682	Prospects for targeting PD-1 and PD-L1 in various tumor types.	Oncology (Williston Park, N.Y.)	2014	-42.5357143731822	-16.17481152282778	45	1.33
25384886	Prognostic and predictive markers for the new immunotherapies.	Oncology (Williston Park, N.Y.)	2014	34.00555671560145	-3.789432734983869	110	2.94
25382117	Immune checkpoint inhibitors for non-small-cell lung cancer: does that represent a 'new frontier'?	Anti-cancer agents in medicinal chemistry	2015	36.3361481148655	-33.633984610698484	9	0.22
25370533	PD-L1 expression in melanocytic lesions does not correlate with the BRAF V600E mutation.	Cancer immunology research	2015	3.662123970149215	-0.9471878471655232	43	1.32
25361854	High and interrelated rates of PD-L1+CD14+ antigen-presenting cells and regulatory T cells mark the microenvironment of metastatic lymph nodes from patients with cervical cancer.	Cancer immunology research	2015	-4.2221787243271365	35.28150171421077	80	2.54
30190821	How anti-PD1 treatments are changing the management of melanoma.	Melanoma management	2014	28.732226387813448	3.1203967395029117	3	0.07
25358006	Generation of a monoclonal antibody recognizing mouse PD-1.	Monoclonal antibodies in immunodiagnosis and immunotherapy	2014	-48.35215278499214	-29.774452777978365	2	0.06
25355681	Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma.	Neuro-oncology	2015	-24.160324185361063	51.34698285911405	398	13.58
25355407	New antibody approaches to lymphoma therapy.	Journal of hematology & oncology	2014	-9.183782245708093	-50.21290977797377	40	1.31
25354479	Programmed death-1 blockade enhances the antitumor effects of peptide vaccine-induced peptide-specific cytotoxic T lymphocytes.	International journal of oncology	2015	-23.358215767380614	-16.63549038398924	61	1.95
25349974	PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients.	British journal of cancer	2015	9.25720536993557	-31.30265998982353	453	15.26
25349132	PD-1, PD-L1, PD-L2 expression in the chordoma microenvironment.	Journal of neuro-oncology	2015	-18.27017547458134	26.91449397052632	50	1.61
25343703	Decreased frequencies of circulating CD4⁺ T follicular helper cells associated with diminished plasma IL-21 in active pulmonary tuberculosis.	PloS one	2014	-85.89236883254881	6.451476375688549	21	0.67
25341119	Overcoming tumor-mediated immunosuppression.	Immunotherapy	2014	19.82290770247852	12.792522213988365	31	0.93
25323844	Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies.	International immunology	2015	28.943786078912517	1.5921943719068397	242	8.13
25314639	Tumour-infiltrating lymphocytes and expression of programmed death ligand 1 (PD-L1) in melanoma brain metastases.	Histopathology	2015	4.98619158376217	-0.9267886883570392	88	3.02
25299080	Changes in the PD-1 and PD-L1 expressions of splenic dendritic cells in multiple-organ dysfunction syndrome mice and their significance.	Genetics and molecular research : GMR	2014	-64.72805957049829	29.461763284063263	8	0.28
25287118	Lichenoid dermatitis in three patients with metastatic melanoma treated with anti-PD-1 therapy.	Cancer immunology research	2015	70.72667046464618	-24.525387982734703	76	3.06
25275395	Brugia malayi microfilariae induce a regulatory monocyte/macrophage phenotype that suppresses innate and adaptive immune responses.	PLoS neglected tropical diseases	2014	-65.38977971191576	14.52267440780636	28	0.99
25253438	Emerging drugs targeting PD-1 and PD-L1: reality or hope?	Expert opinion on emerging drugs	2014	31.499621143614466	-32.41812743490944	9	0.21
25248890	[Targeting the PD-1/PD-L1 immune checkpoint signal - a new treatment strategy for cancer].	Gan to kagaku ryoho. Cancer & chemotherapy	2014	-40.94121300972547	-14.423200937676969	8	0.23
25248887	[Suppression of tumor antigen-specific T cell immune responses by regulatory T cells].	Gan to kagaku ryoho. Cancer & chemotherapy	2014	-70.50397497034906	2.66128401589056	0	0.0
25236923	PD-1 is not required for natural or peripherally induced regulatory T cells: Severe autoimmunity despite normal production of regulatory T cells.	European journal of immunology	2014	-65.27362826202268	2.1724006499405464	31	0.79
25232304	Regulation of Neuroinflammation through Programed Death-1/Programed Death Ligand Signaling in Neurological Disorders.	Frontiers in cellular neuroscience	2014	-75.11714774301045	-5.736875856854271	31	1.02
25225461	Exhaustion of bacteria-specific CD4 T cells and microbial translocation in common variable immunodeficiency disorders.	The Journal of experimental medicine	2014	-80.15182394095352	16.441165115396974	81	2.37
25223485	PD-L1 marks a subset of melanomas with a shorter overall survival and distinct genetic and morphological characteristics.	Annals of oncology : official journal of the European Society for Medical Oncology	2014	6.347203884248633	-1.8494079692761565	112	3.31
25211661	Immune modulation for cancer therapy.	British journal of cancer	2014	32.381700139410846	3.8181757031604335	108	3.15
25207460	The targeting of indoleamine 2,3 dioxygenase -mediated immune escape in cancer.	Basic & clinical pharmacology & toxicology	2015	34.566886105781016	3.6587047888207263	28	0.94
25202350	Role of programmed death ligands in effective T-cell interactions in extranodal natural killer/T-cell lymphoma.	Oncology letters	2014	-38.12877360040828	23.839317700742168	39	1.11
25197343	Role of biphasic changes in splenic dendritic cell activity in a mouse model of multiple organ dysfunction syndrome.	International journal of clinical and experimental pathology	2014	-64.75413628066042	29.453535975946536	1	0.05
25189716	Immune checkpoint inhibitors in clinical trials.	Chinese journal of cancer	2014	25.09178225872362	8.7137613475704	78	2.18
25157219	Targeting immune co-stimulatory effects of PD-L1 and PD-L2 might represent an effective therapeutic strategy in stroke.	Frontiers in cellular neuroscience	2014	-76.81469798653573	-7.480015594437289	10	0.34
25148289	Immunotherapy: is a minor god yet in the pantheon of treatments for lung cancer?	Expert review of anticancer therapy	2014	35.53456116856992	-34.13352996062735	21	0.65
25144233	Inhibitory phenotype of HBV-specific CD4+ T-cells is characterized by high PD-1 expression but absent coregulation of multiple inhibitory molecules.	PloS one	2014	-74.98883566228892	23.837365585916277	50	1.44
25114573	PD-1 as an emerging therapeutic target in renal cell carcinoma: current evidence.	OncoTargets and therapy	2014	62.7764173280039	31.88890376118425	31	0.79
25113973	Interplay between regulatory T cells and PD-1 in modulating T cell exhaustion and viral control during chronic LCMV infection.	The Journal of experimental medicine	2014	-75.4509959326726	14.35882601160706	165	4.3
25098290	Blockade of the B7-H1/PD-1 pathway as a basis for combination anticancer therapy.	Cancer journal (Sudbury, Mass.)	2014	-36.732012033869886	-16.842292498915768	26	0.72
25098289	B7-H1/PD-1 blockade therapy in non-small cell lung cancer: current status and future direction.	Cancer journal (Sudbury, Mass.)	2014	31.844151748164023	-31.38770618892165	57	1.51
25098288	Subverting the B7-H1/PD-1 pathway in advanced melanoma and kidney cancer.	Cancer journal (Sudbury, Mass.)	2014	-37.12409313161113	-15.278211992744524	17	0.43
25098287	Biochemical signaling of PD-1 on T cells and its functional implications.	Cancer journal (Sudbury, Mass.)	2014	-57.265702507087134	-0.765632283116752	127	3.66
25098286	PD-1 as an immune modulatory receptor.	Cancer journal (Sudbury, Mass.)	2014	-50.560262315589306	-11.428026534648916	54	1.68
25098285	Inducible expression of B7-H1 (PD-L1) and its selective role in tumor site immune modulation.	Cancer journal (Sudbury, Mass.)	2014	-42.31823155060342	-13.22902668818918	110	3.09
25093496	PD-1(+) CD8(+) T cells are exhausted in tumours and functional in draining lymph nodes of colorectal cancer patients.	British journal of cancer	2014	-6.98689157032896	11.917484722641802	76	2.05
25080485	Programmed death-1 pathway in host tissues ameliorates Th17/Th1-mediated experimental chronic graft-versus-host disease.	Journal of immunology (Baltimore, Md. : 1950)	2014	-64.87456808122118	-4.740193989676301	60	1.8
25073001	Blockade of the programmed death-1 pathway restores sarcoidosis CD4(+) T-cell proliferative capacity.	American journal of respiratory and critical care medicine	2014	-55.617006720637285	17.433802070348214	91	3.25
25070848	TLR4 activation enhances the PD-L1-mediated tolerogenic capacity of colonic CD90+ stromal cells.	Journal of immunology (Baltimore, Md. : 1950)	2014	-58.957650269212365	19.04945403945988	63	1.85
25057927	Programmed cell death receptor ligand 1 modulates the regulatory T cells' capacity to repress shock/sepsis-induced indirect acute lung injury by recruiting phosphatase SRC homology region 2 domain-containing phosphatase 1.	Shock (Augusta, Ga.)	2015	-60.83257656066675	31.42644733909468	27	0.96
25050210	A novel combinatorial cancer immunotherapy: poly-IC and blockade of the PD-1/PD-L1 pathway.	Oncoimmunology	2014	26.77545231002558	-1.7075288359987313	15	0.45
25047812	Programmed cell death 1 (PD-1) regulates the effector function of CD8 T cells via PD-L1 expressed on target keratinocytes.	Journal of autoimmunity	2014	-62.2476707066943	-16.03968682957129	46	1.32
25041075	Pig to rat cell transplantation: reduced cellular and antibody responses to xenografts overexpressing PD-L1.	Xenotransplantation	2014	-67.78365784727598	-2.2280895633530773	20	0.79
25027969	Type 1 interferon-induced IL-7 maintains CD8+ T-cell responses and homeostasis by suppressing PD-1 expression in viral hepatitis.	Cellular & molecular immunology	2015	-70.3858366384276	21.92786988910325	22	0.63
25027060	Role of the Programmed Death-1 (PD-1) pathway in regulation of Theiler's murine encephalomyelitis virus-induced demyelinating disease.	Journal of neuroimmunology	2014	-73.58039445942339	-5.5911323866495	8	0.26
24997656	DCs sensitized with mPD-L1-Ig fusion protein improve the effect of heart transplantation in mice by promoting the generation of T-reg cells.	Cellular immunology	2014	-62.43840506141626	-4.1548294402780135	5	0.14
24977331	Telomere shortening and immune activity in war veterans with posttraumatic stress disorder.	Progress in neuro-psychopharmacology & biological psychiatry	2014	-71.28368507177211	11.247213857777943	55	2.41
24975127	PD-1 regulates extrathymic regulatory T-cell differentiation.	European journal of immunology	2014	-65.27316036349195	2.176527980778275	77	2.13
24969595	[Expression of programmed death-1 and programmed death ligand-1 in the peripheral T-lymphocytes from patients with chronic periodontitis].	Zhonghua kou qiang yi xue za zhi = Zhonghua kouqiang yixue zazhi = Chinese journal of stomatology	2014	-65.69295032113445	-21.24853273612997	6	0.24
24969320	Antibody therapies for melanoma: new and emerging opportunities to activate immunity (Review).	Oncology reports	2014	30.502638374982524	4.766466161051158	26	0.78
24955707	PD-1 pathway inhibitors: changing the landscape of cancer immunotherapy.	Cancer control : journal of the Moffitt Cancer Center	2014	30.59635346923592	-2.2143981366009924	103	3.15
24915569	Expression of PD-L1 on canine tumor cells and enhancement of IFN-γ production from tumor-infiltrating cells by PD-L1 blockade.	PloS one	2014	-16.497454445350243	-14.413107781492862	83	2.86
24908630	The PD-1/PD-Ls pathway and autoimmune diseases.	Cellular immunology	2014	-50.15599471087048	-13.584462845081934	248	7.83
24904561	Malaria drives T cells to exhaustion.	Frontiers in microbiology	2014	-75.38605434379878	3.083113374296404	57	1.77
24902766	Protective effects of Fc-fused PD-L1 on two different animal models of colitis.	Gut	2015	-60.57192752788672	18.6836526309028	74	2.34
24892254	Programmed death-1 inhibition in renal cell carcinoma: clinical insights and future directions.	Clinical advances in hematology & oncology : H&O	2014	66.37230786828457	33.6392669297199	12	0.35
24891762	Blockade of ICAM-1 improves the outcome of polymicrobial sepsis via modulating neutrophil migration and reversing immunosuppression.	Mediators of inflammation	2014	-59.646160723900685	36.24527357662708	22	0.77
24890099	Glial cells suppress postencephalitic CD8+ T lymphocytes through PD-L1.	Glia	2014	-75.54297951358177	-3.7841486499351857	50	1.49
24886298	The development of endometrial hyperplasia in aged PD-1-deficient female mice.	Diagnostic pathology	2014	-70.21917736086709	-19.48615073447854	4	0.14
24880949	Immune checkpoint blockade.	Hematology/oncology clinics of North America	2014	32.183398348458084	3.689951811788775	59	1.59
24880938	Immunotherapy in the treatment of non-small cell lung cancer.	Lung cancer (Amsterdam, Netherlands)	2014	34.805820148792016	-33.79202558062196	82	2.43
24872026	In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates.	Cancer immunology research	2014	11.277914689889844	-47.70015519373818	434	12.81
24860567	Does the immune system naturally protect against cancer?	Frontiers in immunology	2014	19.58320888313454	7.83331352739922	141	4.36
24852398	Clinical Trials of PD-1 and PD-L1 inhibitors in NSCLC.	Clinical advances in hematology & oncology : H&O	2014	50.82635673891336	-46.195047192770986	0	0.0
24848257	Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy.	Science translational medicine	2014	-49.43974627202418	27.07298456796301	504	14.72
24845976	Identification and characterization of bovine programmed death-ligand 2.	Microbiology and immunology	2014	-58.54080656408063	-26.792838584459197	1	0.05
24843833	Immune checkpoints: A therapeutic target in triple negative breast cancer.	Oncoimmunology	2014	24.769429374782277	-1.931999956279924	32	0.87
24842267	Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer.	Breast cancer research and treatment	2014	-10.425440216447932	15.618498506333506	418	13.3
24819861	The role of the PD-L1:PD-1 pathway in squamous cell carcinoma of the head and neck.	Oral oncology	2014	-37.40922972121171	-8.330199032652404	158	4.95
24819296	A soluble form of CD80 enhances antitumor immunity by neutralizing programmed death ligand-1 and simultaneously providing costimulation.	Cancer immunology research	2014	-47.63119850837002	-2.1857748592050408	32	0.88
24816853	PD-L1 gene polymorphisms and low serum level of PD-L1 protein are associated to type 1 diabetes in Chile.	Diabetes/metabolism research and reviews	2014	-62.02268995250905	14.498399197470151	33	0.94
24816762	T helper responses are maintained by basal-like breast cancer cells and confer to immune modulation via upregulation of PD-1 ligands.	Breast cancer research and treatment	2014	-14.441857162251104	18.932591515098306	21	0.65
24815784	Harnessing the power of the immune system via blockade of PD-1 and PD-L1: a promising new anticancer strategy.	Immunotherapy	2014	-38.59069194500715	-17.208032052329735	78	2.26
24812408	Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma.	Clinical cancer research : an official journal of the American Association for Cancer Research	2014	-13.55256700207777	-20.226961052349925	267	7.16
24795456	Steady-state antigen scavenging, cross-presentation, and CD8+ T cell priming: a new role for lymphatic endothelial cells.	Journal of immunology (Baltimore, Md. : 1950)	2014	-71.77687213997851	-0.1111409318650759	150	4.49
24780173	Programmed death-1 pathway in cancer and autoimmunity.	Clinical immunology (Orlando, Fla.)	2014	-47.96834900565224	-12.3168044560265	196	6.14
24778419	PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation.	The Journal of experimental medicine	2014	-29.727152365145727	-1.2113668999791565	1333	42.47
24748806	Protein expression of programmed death 1 ligand 1 and ligand 2 independently predict poor prognosis in surgically resected lung adenocarcinoma.	OncoTargets and therapy	2014	9.163159554658057	-27.97451870505571	186	5.8
24739950	Regulatory B cells inhibit cytotoxic T lymphocyte (CTL) activity and elimination of infected CD4 T cells after in vitro reactivation of HIV latent reservoirs.	PloS one	2014	-81.4692419840221	17.013869251615592	31	1.02
24732592	High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial.	Leukemia	2014	-45.73761188304711	21.49369158729433	253	7.5
24728077	Accumulation of memory precursor CD8 T cells in regressing tumors following combination therapy with vaccine and anti-PD-1 antibody.	Cancer research	2014	-26.9275534508568	-14.477018513410664	112	3.12
24725474	High STAT1 mRNA levels but not its tyrosine phosphorylation are associated with macrophage infiltration and bad prognosis in breast cancer.	BMC cancer	2014	-14.86533822049538	16.083629860990428	59	1.76
24714771	Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy.	Clinical cancer research : an official journal of the American Association for Cancer Research	2014	9.220054281188007	0.435028746863829	1799	57.31
24710745	Expression profile and in vitro blockade of programmed death-1 in human papillomavirus-negative head and neck squamous cell carcinoma.	Head & neck	2015	-4.8637523014030375	-7.251069331458336	51	1.67
24701370	Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy.	Oncoimmunology	2014	21.9173199961978	6.611214697024483	100	2.86
24696476	HIV-1 Tat protein induces PD-L1 (B7-H1) expression on dendritic cells through tumor necrosis factor alpha- and toll-like receptor 4-mediated mechanisms.	Journal of virology	2014	-83.53987164656154	12.984089079337569	43	1.33
24691993	VISTA is an immune checkpoint molecule for human T cells.	Cancer research	2014	-39.5731863836818	38.09477177202799	315	8.94
24691018	Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors.	Clinical cancer research : an official journal of the American Association for Cancer Research	2014	-28.528126003384045	57.09701505661125	415	12.93
24685885	Emerging immunotherapies in the treatment of non-small cell lung cancer (NSCLC): the role of immune checkpoint inhibitors.	American journal of clinical oncology	2015	38.18557766107626	-33.052118030926195	60	1.85
24684873	Latest advances in chemotherapeutic, targeted, and immune approaches in the treatment of metastatic melanoma.	Mayo Clinic proceedings	2014	32.18442931230992	30.03870094746729	65	2.4
24672527	Autoimmunity as a double agent in tumor killing and cancer promotion.	Frontiers in immunology	2014	-42.97010419388926	-8.76909444980401	34	1.0
24672046	Coregulatory interactions among CD8α dendritic cells, the latency-associated transcript, and programmed death 1 contribute to higher levels of herpes simplex virus 1 latency.	Journal of virology	2014	-74.05129630610254	9.947228235460342	15	0.55
24626392	Immune suppression by neutrophils in HIV-1 infection: role of PD-L1/PD-1 pathway.	PLoS pathogens	2014	-83.31179866998562	11.345939309747402	186	5.98
24620782	Sipuleucel-T and immunotherapy in the treatment of prostate cancer.	Expert opinion on biological therapy	2014	23.75001980376324	17.20478029041487	8	0.26
24615548	Targeting the PD-1 pathway: a promising future for the treatment of melanoma.	Archives of dermatological research	2014	32.24991705821857	-0.5837581751678167	50	1.47
24589924	Immune cell-poor melanomas benefit from PD-1 blockade after targeted type I IFN activation.	Cancer discovery	2014	-21.888743752206164	-19.36994554614201	195	5.01
24563823	High-affinity peptide-based anticancer vaccination to overcome resistance to immunostimulatory antibodies.	Oncoimmunology	2013	-45.273178524446685	-48.05138009235785	2	0.04
24563671	PD-L1 Expression in Clear Cell Renal Cell Carcinoma: An Analysis of Nephrectomy and Sites of Metastases.	Journal of Cancer	2014	15.55985042828247	26.594594966426754	124	3.65
24529703	Tissue-expressed B7-H1 critically controls intestinal inflammation.	Cell reports	2014	-60.20420866562792	-12.506052661613175	44	1.28
24510967	Negative regulation by PD-L1 during drug-specific priming of IL-22-secreting T cells and the influence of PD-1 on effector T cell function.	Journal of immunology (Baltimore, Md. : 1950)	2014	-63.88355303588475	0.0476398869105462	46	1.63
24510674	Development and use of IgM/J-chain fusion proteins for characterization of immunoglobulin superfamily ligand-receptor interactions.	Current protocols in protein science	2014	-49.63037963711336	-32.64411005706715	1	0.04
24509608	Prognostic impact of programmed cell death 1 ligand 1 expression in human leukocyte antigen class I-positive hepatocellular carcinoma after curative hepatectomy.	Journal of gastroenterology	2015	-22.538024462313956	40.21554108299369	80	2.58
24506960	[Expression of PD-1/PD-L1 in peripheral blood mononuclear cells in lung cancer patients and its biological significance].	Zhonghua zhong liu za zhi [Chinese journal of oncology]	2013	7.474120646074931	-21.46285673460236	3	0.09
24504486	Potential of new therapies like anti-PD1 in kidney cancer.	Current treatment options in oncology	2014	62.376730836141874	31.2541835122676	36	0.95
24496394	Essential role of program death 1-ligand 1 in regulatory T-cell-afforded protection against blood-brain barrier damage after stroke.	Stroke	2014	-75.55387544768138	-7.920531800147052	91	2.96
24485523	Orchestrating immune check-point blockade for cancer immunotherapy in combinations.	Current opinion in immunology	2014	29.72017499126317	5.980591066135321	83	2.45
24481903	Comparison of dynamic expressions of Tim-3 and PD-1 in the brains between toxoplasmic encephalitis-resistant BALB/c and -susceptible C57BL/6 mice.	Parasitology research	2014	-73.35149895054535	4.56904713388819	8	0.28
24455752	Antigen-specific bacterial vaccine combined with anti-PD-L1 rescues dysfunctional endogenous T cells to reject long-established cancer.	Cancer immunology research	2013	-38.111682262301976	-0.0282017474842158	58	1.5
24452537	The phenotype and activation status of regulatory T cells during Friend retrovirus infection.	Virologica Sinica	2014	-78.29998354095872	13.627134054835516	20	0.56
24440150	Tuning of antigen sensitivity by T cell receptor-dependent negative feedback controls T cell effector function in inflamed tissues.	Immunity	2014	-56.34993401320593	-2.2479693695943954	167	4.04
24424272	The perspective of immunotherapy: new molecules and new mechanisms of action in immune modulation.	Current opinion in oncology	2014	29.15455097809379	4.972435180329968	60	1.84
24406080	PD-1/PD-Ls pathways between CD4(+) T cells and pleural mesothelial cells in human tuberculous pleurisy.	Tuberculosis (Edinburgh, Scotland)	2014	-84.5366740520071	0.4542976262832846	10	0.29
24405267	Influence of PD-L1 cross-linking on cell death in PD-L1-expressing cell lines and bovine lymphocytes.	Immunology	2014	-58.42957886730924	-26.21747317111131	38	1.51
24403232	PD-1 as a potential target in cancer therapy.	Cancer medicine	2013	-40.45322210757118	-16.810664677829738	295	8.24
24401835	Interference with PD-L1/PD-1 co-stimulation during antigen presentation enhances the multifunctionality of antigen-specific T cells.	Gene therapy	2014	-58.17764105529534	-6.794019692657295	63	1.94
24391505	Enhancing virus-specific immunity in vivo by combining therapeutic vaccination and PD-L1 blockade in chronic hepadnaviral infection.	PLoS pathogens	2014	-72.86472573139534	20.19036327566761	192	6.09
24387680	Targeting the programmed cell death 1: programmed cell death ligand 1 pathway reverses T cell exhaustion in patients with sepsis.	Critical care (London, England)	2014	-58.52630609246884	34.72498507127186	191	6.28
24376539	TLR2 directing PD-L2 expression inhibit T cells response in Schistosoma japonicum infection.	PloS one	2013	-67.66660351183143	14.315606252050785	23	0.63
24359606	PD1 (CD279) and PD-L1 (CD274, B7H1) expression in primary central nervous system lymphomas (PCNSL).	Clinical neuropathology	2014	-34.551463978324044	32.0452804468244	87	2.78
24357746	Update on immune checkpoint inhibitors in lung cancer.	Cancer control : journal of the Moffitt Cancer Center	2014	38.69905298245442	-31.64748515438258	65	1.77
24352453	Differential impact of PD-1 and/or interleukin-10 blockade on HIV-1-specific CD4 T cell and antigen-presenting cell functions.	Journal of virology	2014	-82.39158211564275	15.405185770069414	53	1.5
24349382	Tumor infiltrating PD1-positive lymphocytes and the expression of PD-L1 predict poor prognosis of soft tissue sarcomas.	PloS one	2013	-19.85679151555733	19.47734055689168	219	6.57
24341237	[Melanoma: from molecular studies to the treatment breakthrough].	Arkhiv patologii	2013	31.340101042722047	31.05529102535988	1	0.03
24336068	A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells.	Cancer research	2014	-29.662176844087806	-1.2390795554660106	501	15.23
24328503	Fus1/Tusc2 is a novel regulator of mitochondrial calcium handling, Ca2+-coupled mitochondrial processes, and Ca2+-dependent NFAT and NF-κB pathways in CD4+ T cells.	Antioxidants & redox signaling	2014	-28.401231824823792	-28.30012945570036	32	0.99
24324295	PD-L1 blockade attenuated sepsis-induced liver injury in a mouse cecal ligation and puncture model.	Mediators of inflammation	2013	-60.502850965874494	34.64429529185441	39	1.18
24319287	Negative role of inducible PD-1 on survival of activated dendritic cells.	Journal of leukocyte biology	2014	-58.58361847560203	-7.953337850444326	35	0.98
24297569	Programmed death ligand-1 over-expression correlates with malignancy and contributes to immune regulation in ovarian cancer.	Cancer immunology, immunotherapy : CII	2014	-20.796445392615627	11.841353751094012	90	2.75
24283718	The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies.	Journal of hematology & oncology	2013	-45.73571289177397	-9.489686693203604	204	5.92
24270737	Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents.	Leukemia	2014	-35.03713006145353	13.15095947943183	507	14.9
24257598	Highly pathological influenza A virus infection is associated with augmented expression of PD-1 by functionally compromised virus-specific CD8+ T cells.	Journal of virology	2014	-76.00152255398709	8.13251919262301	76	2.14
24224477	Effect of the infectious dose and the presence of hepatitis C virus core gene on mouse intrahepatic CD8 T cells.	Hepatology research : the official journal of the Japan Society of Hepatology	2014	-76.82954888661021	25.55926801637472	1	0.03
24217091	Programmed death ligand-1 expression in non-small cell lung cancer.	Laboratory investigation; a journal of technical methods and pathology	2014	13.174506413211905	-32.15732426619318	633	19.85
24211847	Therapeutic polyclonal human CD8+ CD25+ Fox3+ TNFR2+ PD-L1+ regulatory cells induced ex-vivo.	Clinical immunology (Orlando, Fla.)	2013	-68.3283272780961	2.146846508913552	35	0.93
24210882	Challenging resistance mechanisms to therapies for metastatic melanoma.	Trends in pharmacological sciences	2013	30.48561107380994	30.998597275763537	77	2.25
24209771	Transcriptional profiling of feline infectious peritonitis virus infection in CRFK cells and in PBMCs from FIP diagnosed cats.	Virology journal	2013	-79.90677903555644	9.126538870263063	16	0.61
24204962	PD-1 blockade in chronically HIV-1-infected humanized mice suppresses viral loads.	PloS one	2013	-83.10834229224052	15.018401127277544	73	1.88
24196313	Recent advances in immunotherapy for non-small-cell lung cancer.	Human vaccines & immunotherapeutics	2014	35.8101945717581	-34.02771944058346	12	0.3
24193166	In vitro assay to evaluate the impact of immunoregulatory pathways on HIV-specific CD4 T cell effector function.	Journal of visualized experiments : JoVE	2013	-81.49547335956706	15.214417323086447	4	0.09
24188664	Immune modulation in cancer with antibodies.	Annual review of medicine	2014	32.3838238721777	3.746661778000844	388	11.07
24187568	PD-L1 expression induced by the 2009 pandemic influenza A(H1N1) virus impairs the human T cell response.	Clinical & developmental immunology	2013	-76.75021211099313	7.705761589140941	22	0.59
24182347	Increased soluble programmed death-1 (sPD-1) is associated with disease activity and radiographic progression in early rheumatoid arthritis.	Scandinavian journal of rheumatology	2014	-51.4179904397663	15.229593391536769	66	2.21
24175978	Interferon-induced programmed death-ligand 1 (PD-L1/B7-H1) expression increases on human acute myeloid leukemia blast cells during treatment.	European journal of haematology	2014	-36.1397471140341	16.80055688870737	80	2.24
24162015	Alterations of immune response of Non-Small Cell Lung Cancer with Azacytidine.	Oncotarget	2013	-0.6342503635992287	-31.935113762104884	280	7.3
24161671	Checkpoint blocking antibodies in cancer immunotherapy.	FEBS letters	2014	26.377400557266604	5.36580890966624	175	5.48
24153012	Coinhibitory molecule PD-1 as a potential target for the immunotherapy of multiple myeloma.	Leukemia	2014	-33.01674245231696	7.929388435691326	87	2.61
24105749	What lies within: novel strategies in immunotherapy for non-small cell lung cancer.	The oncologist	2013	35.85562952940596	-33.67861224606391	31	0.92
24096708	Human amnion mesenchymal cells negative co-stimulatory molecules PD-L1 expression and its capacity of modulating microglial activation of CNS.	Cell biochemistry and biophysics	2014	-55.96663067568059	22.357831993080133	12	0.53
24091833	Harnessing PD-L1-specific cytotoxic T cells for anti-leukemia immunotherapy to defeat mechanisms of immune escape mediated by the PD-1 pathway.	Leukemia	2014	-39.91078917974973	-6.17351269060023	34	0.88
24089443	CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients.	Clinical cancer research : an official journal of the American Association for Cancer Research	2013	28.853491662529567	3.603041135266866	498	14.2
24078774	Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors.	Cancer discovery	2013	4.7443480758743455	-32.82501367659465	959	26.48
24065812	Suppression of IL-22-producing T helper 22 cells by RPE cells via PD-L1/PD-1 interactions.	Investigative ophthalmology & visual science	2013	-65.47490670312544	-13.857378308358394	19	0.63
24048330	Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer--letter.	Clinical cancer research : an official journal of the American Association for Cancer Research	2013	-17.263065579918187	-61.6884002870037	14	0.39
24048329	Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer--response.	Clinical cancer research : an official journal of the American Association for Cancer Research	2013	-17.262500613002473	-61.68795915735767	96	2.37
24047772	[Anti-PD-1 antibody: basics and clinical application].	Gan to kagaku ryoho. Cancer & chemotherapy	2013	-40.01610687122104	-19.626265073651417	2	0.05
24031027	PD-1 blockage delays murine squamous cell carcinoma development.	Carcinogenesis	2014	-36.59966159346127	-9.009311731667482	35	1.02
24030385	Host programmed death ligand 1 is dominant over programmed death ligand 2 expression in regulating graft-versus-host disease lethality.	Blood	2013	-64.72314028181097	-4.572473624479035	143	3.72
24029602	Targeting the PD1/PD-L1 axis in melanoma: biological rationale, clinical challenges and opportunities.	Critical reviews in oncology/hematology	2014	-35.261395692050925	-16.161311441015705	120	3.59
24021877	DEC-205-mediated antigen targeting to steady-state dendritic cells induces deletion of diabetogenic CD8⁺ T cells independently of PD-1 and PD-L1.	International immunology	2013	-61.53637353500456	1.936349327650305	20	0.49
24021786	[Effect of antiviral treatment on expression of programmed death 1 and programmed death ligand 1 on peripheral T lymphocytes in patients with chronic hepatitis C].	Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology	2013	-76.04075044614831	22.93405925290924	0	0.0
24015822	PD-L1 enhances CNS inflammation and infarct volume following experimental stroke in mice in opposition to PD-1.	Journal of neuroinflammation	2013	-76.7496497387307	-7.568258285113432	52	1.56
24009988	PD-1 Interaction with PD-L1 but not PD-L2 on B-cells Mediates Protective Effects of Estrogen against EAE.	Journal of clinical & cellular immunology	2013	-72.55479843403216	-7.26605860655421	42	1.22
24004819	Mammary carcinoma cell derived cyclooxygenase 2 suppresses tumor immune surveillance by enhancing intratumoral immune checkpoint activity.	Breast cancer research : BCR	2013	-17.8413908571467	-1.9335421605489576	45	1.39
24004672	Better performance of CARs deprived of the PD-1 brake.	Clinical cancer research : an official journal of the American Association for Cancer Research	2013	-39.81699683178854	2.050079250040625	10	0.22
23977133	A missing PD-L1/PD-1 coinhibition regulates diabetes induction by preproinsulin-specific CD8 T-cells in an epitope-specific manner.	PloS one	2013	-62.5495824298853	1.9344597535358816	4	0.1
23975756	Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancer.	Cancer research	2013	-32.4544483698513	-14.465964647054134	215	5.81
23971530	CD40 signaling to the rescue: A CD8 exhaustion perspective in chronic infectious diseases.	Critical reviews in immunology	2013	-76.54882421456242	16.094374690127378	7	0.17
23924497	Programmed death 1 and programmed death ligand 1 expressions in patients with chronic hepatitis B.	Hepatobiliary & pancreatic diseases international : HBPD INT	2013	-71.2534031366653	23.743098080930125	12	0.38
23922299	Merkel polyomavirus-specific T cells fluctuate with merkel cell carcinoma burden and express therapeutically targetable PD-1 and Tim-3 exhaustion markers.	Clinical cancer research : an official journal of the American Association for Cancer Research	2013	43.61376564604583	52.04583690835528	145	4.4
23873688	Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells.	Clinical cancer research : an official journal of the American Association for Cancer Research	2013	-39.92499737949439	2.0913791301880327	521	13.98
23870385	Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond.	European journal of cancer (Oxford, England : 1990)	2013	31.962666768773964	30.64095473157532	31	0.96
23861247	Expression profiling of TCR-engineered T cells demonstrates overexpression of multiple inhibitory receptors in persisting lymphocytes.	Blood	2013	-48.5498931726149	1.028048272930426	69	1.77
23847336	Q&A: Suzanne Topalian on immune therapies.	Cancer discovery	2013	31.24067996511415	-0.6130669638005042	0	0.0
23824147	Programmed death-1 (PD-1)-dependent functional impairment of CD4(+) T cells in recurrent genital papilloma.	Clinical and experimental medicine	2014	-1.4554961631629255	-11.534018533303822	13	0.35
23812070	[Recent clinical trials of tumor immunotherapy].	Nihon Rinsho Men'eki Gakkai kaishi = Japanese journal of clinical immunology	2013	28.091944575289684	3.756005438972724	0	0.0
23810579	The heart of the matter: protection of the myocardium from T cells.	Journal of autoimmunity	2013	-61.43838971422705	6.710126431546237	54	1.47
23804712	Cutting edge: IL-12 and type I IFN differentially program CD8 T cells for programmed death 1 re-expression levels and tumor control.	Journal of immunology (Baltimore, Md. : 1950)	2013	-43.80195985507464	-2.4328872710707268	57	1.36
23792703	Recent insights into the role of the PD-1/PD-L1 pathway in immunological tolerance and autoimmunity.	Autoimmunity reviews	2013	-56.90330193630864	0.8751726207996485	200	5.87
23773130	Characteristics of splenic CD8+ T cell exhaustion in patients with hepatitis C.	Clinical and experimental immunology	2013	-77.95633149766944	26.18006621230373	19	0.53
23766529	Kupffer cells potentiate liver sinusoidal endothelial cell injury in sepsis by ligating programmed cell death ligand-1.	Journal of leukocyte biology	2013	-60.58433354854395	34.377054914653435	40	1.22
23762795	Adaptive immune resistance in HPV-associated head and neck squamous cell carcinoma.	Oncoimmunology	2013	-2.255477906509353	-8.073329105404214	8	0.22
23756627	The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer.	Breast cancer research and treatment	2013	-7.173956177644147	16.8927738475987	252	7.18
23723978	VIPhyb, an antagonist of vasoactive intestinal peptide receptor, enhances cellular antiviral immunity in murine cytomegalovirus infected mice.	PloS one	2013	-67.66264427867465	-7.18002946358129	13	0.4
23714659	[Effect of soluble PD-L1 released by lung cancer cells in regulating the function of T lymphocytes].	Zhonghua zhong liu za zhi [Chinese journal of oncology]	2013	-47.98274133066081	18.041859528053564	20	0.55
23676558	Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1).	Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer	2013	5.810540138483103	-25.53796049639388	125	3.64
23676462	PD-L1 blockade synergizes with IL-2 therapy in reinvigorating exhausted T cells.	The Journal of clinical investigation	2013	-73.79517385941638	13.682595068775155	213	5.44
23674495	PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies.	Clinical cancer research : an official journal of the American Association for Cancer Research	2013	-34.39741197809207	24.40347178559866	619	18.72
23667165	At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy.	Journal of leukocyte biology	2013	26.52603192011064	4.732969048847508	241	6.89
23663657	Blockade of the negative co-stimulatory molecules PD-1 and CTLA-4 improves survival in primary and secondary fungal sepsis.	Critical care (London, England)	2013	-60.267439531621896	37.13128468557409	182	5.51
23661793	Inhibiting the programmed death 1 pathway rescues Mycobacterium tuberculosis-specific interferon γ-producing T cells from apoptosis in patients with pulmonary tuberculosis.	The Journal of infectious diseases	2013	-84.29810625629982	1.4342967984542037	117	3.44
23656736	PD-L1/B7-H1 regulates the survival but not the function of CD8+ T cells in herpes simplex virus type 1 latently infected trigeminal ganglia.	Journal of immunology (Baltimore, Md. : 1950)	2013	-73.96128789855337	9.90046435128352	24	0.71
23633484	Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors.	Cancer research	2013	-27.92005112668077	-8.345714261635703	507	14.1
23625198	At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy.	Journal of leukocyte biology	2013	26.20913264766656	3.697644652670751	264	7.46
23616570	Programmed death receptor-1/programmed death receptor ligand-1 blockade after transient lymphodepletion to treat myeloma.	Journal of immunology (Baltimore, Md. : 1950)	2013	-34.47054190997961	8.070701133733644	80	2.2
23587922	Potentiating functional antigen-specific CD8⁺ T cell immunity by a novel PD1 isoform-based fusion DNA vaccine.	Molecular therapy : the journal of the American Society of Gene Therapy	2013	-86.18883448524109	12.895940578356026	17	0.42
23567227	[Pigmentary disorders induced by anticancer agents. Part II: targeted therapies].	Annales de dermatologie et de venereologie	2013	72.3886611400359	-24.930648997181656	16	0.69
23555047	Lack of PD-L1 expression by iNKT cells improves the course of influenza A infection.	PloS one	2013	-76.91444179064123	6.822891780634286	18	0.48
23548749	PD-1 coinhibitory signals: the link between pathogenesis and protection.	Seminars in immunology	2013	-81.23873426435301	13.18411772922629	46	1.14
23545706	PD-1, but not PD-L1, expressed by islet-reactive CD4+ T cells suppresses infiltration of the pancreas during type 1 diabetes.	Diabetes	2013	-60.42954557592402	2.68075962450995	58	1.49
23522708	[What's new in oncology?].	Annales de dermatologie et de venereologie	2012	32.84385450447424	31.927563806910413	0	0.0
23536636	Restoring immune function of tumor-specific CD4+ T cells during recurrence of melanoma.	Journal of immunology (Baltimore, Md. : 1950)	2013	-27.7744780335566	2.008416285395532	144	3.58
23530125	PD-1 promotes immune exhaustion by inducing antiviral T cell motility paralysis.	The Journal of experimental medicine	2013	-74.893968716336	14.551433858228776	175	4.15
23524510	Blockade of the PD-1 pathway enhances the efficacy of adoptive cell therapy against cancer.	Oncoimmunology	2013	-41.98691159048248	-3.618372358078237	28	0.71
23521696	Increased expression of programmed death (PD)-1 and its ligand PD-L1 correlates with impaired cell-mediated immunity in high-risk human papillomavirus-related cervical intraepithelial neoplasia.	Immunology	2013	-0.8450086890692401	-11.803049150216706	145	4.48
23516361	Th2 cell-intrinsic hypo-responsiveness determines susceptibility to helminth infection.	PLoS pathogens	2013	-66.35759753705331	14.4858251487958	48	1.37
23511566	Exploiting CTLA-4, PD-1 and PD-L1 to reactivate the host immune response against cancer.	British journal of cancer	2013	22.232597354590837	5.452166202246688	111	2.89
23478000	Clinical impact of programmed cell death ligand 1 expression in colorectal cancer.	European journal of cancer (Oxford, England : 1990)	2013	-5.225737373834225	10.968209750873353	341	9.85
23475201	Inadequate T follicular cell help impairs B cell immunity during HIV infection.	Nature medicine	2013	-85.19529265700082	9.979081493177697	291	7.61
23462419	Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas.	International journal of radiation oncology, biology, physics	2013	-31.015968947552917	56.3512072727585	635	19.32
23460536	Use of oligonucleotide aptamer ligands to modulate the function of immune receptors.	Clinical cancer research : an official journal of the American Association for Cancer Research	2013	-24.94839600589513	-58.71773168062767	54	1.75
23460533	Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer.	Clinical cancer research : an official journal of the American Association for Cancer Research	2013	-38.91543306248899	-15.924611113502982	403	11.12
23460532	Biomarkers for immunostimulatory monoclonal antibodies in combination strategies for melanoma and other tumor types.	Clinical cancer research : an official journal of the American Association for Cancer Research	2013	30.93147708784407	2.827180168871245	118	3.08
23454765	Virus-induced hepatocellular carcinomas cause antigen-specific local tolerance.	The Journal of clinical investigation	2013	-76.0911490965544	26.583426873031552	38	0.94
23434518	Regulatory B cell frequency correlates with markers of HIV disease progression and attenuates anti-HIV CD8⁺ T cell function in vitro.	Journal of leukocyte biology	2013	-81.4899038150415	17.011845683021882	84	2.54
23428837	Dendritic and stromal cells from the spleen of lupic mice present phenotypic and functional abnormalities.	Molecular immunology	2013	-54.659844510693176	10.344205722944652	13	0.41
23419694	Tumor-specific T cells in human Merkel cell carcinomas: a possible role for Tregs and T-cell exhaustion in reducing T-cell responses.	The Journal of investigative dermatology	2013	43.19014494707811	51.97748195288849	76	2.3
23417675	Structure and interactions of the human programmed cell death 1 receptor.	The Journal of biological chemistry	2013	-48.008376339155255	-38.29687124276748	212	5.75
23411785	Batf3-dependent dendritic cells in the renal lymph node induce tolerance against circulating antigens.	Journal of the American Society of Nephrology : JASN	2013	-54.8243728926247	5.06297302619291	30	0.75
23409193	A potential new pathway for PD-L1 costimulation of the CD8-T cell response to Listeria monocytogenes infection.	PloS one	2013	-68.4397542253091	8.137124385160279	18	0.4
23398844	Increased PD-1 on CD4(+)CD28(-) T cell and soluble PD-1 ligand-1 in patients with T2DM: association with atherosclerotic macrovascular diseases.	Metabolism: clinical and experimental	2013	-59.07833004699695	8.658805888608223	59	1.73
23391724	SHP-1 phosphatase activity counteracts increased T cell receptor affinity.	The Journal of clinical investigation	2013	-47.21761258303627	-5.40325406655566	90	2.2
23383287	Increased level of myeloid-derived suppressor cells, programmed death receptor ligand 1/programmed death receptor 1, and soluble CD25 in Sokal high risk chronic myeloid leukemia.	PloS one	2013	-40.56528989178072	15.218456466440037	93	2.72
23381841	Sinomenine inhibits the expression of PD‑L1 in the peripheral blood mononuclear cells of mesangial proliferative nephritis patients.	Molecular medicine reports	2013	-51.41695809963305	9.914892080911295	11	0.46
23374153	Myeloid dendritic cells can kill T cells during chronic hepatitis C virus infection.	Viral immunology	2013	-78.09998933202485	23.96833405280059	11	0.31
23371260	[Personalized therapy concepts for malignant melanoma].	Der Internist	2013	32.27441817666614	30.69589152643908	2	0.1
23354626	Modulation of p38 MAPK signaling enhances dendritic cell activation of human CD4+ Th17 responses to ovarian tumor antigen.	Cancer immunology, immunotherapy : CII	2013	-26.77193450801408	-8.103890109739476	21	0.6
23337984	Adenovirus expressing both thymidine kinase and soluble PD1 enhances antitumor immunity by strengthening CD8 T-cell response.	Molecular therapy : the journal of the American Society of Gene Therapy	2013	-38.20652034158363	53.50364470749171	47	1.36
23328703	Immunohistochemical staining of B7-H1 (PD-L1) on paraffin-embedded slides of pancreatic adenocarcinoma tissue.	Journal of visualized experiments : JoVE	2013	-14.722474738693592	-0.532191476913185	40	1.05
23300177	The PD-1/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia.	Haematologica	2013	-40.431783755407466	20.57910704680896	161	4.41
23297127	High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells.	Blood	2013	-21.917598462516032	29.78755426764992	129	3.33
23288508	Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma.	Cancer research	2013	-2.681667350704574	-7.707582247643887	573	18.21
25095515	Immunoregulation and allogenicity in cardiac stem cell regenerative therapy.	Clinical transplants	2013	-57.2401232278262	22.183108761791956	0	0.0
24829751	Anti-PD-1 antibody significantly increases therapeutic efficacy of Listeria monocytogenes (Lm)-LLO immunotherapy.	Journal for immunotherapy of cancer	2013	-24.27923730427756	-19.17458208706893	50	1.37
23267208	PD-1 regulates the growth of human mastocytosis cells.	Allergology international : official journal of the Japanese Society of Allergology	2013	-30.1023544629907	14.851600291393533	18	0.56
23263823	Programmed death 1 pathway inhibition in metastatic renal cell cancer and prostate cancer.	Current oncology reports	2013	-37.16228745084101	-15.283650099493176	34	0.96
23255900	Synergistic effects of soluble PD-1 and IL-21 on antitumor immunity against H22 murine hepatocellular carcinoma.	Oncology letters	2013	-25.62499652131021	-17.51556182498383	22	0.63
23243584	Targeting PD-1/PD-L1 interactions for cancer immunotherapy.	Oncoimmunology	2012	29.063774516452774	1.3942611682147976	263	7.14
23242415	The receptor PD-1 controls follicular regulatory T cells in the lymph nodes and blood.	Nature immunology	2013	-57.48015844799346	-4.625605894085888	349	8.61
23230000	Programmed death 1 protects from fatal circulatory failure during systemic virus infection of mice.	The Journal of experimental medicine	2012	-75.12146099533017	12.050117680300106	140	3.04
23215674	New therapeutic options in systemic treatment of advanced cutaneous melanoma.	Expert opinion on investigational drugs	2013	32.13837013522572	30.07602018354618	9	0.29
23187291	Immune characteristics of different immune phases in natural course of chronic HBV infection.	Hepato-gastroenterology	2013	-72.47705697474997	24.1193466776408	9	0.3
23175469	Myeloid leukemia cells with a B7-2(+) subpopulation provoke Th-cell responses and become immuno-suppressive through the modulation of B7 ligands.	European journal of immunology	2013	-38.15974715833956	16.029993084930354	42	1.09
23170254	B7-H1 limits the entry of effector CD8(+) T cells to the memory pool by upregulating Bim.	Oncoimmunology	2012	-58.885936297381534	-10.669782145031691	34	0.78
23161479	The genetics of Behçet's disease in a Chinese population.	Frontiers of medicine	2012	-63.55232400677146	15.352026923282263	16	0.53
23135914	PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer.	Cancer research	2013	-2.863299906476019	-8.948610707494828	464	14.12
23114578	T cell coinhibition and immunotherapy in human breast cancer.	Discovery medicine	2012	-45.761750614501246	38.94201822337748	29	0.7
23098512	Reconstructed adeno-associated virus with the extracellular domain of murine PD-1 induces antitumor immunity.	Asian Pacific journal of cancer prevention : APJCP	2012	-50.22879307798322	-26.1438773547966	47	1.2
23090063	Cross-reactivity of anti-programmed death ligand 2 polyclonal antibody in mouse tissues.	Science China. Life sciences	2012	-52.46391913809616	-31.92750059350726	2	0.06
23087408	Molecular pathways: next-generation immunotherapy--inhibiting programmed death-ligand 1 and programmed death-1.	Clinical cancer research : an official journal of the American Association for Cancer Research	2012	-42.22227234386321	-19.97473493696857	439	11.53
23077245	Role of TLR2-dependent IL-10 production in the inhibition of the initial IFN-γ T cell response to Porphyromonas gingivalis.	Journal of leukocyte biology	2013	-82.20805334451732	9.241022569592255	45	1.62
23060883	Lymphatic endothelial cells - key players in regulation of tolerance and immunity.	Frontiers in immunology	2012	-71.80180256870722	-0.0623643049117399	58	1.48
23040891	Tubular cell HIV-entry through apoptosed CD4 T cells: a novel pathway.	Virology	2012	-55.25744908246797	6.204284157086804	13	0.39
23039892	Dysregulated immunophenotypic attributes of plasmacytoid but not myeloid dendritic cells in HIV-1 infected individuals in the absence of highly active anti-retroviral therapy.	Clinical and experimental immunology	2012	-83.63390000525679	12.325289718806514	17	0.44
23028899	Mesenchymal stem cells repress Th17 molecular program through the PD-1 pathway.	PloS one	2012	-54.542324980185874	22.232270756899485	137	4.16
23028594	Foxp3+ regulatory T cells among tuberculosis patients: impact on prognosis and restoration of antigen specific IFN-γ producing T cells.	PloS one	2012	-85.2518964166711	4.472520781307566	67	1.96
23005593	The characteristic expression of B7-H3 and B7-H4 in liver biopsies from patients with HBV-related acute-on-chronic liver failure.	Pathology international	2012	-70.41302487408949	25.32402061980354	8	0.25
22993390	Lymphatic endothelial cells induce tolerance via PD-L1 and lack of costimulation leading to high-level PD-1 expression on CD8 T cells.	Blood	2012	-71.75204494060723	-0.1504114189521769	194	4.76
22989568	Inhibition of inflammatory CD4 T cell activity by murine liver sinusoidal endothelial cells.	Journal of hepatology	2013	-70.42137490934607	19.905107188949376	76	2.17
22939904	In vitro-expanded CD4(+)CD25(high)Foxp3(+) regulatory T cells controls corneal allograft rejection.	Human immunology	2012	-68.33198321760185	1.961029972700882	26	0.98
22929808	Combined blockade of programmed death-1 and activation of CD137 increase responses of human liver T cells against HBV, but not HCV.	Gastroenterology	2012	-75.04716409913374	22.66389659736451	91	2.29
22906740	IgA plasma cells express the negative regulatory co-stimulatory molecule programmed cell death 1 ligand and have a potential tolerogenic role in the intestine.	Biochemical and biophysical research communications	2012	-62.26768476386631	19.246699626497676	13	0.32
22903385	Improving dendritic cell vaccine immunogenicity by silencing PD-1 ligands using siRNA-lipid nanoparticles combined with antigen mRNA electroporation.	Cancer immunology, immunotherapy : CII	2013	-54.28546632656463	-19.929423642357847	94	2.7
22900886	Role of the PD-1 pathway in the immune response.	American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons	2012	-61.60002375646351	-3.0973707858088737	294	7.7
22895698	Intrahepatic expression of programmed death-1 and its ligands in patients with HBV-related acute-on-chronic liver failure.	Inflammation	2013	-70.59039552545777	25.17836162661806	27	0.84
22894700	Longitudinal fluctuations in PD1 and PD-L1 expression in association with changes in anti-viral immune response in chronic hepatitis B.	BMC gastroenterology	2012	-71.36997977036944	23.746150413873146	26	0.71
22891289	Myeloid-derived suppressor cells from tumor-bearing mice impair TGF-β-induced differentiation of CD4+CD25+FoxP3+ Tregs from CD4+CD25-FoxP3- T cells.	Journal of leukocyte biology	2012	-50.65564840851728	27.06467354312987	64	1.69
22859605	Polyfunctional CD4⁺ T cells are essential for eradicating advanced B-cell lymphoma after chemotherapy.	Blood	2012	-27.89237343669492	1.4649649963409586	57	1.32
22850568	Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma.	Clinical cancer research : an official journal of the American Association for Cancer Research	2012	-13.145572178235476	-20.6015944558056	231	5.67
22837483	B7-DC-Ig enhances vaccine effect by a novel mechanism dependent on PD-1 expression level on T cell subsets.	Journal of immunology (Baltimore, Md. : 1950)	2012	-59.55087830822991	-11.017917216597612	42	1.0
22797302	Viral acute lower respiratory infections impair CD8+ T cells through PD-1.	The Journal of clinical investigation	2012	-76.2371763427426	8.496163921360703	128	3.15
22761734	PD-1 blockage reverses immune dysfunction and hepatitis B viral persistence in a mouse animal model.	PloS one	2012	-74.1001794844134	21.947182995914652	106	2.86
22752249	Synthetic small peptides acting on B7H1 enhance apoptosis in pancreatic cancer cells.	Molecular medicine reports	2012	-14.813368849529343	-0.7037296564426002	5	0.14
22705008	Successful vaccination induces multifunctional memory T-cell precursors associated with early control of hepatitis C virus.	Gastroenterology	2012	-77.01926036012736	21.07428776011715	53	1.35
22683854	Persistence of gene expression profile in CD200 transgenic skin allografts is associated with graft survival on retransplantation to normal recipients.	Transplantation	2012	-68.40709808813565	-4.590096890371136	8	0.21
22670772	Cytosine-phosphate-guanosine-DNA induces CD274 expression in human B cells and suppresses T helper type 2 cytokine production in pollen antigen-stimulated CD4-positive cells.	Clinical and experimental immunology	2012	-54.647113304299126	-8.755585992599215	17	0.5
22661084	B7-H1, which represses EBV-immortalized B cell killing by autologous T and NK cells, is oppositely regulated by c-Myc and EBV latency III program at both mRNA and secretory lysosome levels.	Journal of immunology (Baltimore, Md. : 1950)	2012	-70.04319243342167	17.14119732186684	28	0.68
22658128	Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.	The New England journal of medicine	2012	53.01269194273874	-8.106912318864335	5743	167.21
22658127	Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.	The New England journal of medicine	2012	53.04487773271659	-8.123778308402922	9060	267.01
22641383	Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2.	The Journal of experimental medicine	2012	-48.14427143645114	-6.605229989131382	719	17.51
22635166	Neuronal programmed cell death-1 ligand expression regulates retinal ganglion cell number in neonatal and adult mice.	Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society	2012	-68.51349396147009	-13.928371403291967	8	0.23
22634051	Suppression of furin by interferon-γ and the impact on hepatitis B virus antigen biosynthesis in human hepatocytes.	The American journal of pathology	2012	-71.07948397371018	21.718087844311547	17	0.57
22612856	Molecular characterization of immunoinhibitory factors PD-1/PD-L1 in chickens infected with Marek's disease virus.	Virology journal	2012	-57.28006503713848	-26.293591196367395	15	0.54
22611421	Programmed death ligand 2 in cancer-induced immune suppression.	Clinical & developmental immunology	2012	-49.60049802668955	-12.967611588465363	247	6.54
22588271	PD-1/PD-L1 blockade can enhance HIV-1 Gag-specific T cell immunity elicited by dendritic cell-directed lentiviral vaccines.	Molecular therapy : the journal of the American Society of Gene Therapy	2012	-84.77536403122136	13.472930658829975	27	0.65
22566929	The role of coinhibitory signaling pathways in transplantation and tolerance.	Frontiers in immunology	2012	-60.8110657987596	-4.252454979248326	52	1.38
22539813	PD-1-mediated attrition of polyfunctional memory CD8+ T cells in chronic toxoplasma infection.	The Journal of infectious diseases	2012	-73.7954324793828	5.191574173512492	50	1.36
22532845	Programmed death-1 and its ligand are novel immunotolerant molecules expressed on leukemic B cells in chronic lymphocytic leukemia.	PloS one	2012	-40.0695784867124	20.91832873640945	62	1.65
22524673	Immunomodulating antibodies in the treatment of metastatic melanoma: the experience with anti-CTLA-4, anti-CD137, and anti-PD1.	Journal of immunotoxicology	2012	30.18944750652852	3.9779952978509865	64	1.67
22503210	Tumor PD-L1 co-stimulates primary human CD8(+) cytotoxic T cells modified to express a PD1:CD28 chimeric receptor.	Molecular immunology	2012	-44.89994634218805	-1.605073767746395	132	3.03
22491251	PD-1 protects against inflammation and myocyte damage in T cell-mediated myocarditis.	Journal of immunology (Baltimore, Md. : 1950)	2012	-62.0523340126769	7.311141782040107	190	4.92
22474484	PD-L1-expressing dendritic cells contribute to viral resistance during acute HSV-1 infection.	Clinical & developmental immunology	2012	-75.68038210026548	10.565720103847893	17	0.53
22462616	Contribution of PD-L1 to oncogenesis of lymphoma and its RNAi-based targeting therapy.	Leukemia & lymphoma	2012	-44.71395381573919	-11.501139039055603	31	0.75
22441249	PD-1 and its ligand PD-L1 are progressively up-regulated on CD4 and CD8 T-cells in HIV-2 infection irrespective of the presence of viremia.	AIDS (London, England)	2012	-81.51758831361947	12.947951896300506	17	0.46
22427351	Cancer-induced immunosuppression: IL-18-elicited immunoablative NK cells.	Cancer research	2012	-25.6530525459597	7.821566459293825	84	2.04
22381170	Overexpression of programmed death ligand 1 in dendritic cells inhibits allogeneic lymphocyte activation in mice.	The Journal of surgical research	2012	-57.18418631549555	-7.189777031320688	5	0.11
22337949	Lack of full CD8 functional restoration after antiviral treatment for acute and chronic hepatitis C virus infection.	Gut	2012	-76.54755118339621	25.089159846791564	46	1.15
22322668	Immune suppression in premalignant respiratory papillomas: enriched functional CD4+Foxp3+ regulatory T cells and PD-1/PD-L1/L2 expression.	Clinical cancer research : an official journal of the American Association for Cancer Research	2012	-1.4925057168976186	-9.98053391392158	74	2.0
22319445	The CTLA-4 and PD-1/PD-L1 inhibitory pathways independently regulate host resistance to Plasmodium-induced acute immune pathology.	PLoS pathogens	2012	-75.49032467758482	2.30850898825929	95	2.54
22318430	PD-L1 co-stimulation, ligand-induced TCR down-modulation and anti-tumor immunotherapy.	Oncoimmunology	2012	-51.315418858723824	-6.388108585264838	32	0.75
22306905	PD-1 blockade augments Th1 and Th17 and suppresses Th2 responses in peripheral blood from patients with prostate and advanced melanoma cancer.	Journal of immunotherapy (Hagerstown, Md. : 1997)	2012	-29.778549819267248	-10.572634280036128	228	6.25
22300137	The PD-1/PD-L1 pathway in human pathology.	Current molecular medicine	2012	-53.2186663778437	-7.495754847332445	50	1.41
22271878	Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy.	Clinical cancer research : an official journal of the American Association for Cancer Research	2012	-36.363679526483615	23.907386544878182	509	14.01
22236695	Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity.	Current opinion in immunology	2012	-39.14651588077478	-16.51542163143181	969	26.34
22233255	Inhibition of viral replication downregulates CD4(+)CD25(high) regulatory T cells and programmed death-ligand 1 in chronic hepatitis B.	Viral immunology	2012	-73.77110397217152	24.91835684490203	24	0.65
22169317	[Research update on PD-1/PD-L1 pathway in hematological diseases].	Zhongguo shi yan xue ye xue za zhi	2011	-45.8179771730025	-9.363382854944968	1	0.02
22157630	Therapeutic blockade of PD-L1 and LAG-3 rapidly clears established blood-stage Plasmodium infection.	Nature immunology	2011	-75.0402466001798	2.672190427276175	365	8.68
22133510	Blockade of B7-H1 enhances dendritic cell-mediated T cell response and antiviral immunity in HBV transgenic mice.	Vaccine	2012	-60.327800360755006	-9.881970144078036	17	0.54
22122502	Ontogeny of the immune response in the ovine lung.	Immunological investigations	2012	-82.30867457937988	-3.559152370943474	11	0.43
22113316	siRNA-mediated silencing of PD-1 ligands enhances tumor-specific human T-cell effector functions.	Gene therapy	2012	-51.33866697909568	-21.375993775780387	43	1.09
22067141	Human brain endothelial cells endeavor to immunoregulate CD8 T cells via PD-1 ligand expression in multiple sclerosis.	Journal of neuroinflammation	2011	-75.42151579153011	-3.70273627889829	47	1.08
22046170	Improved Immunological Tolerance Following Combination Therapy with CTLA-4/Ig and AAV-Mediated PD-L1/2 Muscle Gene Transfer.	Frontiers in microbiology	2011	-47.85457709987395	3.72554705437989	17	0.4
22039410	Lack of an association of PD-1 and its ligand genes with Behcet's disease in a Chinese Han population.	PloS one	2011	-63.33284877263906	14.971902355124897	12	0.36
22023178	Therapeutic intervention in cancer and chronic viral infections: antibody mediated manipulation of PD-1/PD-L1 interaction.	Reviews on recent clinical trials	2012	-50.71050476707142	-5.319059724714959	31	0.76
22022563	The expression of PD-1 ligands and their involvement in regulation of T cell functions in acute and chronic woodchuck hepatitis virus infection.	PloS one	2011	-72.59908235373	19.994858473301253	31	0.82
21997806	Mechanisms of indirect acute lung injury: a novel role for the coinhibitory receptor, programmed death-1.	Annals of surgery	2012	-60.7696038726513	31.502782884847107	43	1.24
21960736	The PD-1/PD-L1 (B7-H1) pathway in chronic infection-induced cytotoxic T lymphocyte exhaustion.	Journal of biomedicine & biotechnology	2011	-75.41605655460205	16.088031115333283	101	2.37
21943148	Increase of cells expressing PD-L1 in bovine leukemia virus infection and enhancement of anti-viral immune responses in vitro via PD-L1 blockade.	Veterinary research	2011	-58.43679029593732	-26.581715077973183	57	1.68
21912640	Upregulation of circulating PD-L1/PD-1 is associated with poor post-cryoablation prognosis in patients with HBV-related hepatocellular carcinoma.	PloS one	2011	-23.48762852656824	40.83132726408468	134	3.31
21884581	A fiber-modified adenoviral vector interacts with immunoevasion molecules of the B7 family at the surface of murine leukemia cells derived from dormant tumors.	Molecular cancer	2011	-34.66145234111799	5.946522792206137	8	0.2
21876620	Immunostaining of PD-1/PD-Ls in liver tissues of patients with hepatitis and hepatocellular carcinoma.	World journal of gastroenterology	2011	-23.52775101924691	39.449238387779154	110	2.54
21856939	HIV-mediated phosphatidylinositol 3-kinase/serine-threonine kinase activation in APCs leads to programmed death-1 ligand upregulation and suppression of HIV-specific CD8 T cells.	Journal of immunology (Baltimore, Md. : 1950)	2011	-82.16299544702271	13.093542861029444	25	0.53
21851845	Programmed death-1 (PD-1)/PD-1 ligand pathway-mediated immune responses against human T-lymphotropic virus type 1 (HTLV-1) in HTLV-1-associated myelopathy/tropical spastic paraparesis and carriers with autoimmune disorders.	Human immunology	2011	-67.62044016302168	18.51486052266907	25	0.61
21824094	PD-1 signaling in HIV and chronic viral infection--potential for therapeutic intervention?	Current medicinal chemistry	2011	-81.83458855293433	12.468828427044972	14	0.35
21823008	Relatively increased number of liver Foxp(3+) regulatory T cells against hepatic lesions in murine lupus.	Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban	2011	-65.80795950430131	4.581097661158427	4	0.1
21792877	PD-L1 blockade overrides Salmonella typhimurium-mediated diabetes prevention in NOD mice: no role for Tregs.	European journal of immunology	2011	-61.91608778697511	3.744117384293398	11	0.28
21791547	Effects of genetic polymorphisms of programmed cell death 1 and its ligands on the development of ankylosing spondylitis.	Rheumatology (Oxford, England)	2011	-63.42140770759394	14.565646489575348	30	0.74
21763239	Inhibitory molecules that regulate expansion and restoration of HCV-specific CD4+ T cells in patients with chronic infection.	Gastroenterology	2011	-75.77296225276156	23.845111038126305	61	1.39
21752471	PD-L2 is expressed on activated human T cells and regulates their function.	Molecular immunology	2011	-55.058848173201554	-6.906090623549376	87	1.88
21742975	4-1BB signaling synergizes with programmed death ligand 1 blockade to augment CD8 T cell responses during chronic viral infection.	Journal of immunology (Baltimore, Md. : 1950)	2011	-74.35437405289464	13.393844431090988	75	1.53
21739608	PD-L1 co-stimulation contributes to ligand-induced T cell receptor down-modulation on CD8+ T cells.	EMBO molecular medicine	2011	-56.56835935312454	-6.7373557665269725	186	4.21
21733718	Development of a sandwich ELISA for evaluating soluble PD-L1 (CD274) in human sera of different ages as well as supernatants of PD-L1+ cell lines.	Cytokine	2011	-45.65333758942534	19.02831470118664	186	4.41
21719113	T-regulatory cells infected with feline immunodeficiency virus up-regulate programmed death-1 (PD-1).	Veterinary immunology and immunopathology	2011	-79.63563449504984	10.49647742051338	12	0.34
21717461	PD-1 expression on Melan-A-reactive T cells increases during progression to metastatic disease.	International journal of cancer	2012	5.980530627217376	-2.2691633963521967	29	0.76
21717068	T-cell-mediated tumor immune surveillance and expression of B7 co-inhibitory molecules in cancers of the upper gastrointestinal tract.	Immunologic research	2011	-11.651683449676735	28.65774172197847	59	1.4
21659460	PD-1/PD-L1 interactions contribute to functional T-cell impairment in patients who relapse with cancer after allogeneic stem cell transplantation.	Cancer research	2011	-64.19359568323983	-6.718516177251987	123	2.83
21652684	Responsiveness of HIV-specific CD4 T cells to PD-1 blockade.	Blood	2011	-82.12054218310429	14.763187030149062	126	2.77
21651862	[Cloning and expression of human sPD-1-Fc in Cos-7 cells].	Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology	2011	-45.28327814213901	18.21118048121881	1	0.02
21645420	Characteristics and PD-1 expression of peripheral CD4+CD127loCD25hiFoxP3+ Treg cells in chronic HCV infected-patients.	Virology journal	2011	-74.78875477011233	19.55638967004928	31	0.75
21615390	Modulation of CD4⁺ T cell responses following splenectomy in hepatitis C virus-related liver cirrhosis.	Clinical and experimental immunology	2011	-78.10079811430498	26.318611962545862	33	0.9
21589883	T cells from Programmed Death-1 deficient mice respond poorly to Mycobacterium tuberculosis infection.	PloS one	2011	-83.92802774494582	2.1732330243328826	64	1.55
21577144	PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion vaccine.	Journal of immunotherapy (Hagerstown, Md. : 1997)	2011	-28.390696637580824	-13.191568359788116	233	5.72
21574973	Altered expression of costimulatory molecules in Behçet's disease according to clinical activity.	The British journal of dermatology	2011	-72.01159935756453	-3.640990087818389	13	0.39
21540239	Programmed death ligand 1 is expressed by non-hodgkin lymphomas and inhibits the activity of tumor-associated T cells.	Clinical cancer research : an official journal of the American Association for Cancer Research	2011	-35.446528178809984	23.392618409069264	267	6.28
21538347	Combination of lentivector immunization and low-dose chemotherapy or PD-1/PD-L1 blocking primes self-reactive T cells and induces anti-tumor immunity.	European journal of immunology	2011	-38.03520426043772	-0.5200602048803151	61	1.38
21536144	Immunosuppressive effects of multiple myeloma are overcome by PD-L1 blockade.	Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation	2011	-34.610252734455905	8.113380961425813	131	3.08
21518556	Programmed death 1 mRNA in peripheral blood as biomarker of acute renal allograft rejection.	Chinese medical journal	2011	-57.58714096830344	44.91535321874827	7	0.18
21514692	A potential role for the PD1/PD-L1 pathway in the neuroinflammation of Alzheimer's disease.	Neurobiology of aging	2012	-77.53701952830858	-4.689296818896947	30	0.8
21509782	Programmed death ligand 1 is over-expressed by neutrophils in the blood of patients with active tuberculosis.	European journal of immunology	2011	-84.12901144231802	1.4922833288602475	86	2.15
21481848	Bim-mediated apoptosis and PD-1/PD-L1 pathway impair reactivity of PD1(+)/CD127(-) HCV-specific CD8(+) cells targeting the virus in chronic hepatitis C virus infection.	Cellular immunology	2011	-76.84310351068599	23.996053209369293	32	0.71
21457347	The high expression level of programmed death-1 ligand 2 in oral lichen planus and the possible costimulatory effect on human T cells.	Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology	2011	-63.15920153043166	-16.897902196440725	14	0.38
21442435	Enhanced programmed death 1 (PD-1) and PD-1 ligand (PD-L1) expression in patients with actinic cheilitis and oral squamous cell carcinoma.	Cancer immunology, immunotherapy : CII	2011	-8.424357555265875	-12.635656652440057	56	1.53
21435468	A novel function for programmed death ligand-1 regulation of angiogenesis.	The American journal of pathology	2011	-67.28044538777615	-14.28853002273934	44	1.15
21422469	LAG-3, TGF-β, and cell-intrinsic PD-1 inhibitory pathways contribute to CD8 but not CD4 T-cell tolerance induced by allogeneic BMT with anti-CD40L.	Blood	2011	-59.94140186749194	-2.262778170685693	35	0.77
21419713	Expansion of interferon-gamma-producing multifunctional CD4+ T-cells and dysfunctional CD8+ T-cells by glypican-3 peptide library in hepatocellular carcinoma patients.	Clinical immunology (Orlando, Fla.)	2011	-43.24433669467564	8.185007210734653	17	0.39
21418617	Programmed death-1 levels correlate with increased mortality, nosocomial infection and immune dysfunctions in septic shock patients.	Critical care (London, England)	2011	-58.10874696604489	34.45272872939462	221	5.99
21408177	Early T cell signalling is reversibly altered in PD-1+ T lymphocytes infiltrating human tumors.	PloS one	2011	-44.60182579070987	-4.855156221479127	70	1.48
21393583	Impairment of the programmed cell death-1 pathway increases atherosclerotic lesion development and inflammation.	Arteriosclerosis, thrombosis, and vascular biology	2011	-59.22546332637415	8.793161813556155	160	3.64
21389868	Enhancement of vaccine-induced primary and memory CD8(+) T-cell responses by soluble PD-1.	Journal of immunotherapy (Hagerstown, Md. : 1997)	2011	-27.675004116932744	-10.91329943640433	84	2.1
21360758	The majority of infiltrating CD8 T lymphocytes in multiple sclerosis lesions is insensitive to enhanced PD-L1 levels on CNS cells.	Glia	2011	-75.43768929930508	-3.882212555010035	38	0.85
21357717	Regulation of Trypanosoma cruzi-induced myocarditis by programmed death cell receptor 1.	Infection and immunity	2011	-68.81021906135385	10.98493985126541	38	0.99
21349174	Upregulation of programmed death-1 on T cells and programmed death ligand-1 on monocytes in septic shock patients.	Critical care (London, England)	2011	-58.57626687891212	34.47424805076553	167	4.58
21346771	Progressive upregulation of PD-1 in primary and metastatic melanomas associated with blunted TCR signaling in infiltrating T lymphocytes.	The Journal of investigative dermatology	2011	-27.45481272430021	0.0340581803651454	68	1.5
21307196	The role of LAT in increased CD8+ T cell exhaustion in trigeminal ganglia of mice latently infected with herpes simplex virus 1.	Journal of virology	2011	-73.96691784220803	9.937924591414788	94	2.49
21303364	Programmed death ligand 2 regulates arginase induction and modifies Trypanosoma cruzi survival in macrophages during murine experimental infection.	Immunology	2011	-68.71087761905726	10.977713906799693	28	0.71
21276005	The role of the PD-1 pathway in autoimmunity and peripheral tolerance.	Annals of the New York Academy of Sciences	2011	-57.32357350608387	-0.6291247387314416	241	5.78
21269571	Association of polymorphisms in the programmed cell death 1 (PD-1) and PD-1 ligand genes with ankylosing spondylitis in a Chinese population.	Clinical and experimental rheumatology	2011	-63.436902894848345	14.645116025404182	24	0.65
21268005	Expression and function of PD-1 in human γδ T cells that recognize phosphoantigens.	European journal of immunology	2011	-51.75589272937477	-3.297635169769204	112	2.57
21240487	Targeting NKT cells and PD-L1 pathway results in augmented anti-tumor responses in a melanoma model.	Cancer immunology, immunotherapy : CII	2011	-68.90100954255216	-9.516525671473916	33	0.76
21203985	A dimeric structure of PD-L1: functional units or evolutionary relics?	Protein & cell	2010	-46.96824576645346	-37.74735689245956	58	1.24
21172867	CD4 T cells promote rather than control tuberculosis in the absence of PD-1-mediated inhibition.	Journal of immunology (Baltimore, Md. : 1950)	2011	-83.91971158417918	2.331642771626369	221	5.26
21154120	Anti-GITR antibodies--potential clinical applications for tumor immunotherapy.	Current opinion in investigational drugs (London, England : 2000)	2010	-17.476648494215834	-51.624897722284686	30	0.57
21154117	Clinical development of mAbs to block the PD1 pathway as an immunotherapy for cancer.	Current opinion in investigational drugs (London, England : 2000)	2010	-39.688302527218816	-18.585692161365625	57	1.2
21120686	Hepatitis B e-antigen persistency is associated with the properties of HBV-specific CD8 T cells in CHB patients.	Journal of clinical immunology	2011	-74.52397197840469	24.602060598625965	28	0.72
21118528	PD-L1 blockade improves survival in experimental sepsis by inhibiting lymphocyte apoptosis and reversing monocyte dysfunction.	Critical care (London, England)	2010	-59.63520366698528	35.47404314552083	212	5.07
21116786	Forced expression of programmed death-1 gene on T cell decreased the incidence of type 1 diabetes.	Archives of pharmacal research	2010	-60.27382540486082	3.087447630834345	12	0.29
21110433	[Research of PD-1 expression in CD8+ T cell of peripheral blood with HBV-associated acute-on-chronic liver failure].	Zhonghua shi yan he lin chuang bing du xue za zhi = Zhonghua shiyan he linchuang bingduxue zazhi = Chinese journal of experimental and clinical virology	2010	-70.88257532781945	25.53967246605387	4	0.1
21097698	Expression of PD-L1 and PD-L2 on human macrophages is up-regulated by HIV-1 and differentially modulated by IL-10.	Journal of leukocyte biology	2011	-82.55512734900917	10.695647212846652	86	2.09
21079547	Urinary cell levels of mRNA for OX40, OX40L, PD-1, PD-L1, or PD-L2 and acute rejection of human renal allografts.	Transplantation	2010	-57.58068661629722	44.92599735595513	47	1.21
21074066	Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies.	Seminars in oncology	2010	-39.80320690596088	-20.279633649749627	229	4.89
21063028	PD-L1 blockade effectively restores strong graft-versus-leukemia effects without graft-versus-host disease after delayed adoptive transfer of T-cell receptor gene-engineered allogeneic CD8+ T cells.	Blood	2011	-64.97432939656278	-6.954551671825601	65	1.44
21061440	B7-H1 expression on non-B and non-T cells promotes distinct effects on T- and B-cell responses in autoimmune arthritis.	European journal of immunology	2010	-60.1704475516682	-11.416385430470624	59	1.13
21061197	Role of PD-1 in regulating T-cell immunity.	Current topics in microbiology and immunology	2011	-50.94363339365096	-12.37971033954081	227	5.47
21059890	Increased B7-H1 expression on dendritic cells correlates with programmed death 1 expression on T cells in simian immunodeficiency virus-infected macaques and may contribute to T cell dysfunction and disease progression.	Journal of immunology (Baltimore, Md. : 1950)	2010	-83.529641243397	12.389444141785312	38	0.8
21047981	PD-1-PD-L1 pathway impairs T(h)1 immune response in the late stage of infection with Mycobacterium bovis bacillus Calmette-Guérin.	International immunology	2010	-83.94288696978504	2.901554619747992	41	0.87
21042726	Slumbering mucosal immune response in the cervix of human papillomavirus DNA-positive and -negative women.	International journal of oncology	2010	-1.50162766546582	-10.848395158917585	10	0.23
21041733	Blockade of programmed death-1 in young (New Zealand black x New Zealand white)F1 mice promotes the activity of suppressive CD8+ T cells that protect from lupus-like disease.	Journal of immunology (Baltimore, Md. : 1950)	2010	-54.23579177813477	8.601623441712578	29	0.64
20978352	Nonhematopoietic antigen blocks memory programming of alloreactive CD8+ T cells and drives their eventual exhaustion in mouse models of bone marrow transplantation.	The Journal of clinical investigation	2010	-67.25791992301278	-4.983536600394545	43	0.83
20971039	T cell coinhibition in prostate cancer: new immune evasion pathways and emerging therapeutics.	Trends in molecular medicine	2011	-45.76457695212986	38.95454135390451	36	0.79
20937224	Cisplatin induces programmed death-1-ligand 1(PD-L1) over-expression in hepatoma H22 cells via Erk /MAPK signaling pathway.	Cellular and molecular biology (Noisy-le-Grand, France)	2010	-3.1579885742854974	-28.364360834621998	57	1.32
20948441	Selection of CD8+PD-1+ lymphocytes in fresh human melanomas enriches for tumor-reactive T cells.	Journal of immunotherapy (Hagerstown, Md. : 1997)	2010	-27.49125632224403	0.1993169074708391	148	2.84
20943073	[Programmed death-1 (PD-1) and PD-L1 expression during antiviral treatment of chronic hepatitis B].	Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology	2010	-73.51298023369434	24.32371293931562	4	0.1
20924130	Simultaneous blockade of multiple immune system inhibitory checkpoints enhances antitumor activity mediated by interleukin-15 in a murine metastatic colon carcinoma model.	Clinical cancer research : an official journal of the American Association for Cancer Research	2010	25.000628128299997	19.524338912336844	153	3.18
20886079	Programmed Death-1 expression on Epstein Barr virus specific CD8+ T cells varies by stage of infection, epitope specificity, and T-cell receptor usage.	PloS one	2010	-38.42198800198684	8.924304048111715	27	0.61
20819923	Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients.	The Journal of experimental medicine	2010	-39.65596210553869	-2.3982749866737514	938	20.56
20802088	Essential role of B7-H1 in double-stranded RNA-induced augmentation of an asthma phenotype in mice.	American journal of respiratory cell and molecular biology	2011	-61.76227969782988	-10.14716766268028	10	0.26
20722638	Role of PD-L1 and PD-L2 in allergic diseases and asthma.	Allergy	2011	-65.18862842629473	-10.63359490264805	87	2.23
20718345	[Analyze the bioactivity of PD-1 and PD-L1 recombination protein which expressed by prokaryotic system].	Zhonghua shi yan he lin chuang bing du xue za zhi = Zhonghua shiyan he linchuang bingduxue zazhi = Chinese journal of experimental and clinical virology	2009	-51.312871297317415	-29.13763151559422	0	0.0
20713771	Increased programmed death-1 expression on CD4+ T cells in cutaneous T-cell lymphoma: implications for immune suppression.	Archives of dermatology	2010	-32.38194630936264	15.867164013758016	98	2.49
20693841	Immune regulatory antibodies: are they the next advance?	Cancer journal (Sudbury, Mass.)	2010	26.848980876505934	4.998210683991221	20	0.44
20661763	Intrahepatic levels of PD-1/PD-L correlate with liver inflammation in chronic hepatitis B.	Inflammation research : official journal of the European Histamine Research Society ... [et al.]	2011	-71.09862737277851	23.77799416974312	45	1.11
20653631	Partial restoration of T-cell function in aged mice by in vitro blockade of the PD-1/ PD-L1 pathway.	Aging cell	2010	-53.93480255359477	1.5673853040459569	84	1.63
20646001	Increased programmed death-ligand-1 expression in human gastric epithelial cells in Helicobacter pylori infection.	Clinical and experimental immunology	2010	-11.810513115382308	3.496186890248889	59	1.33
20636820	The PD-1 pathway in tolerance and autoimmunity.	Immunological reviews	2010	-56.982430448301976	-0.413673053557099	1541	35.99
20628145	Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.	Blood	2010	-30.55047409629491	27.35462990235112	920	20.39
20625513	Dendritic cells in chronic mycobacterial granulomas restrict local anti-bacterial T cell response in a murine model.	PloS one	2010	-83.91266841704724	4.366953075570098	39	0.83
20617899	Role played by the programmed death-1-programmed death ligand pathway during innate immunity against Mycobacterium tuberculosis.	The Journal of infectious diseases	2010	-84.00260936863296	0.9945225512995456	99	2.1
20587542	PD-L1 and PD-L2 differ in their molecular mechanisms of interaction with PD-1.	International immunology	2010	-48.470776863067535	-37.93959773366875	163	3.58
20570856	Program death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemia.	Blood	2010	-40.2588349695713	13.59560026238496	218	4.5
20551512	PD-L1 has distinct functions in hematopoietic and nonhematopoietic cells in regulating T cell responses during chronic infection in mice.	The Journal of clinical investigation	2010	-75.48970985545442	12.41470332299454	113	2.16
20534854	CD4 T-cell help programs a change in CD8 T-cell function enabling effective long-term control of murine gammaherpesvirus 68: role of PD-1-PD-L1 interactions.	Journal of virology	2010	-75.55746943435862	13.860272206477529	16	0.35
20530875	Alloantigen expression on non-hematopoietic cells reduces graft-versus-leukemia effects in mice.	The Journal of clinical investigation	2010	-66.36745270710755	-6.233989125638677	71	1.42
20514052	Programmed death-1 upregulation is correlated with dysfunction of tumor-infiltrating CD8+ T lymphocytes in human non-small cell lung cancer.	Cellular & molecular immunology	2010	5.018653387710825	-22.276890437203747	202	4.18
20487259	PD-1/PD-L1 pathway and T-cell exhaustion in chronic hepatitis virus infection.	Journal of viral hepatitis	2010	-75.30621453781941	16.624753532002437	77	1.6
20484136	Deficiency in B7-H1 (PD-L1)/PD-1 coinhibition triggers pancreatic beta-cell destruction by insulin-specific, murine CD8 T-cells.	Diabetes	2010	-62.56982359475638	1.9817794079063715	35	0.75
20480224	CD4+ T cells inhibit the neu-specific CD8+ T-cell exhaustion during the priming phase of immune responses against breast cancer.	Breast cancer research and treatment	2011	-46.53915773903398	9.097257773270105	16	0.32
20473887	PD-1 and PD-L1 upregulation promotes CD8(+) T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients.	International journal of cancer	2011	-24.943432399815613	41.214504631806825	338	8.32
20463584	Immune exhaustion occurs concomitantly with immune activation and decrease in regulatory T cells in viremic chronically HIV-1-infected patients.	Journal of acquired immune deficiency syndromes (1999)	2010	-79.79112850686501	13.347501133137383	62	1.47
20460501	The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody.	Blood	2010	-32.849764713649954	4.228855296105243	626	14.02
20453843	PD-1 regulates germinal center B cell survival and the formation and affinity of long-lived plasma cells.	Nature immunology	2010	-56.88377835298004	-4.380592279584361	520	10.42
20445553	PD-1 on immature and PD-1 ligands on migratory human Langerhans cells regulate antigen-presenting cell activity.	The Journal of investigative dermatology	2010	-59.17359312102033	-16.68002069378049	25	0.49
20445343	Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy.	Journal of immunotherapy (Hagerstown, Md. : 1997)	2010	5.5876204429055525	-7.243730406908159	147	3.04
20443708	Generation and characterization of four novel monoclonal antibodies against human programmed death-1 molecule.	Hybridoma (2005)	2010	-48.17650105264059	-29.836977212841788	7	0.16
20433954	PD-1, gender, and autoimmunity.	Autoimmunity reviews	2010	-50.88632697038833	-14.952927027718555	69	1.63
20393451	Renal tubular PD-L1 (CD274) suppresses alloreactive human T-cell responses.	Kidney international	2010	-54.856605618003954	5.750310086026179	57	1.3
20381020	Overexpression of programmed death-1 ligand-1 on NIT cells lead to negative regulation of allogeneic lymphocyte activation.	Cellular immunology	2010	-59.84867557359144	2.0587636760054484	2	0.04
20363965	Keratinocyte-associated B7-H1 directly regulates cutaneous effector CD8+ T cell responses.	Journal of immunology (Baltimore, Md. : 1950)	2010	-62.07643788798898	-15.188389307007895	35	0.82
20349059	RNA interference targeting programmed death receptor-1 improves immune functions of tumor-specific T cells.	Cancer immunology, immunotherapy : CII	2010	-51.4004754515084	-21.144186575659745	37	0.75
20230680	[Expression of human PD-1Deltaex3 and primary study of its biological activity].	Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology	2010	-51.53105725338868	-28.232145365953237	2	0.06
20218851	Making antigen invisible: a coinhibitory molecule regulates the interaction between T cells and dendritic cells.	Expert review of vaccines	2010	-56.713662926887054	-2.3489013784706705	2	0.05
20208540	Programmed death-1-induced interleukin-10 production by monocytes impairs CD4+ T cell activation during HIV infection.	Nature medicine	2010	-82.25288915674625	10.798631620418949	339	7.63
20194714	Blockade of programmed death ligand 1 enhances the therapeutic efficacy of combination immunotherapy against melanoma.	Journal of immunology (Baltimore, Md. : 1950)	2010	-29.539509256328227	-16.121066700089568	110	2.23
20160101	PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors.	Proceedings of the National Academy of Sciences of the United States of America	2010	-27.80740722949431	-8.375777681418668	1317	29.21
20143437	Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma.	Cancer	2010	6.100191313939912	-2.0534230713381145	517	11.82
20139271	Anti-programmed cell death 1 antibody reduces CD4+PD-1+ T cells and relieves the lupus-like nephritis of NZB/W F1 mice.	Journal of immunology (Baltimore, Md. : 1950)	2010	-54.050965016541255	8.674316929046235	70	1.49
20128032	Natural course of chronic hepatitis B is characterized by changing patterns of programmed death type-1 of CD8-positive T cells.	World journal of gastroenterology	2010	-72.58388537406523	23.657067966634894	11	0.27
20113370	PD-1 signalling in CD4(+) T cells restrains their clonal expansion to an immunogenic stimulus, but is not critically required for peptide-induced tolerance.	Immunology	2010	-57.90800324007099	-2.252599915179602	25	0.49
20048044	Cryptococcus neoformans variants generated by phenotypic switching differ in virulence through effects on macrophage activation.	Infection and immunity	2010	-80.59105854367307	-0.3408110296819714	30	0.84
21473062	[Role of the PD-1/PD-L1 pathway in immunopathology of HBV infection as the chance on the new therapeutic strategy].	Przeglad epidemiologiczny	2010	-72.42940571472627	22.987760909719277	3	0.07
20004555	Pre-existing autoimmunity determines type 1 diabetes outcome after Flt3-ligand treatment.	Journal of autoimmunity	2010	-62.12719293150628	1.385244247348289	20	0.44
19959639	Suppression of bystander T helper 1 cells by iris pigment epithelium-inducing regulatory T cells via negative costimulatory signals.	Investigative ophthalmology & visual science	2010	-65.47828907832631	-13.825372282169164	14	0.34
19955307	Tissue-specific differences in PD-1 and PD-L1 expression during chronic viral infection: implications for CD8 T-cell exhaustion.	Journal of virology	2010	-75.91528026052292	14.572952439939744	98	2.04
19931186	Structure and function of programmed death (PD) molecules.	Veterinary immunology and immunopathology	2010	-51.81499041943308	-12.854741655743355	19	0.43
19931185	Feline programmed death and its ligand: characterization and changes with feline immunodeficiency virus infection.	Veterinary immunology and immunopathology	2010	-79.55663440316923	10.412492022498506	22	0.56
19900372	[Association of PD-1 expression on CD4+ CD25 nt/hi CD127 lo regulatory T cells with disease progression in HIV-1 infected patients].	Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology	2009	-80.29682749634199	12.8127832291553	1	0.02
19891011	Costimulatory molecule programmed death-1 in the cytotoxic response during chronic hepatitis C.	World journal of gastroenterology	2009	-76.93309471575573	23.469897440137306	16	0.34
19841178	Regulatory T cell (Treg) subsets return in patients with refractory lupus following stem cell transplantation, and TGF-beta-producing CD8+ Treg cells are associated with immunological remission of lupus.	Journal of immunology (Baltimore, Md. : 1950)	2009	-67.24862540755537	4.686549671653372	124	3.05
19828602	Enhanced PD-1 expression by T cells in cerebrospinal fluid does not reflect functional exhaustion during chronic human immunodeficiency virus type 1 infection.	Journal of virology	2010	-80.89464671023607	12.101230746340356	11	0.23
19825956	Tumor-expressed B7-H1 and B7-DC in relation to PD-1+ T-cell infiltration and survival of patients with cervical carcinoma.	Clinical cancer research : an official journal of the American Association for Cancer Research	2009	0.3415323096594359	-17.25331632937187	198	4.41
19811426	Intrahepatic PD-1/PD-L1 up-regulation closely correlates with inflammation and virus replication in patients with chronic HBV infection.	Immunological investigations	2009	-71.16857794007687	23.67061031502336	41	0.88
19800335	Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B.	Gastroenterology	2010	-74.2696982515054	22.620772357364448	364	8.27
19799003	[Express the recombinant protein PD-L1 in prokaryotic and analyze its biological activity].	Zhonghua shi yan he lin chuang bing du xue za zhi = Zhonghua shiyan he linchuang bingduxue zazhi = Chinese journal of experimental and clinical virology	2009	-51.259562913827125	-28.91100296682814	0	0.0
19794071	Costimulatory pathways in multiple sclerosis: distinctive expression of PD-1 and PD-L1 in patients with different patterns of disease.	Journal of immunology (Baltimore, Md. : 1950)	2009	-72.56520089136482	-4.05019238732553	71	1.51
19783989	Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal.	Nature immunology	2009	-58.91933115781645	0.0275594411065418	562	10.78
19781375	Expression of programmed death 1 and its ligands in the liver of autoimmune hepatitis C57BL/6 mice.	Chinese medical journal	2009	-68.49120563680601	23.92658610274998	7	0.14
19759858	Variable increased expression of program death-1 and program death-1 ligands on peripheral mononuclear cells is not impaired in patients with systemic lupus erythematosus.	Journal of biomedicine & biotechnology	2009	-52.90178015421078	11.21383476349045	20	0.46
19741598	PD-L1 and PD-L2 modulate airway inflammation and iNKT-cell-dependent airway hyperreactivity in opposing directions.	Mucosal immunology	2010	-65.3008135423459	-10.310156120764749	138	2.86
19726615	Cryopreservation decreases receptor PD-1 and ligand PD-L1 coinhibitory expression on peripheral blood mononuclear cell-derived T cells and monocytes.	Clinical and vaccine immunology : CVI	2009	-84.53320680417382	18.559649354947076	34	0.69
19717280	Immune tolerance: what is unique about the liver.	Journal of autoimmunity	2010	-67.11244414186262	29.124947514374764	255	5.77
19659774	Programmed death (PD)-1 molecule and its ligand PD-L1 distribution among memory CD4 and CD8 T cell subsets in human immunodeficiency virus-1-infected individuals.	Clinical and experimental immunology	2009	-82.30967154934731	13.908529012302685	37	0.77
19651643	PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+ CD25(Hi) regulatory T cells.	International immunology	2009	-29.048288702804264	-8.445926545870975	222	4.35
19635905	Neuron-interacting satellite glial cells in human trigeminal ganglia have an APC phenotype.	Journal of immunology (Baltimore, Md. : 1950)	2009	-77.45261432199986	-1.4925298393498847	62	1.57
19595077	[PD-1 up-regulation influenced apoptosis of HBV-specific CD8 T cells in patients with acute resolved hepatitis B].	Zhonghua yi xue za zhi	2009	-73.06981182339966	22.486727751492257	1	0.02
19562472	siRNA knockdown of PD-L1 and PD-L2 in monocyte-derived dendritic cells only modestly improves proliferative responses to Gag by CD8(+) T cells from HIV-1-infected individuals.	Journal of clinical immunology	2009	-84.7408004007127	13.074692968818486	22	0.43
19543053	Interaction of programmed death-1 and programmed death-1 ligand-1 contributes to testicular immune privilege.	Transplantation	2009	-65.7373967034225	-1.4753767192231748	44	1.01
19499529	B7-H1 and CD8+ Treg: the enigmatic role of B7-H1 in peripheral tolerance.	European journal of immunology	2009	-60.34522822351668	-10.401953655681623	10	0.21
19478458	Immunoregulatory mechanisms triggered by viral infections protect from type 1 diabetes in mice.	The Journal of clinical investigation	2009	-61.13220892451553	3.400898511927724	104	2.22
19426218	PD-1 signaling in primary T cells.	Immunological reviews	2009	-51.27284510146373	-7.611270997919555	546	10.98
19420358	Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T-cell exhaustion and disease progression.	Blood	2009	-40.97917462028092	14.066371848896912	208	4.08
19417208	PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model.	Blood	2009	-39.62256029484514	-6.793928657837716	301	5.81
19395451	Increased expression of soluble inducible costimulator ligand (ICOSL) in patients with systemic lupus erythematosus.	Lupus	2009	-54.8452491671104	12.24375728470122	37	0.83
19395117	Dynamic decrease in PD-1 expression correlates with HBV-specific memory CD8 T-cell development in acute self-limited hepatitis B patients.	Journal of hepatology	2009	-73.19721614239646	22.61958772961636	43	0.86
19394336	Profile of tumor antigen-specific CD8 T cells in patients with hepatitis B virus-related hepatocellular carcinoma.	Gastroenterology	2009	-75.95042972358353	26.81257589398768	132	2.56
19380770	PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients.	Journal of immunology (Baltimore, Md. : 1950)	2009	-39.644708884969454	-2.4324042991232915	126	2.4
19246340	Regulatory T cells differentially modulate the maturation and apoptosis of human CD8+ T-cell subsets.	Blood	2009	-68.59158512423983	3.8177791028439687	42	0.77
19234176	PD-1/PD-L blockade prevents anergy induction and enhances the anti-tumor activities of glycolipid-activated invariant NKT cells.	Journal of immunology (Baltimore, Md. : 1950)	2009	-68.88869966767174	-9.536363569321251	144	2.84
19229109	PD-L1 negatively regulates CD4+CD25+Foxp3+ Tregs by limiting STAT-5 phosphorylation in patients chronically infected with HCV.	The Journal of clinical investigation	2009	-74.74181790482648	19.61768030440837	240	4.69
19201863	Intestinal tolerance is converted to autoimmune enteritis upon PD-1 ligand blockade.	Journal of immunology (Baltimore, Md. : 1950)	2009	-60.53189567499785	0.3195894216510586	96	1.81
19182257	T-cell suppression by programmed cell death 1 ligand 1 on retinal pigment epithelium during inflammatory conditions.	Investigative ophthalmology & visual science	2009	-65.49629494323774	-13.887999548085372	65	1.61
19160960	[Up-expression of PD-1-PD-L induced by immunization with SEA and SMWA of Schistosoma japonicum in mice].	Zhongguo ji sheng chong xue yu ji sheng chong bing za zhi = Chinese journal of parasitology & parasitic diseases	2008	-67.72573575181144	14.259614796746966	0	0.0
19058313	Hepatoma cells up-regulate expression of programmed cell death-1 on T cells.	World journal of gastroenterology	2008	-30.953168803906905	1.4642818450518995	9	0.16
19056397	Contributions of PD-1/PD-L1 pathway to interactions of myeloid DCs with T cells in atherosclerosis.	Journal of molecular and cellular cardiology	2009	-59.09788078746664	9.181460688481549	60	1.21
19035251	[Expression of programmed death 1 and its ligands in iris-ciliary body from mice with anterior chamber-associated immune deviation].	[Zhonghua yan ke za zhi] Chinese journal of ophthalmology	2008	-67.64911673846244	-11.817770840616271	0	0.0
19028999	Regulatory T cells and the PD-L1/PD-1 pathway mediate immune suppression in malignant human brain tumors.	Neuro-oncology	2009	-27.82681587423464	46.9460688148385	176	3.78
19023118	Impaired negative regulation of homeostatically proliferating T cells.	Blood	2009	-44.05836578896017	-7.886310371710844	17	0.35
18981091	The common gamma-chain cytokines IL-2, IL-7, IL-15, and IL-21 induce the expression of programmed death-1 and its ligands.	Journal of immunology (Baltimore, Md. : 1950)	2008	-52.21399003418199	-4.74903707418003	378	7.27
18981087	Cutting edge: Programmed death-1/programmed death ligand 1 interaction regulates the induction and maintenance of invariant NKT cell anergy.	Journal of immunology (Baltimore, Md. : 1950)	2008	-68.88345225772574	-9.517639375282808	115	2.15
18925909	The programmed death (PD)-1/PD-ligand 1 pathway regulates graft-versus-host-reactive CD8 T cells after liver transplantation.	American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons	2008	-65.33233197518769	-4.520605515958822	17	0.37
18841514	Anti-tumor immunotherapy by blockade of the PD-1/PD-L1 pathway with recombinant human PD-1-IgV.	Cytotherapy	2008	-48.604285671999605	-26.113482353658835	14	0.28
18830259	PD-1/PD-L1 expression in human T-cell leukemia virus type 1 carriers and adult T-cell leukemia/lymphoma patients.	Leukemia	2009	-38.30463473514383	21.087311226844804	144	3.08
18825752	PD-1 ligands expressed on myeloid-derived APC in the CNS regulate T-cell responses in EAE.	European journal of immunology	2008	-73.16812221777616	-5.913088099877999	84	1.72
18813109	PD-L1/PD-1 signal deficiency promotes allogeneic immune responses and accelerates heart allograft rejection.	Transplantation	2008	-62.59713202443706	-3.0916881055705465	25	0.48
18799583	Human immunodeficiency virus type 1 Nef induces programmed death 1 expression through a p38 mitogen-activated protein kinase-dependent mechanism.	Journal of virology	2008	-82.35155227735555	12.730461042322602	64	1.24
18775867	Human corneal endothelial cells expressing programmed death-ligand 1 (PD-L1) suppress PD-1+ T helper 1 cells by a contact-dependent mechanism.	Investigative ophthalmology & visual science	2009	-65.79294386881081	-14.20041751661092	56	1.39
18768824	Cutting edge: programmed death-1 up-regulation is involved in the attrition of cytomegalovirus-specific CD8+ T cells in acute self-limited hepatitis B virus infection.	Journal of immunology (Baltimore, Md. : 1950)	2008	-73.1507272697969	22.100973601775262	23	0.51
18760278	PD-1 ligand expression by human colonic myofibroblasts/fibroblasts regulates CD4+ T-cell activity.	Gastroenterology	2008	-58.97916458929439	19.046801155025232	125	2.28
18759926	Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways.	Immunological reviews	2008	-55.95262101112733	-11.029765357221237	681	13.21
18641123	Crystal structure of the complex between programmed death-1 (PD-1) and its ligand PD-L2.	Proceedings of the National Academy of Sciences of the United States of America	2008	-46.50821617213076	-37.469768265340406	153	2.93
18585785	Interaction of human PD-L1 and B7-1.	Molecular immunology	2008	-54.701584201299084	-12.89269589064896	180	3.53
18577709	Peripheral deletional tolerance of alloreactive CD8 but not CD4 T cells is dependent on the PD-1/PD-L1 pathway.	Blood	2008	-59.83134370538749	-2.2667275514202223	58	1.05
18566376	Programmed death (PD)-1:PD-ligand 1/PD-ligand 2 pathway inhibits T cell effector functions during human tuberculosis.	Journal of immunology (Baltimore, Md. : 1950)	2008	-84.20837490930431	1.3946920753981713	196	4.08
18510628	PD-1 expression and IL-2 loss of cytomegalovirus- specific T cells correlates with viremia and reversible functional anergy.	American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons	2008	-80.65582704508306	20.856421895391332	128	2.96
18479731	Programmed death 1 is a marker of angioimmunoblastic T-cell lymphoma and B-cell small lymphocytic lymphoma/chronic lymphocytic leukemia.	Human pathology	2008	-34.29197574163565	23.52910090412792	139	3.01
18421793	B7-H1 restricts neuroantigen-specific T cell responses and confines inflammatory CNS damage: implications for the lesion pathogenesis of multiple sclerosis.	European journal of immunology	2008	-73.89177167504154	-4.100735063462621	61	1.2
18420489	Protective role of programmed death 1 ligand 1 (PD-L1)in nonobese diabetic mice: the paradox in transgenic models.	Diabetes	2008	-60.21350344177908	2.658024563534749	64	1.27
18322304	Association of an A/C single nucleotide polymorphism in programmed cell death-ligand 1 gene with Graves' disease in Japanese patients.	European journal of endocrinology	2008	-62.48135705542303	12.876775900009186	39	0.85
18318992	Fine-tuned expression of programmed death 1 ligands in mature dendritic cells stimulated by CD40 ligand is critical for the induction of an efficient tumor specific immune response.	Cellular & molecular immunology	2008	-57.94158588129992	-7.838953056223056	9	0.15
18296654	PD-L1: PD-1 interaction contributes to the functional suppression of T-cell responses to human uveal melanoma cells in vitro.	Investigative ophthalmology & visual science	2008	1.6591730229805537	0.4393588199928691	87	1.89
18287011	The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors.	Proceedings of the National Academy of Sciences of the United States of America	2008	-46.70865409988259	-37.41385715069425	302	5.96
18280607	Restoration of HCV-specific T cell functions by PD-1/PD-L1 blockade in HCV infection: effect of viremia levels and antiviral treatment.	Journal of hepatology	2008	-76.3141317631245	23.102736697632228	99	2.01
18268348	The PD-1/PD-L costimulatory pathway critically affects host resistance to the pathogenic fungus Histoplasma capsulatum.	Proceedings of the National Academy of Sciences of the United States of America	2008	-68.98985884442527	8.79207195106834	89	1.7
18266718	Soluble PD-1 rescues the proliferative response of simian immunodeficiency virus-specific CD4 and CD8 T cells during chronic infection.	Immunology	2008	-82.51447214657874	13.742777735381363	48	0.96
18253710	TLR-mediated induction of negative regulatory ligands on dendritic cells.	Journal of molecular medicine (Berlin, Germany)	2008	-58.86647227968989	-8.219373105930469	28	0.53
18250483	Up-regulation of programmed death-1 expression on beryllium-specific CD4+ T cells in chronic beryllium disease.	Journal of immunology (Baltimore, Md. : 1950)	2008	-48.88478609446551	17.254115505436328	37	0.92
18184859	Intrarenal antigens activate CD4+ cells via co-stimulatory signals from dendritic cells.	Journal of the American Society of Nephrology : JASN	2008	-54.7745806367251	5.32068427695451	27	0.5
18173375	PD-1 and its ligands in tolerance and immunity.	Annual review of immunology	2008	-51.13882794738512	-12.373263864916614	3712	79.02
18154618	Special regulatory T cell review: The resurgence of the concept of contrasuppression in immunoregulation.	Immunology	2008	-53.271837666340055	-1.9071503133210372	62	1.33
18067228	[PD-1 expression in peripheral T cells of patients with HBV infection and its significance].	Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences	2007	-71.64729466408139	23.91402944547953	0	0.0
18037500	Programmed Death-1: from gene to protein in autoimmune human myasthenia gravis.	Journal of neuroimmunology	2008	-56.6734457813623	2.294018311766608	22	0.47
17942371	CD8(+) T cells specific for both persistent and non-persistent viruses display distinct differentiation phenotypes but have similar level of PD-1 expression in healthy Chinese individuals.	Clinical immunology (Orlando, Fla.)	2008	-76.98445503480538	14.624547722823245	6	0.09
17938288	Endothelial programmed death-1 ligand 1 (PD-L1) regulates CD8+ T-cell mediated injury in the heart.	Circulation	2007	-62.12362979229996	7.506212680224277	188	3.55
17935823	Induction of immunosuppressive molecules and regulatory T cells counteracts the antitumor effect of interleukin-12-based gene therapy in a transgenic mouse model of liver cancer.	Journal of hepatology	2007	-31.793348852900653	45.258710367507575	61	1.21
17924994	Striking dichotomy of PD-L1 and PD-L2 pathways in regulating alloreactive CD4(+) and CD8(+) T cells in vivo.	American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons	2007	-54.98492698978912	-6.65108386665888	44	0.91
17920123	Chemopreventive agents induce programmed death-1-ligand 1 (PD-L1) surface expression in breast cancer cells and promote PD-L1-mediated T cell apoptosis.	Molecular immunology	2008	-34.34688714767816	-19.16059459970221	201	3.83
17911591	PD-1 regulates self-reactive CD8+ T cell responses to antigen in lymph nodes and tissues.	Journal of immunology (Baltimore, Md. : 1950)	2007	-60.3643914734457	0.6088715130571181	188	3.3
17899549	Programmed cell death 1 (PD-1) and its ligand PD-L1 are required for allograft tolerance.	European journal of immunology	2007	-61.75810592420414	-2.803084827324999	61	1.3
17868872	PD-1 upregulation is associated with HBV-specific T cell dysfunction in chronic hepatitis B patients.	Molecular immunology	2008	-73.14089665191914	22.995685913639324	177	3.61
17853943	Proatherogenic immune responses are regulated by the PD-1/PD-L pathway in mice.	The Journal of clinical investigation	2007	-59.30066471693074	8.879685798841509	156	2.93
17721918	Augmented expression of programmed death-1 in both neoplastic and non-neoplastic CD4+ T-cells in adult T-cell leukemia/lymphoma.	International journal of cancer	2007	-38.2858896006142	21.135328627902005	74	1.56
17643252	Artificial phosphatidylserine liposome mimics apoptotic cells in inhibiting maturation and immunostimulatory function of murine myeloid dendritic cells in response to 1-chloro-2,4-dinitrobenze in vitro.	Archives of dermatological research	2007	-33.60862651259764	-59.762097565776585	22	0.45
17629517	Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses.	Immunity	2007	-55.89668519719148	-11.199035263432732	1242	24.64
17610472	Intrahepatic expression of the co-stimulatory molecules programmed death-1, and its ligands in autoimmune liver disease.	Pathology international	2007	-68.48435106464413	23.730884570349247	48	0.99
17606980	PD-1 and PD-1 ligands: from discovery to clinical application.	International immunology	2007	-50.73029756835861	-12.408329963092855	896	17.67
17606978	Specific and high-affinity binding of tetramerized PD-L1 extracellular domain to PD-1-expressing cells: possible application to enhance T cell function.	International immunology	2007	-48.84104975387994	-26.82785488243265	11	0.25
17567698	Upregulation of PD-1 expression on circulating and intrahepatic hepatitis C virus-specific CD8+ T cells associated with reversible immune dysfunction.	Journal of virology	2007	-76.72239413292584	23.50802673185509	299	5.95
17507101	IFN-gamma and TNF-alpha differentially regulate immunomodulation by murine mesenchymal stem cells.	Immunology letters	2007	-55.47904114920565	22.63770763658897	317	7.58
17491706	Costimulation and pancreatic autoimmunity: the PD-1/PD-L conundrum.	The review of diabetic studies : RDS	2006	-53.68843792366552	-7.393295008015007	9	0.17
19372890	Programmed death 1: a critical regulator of T-cell function and a strong target for immunotherapies for chronic viral infections.	Current opinion in HIV and AIDS	2007	-51.16544434639693	-5.121161560581615	16	0.3
17434153	Roles of programmed death-1 (PD-1)/PD-1 ligands pathway in the development of murine acute myocarditis caused by coxsackievirus B3.	Cardiovascular research	2007	-62.3755551747084	7.7309207356143155	46	0.93
17433872	PD-1 and its ligands in T-cell immunity.	Current opinion in immunology	2007	-51.92379540872422	-11.473483033713949	328	6.44
17412283	Expression of programmed-death receptor ligands 1 and 2 may contribute to the poor stimulatory potential of murine immature dendritic cells.	Immunobiology	2007	-57.363779636446345	-7.686402652313749	24	0.47
17404099	Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer.	Clinical cancer research : an official journal of the American Association for Cancer Research	2007	-14.46151214796073	-2.016218663775532	700	14.16
17392506	Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cells.	Blood	2007	-58.683560552853855	-10.459795182399152	150	2.67
17366897	[Preparation and identification of human soluble sPD-L1 and its antibodies].	Sheng wu gong cheng xue bao = Chinese journal of biotechnology	2007	-45.44023530249261	19.311556613809078	2	0.04
17360651	Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer.	Proceedings of the National Academy of Sciences of the United States of America	2007	-20.08170800700408	12.59113661723754	1122	23.21
17326153	Dysfunction and functional restoration of HCV-specific CD8 responses in chronic hepatitis C virus infection.	Hepatology (Baltimore, Md.)	2007	-76.56351525705904	25.13876917456911	230	4.55
17325342	Soluble PD-1 facilitates 4-1BBL-triggered antitumor immunity against murine H22 hepatocarcinoma in vivo.	Clinical cancer research : an official journal of the American Association for Cancer Research	2007	-25.515706761016485	-17.54047855765437	56	1.12
17320975	The PD-1/PD-L pathway is up-regulated during IL-12-induced suppression of EAE mediated by IFN-gamma.	Journal of neuroimmunology	2007	-73.23458267804496	-6.284725926538343	47	0.85
17312113	PD-1:PD-L1 interactions contribute to the functional suppression of virus-specific CD8+ T lymphocytes in the liver.	Journal of immunology (Baltimore, Md. : 1950)	2007	-71.91418889303831	21.664104648337705	194	3.81
17311651	Expression of PD-1, PD-L1, and PD-L2 in the liver in autoimmune liver diseases.	The American journal of gastroenterology	2007	-68.49764476443661	23.797402309143795	62	1.28
17305475	Costimulation, coinhibition and cancer.	Current cancer drug targets	2007	-45.78142504000773	38.92530127699421	78	1.52
17304234	The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection.	Nature immunology	2007	-51.440617793894695	-12.717064353126464	1114	22.28
17287266	Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection.	Journal of virology	2007	-74.11457947843917	23.268685652651563	681	13.73
17272504	PD-1 up-regulation is correlated with HIV-specific memory CD8+ T-cell exhaustion in typical progressors but not in long-term nonprogressors.	Blood	2007	-81.0099704111832	13.672043900715948	239	4.57
17203303	PD-1 gene haplotype is associated with the development of type 1 diabetes mellitus in Japanese children.	Human genetics	2007	-62.36518330646359	14.459382829356576	60	1.23
17198268	Gene transfer of programmed death ligand-1.Ig prolongs cardiac allograft survival.	Transplantation	2006	-62.61037876869823	-3.5701053072272257	41	0.74
17195077	Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion.	Cancer immunology, immunotherapy : CII	2007	-49.56757788701702	-10.26205170612521	347	6.85
17182670	Liver-infiltrating lymphocytes in chronic human hepatitis C virus infection display an exhausted phenotype with high levels of PD-1 and low levels of CD127 expression.	Journal of virology	2007	-76.78529340198426	24.415582460987917	374	7.04
17182110	PD-1/PD-L1, but not PD-1/PD-L2, interactions regulate the severity of experimental autoimmune encephalomyelitis.	Journal of neuroimmunology	2007	-73.16412312278189	-6.45812852169822	144	2.65
17142723	Cutting Edge: Programmed death (PD) ligand-1/PD-1 interaction is required for CD8+ T cell tolerance to tissue antigens.	Journal of immunology (Baltimore, Md. : 1950)	2006	-60.1647113385737	0.650029823977424	108	1.81
17088657	Immunomodulation of allergic responses by targeting costimulatory molecules.	Current opinion in allergy and clinical immunology	2006	-60.50030606888549	-5.606491242598665	9	0.2
17003438	CD4+PD-1+ T cells acting as regulatory cells during the induction of anterior chamber-associated immune deviation.	Investigative ophthalmology & visual science	2006	-67.67316319922018	-11.775622995591828	36	0.72
17000870	Reinvigorating exhausted HIV-specific T cells via PD-1-PD-1 ligand blockade.	The Journal of experimental medicine	2006	-75.00455551734511	15.67889351823114	316	5.77
16921384	PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression.	Nature	2006	-81.46543763245953	13.645453612927785	2055	39.17
16917960	Contribution of the PD-1 ligands/PD-1 signaling pathway to dendritic cell-mediated CD4+ T cell activation.	European journal of immunology	2006	-56.99288007724213	-7.106575903432387	140	2.46
16917489	Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction.	Nature medicine	2006	-81.52735845508444	13.704741857259624	1173	22.17
16877411	Differential effects of costimulatory pathway modulation on corneal allograft survival.	Investigative ophthalmology & visual science	2006	-61.2426646406482	-4.496344525471333	46	0.93
16876901	PD-L1 is induced in hepatocytes by viral infection and by interferon-alpha and -gamma and mediates T cell apoptosis.	Journal of hepatology	2006	-69.60471553997158	22.683946255223372	289	5.32
16819321	Programmed death-1 (PD-1) is a marker of germinal center-associated T cells and angioimmunoblastic T-cell lymphoma.	The American journal of surgical pathology	2006	-34.07328061608686	23.33805668978539	266	5.0
16797416	The role of leukemia-derived B7-H1 (PD-L1) in tumor-T-cell interactions in humans.	Experimental hematology	2006	-34.52676596004157	6.05902649405014	43	0.79
16696901	Expression and purification of soluble human programmed death-1 in Escherichia coli.	Cellular & molecular immunology	2006	-50.45285579528251	-28.159938892109057	6	0.13
16650803	Reviving exhausted T lymphocytes during chronic virus infection by B7-H1 blockade.	Trends in molecular medicine	2006	-75.3995473303564	16.017131372100938	28	0.5
16613922	Involvement of programmed death-ligand 2 (PD-L2) in the development of experimental allergic conjunctivitis in mice.	The British journal of ophthalmology	2006	-66.79089847394492	-11.261896371599434	26	0.48
16606670	Tissue expression of PD-L1 mediates peripheral T cell tolerance.	The Journal of experimental medicine	2006	-59.55125308844542	2.2206275916393623	919	17.12
16584922	Waking up T cells to counteract chronic infections.	Trends in immunology	2006	-76.11288375569303	14.888200847757595	3	0.06
16517716	Differential role of programmed death-ligand 1 [corrected] and programmed death-ligand 2 [corrected] in regulating the susceptibility and chronic progression of experimental autoimmune encephalomyelitis.	Journal of immunology (Baltimore, Md. : 1950)	2006	-73.24701821406458	-6.109493928554378	99	1.78
16482562	Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro.	International journal of cancer	2006	-32.49044833399661	-11.35882687032546	251	4.68
16469690	Rejuvenating exhausted T cells during chronic viral infection.	Cell	2006	-75.49767413920297	15.286858714170483	30	0.52
16461745	High-level expression of B7-H1 molecules by dendritic cells suppresses the function of activated T cells and desensitizes allergen-primed animals.	Journal of leukocyte biology	2006	-60.176596411861766	-10.87910086388745	33	0.65
16455980	Mast cells enhance T cell activation: importance of mast cell costimulatory molecules and secreted TNF.	Journal of immunology (Baltimore, Md. : 1950)	2006	-60.410640213608005	-6.045933299149538	300	6.21
16386962	Delivering PD-1 inhibitory signal concomitant with blocking ICOS co-stimulation suppresses lupus-like syndrome in autoimmune BXSB mice.	Clinical immunology (Orlando, Fla.)	2006	-54.33369809785183	8.712265751178291	54	0.94
16382236	Restoring function in exhausted CD8 T cells during chronic viral infection.	Nature	2006	-75.53739334438478	14.379665632911696	2978	56.13
16301644	Programmed death-1 (PD-1):PD-ligand 1 interactions inhibit TCR-mediated positive selection of thymocytes.	Journal of immunology (Baltimore, Md. : 1950)	2005	-52.35679727960365	-6.235425222071743	108	1.73
16285013	Antibody-mediated signaling through PD-1 costimulates T cells and enhances CD28-dependent proliferation.	European journal of immunology	2005	-53.33886791120532	-8.292265244472187	24	0.39
16265694	Enhanced expression of programmed death-1 (PD-1)/PD-L1 in salivary glands of patients with Sjögren's syndrome.	The Journal of rheumatology	2005	-51.78988250430583	13.281516445855578	66	1.3
16165113	Time courses of B7 family molecules expressed on activated T-cells and their biological significance.	Cellular immunology	2005	-56.99904476029319	-11.13913589995449	24	0.41
16126211	Role of the programmed Death-1 pathway in the suppressive activity of alternatively activated macrophages in experimental cysticercosis.	International journal for parasitology	2005	-70.4961426086729	9.280358450032656	104	2.01
16034097	Blockade of B7-H1 on macrophages suppresses CD4+ T cell proliferation by augmenting IFN-gamma-induced nitric oxide production.	Journal of immunology (Baltimore, Md. : 1950)	2005	-60.83861334732461	-11.528607249558863	116	1.93
15973993	[Eukaryotic expression and functional characterization of PD-1 extracellular domain].	Sheng wu gong cheng xue bao = Chinese journal of biotechnology	2004	-50.52946494846211	-26.88536537967859	2	0.04
15919509	Various costimulatory pathways are essential for induction of regulatory cells by intratracheal delivery of alloantigen.	Transplantation proceedings	2005	-62.63707353383812	-1.687218790055081	7	0.12
15905503	Analysis of the role of negative T cell costimulatory pathways in CD4 and CD8 T cell-mediated alloimmune responses in vivo.	Journal of immunology (Baltimore, Md. : 1950)	2005	-60.87351472830412	-4.0909369169348295	133	2.3
15885642	PD-L1 is expressed by human renal tubular epithelial cells and suppresses T cell cytokine synthesis.	Clinical immunology (Orlando, Fla.)	2005	-54.79998068140423	5.968544266247993	73	1.33
15827960	Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway.	European journal of immunology	2005	-34.513002661925526	9.7936750947441	485	10.37
15781259	Expression of B7-H1 and B7-DC on the airway epithelium is enhanced by double-stranded RNA.	Biochemical and biophysical research communications	2005	-61.69969685383582	-10.181853938493717	34	0.58
15780196	Identification of a novel splice variant of human PD-L1 mRNA encoding an isoform-lacking Igv-like domain.	Acta pharmacologica Sinica	2005	-12.93811991242841	-4.26447868789128	52	0.89
15771580	The B7 family revisited.	Annual review of immunology	2005	-56.459558243990585	-11.068406233935285	1798	33.52
15749874	Role of the programmed death-1 pathway in regulation of alloimmune responses in vivo.	Journal of immunology (Baltimore, Md. : 1950)	2005	-61.32164038965868	-3.2300465848616704	155	2.74
15712495	[Immuno-histological and-cytological examinations on distribution of newly reported co-stimulatory molecules in germinal center of human tonsils].	Nihon Jibiinkoka Gakkai kaiho	2005	-55.31100882309982	-8.721352999106692	3	0.04
15611321	PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells.	International immunology	2005	-35.1069003638314	-9.871354462856146	325	5.33
15599732	Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy.	Cancer immunology, immunotherapy : CII	2005	-50.41126956562403	-10.979564428455998	416	7.47
15598424	PD-1 ligands, negative regulators for activation of naive, memory, and recently activated human CD4+ T cells.	Cellular immunology	2004	-54.75446547483235	-4.122231437734128	61	0.97
15588223	Negative regulation of T-cell function by PD-1.	Critical reviews in immunology	2004	-50.45082809898064	-11.029730943971648	69	1.25
15470033	Blocking programmed death-1 ligand-PD-1 interactions by local gene therapy results in enhancement of antitumor effect of secondary lymphoid tissue chemokine.	Journal of immunology (Baltimore, Md. : 1950)	2004	-50.555698273844335	-26.600298851551784	99	1.62
15374847	Blockade of the interaction between PD-1 and PD-L1 accelerates graft arterial disease in cardiac allografts.	Arteriosclerosis, thrombosis, and vascular biology	2004	-63.22526808948848	-2.702761937389284	77	1.37
15353579	Suppressed T-cell activation by IFN-gamma-induced expression of PD-L1 on renal tubular epithelial cells.	Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association	2004	-54.81247014509356	5.90631133791849	74	1.26
15297412	B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression.	Clinical cancer research : an official journal of the American Association for Cancer Research	2004	0.6034313903067503	-17.708950991265684	574	10.26
15275969	The expression of B7-H1 on keratinocytes in chronic inflammatory mucocutaneous disease and its regulatory role.	Immunology letters	2004	-62.1191618997586	-15.39834566437036	59	1.09
14970911	Refolding and characterization of recombinant human GST-PD-1 fusion protein expressed in Escherichia coli.	Acta biochimica et biophysica Sinica	2004	-50.61471671324097	-28.285361088705443	8	0.14
14764726	B7-DC regulates asthmatic response by an IFN-gamma-dependent mechanism.	Journal of immunology (Baltimore, Md. : 1950)	2004	-60.81830181433744	-11.040902095084954	125	2.04
14724428	Programmed death-1-programmed death-L1 interaction is essential for induction of regulatory cells by intratracheal delivery of alloantigen.	Transplantation	2004	-62.60109839920937	-1.7641656495718163	33	0.54
14662900	Blocking the monocyte chemoattractant protein-1/CCR2 chemokine pathway induces permanent survival of islet allografts through a programmed death-1 ligand-1-dependent mechanism.	Journal of immunology (Baltimore, Md. : 1950)	2003	-60.386233713180864	-3.860977621359746	90	1.71
14609213	CD4+CD25+ regulatory cells from human peripheral blood express very high levels of CD25 ex vivo.	Novartis Foundation symposium	2003	-68.84560474840742	4.211641525710284	57	0.95
14579280	Endothelial expression of PD-L1 and PD-L2 down-regulates CD8+ T cell activation and cytolysis.	European journal of immunology	2003	-62.24445870381428	-12.505928620885165	367	6.02
14534853	Emerging immunomodulatory therapies targeting the co-stimulatory pathways for the prevention of transplant rejection.	IDrugs : the investigational drugs journal	2003	-43.43303269515288	25.084149524749023	5	0.09
14530338	Blockade of B7-H1 suppresses the development of chronic intestinal inflammation.	Journal of immunology (Baltimore, Md. : 1950)	2003	-60.21475655506263	-12.344065606040695	145	2.41
14527172	Interaction of B7RP-1 with ICOS negatively regulates antigen presentation by B cells.	Inflammation	2003	-57.28724177192876	-9.886136582284609	2	0.05
14515261	Preferential contribution of B7-H1 to programmed death-1-mediated regulation of hapten-specific allergic inflammatory responses.	European journal of immunology	2003	-60.09977988297228	-11.06206063195888	107	1.6
14515254	Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses.	European journal of immunology	2003	-59.32132847605305	2.39494475378088	489	8.27
14508368	Stimulating PD-1-negative signals concurrent with blocking CD154 co-stimulation induces long-term islet allograft survival.	Transplantation	2003	-60.610726009556906	-3.9637797067587504	130	2.22
12893276	Differential binding properties of B7-H1 and B7-DC to programmed death-1.	Biochemical and biophysical research communications	2003	-59.13974337242141	-11.503589976538516	158	2.67
12847138	Critical role of the programmed death-1 (PD-1) pathway in regulation of experimental autoimmune encephalomyelitis.	The Journal of experimental medicine	2003	-73.47041327913239	-5.902492370433524	395	6.64
12847137	The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice.	The Journal of experimental medicine	2003	-60.37993080826399	2.7382728746974383	607	10.23
12847136	PD-1 inhibits antiviral immunity at the effector phase in the liver.	The Journal of experimental medicine	2003	-69.30186558698715	22.38090204892287	318	5.21
12697896	PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells.	Proceedings of the National Academy of Sciences of the United States of America	2003	-82.57057074362207	10.258535156530511	476	7.88
12538684	Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production.	Journal of immunology (Baltimore, Md. : 1950)	2003	-57.0329942567562	-7.485293832433934	744	12.68
12517932	Program death-1 engagement upon TCR activation has distinct effects on costimulation and cytokine-driven proliferation: attenuation of ICOS, IL-4, and IL-21, but not CD28, IL-7, and IL-15 responses.	Journal of immunology (Baltimore, Md. : 1950)	2003	-52.86902458051357	-5.512158478716498	227	3.51
12444166	Programmed death-1 targeting can promote allograft survival.	Journal of immunology (Baltimore, Md. : 1950)	2002	-62.60764810114404	-3.4703120620814785	205	3.44
12421930	Expression of programmed death 1 ligands by murine T cells and APC.	Journal of immunology (Baltimore, Md. : 1950)	2002	-59.53678395871357	-11.312803717810482	742	12.36
12244148	B7-H1 is expressed by human endothelial cells and suppresses T cell cytokine synthesis.	Journal of immunology (Baltimore, Md. : 1950)	2002	-61.5943756675358	-12.296112157024815	270	4.42
12218188	Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade.	Proceedings of the National Academy of Sciences of the United States of America	2002	-35.04510191270973	-9.577996625358027	2190	37.31
12161284	Differential expression of PD-L1 and PD-L2, ligands for an inhibitory receptor PD-1, in the cells of lymphohematopoietic tissues.	Immunology letters	2002	-35.23293181616004	18.87888195827732	224	3.57
11932780	Expression and regulation of the PD-L1 immunoinhibitory molecule on microvascular endothelial cells.	Microcirculation (New York, N.Y. : 1994)	2002	-62.05278045655087	-12.491833788770398	228	3.56
11857337	PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2.	European journal of immunology	2002	-52.84304546171413	-6.471345564952324	498	8.15
11500834	Laser capture microdissection-based expression profiling identifies PD1-ligand as a target of the nude locus gene product.	European journal of immunology	2001	-6.62385173531141	-36.47177927551794	33	0.48
11323285	PD-1: an inhibitory immunoreceptor involved in peripheral tolerance.	Trends in immunology	2001	-57.54787885568634	-0.475452957532492	369	6.06
11283156	B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells.	The Journal of experimental medicine	2001	-60.14945164860975	-9.546395835683532	699	11.3
11224527	PD-L2 is a second ligand for PD-1 and inhibits T cell activation.	Nature immunology	2001	-52.93630655092128	-6.558609054589889	2136	36.59
11015443	Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation.	The Journal of experimental medicine	2000	-53.66018773006826	-6.826931750273774	3693	65.33
